A	B-Claim
combination	I-Claim
of	I-Claim
mitoxantrone	I-Claim
plus	I-Claim
prednisone	I-Claim
is	I-Claim
preferable	I-Claim
to	I-Claim
prednisone	I-Claim
alone	I-Claim
for	I-Claim
reduction	I-Claim
of	I-Claim
pain	I-Claim
in	I-Claim
men	I-Claim
with	I-Claim
metastatic,	I-Claim
hormone-resistant,	I-Claim
prostate	I-Claim
cancer.	I-Claim

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
these	O
treatments	O
on	O
health-related	O
quality	O
of	O
life	O
(HQL).	O

Men	O
with	O
metastatic	O
prostate	O
cancer	O
(n	O
=	O
161)	O
were	O
randomized	O
to	O
receive	O
either	O
daily	O
prednisone	O
alone	O
or	O
mitoxantrone	O
(every	O
3	O
weeks)	O
plus	O
prednisone.	O

Those	O
who	O
received	O
prednisone	O
alone	O
could	O
have	O
mitoxantrone	O
added	O
after	O
6	O
weeks	O
if	O
there	O
was	O
no	O
improvement	O
in	O
pain.	O

HQL	O
was	O
assessed	O
before	O
treatment	O
initiation	O
and	O
then	O
every	O
3	O
weeks	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality-of-Life	O
Questionnaire	O
C30	O
(EORTC	O
QLQ-C30)	O
and	O
the	O
Quality	O
of	O
Life	O
Module-Prostate	O
14	O
(QOLM-P14),	O
a	O
trial-specific	O
module	O
developed	O
for	O
this	O
study.	O

An	O
intent-to-treat	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
mean	O
duration	O
of	O
HQL	O
improvement	O
and	O
differences	O
in	O
improvement	O
duration	O
between	O
groups	O
of	O
patients.	O

At	B-Premise
6	I-Premise
weeks,	I-Premise
both	I-Premise
groups	I-Premise
showed	I-Premise
improvement	I-Premise
in	I-Premise
several	I-Premise
HQL	I-Premise
domains,	I-Premise
and	O
only	B-Premise
physical	I-Premise
functioning	I-Premise
and	I-Premise
pain	I-Premise
were	I-Premise
better	I-Premise
in	I-Premise
the	I-Premise
mitoxantrone-plus-prednisone	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
prednisone-alone	I-Premise
group.	I-Premise

After	B-Premise
6	I-Premise
weeks,	I-Premise
patients	I-Premise
taking	I-Premise
prednisone	I-Premise
showed	I-Premise
no	I-Premise
improvement	I-Premise
in	I-Premise
HQL	I-Premise
scores,	I-Premise
whereas	I-Premise
those	I-Premise
taking	I-Premise
mitoxantrone	I-Premise
plus	I-Premise
prednisone	I-Premise
showed	I-Premise
significant	I-Premise
improvements	I-Premise
in	I-Premise
global	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(P	I-Premise
=.009),	I-Premise
four	I-Premise
functioning	I-Premise
domains,	I-Premise
and	I-Premise
nine	I-Premise
symptoms	I-Premise
(.001	I-Premise
<	I-Premise
P	I-Premise
<.	I-Premise
01),	I-Premise
and	O
the	B-Premise
improvement	I-Premise
(>	I-Premise
10	I-Premise
units	I-Premise
on	I-Premise
a	I-Premise
scale	I-Premise
of	I-Premise
0	I-Premise
to100)	I-Premise
lasted	I-Premise
longer	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
prednisone-alone	I-Premise
group	I-Premise
(.004	I-Premise
<	I-Premise
P	I-Premise
<.05).	I-Premise

The	B-Premise
addition	I-Premise
of	I-Premise
mitoxantrone	I-Premise
to	I-Premise
prednisone	I-Premise
after	I-Premise
failure	I-Premise
of	I-Premise
prednisone	I-Premise
alone	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
improvements	I-Premise
in	I-Premise
pain,	I-Premise
pain	I-Premise
impact,	I-Premise
pain	I-Premise
relief,	I-Premise
insomnia,	I-Premise
and	I-Premise
global	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(.001	I-Premise
<	I-Premise
P	I-Premise
<.003).	I-Premise

Treatment	B-Claim
with	I-Claim
mitoxantrone	I-Claim
plus	I-Claim
prednisone	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
greater	I-Claim
and	I-Claim
longer-lasting	I-Claim
improvement	I-Claim
in	I-Claim
several	I-Claim
HQL	I-Claim
domains	I-Claim
and	I-Claim
symptoms	I-Claim
than	I-Claim
treatment	I-Claim
with	I-Claim
prednisone	I-Claim
alone.	I-Claim

In	B-Claim
endocrine	I-Claim
therapy	I-Claim
trials	I-Claim
in	I-Claim
advanced	I-Claim
breast	I-Claim
cancer,	I-Claim
patients	I-Claim
with	I-Claim
response	I-Claim
(complete	I-Claim
response/partial	I-Claim
response	I-Claim
[CR/PR])	I-Claim
and	I-Claim
patients	I-Claim
with	I-Claim
stable	I-Claim
disease	I-Claim
for	I-Claim
at	I-Claim
least	I-Claim
6	I-Claim
months	I-Claim
(SD(6m))	I-Claim
have	I-Claim
shown	I-Claim
similar	I-Claim
survival	I-Claim
and	I-Claim
therefore	I-Claim
are	I-Claim
often	I-Claim
defined	I-Claim
as	I-Claim
a	I-Claim
population	I-Claim
with	I-Claim
clinical	I-Claim
benefit	I-Claim
(patients	I-Claim
with	I-Claim
CR/PR	I-Claim
or	I-Claim
SD(6m)).	I-Claim

We	O
evaluated	O
the	O
impact	O
of	O
response	O
and/or	O
clinical	O
benefit	O
on	O
quality	O
of	O
life	O
(QL)	O
in	O
postmenopausal	O
patients	O
under	O
second-line	O
endocrine	O
treatment	O
after	O
failure	O
of	O
tamoxifen.	O

One	O
hundred	O
twenty-eight	O
of	O
177	O
eligible	O
patients	O
of	O
a	O
randomized	O
trial	O
(Swiss	O
Group	O
for	O
Clinical	O
Cancer	O
Research	O
20/90)	O
receiving	O
either	O
formestane	O
(250	O
mg	O
intramuscularly	O
biweekly)	O
or	O
megestrol	O
acetate	O
(160	O
mg	O
orally	O
daily)	O
were	O
analyzed.	O

The	O
baseline	O
characteristics	O
(with	O
the	O
exception	O
of	O
site	O
of	O
metastases)	O
were	O
balanced	O
among	O
patients	O
with	O
CR/PR,	O
SD(6m),	O
and	O
progressive	O
disease	O
(PD).	O

Patients	O
completed	O
QL	O
indicators	O
at	O
baseline	O
and	O
at	O
1,	O
3,	O
5,	O
7,	O
9,	O
and	O
11	O
months.	O

Responders	O
were	O
separately	O
compared	O
with	O
nonresponders	O
(patients	O
with	O
SD(6m)	O
or	O
PD)	O
and	O
with	O
patients	O
with	O
SD(6m),	O
and	O
patients	O
with	O
clinical	O
benefit	O
were	O
compared	O
with	O
patients	O
with	O
PD	O
by	O
analysis	O
of	O
covariance	O
with	O
adjustment	O
for	O
baseline	O
scores.	O

Overall,	O
88%	O
(557	O
of	O
634)	O
of	O
expected	O
QL	O
forms	O
were	O
received.	O

In	O
the	O
comparison	O
of	O
responders	O
versus	O
patients	O
with	O
both	O
SD(6m)	O
and	O
PD,	O
responders	B-Premise
indicated	I-Premise
better	I-Premise
physical	I-Premise
well-being	I-Premise
(P	I-Premise
=.	I-Premise
004)	I-Premise
and	I-Premise
mood	I-Premise
(P	I-Premise
=.02)	I-Premise
at	I-Premise
month	I-Premise
3.	I-Premise

Compared	B-Premise
only	I-Premise
with	I-Premise
patients	I-Premise
with	I-Premise
SD(6m),	I-Premise
responders	I-Premise
showed	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
baseline	I-Premise
QL	I-Premise
and	I-Premise
time	I-Premise
to	I-Premise
treatment	I-Premise
failure	I-Premise
(328.5	I-Premise
v	I-Premise
340	I-Premise
days).	I-Premise

While	B-Premise
under	I-Premise
treatment,	I-Premise
responders	I-Premise
reported	I-Premise
significantly	I-Premise
better	I-Premise
physical	I-Premise
well-being	I-Premise
(months	I-Premise
3	I-Premise
to	I-Premise
11),	I-Premise
mood	I-Premise
(months	I-Premise
5	I-Premise
to	I-Premise
11),	I-Premise
coping	I-Premise
(months	I-Premise
5	I-Premise
to	I-Premise
9),	I-Premise
and	I-Premise
appetite	I-Premise
(months	I-Premise
7	I-Premise
to	I-Premise
11)	I-Premise
and	I-Premise
less	I-Premise
dizziness	I-Premise
(month	I-Premise
9)	I-Premise
than	I-Premise
patients	I-Premise
with	I-Premise
SD(6m).	I-Premise

The	B-Premise
changes	I-Premise
between	I-Premise
baseline	I-Premise
and	I-Premise
months	I-Premise
5	I-Premise
and	I-Premise
7,	I-Premise
respectively,	I-Premise
indicated	I-Premise
improvement	I-Premise
in	I-Premise
responders	I-Premise
but	I-Premise
heterogeneous	I-Premise
patterns	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
SD(6m).	I-Premise

Although	B-Premise
the	I-Premise
CR/PR	I-Premise
and	I-Premise
SD(6m)	I-Premise
groups	I-Premise
had	I-Premise
similar	I-Premise
times	I-Premise
to	I-Premise
treatment	I-Premise
failure,	I-Premise
patients	B-Claim
with	I-Claim
CR/PR	I-Claim
reported	I-Claim
better	I-Claim
QL,	I-Claim
suggesting	I-Claim
more	I-Claim
beneficial	I-Claim
response	I-Claim
to	I-Claim
second-line	I-Claim
endocrine	I-Claim
treatment.	I-Claim

Patients'	O
subjective	O
perspective	O
should	O
be	O
taken	O
into	O
account	O
in	O
this	O
mainly	O
palliative	O
setting.	O

Future	O
trials	O
should	O
be	O
designed	O
so	O
that	O
the	O
CR/PR	O
and	O
SD(6m)	O
groups	O
are	O
investigated	O
separately.	O

Treatment	B-Claim
with	I-Claim
cisplatin-based	I-Claim
chemotherapy	I-Claim
provides	I-Claim
a	I-Claim
modest	I-Claim
survival	I-Claim
advantage	I-Claim
over	I-Claim
supportive	I-Claim
care	I-Claim
alone	I-Claim
in	I-Claim
advanced	I-Claim
non-small-cell	I-Claim
lung	I-Claim
cancer	I-Claim
(NSCLC).	I-Claim

To	O
determine	O
whether	O
a	O
new	O
agent,	O
paclitaxel,	O
would	O
further	O
improve	O
survival	O
in	O
NSCLC,	O
the	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
conducted	O
a	O
randomized	O
trial	O
comparing	O
paclitaxel	O
plus	O
cisplatin	O
to	O
a	O
standard	O
chemotherapy	O
regimen	O
consisting	O
of	O
cisplatin	O
and	O
etoposide.	O

The	O
study	O
was	O
carried	O
out	O
by	O
a	O
multi-institutional	O
cooperative	O
group	O
in	O
chemotherapy-naive	O
stage	O
IIIB	O
to	O
IV	O
NSCLC	O
patients	O
randomized	O
to	O
receive	O
paclitaxel	O
plus	O
cisplatin	O
or	O
etoposide	O
plus	O
cisplatin.	O

Paclitaxel	O
was	O
administered	O
at	O
two	O
different	O
dose	O
levels	O
(135	O
mg/m(2)	O
and	O
250	O
mg/m(2)),	O
and	O
etoposide	O
was	O
given	O
at	O
a	O
dose	O
of	O
100	O
mg/m(2)	O
daily	O
on	O
days	O
1	O
to	O
3.	O

Each	O
regimen	O
was	O
repeated	O
every	O
21	O
days	O
and	O
each	O
included	O
cisplatin	O
(75	O
mg/m(2)).	O

The	O
characteristics	O
of	O
the	O
599	O
patients	O
were	O
well-balanced	O
across	O
the	O
three	O
treatment	O
groups.	O

Superior	B-Premise
survival	I-Premise
was	I-Premise
observed	I-Premise
with	I-Premise
the	I-Premise
combined	I-Premise
paclitaxel	I-Premise
regimens	I-Premise
(median	I-Premise
survival	I-Premise
time,	I-Premise
9.9	I-Premise
months;	I-Premise
1-year	I-Premise
survival	I-Premise
rate,	I-Premise
38.9%)	I-Premise
compared	I-Premise
with	I-Premise
etoposide	I-Premise
plus	I-Premise
cisplatin	I-Premise
(median	I-Premise
survival	I-Premise
time,	I-Premise
7.6	I-Premise
months;	I-Premise
1-year	I-Premise
survival	I-Premise
rate,	I-Premise
31.8%;	I-Premise
P	I-Premise
=.	I-Premise
048).	I-Premise

Comparing	B-Premise
survival	I-Premise
for	I-Premise
the	I-Premise
two	I-Premise
dose	I-Premise
levels	I-Premise
of	I-Premise
paclitaxel	I-Premise
revealed	I-Premise
no	I-Premise
significant	I-Premise
difference.	I-Premise

The	B-Premise
median	I-Premise
survival	I-Premise
duration	I-Premise
for	I-Premise
the	I-Premise
stage	I-Premise
IIIB	I-Premise
subgroup	I-Premise
was	I-Premise
7.9	I-Premise
months	I-Premise
for	I-Premise
etoposide	I-Premise
plus	I-Premise
cisplatin	I-Premise
patients	I-Premise
versus	I-Premise
13.1	I-Premise
months	I-Premise
for	I-Premise
all	I-Premise
paclitaxel	I-Premise
patients	I-Premise
(P	I-Premise
=.152).	I-Premise

For	B-Premise
the	I-Premise
stage	I-Premise
IV	I-Premise
subgroup,	I-Premise
the	I-Premise
median	I-Premise
survival	I-Premise
time	I-Premise
for	I-Premise
etoposide	I-Premise
plus	I-Premise
cisplatin	I-Premise
was	I-Premise
7.6	I-Premise
months	I-Premise
compared	I-Premise
with	I-Premise
8.9	I-Premise
months	I-Premise
for	I-Premise
paclitaxel	I-Premise
(P	I-Premise
=.246).	I-Premise

With	B-Premise
the	I-Premise
exceptions	I-Premise
of	I-Premise
increased	I-Premise
granulocytopenia	I-Premise
on	I-Premise
the	I-Premise
low-dose	I-Premise
paclitaxel	I-Premise
regimen	I-Premise
and	I-Premise
increased	I-Premise
myalgias,	I-Premise
neurotoxicity,	I-Premise
and,	I-Premise
possibly,	I-Premise
increased	I-Premise
treatment-related	I-Premise
cardiac	I-Premise
events	I-Premise
with	I-Premise
high-dose	I-Premise
paclitaxel,	I-Premise
toxicity	I-Premise
was	I-Premise
similar	I-Premise
across	I-Premise
all	I-Premise
three	I-Premise
arms.	I-Premise

Quality	B-Premise
of	I-Premise
life	I-Premise
(QOL)	I-Premise
declined	I-Premise
significantly	I-Premise
over	I-Premise
the	I-Premise
6	I-Premise
months.	I-Premise

However,	O
QOL	B-Claim
scores	I-Claim
were	I-Claim
not	I-Claim
significantly	I-Claim
different	I-Claim
among	I-Claim
the	I-Claim
regimens.	I-Claim

As	O
a	O
result	O
of	O
these	O
observations,	O
paclitaxel	B-Claim
(135	I-Claim
mg/m(2))	I-Claim
combined	I-Claim
with	I-Claim
cisplatin	I-Claim
has	I-Claim
replaced	I-Claim
etoposide	I-Claim
plus	I-Claim
cisplatin	I-Claim
as	I-Claim
the	I-Claim
reference	I-Claim
regimen	I-Claim
in	I-Claim
our	I-Claim
recently	I-Claim
completed	I-Claim
phase	I-Claim
III	I-Claim
trial.	I-Claim

Extracellular	O
adenosine	O
5'-triphosphate	O
(ATP)	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
a	O
variety	O
of	O
biologic	O
processes,	O
including	O
neurotransmission,	O
muscle	O
contraction,	O
and	O
liver	O
glucose	O
metabolism,	O
via	O
purinergic	O
receptors.	O

In	B-Claim
nonrandomized	I-Claim
studies	I-Claim
involving	I-Claim
patients	I-Claim
with	I-Claim
different	I-Claim
tumor	I-Claim
types	I-Claim
including	I-Claim
non-small-cell	I-Claim
lung	I-Claim
cancer	I-Claim
(NSCLC),	I-Claim
ATP	I-Claim
infusion	I-Claim
appeared	I-Claim
to	I-Claim
inhibit	I-Claim
loss	I-Claim
of	I-Claim
weight	I-Claim
and	I-Claim
deterioration	I-Claim
of	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
(QOL)	I-Claim
and	I-Claim
performance	I-Claim
status.	I-Claim

We	O
conducted	O
a	O
randomized	O
clinical	O
trial	O
to	O
evaluate	O
the	O
effects	O
of	O
ATP	O
in	O
patients	O
with	O
advanced	O
NSCLC	O
(stage	O
IIIB	O
or	O
IV).	O

Fifty-eight	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
10	O
intravenous	O
30-hour	O
ATP	O
infusions,	O
with	O
the	O
infusions	O
given	O
at	O
2-	O
to	O
4-week	O
intervals,	O
or	O
no	O
ATP.	O

Outcome	O
parameters	O
were	O
assessed	O
every	O
4	O
weeks	O
until	O
28	O
weeks.	O

Between-group	O
differences	O
were	O
tested	O
for	O
statistical	O
significance	O
by	O
use	O
of	O
repeated-measures	O
analysis,	O
and	O
reported	O
P	O
values	O
are	O
two-sided.	O

Twenty-eight	O
patients	O
were	O
allocated	O
to	O
receive	O
ATP	O
treatment	O
and	O
30	O
received	O
no	O
ATP.	O

Mean	B-Premise
weight	I-Premise
changes	I-Premise
per	I-Premise
4-week	I-Premise
period	I-Premise
were	I-Premise
-1.0	I-Premise
kg	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
=	I-Premise
-1.5	I-Premise
to	I-Premise
-0.5)	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
and	I-Premise
0.2	I-Premise
kg	I-Premise
(95%	I-Premise
CI	I-Premise
=	I-Premise
-0.2	I-Premise
to	I-Premise
+0.6)	I-Premise
in	I-Premise
the	I-Premise
ATP	I-Premise
group	I-Premise
(P	I-Premise
=.002).	I-Premise

Serum	B-Premise
albumin	I-Premise
concentration	I-Premise
declined	I-Premise
by	I-Premise
-1.2	I-Premise
g/L	I-Premise
(95%	I-Premise
CI=	I-Premise
-2.0	I-Premise
to	I-Premise
-0.4)	I-Premise
per	I-Premise
4	I-Premise
weeks	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
but	I-Premise
remained	I-Premise
stable	I-Premise
(0.0	I-Premise
g/L;	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
-0.3	I-Premise
to	I-Premise
+0.3)	I-Premise
in	I-Premise
the	I-Premise
ATP	I-Premise
group	I-Premise
(P	I-Premise
=.006).	I-Premise

Elbow	B-Premise
flexor	I-Premise
muscle	I-Premise
strength	I-Premise
declined	I-Premise
by	I-Premise
-5.5%	I-Premise
(95%	I-Premise
CI	I-Premise
=	I-Premise
-9.6%	I-Premise
to	I-Premise
-1.	I-Premise
4%)	I-Premise
per	I-Premise
4	I-Premise
weeks	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
but	I-Premise
remained	I-Premise
stable	I-Premise
(0.0%;	I-Premise
95%	I-Premise
CI=	I-Premise
-1.4%	I-Premise
to	I-Premise
+1.4%)	I-Premise
in	I-Premise
the	I-Premise
ATP	I-Premise
group	I-Premise
(P	I-Premise
=.01).	I-Premise

A	B-Premise
similar	I-Premise
pattern	I-Premise
was	I-Premise
observed	I-Premise
for	I-Premise
knee	I-Premise
extensor	I-Premise
muscles	I-Premise
(P	I-Premise
=.02).	I-Premise

The	B-Premise
effects	I-Premise
of	I-Premise
ATP	I-Premise
on	I-Premise
body	I-Premise
weight,	I-Premise
muscle	I-Premise
strength,	I-Premise
and	I-Premise
albumin	I-Premise
concentration	I-Premise
were	I-Premise
especially	I-Premise
marked	I-Premise
in	I-Premise
cachectic	I-Premise
patients	I-Premise
(P	I-Premise
=.0002,	I-Premise
P	I-Premise
=.0001,	I-Premise
and	I-Premise
P	I-Premise
=.	I-Premise
0001,	I-Premise
respectively,	I-Premise
for	I-Premise
ATP	I-Premise
versus	I-Premise
no	I-Premise
ATP).	I-Premise

QOL	B-Premise
score	I-Premise
changes	I-Premise
per	I-Premise
4-week	I-Premise
period	I-Premise
in	I-Premise
the	I-Premise
ATP	I-Premise
group	I-Premise
showed	I-Premise
overall	I-Premise
less	I-Premise
deterioration	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group-physical	I-Premise
scores	I-Premise
(-0.2%	I-Premise
versus	I-Premise
-2.4%;	I-Premise
P	I-Premise
=.	I-Premise
0002);	I-Premise
functional	I-Premise
scores	I-Premise
(+0.4%	I-Premise
versus	I-Premise
-5.5%;	I-Premise
P	I-Premise
=.02);	I-Premise
psychologic	I-Premise
scores	I-Premise
(-0.7%	I-Premise
versus	I-Premise
-2.4%;	I-Premise
P	I-Premise
=.11);	I-Premise
overall	I-Premise
QOL	I-Premise
score	I-Premise
(+0.1%	I-Premise
versus	I-Premise
-3.5%;	I-Premise
P	I-Premise
=.0001).	I-Premise

This	O
randomized	O
trial	O
demonstrates	O
that	O
ATP	B-Claim
has	I-Claim
beneficial	I-Claim
effects	I-Claim
on	I-Claim
weight,	I-Claim
muscle	I-Claim
strength,	I-Claim
and	I-Claim
QOL	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
NSCLC.	I-Claim

This	O
phase	O
III,	O
double-blind,	O
randomized,	O
multicenter	O
study	O
evaluated	O
the	O
efficacy,	O
pharmacodynamics,	O
and	O
safety	O
of	O
the	O
oral	O
aromatase	O
inactivator	O
exemestane	O
(EXE)	O
versus	O
megestrol	O
acetate	O
(MA)	O
in	O
postmenopausal	O
women	O
with	O
progressive	O
advanced	O
breast	O
cancer	O
who	O
experienced	O
failure	O
of	O
tamoxifen.	O

A	O
total	O
of	O
769	O
patients	O
were	O
randomized	O
to	O
EXE	O
25	O
mg/d	O
(n	O
=	O
366)	O
or	O
MA	O
(n	O
=	O
403)	O
40	O
mg	O
four	O
times	O
daily.	O

Tumor	O
response,	O
duration	O
of	O
tumor	O
control,	O
tumor-related	O
signs	O
and	O
symptoms	O
(TRSS),	O
quality	O
of	O
life	O
(QOL),	O
survival,	O
and	O
tolerability	O
were	O
evaluated.	O

Overall	B-Premise
objective	I-Premise
response	I-Premise
(OR)	I-Premise
rates	I-Premise
were	I-Premise
higher	I-Premise
in	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
EXE	I-Premise
than	I-Premise
in	I-Premise
those	I-Premise
treated	I-Premise
with	I-Premise
MA	I-Premise
(15.0%	I-Premise
v	I-Premise
12.4%);	I-Premise
a	B-Premise
similar	I-Premise
trend	I-Premise
was	I-Premise
noted	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
visceral	I-Premise
metastases	I-Premise
(13.5%	I-Premise
v	I-Premise
10.5%).	I-Premise

Median	B-Premise
survival	I-Premise
time	I-Premise
was	I-Premise
significantly	I-Premise
longer	I-Premise
with	I-Premise
EXE	I-Premise
(median	I-Premise
not	I-Premise
reached)	I-Premise
than	I-Premise
with	I-Premise
MA	I-Premise
(123.4	I-Premise
weeks;	I-Premise
P	I-Premise
=.039),	I-Premise
as	I-Premise
were	I-Premise
the	I-Premise
median	I-Premise
duration	I-Premise
of	I-Premise
overall	I-Premise
success	I-Premise
(OR	I-Premise
or	I-Premise
stable	I-Premise
disease	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
24	I-Premise
weeks;	I-Premise
60.1	I-Premise
v	I-Premise
49.1	I-Premise
weeks;	I-Premise
P	I-Premise
=.025),	I-Premise
time	I-Premise
to	I-Premise
tumor	I-Premise
progression	I-Premise
(20.3	I-Premise
v	I-Premise
16.6	I-Premise
weeks;	I-Premise
P	I-Premise
=.037),	I-Premise
and	I-Premise
time	I-Premise
to	I-Premise
treatment	I-Premise
failure	I-Premise
(16.3	I-Premise
v	I-Premise
15.7	I-Premise
weeks;	I-Premise
P	I-Premise
=.042).	I-Premise

Compared	B-Premise
with	I-Premise
MA,	I-Premise
there	I-Premise
were	I-Premise
similar	I-Premise
or	I-Premise
greater	I-Premise
improvements	I-Premise
in	I-Premise
pain,	I-Premise
TRSS,	I-Premise
and	I-Premise
QOL	I-Premise
with	I-Premise
EXE.	I-Premise

Both	B-Claim
drugs	I-Claim
were	I-Claim
well	I-Claim
tolerated.	I-Claim

Grade	B-Premise
3	I-Premise
or	I-Premise
4	I-Premise
weight	I-Premise
changes	I-Premise
were	I-Premise
more	I-Premise
common	I-Premise
with	I-Premise
MA	I-Premise
(17.1%	I-Premise
v	I-Premise
7.6%;	I-Premise
P	I-Premise
=.001).	I-Premise

EXE	B-Claim
prolongs	I-Claim
survival	I-Claim
time,	I-Claim
time	I-Claim
to	I-Claim
tumor	I-Claim
progression,	I-Claim
and	I-Claim
time	I-Claim
to	I-Claim
treatment	I-Claim
failure	I-Claim
compared	I-Claim
with	I-Claim
MA	I-Claim
and	I-Claim
offers	I-Claim
a	I-Claim
well-tolerated	I-Claim
treatment	I-Claim
option	I-Claim
for	I-Claim
postmenopausal	I-Claim
women	I-Claim
with	I-Claim
progressive	I-Claim
advanced	I-Claim
breast	I-Claim
cancer	I-Claim
who	I-Claim
experienced	I-Claim
failure	I-Claim
of	I-Claim
tamoxifen.	I-Claim

This	O
phase	O
III	O
study	O
was	O
performed	O
to	O
determine	O
the	O
superiority	O
of	O
doxorubicin	O
(DOX)	O
and	O
vinorelbine	O
(VNB)	O
(arm	O
1)	O
versus	O
DOX	O
alone	O
(arm	O
2)	O
in	O
metastatic	O
breast	O
cancer	O
(MBC)	O
for	O
overall	O
survival	O
(OS),	O
time	O
to	O
treatment	O
failure	O
(TTF),	O
toxicity,	O
and	O
quality	O
of	O
life	O
(QOL).	O

Three	O
hundred	O
three	O
patients	O
were	O
randomized	O
to	O
DOX	O
50	O
mg/m(2)	O
intravenously	O
(IV)	O
on	O
day	O
1	O
and	O
VNB	O
25	O
mg/m(2)	O
IV	O
on	O
days	O
1	O
and	O
8	O
(arm	O
1)	O
or	O
DOX	O
70	O
mg/m(2)	O
IV	O
on	O
day	O
1	O
(arm	O
2).	O

Both	O
regimens	O
were	O
given	O
every	O
3	O
weeks	O
until	O
a	O
cumulative	O
DOX	O
dose	O
of	O
450	O
mg/m(2).	O

After	O
16	O
of	O
the	O
first	O
65	O
randomized	O
patients	O
experienced	O
febrile	O
neutropenia	O
(FN),	O
the	O
doses	O
were	O
reduced	O
to	O
DOX	O
40	O
mg/m(2)	O
on	O
day	O
1	O
and	O
VNB	O
20	O
mg/m(2)	O
on	O
days	O
1	O
and	O
8	O
versus	O
DOX	O
60	O
mg/m(2)	O
on	O
day	O
1.	O

Eligible	O
patients	O
were	O
vinca	O
alkaloid	O
and	O
anthracycline	O
naive.	O

Chemotherapy	O
was	O
first-line	O
or	O
second-line	O
for	O
MBC.	O

Three	O
patients	O
were	O
ineligible.	O

Thus,	O
300	O
patients	O
were	O
assessable	O
for	O
toxicity	O
and	O
to	O
determine	O
time	O
to	O
disease	O
progression	O
(TTP),	O
TTF,	O
and	O
OS.	O

Two	O
hundred	O
eighty-nine	O
patients	O
were	O
assessable	O
for	O
response,	O
and	O
99	O
responders	O
were	O
assessable	O
for	O
response	O
duration	O
(RD).	O

The	B-Premise
response	I-Premise
rates,	I-Premise
QOL,	I-Premise
and	I-Premise
median	I-Premise
RD,	I-Premise
TTP,	I-Premise
and	I-Premise
TTF	I-Premise
were	I-Premise
not	I-Premise
significantly	I-Premise
different	I-Premise
between	I-Premise
the	I-Premise
arms.	I-Premise

Median	B-Premise
OS	I-Premise
was	I-Premise
13.8	I-Premise
months	I-Premise
for	I-Premise
arm	I-Premise
1	I-Premise
versus	I-Premise
14.4	I-Premise
months	I-Premise
for	I-Premise
arm	I-Premise
2	I-Premise
(P	I-Premise
=.4).	I-Premise

Grade	B-Premise
3	I-Premise
or	I-Premise
4	I-Premise
granulocytopenia	I-Premise
was	I-Premise
equivalent	I-Premise
in	I-Premise
both	I-Premise
arms	I-Premise
but	I-Premise
more	I-Premise
grade	I-Premise
3/4	I-Premise
neurotoxicity,	I-Premise
mild	I-Premise
venous	I-Premise
toxicity,	I-Premise
and	I-Premise
FN	I-Premise
were	I-Premise
seen	I-Premise
on	I-Premise
arm	I-Premise
1.	I-Premise

The	B-Claim
survival	I-Claim
with	I-Claim
DOX	I-Claim
and	I-Claim
VNB	I-Claim
is	I-Claim
not	I-Claim
superior	I-Claim
to	I-Claim
DOX	I-Claim
alone	I-Claim
in	I-Claim
MBC.	I-Claim

Menopausal	B-Claim
symptoms	I-Claim
(e.g.,	I-Claim
hot	I-Claim
flashes,	I-Claim
vaginal	I-Claim
dryness,	I-Claim
and	I-Claim
stress	I-Claim
urinary	I-Claim
incontinence)	I-Claim
are	I-Claim
very	I-Claim
common	I-Claim
in	I-Claim
breast	I-Claim
cancer	I-Claim
survivors	I-Claim
and	I-Claim
cannot	I-Claim
be	I-Claim
managed	I-Claim
with	I-Claim
standard	I-Claim
estrogen	I-Claim
replacement	I-Claim
therapy	I-Claim
(ERT)	I-Claim
in	I-Claim
these	I-Claim
patients.	I-Claim

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
efficacy	O
of	O
a	O
comprehensive	O
menopausal	O
assessment	O
(CMA)	O
intervention	O
program	O
in	O
achieving	O
relief	O
of	O
symptoms,	O
the	O
improvement	O
in	O
quality	O
of	O
life	O
(QOL),	O
and	O
sexual	O
functioning	O
in	O
breast	O
cancer	O
survivors.	O

Using	O
a	O
two-group,	O
randomized	O
controlled	O
design,	O
we	O
assigned	O
76	O
postmenopausal	O
breast	O
cancer	O
survivors	O
with	O
at	O
least	O
one	O
severe	O
target	O
symptom	O
either	O
to	O
the	O
intervention	O
group	O
or	O
to	O
a	O
usual-care	O
group.	O

Seventy-two	O
women	O
were	O
evaluable	O
at	O
the	O
end	O
of	O
the	O
study	O
period.	O

The	O
CMA	O
intervention,	O
delivered	O
by	O
a	O
nurse	O
practitioner,	O
focused	O
on	O
symptom	O
assessment,	O
education,	O
counseling	O
and,	O
as	O
appropriate,	O
specific	O
pharmacologic	O
and	O
behavioral	O
interventions	O
for	O
each	O
of	O
the	O
three	O
target	O
symptoms.	O

Psychosocial	O
symptoms	O
were	O
assessed	O
with	O
the	O
use	O
of	O
a	O
self-report	O
screening	O
instrument,	O
and	O
distressed	O
women	O
were	O
referred	O
for	O
counseling	O
if	O
needed.	O

The	O
intervention	O
took	O
place	O
over	O
a	O
4-month	O
period.	O

Outcomes	O
measured	O
were	O
scores	O
on	O
a	O
composite	O
menopausal	O
symptom	O
scale,	O
the	O
RAND	O
Short	O
Form	O
Health	O
Survey	O
Vitality	O
Scale,	O
and	O
the	O
Cancer	O
Rehabilitation	O
Evaluation	O
System	O
(CARES)	O
Sexual	O
Functioning	O
Scale	O
at	O
baseline	O
and	O
at	O
4-month	O
follow-up.	O

All	O
statistical	O
tests	O
were	O
two-sided	O
and	O
were	O
performed	O
at	O
the	O
alpha	O
=.	O

05	O
significance	O
level.	O

Patients	B-Premise
receiving	I-Premise
the	I-Premise
intervention	I-Premise
demonstrated	I-Premise
statistically	I-Premise
significant	I-Premise
improvement	I-Premise
(P	I-Premise
=.0004)	I-Premise
in	I-Premise
menopausal	I-Premise
symptoms	I-Premise
but	I-Premise
no	I-Premise
significant	I-Premise
change	I-Premise
in	I-Premise
vitality	I-Premise
(P	I-Premise
=.77).	I-Premise

Sexual	B-Premise
functioning	I-Premise
was	I-Premise
statistically	I-Premise
significantly	I-Premise
improved	I-Premise
(P	I-Premise
=.04)	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
usual-care	I-Premise
group.	I-Premise

A	B-Claim
clinical	I-Claim
assessment	I-Claim
and	I-Claim
intervention	I-Claim
program	I-Claim
for	I-Claim
menopausal	I-Claim
symptom	I-Claim
management	I-Claim
in	I-Claim
breast	I-Claim
cancer	I-Claim
survivors	I-Claim
is	I-Claim
feasible	I-Claim
and	I-Claim
acceptable	I-Claim
to	I-Claim
patients,	I-Claim
leading	I-Claim
to	I-Claim
reduction	I-Claim
in	I-Claim
symptoms	I-Claim
and	I-Claim
improvement	I-Claim
in	I-Claim
sexual	I-Claim
functioning.	I-Claim

Measurable	B-Claim
improvement	I-Claim
in	I-Claim
a	I-Claim
general	I-Claim
QOL	I-Claim
measure	I-Claim
was	I-Claim
not	I-Claim
demonstrated.	I-Claim

In	B-Claim
phase	I-Claim
II	I-Claim
trials,	I-Claim
paclitaxel	I-Claim
has	I-Claim
been	I-Claim
shown	I-Claim
to	I-Claim
have	I-Claim
antitumor	I-Claim
activity	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
non-small-cell	I-Claim
lung	I-Claim
cancer	I-Claim
(NSCLC).	I-Claim

However,	O
the	O
survival	O
and	O
quality-of-life	O
(QOL)	O
benefits	O
of	O
paclitaxel	O
used	O
as	O
a	O
single	O
agent	O
compared	O
with	O
supportive	O
care	O
alone	O
have	O
not	O
been	O
assessed	O
in	O
a	O
randomized	O
clinical	O
trial.	O

A	O
total	O
of	O
157	O
patients	O
with	O
stage	O
IIIB	O
or	O
IV	O
NSCLC	O
who	O
had	O
received	O
no	O
prior	O
chemotherapy	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
best	O
supportive	O
care	O
alone	O
(78	O
patients)	O
or	O
paclitaxel	O
plus	O
supportive	O
care	O
(79	O
patients).	O

Paclitaxel	O
was	O
administered	O
as	O
a	O
3-hour	O
intravenous	O
infusion	O
every	O
3	O
weeks.	O

Supportive	O
care	O
included	O
palliative	O
radiotherapy	O
and	O
supportive	O
therapy	O
with	O
corticosteroids,	O
antibiotics,	O
analgesics,	O
antiemetics,	O
transfusions,	O
and	O
other	O
symptomatic	O
therapy	O
as	O
required.	O

The	O
primary	O
end	O
point	O
of	O
the	O
study	O
was	O
survival.	O

Time	O
to	O
disease	O
progression,	O
response	O
rate,	O
adverse	O
events,	O
and	O
QOL	O
were	O
secondary	O
end	O
points.	O

Pretreatment	O
characteristics	O
were	O
evenly	O
distributed	O
between	O
the	O
two	O
arms.	O

Survival	B-Premise
was	I-Premise
statistically	I-Premise
significantly	I-Premise
better	I-Premise
in	I-Premise
the	I-Premise
paclitaxel	I-Premise
plus	I-Premise
supportive	I-Premise
care	I-Premise
arm	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
supportive	I-Premise
care	I-Premise
alone	I-Premise
arm	I-Premise
(two-sided	I-Premise
P	I-Premise
=.037)	I-Premise
(median	I-Premise
survival	I-Premise
=	I-Premise
6.8	I-Premise
months	I-Premise
versus	I-Premise
4.8	I-Premise
months).	I-Premise

Cox	B-Premise
multivariate	I-Premise
analysis	I-Premise
showed	I-Premise
paclitaxel	I-Premise
plus	I-Premise
supportive	I-Premise
care	I-Premise
to	I-Premise
be	I-Premise
statistically	I-Premise
significantly	I-Premise
associated	I-Premise
with	I-Premise
improved	I-Premise
survival	I-Premise
(two-sided	I-Premise
P	I-Premise
=.048).	I-Premise

QOL	B-Premise
was	I-Premise
similar	I-Premise
for	I-Premise
both	I-Premise
treatment	I-Premise
arms,	I-Premise
except	B-Premise
for	I-Premise
the	I-Premise
functional	I-Premise
activity	I-Premise
score	I-Premise
of	I-Premise
the	I-Premise
Rotterdam	I-Premise
Symptom	I-Premise
Checklist,	I-Premise
where	I-Premise
QOL	I-Premise
data	I-Premise
statistically	I-Premise
significantly	I-Premise
favored	I-Premise
the	I-Premise
paclitaxel	I-Premise
plus	I-Premise
supportive	I-Premise
care	I-Premise
arm	I-Premise
(two-sided	I-Premise
P	I-Premise
=.043).	I-Premise

The	B-Claim
addition	I-Claim
of	I-Claim
paclitaxel	I-Claim
to	I-Claim
best	I-Claim
supportive	I-Claim
care	I-Claim
significantly	I-Claim
improved	I-Claim
survival	I-Claim
and	I-Claim
time	I-Claim
to	I-Claim
disease	I-Claim
progression	I-Claim
compared	I-Claim
with	I-Claim
best	I-Claim
supportive	I-Claim
care	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
NSCLC	I-Claim
and	I-Claim
may	I-Claim
improve	I-Claim
some	I-Claim
aspects	I-Claim
of	I-Claim
QOL.	I-Claim

The	O
aim	O
of	O
the	O
project	O
was	O
to	O
identify	O
clinical	O
and	O
quality	O
of	O
life	O
(QL)	O
factors	O
that	O
together	O
predict	O
survival	O
and	O
response	O
to	O
chemotherapy	O
in	O
advanced	O
breast	O
cancer.	O

Potential	O
prognostic	O
factors	O
were	O
studied	O
in	O
187	O
women	O
with	O
baseline	O
QL	O
data	O
from	O
a	O
trial	O
of	O
paclitaxel	O
versus	O
doxorubicin	O
as	O
first-line	O
chemotherapy.	O

Demographic	O
and	O
clinical	O
factors	O
studied	O
were	O
age,	O
performance	O
status,	O
dominant	O
site	O
of	O
disease	O
and	O
preceding	O
disease-free	O
interval	O
(DFI).	O

Factors	O
from	O
the	O
EORTC	O
QLQ-C30	O
were	O
all	O
function	O
scales,	O
fatigue,	O
nausea/vomiting,	O
pain,	O
dyspnoea,	O
insomnia,	O
loss	O
of	O
appetite	O
and	O
global	O
QL.	O

The	O
proportional	O
hazards	O
regression	O
model	O
with	O
stratification	O
for	O
treatment,	O
and	O
the	O
logistic	O
regression	O
model	O
adjusting	O
for	O
treatment	O
arm	O
were	O
used	O
for	O
univariate	O
and	O
multivariate	O
analyses	O
of	O
survival	O
and	O
response	O
to	O
treatment,	O
respectively.	O

For	B-Premise
survival,	I-Premise
multiple	I-Premise
sites	I-Premise
of	I-Premise
visceral	I-Premise
disease,	I-Premise
pain,	I-Premise
global	I-Premise
QL	I-Premise
and	I-Premise
fatigue	I-Premise
were	I-Premise
significant	I-Premise
prognostic	I-Premise
factors	I-Premise
in	I-Premise
the	I-Premise
univariate	I-Premise
analysis.	I-Premise

The	B-Premise
final	I-Premise
multivariate	I-Premise
model	I-Premise
predicted	I-Premise
poor	I-Premise
survival	I-Premise
with	I-Premise
multiple	I-Premise
sites	I-Premise
of	I-Premise
visceral	I-Premise
disease	I-Premise
(P=0.003),	I-Premise
DFI	I-Premise
</=2	I-Premise
years	I-Premise
(P=0.026)	I-Premise
and	I-Premise
pain	I-Premise
(P=0.003).	I-Premise

For	B-Premise
response,	I-Premise
age,	I-Premise
dyspnoea,	I-Premise
fatigue	I-Premise
and	I-Premise
global	I-Premise
QL	I-Premise
were	I-Premise
significant	I-Premise
predictive	I-Premise
factors	I-Premise
in	I-Premise
the	I-Premise
univariate	I-Premise
analysis.	I-Premise

The	B-Premise
final	I-Premise
multivariate	I-Premise
model	I-Premise
for	I-Premise
response	I-Premise
selected	I-Premise
DFI	I-Premise
(P=0.009),	I-Premise
multiple	I-Premise
sites	I-Premise
of	I-Premise
visceral	I-Premise
disease	I-Premise
(P=0.037)	I-Premise
and	I-Premise
dyspnoea	I-Premise
(P=<0.001)	I-Premise
using	I-Premise
forward	I-Premise
selection,	I-Premise
but	B-Premise
model	I-Premise
instability	I-Premise
was	I-Premise
indicated	I-Premise
by	I-Premise
the	I-Premise
inclusion	I-Premise
of	I-Premise
fatigue	I-Premise
and	I-Premise
emotional	I-Premise
function	I-Premise
in	I-Premise
the	I-Premise
final	I-Premise
model	I-Premise
when	I-Premise
backward	I-Premise
selection	I-Premise
was	I-Premise
used.	I-Premise

In	O
addition	O
to	O
known	O
clinical	O
factors,	O
patient-assessed	B-Claim
QL	I-Claim
variables	I-Claim
appear	I-Claim
to	I-Claim
be	I-Claim
prognostic	I-Claim
for	I-Claim
survival	I-Claim
and	I-Claim
response	I-Claim
to	I-Claim
chemotherapy	I-Claim
in	I-Claim
women	I-Claim
with	I-Claim
advanced	I-Claim
breast	I-Claim
cancer.	I-Claim

However,	B-Claim
identification	I-Claim
of	I-Claim
prognostic	I-Claim
factors	I-Claim
from	I-Claim
responses	I-Claim
to	I-Claim
questionnaires	I-Claim
may	I-Claim
be	I-Claim
unstable,	I-Claim
and	I-Claim
their	I-Claim
reliability	I-Claim
and	I-Claim
clinical	I-Claim
utility	I-Claim
should	I-Claim
be	I-Claim
tested	I-Claim
prospectively.	I-Claim

In	O
a	O
previous	O
study	O
of	O
treatment	O
for	O
advanced	O
colorectal	O
cancer,	O
the	O
LV5FU2	O
regimen,	O
comprising	O
leucovorin	O
(LV)	O
plus	O
bolus	O
and	O
infusional	O
fluorouracil	O
(5FU)	O
every	O
2	O
weeks,	O
was	O
superior	O
to	O
the	O
standard	O
North	O
Central	O
Cancer	O
Treatment	O
Group/Mayo	O
Clinic	O
5-day	O
bolus	O
5FU/LV	O
regimen.	O

This	O
phase	O
III	O
study	O
investigated	O
the	O
effect	O
of	O
combining	O
oxaliplatin	O
with	O
LV5FU2,	O
with	O
progression-free	O
survival	O
as	O
the	O
primary	O
end	O
point.	O

Four	O
hundred	O
twenty	O
previously	O
untreated	O
patients	O
with	O
measurable	O
disease	O
were	O
randomized	O
to	O
receive	O
a	O
2-hour	O
infusion	O
of	O
LV	O
(200	O
mg/m(2)/d)	O
followed	O
by	O
a	O
5FU	O
bolus	O
(400	O
mg/m(2)/d)	O
and	O
22-hour	O
infusion	O
(600	O
mg/m(2)/d)	O
for	O
2	O
consecutive	O
days	O
every	O
2	O
weeks,	O
either	O
alone	O
or	O
together	O
with	O
oxaliplatin	O
85	O
mg/m(2)	O
as	O
a	O
2-hour	O
infusion	O
on	O
day	O
1.	O

Patients	B-Premise
allocated	I-Premise
to	I-Premise
oxaliplatin	I-Premise
plus	I-Premise
LV5FU2	I-Premise
had	I-Premise
significantly	I-Premise
longer	I-Premise
progression-free	I-Premise
survival	I-Premise
(median,	I-Premise
9.0	I-Premise
v	I-Premise
6.2	I-Premise
months;	I-Premise
P	I-Premise
=.0003)	I-Premise
and	I-Premise
better	I-Premise
response	I-Premise
rate	I-Premise
(50.7%	I-Premise
v	I-Premise
22.3%;	I-Premise
P	I-Premise
=.0001)	I-Premise
when	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
control	I-Premise
arm.	I-Premise

The	B-Premise
improvement	I-Premise
in	I-Premise
overall	I-Premise
survival	I-Premise
did	I-Premise
not	I-Premise
reach	I-Premise
significance	I-Premise
(median,	I-Premise
16.2	I-Premise
v	I-Premise
14.7	I-Premise
months;	I-Premise
P	I-Premise
=.	I-Premise
12).	I-Premise

LV5FU2	B-Premise
plus	I-Premise
oxaliplatin	I-Premise
gave	I-Premise
higher	I-Premise
frequencies	I-Premise
of	I-Premise
National	I-Premise
Cancer	I-Premise
Institute	I-Premise
common	I-Premise
toxicity	I-Premise
criteria	I-Premise
grade	I-Premise
3/4	I-Premise
neutropenia	I-Premise
(41.	I-Premise
7%	I-Premise
v	I-Premise
5.3%	I-Premise
of	I-Premise
patients),	I-Premise
grade	I-Premise
3/4	I-Premise
diarrhea	I-Premise
(11.9%	I-Premise
v	I-Premise
5.3%),	I-Premise
and	I-Premise
grade	I-Premise
3	I-Premise
neurosensory	I-Premise
toxicity	I-Premise
(18.2%	I-Premise
v	I-Premise
0%),	I-Premise
but	I-Premise
this	I-Premise
did	I-Premise
not	I-Premise
result	I-Premise
in	I-Premise
impairment	I-Premise
of	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(QoL).	I-Premise

Survival	B-Premise
without	I-Premise
disease	I-Premise
progression	I-Premise
or	I-Premise
deterioration	I-Premise
in	I-Premise
global	I-Premise
health	I-Premise
status	I-Premise
was	I-Premise
longer	I-Premise
in	I-Premise
patients	I-Premise
allocated	I-Premise
to	I-Premise
oxaliplatin	I-Premise
treatment	I-Premise
(P	I-Premise
=.004).	I-Premise

The	B-Claim
LV5FU2-oxaliplatin	I-Claim
combination	I-Claim
seems	I-Claim
beneficial	I-Claim
as	I-Claim
first-line	I-Claim
therapy	I-Claim
in	I-Claim
advanced	I-Claim
colorectal	I-Claim
cancer,	I-Claim
demonstrating	I-Claim
a	I-Claim
prolonged	I-Claim
progression-free	I-Claim
survival	I-Claim
with	I-Claim
acceptable	I-Claim
tolerability	I-Claim
and	I-Claim
maintenance	I-Claim
of	I-Claim
QoL.	I-Claim

A	O
randomized	O
phase	O
III	O
trial	O
was	O
conducted	O
to	O
determine	O
whether	O
combination	O
therapy	O
with	O
13-cis-retinoic	O
acid	O
(13-CRA)	O
plus	O
interferon	O
alfa-2a	O
(IFNalpha2a)	O
is	O
superior	O
to	O
IFNalpha2a	O
alone	O
in	O
patients	O
with	O
advanced	O
renal	O
cell	O
carcinoma	O
(RCC).	O

Two	O
hundred	O
eighty-four	O
patients	O
were	O
randomized	O
to	O
treatment	O
with	O
IFNalpha2a	O
plus	O
13-CRA	O
or	O
treatment	O
with	O
IFNalpha2a	O
alone.	O

IFNalpha2a	O
was	O
given	O
daily	O
subcutaneously,	O
starting	O
at	O
a	O
dose	O
of	O
3	O
million	O
units	O
(MU).	O

The	O
dose	O
was	O
escalated	O
every	O
7	O
days	O
from	O
3	O
to	O
9	O
MU	O
(by	O
increments	O
of	O
3	O
MU),	O
unless	O
>/=	O
grade	O
2	O
toxicity	O
occurred,	O
in	O
which	O
case	O
dose	O
escalation	O
was	O
stopped.	O

Patients	O
randomized	O
to	O
combination	O
therapy	O
were	O
given	O
oral	O
13-CRA	O
1	O
mg/kg/d	O
plus	O
IFNalpha2a.	O

Quality	O
of	O
life	O
(QOL)	O
was	O
assessed.	O

Complete	B-Premise
or	I-Premise
partial	I-Premise
responses	I-Premise
were	I-Premise
achieved	I-Premise
by	I-Premise
12%	I-Premise
of	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
IFNalpha2a	I-Premise
plus	I-Premise
13-CRA	I-Premise
and	I-Premise
6%	I-Premise
of	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
IFNalpha2a	I-Premise
(P	I-Premise
=.14).	I-Premise

Median	B-Premise
duration	I-Premise
of	I-Premise
response	I-Premise
(complete	I-Premise
and	I-Premise
partial	I-Premise
combined)	I-Premise
in	I-Premise
the	I-Premise
group	I-Premise
treated	I-Premise
with	I-Premise
the	I-Premise
combination	I-Premise
was	I-Premise
33	I-Premise
months	I-Premise
(range,	I-Premise
9	I-Premise
to	I-Premise
50	I-Premise
months),	I-Premise
versus	I-Premise
22	I-Premise
months	I-Premise
(range,	I-Premise
5	I-Premise
to	I-Premise
38	I-Premise
months)	I-Premise
for	I-Premise
the	I-Premise
second	I-Premise
group	I-Premise
(P	I-Premise
=.03).	I-Premise

Nineteen	B-Premise
percent	I-Premise
of	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
IFNalpha2a	I-Premise
plus	I-Premise
13-CRA	I-Premise
were	I-Premise
progression-free	I-Premise
at	I-Premise
24	I-Premise
months,	I-Premise
compared	I-Premise
with	I-Premise
10%	I-Premise
of	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
IFNalpha2a	I-Premise
alone	I-Premise
(P	I-Premise
=.05).	I-Premise

Median	B-Premise
survival	I-Premise
time	I-Premise
for	I-Premise
all	I-Premise
patients	I-Premise
was	I-Premise
15	I-Premise
months,	I-Premise
with	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
survival	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
treatment	I-Premise
arms	I-Premise
(P	I-Premise
=.26).	I-Premise

QOL	B-Premise
decreased	I-Premise
during	I-Premise
the	I-Premise
first	I-Premise
8	I-Premise
weeks	I-Premise
of	I-Premise
treatment,	I-Premise
and	I-Premise
a	I-Premise
partial	I-Premise
recovery	I-Premise
followed.	I-Premise

Lower	B-Premise
scores	I-Premise
were	I-Premise
associated	I-Premise
with	I-Premise
the	I-Premise
combination	I-Premise
therapy.	I-Premise

Response	B-Claim
proportion	I-Claim
and	I-Claim
survival	I-Claim
did	I-Claim
not	I-Claim
improve	I-Claim
significantly	I-Claim
with	I-Claim
the	I-Claim
addition	I-Claim
of	I-Claim
13-CRA	I-Claim
to	I-Claim
IFNalpha2a	I-Claim
therapy	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
RCC.	I-Claim

13-CRA	B-Claim
may	I-Claim
lengthen	I-Claim
response	I-Claim
to	I-Claim
IFNalpha2a	I-Claim
therapy	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
IFNalpha2a-sensitive	I-Claim
tumors.	I-Claim

Treatment,	B-Claim
particularly	I-Claim
the	I-Claim
combination	I-Claim
therapy,	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
a	I-Claim
decrease	I-Claim
in	I-Claim
QOL.	I-Claim

Postoperative	B-Claim
adjuvant	I-Claim
chemoradiation	I-Claim
treatment	I-Claim
after	I-Claim
curative	I-Claim
resection	I-Claim
for	I-Claim
rectal	I-Claim
cancer	I-Claim
was	I-Claim
needed	I-Claim
to	I-Claim
reduce	I-Claim
recurrence	I-Claim
and	I-Claim
improve	I-Claim
a	I-Claim
survival	I-Claim
rate.	I-Claim

Intravenous	B-Claim
5-fluorouracil	I-Claim
(5-FU)	I-Claim
and	I-Claim
leucovorin	I-Claim
has	I-Claim
been	I-Claim
a	I-Claim
mainstay	I-Claim
of	I-Claim
chemotherapy,	I-Claim
but	O
oral	B-Claim
5-FU	I-Claim
derivatives	I-Claim
have	I-Claim
been	I-Claim
shown	I-Claim
a	I-Claim
comparable	I-Claim
antitumor	I-Claim
activity.	I-Claim

Intravenous	O
5-FU	O
and	O
oral	O
doxifluridine	O
were	O
compared	O
with	O
respect	O
to	O
therapeutic	O
efficacy,	O
drug	O
toxicity,	O
and	O
quality	O
of	O
life.	O

A	O
total	O
of	O
166	O
patients	O
were	O
randomized	O
to	O
receive	O
intravenous	O
5-FU	O
(450	O
mg/m2/day)	O
or	O
oral	O
doxifluridine	O
(900	O
mg/m2/day)	O
in	O
combination	O
with	O
leucovorin	O
(20	O
mg/m2/day)	O
for	O
depth	O
of	O
invasion,	O
nodal	O
status,	O
metastasis	O
(TNM)	O
stage	O
II	O
and	O
III	O
patients	O
between	O
October	O
1997	O
and	O
February	O
1999.	O

Consecutive	O
daily	O
intravenous	O
infusion	O
for	O
5	O
days	O
per	O
every	O
month	O
for	O
a	O
total	O
of	O
12	O
cycles	O
(IV	O
arm,	O
n	O
=	O
74)	O
and	O
oral	O
doxifluridine	O
daily	O
for	O
3	O
weeks	O
and	O
1	O
week	O
rest	O
for	O
a	O
total	O
of	O
12	O
cycles	O
(oral	O
arm,	O
n	O
=	O
92).	O

Drug	O
toxicity	O
and	O
quality	O
of	O
life	O
were	O
observed.	O

Quality	O
of	O
life	O
was	O
scored	O
according	O
to	O
22	O
daily	O
activity	O
items	O
(good,	O
>	O
or	O
=71;	O
fair,	O
<	O
70;	O
poor,	O
<	O
52).	O

There	O
was	O
no	O
difference	O
of	O
sex	O
between	O
two	O
groups	O
(IV	O
arm:	O
male/female	O
=	O
45/29,	O
oral	O
arm:	O
male/female	O
=	O
59/33).	O

The	O
mean	O
age	O
was	O
52.3	O
vs.	O
59.5,	O
respectively.	O

There	O
was	O
also	O
no	O
difference	O
of	O
TNM	O
stage	O
distribution	O
and	O
type	O
of	O
operation	O
between	O
groups	O
(P>.05).	O

Mean	B-Premise
numbers	I-Premise
of	I-Premise
chemotherapy	I-Premise
cycles	I-Premise
were	I-Premise
6.5+/-3.7	I-Premise
(IV	I-Premise
arm)	I-Premise
vs.	I-Premise
7.2+/-4.3	I-Premise
(oral	I-Premise
arm),	I-Premise
respectively.	I-Premise

The	B-Premise
rate	I-Premise
of	I-Premise
recurrence	I-Premise
was	I-Premise
9/74	I-Premise
(12.1%)	I-Premise
in	I-Premise
the	I-Premise
IV	I-Premise
arm	I-Premise
and	I-Premise
6/92	I-Premise
(6.5	I-Premise
%)	I-Premise
in	I-Premise
the	I-Premise
oral	I-Premise
arm,	I-Premise
respectively	I-Premise
(P	I-Premise
=	I-Premise
.937).	I-Premise

Local	B-Premise
recurrence	I-Premise
was	I-Premise
2/74	I-Premise
(stage	I-Premise
III;	I-Premise
2.7%)	I-Premise
in	I-Premise
the	I-Premise
IV	I-Premise
arm	I-Premise
and	I-Premise
1/92	I-Premise
(stage	I-Premise
II;	I-Premise
1.1%)	I-Premise
in	I-Premise
the	I-Premise
oral	I-Premise
arm,	I-Premise
respectively.	I-Premise

Systemic	B-Premise
recurrence	I-Premise
was	I-Premise
7/74	I-Premise
(stage	I-Premise
III;	I-Premise
9.4%)	I-Premise
in	I-Premise
the	I-Premise
IV	I-Premise
arm	I-Premise
and	I-Premise
5/92	I-Premise
(stage	I-Premise
III;	I-Premise
5.4%)	I-Premise
in	I-Premise
the	I-Premise
oral	I-Premise
arm,	I-Premise
respectively.	I-Premise

The	B-Premise
most	I-Premise
common	I-Premise
site	I-Premise
of	I-Premise
systemic	I-Premise
recurrence	I-Premise
was	I-Premise
the	I-Premise
liver.	I-Premise

Toxicity	B-Premise
profile	I-Premise
was	I-Premise
as	I-Premise
follows:	I-Premise
leukopenia	I-Premise
(30/74	I-Premise
vs.	I-Premise
17/92)	I-Premise
and	I-Premise
alopecia	I-Premise
(21/74	I-Premise
vs.	I-Premise
13/92)	I-Premise
were	I-Premise
statistically	I-Premise
more	I-Premise
common	I-Premise
in	I-Premise
the	I-Premise
IV	I-Premise
arm.	I-Premise

Diarrhea	B-Premise
was	I-Premise
more	I-Premise
common	I-Premise
in	I-Premise
the	I-Premise
oral	I-Premise
arm.	I-Premise

Poor	B-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
score	I-Premise
between	I-Premise
two	I-Premise
groups	I-Premise
was	I-Premise
observed	I-Premise
at	I-Premise
1	I-Premise
month	I-Premise
(23.9%	I-Premise
vs.	I-Premise
13%)	I-Premise
and	I-Premise
2	I-Premise
months	I-Premise
(15.8%	I-Premise
vs.	I-Premise
3.7%)	I-Premise
after	I-Premise
chemotherapy.	I-Premise

Good	B-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
score	I-Premise
was	I-Premise
observed	I-Premise
at	I-Premise
1	I-Premise
month	I-Premise
(19.5%	I-Premise
vs.	I-Premise
49%)	I-Premise
and	I-Premise
2	I-Premise
months	I-Premise
(47%	I-Premise
vs.	I-Premise
72%),	I-Premise
respectively	I-Premise
(P<.05).	I-Premise

Oral	B-Claim
doxifluridine	I-Claim
with	I-Claim
leucovorin	I-Claim
shows	I-Claim
a	I-Claim
comparable	I-Claim
therapeutic	I-Claim
efficacy	I-Claim
to	I-Claim
intravenous	I-Claim
5-FU	I-Claim
regimen	I-Claim
with	I-Claim
high	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
as	I-Claim
postoperative	I-Claim
adjuvant	I-Claim
therapy.	I-Claim

The	B-Claim
oral	I-Claim
regimen	I-Claim
also	I-Claim
can	I-Claim
be	I-Claim
safely	I-Claim
given	I-Claim
with	I-Claim
appropriate	I-Claim
toxicity	I-Claim
and	I-Claim
tolerability.	I-Claim

The	O
aim	O
of	O
this	O
randomised	O
trial	O
was	O
to	O
evaluate	O
the	O
activity	O
and	O
toxicity	O
of	O
a	O
biweekly	O
regimen	O
including	O
6S-leucovorin-modulated	O
5-fluorouracil	O
(LFA-5-FU),	O
combined	O
with	O
either	O
irinotecan	O
(CPT-11	O
+	O
LFA	O
5-FU)	O
or	O
raltitrexed	O
(Tomudex)	O
(TOM	O
+	O
LFA-5-FU),	O
in	O
advanced	O
colorectal	O
cancer	O
patients,	O
and	O
to	O
make	O
a	O
preliminary	O
comparison	O
of	O
both	O
these	O
experimental	O
regimens	O
with	O
a	O
biweekly	O
administration	O
of	O
LFA-5-FU	O
modulated	O
by	O
methotrexate	O
(MTX	O
+	O
LFA-5-FU).	O

One	O
hundred	O
fifty-nine	O
patients	O
with	O
advanced	O
colorectal	O
carcinoma	O
previously	O
untreated	O
for	O
the	O
metastatic	O
disease	O
(34	O
of	O
them	O
previously	O
exposed	O
to	O
adjuvant	O
5-FU)	O
were	O
randomly	O
allocated	O
to	O
receive:	O
CPT-11,	O
200	O
mg/m2	O
i.v.	O
on	O
day	O
1,	O
followed	O
on	O
day	O
2	O
by	O
LFA,	O
250	O
mg/m2	O
i.v.	O
infusion	O
and	O
5-FU,	O
850	O
mg/m2	O
s	O
i.v.	O
bolus	O
(arm	O
A);	O
TOM,	O
3	O
mg/m2	O
i.v.	O
on	O
day	O
1,	O
followed	O
on	O
day	O
2	O
by	O
LFA,	O
250	O
mg/m2	O
i.v.	O
infusion	O
and	O
5-FU,	O
1050	O
mg/m2	O
i.v.	O
bolus	O
(arm	O
B);	O
or	O
MTX,	O
750	O
mg/m2	O
i.v.	O
on	O
day	O
1,	O
followed	O
on	O
day	O
2	O
by	O
LFA,	O
250	O
mg/m2	O
i.v.	O
infusion	O
and	O
5-FU,	O
800	O
mg/m2	O
i.v.	O
bolus	O
(arm	O
C).	O

Courses	O
were	O
repeated	O
every	O
two	O
weeks	O
in	O
all	O
arms	O
of	O
the	O
trial.	O

Response	O
rate	O
(RR)	O
was	O
evaluated	O
after	O
every	O
four	O
courses.	O

The	O
sample	O
size	O
was	O
defined	O
to	O
have	O
an	O
80%	O
power	O
to	O
detect	O
a	O
35%	O
RR	O
for	O
each	O
experimental	O
treatment,	O
and	O
to	O
show	O
a	O
difference	O
of	O
at	O
least	O
4%	O
in	O
RR	O
with	O
the	O
standard	O
treatment	O
if	O
the	O
true	O
difference	O
is	O
15%	O
or	O
more.	O

The	O
RRs	O
were:	O
34%	O
(95%	O
confidence	O
interval	O
(95%,	O
CI):	O
21%-48%)	O
in	O
arm	O
A,	O
including	O
3	O
complete	O
responses	O
(CRs)	O
and	O
15	O
partial	O
responses	O
(PRs),	O
24%	O
(95%	O
CI:	O
14%-38%)	O
in	O
arm	O
B,	O
including	O
2	O
CRs	O
and	O
11	O
PRs,	O
and	O
24%	O
(95%	O
CI:	O
14%-38%),	O
with	O
2	O
CRs	O
and	O
11	O
PRs,	O
in	O
arm	O
C.	O

After	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
time	I-Premise
of	I-Premise
62	I-Premise
(range	I-Premise
18-108)	I-Premise
weeks,	I-Premise
the	I-Premise
median	I-Premise
time	I-Premise
to	I-Premise
progression	I-Premise
was	I-Premise
38,	I-Premise
25,	I-Premise
and	I-Premise
27	I-Premise
weeks	I-Premise
for	I-Premise
arm	I-Premise
A,	I-Premise
B,	I-Premise
and	I-Premise
C,	I-Premise
respectively.	I-Premise

With	B-Premise
94	I-Premise
patients	I-Premise
still	I-Premise
alive,	I-Premise
the	I-Premise
one-year	I-Premise
probability	I-Premise
of	I-Premise
survival	I-Premise
was	I-Premise
61%,	I-Premise
54%,	I-Premise
and	I-Premise
59%,	I-Premise
respectively.	I-Premise

WHO	B-Premise
grade	I-Premise
3	I-Premise
or	I-Premise
4	I-Premise
neutropenia	I-Premise
and	I-Premise
diarrhoea	I-Premise
affected	I-Premise
46%	I-Premise
and	I-Premise
16%,	I-Premise
respectively,	I-Premise
of	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
CPT-11	I-Premise
+	I-Premise
LFA	I-Premise
5-FU.	I-Premise

Median	B-Premise
relative	I-Premise
dose	I-Premise
intensity	I-Premise
over	I-Premise
eight	I-Premise
cycles	I-Premise
(DI8)	I-Premise
was	I-Premise
78%	I-Premise
for	I-Premise
CPT-11	I-Premise
and	I-Premise
82%	I-Premise
for	I-Premise
5-FU.	I-Premise

Severe	B-Premise
toxicities	I-Premise
of	I-Premise
TOM	I-Premise
+	I-Premise
LFA-5-FU	I-Premise
were	I-Premise
neutropenia	I-Premise
(16%)	I-Premise
and	I-Premise
diarrhoea	I-Premise
(16%),	I-Premise
but	I-Premise
median	I-Premise
relative	I-Premise
DI8	I-Premise
was	I-Premise
93%	I-Premise
for	I-Premise
TOM,	I-Premise
and	I-Premise
82%	I-Premise
for	I-Premise
5-FU.	I-Premise

CPT-11	B-Premise
+	I-Premise
LFA-5-FU	I-Premise
compares	I-Premise
favorably	I-Premise
in	I-Premise
term	I-Premise
of	I-Premise
activity	I-Premise
and	I-Premise
toxicity	I-Premise
with	I-Premise
other	I-Premise
combination	I-Premise
regimens	I-Premise
including	I-Premise
CPT-11	I-Premise
and	I-Premise
continuous	I-Premise
infusional	I-Premise
5-FU.	I-Premise

The	B-Claim
hypothesis	I-Claim
of	I-Claim
a	I-Claim
RR	I-Claim
15%	I-Claim
higher	I-Claim
than	I-Claim
the	I-Claim
MTX	I-Claim
+	I-Claim
LFA-5-FU	I-Claim
treatment	I-Claim
can	I-Claim
not	I-Claim
be	I-Claim
ruled	I-Claim
out	I-Claim
after	I-Claim
this	I-Claim
interim	I-Claim
analysis.	I-Claim

The	B-Claim
TOM	I-Claim
+	I-Claim
LFA	I-Claim
5-FU	I-Claim
regimen	I-Claim
showed	I-Claim
a	I-Claim
RR	I-Claim
and	I-Claim
a	I-Claim
toxicity	I-Claim
profile	I-Claim
very	I-Claim
close	I-Claim
to	I-Claim
the	I-Claim
MTX	I-Claim
+	I-Claim
LFA	I-Claim
5-FU	I-Claim
combination,	I-Claim
and	I-Claim
does	I-Claim
not	I-Claim
deserve	I-Claim
further	I-Claim
evaluation	I-Claim
in	I-Claim
advanced	I-Claim
colorectal	I-Claim
cancer	I-Claim
patients.	I-Claim

We	O
have	O
recently	O
suggested	O
that	O
bolus	O
5-fluorouracil	O
(5-FU)	O
may	O
work	O
via	O
a	O
RNA	O
directed	O
mechanism	O
while	O
continuous	O
infusion	O
5-FU	O
may	O
kill	O
cells	O
via	O
a	O
thymidylate	O
synthase	O
related	O
pathway.	O

It	O
may	O
thus	O
be	O
possible	O
to	O
selectively	O
modulate	O
each	O
schedule	O
biochemically.	O

We	O
have	O
compared	O
an	O
alternating	O
regimen	O
of	O
bolus	O
and	O
continuous	O
infusion	O
5-FU,	O
selectively	O
modulated	O
for	O
the	O
schedule	O
of	O
administration,	O
with	O
modulated	O
bolus	O
5-FU	O
in	O
advanced	O
colorectal	O
cancer	O
patients.	O

Two	O
hundred	O
fourteen	O
patients	O
from	O
nineteen	O
Italian	O
centers	O
were	O
randomized	O
to	O
the	O
control	O
arm	O
consisting	O
of	O
biweekly	O
cycles	O
of	O
MTX,	O
200	O
mg/m2	O
on	O
day	O
1,	O
followed	O
by	O
bolus	O
5-FU	O
600	O
mg/m2	O
on	O
day	O
2	O
and	O
6-S-leucovorin	O
rescue,	O
or	O
to	O
the	O
experimental	O
arm	O
consisting	O
of	O
two	O
biweekly	O
cycles	O
of	O
the	O
same	O
regimen	O
as	O
in	O
the	O
control	O
arm	O
alternated	O
to	O
three	O
weeks	O
of	O
continuous	O
infusion	O
5-FU	O
(200	O
mg/m2	O
day)	O
+	O
weekly	O
bolus	O
6-S-leucovorin,	O
20	O
mg/m2.	O

Nine	B-Premise
CR	I-Premise
and	I-Premise
twenty-seven	I-Premise
PR	I-Premise
were	I-Premise
obtained	I-Premise
on	I-Premise
one	I-Premise
hundred	I-Premise
eleven	I-Premise
evaluable	I-Premise
patients	I-Premise
treated	I-Premise
in	I-Premise
experimental	I-Premise
arm	I-Premise
(RR	I-Premise
=	I-Premise
32%,	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
(95%	I-Premise
CI):	I-Premise
24%-42%),	I-Premise
while	I-Premise
two	I-Premise
CR	I-Premise
and	I-Premise
eleven	I-Premise
PR	I-Premise
were	I-Premise
observed	I-Premise
among	I-Premise
one	I-Premise
hundred	I-Premise
three	I-Premise
evaluable	I-Premise
patients	I-Premise
in	I-Premise
control	I-Premise
arm	I-Premise
(RR	I-Premise
=	I-Premise
13%,	I-Premise
95%	I-Premise
CI:	I-Premise
7%-21%).	I-Premise

WHO	B-Premise
grade	I-Premise
3-4	I-Premise
toxicity	I-Premise
occurred	I-Premise
in	I-Premise
13%	I-Premise
of	I-Premise
cycles	I-Premise
of	I-Premise
experimental	I-Premise
arm	I-Premise
and	I-Premise
in	I-Premise
8%	I-Premise
of	I-Premise
cycles	I-Premise
in	I-Premise
control	I-Premise
arm.	I-Premise

The	B-Premise
PFS	I-Premise
was	I-Premise
significantly	I-Premise
longer	I-Premise
in	I-Premise
experimental	I-Premise
arm	I-Premise
(6.2	I-Premise
vs.	I-Premise
4.3	I-Premise
months,	I-Premise
odds	I-Premise
ratio	I-Premise
0.66,	I-Premise
P	I-Premise
=	I-Premise
0.003),	I-Premise
while	O
the	B-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
similar	I-Premise
in	I-Premise
both	I-Premise
arms	I-Premise
(14.8	I-Premise
months	I-Premise
in	I-Premise
experimental	I-Premise
arm	I-Premise
vs.	I-Premise
14.1	I-Premise
months	I-Premise
in	I-Premise
control	I-Premise
arm);	I-Premise
quality	B-Claim
of	I-Claim
life	I-Claim
was	I-Claim
similar	I-Claim
as	I-Claim
well.	I-Claim

Eighty	B-Premise
percent	I-Premise
of	I-Premise
patients	I-Premise
receiving	I-Premise
second-line	I-Premise
chemotherapy	I-Premise
in	I-Premise
control	I-Premise
arm	I-Premise
were	I-Premise
treated	I-Premise
with	I-Premise
continuous	I-Premise
infusion	I-Premise
5-FU.	I-Premise

Alternating,	O
schedule-specific	B-Claim
biochemical	I-Claim
modulation	I-Claim
of	I-Claim
FU	I-Claim
is	I-Claim
more	I-Claim
active	I-Claim
than	I-Claim
MTX	I-Claim
-->	I-Claim
5-FU	I-Claim
as	I-Claim
first-line	I-Claim
treatment	I-Claim
of	I-Claim
advanced	I-Claim
colorectal	I-Claim
cancer.	I-Claim

However,	B-Claim
the	I-Claim
overall	I-Claim
survival	I-Claim
was	I-Claim
similar	I-Claim
suggesting	I-Claim
that	I-Claim
alternating	I-Claim
bolus	I-Claim
and	I-Claim
infusional	I-Claim
5-FU	I-Claim
upfront	I-Claim
may	I-Claim
be	I-Claim
as	I-Claim
effective	I-Claim
as	I-Claim
giving	I-Claim
them	I-Claim
in	I-Claim
sequence	I-Claim
as	I-Claim
first-	I-Claim
and	I-Claim
second-line	I-Claim
treatment.	I-Claim

The	B-Claim
combination	I-Claim
of	I-Claim
etoposide	I-Claim
plus	I-Claim
cisplatin	I-Claim
(EP)	I-Claim
is	I-Claim
considered	I-Claim
to	I-Claim
be	I-Claim
standard	I-Claim
therapy	I-Claim
for	I-Claim
small-cell	I-Claim
lung	I-Claim
cancer	I-Claim
(SCLC).	I-Claim

To	O
determine	O
whether	O
drug	O
intensification	O
improves	O
survival	O
of	O
patients	O
with	O
extensive	O
SCLC,	O
we	O
compared	O
this	O
treatment	O
with	O
a	O
four-drug	O
regimen	O
containing	O
EP	O
plus	O
cyclophosphamide	O
and	O
4'-epidoxorubicin	O
(PCDE).	O

In	O
a	O
phase	O
III	O
clinical	O
trial	O
organized	O
by	O
the	O
French	O
Federation	O
of	O
Cancer	O
Institutes,	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
EP	O
(n	O
=	O
109;	O
etoposide	O
at	O
a	O
dose	O
of	O
100	O
mg/m(2)	O
on	O
days	O
1-3	O
plus	O
cisplatin	O
at	O
100	O
mg/m(2)	O
on	O
day	O
2)	O
or	O
PCDE	O
(n	O
=	O
117;	O
etoposide	O
and	O
cisplatin	O
given	O
as	O
in	O
EP	O
plus	O
cyclophosphamide	O
at	O
400	O
mg/m(2)	O
on	O
days	O
1-3	O
and	O
4'-epidoxorubicin	O
at	O
40	O
mg/m(2)	O
on	O
day	O
1)	O
every	O
4	O
weeks.	O

Both	O
groups	O
received	O
a	O
total	O
of	O
six	O
cycles.	O

Survival	O
differences	O
were	O
analyzed	O
by	O
Wilcoxon	O
and	O
log-rank	O
tests.	O

Associations	O
of	O
treatment	O
group	O
and	O
putative	O
prognostic	O
variables	O
with	O
survival	O
were	O
tested	O
in	O
the	O
Cox	O
proportional	O
hazards	O
model.	O

Quality	O
of	O
life	O
was	O
assessed	O
from	O
the	O
responses	O
to	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
quality-of-life	O
questionnaire	O
(C30,	O
health	O
status	O
and	O
lung	O
cancer	O
module	O
13).	O

All	O
statistical	O
tests	O
were	O
two-sided.	O

Patients	B-Premise
in	I-Premise
the	I-Premise
PCDE	I-Premise
arm	I-Premise
had	I-Premise
a	I-Premise
statistically	I-Premise
significant	I-Premise
higher	I-Premise
frequency	I-Premise
of	I-Premise
combined	I-Premise
complete	I-Premise
plus	I-Premise
partial	I-Premise
responses	I-Premise
compared	I-Premise
with	I-Premise
those	I-Premise
in	I-Premise
the	I-Premise
EP	I-Premise
arm	I-Premise
(21%	I-Premise
plus	I-Premise
55%	I-Premise
versus	I-Premise
13%	I-Premise
plus	I-Premise
48%,	I-Premise
respectively;	I-Premise
P	I-Premise
=.02	I-Premise
for	I-Premise
difference	I-Premise
in	I-Premise
combined	I-Premise
objective	I-Premise
responses).	I-Premise

Patients	B-Premise
in	I-Premise
the	I-Premise
PCDE	I-Premise
arm	I-Premise
survived	I-Premise
longer	I-Premise
than	I-Premise
those	I-Premise
in	I-Premise
the	I-Premise
EP	I-Premise
arm	I-Premise
(1-year	I-Premise
survival	I-Premise
rate:	I-Premise
40%	I-Premise
and	I-Premise
29%,	I-Premise
respectively;	I-Premise
median	I-Premise
survival:	I-Premise
10.5	I-Premise
and	I-Premise
9.3	I-Premise
months,	I-Premise
respectively;	I-Premise
log-rank	I-Premise
P	I-Premise
=.0067).	I-Premise

In	B-Premise
the	I-Premise
Cox	I-Premise
model,	I-Premise
the	I-Premise
relative	I-Premise
risk	I-Premise
of	I-Premise
death	I-Premise
for	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
PCDE	I-Premise
arm	I-Premise
compared	I-Premise
with	I-Premise
those	I-Premise
in	I-Premise
the	I-Premise
EP	I-Premise
arm	I-Premise
was	I-Premise
0.70	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
=	I-Premise
0.51	I-Premise
to	I-Premise
0.95);	I-Premise
the	B-Premise
disease	I-Premise
also	I-Premise
progressed	I-Premise
more	I-Premise
slowly	I-Premise
in	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
PCDE	I-Premise
arm.	I-Premise

Hematologic	B-Premise
toxicity	I-Premise
was	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
PCDE	I-Premise
arm	I-Premise
(22%	I-Premise
with	I-Premise
documented	I-Premise
infections	I-Premise
compared	I-Premise
with	I-Premise
8%	I-Premise
in	I-Premise
the	I-Premise
EP	I-Premise
arm;	I-Premise
P	I-Premise
=.0038),	I-Premise
and	O
the	B-Premise
toxicity-related	I-Premise
death	I-Premise
rate	I-Premise
was	I-Premise
9%	I-Premise
in	I-Premise
the	I-Premise
PCDE	I-Premise
arm	I-Premise
versus	I-Premise
5.5%	I-Premise
in	I-Premise
the	I-Premise
EP	I-Premise
arm	I-Premise
(P	I-Premise
=.22).	I-Premise

The	B-Claim
global	I-Claim
health	I-Claim
status	I-Claim
showed	I-Claim
similar	I-Claim
improvement	I-Claim
in	I-Claim
both	I-Claim
arms	I-Claim
during	I-Claim
treatment.	I-Claim

Compared	B-Claim
with	I-Claim
the	I-Claim
EP	I-Claim
regimen,	I-Claim
the	I-Claim
PCDE	I-Claim
regimen	I-Claim
yielded	I-Claim
higher	I-Claim
response	I-Claim
rates	I-Claim
and	I-Claim
better	I-Claim
survival	I-Claim
rates	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
extensive	I-Claim
SCLC	I-Claim
without	I-Claim
affecting	I-Claim
the	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
of	I-Claim
the	I-Claim
patients	I-Claim
during	I-Claim
chemotherapy.	I-Claim

To	O
test	O
the	O
equivalence	O
of	O
three	O
versus	O
four	O
cycles	O
of	O
bleomycin,	O
etoposide,	O
and	O
cisplatin	O
(BEP)	O
and	O
of	O
the	O
5-day	O
schedule	O
versus	O
3	O
days	O
per	O
cycle	O
in	O
good-prognosis	O
germ	O
cell	O
cancer.	O

The	O
study	O
was	O
designed	O
as	O
a	O
2	O
x	O
2	O
factorial	O
trial.	O

The	O
aim	O
was	O
to	O
rule	O
out	O
a	O
5%	O
decrease	O
in	O
the	O
2-year	O
progression-free	O
survival	O
(PFS)	O
rate.	O

The	O
study	O
included	O
the	O
assessment	O
of	O
patient	O
quality	O
of	O
life.	O

A	O
cycle	O
of	O
BEP	O
consisted	O
of	O
etoposide	O
500	O
mg/m(2),	O
administered	O
at	O
either	O
100	O
mg/m(2)	O
days	O
1	O
through	O
5	O
or	O
165	O
mg/m(2)	O
days	O
1	O
through	O
3,	O
cisplatin	O
100	O
mg/m(2),	O
administered	O
at	O
either	O
20	O
mg/m(2)	O
days	O
1	O
through	O
5	O
or	O
50	O
mg/m(2)	O
days	O
1	O
and	O
2.	O

Bleomycin	O
30	O
mg	O
was	O
administered	O
on	O
days	O
1,	O
8,	O
and	O
15	O
during	O
cycles	O
1	O
through	O
3.	O

The	O
randomization	O
procedure	O
allowed	O
some	O
investigators	O
to	O
participate	O
only	O
in	O
the	O
comparison	O
of	O
three	O
versus	O
four	O
cycles.	O

From	O
March	O
1995	O
until	O
April	O
1998,	O
812	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
three	O
or	O
four	O
cycles:	O
of	O
these,	O
681	O
were	O
also	O
randomly	O
assigned	O
to	O
the	O
5-day	O
or	O
the	O
3-day	O
schedule.	O

Histology,	O
marker	O
values,	O
and	O
disease	O
extent	O
are	O
well	O
balanced	O
in	O
the	O
treatment	O
arms	O
of	O
the	O
two	O
comparisons.	O

The	B-Premise
projected	I-Premise
2-year	I-Premise
PFS	I-Premise
is	I-Premise
90.4%	I-Premise
on	I-Premise
three	I-Premise
cycles	I-Premise
and	I-Premise
89.4%	I-Premise
on	I-Premise
four	I-Premise
cycles.	I-Premise

The	B-Premise
difference	I-Premise
in	I-Premise
PFS	I-Premise
between	I-Premise
three	I-Premise
and	I-Premise
four	I-Premise
cycles	I-Premise
is	I-Premise
-1.0%	I-Premise
(80%	I-Premise
confidence	I-Premise
limit	I-Premise
[CL],	I-Premise
-3.8%,	I-Premise
+1.8%).	I-Premise

Equivalence	B-Claim
for	I-Claim
three	I-Claim
versus	I-Claim
four	I-Claim
cycles	I-Claim
is	I-Claim
claimed	I-Claim
because	I-Claim
both	I-Claim
the	I-Claim
upper	I-Claim
and	I-Claim
lower	I-Claim
bounds	I-Claim
of	I-Claim
the	I-Claim
80%	I-Claim
CL	I-Claim
are	I-Claim
less	I-Claim
than	I-Claim
5%.	I-Claim

In	B-Premise
the	I-Premise
5-	I-Premise
versus	I-Premise
3-day	I-Premise
comparison,	I-Premise
the	I-Premise
projected	I-Premise
2-year	I-Premise
PFS	I-Premise
is	I-Premise
88.8%	I-Premise
and	I-Premise
89.7%,	I-Premise
respectively	I-Premise
(difference,	I-Premise
-0.9%,	I-Premise
(80%	I-Premise
CL,	I-Premise
-4.1%,	I-Premise
+2.2%).	I-Premise

Hence,	O
equivalence	B-Claim
is	I-Claim
claimed	I-Claim
in	I-Claim
this	I-Claim
comparison	I-Claim
also.	I-Claim

Frequencies	B-Premise
of	I-Premise
hematologic	I-Premise
and	I-Premise
nonhematologic	I-Premise
toxicities	I-Premise
were	I-Premise
essentially	I-Premise
similar.	I-Premise

Quality	B-Premise
of	I-Premise
life	I-Premise
was	I-Premise
maintained	I-Premise
better	I-Premise
in	I-Premise
patients	I-Premise
receiving	I-Premise
three	I-Premise
cycles;	I-Premise
no	B-Premise
differences	I-Premise
were	I-Premise
detected	I-Premise
between	I-Premise
3	I-Premise
and	I-Premise
5	I-Premise
days	I-Premise
of	I-Premise
treatment.	I-Premise

We	O
conclude	O
that	O
three	B-Claim
cycles	I-Claim
of	I-Claim
BEP,	I-Claim
with	I-Claim
etoposide	I-Claim
at	I-Claim
500	I-Claim
mg/m(2),	I-Claim
is	I-Claim
sufficient	I-Claim
therapy	I-Claim
in	I-Claim
good-prognosis	I-Claim
germ	I-Claim
cell	I-Claim
cancer	I-Claim
and	O
that	O
the	B-Claim
administration	I-Claim
of	I-Claim
the	I-Claim
chemotherapy	I-Claim
in	I-Claim
3	I-Claim
days	I-Claim
has	I-Claim
no	I-Claim
detrimental	I-Claim
effect	I-Claim
on	I-Claim
the	I-Claim
effectiveness	I-Claim
of	I-Claim
the	I-Claim
BEP	I-Claim
regimen.	I-Claim

To	O
determine	O
the	O
efficacy	O
of	O
topotecan	O
in	O
combination	O
with	O
standard	O
chemotherapy	O
in	O
previously	O
untreated	O
patients	O
with	O
extensive-stage	O
small-cell	O
lung	O
cancer	O
(SCLC),	O
the	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(ECOG)	O
conducted	O
a	O
phase	O
III	O
trial.	O

Eligible	O
patients	O
had	O
measurable	O
or	O
assessable	O
disease	O
and	O
an	O
ECOG	O
performance	O
status	O
of	O
0	O
to	O
2;	O
stable	O
brain	O
metastases	O
were	O
allowed.	O

All	O
patients	O
received	O
four	O
cycles	O
of	O
cisplatin	O
and	O
etoposide	O
every	O
3	O
weeks	O
(step	O
1;	O
PE).	O

Patients	O
with	O
stable	O
or	O
responding	O
disease	O
were	O
then	O
randomized	O
to	O
observation	O
or	O
four	O
cycles	O
of	O
topotecan	O
(1.5	O
mg/m(2)/d	O
for	O
5	O
days,	O
every	O
3	O
weeks;	O
step	O
2).	O

A	O
total	O
of	O
402	O
eligible	O
patients	O
were	O
registered	O
to	O
step	O
1,	O
and	O
223	O
eligible	O
patients	O
were	O
registered	O
to	O
step	O
2	O
(observation,	O
n	O
=	O
111;	O
topotecan,	O
n	O
=	O
112).	O

Complete	B-Premise
and	I-Premise
partial	I-Premise
response	I-Premise
rates	I-Premise
to	I-Premise
induction	I-Premise
PE	I-Premise
were	I-Premise
3%	I-Premise
and	I-Premise
32%,	I-Premise
respectively.	I-Premise

A	B-Premise
7%	I-Premise
response	I-Premise
rate	I-Premise
was	I-Premise
observed	I-Premise
with	I-Premise
topotecan	I-Premise
(complete	I-Premise
response,	I-Premise
2%;	I-Premise
partial	I-Premise
response,	I-Premise
5%).	I-Premise

The	B-Premise
median	I-Premise
survival	I-Premise
time	I-Premise
for	I-Premise
all	I-Premise
402	I-Premise
eligible	I-Premise
patients	I-Premise
was	I-Premise
9.6	I-Premise
months.	I-Premise

Progression-free	B-Premise
survival	I-Premise
(PFS)	I-Premise
from	I-Premise
date	I-Premise
of	I-Premise
randomization	I-Premise
on	I-Premise
step	I-Premise
2	I-Premise
was	I-Premise
significantly	I-Premise
better	I-Premise
with	I-Premise
topotecan	I-Premise
compared	I-Premise
with	I-Premise
observation	I-Premise
(3.6	I-Premise
months	I-Premise
v	I-Premise
2.3	I-Premise
months;	I-Premise
P	I-Premise
<.001).	I-Premise

However,	O
overall	B-Premise
survival	I-Premise
from	I-Premise
date	I-Premise
of	I-Premise
randomization	I-Premise
on	I-Premise
step	I-Premise
2	I-Premise
was	I-Premise
not	I-Premise
significantly	I-Premise
different	I-Premise
between	I-Premise
the	I-Premise
observation	I-Premise
and	I-Premise
topotecan	I-Premise
arms	I-Premise
(8.9	I-Premise
months	I-Premise
v	I-Premise
9.3	I-Premise
months;	I-Premise
P	I-Premise
=.43).	I-Premise

Grade	B-Premise
4	I-Premise
neutropenia	I-Premise
and	I-Premise
thrombocytopenia	I-Premise
occurred	I-Premise
in	I-Premise
50%	I-Premise
and	I-Premise
3%,	I-Premise
respectively,	I-Premise
of	I-Premise
PE	I-Premise
patients	I-Premise
in	I-Premise
step	I-Premise
1	I-Premise
and	I-Premise
60%	I-Premise
and	I-Premise
13%	I-Premise
of	I-Premise
topotecan	I-Premise
patients	I-Premise
in	I-Premise
step	I-Premise
2.	I-Premise

Grade	B-Premise
4/5	I-Premise
infection	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
4.6%	I-Premise
of	I-Premise
PE	I-Premise
patients	I-Premise
and	I-Premise
1.8%	I-Premise
of	I-Premise
topotecan	I-Premise
patients.	I-Premise

Grade	B-Premise
3/4	I-Premise
anemia	I-Premise
developed	I-Premise
in	I-Premise
22%	I-Premise
of	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
topotecan.	I-Premise

No	B-Premise
difference	I-Premise
in	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
between	I-Premise
topotecan	I-Premise
and	I-Premise
observation	I-Premise
was	I-Premise
observed	I-Premise
at	I-Premise
any	I-Premise
assessment	I-Premise
time	I-Premise
or	I-Premise
for	I-Premise
any	I-Premise
of	I-Premise
the	I-Premise
subscale	I-Premise
scores.	I-Premise

Four	B-Claim
cycles	I-Claim
of	I-Claim
PE	I-Claim
induction	I-Claim
therapy	I-Claim
followed	I-Claim
by	I-Claim
four	I-Claim
cycles	I-Claim
of	I-Claim
topotecan	I-Claim
improved	I-Claim
PFS	I-Claim
but	I-Claim
failed	I-Claim
to	I-Claim
improve	I-Claim
overall	I-Claim
survival	I-Claim
or	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
in	I-Claim
extensive-stage	I-Claim
SCLC.	I-Claim

Four	B-Claim
cycles	I-Claim
of	I-Claim
standard	I-Claim
PE	I-Claim
remains	I-Claim
an	I-Claim
appropriate	I-Claim
first-line	I-Claim
treatment	I-Claim
for	I-Claim
extensive-stage	I-Claim
SCLC	I-Claim
patients	I-Claim
with	I-Claim
good	I-Claim
performance	I-Claim
status.	I-Claim

The	B-Claim
role	I-Claim
of	I-Claim
adjuvant	I-Claim
chemotherapy	I-Claim
in	I-Claim
postmenopausal	I-Claim
patients	I-Claim
with	I-Claim
lymph	I-Claim
node-negative	I-Claim
breast	I-Claim
cancer	I-Claim
is	I-Claim
controversial.	I-Claim

After	O
demonstrating	O
the	O
efficacy	O
of	O
chemotherapy	O
combined	O
with	O
tamoxifen	O
for	O
postmenopausal	O
patients	O
with	O
lymph	O
node-positive	O
disease,	O
the	O
International	O
Breast	O
Cancer	O
Study	O
Group	O
launched	O
a	O
randomized	O
trial	O
(Trial	O
IX)	O
to	O
evaluate	O
the	O
role	O
of	O
adjuvant	O
chemotherapy	O
preceding	O
treatment	O
with	O
tamoxifen	O
for	O
patients	O
with	O
lymph	O
node-negative	O
disease.	O

After	O
stratification	O
by	O
estrogen	O
receptor	O
(ER)	O
status,	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
three	O
28-day	O
courses	O
of	O
"classical"	O
adjuvant	O
CMF	O
chemotherapy	O
(cyclophosphamide	O
at	O
100	O
mg/m(2)	O
on	O
days	O
1-14,	O
orally;	O
methotrexate	O
at	O
40	O
mg/m(2)	O
on	O
days	O
1	O
and	O
8,	O
intravenously;	O
and	O
5-fluorouracil	O
at	O
600	O
mg/m(2)	O
on	O
days	O
1	O
and	O
8,	O
intravenously)	O
followed	O
by	O
tamoxifen	O
(20	O
mg/day,	O
orally	O
for	O
57	O
months)	O
(CMF-->tamoxifen)	O
or	O
to	O
receive	O
tamoxifen	O
alone	O
(20	O
mg/day,	O
orally	O
for	O
60	O
months).	O

We	O
enrolled	O
1669	O
eligible	O
patients,	O
382	O
(23%)	O
with	O
ER-negative	O
tumors,	O
1217	O
(73%)	O
with	O
ER-positive	O
tumors,	O
and	O
70	O
(4%)	O
with	O
unknown	O
ER	O
status.	O

The	O
median	O
follow-up	O
was	O
71	O
months.	O

All	O
statistical	O
tests	O
were	O
two-sided.	O

The	B-Premise
added	I-Premise
benefit	I-Premise
of	I-Premise
CMF	I-Premise
followed	I-Premise
by	I-Premise
tamoxifen	I-Premise
over	I-Premise
tamoxifen	I-Premise
alone	I-Premise
was	I-Premise
statistically	I-Premise
significantly	I-Premise
dependent	I-Premise
on	I-Premise
ER	I-Premise
status	I-Premise
(tests	I-Premise
for	I-Premise
interaction:	I-Premise
P	I-Premise
=.01	I-Premise
for	I-Premise
disease-free	I-Premise
survival	I-Premise
[DFS]	I-Premise
and	I-Premise
P	I-Premise
=.07	I-Premise
for	I-Premise
overall	I-Premise
survival	I-Premise
[OS]).	I-Premise

For	B-Premise
patients	I-Premise
with	I-Premise
ER-negative	I-Premise
tumors,	I-Premise
the	I-Premise
addition	I-Premise
of	I-Premise
CMF	I-Premise
statistically	I-Premise
significantly	I-Premise
improved	I-Premise
DFS	I-Premise
(5-year	I-Premise
DFS	I-Premise
=	I-Premise
84%	I-Premise
for	I-Premise
CMF-->tamoxifen	I-Premise
versus	I-Premise
69%	I-Premise
for	I-Premise
tamoxifen	I-Premise
alone;	I-Premise
difference	I-Premise
=	I-Premise
15%;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
=	I-Premise
6%	I-Premise
to	I-Premise
24%;	I-Premise
risk	I-Premise
ratio	I-Premise
[RR]	I-Premise
=	I-Premise
0.52;	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
0.34	I-Premise
to	I-Premise
0.79;	I-Premise
P	I-Premise
=.003)	I-Premise
and	I-Premise
OS	I-Premise
(5-year	I-Premise
OS	I-Premise
=	I-Premise
89%	I-Premise
for	I-Premise
CMF-->tamoxifen	I-Premise
versus	I-Premise
81%	I-Premise
for	I-Premise
tamoxifen	I-Premise
alone;	I-Premise
difference	I-Premise
=	I-Premise
8%;	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
0%	I-Premise
to	I-Premise
16%;	I-Premise
RR	I-Premise
=	I-Premise
0.51;	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
0.30	I-Premise
to	I-Premise
0.87;	I-Premise
P	I-Premise
=.01).	I-Premise

By	B-Premise
contrast,	I-Premise
for	I-Premise
patients	I-Premise
with	I-Premise
ER-positive	I-Premise
tumors,	I-Premise
addition	I-Premise
of	I-Premise
CMF	I-Premise
provided	I-Premise
no	I-Premise
benefit	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
DFS	I-Premise
(5-year	I-Premise
DFS	I-Premise
=	I-Premise
84%	I-Premise
for	I-Premise
CMF-->tamoxifen	I-Premise
versus	I-Premise
85%	I-Premise
for	I-Premise
tamoxifen	I-Premise
alone;	I-Premise
difference	I-Premise
=	I-Premise
-1;	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
-6%	I-Premise
to	I-Premise
4%;	I-Premise
RR	I-Premise
=	I-Premise
0.99;	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
0.75	I-Premise
to	I-Premise
1.30;	I-Premise
P	I-Premise
=.92)	I-Premise
or	I-Premise
OS	I-Premise
(5-year	I-Premise
OS	I-Premise
=	I-Premise
95%	I-Premise
for	I-Premise
CMF-->tamoxifen	I-Premise
versus	I-Premise
93%	I-Premise
for	I-Premise
tamoxifen	I-Premise
alone;	I-Premise
difference	I-Premise
=	I-Premise
2%;	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
-1%	I-Premise
to	I-Premise
5%;	I-Premise
RR	I-Premise
=	I-Premise
0.95;	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
0.64	I-Premise
to	I-Premise
1.40;	I-Premise
P	I-Premise
=.80).	I-Premise

Postmenopausal	B-Claim
patients	I-Claim
with	I-Claim
lymph	I-Claim
node-negative	I-Claim
breast	I-Claim
cancer	I-Claim
benefited	I-Claim
substantially	I-Claim
from	I-Claim
adjuvant	I-Claim
chemotherapy	I-Claim
if	I-Claim
their	I-Claim
cancer	I-Claim
was	I-Claim
ER-negative	I-Claim
(i.e.,	I-Claim
endocrine-nonresponsive).	I-Claim

In	B-Claim
contrast,	I-Claim
if	I-Claim
their	I-Claim
cancer	I-Claim
was	I-Claim
ER-positive	I-Claim
(i.e.,	I-Claim
endocrine-responsive),	I-Claim
they	I-Claim
obtained	I-Claim
no	I-Claim
benefit	I-Claim
from	I-Claim
the	I-Claim
combination	I-Claim
treatment	I-Claim
compared	I-Claim
with	I-Claim
tamoxifen	I-Claim
alone.	I-Claim

To	O
assess	O
the	O
efficacy	O
of	O
a	O
novel	O
coloplasty	O
colonic	O
pouch	O
design	O
in	O
optimizing	O
bowel	O
function	O
after	O
ultralow	O
anterior	O
resection.	O

A	B-Claim
colonic	I-Claim
J-pouch	I-Claim
may	I-Claim
reduce	I-Claim
excessive	I-Claim
stool	I-Claim
frequency	I-Claim
and	I-Claim
incontinence	I-Claim
after	I-Claim
anterior	I-Claim
resection,	I-Claim
but	I-Claim
at	I-Claim
the	I-Claim
risk	I-Claim
of	I-Claim
evacuation	I-Claim
problems.	I-Claim

Experimental	B-Claim
surgery	I-Claim
on	I-Claim
pigs	I-Claim
has	I-Claim
suggested	I-Claim
that	I-Claim
a	I-Claim
coloplasty	I-Claim
pouch	I-Claim
(CP)	I-Claim
may	I-Claim
be	I-Claim
a	I-Claim
useful	I-Claim
alternative.	I-Claim

Although	O
CP	O
has	O
recently	O
been	O
shown	O
to	O
be	O
feasible	O
in	O
patients,	O
there	O
is	O
no	O
randomized	O
controlled	O
trial	O
comparing	O
bowel	O
function	O
with	O
the	O
J-pouch.	O

After	O
anterior	O
resection	O
for	O
cancer,	O
patients	O
were	O
allocated	O
to	O
either	O
J-pouch	O
or	O
CP-anal	O
anastomoses.	O

Continence	O
scoring,	O
anorectal	O
manometry,	O
and	O
endoanal	O
ultrasound	O
assessments	O
were	O
made	O
before	O
surgery.	O

All	O
complications	O
were	O
recorded,	O
and	O
these	O
preoperative	O
assessments	O
were	O
repeated	O
at	O
4	O
months.	O

The	O
assessments	O
were	O
repeated	O
again	O
at	O
1	O
year,	O
and	O
a	O
quality	O
of	O
life	O
questionnaire	O
was	O
added.	O

Eighty-eight	O
patients	O
were	O
recruited	O
from	O
October	O
1998	O
to	O
April	O
2000.	O

Both	O
groups	O
were	O
well	O
matched	O
for	O
age,	O
gender,	O
staging,	O
adjuvant	O
therapy,	O
and	O
mean	O
follow-up.	O

There	O
were	O
no	O
differences	O
in	O
the	O
intraoperative	O
time	O
and	O
hospital	O
stay.	O

CP	B-Premise
resulted	I-Premise
in	I-Premise
more	I-Premise
anastomotic	I-Premise
leaks.	I-Premise

At	B-Premise
4	I-Premise
months,	I-Premise
J-pouch	I-Premise
patients	I-Premise
had	I-Premise
10.3%	I-Premise
less	I-Premise
stool	I-Premise
fragmentation	I-Premise
but	I-Premise
poorer	I-Premise
stool	I-Premise
deferment	I-Premise
and	I-Premise
more	I-Premise
nocturnal	I-Premise
leakage.	I-Premise

However,	O
there	B-Premise
were	I-Premise
no	I-Premise
differences	I-Premise
in	I-Premise
the	I-Premise
bowel	I-Premise
function,	I-Premise
continence	I-Premise
score,	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
at	I-Premise
1	I-Premise
year.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
differences	I-Premise
in	I-Premise
the	I-Premise
anorectal	I-Premise
manometry	I-Premise
and	I-Premise
endoanal	I-Premise
ultrasound	I-Premise
findings.	I-Premise

Coloplasty	B-Claim
pouches	I-Claim
resulted	I-Claim
in	I-Claim
more	I-Claim
anastomotic	I-Claim
leaks	I-Claim
and	I-Claim
minimal	I-Claim
differences	I-Claim
in	I-Claim
bowel	I-Claim
function.	I-Claim

At	O
present,	O
the	B-Claim
J-pouch	I-Claim
remains	I-Claim
the	I-Claim
benchmark	I-Claim
for	I-Claim
routine	I-Claim
clinical	I-Claim
practice,	I-Claim
and	O
due	B-Claim
care	I-Claim
(including	I-Claim
defunctioning	I-Claim
stoma)	I-Claim
should	I-Claim
be	I-Claim
exercised	I-Claim
in	I-Claim
situations	I-Claim
requiring	I-Claim
CP.	I-Claim

Chemotherapy	B-Claim
is	I-Claim
moderately	I-Claim
efficient	I-Claim
as	I-Claim
a	I-Claim
treatment	I-Claim
for	I-Claim
pancreatic	I-Claim
adenocarcinoma,	I-Claim
but	B-Claim
patient	I-Claim
survival	I-Claim
and	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
has	I-Claim
improved	I-Claim
with	I-Claim
this	I-Claim
modality	I-Claim
in	I-Claim
some	I-Claim
trials.	I-Claim

In	O
a	O
previous	O
phase	O
II	O
trial,	O
5-fluorouracil	O
(5-FU)	O
plus	O
cisplatin	O
(FUP)	O
yielded	O
a	O
26.5%	O
response	O
rate	O
and	O
a	O
29%	O
survival	O
rate	O
at	O
1	O
year.	O

The	O
present	O
study	O
aimed	O
to	O
compare	O
FUP	O
with	O
5-FU	O
alone,	O
which	O
was	O
the	O
control	O
arm	O
in	O
former	O
Mayo	O
Clinic	O
trials.	O

Patients	O
with	O
untreated	O
cytologically	O
or	O
histologically	O
proven	O
metastatic	O
or	O
locally	O
advanced	O
adenocarcinoma	O
of	O
the	O
pancreas	O
were	O
deemed	O
measurable	O
or	O
evaluable.	O

Chemotherapy	O
regimens	O
consisted	O
of	O
a	O
control	O
FU	O
arm	O
(5-FU	O
500	O
mg/m(2)/day	O
for	O
5	O
days)	O
and	O
the	O
investigational	O
FUP	O
arm	O
(continuous	O
5-FU	O
1000	O
mg/m(2)/day	O
for	O
5	O
days	O
plus	O
cisplatin	O
100	O
mg/m(2)	O
on	O
day	O
1	O
or	O
day	O
2).	O

In	O
both	O
arms,	O
chemotherapy	O
was	O
repeated	O
at	O
day	O
29.	O

Two-hundred	O
and	O
seven	O
patients	O
from	O
18	O
centres	O
were	O
randomised:	O
103	O
in	O
the	O
FU	O
arm	O
and	O
104	O
in	O
FUP	O
arm.	O

Treatment	O
arms	O
were	O
balanced	O
with	O
respect	O
to	O
performance	O
status	O
grade	O
0-1	O
(83%	O
versus	O
86%,	O
respectively)	O
and	O
the	O
presence	O
of	O
metastases	O
(92%	O
versus	O
89%,	O
respectively).	O

The	O
median	O
number	O
of	O
cycles	O
administered	O
was	O
two	O
in	O
both	O
arms	O
(range	O
0-14).	O

Five	O
patients	O
did	O
not	O
receive	O
any	O
chemotherapy	O
and	O
45	O
received	O
only	O
one	O
cycle.	O

Toxicity	B-Premise
(WHO	I-Premise
grade	I-Premise
3-4)	I-Premise
was	I-Premise
lower	I-Premise
with	I-Premise
FU	I-Premise
than	I-Premise
with	I-Premise
FUP	I-Premise
(20%	I-Premise
versus	I-Premise
48%,	I-Premise
P	I-Premise
<0.001),	I-Premise
as	I-Premise
was	I-Premise
neutropenia	I-Premise
(6%	I-Premise
versus	I-Premise
23%),	I-Premise
vomiting	I-Premise
(4%	I-Premise
versus	I-Premise
17%)	I-Premise
and	I-Premise
toxicity-related	I-Premise
deaths	I-Premise
(one	I-Premise
versus	I-Premise
four	I-Premise
early	I-Premise
in	I-Premise
the	I-Premise
trial).	I-Premise

The	B-Premise
response	I-Premise
rate	I-Premise
was	I-Premise
low	I-Premise
in	I-Premise
both	I-Premise
arms,	I-Premise
but	I-Premise
superior	I-Premise
in	I-Premise
the	I-Premise
FUP	I-Premise
arm:	I-Premise
12%	I-Premise
versus	I-Premise
0%	I-Premise
(intention-to-treat	I-Premise
analysis,	I-Premise
P	I-Premise
<0.01).	I-Premise

The	B-Premise
survival	I-Premise
rates	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
were	I-Premise
28%	I-Premise
and	I-Premise
38%	I-Premise
for	I-Premise
the	I-Premise
FU	I-Premise
and	I-Premise
FUP	I-Premise
arms,	I-Premise
respectively,	I-Premise
and	I-Premise
1-year	I-Premise
survival	I-Premise
rates	I-Premise
were	I-Premise
9%	I-Premise
and	I-Premise
17%	I-Premise
(log-rank	I-Premise
test,	I-Premise
P	I-Premise
=	I-Premise
0.10).	I-Premise

One-year	B-Premise
progression-free	I-Premise
survival	I-Premise
was	I-Premise
0%	I-Premise
with	I-Premise
FU	I-Premise
versus	I-Premise
10%	I-Premise
with	I-Premise
FUP	I-Premise
(log-rank	I-Premise
test,	I-Premise
P	I-Premise
=	I-Premise
0.0001).	I-Premise

In	B-Claim
advanced	I-Claim
pancreatic	I-Claim
carcinomas	I-Claim
with	I-Claim
a	I-Claim
poor	I-Claim
prognosis,	I-Claim
FUP	I-Claim
was	I-Claim
superior	I-Claim
to	I-Claim
FU	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
response	I-Claim
and	I-Claim
progression-free	I-Claim
survival,	I-Claim
but	I-Claim
not	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
overall	I-Claim
survival.	I-Claim

The	O
low	O
response	O
rate	O
is	O
partly	O
related	O
to	O
the	O
number	O
of	O
patients	O
who	O
received	O
only	O
one	O
cycle	O
of	O
chemotherapy.	O

A	B-Claim
more	I-Claim
effective,	I-Claim
better	I-Claim
tolerated	I-Claim
version	I-Claim
of	I-Claim
this	I-Claim
FUP	I-Claim
combination	I-Claim
is	I-Claim
needed.	I-Claim

Amitriptyline	B-Claim
is	I-Claim
the	I-Claim
most	I-Claim
common	I-Claim
analgesic	I-Claim
adjuvant	I-Claim
used	I-Claim
in	I-Claim
cancer	I-Claim
patients	I-Claim
with	I-Claim
neuropathic	I-Claim
pain,	I-Claim
even	O
though	O
no	B-Claim
specific	I-Claim
studies	I-Claim
have	I-Claim
demonstrated	I-Claim
a	I-Claim
benefit.	I-Claim

A	O
randomized	O
placebo-controlled,	O
double-blind	O
crossover	O
study	O
was	O
designed	O
to	O
evidence	O
the	O
effects	O
of	O
amitriptyline	O
in	O
patients	O
with	O
neuropathic	O
cancer	O
pain.	O

Sixteen	O
advanced	O
cancer	O
patients	O
with	O
neuropathic	O
pain	O
on	O
systemic	O
morphine	O
therapy,	O
no	O
longer	O
receiving	O
oncologic	O
treatment,	O
presenting	O
moderate	O
pain	O
(about	O
4	O
or	O
more,	O
but	O
less	O
than	O
7,	O
on	O
a	O
numerical	O
scale	O
of	O
0-10)	O
in	O
the	O
last	O
week,	O
and	O
given	O
a	O
stable	O
morphine	O
dose	O
in	O
the	O
last	O
2	O
days	O
were	O
admitted	O
to	O
the	O
study.	O

During	O
the	O
first	O
week	O
of	O
study,	O
patients	O
were	O
administered	O
25	O
mg	O
of	O
amitriptyline	O
or	O
equivalent	O
drops	O
of	O
placebo	O
at	O
night	O
for	O
3	O
days	O
and	O
50	O
mg	O
for	O
the	O
following	O
4	O
days.	O

Doses	O
for	O
patients	O
aged	O
more	O
than	O
65	O
years	O
were	O
15	O
mg	O
(first	O
3	O
days)	O
and	O
30	O
mg	O
(3	O
days	O
after).	O

After	O
a	O
week,	O
a	O
crossover	O
took	O
place	O
for	O
the	O
second	O
week,	O
with	O
the	O
other	O
treatment	O
at	O
an	O
inverse	O
sequence.	O

Opioid	O
consumption,	O
pain	O
intensity,	O
symptoms	O
and	O
adverse	O
effects,	O
mood,	O
sleep,	O
patient's	O
preference,	O
quality	O
of	O
life	O
before	O
starting	O
the	O
study,	O
the	O
first	O
week	O
after	O
and	O
the	O
second	O
week	O
after	O
were	O
recorded.	O

No	B-Premise
significant	I-Premise
benefits	I-Premise
in	I-Premise
analgesia	I-Premise
were	I-Premise
found	I-Premise
in	I-Premise
the	I-Premise
global	I-Premise
pain	I-Premise
intensity	I-Premise
of	I-Premise
the	I-Premise
previous	I-Premise
week	I-Premise
of	I-Premise
treatment,	I-Premise
the	I-Premise
least	I-Premise
pain	I-Premise
intensity	I-Premise
or	I-Premise
the	I-Premise
pain	I-Premise
evaluated	I-Premise
just	I-Premise
after	I-Premise
a	I-Premise
week	I-Premise
of	I-Premise
treatment,	I-Premise
at	I-Premise
the	I-Premise
moment	I-Premise
of	I-Premise
the	I-Premise
visit,	I-Premise
when	I-Premise
amitriptyline	I-Premise
was	I-Premise
compared	I-Premise
with	I-Premise
placebo.	I-Premise

A	B-Premise
significant	I-Premise
difference	I-Premise
was	I-Premise
evidenced	I-Premise
for	I-Premise
the	I-Premise
worst	I-Premise
pain	I-Premise
(P	I-Premise
<	I-Premise
0.035).	I-Premise

No	B-Premise
differences	I-Premise
in	I-Premise
opioid	I-Premise
doses	I-Premise
during	I-Premise
the	I-Premise
period	I-Premise
of	I-Premise
study	I-Premise
were	I-Premise
found.	I-Premise

Drowsiness,	B-Premise
confusion	I-Premise
and	I-Premise
dry	I-Premise
mouth	I-Premise
were	I-Premise
significantly	I-Premise
more	I-Premise
intense	I-Premise
with	I-Premise
amitriptyline	I-Premise
than	I-Premise
with	I-Premise
placebo	I-Premise
(P	I-Premise
<	I-Premise
0.036,	I-Premise
0.003,	I-Premise
and	I-Premise
0.034,	I-Premise
respectively).	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
substantial	I-Premise
differences	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
treatments	I-Premise
in	I-Premise
Spitzer's	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
score	I-Premise
and	I-Premise
for	I-Premise
each	I-Premise
item.	I-Premise

No	B-Premise
differences	I-Premise
in	I-Premise
patients'	I-Premise
preference	I-Premise
for	I-Premise
the	I-Premise
two	I-Premise
treatment	I-Premise
periods	I-Premise
were	I-Premise
found.	I-Premise

The	B-Claim
analgesic	I-Claim
effects	I-Claim
of	I-Claim
amitriptyline	I-Claim
were	I-Claim
slight	I-Claim
and	I-Claim
associated	I-Claim
with	I-Claim
adverse	I-Claim
effects.	I-Claim

In	O
light	O
of	O
the	O
results	O
obtained	O
in	O
the	O
study,	O
the	B-Claim
extensive	I-Claim
use	I-Claim
of	I-Claim
the	I-Claim
drug	I-Claim
for	I-Claim
cancer	I-Claim
pain	I-Claim
should	I-Claim
be	I-Claim
questioned.	I-Claim

To	O
determine	O
whether	O
patients	O
with	O
locally	O
advanced	O
non-small	O
cell	O
lung	O
cancer	O
unsuitable	O
for	O
resection	O
or	O
radical	O
radiotherapy,	O
and	O
with	O
minimal	O
thoracic	O
symptoms,	O
should	O
be	O
given	O
palliative	O
thoracic	O
radiotherapy	O
immediately	O
or	O
as	O
needed	O
to	O
treat	O
symptoms.	O

Multicentre	O
randomised	O
controlled	O
trial.	O

23	O
centres	O
in	O
the	O
United	O
Kingdom,	O
Ireland,	O
and	O
South	O
Africa.	O

230	O
patients	O
with	O
previously	O
untreated,	O
non-small	O
cell	O
lung	O
cancer	O
that	O
is	O
locally	O
too	O
advanced	O
for	O
resection	O
or	O
radical	O
radiotherapy	O
with	O
curative	O
intent,	O
with	O
minimal	O
thoracic	O
symptoms,	O
and	O
with	O
no	O
indication	O
for	O
immediate	O
thoracic	O
radiotherapy.	O

All	O
patients	O
were	O
given	O
supportive	O
treatment	O
and	O
were	O
randomised	O
to	O
receive	O
palliative	O
thoracic	O
radiotherapy	O
either	O
immediately	O
or	O
delayed	O
until	O
needed	O
to	O
treat	O
symptoms.	O

The	O
recommended	O
regimens	O
were	O
17	O
Gy	O
in	O
two	O
fractions	O
one	O
week	O
apart	O
or	O
10	O
Gy	O
as	O
a	O
single	O
dose.	O

Primary--patients	O
alive	O
and	O
without	O
moderate	O
or	O
severe	O
cough,	O
chest	O
pain,	O
haemoptysis,	O
or	O
dyspnoea	O
six	O
months	O
from	O
randomisation,	O
as	O
recorded	O
by	O
clinicians.	O

Secondary--quality	O
of	O
life,	O
adverse	O
events,	O
survival.	O

From	O
December	O
1992	O
to	O
May	O
1999,	O
230	O
patients	O
were	O
randomised.	O

104/115	O
of	O
the	O
patients	O
in	O
the	O
immediate	O
treatment	O
group	O
received	O
thoracic	O
radiotherapy	O
(90	O
received	O
one	O
of	O
the	O
recommended	O
regimens).	O

In	O
the	O
delayed	O
treatment	O
group,	O
48/115	O
(42%)	O
patients	O
received	O
thoracic	O
radiotherapy	O
(29	O
received	O
one	O
of	O
the	O
recommended	O
regimens);	O
64	O
(56%)	O
died	O
without	O
receiving	O
thoracic	O
radiotherapy;	O
the	O
remaining	O
three	O
(3%)	O
were	O
alive	O
at	O
the	O
end	O
of	O
the	O
study	O
without	O
having	O
received	O
the	O
treatment.	O

For	O
patients	O
who	O
received	O
thoracic	O
radiotherapy,	O
the	O
median	O
time	O
to	O
start	O
was	O
15	O
days	O
in	O
the	O
immediate	O
treatment	O
group	O
and	O
125	O
days	O
in	O
the	O
delayed	O
treatment	O
group.	O

The	B-Premise
primary	I-Premise
outcome	I-Premise
measure	I-Premise
was	I-Premise
achieved	I-Premise
in	I-Premise
28%	I-Premise
of	I-Premise
the	I-Premise
immediate	I-Premise
treatment	I-Premise
group	I-Premise
and	I-Premise
26%	I-Premise
of	I-Premise
patients	I-Premise
from	I-Premise
the	I-Premise
delayed	I-Premise
treatment	I-Premise
group	I-Premise
(27/97	I-Premise
and	I-Premise
27/103,	I-Premise
respectively;	I-Premise
absolute	I-Premise
difference	I-Premise
1.6%,	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
-10.7%	I-Premise
to	I-Premise
13.9%).	I-Premise

No	B-Premise
evidence	I-Premise
of	I-Premise
a	I-Premise
difference	I-Premise
was	I-Premise
observed	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
treatment	I-Premise
groups	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
activity	I-Premise
level,	I-Premise
anxiety,	I-Premise
depression,	I-Premise
and	I-Premise
psychological	I-Premise
distress,	I-Premise
as	I-Premise
recorded	I-Premise
by	I-Premise
the	I-Premise
patients.	I-Premise

Adverse	B-Premise
events	I-Premise
were	I-Premise
more	I-Premise
common	I-Premise
in	I-Premise
the	I-Premise
immediate	I-Premise
treatment	I-Premise
group.	I-Premise

Neither	B-Premise
group	I-Premise
had	I-Premise
a	I-Premise
survival	I-Premise
advantage	I-Premise
(hazard	I-Premise
ratio	I-Premise
0.95,	I-Premise
0.73	I-Premise
to	I-Premise
1.24;	I-Premise
P=0.71).	I-Premise

Median	B-Premise
survival	I-Premise
was	I-Premise
8.3	I-Premise
months	I-Premise
and	I-Premise
7.9	I-Premise
months,	I-Premise
and	O
the	B-Premise
survival	I-Premise
rates	I-Premise
were	I-Premise
31%	I-Premise
and	I-Premise
29%	I-Premise
at	I-Premise
12	I-Premise
months,	I-Premise
for	I-Premise
the	I-Premise
immediate	I-Premise
and	I-Premise
delayed	I-Premise
treatment	I-Premise
groups,	I-Premise
respectively.	I-Premise

In	B-Claim
minimally	I-Claim
symptomatic	I-Claim
patients	I-Claim
with	I-Claim
locally	I-Claim
advanced	I-Claim
non-small	I-Claim
cell	I-Claim
lung	I-Claim
cancer,	I-Claim
no	I-Claim
persuasive	I-Claim
evidence	I-Claim
was	I-Claim
found	I-Claim
to	I-Claim
indicate	I-Claim
that	I-Claim
giving	I-Claim
immediate	I-Claim
palliative	I-Claim
thoracic	I-Claim
radiotherapy	I-Claim
improves	I-Claim
symptom	I-Claim
control,	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
or	I-Claim
survival	I-Claim
when	I-Claim
compared	I-Claim
with	I-Claim
delaying	I-Claim
until	I-Claim
symptoms	I-Claim
require	I-Claim
treatment.	I-Claim

To	O
compare	O
the	O
outcome	O
of	O
treatment	O
of	O
mediastinoscopy-verified	O
N2	O
non-small-cell	O
lung	O
cancer	O
treated	O
with	O
induction	O
chemotherapy	O
followed	O
by	O
either	O
surgery	O
or	O
radiotherapy	O
(RT),	O
with	O
both	O
options	O
followed	O
by	O
consolidation	O
chemotherapy.	O

A	O
randomized	O
Phase	O
III	O
trial	O
for	O
Stage	O
IIIA	O
(T1-T3N2M0)	O
non-small	O
cell	O
lung	O
cancer	O
was	O
conducted	O
by	O
the	O
Radiation	O
Therapy	O
Oncology	O
Group	O
(RTOG)	O
and	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
between	O
April	O
1990	O
and	O
April	O
1994.	O

After	O
documentation	O
of	O
N2	O
disease	O
by	O
mediastinoscopy	O
or	O
anterior	O
mediastinotomy,	O
patients	O
received	O
induction	O
chemotherapy	O
with	O
cisplatin,	O
vinblastine,	O
and	O
mitomycin-C.	O

Mitomycin-C	O
was	O
later	O
dropped	O
from	O
the	O
induction	O
regimen.	O

Patients	O
were	O
then	O
randomized	O
to	O
surgery	O
or	O
RT	O
(64	O
Gy	O
in	O
7	O
weeks)	O
followed	O
by	O
cisplatin	O
and	O
vinblastine.	O

RTOG	O
89-01	O
accrued	O
75	O
patients,	O
of	O
whom	O
73	O
were	O
eligible	O
and	O
analyzable.	O

Twelve	O
patients	O
received	O
induction	O
chemotherapy	O
but	O
were	O
not	O
randomized	O
to	O
RT	O
or	O
surgery	O
thereafter.	O

Forty-five	O
patients	O
were	O
randomized	O
to	O
postinduction	O
RT	O
or	O
surgery.	O

Of	O
the	O
analyzable	O
patients,	O
90%	O
had	O
a	O
Karnofsky	O
performance	O
score	O
of	O
90-100,	O
18%	O
had	O
weight	O
loss	O
>5%,	O
37%	O
had	O
squamous	O
cell	O
histologic	O
features,	O
and	O
54%	O
had	O
bulky	O
N2	O
disease.	O

The	O
distribution	O
of	O
bulky	O
N2	O
disease	O
was	O
uniform	O
among	O
the	O
treatment	O
arms.	O

The	B-Premise
incidence	I-Premise
of	I-Premise
Grade	I-Premise
4	I-Premise
toxicity	I-Premise
was	I-Premise
56%	I-Premise
in	I-Premise
patients	I-Premise
receiving	I-Premise
mitomycin-C	I-Premise
and	I-Premise
29%	I-Premise
in	I-Premise
those	I-Premise
who	I-Premise
did	I-Premise
not.	I-Premise

Only	B-Premise
1	I-Premise
patient	I-Premise
in	I-Premise
each	I-Premise
group	I-Premise
had	I-Premise
acute	I-Premise
nonhematologic	I-Premise
toxicity	I-Premise
greater	I-Premise
than	I-Premise
Grade	I-Premise
3	I-Premise
(nausea	I-Premise
and	I-Premise
vomiting).	I-Premise

No	B-Premise
acute	I-Premise
Grade	I-Premise
4	I-Premise
radiation	I-Premise
toxicity	I-Premise
developed.	I-Premise

The	B-Premise
incidences	I-Premise
of	I-Premise
long-term	I-Premise
toxicity	I-Premise
were	I-Premise
equivalent	I-Premise
across	I-Premise
the	I-Premise
arms.	I-Premise

Three	B-Premise
treatment-related	I-Premise
deaths	I-Premise
occurred:	I-Premise
2	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
surgical	I-Premise
arms	I-Premise
(one	I-Premise
late	I-Premise
pulmonary	I-Premise
toxicity	I-Premise
and	I-Premise
one	I-Premise
pulmonary	I-Premise
embolus),	I-Premise
and	I-Premise
1	I-Premise
patient	I-Premise
in	I-Premise
the	I-Premise
radiation	I-Premise
arm	I-Premise
(radiation	I-Premise
pneumonitis).	I-Premise

Induction	B-Premise
chemotherapy	I-Premise
was	I-Premise
completed	I-Premise
in	I-Premise
78%	I-Premise
of	I-Premise
the	I-Premise
patients.	I-Premise

Complete	B-Premise
resection	I-Premise
was	I-Premise
performed	I-Premise
in	I-Premise
73%	I-Premise
of	I-Premise
26	I-Premise
patients	I-Premise
undergoing	I-Premise
thoracotomy.	I-Premise

Consolidation	B-Premise
chemotherapy	I-Premise
was	I-Premise
completed	I-Premise
in	I-Premise
75%	I-Premise
of	I-Premise
the	I-Premise
patients.	I-Premise

No	B-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
was	I-Premise
found	I-Premise
among	I-Premise
the	I-Premise
treatment	I-Premise
arms.	I-Premise

The	B-Premise
overall	I-Premise
progression-free	I-Premise
survival	I-Premise
rate	I-Premise
was	I-Premise
53%	I-Premise
at	I-Premise
1	I-Premise
year	I-Premise
and	I-Premise
17%	I-Premise
at	I-Premise
3	I-Premise
years.	I-Premise

The	B-Premise
median	I-Premise
progression-free	I-Premise
survival	I-Premise
was	I-Premise
14	I-Premise
months.	I-Premise

No	B-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
1-year	I-Premise
survival	I-Premise
rate	I-Premise
(70%	I-Premise
vs.	I-Premise
66%)	I-Premise
or	I-Premise
median	I-Premise
survival	I-Premise
time	I-Premise
(19.4	I-Premise
vs.	I-Premise
17.4	I-Premise
months)	I-Premise
between	I-Premise
the	I-Premise
surgery	I-Premise
and	I-Premise
RT	I-Premise
arms.	I-Premise

The	B-Premise
median	I-Premise
survival	I-Premise
in	I-Premise
the	I-Premise
patients	I-Premise
receiving	I-Premise
induction	I-Premise
chemotherapy	I-Premise
only	I-Premise
was	I-Premise
8.9	I-Premise
months.	I-Premise

Mitomycin-C	B-Premise
had	I-Premise
no	I-Premise
impact	I-Premise
on	I-Premise
survival	I-Premise
(p	I-Premise
=	I-Premise
0.75).	I-Premise

No	B-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
was	I-Premise
noted	I-Premise
in	I-Premise
the	I-Premise
time	I-Premise
to	I-Premise
local	I-Premise
failure	I-Premise
between	I-Premise
the	I-Premise
surgical	I-Premise
and	I-Premise
RT	I-Premise
arms.	I-Premise

The	B-Claim
patient	I-Claim
accrual	I-Claim
to	I-Claim
this	I-Claim
trial	I-Claim
made	I-Claim
its	I-Claim
results	I-Claim
inconclusive,	I-Claim
but	O
several	O
observations	O
are	O
notable.	O

In	O
this	O
trial,	O
histologic	B-Claim
confirmation	I-Claim
of	I-Claim
N2	I-Claim
disease	I-Claim
in	I-Claim
the	I-Claim
surgical	I-Claim
and	I-Claim
nonsurgical	I-Claim
arms	I-Claim
eliminated	I-Claim
the	I-Claim
usual	I-Claim
biases	I-Claim
from	I-Claim
clinical	I-Claim
staging.	I-Claim

In	O
this	O
setting,	O
local	B-Claim
control	I-Claim
and	I-Claim
survival	I-Claim
were	I-Claim
essentially	I-Claim
equal	I-Claim
between	I-Claim
the	I-Claim
surgical	I-Claim
and	I-Claim
RT	I-Claim
arms.	I-Claim

The	B-Claim
3-	I-Claim
and	I-Claim
5-year	I-Claim
survival	I-Claim
rates	I-Claim
of	I-Claim
nonsurgical	I-Claim
therapy	I-Claim
were	I-Claim
comparable	I-Claim
to	I-Claim
published	I-Claim
surgical	I-Claim
trials	I-Claim
of	I-Claim
N2	I-Claim
disease.	I-Claim

Mucositis	B-Premise
occurs	I-Premise
in	I-Premise
almost	I-Premise
all	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
radiotherapy	I-Premise
for	I-Premise
head	I-Premise
and	I-Premise
neck	I-Premise
cancer.	I-Premise

The	O
aim	O
of	O
this	O
multicenter,	O
double-blind,	O
prospective,	O
randomized	O
trial	O
was	O
to	O
evaluate	O
the	O
clinical	O
efficacy	O
of	O
an	O
economically	O
viable	O
antimicrobial	O
lozenge	O
(bacitracin,	O
clotrimazole,	O
and	O
gentamicin	O
[BcoG])	O
in	O
the	O
alleviation	O
of	O
radiation-induced	O
mucositis	O
in	O
patients	O
with	O
head	O
and	O
neck	O
cancer.	O

One	O
hundred	O
thirty-seven	O
eligible	O
patients	O
were	O
randomized	O
to	O
treatment	O
with	O
either	O
antimicrobial	O
lozenge	O
(69	O
patients)	O
or	O
placebo	O
lozenge	O
(68	O
patients).	O

The	O
primary	O
end	O
point	O
of	O
the	O
study	O
was	O
the	O
time	O
to	O
development	O
of	O
severe	O
mucositis	O
from	O
the	O
start	O
of	O
radiotherapy.	O

Secondary	O
end	O
points	O
included	O
severity	O
and	O
duration	O
of	O
mucositis,	O
pain	O
measurement,	O
radiation	O
therapy	O
interruption,	O
and	O
quality	O
of	O
life.	O

Mucositis	O
was	O
scored	O
using	O
a	O
validated	O
mucositis	O
scoring	O
system.	O

Toxicity	B-Premise
profiles	I-Premise
were	I-Premise
similar	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
arms	I-Premise
of	I-Premise
the	I-Premise
study.	I-Premise

The	B-Premise
median	I-Premise
time	I-Premise
to	I-Premise
development	I-Premise
of	I-Premise
severe	I-Premise
mucositis	I-Premise
from	I-Premise
the	I-Premise
start	I-Premise
of	I-Premise
radiotherapy	I-Premise
was	I-Premise
3.61	I-Premise
weeks	I-Premise
on	I-Premise
BCoG	I-Premise
and	I-Premise
3.96	I-Premise
weeks	I-Premise
on	I-Premise
placebo	I-Premise
(P	I-Premise
=.61).	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
the	I-Premise
arms	I-Premise
in	I-Premise
the	I-Premise
extent	I-Premise
of	I-Premise
severe	I-Premise
mucositis	I-Premise
as	I-Premise
measured	I-Premise
by	I-Premise
physician,	I-Premise
in	I-Premise
oral	I-Premise
toxicities	I-Premise
as	I-Premise
recorded	I-Premise
by	I-Premise
patients,	I-Premise
or	I-Premise
in	I-Premise
radiotherapy	I-Premise
delays.	I-Premise

This	O
study	O
was	O
conducted	O
on	O
the	O
basis	O
of	O
a	O
pilot	O
study	O
that	O
demonstrated	O
the	O
BCoG	O
lozenge	O
to	O
be	O
tolerable	O
and	O
microbiologically	O
efficacious.	O

A	O
validated	O
mucositis	O
scoring	O
system	O
was	O
used.	O

However,	O
in	B-Claim
this	I-Claim
group	I-Claim
of	I-Claim
patients	I-Claim
treated	I-Claim
with	I-Claim
conventional	I-Claim
radiotherapy,	I-Claim
the	I-Claim
lozenge	I-Claim
did	I-Claim
not	I-Claim
impact	I-Claim
significantly	I-Claim
on	I-Claim
the	I-Claim
severity	I-Claim
of	I-Claim
mucositis.	I-Claim

Whether	B-Claim
such	I-Claim
a	I-Claim
lozenge	I-Claim
would	I-Claim
be	I-Claim
beneficial	I-Claim
in	I-Claim
treatment	I-Claim
situations	I-Claim
where	I-Claim
rate	I-Claim
of	I-Claim
severe	I-Claim
mucositis	I-Claim
is	I-Claim
higher	I-Claim
(ie,	I-Claim
in	I-Claim
patients	I-Claim
treated	I-Claim
with	I-Claim
unconventional	I-Claim
fractionation	I-Claim
or	I-Claim
with	I-Claim
concomitant	I-Claim
chemotherapy)	I-Claim
is	I-Claim
unknown.	I-Claim

Bone	B-Claim
metastases	I-Claim
are	I-Claim
a	I-Claim
common	I-Claim
cause	I-Claim
of	I-Claim
morbidity	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
prostate	I-Claim
carcinoma.	I-Claim

We	O
studied	O
the	O
effect	O
of	O
a	O
new	O
bisphosphonate,	O
zoledronic	O
acid,	O
which	O
blocks	O
bone	O
destruction,	O
on	O
skeletal	O
complications	O
in	O
prostate	O
cancer	O
patients	O
with	O
bone	O
metastases.	O

Patients	O
with	O
hormone-refractory	O
prostate	O
cancer	O
and	O
a	O
history	O
of	O
bone	O
metastases	O
were	O
randomly	O
assigned	O
to	O
a	O
double-blind	O
treatment	O
regimen	O
of	O
intravenous	O
zoledronic	O
acid	O
at	O
4	O
mg	O
(N	O
=	O
214),	O
zoledronic	O
acid	O
at	O
8	O
mg	O
(subsequently	O
reduced	O
to	O
4	O
mg;	O
8/4)	O
(N	O
=	O
221),	O
or	O
placebo	O
(N	O
=	O
208)	O
every	O
3	O
weeks	O
for	O
15	O
months.	O

Proportions	O
of	O
patients	O
with	O
skeletal-related	O
events,	O
time	O
to	O
the	O
first	O
skeletal-related	O
event,	O
skeletal	O
morbidity	O
rate,	O
pain	O
and	O
analgesic	O
scores,	O
disease	O
progression,	O
and	O
safety	O
were	O
assessed.	O

All	O
statistical	O
tests	O
were	O
two-sided.	O

Approximately	O
38%	O
of	O
patients	O
who	O
received	O
zoledronic	O
acid	O
at	O
4	O
mg,	O
28%	O
who	O
received	O
zoledronic	O
acid	O
at	O
8/4	O
mg,	O
and	O
31%	O
who	O
received	O
placebo	O
completed	O
the	O
study.	O

A	B-Premise
greater	I-Premise
proportion	I-Premise
of	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
placebo	I-Premise
had	I-Premise
skeletal-related	I-Premise
events	I-Premise
than	I-Premise
those	I-Premise
who	I-Premise
received	I-Premise
zoledronic	I-Premise
acid	I-Premise
at	I-Premise
4	I-Premise
mg	I-Premise
(44.2%	I-Premise
versus	I-Premise
33.2%;	I-Premise
difference	I-Premise
=	I-Premise
-11.0%,	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
=	I-Premise
-20.3%	I-Premise
to	I-Premise
-1.8%;	I-Premise
P	I-Premise
=.021)	I-Premise
or	I-Premise
those	I-Premise
who	I-Premise
received	I-Premise
zoledronic	I-Premise
acid	I-Premise
at	I-Premise
8/4	I-Premise
mg	I-Premise
(38.5%;	I-Premise
difference	I-Premise
versus	I-Premise
placebo	I-Premise
=	I-Premise
-5.8%,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
-15.1%	I-Premise
to	I-Premise
3.6%;	I-Premise
P	I-Premise
=.222).	I-Premise

Median	B-Premise
time	I-Premise
to	I-Premise
first	I-Premise
skeletal-related	I-Premise
event	I-Premise
was	I-Premise
321	I-Premise
days	I-Premise
for	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
placebo,	I-Premise
was	I-Premise
not	I-Premise
reached	I-Premise
for	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
zoledronic	I-Premise
acid	I-Premise
at	I-Premise
4	I-Premise
mg	I-Premise
(P	I-Premise
=.011	I-Premise
versus	I-Premise
placebo),	I-Premise
and	I-Premise
was	I-Premise
363	I-Premise
days	I-Premise
for	I-Premise
those	I-Premise
who	I-Premise
received	I-Premise
zoledronic	I-Premise
acid	I-Premise
at	I-Premise
8/4	I-Premise
mg	I-Premise
(P	I-Premise
=.491	I-Premise
versus	I-Premise
placebo).	I-Premise

Compared	B-Premise
with	I-Premise
urinary	I-Premise
markers	I-Premise
in	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
placebo,	I-Premise
urinary	I-Premise
markers	I-Premise
of	I-Premise
bone	I-Premise
resorption	I-Premise
were	I-Premise
statistically	I-Premise
significantly	I-Premise
decreased	I-Premise
in	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
zoledronic	I-Premise
acid	I-Premise
at	I-Premise
either	I-Premise
dose	I-Premise
(P	I-Premise
=.001).	I-Premise

Pain	B-Premise
and	I-Premise
analgesic	I-Premise
scores	I-Premise
increased	I-Premise
more	I-Premise
in	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
placebo	I-Premise
than	I-Premise
in	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
zoledronic	I-Premise
acid,	I-Premise
but	O
there	B-Premise
were	I-Premise
no	I-Premise
differences	I-Premise
in	I-Premise
disease	I-Premise
progression,	I-Premise
performance	I-Premise
status,	I-Premise
or	I-Premise
quality-of-life	I-Premise
scores	I-Premise
among	I-Premise
the	I-Premise
groups.	I-Premise

Zoledronic	B-Claim
acid	I-Claim
at	I-Claim
4	I-Claim
mg	I-Claim
given	I-Claim
as	I-Claim
a	I-Claim
15-minute	I-Claim
infusion	I-Claim
was	I-Claim
well	I-Claim
tolerated,	I-Claim
but	O
the	B-Claim
8-mg	I-Claim
dose	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
renal	I-Claim
function	I-Claim
deterioration.	I-Claim

Zoledronic	B-Claim
acid	I-Claim
at	I-Claim
4	I-Claim
mg	I-Claim
reduced	I-Claim
skeletal-related	I-Claim
events	I-Claim
in	I-Claim
prostate	I-Claim
cancer	I-Claim
patients	I-Claim
with	I-Claim
bone	I-Claim
metastases.	I-Claim

In	O
the	O
Asia-Pacific	O
region	O
and	O
elsewhere,	O
almost	O
85%	O
of	O
patients	O
with	O
hepatocellular	O
carcinoma	O
(HCC)	O
are	O
inoperable	O
at	O
diagnosis	O
and	O
have	O
a	O
dismal	O
prognosis.	O

Tamoxifen	B-Claim
(TMX)	I-Claim
is	I-Claim
believed	I-Claim
to	I-Claim
inhibit	I-Claim
HCC	I-Claim
positive	I-Claim
for	I-Claim
estrogen	I-Claim
receptor	I-Claim
(ER),	I-Claim
but	I-Claim
most	I-Claim
HCCs	I-Claim
are	I-Claim
ER	I-Claim
negative.	I-Claim

Results	B-Claim
of	I-Claim
previous	I-Claim
phase	I-Claim
3	I-Claim
trials	I-Claim
in	I-Claim
inoperable	I-Claim
HCC	I-Claim
have	I-Claim
been	I-Claim
conflicting	I-Claim
and	I-Claim
inconclusive.	I-Claim

At	B-Claim
higher	I-Claim
doses,	I-Claim
however,	I-Claim
TMX	I-Claim
inhibits	I-Claim
HCC	I-Claim
through	I-Claim
ER-independent	I-Claim
mechanisms.	I-Claim

A	O
multicenter	O
randomized	O
controlled	O
trial	O
was	O
performed	O
to	O
assess	O
the	O
role	O
of	O
high-dose	O
TMX	O
versus	O
placebo	O
(P)	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
inoperable	O
HCC	O
with	O
respect	O
to	O
survival	O
and	O
quality	O
of	O
life	O
(QoL).	O

A	O
total	O
of	O
329	O
patients	O
from	O
10	O
centers	O
in	O
9	O
countries	O
in	O
the	O
Asia-Pacific	O
region	O
enrolled	O
in	O
a	O
double-blind	O
randomized	O
controlled	O
trial	O
of	O
TMX	O
120	O
mg/d	O
(TMX120)	O
against	O
P	O
as	O
a	O
control	O
arm	O
with	O
an	O
intermediate	O
dosage	O
of	O
TMX	O
60	O
mg/d	O
(TMX60)	O
to	O
assess	O
possible	O
dose	O
response.	O

An	O
independent	O
data	O
monitoring	O
committee	O
reviewed	O
all	O
aspects	O
of	O
the	O
trial.	O

QoL	O
was	O
assessed	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
QLQ-C30	O
questionnaire.	O

Three-month	B-Premise
survival	I-Premise
rates	I-Premise
for	I-Premise
the	I-Premise
P,	I-Premise
TMX60,	I-Premise
and	I-Premise
TMX120	I-Premise
groups	I-Premise
were	I-Premise
44%,	I-Premise
41%,	I-Premise
and	I-Premise
35%,	I-Premise
respectively,	I-Premise
with	I-Premise
a	I-Premise
statistically	I-Premise
significant	I-Premise
trend	I-Premise
difference	I-Premise
in	I-Premise
survival	I-Premise
across	I-Premise
the	I-Premise
3	I-Premise
treatment	I-Premise
regimens	I-Premise
(P	I-Premise
=.011).	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
significantly	I-Premise
higher	I-Premise
risk	I-Premise
of	I-Premise
death	I-Premise
in	I-Premise
the	I-Premise
TMX120	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
P	I-Premise
group	I-Premise
(hazard	I-Premise
ratio,	I-Premise
1.39;	I-Premise
95%	I-Premise
confidence	I-Premise
interval,	I-Premise
1.07-1.81).	I-Premise

Adverse	B-Premise
drug	I-Premise
reactions	I-Premise
were	I-Premise
reported	I-Premise
in	I-Premise
3%	I-Premise
(9	I-Premise
patients),	I-Premise
and	O
8	B-Premise
patients	I-Premise
were	I-Premise
lost	I-Premise
to	I-Premise
follow-up.	I-Premise

In	O
conclusion,	O
TMX	B-Claim
does	I-Claim
not	I-Claim
prolong	I-Claim
survival	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
inoperable	I-Claim
HCC	I-Claim
and	I-Claim
has	I-Claim
an	I-Claim
increasingly	I-Claim
negative	I-Claim
impact	I-Claim
with	I-Claim
increasing	I-Claim
dose.	I-Claim

No	B-Claim
appreciable	I-Claim
advantage	I-Claim
to	I-Claim
QoL	I-Claim
with	I-Claim
TMX	I-Claim
was	I-Claim
observed.	I-Claim

Increased	B-Claim
expression	I-Claim
of	I-Claim
metalloproteinases	I-Claim
is	I-Claim
associated	I-Claim
with	I-Claim
poor	I-Claim
prognosis	I-Claim
in	I-Claim
small-cell	I-Claim
lung	I-Claim
cancer	I-Claim
(SCLC).	I-Claim

This	O
trial	O
was	O
undertaken	O
to	O
determine	O
whether	O
adjuvant	O
treatment	O
with	O
the	O
metalloproteinase	O
inhibitor	O
marimastat	O
could	O
prolong	O
survival	O
in	O
responding	O
patients	O
with	O
SCLC	O
after	O
chemotherapy.	O

SCLC	O
patients	O
in	O
complete	O
or	O
partial	O
remission	O
were	O
eligible.	O

They	O
were	O
stratified	O
by	O
radiotherapy	O
(early,	O
late,	O
or	O
none),	O
stage	O
(extensive	O
or	O
limited),	O
response	O
(complete	O
or	O
partial),	O
and	O
cooperative	O
group	O
(National	O
Cancer	O
Institute	O
of	O
Canada-Clinical	O
Trials	O
Group	O
or	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer).	O

They	O
were	O
randomized	O
to	O
receive	O
marimastat	O
10	O
mg	O
or	O
placebo	O
orally	O
bid	O
for	O
up	O
to	O
2	O
years.	O

There	O
were	O
532	O
eligible	O
patients	O
(266	O
marimastat	O
and	O
266	O
placebo).	O

Stage	O
was	O
limited	O
for	O
279	O
patients	O
(52%)	O
and	O
extensive	O
for	O
253	O
(48%).	O

Best	B-Premise
response	I-Premise
to	I-Premise
induction	I-Premise
therapy	I-Premise
was	I-Premise
complete	I-Premise
remission	I-Premise
for	I-Premise
176	I-Premise
patients	I-Premise
(33%),	I-Premise
partial	I-Premise
remission	I-Premise
for	I-Premise
341	I-Premise
(64%),	I-Premise
and	I-Premise
15	I-Premise
patients	I-Premise
(3%)	I-Premise
had	I-Premise
undergone	I-Premise
surgical	I-Premise
resection.	I-Premise

The	B-Premise
median	I-Premise
time	I-Premise
to	I-Premise
progression	I-Premise
for	I-Premise
marimastat	I-Premise
patients	I-Premise
was	I-Premise
4.3	I-Premise
months	I-Premise
compared	I-Premise
with	I-Premise
4.4	I-Premise
months	I-Premise
for	I-Premise
placebo	I-Premise
patients	I-Premise
(P	I-Premise
=.81).	I-Premise

Median	B-Premise
survivals	I-Premise
for	I-Premise
marimastat	I-Premise
and	I-Premise
placebo	I-Premise
patients	I-Premise
were	I-Premise
9.3	I-Premise
months	I-Premise
and	I-Premise
9.7	I-Premise
months,	I-Premise
respectively	I-Premise
(P	I-Premise
=.90).	I-Premise

Toxicity	B-Premise
was	I-Premise
generally	I-Premise
limited	I-Premise
to	I-Premise
musculoskeletal	I-Premise
symptoms	I-Premise
(18%	I-Premise
grade	I-Premise
3/4	I-Premise
for	I-Premise
marimastat).	I-Premise

Dose	B-Premise
modifications	I-Premise
for	I-Premise
musculoskeletal	I-Premise
toxicity	I-Premise
were	I-Premise
required	I-Premise
in	I-Premise
90	I-Premise
patients	I-Premise
(33%)	I-Premise
on	I-Premise
the	I-Premise
marimastat	I-Premise
arm,	I-Premise
and	I-Premise
87	I-Premise
(32%)	I-Premise
permanently	I-Premise
stopped	I-Premise
marimastat	I-Premise
because	I-Premise
of	I-Premise
toxicity.	I-Premise

Patients	B-Premise
on	I-Premise
marimastat	I-Premise
had	I-Premise
significantly	I-Premise
poorer	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
at	I-Premise
3	I-Premise
and	I-Premise
6	I-Premise
months.	I-Premise

Treatment	B-Claim
with	I-Claim
marimastat	I-Claim
after	I-Claim
induction	I-Claim
therapy	I-Claim
for	I-Claim
SCLC	I-Claim
did	I-Claim
not	I-Claim
result	I-Claim
in	I-Claim
improved	I-Claim
survival	I-Claim
and	I-Claim
had	I-Claim
a	I-Claim
negative	I-Claim
impact	I-Claim
on	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

Morbidity	B-Claim
associated	I-Claim
with	I-Claim
wound	I-Claim
complications	I-Claim
may	I-Claim
translate	I-Claim
into	I-Claim
disability	I-Claim
and	I-Claim
quality-of-life	I-Claim
disadvantages	I-Claim
for	I-Claim
patients	I-Claim
treated	I-Claim
with	I-Claim
radiotherapy	I-Claim
(RT)	I-Claim
for	I-Claim
soft	I-Claim
tissue	I-Claim
sarcoma	I-Claim
(STS)	I-Claim
of	I-Claim
the	I-Claim
extremities.	I-Claim

Functional	O
outcome	O
and	O
health	O
status	O
of	O
extremity	O
STS	O
patients	O
randomized	O
in	O
a	O
phase	O
III	O
trial	O
comparing	O
preoperative	O
versus	O
postoperative	O
RT	O
is	O
described.	O

One	O
hundred	O
ninety	O
patients	O
with	O
extremity	O
STS	O
were	O
randomized	O
after	O
stratification	O
by	O
tumor	O
size	O
dichotomized	O
at	O
10	O
cm.	O

Function	O
and	O
quality	O
of	O
life	O
were	O
measured	O
by	O
the	O
Musculoskeletal	O
Tumor	O
Society	O
Rating	O
Scale	O
(MSTS),	O
the	O
Toronto	O
Extremity	O
Salvage	O
Score	O
(TESS),	O
and	O
the	O
Short	O
Form-36	O
(SF-36)	O
at	O
randomization,	O
6	O
weeks,	O
and	O
3,	O
6,	O
12,	O
and	O
24	O
months	O
after	O
surgery.	O

One	O
hundred	O
eighty-five	O
patients	O
had	O
function	O
data.	O

Patients	B-Premise
treated	I-Premise
with	I-Premise
postoperative	I-Premise
RT	I-Premise
had	I-Premise
better	I-Premise
function	I-Premise
with	I-Premise
higher	I-Premise
MSTS	I-Premise
(25.8	I-Premise
v	I-Premise
21.3,	I-Premise
P	I-Premise
<.01),	I-Premise
TESS	I-Premise
(69.8	I-Premise
v	I-Premise
60.6,	I-Premise
P	I-Premise
=.01),	I-Premise
and	I-Premise
SF-36	I-Premise
bodily	I-Premise
pain	I-Premise
(67.7	I-Premise
v	I-Premise
58.5,	I-Premise
P	I-Premise
=.03)	I-Premise
scores	I-Premise
at	I-Premise
6	I-Premise
weeks	I-Premise
after	I-Premise
surgery.	I-Premise

There	O
were	O
no	O
differences	O
at	O
later	O
time	O
points.	O

Scores	B-Premise
on	I-Premise
the	I-Premise
physical	I-Premise
function,	I-Premise
role-physical,	I-Premise
and	I-Premise
general	I-Premise
health	I-Premise
subscales	I-Premise
of	I-Premise
the	I-Premise
SF-36	I-Premise
were	I-Premise
significantly	I-Premise
lower	I-Premise
than	I-Premise
Canadian	I-Premise
normative	I-Premise
data	I-Premise
at	I-Premise
all	I-Premise
time	I-Premise
points.	I-Premise

After	O
treatment	O
arm	O
was	O
controlled	O
for,	O
MSTS	O
change	O
scores	O
were	O
predicted	O
by	O
a	O
lower-extremity	O
tumor,	O
a	O
large	O
resection	O
specimen,	O
and	O
motor	O
nerve	O
sacrifice;	O
TESS	O
change	O
scores	O
were	O
predicted	O
by	O
lower-extremity	O
tumor	O
and	O
prior	O
incomplete	O
excision.	O

When	B-Premise
wound	I-Premise
complication	I-Premise
was	I-Premise
included	I-Premise
in	I-Premise
the	I-Premise
model,	I-Premise
patients	I-Premise
with	I-Premise
complications	I-Premise
had	I-Premise
lower	I-Premise
MSTS	I-Premise
and	I-Premise
TESS	I-Premise
scores	I-Premise
in	I-Premise
the	I-Premise
first	I-Premise
2	I-Premise
years	I-Premise
after	I-Premise
treatment.	I-Premise

The	B-Claim
timing	I-Claim
of	I-Claim
RT	I-Claim
has	I-Claim
minimal	I-Claim
impact	I-Claim
on	I-Claim
the	I-Claim
function	I-Claim
of	I-Claim
STS	I-Claim
patients	I-Claim
in	I-Claim
the	I-Claim
first	I-Claim
year	I-Claim
after	I-Claim
surgery.	I-Claim

Tumor	B-Claim
characteristics	I-Claim
and	I-Claim
wound	I-Claim
complications	I-Claim
have	I-Claim
a	I-Claim
detrimental	I-Claim
effect	I-Claim
on	I-Claim
patient	I-Claim
function.	I-Claim

The	O
standard	O
doublet,	O
vinorelbine-cisplatin,	O
was	O
compared	O
with	O
a	O
triplet	O
of	O
vinorelbine-ifosfamide-cisplatin,	O
in	O
terms	O
of	O
survival,	O
in	O
patients	O
with	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(NSCLC).	O

From	O
February	O
1998	O
to	O
June	O
1999,	O
259	O
chemonave	O
patients	O
entered	O
the	O
study	O
and	O
were	O
randomised	O
to	O
receive	O
either	O
vinorelbine-cisplatin	O
(NP;	O
vinorelbine	O
30	O
mg/m(2)	O
on	O
days	O
1,	O
8	O
and	O
15	O
with	O
cisplatin	O
80	O
mg/m(2)	O
on	O
day	O
1)	O
or	O
vinorelbine-ifosfamide-cisplatin	O
(NIP;	O
vinorelbine	O
25	O
mg/m(2)	O
on	O
days	O
1	O
and	O
8,	O
ifosfamide	O
3	O
g/m(2)	O
on	O
day	O
1	O
and	O
cisplatin	O
75	O
mg/m(2)	O
on	O
day	O
1),	O
with	O
both	O
regimens	O
being	O
repeated	O
every	O
3	O
weeks.	O

All	O
patients	O
had	O
stage	O
IV	O
or	O
relapsed	O
disease	O
and	O
a	O
performance	O
score	O
of	O
0	O
or	O
1.	O

The	B-Premise
overall	I-Premise
response	I-Premise
rate	I-Premise
was	I-Premise
34.6%	I-Premise
for	I-Premise
NP	I-Premise
and	I-Premise
35.7%	I-Premise
for	I-Premise
NIP.	I-Premise

Median	B-Premise
and	I-Premise
1-year	I-Premise
survival	I-Premise
rates	I-Premise
were	I-Premise
10.0	I-Premise
months	I-Premise
and	I-Premise
38.4%	I-Premise
for	I-Premise
NP,	I-Premise
and	I-Premise
8.2	I-Premise
months	I-Premise
and	I-Premise
33.7%	I-Premise
for	I-Premise
NIP,	I-Premise
respectively.	I-Premise

A	O
median	O
of	O
four	O
cycles	O
was	O
administered	O
in	O
each	O
arm.	O

The	B-Premise
major	I-Premise
World	I-Premise
Health	I-Premise
Organization	I-Premise
grade	I-Premise
3-4	I-Premise
toxicities	I-Premise
for	I-Premise
NP	I-Premise
and	I-Premise
NIP,	I-Premise
respectively,	I-Premise
were:	I-Premise
neutropenia	I-Premise
(20.3%	I-Premise
compared	I-Premise
with	I-Premise
9%	I-Premise
of	I-Premise
cycles),	I-Premise
anaemia	I-Premise
(4.1%	I-Premise
compared	I-Premise
with	I-Premise
5%	I-Premise
of	I-Premise
cycles),	I-Premise
nausea	I-Premise
and	I-Premise
vomiting	I-Premise
(22.2%	I-Premise
compared	I-Premise
with	I-Premise
19.4%	I-Premise
of	I-Premise
patients)	I-Premise
and	I-Premise
alopecia	I-Premise
(5.6%	I-Premise
compared	I-Premise
with	I-Premise
29.8%	I-Premise
of	I-Premise
patients).	I-Premise

Four	B-Premise
toxic	I-Premise
deaths	I-Premise
occurred	I-Premise
in	I-Premise
the	I-Premise
NP	I-Premise
arm	I-Premise
and	I-Premise
eight	I-Premise
in	I-Premise
the	I-Premise
NIP	I-Premise
arm.	I-Premise

The	B-Premise
different	I-Premise
schedules	I-Premise
of	I-Premise
vinorelbine	I-Premise
in	I-Premise
the	I-Premise
two	I-Premise
arms	I-Premise
led	I-Premise
to	I-Premise
a	I-Premise
greater	I-Premise
survival	I-Premise
in	I-Premise
the	I-Premise
NP	I-Premise
arm	I-Premise
without	I-Premise
impairing	I-Premise
the	I-Premise
tolerance	I-Premise
profile,	I-Premise
although	B-Premise
this	I-Premise
is	I-Premise
not	I-Premise
statistically	I-Premise
significant.	I-Premise

This	B-Claim
confirms	I-Claim
that	I-Claim
the	I-Claim
two-drug	I-Claim
combination	I-Claim
NP	I-Claim
is	I-Claim
a	I-Claim
reference	I-Claim
treatment	I-Claim
for	I-Claim
metastatic	I-Claim
NSCLC.	I-Claim

The	B-Claim
role	I-Claim
of	I-Claim
three-drug	I-Claim
combinations	I-Claim
remains	I-Claim
questionable	I-Claim
in	I-Claim
this	I-Claim
subset	I-Claim
of	I-Claim
patients.	I-Claim

A	O
multicenter	O
trial	O
was	O
conducted	O
to	O
determine	O
the	O
efficacy	O
and	O
toxicity	O
of	O
escalating	O
dosages	O
of	O
liposomal	O
tretinoin	O
(all-trans-retinoic	O
acid)	O
administered	O
once	O
or	O
three	O
times	O
weekly	O
in	O
patients	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
(AIDS)-associated	O
Kaposi	O
sarcoma.	O

Seventy-six	O
patients	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
(AIDS)-associated	O
Kaposi	O
sarcoma	O
were	O
randomized	O
to	O
receive	O
the	O
study	O
drug	O
either	O
once	O
(n	O
=	O
30)	O
or	O
3	O
times	O
weekly	O
(n	O
=	O
46).	O

The	O
starting	O
dosage	O
was	O
60	O
mg/m(2),	O
which	O
was	O
escalated	O
to	O
90	O
mg/m(2)	O
and	O
then	O
120	O
mg/m(2)	O
if	O
the	O
drug	O
was	O
well	O
tolerated	O
(<or=	O
Grade	O
2	O
toxicities	O
[according	O
to	O
the	O
Southwest	O
Oncology	O
Group	O
toxicity	O
scale]).	O

Four	O
weeks	O
of	O
therapy	O
constituted	O
1	O
cycle;	O
patients	O
could	O
receive	O
up	O
to	O
8	O
cycles	O
and	O
those	O
who	O
completed	O
8	O
cycles	O
were	O
given	O
the	O
option	O
of	O
receiving	O
extended	O
therapy.	O

Clinical	O
response	O
was	O
defined	O
as	O
complete	O
response	O
(CR),	O
partial	O
response	O
(PR),	O
or	O
stable	O
disease	O
(SD).	O

Efficacy	O
was	O
assessed	O
after	O
the	O
completion	O
of	O
3	O
treatment	O
cycles;	O
28.9%	O
of	O
patients	O
(22	O
of	O
76	O
patients)	O
responded	O
(no	O
CRs,	O
1	O
PR,	O
and	O
21	O
SDs).	O

Among	B-Premise
the	I-Premise
patients	I-Premise
receiving	I-Premise
treatment	I-Premise
3	I-Premise
times	I-Premise
weekly,	I-Premise
16	I-Premise
of	I-Premise
49	I-Premise
patients	I-Premise
(32.7%)	I-Premise
achieved	I-Premise
a	I-Premise
clinical	I-Premise
response	I-Premise
at	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
the	I-Premise
third	I-Premise
treatment	I-Premise
cycle	I-Premise
(no	I-Premise
CRs,	I-Premise
1	I-Premise
PR,	I-Premise
and	I-Premise
15	I-Premise
SDs).	I-Premise

Concomitant	B-Premise
or	I-Premise
prior	I-Premise
use	I-Premise
of	I-Premise
protease	I-Premise
inhibitors	I-Premise
did	I-Premise
not	I-Premise
appear	I-Premise
to	I-Premise
affect	I-Premise
the	I-Premise
patient's	I-Premise
response	I-Premise
to	I-Premise
treatment	I-Premise
(P	I-Premise
=	I-Premise
0.183).	I-Premise

Liposomal	B-Premise
tretinoin	I-Premise
is	I-Premise
a	I-Premise
new	I-Premise
therapeutic	I-Premise
agent	I-Premise
that	I-Premise
has	I-Premise
been	I-Premise
reported	I-Premise
to	I-Premise
have	I-Premise
some	I-Premise
clinical	I-Premise
activity	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
AIDS-associated	I-Premise
Kaposi	I-Premise
sarcoma.	I-Premise

A	B-Claim
three-times-per-week	I-Claim
dosing	I-Claim
schedule	I-Claim
was	I-Claim
noted	I-Claim
to	I-Claim
be	I-Claim
more	I-Claim
effective	I-Claim
compared	I-Claim
with	I-Claim
a	I-Claim
once-a-week	I-Claim
schedule	I-Claim
without	I-Claim
any	I-Claim
significant	I-Claim
difference	I-Claim
in	I-Claim
toxicity	I-Claim
reported.	I-Claim

To	O
compare	O
in	O
a	O
phase	O
III	O
study	O
the	O
safety	O
and	O
efficacy	O
of	O
fludarabine	O
to	O
that	O
of	O
cyclophosphamide,	O
vincristine,	O
and	O
prednisone	O
(CVP)	O
in	O
recurrent,	O
low-grade,	O
non-Hodgkin's	O
lymphoma	O
after	O
previous	O
response	O
to	O
systemic	O
treatment.	O

Patients	O
were	O
randomized	O
to	O
fludarabine	O
(25	O
mg/m(2)	O
intravenously	O
on	O
days	O
1	O
to	O
5,	O
every	O
28	O
days)	O
or	O
CVP	O
(cyclophosphamide	O
750	O
mg/m(2)	O
and	O
vincristine	O
1.2	O
mg/m(2)	O
both	O
intravenously	O
on	O
day	O
1	O
and	O
prednisone	O
40	O
mg/m(2)	O
orally	O
on	O
days	O
1	O
to	O
5,	O
every	O
21	O
days).	O

The	O
primary	O
outcome	O
assessed	O
was	O
progression-free	O
survival	O
(PFS);	O
secondary	O
outcomes	O
included	O
treatment-free	O
survival	O
(TFS),	O
overall	O
survival	O
(OS),	O
treatment-related	O
toxicity,	O
and	O
quality	O
of	O
life	O
(QoL)	O
according	O
to	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer's	O
Quality	O
of	O
Life	O
Questionnaire	O
C-30	O
version	O
1.0	O
instrument.	O

Ninety-one	O
patients	O
were	O
randomized,	O
47	O
to	O
fludarabine	O
and	O
44	O
to	O
CVP.	O

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
response	I-Premise
rates,	I-Premise
with	I-Premise
64%	I-Premise
(complete	I-Premise
response	I-Premise
[CR],	I-Premise
9%)	I-Premise
for	I-Premise
fludarabine	I-Premise
versus	I-Premise
52%	I-Premise
(CR,	I-Premise
7%)	I-Premise
for	I-Premise
CVP	I-Premise
(P	I-Premise
=.72).	I-Premise

With	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
42	I-Premise
months,	I-Premise
median	I-Premise
PFS	I-Premise
(11	I-Premise
months	I-Premise
v	I-Premise
9.1	I-Premise
months;	I-Premise
P	I-Premise
=.03)	I-Premise
and	I-Premise
TFS	I-Premise
(15	I-Premise
months	I-Premise
v	I-Premise
11	I-Premise
months;	I-Premise
P	I-Premise
=.02)	I-Premise
were	I-Premise
superior	I-Premise
in	I-Premise
patients	I-Premise
receiving	I-Premise
fludarabine.	I-Premise

No	B-Premise
difference	I-Premise
in	I-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
detected	I-Premise
(57	I-Premise
months	I-Premise
for	I-Premise
fludarabine	I-Premise
v	I-Premise
44	I-Premise
months	I-Premise
for	I-Premise
CVP;	I-Premise
P	I-Premise
=.95).	I-Premise

Three	B-Premise
patients	I-Premise
receiving	I-Premise
fludarabine	I-Premise
died	I-Premise
of	I-Premise
treatment-related	I-Premise
toxicity	I-Premise
compared	I-Premise
with	I-Premise
none	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
receiving	I-Premise
CVP.	I-Premise

Peripheral	B-Premise
neuropathy	I-Premise
and	I-Premise
alopecia	I-Premise
were	I-Premise
more	I-Premise
common	I-Premise
with	I-Premise
CVP.	I-Premise

Patients	B-Premise
receiving	I-Premise
fludarabine	I-Premise
had	I-Premise
higher	I-Premise
scores	I-Premise
for	I-Premise
social	I-Premise
function	I-Premise
(P	I-Premise
=.008);	I-Premise
no	B-Premise
other	I-Premise
differences	I-Premise
in	I-Premise
QoL	I-Premise
were	I-Premise
detected.	I-Premise

In	B-Claim
recurrent	I-Claim
low-grade	I-Claim
lymphoma,	I-Claim
fludarabine	I-Claim
improves	I-Claim
PFS,	I-Claim
TFS,	I-Claim
and	I-Claim
social	I-Claim
function	I-Claim
scores	I-Claim
in	I-Claim
comparison	I-Claim
with	I-Claim
CVP	I-Claim
but	I-Claim
does	I-Claim
not	I-Claim
improve	I-Claim
OS.	I-Claim

Anemia,	B-Claim
highly	I-Claim
common	I-Claim
among	I-Claim
cancer	I-Claim
patients,	I-Claim
is	I-Claim
often	I-Claim
an	I-Claim
underlying	I-Claim
cause	I-Claim
of	I-Claim
cancer-related	I-Claim
fatigue	I-Claim
and	I-Claim
other	I-Claim
quality-of-life	I-Claim
(QOL)	I-Claim
deficits.	I-Claim

Although	O
randomized	O
clinical	O
trials	O
have	O
shown	O
that	O
treatment	O
with	O
epoetin	O
alfa	O
increases	O
hemoglobin	O
levels,	O
reduces	O
fatigue,	O
lessens	O
transfusion	O
requirements,	O
and	O
improves	O
overall	O
QOL,	O
cancer-related	O
anemia	O
and	O
fatigue	O
remain	O
undertreated.	O

This	O
is,	O
in	O
part,	O
because	O
scales	O
and	O
measures	O
of	O
QOL	O
are	O
still	O
relatively	O
unfamiliar	O
to	O
most	O
clinicians	O
and	O
because	O
population-based	O
reference	O
ranges	O
are	O
lacking,	O
thus	O
making	O
clinical	O
trial	O
results	O
difficult	O
to	O
interpret.	O

To	O
aid	O
in	O
the	O
interpretation	O
of	O
QOL	O
results	O
from	O
clinical	O
trials,	O
we	O
administered	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Anemia	O
(FACT-An)	O
QOL	O
instrument	O
to	O
a	O
nationally	O
representative	O
sample	O
of	O
1,400	O
people	O
using	O
an	O
Internet	O
survey	O
panel	O
in	O
the	O
United	O
States.	O

We	O
then	O
compared	O
the	O
FACT-An	O
data	O
from	O
the	O
Internet	O
survey	O
with	O
the	O
QOL	O
data	O
of	O
a	O
375-patient	O
randomized,	O
double-blind	O
clinical	O
trial	O
evaluating	O
epoetin	O
alfa	O
versus	O
placebo	O
in	O
anemic	O
cancer	O
patients.	O

FACT-An,	O
as	O
administered	O
to	O
the	O
survey	O
population,	O
displayed	O
good	O
psychometric	O
properties	O
and	O
was	O
able	O
to	O
discriminate	O
between	O
respondents	O
with	O
histories	O
of	O
specified	O
illnesses,	O
including	O
anemia	O
and	O
cancer,	O
and	O
those	O
without.	O

Comparison	B-Premise
of	I-Premise
the	I-Premise
population	I-Premise
norm	I-Premise
and	I-Premise
clinical	I-Premise
trial	I-Premise
data	I-Premise
showed	I-Premise
that	I-Premise
treatment	I-Premise
with	I-Premise
epoetin	I-Premise
alfa	I-Premise
resulted	I-Premise
in	I-Premise
clinically	I-Premise
meaningful	I-Premise
as	I-Premise
well	I-Premise
as	I-Premise
statistically	I-Premise
significant	I-Premise
improvements	I-Premise
in	I-Premise
QOL	I-Premise
(P	I-Premise
<.01).	I-Premise

Reliable	O
population	O
norm	O
data	O
are	O
now	O
available	O
to	O
aid	O
in	O
the	O
interpretation	O
of	O
clinical	O
trial	O
results	O
where	O
the	O
FACT-An	O
questionnaire	O
is	O
administered.	O

In	B-Claim
the	I-Claim
clinical	I-Claim
trial,	I-Claim
treatment	I-Claim
with	I-Claim
epoetin	I-Claim
alfa	I-Claim
overcame	I-Claim
much	I-Claim
of	I-Claim
the	I-Claim
QOL	I-Claim
deficit	I-Claim
seen	I-Claim
in	I-Claim
anemic	I-Claim
cancer	I-Claim
patients	I-Claim
compared	I-Claim
with	I-Claim
the	I-Claim
norm	I-Claim
population	I-Claim
sample.	I-Claim

To	O
examine	O
the	O
effect	O
of	O
a	O
progressive	O
upper-body	O
exercise	O
program	O
on	O
lymphedema	O
secondary	O
to	O
breast	O
cancer	O
treatment.	O

Fourteen	O
breast	O
cancer	O
survivors	O
with	O
unilateral	O
upper	O
extremity	O
lymphedema	O
were	O
randomly	O
assigned	O
to	O
an	O
exercise	O
(n	O
=	O
7)	O
or	O
control	O
group	O
(n	O
=	O
7).	O

The	O
exercise	O
group	O
followed	O
a	O
progressive,	O
8-week	O
upper-body	O
exercise	O
program	O
consisting	O
of	O
resistance	O
training	O
plus	O
aerobic	O
exercise	O
using	O
a	O
Monark	O
Rehab	O
Trainer	O
arm	O
ergometer.	O

Lymphedema	O
was	O
assessed	O
by	O
arm	O
circumference	O
and	O
measurement	O
of	O
arm	O
volume	O
by	O
water	O
displacement.	O

Patients	O
were	O
evaluated	O
on	O
five	O
occasions	O
over	O
the	O
experimental	O
period.	O

The	O
Medical	O
Outcomes	O
Trust	O
Short-Form	O
36	O
Survey	O
was	O
used	O
to	O
measure	O
quality	O
of	O
life	O
before	O
and	O
after	O
the	O
intervention.	O

Significance	O
was	O
set	O
at	O
alpha	O
<	O
or	O
=	O
0.01.	O

No	B-Premise
changes	I-Premise
were	I-Premise
found	I-Premise
in	I-Premise
arm	I-Premise
circumference	I-Premise
or	I-Premise
arm	I-Premise
volume	I-Premise
as	I-Premise
a	I-Premise
result	I-Premise
of	I-Premise
the	I-Premise
exercise	I-Premise
program.	I-Premise

Three	B-Premise
of	I-Premise
the	I-Premise
quality-of-life	I-Premise
domains	I-Premise
showed	I-Premise
trends	I-Premise
toward	I-Premise
increases	I-Premise
in	I-Premise
the	I-Premise
exercise	I-Premise
group:	I-Premise
physical	I-Premise
functioning	I-Premise
(P	I-Premise
=.050),	I-Premise
general	I-Premise
health	I-Premise
(P	I-Premise
=.048),	I-Premise
and	I-Premise
vitality	I-Premise
(P	I-Premise
=.023).	I-Premise

Mental	B-Premise
health	I-Premise
increased,	I-Premise
although	I-Premise
not	I-Premise
significantly,	I-Premise
for	I-Premise
all	I-Premise
subjects	I-Premise
(P	I-Premise
=.019).	I-Premise

Arm	B-Premise
volume	I-Premise
measured	I-Premise
by	I-Premise
water	I-Premise
displacement	I-Premise
was	I-Premise
correlated	I-Premise
with	I-Premise
calculated	I-Premise
arm	I-Premise
volume	I-Premise
(r	I-Premise
=.973,	I-Premise
P	I-Premise
<.001),	I-Premise
although	B-Premise
the	I-Premise
exercise	I-Premise
and	I-Premise
control	I-Premise
group	I-Premise
means	I-Premise
were	I-Premise
significantly	I-Premise
different	I-Premise
(P	I-Premise
<.001).	I-Premise

Participation	B-Claim
in	I-Claim
an	I-Claim
upper-body	I-Claim
exercise	I-Claim
program	I-Claim
caused	I-Claim
no	I-Claim
changes	I-Claim
in	I-Claim
arm	I-Claim
circumference	I-Claim
or	I-Claim
arm	I-Claim
volume	I-Claim
in	I-Claim
women	I-Claim
with	I-Claim
lymphedema	I-Claim
after	I-Claim
breast	I-Claim
cancer,	I-Claim
and	I-Claim
they	I-Claim
may	I-Claim
have	I-Claim
experienced	I-Claim
an	I-Claim
increase	I-Claim
in	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

Additional	B-Claim
studies	I-Claim
should	I-Claim
be	I-Claim
done	I-Claim
in	I-Claim
this	I-Claim
area	I-Claim
to	I-Claim
determine	I-Claim
the	I-Claim
optimum	I-Claim
training	I-Claim
program.	I-Claim

Radiotherapy	B-Claim
is	I-Claim
an	I-Claim
effective	I-Claim
palliative	I-Claim
treatment	I-Claim
for	I-Claim
cancer	I-Claim
patients	I-Claim
with	I-Claim
painful	I-Claim
bone	I-Claim
metastases.	I-Claim

Although	O
single-	O
and	O
multiple-fraction	O
radiotherapy	O
are	O
thought	O
to	O
provide	O
equal	O
palliation,	O
which	O
treatment	O
schedule	O
provides	O
better	O
value	O
for	O
the	O
money	O
is	O
unknown.	O

We	O
compared	O
quality-adjusted	O
life	O
expectancy	O
(the	O
overall	O
valuation	O
of	O
the	O
health	O
of	O
the	O
patients)	O
and	O
societal	O
costs	O
for	O
patients	O
receiving	O
either	O
single-	O
or	O
multiple-fraction	O
radiotherapy.	O

A	O
societal	O
cost-utility	O
analysis	O
was	O
performed	O
on	O
a	O
Dutch	O
randomized,	O
controlled	O
trial	O
of	O
1157	O
patients	O
with	O
painful	O
bone	O
metastases	O
that	O
compared	O
pain	O
responses	O
and	O
quality	O
of	O
life	O
from	O
a	O
single-fraction	O
treatment	O
schedule	O
of	O
8	O
Gy	O
with	O
a	O
treatment	O
schedule	O
of	O
six	O
fractions	O
of	O
4	O
Gy	O
each.	O

The	O
societal	O
values	O
of	O
life	O
expectancies	O
were	O
assessed	O
with	O
the	O
EuroQol	O
classification	O
system	O
(EQ-5D)	O
questionnaire.	O

A	O
subset	O
of	O
166	O
patients	O
also	O
answered	O
additional	O
questionnaires	O
to	O
estimate	O
nonradiotherapy	O
and	O
nonmedical	O
costs.	O

Statistical	O
tests	O
were	O
two-sided.	O

Comparing	B-Premise
the	I-Premise
single-	I-Premise
and	I-Premise
multiple-fraction	I-Premise
radiotherapy	I-Premise
schedules,	I-Premise
no	I-Premise
differences	I-Premise
were	I-Premise
found	I-Premise
in	I-Premise
life	I-Premise
expectancy	I-Premise
(43.0	I-Premise
versus	I-Premise
40.4	I-Premise
weeks,	I-Premise
P	I-Premise
=.20)	I-Premise
or	I-Premise
quality-adjusted	I-Premise
life	I-Premise
expectancy	I-Premise
(17.7	I-Premise
versus	I-Premise
16.0	I-Premise
weeks,	I-Premise
P	I-Premise
=.21).	I-Premise

The	B-Premise
estimated	I-Premise
cost	I-Premise
of	I-Premise
radiotherapy,	I-Premise
including	I-Premise
retreatments	I-Premise
and	I-Premise
nonmedical	I-Premise
costs,	I-Premise
was	I-Premise
statistically	I-Premise
significantly	I-Premise
lower	I-Premise
for	I-Premise
the	I-Premise
single-fraction	I-Premise
schedule	I-Premise
than	I-Premise
for	I-Premise
the	I-Premise
multiple-fraction	I-Premise
schedule	I-Premise
($2438	I-Premise
versus	I-Premise
$3311,	I-Premise
difference	I-Premise
=	I-Premise
$873,	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
on	I-Premise
the	I-Premise
difference	I-Premise
=	I-Premise
$449	I-Premise
to	I-Premise
$1297;	I-Premise
P<.001).	I-Premise

The	B-Premise
estimated	I-Premise
difference	I-Premise
in	I-Premise
total	I-Premise
societal	I-Premise
costs	I-Premise
was	I-Premise
larger,	I-Premise
also	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
the	I-Premise
single-fraction	I-Premise
schedule,	I-Premise
but	B-Premise
it	I-Premise
was	I-Premise
not	I-Premise
statistically	I-Premise
significant	I-Premise
($4700	I-Premise
versus	I-Premise
$6453,	I-Premise
difference	I-Premise
=	I-Premise
$1753,	I-Premise
95%	I-Premise
CI	I-Premise
on	I-Premise
the	I-Premise
difference	I-Premise
=	I-Premise
-$99	I-Premise
to	I-Premise
$3604;	I-Premise
P	I-Premise
=.06).	I-Premise

For	B-Premise
willingness-to-pay	I-Premise
between	I-Premise
$5000	I-Premise
and	I-Premise
$40	I-Premise
000	I-Premise
per	I-Premise
quality-adjusted	I-Premise
life	I-Premise
year,	I-Premise
the	I-Premise
single-fraction	I-Premise
schedule	I-Premise
was	I-Premise
statistically	I-Premise
significantly	I-Premise
more	I-Premise
cost-effective	I-Premise
than	I-Premise
the	I-Premise
multiple-fraction	I-Premise
schedule	I-Premise
(P<	I-Premise
or	I-Premise
=.05).	I-Premise

Compared	B-Claim
with	I-Claim
multiple-fraction	I-Claim
radiotherapy,	I-Claim
single-fraction	I-Claim
radiotherapy	I-Claim
provides	I-Claim
equal	I-Claim
palliation	I-Claim
and	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
and	I-Claim
has	I-Claim
lower	I-Claim
medical	I-Claim
and	I-Claim
societal	I-Claim
costs,	I-Claim
at	I-Claim
least	I-Claim
in	I-Claim
The	I-Claim
Netherlands.	I-Claim

Therefore,	B-Claim
single-fraction	I-Claim
radiotherapy	I-Claim
should	I-Claim
be	I-Claim
considered	I-Claim
as	I-Claim
the	I-Claim
palliative	I-Claim
treatment	I-Claim
of	I-Claim
choice	I-Claim
for	I-Claim
cancer	I-Claim
patients	I-Claim
with	I-Claim
painful	I-Claim
bone	I-Claim
metastases.	I-Claim

Randomized	B-Claim
trials	I-Claim
in	I-Claim
fluorouracil	I-Claim
(FU)-refractory	I-Claim
colorectal	I-Claim
cancer	I-Claim
demonstrate	I-Claim
significant	I-Claim
survival	I-Claim
advantages	I-Claim
for	I-Claim
patients	I-Claim
receiving	I-Claim
irinotecan.	I-Claim

We	O
prospectively	O
compared	O
the	O
efficacy	O
and	O
tolerability	O
of	O
two	O
irinotecan	O
regimens	O
(once	O
a	O
week	O
for	O
4	O
weeks	O
followed	O
by	O
a	O
2-week	O
rest	O
period	O
[weekly]	O
v	O
once	O
every	O
3	O
weeks)	O
in	O
such	O
patients.	O

This	O
multicenter,	O
open-label,	O
phase	O
III	O
study	O
randomly	O
assigned	O
patients	O
in	O
a	O
1:2	O
ratio	O
to	O
irinotecan	O
given	O
either	O
weekly	O
(125	O
mg/m(2))	O
or	O
once	O
every	O
3	O
weeks	O
(350	O
mg/m(2),	O
or	O
300	O
mg/m(2)	O
in	O
patients	O
who	O
were	O
>/=	O
70	O
years	O
of	O
age,	O
who	O
had	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
equal	O
to	O
2,	O
or	O
who	O
had	O
prior	O
pelvic	O
irradiation).	O

With	B-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
15.8	I-Premise
months,	I-Premise
there	I-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
1-year	I-Premise
survival	I-Premise
(46%	I-Premise
v	I-Premise
41%,	I-Premise
respectively;	I-Premise
P	I-Premise
=.42),	I-Premise
median	I-Premise
survival	I-Premise
(9.9	I-Premise
v	I-Premise
9.9	I-Premise
months,	I-Premise
respectively;	I-Premise
P	I-Premise
=.43),	I-Premise
or	I-Premise
median	I-Premise
time	I-Premise
to	I-Premise
progression	I-Premise
(4.0	I-Premise
v	I-Premise
3.0	I-Premise
months,	I-Premise
respectively;	I-Premise
P	I-Premise
=.54)	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
regimens.	I-Premise

Grade	B-Premise
3/4	I-Premise
diarrhea	I-Premise
occurred	I-Premise
in	I-Premise
36%	I-Premise
of	I-Premise
patients	I-Premise
treated	I-Premise
weekly	I-Premise
and	I-Premise
in	I-Premise
19%	I-Premise
of	I-Premise
those	I-Premise
treated	I-Premise
once	I-Premise
every	I-Premise
3	I-Premise
weeks	I-Premise
(P	I-Premise
=.002).	I-Premise

Grade	B-Premise
3/4	I-Premise
neutropenia	I-Premise
occurred	I-Premise
in	I-Premise
29%	I-Premise
of	I-Premise
patients	I-Premise
treated	I-Premise
weekly	I-Premise
and	I-Premise
34%	I-Premise
of	I-Premise
those	I-Premise
treated	I-Premise
once	I-Premise
every	I-Premise
3	I-Premise
weeks	I-Premise
(P	I-Premise
=.35).	I-Premise

Treatment-related	B-Premise
mortality	I-Premise
occurred	I-Premise
in	I-Premise
five	I-Premise
patients	I-Premise
(5.3%)	I-Premise
receiving	I-Premise
irinotecan	I-Premise
weekly	I-Premise
and	I-Premise
three	I-Premise
patients	I-Premise
(1.6%)	I-Premise
given	I-Premise
therapy	I-Premise
once	I-Premise
every	I-Premise
3	I-Premise
weeks	I-Premise
(P	I-Premise
=.12).	I-Premise

Global	B-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
was	I-Premise
not	I-Premise
statistically	I-Premise
different	I-Premise
between	I-Premise
treatment	I-Premise
groups.	I-Premise

Irinotecan	B-Claim
schedules	I-Claim
of	I-Claim
weekly	I-Claim
and	I-Claim
of	I-Claim
once	I-Claim
every	I-Claim
3	I-Claim
weeks	I-Claim
demonstrated	I-Claim
similar	I-Claim
efficacy	I-Claim
and	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
FU-refractory,	I-Claim
metastatic	I-Claim
colorectal	I-Claim
cancer.	I-Claim

The	B-Claim
regimen	I-Claim
of	I-Claim
once	I-Claim
every	I-Claim
3	I-Claim
weeks	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
a	I-Claim
significantly	I-Claim
lower	I-Claim
incidence	I-Claim
of	I-Claim
severe	I-Claim
diarrhea.	I-Claim

To	O
compare	O
the	O
efficacy	O
of	O
a	O
standard	O
anthracycline-based	O
regimen	O
to	O
a	O
dose-intensified	O
anthracycline	O
regimen	O
in	O
locally	O
advanced	O
breast	O
cancer.	O

Locally	O
advanced	O
breast	O
cancer	O
patients	O
were	O
randomly	O
assigned	O
onto	O
a	O
study	O
comparing	O
cyclophosphamide	O
(C;	O
75	O
mg/m(2)	O
orally	O
days	O
1	O
to	O
14),	O
epirubicin	O
(E;	O
60	O
mg/m(2)	O
intravenously	O
[IV]	O
days	O
1,	O
8),	O
and	O
fluorouracil	O
(F;	O
500	O
mg/m(2)	O
IV	O
days	O
1,	O
8)	O
six	O
cycles	O
every	O
28	O
days	O
versus	O
E	O
(120	O
mg/m(2)	O
IV	O
day	O
1),	O
C	O
(830	O
mg/m(2)	O
IV	O
day	O
1),	O
and	O
granulocyte	O
colony-stimulating	O
factor	O
(filgrastim;	O
5	O
micro	O
g/kg/d	O
subcutaneously	O
days	O
2	O
to	O
13)	O
six	O
cycles	O
every	O
14	O
days.	O

The	O
study	O
was	O
designed	O
to	O
detect	O
a	O
15%	O
improvement;	O
that	O
is,	O
from	O
50%	O
to	O
65%	O
in	O
median	O
progression-free	O
survival	O
(PFS)	O
in	O
favor	O
of	O
the	O
dose-intensified	O
regimen.	O

A	O
total	O
of	O
448	O
patients	O
were	O
enrolled	O
over	O
a	O
period	O
of	O
3	O
years.	O

The	O
median	O
dose	O
intensity	O
delivered	O
for	O
C	O
and	O
E	O
reached,	O
respectively,	O
85%	O
and	O
87%	O
of	O
that	O
planned	O
in	O
the	O
CEF	O
arm	O
and	O
96%	O
and	O
95%	O
of	O
that	O
planned	O
in	O
the	O
EC	O
arm.	O

The	B-Premise
dose-intensified	I-Premise
arm	I-Premise
was	I-Premise
slightly	I-Premise
more	I-Premise
emetogenic	I-Premise
and	I-Premise
generated	I-Premise
more	I-Premise
grade	I-Premise
3	I-Premise
to	I-Premise
4	I-Premise
anemia	I-Premise
but	I-Premise
less	I-Premise
febrile	I-Premise
neutropenia	I-Premise
episodes.	I-Premise

After	O
a	O
median	O
follow-up	O
of	O
5.5	O
years,	O
277	O
events	O
have	O
been	O
reported.	O

The	B-Premise
median	I-Premise
PFS	I-Premise
was	I-Premise
34	I-Premise
and	I-Premise
33.7	I-Premise
months	I-Premise
for	I-Premise
CEF	I-Premise
and	I-Premise
EC,	I-Premise
respectively	I-Premise
(P	I-Premise
=.68),	I-Premise
and	I-Premise
the	I-Premise
5-year	I-Premise
survival	I-Premise
rate	I-Premise
was	I-Premise
53%	I-Premise
and	I-Premise
51%	I-Premise
for	I-Premise
CEF	I-Premise
and	I-Premise
EC,	I-Premise
respectively	I-Premise
(P	I-Premise
=.94).	I-Premise

Dose-intensified	B-Claim
EC	I-Claim
does	I-Claim
not	I-Claim
provide	I-Claim
a	I-Claim
measurable	I-Claim
therapeutic	I-Claim
benefit	I-Claim
over	I-Claim
CEF	I-Claim
as	I-Claim
neoadjuvant	I-Claim
chemotherapy	I-Claim
for	I-Claim
unselected	I-Claim
locally	I-Claim
advanced	I-Claim
breast	I-Claim
cancer	I-Claim
patients.	I-Claim

Several	O
multicomponent	O
regimens	O
have	O
been	O
reported	O
to	O
be	O
useful	O
in	O
advanced	O
androgen-independent	O
prostate	O
cancer.	O

We	O
used	O
a	O
randomized	O
phase	O
II	O
design	O
to	O
evaluate	O
and	O
compare	O
two	O
such	O
regimens.	O

Patients	O
were	O
accrued	O
primarily	O
in	O
the	O
community	O
setting.	O

Patients	O
with	O
progressive,	O
androgen-independent	O
prostate	O
cancer	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
treatments:	O
either	O
ketoconazole/doxorubicin	O
alternating	O
with	O
vinblastine/estramustine	O
(KA/VE)	O
or	O
paclitaxel,	O
estramustine,	O
and	O
oral	O
etoposide	O
(TEE).	O

Patients	O
were	O
prospectively	O
stratified	O
on	O
the	O
basis	O
of	O
disease	O
volume.	O

The	O
primary	O
end	O
points	O
were	O
response	O
and	O
overall	O
survival	O
time.	O

A	O
total	O
of	O
75	O
patients	O
were	O
registered;	O
71	O
are	O
included	O
in	O
the	O
analysis.	O

By	O
the	O
criterion	O
of	O
an	O
80%	O
prostate-specific	O
antigen	O
reduction	O
maintained	O
for	O
at	O
least	O
8	O
weeks,	O
11	O
(30%)	O
of	O
37	O
patients	O
in	O
the	O
TEE	O
arm	O
responded,	O
whereas	O
11	O
(32%)	O
of	O
34	O
assigned	O
to	O
KA/VE	O
responded.	O

Median	B-Premise
survival	I-Premise
was	I-Premise
16.9	I-Premise
months	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI],	I-Premise
10.5	I-Premise
to	I-Premise
21.2	I-Premise
months)	I-Premise
in	I-Premise
the	I-Premise
TEE	I-Premise
arm	I-Premise
and	I-Premise
23.4	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
12.9	I-Premise
to	I-Premise
30.6	I-Premise
months)	I-Premise
for	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
KA/VE.	I-Premise

Many	B-Premise
patients	I-Premise
(24%)	I-Premise
failed	I-Premise
to	I-Premise
complete	I-Premise
at	I-Premise
least	I-Premise
6	I-Premise
weeks	I-Premise
of	I-Premise
therapy,	I-Premise
including	I-Premise
five	I-Premise
(8%)	I-Premise
treatment-related	I-Premise
early	I-Premise
deaths.	I-Premise

Each	B-Claim
of	I-Claim
these	I-Claim
regimens	I-Claim
produced	I-Claim
clinically	I-Claim
significant	I-Claim
responses,	I-Claim
and	O
the	B-Claim
observed	I-Claim
median	I-Claim
survival	I-Claim
(18.9	I-Claim
months	I-Claim
for	I-Claim
all	I-Claim
71	I-Claim
patients)	I-Claim
compares	I-Claim
favorably	I-Claim
with	I-Claim
previously	I-Claim
published	I-Claim
results,	I-Claim
especially	I-Claim
in	I-Claim
the	I-Claim
community	I-Claim
setting.	I-Claim

Nonetheless,	B-Claim
it	I-Claim
is	I-Claim
apparent	I-Claim
that	I-Claim
these	I-Claim
first-generation	I-Claim
regimens	I-Claim
must	I-Claim
be	I-Claim
applied	I-Claim
judiciously,	I-Claim
and	O
thus	B-Claim
we	I-Claim
view	I-Claim
efforts	I-Claim
at	I-Claim
better	I-Claim
patient	I-Claim
selection	I-Claim
and	I-Claim
the	I-Claim
development	I-Claim
of	I-Claim
more	I-Claim
tolerable	I-Claim
therapies	I-Claim
as	I-Claim
higher	I-Claim
priorities	I-Claim
than	I-Claim
carrying	I-Claim
either	I-Claim
of	I-Claim
these	I-Claim
regimens	I-Claim
to	I-Claim
phase	I-Claim
III	I-Claim
evaluation	I-Claim
in	I-Claim
the	I-Claim
cooperative	I-Claim
group	I-Claim
setting.	I-Claim

Vinorelbine	B-Claim
prolongs	I-Claim
survival	I-Claim
and	I-Claim
improves	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
in	I-Claim
elderly	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
non-small-cell	I-Claim
lung	I-Claim
cancer	I-Claim
(NSCLC).	I-Claim

Some	B-Claim
studies	I-Claim
have	I-Claim
also	I-Claim
suggested	I-Claim
that	I-Claim
gemcitabine	I-Claim
is	I-Claim
well	I-Claim
tolerated	I-Claim
and	I-Claim
effective	I-Claim
in	I-Claim
such	I-Claim
patients.	I-Claim

We	O
compared	O
the	O
effectiveness	O
and	O
toxicity	O
of	O
the	O
combination	O
of	O
vinorelbine	O
plus	O
gemcitabine	O
with	O
those	O
of	O
each	O
drug	O
given	O
alone	O
in	O
an	O
open-label,	O
randomized	O
phase	O
III	O
trial	O
in	O
elderly	O
patients	O
with	O
advanced	O
NSCLC.	O

Patients	O
aged	O
70	O
years	O
and	O
older,	O
enrolled	O
between	O
December	O
1997	O
and	O
November	O
2000,	O
were	O
randomly	O
assigned	O
to	O
receive	O
intravenous	O
vinorelbine	O
(30	O
mg/m(2)	O
of	O
body	O
surface	O
area),	O
gemcitabine	O
(1200	O
mg/m(2)),	O
or	O
vinorelbine	O
(25	O
mg/m(2))	O
plus	O
gemcitabine	O
(1000	O
mg/m(2)).	O

All	O
treatments	O
were	O
delivered	O
on	O
days	O
1	O
and	O
8	O
every	O
3	O
weeks	O
for	O
a	O
maximum	O
of	O
six	O
cycles.	O

The	O
primary	O
endpoint	O
was	O
survival.	O

Survival	O
curves	O
were	O
drawn	O
using	O
the	O
Kaplan-Meier	O
method	O
and	O
analyzed	O
by	O
the	O
Mantel-Haenszel	O
test.	O

Secondary	O
endpoints	O
were	O
quality	O
of	O
life	O
and	O
toxicity.	O

Of	O
698	O
patients	O
available	O
for	O
intention-to-treat	O
analysis,	O
233	O
were	O
assigned	O
to	O
receive	O
vinorelbine,	O
233	O
to	O
gemcitabine,	O
and	O
232	O
to	O
vinorelbine	O
plus	O
gemcitabine.	O

Compared	B-Premise
with	I-Premise
each	I-Premise
single	I-Premise
drug,	I-Premise
the	I-Premise
combination	I-Premise
treatment	I-Premise
did	I-Premise
not	I-Premise
improve	I-Premise
survival.	I-Premise

The	B-Premise
hazard	I-Premise
ratio	I-Premise
of	I-Premise
death	I-Premise
for	I-Premise
patients	I-Premise
receiving	I-Premise
the	I-Premise
combination	I-Premise
treatment	I-Premise
was	I-Premise
1.17	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
=	I-Premise
0.95	I-Premise
to	I-Premise
1.44)	I-Premise
that	I-Premise
of	I-Premise
patients	I-Premise
receiving	I-Premise
vinorelbine	I-Premise
and	I-Premise
1.06	I-Premise
(95%	I-Premise
CI	I-Premise
=	I-Premise
0.86	I-Premise
to	I-Premise
1.29)	I-Premise
that	I-Premise
of	I-Premise
patients	I-Premise
receiving	I-Premise
gemcitabine.	I-Premise

Although	B-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
was	I-Premise
similar	I-Premise
across	I-Premise
the	I-Premise
three	I-Premise
treatment	I-Premise
arms,	I-Premise
the	B-Premise
combination	I-Premise
treatment	I-Premise
was	I-Premise
more	I-Premise
toxic	I-Premise
than	I-Premise
the	I-Premise
two	I-Premise
drugs	I-Premise
given	I-Premise
singly.	I-Premise

The	B-Claim
combination	I-Claim
of	I-Claim
vinorelbine	I-Claim
plus	I-Claim
gemcitabine	I-Claim
is	I-Claim
not	I-Claim
more	I-Claim
effective	I-Claim
than	I-Claim
single-agent	I-Claim
vinorelbine	I-Claim
or	I-Claim
gemcitabine	I-Claim
in	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
elderly	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
NSCLC.	I-Claim

This	O
randomized,	O
multicenter,	O
phase	O
III	O
study	O
compared	O
doxorubicin	O
and	O
docetaxel	O
(AT)	O
with	O
doxorubicin	O
and	O
cyclophosphamide	O
(AC)	O
as	O
first-line	O
chemotherapy	O
(CT)	O
in	O
metastatic	O
breast	O
cancer	O
(MBC).	O

Patients	O
(n	O
=	O
429)	O
were	O
randomly	O
assigned	O
to	O
receive	O
doxorubicin	O
50	O
mg/m(2)	O
plus	O
docetaxel	O
75	O
mg/m(2)	O
(n	O
=	O
214)	O
or	O
doxorubicin	O
60	O
mg/m(2)	O
plus	O
cyclophosphamide	O
600	O
mg/m(2)	O
(n	O
=	O
215)	O
on	O
day	O
1,	O
every	O
3	O
weeks	O
for	O
up	O
to	O
eight	O
cycles.	O

Time	B-Premise
to	I-Premise
progression	I-Premise
(TTP;	I-Premise
primary	I-Premise
end	I-Premise
point)	I-Premise
and	I-Premise
time	I-Premise
to	I-Premise
treatment	I-Premise
failure	I-Premise
(TTF)	I-Premise
were	I-Premise
significantly	I-Premise
longer	I-Premise
with	I-Premise
AT	I-Premise
than	I-Premise
AC	I-Premise
(median	I-Premise
TTP,	I-Premise
37.3	I-Premise
v	I-Premise
31.9	I-Premise
weeks;	I-Premise
log-rank	I-Premise
P	I-Premise
=.014;	I-Premise
median	I-Premise
TTF,	I-Premise
25.6	I-Premise
v	I-Premise
23.7	I-Premise
weeks;	I-Premise
log-rank	I-Premise
P	I-Premise
=.048).	I-Premise

The	B-Premise
overall	I-Premise
response	I-Premise
rate	I-Premise
(ORR)	I-Premise
was	I-Premise
significantly	I-Premise
greater	I-Premise
for	I-Premise
patients	I-Premise
taking	I-Premise
AT	I-Premise
(59%,	I-Premise
with	I-Premise
10%	I-Premise
complete	I-Premise
response	I-Premise
[CR],	I-Premise
49%	I-Premise
partial	I-Premise
response	I-Premise
[PR])	I-Premise
than	I-Premise
for	I-Premise
those	I-Premise
taking	I-Premise
AC	I-Premise
(47%,	I-Premise
with	I-Premise
7%	I-Premise
CR,	I-Premise
39%	I-Premise
PR)	I-Premise
(P	I-Premise
=.009).	I-Premise

The	B-Premise
ORR	I-Premise
was	I-Premise
also	I-Premise
higher	I-Premise
with	I-Premise
AT	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
visceral	I-Premise
involvement	I-Premise
(58%	I-Premise
v	I-Premise
41%;	I-Premise
liver,	I-Premise
62%	I-Premise
v	I-Premise
42%;	I-Premise
lung,	I-Premise
58%	I-Premise
v	I-Premise
35%),	I-Premise
three	I-Premise
or	I-Premise
more	I-Premise
organs	I-Premise
involved	I-Premise
(59%	I-Premise
v	I-Premise
40%),	I-Premise
or	I-Premise
prior	I-Premise
adjuvant	I-Premise
CT	I-Premise
(53%	I-Premise
v	I-Premise
41%).	I-Premise

Overall	B-Premise
survival	I-Premise
(OS)	I-Premise
was	I-Premise
comparable	I-Premise
in	I-Premise
both	I-Premise
arms.	I-Premise

Grade	B-Premise
3/4	I-Premise
neutropenia	I-Premise
was	I-Premise
frequent	I-Premise
in	I-Premise
both	I-Premise
groups,	I-Premise
although	B-Premise
febrile	I-Premise
neutropenia	I-Premise
and	I-Premise
infections	I-Premise
were	I-Premise
more	I-Premise
frequent	I-Premise
for	I-Premise
patients	I-Premise
taking	I-Premise
AT	I-Premise
(respectively,	I-Premise
33%	I-Premise
v	I-Premise
10%,	I-Premise
P	I-Premise
<.001;	I-Premise
8%	I-Premise
v	I-Premise
2%,	I-Premise
P	I-Premise
=.01).	I-Premise

Severe	B-Premise
nonhematologic	I-Premise
toxicity	I-Premise
was	I-Premise
infrequent	I-Premise
in	I-Premise
both	I-Premise
groups,	I-Premise
including	I-Premise
grade	I-Premise
3/4	I-Premise
cardiac	I-Premise
events	I-Premise
(AT,	I-Premise
3%;	I-Premise
AC,	I-Premise
4%).	I-Premise

AT	B-Claim
significantly	I-Claim
improves	I-Claim
TTP	I-Claim
and	I-Claim
ORR	I-Claim
compared	I-Claim
with	I-Claim
AC	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
MBC,	I-Claim
but	B-Claim
there	I-Claim
is	I-Claim
no	I-Claim
difference	I-Claim
in	I-Claim
OS.	I-Claim

AT	B-Claim
represents	I-Claim
a	I-Claim
valid	I-Claim
option	I-Claim
for	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
MBC.	I-Claim

Despite	B-Claim
considerable	I-Claim
improvement	I-Claim
in	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
advanced	I-Claim
ovarian	I-Claim
cancer,	I-Claim
the	I-Claim
optimization	I-Claim
of	I-Claim
efficacy	I-Claim
and	I-Claim
tolerability	I-Claim
remains	I-Claim
an	I-Claim
important	I-Claim
issue.	I-Claim

Therefore,	O
we	O
performed	O
a	O
randomized,	O
phase	O
III	O
non-inferiority	O
trial	O
comparing	O
paclitaxel	O
plus	O
cisplatin	O
(PT)	O
with	O
paclitaxel	O
plus	O
carboplatin	O
(TC)	O
in	O
patients	O
with	O
advanced	O
ovarian	O
cancer.	O

A	O
total	O
of	O
798	O
patients	O
with	O
International	O
Federation	O
of	O
Gynecology	O
and	O
Obstetrics	O
stage	O
IIB-IV	O
were	O
randomly	O
assigned	O
to	O
receive	O
six	O
courses	O
of	O
either	O
PT	O
or	O
TC	O
at	O
3-week	O
intervals.	O

The	O
primary	O
endpoint	O
was	O
the	O
proportion	O
of	O
patients	O
without	O
progression	O
at	O
2	O
years.	O

Secondary	O
endpoints	O
included	O
toxicity,	O
response	O
to	O
treatment,	O
quality	O
of	O
life,	O
and	O
overall	O
and	O
progression-free	O
survival	O
time.	O

Quality	O
of	O
life	O
was	O
evaluated	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
quality-of-life	O
questionnaire	O
(QLQ)-C30,	O
version	O
2.0.	O

Survival	O
curves	O
were	O
calculated	O
using	O
the	O
Kaplan-Meier	O
method,	O
and	O
hazard	O
ratios	O
were	O
estimated	O
using	O
the	O
Cox	O
proportional	O
hazards	O
model.	O

The	B-Premise
proportion	I-Premise
of	I-Premise
patients	I-Premise
without	I-Premise
progression	I-Premise
at	I-Premise
2	I-Premise
years	I-Premise
was	I-Premise
not	I-Premise
statistically	I-Premise
significantly	I-Premise
different	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
treatment	I-Premise
arms	I-Premise
(40.0%	I-Premise
for	I-Premise
PT	I-Premise
versus	I-Premise
37.5%	I-Premise
for	I-Premise
TC,	I-Premise
difference	I-Premise
=	I-Premise
2.5%,	I-Premise
one-sided	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
=	I-Premise
-	I-Premise
infinity	I-Premise
to	I-Premise
8.2%).	I-Premise

Median	B-Premise
progression-free	I-Premise
survival	I-Premise
time	I-Premise
in	I-Premise
the	I-Premise
TC	I-Premise
arm	I-Premise
(17.2	I-Premise
months,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
15.2	I-Premise
to	I-Premise
19.3	I-Premise
months)	I-Premise
and	I-Premise
the	I-Premise
PT	I-Premise
arm	I-Premise
(19.1	I-Premise
months,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
16.7	I-Premise
to	I-Premise
21.5	I-Premise
months)	I-Premise
were	I-Premise
also	I-Premise
not	I-Premise
statistically	I-Premise
significantly	I-Premise
different;	I-Premise
the	B-Premise
same	I-Premise
was	I-Premise
true	I-Premise
of	I-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
time	I-Premise
(43.3	I-Premise
months,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
37.2	I-Premise
to	I-Premise
47.8	I-Premise
months	I-Premise
versus	I-Premise
44.1	I-Premise
months,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
40.2	I-Premise
to	I-Premise
49.4	I-Premise
months,	I-Premise
for	I-Premise
the	I-Premise
TC	I-Premise
and	I-Premise
PT	I-Premise
arms,	I-Premise
respectively).	I-Premise

The	B-Premise
TC	I-Premise
regimen	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
a	I-Premise
higher	I-Premise
frequency	I-Premise
of	I-Premise
hematologic	I-Premise
toxicity,	I-Premise
but	B-Premise
a	I-Premise
lower	I-Premise
frequency	I-Premise
of	I-Premise
gastrointestinal	I-Premise
and	I-Premise
neurologic	I-Premise
toxicity,	I-Premise
than	I-Premise
the	I-Premise
PT	I-Premise
regimen.	I-Premise

Mean	B-Premise
global	I-Premise
quality-of-life	I-Premise
scores	I-Premise
at	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
treatment	I-Premise
were	I-Premise
statistically	I-Premise
significantly	I-Premise
better	I-Premise
in	I-Premise
the	I-Premise
TC	I-Premise
arm	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
PT	I-Premise
arm	I-Premise
(65.25	I-Premise
versus	I-Premise
51.97,	I-Premise
respectively;	I-Premise
difference	I-Premise
=	I-Premise
-13.28,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
-18.88	I-Premise
to	I-Premise
-7.68).	I-Premise

The	B-Claim
TC	I-Claim
regimen	I-Claim
achieved	I-Claim
comparable	I-Claim
efficacy	I-Claim
to	I-Claim
the	I-Claim
PT	I-Claim
regimen	I-Claim
but	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
better	I-Claim
tolerability	I-Claim
and	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
and	I-Claim
should,	I-Claim
therefore,	I-Claim
be	I-Claim
considered	I-Claim
as	I-Claim
an	I-Claim
important	I-Claim
alternative	I-Claim
for	I-Claim
standard	I-Claim
first-line	I-Claim
chemotherapy	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
ovarian	I-Claim
cancer.	I-Claim

This	O
trial	O
was	O
conducted	O
to	O
determine	O
whether	O
high-dose	O
fluorouracil	O
(FU)	O
given	O
as	O
a	O
weekly	O
24-hour	O
infusion	O
is	O
more	O
active	O
than	O
bolus	O
FU	O
+	O
leucovorin	O
(LV),	O
and	O
whether	O
high-dose	O
infusional	O
FU	O
can	O
be	O
modulated	O
by	O
LV.	O

A	O
total	O
of	O
497	O
patients	O
with	O
previously	O
untreated	O
metastatic	O
colorectal	O
cancer	O
were	O
randomly	O
assigned	O
to	O
receive	O
bolus	O
FU	O
425	O
mg/m2	O
intravenously	O
+	O
LV	O
20	O
mg/m2	O
on	O
days	O
1	O
to	O
5	O
and	O
repeated	O
on	O
day	O
28	O
(FU	O
+	O
LV),	O
or	O
FU	O
2600	O
mg/m2	O
as	O
a	O
24-hour	O
infusion	O
alone	O
(FU24h)	O
or	O
in	O
combination	O
with	O
500	O
mg/m2	O
LV	O
(FU24h	O
+	O
LV)-all	O
given	O
weekly	O
x6	O
followed	O
by	O
a	O
2-week	O
rest	O
period.	O

Survival	O
was	O
the	O
major	O
study	O
end	O
point.	O

With	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
more	I-Premise
than	I-Premise
3	I-Premise
years,	I-Premise
survival	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
among	I-Premise
the	I-Premise
treatment	I-Premise
groups	I-Premise
(median	I-Premise
FU	I-Premise
+	I-Premise
LV,	I-Premise
11.1	I-Premise
months	I-Premise
[95%	I-Premise
CI,	I-Premise
10.2	I-Premise
to	I-Premise
15.0	I-Premise
months];	I-Premise
FU24h,	I-Premise
13.0	I-Premise
months	I-Premise
[95%	I-Premise
CI,	I-Premise
10.4	I-Premise
to	I-Premise
15.4	I-Premise
months];	I-Premise
FU24h	I-Premise
+	I-Premise
LV,	I-Premise
13.7	I-Premise
months	I-Premise
[95%	I-Premise
CI,	I-Premise
12.0	I-Premise
to	I-Premise
16.4	I-Premise
months];	I-Premise
P	I-Premise
=.724).	I-Premise

Progression-free	B-Premise
survival	I-Premise
(PFS)	I-Premise
was	I-Premise
significantly	I-Premise
longer	I-Premise
for	I-Premise
FU24h	I-Premise
+	I-Premise
LV	I-Premise
(median	I-Premise
FU	I-Premise
+	I-Premise
LV,	I-Premise
4.0	I-Premise
months	I-Premise
[95%	I-Premise
CI,	I-Premise
3.4	I-Premise
to	I-Premise
4.9];	I-Premise
FU24h,	I-Premise
4.1	I-Premise
months	I-Premise
[95%	I-Premise
CI,	I-Premise
3.4	I-Premise
to	I-Premise
5.0];	I-Premise
FU24h	I-Premise
+	I-Premise
LV	I-Premise
5.6	I-Premise
months	I-Premise
[95%	I-Premise
CI,	I-Premise
4.4	I-Premise
to	I-Premise
6.7];	I-Premise
P	I-Premise
=.029).	I-Premise

The	B-Premise
response	I-Premise
rates	I-Premise
in	I-Premise
the	I-Premise
subgroup	I-Premise
of	I-Premise
patients	I-Premise
with	I-Premise
measurable	I-Premise
disease	I-Premise
were	I-Premise
12%,	I-Premise
10%,	I-Premise
and	I-Premise
17%	I-Premise
for	I-Premise
FU	I-Premise
+	I-Premise
LV,	I-Premise
FU24h,	I-Premise
and	I-Premise
FU24h	I-Premise
+	I-Premise
LV,	I-Premise
respectively	I-Premise
(not	I-Premise
significant).	I-Premise

Occurrence	B-Premise
of	I-Premise
grade	I-Premise
3	I-Premise
and	I-Premise
4	I-Premise
diarrhea	I-Premise
was	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
FU24h	I-Premise
+	I-Premise
LV	I-Premise
arm	I-Premise
(22%)	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
FU24h	I-Premise
(6%)	I-Premise
or	I-Premise
FU	I-Premise
+	I-Premise
LV	I-Premise
(9%)	I-Premise
arms;	I-Premise
however,	B-Premise
stomatitis	I-Premise
(11%	I-Premise
in	I-Premise
FU	I-Premise
+	I-Premise
LV	I-Premise
v	I-Premise
3%	I-Premise
in	I-Premise
FU24h	I-Premise
v	I-Premise
5%	I-Premise
in	I-Premise
FU24h	I-Premise
+	I-Premise
LV	I-Premise
arms)	I-Premise
and	I-Premise
hematologic	I-Premise
toxicity	I-Premise
were	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
bolus	I-Premise
FU	I-Premise
+	I-Premise
LV	I-Premise
arm.	I-Premise

Global	B-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
did	I-Claim
not	I-Claim
differ	I-Claim
within	I-Claim
the	I-Claim
three	I-Claim
arms.	I-Claim

Neither	B-Claim
FU24h	I-Claim
+	I-Claim
LV	I-Claim
nor	I-Claim
FU24h	I-Claim
prolong	I-Claim
survival,	I-Claim
relative	I-Claim
to	I-Claim
bolus	I-Claim
FU	I-Claim
+	I-Claim
LV.	I-Claim

Leucovorin	B-Claim
increases	I-Claim
PFS	I-Claim
if	I-Claim
added	I-Claim
to	I-Claim
FU24h,	I-Claim
but	I-Claim
increases	I-Claim
toxicity.	I-Claim

To	O
assess	O
patient-reported	O
prostate	O
cancer-specific	O
quality	O
of	O
life	O
2	O
and	O
3	O
years	O
after	O
radiotherapy	O
to	O
the	O
prostate	O
in	O
a	O
randomized	O
dose-escalation	O
trial	O
of	O
70	O
versus	O
78	O
Gy	O
conducted	O
from	O
1993	O
to	O
1998.	O

Two	O
years	O
after	O
completing	O
radiotherapy,	O
a	O
questionnaire	O
that	O
assessed	O
bladder,	O
rectal,	O
and	O
sexual	O
function	O
was	O
sent	O
to	O
301	O
patients	O
in	O
the	O
study.	O

Three	O
years	O
after	O
treatment,	O
a	O
second	O
questionnaire	O
was	O
sent	O
to	O
the	O
175	O
patients	O
with	O
adequate	O
follow-up.	O

Three	B-Premise
years	I-Premise
after	I-Premise
radiotherapy,	I-Premise
urinary	I-Premise
incontinence	I-Premise
was	I-Premise
reported	I-Premise
by	I-Premise
35%	I-Premise
of	I-Premise
patients,	I-Premise
but	I-Premise
only	I-Premise
6%	I-Premise
required	I-Premise
the	I-Premise
use	I-Premise
of	I-Premise
a	I-Premise
pad	I-Premise
or	I-Premise
other	I-Premise
protective	I-Premise
device.	I-Premise

Patients	B-Premise
reported	I-Premise
increased	I-Premise
leakage	I-Premise
with	I-Premise
a	I-Premise
full	I-Premise
bladder	I-Premise
(urge	I-Premise
incontinence)	I-Premise
between	I-Premise
the	I-Premise
2	I-Premise
and	I-Premise
3-year	I-Premise
questionnaires	I-Premise
(42%	I-Premise
versus	I-Premise
50%;	I-Premise
P	I-Premise
=	I-Premise
0.03).	I-Premise

At	B-Premise
3	I-Premise
years,	I-Premise
33%	I-Premise
of	I-Premise
patients	I-Premise
reported	I-Premise
rectal	I-Premise
bleeding	I-Premise
compared	I-Premise
with	I-Premise
47%	I-Premise
at	I-Premise
2	I-Premise
years	I-Premise
(P	I-Premise
=	I-Premise
0.006).	I-Premise

Patients	B-Premise
in	I-Premise
the	I-Premise
78-Gy	I-Premise
arm	I-Premise
reported	I-Premise
more	I-Premise
frequent	I-Premise
bowel	I-Premise
movements	I-Premise
at	I-Premise
3	I-Premise
years	I-Premise
and	I-Premise
less	I-Premise
change	I-Premise
in	I-Premise
bowel	I-Premise
function	I-Premise
at	I-Premise
2	I-Premise
years	I-Premise
than	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
70-Gy	I-Premise
arm.	I-Premise

Before	B-Premise
radiotherapy,	I-Premise
84%	I-Premise
of	I-Premise
patients	I-Premise
reported	I-Premise
erections	I-Premise
adequate	I-Premise
for	I-Premise
intercourse	I-Premise
at	I-Premise
least	I-Premise
a	I-Premise
few	I-Premise
times	I-Premise
during	I-Premise
the	I-Premise
previous	I-Premise
year.	I-Premise

After	B-Premise
2	I-Premise
and	I-Premise
3	I-Premise
years,	I-Premise
this	I-Premise
had	I-Premise
decreased	I-Premise
to	I-Premise
49%	I-Premise
and	I-Premise
41%,	I-Premise
respectively	I-Premise
(P	I-Premise
<0.02).	I-Premise

By	B-Claim
patient-reported	I-Claim
questionnaire,	I-Claim
78	I-Claim
Gy	I-Claim
produced	I-Claim
an	I-Claim
increase	I-Claim
in	I-Claim
bowel	I-Claim
movement	I-Claim
frequency	I-Claim
and	I-Claim
no	I-Claim
increase	I-Claim
in	I-Claim
bladder	I-Claim
or	I-Claim
sexual	I-Claim
side	I-Claim
effects	I-Claim
at	I-Claim
3	I-Claim
years	I-Claim
compared	I-Claim
with	I-Claim
70	I-Claim
Gy.	I-Claim

Comparing	B-Claim
the	I-Claim
results	I-Claim
2	I-Claim
and	I-Claim
3	I-Claim
years	I-Claim
after	I-Claim
radiotherapy,	I-Claim
the	I-Claim
symptoms	I-Claim
of	I-Claim
rectal	I-Claim
bleeding	I-Claim
had	I-Claim
improved,	I-Claim
erectile	I-Claim
function	I-Claim
had	I-Claim
decreased,	I-Claim
and	I-Claim
urinary	I-Claim
urge	I-Claim
incontinence	I-Claim
had	I-Claim
increased.	I-Claim

In	B-Premise
a	I-Premise
multinational	I-Premise
trial	I-Premise
of	I-Premise
anaemic	I-Premise
patients	I-Premise
with	I-Premise
cancer	I-Premise
receiving	I-Premise
nonplatinum-containing	I-Premise
chemotherapy,	I-Premise
epoetin-alfa	I-Premise
effectively	I-Premise
increased	I-Premise
haemoglobin	I-Premise
levels,	I-Premise
reduced	I-Premise
red	I-Premise
blood	I-Premise
cell	I-Premise
transfusion	I-Premise
requirements,	I-Premise
and	I-Premise
improved	I-Premise
QOL.	I-Premise

Although	O
the	O
study	O
was	O
not	O
designed	O
or	O
powered	O
to	O
evaluate	O
survival,	O
a	B-Premise
survival	I-Premise
trend	I-Premise
was	I-Premise
noted	I-Premise
favouring	I-Premise
epoetin-alfa	I-Premise
compared	I-Premise
with	I-Premise
placebo	I-Premise
(median	I-Premise
survival	I-Premise
17	I-Premise
vs	I-Premise
11	I-Premise
months	I-Premise
[p	I-Premise
=	I-Premise
0.126]).	I-Premise

To	O
determine	O
the	O
incremental	O
cost	O
utility	O
of	O
epoetin-alfa	O
versus	O
placebo	O
in	O
anaemic	O
patients	O
with	O
stage	O
IV	O
breast	O
cancer	O
from	O
a	O
UK	O
National	O
Health	O
Service	O
perspective.	O

Patient	O
data	O
regarding	O
transfusions,	O
epoetin-alfa	O
usage,	O
chemotherapy	O
treatment	O
cycles,	O
and	O
adverse	O
events	O
were	O
recorded,	O
with	O
survival	O
follow-up	O
for	O
12-36	O
months	O
post-study.	O

Stage	O
IV	O
breast	O
cancer	O
therapy	O
costs	O
were	O
collected	O
by	O
surveying	O
UK	O
oncologists,	O
and	O
utilities	O
for	O
associated	O
health	O
states	O
were	O
from	O
published	O
sources.	O

Costs	O
were	O
in	O
British	O
pounds	O
and	O
year	O
2000	O
values.	O

Costs	O
and	O
benefits	O
were	O
jointly	O
determined	O
for	O
the	O
stage	O
IV	O
breast	O
cancer	O
subgroup	O
(n	O
=	O
55).	O

Incremental	O
cost-utility	O
ratios	O
(ICURs)	O
were	O
calculated	O
assuming	O
a	O
6%	O
annual	O
discount	O
rate	O
for	O
costs	O
and	O
a	O
1.5%	O
annual	O
discount	O
rate	O
for	O
benefits.	O

Bootstrap	O
simulations	O
(10,000	O
iterations)	O
were	O
conducted	O
to	O
account	O
for	O
uncertainty,	O
and	O
sensitivity	O
analyses	O
were	O
conducted	O
to	O
establish	O
robustness.	O

The	B-Premise
ICUR	I-Premise
for	I-Premise
epoetin-alfa	I-Premise
treatment	I-Premise
was	I-Premise
pounds	I-Premise
8,851	I-Premise
per	I-Premise
QALY,	I-Premise
with	I-Premise
a	I-Premise
99%	I-Premise
probability	I-Premise
of	I-Premise
a	I-Premise
positive	I-Premise
net	I-Premise
benefit	I-Premise
in	I-Premise
QALYs	I-Premise
(net	I-Premise
benefit	I-Premise
=	I-Premise
0.4805	I-Premise
years	I-Premise
of	I-Premise
perfect	I-Premise
life)	I-Premise
and	I-Premise
a	I-Premise
94%	I-Premise
probability	I-Premise
of	I-Premise
being	I-Premise
acceptable	I-Premise
using	I-Premise
a	I-Premise
threshold	I-Premise
ICUR	I-Premise
of	I-Premise
pounds	I-Premise
30,000/QALY.	I-Premise

The	B-Premise
main	I-Premise
cost	I-Premise
drivers	I-Premise
distinguishing	I-Premise
epoetin-alfa	I-Premise
from	I-Premise
placebo	I-Premise
were	I-Premise
the	I-Premise
costs	I-Premise
of	I-Premise
drug	I-Premise
and	I-Premise
patient	I-Premise
care	I-Premise
due	I-Premise
to	I-Premise
increased	I-Premise
survival.	I-Premise

The	B-Claim
available	I-Claim
data	I-Claim
suggest	I-Claim
a	I-Claim
high	I-Claim
probability	I-Claim
of	I-Claim
favourable	I-Claim
cost-utility	I-Claim
outcomes	I-Claim
with	I-Claim
epoetin-alfa	I-Claim
treatment	I-Claim
for	I-Claim
anaemia	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
stage	I-Claim
IV	I-Claim
breast	I-Claim
cancer	I-Claim
receiving	I-Claim
nonplatinum-containing	I-Claim
chemotherapy.	I-Claim

Additional	B-Claim
studies	I-Claim
are	I-Claim
warranted.	I-Claim

In	B-Claim
advanced	I-Claim
not	I-Claim
selected	I-Claim
NSCLC	I-Claim
chemotherapy	I-Claim
achieved	I-Claim
an	I-Claim
advantage	I-Claim
of	I-Claim
approximately	I-Claim
1-2	I-Claim
months	I-Claim
on	I-Claim
median	I-Claim
survival	I-Claim
versus	I-Claim
best	I-Claim
supportive	I-Claim
care.	I-Claim

Chemotherapy	B-Claim
seems	I-Claim
to	I-Claim
improve	I-Claim
symptoms	I-Claim
control,	I-Claim
even	O
if	O
randomised	O
studies	O
with	O
quality	O
of	O
life	O
as	O
first	O
endpoint	O
are	O
lacking	O
and	O
often	O
chemotherapy	O
toxicity	O
compromises	O
the	O
frail	O
cost/benefit	O
ratio.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
evaluate	O
the	O
impact	O
on	O
QoL,	O
substituting	O
cisplatin,	O
a	O
pivot	O
drug	O
in	O
NSCLC	O
therapy,	O
with	O
carboplatin,	O
an	O
analogue	O
with	O
an	O
improved	O
toxicity	O
profile.	O

The	O
combination	O
of	O
cisplatin	O
with	O
Mitomycin	O
and	O
Vinblastine	O
was	O
one	O
of	O
the	O
most	O
frequently	O
used	O
in	O
the	O
palliative	O
setting	O
at	O
the	O
time	O
of	O
design	O
of	O
our	O
study.	O

Patients	O
were	O
randomized	O
to	O
receive	O
MVP	O
regimen	O
(Mitomycin-C	O
8	O
mg/m2	O
d1,	O
Vinblastine	O
4	O
mg/m2	O
d	O
1-8,	O
Cisplatin	O
100	O
mg/m2	O
d1)	O
or	O
MVC	O
regimen	O
(Mitomycin-C	O
8	O
mg/m2	O
d1,	O
Vinblastine	O
4	O
mg/m2	O
d	O
1-8,	O
Carboplatin	O
300	O
mg/m2	O
d1)	O
every	O
3	O
weeks.	O

The	O
QoL	O
was	O
evaluated	O
by	O
the	O
Spitzer	O
QL-Index	O
and	O
by	O
the	O
EORTC	O
QLQ-C30+LC	O
13	O
questionnaires	O
before	O
chemotherapy,	O
after	O
one	O
cycle,	O
after	O
three	O
cycles,	O
and	O
then	O
every	O
6	O
weeks	O
in	O
the	O
first	O
6	O
months	O
and	O
every	O
3	O
months	O
thenafter.	O

From	O
September	O
1994	O
to	O
July	O
1997,	O
153	O
consecutive	O
patients	O
were	O
randomized	O
to	O
MVP	O
(75	O
patients)	O
or	O
MVC	O
arm	O
(78	O
patients).	O

Despite	B-Premise
difficulties	I-Premise
in	I-Premise
carrying	I-Premise
out	I-Premise
and	I-Premise
analysing	I-Premise
QoL	I-Premise
items	I-Premise
in	I-Premise
such	I-Premise
patients,	I-Premise
the	I-Premise
global	I-Premise
QoL	I-Premise
evaluated	I-Premise
by	I-Premise
the	I-Premise
Spitzer's	I-Premise
questionnaire	I-Premise
suggested	I-Premise
an	I-Premise
advantage	I-Premise
for	I-Premise
MVC	I-Premise
regimen	I-Premise
(P=0.05)	I-Premise
and	I-Premise
a	I-Premise
significant	I-Premise
difference	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
global	I-Premise
health	I-Premise
subdomain	I-Premise
(P=0.04).	I-Premise

The	B-Premise
disease-related	I-Premise
symptoms	I-Premise
improved	I-Premise
with	I-Premise
time,	I-Premise
and	O
the	B-Premise
benefits	I-Premise
lasted	I-Premise
for	I-Premise
the	I-Premise
entire	I-Premise
treatment	I-Premise
period.	I-Premise

When	B-Premise
evaluated	I-Premise
with	I-Premise
the	I-Premise
EORTC	I-Premise
questionnaire	I-Premise
there	I-Premise
was	I-Premise
significantly	I-Premise
less	I-Premise
nausea	I-Premise
and	I-Premise
vomiting	I-Premise
(P=0.0001),	I-Premise
appetite	I-Premise
loss	I-Premise
(P=0.01),	I-Premise
insomnia	I-Premise
(P=0.03),	I-Premise
constipation	I-Premise
(P=0.01)	I-Premise
and	I-Premise
peripheral	I-Premise
neuropathy	I-Premise
(P=0.01)	I-Premise
in	I-Premise
favour	I-Premise
of	I-Premise
MVC,	I-Premise
and	I-Premise
a	I-Premise
trend	I-Premise
for	I-Premise
less	I-Premise
hair	I-Premise
loss	I-Premise
(P=0.05).	I-Premise

The	B-Premise
advantage	I-Premise
lasted	I-Premise
for	I-Premise
all	I-Premise
the	I-Premise
duration	I-Premise
of	I-Premise
chemotherapy.	I-Premise

No	B-Premise
differences	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
global	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
subdomain	I-Premise
(P=0.40)	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
regimen.	I-Premise

QoL	O
was	O
the	O
first	O
endpoint	O
and	O
the	O
statistical	O
power	O
was	O
inadequate	O
to	O
assess	O
other	O
parameters.	O

However,	O
we	B-Premise
reported	I-Premise
a	I-Premise
response	I-Premise
rate	I-Premise
of	I-Premise
43.1	I-Premise
and	I-Premise
38.6%,	I-Premise
respectively,	I-Premise
in	I-Premise
MVP	I-Premise
and	I-Premise
MVC	I-Premise
arm	I-Premise
(P=0.59)	I-Premise
and	I-Premise
a	I-Premise
median	I-Premise
survival	I-Premise
of	I-Premise
10.2	I-Premise
and	I-Premise
7.2	I-Premise
months,	I-Premise
respectively,	I-Premise
for	I-Premise
cisplatin	I-Premise
and	I-Premise
carboplatin	I-Premise
arm	I-Premise
(P=0.39).	I-Premise

The	B-Premise
carboplatin	I-Premise
containing	I-Premise
regimen	I-Premise
(MVC)	I-Premise
has	I-Premise
a	I-Premise
significant	I-Premise
better	I-Premise
toxicity	I-Premise
profile	I-Premise
than	I-Premise
the	I-Premise
cisplatin	I-Premise
containing	I-Premise
(MVP)	I-Premise
regimen	I-Premise
as	I-Premise
proven	I-Premise
both	I-Premise
by	I-Premise
the	I-Premise
EORTC	I-Premise
questionnaires	I-Premise
and	I-Premise
by	I-Premise
the	I-Premise
WHO	I-Premise
toxicity	I-Premise
data	I-Premise
reported	I-Premise
by	I-Premise
physicians.	I-Premise

No	B-Claim
significant	I-Claim
differences	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
response	I-Claim
rate,	I-Claim
time	I-Claim
to	I-Claim
progression	I-Claim
and	I-Claim
overall	I-Claim
survival	I-Claim
were	I-Claim
observed	I-Claim
between	I-Claim
the	I-Claim
two	I-Claim
regimen.	I-Claim

The	B-Claim
two	I-Claim
chemotherapy	I-Claim
regimen	I-Claim
showed	I-Claim
a	I-Claim
similar	I-Claim
effectiveness	I-Claim
in	I-Claim
symptom	I-Claim
palliation	I-Claim
when	I-Claim
evaluated	I-Claim
with	I-Claim
C30	I-Claim
addendum	I-Claim
of	I-Claim
EORTC	I-Claim
QOL	I-Claim
questionnaire.	I-Claim

With	B-Premise
the	I-Premise
Spitzer's	I-Premise
questionnaires	I-Premise
a	I-Premise
trend	I-Premise
towards	I-Premise
an	I-Premise
improved	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
index	I-Premise
was	I-Premise
observed	I-Premise
during	I-Premise
treatment	I-Premise
with	I-Premise
the	I-Premise
carboplatin	I-Premise
combination	I-Premise
in	I-Premise
comparison	I-Premise
to	I-Premise
the	I-Premise
cisplatin	I-Premise
combination.	I-Premise

This	B-Premise
difference,	I-Premise
however,	I-Premise
was	I-Premise
not	I-Premise
observed	I-Premise
when	I-Premise
the	I-Premise
global	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
was	I-Premise
evaluated	I-Premise
with	I-Premise
the	I-Premise
EORTC	I-Premise
patients	I-Premise
compiled	I-Premise
questionnaires.	I-Premise

A	B-Claim
carboplatin	I-Claim
containing	I-Claim
regimen	I-Claim
with	I-Claim
better	I-Claim
toxicity	I-Claim
profile	I-Claim
and	I-Claim
a	I-Claim
similar	I-Claim
potentiality	I-Claim
for	I-Claim
symptoms	I-Claim
control	I-Claim
offers	I-Claim
an	I-Claim
option	I-Claim
in	I-Claim
comparison	I-Claim
to	I-Claim
similar	I-Claim
cisplatin	I-Claim
containing	I-Claim
combinations	I-Claim
in	I-Claim
the	I-Claim
palliative	I-Claim
treatment	I-Claim
of	I-Claim
advanced	I-Claim
NSCLC.	I-Claim

N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine	O
(DPPE;	O
tesmilifene)	O
is	O
a	O
novel	O
agent	O
that	O
augments	O
chemotherapy	O
cytotoxicity	O
in	O
vitro	O
and	O
in	O
vivo.	O

A	O
phase	O
II	O
trial	O
combining	O
DPPE	O
and	O
doxorubicin	O
(DOX)	O
in	O
metastatic	O
breast	O
carcinoma	O
showed	O
increased	O
response	O
over	O
that	O
expected	O
with	O
DOX.	O

We	O
report	O
a	O
phase	O
III	O
trial	O
comparing	O
DOX	O
with	O
DPPE	O
plus	O
DOX	O
in	O
metastatic	O
or	O
recurrent	O
breast	O
cancer.	O

Anthracycline-naive	O
women	O
with	O
measurable	O
metastatic	O
disease	O
were	O
randomly	O
assigned	O
to	O
receive,	O
every	O
21	O
days,	O
either	O
DOX	O
60	O
mg/m(2)	O
intravenously	O
or	O
DOX	O
during	O
the	O
last	O
20	O
minutes	O
of	O
an	O
80-minute	O
infusion	O
of	O
DPPE	O
(5.3	O
mg/kg),	O
in	O
both	O
cases	O
to	O
cumulative	O
DOX	O
doses	O
of	O
450	O
mg/m(2).	O

Patients	O
receiving	O
DPPE	O
were	O
aggressively	O
premedicated	O
to	O
ameliorate	O
toxicity.	O

End	O
points	O
included	O
progression-free	O
survival	O
(PFS),	O
response	O
rate	O
(RR),	O
and	O
response	O
duration	O
(RD),	O
quality	O
of	O
life	O
(QOL),	O
toxicity,	O
and	O
overall	O
survival	O
(OS).	O

A	O
planned	O
interim	O
analysis	O
failed	O
to	O
detect	O
an	O
RR	O
difference	O
more	O
than	O
5%.	O

The	O
study	O
was	O
closed	O
to	O
additional	O
accrual	O
and	O
all	O
DPPE	O
was	O
discontinued.	O

The	O
final	O
analysis	O
was	O
conducted	O
as	O
planned	O
after	O
256	O
progression	O
events	O
(median	O
follow-up,	O
20.5	O
months).	O

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
RR,	I-Premise
RD,	I-Premise
or	I-Premise
PFS	I-Premise
between	I-Premise
arms.	I-Premise

DPPE	B-Premise
plus	I-Premise
DOX	I-Premise
was	I-Premise
statistically	I-Premise
superior	I-Premise
to	I-Premise
DOX	I-Premise
in	I-Premise
OS	I-Premise
(hazard	I-Premise
ratio,	I-Premise
0.66;	I-Premise
95%	I-Premise
CI,	I-Premise
0.48	I-Premise
to	I-Premise
0.91;	I-Premise
P	I-Premise
=.021).	I-Premise

DPPE	B-Premise
plus	I-Premise
DOX	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
more	I-Premise
gastrointestinal	I-Premise
and	I-Premise
CNS	I-Premise
toxicity.	I-Premise

No	B-Premise
consistent	I-Premise
influence	I-Premise
on	I-Premise
QOL	I-Premise
was	I-Premise
detected.	I-Premise

This	B-Claim
study	I-Claim
demonstrated	I-Claim
no	I-Claim
advantage	I-Claim
in	I-Claim
RR,	I-Claim
RD,	I-Claim
or	I-Claim
PFS	I-Claim
but	I-Claim
significantly	I-Claim
superior	I-Claim
OS	I-Claim
for	I-Claim
DPPE	I-Claim
plus	I-Claim
DOX.	I-Claim

Additional	B-Claim
studies	I-Claim
of	I-Claim
DPPE	I-Claim
are	I-Claim
warranted.	I-Claim

To	O
investigate	O
whether	O
the	O
effect	O
of	O
hypofractionated	O
thoracic	O
radiotherapy	O
(TRT)	O
is	O
comparable	O
to	O
more	O
standard	O
fractionated	O
radiotherapy	O
(RT)	O
in	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(NSCLC).	O

A	O
total	O
of	O
421	O
patients	O
with	O
locally	O
advanced	O
stage	O
III	O
or	O
stage	O
IV	O
NSCLC	O
tumors	O
were	O
included.	O

Inclusion	O
criteria	O
were	O
inoperable,	O
disease	O
too	O
advanced	O
for	O
curative	O
radiotherapy,	O
and	O
chest	O
symptoms	O
or	O
central	O
tumor	O
threatening	O
the	O
airways.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
three	O
arms:	O
A,	O
17	O
Gy	O
per	O
two	O
fractions	O
(n	O
=	O
146);	O
B,	O
42	O
Gy	O
per	O
15	O
fractions	O
(n	O
=	O
145);	O
and	O
C,	O
50	O
Gy	O
per	O
25	O
fractions	O
(n	O
=	O
130).	O

Four	O
hundred	O
seven	O
patients	O
were	O
eligible	O
for	O
the	O
study;	O
395	O
patients	O
(97%)	O
participated	O
in	O
the	O
health-related	O
quality-of-life	O
(HRQOL)	O
study.	O

The	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
Quality	O
of	O
Life	O
Questionnaire	O
(QLQ)-C30	O
and	O
EORTC	O
QLQ-lung	O
cancer-specific	O
module	O
(LC13)	O
were	O
used	O
to	O
investigate	O
airway	O
symptom	O
relief	O
and	O
changes	O
in	O
HRQOL.	O

Assessments	O
were	O
performed	O
before	O
TRT	O
and	O
until	O
week	O
54.	O

Clinicians'	O
assessments	O
of	O
symptom	O
improvement	O
were	O
at	O
2,	O
6,	O
and	O
14	O
weeks	O
after	O
completion	O
of	O
TRT.	O

The	O
patients	O
were	O
observed	O
for	O
a	O
minimum	O
of	O
3	O
years.	O

Results	O
Baseline	O
prognostic	O
data	O
were	O
equally	O
distributed	O
in	O
the	O
treatment	O
groups.	O

Patient	O
compliance	O
with	O
respect	O
to	O
the	O
HRQOL	O
investigation	O
was	O
minimum	O
74%.	O

HRQOL	B-Premise
and	I-Premise
symptom	I-Premise
relief	I-Premise
were	I-Premise
equivalent	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
arms.	I-Premise

No	B-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
survival	I-Premise
among	I-Premise
arms	I-Premise
A,	I-Premise
B,	I-Premise
and	I-Premise
C	I-Premise
was	I-Premise
found,	I-Premise
with	I-Premise
median	I-Premise
survival	I-Premise
8.2,	I-Premise
7.0,	I-Premise
and	I-Premise
6.8	I-Premise
months,	I-Premise
respectively.	I-Premise

Our	B-Claim
data	I-Claim
indicate	I-Claim
that	I-Claim
protracted	I-Claim
palliative	I-Claim
TRT	I-Claim
renders	I-Claim
no	I-Claim
improvement	I-Claim
in	I-Claim
symptom	I-Claim
relief,	I-Claim
HRQOL,	I-Claim
or	I-Claim
survival	I-Claim
when	I-Claim
compared	I-Claim
with	I-Claim
short-term	I-Claim
hypofractionated	I-Claim
treatment	I-Claim
in	I-Claim
advanced	I-Claim
NSCLC.	I-Claim

During	B-Premise
the	I-Premise
last	I-Premise
decade,	I-Premise
survival	I-Premise
rates	I-Premise
for	I-Premise
breast	I-Premise
cancer	I-Premise
have	I-Premise
increased	I-Premise
as	I-Premise
a	I-Premise
result	I-Premise
of	I-Premise
earlier	I-Premise
detection	I-Premise
and	I-Premise
increased	I-Premise
use	I-Premise
of	I-Premise
adjuvant	I-Premise
therapy.	I-Premise

Limited	O
data	O
exist	O
on	O
the	O
psychosocial	O
aspects	O
of	O
the	O
transitional	O
period	O
between	O
the	O
end	O
of	O
primary	O
treatment	O
and	O
survivorship.	O

We	O
investigated	O
the	O
baseline	O
psychosocial	O
status	O
of	O
women	O
enrolled	O
in	O
a	O
randomized	O
trial	O
testing	O
two	O
psychosocial	O
interventions	O
for	O
women	O
at	O
the	O
end	O
of	O
primary	O
treatment.	O

Participants,	O
identified	O
within	O
1	O
month	O
after	O
surgery	O
(registration),	O
provided	O
demographic	O
information	O
and	O
limited	O
measures	O
of	O
quality	O
of	O
life.	O

They	O
were	O
followed	O
until	O
they	O
finished	O
primary	O
treatment	O
(enrollment),	O
at	O
which	O
time	O
they	O
completed	O
a	O
mailed	O
baseline	O
survey	O
that	O
included	O
standardized	O
measures	O
of	O
quality	O
of	O
life	O
(including	O
standardized	O
scales	O
of	O
physical	O
and	O
emotional	O
functioning),	O
mood,	O
symptoms,	O
and	O
sexual	O
functioning.	O

A	O
total	O
of	O
558	O
patients	O
(mean	O
age	O
=	O
56.9	O
years)	O
were	O
enrolled	O
in	O
the	O
study	O
between	O
July	O
1,	O
1999,	O
and	O
June	O
30,	O
2002.	O

Health	O
outcomes	O
were	O
examined	O
according	O
to	O
treatment	O
received:	O
mastectomy	O
with	O
and	O
without	O
chemotherapy,	O
and	O
lumpectomy	O
with	O
and	O
without	O
chemotherapy.	O

All	O
statistical	O
tests	O
were	O
two-sided.	O

Among	B-Premise
all	I-Premise
treatment	I-Premise
groups,	I-Premise
patients	I-Premise
who	I-Premise
had	I-Premise
a	I-Premise
mastectomy	I-Premise
had	I-Premise
the	I-Premise
poorest	I-Premise
physical	I-Premise
functioning	I-Premise
at	I-Premise
registration	I-Premise
(P<.001)	I-Premise
and	I-Premise
at	I-Premise
enrollment	I-Premise
(P=.05).	I-Premise

At	B-Premise
enrollment,	I-Premise
mood	I-Premise
and	I-Premise
emotional	I-Premise
functioning	I-Premise
were	I-Premise
similar	I-Premise
among	I-Premise
all	I-Premise
patients,	I-Premise
with	I-Premise
no	I-Premise
differences	I-Premise
by	I-Premise
type	I-Premise
of	I-Premise
treatment	I-Premise
received.	I-Premise

At	B-Premise
enrollment,	I-Premise
symptoms,	I-Premise
including	I-Premise
muscle	I-Premise
stiffness,	I-Premise
breast	I-Premise
sensitivity,	I-Premise
aches	I-Premise
and	I-Premise
pains,	I-Premise
tendency	I-Premise
to	I-Premise
take	I-Premise
naps,	I-Premise
and	I-Premise
difficulty	I-Premise
concentrating,	I-Premise
were	I-Premise
common	I-Premise
among	I-Premise
patients	I-Premise
in	I-Premise
all	I-Premise
groups	I-Premise
and	I-Premise
were	I-Premise
statistically	I-Premise
significantly	I-Premise
associated	I-Premise
with	I-Premise
poor	I-Premise
physical	I-Premise
functioning	I-Premise
and	I-Premise
emotional	I-Premise
well-being.	I-Premise

Sexual	B-Premise
functioning	I-Premise
was	I-Premise
worse	I-Premise
for	I-Premise
women	I-Premise
who	I-Premise
received	I-Premise
chemotherapy	I-Premise
than	I-Premise
for	I-Premise
those	I-Premise
who	I-Premise
did	I-Premise
not,	I-Premise
regardless	I-Premise
of	I-Premise
type	I-Premise
of	I-Premise
surgery	I-Premise
(P<.001).	I-Premise

At	B-Claim
the	I-Claim
end	I-Claim
of	I-Claim
primary	I-Claim
treatment	I-Claim
for	I-Claim
breast	I-Claim
cancer,	I-Claim
women	I-Claim
in	I-Claim
all	I-Claim
treatment	I-Claim
groups	I-Claim
report	I-Claim
good	I-Claim
emotional	I-Claim
functioning	I-Claim
but	I-Claim
report	I-Claim
decreased	I-Claim
physical	I-Claim
functioning,	I-Claim
particularly	I-Claim
among	I-Claim
women	I-Claim
who	I-Claim
have	I-Claim
a	I-Claim
mastectomy	I-Claim
or	I-Claim
receive	I-Claim
chemotherapy.	I-Claim

Clinical	B-Claim
interventions	I-Claim
to	I-Claim
address	I-Claim
common	I-Claim
symptoms	I-Claim
associated	I-Claim
with	I-Claim
treatment	I-Claim
should	I-Claim
be	I-Claim
considered	I-Claim
to	I-Claim
improve	I-Claim
physical	I-Claim
and	I-Claim
emotional	I-Claim
functioning	I-Claim
at	I-Claim
the	I-Claim
end	I-Claim
of	I-Claim
primary	I-Claim
treatment	I-Claim
for	I-Claim
breast	I-Claim
cancer.	I-Claim

The	O
World	O
Health	O
Organization	O
(WHO)	O
guidelines	O
for	O
the	O
treatment	O
of	O
cancer	O
pain	O
recommend	O
nonopioid	O
analgesics	O
as	O
first-line	O
therapy,	O
so-called	O
"weak"	O
analgesics	O
combined	O
with	O
nonopioid	O
analgesics	O
as	O
second-line	O
therapy,	O
and	O
so-called	O
"strong"	O
opioids	O
(with	O
nonopioid	O
analgesics)	O
only	O
as	O
third-line	O
therapy.	O

However,	O
these	O
guidelines	O
can	O
be	O
questioned	O
with	O
regard	O
to	O
the	O
extent	O
of	O
efficacy	O
as	O
well	O
as	O
the	O
rationale	O
for	O
not	O
using	O
strong	O
opioids	O
as	O
first-line	O
treatment,	O
especially	O
in	O
terminal	O
cancer	O
patients.	O

The	O
purpose	O
of	O
this	O
randomized	O
study	O
was	O
to	O
prospectively	O
compare	O
the	O
efficacy	O
and	O
tolerability	O
of	O
strong	O
opioids	O
as	O
first-line	O
agents	O
with	O
the	O
recommendations	O
of	O
the	O
WHO	O
in	O
terminal	O
cancer	O
patients.	O

One	O
hundred	O
patients	O
with	O
mild-moderate	O
pain	O
were	O
randomized	O
to	O
treatment	O
according	O
to	O
WHO	O
guidelines	O
or	O
to	O
treatment	O
with	O
strong	O
opioids.	O

Evaluated	O
outcomes	O
included	O
pain	O
intensity,	O
need	O
for	O
change	O
in	O
therapy,	O
quality	O
of	O
life,	O
Karnofsky	O
Performance	O
Status,	O
general	O
condition	O
of	O
the	O
patient,	O
and	O
adverse	O
events.	O

No	B-Premise
between-treatment	I-Premise
differences	I-Premise
were	I-Premise
observed	I-Premise
for	I-Premise
changes	I-Premise
in	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
or	I-Premise
performance	I-Premise
status,	I-Premise
but	O
patients	B-Premise
started	I-Premise
on	I-Premise
strong	I-Premise
opioids	I-Premise
had	I-Premise
significantly	I-Premise
better	I-Premise
pain	I-Premise
relief	I-Premise
than	I-Premise
patients	I-Premise
treated	I-Premise
according	I-Premise
to	I-Premise
WHO	I-Premise
guidelines	I-Premise
(P=0.041).	I-Premise

Additionally,	B-Premise
patients	I-Premise
started	I-Premise
on	I-Premise
strong	I-Premise
opioids	I-Premise
required	I-Premise
significantly	I-Premise
fewer	I-Premise
changes	I-Premise
in	I-Premise
therapy,	I-Premise
had	I-Premise
greater	I-Premise
reduction	I-Premise
in	I-Premise
pain	I-Premise
when	I-Premise
a	I-Premise
change	I-Premise
was	I-Premise
initiated,	I-Premise
and	I-Premise
reported	I-Premise
greater	I-Premise
satisfaction	I-Premise
with	I-Premise
treatment	I-Premise
than	I-Premise
the	I-Premise
comparator	I-Premise
group	I-Premise
(P=0.041).	I-Premise

Strong	B-Claim
opioids	I-Claim
were	I-Claim
safe	I-Claim
and	I-Claim
well-tolerated,	I-Claim
with	I-Claim
no	I-Claim
development	I-Claim
of	I-Claim
tolerance	I-Claim
or	I-Claim
serious	I-Claim
adverse	I-Claim
events.	I-Claim

These	B-Claim
data	I-Claim
suggest	I-Claim
the	I-Claim
utility	I-Claim
of	I-Claim
strong	I-Claim
opioids	I-Claim
for	I-Claim
first-line	I-Claim
treatment	I-Claim
of	I-Claim
pain	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
terminal	I-Claim
cancer.	I-Claim

To	O
determine	O
if	O
the	O
type	O
of	O
embolic	O
material	O
used	O
for	O
uterine	O
artery	O
embolization	O
(UAE)	O
for	O
leiomyomas	O
has	O
an	O
impact	O
on	O
short-term	O
recovery	O
or	O
the	O
effectiveness	O
of	O
embolization.	O

One	O
hundred	O
patients	O
were	O
randomly	O
assigned	O
to	O
undergo	O
UAE	O
with	O
polyvinyl	O
alcohol	O
(PVA)	O
particles	O
or	O
tris-acryl	O
gelatin	O
microspheres.	O

Short-term,	O
in-hospital	O
medication	O
use	O
and	O
pain	O
levels	O
were	O
recorded.	O

After	O
discharge,	O
symptom	O
severity,	O
temperature,	O
and	O
medications	O
used	O
were	O
recorded	O
daily	O
for	O
1	O
week	O
and	O
symptom	O
levels	O
were	O
measured	O
for	O
weeks	O
2-4.	O

Three	O
months	O
after	O
embolization,	O
contrast	O
material-enhanced	O
magnetic	O
resonance	O
imaging	O
examinations	O
were	O
evaluated	O
blindly	O
to	O
determine	O
the	O
extent	O
of	O
leiomyoma	O
infarction.	O

Symptom	O
and	O
quality	O
of	O
life	O
(QOL)	O
status	O
was	O
determined	O
with	O
use	O
of	O
questionnaires.	O

Analysis	O
was	O
completed	O
with	O
use	O
of	O
chi(2)	O
analysis,	O
Fisher	O
exact	O
tests,	O
Student	O
t	O
tests,	O
and	O
analysis	O
of	O
variance	O
as	O
appropriate.	O

Regression	O
analysis	O
was	O
used	O
to	O
analyze	O
the	O
impact	O
on	O
outcome	O
of	O
baseline	O
factors	O
(other	O
than	O
type	O
of	O
embolic	O
agent).	O

No	O
significant	O
differences	O
were	O
noted	O
at	O
baseline	O
between	O
the	O
two	O
treatment	O
groups.	O

On	B-Premise
average,	I-Premise
there	I-Premise
were	I-Premise
significantly	I-Premise
higher	I-Premise
volumes	I-Premise
of	I-Premise
tris-acryl	I-Premise
microspheres	I-Premise
used	I-Premise
(9.0	I-Premise
mL	I-Premise
vs	I-Premise
3.0	I-Premise
mL;	I-Premise
P	I-Premise
=.0001),	I-Premise
whereas	O
microcatheter	B-Premise
occlusion	I-Premise
was	I-Premise
more	I-Premise
common	I-Premise
with	I-Premise
PVA	I-Premise
(28%	I-Premise
vs	I-Premise
4%,	I-Premise
P	I-Premise
=.001).	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
differences	I-Premise
in	I-Premise
pain	I-Premise
severity,	I-Premise
other	I-Premise
postprocedural	I-Premise
symptoms,	I-Premise
or	I-Premise
medication	I-Premise
use	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
treatment	I-Premise
groups.	I-Premise

There	B-Premise
were	I-Premise
also	I-Premise
no	I-Premise
differences	I-Premise
in	I-Premise
the	I-Premise
frequency	I-Premise
of	I-Premise
incompletely	I-Premise
infarcted	I-Premise
leiomyomas,	I-Premise
degree	I-Premise
of	I-Premise
improvement	I-Premise
in	I-Premise
symptom	I-Premise
score,	I-Premise
patient	I-Premise
satisfaction,	I-Premise
or	I-Premise
QOL.	I-Premise

No	B-Claim
substantive	I-Claim
differences	I-Claim
were	I-Claim
detected	I-Claim
between	I-Claim
outcomes	I-Claim
of	I-Claim
embolization	I-Claim
with	I-Claim
PVA	I-Claim
particles	I-Claim
or	I-Claim
tris-acryl	I-Claim
gelatin	I-Claim
microspheres.	I-Claim

Fatigue	O
is	O
a	O
frequent	O
problem	O
after	O
surgical	O
treatment	O
of	O
solid	O
tumours.	O

Aerobic	B-Claim
exercise	I-Claim
and	I-Claim
psychosocial	I-Claim
interventions	I-Claim
have	I-Claim
been	I-Claim
shown	I-Claim
to	I-Claim
reduce	I-Claim
the	I-Claim
severity	I-Claim
of	I-Claim
this	I-Claim
symptom	I-Claim
in	I-Claim
cancer	I-Claim
patients.	I-Claim

Therefore,	O
we	O
compared	O
the	O
effect	O
of	O
the	O
two	O
therapies	O
on	O
fatigue	O
in	O
a	O
randomised	O
controlled	O
study.	O

Seventy-two	O
patients	O
who	O
underwent	O
surgery	O
for	O
lung	O
(n=27)	O
or	O
gastrointestinal	O
tumours	O
(n=42)	O
were	O
assigned	O
to	O
an	O
aerobic	O
exercise	O
group	O
(stationary	O
biking	O
30	O
min	O
five	O
times	O
weekly)	O
or	O
a	O
progressive	O
relaxation	O
training	O
group	O
(45	O
min	O
three	O
times	O
per	O
week).	O

Both	O
interventions	O
were	O
carried	O
out	O
for	O
3	O
weeks.	O

At	O
the	O
beginning	O
and	O
the	O
end	O
of	O
the	O
study,	O
we	O
evaluated	O
physical,	O
cognitive	O
and	O
emotional	O
status	O
and	O
somatic	O
complaints	O
with	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
Core	O
Module	O
(EORTC-QLQ-30)	O
questionnaire,	O
and	O
maximal	O
physical	O
performance	O
with	O
an	O
ergometric	O
stress	O
test.	O

Physical	B-Premise
performance	I-Premise
of	I-Premise
the	I-Premise
training	I-Premise
group	I-Premise
improved	I-Premise
significantly	I-Premise
during	I-Premise
the	I-Premise
programme	I-Premise
(9.4+/-20	I-Premise
watts,	I-Premise
p=0.01)	I-Premise
but	I-Premise
remained	I-Premise
unchanged	I-Premise
in	I-Premise
the	I-Premise
relaxation	I-Premise
group	I-Premise
(1.5+/-14.8	I-Premise
watts,	I-Premise
p=0.37).	I-Premise

Fatigue	B-Premise
and	I-Premise
global	I-Premise
health	I-Premise
scores	I-Premise
improved	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
during	I-Premise
the	I-Premise
intervention	I-Premise
(fatigue:	I-Premise
training	I-Premise
group	I-Premise
21%,	I-Premise
relaxation	I-Premise
group	I-Premise
19%;	I-Premise
global	I-Premise
health	I-Premise
of	I-Premise
both	I-Premise
groups	I-Premise
19%,	I-Premise
p	I-Premise
for	I-Premise
all	I-Premise
<	I-Premise
or	I-Premise
=0.01);	I-Premise
however,	B-Premise
there	I-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
changes	I-Premise
in	I-Premise
the	I-Premise
scores	I-Premise
of	I-Premise
both	I-Premise
groups	I-Premise
(p=0.67).	I-Premise

We	B-Claim
conclude	I-Claim
that	I-Claim
a	I-Claim
structured	I-Claim
aerobic	I-Claim
training	I-Claim
programme	I-Claim
improves	I-Claim
the	I-Claim
physical	I-Claim
performance	I-Claim
of	I-Claim
patients	I-Claim
recovering	I-Claim
from	I-Claim
surgery	I-Claim
for	I-Claim
solid	I-Claim
tumours.	I-Claim

However,	B-Claim
exercise	I-Claim
is	I-Claim
not	I-Claim
better	I-Claim
than	I-Claim
progressive	I-Claim
relaxation	I-Claim
training	I-Claim
for	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
fatigue	I-Claim
in	I-Claim
this	I-Claim
setting.	I-Claim

To	O
examine	O
the	O
effects	O
of	O
a	O
seated	O
exercise	O
program	O
on	O
fatigue	O
and	O
quality	O
of	O
life	O
(QOL)	O
in	O
women	O
with	O
metastatic	O
breast	O
cancer.	O

Randomized,	O
controlled,	O
longitudinal	O
trial.	O

Outpatient	O
clinic	O
of	O
a	O
comprehensive	O
cancer	O
center.	O

Convenience	O
sample	O
of	O
38	O
women	O
who	O
were	O
beginning	O
outpatient	O
chemotherapy.	O

Subjects	O
were	O
randomized	O
to	O
a	O
control	O
or	O
intervention	O
group;	O
the	O
intervention	O
was	O
performance	O
of	O
a	O
seated	O
exercise	O
program	O
using	O
home	O
videotape	O
three	O
times	O
per	O
week	O
for	O
four	O
cycles	O
of	O
chemotherapy.	O

All	O
subjects	O
completed	O
the	O
Functional	O
Assessment	O
of	O
Chronic	O
Illness	O
Therapy	O
Fatigue	O
Version	O
IV	O
(FACIT	O
F)	O
at	O
baseline	O
and	O
at	O
the	O
time	O
of	O
the	O
next	O
three	O
cycles.	O

Subjects	O
were	O
asked	O
to	O
document	O
the	O
frequency,	O
duration,	O
and	O
intensity	O
of	O
all	O
exercise	O
participation	O
on	O
monthly	O
calendars.	O

Exercise,	O
fatigue,	O
and	O
QOL.	O

32	O
subjects,	O
16	O
per	O
group,	O
completed	O
the	O
study	O
follow-up.	O

With	B-Premise
a	I-Premise
mixed	I-Premise
modeling	I-Premise
approach,	I-Premise
total	I-Premise
FACIT	I-Premise
F	I-Premise
scores	I-Premise
for	I-Premise
the	I-Premise
entire	I-Premise
sample	I-Premise
declined	I-Premise
at	I-Premise
a	I-Premise
significant	I-Premise
rate	I-Premise
(p	I-Premise
=	I-Premise
0.003)	I-Premise
beginning	I-Premise
with	I-Premise
cycle	I-Premise
3	I-Premise
but	B-Premise
at	I-Premise
a	I-Premise
slower	I-Premise
rate	I-Premise
for	I-Premise
the	I-Premise
experimental	I-Premise
group	I-Premise
(p	I-Premise
=	I-Premise
0.02).	I-Premise

Fatigue	B-Premise
scores	I-Premise
indicated	I-Premise
less	I-Premise
increase	I-Premise
and	I-Premise
physical	I-Premise
well-being	I-Premise
subscale	I-Premise
scores	I-Premise
showed	I-Premise
less	I-Premise
decline	I-Premise
for	I-Premise
the	I-Premise
experimental	I-Premise
group	I-Premise
(p	I-Premise
=	I-Premise
0.008	I-Premise
and	I-Premise
p	I-Premise
=	I-Premise
0.02,	I-Premise
respectively).	I-Premise

Women	B-Premise
with	I-Premise
advanced	I-Premise
breast	I-Premise
cancer	I-Premise
randomized	I-Premise
to	I-Premise
the	I-Premise
seated	I-Premise
exercise	I-Premise
intervention	I-Premise
had	I-Premise
a	I-Premise
slower	I-Premise
decline	I-Premise
in	I-Premise
total	I-Premise
and	I-Premise
physical	I-Premise
well-being	I-Premise
and	I-Premise
less	I-Premise
increase	I-Premise
in	I-Premise
fatigue	I-Premise
scores	I-Premise
starting	I-Premise
with	I-Premise
the	I-Premise
third	I-Premise
cycle	I-Premise
of	I-Premise
chemotherapy.	I-Premise

Seated	B-Claim
exercise	I-Claim
may	I-Claim
be	I-Claim
a	I-Claim
feasible	I-Claim
exercise	I-Claim
program	I-Claim
for	I-Claim
women	I-Claim
with	I-Claim
advanced	I-Claim
cancer	I-Claim
for	I-Claim
controlling	I-Claim
fatigue	I-Claim
and	I-Claim
improving	I-Claim
physical	I-Claim
well-being.	I-Claim

To	O
determine	O
whether	O
weekly	O
epoetin	O
alfa	O
could	O
improve	O
hemoglobin	O
(HgB)	O
levels,	O
reduce	O
RBC	O
transfusions,	O
and	O
improve	O
quality	O
of	O
life	O
(QOL)	O
in	O
patients	O
with	O
advanced	O
cancer	O
and	O
with	O
anemia	O
after	O
receiving	O
myelosuppressive	O
chemotherapy.	O

This	O
double-blind,	O
placebo-controlled	O
study	O
randomly	O
assigned	O
patients	O
to	O
placebo	O
or	O
epoetin	O
alfa	O
(Ortho	O
Biotech,	O
Bridgewater,	O
NJ)	O
40,000	O
U	O
subcutaneous	O
weekly	O
for	O
16	O
weeks.	O

QOL,	O
HgB,	O
and	O
RBC	O
transfusions	O
were	O
measured	O
pretreatment	O
and	O
monthly.	O

The	O
study	O
accrued	O
344	O
patients;	O
330	O
were	O
assessable	O
for	O
efficacy	O
and	O
305	O
were	O
assessable	O
for	O
QOL.	O

Placebo-treated	B-Premise
patients	I-Premise
had	I-Premise
a	I-Premise
mean	I-Premise
increase	I-Premise
in	I-Premise
HgB	I-Premise
of	I-Premise
0.9	I-Premise
g/dL	I-Premise
(range,	I-Premise
-3.8	I-Premise
to	I-Premise
+5.3)	I-Premise
compared	I-Premise
with	I-Premise
2.8	I-Premise
g/dL	I-Premise
(range,	I-Premise
-2.2	I-Premise
to	I-Premise
+7.5)	I-Premise
for	I-Premise
epoetin-treated	I-Premise
patients	I-Premise
(P	I-Premise
<	I-Premise
.0001).	I-Premise

During	B-Premise
the	I-Premise
study,	I-Premise
31.7%	I-Premise
of	I-Premise
placebo-treated	I-Premise
patients	I-Premise
achieved	I-Premise
a	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
2	I-Premise
g/dL	I-Premise
HgB	I-Premise
increase	I-Premise
compared	I-Premise
with	I-Premise
72.7%	I-Premise
of	I-Premise
epoetin-treated	I-Premise
patients	I-Premise
(P	I-Premise
<	I-Premise
.0001).	I-Premise

The	B-Premise
incidence	I-Premise
of	I-Premise
RBC	I-Premise
transfusion	I-Premise
for	I-Premise
placebo	I-Premise
and	I-Premise
epoetin	I-Premise
treatment	I-Premise
arms	I-Premise
was	I-Premise
39.6%	I-Premise
and	I-Premise
25.3%	I-Premise
(P	I-Premise
=	I-Premise
.005),	I-Premise
respectively.	I-Premise

The	O
placebo	O
group	O
received	O
256	O
units	O
of	O
RBCs	O
compared	O
with	O
127	O
units	O
in	O
the	O
epoetin	O
group	O
(P	O
<	O
.0001).	O

The	B-Premise
incidence	I-Premise
of	I-Premise
toxicity	I-Premise
in	I-Premise
the	I-Premise
groups	I-Premise
was	I-Premise
similar.	I-Premise

Changes	B-Premise
in	I-Premise
the	I-Premise
average	I-Premise
QOL	I-Premise
scores	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
the	I-Premise
study	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
the	I-Premise
two	I-Premise
groups	I-Premise
(P	I-Premise
=	I-Premise
not	I-Premise
significant).	I-Premise

The	B-Premise
HgB	I-Premise
responders	I-Premise
(irrespective	I-Premise
of	I-Premise
treatment	I-Premise
arm)	I-Premise
had	I-Premise
a	I-Premise
mean	I-Premise
change	I-Premise
in	I-Premise
Functional	I-Premise
Assessment	I-Premise
of	I-Premise
Cancer	I-Premise
Therapy	I-Premise
(FACT)	I-Premise
fatigue	I-Premise
score	I-Premise
from	I-Premise
a	I-Premise
baseline	I-Premise
of	I-Premise
+5.1	I-Premise
compared	I-Premise
with	I-Premise
-2.1	I-Premise
for	I-Premise
the	I-Premise
nonresponders	I-Premise
(P	I-Premise
=	I-Premise
.006).	I-Premise

Epoetin	B-Claim
alfa	I-Claim
significantly	I-Claim
improved	I-Claim
HgB	I-Claim
and	I-Claim
reduced	I-Claim
transfusions	I-Claim
in	I-Claim
this	I-Claim
patient	I-Claim
population.	I-Claim

These	B-Claim
results	I-Claim
support	I-Claim
the	I-Claim
use	I-Claim
of	I-Claim
weekly	I-Claim
epoetin	I-Claim
alfa	I-Claim
as	I-Claim
an	I-Claim
ameliorative	I-Claim
agent	I-Claim
for	I-Claim
cancer-related	I-Claim
anemia.	I-Claim

Epoetin	B-Claim
alfa	I-Claim
administered	I-Claim
at	I-Claim
40,000	I-Claim
U	I-Claim
once	I-Claim
weekly	I-Claim
(qw)	I-Claim
to	I-Claim
anemic	I-Claim
cancer	I-Claim
patients	I-Claim
receiving	I-Claim
chemotherapy	I-Claim
increases	I-Claim
hemoglobin	I-Claim
levels,	I-Claim
improves	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
(QOL),	I-Claim
and	I-Claim
reduces	I-Claim
transfusions.	I-Claim

The	O
benefit	O
of	O
epoetin	O
alfa	O
in	O
maintaining	O
hemoglobin	O
levels	O
in	O
cancer	O
patients	O
with	O
hemoglobin	O
less	O
than	O
12	O
g/dL	O
has	O
not	O
been	O
evaluated.	O

Breast	O
cancer	O
patients	O
(N	O
=	O
354)	O
receiving	O
chemotherapy	O
were	O
randomly	O
assigned	O
in	O
1:1	O
ratio	O
to	O
epoetin	O
alfa	O
(40,000	O
U	O
qw)	O
or	O
standard	O
of	O
care	O
(SOC).	O

QOL	O
was	O
assessed	O
at	O
baseline	O
and	O
week	O
12.	O

Hemoglobin	O
responses,	O
transfusion	O
requirements,	O
and	O
prognostic	O
factors	O
for	O
responses	O
were	O
measured.	O

At	B-Premise
week	I-Premise
12,	I-Premise
Functional	I-Premise
Assessment	I-Premise
of	I-Premise
Cancer	I-Premise
Therapy-Anemia	I-Premise
(FACT-An;	I-Premise
mean,	I-Premise
2.16	I-Premise
+/-	I-Premise
12.84	I-Premise
for	I-Premise
epoetin	I-Premise
alfa	I-Premise
v	I-Premise
-4.43	I-Premise
+/-	I-Premise
13.42	I-Premise
for	I-Premise
SOC)	I-Premise
and	I-Premise
FACT-An	I-Premise
fatigue	I-Premise
(mean,	I-Premise
1.85	I-Premise
+/-	I-Premise
10.52	I-Premise
for	I-Premise
epoetin	I-Premise
alfa	I-Premise
v	I-Premise
-3.55	I-Premise
+/-	I-Premise
11.14	I-Premise
for	I-Premise
SOC)	I-Premise
change	I-Premise
scores	I-Premise
were	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
epoetin	I-Premise
alfa	I-Premise
group	I-Premise
(P	I-Premise
<	I-Premise
.0001).	I-Premise

Hemoglobin	B-Premise
responses	I-Premise
defined	I-Premise
as	I-Premise
mean	I-Premise
hemoglobin	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
12	I-Premise
g/dL	I-Premise
or	I-Premise
a	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
2	I-Premise
g/dL	I-Premise
increase	I-Premise
compared	I-Premise
with	I-Premise
baseline	I-Premise
were	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
epoetin	I-Premise
alfa	I-Premise
group	I-Premise
versus	I-Premise
SOC:	I-Premise
52.0%	I-Premise
v	I-Premise
5.1%	I-Premise
and	I-Premise
65.7%	I-Premise
v	I-Premise
6.3%,	I-Premise
respectively	I-Premise
(P	I-Premise
<	I-Premise
.0001	I-Premise
for	I-Premise
both	I-Premise
comparisons).	I-Premise

Percentage	B-Premise
transfused	I-Premise
was	I-Premise
significantly	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
epoetin	I-Premise
alfa	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
SOC	I-Premise
(8.6%	I-Premise
v	I-Premise
22.9%).	I-Premise

More	B-Premise
than	I-Premise
90%	I-Premise
of	I-Premise
patients	I-Premise
did	I-Premise
not	I-Premise
require	I-Premise
a	I-Premise
dose	I-Premise
increase	I-Premise
and	I-Premise
28.7%	I-Premise
had	I-Premise
a	I-Premise
dose	I-Premise
reduction.	I-Premise

Epoetin	B-Claim
alfa	I-Claim
administered	I-Claim
at	I-Claim
40,000	I-Claim
U	I-Claim
qw	I-Claim
is	I-Claim
effective	I-Claim
in	I-Claim
improving	I-Claim
QOL,	I-Claim
maintaining	I-Claim
hemoglobin	I-Claim
level,	I-Claim
and	I-Claim
reducing	I-Claim
transfusion	I-Claim
requirements	I-Claim
in	I-Claim
breast	I-Claim
cancer	I-Claim
patients.	I-Claim

The	B-Claim
high	I-Claim
effectiveness	I-Claim
observed	I-Claim
could	I-Claim
be	I-Claim
attributed	I-Claim
in	I-Claim
part	I-Claim
to	I-Claim
early	I-Claim
treatment	I-Claim
with	I-Claim
epoetin	I-Claim
alfa.	I-Claim

Increased	O
attention	O
has	O
focused	O
on	O
exercise	O
as	O
a	O
quality	O
of	O
life	O
intervention	O
for	O
breast	O
cancer	O
survivors	O
during	O
and	O
after	O
adjuvant	O
therapy.	O

Our	O
objective	O
was	O
to	O
examine	O
the	O
effects	O
of	O
an	O
oncologist's	O
recommendation	O
to	O
exercise	O
on	O
self-reported	O
exercise	O
behavior	O
in	O
newly	O
diagnosed	O
breast	O
cancer	O
survivors	O
attending	O
their	O
first	O
adjuvant	O
therapy	O
consultation.	O

Using	O
a	O
single-blinded,	O
3-armed,	O
randomized	O
controlled	O
trial,	O
450	O
breast	O
cancer	O
survivors	O
were	O
randomly	O
assigned	O
to	O
receive	O
an	O
oncologist	O
exercise	O
recommendation	O
only,	O
an	O
oncologist	O
exercise	O
recommendation	O
plus	O
referral	O
to	O
an	O
exercise	O
specialist,	O
or	O
usual	O
care.	O

The	O
primary	O
outcome	O
was	O
self-reported	O
total	O
exercise	O
(in	O
metabolic	O
equivalent	O
[MET]	O
hours	O
per	O
week)	O
at	O
5	O
weeks	O
postconsultation.	O

The	O
follow-up	O
assessment	O
rate	O
was	O
73%	O
(329	O
of	O
450).	O

Intention-to-treat	B-Premise
analysis	I-Premise
based	I-Premise
on	I-Premise
participants	I-Premise
with	I-Premise
follow-up	I-Premise
data	I-Premise
indicated	I-Premise
a	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
total	I-Premise
exercise	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
the	I-Premise
recommendation-only	I-Premise
group	I-Premise
over	I-Premise
the	I-Premise
usual	I-Premise
care	I-Premise
group	I-Premise
(mean	I-Premise
difference,	I-Premise
3.4	I-Premise
MET	I-Premise
hr	I-Premise
per	I-Premise
week;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI],	I-Premise
0.7-6.1	I-Premise
MET	I-Premise
hr	I-Premise
per	I-Premise
week;	I-Premise
p	I-Premise
=	I-Premise
.011).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
the	I-Premise
recommendation-plus-referral	I-Premise
group	I-Premise
and	I-Premise
the	I-Premise
usual	I-Premise
care	I-Premise
group	I-Premise
(mean	I-Premise
difference,	I-Premise
1.5	I-Premise
MET	I-Premise
hr	I-Premise
per	I-Premise
week;	I-Premise
95%	I-Premise
CI,	I-Premise
-1.0	I-Premise
to	I-Premise
4.0	I-Premise
MET	I-Premise
hr	I-Premise
per	I-Premise
week;	I-Premise
p	I-Premise
=	I-Premise
.244).	I-Premise

Ancillary	B-Premise
"on-treatment"	I-Premise
analyzes	I-Premise
showed	I-Premise
that	I-Premise
participants	I-Premise
who	I-Premise
recalled	I-Premise
an	I-Premise
exercise	I-Premise
recommendation	I-Premise
reported	I-Premise
significantly	I-Premise
more	I-Premise
total	I-Premise
exercise	I-Premise
than	I-Premise
participants	I-Premise
who	I-Premise
did	I-Premise
not	I-Premise
recall	I-Premise
an	I-Premise
exercise	I-Premise
recommendation	I-Premise
(mean	I-Premise
difference,	I-Premise
4.1	I-Premise
MET	I-Premise
hr	I-Premise
per	I-Premise
week:	I-Premise
95%	I-Premise
CI,	I-Premise
1.9-6.4	I-Premise
MET	I-Premise
hr	I-Premise
per	I-Premise
week;	I-Premise
p	I-Premise
<	I-Premise
.001).	I-Premise

Our	B-Claim
findings	I-Claim
suggest	I-Claim
that	I-Claim
an	I-Claim
oncologist	I-Claim
recommendation	I-Claim
may	I-Claim
increase	I-Claim
exercise	I-Claim
behavior	I-Claim
in	I-Claim
newly	I-Claim
diagnosed	I-Claim
breast	I-Claim
cancer	I-Claim
survivors,	I-Claim
particularly	I-Claim
if	I-Claim
it	I-Claim
is	I-Claim
recalled	I-Claim
1	I-Claim
week	I-Claim
after	I-Claim
the	I-Claim
recommendation.	I-Claim

Kaposi's	O
sarcoma	O
is	O
currently	O
the	O
most	O
common	O
tumor	O
in	O
Zimbabwe.	O

The	O
purpose	O
of	O
our	O
study	O
is	O
to	O
compare	O
the	O
effectiveness	O
of	O
supportive	O
care	O
vs.	O
3	O
intervention	O
approaches,	O
namely	O
oral	O
Etoposide,	O
a	O
3-drug	O
combination,	O
and	O
radiotherapy	O
using	O
quality	O
of	O
life	O
(QOL)	O
as	O
the	O
primary	O
measure	O
of	O
success.	O

In	O
addition,	O
our	O
study	O
was	O
to	O
determine	O
whether	O
a	O
disease-specific	O
module	O
has	O
greater	O
sensitivity	O
to	O
group	O
differences	O
than	O
a	O
generic	O
QOL	O
questionnaire	O
and	O
to	O
determine	O
the	O
most	O
pragmatic	O
approach	O
to	O
treating	O
epidemic	O
Kaposi's	O
sarcoma	O
(EKS)	O
in	O
Zimbabwe.	O

Histologically	O
confirmed	O
HIV-positive	O
patients	O
with	O
Kaposi's	O
sarcoma	O
were	O
randomized	O
to	O
receive	O
supportive	O
care	O
only	O
or	O
supportive	O
care	O
plus	O
either	O
radiotherapy,	O
oral	O
Etoposide	O
or	O
a	O
3-drug	O
combination	O
consisting	O
of	O
actinomycin-D,	O
vincristine	O
and	O
bleomycin.	O

No	O
patient	O
received	O
antiretroviral	O
therapy.	O

The	O
primary	O
outcome	O
was	O
QOL	O
measured	O
by	O
the	O
functional	O
living	O
index-cancer	O
(FLI-C)	O
and	O
supplemented	O
by	O
the	O
Kaposi's	O
sarcoma	O
module	O
(KSM).	O

From	O
1994-1999,	O
495	O
EKS	O
patients	O
were	O
accrued,	O
and	O
470	O
were	O
evaluable.	O

Of	O
these,	O
433	O
are	O
known	O
to	O
be	O
dead,	O
26	O
are	O
lost	O
to	O
follow-up	O
and	O
11	O
are	O
still	O
alive.	O

The	B-Premise
group	I-Premise
treated	I-Premise
with	I-Premise
oral	I-Premise
Etoposide	I-Premise
had	I-Premise
a	I-Premise
significantly	I-Premise
better	I-Premise
QOL	I-Premise
than	I-Premise
the	I-Premise
radiotherapy	I-Premise
group	I-Premise
for	I-Premise
the	I-Premise
total	I-Premise
FLI-C	I-Premise
score	I-Premise
(adjusted	I-Premise
mean	I-Premise
plus	I-Premise
standard	I-Premise
error	I-Premise
at	I-Premise
3-months	I-Premise
89	I-Premise
+/-	I-Premise
3	I-Premise
vs.	I-Premise
76	I-Premise
+/-	I-Premise
3;	I-Premise
p	I-Premise
=	I-Premise
0.004)	I-Premise
and	I-Premise
for	I-Premise
the	I-Premise
hardship	I-Premise
(11	I-Premise
+/-	I-Premise
0.4	I-Premise
vs.	I-Premise
9	I-Premise
+/-	I-Premise
0.4;	I-Premise
p	I-Premise
=	I-Premise
0.001);	I-Premise
social	I-Premise
(10	I-Premise
+/-	I-Premise
0.4	I-Premise
vs.	I-Premise
8	I-Premise
+/-	I-Premise
0.4;	I-Premise
p	I-Premise
=	I-Premise
0.001)	I-Premise
and	I-Premise
nausea	I-Premise
(9	I-Premise
+/-	I-Premise
0.4	I-Premise
vs.	I-Premise
8	I-Premise
+/-	I-Premise
0.4;	I-Premise
p	I-Premise
=	I-Premise
0.002)	I-Premise
subscales.	I-Premise

In	B-Premise
addition,	I-Premise
on	I-Premise
the	I-Premise
physical	I-Premise
and	I-Premise
psychological	I-Premise
subscales,	I-Premise
the	I-Premise
Etoposide	I-Premise
group	I-Premise
had	I-Premise
a	I-Premise
significantly	I-Premise
better	I-Premise
QOL	I-Premise
than	I-Premise
the	I-Premise
other	I-Premise
3	I-Premise
treatment	I-Premise
groups	I-Premise
(p	I-Premise
<	I-Premise
0.04).	I-Premise

The	B-Premise
3-drug	I-Premise
combination,	I-Premise
supportive	I-Premise
care	I-Premise
and	I-Premise
radiotherapy	I-Premise
groups	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
significantly	I-Premise
from	I-Premise
each	I-Premise
other	I-Premise
with	I-Premise
respect	I-Premise
to	I-Premise
the	I-Premise
total	I-Premise
FLI-C	I-Premise
score	I-Premise
or	I-Premise
its	I-Premise
subscales.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
group	I-Premise
differences	I-Premise
with	I-Premise
respect	I-Premise
to	I-Premise
survival.	I-Premise

Oral	B-Claim
Etoposide	I-Claim
therapy	I-Claim
resulted	I-Claim
in	I-Claim
better	I-Claim
total	I-Claim
FLI-C	I-Claim
QOL	I-Claim
score	I-Claim
than	I-Claim
radiotherapy.	I-Claim

As	O
well,	O
Etoposide	B-Claim
resulted	I-Claim
in	I-Claim
better	I-Claim
physical	I-Claim
and	I-Claim
psychological	I-Claim
subscale	I-Claim
scores	I-Claim
than	I-Claim
radiotherapy,	I-Claim
3-drugs	I-Claim
and	I-Claim
supportive	I-Claim
care.	I-Claim

Thus,	B-Claim
funds	I-Claim
permitting,	I-Claim
oral	I-Claim
Etoposide	I-Claim
is	I-Claim
a	I-Claim
pragmatic	I-Claim
approach	I-Claim
to	I-Claim
treating	I-Claim
EKS	I-Claim
in	I-Claim
an	I-Claim
environment	I-Claim
where	I-Claim
antiretroviral	I-Claim
drugs	I-Claim
are	I-Claim
not	I-Claim
universally	I-Claim
available.	I-Claim

The	B-Claim
study	I-Claim
underscores	I-Claim
the	I-Claim
value	I-Claim
of	I-Claim
undertaking	I-Claim
studies	I-Claim
in	I-Claim
areas	I-Claim
of	I-Claim
disease	I-Claim
prevalence	I-Claim
and	I-Claim
the	I-Claim
necessity	I-Claim
of	I-Claim
selecting	I-Claim
appropriate	I-Claim
outcome	I-Claim
measures.	I-Claim

To	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
biweekly	O
regimen	O
of	O
leucovorin	O
(LV)	O
plus	O
fluorouracil	O
(FU)	O
alone	O
or	O
in	O
combination	O
with	O
cisplatin	O
or	O
irinotecan	O
in	O
patients	O
with	O
previously	O
untreated	O
metastatic	O
gastric	O
adenocarcinoma	O
and	O
to	O
select	O
the	O
best	O
arm	O
for	O
a	O
phase	O
III	O
study.	O

One	O
hundred	O
thirty-six	O
patients	O
(two	O
were	O
ineligible)	O
were	O
enrolled	O
onto	O
the	O
randomized	O
multicenter	O
phase	O
II	O
trial.	O

Patients	O
received	O
LV	O
200	O
mg/m(2)	O
(2-hour	O
infusion)	O
followed	O
by	O
FU	O
400	O
mg/m(2)	O
(bolus)	O
and	O
FU	O
600	O
mg/m(2)	O
(22-hour	O
continuous	O
infusion)	O
on	O
days	O
1	O
and	O
2	O
every	O
14	O
days	O
(LV5FU2;	O
arm	O
A),	O
LV5FU2	O
plus	O
cisplatin	O
50	O
mg/m(2)	O
(1-hour	O
infusion)	O
on	O
day	O
1	O
or	O
2	O
(arm	O
B),	O
or	O
LV5FU2	O
plus	O
irinotecan	O
180	O
mg/m(2)	O
(2-hour	O
infusion)	O
on	O
day	O
1	O
(arm	O
C).	O

The	B-Premise
overall	I-Premise
response	I-Premise
rates,	I-Premise
which	I-Premise
were	I-Premise
confirmed	I-Premise
by	I-Premise
an	I-Premise
independent	I-Premise
expert	I-Premise
panel,	I-Premise
were	I-Premise
13%	I-Premise
(95%	I-Premise
CI,	I-Premise
3.4%	I-Premise
to	I-Premise
23.3%),	I-Premise
27%	I-Premise
(95%	I-Premise
CI,	I-Premise
14.1%	I-Premise
to	I-Premise
40.4%),	I-Premise
and	I-Premise
40%	I-Premise
(95%	I-Premise
CI,	I-Premise
25.7%	I-Premise
to	I-Premise
54.3%)	I-Premise
for	I-Premise
arms	I-Premise
A,	I-Premise
B,	I-Premise
and	I-Premise
C,	I-Premise
respectively.	I-Premise

Median	B-Premise
progression-free	I-Premise
survival	I-Premise
and	I-Premise
overall	I-Premise
survival	I-Premise
times	I-Premise
were	I-Premise
3.2	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
1.8	I-Premise
to	I-Premise
4.6	I-Premise
months)	I-Premise
and	I-Premise
6.8	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
2.6	I-Premise
to	I-Premise
11.1	I-Premise
months)	I-Premise
with	I-Premise
LV5FU2,	I-Premise
respectively;	I-Premise
4.9	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
3.5	I-Premise
to	I-Premise
6.3	I-Premise
months)	I-Premise
and	I-Premise
9.5	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
6.9	I-Premise
to	I-Premise
12.2	I-Premise
months)	I-Premise
with	I-Premise
LV5FU2-cisplatin,	I-Premise
respectively;	I-Premise
and	I-Premise
6.9	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
5.5	I-Premise
to	I-Premise
8.3	I-Premise
months)	I-Premise
and	I-Premise
11.3	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
9.3	I-Premise
to	I-Premise
13.3	I-Premise
months)	I-Premise
with	I-Premise
LV5FU2-irinotecan,	I-Premise
respectively.	I-Premise

Of	B-Claim
the	I-Claim
three	I-Claim
regimens	I-Claim
tested,	I-Claim
the	I-Claim
combination	I-Claim
of	I-Claim
LV5FU2-irinotecan	I-Claim
is	I-Claim
the	I-Claim
most	I-Claim
promising	I-Claim
and	I-Claim
will	I-Claim
be	I-Claim
assessed	I-Claim
in	I-Claim
a	I-Claim
phase	I-Claim
III	I-Claim
trial.	I-Claim

Treatment-induced	O
arm	O
lymphoedema	O
is	O
a	O
common	O
and	O
distressing	O
complication	O
of	O
curative	O
surgery	O
and	O
radiotherapy	O
for	O
early	O
breast	O
cancer.	O

A	O
number	O
of	O
studies	O
testing	O
alpha-tocopherol	O
(vitamin	O
E)	O
and	O
pentoxifylline	O
suggest	O
evidence	O
of	O
clinical	O
regression	O
of	O
superficial	O
radiation-induced	O
fibrosis	O
but	O
there	O
is	O
only	O
very	O
limited	O
evidence	O
from	O
randomised	O
trials.	O

Arm	O
lymphoedema	O
after	O
lymphatic	O
radiotherapy	O
and	O
surgery	O
has	O
been	O
used	O
in	O
the	O
present	O
study	O
as	O
a	O
clinical	O
system	O
for	O
testing	O
these	O
drugs	O
in	O
a	O
double-blind	O
placebo-controlled	O
randomised	O
phase	O
II	O
trial.	O

Sixty-eight	O
eligible	O
research	O
volunteers	O
with	O
a	O
minimum	O
20%	O
increase	O
in	O
arm	O
volume	O
at	O
a	O
median	O
15.5	O
years	O
(range	O
2-41)	O
after	O
axillary/supraclavicular	O
radiotherapy	O
(plus	O
axillary	O
surgery	O
in	O
51/68	O
(75%)	O
cases)	O
were	O
randomised	O
to	O
active	O
drugs	O
or	O
placebo.	O

All	O
volunteers	O
were	O
given	O
dl-alpha	O
tocopheryl	O
acetate	O
500	O
mg	O
twice	O
a	O
day	O
orally	O
plus	O
pentoxifylline	O
400	O
mg	O
twice	O
a	O
day	O
orally,	O
or	O
corresponding	O
placebos,	O
for	O
6	O
months.	O

The	O
primary	O
endpoint	O
was	O
volume	O
of	O
the	O
ipsilateral	O
limb	O
measured	O
opto-electronically	O
using	O
a	O
perometer	O
and	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
contralateral	O
limb	O
volume.	O

At	B-Premise
12	I-Premise
months	I-Premise
post-randomisation,	I-Premise
there	I-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
treatment	I-Premise
and	I-Premise
control	I-Premise
groups	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
arm	I-Premise
volume.	I-Premise

Absolute	B-Premise
change	I-Premise
in	I-Premise
arm	I-Premise
volume	I-Premise
at	I-Premise
12	I-Premise
months	I-Premise
was	I-Premise
2.5%	I-Premise
(95%	I-Premise
CI	I-Premise
-0.40	I-Premise
to	I-Premise
5.3)	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group	I-Premise
compared	I-Premise
to	I-Premise
1.2%	I-Premise
(95%	I-Premise
CI	I-Premise
-2.8	I-Premise
to	I-Premise
5.1)	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group.	I-Premise

The	B-Premise
difference	I-Premise
in	I-Premise
mean	I-Premise
volume	I-Premise
change	I-Premise
between	I-Premise
randomisation	I-Premise
groups	I-Premise
at	I-Premise
12	I-Premise
months	I-Premise
was	I-Premise
not	I-Premise
statistically	I-Premise
significant	I-Premise
(P	I-Premise
=	I-Premise
0.6),	I-Premise
-1.3%	I-Premise
(95%	I-Premise
CI	I-Premise
-6.1	I-Premise
to	I-Premise
3.5),	I-Premise
nor	I-Premise
was	I-Premise
there	I-Premise
a	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
response	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
(P	I-Premise
=	I-Premise
0.7),	I-Premise
where	I-Premise
mean	I-Premise
change	I-Premise
in	I-Premise
arm	I-Premise
volume	I-Premise
from	I-Premise
baseline	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
and	I-Premise
placebo	I-Premise
groups	I-Premise
was	I-Premise
-2.3%	I-Premise
(95%	I-Premise
CI	I-Premise
-7.9	I-Premise
to	I-Premise
3.4)	I-Premise
and	I-Premise
-1.1%	I-Premise
(95%	I-Premise
CI	I-Premise
-3.9	I-Premise
to	I-Premise
1.7),	I-Premise
respectively.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
randomised	I-Premise
groups	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
secondary	I-Premise
endpoints,	I-Premise
including	I-Premise
tissue	I-Premise
induration	I-Premise
(fibrosis)	I-Premise
in	I-Premise
the	I-Premise
irradiated	I-Premise
breast	I-Premise
or	I-Premise
chest	I-Premise
wall,	I-Premise
pectoral	I-Premise
fold	I-Premise
or	I-Premise
supraclavicular	I-Premise
fossa,	I-Premise
change	I-Premise
in	I-Premise
photographic	I-Premise
breast/chest	I-Premise
wall	I-Premise
appearance	I-Premise
or	I-Premise
patient	I-Premise
self-assessment	I-Premise
of	I-Premise
function	I-Premise
and	I-Premise
Quality	I-Premise
of	I-Premise
Life	I-Premise
at	I-Premise
either	I-Premise
6	I-Premise
or	I-Premise
12	I-Premise
months.	I-Premise

The	B-Claim
study	I-Claim
fails	I-Claim
to	I-Claim
demonstrate	I-Claim
efficacy	I-Claim
of	I-Claim
dl-alpha	I-Claim
tocopheryl	I-Claim
acetate	I-Claim
plus	I-Claim
pentoxifylline	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
arm	I-Claim
lymphoedema	I-Claim
following	I-Claim
axillary	I-Claim
surgery	I-Claim
and	I-Claim
lymphatic	I-Claim
radiotherapy,	I-Claim
nor	I-Claim
does	I-Claim
it	I-Claim
suggest	I-Claim
any	I-Claim
benefits	I-Claim
of	I-Claim
these	I-Claim
drugs	I-Claim
in	I-Claim
radiation-induced	I-Claim
induration	I-Claim
(fibrosis)	I-Claim
in	I-Claim
the	I-Claim
breast,	I-Claim
chest	I-Claim
wall,	I-Claim
pectoral	I-Claim
fold,	I-Claim
axilla	I-Claim
or	I-Claim
supraclavicular	I-Claim
fossa.	I-Claim

Chemotherapy	O
with	O
a	O
platinum	O
agent	O
and	O
a	O
taxane	O
(paclitaxel)	O
is	O
considered	O
the	O
standard	O
of	O
care	O
for	O
treatment	O
of	O
ovarian	O
carcinoma.	O

We	O
compared	O
the	O
combination	O
of	O
docetaxel-carboplatin	O
with	O
the	O
combination	O
of	O
paclitaxel-carboplatin	O
as	O
first-line	O
chemotherapy	O
for	O
stage	O
Ic-IV	O
epithelial	O
ovarian	O
or	O
primary	O
peritoneal	O
cancer.	O

We	O
randomly	O
assigned	O
1077	O
patients	O
to	O
receive	O
docetaxel	O
at	O
75	O
mg/m2	O
of	O
body	O
surface	O
area	O
(1-hour	O
intravenous	O
infusion)	O
or	O
paclitaxel	O
at	O
175	O
mg/m2	O
(3-hour	O
intravenous	O
infusion).	O

Both	O
treatments	O
then	O
were	O
followed	O
by	O
carboplatin	O
to	O
an	O
area	O
under	O
the	O
plasma	O
concentration-time	O
curve	O
of	O
5.	O

The	O
treatments	O
were	O
repeated	O
every	O
3	O
weeks	O
for	O
six	O
cycles;	O
in	O
responding	O
patients,	O
an	O
additional	O
three	O
cycles	O
of	O
single-agent	O
carboplatin	O
was	O
permitted.	O

Survival	O
curves	O
were	O
calculated	O
by	O
the	O
Kaplan-Meier	O
method,	O
and	O
hazard	O
ratios	O
were	O
estimated	O
with	O
the	O
Cox	O
proportional	O
hazards	O
model.	O

All	O
statistical	O
tests	O
were	O
two-sided.	O

After	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
23	I-Premise
months,	I-Premise
both	I-Premise
groups	I-Premise
had	I-Premise
similar	I-Premise
progression-free	I-Premise
survival	I-Premise
(medians	I-Premise
of	I-Premise
15.0	I-Premise
months	I-Premise
for	I-Premise
docetaxel-carboplatin	I-Premise
and	I-Premise
14.8	I-Premise
months	I-Premise
for	I-Premise
paclitaxel-carboplatin;	I-Premise
hazard	I-Premise
ratio	I-Premise
[HR]	I-Premise
docetaxel-paclitaxel	I-Premise
=	I-Premise
0.97,	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
=	I-Premise
0.83	I-Premise
to	I-Premise
1.13;	I-Premise
P	I-Premise
=	I-Premise
.707),	I-Premise
overall	I-Premise
survival	I-Premise
rates	I-Premise
at	I-Premise
2	I-Premise
years	I-Premise
(64.2%	I-Premise
and	I-Premise
68.9%,	I-Premise
respectively;	I-Premise
HR	I-Premise
=	I-Premise
1.13,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
0.92	I-Premise
to	I-Premise
1.39;	I-Premise
P	I-Premise
=	I-Premise
.238),	I-Premise
and	I-Premise
objective	I-Premise
tumor	I-Premise
(58.7%	I-Premise
and	I-Premise
59.5%,	I-Premise
respectively;	I-Premise
difference	I-Premise
between	I-Premise
docetaxel	I-Premise
and	I-Premise
paclitaxel	I-Premise
=	I-Premise
-0.8%,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
-8.6%	I-Premise
to	I-Premise
7.1%;	I-Premise
P	I-Premise
=	I-Premise
.868)	I-Premise
and	I-Premise
CA-125	I-Premise
(75.8%	I-Premise
and	I-Premise
76.8%,	I-Premise
respectively;	I-Premise
difference	I-Premise
docetaxel-paclitaxel	I-Premise
=	I-Premise
-1.0%,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
-7.2%	I-Premise
to	I-Premise
5.1%;	I-Premise
P	I-Premise
=	I-Premise
.794)	I-Premise
response	I-Premise
rates.	I-Premise

However,	B-Premise
docetaxel-carboplatin	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
substantially	I-Premise
less	I-Premise
overall	I-Premise
and	I-Premise
grade	I-Premise
2	I-Premise
or	I-Premise
higher	I-Premise
neurotoxicity	I-Premise
than	I-Premise
paclitaxel-carboplatin	I-Premise
(grade	I-Premise
>	I-Premise
or	I-Premise
=2	I-Premise
neurosensory	I-Premise
toxicity	I-Premise
in	I-Premise
11%	I-Premise
versus	I-Premise
30%,	I-Premise
difference	I-Premise
=	I-Premise
19%,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
15%	I-Premise
to	I-Premise
24%;	I-Premise
P<.001;	I-Premise
grade	I-Premise
>	I-Premise
or	I-Premise
=2	I-Premise
neuromotor	I-Premise
toxicity	I-Premise
in	I-Premise
3%	I-Premise
versus	I-Premise
7%,	I-Premise
difference	I-Premise
=	I-Premise
4%,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
1%	I-Premise
to	I-Premise
7%;	I-Premise
P<.001).	I-Premise

Treatment	B-Premise
with	I-Premise
docetaxel-carboplatin	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
statistically	I-Premise
significantly	I-Premise
more	I-Premise
grade	I-Premise
3-4	I-Premise
neutropenia	I-Premise
(94%	I-Premise
versus	I-Premise
84%,	I-Premise
difference	I-Premise
=	I-Premise
11%,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
7%	I-Premise
to	I-Premise
14%;	I-Premise
P<.001)	I-Premise
and	I-Premise
neutropenic	I-Premise
complications	I-Premise
than	I-Premise
treatment	I-Premise
with	I-Premise
paclitaxel-carboplatin,	I-Premise
although	B-Premise
myelosuppression	I-Premise
did	I-Premise
not	I-Premise
influence	I-Premise
dose	I-Premise
delivery	I-Premise
or	I-Premise
patient	I-Premise
safety.	I-Premise

Global	B-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
was	I-Premise
similar	I-Premise
in	I-Premise
both	I-Premise
arms,	I-Premise
but	B-Premise
substantive	I-Premise
differences	I-Premise
in	I-Premise
many	I-Premise
symptom	I-Premise
scores	I-Premise
favored	I-Premise
docetaxel.	I-Premise

Docetaxel-carboplatin	B-Claim
appears	I-Claim
to	I-Claim
be	I-Claim
similar	I-Claim
to	I-Claim
paclitaxel-carboplatin	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
progression-free	I-Claim
survival	I-Claim
and	I-Claim
response,	I-Claim
although	B-Claim
longer	I-Claim
follow-up	I-Claim
is	I-Claim
required	I-Claim
for	I-Claim
a	I-Claim
definitive	I-Claim
statement	I-Claim
on	I-Claim
survival.	I-Claim

Thus,	B-Claim
docetaxel-carboplatin	I-Claim
represents	I-Claim
an	I-Claim
alternative	I-Claim
first-line	I-Claim
chemotherapy	I-Claim
regimen	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
newly	I-Claim
diagnosed	I-Claim
ovarian	I-Claim
cancer.	I-Claim

This	O
phase	O
III	O
randomized	O
trial	O
compared	O
two	O
chemotherapy	O
regimens,	O
gemcitabine	O
plus	O
carboplatin	O
and	O
mitomycin,	O
ifosfamide,	O
and	O
cisplatin,	O
in	O
chemotherapy-naive	O
patients	O
with	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(NSCLC).	O

The	O
regimens	O
were	O
compared	O
with	O
regard	O
to	O
effects	O
on	O
survival,	O
response	O
rates,	O
toxicity,	O
and	O
quality	O
of	O
life.	O

Eligible	O
patients	O
had	O
previously	O
untreated	O
stage	O
IIIB	O
or	O
IV	O
NSCLC	O
suitable	O
for	O
cisplatin-based	O
chemotherapy.	O

Randomly	O
assigned	O
patients	O
were	O
to	O
receive	O
four	O
cycles,	O
each	O
at	O
3-week	O
intervals,	O
of	O
carboplatin	O
area	O
under	O
the	O
curve	O
of	O
5	O
on	O
day	O
1	O
plus	O
gemcitabine	O
1,200	O
mg/m(2)	O
on	O
days	O
1	O
and	O
8	O
(GCa)	O
or	O
mitomycin	O
6	O
mg/m(2),	O
ifosfamide	O
3g/m(2),	O
and	O
cisplatin	O
50	O
mg/m(2)	O
on	O
day	O
1	O
(MIC).	O

Between	O
February	O
1999	O
and	O
August	O
2001,	O
422	O
patients	O
(GCa,	O
n	O
=	O
212;	O
MIC,	O
n	O
=	O
210)	O
were	O
randomly	O
assigned	O
in	O
the	O
United	O
Kingdom.	O

The	O
majority	O
of	O
patients	O
received	O
the	O
intended	O
four	O
cycles	O
(GCa,	O
64%;	O
MIC,	O
61%).	O

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
survival	I-Premise
advantage	I-Premise
for	I-Premise
GCa	I-Premise
compared	I-Premise
with	I-Premise
MIC	I-Premise
(hazard	I-Premise
ratio,	I-Premise
0.76;	I-Premise
95%	I-Premise
CI,	I-Premise
0.61	I-Premise
to	I-Premise
0.	I-Premise
93;	I-Premise
P	I-Premise
=	I-Premise
.008).	I-Premise

Median	B-Premise
survival	I-Premise
was	I-Premise
10	I-Premise
months	I-Premise
with	I-Premise
GCa	I-Premise
and	I-Premise
7.6	I-Premise
months	I-Premise
with	I-Premise
MIC	I-Premise
(difference,	I-Premise
2.4	I-Premise
months;	I-Premise
95%	I-Premise
CI,	I-Premise
1.0	I-Premise
to	I-Premise
4.0),	I-Premise
and	I-Premise
1-year	I-Premise
survival	I-Premise
was	I-Premise
40%	I-Premise
with	I-Premise
GCa	I-Premise
and	I-Premise
30%	I-Premise
with	I-Premise
MIC	I-Premise
(difference,	I-Premise
10%;	I-Premise
95%	I-Premise
CI,	I-Premise
3%	I-Premise
to	I-Premise
18%).	I-Premise

Overall	B-Premise
response	I-Premise
rates	I-Premise
were	I-Premise
similar	I-Premise
(42%	I-Premise
for	I-Premise
GCa	I-Premise
v	I-Premise
41%	I-Premise
for	I-Premise
MIC;	I-Premise
P	I-Premise
=	I-Premise
.84).	I-Premise

More	B-Premise
thrombocytopenia	I-Premise
occurred	I-Premise
with	I-Premise
GCa	I-Premise
(P	I-Premise
=	I-Premise
.03),	I-Premise
but	B-Premise
this	I-Premise
was	I-Premise
not	I-Premise
associated	I-Premise
with	I-Premise
increased	I-Premise
hospital	I-Premise
admission	I-Premise
or	I-Premise
fatality.	I-Premise

GCa	B-Premise
caused	I-Premise
less	I-Premise
nausea,	I-Premise
vomiting,	I-Premise
constipation,	I-Premise
and	I-Premise
alopecia	I-Premise
and	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
fewer	I-Premise
admissions	I-Premise
for	I-Premise
administration	I-Premise
and	I-Premise
better	I-Premise
quality	I-Premise
of	I-Premise
life.	I-Premise

In	B-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
NSCLC,	I-Claim
GCa	I-Claim
chemotherapy	I-Claim
was	I-Claim
shown	I-Claim
to	I-Claim
be	I-Claim
a	I-Claim
better-tolerated	I-Claim
treatment	I-Claim
that	I-Claim
conferred	I-Claim
a	I-Claim
survival	I-Claim
advantage	I-Claim
over	I-Claim
MIC.	I-Claim

The	B-Claim
role	I-Claim
of	I-Claim
high-dose	I-Claim
chemotherapy	I-Claim
(HDCT)	I-Claim
in	I-Claim
metastatic	I-Claim
breast	I-Claim
cancer	I-Claim
remains	I-Claim
controversial.	I-Claim

Trials	B-Claim
with	I-Claim
late	I-Claim
intensification	I-Claim
HDCT	I-Claim
have	I-Claim
failed	I-Claim
to	I-Claim
show	I-Claim
an	I-Claim
advantage	I-Claim
in	I-Claim
overall	I-Claim
survival.	I-Claim

This	O
study	O
was	O
initiated	O
to	O
compare	O
up-front	O
tandem	O
HDCT	O
and	O
standard	O
combination	O
therapy	O
in	O
patients	O
with	O
metastatic	O
breast	O
cancer.	O

Patients	O
without	O
prior	O
chemotherapy	O
for	O
metastatic	O
disease	O
were	O
randomly	O
assigned	O
to	O
standard	O
combination	O
therapy	O
with	O
doxorubicin	O
and	O
paclitaxel	O
(AT)	O
or	O
double	O
HDCT	O
with	O
cyclophosphamide,	O
mitoxantrone,	O
and	O
etoposide	O
followed	O
by	O
peripheral-blood	O
stem-cell	O
transplantation.	O

HDCT	O
was	O
repeated	O
after	O
6	O
weeks.	O

Patients	O
were	O
stratified	O
by	O
menopausal	O
and	O
hormone-receptor	O
status.	O

The	O
primary	O
objective	O
was	O
to	O
compare	O
complete	O
response	O
(CR)	O
rates.	O

A	O
total	O
of	O
93	O
patients	O
were	O
enrolled	O
onto	O
the	O
trial.	O

Intent-to-treat	B-Premise
CR	I-Premise
rates	I-Premise
for	I-Premise
patients	I-Premise
randomized	I-Premise
to	I-Premise
HDCT	I-Premise
and	I-Premise
AT	I-Premise
were	I-Premise
12.5%	I-Premise
and	I-Premise
11.1%,	I-Premise
respectively	I-Premise
(P	I-Premise
=	I-Premise
.84).	I-Premise

Objective	B-Premise
response	I-Premise
rates	I-Premise
were	I-Premise
66.7%	I-Premise
for	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
high-dose	I-Premise
group	I-Premise
and	I-Premise
64.4%	I-Premise
for	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
AT	I-Premise
arm	I-Premise
(P	I-Premise
=	I-Premise
.82).	I-Premise

In	B-Premise
an	I-Premise
intent-to-treat	I-Premise
analysis,	I-Premise
there	I-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
treatments	I-Premise
in	I-Premise
median	I-Premise
time	I-Premise
to	I-Premise
progression	I-Premise
(HDCT,	I-Premise
11.1	I-Premise
months;	I-Premise
AT,	I-Premise
10.6	I-Premise
months;	I-Premise
P	I-Premise
=	I-Premise
.67),	I-Premise
duration	I-Premise
of	I-Premise
response	I-Premise
(HDCT,	I-Premise
13.9	I-Premise
months;	I-Premise
AT,	I-Premise
14.3	I-Premise
months;	I-Premise
P	I-Premise
=	I-Premise
.98),	I-Premise
and	I-Premise
overall	I-Premise
survival	I-Premise
(HDCT,	I-Premise
26.9	I-Premise
months;	I-Premise
AT,	I-Premise
23.4	I-Premise
months;	I-Premise
P	I-Premise
=	I-Premise
.60).	I-Premise

HDCT	B-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
significantly	I-Premise
more	I-Premise
myelosuppression,	I-Premise
infection,	I-Premise
diarrhea,	I-Premise
stomatitis,	I-Premise
and	I-Premise
nausea	I-Premise
and	I-Premise
vomiting,	I-Premise
whereas	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
AT	I-Premise
developed	I-Premise
more	I-Premise
neurotoxicity.	I-Premise

This	B-Claim
trial	I-Claim
failed	I-Claim
to	I-Claim
show	I-Claim
a	I-Claim
benefit	I-Claim
for	I-Claim
up-front	I-Claim
tandem	I-Claim
HDCT	I-Claim
compared	I-Claim
with	I-Claim
standard	I-Claim
combination	I-Claim
therapy.	I-Claim

HDCT	B-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
more	I-Claim
acute	I-Claim
adverse	I-Claim
effects.	I-Claim

To	O
determine	O
the	O
efficacy,	O
impact	O
on	O
quality-of-life	O
(QoL)	O
and	O
tolerability	O
of	O
two	O
different	O
irinotecan	O
administration	O
schedules	O
in	O
combination	O
with	O
capecitabine	O
as	O
first-line	O
treatment	O
of	O
metastatic	O
colorectal	O
cancer.	O

We	O
carried	O
out	O
a	O
randomized	O
phase	O
II	O
trial	O
to	O
select	O
one	O
of	O
the	O
following	O
treatment	O
regimens	O
for	O
further	O
investigation:	O
weekly	O
irinotecan	O
at	O
a	O
dose	O
of	O
70	O
mg/m(2)	O
days	O
1,	O
8,	O
15,	O
22,	O
29	O
(arm	O
A)	O
or	O
3-weekly	O
irinotecan	O
at	O
a	O
dose	O
of	O
300/240	O
mg/m(2)	O
day	O
1	O
and	O
days	O
22	O
(arm	O
B)	O
in	O
combination	O
with	O
capecitabine	O
1000	O
mg/m(2)	O
twice	O
daily	O
days	O
1-14	O
and	O
days	O
22-35	O
every	O
6	O
weeks.	O

Seventy-five	O
patients	O
with	O
good	O
performance	O
status	O
entered	O
the	O
trial.	O

The	O
two	O
arms	O
were	O
well	O
balanced	O
for	O
relevant	O
patient	O
and	O
disease	O
characteristics.	O

The	B-Premise
most	I-Premise
frequent	I-Premise
toxic	I-Premise
effects	I-Premise
were	I-Premise
grade	I-Premise
3/4	I-Premise
diarrhea	I-Premise
(arm	I-Premise
A:	I-Premise
34%,	I-Premise
B:	I-Premise
19%),	I-Premise
grade	I-Premise
3/4	I-Premise
neutropenia	I-Premise
(A:	I-Premise
5%,	I-Premise
B:	I-Premise
19%)	I-Premise
and	I-Premise
grade	I-Premise
2/3	I-Premise
alopecia	I-Premise
(A:	I-Premise
26%,	I-Premise
B:	I-Premise
65%).	I-Premise

Other	B-Premise
grade	I-Premise
3/4	I-Premise
toxic	I-Premise
effects	I-Premise
were	I-Premise
rare	I-Premise
(<5%).	I-Premise

Response	B-Premise
rates	I-Premise
were	I-Premise
34%	I-Premise
[95%	I-Premise
confidence	I-Premise
interval	I-Premise
(CI)	I-Premise
20%	I-Premise
to	I-Premise
51%]	I-Premise
in	I-Premise
arm	I-Premise
A	I-Premise
and	I-Premise
35%	I-Premise
(95%	I-Premise
CI:	I-Premise
20%	I-Premise
to	I-Premise
53%)	I-Premise
in	I-Premise
arm	I-Premise
B.	I-Premise

Median	B-Premise
time	I-Premise
to	I-Premise
progression	I-Premise
was	I-Premise
6.9	I-Premise
(4.6-10.1)	I-Premise
and	I-Premise
9.2	I-Premise
(7.9-11.5)	I-Premise
months	I-Premise
and	I-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
17.4	I-Premise
(12.6-23.0+)	I-Premise
and	I-Premise
24.7	I-Premise
(16.3-26.4+)	I-Premise
months.	I-Premise

Patients	B-Premise
with	I-Premise
an	I-Premise
objective	I-Premise
tumor	I-Premise
response	I-Premise
reported	I-Premise
better	I-Premise
physical	I-Premise
well-being	I-Premise
(P	I-Premise
<	I-Premise
0.01),	I-Premise
mood	I-Premise
(P	I-Premise
<	I-Premise
0.05),	I-Premise
functional	I-Premise
performance	I-Premise
(P	I-Premise
<	I-Premise
0.05)	I-Premise
and	I-Premise
less	I-Premise
effort	I-Premise
to	I-Premise
cope	I-Premise
(P	I-Premise
<	I-Premise
0.05)	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
non-responders	I-Premise
and	I-Premise
stable	I-Premise
disease	I-Premise
patients.	I-Premise

The	O
primary	O
end	O
point	O
of	O
this	O
study	O
was	O
the	O
objective	O
response	O
rate	O
and	O
based	O
on	O
the	O
statistical	O
design	O
of	O
the	O
trial,	O
the	O
3-weekly	O
irinotecan	O
schedule	O
was	O
selected	O
over	O
weekly	O
irinotecan	O
administration.	O

The	B-Claim
3-weekly	I-Claim
irinotecan	I-Claim
schedule	I-Claim
also	I-Claim
seemed	I-Claim
advantageous	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
grade	I-Claim
3/4	I-Claim
diarrhea,	I-Claim
time	I-Claim
to	I-Claim
progression,	I-Claim
overall	I-Claim
survival	I-Claim
and	I-Claim
patient	I-Claim
convenience,	I-Claim
but	B-Claim
the	I-Claim
study	I-Claim
was	I-Claim
not	I-Claim
designed	I-Claim
to	I-Claim
detect	I-Claim
differences	I-Claim
in	I-Claim
these	I-Claim
parameters.	I-Claim

In	O
addition,	O
tumor	B-Claim
response	I-Claim
was	I-Claim
shown	I-Claim
to	I-Claim
have	I-Claim
a	I-Claim
beneficial	I-Claim
effect	I-Claim
on	I-Claim
QoL	I-Claim
indicators.	I-Claim

To	O
investigate	O
the	O
impact	O
of	O
dietary	O
counseling	O
or	O
nutritional	O
supplements	O
on	O
outcomes	O
in	O
cancer	O
patients:	O
nutritional,	O
morbidity,	O
and	O
quality	O
of	O
life	O
(QoL)	O
during	O
and	O
3	O
months	O
after	O
radiotherapy.	O

A	O
total	O
of	O
111	O
colorectal	O
cancer	O
outpatients	O
referred	O
for	O
radiotherapy,	O
stratified	O
by	O
staging,	O
were	O
randomly	O
assigned:	O
group	O
1	O
(G1;	O
n	O
=	O
37),	O
dietary	O
counseling	O
(regular	O
foods);	O
group	O
2	O
(G2;	O
n	O
=	O
37),	O
protein	O
supplements;	O
and	O
group	O
3	O
(G3;	O
n	O
=	O
37),	O
ad	O
libitum	O
intake.	O

Nutritional	O
intake	O
(diet	O
history),	O
status	O
(Ottery's	O
Subjective	O
Global	O
Assessment),	O
and	O
QoL	O
(European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
version	O
3.0)	O
were	O
evaluated	O
at	O
baseline,	O
at	O
the	O
end,	O
and	O
3	O
months	O
after	O
radiotherapy.	O

At	B-Premise
radiotherapy	I-Premise
completion,	I-Premise
energy	I-Premise
intake	I-Premise
increased	I-Premise
in	I-Premise
G1/G2	I-Premise
(P	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
.04),	I-Premise
G1	I-Premise
more	I-Premise
than	I-Premise
G2	I-Premise
(P	I-Premise
=	I-Premise
.001),	I-Premise
and	I-Premise
decreased	I-Premise
in	I-Premise
G3	I-Premise
(P	I-Premise
<	I-Premise
.01).	I-Premise

Protein	B-Premise
intake	I-Premise
increased	I-Premise
in	I-Premise
G1/G2	I-Premise
(P	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
.007),	I-Premise
G1	I-Premise
less	I-Premise
than	I-Premise
G2	I-Premise
(not	I-Premise
significant),	I-Premise
and	I-Premise
decreased	I-Premise
in	I-Premise
G3	I-Premise
(P	I-Premise
<	I-Premise
.01).	I-Premise

At	B-Premise
3	I-Premise
months,	I-Premise
G1	I-Premise
maintained	I-Premise
nutritional	I-Premise
intake	I-Premise
and	I-Premise
G2/G3	I-Premise
returned	I-Premise
to	I-Premise
baseline.	I-Premise

After	B-Premise
radiotherapy	I-Premise
and	I-Premise
at	I-Premise
3	I-Premise
months,	I-Premise
rates	I-Premise
of	I-Premise
anorexia,	I-Premise
nausea,	I-Premise
vomiting,	I-Premise
and	I-Premise
diarrhea	I-Premise
were	I-Premise
higher	I-Premise
in	I-Premise
G3	I-Premise
(P	I-Premise
<	I-Premise
.05).	I-Premise

At	B-Premise
radiotherapy	I-Premise
completion,	I-Premise
in	I-Premise
G1	I-Premise
all	I-Premise
QoL	I-Premise
function	I-Premise
scores	I-Premise
improved	I-Premise
proportionally	I-Premise
to	I-Premise
adequate	I-Premise
intake	I-Premise
or	I-Premise
nutritional	I-Premise
status	I-Premise
(P	I-Premise
<	I-Premise
.05);	I-Premise
whereas	I-Premise
in	I-Premise
G2	I-Premise
only	I-Premise
three	I-Premise
of	I-Premise
six	I-Premise
function	I-Premise
scores	I-Premise
improved	I-Premise
proportionally	I-Premise
to	I-Premise
protein	I-Premise
intake	I-Premise
(P	I-Premise
=	I-Premise
.04),	I-Premise
and	I-Premise
in	I-Premise
G3	I-Premise
all	I-Premise
scores	I-Premise
worsened	I-Premise
(P	I-Premise
<	I-Premise
.05).	I-Premise

At	B-Premise
3	I-Premise
months,	I-Premise
G1	I-Premise
patients	I-Premise
maintained/improved	I-Premise
function,	I-Premise
symptoms,	I-Premise
and	I-Premise
single-item	I-Premise
scores	I-Premise
(P	I-Premise
<	I-Premise
.02);	I-Premise
in	I-Premise
G2,	I-Premise
only	I-Premise
few	I-Premise
function	I-Premise
and	I-Premise
symptom	I-Premise
scales	I-Premise
improved	I-Premise
(P	I-Premise
<	I-Premise
.05);	I-Premise
in	I-Premise
G3,	I-Premise
QoL	I-Premise
remained	I-Premise
as	I-Premise
poor	I-Premise
as	I-Premise
after	I-Premise
radiotherapy.	I-Premise

In	B-Premise
G1/G2,	I-Premise
respectively,	I-Premise
improvement/deterioration	I-Premise
of	I-Premise
QoL	I-Premise
correlated	I-Premise
with	I-Premise
better	I-Premise
or	I-Premise
poorer	I-Premise
intake	I-Premise
or	I-Premise
nutritional	I-Premise
status	I-Premise
(P	I-Premise
<	I-Premise
.003).	I-Premise

During	B-Claim
radiotherapy,	I-Claim
both	I-Claim
interventions	I-Claim
positively	I-Claim
influenced	I-Claim
outcomes;	I-Claim
dietary	B-Claim
counseling	I-Claim
was	I-Claim
of	I-Claim
similar	I-Claim
or	I-Claim
higher	I-Claim
benefit,	I-Claim
whereas	I-Claim
even	I-Claim
3	I-Claim
months	I-Claim
after	I-Claim
RT,	I-Claim
it	I-Claim
was	I-Claim
the	I-Claim
only	I-Claim
method	I-Claim
to	I-Claim
sustain	I-Claim
a	I-Claim
significant	I-Claim
impact	I-Claim
on	I-Claim
patient	I-Claim
outcomes.	I-Claim

To	O
evaluate	O
the	O
incidence	O
and	O
temporal	O
resolution	O
of	O
dysuria	O
after	O
permanent	O
prostate	O
brachytherapy,	O
and	O
to	O
identify	O
predictors	O
of	O
brachytherapy-related	O
dysuria.	O

The	O
study	O
included	O
130	O
patients	O
with	O
no	O
history	O
of	O
transurethral	O
resection	O
of	O
the	O
prostate	O
before	O
treatment,	O
who	O
had	O
brachytherapy	O
on	O
one	O
of	O
two	O
prospective	O
randomized	O
trials,	O
with	O
explicitly	O
planned	O
and	O
executed	O
urethral-sparing	O
techniques	O
(100-150%	O
minimum	O
peripheral	O
dose)	O
using	O
either	O
103Pd	O
or	O
125I	O
for	O
clinical	O
T1c-T2c	O
prostate	O
cancer.	O

The	O
median	O
follow-up	O
was	O
22.6	O
months.	O

An	O
alpha-blocker	O
was	O
initiated	O
either	O
prophylactically	O
2	O
weeks	O
before	O
implantation	O
and	O
continued	O
at	O
least	O
until	O
the	O
International	O
Prostate	O
Symptom	O
Score	O
(IPSS)	O
returned	O
to	O
normal,	O
or	O
withheld	O
until	O
the	O
onset	O
of	O
significant	O
brachytherapy-related	O
urinary	O
morbidity.	O

Dysuria	O
was	O
evaluated	O
on	O
a	O
0-10	O
scale,	O
before	O
brachytherapy	O
and	O
then	O
at	O
1,	O
3,	O
6	O
and	O
12	O
months	O
afterward,	O
with	O
a	O
median	O
of	O
four	O
dysuria	O
questionnaires	O
per	O
patient.	O

Clinical,	O
treatment	O
and	O
dosimetric	O
variables	O
evaluated	O
included	O
alpha-blocker,	O
age,	O
IPSS	O
before	O
and	O
the	O
maximum	O
after	O
treatment,	O
prostate	O
volume	O
on	O
ultrasonography,	O
hormonal	O
status,	O
supplemental	O
radiotherapy,	O
isotope,	O
urethral	O
dose,	O
V(100/200),	O
D90,	O
and	O
time	O
to	O
obtaining	O
a	O
normal	O
IPSS.	O

The	O
maximum	O
incidence	O
of	O
dysuria	O
was	O
85%	O
at	O
1	O
month	O
after	O
brachytherapy,	O
with	O
subsequent	O
resolution	O
over	O
time.	O

The	B-Premise
use	I-Premise
of	I-Premise
prophylactic	I-Premise
tamsulosin	I-Premise
resulted	I-Premise
in	I-Premise
a	I-Premise
statistically	I-Premise
lower	I-Premise
dysuria	I-Premise
severity	I-Premise
score	I-Premise
(difference	I-Premise
of	I-Premise
2.7	I-Premise
vs	I-Premise
4.2,	I-Premise
P	I-Premise
<	I-Premise
0.005)	I-Premise
at	I-Premise
1	I-Premise
month,	I-Premise
with	I-Premise
no	I-Premise
discernible	I-Premise
differences	I-Premise
at	I-Premise
3,	I-Premise
6,	I-Premise
12	I-Premise
and	I-Premise
18	I-Premise
months.	I-Premise

Patients	B-Premise
with	I-Premise
dysuria	I-Premise
had	I-Premise
a	I-Premise
statistically	I-Premise
higher	I-Premise
IPSS.	I-Premise

The	B-Premise
dysuria	I-Premise
resolved	I-Premise
faster	I-Premise
in	I-Premise
patients	I-Premise
implanted	I-Premise
with	I-Premise
103Pd	I-Premise
but	B-Premise
was	I-Premise
unaffected	I-Premise
by	I-Premise
the	I-Premise
use	I-Premise
of	I-Premise
supplemental	I-Premise
radiotherapy	I-Premise
and/or	I-Premise
androgen	I-Premise
deprivation	I-Premise
therapy.	I-Premise

In	B-Premise
multivariate	I-Premise
analysis,	I-Premise
prophylactic	I-Premise
alpha-blockers	I-Premise
resulted	I-Premise
in	I-Premise
statistically	I-Premise
lower	I-Premise
maximum	I-Premise
dysuria	I-Premise
scores,	I-Premise
while	B-Premise
the	I-Premise
maximum	I-Premise
IPSS	I-Premise
after	I-Premise
implantation	I-Premise
and	I-Premise
isotope	I-Premise
type	I-Premise
(but	I-Premise
only	I-Premise
at	I-Premise
6	I-Premise
months)	I-Premise
were	I-Premise
the	I-Premise
best	I-Premise
predictors	I-Premise
of	I-Premise
the	I-Premise
resolution	I-Premise
of	I-Premise
dysuria.	I-Premise

Dysuria	B-Claim
is	I-Claim
common	I-Claim
after	I-Claim
brachytherapy	I-Claim
but	I-Claim
is	I-Claim
typically	I-Claim
mild.	I-Claim

Prophylactic	B-Claim
alpha-blockers	I-Claim
gave	I-Claim
significantly	I-Claim
lower	I-Claim
maximum	I-Claim
dysuria	I-Claim
scores	I-Claim
but	B-Claim
did	I-Claim
not	I-Claim
affect	I-Claim
the	I-Claim
time	I-Claim
to	I-Claim
the	I-Claim
resolution	I-Claim
of	I-Claim
dysuria.	I-Claim

The	B-Claim
maximum	I-Claim
IPSS	I-Claim
after	I-Claim
the	I-Claim
implant	I-Claim
was	I-Claim
the	I-Claim
best	I-Claim
predictor	I-Claim
of	I-Claim
the	I-Claim
resolution	I-Claim
of	I-Claim
dysuria.	I-Claim

This	O
randomized	O
phase	O
II	O
study	O
compared	O
two	O
treatment	O
schedules	O
of	O
gemcitabine	O
in	O
patients	O
with	O
non-small-cell	O
lung	O
cancer	O
(NSCLC)	O
and	O
impaired	O
Karnofsky	O
performance	O
status	O
(KP).	O

Primary	O
objectives	O
were	O
to	O
record	O
changes	O
from	O
baseline	O
KP	O
and	O
to	O
assess	O
symptom	O
palliation.	O

Secondary	O
objectives	O
were	O
overall	O
survival,	O
tumor	O
response,	O
and	O
toxicity.	O

Patients	O
with	O
stage	O
IIIb	O
and	O
IV	O
NSCLC	O
and	O
KP	O
</=	O
70	O
were	O
randomly	O
assigned	O
to	O
receive	O
gemcitabine	O
1,000	O
mg/m(2)	O
on	O
days	O
1,	O
8,	O
and	O
15	O
of	O
each	O
28-day	O
cycle	O
(3w4)	O
or	O
gemcitabine	O
1,500	O
mg/m(2)	O
on	O
days	O
1	O
and	O
8	O
of	O
each	O
21-day	O
cycle	O
(2w3),	O
both	O
for	O
up	O
to	O
six	O
cycles.	O

KP,	O
toxicity,	O
and	O
SS14	O
lung	O
cancer	O
specific	O
questions	O
were	O
recorded	O
before	O
each	O
cycle	O
of	O
treatment.	O

Response	O
was	O
evaluated	O
4	O
weeks	O
after	O
the	O
last	O
cycle.	O

One	O
hundred	O
seventy-four	O
patients	O
were	O
enrolled.	O

There	B-Premise
was	I-Premise
significant	I-Premise
early	I-Premise
attrition	I-Premise
due	I-Premise
to	I-Premise
disease	I-Premise
progression;	I-Premise
only	I-Premise
61.5%	I-Premise
of	I-Premise
patients	I-Premise
were	I-Premise
alive	I-Premise
at	I-Premise
2	I-Premise
months.	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
KP	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
pre-cycle	I-Premise
3	I-Premise
in	I-Premise
both	I-Premise
arms,	I-Premise
with	I-Premise
a	I-Premise
trend	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
the	I-Premise
3w4	I-Premise
regimen	I-Premise
for	I-Premise
duration	I-Premise
and	I-Premise
faster	I-Premise
onset	I-Premise
of	I-Premise
improvement.	I-Premise

Eight	B-Premise
of	I-Premise
the	I-Premise
17	I-Premise
quality-of-life	I-Premise
(QOL)	I-Premise
variables	I-Premise
assessed	I-Premise
showed	I-Premise
an	I-Premise
improvement	I-Premise
of	I-Premise
more	I-Premise
than	I-Premise
10%	I-Premise
between	I-Premise
baseline	I-Premise
and	I-Premise
the	I-Premise
start	I-Premise
of	I-Premise
the	I-Premise
third	I-Premise
cycle	I-Premise
of	I-Premise
treatment.	I-Premise

Response	B-Premise
rate,	I-Premise
survival,	I-Premise
and	I-Premise
duration	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
both	I-Premise
arms.	I-Premise

There	B-Claim
was	I-Claim
no	I-Claim
significant	I-Claim
difference	I-Claim
between	I-Claim
the	I-Claim
two	I-Claim
schedules	I-Claim
examined	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
improvement	I-Claim
in	I-Claim
KP	I-Claim
or	I-Claim
QOL,	I-Claim
but	I-Claim
there	I-Claim
seemed	I-Claim
to	I-Claim
be	I-Claim
a	I-Claim
trend	I-Claim
in	I-Claim
favor	I-Claim
of	I-Claim
the	I-Claim
3w4	I-Claim
schedule.	I-Claim

To	O
determine	O
whether	O
palliation	O
of	O
chest	O
symptoms	O
from	O
a	O
10	O
Gy	O
single	O
fraction	O
(regimen	O
1)	O
was	O
equivalent	O
to	O
that	O
from	O
30	O
Gy	O
in	O
10	O
fractions	O
(regimen	O
2).	O

Patients	O
with	O
cytologically	O
proven,	O
symptomatic	O
lung	O
cancer	O
not	O
amenable	O
to	O
curative	O
therapy,	O
with	O
performance	O
status	O
0-3,	O
were	O
randomised	O
to	O
receive	O
either	O
30	O
Gy	O
in	O
10	O
fractions	O
or	O
a	O
10	O
Gy	O
single	O
fraction.	O

Local	O
symptoms	O
were	O
scored	O
on	O
a	O
physician-assessed,	O
five-point	O
categorical	O
scale	O
and	O
summed	O
to	O
produce	O
a	O
total	O
symptom	O
score	O
(TSS).	O

This,	O
performance	O
status,	O
Hospital	O
Anxiety	O
and	O
Depression	O
(HAD)	O
score	O
and	O
Spitzer's	O
quality-of-life	O
index	O
were	O
noted	O
before	O
treatment,	O
at	O
1	O
month	O
after	O
treatment	O
and	O
every	O
2	O
months	O
thereafter.	O

Palliation	O
was	O
defined	O
as	O
an	O
improvement	O
of	O
one	O
point	O
or	O
more	O
in	O
the	O
categorical	O
scale.	O

Equivalence	O
was	O
defined	O
as	O
less	O
than	O
20%	O
difference	O
in	O
the	O
number	O
achieving	O
an	O
improvement	O
in	O
the	O
TSS.	O

We	O
randomised	O
149	O
patients	O
and	O
analysed	O
74	O
in	O
each	O
arm.	O

According	O
to	O
the	O
design	O
criteria,	O
palliation	O
was	O
equivalent	O
between	O
the	O
two	O
arms.	O

TSS	B-Premise
improved	I-Premise
in	I-Premise
49	I-Premise
patients	I-Premise
(77%)	I-Premise
on	I-Premise
regimen	I-Premise
1,	I-Premise
and	I-Premise
in	I-Premise
57	I-Premise
(92%)	I-Premise
patients	I-Premise
on	I-Premise
regimen	I-Premise
2,	I-Premise
a	I-Premise
difference	I-Premise
of	I-Premise
15%	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
3-28)	I-Premise
in	I-Premise
the	I-Premise
proportion	I-Premise
improving	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
regimens.	I-Premise

A	B-Premise
complete	I-Premise
resolution	I-Premise
of	I-Premise
all	I-Premise
symptoms	I-Premise
was	I-Premise
achieved	I-Premise
in	I-Premise
three	I-Premise
(5%)	I-Premise
on	I-Premise
regimen	I-Premise
1,	I-Premise
and	I-Premise
in	I-Premise
14	I-Premise
(23%)	I-Premise
patients	I-Premise
on	I-Premise
regimen	I-Premise
2	I-Premise
(P	I-Premise
<	I-Premise
0.001),	I-Premise
a	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
proportion	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
regimens	I-Premise
of	I-Premise
21%	I-Premise
(95%	I-Premise
CI	I-Premise
10-33).	I-Premise

A	B-Premise
significantly	I-Premise
higher	I-Premise
proportion	I-Premise
of	I-Premise
patients	I-Premise
experienced	I-Premise
palliation	I-Premise
and	I-Premise
complete	I-Premise
resolution	I-Premise
of	I-Premise
chest	I-Premise
pain	I-Premise
and	I-Premise
dyspnoea	I-Premise
with	I-Premise
regimen	I-Premise
2.	I-Premise

No	B-Premise
differences	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
toxicity.	I-Premise

The	B-Premise
median	I-Premise
survival	I-Premise
was	I-Premise
22.7	I-Premise
weeks	I-Premise
for	I-Premise
regimen	I-Premise
1	I-Premise
and	I-Premise
28.3	I-Premise
weeks	I-Premise
for	I-Premise
regimen	I-Premise
2	I-Premise
(P	I-Premise
=	I-Premise
0.197).	I-Premise

Although	B-Claim
this	I-Claim
trial	I-Claim
met	I-Claim
the	I-Claim
pre-determined	I-Claim
criteria	I-Claim
for	I-Claim
equivalence	I-Claim
between	I-Claim
the	I-Claim
two	I-Claim
palliative	I-Claim
regimens,	I-Claim
significantly	B-Claim
more	I-Claim
patients	I-Claim
achieved	I-Claim
complete	I-Claim
resolution	I-Claim
of	I-Claim
symptoms	I-Claim
and	I-Claim
palliation	I-Claim
of	I-Claim
chest	I-Claim
pain	I-Claim
and	I-Claim
dyspnoea	I-Claim
with	I-Claim
the	I-Claim
fractionated	I-Claim
regimen.	I-Claim

Bevacizumab,	B-Claim
a	I-Claim
monoclonal	I-Claim
antibody	I-Claim
against	I-Claim
vascular	I-Claim
endothelial	I-Claim
growth	I-Claim
factor,	I-Claim
increases	I-Claim
survival	I-Claim
when	I-Claim
combined	I-Claim
with	I-Claim
irinotecan-based	I-Claim
chemotherapy	I-Claim
in	I-Claim
first-line	I-Claim
treatment	I-Claim
of	I-Claim
metastatic	I-Claim
colorectal	I-Claim
cancer	I-Claim
(CRC).	I-Claim

This	O
randomized,	O
phase	O
II	O
trial	O
compared	O
bevacizumab	O
plus	O
fluorouracil	O
and	O
leucovorin	O
(FU/LV)	O
versus	O
placebo	O
plus	O
FU/LV	O
as	O
first-line	O
therapy	O
in	O
patients	O
considered	O
nonoptimal	O
candidates	O
for	O
first-line	O
irinotecan.	O

Patients	O
had	O
metastatic	O
CRC	O
and	O
one	O
of	O
the	O
following	O
characteristics:	O
age	O
>	O
or	O
=	O
65	O
years,	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
1	O
or	O
2,	O
serum	O
albumin	O
<	O
or	O
=	O
3.5	O
g/dL,	O
or	O
prior	O
abdominal/pelvic	O
radiotherapy.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
FU/LV/placebo	O
(n	O
=	O
105)	O
or	O
FU/LV/bevacizumab	O
(n	O
=	O
104).	O

The	O
primary	O
end	O
point	O
was	O
overall	O
survival.	O

Secondary	O
end	O
points	O
were	O
progression-free	O
survival,	O
response	O
rate,	O
response	O
duration,	O
and	O
quality	O
of	O
life.	O

Safety	O
was	O
also	O
assessed.	O

Median	B-Premise
survival	I-Premise
was	I-Premise
16.6	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
FU/LV/bevacizumab	I-Premise
group	I-Premise
and	I-Premise
12.9	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
FU/LV/placebo	I-Premise
group	I-Premise
(hazard	I-Premise
ratio,	I-Premise
0.79;	I-Premise
P	I-Premise
=	I-Premise
.16).	I-Premise

Median	B-Premise
progression-free	I-Premise
survival	I-Premise
was	I-Premise
9.2	I-Premise
months	I-Premise
(FU/LV/bevacizumab)	I-Premise
and	I-Premise
5.5	I-Premise
months	I-Premise
(FU/LV/placebo);	I-Premise
hazard	B-Premise
ratio	I-Premise
was	I-Premise
0.50;	I-Premise
P	I-Premise
=	I-Premise
.0002.	I-Premise

Response	B-Premise
rates	I-Premise
were	I-Premise
26.0%	I-Premise
(FU/LV/bevacizumab)	I-Premise
and	I-Premise
15.2%	I-Premise
(FU/LV/placebo)	I-Premise
(P	I-Premise
=	I-Premise
.055);	I-Premise
duration	B-Premise
of	I-Premise
response	I-Premise
was	I-Premise
9.2	I-Premise
months	I-Premise
(FU/LV/bevacizumab)	I-Premise
and	I-Premise
6.8	I-Premise
months	I-Premise
(FU/LV/placebo);	I-Premise
hazard	B-Premise
ratio	I-Premise
was	I-Premise
0.42;	I-Premise
P	I-Premise
=	I-Premise
.088.	I-Premise

Grade	B-Premise
3	I-Premise
hypertension	I-Premise
was	I-Premise
more	I-Premise
common	I-Premise
with	I-Premise
bevacizumab	I-Premise
treatment	I-Premise
(16%	I-Premise
v	I-Premise
3%)	I-Premise
but	B-Premise
was	I-Premise
controlled	I-Premise
with	I-Premise
oral	I-Premise
medication	I-Premise
and	I-Premise
did	I-Premise
not	I-Premise
cause	I-Premise
study	I-Premise
drug	I-Premise
discontinuation.	I-Premise

Addition	B-Claim
of	I-Claim
bevacizumab	I-Claim
to	I-Claim
FU/LV	I-Claim
as	I-Claim
first-line	I-Claim
therapy	I-Claim
in	I-Claim
CRC	I-Claim
patients	I-Claim
who	I-Claim
were	I-Claim
not	I-Claim
considered	I-Claim
optimal	I-Claim
candidates	I-Claim
for	I-Claim
first-line	I-Claim
irinotecan	I-Claim
treatment	I-Claim
provided	I-Claim
clinically	I-Claim
significant	I-Claim
patient	I-Claim
benefit,	I-Claim
including	I-Claim
statistically	I-Claim
significant	I-Claim
improvement	I-Claim
in	I-Claim
progression-free	I-Claim
survival.	I-Claim

Impaired	B-Claim
cognition,	I-Claim
fatigue,	I-Claim
and	I-Claim
diminished	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
(QOL)	I-Claim
are	I-Claim
commonly	I-Claim
associated	I-Claim
with	I-Claim
breast	I-Claim
cancer	I-Claim
chemotherapy.	I-Claim

This	O
randomized,	O
double-blind,	O
placebo-controlled	O
pilot	O
trial	O
assessed	O
the	O
feasibility	O
of	O
quantifying	O
the	O
effects	O
of	O
epoetin	O
alfa	O
on	O
cognitive	O
function	O
and	O
mood,	O
and	O
evaluated	O
its	O
effects	O
on	O
fatigue	O
and	O
QOL	O
in	O
patients	O
with	O
breast	O
cancer	O
treated	O
with	O
anthracycline-based	O
adjuvant	O
or	O
neoadjuvant	O
chemotherapy.	O

Patients	O
were	O
randomized	O
to	O
receive	O
epoetin	O
alfa	O
40,000	O
U	O
subcutaneously	O
once	O
weekly	O
or	O
placebo	O
at	O
the	O
beginning	O
of	O
4	O
cycles	O
of	O
chemotherapy	O
administered	O
over	O
12	O
weeks.	O

Cognitive	O
function	O
was	O
assessed	O
by	O
Executive	O
Interview	O
(EXIT25)	O
and	O
Clock	O
Drawing	O
Tasks;	O
mood	O
by	O
Profile	O
of	O
Mood	O
States;	O
anemia-related	O
symptoms,	O
including	O
fatigue,	O
by	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Anemia	O
(FACT-An)	O
subscale;	O
and	O
QOL	O
by	O
Linear	O
Analog	O
Scale	O
Assessment.	O

Ninety-four	O
patients	O
were	O
evaluable	O
for	O
efficacy	O
and	O
safety.	O

Mean	B-Premise
change	I-Premise
in	I-Premise
EXIT25	I-Premise
scores	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
cycle	I-Premise
4	I-Premise
in	I-Premise
the	I-Premise
epoetin	I-Premise
alfa	I-Premise
group	I-Premise
was	I-Premise
1.3	I-Premise
+/-	I-Premise
3.3;	I-Premise
the	B-Premise
mean	I-Premise
change	I-Premise
was	I-Premise
0.3	I-Premise
+/-	I-Premise
2.4	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group	I-Premise
(a	I-Premise
negative	I-Premise
change	I-Premise
indicates	I-Premise
improved	I-Premise
executive	I-Premise
function).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
between	I-Premise
groups	I-Premise
in	I-Premise
mean	I-Premise
change	I-Premise
in	I-Premise
EXIT25	I-Premise
score	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
6-month	I-Premise
follow-up	I-Premise
assessment.	I-Premise

Mean	B-Premise
hemoglobin	I-Premise
levels	I-Premise
were	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
epoetin	I-Premise
alfa	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
placebo	I-Premise
group	I-Premise
after	I-Premise
4	I-Premise
cycles	I-Premise
of	I-Premise
chemotherapy.	I-Premise

Epoetin	B-Premise
alfa	I-Premise
recipients	I-Premise
had	I-Premise
less	I-Premise
of	I-Premise
a	I-Premise
decrease	I-Premise
in	I-Premise
FACT-An	I-Premise
subscale	I-Premise
scores	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
cycle	I-Premise
4	I-Premise
and	I-Premise
improvement	I-Premise
in	I-Premise
FACT-An	I-Premise
subscale	I-Premise
scores	I-Premise
at	I-Premise
6-month	I-Premise
follow-up	I-Premise
assessment	I-Premise
compared	I-Premise
with	I-Premise
placebo.	I-Premise

Epoetin	B-Claim
alfa	I-Claim
therapy	I-Claim
was	I-Claim
well	I-Claim
tolerated.	I-Claim

These	B-Claim
data	I-Claim
suggest	I-Claim
that	I-Claim
epoetin	I-Claim
alfa	I-Claim
may	I-Claim
have	I-Claim
attenuated	I-Claim
the	I-Claim
cognitive	I-Claim
impairment	I-Claim
and	I-Claim
fatigue	I-Claim
that	I-Claim
occurred	I-Claim
during	I-Claim
adjuvant	I-Claim
breast	I-Claim
cancer	I-Claim
chemotherapy.	I-Claim

To	O
pilot	O
an	O
investigation	O
of	O
individualized	O
homeopathy	O
for	O
symptoms	O
of	O
estrogen	O
withdrawal	O
in	O
breast	O
cancer	O
survivors.	O

Randomized,	O
double-blinded,	O
placebo-controlled	O
trial.	O

Outpatient	O
department	O
of	O
a	O
National	O
Health	O
Service	O
(NHS)	O
homeopathic	O
hospital.	O

Fifty-seven	O
(57)	O
women	O
met	O
inclusion	O
criteria	O
and	O
53	O
were	O
randomized	O
to	O
the	O
study.	O

After	O
2	O
weeks	O
of	O
baseline	O
assessment,	O
all	O
participants	O
received	O
a	O
consultation	O
plus	O
either	O
oral	O
homeopathic	O
medicine	O
or	O
placebo,	O
assessed	O
every	O
4	O
weeks	O
for	O
16	O
weeks.	O

The	O
primary	O
outcome	O
measures	O
were	O
the	O
activity	O
score	O
and	O
profile	O
score	O
of	O
the	O
Measure	O
Yourself	O
Medical	O
Outcome	O
Profile	O
(MYMOP).	O

Eighty-five	O
percent	O
(85%)	O
(45/53)	O
of	O
women	O
completed	O
the	O
study.	O

There	B-Premise
was	I-Premise
no	I-Premise
evidence	I-Premise
of	I-Premise
a	I-Premise
difference	I-Premise
seen	I-Premise
between	I-Premise
groups	I-Premise
for	I-Premise
either	I-Premise
activity	I-Premise
(adjusted	I-Premise
difference	I-Premise
=-0.4,	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
CI	I-Premise
-1.0	I-Premise
to	I-Premise
0.2,	I-Premise
p	I-Premise
=	I-Premise
0.17)	I-Premise
or	I-Premise
profile	I-Premise
scores	I-Premise
(adjusted	I-Premise
difference	I-Premise
=	I-Premise
-0.4,	I-Premise
95%	I-Premise
CI	I-Premise
-0.9	I-Premise
to	I-Premise
0.1,	I-Premise
p	I-Premise
=	I-Premise
0.13)	I-Premise
using	I-Premise
this	I-Premise
trial	I-Premise
design,	I-Premise
although	B-Claim
post	I-Claim
hoc	I-Claim
power	I-Claim
calculations	I-Claim
suggests	I-Claim
that	I-Claim
65-175	I-Claim
would	I-Claim
be	I-Claim
needed	I-Claim
per	I-Claim
group	I-Claim
to	I-Claim
detect	I-Claim
differences	I-Claim
of	I-Claim
this	I-Claim
magnitude	I-Claim
with	I-Claim
sufficient	I-Claim
precision.	I-Claim

Clinically	B-Premise
relevant	I-Premise
improvements	I-Premise
in	I-Premise
symptoms	I-Premise
and	I-Premise
mood	I-Premise
disturbance	I-Premise
were	I-Premise
seen	I-Premise
for	I-Premise
both	I-Premise
groups	I-Premise
over	I-Premise
the	I-Premise
study	I-Premise
period.	I-Premise

Improvements	B-Claim
were	I-Claim
seen	I-Claim
for	I-Claim
symptom	I-Claim
scores	I-Claim
over	I-Claim
the	I-Claim
study	I-Claim
period.	I-Claim

However,	B-Claim
presuming	I-Claim
these	I-Claim
improvements	I-Claim
were	I-Claim
caused	I-Claim
by	I-Claim
the	I-Claim
individualized	I-Claim
homeopathic	I-Claim
approach,	I-Claim
the	I-Claim
study	I-Claim
failed	I-Claim
to	I-Claim
show	I-Claim
clearly	I-Claim
that	I-Claim
the	I-Claim
specific	I-Claim
effect	I-Claim
of	I-Claim
the	I-Claim
remedy	I-Claim
added	I-Claim
further	I-Claim
to	I-Claim
the	I-Claim
nonspecific	I-Claim
effects	I-Claim
of	I-Claim
the	I-Claim
consultation.	I-Claim

Future	B-Claim
trial	I-Claim
design	I-Claim
must	I-Claim
ensure	I-Claim
adequate	I-Claim
power	I-Claim
to	I-Claim
account	I-Claim
for	I-Claim
the	I-Claim
nonspecific	I-Claim
impact	I-Claim
of	I-Claim
such	I-Claim
complex	I-Claim
individualized	I-Claim
interventions	I-Claim
while	I-Claim
pragmatic	I-Claim
designs	I-Claim
may	I-Claim
more	I-Claim
readily	I-Claim
answer	I-Claim
questions	I-Claim
of	I-Claim
clinical	I-Claim
and	I-Claim
cost	I-Claim
effectiveness.	I-Claim

To	O
carry	O
out	O
a	O
preliminary	O
trial	O
evaluating	O
the	O
effectiveness	O
of	O
two	O
types	O
of	O
homeopathy	O
for	O
the	O
treatment	O
of	O
menopausal	O
symptoms	O
in	O
breast	O
cancer	O
survivors.	O

Randomized,	O
double-blinded,	O
placebo-controlled.	O

Private	O
medical	O
clinic,	O
Seattle,	O
WA.	O

Women	O
with	O
a	O
history	O
of	O
breast	O
cancer	O
who	O
had	O
completed	O
all	O
surgery,	O
chemotherapy,	O
and	O
radiation	O
treatment	O
and	O
who	O
had	O
an	O
average	O
of	O
at	O
least	O
three	O
hot	O
flashes	O
per	O
day	O
for	O
the	O
previous	O
month.	O

Subjects	O
were	O
randomized	O
to	O
receive	O
either	O
an	O
individualized	O
homeopathic	O
single	O
remedy,	O
a	O
homeopathic	O
combination	O
medicine,	O
or	O
placebo.	O

Patients	O
were	O
seen	O
by	O
homeopathic	O
providers	O
every	O
2	O
months	O
for	O
1	O
year.	O

Hot	O
flash	O
frequency	O
and	O
severity,	O
Kupperman	O
Menopausal	O
Index	O
(KMI),	O
Short	O
Form	O
36	O
(SF-36).	O

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
found	I-Premise
in	I-Premise
the	I-Premise
primary	I-Premise
outcome	I-Premise
measure,	I-Premise
the	I-Premise
hot	I-Premise
flash	I-Premise
severity	I-Premise
score,	I-Premise
although	B-Premise
there	I-Premise
was	I-Premise
a	I-Premise
positive	I-Premise
trend	I-Premise
in	I-Premise
the	I-Premise
single	I-Premise
remedy	I-Premise
group	I-Premise
during	I-Premise
the	I-Premise
first	I-Premise
3	I-Premise
months	I-Premise
of	I-Premise
the	I-Premise
study	I-Premise
(p	I-Premise
=	I-Premise
0.1).	I-Premise

A	B-Premise
statistically	I-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
general	I-Premise
health	I-Premise
score	I-Premise
in	I-Premise
both	I-Premise
homeopathy	I-Premise
groups	I-Premise
(p	I-Premise
<	I-Premise
0.05)	I-Premise
on	I-Premise
the	I-Premise
SF-36	I-Premise
after	I-Premise
1	I-Premise
year	I-Premise
was	I-Premise
found.	I-Premise

Evidence	B-Premise
of	I-Premise
a	I-Premise
homeopathic	I-Premise
"drug	I-Premise
proving"	I-Premise
in	I-Premise
the	I-Premise
subjects	I-Premise
receiving	I-Premise
the	I-Premise
homeopathic	I-Premise
combination	I-Premise
medicine	I-Premise
who	I-Premise
were	I-Premise
not	I-Premise
taking	I-Premise
tamoxifen	I-Premise
also	I-Premise
was	I-Premise
found.	I-Premise

Small	B-Claim
sample	I-Claim
size	I-Claim
precludes	I-Claim
definitive	I-Claim
answers,	I-Claim
but	B-Claim
results	I-Claim
from	I-Claim
this	I-Claim
preliminary	I-Claim
trial	I-Claim
suggest	I-Claim
that	I-Claim
homeopathy	I-Claim
may	I-Claim
be	I-Claim
of	I-Claim
value	I-Claim
in	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
menopausal	I-Claim
symptoms	I-Claim
and	I-Claim
improving	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
especially	I-Claim
in	I-Claim
those	I-Claim
women	I-Claim
not	I-Claim
on	I-Claim
tamoxifen.	I-Claim

Larger	B-Claim
studies	I-Claim
should	I-Claim
be	I-Claim
carried	I-Claim
out	I-Claim
that	I-Claim
also	I-Claim
include	I-Claim
healthy	I-Claim
women	I-Claim
who	I-Claim
want	I-Claim
to	I-Claim
avoid	I-Claim
hormone	I-Claim
replacement	I-Claim
therapy.	I-Claim

Proinflammatory	O
cytokines,	O
especially	O
tumour	O
necrosis	O
factor	O
alpha	O
(TNF-alpha),	O
play	O
a	O
prominent	O
role	O
in	O
the	O
pathogenesis	O
of	O
cancer	O
cachexia.	O

Thalidomide,	B-Claim
which	I-Claim
is	I-Claim
an	I-Claim
inhibitor	I-Claim
of	I-Claim
TNF-alpha	I-Claim
synthesis,	I-Claim
may	I-Claim
represent	I-Claim
a	I-Claim
novel	I-Claim
and	I-Claim
rational	I-Claim
approach	I-Claim
to	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
cancer	I-Claim
cachexia.	I-Claim

To	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
thalidomide	O
in	O
attenuating	O
weight	O
loss	O
in	O
patients	O
with	O
cachexia	O
secondary	O
to	O
advanced	O
pancreatic	O
cancer.	O

Fifty	O
patients	O
with	O
advanced	O
pancreatic	O
cancer	O
who	O
had	O
lost	O
at	O
least	O
10%	O
of	O
their	O
body	O
weight	O
were	O
randomised	O
to	O
receive	O
thalidomide	O
200	O
mg	O
daily	O
or	O
placebo	O
for	O
24	O
weeks	O
in	O
a	O
single	O
centre,	O
double	O
blind,	O
randomised	O
controlled	O
trial.	O

The	O
primary	O
outcome	O
was	O
change	O
in	O
weight	O
and	O
nutritional	O
status.	O

Thirty	O
three	O
patients	O
(16	O
control,	O
17	O
thalidomide)	O
were	O
evaluated	O
at	O
four	O
weeks,	O
and	O
20	O
patients	O
(eight	O
control,	O
12	O
thalidomide)	O
at	O
eight	O
weeks.	O

At	B-Premise
four	I-Premise
weeks,	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
thalidomide	I-Premise
had	I-Premise
gained	I-Premise
on	I-Premise
average	I-Premise
0.37	I-Premise
kg	I-Premise
in	I-Premise
weight	I-Premise
and	I-Premise
1.0	I-Premise
cm(3)	I-Premise
in	I-Premise
arm	I-Premise
muscle	I-Premise
mass	I-Premise
(AMA)	I-Premise
compared	I-Premise
with	I-Premise
a	I-Premise
loss	I-Premise
of	I-Premise
2.21	I-Premise
kg	I-Premise
(absolute	I-Premise
difference	I-Premise
-2.59	I-Premise
kg	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
(CI)	I-Premise
-4.3	I-Premise
to	I-Premise
-0.8);	I-Premise
p	I-Premise
=	I-Premise
0.005)	I-Premise
and	I-Premise
4.46	I-Premise
cm(3)	I-Premise
(absolute	I-Premise
difference	I-Premise
-5.6	I-Premise
cm(3)	I-Premise
(95%	I-Premise
CI	I-Premise
-8.9	I-Premise
to	I-Premise
-2.2);	I-Premise
p	I-Premise
=	I-Premise
0.002)	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group.	I-Premise

At	B-Premise
eight	I-Premise
weeks,	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
thalidomide	I-Premise
group	I-Premise
had	I-Premise
lost	I-Premise
0.06	I-Premise
kg	I-Premise
in	I-Premise
weight	I-Premise
and	I-Premise
0.5	I-Premise
cm(3)	I-Premise
in	I-Premise
AMA	I-Premise
compared	I-Premise
with	I-Premise
a	I-Premise
loss	I-Premise
of	I-Premise
3.62	I-Premise
kg	I-Premise
(absolute	I-Premise
difference	I-Premise
-3.57	I-Premise
kg	I-Premise
(95%	I-Premise
CI	I-Premise
-6.8	I-Premise
to	I-Premise
-0.3);	I-Premise
p	I-Premise
=	I-Premise
0.034)	I-Premise
and	I-Premise
8.4	I-Premise
cm(3)	I-Premise
(absolute	I-Premise
difference	I-Premise
-7.9	I-Premise
cm(3)	I-Premise
(95%	I-Premise
CI	I-Premise
-14.0	I-Premise
to	I-Premise
-1.8);	I-Premise
p	I-Premise
=	I-Premise
0.014)	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group.	I-Premise

Improvement	B-Premise
in	I-Premise
physical	I-Premise
functioning	I-Premise
correlated	I-Premise
positively	I-Premise
with	I-Premise
weight	I-Premise
gain	I-Premise
(r	I-Premise
=	I-Premise
0.56,	I-Premise
p	I-Premise
=	I-Premise
0.001).	I-Premise

Thalidomide	B-Claim
was	I-Claim
well	I-Claim
tolerated	I-Claim
and	I-Claim
effective	I-Claim
at	I-Claim
attenuating	I-Claim
loss	I-Claim
of	I-Claim
weight	I-Claim
and	I-Claim
lean	I-Claim
body	I-Claim
mass	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
cachexia	I-Claim
due	I-Claim
to	I-Claim
advanced	I-Claim
pancreatic	I-Claim
cancer.	I-Claim

To	O
test	O
the	O
ability	O
of	O
the	O
cytoprotectant,	O
amifostine,	O
to	O
reduce	O
chemoradiotherapy-induced	O
esophagitis	O
and	O
evaluate	O
its	O
influence	O
on	O
quality	O
of	O
life	O
(QOL)	O
and	O
swallowing	O
symptoms.	O

A	O
total	O
of	O
243	O
patients	O
with	O
stage	O
II	O
to	O
IIIA/B	O
non-small-cell	O
lung	O
cancer	O
received	O
induction	O
paclitaxel	O
225	O
mg/m(2)	O
intravenously	O
(IV)	O
days	O
1	O
and	O
22	O
and	O
carboplatin	O
area	O
under	O
the	O
curve	O
(AUC)	O
days	O
1	O
and	O
22,	O
followed	O
by	O
concurrent	O
weekly	O
paclitaxel	O
(50	O
mg/m(2)	O
IV)	O
and	O
carboplatin	O
(AUC	O
2),	O
and	O
hyperfractionated	O
radiation	O
therapy	O
(69.6	O
Gy	O
at	O
1.2	O
Gy	O
bid).	O

Patients	O
were	O
randomly	O
assigned	O
at	O
registration	O
to	O
amifostine	O
(AM)	O
500	O
mg	O
IV	O
four	O
times	O
per	O
week	O
or	O
no	O
AM	O
during	O
chemoradiotherapy.	O

Beyond	O
standard	O
toxicity	O
end	O
points,	O
physician	O
dysphagia	O
logs	O
(PDLs),	O
daily	O
patient	O
swallowing	O
diaries,	O
and	O
QOL	O
(EORTC	O
QLQ-C30/LC-13)	O
were	O
also	O
collected.	O

Swallowing	O
AUC	O
analyses	O
were	O
calculated	O
from	O
patient	O
diaries	O
and	O
PDLs.	O

A	O
total	O
of	O
120	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
AM,	O
and	O
122,	O
to	O
receive	O
no	O
AM	O
(one	O
patient	O
was	O
ineligible);	O
72%	O
received	O
AM	O
per	O
protocol	O
or	O
with	O
a	O
minor	O
deviation.	O

AM	B-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
higher	I-Premise
rates	I-Premise
of	I-Premise
acute	I-Premise
nausea	I-Premise
(P	I-Premise
=	I-Premise
.03),	I-Premise
vomiting	I-Premise
(P	I-Premise
=	I-Premise
.007),	I-Premise
cardiovascular	I-Premise
toxicity	I-Premise
(P	I-Premise
=	I-Premise
.0001),	I-Premise
and	I-Premise
infection	I-Premise
or	I-Premise
febrile	I-Premise
neutropenia	I-Premise
(P	I-Premise
=	I-Premise
.03).	I-Premise

The	B-Premise
rate	I-Premise
of	I-Premise
>/=	I-Premise
grade	I-Premise
3	I-Premise
esophagitis	I-Premise
was	I-Premise
30%	I-Premise
with	I-Premise
AM	I-Premise
versus	I-Premise
34%	I-Premise
without	I-Premise
AM	I-Premise
(P	I-Premise
=	I-Premise
.9).	I-Premise

Patient	B-Premise
diaries	I-Premise
demonstrated	I-Premise
lower	I-Premise
swallowing	I-Premise
dysfunction	I-Premise
AUC	I-Premise
with	I-Premise
amifostine	I-Premise
(z	I-Premise
test	I-Premise
P	I-Premise
=	I-Premise
.025).	I-Premise

QOL	B-Premise
was	I-Premise
not	I-Premise
significantly	I-Premise
different	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
arms,	I-Premise
except	I-Premise
for	I-Premise
pain,	I-Premise
which	I-Premise
showed	I-Premise
more	I-Premise
clinically	I-Premise
meaningful	I-Premise
improvement	I-Premise
and	I-Premise
less	I-Premise
deterioration	I-Premise
at	I-Premise
6	I-Premise
weeks	I-Premise
follow-up	I-Premise
(v	I-Premise
pretreatment)	I-Premise
in	I-Premise
the	I-Premise
AM	I-Premise
arm	I-Premise
(P	I-Premise
=	I-Premise
.003).	I-Premise

The	B-Premise
median	I-Premise
survival	I-Premise
rates	I-Premise
for	I-Premise
both	I-Premise
arms	I-Premise
were	I-Premise
comparable	I-Premise
(AM,	I-Premise
17.3	I-Premise
v	I-Premise
no	I-Premise
AM,	I-Premise
17.9	I-Premise
months;	I-Premise
P	I-Premise
=	I-Premise
.87).	I-Premise

AM	B-Claim
did	I-Claim
not	I-Claim
significantly	I-Claim
reduce	I-Claim
esophagitis	I-Claim
>/=	I-Claim
grade	I-Claim
3	I-Claim
in	I-Claim
patients	I-Claim
receiving	I-Claim
hyperfractionated	I-Claim
radiation	I-Claim
and	I-Claim
chemotherapy.	I-Claim

However,	B-Claim
patient	I-Claim
self-assessments	I-Claim
suggested	I-Claim
a	I-Claim
possible	I-Claim
advantage	I-Claim
to	I-Claim
AM	I-Claim
that	I-Claim
is	I-Claim
being	I-Claim
explored	I-Claim
with	I-Claim
modified	I-Claim
dosing	I-Claim
route	I-Claim
strategies.	I-Claim

Many	O
patients	O
with	O
advanced	O
ovarian	O
cancer	O
will	O
develop	O
recurrent	O
disease.	O

For	B-Premise
those	I-Premise
patients	I-Premise
who	I-Premise
have	I-Premise
recurrence	I-Premise
of	I-Premise
disease	I-Premise
at	I-Premise
least	I-Premise
6	I-Premise
months	I-Premise
after	I-Premise
initial	I-Premise
therapy,	I-Premise
the	I-Premise
paclitaxel-platinum	I-Premise
combination	I-Premise
has	I-Premise
been	I-Premise
shown	I-Premise
to	I-Premise
be	I-Premise
a	I-Premise
superior	I-Premise
treatment	I-Premise
to	I-Premise
platinum	I-Premise
monotherapy.	I-Premise

However,	B-Claim
many	I-Claim
patients	I-Claim
develop	I-Claim
clinically	I-Claim
relevant	I-Claim
neurotoxicity,	I-Claim
frequently	I-Claim
resulting	I-Claim
in	I-Claim
treatment	I-Claim
discontinuation.	I-Claim

The	O
efficacy	O
and	O
safety	O
of	O
an	O
alternative	O
regimen	O
that	O
does	O
not	O
show	O
significant	O
neurotoxicity	O
were	O
evaluated	O
by	O
comparing	O
gemcitabine-carboplatin	O
with	O
carboplatin	O
in	O
platinum-sensitive	O
recurrent	O
ovarian	O
cancer	O
patients	O
in	O
a	O
Gynecologic	O
Cancer	O
InterGroup	O
trial	O
of	O
the	O
Arbeitsgemeinschaft	O
Gynakologische	O
Onkologie	O
Ovarian	O
Cancer	O
Study	O
Group,	O
the	O
National	O
Cancer	O
Institute	O
of	O
Canada	O
Clinical	O
Trials	O
Group,	O
and	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Gynaecological	O
Cancer	O
Group.	O

Participants	O
with	O
recurrent	O
platinum-sensitive	O
ovarian	O
cancer	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
gemcitabine-carboplatin	O
or	O
carboplatin	O
every	O
21	O
days.	O

The	O
primary	O
objective	O
was	O
to	O
compare	O
progression-free	O
survival	O
(PFS)	O
between	O
the	O
groups.	O

From	O
September	O
1999	O
to	O
April	O
2002,	O
356	O
patients	O
(178	O
participants	O
received	O
gemcitabine-carboplatin,	O
178	O
received	O
carboplatin	O
only)	O
were	O
randomized	O
to	O
treatment.	O

Patients	O
received	O
six	O
cycles	O
of	O
either	O
gemcitabine-carboplatin	O
or	O
carboplatin.	O

With	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
17	I-Premise
months,	I-Premise
median	I-Premise
PFS	I-Premise
was	I-Premise
8.6	I-Premise
months	I-Premise
for	I-Premise
gemcitabine-carboplatin	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
7.9-9.7	I-Premise
months)	I-Premise
and	I-Premise
5.8	I-Premise
months	I-Premise
for	I-Premise
carboplatin	I-Premise
(95%	I-Premise
CI	I-Premise
5.2-7.1	I-Premise
months;	I-Premise
hazard	I-Premise
ratio	I-Premise
[HR]	I-Premise
0.72	I-Premise
[95%	I-Premise
CI	I-Premise
0.58-0.90;	I-Premise
P	I-Premise
=	I-Premise
0.0032]).	I-Premise

The	B-Premise
response	I-Premise
rate	I-Premise
for	I-Premise
the	I-Premise
gemcitabine-carboplatin	I-Premise
group	I-Premise
was	I-Premise
47.2%	I-Premise
(95%	I-Premise
CI	I-Premise
39.9-54.5%)	I-Premise
and	I-Premise
30.9%	I-Premise
for	I-Premise
carboplatin	I-Premise
group	I-Premise
(95%	I-Premise
CI	I-Premise
24.1-37.7%;	I-Premise
P	I-Premise
=	I-Premise
0.0016).	I-Premise

The	B-Premise
HR	I-Premise
for	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
0.96	I-Premise
(95%	I-Premise
CI	I-Premise
0.75-1.23;	I-Premise
P	I-Premise
=	I-Premise
0.7349).	I-Premise

Patients	B-Premise
treated	I-Premise
with	I-Premise
gemcitabine-carboplatin	I-Premise
reported	I-Premise
significantly	I-Premise
faster	I-Premise
palliation	I-Premise
of	I-Premise
abdominal	I-Premise
symptoms	I-Premise
and	I-Premise
a	I-Premise
significantly	I-Premise
improved	I-Premise
global	I-Premise
quality	I-Premise
of	I-Premise
life.	I-Premise

Gemcitabine-carboplatin	B-Claim
treatment	I-Claim
significantly	I-Claim
improves	I-Claim
the	I-Claim
PFS	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
platinum-sensitive	I-Claim
recurrent	I-Claim
ovarian	I-Claim
cancer.	I-Claim

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
specialized	O
supportive	O
enteral	O
and	O
parenteral	O
feeding	O
have	O
superior	O
effects	O
compared	O
to	O
oral	O
nutrition	O
on	O
recovery	O
during	O
long-term	O
postoperative	O
treatment	O
of	O
cancer	O
patients	O
with	O
preoperative	O
weight	O
loss	O
and	O
reduced	O
maximum	O
exercise	O
capacity.	O

One	O
hundred	O
twenty-six	O
patients	O
referred	O
for	O
resection	O
of	O
the	O
esophagus	O
(n	O
=	O
48),	O
stomach	O
(n	O
=	O
28),	O
or	O
pancreas	O
(n	O
=	O
50)	O
were	O
considered	O
to	O
be	O
included	O
before	O
operation.	O

Included	O
patients	O
(n	O
=	O
80)	O
received	O
supportive	O
enteral	O
or	O
parenteral	O
nutrition	O
postoperatively	O
at	O
home	O
corresponding	O
to	O
1000	O
kcal/d	O
until	O
the	O
patients	O
did	O
not	O
wish	O
to	O
continue	O
with	O
artificial	O
nutrition	O
for	O
any	O
reason.	O

Patients	O
randomized	O
to	O
oral	O
nutrition	O
only	O
served	O
as	O
control	O
subjects.	O

Caloric	O
intake,	O
body	O
composition	O
(dual-energy	O
x-ray	O
absorptiometry),	O
and	O
respiratory	O
gas	O
exchanges	O
at	O
rest	O
and	O
during	O
exercise	O
were	O
measured	O
including	O
health-related	O
quality	O
of	O
life.	O

Survival	B-Premise
and	I-Premise
hospital	I-Premise
stay	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
among	I-Premise
the	I-Premise
groups,	I-Premise
whereas	I-Premise
overall	I-Premise
complications	I-Premise
were	I-Premise
higher	I-Premise
on	I-Premise
artificial	I-Premise
nutrition	I-Premise
(P	I-Premise
<	I-Premise
.05).	I-Premise

Changes	B-Premise
in	I-Premise
resting	I-Premise
energy	I-Premise
expenditure	I-Premise
and	I-Premise
biochemical	I-Premise
tests	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
during	I-Premise
follow-up	I-Premise
among	I-Premise
the	I-Premise
groups.	I-Premise

Body	B-Premise
weight	I-Premise
and	I-Premise
whole	I-Premise
body	I-Premise
fat	I-Premise
declined	I-Premise
similarly	I-Premise
over	I-Premise
time	I-Premise
in	I-Premise
all	I-Premise
groups	I-Premise
(P	I-Premise
<	I-Premise
.005),	I-Premise
whereas	O
lean	B-Premise
body	I-Premise
mass	I-Premise
was	I-Premise
unchanged	I-Premise
during	I-Premise
follow-up	I-Premise
compared	I-Premise
to	I-Premise
preoperative	I-Premise
values.	I-Premise

Maximum	B-Premise
exercise	I-Premise
capacity	I-Premise
and	I-Premise
maximum	I-Premise
oxygen	I-Premise
consumption	I-Premise
were	I-Premise
normalized	I-Premise
within	I-Premise
6	I-Premise
months	I-Premise
postoperatively	I-Premise
in	I-Premise
all	I-Premise
groups.	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
recovery	I-Premise
of	I-Premise
food	I-Premise
intake	I-Premise
among	I-Premise
the	I-Premise
groups.	I-Premise

Parenteral	B-Claim
feeding	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
the	I-Claim
highest	I-Claim
rate	I-Claim
of	I-Claim
nutrition-related	I-Claim
complications,	I-Claim
whereas	O
enteral	B-Claim
feeding	I-Claim
reduced	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
most	I-Claim
extensively.	I-Claim

After	B-Claim
major	I-Claim
surgery,	I-Claim
specialized	I-Claim
supportive	I-Claim
enteral	I-Claim
and	I-Claim
parenteral	I-Claim
nutrition	I-Claim
are	I-Claim
not	I-Claim
superior	I-Claim
to	I-Claim
oral	I-Claim
nutrition	I-Claim
only	I-Claim
when	I-Claim
guided	I-Claim
by	I-Claim
a	I-Claim
dietitian.	I-Claim

Facial	B-Claim
hirsutism	I-Claim
is	I-Claim
one	I-Claim
of	I-Claim
the	I-Claim
characteristic	I-Claim
features	I-Claim
of	I-Claim
polycystic	I-Claim
ovary	I-Claim
syndrome	I-Claim
(PCOS),	I-Claim
and	I-Claim
this	I-Claim
can	I-Claim
lead	I-Claim
to	I-Claim
high	I-Claim
levels	I-Claim
of	I-Claim
depression	I-Claim
and	I-Claim
anxiety.	I-Claim

To	O
evaluate	O
the	O
impact	O
of	O
laser	O
treatment	O
on	O
the	O
severity	O
of	O
facial	O
hirsutism	O
and	O
on	O
psychological	O
morbidity	O
in	O
women	O
with	O
PCOS.	O

A	O
randomized	O
controlled	O
trial	O
of	O
five	O
high-fluence	O
treatments	O
(intervention)	O
vs.	O
five	O
low-fluence	O
treatments	O
(control)	O
was	O
performed	O
over	O
6	O
months	O
in	O
a	O
National	O
Health	O
Service	O
teaching	O
hospital.	O

Subjects	O
were	O
88	O
women	O
with	O
facial	O
hirsutism	O
due	O
to	O
PCOS	O
recruited	O
from	O
hospital	O
outpatient	O
clinics	O
and	O
a	O
patient	O
support	O
group	O
in	O
2001-2002.	O

The	O
main	O
outcomes	O
were	O
self-reported	O
severity	O
of	O
facial	O
hair	O
(measured	O
on	O
a	O
scale	O
of	O
1-10),	O
depression,	O
anxiety	O
(measured	O
on	O
the	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale)	O
and	O
quality	O
of	O
life	O
(measured	O
on	O
the	O
WHOQOL-BREF).	O

Self-reported	B-Premise
severity	I-Premise
of	I-Premise
facial	I-Premise
hair	I-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
group	I-Premise
(n	I-Premise
=	I-Premise
51)	I-Premise
fell	I-Premise
from	I-Premise
7.3	I-Premise
to	I-Premise
3.6	I-Premise
over	I-Premise
the	I-Premise
6-month	I-Premise
study	I-Premise
period;	I-Premise
for	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(n	I-Premise
=	I-Premise
37)	I-Premise
the	I-Premise
corresponding	I-Premise
scores	I-Premise
were	I-Premise
7.1	I-Premise
and	I-Premise
6.1.	I-Premise

The	B-Premise
change	I-Premise
was	I-Premise
significantly	I-Premise
greater	I-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
group	I-Premise
[ancova	I-Premise
F((1,83))	I-Premise
=	I-Premise
24.5,	I-Premise
P	I-Premise
<	I-Premise
0.05].	I-Premise

Self-reported	B-Premise
time	I-Premise
spent	I-Premise
on	I-Premise
hair	I-Premise
removal	I-Premise
declined	I-Premise
from	I-Premise
112	I-Premise
to	I-Premise
21	I-Premise
min	I-Premise
per	I-Premise
week	I-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
group	I-Premise
and	I-Premise
from	I-Premise
92	I-Premise
to	I-Premise
56	I-Premise
min	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
[F((1,80))	I-Premise
=	I-Premise
10.2,	I-Premise
P	I-Premise
</=	I-Premise
0.05].	I-Premise

Mean	B-Premise
depression	I-Premise
scores	I-Premise
fell	I-Premise
from	I-Premise
6.7	I-Premise
to	I-Premise
3.6	I-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
group,	I-Premise
compared	I-Premise
with	I-Premise
6.1	I-Premise
to	I-Premise
5.4	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
[F((1,83))	I-Premise
=	I-Premise
14.7,	I-Premise
P	I-Premise
<	I-Premise
0.05].	I-Premise

A	B-Premise
similar	I-Premise
change	I-Premise
was	I-Premise
seen	I-Premise
for	I-Premise
mean	I-Premise
anxiety	I-Premise
scores:	I-Premise
intervention	I-Premise
11.1	I-Premise
to	I-Premise
8.2,	I-Premise
control	I-Premise
9.6	I-Premise
to	I-Premise
9.3	I-Premise
[F((1,84))	I-Premise
=	I-Premise
17.8,	I-Premise
P	I-Premise
<	I-Premise
0.05].	I-Premise

Psychological	B-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
also	I-Premise
improved	I-Premise
more	I-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
group,	I-Premise
from	I-Premise
49.6	I-Premise
to	I-Premise
61.2	I-Premise
vs.	I-Premise
50.1	I-Premise
to	I-Premise
51.5	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
[F((1,84))	I-Premise
=	I-Premise
10.9,	I-Premise
P	I-Premise
<	I-Premise
0.05].	I-Premise

Laser	B-Claim
treatment	I-Claim
appeared	I-Claim
to	I-Claim
reduce	I-Claim
the	I-Claim
severity	I-Claim
of	I-Claim
facial	I-Claim
hair	I-Claim
and	I-Claim
time	I-Claim
spent	I-Claim
on	I-Claim
hair	I-Claim
removal	I-Claim
as	I-Claim
well	I-Claim
as	I-Claim
alleviating	I-Claim
depression	I-Claim
and	I-Claim
anxiety	I-Claim
in	I-Claim
women	I-Claim
with	I-Claim
PCOS.	I-Claim

These	B-Claim
findings	I-Claim
suggest	I-Claim
that	I-Claim
ways	I-Claim
of	I-Claim
making	I-Claim
this	I-Claim
method	I-Claim
of	I-Claim
hair	I-Claim
removal	I-Claim
more	I-Claim
widely	I-Claim
available	I-Claim
to	I-Claim
women	I-Claim
with	I-Claim
facial	I-Claim
hirsutism	I-Claim
should	I-Claim
be	I-Claim
considered.	I-Claim

For	B-Claim
patients	I-Claim
with	I-Claim
anthracycline-pretreated	I-Claim
metastatic	I-Claim
breast	I-Claim
carcinoma,	I-Claim
capecitabine	I-Claim
plus	I-Claim
docetaxel	I-Claim
significantly	I-Claim
increased	I-Claim
overall	I-Claim
survival	I-Claim
compared	I-Claim
with	I-Claim
docetaxel	I-Claim
alone.	I-Claim

The	O
current	O
study	O
evaluated	O
the	O
cost-effectiveness	O
of	O
the	O
capecitabine/docetaxel	O
combination	O
versus	O
docetaxel	O
monotherapy,	O
comparing	O
the	O
gain	O
in	O
quality-adjusted	O
survival	O
with	O
associated	O
health	O
care	O
costs.	O

Patients	O
were	O
randomized	O
to	O
receive	O
21-day	O
cycles	O
of	O
oral	O
capecitabine	O
1250	O
mg/m2	O
twice	O
daily,	O
on	O
Days	O
1-14,	O
plus	O
docetaxel	O
75	O
mg/m2	O
Day	O
1	O
(n	O
=	O
255),	O
or	O
docetaxel	O
100	O
mg/m2	O
on	O
Day	O
1	O
(n	O
=	O
256).	O

Health	O
and	O
cost	O
outcomes	O
in	O
the	O
two	O
arms	O
were	O
compared,	O
and	O
cost-effectiveness	O
was	O
estimated.	O

Data	O
on	O
survival	O
time	O
and	O
medical	O
care	O
resource	O
use	O
were	O
prospectively	O
collected	O
in	O
the	O
trial.	O

Costs	O
associated	O
with	O
medical	O
care	O
resource	O
use	O
and	O
quality-of-life	O
adjustments	O
were	O
obtained	O
from	O
the	O
published	O
literature.	O

The	O
incremental	O
cost-effectiveness	O
ratio	O
was	O
calculated	O
as	O
the	O
cost	O
per	O
quality-adjusted	O
life	O
year	O
(QALY)	O
gained.	O

Capecitabine/docetaxel	B-Premise
increased	I-Premise
the	I-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
by	I-Premise
3	I-Premise
months	I-Premise
compared	I-Premise
with	I-Premise
docetaxel	I-Premise
alone	I-Premise
(14.5	I-Premise
vs.	I-Premise
11.5	I-Premise
months).	I-Premise

The	B-Premise
mean	I-Premise
quality-adjusted	I-Premise
survival	I-Premise
was	I-Premise
increased	I-Premise
by	I-Premise
1.8	I-Premise
months	I-Premise
in	I-Premise
the	I-Premise
capecitabine/docetaxel	I-Premise
group.	I-Premise

The	B-Premise
total	I-Premise
medical-resource	I-Premise
utilization	I-Premise
cost	I-Premise
per	I-Premise
patient	I-Premise
was	I-Premise
8.9%	I-Premise
higher	I-Premise
with	I-Premise
the	I-Premise
combination:	I-Premise
24,475	I-Premise
dollars	I-Premise
for	I-Premise
combination	I-Premise
therapy	I-Premise
versus	I-Premise
22,477	I-Premise
dollars	I-Premise
for	I-Premise
single-agent	I-Premise
docetaxel.	I-Premise

The	B-Premise
mean	I-Premise
cost	I-Premise
per	I-Premise
QALY	I-Premise
gained	I-Premise
with	I-Premise
combination	I-Premise
therapy	I-Premise
was	I-Premise
13,558	I-Premise
dollars	I-Premise
(standard	I-Premise
deviation,	I-Premise
6742	I-Premise
dollars).	I-Premise

Cost	B-Premise
savings	I-Premise
due	I-Premise
to	I-Premise
reduced	I-Premise
docetaxel	I-Premise
dose	I-Premise
and	I-Premise
hospital	I-Premise
use	I-Premise
were	I-Premise
the	I-Premise
major	I-Premise
cost	I-Premise
offsets	I-Premise
with	I-Premise
the	I-Premise
combination.	I-Premise

Sensitivity	B-Premise
analyses	I-Premise
showed	I-Premise
that	I-Premise
varying	I-Premise
the	I-Premise
mean	I-Premise
hospital	I-Premise
cost	I-Premise
per	I-Premise
day	I-Premise
from	I-Premise
the	I-Premise
5th	I-Premise
to	I-Premise
the	I-Premise
95th	I-Premise
percentile	I-Premise
resulted	I-Premise
in	I-Premise
cost-utility	I-Premise
ratios	I-Premise
ranging	I-Premise
from	I-Premise
20,326	I-Premise
dollars	I-Premise
to	I-Premise
as	I-Premise
low	I-Premise
as	I-Premise
6360	I-Premise
dollars.	I-Premise

Capecitabine/docetaxel	B-Claim
was	I-Claim
a	I-Claim
cost-effective	I-Claim
treatment	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
anthracycline-pretreated	I-Claim
advanced	I-Claim
breast	I-Claim
carcinoma,	I-Claim
and	I-Claim
had	I-Claim
an	I-Claim
incremental	I-Claim
cost-effectiveness	I-Claim
ratio	I-Claim
that	I-Claim
compares	I-Claim
very	I-Claim
favorably	I-Claim
with	I-Claim
that	I-Claim
of	I-Claim
many	I-Claim
other	I-Claim
oncology	I-Claim
therapies.	I-Claim

We	O
aimed	O
to	O
determine	O
the	O
effect	O
of	O
dietary	O
counseling	O
or	O
oral	O
supplements	O
on	O
outcome	O
for	O
patients	O
with	O
cancer,	O
specifically,	O
nutritional	O
outcome,	O
morbidity,	O
and	O
quality	O
of	O
life	O
(QOL),	O
during	O
and	O
3	O
months	O
after	O
radiotherapy.	O

Seventy-five	O
patients	O
with	O
head	O
and	O
neck	O
cancer	O
who	O
were	O
referred	O
for	O
radiotherapy	O
(RT)	O
were	O
randomized	O
to	O
the	O
following	O
groups:	O
group	O
1	O
(n	O
=	O
25),	O
patients	O
who	O
received	O
dietary	O
counseling	O
with	O
regular	O
foods;	O
group	O
2	O
(n	O
=	O
25),	O
patients	O
who	O
maintained	O
usual	O
diet	O
plus	O
supplements;	O
and	O
group	O
3	O
(n	O
=	O
25),	O
patients	O
who	O
maintained	O
intake	O
ad	O
lib.	O

Nutritional	O
intake	O
(determined	O
by	O
diet	O
history)	O
and	O
status	O
(determined	O
by	O
Ottery's	O
Subjective	O
Global	O
Assessment),	O
and	O
QOL	O
(determined	O
by	O
the	O
European	O
Organization	O
for	O
the	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
version	O
3.0	O
[EORTC	O
QLQ-C30])	O
were	O
evaluated	O
at	O
baseline,	O
at	O
the	O
end	O
of	O
RT,	O
and	O
at	O
3	O
months.	O

Energy	B-Premise
intake	I-Premise
after	I-Premise
RT	I-Premise
increased	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
1	I-Premise
and	I-Premise
2	I-Premise
(p	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
.05).	I-Premise

Protein	B-Premise
intake	I-Premise
also	I-Premise
increased	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
1	I-Premise
and	I-Premise
2	I-Premise
(p	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
.006).	I-Premise

Both	B-Premise
energy	I-Premise
and	I-Premise
protein	I-Premise
intake	I-Premise
decreased	I-Premise
significantly	I-Premise
in	I-Premise
group	I-Premise
3	I-Premise
(p	I-Premise
<	I-Premise
.01).	I-Premise

At	B-Premise
3	I-Premise
months,	I-Premise
group	I-Premise
1	I-Premise
maintained	I-Premise
intakes,	I-Premise
whereas	I-Premise
groups	I-Premise
2	I-Premise
and	I-Premise
3	I-Premise
returned	I-Premise
to	I-Premise
or	I-Premise
below	I-Premise
baseline	I-Premise
levels.	I-Premise

After	B-Premise
RT,	I-Premise
>90%	I-Premise
of	I-Premise
patients	I-Premise
experienced	I-Premise
RT	I-Premise
toxicity;	I-Premise
this	B-Premise
was	I-Premise
not	I-Premise
significantly	I-Premise
different	I-Premise
between	I-Premise
groups,	I-Premise
with	I-Premise
a	I-Premise
trend	I-Premise
for	I-Premise
reduced	I-Premise
symptomatology	I-Premise
in	I-Premise
group	I-Premise
1	I-Premise
versus	I-Premise
group	I-Premise
2/group	I-Premise
3	I-Premise
(p	I-Premise
<	I-Premise
.07).	I-Premise

At	B-Premise
3	I-Premise
months,	I-Premise
the	I-Premise
reduction	I-Premise
of	I-Premise
incidence/severity	I-Premise
of	I-Premise
grade	I-Premise
1+2	I-Premise
anorexia,	I-Premise
nausea/vomiting,	I-Premise
xerostomia,	I-Premise
and	I-Premise
dysgeusia	I-Premise
was	I-Premise
different:	I-Premise
90%	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
improved	I-Premise
in	I-Premise
group	I-Premise
1	I-Premise
versus	I-Premise
67%	I-Premise
in	I-Premise
group	I-Premise
2	I-Premise
versus	I-Premise
51%	I-Premise
in	I-Premise
group	I-Premise
3	I-Premise
(p	I-Premise
<	I-Premise
.0001).	I-Premise

After	B-Premise
RT,	I-Premise
QOL	I-Premise
function	I-Premise
scores	I-Premise
improved	I-Premise
(p	I-Premise
<	I-Premise
.003)	I-Premise
proportionally	I-Premise
with	I-Premise
improved	I-Premise
nutritional	I-Premise
intake	I-Premise
and	I-Premise
status	I-Premise
in	I-Premise
group	I-Premise
1/group	I-Premise
2	I-Premise
(p	I-Premise
<	I-Premise
.05)	I-Premise
and	I-Premise
worsened	I-Premise
in	I-Premise
group	I-Premise
3	I-Premise
(p	I-Premise
<	I-Premise
.05);	I-Premise
at	B-Premise
3	I-Premise
months,	I-Premise
patients	I-Premise
in	I-Premise
group	I-Premise
1	I-Premise
maintained	I-Premise
or	I-Premise
improved	I-Premise
overall	I-Premise
QOL,	I-Premise
whereas	I-Premise
patients	I-Premise
in	I-Premise
groups	I-Premise
2	I-Premise
and	I-Premise
3	I-Premise
maintained	I-Premise
or	I-Premise
worsened	I-Premise
overall	I-Premise
QOL.	I-Premise

During	B-Claim
RT,	I-Claim
nutritional	I-Claim
interventions	I-Claim
positively	I-Claim
influenced	I-Claim
outcomes,	I-Claim
and	I-Claim
counseling	I-Claim
was	I-Claim
of	I-Claim
similar/higher	I-Claim
benefit;	I-Claim
in	B-Claim
the	I-Claim
medium	I-Claim
term,	I-Claim
only	I-Claim
counseling	I-Claim
exerted	I-Claim
a	I-Claim
significant	I-Claim
impact	I-Claim
on	I-Claim
patient	I-Claim
outcomes.	I-Claim

This	O
is	O
a	O
randomized	O
phase	O
II	O
study	O
designed	O
to	O
compare	O
the	O
toxicity	O
profile	O
of	O
a	O
non-platinum-based	O
with	O
a	O
platinum-based	O
regimen	O
in	O
the	O
treatment	O
of	O
advanced	O
non-small	O
cell	O
lung	O
cancer.	O

Eighty-nine	O
chemotherapy-nave	O
patients	O
were	O
randomized	O
either	O
to	O
gemcitabine	O
(1,000	O
mg/m2,	O
30-min	O
infusion	O
on	O
days	O
1,	O
8	O
and	O
15)	O
and	O
oral	O
etoposide	O
(50	O
mg,	O
days	O
1-14;	O
GE	O
group)	O
or	O
gemcitabine	O
at	O
the	O
same	O
schedule	O
and	O
cisplatin	O
(75	O
mg/m2	O
on	O
day	O
15;	O
GP	O
group).	O

The	O
primary	O
endpoint	O
is	O
toxicity,	O
and	O
secondary	O
endpoints	O
include	O
response	O
rate,	O
survival	O
outcome	O
and	O
quality	O
of	O
life	O
(QOL).	O

The	B-Premise
incidence	I-Premise
of	I-Premise
WHO	I-Premise
grade	I-Premise
3	I-Premise
or	I-Premise
4	I-Premise
anemia,	I-Premise
neutropenia	I-Premise
and	I-Premise
thrombocytopenia	I-Premise
was	I-Premise
29,	I-Premise
44	I-Premise
and	I-Premise
22%	I-Premise
(GE	I-Premise
group),	I-Premise
and	I-Premise
28,	I-Premise
49	I-Premise
and	I-Premise
23%	I-Premise
(GP	I-Premise
group),	I-Premise
respectively	I-Premise
(p	I-Premise
=	I-Premise
0.75,	I-Premise
0.95	I-Premise
and	I-Premise
0.87,	I-Premise
respectively).	I-Premise

The	B-Premise
rate	I-Premise
of	I-Premise
grade	I-Premise
2	I-Premise
or	I-Premise
above	I-Premise
nausea	I-Premise
was	I-Premise
numerically	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
GP	I-Premise
arm,	I-Premise
but	B-Premise
the	I-Premise
difference	I-Premise
was	I-Premise
not	I-Premise
statistically	I-Premise
significant	I-Premise
(GE	I-Premise
15.5%,	I-Premise
GP	I-Premise
27.7%,	I-Premise
p	I-Premise
=	I-Premise
0.20).	I-Premise

The	B-Premise
rate	I-Premise
of	I-Premise
vomiting	I-Premise
in	I-Premise
the	I-Premise
GE	I-Premise
and	I-Premise
GP	I-Premise
arms	I-Premise
was	I-Premise
20.0	I-Premise
and	I-Premise
20.5%,	I-Premise
respectively	I-Premise
(p	I-Premise
=	I-Premise
0.96).	I-Premise

However,	B-Premise
subjective	I-Premise
changes	I-Premise
in	I-Premise
QOL	I-Premise
scores	I-Premise
on	I-Premise
nausea	I-Premise
and	I-Premise
vomiting	I-Premise
were	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
GP	I-Premise
arm	I-Premise
(p	I-Premise
=	I-Premise
0.001).	I-Premise

Other	B-Premise
symptoms	I-Premise
including	I-Premise
sore	I-Premise
mouth	I-Premise
and	I-Premise
hair	I-Premise
loss	I-Premise
were	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
GE	I-Premise
arm	I-Premise
(p	I-Premise
=	I-Premise
0.003	I-Premise
and	I-Premise
0.007,	I-Premise
respectively).	I-Premise

There	B-Premise
were	I-Premise
also	I-Premise
significant	I-Premise
differences	I-Premise
observed	I-Premise
in	I-Premise
emotional	I-Premise
(p	I-Premise
=	I-Premise
0.014),	I-Premise
cognitive	I-Premise
(p	I-Premise
=	I-Premise
0.028)	I-Premise
and	I-Premise
social	I-Premise
functioning	I-Premise
(p	I-Premise
=	I-Premise
0.034)	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
GP.	I-Premise

The	B-Premise
differences	I-Premise
in	I-Premise
tumor	I-Premise
response	I-Premise
(35.5	I-Premise
and	I-Premise
46.5%	I-Premise
for	I-Premise
GE	I-Premise
and	I-Premise
GP,	I-Premise
respectively)	I-Premise
were	I-Premise
not	I-Premise
significantly	I-Premise
different.	I-Premise

Median	B-Premise
time	I-Premise
to	I-Premise
disease	I-Premise
progression	I-Premise
(33.8	I-Premise
and	I-Premise
40.7	I-Premise
weeks,	I-Premise
respectively)	I-Premise
and	I-Premise
overall	I-Premise
survival	I-Premise
(41.4	I-Premise
and	I-Premise
57.3	I-Premise
weeks,	I-Premise
respectively)	I-Premise
were	I-Premise
of	I-Premise
borderline	I-Premise
significance	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
the	I-Premise
GP	I-Premise
arm	I-Premise
(p	I-Premise
=	I-Premise
0.055).	I-Premise

This	B-Claim
toxicity	I-Claim
profile	I-Claim
of	I-Claim
GE	I-Claim
is	I-Claim
similar	I-Claim
to	I-Claim
GP,	I-Claim
but	B-Claim
the	I-Claim
apparent	I-Claim
inferior	I-Claim
efficacy	I-Claim
may	I-Claim
discourage	I-Claim
further	I-Claim
investigation.	I-Claim

A	O
multidimensional	O
rehabilitation	O
program	O
for	O
cancer	O
survivors	O
was	O
developed	O
to	O
overcome	O
cancer-related	O
problems	O
and	O
to	O
improve	O
quality	O
of	O
life.	O

The	O
two	O
purposes	O
of	O
the	O
study	O
were	O
to	O
describe	O
the	O
effectiveness	O
of	O
the	O
program	O
and	O
to	O
obtain	O
information	O
about	O
patient	O
preferences	O
for	O
multi	O
or	O
mono	O
dimensional	O
rehabilitation	O
programs.	O
cancer	O
survivors	O
with	O
different	O
diagnoses,	O
and	O
cancer-related	O
physical	O
and	O
psychosocial	O
problems.	O

a	O
15-week	O
rehabilitation	O
program	O
including	O
individual	O
exercise,	O
sports,	O
psycho-education,	O
and	O
information.	O

Group-wise	O
randomization	O
was	O
implemented	O
by	O
assigning	O
one	O
half	O
of	O
the	O
patients	O
to	O
the	O
complete	O
program	O
while	O
the	O
other	O
half	O
were	O
allowed	O
to	O
choose	O
which	O
program	O
components	O
they	O
considered	O
relevant.	O

Health-Related	O
Quality	O
of	O
Life	O
[RAND-36	O
and	O
Rotterdam	O
Symptom	O
Check	O
List	O
(RSCL)],	O
exercise	O
capacity	O
(symptom	O
limited	O
bicycle	O
ergometry),	O
muscle	O
force	O
(hand-held	O
dynamometry),	O
and	O
patient	O
preferences.	O

Measurements	O
were	O
performed	O
before	O
(T0)	O
and	O
after	O
the	O
rehabilitation	O
program	O
(T1),	O
and	O
at	O
a	O
3-month	O
follow-up	O
(T2).	O

After	B-Premise
the	I-Premise
rehabilitation	I-Premise
program,	I-Premise
cancer	I-Premise
survivors	I-Premise
(n=63)	I-Premise
displayed	I-Premise
statistically	I-Premise
significant	I-Premise
improvements	I-Premise
on	I-Premise
health-related	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
with	I-Premise
effect	I-Premise
sizes	I-Premise
(ES)	I-Premise
varying	I-Premise
from	I-Premise
0.38	I-Premise
to	I-Premise
0.99	I-Premise
(RAND-36)	I-Premise
and	I-Premise
from	I-Premise
-0.34	I-Premise
to	I-Premise
-0.57	I-Premise
(RSCL),	I-Premise
most	I-Premise
persistent	I-Premise
at	I-Premise
3-month	I-Premise
follow-up.	I-Premise

Furthermore,	B-Premise
statistically	I-Premise
significant	I-Premise
improvements	I-Premise
in	I-Premise
exercise	I-Premise
capacity	I-Premise
and	I-Premise
muscle	I-Premise
force	I-Premise
of	I-Premise
upper	I-Premise
and	I-Premise
lower	I-Premise
extremities	I-Premise
were	I-Premise
displayed	I-Premise
after	I-Premise
rehabilitation.	I-Premise

If	B-Premise
offered	I-Premise
a	I-Premise
choice,	I-Premise
80%	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
prior	I-Premise
to	I-Premise
start	I-Premise
and	I-Premise
58%	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
after	I-Premise
completion	I-Premise
of	I-Premise
the	I-Premise
program	I-Premise
indicated	I-Premise
that	I-Premise
they	I-Premise
preferred	I-Premise
the	I-Premise
entire	I-Premise
multidimensional	I-Premise
program.	I-Premise

A	B-Claim
multidimensional	I-Claim
rehabilitation	I-Claim
program	I-Claim
has	I-Claim
statistically	I-Claim
and	I-Claim
clinically	I-Claim
relevant	I-Claim
beneficial	I-Claim
effects	I-Claim
on	I-Claim
health-related	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
exercise	I-Claim
capacity,	I-Claim
and	I-Claim
muscle	I-Claim
force	I-Claim
in	I-Claim
cancer	I-Claim
patients	I-Claim
with	I-Claim
different	I-Claim
diagnoses.	I-Claim

Furthermore,	O
if	B-Claim
offered	I-Claim
the	I-Claim
choice,	I-Claim
the	I-Claim
majority	I-Claim
of	I-Claim
cancer	I-Claim
survivors	I-Claim
seem	I-Claim
to	I-Claim
prefer	I-Claim
multidimensional	I-Claim
programs	I-Claim
to	I-Claim
programs	I-Claim
with	I-Claim
only	I-Claim
one	I-Claim
component.	I-Claim

Evidence	B-Claim
suggests	I-Claim
that	I-Claim
the	I-Claim
re-entry	I-Claim
phase	I-Claim
(ie,	I-Claim
early	I-Claim
period	I-Claim
after	I-Claim
medical	I-Claim
treatment	I-Claim
completion)	I-Claim
presents	I-Claim
distinct	I-Claim
challenges	I-Claim
for	I-Claim
cancer	I-Claim
patients.	I-Claim

To	O
facilitate	O
the	O
transition	O
to	O
recovery,	O
we	O
conducted	O
the	O
Moving	O
Beyond	O
Cancer	O
(MBC)	O
trial,	O
a	O
multisite,	O
randomized,	O
controlled	O
trial	O
of	O
psychoeducational	O
interventions	O
for	O
breast	O
cancer	O
patients.	O

Breast	O
cancer	O
patients	O
were	O
registered	O
within	O
6	O
weeks	O
after	O
surgery.	O

After	O
medical	O
treatment,	O
they	O
completed	O
baseline	O
measures	O
and	O
were	O
randomly	O
assigned	O
to	O
standard	O
National	O
Cancer	O
Institute	O
print	O
material	O
(CTL);	O
standard	O
print	O
material	O
and	O
peer-modeling	O
videotape	O
(VID);	O
or	O
standard	O
print	O
material,	O
videotape,	O
two	O
sessions	O
with	O
a	O
trained	O
cancer	O
educator,	O
and	O
informational	O
workbook	O
(EDU).	O

Two	O
primary	O
end	O
points	O
were	O
examined:	O
energy/fatigue	O
and	O
cancer-specific	O
distress.	O

Secondary	O
end	O
points	O
were	O
depressive	O
symptoms	O
and	O
post-traumatic	O
growth.	O

Perceived	O
preparedness	O
for	O
re-entry	O
was	O
analyzed	O
as	O
a	O
moderator	O
of	O
effects.	O

Of	O
558	O
women	O
randomly	O
assigned	O
to	O
treatment,	O
418	O
completed	O
the	O
6-month	O
assessment	O
and	O
399	O
completed	O
the	O
12-month	O
assessment.	O

In	B-Premise
analyses	I-Premise
controlling	I-Premise
for	I-Premise
study	I-Premise
site	I-Premise
and	I-Premise
baseline	I-Premise
depressive	I-Premise
symptoms,	I-Premise
VID	I-Premise
produced	I-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
energy/fatigue	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
relative	I-Premise
to	I-Premise
CTL,	I-Premise
particularly	I-Premise
among	I-Premise
women	I-Premise
who	I-Premise
felt	I-Premise
less	I-Premise
prepared	I-Premise
for	I-Premise
re-entry	I-Premise
at	I-Premise
baseline.	I-Premise

No	B-Premise
significant	I-Premise
main	I-Premise
effect	I-Premise
of	I-Premise
the	I-Premise
interventions	I-Premise
emerged	I-Premise
on	I-Premise
cancer-specific	I-Premise
distress,	I-Premise
but	B-Premise
EDU	I-Premise
prompted	I-Premise
greater	I-Premise
reduction	I-Premise
in	I-Premise
this	I-Premise
outcome	I-Premise
relative	I-Premise
to	I-Premise
CTL	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
for	I-Premise
patients	I-Premise
who	I-Premise
felt	I-Premise
more	I-Premise
prepared	I-Premise
for	I-Premise
re-entry.	I-Premise

Between-group	B-Premise
differences	I-Premise
in	I-Premise
the	I-Premise
primary	I-Premise
outcomes	I-Premise
were	I-Premise
not	I-Premise
significant	I-Premise
at	I-Premise
12	I-Premise
months,	I-Premise
and	B-Premise
no	I-Premise
significant	I-Premise
effects	I-Premise
emerged	I-Premise
on	I-Premise
the	I-Premise
secondary	I-Premise
end	I-Premise
points.	I-Premise

A	B-Claim
peer-modeling	I-Claim
videotape	I-Claim
can	I-Claim
accelerate	I-Claim
the	I-Claim
recovery	I-Claim
of	I-Claim
energy	I-Claim
during	I-Claim
the	I-Claim
re-entry	I-Claim
phase	I-Claim
in	I-Claim
women	I-Claim
treated	I-Claim
for	I-Claim
breast	I-Claim
cancer,	I-Claim
particularly	I-Claim
among	I-Claim
those	I-Claim
who	I-Claim
feel	I-Claim
less	I-Claim
prepared	I-Claim
for	I-Claim
re-entry.	I-Claim

To	O
evaluate	O
the	O
efficacy	O
of	O
a	O
psychoeducational	O
intervention	O
in	O
improving	O
cancer-related	O
fatigue.	O

This	O
randomized	O
controlled	O
trial	O
involved	O
109	O
women	O
commencing	O
adjuvant	O
chemotherapy	O
for	O
stage	O
I	O
or	O
II	O
breast	O
cancer	O
in	O
five	O
chemotherapy	O
treatment	O
centers.	O

Intervention	O
group	O
patients	O
received	O
an	O
individualized	O
fatigue	O
education	O
and	O
support	O
program	O
delivered	O
in	O
the	O
clinic	O
and	O
by	O
phone	O
over	O
three	O
10-	O
to	O
20-minute	O
sessions	O
1	O
week	O
apart.	O

Instruments	O
included	O
a	O
numeric	O
rating	O
scale	O
assessing	O
confidence	O
with	O
managing	O
fatigue;	O
11-point	O
numeric	O
rating	O
scales	O
measuring	O
fatigue	O
at	O
worst,	O
average,	O
and	O
best;	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Fatigue	O
and	O
Piper	O
Fatigue	O
Scales;	O
the	O
Cancer	O
Self-Efficacy	O
Scale;	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
C30;	O
and	O
the	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale.	O

For	O
each	O
outcome,	O
separate	O
analyses	O
of	O
covariance	O
of	O
change	O
scores	O
between	O
baseline	O
(T1)	O
and	O
the	O
three	O
follow-up	O
time	O
points	O
(T2,	O
T3,	O
and	O
T4)	O
were	O
conducted,	O
controlling	O
for	O
the	O
variable's	O
corresponding	O
baseline	O
value.	O

Compared	B-Premise
with	I-Premise
the	I-Premise
intervention	I-Premise
group,	I-Premise
mean	I-Premise
difference	I-Premise
scores	I-Premise
between	I-Premise
the	I-Premise
baseline	I-Premise
(T1)	I-Premise
and	I-Premise
immediate	I-Premise
after	I-Premise
the	I-Premise
test	I-Premise
(T2)	I-Premise
assessments	I-Premise
increased	I-Premise
significantly	I-Premise
more	I-Premise
for	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
for	I-Premise
worst	I-Premise
and	I-Premise
average	I-Premise
fatigue,	I-Premise
Functional	I-Premise
Assessment	I-Premise
of	I-Premise
Cancer	I-Premise
Therapy-Fatigue,	I-Premise
and	I-Premise
Piper	I-Premise
fatigue	I-Premise
severity	I-Premise
and	I-Premise
interference	I-Premise
measures.	I-Premise

These	B-Premise
differences	I-Premise
were	I-Premise
not	I-Premise
observed	I-Premise
between	I-Premise
baseline	I-Premise
and	I-Premise
T3	I-Premise
and	I-Premise
T4	I-Premise
assessments.	I-Premise

No	B-Premise
significant	I-Premise
differences	I-Premise
were	I-Premise
identified	I-Premise
for	I-Premise
any	I-Premise
pre-	I-Premise
or	I-Premise
post-test	I-Premise
change	I-Premise
scores	I-Premise
for	I-Premise
confidence	I-Premise
with	I-Premise
managing	I-Premise
fatigue,	I-Premise
cancer	I-Premise
self-efficacy,	I-Premise
anxiety,	I-Premise
depression,	I-Premise
or	I-Premise
quality	I-Premise
of	I-Premise
life.	I-Premise

Preparatory	B-Claim
education	I-Claim
and	I-Claim
support	I-Claim
has	I-Claim
the	I-Claim
potential	I-Claim
to	I-Claim
assist	I-Claim
women	I-Claim
to	I-Claim
cope	I-Claim
with	I-Claim
cancer-related	I-Claim
fatigue	I-Claim
in	I-Claim
the	I-Claim
short	I-Claim
term.	I-Claim

However,	B-Claim
further	I-Claim
research	I-Claim
is	I-Claim
needed	I-Claim
to	I-Claim
identify	I-Claim
ways	I-Claim
to	I-Claim
improve	I-Claim
the	I-Claim
potency	I-Claim
and	I-Claim
sustainability	I-Claim
of	I-Claim
psychoeducational	I-Claim
interventions	I-Claim
for	I-Claim
managing	I-Claim
cancer-related	I-Claim
fatigue.	I-Claim

To	O
evaluate	O
the	O
impact	O
of	O
letrozole	O
compared	O
with	O
placebo	O
after	O
adjuvant	O
tamoxifen	O
on	O
quality	O
of	O
life	O
(QOL)	O
in	O
the	O
MA.17	O
trial.	O

Patients	O
completed	O
the	O
Short	O
Form	O
36-item	O
Health	O
Survey	O
(SF-36)	O
and	O
the	O
Menopause	O
Specific	O
Quality	O
of	O
Life	O
Questionnaire	O
(MENQOL)	O
at	O
baseline,	O
6	O
months,	O
and	O
annually.	O

Mean	O
change	O
scores	O
from	O
baseline	O
were	O
compared	O
between	O
groups	O
for	O
summary	O
measures	O
and	O
domains.	O

A	O
response	O
analysis	O
compared	O
the	O
proportion	O
of	O
patients	O
who	O
demonstrated	O
an	O
important	O
change	O
in	O
QOL.	O

Of	O
5,187	O
randomly	O
assigned	O
women	O
in	O
the	O
trial,	O
3,612	O
(69.9%)	O
participated	O
in	O
the	O
QOL	O
substudy:	O
1,799	O
were	O
allocated	O
to	O
placebo	O
and	O
1,813	O
were	O
allocated	O
to	O
letrozole.	O

No	B-Premise
differences	I-Premise
were	I-Premise
seen	I-Premise
between	I-Premise
groups	I-Premise
in	I-Premise
mean	I-Premise
change	I-Premise
scores	I-Premise
from	I-Premise
baseline	I-Premise
for	I-Premise
the	I-Premise
SF-36	I-Premise
physical	I-Premise
and	I-Premise
mental	I-Premise
component	I-Premise
summary	I-Premise
scores	I-Premise
at	I-Premise
6,	I-Premise
12,	I-Premise
24,	I-Premise
and	I-Premise
36	I-Premise
months.	I-Premise

Small	B-Premise
(<	I-Premise
0.2	I-Premise
standard	I-Premise
deviations)	I-Premise
but	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
mean	I-Premise
change	I-Premise
scores	I-Premise
from	I-Premise
baseline	I-Premise
were	I-Premise
seen	I-Premise
for	I-Premise
the	I-Premise
SF-36	I-Premise
domains	I-Premise
of	I-Premise
physical	I-Premise
functioning	I-Premise
(12	I-Premise
months),	I-Premise
bodily	I-Premise
pain	I-Premise
(6	I-Premise
months)	I-Premise
and	I-Premise
vitality	I-Premise
(6	I-Premise
and	I-Premise
12	I-Premise
months),	I-Premise
and	I-Premise
the	I-Premise
MENQOL	I-Premise
vasomotor	I-Premise
(6,	I-Premise
12,	I-Premise
and	I-Premise
24	I-Premise
months)	I-Premise
and	I-Premise
sexual	I-Premise
domains	I-Premise
(12	I-Premise
and	I-Premise
24	I-Premise
months).	I-Premise

On	B-Premise
the	I-Premise
response	I-Premise
analysis,	I-Premise
a	I-Premise
significant	I-Premise
difference	I-Premise
was	I-Premise
seen	I-Premise
between	I-Premise
groups	I-Premise
for	I-Premise
the	I-Premise
bodily	I-Premise
pain	I-Premise
domain	I-Premise
(percentage	I-Premise
of	I-Premise
patients	I-Premise
reporting	I-Premise
a	I-Premise
worsening	I-Premise
of	I-Premise
QOL,	I-Premise
47%	I-Premise
placebo	I-Premise
v	I-Premise
51%	I-Premise
letrozole;	I-Premise
P	I-Premise
=	I-Premise
.009)	I-Premise
and	I-Premise
the	I-Premise
vasomotor	I-Premise
domain	I-Premise
(22%	I-Premise
placebo	I-Premise
v	I-Premise
29%	I-Premise
letrozole;	I-Premise
P	I-Premise
=	I-Premise
.001).	I-Premise

Letrozole	B-Claim
did	I-Claim
not	I-Claim
have	I-Claim
an	I-Claim
adverse	I-Claim
impact	I-Claim
on	I-Claim
overall	I-Claim
QOL.	I-Claim

Small	B-Claim
effects	I-Claim
were	I-Claim
seen	I-Claim
in	I-Claim
some	I-Claim
domains	I-Claim
consistent	I-Claim
with	I-Claim
a	I-Claim
minority	I-Claim
of	I-Claim
patients	I-Claim
experiencing	I-Claim
changes	I-Claim
in	I-Claim
QOL	I-Claim
compatible	I-Claim
with	I-Claim
a	I-Claim
reduction	I-Claim
in	I-Claim
estrogen	I-Claim
synthesis.	I-Claim

This	O
study	O
is	O
the	O
first	O
large	O
prospective	O
RCT	O
of	O
sentinel	O
node	O
biopsy	O
(SNB)	O
compared	O
with	O
standard	O
axillary	O
treatment	O
(level	O
I-III	O
axillary	O
lymph	O
node	O
dissection	O
or	O
four	O
node	O
sampling),	O
which	O
includes	O
comprehensive	O
and	O
repeated	O
quality	O
of	O
life	O
(QOL)	O
assessments	O
over	O
18	O
months.	O

Patients	O
(n	O
=	O
829)	O
completed	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy	O
-	O
Breast	O
(FACT-B+4)	O
and	O
the	O
Spielberger	O
State/Trait	O
Anxiety	O
Inventory	O
(STAI)	O
at	O
baseline	O
(pre-surgery)	O
and	O
at	O
1,	O
3,	O
6,	O
12,	O
and	O
18	O
months	O
post-surgery.	O

There	B-Claim
were	I-Claim
significant	I-Claim
differences	I-Claim
between	I-Claim
treatment	I-Claim
groups	I-Claim
favouring	I-Claim
the	I-Claim
SNB	I-Claim
group	I-Claim
throughout	I-Claim
the	I-Claim
18	I-Claim
months	I-Claim
assessment.	I-Claim

Patients	B-Premise
in	I-Premise
the	I-Premise
standard	I-Premise
treatment	I-Premise
group	I-Premise
showed	I-Premise
a	I-Premise
greater	I-Premise
decline	I-Premise
in	I-Premise
Trial	I-Premise
Outcome	I-Premise
Index	I-Premise
(TOI)	I-Premise
scores	I-Premise
(physical	I-Premise
well-being,	I-Premise
functional	I-Premise
well-being	I-Premise
and	I-Premise
breast	I-Premise
cancer	I-Premise
concerns	I-Premise
subscales	I-Premise
in	I-Premise
FACT-B+4)	I-Premise
and	I-Premise
recovered	I-Premise
more	I-Premise
slowly	I-Premise
than	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
SNB	I-Premise
group	I-Premise
(p	I-Premise
<	I-Premise
0.01).	I-Premise

The	B-Premise
change	I-Premise
in	I-Premise
total	I-Premise
FACT-B+4	I-Premise
scores	I-Premise
(measuring	I-Premise
global	I-Premise
QOL)	I-Premise
closely	I-Premise
resembled	I-Premise
the	I-Premise
TOI	I-Premise
results.	I-Premise

18	B-Premise
months	I-Premise
post-surgery	I-Premise
approximately	I-Premise
twice	I-Premise
as	I-Premise
many	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
standard	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
SNB	I-Premise
group	I-Premise
reported	I-Premise
substantial	I-Premise
arm	I-Premise
swelling	I-Premise
(14%	I-Premise
versus	I-Premise
7%)	I-Premise
(p	I-Premise
=	I-Premise
0.002)	I-Premise
or	I-Premise
numbness	I-Premise
(19%	I-Premise
versus	I-Premise
8.7%)	I-Premise
(p	I-Premise
<	I-Premise
0.001).	I-Premise

Despite	O
the	O
uncertainty	O
about	O
undergoing	O
a	O
relatively	O
new	O
procedure	O
and	O
the	O
possible	O
need	O
for	O
further	O
surgery,	O
there	B-Premise
was	I-Premise
no	I-Premise
evidence	I-Premise
of	I-Premise
increased	I-Premise
anxiety	I-Premise
amongst	I-Premise
patients	I-Premise
randomised	I-Premise
to	I-Premise
SNB	I-Premise
(p	I-Premise
>	I-Premise
0.05).	I-Premise

For	B-Premise
6	I-Premise
months	I-Premise
post-surgery	I-Premise
younger	I-Premise
patients	I-Premise
reported	I-Premise
less	I-Premise
favourable	I-Premise
QOL	I-Premise
scores	I-Premise
(p	I-Premise
<	I-Premise
0.001)	I-Premise
and	I-Premise
greater	I-Premise
levels	I-Premise
of	I-Premise
anxiety	I-Premise
(p	I-Premise
<	I-Premise
0.01).	I-Premise

In	B-Claim
view	I-Claim
of	I-Claim
the	I-Claim
benefits	I-Claim
regarding	I-Claim
arm	I-Claim
functioning	I-Claim
and	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
the	I-Claim
data	I-Claim
from	I-Claim
this	I-Claim
randomised	I-Claim
study	I-Claim
support	I-Claim
the	I-Claim
use	I-Claim
of	I-Claim
SNB	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
clinically	I-Claim
node	I-Claim
negative	I-Claim
breast	I-Claim
cancer.	I-Claim

To	O
describe	O
the	O
Food	O
and	O
Drug	O
Administration	O
(FDA)	O
review	O
and	O
approval	O
of	O
erlotinib	O
(Tarceva,	O
OSI	O
Pharmaceuticals,	O
Melville,	O
NY)	O
for	O
treatment	O
of	O
patients	O
with	O
locally	O
advanced	O
or	O
metastatic	O
non-small	O
cell	O
lung	O
cancer	O
(NSCLC)	O
after	O
failure	O
of	O
at	O
least	O
one	O
prior	O
chemotherapy	O
regimen.	O

The	O
FDA	O
reviewed	O
raw	O
data	O
in	O
electronic	O
format	O
from	O
a	O
randomized	O
controlled	O
clinical	O
trial	O
comparing	O
erlotinib	O
with	O
placebo	O
in	O
patients	O
with	O
locally	O
advanced	O
or	O
metastatic	O
NSCLC	O
after	O
failure	O
of	O
at	O
least	O
one	O
prior	O
chemotherapy	O
regimen.	O

Patients	O
were	O
randomized	O
in	O
a	O
2:1	O
ratio	O
(erlotinib,	O
n	O
=	O
488	O
and	O
placebo,	O
n	O
=	O
243).	O

Erlotinib	B-Claim
was	I-Claim
superior	I-Claim
to	I-Claim
placebo	I-Claim
for	I-Claim
survival,	I-Claim
progression-free	I-Claim
survival,	I-Claim
and	I-Claim
tumor	I-Claim
response	I-Claim
rate.	I-Claim

Exploratory	B-Claim
analyses	I-Claim
indicate	I-Claim
that	I-Claim
epidermal	I-Claim
growth	I-Claim
factor	I-Claim
receptor	I-Claim
status	I-Claim
may	I-Claim
be	I-Claim
an	I-Claim
important	I-Claim
predictor	I-Claim
of	I-Claim
the	I-Claim
erlotinib	I-Claim
survival	I-Claim
effect.	I-Claim

Rash	B-Premise
(75%	I-Premise
versus	I-Premise
17%)	I-Premise
and	I-Premise
diarrhea	I-Premise
(54%	I-Premise
versus	I-Premise
18%)	I-Premise
in	I-Premise
the	I-Premise
erlotnib	I-Premise
and	I-Premise
placebo	I-Premise
group	I-Premise
respectively	I-Premise
were	I-Premise
the	I-Premise
most	I-Premise
common	I-Premise
adverse	I-Premise
events.	I-Premise

Severe	B-Premise
rash	I-Premise
occurred	I-Premise
in	I-Premise
9%	I-Premise
and	I-Premise
severe	I-Premise
diarrhea	I-Premise
in	I-Premise
6%	I-Premise
of	I-Premise
erlotinib-treated	I-Premise
patients	I-Premise
and	I-Premise
each	I-Premise
resulted	I-Premise
in	I-Premise
study	I-Premise
discontinuation	I-Premise
in	I-Premise
1%	I-Premise
of	I-Premise
patients.	I-Premise

Dose	B-Premise
reductions	I-Premise
were	I-Premise
required	I-Premise
for	I-Premise
10%	I-Premise
of	I-Premise
patients	I-Premise
with	I-Premise
rash	I-Premise
and	I-Premise
4%	I-Premise
of	I-Premise
patients	I-Premise
with	I-Premise
diarrhea.	I-Premise

On	O
November	O
18,	O
2004,	O
the	O
FDA	O
granted	O
erlotinib	O
regular	O
approval	O
for	O
treatment	O
of	O
patients	O
with	O
locally	O
advanced	O
or	O
metastatic	O
NSCLC	O
after	O
failure	O
of	O
at	O
least	O
one	O
prior	O
chemotherapy	O
regimen.	O

The	O
applicant	O
has	O
committed	O
to	O
conduct	O
post-marketing	O
clinical	O
trials	O
to	O
assess	O
further	O
the	O
effect	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
expression,	O
measured	O
with	O
immunohistochemical	O
staining,	O
on	O
erlotinib	O
treatment	O
effect.	O

Approximately	O
30%	O
of	O
lung	O
cancer	O
cases	O
are	O
diagnosed	O
in	O
patients	O
>	O
70	O
years	O
of	O
age.	O

Standard	B-Claim
chemotherapy	I-Claim
regimens	I-Claim
are	I-Claim
generally	I-Claim
considered	I-Claim
too	I-Claim
toxic	I-Claim
for	I-Claim
elderly	I-Claim
patients.	I-Claim

We	O
conducted	O
a	O
multicenter	O
phase	O
II	O
trial	O
to	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
carboplatin	O
combined	O
with	O
vinorelbine	O
every	O
4	O
weeks	O
as	O
first-line	O
treatment	O
for	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(NSCLC)	O
in	O
elderly	O
patients.	O

Patients	O
were	O
eligible	O
if	O
they	O
were	O
aged	O
>OR=	O
70	O
years,	O
had	O
stage	O
IIIB	O
(with	O
pleural	O
effusion)	O
or	O
stage	O
IV	O
NSCLC,	O
had	O
a	O
performance	O
status	O
of	O
0/1,	O
had	O
not	O
previously	O
received	O
chemotherapy,	O
and	O
had	O
normal	O
organ	O
function.	O

Forty	O
patients	O
(31	O
men	O
and	O
9	O
women)	O
were	O
enrolled	O
and	O
received	O
3-5	O
courses	O
of	O
treatment.	O

Median	O
age	O
was	O
72	O
years	O
(range,	O
70-82	O
years).	O

Eighty	O
percent	O
of	O
patients	O
had	O
stage	O
IV	O
NSCLC,	O
with	O
squamous	O
cell	O
(n=21),	O
adenocarcinoma	O
(n=12),	O
and	O
undifferentiated	O
(n=7)	O
histologies.	O

Forty	O
patients	O
were	O
assessable	O
for	O
toxicity	O
and	O
32	O
for	O
treatment	O
response.	O

Among	B-Premise
these	I-Premise
32	I-Premise
patients,	I-Premise
8	I-Premise
had	I-Premise
a	I-Premise
partial	I-Premise
response	I-Premise
(intent-to-treat	I-Premise
response	I-Premise
rate,	I-Premise
20%),	I-Premise
and	I-Premise
10	I-Premise
(25%)	I-Premise
had	I-Premise
stable	I-Premise
disease.	I-Premise

The	B-Premise
median	I-Premise
survival	I-Premise
was	I-Premise
7.8	I-Premise
months	I-Premise
(range,	I-Premise
4-11.6	I-Premise
months).	I-Premise

The	B-Premise
1-	I-Premise
and	I-Premise
2-year	I-Premise
survival	I-Premise
rates	I-Premise
were	I-Premise
25%	I-Premise
and	I-Premise
7%,	I-Premise
respectively;	I-Premise
median	B-Premise
time	I-Premise
to	I-Premise
progression	I-Premise
was	I-Premise
4.3	I-Premise
months	I-Premise
(range,	I-Premise
0.2-13.8	I-Premise
months).	I-Premise

Grade	B-Premise
3/4	I-Premise
neutropenia	I-Premise
was	I-Premise
seen	I-Premise
in	I-Premise
27	I-Premise
patients	I-Premise
(68%),	I-Premise
and	I-Premise
grade	I-Premise
3/4	I-Premise
anemia	I-Premise
was	I-Premise
seen	I-Premise
in	I-Premise
5	I-Premise
patients	I-Premise
(13%).	I-Premise

One	B-Premise
patient	I-Premise
died	I-Premise
of	I-Premise
febrile	I-Premise
neutropenia	I-Premise
during	I-Premise
treatment.	I-Premise

The	B-Premise
main	I-Premise
nonhematologic	I-Premise
adverse	I-Premise
effect	I-Premise
was	I-Premise
fatigue	I-Premise
(grade	I-Premise
3/4	I-Premise
in	I-Premise
18%	I-Premise
of	I-Premise
patients).	I-Premise

Carboplatin/vinorelbine	B-Claim
is	I-Claim
well	I-Claim
tolerated	I-Claim
by	I-Claim
elderly	I-Claim
patients	I-Claim
with	I-Claim
extensive-stage	I-Claim
NSCLC.	I-Claim

Efficacy	B-Claim
is	I-Claim
low	I-Claim
but	I-Claim
similar	I-Claim
to	I-Claim
that	I-Claim
of	I-Claim
other	I-Claim
treatments	I-Claim
used	I-Claim
in	I-Claim
this	I-Claim
setting.	I-Claim

On	O
March	O
15,	O
2005,	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
approved	O
temozolomide	O
(Temodar	O
capsules,	O
Schering-Plough	O
Research	O
Institute)	O
for	O
the	O
treatment	O
of	O
adult	O
patients	O
with	O
newly	O
diagnosed	O
glioblastoma	O
multiforme	O
concomitantly	O
with	O
radiotherapy	O
and	O
then	O
as	O
maintenance	O
treatment.	O

Five	O
hundred	O
seventy-three	O
glioblastoma	O
multiforme	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
temozolomide	O
+	O
radiotherapy	O
(n	O
=	O
287)	O
or	O
radiotherapy	O
alone	O
(n	O
=	O
286).	O

Patients	O
in	O
the	O
temozolomide	O
+	O
radiotherapy	O
arm	O
received	O
concomitant	O
temozolomide	O
(75	O
mg/m2)	O
once	O
daily	O
for	O
the	O
duration	O
of	O
radiation	O
therapy	O
(42-49	O
days).	O

This	O
was	O
followed,	O
4	O
weeks	O
later,	O
by	O
six	O
cycles	O
of	O
temozolomide,	O
150	O
or	O
200	O
mg/m2	O
daily	O
for	O
5	O
days,	O
every	O
4	O
weeks.	O

Patients	O
in	O
the	O
control	O
arm	O
received	O
radiotherapy	O
only.	O

In	O
both	O
arms,	O
radiotherapy	O
was	O
delivered	O
as	O
60	O
Gy/30	O
fractions	O
to	O
the	O
tumor	O
site	O
with	O
a	O
2	O
to	O
3	O
cm	O
margin.	O

Pneumocystis	O
carinii	O
pneumonia	O
prophylaxis	O
was	O
required	O
during	O
temozolomide	O
+	O
radiotherapy	O
treatment	O
and	O
was	O
continued	O
until	O
recovery	O
of	O
lymphocytopenia	O
(Common	O
Toxicity	O
Criteria	O
grade	O
<1).	O

At	O
disease	O
progression,	O
temozolomide	O
salvage	O
treatment	O
was	O
given	O
to	O
161	O
of	O
282	O
patients	O
(57%)	O
in	O
the	O
radiotherapy	O
alone	O
arm,	O
and	O
to	O
62	O
of	O
277	O
patients	O
(22%)	O
in	O
the	O
temozolomide	O
+	O
radiotherapy	O
arm.	O

Patients	B-Claim
receiving	I-Claim
concomitant	I-Claim
and	I-Claim
maintenance	I-Claim
temozolomide	I-Claim
+	I-Claim
radiotherapy	I-Claim
had	I-Claim
significantly	I-Claim
improved	I-Claim
overall	I-Claim
survival.	I-Claim

The	B-Premise
hazard	I-Premise
ratio	I-Premise
was	I-Premise
0.63	I-Premise
(95%	I-Premise
confidence	I-Premise
interval,	I-Premise
0.52-0.75;	I-Premise
log-rank,	I-Premise
P	I-Premise
<	I-Premise
0.0001).	I-Premise

Median	B-Premise
survival	I-Premise
was	I-Premise
14.6	I-Premise
months	I-Premise
(temozolomide	I-Premise
+	I-Premise
radiotherapy)	I-Premise
versus	I-Premise
12.1	I-Premise
months	I-Premise
(radiotherapy	I-Premise
alone).	I-Premise

Adverse	B-Claim
events	I-Claim
during	I-Claim
temozolomide	I-Claim
treatment	I-Claim
included	I-Claim
thrombocytopenia,	I-Claim
nausea,	I-Claim
vomiting,	I-Claim
anorexia,	I-Claim
constipation,	I-Claim
alopecia,	I-Claim
headache,	I-Claim
fatigue,	I-Claim
and	I-Claim
convulsions.	I-Claim

The	B-Claim
combination	I-Claim
of	I-Claim
interferon	I-Claim
alfa	I-Claim
(IFNalpha)	I-Claim
and	I-Claim
isotretinoin	I-Claim
has	I-Claim
shown	I-Claim
a	I-Claim
direct	I-Claim
antiproliferative	I-Claim
effect	I-Claim
on	I-Claim
human	I-Claim
melanoma	I-Claim
cell	I-Claim
lines,	I-Claim
but	B-Claim
it	I-Claim
remained	I-Claim
unclear	I-Claim
whether	I-Claim
this	I-Claim
combination	I-Claim
is	I-Claim
more	I-Claim
effective	I-Claim
than	I-Claim
IFNalpha	I-Claim
alone	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
metastatic	I-Claim
melanoma.	I-Claim

We	O
evaluated	O
safety	O
and	O
efficacy	O
of	O
IFNalpha	O
and	O
isotretinoin	O
compared	O
with	O
IFNalpha	O
alone	O
as	O
adjuvant	O
treatment	O
in	O
patients	O
with	O
primary	O
malignant	O
melanoma	O
stage	O
IIA	O
and	O
IIB.	O

In	O
a	O
prospective,	O
randomized,	O
double-blind,	O
placebo-controlled	O
trial,	O
407	O
melanoma	O
patients	O
in	O
stage	O
IIA	O
(301	O
patients)	O
and	O
IIB	O
(106	O
patients)	O
were	O
randomly	O
assigned	O
to	O
either	O
IFNalpha	O
and	O
isotretinoin	O
(isotretinoin	O
group;	O
206	O
patients)	O
or	O
IFNalpha	O
and	O
placebo	O
(placebo	O
group;	O
201	O
patients)	O
after	O
excision	O
of	O
the	O
primary	O
tumor.	O

IFNalpha	O
was	O
administered	O
three	O
times	O
a	O
week	O
at	O
a	O
dose	O
of	O
3	O
million	O
units	O
subcutaneously	O
for	O
24	O
months.	O

Isotretinoin	O
at	O
a	O
dose	O
of	O
20	O
mg	O
for	O
patients	O
<	O
or	O
=	O
73	O
kg,	O
30	O
mg	O
for	O
patients	O
greater	O
than	O
73	O
kg,	O
or	O
placebo	O
daily	O
for	O
24	O
months.	O

A	B-Premise
scheduled	I-Premise
interim	I-Premise
analysis	I-Premise
revealed	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
survival	I-Premise
rates,	I-Premise
with	I-Premise
the	I-Premise
isotretinoin	I-Premise
group	I-Premise
and	I-Premise
the	I-Premise
placebo	I-Premise
group	I-Premise
showing	I-Premise
5-year	I-Premise
disease-free	I-Premise
survival	I-Premise
rates	I-Premise
of	I-Premise
55%	I-Premise
(95%	I-Premise
CI,	I-Premise
46%	I-Premise
to	I-Premise
65%)	I-Premise
and	I-Premise
67%	I-Premise
(95%	I-Premise
CI,	I-Premise
59%	I-Premise
to	I-Premise
75%),	I-Premise
respectively,	I-Premise
and	I-Premise
overall	I-Premise
5-year	I-Premise
survival	I-Premise
rates	I-Premise
of	I-Premise
76%	I-Premise
(95%	I-Premise
CI,	I-Premise
67%	I-Premise
to	I-Premise
84%)	I-Premise
and	I-Premise
81%	I-Premise
(95%	I-Premise
CI,	I-Premise
74%	I-Premise
to	I-Premise
88%),	I-Premise
respectively.	I-Premise

The	O
trial	O
was	O
stopped	O
for	O
futility.	O

The	B-Claim
addition	I-Claim
of	I-Claim
isotretinoin	I-Claim
to	I-Claim
an	I-Claim
adjuvant	I-Claim
treatment	I-Claim
of	I-Claim
low-dose	I-Claim
IFNalpha	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
stage	I-Claim
IIA	I-Claim
and	I-Claim
IIB	I-Claim
melanoma	I-Claim
had	I-Claim
no	I-Claim
significant	I-Claim
effect	I-Claim
on	I-Claim
disease-free	I-Claim
or	I-Claim
overall	I-Claim
survival	I-Claim
and	I-Claim
is	I-Claim
therefore	I-Claim
not	I-Claim
recommended.	I-Claim

We	O
investigated	O
the	O
role	O
of	O
tamoxifen	O
and	O
radiotherapy	O
(RT)	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
gynecomastia	O
and	O
breast	O
pain	O
during	O
adjuvant	O
bicalutamide	O
monotherapy	O
after	O
radical	O
prostatectomy	O
(RP)	O
in	O
patients	O
with	O
prostate	O
cancer.	O

Also,	O
we	O
evaluated	O
their	O
effects	O
on	O
patient	O
hormonal	O
status,	O
quality	O
of	O
life	O
(QOL),	O
sexual	O
function	O
and	O
prostate	O
specific	O
antigen	O
relapse-free	O
survival.	O

This	O
was	O
a	O
multicenter	O
prospective	O
trial.	O

From	O
January	O
2002	O
to	O
February	O
2004,	O
102	O
patients	O
who	O
had	O
undergone	O
RP	O
for	O
localized	O
or	O
locally	O
advanced	O
prostate	O
cancer	O
were	O
recruited	O
and	O
randomized	O
into	O
3	O
groups,	O
namely	O
group	O
1-those	O
receiving	O
only	O
150	O
mg	O
bicalutamide	O
as	O
adjuvant	O
hormonal	O
therapy,	O
group	O
2-those	O
receiving	O
bicalutamide	O
and	O
10	O
mg	O
tamoxifen,	O
and	O
group	O
3-those	O
receiving	O
bicalutamide	O
and	O
RT.	O

Patients	O
in	O
group	O
1	O
in	O
whom	O
gynecomastia	O
or	O
breast	O
pain	O
developed	O
were	O
subsequently	O
randomized	O
to	O
receive	O
tamoxifen	O
or	O
RT	O
soon	O
after	O
symptoms	O
started.	O

Gynecomastia,	O
breast	O
pain,	O
prostate	O
specific	O
antigen,	O
QOL,	O
sexual	O
function	O
and	O
hormonal	O
levels	O
were	O
assessed.	O

Minimum	O
followup	O
was	O
12	O
months.	O

Of	B-Premise
group	I-Premise
1	I-Premise
patients	I-Premise
67%	I-Premise
had	I-Premise
gynecomastia	I-Premise
compared	I-Premise
with	I-Premise
8%	I-Premise
in	I-Premise
group	I-Premise
2	I-Premise
and	I-Premise
34%	I-Premise
in	I-Premise
group	I-Premise
3.	I-Premise

Breast	B-Premise
pain	I-Premise
was	I-Premise
more	I-Premise
frequent	I-Premise
in	I-Premise
group	I-Premise
1	I-Premise
than	I-Premise
in	I-Premise
groups	I-Premise
2	I-Premise
and	I-Premise
3	I-Premise
(58%	I-Premise
vs	I-Premise
7%	I-Premise
and	I-Premise
30%,	I-Premise
respectively).	I-Premise

Differences	B-Premise
were	I-Premise
significant	I-Premise
between	I-Premise
groups	I-Premise
1	I-Premise
and	I-Premise
2	I-Premise
(OR	I-Premise
0.12	I-Premise
p	I-Premise
<0.001),	I-Premise
and	I-Premise
groups	I-Premise
1	I-Premise
and	I-Premise
3	I-Premise
(OR	I-Premise
0.52	I-Premise
p	I-Premise
<	I-Premise
0.01).	I-Premise

In	B-Premise
patients	I-Premise
in	I-Premise
group	I-Premise
1	I-Premise
who	I-Premise
had	I-Premise
gynecomastia	I-Premise
or	I-Premise
breast	I-Premise
pain	I-Premise
a	I-Premise
significant	I-Premise
decrease	I-Premise
in	I-Premise
symptoms	I-Premise
was	I-Premise
achieved	I-Premise
in	I-Premise
those	I-Premise
receiving	I-Premise
tamoxifen	I-Premise
(p	I-Premise
<0.05).	I-Premise

Treatments	B-Premise
were	I-Premise
well	I-Premise
tolerated	I-Premise
in	I-Premise
the	I-Premise
3	I-Premise
groups.	I-Premise

No	B-Premise
differences	I-Premise
in	I-Premise
QOL	I-Premise
between	I-Premise
groups	I-Premise
2	I-Premise
and	I-Premise
3	I-Premise
were	I-Premise
found.	I-Premise

At	B-Premise
a	I-Premise
median	I-Premise
followup	I-Premise
of	I-Premise
26	I-Premise
months	I-Premise
we	I-Premise
observed	I-Premise
12	I-Premise
biochemical	I-Premise
relapses.	I-Premise

Gynecomastia	B-Claim
and	I-Claim
breast	I-Claim
pain	I-Claim
induced	I-Claim
by	I-Claim
bicalutamide	I-Claim
monotherapy	I-Claim
after	I-Claim
RP	I-Claim
can	I-Claim
be	I-Claim
prevented	I-Claim
and	I-Claim
treated.	I-Claim

Tamoxifen	B-Claim
has	I-Claim
been	I-Claim
shown	I-Claim
to	I-Claim
be	I-Claim
more	I-Claim
effective	I-Claim
and	I-Claim
safe	I-Claim
than	I-Claim
RT	I-Claim
in	I-Claim
this	I-Claim
setting.	I-Claim

QOL	B-Claim
and	I-Claim
sexual	I-Claim
function	I-Claim
are	I-Claim
not	I-Claim
negatively	I-Claim
influenced	I-Claim
by	I-Claim
these	I-Claim
2	I-Claim
treatment	I-Claim
options.	I-Claim

The	O
majority	O
of	O
prostate	O
carcinoma	O
survivors	O
experience	O
enduring	O
sexual	O
difficulties	O
and	O
associated	O
distress	O
in	O
the	O
years	O
after	O
definitive	O
treatment.	O

A	O
counseling	O
intervention	O
aimed	O
at	O
improving	O
levels	O
of	O
sexual	O
satisfaction	O
and	O
increasing	O
successful	O
utilization	O
of	O
medical	O
treatment	O
for	O
erectile	O
dysfunction	O
(ED)	O
was	O
developed	O
and	O
pilot-tested	O
for	O
both	O
the	O
survivor	O
of	O
prostate	O
carcinoma	O
and	O
his	O
partner.	O

All	O
male	O
participants	O
were	O
3-month	O
to	O
5-year	O
survivors	O
of	O
localized	O
prostate	O
carcinoma	O
who	O
had	O
been	O
treated	O
with	O
radical	O
prostatectomy	O
or	O
radiation	O
therapy,	O
and	O
were	O
married	O
or	O
in	O
a	O
committed	O
relationship.	O

Couples	O
were	O
randomized	O
to	O
attend	O
four	O
sessions	O
of	O
counseling	O
together	O
or	O
to	O
have	O
the	O
man	O
attend	O
alone.	O

In	O
both	O
groups,	O
partners	O
completed	O
behavioral	O
homework.	O

The	O
sessions	O
included	O
education	O
on	O
prostate	O
carcinoma	O
and	O
sexual	O
function	O
and	O
options	O
to	O
treat	O
ED	O
as	O
well	O
as	O
sexual	O
communication	O
and	O
stimulation	O
skills.	O

Standardized	O
questionnaires	O
at	O
baseline,	O
posttreatment,	O
and	O
at	O
3-month	O
and	O
6-month	O
follow-up	O
assessed	O
sexual	O
function,	O
marital	O
adjustment,	O
psychologic	O
distress,	O
and	O
utilization	O
of	O
treatments	O
for	O
ED.	O

Fifty-one	O
of	O
84	O
couples	O
randomized	O
to	O
treatment	O
completed	O
the	O
intervention	O
(61%).	O

Attendance	O
by	O
the	O
partner	O
did	O
not	O
affect	O
outcomes.	O

Participants	B-Premise
completing	I-Premise
the	I-Premise
intervention	I-Premise
demonstrated	I-Premise
improvement	I-Premise
in	I-Premise
male	I-Premise
overall	I-Premise
distress	I-Premise
(P	I-Premise
<	I-Premise
0.01),	I-Premise
male	I-Premise
global	I-Premise
sexual	I-Premise
function	I-Premise
(P	I-Premise
<	I-Premise
0.0001),	I-Premise
and	I-Premise
female	I-Premise
global	I-Premise
sexual	I-Premise
function	I-Premise
(P	I-Premise
<	I-Premise
0.05)	I-Premise
at	I-Premise
3-month	I-Premise
follow-up,	I-Premise
but	B-Premise
regression	I-Premise
toward	I-Premise
baseline	I-Premise
was	I-Premise
noted	I-Premise
at	I-Premise
6-month	I-Premise
follow-up.	I-Premise

However,	B-Premise
utilization	I-Premise
of	I-Premise
ED	I-Premise
treatments	I-Premise
increased	I-Premise
from	I-Premise
31%	I-Premise
at	I-Premise
the	I-Premise
time	I-Premise
of	I-Premise
study	I-Premise
entry	I-Premise
to	I-Premise
49%	I-Premise
at	I-Premise
the	I-Premise
6-month	I-Premise
follow-up	I-Premise
(P	I-Premise
=	I-Premise
0.003).	I-Premise

The	B-Claim
results	I-Claim
of	I-Claim
this	I-Claim
brief	I-Claim
pilot	I-Claim
counseling	I-Claim
intervention	I-Claim
demonstrated	I-Claim
significant	I-Claim
gains	I-Claim
in	I-Claim
sexual	I-Claim
function	I-Claim
and	I-Claim
satisfaction	I-Claim
and	I-Claim
increased	I-Claim
utilization	I-Claim
of	I-Claim
treatments	I-Claim
for	I-Claim
ED.	I-Claim

However,	B-Claim
modifications	I-Claim
are	I-Claim
needed	I-Claim
in	I-Claim
future	I-Claim
randomized	I-Claim
trials	I-Claim
to	I-Claim
reduce	I-Claim
the	I-Claim
rate	I-Claim
of	I-Claim
premature	I-Claim
termination	I-Claim
and	I-Claim
to	I-Claim
improve	I-Claim
long-term	I-Claim
maintenance	I-Claim
of	I-Claim
gains.	I-Claim

To	O
compare	O
the	O
outcomes	O
of	O
uterine	O
artery	O
embolization	O
(UAE)	O
for	O
leiomyomas	O
with	O
use	O
of	O
tris-acryl	O
gelatin	O
microspheres	O
(TAGM)	O
versus	O
spherical	O
polyvinyl	O
alcohol	O
(PVA)	O
particles.	O

Patients	O
undergoing	O
UAE	O
were	O
randomly	O
assigned	O
to	O
receive	O
TAGMs	O
or	O
PVA.	O

Embolization	O
was	O
performed	O
in	O
a	O
standardized	O
manner.	O

Outcome	O
data	O
were	O
collected	O
at	O
3	O
months	O
after	O
embolization,	O
including	O
assessment	O
of	O
clinical	O
symptoms,	O
scores	O
from	O
a	O
fibroid	O
tumor-specific	O
symptom	O
and	O
quality	O
of	O
life	O
(QOL)	O
questionnaire,	O
and	O
findings	O
on	O
contrast	O
material-enhanced	O
magnetic	O
resonance	O
(MR)	O
imaging,	O
including	O
the	O
degree	O
of	O
tumor	O
infarction	O
and	O
volume	O
reduction.	O

Data	O
were	O
analyzed	O
with	O
use	O
of	O
t	O
tests,	O
the	O
Mann-Whitney	O
U	O
test,	O
and	O
chi2	O
tests	O
as	O
appropriate.	O

Thirty-six	O
patients	O
were	O
treated.	O

There	O
were	O
no	O
differences	O
in	O
the	O
two	O
treatment	O
groups	O
at	O
baseline.	O

Clinical	O
follow-up	O
was	O
obtained	O
in	O
35	O
patients.	O

Among	B-Premise
the	I-Premise
clinical	I-Premise
outcome	I-Premise
measures,	I-Premise
QOL	I-Premise
score	I-Premise
improvement	I-Premise
was	I-Premise
greater	I-Premise
for	I-Premise
UAE	I-Premise
with	I-Premise
TAGMs	I-Premise
compared	I-Premise
with	I-Premise
PVA	I-Premise
(49.0	I-Premise
vs	I-Premise
27.9;	I-Premise
P	I-Premise
=	I-Premise
.02),	I-Premise
but	B-Premise
no	I-Premise
other	I-Premise
differences	I-Premise
were	I-Premise
noted.	I-Premise

Of	B-Premise
the	I-Premise
25	I-Premise
patients	I-Premise
in	I-Premise
whom	I-Premise
3-month	I-Premise
MR	I-Premise
imaging	I-Premise
follow-up	I-Premise
was	I-Premise
completed,	I-Premise
those	I-Premise
treated	I-Premise
with	I-Premise
TAGM	I-Premise
were	I-Premise
significantly	I-Premise
more	I-Premise
likely	I-Premise
to	I-Premise
have	I-Premise
complete	I-Premise
infarction	I-Premise
of	I-Premise
all	I-Premise
leiomyomas	I-Premise
(six	I-Premise
patients	I-Premise
vs	I-Premise
one	I-Premise
patient;	I-Premise
P	I-Premise
=	I-Premise
.02),	I-Premise
were	I-Premise
more	I-Premise
likely	I-Premise
to	I-Premise
have	I-Premise
at	I-Premise
least	I-Premise
90%	I-Premise
tumor	I-Premise
infarction	I-Premise
(eight	I-Premise
patients	I-Premise
vs	I-Premise
four	I-Premise
patients;	I-Premise
P	I-Premise
=	I-Premise
.03),	I-Premise
and	I-Premise
had	I-Premise
a	I-Premise
lower	I-Premise
mean	I-Premise
percent	I-Premise
of	I-Premise
residual	I-Premise
perfused	I-Premise
fibroid	I-Premise
tumor	I-Premise
tissue	I-Premise
(9.6%	I-Premise
vs	I-Premise
44.3%;	I-Premise
P	I-Premise
=	I-Premise
.004)	I-Premise
compared	I-Premise
with	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
PVA.	I-Premise

Based	O
on	O
these	O
differences	O
between	O
the	O
embolic	O
agents,	O
enrollment	O
in	O
this	O
study	O
was	O
terminated.	O

The	B-Claim
use	I-Claim
of	I-Claim
spherical	I-Claim
PVA	I-Claim
particles	I-Claim
in	I-Claim
the	I-Claim
manner	I-Claim
described	I-Claim
herein	I-Claim
results	I-Claim
in	I-Claim
an	I-Claim
unacceptably	I-Claim
high	I-Claim
rate	I-Claim
of	I-Claim
failed	I-Claim
tumor	I-Claim
infarction	I-Claim
in	I-Claim
UAE.	I-Claim

A	O
randomised	O
controlled	O
trial	O
of	O
radiotherapy	O
alone	O
versus	O
radiotherapy	O
with	O
concomitant	O
and	O
adjuvant	O
temozolomide	O
for	O
patients	O
with	O
glioblastoma	O
showed	O
that	O
survival	O
was	O
higher	O
for	O
patients	O
assigned	O
combination	O
treatment	O
compared	O
with	O
those	O
assigned	O
standard	O
radiotherapy	O
alone.	O

This	O
paper	O
reports	O
the	O
health-related	O
quality	O
of	O
life	O
(HRQOL)	O
of	O
the	O
patients	O
in	O
this	O
trial.	O

573	O
patients	O
with	O
newly	O
diagnosed	O
glioblastoma	O
were	O
randomly	O
allocated	O
either	O
radiotherapy	O
alone	O
or	O
radiotherapy	O
and	O
temozolomide.	O

The	O
primary	O
endpoint	O
was	O
survival,	O
and	O
HRQOL	O
was	O
a	O
secondary	O
endpoint.	O

We	O
assessed	O
HRQOL	O
at	O
baseline	O
and	O
at	O
every	O
3	O
months	O
during	O
treatment	O
until	O
progression	O
using	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
quality	O
of	O
life	O
questionnaire	O
core-30	O
(QLQ-C30)	O
and	O
the	O
EORTC	O
brain	O
cancer	O
module	O
(EORTC	O
BN-20).	O

We	O
calculated	O
changes	O
from	O
baseline	O
score	O
for	O
seven	O
predefined	O
HRQOL	O
measures	O
(fatigue,	O
overall	O
health,	O
social	O
function,	O
emotional	O
function,	O
future	O
uncertainty,	O
insomnia,	O
and	O
communication	O
deficit)	O
and	O
differences	O
between	O
groups	O
for	O
these	O
measures	O
at	O
every	O
time	O
point.	O

The	O
significance	O
of,	O
and	O
proportions	O
of	O
patients	O
with,	O
improved	O
HRQOL	O
scores--defined	O
as	O
a	O
change	O
of	O
10	O
points	O
or	O
more--were	O
recorded.	O

Baseline	O
questionnaires	O
were	O
available	O
for	O
490	O
(86%)	O
patients.	O

Baseline	O
HRQOL	O
scores	O
did	O
not	O
differ	O
between	O
groups.	O

At	B-Premise
first	I-Premise
follow-up,	I-Premise
groups	I-Premise
differed	I-Premise
only	I-Premise
in	I-Premise
social	I-Premise
functioning,	I-Premise
favouring	I-Premise
the	I-Premise
radiotherapy-only	I-Premise
group	I-Premise
(mean	I-Premise
score	I-Premise
79.0	I-Premise
[SD	I-Premise
3.2]	I-Premise
for	I-Premise
patients	I-Premise
assigned	I-Premise
radiotherapy	I-Premise
vs	I-Premise
67.4	I-Premise
[2.7]	I-Premise
for	I-Premise
those	I-Premise
assigned	I-Premise
radiotherapy	I-Premise
and	I-Premise
temozolomide;	I-Premise
difference	I-Premise
between	I-Premise
groups	I-Premise
11.6	I-Premise
points	I-Premise
[95%	I-Premise
CI	I-Premise
3.5-19.7],	I-Premise
p=0.0052).	I-Premise

Over	B-Premise
subsequent	I-Premise
assessments,	I-Premise
HRQOL	I-Premise
was	I-Premise
much	I-Premise
the	I-Premise
same	I-Premise
between	I-Premise
treatment	I-Premise
groups.	I-Premise

Addition	B-Claim
of	I-Claim
temozolomide	I-Claim
during	I-Claim
and	I-Claim
after	I-Claim
radiotherapy	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
newly	I-Claim
diagnosed	I-Claim
glioblastoma	I-Claim
significantly	I-Claim
improved	I-Claim
survival	I-Claim
without	I-Claim
a	I-Claim
negative	I-Claim
effect	I-Claim
on	I-Claim
HRQOL.	I-Claim

Axillary	B-Claim
clearance	I-Claim
in	I-Claim
early	I-Claim
breast	I-Claim
cancer	I-Claim
aims	I-Claim
to	I-Claim
improve	I-Claim
locoregional	I-Claim
control	I-Claim
and	I-Claim
provide	I-Claim
staging	I-Claim
information	I-Claim
but	O
is	O
associated	O
with	O
undesirable	O
morbidity.	O

We	O
therefore	O
investigated	O
whether	O
avoiding	O
axillary	O
surgery	O
in	O
older	O
women	O
would	O
result	O
in	O
improved	O
quality	O
of	O
life	O
(QL)	O
with	O
similar	O
disease-free	O
survival	O
(DFS)	O
and	O
overall	O
survival	O
(OS).	O

Between	O
1993	O
and	O
2002,	O
women	O
>	O
or	O
=	O
60	O
years	O
old	O
with	O
clinically	O
node-negative	O
operable	O
breast	O
cancer	O
in	O
whom	O
adjuvant	O
tamoxifen	O
was	O
considered	O
indicated	O
regardless	O
of	O
pathologic	O
nodal	O
status	O
were	O
randomly	O
assigned	O
to	O
primary	O
surgery	O
plus	O
axillary	O
clearance	O
(Sx	O
+	O
Ax)	O
followed	O
by	O
tamoxifen	O
(Tam)	O
versus	O
Sx	O
without	O
Ax	O
followed	O
by	O
Tam	O
for	O
5	O
consecutive	O
years.	O

The	O
primary	O
end	O
point	O
was	O
QL	O
reported	O
by	O
the	O
patient	O
and	O
by	O
physician	O
assessment.	O

A	O
total	O
of	O
473	O
patients	O
(234	O
to	O
Sx	O
+	O
Ax,	O
239	O
to	O
Sx)	O
were	O
randomly	O
assigned.	O

The	O
median	O
age	O
was	O
74	O
years;	O
80%	O
had	O
estrogen	O
receptor-positive	O
disease.	O

In	B-Premise
both	I-Premise
the	I-Premise
patients'	I-Premise
subjective	I-Premise
assessment	I-Premise
of	I-Premise
their	I-Premise
QL	I-Premise
and	I-Premise
the	I-Premise
physicians'	I-Premise
perception	I-Premise
of	I-Premise
the	I-Premise
patients'	I-Premise
QL,	I-Premise
the	I-Premise
largest	I-Premise
adverse	I-Premise
QL	I-Premise
effects	I-Premise
of	I-Premise
Ax	I-Premise
were	I-Premise
observed	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
the	I-Premise
first	I-Premise
postoperative	I-Premise
assessment,	I-Premise
but	B-Premise
the	I-Premise
differences	I-Premise
tended	I-Premise
to	I-Premise
disappear	I-Premise
in	I-Premise
6	I-Premise
to	I-Premise
12	I-Premise
months.	I-Premise

At	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
6.6	I-Premise
years,	I-Premise
results	I-Premise
for	I-Premise
Sx	I-Premise
+	I-Premise
Ax	I-Premise
and	I-Premise
Sx	I-Premise
yielded	I-Premise
similar	I-Premise
DFS	I-Premise
(6-year	I-Premise
DFS,	I-Premise
67%	I-Premise
v	I-Premise
66%;	I-Premise
hazard	I-Premise
ratio	I-Premise
[HR]	I-Premise
Sx	I-Premise
+	I-Premise
Ax/Sx,	I-Premise
1.06;	I-Premise
95%	I-Premise
CI,	I-Premise
0.79	I-Premise
to	I-Premise
1.42;	I-Premise
P	I-Premise
=	I-Premise
.69)	I-Premise
and	I-Premise
OS	I-Premise
(6-year	I-Premise
OS,	I-Premise
75%	I-Premise
v	I-Premise
73%;	I-Premise
HR	I-Premise
Sx	I-Premise
+	I-Premise
Ax/Sx,	I-Premise
1.05;	I-Premise
95%	I-Premise
CI,	I-Premise
0.76	I-Premise
to	I-Premise
1.46;	I-Premise
P	I-Premise
=	I-Premise
.77).	I-Premise

Avoiding	B-Claim
axillary	I-Claim
clearance	I-Claim
for	I-Claim
women	I-Claim
>	I-Claim
or	I-Claim
=	I-Claim
60	I-Claim
years	I-Claim
old	I-Claim
who	I-Claim
have	I-Claim
clinically	I-Claim
node-negative	I-Claim
disease	I-Claim
and	I-Claim
receive	I-Claim
Tam	I-Claim
for	I-Claim
endocrine-responsive	I-Claim
disease	I-Claim
yields	I-Claim
similar	I-Claim
efficacy	I-Claim
with	I-Claim
better	I-Claim
early	I-Claim
QL.	I-Claim

Chemotherapy	B-Claim
can	I-Claim
profoundly	I-Claim
affect	I-Claim
patients'	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
(QOL),	I-Claim
yet	O
few	O
clinical	O
trials	O
in	O
advanced	O
cervical	O
cancer	O
have	O
included	O
QOL	O
outcomes.	O

Our	O
purpose	O
was	O
to	O
assess	O
the	O
impact	O
of	O
cisplatin	O
(C)	O
versus	O
cisplatin	O
plus	O
paclitaxel	O
(CP)	O
on	O
overall	O
QOL	O
and	O
pain	O
in	O
cervical	O
cancer	O
patients.	O

QOL	O
was	O
assessed	O
using	O
FACT-Cx,	O
consisting	O
of	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy	O
(FACT-G)	O
plus	O
a	O
cervix	O
cancer-specific	O
subscale,	O
the	O
Brief	O
Pain	O
Inventory-Short	O
Form	O
(BPI-SF),	O
and	O
a	O
neurotoxicity	O
subscale.	O

Time	O
points	O
were:	O
baseline	O
(prior	O
to	O
randomization)	O
and	O
prior	O
to	O
chemotherapy	O
cycles	O
2,	O
3,	O
and	O
4.	O

Overall	B-Premise
(FACT-G)	I-Premise
scores	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
significantly	I-Premise
between	I-Premise
arms	I-Premise
at	I-Premise
the	I-Premise
fourth	I-Premise
assessment	I-Premise
(C	I-Premise
=	I-Premise
70.3	I-Premise
(19.6);	I-Premise
CP	I-Premise
=	I-Premise
72.8	I-Premise
(17.4)).	I-Premise

Scores	B-Premise
were	I-Premise
stable	I-Premise
over	I-Premise
time	I-Premise
and	I-Premise
considerably	I-Premise
lower	I-Premise
than	I-Premise
the	I-Premise
general	I-Premise
population	I-Premise
norms.	I-Premise

The	B-Premise
BPI-SF	I-Premise
revealed	I-Premise
a	I-Premise
decline	I-Premise
in	I-Premise
pain	I-Premise
scores	I-Premise
in	I-Premise
both	I-Premise
arms	I-Premise
from	I-Premise
the	I-Premise
first	I-Premise
to	I-Premise
fourth	I-Premise
assessments.	I-Premise

The	B-Premise
CP	I-Premise
arm	I-Premise
produced	I-Premise
a	I-Premise
significantly	I-Premise
higher	I-Premise
response	I-Premise
rate	I-Premise
and	I-Premise
progression-free	I-Premise
survival	I-Premise
(PFS)	I-Premise
but	B-Premise
not	I-Premise
overall	I-Premise
survival	I-Premise
(OS).	I-Premise

Greater	B-Premise
myelosuppression	I-Premise
was	I-Premise
reported	I-Premise
in	I-Premise
the	I-Premise
combination	I-Premise
arm.	I-Premise

The	B-Premise
rate	I-Premise
of	I-Premise
QOL	I-Premise
drop-out	I-Premise
for	I-Premise
any	I-Premise
reason	I-Premise
was	I-Premise
higher	I-Premise
for	I-Premise
C	I-Premise
(53%)	I-Premise
compared	I-Premise
to	I-Premise
CP	I-Premise
(38%)	I-Premise
(P	I-Premise
<	I-Premise
0.05).	I-Premise

At	O
the	O
fourth	O
time	O
point,	O
60%	O
of	O
living	O
patients	O
in	O
both	O
arms	O
completed	O
a	O
QOL	O
assessment.	O

There	B-Claim
was	I-Claim
no	I-Claim
significant	I-Claim
difference	I-Claim
in	I-Claim
overall	I-Claim
QOL	I-Claim
scores	I-Claim
between	I-Claim
treatment	I-Claim
arms	I-Claim
or	I-Claim
serially.	I-Claim

Combined	B-Claim
with	I-Claim
QOL	I-Claim
results,	I-Claim
the	I-Claim
significant	I-Claim
increase	I-Claim
in	I-Claim
response	I-Claim
and	I-Claim
PFS	I-Claim
in	I-Claim
the	I-Claim
CP	I-Claim
arm	I-Claim
and	I-Claim
the	I-Claim
higher	I-Claim
drop-out	I-Claim
rate	I-Claim
in	I-Claim
the	I-Claim
C	I-Claim
arm	I-Claim
suggest	I-Claim
a	I-Claim
better	I-Claim
outcome	I-Claim
for	I-Claim
the	I-Claim
combination	I-Claim
regimen	I-Claim
despite	I-Claim
its	I-Claim
increased	I-Claim
myelosuppression.	I-Claim

After	O
surgery	O
for	O
differentiated	O
thyroid	O
carcinoma,	O
many	O
patients	O
are	O
treated	O
with	O
radioiodine	O
to	O
ablate	O
remnant	O
thyroid	O
tissue.	O

This	B-Claim
procedure	I-Claim
has	I-Claim
been	I-Claim
performed	I-Claim
with	I-Claim
the	I-Claim
patient	I-Claim
in	I-Claim
the	I-Claim
hypothyroid	I-Claim
state	I-Claim
to	I-Claim
promote	I-Claim
endogenous	I-Claim
TSH	I-Claim
stimulation	I-Claim
and	I-Claim
is	I-Claim
often	I-Claim
associated	I-Claim
with	I-Claim
hypothyroid	I-Claim
symptoms	I-Claim
and	I-Claim
impaired	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

This	O
international,	O
randomized,	O
controlled,	O
multicenter	O
trial	O
aimed	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
recombinant	O
human	O
TSH	O
(rhTSH)	O
to	O
prepare	O
euthyroid	O
patients	O
on	O
L-thyroxine	O
therapy	O
(euthyroid	O
group)	O
to	O
ablate	O
remnant	O
thyroid	O
tissue	O
with	O
3.7	O
GBq	O
(100	O
mCi)	O
131I,	O
compared	O
with	O
that	O
with	O
conventional	O
remnant	O
ablation	O
performed	O
in	O
the	O
hypothyroid	O
state	O
(hypothyroid	O
group).	O

Quality	O
of	O
life	O
was	O
determined	O
at	O
the	O
time	O
of	O
randomization	O
and	O
ablation.	O

After	O
the	O
administration	O
of	O
the	O
131-I	O
dose,	O
the	O
rate	O
of	O
radiation	O
clearance	O
from	O
blood,	O
thyroid	O
remnant,	O
and	O
whole	O
body	O
was	O
measured.	O

The	O
predefined	O
primary	O
criterion	O
for	O
successful	O
ablation	O
was	O
"no	O
visible	O
uptake	O
in	O
the	O
thyroid	O
bed,	O
or	O
if	O
visible,	O
fractional	O
uptake	O
less	O
than	O
0.1%"	O
on	O
neck	O
scans	O
performed	O
8	O
months	O
after	O
therapy	O
and	O
was	O
satisfied	O
in	O
100%	O
of	O
patients	O
in	O
both	O
groups.	O

A	O
secondary	O
criterion	O
for	O
ablation,	O
an	O
rhTSH-stimulated	O
serum	O
thyroglobulin	O
concentration	O
less	O
than	O
2	O
ng/ml,	O
was	O
fulfilled	O
by	O
23	O
of	O
24	O
(96%)	O
euthyroid	O
patients	O
and	O
18	O
of	O
21	O
(86%)	O
hypothyroid	O
patients	O
(P	O
=	O
0.2341).	O

Quality	B-Premise
of	I-Premise
life	I-Premise
was	I-Premise
well	I-Premise
preserved	I-Premise
in	I-Premise
the	I-Premise
euthyroid	I-Premise
group,	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
hypothyroid	I-Premise
group,	I-Premise
as	I-Premise
demonstrated	I-Premise
by	I-Premise
their	I-Premise
lower	I-Premise
pretreatment	I-Premise
scores	I-Premise
on	I-Premise
the	I-Premise
Billewicz	I-Premise
scale	I-Premise
for	I-Premise
hypothyroid	I-Premise
signs	I-Premise
and	I-Premise
symptoms,	I-Premise
27	I-Premise
+/-	I-Premise
7	I-Premise
vs.	I-Premise
18	I-Premise
+/-	I-Premise
4	I-Premise
(P	I-Premise
<	I-Premise
0.0001)	I-Premise
and	I-Premise
their	I-Premise
significantly	I-Premise
higher	I-Premise
Short	I-Premise
Form-36	I-Premise
Health	I-Premise
Assessment	I-Premise
Scale	I-Premise
scores	I-Premise
in	I-Premise
five	I-Premise
of	I-Premise
eight	I-Premise
categories.	I-Premise

Euthyroid	B-Premise
patients	I-Premise
had	I-Premise
a	I-Premise
statistically	I-Premise
significant	I-Premise
one	I-Premise
third	I-Premise
lower	I-Premise
radiation	I-Premise
dose	I-Premise
to	I-Premise
the	I-Premise
blood,	I-Premise
compared	I-Premise
with	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
hypothyroid	I-Premise
group.	I-Premise

This	B-Claim
study	I-Claim
demonstrates	I-Claim
comparable	I-Claim
remnant	I-Claim
ablation	I-Claim
rates	I-Claim
in	I-Claim
patients	I-Claim
prepared	I-Claim
for	I-Claim
131I	I-Claim
remnant	I-Claim
ablation	I-Claim
with	I-Claim
3.7	I-Claim
GBq	I-Claim
by	I-Claim
either	I-Claim
administering	I-Claim
rhTSH	I-Claim
or	I-Claim
withholding	I-Claim
thyroid	I-Claim
hormone.	I-Claim

rhTSH-prepared	B-Claim
patients	I-Claim
maintained	I-Claim
a	I-Claim
higher	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
and	I-Claim
received	I-Claim
less	I-Claim
radiation	I-Claim
exposure	I-Claim
to	I-Claim
the	I-Claim
blood.	I-Claim

Patients	O
with	O
cancer	O
are	O
characterized	O
by	O
a	O
profound	O
impairment	O
of	O
glucose	O
utilization,	O
with	O
lipids	O
being	O
the	O
preferred	O
metabolic	O
fuel.	O

In	O
contrast,	O
the	O
energy	O
needs	O
of	O
malignant	O
tumors	O
are	O
almost	O
entirely	O
met	O
by	O
glucose.	O

We	O
therefore	O
studied	O
the	O
effects	O
of	O
a	O
high-fat	O
diet,	O
particularly	O
on	O
body	O
composition.	O

Twenty-three	O
moderately	O
malnourished	O
patients	O
with	O
gastrointestinal	O
carcinomas	O
were	O
randomized	O
to	O
receive	O
either	O
a	O
conventional	O
diet	O
supplying	O
35	O
nonprotein	O
kcal	O
and	O
1.1	O
g	O
of	O
protein/kg	O
per	O
day	O
(group	O
A,	O
n	O
=	O
11)	O
or	O
a	O
fat-enriched	O
artificial	O
liquid	O
diet	O
(20	O
nonprotein	O
kcal/kg	O
per	O
day)	O
plus	O
normal	O
meals	O
(group	O
B,	O
n	O
=	O
12)	O
for	O
a	O
period	O
of	O
eight	O
weeks,	O
i.e.,	O
from	O
the	O
first	O
to	O
the	O
third	O
chemotherapy	O
cycle.	O

The	O
fat	O
content	O
of	O
the	O
artificial	O
diet	O
was	O
66%	O
of	O
the	O
nonprotein	O
calories.	O

The	O
day	O
before	O
the	O
nutritional	O
interventions,	O
and	O
again	O
after	O
four	O
and	O
eight	O
weeks,	O
body	O
compartments	O
were	O
determined	O
using	O
bioelectrical	O
impedance	O
analysis,	O
lymphocyte	O
subpopulations	O
were	O
quantified	O
using	O
flow	O
cytometry,	O
and	O
some	O
aspects	O
of	O
the	O
quality	O
of	O
life	O
were	O
rated	O
using	O
four	O
linear	O
analog	O
self-assessment	O
(LASA)	O
scales.	O

The	O
statistical	O
calculations	O
were	O
done	O
as	O
an	O
exploratory	O
data	O
analysis.	O

The	O
consumption	O
of	O
non-protein	O
calories	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
patient	O
groups.	O

An	B-Premise
average	I-Premise
weight	I-Premise
gain	I-Premise
in	I-Premise
group	I-Premise
B	I-Premise
contrasted	I-Premise
with	I-Premise
an	I-Premise
average	I-Premise
weight	I-Premise
loss	I-Premise
in	I-Premise
group	I-Premise
A	I-Premise
after	I-Premise
four	I-Premise
(P	I-Premise
<	I-Premise
0.01)	I-Premise
and	I-Premise
eight	I-Premise
weeks	I-Premise
(P	I-Premise
<	I-Premise
0.05).	I-Premise

Fat-free	B-Premise
mass	I-Premise
showed	I-Premise
an	I-Premise
intergroup	I-Premise
difference	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
group	I-Premise
B	I-Premise
after	I-Premise
eight	I-Premise
weeks	I-Premise
(P	I-Premise
<	I-Premise
0.05).	I-Premise

Body	B-Premise
cell	I-Premise
mass	I-Premise
was	I-Premise
maintained	I-Premise
throughout	I-Premise
the	I-Premise
study	I-Premise
in	I-Premise
group	I-Premise
B,	I-Premise
but	I-Premise
declined	I-Premise
significantly	I-Premise
up	I-Premise
to	I-Premise
weeks	I-Premise
4	I-Premise
and	I-Premise
8	I-Premise
in	I-Premise
group	I-Premise
A	I-Premise
(intergroup	I-Premise
difference:	I-Premise
P	I-Premise
<	I-Premise
0.05	I-Premise
and	I-Premise
0.01,	I-Premise
respectively).	I-Premise

A	B-Premise
decrease	I-Premise
in	I-Premise
the	I-Premise
total	I-Premise
lymphocyte	I-Premise
count	I-Premise
by	I-Premise
559	I-Premise
cells/mul	I-Premise
occurred	I-Premise
with	I-Premise
the	I-Premise
fat-enriched	I-Premise
diet	I-Premise
(P	I-Premise
<	I-Premise
0.05).	I-Premise

Several	B-Premise
aspects	I-Premise
of	I-Premise
the	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
were	I-Premise
rated	I-Premise
to	I-Premise
be	I-Premise
better	I-Premise
in	I-Premise
group	I-Premise
B	I-Premise
than	I-Premise
in	I-Premise
group	I-Premise
A,	I-Premise
although	B-Premise
not	I-Premise
all	I-Premise
differences	I-Premise
reached	I-Premise
statistical	I-Premise
significance.	I-Premise

In	B-Claim
patients	I-Claim
with	I-Claim
cancer,	I-Claim
a	I-Claim
high-fat	I-Claim
diet	I-Claim
may	I-Claim
possibly	I-Claim
support	I-Claim
the	I-Claim
maintenance	I-Claim
of	I-Claim
both	I-Claim
body	I-Claim
weight	I-Claim
and	I-Claim
body	I-Claim
cell	I-Claim
mass.	I-Claim

However,	B-Claim
monitoring	I-Claim
the	I-Claim
lymphocyte	I-Claim
count	I-Claim
is	I-Claim
advisable.	I-Claim

For	B-Claim
malignant	I-Claim
pleural	I-Claim
mesothelioma	I-Claim
(MPM)	I-Claim
patients	I-Claim
with	I-Claim
a	I-Claim
poor	I-Claim
prognosis,	I-Claim
maintaining	I-Claim
health-related	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
(HRQOL)	I-Claim
is	I-Claim
important.	I-Claim

This	O
article	O
compares	O
the	O
impact	O
on	O
HRQOL	O
of	O
first-line	O
treatment	O
with	O
cisplatin	O
versus	O
raltitrexed	O
and	O
cisplatin.	O

Patients	O
with	O
histologically-proven	O
unresectable	O
MPM,	O
not	O
pretreated	O
with	O
chemotherapy	O
were	O
randomly	O
assigned	O
to	O
receive	O
cisplatin	O
80	O
mg/m2	O
intravenously	O
on	O
day	O
1,	O
with	O
or	O
without	O
preceding	O
infusion	O
of	O
raltitrexed	O
3	O
mg/m2.	O

HRQOL	O
was	O
assessed	O
with	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Core	O
Quality	O
of	O
Life	O
Questionnaire	O
C30	O
(EORTC	O
QLQ-C30)	O
and	O
EORTC	O
Lung	O
Cancer	O
Module	O
(QLQ-LC13)	O
tools.	O

Assessments	O
were	O
conducted	O
at	O
baseline,	O
immediately	O
before	O
every	O
treatment	O
cycle,	O
at	O
the	O
end	O
of	O
treatment,	O
and	O
every	O
six	O
weeks	O
for	O
12	O
months.	O

Two	O
hundred	O
fifty	O
patients	O
were	O
randomly	O
assigned,	O
80%	O
were	O
male	O
with	O
a	O
median	O
age	O
of	O
58	O
years,	O
WHO	O
performance	O
status	O
0,	O
1,	O
and	O
2,	O
in	O
25%,	O
62%,	O
and	O
13%	O
of	O
cases.	O

The	B-Premise
clinical	I-Premise
results	I-Premise
found	I-Premise
raltitrexed	I-Premise
and	I-Premise
cisplatin	I-Premise
to	I-Premise
be	I-Premise
superior	I-Premise
to	I-Premise
cisplatin	I-Premise
with	I-Premise
regard	I-Premise
to	I-Premise
overall	I-Premise
survival	I-Premise
(P	I-Premise
=	I-Premise
.048).	I-Premise

The	B-Premise
global	I-Premise
HRQOL	I-Premise
scale	I-Premise
was	I-Premise
comparable	I-Premise
at	I-Premise
baseline	I-Premise
on	I-Premise
both	I-Premise
treatment	I-Premise
arms	I-Premise
(P	I-Premise
=	I-Premise
.848);	I-Premise
at	B-Premise
no	I-Premise
point	I-Premise
was	I-Premise
any	I-Premise
significant	I-Premise
difference	I-Premise
apparent	I-Premise
on	I-Premise
this	I-Premise
end	I-Premise
point.	I-Premise

Both	B-Premise
treatments	I-Premise
led	I-Premise
to	I-Premise
an	I-Premise
improvement,	I-Premise
over	I-Premise
time,	I-Premise
in	I-Premise
dyspnoea.	I-Premise

This	B-Claim
effect	I-Claim
is	I-Claim
an	I-Claim
important	I-Claim
clinically	I-Claim
meaningful	I-Claim
reduction	I-Claim
from	I-Claim
baseline	I-Claim
in	I-Claim
the	I-Claim
cisplatin/raltitrexed	I-Claim
arm.	I-Claim

However,	B-Premise
the	I-Premise
majority	I-Premise
of	I-Premise
scales	I-Premise
of	I-Premise
the	I-Premise
EORTC	I-Premise
QLQ-C30	I-Premise
or	I-Premise
LC13	I-Premise
showed	I-Premise
stabilization	I-Premise
of	I-Premise
HRQOL	I-Premise
with	I-Premise
few	I-Premise
clinically	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
the	I-Premise
treatment	I-Premise
arms.	I-Premise

This	B-Claim
study	I-Claim
provides	I-Claim
important	I-Claim
information	I-Claim
about	I-Claim
the	I-Claim
HRQOL	I-Claim
of	I-Claim
chemotherapy-treated	I-Claim
MPM	I-Claim
patients.	I-Claim

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
impact	O
of	O
neuronavigation	O
on	O
the	O
cytoreductive	O
treatment	O
of	O
solitary	O
contrast-enhancing	O
intracerebral	O
tumors	O
and	O
outcomes	O
of	O
this	O
treatment	O
in	O
cases	O
in	O
which	O
neuronavigation	O
was	O
preoperatively	O
judged	O
to	O
be	O
redundant.	O

The	O
authors	O
conducted	O
a	O
prospective	O
randomized	O
study	O
in	O
which	O
45	O
patients,	O
each	O
harboring	O
a	O
solitary	O
contrast-enhancing	O
intracerebral	O
tumor,	O
were	O
randomized	O
for	O
surgery	O
with	O
or	O
without	O
neuronavigation.	O

Peri-	O
and	O
postoperative	O
parameters	O
under	O
investigation	O
included	O
the	O
following:	O
duration	O
of	O
the	O
procedure;	O
surgeon's	O
estimate	O
of	O
the	O
usefulness	O
of	O
neuronavigation;	O
quantification	O
of	O
the	O
extent	O
of	O
resection,	O
determined	O
using	O
magnetic	O
resonance	O
imaging;	O
and	O
the	O
postoperative	O
course,	O
as	O
evaluated	O
by	O
neurological	O
examinations,	O
the	O
patient's	O
quality-of-life	O
self-assessment,	O
application	O
of	O
the	O
Barthel	O
index	O
and	O
the	O
Karnofsky	O
Performance	O
Scale	O
score,	O
and	O
the	O
patient's	O
time	O
of	O
death.	O

The	B-Premise
mean	I-Premise
amount	I-Premise
of	I-Premise
residual	I-Premise
tumor	I-Premise
tissue	I-Premise
was	I-Premise
28.9%	I-Premise
for	I-Premise
standard	I-Premise
surgery	I-Premise
(SS)	I-Premise
and	I-Premise
13.8%	I-Premise
for	I-Premise
surgery	I-Premise
involving	I-Premise
neuronavigation	I-Premise
(SN).	I-Premise

The	B-Premise
corresponding	I-Premise
mean	I-Premise
amounts	I-Premise
of	I-Premise
residual	I-Premise
contrast-enhancing	I-Premise
tumor	I-Premise
tissue	I-Premise
were	I-Premise
29.2	I-Premise
and	I-Premise
24.4%,	I-Premise
respectively.	I-Premise

These	B-Premise
differences	I-Premise
were	I-Premise
not	I-Premise
significant.	I-Premise

Gross-total	B-Premise
removal	I-Premise
(GTR)	I-Premise
was	I-Premise
achieved	I-Premise
in	I-Premise
five	I-Premise
patients	I-Premise
who	I-Premise
underwent	I-Premise
SS	I-Premise
and	I-Premise
in	I-Premise
three	I-Premise
who	I-Premise
underwent	I-Premise
SN.	I-Premise

Median	B-Premise
survival	I-Premise
was	I-Premise
significantly	I-Premise
shorter	I-Premise
in	I-Premise
the	I-Premise
SN	I-Premise
group	I-Premise
(5.6	I-Premise
months	I-Premise
compared	I-Premise
with	I-Premise
9	I-Premise
months,	I-Premise
unadjusted	I-Premise
hazard	I-Premise
ratio	I-Premise
=	I-Premise
1.6);	I-Premise
however,	B-Premise
this	I-Premise
difference	I-Premise
may	I-Premise
be	I-Premise
attributable	I-Premise
to	I-Premise
the	I-Premise
coincidental	I-Premise
early	I-Premise
death	I-Premise
of	I-Premise
three	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
SN	I-Premise
group.	I-Premise

No	B-Premise
discernible	I-Premise
important	I-Premise
effect	I-Premise
on	I-Premise
the	I-Premise
patients'	I-Premise
3-month	I-Premise
postoperative	I-Premise
course	I-Premise
was	I-Premise
identified.	I-Premise

There	B-Claim
is	I-Claim
no	I-Claim
rationale	I-Claim
for	I-Claim
the	I-Claim
routine	I-Claim
use	I-Claim
of	I-Claim
neuronavigation	I-Claim
to	I-Claim
improve	I-Claim
the	I-Claim
extent	I-Claim
of	I-Claim
tumor	I-Claim
resection	I-Claim
and	I-Claim
prognosis	I-Claim
in	I-Claim
patients	I-Claim
harboring	I-Claim
a	I-Claim
solitary	I-Claim
enhancing	I-Claim
intracerebral	I-Claim
lesion	I-Claim
when	I-Claim
neuronavigation	I-Claim
is	I-Claim
not	I-Claim
already	I-Claim
deemed	I-Claim
advantageous	I-Claim
because	I-Claim
of	I-Claim
the	I-Claim
size	I-Claim
or	I-Claim
location	I-Claim
of	I-Claim
the	I-Claim
lesion.	I-Claim

Experimental	B-Claim
and	I-Claim
early	I-Claim
clinical	I-Claim
investigations	I-Claim
have	I-Claim
demonstrated	I-Claim
encouraging	I-Claim
results	I-Claim
for	I-Claim
estramustine	I-Claim
in	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
malignant	I-Claim
glioma.	I-Claim

The	O
present	O
study	O
is	O
an	O
open	O
randomized	O
clinical	O
trial	O
comparing	O
estramustine	O
phosphate	O
(Estracyt)	O
in	O
addition	O
to	O
radiotherapy	O
with	O
radiotherapy	O
alone	O
as	O
first	O
line	O
treatment	O
of	O
astrocytoma	O
grade	O
III	O
and	O
IV.	O

The	O
140	O
patients	O
included	O
were	O
in	O
a	O
good	O
clinical	O
condition	O
with	O
a	O
median	O
age	O
of	O
55	O
years	O
(range	O
22-87).	O

Estramustine	O
was	O
given	O
orally,	O
280	O
mg	O
twice	O
daily,	O
as	O
soon	O
as	O
the	O
diagnosis	O
was	O
established,	O
during	O
and	O
after	O
the	O
radiotherapy	O
for	O
a	O
period	O
of	O
in	O
total	O
3	O
months.	O

Radiotherapy	O
was	O
delivered	O
on	O
weekdays	O
2	O
Gy	O
daily	O
up	O
to	O
56	O
Gy.	O

Eighteen	O
patients	O
were	O
excluded	O
due	O
to	O
misclassification,	O
leaving	O
122	O
patients	O
eligible	O
for	O
evaluation.	O

Overall	B-Premise
the	I-Premise
treatment	I-Premise
was	I-Premise
well	I-Premise
tolerated.	I-Premise

Mild	B-Premise
or	I-Premise
moderate	I-Premise
nausea	I-Premise
was	I-Premise
the	I-Premise
most	I-Premise
common	I-Premise
side	I-Premise
effect	I-Premise
of	I-Premise
estramustine.	I-Premise

The	O
minimum	O
follow-up	O
time	O
was	O
5.2	O
years	O
for	O
the	O
surviving	O
patients.	O

For	B-Premise
astrocytoma	I-Premise
grade	I-Premise
III	I-Premise
the	I-Premise
median	I-Premise
survival	I-Premise
time	I-Premise
was	I-Premise
10.6	I-Premise
(1.3-92.7)	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
radiotherapy	I-Premise
only	I-Premise
group	I-Premise
and	I-Premise
17.3	I-Premise
(0.4-96.9+)	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
estramustine	I-Premise
+	I-Premise
radiotherapy	I-Premise
group.	I-Premise

In	B-Premise
grade	I-Premise
IV	I-Premise
the	I-Premise
corresponding	I-Premise
median	I-Premise
survival	I-Premise
time	I-Premise
was	I-Premise
12.3	I-Premise
(2.1-89.2)	I-Premise
and	I-Premise
10.3	I-Premise
(0.3-91.7+)	I-Premise
months,	I-Premise
respectively.	I-Premise

Median	B-Premise
time	I-Premise
to	I-Premise
progress	I-Premise
for	I-Premise
radiotherapy	I-Premise
only	I-Premise
and	I-Premise
radiotherapy	I-Premise
and	I-Premise
estramustin	I-Premise
group	I-Premise
in	I-Premise
grade	I-Premise
III	I-Premise
tumours	I-Premise
was	I-Premise
6.5	I-Premise
and	I-Premise
10.1	I-Premise
months,	I-Premise
respectively.	I-Premise

In	B-Premise
grade	I-Premise
IV	I-Premise
tumours	I-Premise
the	I-Premise
corresponding	I-Premise
figures	I-Premise
were	I-Premise
5.1	I-Premise
and	I-Premise
3.3	I-Premise
months,	I-Premise
respectively.	I-Premise

Although	B-Premise
there	I-Premise
was	I-Premise
a	I-Premise
tendency	I-Premise
for	I-Premise
improved	I-Premise
survival	I-Premise
in	I-Premise
grade	I-Premise
III,	I-Premise
no	I-Premise
statistical	I-Premise
significant	I-Premise
differences	I-Premise
were	I-Premise
found	I-Premise
between	I-Premise
the	I-Premise
treatment	I-Premise
groups.	I-Premise

No	B-Premise
differences	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
treatment	I-Premise
groups	I-Premise
were	I-Premise
evident	I-Premise
with	I-Premise
respect	I-Premise
to	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
according	I-Premise
to	I-Premise
the	I-Premise
EORTC	I-Premise
QLQ-protocol.	I-Premise

In	B-Claim
conclusion,	I-Claim
this	I-Claim
first	I-Claim
randomized	I-Claim
study	I-Claim
did	I-Claim
not	I-Claim
demonstrate	I-Claim
any	I-Claim
significant	I-Claim
improvement	I-Claim
of	I-Claim
using	I-Claim
estramustine	I-Claim
in	I-Claim
addition	I-Claim
to	I-Claim
conventional	I-Claim
radiotherapy,	I-Claim
however,	B-Claim
a	I-Claim
trend	I-Claim
for	I-Claim
a	I-Claim
positive	I-Claim
response	I-Claim
for	I-Claim
the	I-Claim
estramustine	I-Claim
group	I-Claim
was	I-Claim
found	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
grade	I-Claim
III	I-Claim
glioma.	I-Claim

Sentinel	B-Claim
lymph	I-Claim
node	I-Claim
biopsy	I-Claim
in	I-Claim
women	I-Claim
with	I-Claim
operable	I-Claim
breast	I-Claim
cancer	I-Claim
is	I-Claim
routinely	I-Claim
used	I-Claim
in	I-Claim
some	I-Claim
countries	I-Claim
for	I-Claim
staging	I-Claim
the	I-Claim
axilla	I-Claim
despite	I-Claim
limited	I-Claim
data	I-Claim
from	I-Claim
randomized	I-Claim
trials	I-Claim
on	I-Claim
morbidity	I-Claim
and	I-Claim
mortality	I-Claim
outcomes.	I-Claim

We	O
conducted	O
a	O
multicenter	O
randomized	O
trial	O
to	O
compare	O
quality-of-life	O
outcomes	O
between	O
patients	O
with	O
clinically	O
node-negative	O
invasive	O
breast	O
cancer	O
who	O
received	O
sentinel	O
lymph	O
node	O
biopsy	O
and	O
patients	O
who	O
received	O
standard	O
axillary	O
treatment.	O

The	O
primary	O
outcome	O
measures	O
were	O
arm	O
and	O
shoulder	O
morbidity	O
and	O
quality	O
of	O
life.	O

From	O
November	O
1999	O
to	O
October	O
2003,	O
1031	O
patients	O
were	O
randomly	O
assigned	O
to	O
undergo	O
sentinel	O
lymph	O
node	O
biopsy	O
(n	O
=	O
515)	O
or	O
standard	O
axillary	O
surgery	O
(n	O
=	O
516).	O

Patients	O
with	O
sentinel	O
lymph	O
node	O
metastases	O
proceeded	O
to	O
delayed	O
axillary	O
clearance	O
or	O
received	O
axillary	O
radiotherapy	O
(depending	O
on	O
the	O
protocol	O
at	O
the	O
treating	O
institution).	O

Intention-to-treat	O
analyses	O
of	O
data	O
at	O
1,	O
3,	O
6,	O
and	O
12	O
months	O
after	O
surgery	O
are	O
presented.	O

All	O
statistical	O
tests	O
were	O
two-sided.	O

The	B-Premise
relative	I-Premise
risks	I-Premise
of	I-Premise
any	I-Premise
lymphedema	I-Premise
and	I-Premise
sensory	I-Premise
loss	I-Premise
for	I-Premise
the	I-Premise
sentinel	I-Premise
lymph	I-Premise
node	I-Premise
biopsy	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
standard	I-Premise
axillary	I-Premise
treatment	I-Premise
group	I-Premise
at	I-Premise
12	I-Premise
months	I-Premise
were	I-Premise
0.37	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
=	I-Premise
0.23	I-Premise
to	I-Premise
0.60;	I-Premise
absolute	I-Premise
rates:	I-Premise
5%	I-Premise
versus	I-Premise
13%)	I-Premise
and	I-Premise
0.37	I-Premise
(95%	I-Premise
CI	I-Premise
=	I-Premise
0.27	I-Premise
to	I-Premise
0.50;	I-Premise
absolute	I-Premise
rates:	I-Premise
11%	I-Premise
versus	I-Premise
31%),	I-Premise
respectively.	I-Premise

Drain	B-Premise
usage,	I-Premise
length	I-Premise
of	I-Premise
hospital	I-Premise
stay,	I-Premise
and	I-Premise
time	I-Premise
to	I-Premise
resumption	I-Premise
of	I-Premise
normal	I-Premise
day-to-day	I-Premise
activities	I-Premise
after	I-Premise
surgery	I-Premise
were	I-Premise
statistically	I-Premise
significantly	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
sentinel	I-Premise
lymph	I-Premise
node	I-Premise
biopsy	I-Premise
group	I-Premise
(all	I-Premise
P	I-Premise
<	I-Premise
.001),	I-Premise
and	I-Premise
axillary	I-Premise
operative	I-Premise
time	I-Premise
was	I-Premise
reduced	I-Premise
(P	I-Premise
=	I-Premise
.055).	I-Premise

Overall	B-Premise
patient-recorded	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
and	I-Premise
arm	I-Premise
functioning	I-Premise
scores	I-Premise
were	I-Premise
statistically	I-Premise
significantly	I-Premise
better	I-Premise
in	I-Premise
the	I-Premise
sentinel	I-Premise
lymph	I-Premise
node	I-Premise
biopsy	I-Premise
group	I-Premise
throughout	I-Premise
(all	I-Premise
P	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
.003).	I-Premise

These	B-Premise
benefits	I-Premise
were	I-Premise
seen	I-Premise
with	I-Premise
no	I-Premise
increase	I-Premise
in	I-Premise
anxiety	I-Premise
levels	I-Premise
in	I-Premise
the	I-Premise
sentinel	I-Premise
lymph	I-Premise
node	I-Premise
biopsy	I-Premise
group	I-Premise
(P	I-Premise
>	I-Premise
.05).	I-Premise

Sentinel	B-Claim
lymph	I-Claim
node	I-Claim
biopsy	I-Claim
is	I-Claim
associated	I-Claim
with	I-Claim
reduced	I-Claim
arm	I-Claim
morbidity	I-Claim
and	I-Claim
better	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
than	I-Claim
standard	I-Claim
axillary	I-Claim
treatment	I-Claim
and	I-Claim
should	I-Claim
be	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
choice	I-Claim
for	I-Claim
patients	I-Claim
who	I-Claim
have	I-Claim
early-stage	I-Claim
breast	I-Claim
cancer	I-Claim
with	I-Claim
clinically	I-Claim
negative	I-Claim
nodes.	I-Claim

Patients	B-Claim
with	I-Claim
advanced	I-Claim
non-small	I-Claim
cell	I-Claim
lung	I-Claim
cancer	I-Claim
(NSCLC)	I-Claim
do	I-Claim
not	I-Claim
have	I-Claim
curative	I-Claim
treatment	I-Claim
options;	I-Claim
therefore,	O
treatments	O
should	O
prolong	O
survival	O
and	O
improve	O
quality	O
of	O
life	O
(QoL).	O

We	O
compared	O
the	O
effect	O
on	O
QoL	O
of	O
two	O
docetaxel-platinum	O
regimens	O
with	O
vinorelbine-cisplatin.	O

QoL	O
was	O
assessed	O
by	O
the	O
Lung	O
Cancer	O
Symptom	O
Scale	O
(LCSS)	O
and	O
the	O
general	O
EuroQol	O
five-dimensional	O
questionnaire	O
(EQ-5D)	O
in	O
926	O
chemotherapy-nave	O
patients	O
with	O
stages	O
IIIB	O
to	O
IV	O
NSCLC.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive:	O
docetaxel	O
75	O
mg/m2	O
plus	O
cisplatin	O
75	O
mg/m2,	O
every	O
3	O
weeks	O
(DC);	O
docetaxel	O
75	O
mg/m2	O
and	O
carboplatin	O
6	O
mg/ml	O
min,	O
every	O
3	O
weeks	O
(DCb);	O
or	O
vinorelbine	O
25	O
mg/m2/week	O
plus	O
cisplatin	O
100	O
mg/m2,	O
every	O
4	O
weeks	O
(VC).	O

Overall,	B-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
either	I-Premise
docetaxel-containing	I-Premise
regimen	I-Premise
had	I-Premise
better	I-Premise
QoL	I-Premise
than	I-Premise
VC-treated	I-Premise
patients	I-Premise
(LCSS	I-Premise
global	I-Premise
item	I-Premise
"QoL	I-Premise
today":	I-Premise
P=0.064	I-Premise
for	I-Premise
DC	I-Premise
and	I-Premise
P=0.016	I-Premise
for	I-Premise
DCb	I-Premise
versus	I-Premise
VC;	I-Premise
EQ-5D	I-Premise
global	I-Premise
item	I-Premise
"health	I-Premise
state	I-Premise
today":	I-Premise
P=0.016	I-Premise
for	I-Premise
DC	I-Premise
and	I-Premise
P<0.001	I-Premise
for	I-Premise
DCb	I-Premise
versus	I-Premise
VC).	I-Premise

DC-treated	B-Premise
patients	I-Premise
experienced	I-Premise
improved	I-Premise
pain	I-Premise
relief	I-Premise
compared	I-Premise
with	I-Premise
VC	I-Premise
(P=0.033),	I-Premise
whereas	O
pain	B-Premise
relief	I-Premise
with	I-Premise
DCb	I-Premise
and	I-Premise
VC	I-Premise
was	I-Premise
similar.	I-Premise

Patients	B-Premise
treated	I-Premise
with	I-Premise
either	I-Premise
docetaxel	I-Premise
regimen	I-Premise
had	I-Premise
more	I-Premise
favorable	I-Premise
changes	I-Premise
in	I-Premise
performance	I-Premise
status	I-Premise
(P=0.065	I-Premise
for	I-Premise
DC	I-Premise
and	I-Premise
P<0.001	I-Premise
for	I-Premise
DCb	I-Premise
versus	I-Premise
VC)	I-Premise
and	I-Premise
mean	I-Premise
weight	I-Premise
loss	I-Premise
(0.06	I-Premise
kg,	I-Premise
gain	I-Premise
of	I-Premise
0.08	I-Premise
kg,	I-Premise
and	I-Premise
2.27	I-Premise
kg	I-Premise
for	I-Premise
DC,	I-Premise
DCb,	I-Premise
and	I-Premise
VC,	I-Premise
respectively;	I-Premise
P<0.001	I-Premise
for	I-Premise
both	I-Premise
DC	I-Premise
versus	I-Premise
VC	I-Premise
and	I-Premise
DCb	I-Premise
versus	I-Premise
VC).	I-Premise

The	B-Claim
TAX	I-Claim
326	I-Claim
study	I-Claim
shows	I-Claim
that	I-Claim
docetaxel-platinum	I-Claim
regimens	I-Claim
relieve	I-Claim
symptoms	I-Claim
and	I-Claim
improve	I-Claim
QoL	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
NSCLC.	I-Claim

DCb	B-Claim
and	I-Claim
DC	I-Claim
were	I-Claim
superior	I-Claim
to	I-Claim
VC	I-Claim
in	I-Claim
all	I-Claim
QoL	I-Claim
outcomes	I-Claim
assessed	I-Claim
except	I-Claim
for	I-Claim
the	I-Claim
difference	I-Claim
between	I-Claim
DC	I-Claim
and	I-Claim
VC	I-Claim
in	I-Claim
LCSS	I-Claim
"QoL	I-Claim
today",	I-Claim
which	I-Claim
was	I-Claim
not	I-Claim
significant.	I-Claim

The	O
purpose	O
of	O
this	O
pilot	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
a	O
combined	O
cardiorespiratory	O
and	O
resistance	O
exercise	O
training	O
program	O
of	O
short	O
duration	O
on	O
the	O
cardiorespiratory	O
fitness,	O
strength	O
endurance,	O
task	O
specific	O
functional	O
muscle	O
capacity,	O
body	O
composition	O
and	O
quality	O
of	O
life	O
(QOL)	O
in	O
women	O
breast	O
cancer	O
survivors.	O

Sixteen	O
subjects	O
were	O
randomly	O
assigned	O
to	O
either	O
a	O
training	O
(n	O
=	O
8;	O
age:	O
50	O
+/-	O
5	O
yrs)	O
or	O
control	O
non-exercising	O
group	O
(n	O
=	O
8;	O
age:	O
51	O
+/-	O
10	O
yrs).	O

The	O
training	O
group	O
followed	O
an	O
8-week	O
exercise	O
program	O
consisting	O
of	O
3	O
weekly	O
sessions	O
of	O
90-min	O
duration,	O
supervised	O
by	O
an	O
experienced	O
investigator	O
and	O
divided	O
into	O
resistance	O
exercises	O
and	O
aerobic	O
training.	O

Before	O
and	O
after	O
the	O
intervention	O
period,	O
all	O
of	O
the	O
subjects	O
performed	O
a	O
cardiorespiratory	O
test	O
to	O
measure	O
peak	O
oxygen	O
uptake	O
(VO2peak),	O
a	O
dynamic	O
strength	O
endurance	O
test	O
(maximum	O
number	O
of	O
repetitions	O
for	O
chest	O
and	O
leg	O
press	O
exercise	O
at	O
30	O
-	O
35	O
%	O
and	O
100	O
-	O
110	O
%	O
of	O
body	O
mass,	O
respectively)	O
and	O
a	O
sit-stand	O
test.	O

Quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
QLQ-C30	O
(EORTC-C30)	O
questionnaire.	O

In	B-Premise
response	I-Premise
to	I-Premise
training,	I-Premise
QOL,	I-Premise
VO2peak	I-Premise
(mean	I-Premise
3.9	I-Premise
ml/kg/min;	I-Premise
95	I-Premise
%	I-Premise
CI,	I-Premise
0.93,	I-Premise
6.90)	I-Premise
performance	I-Premise
in	I-Premise
leg	I-Premise
press	I-Premise
(17.9	I-Premise
kg;	I-Premise
95	I-Premise
%	I-Premise
CI,	I-Premise
12.8,	I-Premise
22.4)	I-Premise
and	I-Premise
sit-stand	I-Premise
test	I-Premise
(-	I-Premise
0.67	I-Premise
s;	I-Premise
95	I-Premise
%	I-Premise
CI,	I-Premise
-	I-Premise
0.52,	I-Premise
-	I-Premise
1.2)	I-Premise
improved	I-Premise
(p	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
0.05).	I-Premise

We	B-Premise
observed	I-Premise
no	I-Premise
significant	I-Premise
changes	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

Combined	B-Claim
cardiorespiratory	I-Claim
and	I-Claim
resistance	I-Claim
training,	I-Claim
even	I-Claim
of	I-Claim
very	I-Claim
brief	I-Claim
duration,	I-Claim
improves	I-Claim
the	I-Claim
QOL	I-Claim
and	I-Claim
the	I-Claim
overall	I-Claim
physical	I-Claim
fitness	I-Claim
of	I-Claim
women	I-Claim
breast	I-Claim
cancer	I-Claim
survivors.	I-Claim

LV5FU2	O
with	O
high-dose	O
leucovorin	O
(LV),	O
weekly	O
infusional	O
5-fluorouracil	O
(5FU)	O
(AIO	O
schedule)	O
and	O
raltitrexed	O
have	O
been	O
demonstrated	O
to	O
be	O
active	O
agents	O
in	O
first-line	O
treatment	O
of	O
colorectal	O
cancer.	O

We	O
performed	O
a	O
4-arm	O
randomised	O
trial	O
to	O
compare	O
(1)	O
a	O
low-dose	O
intravenous	O
bolus	O
of	O
LV	O
(20	O
mg/m2),	O
followed	O
by	O
an	O
intravenous	O
bolus	O
of	O
5FU	O
(400	O
mg/m2),	O
followed	O
by	O
a	O
22-hour	O
continuous	O
infusion	O
of	O
5FU	O
(600	O
mg/m2)	O
on	O
day	O
1	O
and	O
day	O
2/2	O
weeks	O
(ldLV5FU2	O
arm),	O
(2)	O
a	O
weekly	O
continuous	O
infusion	O
of	O
high-dose	O
5FU	O
(2.6	O
g/m2/week)	O
for	O
6	O
weeks	O
followed	O
by	O
a	O
rest	O
week	O
(HD-FU	O
arm)	O
and	O
(3)	O
raltitrexed	O
(Tomudex	O
arm;	O
3	O
mg/m2/3	O
weeks)	O
to	O
standard	O
LV5FU2.	O

From	O
1997	O
to	O
2001,	O
294	O
patients	O
were	O
included.	O

The	O
4	O
arms	O
were	O
well	O
balanced	O
for	O
sex	O
ratio,	O
age,	O
WHO	O
performance	O
status,	O
the	O
primary	O
tumour	O
site	O
and	O
prior	O
adjuvant	O
chemotherapy.	O

Treatment	O
was	O
stopped	O
due	O
to	O
low	O
accrual.	O

Two	B-Premise
toxicity-related	I-Premise
deaths	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
Tomudex	I-Premise
arm.	I-Premise

The	B-Premise
treatments	I-Premise
gave	I-Premise
rise	I-Premise
to	I-Premise
different	I-Premise
rates	I-Premise
of	I-Premise
grade	I-Premise
3-4	I-Premise
neutropenia	I-Premise
(3,	I-Premise
4,	I-Premise
11	I-Premise
and	I-Premise
14%	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
LV5FU2,	I-Premise
ldLV5FU2,	I-Premise
HD-FU	I-Premise
and	I-Premise
Tomudex	I-Premise
arms,	I-Premise
respectively,	I-Premise
p	I-Premise
=	I-Premise
0.028),	I-Premise
leucopenia	I-Premise
and	I-Premise
vomiting.	I-Premise

At	B-Premise
least	I-Premise
one	I-Premise
episode	I-Premise
of	I-Premise
grade	I-Premise
3-4	I-Premise
toxicity	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
27,	I-Premise
25,	I-Premise
38	I-Premise
and	I-Premise
47%	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
LV5FU2,	I-Premise
ldLV5FU2,	I-Premise
HD-FU	I-Premise
and	I-Premise
Tomudex	I-Premise
arms,	I-Premise
respectively	I-Premise
(p	I-Premise
=	I-Premise
0.016).	I-Premise

An	B-Premise
objective	I-Premise
response	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
28,	I-Premise
21,	I-Premise
22	I-Premise
and	I-Premise
10%	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
LV5FU2,	I-Premise
ldLV5FU2,	I-Premise
HD-FU	I-Premise
and	I-Premise
Tomudex	I-Premise
arms,	I-Premise
respectively	I-Premise
(p	I-Premise
=	I-Premise
0.04).	I-Premise

Progression-free	B-Premise
survival	I-Premise
(PFS)	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
Tomudex	I-Premise
arm	I-Premise
was	I-Premise
statistically	I-Premise
lower	I-Premise
compared	I-Premise
to	I-Premise
that	I-Premise
of	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
LV5FU2	I-Premise
or	I-Premise
ldLV5FU2	I-Premise
(combined	I-Premise
group;	I-Premise
p	I-Premise
=	I-Premise
0.013,	I-Premise
log	I-Premise
rank	I-Premise
test).	I-Premise

In	B-Claim
conclusion,	I-Claim
Tomudex	I-Claim
is	I-Claim
more	I-Claim
toxic	I-Claim
and	I-Claim
yields	I-Claim
shorter	I-Claim
PFS	I-Claim
than	I-Claim
infusional	I-Claim
5FU.	I-Claim

Despite	B-Claim
the	I-Claim
early	I-Claim
closure	I-Claim
of	I-Claim
the	I-Claim
study	I-Claim
and	I-Claim
the	I-Claim
lack	I-Claim
of	I-Claim
power	I-Claim
of	I-Claim
the	I-Claim
comparison,	I-Claim
it	I-Claim
seems	I-Claim
that	I-Claim
ldLV5FU2	I-Claim
could	I-Claim
be	I-Claim
considered	I-Claim
as	I-Claim
an	I-Claim
active,	I-Claim
easier	I-Claim
and	I-Claim
less	I-Claim
expensive	I-Claim
option	I-Claim
for	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
metastatic	I-Claim
colorectal	I-Claim
cancer	I-Claim
compared	I-Claim
to	I-Claim
classic	I-Claim
LV5FU2	I-Claim
or	I-Claim
weekly	I-Claim
HD-FU.	I-Claim

DPPE	B-Claim
(tesmilifene)	I-Claim
plus	I-Claim
doxorubicin	I-Claim
(DOX)	I-Claim
demonstrated	I-Claim
a	I-Claim
significant	I-Claim
improvement	I-Claim
in	I-Claim
survival	I-Claim
versus	I-Claim
DOX	I-Claim
in	I-Claim
a	I-Claim
phase	I-Claim
III	I-Claim
clinical	I-Claim
trial	I-Claim
in	I-Claim
advanced	I-Claim
breast	I-Claim
cancer.	I-Claim

However,	B-Premise
DPPE	I-Premise
is	I-Premise
associated	I-Premise
with	I-Premise
unusual	I-Premise
toxicity	I-Premise
in	I-Premise
the	I-Premise
form	I-Premise
of	I-Premise
hallucinations,	I-Premise
nausea	I-Premise
and	I-Premise
vomiting	I-Premise
which	I-Premise
were	I-Premise
anticipated	I-Premise
to	I-Premise
impact	I-Premise
on	I-Premise
short-term	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(QOL).	I-Premise

Standard	O
National	O
Cancer	O
Institute	O
of	O
Canada	O
Clinical	O
Trials	O
Group	O
(NCIC	O
CTG)	O
approaches	O
were	O
applied	O
as	O
the	O
primary	O
method	O
to	O
analyze	O
the	O
QOL	O
data	O
from	O
this	O
trial.	O

This	O
includes	O
cross-sectional	O
comparisons,	O
together	O
with	O
a	O
global	O
test	O
for	O
the	O
QOL	O
response	O
rate.	O

Sensitivity	O
analyses	O
were	O
also	O
performed	O
for	O
selected	O
QOL	O
domains	O
and	O
items,	O
using	O
other	O
types	O
of	O
summary	O
measures	O
and	O
statistics.	O

Two	O
hundred	O
seventy	O
one	O
patients	O
(89%	O
of	O
randomized)	O
submitted	O
the	O
baseline	O
QOL	O
questionnaires	O
and	O
were	O
included	O
in	O
the	O
QOL	O
analysis.	O

No	B-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
QOL	I-Premise
response	I-Premise
between	I-Premise
treatment	I-Premise
arms	I-Premise
was	I-Premise
found	I-Premise
for	I-Premise
any	I-Premise
domain	I-Premise
or	I-Premise
item	I-Premise
except	I-Premise
nausea	I-Premise
and	I-Premise
vomiting	I-Premise
(P	I-Premise
=	I-Premise
0.04).	I-Premise

Cross-sectional	B-Premise
comparisons	I-Premise
showed	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
for	I-Premise
some	I-Premise
domains/items	I-Premise
at	I-Premise
specific	I-Premise
assessment	I-Premise
times	I-Premise
with	I-Premise
all	I-Premise
differences	I-Premise
favoring	I-Premise
the	I-Premise
DOX	I-Premise
alone	I-Premise
arm.	I-Premise

Patients	B-Premise
on	I-Premise
DPPE/DOX	I-Premise
arm	I-Premise
were	I-Premise
significantly	I-Premise
worse	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
average	I-Premise
and	I-Premise
median	I-Premise
pain	I-Premise
change	I-Premise
scores.	I-Premise

Different	B-Claim
analyses	I-Claim
yielded	I-Claim
slightly	I-Claim
different	I-Claim
conclusions	I-Claim
but,	O
in	B-Claim
general,	I-Claim
the	I-Claim
QOL	I-Claim
analyses	I-Claim
were	I-Claim
concordant	I-Claim
and	I-Claim
showed	I-Claim
that	I-Claim
patients	I-Claim
on	I-Claim
DOX	I-Claim
alone	I-Claim
had	I-Claim
fewer	I-Claim
disease	I-Claim
and	I-Claim
treatment	I-Claim
related	I-Claim
adverse	I-Claim
events	I-Claim
and	I-Claim
better	I-Claim
QOL.	I-Claim

Interestingly,	B-Claim
the	I-Claim
QOL	I-Claim
response	I-Claim
analysis	I-Claim
also	I-Claim
showed	I-Claim
that	I-Claim
aggressive	I-Claim
premedication	I-Claim
regimens	I-Claim
appear	I-Claim
to	I-Claim
ameliorate	I-Claim
potential	I-Claim
negative	I-Claim
effects	I-Claim
of	I-Claim
DPPE	I-Claim
on	I-Claim
emesis	I-Claim
and	I-Claim
nausea	I-Claim
as	I-Claim
measured	I-Claim
by	I-Claim
patient	I-Claim
assessed	I-Claim
QOL.	I-Claim

Recent	B-Claim
studies	I-Claim
have	I-Claim
shown	I-Claim
that	I-Claim
administering	I-Claim
the	I-Claim
aromatase	I-Claim
inhibitor	I-Claim
exemestane	I-Claim
after	I-Claim
2-3	I-Claim
years	I-Claim
of	I-Claim
tamoxifen	I-Claim
therapy	I-Claim
significantly	I-Claim
improves	I-Claim
disease-free	I-Claim
survival	I-Claim
in	I-Claim
postmenopausal	I-Claim
women	I-Claim
with	I-Claim
primary	I-Claim
breast	I-Claim
cancer	I-Claim
in	I-Claim
comparison	I-Claim
with	I-Claim
standard	I-Claim
5-year	I-Claim
tamoxifen	I-Claim
treatment.	I-Claim

Although	O
many	O
of	O
the	O
adverse	O
effects	O
associated	O
with	O
exemestane	O
and	O
tamoxifen	O
have	O
been	O
analysed,	O
there	O
are	O
no	O
comparative	O
data	O
concerning	O
body	O
weight	O
and	O
body	O
composition.	O

The	O
aim	O
of	O
this	O
randomised	O
study	O
was	O
to	O
evaluate	O
the	O
longitudinal	O
changes	O
in	O
body	O
composition	O
and	O
lipid	O
profiles	O
in	O
postmenopausal	O
women	O
switched	O
from	O
tamoxifen	O
to	O
exemestane.	O

In	O
total,	O
60	O
overweight	O
or	O
obese	O
postmenopausal	O
patients	O
were	O
enrolled.	O

Their	O
anthropometric	O
data,	O
body	O
composition,	O
including	O
fat	O
mass	O
(FM)	O
and	O
fat-free	O
mass	O
(FFM),	O
and	O
lipid	O
profiles,	O
caloric	O
intake	O
and	O
physical	O
activity	O
were	O
assessed	O
1	O
week	O
before	O
randomisation,	O
and	O
6	O
and	O
12	O
months	O
later.	O

In	O
all,	O
55	O
patients	O
(27	O
on	O
tamoxifen	O
and	O
28	O
on	O
exemestane)	O
completed	O
the	O
1-year	O
study	O
period.	O

Fat	B-Premise
mass	I-Premise
had	I-Premise
significantly	I-Premise
decreased	I-Premise
by	I-Premise
month	I-Premise
12	I-Premise
in	I-Premise
the	I-Premise
exemestane,	I-Premise
but	I-Premise
not	I-Premise
in	I-Premise
the	I-Premise
tamoxifen	I-Premise
group;	I-Premise
the	B-Premise
between-group	I-Premise
difference	I-Premise
was	I-Premise
statistically	I-Premise
significant	I-Premise
(P<0.01).	I-Premise

The	B-Premise
FFM/FM	I-Premise
ratio	I-Premise
had	I-Premise
significantly	I-Premise
increased	I-Premise
in	I-Premise
the	I-Premise
exemestane	I-Premise
group,	I-Premise
but	I-Premise
not	I-Premise
the	I-Premise
tamoxifen	I-Premise
group;	I-Premise
the	B-Premise
between-group	I-Premise
difference	I-Premise
was	I-Premise
statistically	I-Premise
significant	I-Premise
(P<0.05).	I-Premise

Triglycerides	B-Premise
and	I-Premise
high-density	I-Premise
lipoprotein	I-Premise
cholesterol	I-Premise
significantly	I-Premise
decreased	I-Premise
(P<0.01;	I-Premise
P<0.05),	I-Premise
and	O
low-density	B-Premise
lipoprotein	I-Premise
cholesterol	I-Premise
significantly	I-Premise
increased	I-Premise
(P<0.01)	I-Premise
in	I-Premise
the	I-Premise
exemestane	I-Premise
group	I-Premise
at	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
the	I-Premise
1-year	I-Premise
study	I-Premise
period.	I-Premise

Our	B-Claim
findings	I-Claim
suggest	I-Claim
that	I-Claim
switching	I-Claim
patients	I-Claim
to	I-Claim
adjuvant	I-Claim
exemestane	I-Claim
treatment	I-Claim
after	I-Claim
at	I-Claim
least	I-Claim
2	I-Claim
years	I-Claim
of	I-Claim
tamoxifen	I-Claim
therapy	I-Claim
may	I-Claim
be	I-Claim
associated	I-Claim
with	I-Claim
an	I-Claim
advantage	I-Claim
over	I-Claim
continuing	I-Claim
adjuvant	I-Claim
tamoxifen	I-Claim
treatment	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
body	I-Claim
composition.	I-Claim

To	O
compare	O
the	O
effects	O
of	O
cannabis	O
extract	O
(CE),	O
delta-9-tetrahydrocannabinol	O
(THC),	O
and	O
placebo	O
(PL)	O
on	O
appetite	O
and	O
quality	O
of	O
life	O
(QOL)	O
in	O
patients	O
with	O
cancer-related	O
anorexia-cachexia	O
syndrome	O
(CACS).	O

Adult	O
patients	O
with	O
advanced	O
cancer,	O
CACS,	O
weight	O
loss	O
(>	O
or	O
=	O
5%	O
over	O
6	O
months),	O
and	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(ECOG)	O
performance	O
status	O
(PS)	O
<	O
or	O
=	O
2	O
were	O
randomly	O
assigned	O
(2:2:1)	O
to	O
receive	O
CE	O
(standardized	O
for	O
2.5	O
mg	O
THC	O
and	O
1	O
mg	O
cannabidiol)	O
or	O
THC	O
(2.5	O
mg)	O
or	O
PL	O
orally,	O
twice	O
daily	O
for	O
6	O
weeks.	O

Appetite,	O
mood,	O
and	O
nausea	O
were	O
monitored	O
daily	O
with	O
a	O
visual	O
analog	O
scale	O
(VAS);	O
QOL	O
was	O
assessed	O
with	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
C30	O
(composite	O
score:	O
questions	O
29	O
and	O
30).	O

Cannabinoid-related	O
toxicity	O
was	O
assessed	O
every	O
2	O
weeks.	O

Of	O
289	O
patients	O
screened,	O
243	O
were	O
randomly	O
assigned	O
and	O
164	O
(CE,	O
66	O
of	O
95	O
patients;	O
THC,	O
65	O
of	O
100	O
patients;	O
and	O
PL,	O
33	O
of	O
48	O
patients)	O
completed	O
treatment.	O

At	O
baseline,	O
groups	O
were	O
comparable	O
for	O
age	O
(mean,	O
61	O
years),	O
sex	O
(54%	O
men),	O
weight	O
loss	O
(32%	O
>	O
or	O
=	O
10%),	O
PS	O
(13%	O
ECOG	O
=	O
2),	O
antineoplastic	O
treatment	O
(50%),	O
appetite	O
(mean	O
VAS	O
score,	O
31/100	O
mm),	O
and	O
QOL	O
(mean	O
score,	O
30/100).	O

Intent-to-treat	B-Premise
analysis	I-Premise
showed	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
the	I-Premise
three	I-Premise
arms	I-Premise
for	I-Premise
appetite,	I-Premise
QOL,	I-Premise
or	I-Premise
cannabinoid-related	I-Premise
toxicity.	I-Premise

Increased	B-Premise
appetite	I-Premise
was	I-Premise
reported	I-Premise
by	I-Premise
73%,	I-Premise
58%,	I-Premise
and	I-Premise
69%	I-Premise
of	I-Premise
patients	I-Premise
receiving	I-Premise
CE,	I-Premise
THC,	I-Premise
or	I-Premise
PL,	I-Premise
respectively.	I-Premise

An	O
independent	O
data	O
review	O
board	O
recommended	O
termination	O
of	O
recruitment	O
because	O
of	O
insufficient	O
differences	O
between	O
study	O
arms.	O

CE	B-Premise
at	I-Premise
the	I-Premise
oral	I-Premise
dose	I-Premise
administered	I-Premise
was	I-Premise
well	I-Premise
tolerated	I-Premise
by	I-Premise
these	I-Premise
patients	I-Premise
with	I-Premise
CACS.	I-Premise

No	B-Claim
differences	I-Claim
in	I-Claim
patients'	I-Claim
appetite	I-Claim
or	I-Claim
QOL	I-Claim
were	I-Claim
found	I-Claim
either	I-Claim
between	I-Claim
CE,	I-Claim
THC,	I-Claim
and	I-Claim
PL	I-Claim
or	I-Claim
between	I-Claim
CE	I-Claim
and	I-Claim
THC	I-Claim
at	I-Claim
the	I-Claim
dosages	I-Claim
investigated.	I-Claim

Docetaxel	B-Claim
has	I-Claim
shown	I-Claim
activity	I-Claim
in	I-Claim
elderly	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
non-small-cell	I-Claim
lung	I-Claim
cancer	I-Claim
(NSCLC).	I-Claim

This	O
randomized	O
phase	O
III	O
trial	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
docetaxel	O
versus	O
vinorelbine	O
(the	O
current	O
standard	O
treatment)	O
in	O
elderly	O
patients.	O

Chemotherapy-nave	O
patients	O
age	O
70	O
years	O
or	O
older	O
with	O
stage	O
IIIB/IV	O
NSCLC	O
and	O
performance	O
status	O
2	O
or	O
lower	O
were	O
eligible.	O

Patients	O
randomly	O
received	O
docetaxel	O
60	O
mg/m2	O
(day	O
1)	O
or	O
vinorelbine	O
25	O
mg/m2	O
(days	O
1	O
and	O
8)	O
every	O
21	O
days	O
for	O
four	O
cycles.	O

The	O
primary	O
end	O
point	O
was	O
overall	O
survival.	O

Overall	O
disease-related	O
symptom	O
improvement	O
was	O
assessed	O
using	O
an	O
eight-item	O
questionnaire.	O

In	O
total,	O
182	O
patients	O
were	O
enrolled.	O

Median	O
age	O
was	O
76	O
years	O
(range,	O
70	O
years	O
to	O
86	O
years).	O

There	B-Premise
was	I-Premise
no	I-Premise
statistical	I-Premise
difference	I-Premise
in	I-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
with	I-Premise
docetaxel	I-Premise
versus	I-Premise
vinorelbine	I-Premise
(14.3	I-Premise
months	I-Premise
v	I-Premise
9.9	I-Premise
months;	I-Premise
hazard	I-Premise
ratio,	I-Premise
0.780;	I-Premise
95%	I-Premise
CI,	I-Premise
0.561	I-Premise
to	I-Premise
1.085;	I-Premise
P	I-Premise
=	I-Premise
.138).	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
median	I-Premise
progression-free	I-Premise
survival	I-Premise
(5.5	I-Premise
months	I-Premise
v	I-Premise
3.1	I-Premise
months;	I-Premise
P	I-Premise
<	I-Premise
.001).	I-Premise

Response	B-Premise
rates	I-Premise
were	I-Premise
also	I-Premise
significantly	I-Premise
improved	I-Premise
with	I-Premise
docetaxel	I-Premise
versus	I-Premise
vinorelbine	I-Premise
(22.7%	I-Premise
v	I-Premise
9.9%;	I-Premise
P	I-Premise
=	I-Premise
.019).	I-Premise

The	B-Premise
most	I-Premise
common	I-Premise
grade	I-Premise
3	I-Premise
to	I-Premise
4	I-Premise
toxicities	I-Premise
were	I-Premise
neutropenia	I-Premise
(82.9%	I-Premise
for	I-Premise
docetaxel;	I-Premise
69.2%	I-Premise
for	I-Premise
vinorelbine;	I-Premise
P	I-Premise
=	I-Premise
.031)	I-Premise
and	I-Premise
leukopenia	I-Premise
(58.0%	I-Premise
for	I-Premise
docetaxel;	I-Premise
51.7%	I-Premise
for	I-Premise
vinorelbine).	I-Premise

Other	B-Premise
toxicities	I-Premise
were	I-Premise
mild	I-Premise
and	I-Premise
generally	I-Premise
well	I-Premise
tolerated.	I-Premise

Docetaxel	B-Premise
improved	I-Premise
overall	I-Premise
disease-related	I-Premise
symptoms	I-Premise
over	I-Premise
vinorelbine	I-Premise
(odds	I-Premise
ratio,	I-Premise
1.86;	I-Premise
95%	I-Premise
CI,	I-Premise
1.09	I-Premise
to	I-Premise
3.20).	I-Premise

Docetaxel	B-Premise
improved	I-Premise
progression-free	I-Premise
survival,	I-Premise
response	I-Premise
rate,	I-Premise
and	I-Premise
disease-related	I-Premise
symptoms	I-Premise
versus	I-Premise
vinorelbine.	I-Premise

Overall	B-Claim
survival	I-Claim
was	I-Claim
not	I-Claim
statistically	I-Claim
significantly	I-Claim
improved	I-Claim
at	I-Claim
this	I-Claim
time.	I-Claim

Docetaxel	B-Claim
monotherapy	I-Claim
may	I-Claim
be	I-Claim
considered	I-Claim
as	I-Claim
an	I-Claim
option	I-Claim
in	I-Claim
the	I-Claim
standard	I-Claim
treatment	I-Claim
of	I-Claim
elderly	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
NSCLC.	I-Claim

The	O
combination	O
of	O
carboplatin	O
and	O
paclitaxel	O
is	O
the	O
standard	O
of	O
care	O
for	O
the	O
treatment	O
of	O
ovarian	O
cancer,	O
yet	O
rates	O
of	O
recurrence	O
and	O
death	O
remain	O
high.	O

We	O
performed	O
a	O
prospective	O
randomized	O
phase	O
III	O
study	O
to	O
examine	O
whether	O
sequential	O
administration	O
of	O
topotecan	O
can	O
improve	O
the	O
efficacy	O
of	O
carboplatin	O
and	O
paclitaxel	O
in	O
first-line	O
treatment	O
of	O
advanced	O
epithelial	O
ovarian	O
cancer.	O

A	O
total	O
of	O
1308	O
patients	O
with	O
previously	O
untreated	O
ovarian	O
cancer	O
(International	O
Federation	O
of	O
Gynecology	O
and	O
Obstetrics	O
stages	O
IIB-IV)	O
were	O
randomly	O
assigned	O
to	O
receive	O
six	O
cycles	O
of	O
paclitaxel	O
and	O
carboplatin	O
followed	O
by	O
either	O
four	O
cycles	O
of	O
topotecan	O
(TC-Top;	O
658	O
patients)	O
or	O
surveillance	O
(TC;	O
650	O
patients)	O
on	O
a	O
3-week	O
per	O
cycle	O
schedule.	O

The	O
primary	O
endpoint	O
was	O
overall	O
survival,	O
and	O
secondary	O
endpoints	O
were	O
progression-free	O
survival,	O
response	O
rate,	O
toxicity,	O
and	O
quality	O
of	O
life.	O

Time-to-event	O
data	O
were	O
analyzed	O
using	O
the	O
Kaplan-Meier	O
method,	O
and	O
a	O
stratified	O
log-rank	O
test	O
was	O
used	O
to	O
compare	O
distributions	O
between	O
treatment	O
groups.	O

Hazard	O
ratios	O
(HRs)	O
with	O
95%	O
confidence	O
intervals	O
(CIs)	O
were	O
estimated	O
using	O
a	O
Cox	O
proportional	O
hazards	O
model.	O

Categorical	O
data	O
were	O
compared	O
using	O
a	O
stratified	O
Cochran-Mantel-Haenszel	O
test.	O

All	O
statistical	O
tests	O
were	O
two-sided.	O

Median	B-Premise
progression-free	I-Premise
survival	I-Premise
was	I-Premise
18.2	I-Premise
months	I-Premise
in	I-Premise
the	I-Premise
TC-Top	I-Premise
arm	I-Premise
versus	I-Premise
18.5	I-Premise
months	I-Premise
in	I-Premise
the	I-Premise
TC	I-Premise
arm	I-Premise
(stratum-adjusted	I-Premise
HR	I-Premise
=	I-Premise
0.97	I-Premise
[95%	I-Premise
CI	I-Premise
=	I-Premise
0.85	I-Premise
to	I-Premise
1.10];	I-Premise
P	I-Premise
=	I-Premise
.688).	I-Premise

Median	B-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
43.1	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
TC-Top	I-Premise
arm	I-Premise
versus	I-Premise
44.5	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
TC	I-Premise
arm	I-Premise
(stratum-adjusted	I-Premise
HR	I-Premise
=	I-Premise
1.01	I-Premise
[95%	I-Premise
CI	I-Premise
=	I-Premise
0.86	I-Premise
to	I-Premise
1.18];	I-Premise
P	I-Premise
=	I-Premise
.885).	I-Premise

At	B-Premise
3	I-Premise
years,	I-Premise
overall	I-Premise
survival	I-Premise
in	I-Premise
both	I-Premise
arms	I-Premise
was	I-Premise
57%	I-Premise
(58.5%	I-Premise
in	I-Premise
the	I-Premise
TC	I-Premise
arm	I-Premise
and	I-Premise
55.7%	I-Premise
in	I-Premise
the	I-Premise
TC-Top	I-Premise
arm).	I-Premise

Compared	B-Premise
with	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
TC	I-Premise
arm,	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
TC-Top	I-Premise
arm	I-Premise
had	I-Premise
more	I-Premise
grade	I-Premise
3-4	I-Premise
hematologic	I-Premise
toxic	I-Premise
effects	I-Premise
(requiring	I-Premise
more	I-Premise
supportive	I-Premise
care)	I-Premise
and	I-Premise
more	I-Premise
grade	I-Premise
3-4	I-Premise
infections	I-Premise
(5.1%	I-Premise
versus	I-Premise
2.7%;	I-Premise
P	I-Premise
=	I-Premise
.034)	I-Premise
but	I-Premise
did	I-Premise
not	I-Premise
have	I-Premise
a	I-Premise
statistically	I-Premise
significant	I-Premise
increase	I-Premise
in	I-Premise
febrile	I-Premise
neutropenia	I-Premise
(3.3%	I-Premise
versus	I-Premise
3.1%;	I-Premise
P	I-Premise
=	I-Premise
.80).	I-Premise

Among	B-Premise
patients	I-Premise
who	I-Premise
had	I-Premise
measurable	I-Premise
disease	I-Premise
(TC,	I-Premise
n	I-Premise
=	I-Premise
147;	I-Premise
TC-Top,	I-Premise
n	I-Premise
=	I-Premise
145),	I-Premise
overall	I-Premise
(i.e.,	I-Premise
complete	I-Premise
or	I-Premise
partial)	I-Premise
response	I-Premise
was	I-Premise
69.0%	I-Premise
(95%	I-Premise
CI	I-Premise
=	I-Premise
61.4%	I-Premise
to	I-Premise
76.5%)	I-Premise
in	I-Premise
the	I-Premise
TC-Top	I-Premise
arm	I-Premise
and	I-Premise
76.2%	I-Premise
(95%	I-Premise
CI	I-Premise
=	I-Premise
69.3%	I-Premise
to	I-Premise
83.1%)	I-Premise
in	I-Premise
the	I-Premise
TC	I-Premise
arm	I-Premise
(P	I-Premise
=	I-Premise
.166).	I-Premise

The	B-Claim
sequential	I-Claim
addition	I-Claim
of	I-Claim
topotecan	I-Claim
to	I-Claim
carboplatin-paclitaxel	I-Claim
did	I-Claim
not	I-Claim
result	I-Claim
in	I-Claim
superior	I-Claim
overall	I-Claim
response	I-Claim
or	I-Claim
progression-free	I-Claim
or	I-Claim
overall	I-Claim
survival.	I-Claim

Therefore,	B-Claim
this	I-Claim
regimen	I-Claim
is	I-Claim
not	I-Claim
recommended	I-Claim
as	I-Claim
standard	I-Claim
of	I-Claim
care	I-Claim
treatment	I-Claim
for	I-Claim
ovarian	I-Claim
cancer.	I-Claim

This	O
report	O
describes	O
the	O
quality	O
of	O
life	O
(QOL)	O
findings	O
of	O
a	O
randomized	O
placebo	O
controlled	O
study	O
of	O
erlotinib,	O
an	O
epidermal	O
growth	O
factor	O
receptor	O
inhibitor,	O
in	O
patients	O
with	O
non-small-cell	O
lung	O
cancer	O
(NSCLC).	O

This	O
double-blind	O
phase	O
III	O
trial	O
randomly	O
assigned	O
731	O
patients	O
with	O
NSCLC	O
who	O
had	O
progressed	O
after	O
prior	O
chemotherapy	O
to	O
erlotinib	O
150	O
mg	O
daily	O
or	O
placebo,	O
with	O
survival	O
as	O
the	O
primary	O
study	O
outcome.	O

QOL	O
was	O
assessed	O
by	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
QLQ-C30	O
and	O
the	O
lung	O
cancer	O
module	O
QLQ-LC13.	O

The	O
primary	O
end	O
points	O
for	O
QOL	O
analysis	O
were	O
time	O
to	O
deterioration	O
of	O
three	O
common	O
lung	O
cancer	O
symptoms:	O
cough,	O
dyspnea,	O
and	O
pain.	O

Survival	B-Premise
was	I-Premise
significantly	I-Premise
longer	I-Premise
(hazard	I-Premise
ratio,	I-Premise
0.70;	I-Premise
P	I-Premise
<	I-Premise
.0001)	I-Premise
in	I-Premise
the	I-Premise
erlotinib	I-Premise
arm.	I-Premise

Compliance	B-Premise
with	I-Premise
QOL	I-Premise
was	I-Premise
87%	I-Premise
at	I-Premise
baseline	I-Premise
and	I-Premise
more	I-Premise
than	I-Premise
70%	I-Premise
during	I-Premise
treatment.	I-Premise

Patients	B-Premise
receiving	I-Premise
erlotinib	I-Premise
had	I-Premise
significantly	I-Premise
longer	I-Premise
median	I-Premise
time	I-Premise
to	I-Premise
deterioration	I-Premise
for	I-Premise
all	I-Premise
three	I-Premise
symptoms	I-Premise
(4.9	I-Premise
v	I-Premise
3.7	I-Premise
months	I-Premise
for	I-Premise
cough	I-Premise
[P	I-Premise
=	I-Premise
.04];	I-Premise
4.7	I-Premise
v	I-Premise
2.9	I-Premise
months	I-Premise
for	I-Premise
dyspnea	I-Premise
[P	I-Premise
=	I-Premise
.04],	I-Premise
and	I-Premise
2.8	I-Premise
v	I-Premise
1.9	I-Premise
months	I-Premise
for	I-Premise
pain	I-Premise
[P	I-Premise
=	I-Premise
.03]).	I-Premise

QOL	B-Premise
response	I-Premise
analyses	I-Premise
showed	I-Premise
that	I-Premise
44%,	I-Premise
34%,	I-Premise
and	I-Premise
42%	I-Premise
of	I-Premise
patients	I-Premise
receiving	I-Premise
erlotinib	I-Premise
had	I-Premise
improvement	I-Premise
in	I-Premise
these	I-Premise
three	I-Premise
symptoms,	I-Premise
respectively.	I-Premise

This	B-Premise
was	I-Premise
accompanied	I-Premise
by	I-Premise
a	I-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
the	I-Premise
physical	I-Premise
function	I-Premise
(31%	I-Premise
erlotinib	I-Premise
v	I-Premise
19%	I-Premise
placebo,	I-Premise
P	I-Premise
=	I-Premise
.01),	I-Premise
and	I-Premise
global	I-Premise
QOL	I-Premise
(35%	I-Premise
v	I-Premise
26%,	I-Premise
P	I-Premise
<	I-Premise
.0001).	I-Premise

Patients	B-Premise
with	I-Premise
complete	I-Premise
or	I-Premise
partial	I-Premise
response	I-Premise
were	I-Premise
more	I-Premise
likely	I-Premise
to	I-Premise
have	I-Premise
improvement	I-Premise
in	I-Premise
the	I-Premise
QOL	I-Premise
response	I-Premise
than	I-Premise
patients	I-Premise
with	I-Premise
stable	I-Premise
or	I-Premise
progressive	I-Premise
disease	I-Premise
(P	I-Premise
<	I-Premise
.01).	I-Premise

Erlotinib	B-Claim
not	I-Claim
only	I-Claim
improves	I-Claim
survival	I-Claim
in	I-Claim
previously	I-Claim
treated	I-Claim
patients	I-Claim
with	I-Claim
NSCLC,	I-Claim
but	I-Claim
also	I-Claim
improves	I-Claim
tumor-related	I-Claim
symptoms	I-Claim
and	I-Claim
important	I-Claim
aspects	I-Claim
of	I-Claim
QOL.	I-Claim

To	O
compare	O
the	O
effectiveness	O
and	O
tolerability	O
of	O
gemcitabine	O
plus	O
cisplatin	O
with	O
single-agent	O
gemcitabine	O
as	O
first-line	O
chemotherapy	O
for	O
locally	O
advanced	O
or	O
metastatic	O
pancreatic	O
cancer.	O

Patients	O
with	O
advanced	O
adenocarcinoma	O
of	O
the	O
pancreas	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
gemcitabine	O
1,000	O
mg/m2	O
and	O
cisplatin	O
50	O
mg/m2	O
given	O
on	O
days	O
1	O
and	O
15	O
of	O
a	O
4-week	O
cycle	O
(GemCis	O
arm)	O
or	O
gemcitabine	O
alone	O
at	O
a	O
dose	O
of	O
1,000	O
mg/m2	O
on	O
days	O
1,	O
8,	O
and	O
15	O
of	O
a	O
4-week	O
regimen	O
(Gem	O
arm).	O

The	O
primary	O
end	O
point	O
was	O
overall	O
survival;	O
secondary	O
end	O
points	O
were	O
progression-free	O
survival,	O
response	O
rate,	O
safety,	O
and	O
quality	O
of	O
life.	O

One	O
hundred	O
ninety-five	O
patients	O
were	O
enrolled	O
and	O
showed	O
baseline	O
characteristics	O
well	O
balanced	O
between	O
treatment	O
arms.	O

Combination	B-Premise
treatment	I-Premise
in	I-Premise
the	I-Premise
GemCis	I-Premise
arm	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
a	I-Premise
prolonged	I-Premise
median	I-Premise
progression-free	I-Premise
survival	I-Premise
(5.3	I-Premise
months	I-Premise
v	I-Premise
3.1	I-Premise
months;	I-Premise
hazard	I-Premise
ratio	I-Premise
[HR]	I-Premise
=	I-Premise
0.75;	I-Premise
P	I-Premise
=	I-Premise
.053).	I-Premise

Also,	B-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
superior	I-Premise
for	I-Premise
patients	I-Premise
treated	I-Premise
in	I-Premise
the	I-Premise
GemCis	I-Premise
arm	I-Premise
as	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
Gem	I-Premise
arm	I-Premise
(7.5	I-Premise
v	I-Premise
6.0	I-Premise
months),	I-Premise
an	B-Premise
advantage	I-Premise
which	I-Premise
did	I-Premise
not,	I-Premise
however,	I-Premise
reach	I-Premise
statistical	I-Premise
significance	I-Premise
(HR	I-Premise
=	I-Premise
0.80;	I-Premise
P	I-Premise
=	I-Premise
.15).	I-Premise

Tumor	B-Premise
response	I-Premise
rates	I-Premise
were	I-Premise
comparable	I-Premise
between	I-Premise
treatment	I-Premise
arms	I-Premise
(10.2%	I-Premise
v	I-Premise
8.2%).	I-Premise

The	B-Premise
rate	I-Premise
of	I-Premise
stable	I-Premise
disease	I-Premise
was,	I-Premise
however,	I-Premise
greater	I-Premise
in	I-Premise
the	I-Premise
combination	I-Premise
arm	I-Premise
(60.2%	I-Premise
v	I-Premise
40.2%;	I-Premise
P	I-Premise
<	I-Premise
.001).	I-Premise

Grade	B-Premise
3	I-Premise
to	I-Premise
4	I-Premise
hematologic	I-Premise
toxicity	I-Premise
did	I-Premise
not	I-Premise
exceed	I-Premise
15%	I-Premise
in	I-Premise
both	I-Premise
treatment	I-Premise
arms.	I-Premise

These	B-Claim
results	I-Claim
support	I-Claim
the	I-Claim
efficacy	I-Claim
and	I-Claim
safety	I-Claim
of	I-Claim
an	I-Claim
every-2-weeks	I-Claim
treatment	I-Claim
with	I-Claim
gemcitabine	I-Claim
plus	I-Claim
cisplatin.	I-Claim

Median	B-Claim
overall	I-Claim
survival	I-Claim
and	I-Claim
progression-free	I-Claim
survival	I-Claim
were	I-Claim
more	I-Claim
favorable	I-Claim
in	I-Claim
the	I-Claim
combination	I-Claim
arm	I-Claim
as	I-Claim
compared	I-Claim
with	I-Claim
gemcitabine	I-Claim
alone,	I-Claim
although	B-Premise
the	I-Premise
difference	I-Premise
did	I-Premise
not	I-Premise
attain	I-Premise
statistical	I-Premise
significance.	I-Premise

Chemotherapy	B-Claim
prolongs	I-Claim
survival	I-Claim
and	I-Claim
improves	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
(QOL)	I-Claim
for	I-Claim
good	I-Claim
performance	I-Claim
status	I-Claim
(PS)	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
non-small	I-Claim
cell	I-Claim
lung	I-Claim
cancer	I-Claim
(NSCLC).	I-Claim

Targeted	B-Claim
therapies	I-Claim
may	I-Claim
improve	I-Claim
chemotherapy	I-Claim
effectiveness	I-Claim
without	I-Claim
worsening	I-Claim
toxicity.	I-Claim

SGN-15	O
is	O
an	O
antibody-drug	O
conjugate	O
(ADC),	O
consisting	O
of	O
a	O
chimeric	O
murine	O
monoclonal	O
antibody	O
recognizing	O
the	O
Lewis	O
Y	O
(Le(y))	O
antigen,	O
conjugated	O
to	O
doxorubicin.	O

Le(y)	B-Claim
is	I-Claim
an	I-Claim
attractive	I-Claim
target	I-Claim
since	I-Claim
it	I-Claim
is	I-Claim
expressed	I-Claim
by	I-Claim
most	I-Claim
NSCLC.	I-Claim

SGN-15	B-Premise
was	I-Premise
active	I-Premise
against	I-Premise
Le(y)-positive	I-Premise
tumors	I-Premise
in	I-Premise
early	I-Premise
phase	I-Premise
clinical	I-Premise
trials	I-Premise
and	I-Premise
was	I-Premise
synergistic	I-Premise
with	I-Premise
docetaxel	I-Premise
in	I-Premise
preclinical	I-Premise
experiments.	I-Premise

This	O
Phase	O
II,	O
open-label	O
study	O
was	O
conducted	O
to	O
confirm	O
the	O
activity	O
of	O
SGN-15	O
plus	O
docetaxel	O
in	O
previously	O
treated	O
NSCLC	O
patients.	O

Sixty-two	O
patients	O
with	O
recurrent	O
or	O
metastatic	O
NSCLC	O
expressing	O
Le(y),	O
one	O
or	O
two	O
prior	O
chemotherapy	O
regimens,	O
and	O
PS<	O
or	O
=2	O
were	O
randomized	O
2:1	O
to	O
receive	O
SGN-15	O
200	O
mg/m2/week	O
with	O
docetaxel	O
35	O
mg/m2/week	O
(Arm	O
A)	O
or	O
docetaxel	O
35	O
mg/m2/week	O
alone	O
(Arm	O
B)	O
for	O
6	O
of	O
8	O
weeks.	O

Intrapatient	O
dose-escalation	O
of	O
SGN-15	O
to	O
350	O
mg/m2	O
was	O
permitted	O
in	O
the	O
second	O
half	O
of	O
the	O
study.	O

Endpoints	O
were	O
survival,	O
safety,	O
efficacy,	O
and	O
quality	O
of	O
life.	O

Forty	O
patients	O
on	O
Arm	O
A	O
and	O
19	O
on	O
Arm	O
B	O
received	O
at	O
least	O
one	O
treatment.	O

Patients	B-Premise
on	I-Premise
Arms	I-Premise
A	I-Premise
and	I-Premise
B	I-Premise
had	I-Premise
median	I-Premise
survivals	I-Premise
of	I-Premise
31.4	I-Premise
and	I-Premise
25.3	I-Premise
weeks,	I-Premise
12-month	I-Premise
survivals	I-Premise
of	I-Premise
29%	I-Premise
and	I-Premise
24%,	I-Premise
and	I-Premise
18-month	I-Premise
survivals	I-Premise
of	I-Premise
18%	I-Premise
and	I-Premise
8%,	I-Premise
respectively.	I-Premise

Toxicity	B-Premise
was	I-Premise
mild	I-Premise
in	I-Premise
both	I-Premise
arms.	I-Premise

QOL	B-Premise
analyses	I-Premise
favored	I-Premise
Arm	I-Premise
A.	I-Premise

SGN-15	B-Claim
plus	I-Claim
docetaxel	I-Claim
is	I-Claim
a	I-Claim
well-tolerated	I-Claim
and	I-Claim
active	I-Claim
second	I-Claim
and	I-Claim
third	I-Claim
line	I-Claim
treatment	I-Claim
for	I-Claim
NSCLC	I-Claim
patients.	I-Claim

Ongoing	O
studies	O
are	O
exploring	O
alternate	O
schedules	O
to	O
maximize	O
synergy	O
between	O
these	O
agents.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
efficacy	O
and	O
safety	O
of	O
association	O
of	O
duloxetine	O
and	O
rehabilitation	O
compared	O
with	O
rehabilitation	O
alone	O
in	O
men	O
with	O
SUI	O
after	O
radical	O
retropubic	O
prostatectomy	O
(RRP),	O
and	O
to	O
compare	O
continence	O
rate	O
even	O
after	O
planned	O
duloxetine	O
suspension.	O

After	O
catheter	O
removal,	O
112	O
patients	O
were	O
randomized	O
to	O
receive	O
rehabilitation	O
and	O
duloxetine	O
(group	O
A)	O
or	O
rehabilitation	O
alone	O
(group	O
B),	O
for	O
16	O
wk.	O
postprostatectomy	O
SUI	O
with	O
daily	O
incontinent	O
episodes	O
frequency	O
(IEF)	O
of	O
four	O
or	O
greater.	O

After	O
16	O
wk	O
both	O
groups	O
suspended	O
duloxetine/placebo	O
and	O
continued	O
rehabilitation.	O

All	O
patients	O
completed	O
incontinence	O
quality	O
of	O
life	O
(I-QoL)	O
questionnaire	O
and	O
bladder	O
diary.	O

Wilcoxon	O
test	O
was	O
used	O
to	O
analyse	O
changes	O
in	O
IEF	O
and	O
in	O
I-QoL	O
score;	O
Fisher	O
exact	O
test	O
was	O
used	O
to	O
compare	O
continent	O
patients	O
between	O
the	O
groups.	O

Adverse	O
events	O
for	O
duloxetine	O
was	O
15.2%.	O

102	O
men	O
completed	O
the	O
study.	O

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
decrease	I-Premise
in	I-Premise
pad	I-Premise
use	I-Premise
in	I-Premise
group	I-Premise
A.	I-Premise

After	B-Premise
16	I-Premise
wk,	I-Premise
39	I-Premise
patients	I-Premise
versus	I-Premise
27	I-Premise
were	I-Premise
dry	I-Premise
(p=0.007).	I-Premise

At	B-Premise
20	I-Premise
wk,	I-Premise
4	I-Premise
wk	I-Premise
after	I-Premise
planned	I-Premise
interruption	I-Premise
of	I-Premise
duloxetine,	I-Premise
we	I-Premise
observed	I-Premise
a	I-Premise
U-turn,	I-Premise
23	I-Premise
patients	I-Premise
were	I-Premise
completely	I-Premise
dry	I-Premise
in	I-Premise
group	I-Premise
A	I-Premise
versus	I-Premise
38	I-Premise
in	I-Premise
group	I-Premise
B	I-Premise
(p=0.008).	I-Premise

Whereas,	B-Premise
after	I-Premise
24	I-Premise
wk,	I-Premise
31	I-Premise
in	I-Premise
group	I-Premise
A	I-Premise
versus	I-Premise
41	I-Premise
in	I-Premise
group	I-Premise
B	I-Premise
were	I-Premise
dry	I-Premise
(p=0.08).	I-Premise

The	B-Claim
decrease	I-Claim
in	I-Claim
IEF	I-Claim
and	I-Claim
improvements	I-Claim
in	I-Claim
I-QoL	I-Claim
scores	I-Claim
were	I-Claim
significantly	I-Claim
greater	I-Claim
in	I-Claim
group	I-Claim
A	I-Claim
for	I-Claim
the	I-Claim
first	I-Claim
16	I-Claim
wk.	I-Claim

The	B-Claim
data	I-Claim
suggest	I-Claim
that	I-Claim
combination	I-Claim
therapy	I-Claim
might	I-Claim
provide	I-Claim
another	I-Claim
treatment	I-Claim
option	I-Claim
for	I-Claim
SUI	I-Claim
in	I-Claim
men	I-Claim
that	I-Claim
might	I-Claim
increase	I-Claim
the	I-Claim
percentage	I-Claim
of	I-Claim
early	I-Claim
postsurgery	I-Claim
continence.	I-Claim

The	B-Claim
impact	I-Claim
of	I-Claim
treatment	I-Claim
on	I-Claim
health-related	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
(HRQoL)	I-Claim
is	I-Claim
an	I-Claim
important	I-Claim
consideration	I-Claim
in	I-Claim
the	I-Claim
adjuvant	I-Claim
treatment	I-Claim
of	I-Claim
operable	I-Claim
breast	I-Claim
cancer.	I-Claim

Here	O
we	O
report	O
mature	O
HRQoL	O
outcomes	O
from	O
the	O
ATAC	O
trial,	O
comparing	O
anastrozole	O
with	O
tamoxifen	O
as	O
primary	O
adjuvant	O
therapy	O
for	O
postmenopausal	O
women	O
with	O
localized	O
breast	O
cancer.	O

Patients	O
completed	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Breast	O
(FACT-B)	O
questionnaire	O
plus	O
endocrine	O
subscale	O
(ES)	O
at	O
baseline,	O
3	O
and	O
6	O
months,	O
and	O
every	O
6	O
months	O
thereafter.	O

Baseline	O
characteristics	O
in	O
the	O
HRQoL	O
sub-protocol	O
were	O
well	O
balanced	O
between	O
the	O
anastrozole	O
(n	O
=	O
335)	O
and	O
tamoxifen	O
(n	O
=	O
347)	O
groups	O
in	O
the	O
primary	O
analysis	O
population.	O

As	B-Premise
with	I-Premise
previously	I-Premise
published	I-Premise
results	I-Premise
at	I-Premise
2	I-Premise
years,	I-Premise
there	I-Premise
was	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
Trial	I-Premise
Outcome	I-Premise
Index	I-Premise
of	I-Premise
the	I-Premise
FACT-B,	I-Premise
the	I-Premise
primary	I-Premise
endpoint	I-Premise
of	I-Premise
the	I-Premise
study,	I-Premise
between	I-Premise
treatments	I-Premise
at	I-Premise
5	I-Premise
years.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
treatment	I-Premise
groups	I-Premise
in	I-Premise
ES	I-Premise
total	I-Premise
scores.	I-Premise

Consistent	O
with	O
the	O
2-year	O
analysis,	O
there	B-Claim
were	I-Claim
differences	I-Claim
between	I-Claim
treatment	I-Claim
groups	I-Claim
in	I-Claim
patient-reported	I-Claim
side	I-Claim
effects:	I-Claim
diarrhea	B-Premise
(anastrozole	I-Premise
3.1%	I-Premise
vs.	I-Premise
tamoxifen	I-Premise
1.3%),	I-Premise
vaginal	I-Premise
dryness	I-Premise
(18.5%	I-Premise
vs.	I-Premise
9.1%),	I-Premise
diminished	I-Premise
libido	I-Premise
(34.0%	I-Premise
vs.	I-Premise
26.1%),	I-Premise
and	I-Premise
dyspareunia	I-Premise
(17.3%	I-Premise
vs.	I-Premise
8.1%)	I-Premise
were	I-Premise
significantly	I-Premise
more	I-Premise
frequent	I-Premise
with	I-Premise
anastrozole	I-Premise
compared	I-Premise
to	I-Premise
tamoxifen.	I-Premise

Dizziness	B-Premise
(3.1%	I-Premise
vs.	I-Premise
5.4%)	I-Premise
and	I-Premise
vaginal	I-Premise
discharge	I-Premise
(1.2%	I-Premise
vs.	I-Premise
5.2%)	I-Premise
were	I-Premise
significantly	I-Premise
less	I-Premise
frequent	I-Premise
with	I-Premise
anastrozole	I-Premise
compared	I-Premise
to	I-Premise
tamoxifen.	I-Premise

In	B-Claim
this,	I-Claim
the	I-Claim
first	I-Claim
report	I-Claim
of	I-Claim
HRQoL	I-Claim
over	I-Claim
5	I-Claim
years	I-Claim
of	I-Claim
initial	I-Claim
adjuvant	I-Claim
therapy	I-Claim
with	I-Claim
an	I-Claim
aromatase	I-Claim
inhibitor,	I-Claim
we	I-Claim
conclude	I-Claim
that	I-Claim
anastrozole	I-Claim
and	I-Claim
tamoxifen	I-Claim
had	I-Claim
similar	I-Claim
impacts	I-Claim
on	I-Claim
HRQoL,	I-Claim
which	I-Claim
was	I-Claim
maintained	I-Claim
or	I-Claim
slightly	I-Claim
improved	I-Claim
during	I-Claim
the	I-Claim
treatment	I-Claim
period	I-Claim
for	I-Claim
both	I-Claim
groups.	I-Claim

To	O
assess	O
the	O
safety	O
and	O
health-related	O
quality	O
of	O
life	O
(HRQOL)	O
of	O
continuous	O
combined	O
hormone	O
replacement	O
therapy	O
(ccHRT)	O
with	O
estradiol	O
valerate/medroxyprogesterone	O
acetate	O
(E(2)V/MPA)	O
over	O
nine	O
years	O
and	O
at	O
follow-up	O
one	O
year	O
after	O
discontinuation.	O

A	O
total	O
of	O
419	O
women	O
were	O
randomized	O
to	O
one	O
of	O
four	O
treatments:	O
once-daily	O
1	O
mg	O
E2V/2.5	O
mg	O
MPA	O
(1	O
+	O
2.5	O
group);	O
1	O
mg	O
E2V/5	O
mg	O
MPA	O
daily	O
(1	O
+	O
5	O
group);	O
2	O
mg	O
E2V/2.5	O
mg	O
MPA	O
daily	O
(2	O
+	O
2.5	O
group);	O
2	O
mg	O
E2V/5	O
mg	O
MPA	O
daily	O
(2	O
+	O
5	O
group)	O
(Indivina,	O
Orion	O
Pharma).	O

For	O
the	O
last	O
six	O
months,	O
all	O
received	O
the	O
1	O
+	O
2.5	O
dosage.	O

The	O
2	O
+	O
2.5	O
dosage	O
was	O
discontinued	O
at	O
the	O
end	O
of	O
year	O
7.	O

A	O
total	O
of	O
198	O
women	O
continued	O
after	O
year	O
7.	O

Annualized	O
percentage	O
rates	O
for	O
cardiovascular	O
events	O
[corrected]	O
and	O
endometrial	O
cancers	O
[corrected]	O
were	O
below	O
national	O
rates	O
for	O
Finland	O
and	O
those	O
reported	O
for	O
the	O
Women's	O
Health	O
Initiative.	O

There	B-Premise
were	I-Premise
no	I-Premise
serious	I-Premise
events	I-Premise
with	I-Premise
the	I-Premise
1	I-Premise
+	I-Premise
2.5	I-Premise
dosage	I-Premise
or	I-Premise
after	I-Premise
ccHRT	I-Premise
discontinuation.	I-Premise

Climacteric	B-Premise
symptoms	I-Premise
remained	I-Premise
significantly	I-Premise
below	I-Premise
baseline	I-Premise
values	I-Premise
after	I-Premise
dosage	I-Premise
reduction;	I-Premise
some	B-Premise
symptoms	I-Premise
recurred	I-Premise
after	I-Premise
discontinuation	I-Premise
of	I-Premise
ccHRT.	I-Premise

HRQOL	B-Premise
ratings	I-Premise
improved	I-Premise
with	I-Premise
ccHRT,	I-Premise
irrespective	I-Premise
of	I-Premise
dosage,	I-Premise
including	I-Premise
depressed	I-Premise
mood,	I-Premise
anxiety,	I-Premise
health	I-Premise
perception	I-Premise
and	I-Premise
sexual	I-Premise
interest.	I-Premise

Scores	B-Premise
on	I-Premise
a	I-Premise
scale	I-Premise
assessing	I-Premise
daily	I-Premise
functioning	I-Premise
and	I-Premise
enjoyment	I-Premise
(Q-LES-Q)	I-Premise
improved	I-Premise
from	I-Premise
year	I-Premise
7	I-Premise
to	I-Premise
year	I-Premise
9.	I-Premise

They	B-Premise
deteriorated	I-Premise
during	I-Premise
follow-up	I-Premise
in	I-Premise
women	I-Premise
not	I-Premise
continuing	I-Premise
ccHRT.	I-Premise

Lower	B-Claim
dosages	I-Claim
of	I-Claim
HRT	I-Claim
were	I-Claim
as	I-Claim
effective	I-Claim
as	I-Claim
higher	I-Claim
doses	I-Claim
in	I-Claim
improving	I-Claim
climacteric	I-Claim
symptoms	I-Claim
and	I-Claim
HRQOL	I-Claim
ratings	I-Claim
and	I-Claim
had	I-Claim
fewer	I-Claim
safety	I-Claim
concerns.	I-Claim

Following	B-Premise
discontinuation	I-Premise
of	I-Premise
ccHRT,	I-Premise
patient	I-Premise
satisfaction	I-Premise
was	I-Premise
variable,	I-Premise
with	I-Premise
15%	I-Premise
electing	I-Premise
to	I-Premise
continue	I-Premise
or	I-Premise
restart	I-Premise
HRT	I-Premise
and	I-Premise
7%	I-Premise
resuming	I-Premise
at	I-Premise
follow-up.	I-Premise

This	B-Claim
supports	I-Claim
the	I-Claim
need	I-Claim
for	I-Claim
an	I-Claim
individualized	I-Claim
approach	I-Claim
to	I-Claim
therapy	I-Claim
recommendations.	I-Claim

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
toxicity	O
and	O
efficacy	O
of	O
radiation	O
therapy	O
(RT)	O
for	O
localized	O
carcinoma	O
of	O
the	O
prostate,	O
using	O
a	O
hypofractionated	O
(55	O
Gy/20	O
fractions/4	O
weeks)	O
vs.	O
a	O
conventionally	O
fractionated	O
(64	O
Gy/32	O
fractions/6.5	O
weeks)	O
dose	O
schedule.	O

A	O
total	O
of	O
217	O
patients	O
were	O
randomized	O
to	O
either	O
the	O
hypofractionated	O
(108	O
patients)	O
or	O
the	O
conventional	O
(109	O
patients)	O
dose	O
schedule,	O
with	O
planning	O
with	O
two-dimensional	O
(2D)	O
CT	O
scan	O
planning	O
methodology	O
in	O
the	O
majority	O
of	O
cases.	O

All	O
patients	O
were	O
followed	O
for	O
a	O
median	O
of	O
48	O
(6-108)	O
months.	O

Gastrointestinal	O
(GI)	O
and	O
genitourinary	O
(GU)	O
toxicity	O
was	O
evaluated	O
before	O
RT	O
and	O
after	O
its	O
completion	O
using	O
modified	O
late	O
effects	O
of	O
normal	O
tissue-subjective,	O
objective,	O
management,	O
analytic	O
(LENT-SOMA)	O
scales	O
and	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
sexual	O
function	O
questionnaire.	O

Efficacy	O
of	O
RT	O
based	O
on	O
clinical,	O
radiologic,	O
and	O
prostate-specific	O
antigen	O
data	O
were	O
also	O
evaluated	O
at	O
baseline	O
and	O
after	O
RT.	O

Gastrointestinal	B-Premise
and	I-Premise
GU	I-Premise
toxicity	I-Premise
persisted	I-Premise
5	I-Premise
years	I-Premise
after	I-Premise
RT	I-Premise
and	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
dose	I-Premise
schedules	I-Premise
other	I-Premise
than	I-Premise
in	I-Premise
regard	I-Premise
to	I-Premise
urgency	I-Premise
of	I-Premise
defecation.	I-Premise

However,	B-Premise
1-month	I-Premise
GI	I-Premise
toxicity	I-Premise
was	I-Premise
not	I-Premise
only	I-Premise
worse	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
the	I-Premise
hypofractionated	I-Premise
RT	I-Premise
schedule	I-Premise
but	I-Premise
also	I-Premise
adversely	I-Premise
affected	I-Premise
daily	I-Premise
activities.	I-Premise

Nadir	B-Premise
prostate-specific	I-Premise
antigen	I-Premise
values	I-Premise
occurred	I-Premise
at	I-Premise
a	I-Premise
median	I-Premise
of	I-Premise
18.0	I-Premise
(3.0-54.0)	I-Premise
months	I-Premise
after	I-Premise
RT.	I-Premise

A	B-Premise
total	I-Premise
of	I-Premise
76	I-Premise
biochemical	I-Premise
relapses,	I-Premise
with	I-Premise
or	I-Premise
without	I-Premise
clinical	I-Premise
relapses,	I-Premise
have	I-Premise
occurred	I-Premise
since;	I-Premise
of	I-Premise
these,	I-Premise
37	I-Premise
were	I-Premise
in	I-Premise
the	I-Premise
hypofractionated	I-Premise
and	I-Premise
39	I-Premise
in	I-Premise
the	I-Premise
conventional	I-Premise
schedule.	I-Premise

The	B-Premise
5-year	I-Premise
biochemical	I-Premise
+/-	I-Premise
clinical	I-Premise
relapse-free	I-Premise
and	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
55.9%	I-Premise
and	I-Premise
85.3%	I-Premise
respectively	I-Premise
for	I-Premise
all	I-Premise
patients,	I-Premise
and	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
schedules.	I-Premise

Radiation	B-Claim
therapy	I-Claim
for	I-Claim
prostate	I-Claim
carcinoma	I-Claim
causes	I-Claim
persistent	I-Claim
GI	I-Claim
toxicity	I-Claim
that	I-Claim
is	I-Claim
largely	I-Claim
independent	I-Claim
of	I-Claim
the	I-Claim
two	I-Claim
dose	I-Claim
schedules.	I-Claim

The	B-Claim
hypofractionated	I-Claim
schedule	I-Claim
is	I-Claim
equivalent	I-Claim
in	I-Claim
efficacy	I-Claim
to	I-Claim
the	I-Claim
conventional	I-Claim
schedule.	I-Claim

Most	B-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
ovarian	I-Claim
cancer	I-Claim
develop	I-Claim
recurrent	I-Claim
disease.	I-Claim

For	B-Claim
those	I-Claim
patients	I-Claim
who	I-Claim
recur	I-Claim
at	I-Claim
least	I-Claim
6	I-Claim
months	I-Claim
after	I-Claim
initial	I-Claim
therapy,	I-Claim
paclitaxel	I-Claim
platinum	I-Claim
has	I-Claim
shown	I-Claim
a	I-Claim
modest	I-Claim
survival	I-Claim
advantage	I-Claim
over	I-Claim
platinum	I-Claim
without	I-Claim
paclitaxel;	I-Claim
however,	B-Premise
many	I-Premise
patients	I-Premise
develop	I-Premise
clinically	I-Premise
relevant	I-Premise
neurotoxicity,	I-Premise
frequently	I-Premise
resulting	I-Premise
in	I-Premise
treatment	I-Premise
discontinuation.	I-Premise

Thus,	O
an	O
alternative	O
regimen	O
without	O
significant	O
neurotoxicity	O
was	O
evaluated	O
by	O
comparing	O
gemcitabine	O
plus	O
carboplatin	O
with	O
single-agent	O
carboplatin	O
in	O
platinum-sensitive	O
recurrent	O
ovarian	O
cancer	O
patients.	O

Patients	O
with	O
platinum-sensitive	O
recurrent	O
ovarian	O
cancer	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
gemcitabine	O
plus	O
carboplatin	O
or	O
carboplatin	O
alone,	O
every	O
21	O
days.	O

The	O
primary	O
objective	O
was	O
to	O
compare	O
progression-free	O
survival	O
(PFS).	O

Three	O
hundred	O
fifty-six	O
patients	O
(178	O
gemcitabine	O
plus	O
carboplatin;	O
178	O
carboplatin)	O
were	O
randomly	O
assigned.	O

Patients	O
received	O
a	O
median	O
of	O
six	O
cycles	O
in	O
both	O
arms.	O

With	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
17	I-Premise
months,	I-Premise
median	I-Premise
PFS	I-Premise
was	I-Premise
8.6	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
7.9	I-Premise
to	I-Premise
9.7	I-Premise
months)	I-Premise
for	I-Premise
gemcitabine	I-Premise
plus	I-Premise
carboplatin	I-Premise
and	I-Premise
5.8	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
5.2	I-Premise
to	I-Premise
7.1	I-Premise
months)	I-Premise
for	I-Premise
carboplatin.	I-Premise

The	B-Premise
hazard	I-Premise
ration	I-Premise
(HR)	I-Premise
for	I-Premise
PFS	I-Premise
was	I-Premise
0.72	I-Premise
(95%	I-Premise
CI,	I-Premise
0.58	I-Premise
to	I-Premise
0.90;	I-Premise
P	I-Premise
=	I-Premise
.0031).	I-Premise

Response	B-Premise
rate	I-Premise
was	I-Premise
47.2%	I-Premise
(95%	I-Premise
CI,	I-Premise
39.9%	I-Premise
to	I-Premise
54.5%)	I-Premise
for	I-Premise
gemcitabine	I-Premise
plus	I-Premise
carboplatin	I-Premise
and	I-Premise
30.9%	I-Premise
(95%	I-Premise
CI,	I-Premise
24.1%	I-Premise
to	I-Premise
37.7%)	I-Premise
for	I-Premise
carboplatin	I-Premise
(P	I-Premise
=	I-Premise
.0016).	I-Premise

The	B-Premise
HR	I-Premise
for	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
0.96	I-Premise
(95%	I-Premise
CI,	I-Premise
0.75	I-Premise
to1.23;	I-Premise
P	I-Premise
=	I-Premise
.7349).	I-Premise

While	B-Premise
myelosuppression	I-Premise
was	I-Premise
significantly	I-Premise
more	I-Premise
common	I-Premise
in	I-Premise
the	I-Premise
combination,	I-Premise
sequelae	I-Premise
such	I-Premise
as	I-Premise
febrile	I-Premise
neutropenia	I-Premise
or	I-Premise
infections	I-Premise
were	I-Premise
uncommon.	I-Premise

No	B-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
scores	I-Premise
between	I-Premise
arms	I-Premise
were	I-Premise
noted.	I-Premise

Gemcitabine	B-Claim
plus	I-Claim
carboplatin	I-Claim
significantly	I-Claim
improves	I-Claim
PFS	I-Claim
and	I-Claim
response	I-Claim
rate	I-Claim
without	I-Claim
worsening	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
platinum-sensitive	I-Claim
recurrent	I-Claim
ovarian	I-Claim
cancer.	I-Claim

Radiation-induced	O
mucositis	O
is	O
an	O
acute	O
reaction	O
of	O
the	O
mucosa	O
of	O
patients	O
undergoing	O
head	O
and	O
neck	O
radiotherapy.	O

It	O
can	O
have	O
debilitating	O
and	O
dose-limiting	O
consequences.	O

There	B-Claim
is	I-Claim
no	I-Claim
consensus	I-Claim
on	I-Claim
an	I-Claim
accepted	I-Claim
intervention	I-Claim
that	I-Claim
significantly	I-Claim
reduces	I-Claim
its	I-Claim
severity.	I-Claim

Misoprostol	O
is	O
a	O
synthetic	O
prostaglandin	O
E1	O
analogue,	O
with	O
properties	O
of	O
a	O
mucosal	O
cytoprotectant.	O

We	O
designed	O
a	O
randomized,	O
double-blind,	O
placebo-controlled	O
trial	O
of	O
misoprostol	O
in	O
patients	O
with	O
head	O
and	O
neck	O
cancer.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
topical	O
misoprostol	O
was	O
effective	O
in	O
reducing	O
the	O
severity	O
of	O
radiation-induced	O
mucositis	O
in	O
patients	O
receiving	O
radical	O
dose	O
radiotherapy.	O

The	O
effect	O
of	O
this	O
intervention	O
on	O
a	O
patient's	O
general	O
well-being	O
was	O
also	O
investigated.	O

The	O
primary	O
end-point	O
of	O
the	O
study	O
was	O
the	O
incidence	O
of	O
Radiation	O
Therapy	O
Oncology	O
Group	O
grade	O
3	O
mucositis.	O

Between	O
1999	O
and	O
2002,	O
83	O
patients	O
were	O
recruited	O
into	O
the	O
study	O
at	O
Westmead	O
and	O
Nepean	O
Hospitals,	O
Sydney.	O

Forty-two	O
patients	O
were	O
randomized	O
to	O
receive	O
misoprostol	O
and	O
41	O
to	O
receive	O
a	O
placebo.	O

Most	O
patients	O
received	O
radiotherapy	O
in	O
the	O
adjuvant	O
setting	O
(52	O
of	O
the	O
83)	O
and	O
had	O
either	O
an	O
oral	O
cavity	O
(42	O
of	O
the	O
83)	O
or	O
an	O
oropharyngeal	O
(16	O
of	O
the	O
83)	O
cancer.	O

We	B-Claim
could	I-Claim
not	I-Claim
identify	I-Claim
any	I-Claim
significant	I-Claim
difference	I-Claim
in	I-Claim
the	I-Claim
incidence	I-Claim
of	I-Claim
severe	I-Claim
mucositis	I-Claim
based	I-Claim
on	I-Claim
whether	I-Claim
patients	I-Claim
were	I-Claim
allocated	I-Claim
to	I-Claim
receive	I-Claim
misoprostol	I-Claim
or	I-Claim
placebo.	I-Claim

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
mean	I-Premise
area	I-Premise
under	I-Premise
the	I-Premise
mucositis	I-Premise
curve	I-Premise
(13.2	I-Premise
vs	I-Premise
16.6;	I-Premise
P	I-Premise
=	I-Premise
0.1).	I-Premise

Patients	B-Premise
allocated	I-Premise
to	I-Premise
misoprostol	I-Premise
did	I-Premise
report	I-Premise
slightly	I-Premise
increased	I-Premise
soreness	I-Premise
(7.6	I-Premise
vs	I-Premise
6.9;	I-Premise
P	I-Premise
=	I-Premise
0.04)	I-Premise
and	I-Premise
a	I-Premise
greater	I-Premise
use	I-Premise
of	I-Premise
analgesics.	I-Premise

However,	B-Premise
this	I-Premise
difference	I-Premise
did	I-Premise
not	I-Premise
translate	I-Premise
into	I-Premise
a	I-Premise
worse	I-Premise
feeling	I-Premise
of	I-Premise
general	I-Premise
well-being	I-Premise
as	I-Premise
measured	I-Premise
by	I-Premise
a	I-Premise
simple	I-Premise
visual	I-Premise
analogue	I-Premise
scale	I-Premise
(5.8	I-Premise
vs	I-Premise
5.2;	I-Premise
P	I-Premise
=	I-Premise
0.3).	I-Premise

In	B-Claim
conclusion,	I-Claim
we	I-Claim
were	I-Claim
unable	I-Claim
to	I-Claim
identify	I-Claim
a	I-Claim
reduction	I-Claim
in	I-Claim
radiation-induced	I-Claim
mucositis	I-Claim
in	I-Claim
patients	I-Claim
receiving	I-Claim
misoprostol.	I-Claim

There	B-Claim
is	I-Claim
a	I-Claim
paucity	I-Claim
of	I-Claim
high-level	I-Claim
evidence	I-Claim
on	I-Claim
potentially	I-Claim
useful	I-Claim
interventions	I-Claim
and	I-Claim
a	I-Claim
continued	I-Claim
need	I-Claim
for	I-Claim
new	I-Claim
and	I-Claim
innovative	I-Claim
research,	I-Claim
incorporating	I-Claim
quality-of-life	I-Claim
measurements,	I-Claim
in	I-Claim
patients	I-Claim
experiencing	I-Claim
radiation-induced	I-Claim
mucositis.	I-Claim

In	B-Claim
vivo	I-Claim
data	I-Claim
have	I-Claim
shown	I-Claim
a	I-Claim
more	I-Claim
potent	I-Claim
antiangiogenic	I-Claim
effect	I-Claim
and	I-Claim
a	I-Claim
higher	I-Claim
antitumor	I-Claim
activity	I-Claim
of	I-Claim
low-dose	I-Claim
interferon	I-Claim
(IFN)	I-Claim
given	I-Claim
twice	I-Claim
daily.	I-Claim

In	O
a	O
randomized	O
Phase	O
II	O
trial,	O
the	O
authors	O
tested	O
the	O
hypothesis	O
that	O
twice-daily	O
low-dose	O
IFN	O
is	O
more	O
effective	O
than	O
daily	O
intermediate-dose	O
IFN	O
in	O
patients	O
with	O
metastatic	O
renal	O
cell	O
cancer	O
(MRCC).	O

A	O
total	O
of	O
118	O
patients	O
(59	O
per	O
arm)	O
were	O
randomly	O
assigned	O
to	O
receive	O
IFN	O
at	O
a	O
dose	O
of	O
0.5	O
million	O
units	O
(MU)	O
given	O
subcutaneously	O
twice	O
daily	O
(IFN1)	O
or	O
IFN	O
at	O
a	O
dose	O
of	O
5	O
MU	O
given	O
subcutaneously	O
daily	O
(IFN5).	O

The	O
primary	O
endpoint	O
was	O
progression-free	O
survival	O
(PFS).	O

Secondary	O
endpoints	O
included	O
response	O
rate	O
(RR),	O
overall	O
survival	O
(OS),	O
toxicity,	O
and	O
quality	O
of	O
life	O
(QOL).	O

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
either	I-Premise
PFS	I-Premise
or	I-Premise
OS	I-Premise
between	I-Premise
IFN1	I-Premise
and	I-Premise
IFN5	I-Premise
(median	I-Premise
of	I-Premise
3.7	I-Premise
months	I-Premise
and	I-Premise
median	I-Premise
of	I-Premise
3.4	I-Premise
months	I-Premise
PFS,	I-Premise
respectively;	I-Premise
median	I-Premise
of	I-Premise
25.5	I-Premise
months	I-Premise
and	I-Premise
median	I-Premise
of	I-Premise
17.5	I-Premise
months	I-Premise
OS,	I-Premise
respectively).	I-Premise

The	B-Premise
RRs	I-Premise
were	I-Premise
identical	I-Premise
in	I-Premise
the	I-Premise
2	I-Premise
arms	I-Premise
(6.7%;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
[95%	I-Premise
CI],	I-Premise
1.8-16.5%).	I-Premise

Two	B-Premise
patients,	I-Premise
1	I-Premise
in	I-Premise
each	I-Premise
arm,	I-Premise
remained	I-Premise
in	I-Premise
complete	I-Premise
remission	I-Premise
at	I-Premise
the	I-Premise
time	I-Premise
of	I-Premise
last	I-Premise
follow-up,	I-Premise
at	I-Premise
45+	I-Premise
and	I-Premise
38+	I-Premise
months	I-Premise
from	I-Premise
treatment.	I-Premise

Thirty-two	B-Premise
patients	I-Premise
receiving	I-Premise
IFN5	I-Premise
and	I-Premise
19	I-Premise
patients	I-Premise
receiving	I-Premise
IFN1	I-Premise
experienced	I-Premise
Grade	I-Premise
3	I-Premise
or	I-Premise
higher	I-Premise
adverse	I-Premise
events	I-Premise
(graded	I-Premise
using	I-Premise
the	I-Premise
National	I-Premise
Cancer	I-Premise
Institute	I-Premise
Common	I-Premise
Toxicity	I-Premise
Criteria	I-Premise
[version	I-Premise
2.0])	I-Premise
(P	I-Premise
=	I-Premise
.025).	I-Premise

Eighteen	B-Premise
patients	I-Premise
receiving	I-Premise
IFN5	I-Premise
and	I-Premise
4	I-Premise
patients	I-Premise
receiving	I-Premise
IFN1	I-Premise
had	I-Premise
dose	I-Premise
reductions	I-Premise
(P	I-Premise
=	I-Premise
.002).	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
deterioration	I-Premise
in	I-Premise
QOL	I-Premise
and	I-Premise
an	I-Premise
increase	I-Premise
in	I-Premise
depression	I-Premise
associated	I-Premise
with	I-Premise
IFN5	I-Premise
but	I-Premise
no	I-Premise
change	I-Premise
was	I-Premise
noted	I-Premise
with	I-Premise
IFN1.	I-Premise

Compared	B-Claim
with	I-Claim
IFN5,	I-Claim
IFN1	I-Claim
is	I-Claim
neither	I-Claim
more	I-Claim
nor	I-Claim
less	I-Claim
effective	I-Claim
but	I-Claim
is	I-Claim
less	I-Claim
toxic,	I-Claim
with	I-Claim
a	I-Claim
better	I-Claim
reported	I-Claim
QOL.	I-Claim

These	B-Claim
results	I-Claim
may	I-Claim
have	I-Claim
implications	I-Claim
for	I-Claim
the	I-Claim
design	I-Claim
of	I-Claim
combination	I-Claim
regimens	I-Claim
incorporating	I-Claim
IFN	I-Claim
with	I-Claim
targeted	I-Claim
agents.	I-Claim

To	O
determine	O
whether	O
the	O
impact	O
of	O
"laying	O
on	O
of	O
hands"	O
on	O
the	O
well-being	O
of	O
patients	O
with	O
advanced	O
cancer	O
is	O
more	O
efficient	O
when	O
performed	O
by	O
a	O
person	O
with	O
self-declared	O
"healing	O
powers"	O
as	O
compared	O
to	O
an	O
actor	O
mimicking	O
the	O
healer	O
in	O
close	O
detail.	O

A	O
total	O
of	O
80	O
patients	O
were	O
registered	O
to	O
participate	O
in	O
a	O
randomized,	O
single-blind	O
phase	O
III	O
trial	O
to	O
evaluate	O
the	O
difference	O
in	O
efficacy	O
of	O
"laying	O
on	O
of	O
hands"	O
by	O
either	O
a	O
"healer"	O
or	O
an	O
actor.	O

Each	O
group	O
consisted	O
of	O
40	O
patients,	O
scheduled	O
to	O
receive	O
treatment	O
for	O
5	O
min,	O
three	O
times	O
a	O
week.	O

The	O
effect	O
of	O
treatment	O
was	O
measured	O
using	O
a	O
"Well-Being	O
scale",	O
with	O
the	O
difference	O
of	O
the	O
average	O
score	O
of	O
the	O
"Well-Being	O
scale"	O
on	O
day	O
10	O
being	O
defined	O
as	O
primary	O
and	O
that	O
on	O
day	O
5	O
as	O
secondary	O
endpoint.	O

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
average	I-Premise
score	I-Premise
values	I-Premise
between	I-Premise
the	I-Premise
"healer"	I-Premise
and	I-Premise
the	I-Premise
actor	I-Premise
with	I-Premise
regard	I-Premise
to	I-Premise
the	I-Premise
primary	I-Premise
(p	I-Premise
=	I-Premise
0.34)	I-Premise
or	I-Premise
the	I-Premise
secondary	I-Premise
endpoint	I-Premise
(p	I-Premise
=	I-Premise
0.94),	I-Premise
but	B-Premise
the	I-Premise
comparison	I-Premise
was	I-Premise
limited	I-Premise
due	I-Premise
to	I-Premise
major	I-Premise
protocol	I-Premise
violations	I-Premise
by	I-Premise
the	I-Premise
"healer"	I-Premise
who	I-Premise
unblinded	I-Premise
his	I-Premise
status	I-Premise
after	I-Premise
the	I-Premise
first	I-Premise
run	I-Premise
and	I-Premise
quit	I-Premise
the	I-Premise
study.	I-Premise

The	O
study	O
was	O
completed	O
by	O
the	O
actor	O
as	O
a	O
descriptive,	O
explorative	O
study	O
on	O
the	O
impact	O
of	O
"laying	O
on	O
of	O
hands".	O

A	B-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
symptoms	I-Premise
after	I-Premise
treatment	I-Premise
was	I-Premise
found	I-Premise
on	I-Premise
day	I-Premise
5	I-Premise
(p	I-Premise
<	I-Premise
0.001)	I-Premise
and	I-Premise
on	I-Premise
day	I-Premise
10	I-Premise
(p	I-Premise
=	I-Premise
0.0002).	I-Premise

"Laying	B-Claim
on	I-Claim
of	I-Claim
hands"	I-Claim
resulted	I-Claim
in	I-Claim
a	I-Claim
significant	I-Claim
improvement	I-Claim
of	I-Claim
cancer-	I-Claim
or	I-Claim
cancer-therapy-associated	I-Claim
symptoms.	I-Claim

The	B-Claim
magnitude	I-Claim
of	I-Claim
improvement	I-Claim
obtained	I-Claim
was	I-Claim
similar	I-Claim
whether	I-Claim
on	I-Claim
a	I-Claim
self-declared-healer-	I-Claim
or	I-Claim
an	I-Claim
actor-provided	I-Claim
"treatment".	I-Claim

This	O
randomised	O
multicentre	O
trial	O
was	O
conducted	O
to	O
establish	O
the	O
optimal	O
duration	O
of	O
palliative	O
chemotherapy	O
in	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(NSCLC).	O

We	O
compared	O
a	O
policy	O
of	O
three	O
vs	O
six	O
courses	O
of	O
new-generation	O
platinum-based	O
combination	O
chemotherapy	O
with	O
regard	O
to	O
effects	O
on	O
quality	O
of	O
life	O
(QoL)	O
and	O
survival.	O

Patients	O
with	O
stage	O
IIIB	O
or	O
IV	O
NSCLC	O
and	O
WHO	O
performance	O
status	O
(PS)	O
0-2	O
were	O
randomised	O
to	O
receive	O
three	O
(C3)	O
or	O
six	O
(C6)	O
courses	O
of	O
carboplatin	O
(area	O
under	O
the	O
curve	O
(AUC)	O
4,	O
Chatelut's	O
formula,	O
equivalent	O
to	O
Calvert's	O
AUC	O
5)	O
on	O
day	O
1	O
and	O
vinorelbine	O
25	O
mg	O
m(-2)	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
3-week	O
cycle.	O

Key	O
end	O
points	O
were	O
QoL	O
at	O
18	O
weeks,	O
measured	O
with	O
EORTC	O
Quality	O
of	O
Life	O
Questionnaire	O
(QLQ)-C30	O
and	O
QLQ-LC13,	O
and	O
overall	O
survival.	O

Secondary	O
end	O
points	O
were	O
progression-free	O
survival	O
and	O
need	O
of	O
palliative	O
radiotherapy.	O

Two	O
hundred	O
and	O
ninety-seven	O
patients	O
were	O
randomised	O
(C3	O
150,	O
C6	O
147).	O

Their	O
median	O
age	O
was	O
65	O
years,	O
30%	O
had	O
PS	O
2	O
and	O
76%	O
stage	O
IV	O
disease.	O

Seventy-eight	O
and	O
54%	O
of	O
C3	O
and	O
C6	O
patients,	O
respectively,	O
completed	O
all	O
scheduled	O
chemotherapy	O
courses.	O

Compliance	O
with	O
QoL	O
questionnaires	O
was	O
88%.	O

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
group	I-Premise
differences	I-Premise
in	I-Premise
global	I-Premise
QoL,	I-Premise
pain	I-Premise
or	I-Premise
fatigue	I-Premise
up	I-Premise
to	I-Premise
26	I-Premise
weeks.	I-Premise

The	B-Premise
dyspnoea	I-Premise
palliation	I-Premise
rate	I-Premise
was	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
C3	I-Premise
arm	I-Premise
at	I-Premise
18	I-Premise
and	I-Premise
26	I-Premise
weeks	I-Premise
(P<0.05),	I-Premise
but	B-Premise
this	I-Premise
finding	I-Premise
was	I-Premise
inconsistent	I-Premise
across	I-Premise
different	I-Premise
methods	I-Premise
of	I-Premise
analysis.	I-Premise

Median	B-Premise
survival	I-Premise
in	I-Premise
the	I-Premise
C3	I-Premise
group	I-Premise
was	I-Premise
28	I-Premise
vs	I-Premise
32	I-Premise
weeks	I-Premise
in	I-Premise
the	I-Premise
C6	I-Premise
group	I-Premise
(P=0.75,	I-Premise
HR	I-Premise
1.04,	I-Premise
95%	I-Premise
CI	I-Premise
0.82-1.31).	I-Premise

One-	B-Premise
and	I-Premise
2-year	I-Premise
survival	I-Premise
rates	I-Premise
were	I-Premise
25	I-Premise
and	I-Premise
9%	I-Premise
vs	I-Premise
25	I-Premise
and	I-Premise
5%	I-Premise
in	I-Premise
the	I-Premise
C3	I-Premise
and	I-Premise
C6	I-Premise
arm,	I-Premise
respectively.	I-Premise

Median	B-Premise
progression-free	I-Premise
survival	I-Premise
was	I-Premise
16	I-Premise
and	I-Premise
21	I-Premise
weeks	I-Premise
in	I-Premise
the	I-Premise
C3	I-Premise
and	I-Premise
C6	I-Premise
groups,	I-Premise
respectively	I-Premise
(P=0.21,	I-Premise
HR	I-Premise
0.86,	I-Premise
95%	I-Premise
CI	I-Premise
0.68-1.08).	I-Premise

In	B-Claim
conclusion,	I-Claim
palliative	I-Claim
chemotherapy	I-Claim
with	I-Claim
carboplatin	I-Claim
and	I-Claim
vinorelbine	I-Claim
beyond	I-Claim
three	I-Claim
courses	I-Claim
conveys	I-Claim
no	I-Claim
survival	I-Claim
or	I-Claim
consistent	I-Claim
QoL	I-Claim
benefits	I-Claim
in	I-Claim
advanced	I-Claim
NSCLC.	I-Claim

In	O
the	O
randomized,	O
multinational	O
phase	O
II/III	O
trial	O
(V325)	O
of	O
untreated	O
advanced	O
gastric	O
cancer	O
patients,	O
the	O
phase	O
II	O
part	O
selected	O
docetaxel,	O
cisplatin,	O
and	O
fluorouracil	O
(DCF)	O
over	O
docetaxel	O
and	O
cisplatin	O
for	O
comparison	O
against	O
cisplatin	O
and	O
fluorouracil	O
(CF;	O
reference	O
regimen)	O
in	O
the	O
phase	O
III	O
part.	O

Advanced	O
gastric	O
cancer	O
patients	O
were	O
randomly	O
assigned	O
to	O
docetaxel	O
75	O
mg/m2	O
and	O
cisplatin	O
75	O
mg/m2	O
(day	O
1)	O
plus	O
fluorouracil	O
750	O
mg/m2/d	O
(days	O
1	O
to	O
5)	O
every	O
3	O
weeks	O
or	O
cisplatin	O
100	O
mg/m2	O
(day	O
1)	O
plus	O
fluorouracil	O
1,000	O
mg/m2/d	O
(days	O
1	O
to	O
5)	O
every	O
4	O
weeks.	O

The	O
primary	O
end	O
point	O
was	O
time-to-progression	O
(TTP).	O

In	O
445	O
randomly	O
assigned	O
and	O
treated	O
patients	O
(DCF	O
=	O
221;	O
CF	O
=	O
224),	O
TTP	O
was	O
longer	O
with	O
DCF	O
versus	O
CF	O
(32%	O
risk	O
reduction;	O
log-rank	O
P	O
<	O
.001).	O

Overall	B-Premise
survival	I-Premise
was	I-Premise
longer	I-Premise
with	I-Premise
DCF	I-Premise
versus	I-Premise
CF	I-Premise
(23%	I-Premise
risk	I-Premise
reduction;	I-Premise
log-rank	I-Premise
P	I-Premise
=	I-Premise
.02).	I-Premise

Two-year	B-Premise
survival	I-Premise
rate	I-Premise
was	I-Premise
18%	I-Premise
with	I-Premise
DCF	I-Premise
and	I-Premise
9%	I-Premise
with	I-Premise
CF.	I-Premise

Overall	B-Premise
response	I-Premise
rate	I-Premise
was	I-Premise
higher	I-Premise
with	I-Premise
DCF	I-Premise
(chi2	I-Premise
P	I-Premise
=	I-Premise
.01).	I-Premise

Grade	B-Premise
3	I-Premise
to	I-Premise
4	I-Premise
treatment-related	I-Premise
adverse	I-Premise
events	I-Premise
occurred	I-Premise
in	I-Premise
69%	I-Premise
(DCF)	I-Premise
v	I-Premise
59%	I-Premise
(CF)	I-Premise
of	I-Premise
patients.	I-Premise

Frequent	B-Premise
grade	I-Premise
3	I-Premise
to	I-Premise
4	I-Premise
toxicities	I-Premise
for	I-Premise
DCF	I-Premise
v	I-Premise
CF	I-Premise
were:	I-Premise
neutropenia	I-Premise
(82%	I-Premise
v	I-Premise
57%),	I-Premise
stomatitis	I-Premise
(21%	I-Premise
v	I-Premise
27%),	I-Premise
diarrhea	I-Premise
(19%	I-Premise
v	I-Premise
8%),	I-Premise
lethargy	I-Premise
(19%	I-Premise
v	I-Premise
14%).	I-Premise

Complicated	B-Premise
neutropenia	I-Premise
was	I-Premise
more	I-Premise
frequent	I-Premise
with	I-Premise
DCF	I-Premise
than	I-Premise
CF	I-Premise
(29%	I-Premise
v	I-Premise
12%).	I-Premise

Adding	B-Claim
docetaxel	I-Claim
to	I-Claim
CF	I-Claim
significantly	I-Claim
improved	I-Claim
TTP,	I-Claim
survival,	I-Claim
and	I-Claim
response	I-Claim
rate	I-Claim
in	I-Claim
gastric	I-Claim
cancer	I-Claim
patients,	I-Claim
but	I-Claim
resulted	I-Claim
in	I-Claim
some	I-Claim
increase	I-Claim
in	I-Claim
toxicity.	I-Claim

Incorporation	B-Claim
of	I-Claim
docetaxel,	I-Claim
as	I-Claim
in	I-Claim
DCF	I-Claim
or	I-Claim
with	I-Claim
other	I-Claim
active	I-Claim
drug(s),	I-Claim
is	I-Claim
a	I-Claim
new	I-Claim
therapy	I-Claim
option	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
untreated	I-Claim
advanced	I-Claim
gastric	I-Claim
cancer.	I-Claim

In	O
Lithuania,	O
about	O
400	O
cases	O
of	O
pancreatic	O
cancer	O
are	O
diagnosed	O
each	O
year,	O
and	O
more	O
than	O
50%	O
of	O
patients	O
are	O
diagnosed	O
with	O
stage	O
IV	O
disease.	O

Quality	B-Claim
of	I-Claim
life	I-Claim
is	I-Claim
an	I-Claim
important	I-Claim
issue	I-Claim
in	I-Claim
pancreatic	I-Claim
cancer	I-Claim
patients.	I-Claim

A	O
prospective	O
randomized	O
clinical	O
study	O
on	O
the	O
treatment	O
of	O
patients	O
with	O
resectable	O
and	O
unresectable	O
pancreatic	O
cancer	O
was	O
conducted	O
at	O
the	O
Department	O
of	O
Oncology	O
of	O
Kaunas	O
University	O
of	O
Medicine	O
Hospital,	O
and	O
in	O
this	O
study,	O
quality	O
of	O
life	O
was	O
analyzed.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
analyze	O
the	O
effect	O
of	O
combined	O
treatment	O
methods	O
on	O
quality	O
of	O
life	O
in	O
patients	O
diagnosed	O
with	O
pancreatic	O
cancer.	O

During	O
2000-2005,	O
two	O
concomitant	O
chemoradiation	O
treatment	O
methods	O
(radiotherapy	O
with	O
5-fluorouracil	O
and	O
radiotherapy	O
with	O
gemcitabine)	O
were	O
analyzed	O
in	O
the	O
study.	O

A	O
total	O
of	O
60	O
patients	O
were	O
enrolled:	O
41	O
patients	O
diagnosed	O
with	O
resectable	O
and	O
19	O
patients	O
diagnosed	O
with	O
unresectable	O
pancreatic	O
cancer.	O

Quality	O
of	O
life	O
was	O
assessed	O
using	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Core	O
30	O
(EORTC	O
QLQ-C30)	O
questionnaire.	O

Three	O
main	O
quality	O
of	O
life	O
scales	O
(general	O
health	O
status,	O
functional,	O
and	O
symptom	O
scales)	O
were	O
assessed	O
and	O
compared	O
between	O
two	O
treatment	O
groups.	O

The	B-Premise
analysis	I-Premise
of	I-Premise
quality	I-Premise
of	I-Premise
live	I-Premise
assessment	I-Premise
showed	I-Premise
a	I-Premise
statistically	I-Premise
significant	I-Premise
decrease	I-Premise
in	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
after	I-Premise
treatment	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
resectable	I-Premise
pancreatic	I-Premise
cancer	I-Premise
and	I-Premise
treated	I-Premise
with	I-Premise
radiotherapy	I-Premise
and	I-Premise
gemcitabine.	I-Premise

Decreased	B-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
later	I-Premise
after	I-Premise
treatment	I-Premise
was	I-Premise
also	I-Premise
observed	I-Premise
in	I-Premise
patients	I-Premise
diagnosed	I-Premise
with	I-Premise
unresectable	I-Premise
pancreatic	I-Premise
cancer	I-Premise
and	I-Premise
treated	I-Premise
with	I-Premise
the	I-Premise
same	I-Premise
regimen.	I-Premise

Treatment	B-Claim
with	I-Claim
radiotherapy	I-Claim
and	I-Claim
5-fluorouracil	I-Claim
changed	I-Claim
only	I-Claim
some	I-Claim
aspects	I-Claim
of	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
and	I-Claim
did	I-Claim
not	I-Claim
have	I-Claim
a	I-Claim
significant	I-Claim
impact	I-Claim
on	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

Surgery	O
and	O
radiotherapy	O
commonly	O
cause	O
adverse	O
musculoskeletal	O
problems,	O
particularly	O
loss	O
of	O
strength	O
and	O
range	O
of	O
motion,	O
in	O
the	O
upper	O
quadrant	O
of	O
breast	O
cancer	O
patients.	O

Few	O
well-designed	O
studies	O
have	O
investigated	O
whether	O
these	O
impairments	O
can	O
be	O
prevented.	O

Stretching	B-Claim
is	I-Claim
an	I-Claim
effective	I-Claim
technique	I-Claim
for	I-Claim
increasing	I-Claim
range	I-Claim
of	I-Claim
motion,	I-Claim
hence	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
a	O
stretching	O
program	O
reduced	O
acute	O
musculoskeletal	O
impairments	O
in	O
patients	O
undergoing	O
radiotherapy	O
for	O
breast	O
cancer.	O

Sixty-four	O
women	O
were	O
recruited	O
prior	O
to	O
commencement	O
of	O
radiotherapy	O
following	O
breast	O
cancer	O
surgery.	O

Participants	O
were	O
randomised	O
to	O
either	O
a	O
control	O
or	O
stretch	O
group.	O

Participants	O
in	O
both	O
groups	O
were	O
reviewed	O
by	O
the	O
physical	O
therapist	O
on	O
a	O
weekly	O
basis	O
for	O
approximately	O
6	O
weeks,	O
and	O
were	O
given	O
general	O
information	O
about	O
skin	O
care	O
and	O
lymphedema.	O

The	O
control	O
group	O
received	O
no	O
advice	O
about	O
exercise.	O

The	O
stretch	O
group	O
received	O
instruction	O
on	O
low-load,	O
prolonged	O
pectoral	O
stretches,	O
which	O
were	O
to	O
be	O
performed	O
daily	O
and	O
were	O
checked	O
at	O
weekly	O
visits.	O

Shoulder	O
range	O
of	O
motion,	O
strength,	O
arm	O
circumference,	O
and	O
quality	O
of	O
life	O
measurements	O
were	O
taken	O
prior	O
to,	O
and	O
at	O
completion	O
of	O
radiotherapy,	O
and	O
at	O
7	O
months	O
after	O
radiotherapy.	O

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
any	I-Premise
outcome	I-Premise
between	I-Premise
groups.	I-Premise

Breast	B-Premise
symptoms	I-Premise
increased	I-Premise
for	I-Premise
both	I-Premise
groups	I-Premise
during	I-Premise
radiotherapy,	I-Premise
without	I-Premise
loss	I-Premise
of	I-Premise
strength	I-Premise
or	I-Premise
range	I-Premise
of	I-Premise
movement.	I-Premise

The	B-Premise
incidence	I-Premise
of	I-Premise
lymphedema	I-Premise
during	I-Premise
the	I-Premise
study	I-Premise
was	I-Premise
low	I-Premise
for	I-Premise
both	I-Premise
groups	I-Premise
and	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
between	I-Premise
groups.	I-Premise

The	B-Premise
pectoral	I-Premise
stretching	I-Premise
program	I-Premise
did	I-Premise
not	I-Premise
influence	I-Premise
the	I-Premise
outcomes	I-Premise
measured	I-Premise
because	I-Premise
the	I-Premise
symptoms	I-Premise
reported	I-Premise
by	I-Premise
patients	I-Premise
were	I-Premise
not	I-Premise
a	I-Premise
consequence	I-Premise
of	I-Premise
contracture.	I-Premise

To	O
compare	O
directly	O
the	O
effect	O
of	O
intensity-modulated	O
radiotherapy	O
(IMRT)	O
vs.	O
conventional	O
radiotherapy	O
(CRT)	O
on	O
salivary	O
flow	O
and	O
quality	O
of	O
life	O
(QoL)	O
in	O
patients	O
with	O
early-stage	O
nasopharyngeal	O
carcinoma	O
(NPC).	O

Fifty-one	O
patients	O
with	O
T2,	O
N0/N1,	O
M0	O
NPC	O
took	O
part	O
in	O
a	O
randomized	O
controlled	O
clinical	O
study	O
and	O
received	O
IMRT	O
or	O
CRT.	O

Stimulated	O
whole	O
(SWS)	O
and	O
parotid	O
(SPS)	O
saliva	O
flow	O
were	O
measured	O
and	O
Medical	O
Outcomes	O
Short	O
Form	O
36	O
(SF-36),	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
core	O
quetionnaire,	O
and	O
EORTC	O
head-and-neck	O
module	O
(QLQ-H&amp;N35)	O
were	O
completed	O
at	O
baseline	O
and	O
2,	O
6,	O
and	O
12	O
months	O
after	O
radiotherapy.	O

Forty-six	B-Premise
patients	I-Premise
(88%)	I-Premise
were	I-Premise
in	I-Premise
disease	I-Premise
remission	I-Premise
12	I-Premise
months	I-Premise
after	I-Premise
radiotherapy.	I-Premise

At	B-Premise
12	I-Premise
months	I-Premise
postradiotherapy,	I-Premise
12	I-Premise
(50.0%)	I-Premise
and	I-Premise
20	I-Premise
patients	I-Premise
(83.3%)	I-Premise
in	I-Premise
the	I-Premise
IMRT	I-Premise
group	I-Premise
had	I-Premise
recovered	I-Premise
at	I-Premise
least	I-Premise
25%	I-Premise
of	I-Premise
preradiotherapy	I-Premise
SWS	I-Premise
and	I-Premise
SPS	I-Premise
flow	I-Premise
respectively,	I-Premise
compared	I-Premise
with	I-Premise
1	I-Premise
(4.8%)	I-Premise
and	I-Premise
2	I-Premise
patients	I-Premise
(9.5%),	I-Premise
respectively,	I-Premise
in	I-Premise
the	I-Premise
CRT	I-Premise
group.	I-Premise

Global	B-Premise
health	I-Premise
scores	I-Premise
showed	I-Premise
continuous	I-Premise
improvement	I-Premise
in	I-Premise
QoL	I-Premise
after	I-Premise
both	I-Premise
treatments	I-Premise
(p	I-Premise
<	I-Premise
0.001).	I-Premise

However,	B-Premise
after	I-Premise
12	I-Premise
months	I-Premise
subscale	I-Premise
scores	I-Premise
for	I-Premise
role-physical,	I-Premise
bodily	I-Premise
pain,	I-Premise
and	I-Premise
physical	I-Premise
function	I-Premise
were	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
IMRT	I-Premise
group,	I-Premise
indicating	I-Premise
a	I-Premise
better	I-Premise
condition	I-Premise
(p	I-Premise
<	I-Premise
0.05).	I-Premise

Dry	B-Premise
mouth	I-Premise
and	I-Premise
sticky	I-Premise
saliva	I-Premise
were	I-Premise
problems	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
2	I-Premise
months	I-Premise
after	I-Premise
treatment.	I-Premise

In	B-Premise
the	I-Premise
IMRT	I-Premise
group,	I-Premise
there	I-Premise
was	I-Premise
consistent	I-Premise
improvement	I-Premise
over	I-Premise
time	I-Premise
with	I-Premise
xerostomia-related	I-Premise
symptoms	I-Premise
significantly	I-Premise
less	I-Premise
common	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
CRT	I-Premise
group	I-Premise
at	I-Premise
12	I-Premise
months	I-Premise
postradiotherapy.	I-Premise

IMRT	B-Claim
was	I-Claim
significantly	I-Claim
better	I-Claim
than	I-Claim
CRT	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
parotid	I-Claim
sparing	I-Claim
and	I-Claim
improved	I-Claim
QoL	I-Claim
for	I-Claim
early-stage	I-Claim
disease.	I-Claim

The	B-Claim
findings	I-Claim
support	I-Claim
the	I-Claim
case	I-Claim
for	I-Claim
assessment	I-Claim
of	I-Claim
health-related	I-Claim
QoL	I-Claim
in	I-Claim
relation	I-Claim
to	I-Claim
head-and-neck	I-Claim
cancer	I-Claim
using	I-Claim
a	I-Claim
site-specific	I-Claim
approach.	I-Claim

The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
compare	O
quality	O
of	O
life	O
(QOL)	O
and	O
menopausal	O
symptoms	O
among	O
premenopausal	O
patients	O
with	O
lymph	O
node-negative	O
breast	O
cancer	O
receiving	O
chemotherapy,	O
goserelin,	O
or	O
their	O
sequential	O
combination,	O
and	O
to	O
investigate	O
differential	O
effects	O
by	O
age.	O

We	O
evaluated	O
QOL	O
data	O
from	O
874	O
pre-	O
and	O
perimenopausal	O
women	O
with	O
lymph	O
node-negative	O
breast	O
cancer	O
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
six	O
courses	O
of	O
classical	O
cyclophosphamide,	O
methotrexate,	O
and	O
fluorouracil	O
(CMF)	O
chemotherapy,	O
ovarian	O
suppression	O
with	O
goserelin	O
for	O
24	O
months,	O
or	O
six	O
courses	O
of	O
classical	O
CMF	O
followed	O
by	O
18	O
months	O
of	O
goserelin.	O

We	O
report	O
QOL	O
data	O
collected	O
during	O
3	O
years	O
after	O
random	O
assignment	O
in	O
patients	O
without	O
disease	O
recurrence.	O

Overall,	B-Premise
patients	I-Premise
receiving	I-Premise
goserelin	I-Premise
alone	I-Premise
showed	I-Premise
a	I-Premise
marked	I-Premise
improvement	I-Premise
or	I-Premise
less	I-Premise
deterioration	I-Premise
in	I-Premise
QOL	I-Premise
measures	I-Premise
over	I-Premise
the	I-Premise
first	I-Premise
6	I-Premise
months	I-Premise
than	I-Premise
those	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
CMF.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
differences	I-Premise
at	I-Premise
3	I-Premise
years	I-Premise
after	I-Premise
random	I-Premise
assignment	I-Premise
according	I-Premise
to	I-Premise
treatment	I-Premise
except	I-Premise
for	I-Premise
hot	I-Premise
flashes.	I-Premise

As	B-Premise
reflected	I-Premise
in	I-Premise
the	I-Premise
hot	I-Premise
flashes	I-Premise
scores,	I-Premise
patients	I-Premise
in	I-Premise
all	I-Premise
three	I-Premise
treatment	I-Premise
groups	I-Premise
experienced	I-Premise
induced	I-Premise
amenorrhea,	I-Premise
but	B-Premise
the	I-Premise
onset	I-Premise
of	I-Premise
ovarian	I-Premise
function	I-Premise
suppression	I-Premise
was	I-Premise
slightly	I-Premise
delayed	I-Premise
for	I-Premise
patients	I-Premise
receiving	I-Premise
chemotherapy.	I-Premise

Younger	B-Premise
patients	I-Premise
(<	I-Premise
40	I-Premise
years)	I-Premise
who	I-Premise
received	I-Premise
goserelin	I-Premise
alone	I-Premise
returned	I-Premise
to	I-Premise
their	I-Premise
premenopausal	I-Premise
status	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
after	I-Premise
the	I-Premise
cessation	I-Premise
of	I-Premise
therapy,	I-Premise
while	I-Premise
those	I-Premise
who	I-Premise
received	I-Premise
CMF	I-Premise
showed	I-Premise
marginal	I-Premise
changes	I-Premise
from	I-Premise
their	I-Premise
baseline	I-Premise
hot	I-Premise
flashes	I-Premise
scores.	I-Premise

Age-adjusted	B-Claim
risk	I-Claim
profiles	I-Claim
that	I-Claim
consider	I-Claim
patient-reported	I-Claim
outcomes	I-Claim
enable	I-Claim
patients	I-Claim
to	I-Claim
adapt	I-Claim
to	I-Claim
their	I-Claim
disease	I-Claim
and	I-Claim
treatment,	I-Claim
such	I-Claim
as	I-Claim
considering	I-Claim
the	I-Claim
trade-offs	I-Claim
between	I-Claim
delayed	I-Claim
endocrine	I-Claim
symptoms,	I-Claim
but	I-Claim
higher	I-Claim
risk	I-Claim
of	I-Claim
permanent	I-Claim
menopause	I-Claim
with	I-Claim
chemotherapy,	I-Claim
and	I-Claim
immediate	I-Claim
but	I-Claim
reversible	I-Claim
endocrine	I-Claim
symptoms	I-Claim
with	I-Claim
goserelin,	I-Claim
in	I-Claim
younger	I-Claim
premenopausal	I-Claim
patients.	I-Claim

Although	O
numerous	O
treatment	O
modalities	O
have	O
been	O
explored	O
in	O
patients	O
with	O
advanced	O
HCC,	O
the	O
therapeutic	O
options	O
are	O
still	O
limited.	O

Somatostatin	B-Claim
has	I-Claim
been	I-Claim
shown	I-Claim
to	I-Claim
have	I-Claim
antimitotic	I-Claim
activity	I-Claim
in	I-Claim
endocrine	I-Claim
as	I-Claim
well	I-Claim
as	I-Claim
in	I-Claim
a	I-Claim
variety	I-Claim
of	I-Claim
nonendocrine	I-Claim
tumors.	I-Claim

Expression	B-Premise
of	I-Premise
somatostatin	I-Premise
receptors	I-Premise
is	I-Premise
found	I-Premise
in	I-Premise
HCCs,	I-Premise
but	O
the	B-Claim
efficacy	I-Claim
of	I-Claim
the	I-Claim
somatostatin	I-Claim
analogue	I-Claim
octreotide	I-Claim
remains	I-Claim
controversial.	I-Claim

Therefore,	O
a	O
randomized	O
double-blind	O
placebo-controlled	O
multicenter	O
trial	O
was	O
performed	O
to	O
assess	O
the	O
efficacy	O
of	O
long-acting	O
octreotide	O
for	O
the	O
treatment	O
of	O
advanced	O
HCC.	O

One	O
hundred	O
twenty	O
untreated	O
patients	O
with	O
histologically	O
confirmed	O
HCC	O
were	O
randomized	O
to	O
receive	O
either	O
long-acting	O
octreotide	O
(Sandostation	O
LAR	O
30	O
mg)	O
intramuscularly	O
every	O
4	O
weeks	O
or	O
placebo.	O

The	O
study	O
groups	O
were	O
comparable	O
with	O
respect	O
to	O
clinical	O
characteristics.	O

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
cumulative	I-Premise
survival.	I-Premise

The	B-Premise
median	I-Premise
survival	I-Premise
time	I-Premise
was	I-Premise
4.7	I-Premise
months	I-Premise
in	I-Premise
the	I-Premise
octreotide	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
5.3	I-Premise
months	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

Six-month	B-Premise
survival	I-Premise
rates	I-Premise
were	I-Premise
41%	I-Premise
for	I-Premise
octreotide	I-Premise
patients	I-Premise
and	I-Premise
42%	I-Premise
for	I-Premise
control	I-Premise
patients,	I-Premise
respectively.	I-Premise

The	B-Premise
unadjusted	I-Premise
relative	I-Premise
risk	I-Premise
for	I-Premise
mortality	I-Premise
in	I-Premise
the	I-Premise
octreotide	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
was	I-Premise
1.11	I-Premise
(95%	I-Premise
CI	I-Premise
0.76-1.63;	I-Premise
P	I-Premise
=	I-Premise
0.59).	I-Premise

When	B-Premise
adjusted	I-Premise
for	I-Premise
Okuda,	I-Premise
CTP,	I-Premise
and	I-Premise
Cancer	I-Premise
of	I-Premise
the	I-Premise
Liver	I-Premise
Italian	I-Premise
Program	I-Premise
(CLIP)	I-Premise
scores,	I-Premise
the	I-Premise
relative	I-Premise
risk	I-Premise
for	I-Premise
octreotide	I-Premise
did	I-Premise
not	I-Premise
change	I-Premise
markedly	I-Premise
and	I-Premise
was	I-Premise
1.05	I-Premise
(95%	I-Premise
CI	I-Premise
0.71-1.55;	I-Premise
P	I-Premise
=	I-Premise
0.83).	I-Premise

The	B-Claim
CLIP	I-Claim
score	I-Claim
seems	I-Claim
to	I-Claim
predict	I-Claim
survival	I-Claim
better	I-Claim
than	I-Claim
both	I-Claim
Okuda	I-Claim
and	I-Claim
CTP	I-Claim
score.	I-Claim

The	B-Claim
randomized	I-Claim
controlled	I-Claim
double-blind	I-Claim
HECTOR	I-Claim
trial	I-Claim
showed	I-Claim
no	I-Claim
survival	I-Claim
benefit	I-Claim
for	I-Claim
HCC	I-Claim
patients	I-Claim
treated	I-Claim
with	I-Claim
long-acting	I-Claim
octreotide	I-Claim
compared	I-Claim
with	I-Claim
placebo.	I-Claim

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
impact	O
of	O
laparoscopic	O
rectal	O
resection	O
on	O
short-term	O
postoperative	O
morbidity	O
and	O
costs.	O

A	O
total	O
of	O
168	O
patients	O
with	O
rectal	O
cancer	O
were	O
randomly	O
assigned	O
to	O
laparoscopic	O
(n	O
=	O
83)	O
or	O
open	O
(n	O
=	O
85)	O
resection.	O

Outcome	O
parameters	O
were:	O
postoperative	O
morbidity,	O
length	O
of	O
hospital	O
stay,	O
quality	O
of	O
life,	O
long-term	O
survival,	O
and	O
local	O
recurrences.	O

The	O
mean	O
follow-up	O
period	O
was	O
53.6	O
months.	O

Cost-benefit	O
analysis	O
was	O
based	O
on	O
hospital	O
costs.	O

Operative	B-Premise
time	I-Premise
was	I-Premise
53	I-Premise
minutes	I-Premise
longer	I-Premise
in	I-Premise
the	I-Premise
laparoscopic	I-Premise
group	I-Premise
(P	I-Premise
<	I-Premise
0.0001).	I-Premise

Postoperative	B-Premise
morbidity	I-Premise
rate	I-Premise
was	I-Premise
28.9	I-Premise
percent	I-Premise
in	I-Premise
the	I-Premise
laparoscopic	I-Premise
vs.	I-Premise
40	I-Premise
percent	I-Premise
in	I-Premise
the	I-Premise
open	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.18).	I-Premise

The	B-Premise
mean	I-Premise
length	I-Premise
of	I-Premise
hospital	I-Premise
stay	I-Premise
was	I-Premise
10	I-Premise
(4.9)	I-Premise
days	I-Premise
in	I-Premise
the	I-Premise
laparoscopic	I-Premise
group	I-Premise
and	I-Premise
13.6	I-Premise
(10)	I-Premise
days	I-Premise
in	I-Premise
the	I-Premise
open	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.004).	I-Premise

Local	B-Premise
recurrence	I-Premise
rate	I-Premise
and	I-Premise
five-year	I-Premise
survival	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
both	I-Premise
groups;	I-Premise
however,	B-Claim
the	I-Claim
limited	I-Claim
number	I-Claim
of	I-Claim
patients	I-Claim
does	I-Claim
not	I-Claim
allow	I-Claim
firm	I-Claim
conclusions.	I-Claim

Quality	B-Premise
of	I-Premise
life	I-Premise
was	I-Premise
better	I-Premise
in	I-Premise
the	I-Premise
laparoscopic	I-Premise
group	I-Premise
only	I-Premise
in	I-Premise
the	I-Premise
first	I-Premise
year	I-Premise
after	I-Premise
surgery	I-Premise
(P	I-Premise
<	I-Premise
0.0001).	I-Premise

The	B-Premise
additional	I-Premise
charge	I-Premise
in	I-Premise
the	I-Premise
laparoscopic	I-Premise
group	I-Premise
was	I-Premise
$1,748	I-Premise
per	I-Premise
patient	I-Premise
randomized	I-Premise
($1,194	I-Premise
the	I-Premise
result	I-Premise
of	I-Premise
surgical	I-Premise
instruments	I-Premise
and	I-Premise
$554	I-Premise
the	I-Premise
result	I-Premise
of	I-Premise
longer	I-Premise
operative	I-Premise
time).	I-Premise

The	B-Premise
saving	I-Premise
in	I-Premise
the	I-Premise
laparoscopic	I-Premise
group	I-Premise
was	I-Premise
$1,396	I-Premise
per	I-Premise
patient	I-Premise
randomized	I-Premise
($647	I-Premise
the	I-Premise
result	I-Premise
of	I-Premise
shorter	I-Premise
length	I-Premise
of	I-Premise
hospital	I-Premise
stay	I-Premise
and	I-Premise
$749	I-Premise
the	I-Premise
result	I-Premise
of	I-Premise
the	I-Premise
lower	I-Premise
cost	I-Premise
of	I-Premise
postoperative	I-Premise
complications).	I-Premise

The	B-Premise
net	I-Premise
balance	I-Premise
resulted	I-Premise
in	I-Premise
$351	I-Premise
extra	I-Premise
cost	I-Premise
per	I-Premise
patient	I-Premise
randomly	I-Premise
allocated	I-Premise
to	I-Premise
the	I-Premise
laparoscopic	I-Premise
group.	I-Premise

Short-term	B-Claim
postoperative	I-Claim
morbidity	I-Claim
was	I-Claim
similar	I-Claim
in	I-Claim
the	I-Claim
two	I-Claim
groups.	I-Claim

Laparoscopic	B-Claim
resection	I-Claim
reduced	I-Claim
length	I-Claim
of	I-Claim
hospital	I-Claim
stay,	I-Claim
improved	I-Claim
first-year	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
and	I-Claim
slightly	I-Claim
increased	I-Claim
hospital	I-Claim
costs.	I-Claim

The	B-Claim
efficacy	I-Claim
and	I-Claim
safety	I-Claim
of	I-Claim
uterine-artery	I-Claim
embolization,	I-Claim
as	I-Claim
compared	I-Claim
with	I-Claim
standard	I-Claim
surgical	I-Claim
methods,	I-Claim
for	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
symptomatic	I-Claim
uterine	I-Claim
fibroids	I-Claim
remain	I-Claim
uncertain.	I-Claim

We	O
conducted	O
a	O
randomized	O
trial	O
comparing	O
uterine-artery	O
embolization	O
and	O
surgery	O
in	O
women	O
with	O
symptomatic	O
uterine	O
fibroids.	O

The	O
primary	O
outcome	O
was	O
quality	O
of	O
life	O
at	O
1	O
year	O
of	O
follow-up,	O
as	O
measured	O
by	O
the	O
Medical	O
Outcomes	O
Study	O
36-Item	O
Short-Form	O
General	O
Health	O
Survey	O
(SF-36).	O

Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
2:1	O
ratio	O
to	O
undergo	O
either	O
uterine-artery	O
embolization	O
or	O
surgery,	O
with	O
106	O
patients	O
undergoing	O
embolization	O
and	O
51	O
undergoing	O
surgery	O
(43	O
hysterectomies	O
and	O
8	O
myomectomies).	O

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
groups	I-Premise
in	I-Premise
any	I-Premise
of	I-Premise
the	I-Premise
eight	I-Premise
components	I-Premise
of	I-Premise
the	I-Premise
SF-36	I-Premise
scores	I-Premise
at	I-Premise
1	I-Premise
year.	I-Premise

The	B-Premise
embolization	I-Premise
group	I-Premise
had	I-Premise
a	I-Premise
shorter	I-Premise
median	I-Premise
duration	I-Premise
of	I-Premise
hospitalization	I-Premise
than	I-Premise
the	I-Premise
surgical	I-Premise
group	I-Premise
(1	I-Premise
day	I-Premise
vs.	I-Premise
5	I-Premise
days,	I-Premise
P<0.001)	I-Premise
and	I-Premise
a	I-Premise
shorter	I-Premise
time	I-Premise
before	I-Premise
returning	I-Premise
to	I-Premise
work	I-Premise
(P<0.001).	I-Premise

At	B-Premise
1	I-Premise
year,	I-Premise
symptom	I-Premise
scores	I-Premise
were	I-Premise
better	I-Premise
in	I-Premise
the	I-Premise
surgical	I-Premise
group	I-Premise
(P=0.03).	I-Premise

During	B-Premise
the	I-Premise
first	I-Premise
year	I-Premise
of	I-Premise
follow-up,	I-Premise
there	I-Premise
were	I-Premise
13	I-Premise
major	I-Premise
adverse	I-Premise
events	I-Premise
in	I-Premise
the	I-Premise
embolization	I-Premise
group	I-Premise
(12%)	I-Premise
and	I-Premise
10	I-Premise
in	I-Premise
the	I-Premise
surgical	I-Premise
group	I-Premise
(20%)	I-Premise
(P=0.22),	I-Premise
mostly	I-Premise
related	I-Premise
to	I-Premise
the	I-Premise
intervention.	I-Premise

Ten	B-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
embolization	I-Premise
group	I-Premise
(9%)	I-Premise
required	I-Premise
repeated	I-Premise
embolization	I-Premise
or	I-Premise
hysterectomy	I-Premise
for	I-Premise
inadequate	I-Premise
symptom	I-Premise
control.	I-Premise

After	B-Premise
the	I-Premise
first	I-Premise
year	I-Premise
of	I-Premise
follow-up,	I-Premise
14	I-Premise
women	I-Premise
in	I-Premise
the	I-Premise
embolization	I-Premise
group	I-Premise
(13%)	I-Premise
required	I-Premise
hospitalization,	I-Premise
3	I-Premise
of	I-Premise
them	I-Premise
for	I-Premise
major	I-Premise
adverse	I-Premise
events	I-Premise
and	I-Premise
11	I-Premise
for	I-Premise
reintervention	I-Premise
for	I-Premise
treatment	I-Premise
failure.	I-Premise

In	B-Claim
women	I-Claim
with	I-Claim
symptomatic	I-Claim
fibroids,	I-Claim
the	I-Claim
faster	I-Claim
recovery	I-Claim
after	I-Claim
embolization	I-Claim
must	I-Claim
be	I-Claim
weighed	I-Claim
against	I-Claim
the	I-Claim
need	I-Claim
for	I-Claim
further	I-Claim
treatment	I-Claim
in	I-Claim
a	I-Claim
minority	I-Claim
of	I-Claim
patients.	I-Claim

To	O
determine	O
functional	O
and	O
psychological	O
benefits	O
of	O
a	O
12	O
week	O
supervised	O
group	O
exercise	O
programme	O
during	O
treatment	O
for	O
early	O
stage	O
breast	O
cancer,	O
with	O
six	O
month	O
follow-up.	O

Pragmatic	O
randomised	O
controlled	O
prospective	O
open	O
trial.	O

Three	O
National	O
Health	O
Service	O
oncology	O
clinics	O
in	O
Scotland	O
and	O
community	O
exercise	O
facilities.	O

203	O
women	O
entered	O
the	O
study;	O
177	O
completed	O
the	O
six	O
month	O
follow-up.	O

Supervised	O
12	O
week	O
group	O
exercise	O
programme	O
in	O
addition	O
to	O
usual	O
care,	O
compared	O
with	O
usual	O
care.	O

Functional	O
assessment	O
of	O
cancer	O
therapy	O
(FACT)	O
questionnaire,	O
Beck	O
depression	O
inventory,	O
positive	O
and	O
negative	O
affect	O
scale,	O
body	O
mass	O
index,	O
seven	O
day	O
recall	O
of	O
physical	O
activity,	O
12	O
minute	O
walk	O
test,	O
and	O
assessment	O
of	O
shoulder	O
mobility.	O

Mixed	B-Premise
effects	I-Premise
models	I-Premise
with	I-Premise
adjustment	I-Premise
for	I-Premise
baseline	I-Premise
values,	I-Premise
study	I-Premise
site,	I-Premise
treatment	I-Premise
at	I-Premise
baseline,	I-Premise
and	I-Premise
age	I-Premise
gave	I-Premise
intervention	I-Premise
effect	I-Premise
estimates	I-Premise
(intervention	I-Premise
minus	I-Premise
control)	I-Premise
at	I-Premise
12	I-Premise
weeks	I-Premise
of	I-Premise
129	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
83	I-Premise
to	I-Premise
176)	I-Premise
for	I-Premise
metres	I-Premise
walked	I-Premise
in	I-Premise
12	I-Premise
minutes,	I-Premise
182	I-Premise
(75	I-Premise
to	I-Premise
289)	I-Premise
for	I-Premise
minutes	I-Premise
of	I-Premise
moderate	I-Premise
intensity	I-Premise
activity	I-Premise
reported	I-Premise
in	I-Premise
a	I-Premise
week,	I-Premise
2.6	I-Premise
(1.6	I-Premise
to	I-Premise
3.7)	I-Premise
for	I-Premise
shoulder	I-Premise
mobility,	I-Premise
2.5	I-Premise
(1.0	I-Premise
to	I-Premise
3.9)	I-Premise
for	I-Premise
breast	I-Premise
cancer	I-Premise
specific	I-Premise
subscale	I-Premise
of	I-Premise
quality	I-Premise
of	I-Premise
life,	I-Premise
and	I-Premise
4.0	I-Premise
(1.8	I-Premise
to	I-Premise
6.3)	I-Premise
for	I-Premise
positive	I-Premise
mood.	I-Premise

No	B-Premise
significant	I-Premise
effect	I-Premise
was	I-Premise
seen	I-Premise
for	I-Premise
general	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(FACT-G),	I-Premise
which	I-Premise
was	I-Premise
the	I-Premise
primary	I-Premise
outcome.	I-Premise

At	B-Premise
the	I-Premise
six	I-Premise
month	I-Premise
follow-up,	I-Premise
most	I-Premise
of	I-Premise
these	I-Premise
effects	I-Premise
were	I-Premise
maintained	I-Premise
and	I-Premise
an	I-Premise
intervention	I-Premise
effect	I-Premise
for	I-Premise
breast	I-Premise
cancer	I-Premise
specific	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
emerged.	I-Premise

No	B-Premise
adverse	I-Premise
effects	I-Premise
were	I-Premise
noted.	I-Premise

Supervised	B-Claim
group	I-Claim
exercise	I-Claim
provided	I-Claim
functional	I-Claim
and	I-Claim
psychological	I-Claim
benefit	I-Claim
after	I-Claim
a	I-Claim
12	I-Claim
week	I-Claim
intervention	I-Claim
and	I-Claim
six	I-Claim
months	I-Claim
later.	I-Claim

Clinicians	B-Claim
should	I-Claim
encourage	I-Claim
activity	I-Claim
for	I-Claim
their	I-Claim
patients.	I-Claim

Policy	B-Claim
makers	I-Claim
should	I-Claim
consider	I-Claim
the	I-Claim
inclusion	I-Claim
of	I-Claim
exercise	I-Claim
opportunities	I-Claim
in	I-Claim
cancer	I-Claim
rehabilitation	I-Claim
services.	I-Claim

Previous	B-Claim
trials	I-Claim
have	I-Claim
suggested	I-Claim
a	I-Claim
quality-of-life	I-Claim
(QOL)	I-Claim
improvement	I-Claim
for	I-Claim
anemic	I-Claim
cancer	I-Claim
patients	I-Claim
treated	I-Claim
with	I-Claim
erythropoietin,	I-Claim
but	I-Claim
few	I-Claim
used	I-Claim
QOL	I-Claim
as	I-Claim
the	I-Claim
primary	I-Claim
outcome.	I-Claim

We	O
designed	O
a	O
trial	O
to	O
investigate	O
the	O
effects	O
of	O
epoetin	O
alfa	O
therapy	O
on	O
the	O
QOL	O
of	O
anemic	O
patients	O
with	O
advanced	O
non-small-cell	O
carcinoma	O
of	O
the	O
lung	O
(NSCLC).	O

A	O
multicenter,	O
randomized,	O
double-blind,	O
placebo-controlled	O
trial	O
was	O
conducted.	O

The	O
proposed	O
sample	O
size	O
was	O
300	O
patients.	O

Eligible	O
patients	O
were	O
required	O
to	O
have	O
NSCLC	O
unsuitable	O
for	O
curative	O
therapy	O
and	O
baseline	O
hemoglobin	O
(Hgb)	O
levels	O
less	O
than	O
121	O
g/L.	O

Patients	O
were	O
assigned	O
to	O
12	O
weekly	O
injections	O
of	O
subcutaneous	O
epoetin	O
alpha	O
or	O
placebo,	O
targeting	O
Hgb	O
levels	O
between	O
120	O
and	O
140	O
g/L.	O

The	O
primary	O
outcome	O
was	O
the	O
difference	O
in	O
the	O
change	O
in	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Anemia	O
scores	O
between	O
baseline	O
and	O
12	O
weeks.	O

Reports	O
of	O
thrombotic	O
events	O
in	O
other	O
epoetin	O
trials	O
prompted	O
an	O
unplanned	O
safety	O
analysis	O
after	O
70	O
patients	O
had	O
been	O
randomly	O
assigned	O
(33	O
to	O
the	O
active	O
arm	O
and	O
37	O
to	O
the	O
placebo	O
arm).	O

This	B-Premise
revealed	I-Premise
a	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
median	I-Premise
survival	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
on	I-Premise
the	I-Premise
placebo	I-Premise
arm	I-Premise
of	I-Premise
the	I-Premise
trial	I-Premise
(63	I-Premise
v	I-Premise
129	I-Premise
days;	I-Premise
hazard	I-Premise
ratio,	I-Premise
1.84;	I-Premise
P	I-Premise
=	I-Premise
.04).	I-Premise

The	O
Steering	O
Committee	O
closed	O
the	O
trial.	O

Patient	B-Premise
numbers	I-Premise
compromised	I-Premise
the	I-Premise
interpretation	I-Premise
of	I-Premise
the	I-Premise
QOL	I-Premise
analysis,	I-Premise
but	O
a	B-Premise
positive	I-Premise
Hgb	I-Premise
response	I-Premise
was	I-Premise
noted	I-Premise
with	I-Premise
epoetin	I-Premise
alfa	I-Premise
treatment.	I-Premise

An	B-Claim
unplanned	I-Claim
safety	I-Claim
analysis	I-Claim
suggested	I-Claim
decreased	I-Claim
overall	I-Claim
survival	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
NSCLC	I-Claim
treated	I-Claim
with	I-Claim
epoetin	I-Claim
alfa.	I-Claim

Although	O
infrequent,	O
other	O
similar	O
reports	O
highlight	O
the	O
need	O
for	O
ongoing	O
trials	O
evaluating	O
erythropoietin	O
receptor	O
agonists	O
to	O
ensure	O
that	O
overall	O
survival	O
is	O
monitored	O
closely.	O

A	O
randomized	O
controlled	O
trial	O
previously	O
conducted	O
in	O
radiation	O
oncology	O
patients	O
demonstrated	O
that	O
nutrition	O
intervention	O
had	O
a	O
beneficial	O
impact	O
on	O
body	O
weight,	O
nutritional	O
status,	O
and	O
quality	O
of	O
life	O
compared	O
with	O
standard	O
practice,	O
but	O
it	O
did	O
not	O
report	O
on	O
dietary	O
intake	O
data.	O

To	O
determine	O
the	O
impact	O
of	O
nutrition	O
intervention	O
compared	O
with	O
standard	O
practice	O
on	O
dietary	O
intake	O
in	O
outpatients	O
receiving	O
radiotherapy.	O

Prospective,	O
randomized,	O
controlled	O
trial.	O

Sixty	O
consecutive	O
radiation	O
oncology	O
outpatients	O
(51	O
men	O
and	O
nine	O
women;	O
age	O
61.9+/-14	O
years	O
[mean+/-standard	O
deviation]).	O

Australian	O
private	O
radiotherapy	O
facility.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
nutrition	O
intervention	O
(n=29)	O
(nutrition	O
counseling	O
following	O
the	O
American	O
Dietetic	O
Association	O
[ADA]	O
medical	O
nutrition	O
therapy	O
[MNT]	O
protocol	O
for	O
radiation	O
oncology)	O
or	O
standard	O
practice	O
(n=31)	O
(general	O
nutrition	O
talk	O
and	O
booklet).	O

Dietary	O
intake	O
(protein,	O
energy,	O
fiber)	O
assessed	O
at	O
baseline	O
and	O
at	O
4,	O
8,	O
and	O
12	O
weeks	O
after	O
starting	O
radiotherapy.	O

Repeated-measures	O
analysis	O
of	O
variance	O
done	O
on	O
an	O
intention	O
to	O
treat	O
basis.	O

The	B-Premise
nutrition	I-Premise
intervention	I-Premise
group	I-Premise
had	I-Premise
a	I-Premise
higher	I-Premise
mean	I-Premise
total	I-Premise
energy	I-Premise
(P=0.029)	I-Premise
and	I-Premise
protein	I-Premise
intake	I-Premise
(P<0.001)	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
standard	I-Premise
practice	I-Premise
group.	I-Premise

Mean	B-Premise
intake	I-Premise
per	I-Premise
kilogram	I-Premise
of	I-Premise
body	I-Premise
weight	I-Premise
for	I-Premise
the	I-Premise
nutrition	I-Premise
intervention	I-Premise
group	I-Premise
ranged	I-Premise
from	I-Premise
28	I-Premise
to	I-Premise
31	I-Premise
kcal/kg/day	I-Premise
compared	I-Premise
with	I-Premise
25	I-Premise
to	I-Premise
29	I-Premise
kcal/kg/day	I-Premise
for	I-Premise
the	I-Premise
standard	I-Premise
practice	I-Premise
group	I-Premise
(P=0.022).	I-Premise

The	B-Premise
nutrition	I-Premise
intervention	I-Premise
group	I-Premise
had	I-Premise
a	I-Premise
higher	I-Premise
mean	I-Premise
protein	I-Premise
intake	I-Premise
(1.1	I-Premise
to	I-Premise
1.3	I-Premise
g/kg/day)	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
standard	I-Premise
practice	I-Premise
group	I-Premise
(1.0	I-Premise
to	I-Premise
1.1	I-Premise
g/kg/day)	I-Premise
(P=0.001).	I-Premise

Although	B-Premise
the	I-Premise
change	I-Premise
in	I-Premise
fiber	I-Premise
intake	I-Premise
between	I-Premise
the	I-Premise
groups	I-Premise
was	I-Premise
not	I-Premise
significant,	I-Premise
there	B-Premise
was	I-Premise
a	I-Premise
trend	I-Premise
in	I-Premise
the	I-Premise
anticipated	I-Premise
direction	I-Premise
(P=0.083).	I-Premise

Intensive	B-Claim
nutrition	I-Claim
intervention	I-Claim
following	I-Claim
the	I-Claim
ADA	I-Claim
MNT	I-Claim
protocol	I-Claim
results	I-Claim
in	I-Claim
improved	I-Claim
dietary	I-Claim
intake	I-Claim
compared	I-Claim
with	I-Claim
standard	I-Claim
practice	I-Claim
and	I-Claim
seems	I-Claim
to	I-Claim
beneficially	I-Claim
impact	I-Claim
nutrition-related	I-Claim
outcomes	I-Claim
previously	I-Claim
observed	I-Claim
in	I-Claim
oncology	I-Claim
outpatients	I-Claim
receiving	I-Claim
radiotherapy.	I-Claim

The	B-Claim
ADA	I-Claim
MNT	I-Claim
protocol	I-Claim
for	I-Claim
radiation	I-Claim
oncology	I-Claim
is	I-Claim
a	I-Claim
useful	I-Claim
guide	I-Claim
to	I-Claim
the	I-Claim
level	I-Claim
of	I-Claim
nutrition	I-Claim
support	I-Claim
required.	I-Claim

Imatinib	O
is	O
the	O
standard	O
treatment	O
of	O
advanced	O
GI	O
stromal	O
tumors	O
(GISTs).	O

It	B-Claim
is	I-Claim
not	I-Claim
known	I-Claim
whether	I-Claim
imatinib	I-Claim
may	I-Claim
be	I-Claim
stopped	I-Claim
in	I-Claim
patients	I-Claim
in	I-Claim
whom	I-Claim
disease	I-Claim
is	I-Claim
controlled.	I-Claim

This	O
prospective,	O
randomized,	O
multicentric	O
phase	O
III	O
study	O
was	O
designed	O
to	O
compare	O
continuous	O
(CONT)	O
compared	O
with	O
interrupted	O
(INT)	O
imatinib	O
beyond	O
1	O
year	O
of	O
treatment	O
in	O
patients	O
with	O
advanced	O
GIST.	O

The	O
primary	O
end	O
point	O
was	O
progression-free	O
survival.	O

Secondary	O
end	O
points	O
included	O
overall	O
survival,	O
response	O
rate	O
after	O
reinitiation	O
of	O
imatinib,	O
and	O
quality	O
of	O
life.	O

Early	O
stopping	O
rules	O
in	O
cases	O
of	O
rapid	O
progression	O
of	O
disease	O
were	O
defined,	O
with	O
preplanned	O
interim	O
analyses.	O

Between	O
May	O
2002	O
and	O
April	O
2004,	O
182	O
patients	O
with	O
advanced	O
GIST	O
were	O
enrolled.	O

Between	O
May	O
2003	O
and	O
April	O
2004,	O
98	O
patients	O
in	O
response	O
or	O
stable	O
disease	O
under	O
imatinib	O
reached	O
more	O
than	O
1	O
year	O
of	O
follow-up.	O

Forty	O
were	O
not	O
eligible	O
for	O
randomization,	O
and	O
58	O
patients	O
were	O
randomly	O
assigned,	O
32	O
and	O
26	O
patients	O
in	O
the	O
INT	O
and	O
CONT	O
arms,	O
respectively.	O

As	B-Premise
of	I-Premise
October	I-Premise
15,	I-Premise
2005,	I-Premise
eight	I-Premise
of	I-Premise
26	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
CONT	I-Premise
group	I-Premise
and	I-Premise
26	I-Premise
of	I-Premise
32	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
INT	I-Premise
group	I-Premise
had	I-Premise
documented	I-Premise
disease	I-Premise
progression	I-Premise
(P	I-Premise
<	I-Premise
.0001).	I-Premise

Twenty-four	B-Premise
of	I-Premise
26	I-Premise
patients	I-Premise
with	I-Premise
documented	I-Premise
progression	I-Premise
in	I-Premise
the	I-Premise
INT	I-Premise
arm	I-Premise
responded	I-Premise
to	I-Premise
imatinib	I-Premise
reintroduction.	I-Premise

No	B-Premise
differences	I-Premise
in	I-Premise
overall	I-Premise
survival	I-Premise
or	I-Premise
imatinib	I-Premise
resistance	I-Premise
were	I-Premise
observed	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
arms.	I-Premise

Quality	B-Premise
of	I-Premise
life	I-Premise
evaluated	I-Premise
6	I-Premise
months	I-Premise
after	I-Premise
random	I-Premise
assignment	I-Premise
using	I-Premise
the	I-Premise
30-item	I-Premise
Quality	I-Premise
of	I-Premise
Life	I-Premise
Questionnaire	I-Premise
was	I-Premise
not	I-Premise
significantly	I-Premise
different	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups	I-Premise
of	I-Premise
randomly	I-Premise
assigned	I-Premise
patients.	I-Premise

Imatinib	B-Claim
interruption	I-Claim
results	I-Claim
in	I-Claim
rapid	I-Claim
progression	I-Claim
in	I-Claim
most	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
GIST,	I-Claim
and	I-Claim
cannot	I-Claim
be	I-Claim
recommended	I-Claim
in	I-Claim
routine	I-Claim
practice	I-Claim
unless	I-Claim
patient	I-Claim
experience	I-Claim
significant	I-Claim
toxicity.	I-Claim

Psychological	B-Claim
interventions	I-Claim
are	I-Claim
efficacious	I-Claim
in	I-Claim
reducing	I-Claim
emotional	I-Claim
distress	I-Claim
for	I-Claim
cancer	I-Claim
patients.	I-Claim

However,	B-Claim
it	I-Claim
is	I-Claim
not	I-Claim
clear	I-Claim
whether	I-Claim
psychological	I-Claim
improvements	I-Claim
are,	I-Claim
in	I-Claim
turn,	I-Claim
related	I-Claim
to	I-Claim
improved	I-Claim
health.	I-Claim

A	O
clinical	O
trial	O
tests	O
whether	O
a	O
psychological	O
intervention	O
for	O
cancer	O
patients	O
can	O
do	O
so,	O
and	O
also	O
tests	O
two	O
routes	O
to	O
achieve	O
better	O
health:	O
(a)	O
reducing	O
patients'	O
Emotional	O
Distress,	O
and/or	O
(b)	O
enhancing	O
their	O
functional	O
immunity.	O

Post-surgery,	O
227	O
breast	O
cancer	O
patients	O
were	O
randomized	O
to	O
intervention	O
or	O
assessment	O
only	O
Study	O
Arms.	O

Conducted	O
in	O
small	O
groups,	O
intervention	O
sessions	O
were	O
offered	O
weekly	O
for	O
4	O
months	O
and	O
followed	O
by	O
monthly	O
sessions	O
for	O
8	O
months.	O

Measures	O
included	O
psychological	O
(distress),	O
biological	O
(immune),	O
and	O
health	O
outcomes	O
(performance	O
status	O
and	O
evaluations	O
of	O
patient's	O
symptomatology,	O
including	O
toxicity	O
from	O
cancer	O
treatment,	O
lab	O
values)	O
collected	O
at	O
baseline,	O
4	O
months,	O
and	O
12	O
months.	O

A	B-Premise
path	I-Premise
model	I-Premise
revealed	I-Premise
that	I-Premise
intervention	I-Premise
participation	I-Premise
directly	I-Premise
improved	I-Premise
health	I-Premise
(p<.05)	I-Premise
at	I-Premise
12	I-Premise
months.	I-Premise

These	B-Premise
effects	I-Premise
remained	I-Premise
when	I-Premise
statistically	I-Premise
controlling	I-Premise
for	I-Premise
baseline	I-Premise
levels	I-Premise
of	I-Premise
distress,	I-Premise
immunity,	I-Premise
and	I-Premise
health	I-Premise
as	I-Premise
well	I-Premise
as	I-Premise
sociodemographic,	I-Premise
disease,	I-Premise
and	I-Premise
cancer	I-Premise
treatment	I-Premise
variables.	I-Premise

Regarding	B-Premise
the	I-Premise
mechanisms	I-Premise
for	I-Premise
achieving	I-Premise
better	I-Premise
health,	I-Premise
support	I-Premise
was	I-Premise
found	I-Premise
for	I-Premise
an	I-Premise
indirect	I-Premise
effect	I-Premise
of	I-Premise
distress	I-Premise
reduction.	I-Premise

That	B-Premise
is,	I-Premise
by	I-Premise
specifically	I-Premise
lowering	I-Premise
intervention	I-Premise
patients'	I-Premise
distress	I-Premise
at	I-Premise
4	I-Premise
months,	I-Premise
their	I-Premise
health	I-Premise
was	I-Premise
improved	I-Premise
at	I-Premise
12	I-Premise
months	I-Premise
(p<.05).	I-Premise

Although	B-Premise
the	I-Premise
intervention	I-Premise
simultaneously	I-Premise
improved	I-Premise
patients'	I-Premise
T-cell	I-Premise
blastogenesis	I-Premise
in	I-Premise
response	I-Premise
to	I-Premise
phytohemagglutinin	I-Premise
(PHA),	I-Premise
the	B-Premise
latter	I-Premise
increases	I-Premise
were	I-Premise
unrelated	I-Premise
to	I-Premise
improved	I-Premise
health.	I-Premise

A	B-Premise
convergence	I-Premise
of	I-Premise
biobehavioral	I-Premise
effects	I-Premise
and	I-Premise
health	I-Premise
improvements	I-Premise
were	I-Premise
observed.	I-Premise

Behavioral	B-Claim
change,	I-Claim
rather	I-Claim
than	I-Claim
immunity	I-Claim
change,	I-Claim
was	I-Claim
influential	I-Claim
in	I-Claim
achieving	I-Claim
lower	I-Claim
levels	I-Claim
of	I-Claim
symptomatology	I-Claim
and	I-Claim
higher	I-Claim
functional	I-Claim
status.	I-Claim

Distress	B-Claim
reduction	I-Claim
is	I-Claim
highlighted	I-Claim
as	I-Claim
an	I-Claim
important	I-Claim
mechanism	I-Claim
by	I-Claim
which	I-Claim
health	I-Claim
can	I-Claim
be	I-Claim
improved.	I-Claim

This	O
study	O
aimed	O
to	O
compare	O
quality	O
of	O
life	O
(QOL),	O
functional	O
outcome,	O
body	O
image,	O
and	O
cosmesis	O
after	O
hand-assisted	O
laparoscopic	O
(LRP)	O
versus	O
open	O
restorative	O
proctocolectomy	O
(ORP).	O

The	O
potential	O
long-term	O
advantages	O
of	O
LRP	O
over	O
ORP	O
remain	O
to	O
be	O
determined.	O

The	O
most	O
likely	O
advantage	O
of	O
LRP	O
is	O
the	O
superior	O
cosmetic	O
result.	O

It	O
is,	O
however,	O
unclear	O
whether	O
the	O
size	O
and	O
location	O
of	O
incisions	O
affect	O
body	O
image	O
and	O
QOL.	O

In	O
a	O
previously	O
conducted	O
randomized	O
trial	O
comparing	O
LRP	O
with	O
ORP,	O
60	O
patients	O
were	O
prospectively	O
evaluated.	O

The	O
primary	O
end	O
points	O
were	O
body	O
image	O
and	O
cosmesis.	O

The	O
secondary	O
end	O
points	O
were	O
morbidity,	O
QOL,	O
and	O
functional	O
outcome.	O

A	O
body	O
image	O
questionnaire	O
was	O
used	O
to	O
evaluate	O
body	O
image	O
and	O
cosmesis.	O

The	O
Short	O
Form-36	O
Health	O
Survey	O
and	O
the	O
Gastrointestinal	O
Quality	O
of	O
Life	O
Inventory	O
were	O
used	O
to	O
assess	O
QOL.	O

Body	O
image	O
and	O
QOL	O
also	O
were	O
assessed	O
preoperatively.	O

A	O
total	O
of	O
53	O
patients	O
completed	O
the	O
QOL	O
and	O
functional	O
outcome	O
questionnaires.	O

There	B-Premise
were	I-Premise
no	I-Premise
differences	I-Premise
in	I-Premise
functional	I-Premise
outcome,	I-Premise
morbidity,	I-Premise
or	I-Premise
QOL	I-Premise
between	I-Premise
LRP	I-Premise
and	I-Premise
ORP.	I-Premise

At	O
a	O
median	O
of	O
2.7	O
years	O
after	O
surgery,	O
46	O
patients	O
returned	O
the	O
questionnaires	O
regarding	O
body	O
image,	O
cosmesis,	O
and	O
morbidity.	O

The	B-Premise
body	I-Premise
image	I-Premise
and	I-Premise
cosmesis	I-Premise
scores	I-Premise
of	I-Premise
female	I-Premise
patients	I-Premise
were	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
LRP	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
ORP	I-Premise
group	I-Premise
(body	I-Premise
image,	I-Premise
17.4	I-Premise
vs	I-Premise
14.9;	I-Premise
cosmesis,	I-Premise
19.1	I-Premise
vs	I-Premise
13.0,	I-Premise
respectively).	I-Premise

The	B-Premise
female	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
ORP	I-Premise
group	I-Premise
had	I-Premise
significantly	I-Premise
lower	I-Premise
body	I-Premise
image	I-Premise
scores	I-Premise
than	I-Premise
the	I-Premise
male	I-Premise
patients	I-Premise
(14.9	I-Premise
vs	I-Premise
18.3).	I-Premise

This	B-Claim
study	I-Claim
is	I-Claim
the	I-Claim
first	I-Claim
to	I-Claim
show	I-Claim
that	I-Claim
ORP	I-Claim
has	I-Claim
a	I-Claim
negative	I-Claim
impact	I-Claim
on	I-Claim
body	I-Claim
image	I-Claim
and	I-Claim
cosmesis	I-Claim
as	I-Claim
compared	I-Claim
with	I-Claim
LRP.	I-Claim

Functional	B-Claim
outcome,	I-Claim
QOL,	I-Claim
and	I-Claim
morbidity	I-Claim
are	I-Claim
similar	I-Claim
for	I-Claim
the	I-Claim
two	I-Claim
approaches.	I-Claim

The	B-Claim
advantages	I-Claim
of	I-Claim
a	I-Claim
long-lasting	I-Claim
improved	I-Claim
body	I-Claim
image	I-Claim
and	I-Claim
cosmesis	I-Claim
for	I-Claim
this	I-Claim
relatively	I-Claim
young	I-Claim
patient	I-Claim
population	I-Claim
may	I-Claim
compensate	I-Claim
for	I-Claim
the	I-Claim
longer	I-Claim
operating	I-Claim
times	I-Claim
and	I-Claim
higher	I-Claim
costs,	I-Claim
particularly	I-Claim
for	I-Claim
women.	I-Claim

Depression,	B-Claim
anxiety,	I-Claim
fatigue,	I-Claim
and	I-Claim
impaired	I-Claim
wellbeing	I-Claim
are	I-Claim
common,	I-Claim
important,	I-Claim
and	I-Claim
closely	I-Claim
related	I-Claim
in	I-Claim
advanced	I-Claim
cancer.	I-Claim

We	O
aimed	O
to	O
identify	O
the	O
effects	O
of	O
an	O
established	O
antidepressant	O
on	O
these	O
symptoms	O
and	O
survival	O
in	O
patients	O
with	O
advanced	O
cancer	O
who	O
did	O
not	O
have	O
major	O
depression	O
as	O
assessed	O
by	O
clinicians.	O

Between	O
July,	O
2001,	O
and	O
February,	O
2006,	O
189	O
patients	O
with	O
advanced	O
cancer	O
were	O
randomly	O
assigned	O
sertraline	O
50	O
mg	O
(n=95),	O
or	O
placebo	O
(n=94),	O
once	O
per	O
day.	O

The	O
primary	O
outcome	O
was	O
depression	O
as	O
assessed	O
by	O
the	O
Centre	O
for	O
Epidemiologic	O
Studies	O
Depression	O
scale	O
(CES-D);	O
the	O
main	O
secondary	O
outcomes	O
were:	O
anxiety	O
as	O
assessed	O
by	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scales	O
(HADS-A);	O
overall	O
quality	O
of	O
life	O
and	O
fatigue	O
as	O
assessed	O
by	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy	O
General	O
and	O
Fatigue	O
scales	O
(FACT-G	O
and	O
FACT-F,	O
respectively);	O
and	O
clinicians'	O
ratings	O
of	O
quality	O
of	O
life	O
by	O
use	O
of	O
Spizter's	O
Quality	O
of	O
Life	O
Index	O
(SQLI).	O

Multiple	O
measures	O
were	O
used	O
for	O
corroboration	O
of	O
the	O
most	O
important	O
outcomes.	O

Primary	O
analyses	O
were	O
done	O
by	O
intention	O
to	O
treat	O
and	O
were	O
based	O
on	O
scale	O
scores	O
at	O
4	O
weeks	O
and	O
8	O
weeks.	O

The	O
benefits	O
of	O
sertraline	O
compared	O
with	O
placebo	O
are	O
expressed	O
on	O
a	O
range	O
from	O
+100	O
(ie,	O
maximum	O
benefit)	O
to	O
-100	O
(ie,	O
maximum	O
harm);	O
a	O
difference	O
of	O
10	O
was	O
deemed	O
clinically	O
significant.	O

This	O
clinical	O
trial	O
is	O
registered	O
at	O
Current	O
Controlled	O
Trials	O
website	O
http://www.controlled-trials.com/ISRCTN72466475.	O

Sertraline	B-Premise
had	I-Premise
no	I-Premise
significant	I-Premise
effect	I-Premise
(scale,	I-Premise
benefit	I-Premise
over	I-Premise
placebo	I-Premise
[95%	I-Premise
CI])	I-Premise
on	I-Premise
depression	I-Premise
(CES-D	I-Premise
0.4	I-Premise
[-2.6	I-Premise
to	I-Premise
3.4]),	I-Premise
anxiety	I-Premise
(HADS-A	I-Premise
2.0	I-Premise
[-1.5	I-Premise
to	I-Premise
5.5]),	I-Premise
fatigue	I-Premise
(FACT-F	I-Premise
0.3	I-Premise
[-4.3	I-Premise
to	I-Premise
4.9]),	I-Premise
overall	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(FACT-G	I-Premise
1.7	I-Premise
[-1.3	I-Premise
to	I-Premise
4.7]),	I-Premise
or	I-Premise
clinicians'	I-Premise
ratings	I-Premise
(SQLI	I-Premise
2.0	I-Premise
[-2.5	I-Premise
to	I-Premise
6.5]),	I-Premise
and	I-Premise
the	I-Premise
95%	I-Premise
CI	I-Premise
ruled	I-Premise
out	I-Premise
a	I-Premise
clinically	I-Premise
significant	I-Premise
benefit	I-Premise
for	I-Premise
all	I-Premise
main	I-Premise
outcomes.	I-Premise

Sertraline	B-Premise
was	I-Premise
discontinued	I-Premise
more	I-Premise
often	I-Premise
and	I-Premise
earlier	I-Premise
than	I-Premise
was	I-Premise
placebo	I-Premise
(hazard	I-Premise
ratio	I-Premise
1.46	I-Premise
[1.03-2.06],	I-Premise
p=0.03).	I-Premise

Recruitment	O
was	O
stopped	O
after	O
the	B-Premise
first	I-Premise
planned	I-Premise
interim	I-Premise
analysis	I-Premise
in	I-Premise
February	I-Premise
2006	I-Premise
(n=150)	I-Premise
showed	I-Premise
that	I-Premise
survival	I-Premise
was	I-Premise
longer	I-Premise
in	I-Premise
patients	I-Premise
assigned	I-Premise
placebo	I-Premise
than	I-Premise
in	I-Premise
patients	I-Premise
assigned	I-Premise
sertraline	I-Premise
(unadjusted	I-Premise
hazard	I-Premise
ratio	I-Premise
1.60	I-Premise
[95%	I-Premise
CI	I-Premise
1.04-2.45],	I-Premise
log-rank	I-Premise
p=0.04;	I-Premise
adjusted	I-Premise
hazard	I-Premise
ratio	I-Premise
1.62	I-Premise
[1.06-2.41],	I-Premise
Cox	I-Premise
model	I-Premise
p=0.02).	I-Premise

However,	B-Premise
at	I-Premise
the	I-Premise
final	I-Premise
analysis	I-Premise
in	I-Premise
July	I-Premise
2006	I-Premise
of	I-Premise
all	I-Premise
patients	I-Premise
(n=189)	I-Premise
and	I-Premise
with	I-Premise
longer	I-Premise
follow-up,	I-Premise
survival	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
significantly	I-Premise
between	I-Premise
the	I-Premise
treatment	I-Premise
groups	I-Premise
(unadjusted	I-Premise
hazard	I-Premise
ratio	I-Premise
1.35	I-Premise
[0.95-1.91],	I-Premise
log-rank	I-Premise
p=0.09;	I-Premise
adjusted	I-Premise
hazard	I-Premise
ratio	I-Premise
1.27	I-Premise
[0.87-1.84],	I-Premise
Cox	I-Premise
model	I-Premise
p=0.20).	I-Premise

The	O
trial	O
was	O
closed	O
because	O
it	O
had	O
ruled	O
out	O
a	O
significant	O
benefit	O
of	O
sertraline.	O

Sertraline	B-Claim
did	I-Claim
not	I-Claim
improve	I-Claim
symptoms,	I-Claim
wellbeing,	I-Claim
or	I-Claim
survival	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
cancer	I-Claim
who	I-Claim
do	I-Claim
not	I-Claim
have	I-Claim
major	I-Claim
depression,	I-Claim
and	I-Claim
should	I-Claim
be	I-Claim
reserved	I-Claim
for	I-Claim
those	I-Claim
with	I-Claim
a	I-Claim
proven	I-Claim
indication.	I-Claim

Recently,	B-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
advanced	I-Claim
gastric	I-Claim
cancer	I-Claim
by	I-Claim
continuous	I-Claim
infusion	I-Claim
of	I-Claim
5-fluorouracil	I-Claim
(5-FU)	I-Claim
with	I-Claim
low-dose	I-Claim
cisplatin	I-Claim
(CDDP)	I-Claim
has	I-Claim
improved	I-Claim
efficacy	I-Claim
without	I-Claim
severe	I-Claim
toxicities.	I-Claim

The	B-Claim
possible	I-Claim
effectiveness	I-Claim
of	I-Claim
5-FU+low-dose	I-Claim
CDDP	I-Claim
for	I-Claim
colorectal	I-Claim
cancer	I-Claim
(CRC)	I-Claim
is	I-Claim
intriguing.	I-Claim

One	O
hundred	O
fifty-five	O
patients	O
with	O
far-advanced	O
CRC	O
including	O
at	O
least	O
one	O
measurable	O
lesion	O
were	O
enrolled	O
in	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
funded	O
by	O
the	O
Japanese	O
Foundation	O
for	O
Multidisciplinary	O
Treatment	O
of	O
Cancer.	O

These	O
patients	O
were	O
assigned	O
to	O
the	O
two	O
arms	O
to	O
assess	O
the	O
value	O
of	O
low-dose	O
CDDP	O
when	O
added	O
to	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
5-FU	O
at	O
a	O
dose	O
of	O
300	O
mg/m(2)/24	O
hrs	O
in	O
a	O
one-week	O
cycle	O
consisting	O
of	O
5	O
days	O
of	O
treatment	O
and	O
2	O
days	O
of	O
rest	O
for	O
at	O
least	O
12	O
weeks.	O

CD-DP	O
was	O
given	O
intravenously	O
at	O
a	O
dose	O
of	O
3	O
mg/m(2)	O
on	O
days	O
1-5	O
and	O
days	O
8-12,	O
and	O
then	O
at	O
a	O
dose	O
of	O
7	O
mg/m(2)	O
twice	O
a	O
week.	O

Three	O
patients	O
were	O
excluded	O
from	O
the	O
trial.	O

The	B-Premise
response	I-Premise
rate	I-Premise
in	I-Premise
the	I-Premise
5-FU+low-dose	I-Premise
CDDP	I-Premise
arm	I-Premise
(n=75)	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
than	I-Premise
that	I-Premise
in	I-Premise
the	I-Premise
5-FU	I-Premise
arm	I-Premise
(n=77)	I-Premise
(25.3%	I-Premise
vs.	I-Premise
11.7%;	I-Premise
P	I-Premise
=	I-Premise
0.037).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
time	I-Premise
between	I-Premise
the	I-Premise
5-FU+low-dose	I-Premise
CDDP	I-Premise
arm	I-Premise
and	I-Premise
the	I-Premise
5-FU	I-Premise
arm	I-Premise
(479	I-Premise
and	I-Premise
491	I-Premise
days,	I-Premise
respectively).	I-Premise

Grades	B-Premise
3/4	I-Premise
toxicities	I-Premise
occurred	I-Premise
infrequently	I-Premise
in	I-Premise
both	I-Premise
arms.	I-Premise

The	B-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
was	I-Premise
almost	I-Premise
the	I-Premise
same	I-Premise
between	I-Premise
the	I-Premise
arms.	I-Premise

Low-dose	B-Claim
CDDP	I-Claim
improved	I-Claim
the	I-Claim
response	I-Claim
rate	I-Claim
while	I-Claim
keeping	I-Claim
toxicities	I-Claim
within	I-Claim
clinically	I-Claim
acceptable	I-Claim
limits.	I-Claim

However,	B-Claim
this	I-Claim
combined	I-Claim
treatment	I-Claim
did	I-Claim
not	I-Claim
confer	I-Claim
a	I-Claim
survival	I-Claim
advantage	I-Claim
over	I-Claim
treatment	I-Claim
with	I-Claim
continuous	I-Claim
infusion	I-Claim
of	I-Claim
5-FU	I-Claim
alone	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
far-advanced	I-Claim
CRC;	I-Claim
that	I-Claim
might	I-Claim
be	I-Claim
attributable	I-Claim
to	I-Claim
the	I-Claim
short	I-Claim
CDDP	I-Claim
administration	I-Claim
setting	I-Claim
of	I-Claim
12	I-Claim
weeks.	I-Claim

The	O
impact	O
of	O
psychotherapeutic	O
support	O
on	O
survival	O
for	O
patients	O
with	O
gastrointestinal	O
cancer	O
undergoing	O
surgery	O
was	O
studied.	O

A	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
in	O
cooperation	O
with	O
the	O
Departments	O
of	O
General	O
Surgery	O
and	O
Medical	O
Psychology,	O
University	O
Hospital	O
of	O
Hamburg,	O
Germany,	O
from	O
January	O
1991	O
to	O
January	O
1993.	O

Consenting	O
patients	O
(N	O
=	O
271)	O
with	O
a	O
preliminary	O
diagnosis	O
of	O
cancer	O
of	O
the	O
esophagus,	O
stomach,	O
liver/gallbladder,	O
pancreas,	O
or	O
colon/rectum	O
were	O
stratified	O
by	O
sex	O
and	O
randomly	O
assigned	O
to	O
a	O
control	O
group	O
that	O
received	O
standard	O
care	O
as	O
provided	O
on	O
the	O
surgical	O
wards,	O
or	O
to	O
an	O
experimental	O
group	O
that	O
received	O
formal	O
psychotherapeutic	O
support	O
in	O
addition	O
to	O
routine	O
care	O
during	O
the	O
hospital	O
stay.	O

From	O
June	O
2003	O
to	O
December	O
2003,	O
the	O
10-year	O
follow-up	O
was	O
conducted.	O

Survival	O
status	O
for	O
all	O
patients	O
was	O
determined	O
from	O
our	O
own	O
records	O
and	O
from	O
three	O
external	O
sources:	O
the	O
Hamburg	O
cancer	O
registry,	O
family	O
doctors,	O
and	O
the	O
general	O
citizen	O
registration	O
offices.	O

Kaplan-Meier	B-Premise
survival	I-Premise
curves	I-Premise
demonstrated	I-Premise
better	I-Premise
survival	I-Premise
for	I-Premise
the	I-Premise
experimental	I-Premise
group	I-Premise
than	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

The	B-Premise
unadjusted	I-Premise
significance	I-Premise
level	I-Premise
for	I-Premise
group	I-Premise
differences	I-Premise
was	I-Premise
P	I-Premise
=	I-Premise
.0006	I-Premise
for	I-Premise
survival	I-Premise
to	I-Premise
10	I-Premise
years.	I-Premise

Cox	B-Premise
regression	I-Premise
models	I-Premise
that	I-Premise
took	I-Premise
TNM	I-Premise
staging	I-Premise
or	I-Premise
the	I-Premise
residual	I-Premise
tumor	I-Premise
classification	I-Premise
and	I-Premise
tumor	I-Premise
site	I-Premise
into	I-Premise
account	I-Premise
also	I-Premise
found	I-Premise
significant	I-Premise
differences	I-Premise
at	I-Premise
10	I-Premise
years.	I-Premise

Secondary	B-Premise
analyses	I-Premise
found	I-Premise
that	I-Premise
differences	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
the	I-Premise
experimental	I-Premise
group	I-Premise
occurred	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
stomach,	I-Premise
pancreatic,	I-Premise
primary	I-Premise
liver,	I-Premise
or	I-Premise
colorectal	I-Premise
cancer.	I-Premise

The	B-Claim
results	I-Claim
of	I-Claim
this	I-Claim
study	I-Claim
indicate	I-Claim
that	I-Claim
patients	I-Claim
with	I-Claim
gastrointestinal	I-Claim
cancer,	I-Claim
who	I-Claim
undergo	I-Claim
surgery	I-Claim
for	I-Claim
stomach,	I-Claim
pancreatic,	I-Claim
primary	I-Claim
liver,	I-Claim
or	I-Claim
colorectal	I-Claim
cancer,	I-Claim
benefit	I-Claim
from	I-Claim
a	I-Claim
formal	I-Claim
program	I-Claim
of	I-Claim
psychotherapeutic	I-Claim
support	I-Claim
during	I-Claim
the	I-Claim
inpatient	I-Claim
hospital	I-Claim
stay	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
long-term	I-Claim
survival.	I-Claim

To	O
assess	O
the	O
long	O
term	O
risks	O
and	O
benefits	O
of	O
hormone	O
replacement	O
therapy	O
(combined	O
hormone	O
therapy	O
versus	O
placebo,	O
and	O
oestrogen	O
alone	O
versus	O
combined	O
hormone	O
therapy).	O

Multicentre,	O
randomised,	O
placebo	O
controlled,	O
double	O
blind	O
trial.	O

General	O
practices	O
in	O
UK	O
(384),	O
Australia	O
(91),	O
and	O
New	O
Zealand	O
(24).	O

Postmenopausal	O
women	O
aged	O
50-69	O
years	O
at	O
randomisation.	O

At	O
early	O
closure	O
of	O
the	O
trial,	O
56,583	O
had	O
been	O
screened,	O
8980	O
entered	O
run-in,	O
and	O
5692	O
(26%	O
of	O
target	O
of	O
22,300)	O
started	O
treatment.	O

Oestrogen	O
only	O
therapy	O
(conjugated	O
equine	O
oestrogens	O
0.625	O
mg	O
orally	O
daily)	O
or	O
combined	O
hormone	O
therapy	O
(conjugated	O
equine	O
oestrogens	O
plus	O
medroxyprogesterone	O
acetate	O
2.5/5.0	O
mg	O
orally	O
daily).	O

Ten	O
years	O
of	O
treatment	O
planned.	O
major	O
cardiovascular	O
disease,	O
osteoporotic	O
fractures,	O
and	O
breast	O
cancer.	O
other	O
cancers,	O
death	O
from	O
all	O
causes,	O
venous	O
thromboembolism,	O
cerebrovascular	O
disease,	O
dementia,	O
and	O
quality	O
of	O
life.	O

The	O
trial	O
was	O
prematurely	O
closed	O
during	O
recruitment,	O
after	O
a	O
median	O
follow-up	O
of	O
11.9	O
months	O
(interquartile	O
range	O
7.1-19.6,	O
total	O
6498	O
women	O
years)	O
in	O
those	O
enrolled,	O
after	O
the	O
publication	O
of	O
early	O
results	O
from	O
the	O
women's	O
health	O
initiative	O
study.	O

The	O
mean	O
age	O
of	O
randomised	O
women	O
was	O
62.8	O
(SD	O
4.8)	O
years.	O

When	B-Premise
combined	I-Premise
hormone	I-Premise
therapy	I-Premise
(n=2196)	I-Premise
was	I-Premise
compared	I-Premise
with	I-Premise
placebo	I-Premise
(n=2189),	I-Premise
there	I-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
increase	I-Premise
in	I-Premise
the	I-Premise
number	I-Premise
of	I-Premise
major	I-Premise
cardiovascular	I-Premise
events	I-Premise
(7	I-Premise
v	I-Premise
0,	I-Premise
P=0.016)	I-Premise
and	I-Premise
venous	I-Premise
thromboembolisms	I-Premise
(22	I-Premise
v	I-Premise
3,	I-Premise
hazard	I-Premise
ratio	I-Premise
7.36	I-Premise
(95%	I-Premise
CI	I-Premise
2.20	I-Premise
to	I-Premise
24.60)).	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
numbers	I-Premise
of	I-Premise
breast	I-Premise
or	I-Premise
other	I-Premise
cancers	I-Premise
(22	I-Premise
v	I-Premise
25,	I-Premise
hazard	I-Premise
ratio	I-Premise
0.88	I-Premise
(0.49	I-Premise
to	I-Premise
1.56)),	I-Premise
cerebrovascular	I-Premise
events	I-Premise
(14	I-Premise
v	I-Premise
19,	I-Premise
0.73	I-Premise
(0.37	I-Premise
to	I-Premise
1.46)),	I-Premise
fractures	I-Premise
(40	I-Premise
v	I-Premise
58,	I-Premise
0.69	I-Premise
(0.46	I-Premise
to	I-Premise
1.03)),	I-Premise
and	I-Premise
overall	I-Premise
deaths	I-Premise
(8	I-Premise
v	I-Premise
5,	I-Premise
1.60	I-Premise
(0.52	I-Premise
to	I-Premise
4.89)).	I-Premise

Comparison	B-Premise
of	I-Premise
combined	I-Premise
hormone	I-Premise
therapy	I-Premise
(n=815)	I-Premise
versus	I-Premise
oestrogen	I-Premise
therapy	I-Premise
(n=826)	I-Premise
outcomes	I-Premise
revealed	I-Premise
no	I-Premise
significant	I-Premise
differences.	I-Premise

Hormone	B-Claim
replacement	I-Claim
therapy	I-Claim
increases	I-Claim
cardiovascular	I-Claim
and	I-Claim
thromboembolic	I-Claim
risk	I-Claim
when	I-Claim
started	I-Claim
many	I-Claim
years	I-Claim
after	I-Claim
the	I-Claim
menopause.	I-Claim

The	B-Claim
results	I-Claim
are	I-Claim
consistent	I-Claim
with	I-Claim
the	I-Claim
findings	I-Claim
of	I-Claim
the	I-Claim
women's	I-Claim
health	I-Claim
initiative	I-Claim
study	I-Claim
and	I-Claim
secondary	I-Claim
prevention	I-Claim
studies.	I-Claim

Research	B-Claim
is	I-Claim
needed	I-Claim
to	I-Claim
assess	I-Claim
the	I-Claim
long	I-Claim
term	I-Claim
risks	I-Claim
and	I-Claim
benefits	I-Claim
of	I-Claim
starting	I-Claim
hormone	I-Claim
replacement	I-Claim
therapy	I-Claim
near	I-Claim
the	I-Claim
menopause,	I-Claim
when	I-Claim
the	I-Claim
effect	I-Claim
may	I-Claim
be	I-Claim
different.	I-Claim

It	B-Claim
has	I-Claim
been	I-Claim
shown	I-Claim
that	I-Claim
nonpharmacologic	I-Claim
interventions	I-Claim
are	I-Claim
effective	I-Claim
management	I-Claim
techniques	I-Claim
for	I-Claim
cancer-related	I-Claim
fatigue	I-Claim
(CRF)	I-Claim
in	I-Claim
cancer	I-Claim
survivors.	I-Claim

However,	O
few	O
studies	O
have	O
investigated	O
their	O
effectiveness	O
in	O
patients	O
who	O
are	O
receiving	O
chemotherapy.	O

In	O
this	O
study,	O
the	O
authors	O
tested	O
the	O
effectiveness	O
of	O
a	O
brief	O
behaviorally	O
oriented	O
intervention	O
in	O
reducing	O
CRF	O
and	O
improving	O
physical	O
function	O
and	O
associated	O
distress	O
in	O
individuals	O
who	O
were	O
receiving	O
chemotherapy.	O

For	O
this	O
randomized	O
controlled	O
trial,	O
60	O
patients	O
with	O
cancer	O
were	O
recruited	O
and	O
received	O
either	O
usual	O
care	O
or	O
the	O
intervention.	O

The	O
intervention	O
was	O
delivered	O
on	O
an	O
individual	O
basis	O
on	O
3	O
occasions	O
over	O
a	O
period	O
from	O
9	O
weeks	O
to	O
12	O
weeks,	O
and	O
the	O
objective	O
of	O
the	O
intervention	O
was	O
to	O
alter	O
fatigue-related	O
thoughts	O
and	O
behavior.	O

Primary	O
outcomes	O
were	O
assessed	O
as	O
follows:	O
CRF	O
using	O
the	O
Visual	O
Analogue	O
Scale-Global	O
Fatigue;	O
physical	O
functioning	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality-of-Life	O
Core	O
30	O
Questionnaire,	O
and	O
CRF-associated	O
distress	O
using	O
the	O
Fatigue	O
Outcome	O
Measure.	O

Assessments	O
were	O
made	O
on	O
4	O
occasions:	O
at	O
baseline	O
(T0),	O
at	O
the	O
end	O
of	O
chemotherapy	O
(T1),	O
1	O
month	O
after	O
chemotherapy	O
(T2),	O
and	O
9	O
months	O
after	O
recruitment	O
(T3).	O

Normally	O
distributed	O
data	O
were	O
analyzed	O
using	O
t	O
tests	O
and	O
random-slope/random-intercept	O
mixed	O
models.	O

The	B-Premise
intervention	I-Premise
demonstrated	I-Premise
a	I-Premise
trend	I-Premise
toward	I-Premise
improved	I-Premise
CRF,	I-Premise
although	B-Premise
this	I-Premise
effect	I-Premise
was	I-Premise
reduced	I-Premise
once	I-Premise
confounders	I-Premise
had	I-Premise
been	I-Premise
controlled	I-Premise
statistically.	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
physical	I-Premise
functioning	I-Premise
(coefficient,	I-Premise
10.0;	I-Premise
95%	I-Premise
confidence	I-Premise
interval,	I-Premise
2.5-17.5;	I-Premise
P	I-Premise
=	I-Premise
.009),	I-Premise
and	I-Premise
this	I-Premise
effect	I-Premise
remained	I-Premise
once	I-Premise
the	I-Premise
confounding	I-Premise
effects	I-Premise
of	I-Premise
mood	I-Premise
disturbance	I-Premise
and	I-Premise
comorbid	I-Premise
disorders	I-Premise
were	I-Premise
controlled	I-Premise
statistically.	I-Premise

No	B-Premise
decrease	I-Premise
in	I-Premise
fatigue-related	I-Premise
distress	I-Premise
was	I-Premise
detected.	I-Premise

The	B-Claim
behaviorally	I-Claim
oriented	I-Claim
intervention	I-Claim
brought	I-Claim
about	I-Claim
significant	I-Claim
improvements	I-Claim
in	I-Claim
physical	I-Claim
functioning,	I-Claim
indicated	I-Claim
a	I-Claim
trend	I-Claim
toward	I-Claim
improved	I-Claim
CRF,	I-Claim
but	I-Claim
detected	I-Claim
no	I-Claim
effect	I-Claim
for	I-Claim
fatigue-related	I-Claim
distress.	I-Claim

Therapy	B-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
gastric	I-Claim
or	I-Claim
gastroesophageal	I-Claim
junction	I-Claim
cancer	I-Claim
should	I-Claim
provide	I-Claim
symptom	I-Claim
relief	I-Claim
and	I-Claim
improve	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
(QOL)	I-Claim
because	I-Claim
most	I-Claim
patients	I-Claim
are	I-Claim
symptomatic	I-Claim
at	I-Claim
baseline.	I-Claim

Using	O
validated	O
instruments,	O
we	O
prospectively	O
assessed	O
QOL	O
(even	O
after	O
completion	O
of	O
protocol	O
treatment)	O
as	O
one	O
of	O
the	O
secondary	O
end	O
points	O
of	O
the	O
V325	O
phase	O
III	O
trial.	O

Four	O
hundred	O
forty-five	O
patients	O
randomly	O
received	O
either	O
docetaxel	O
75	O
mg/m(2)	O
and	O
cisplatin	O
75	O
mg/m(2)	O
each	O
on	O
day	O
1	O
plus	O
fluorouracil	O
750	O
mg/m(2)/d	O
continuous	O
infusion	O
on	O
days	O
1	O
to	O
5	O
every	O
3	O
weeks	O
(DCF)	O
or	O
cisplatin	O
100	O
mg/m(2)	O
on	O
day	O
1	O
plus	O
fluorouracil	O
1,000	O
mg/m(2)/d	O
continuous	O
infusion	O
on	O
days	O
1	O
to	O
5	O
every	O
4	O
weeks	O
(CF).	O

The	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
C30	O
(EORTC	O
QLQ-C30)	O
and,	O
where	O
available,	O
the	O
EuroQOL	O
EQ-5D	O
questionnaire	O
were	O
administered	O
every	O
8	O
weeks	O
from	O
baseline	O
until	O
progression	O
and	O
then	O
every	O
3	O
months.	O

Time	O
to	O
definitive	O
deterioration	O
of	O
QOL	O
parameters	O
was	O
analyzed.	O

The	O
proportions	O
of	O
patients	O
having	O
assessable	O
EORTC	O
QLQ-C30	O
and	O
EQ-5D	O
questionnaires	O
at	O
baseline	O
were	O
86.0%	O
and	O
78.7%	O
with	O
DCF,	O
respectively,	O
and	O
89.7%	O
and	O
92.8%	O
with	O
CF,	O
respectively.	O

Time	B-Premise
to	I-Premise
5%	I-Premise
deterioration	I-Premise
of	I-Premise
global	I-Premise
health	I-Premise
status	I-Premise
(primary	I-Premise
end	I-Premise
point)	I-Premise
significantly	I-Premise
favored	I-Premise
DCF	I-Premise
over	I-Premise
CF	I-Premise
(log-rank	I-Premise
test,	I-Premise
P	I-Premise
=	I-Premise
.01).	I-Premise

QOL	B-Premise
was	I-Premise
preserved	I-Premise
longer	I-Premise
for	I-Premise
patients	I-Premise
on	I-Premise
DCF	I-Premise
than	I-Premise
those	I-Premise
on	I-Premise
CF	I-Premise
for	I-Premise
all	I-Premise
time	I-Premise
to	I-Premise
deterioration	I-Premise
analyses,	I-Premise
demonstrating	I-Premise
the	I-Premise
statistical	I-Premise
superiority	I-Premise
of	I-Premise
DCF	I-Premise
compared	I-Premise
with	I-Premise
CF.	I-Premise

V325	O
represents	O
the	O
largest	O
trial	O
with	O
the	O
longest	O
prospectively	O
controlled	O
evaluations	O
of	O
QOL	O
during	O
protocol	O
chemotherapy	O
and	O
follow-up	O
in	O
patients	O
with	O
advanced	O
gastric	O
or	O
gastroesophageal	O
junction	O
cancer.	O

In	B-Claim
V325,	I-Claim
advanced	I-Claim
gastric	I-Claim
or	I-Claim
gastroesophageal	I-Claim
junction	I-Claim
cancer	I-Claim
patients	I-Claim
receiving	I-Claim
DCF	I-Claim
not	I-Claim
only	I-Claim
had	I-Claim
statistically	I-Claim
improved	I-Claim
overall	I-Claim
survival	I-Claim
and	I-Claim
time	I-Claim
to	I-Claim
tumor-progression,	I-Claim
but	I-Claim
they	I-Claim
also	I-Claim
had	I-Claim
better	I-Claim
preservation	I-Claim
of	I-Claim
QOL	I-Claim
compared	I-Claim
with	I-Claim
patients	I-Claim
receiving	I-Claim
CF.	I-Claim

This	O
randomized	O
phase	O
II	O
trial	O
evaluated	O
two	O
docetaxel-based	O
regimens	O
to	O
see	O
which	O
would	O
be	O
most	O
promising	O
according	O
to	O
overall	O
response	O
rate	O
(ORR)	O
for	O
comparison	O
in	O
a	O
phase	O
III	O
trial	O
with	O
epirubicin-cisplatin-fluorouracil	O
(ECF)	O
as	O
first-line	O
advanced	O
gastric	O
cancer	O
therapy.	O

Chemotherapy-nave	O
patients	O
with	O
measurable	O
unresectable	O
and/or	O
metastatic	O
gastric	O
carcinoma,	O
a	O
performance	O
status	O
<or=	O
1,	O
and	O
adequate	O
hematologic,	O
hepatic,	O
and	O
renal	O
function	O
randomly	O
received	O
<or=	O
eight	O
3-weekly	O
cycles	O
of	O
ECF	O
(epirubicin	O
50	O
mg/m(2)	O
on	O
day	O
1,	O
cisplatin	O
60	O
mg/m(2)	O
on	O
day	O
1,	O
and	O
fluorouracil	O
[FU]	O
200	O
mg/m(2)/d	O
on	O
days	O
1	O
to	O
21),	O
TC	O
(docetaxel	O
initially	O
85	O
mg/m(2)	O
on	O
day	O
1	O
[later	O
reduced	O
to	O
75	O
mg/m(2)	O
as	O
a	O
result	O
of	O
toxicity]	O
and	O
cisplatin	O
75	O
mg/m(2)	O
on	O
day	O
1),	O
or	O
TCF	O
(TC	O
plus	O
FU	O
300	O
mg/m(2)/d	O
on	O
days	O
1	O
to	O
14).	O

Study	O
objectives	O
included	O
response	O
(primary),	O
survival,	O
toxicity,	O
and	O
quality	O
of	O
life	O
(QOL).	O

ORR	B-Premise
was	I-Premise
25.0%	I-Premise
(95%	I-Premise
CI,	I-Premise
13%	I-Premise
to	I-Premise
41%)	I-Premise
for	I-Premise
ECF,	I-Premise
18.5%	I-Premise
(95%	I-Premise
CI,	I-Premise
9%	I-Premise
to	I-Premise
34%)	I-Premise
for	I-Premise
TC,	I-Premise
and	I-Premise
36.6%	I-Premise
(95%	I-Premise
CI,	I-Premise
23%	I-Premise
to	I-Premise
53%)	I-Premise
for	I-Premise
TCF	I-Premise
(n	I-Premise
=	I-Premise
119).	I-Premise

Median	B-Premise
overall	I-Premise
survival	I-Premise
times	I-Premise
were	I-Premise
8.3,	I-Premise
11.0,	I-Premise
and	I-Premise
10.4	I-Premise
months	I-Premise
for	I-Premise
ECF,	I-Premise
TC,	I-Premise
and	I-Premise
TCF,	I-Premise
respectively.	I-Premise

Toxicity	B-Premise
was	I-Premise
acceptable,	I-Premise
with	I-Premise
one	I-Premise
toxic	I-Premise
death	I-Premise
(TC	I-Premise
arm).	I-Premise

Grade	B-Premise
3	I-Premise
or	I-Premise
4	I-Premise
neutropenia	I-Premise
occurred	I-Premise
in	I-Premise
more	I-Premise
treatment	I-Premise
cycles	I-Premise
with	I-Premise
docetaxel	I-Premise
(TC,	I-Premise
49%;	I-Premise
TCF,	I-Premise
57%;	I-Premise
ECF,	I-Premise
34%).	I-Premise

Global	B-Claim
health	I-Claim
status/QOL	I-Claim
substantially	I-Claim
improved	I-Claim
with	I-Claim
ECF	I-Claim
and	I-Claim
remained	I-Claim
similar	I-Claim
to	I-Claim
baseline	I-Claim
with	I-Claim
both	I-Claim
docetaxel	I-Claim
regimens.	I-Claim

Time	B-Premise
to	I-Premise
response	I-Premise
and	I-Premise
ORR	I-Premise
favor	I-Premise
TCF	I-Premise
over	I-Premise
TC	I-Premise
for	I-Premise
further	I-Premise
evaluation,	I-Premise
particularly	I-Premise
in	I-Premise
the	I-Premise
neoadjuvant	I-Premise
setting.	I-Premise

A	B-Premise
trend	I-Premise
towards	I-Premise
increased	I-Premise
myelosuppression	I-Premise
and	I-Premise
infectious	I-Premise
complications	I-Premise
with	I-Premise
TCF	I-Premise
versus	I-Premise
TC	I-Premise
or	I-Premise
ECF	I-Premise
was	I-Premise
observed.	I-Premise

To	O
assess	O
whether	O
omission	O
of	O
postoperative	O
radiotherapy	O
in	O
women	O
with	O
'low-risk'	O
axillary	O
node	O
negative	O
breast	O
cancer	O
(T0-2)	O
treated	O
by	O
breast-conserving	O
surgery	O
and	O
endocrine	O
therapy	O
improves	O
quality	O
of	O
life	O
and	O
is	O
more	O
cost-effective.	O

A	O
randomised	O
controlled	O
clinical	O
trial,	O
using	O
a	O
method	O
of	O
minimisation	O
balanced	O
by	O
centre,	O
grade	O
of	O
cancer,	O
age,	O
lymphatic/vascular	O
invasion	O
and	O
preoperative	O
endocrine	O
therapy,	O
was	O
performed.	O

A	O
non-randomised	O
cohort	O
was	O
also	O
recruited,	O
in	O
order	O
to	O
complete	O
a	O
comprehensive	O
cohort	O
study.	O

The	O
setting	O
was	O
breast	O
cancer	O
clinics	O
in	O
cancer	O
centres	O
in	O
the	O
UK.	O

Patients	O
aged	O
65	O
years	O
or	O
more	O
were	O
eligible	O
provided	O
that	O
their	O
cancers	O
were	O
considered	O
to	O
be	O
at	O
low	O
risk	O
of	O
local	O
recurrence,	O
were	O
suitable	O
for	O
breast-conservation	O
surgery,	O
were	O
receiving	O
endocrine	O
therapy	O
and	O
were	O
able	O
and	O
willing	O
to	O
give	O
informed	O
consent.	O

The	O
standard	O
treatment	O
of	O
postoperative	O
breast	O
irradiation	O
or	O
the	O
omission	O
of	O
radiotherapy.	O

Quality	O
of	O
life	O
was	O
the	O
primary	O
outcome	O
measure,	O
together	O
with	O
anxiety	O
and	O
depression	O
and	O
cost-effectiveness.	O

Secondary	O
outcome	O
measures	O
were	O
recurrence	O
rates,	O
functional	O
status,	O
treatment-related	O
morbidity	O
and	O
cosmesis.	O

The	O
principal	O
method	O
of	O
data	O
collection	O
was	O
by	O
questionnaire,	O
completed	O
at	O
home	O
with	O
a	O
research	O
nurse	O
at	O
four	O
times	O
over	O
15	O
months.	O

The	B-Claim
hypothesised	I-Claim
improvement	I-Claim
in	I-Claim
overall	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
with	I-Claim
the	I-Claim
omission	I-Claim
of	I-Claim
radiotherapy	I-Claim
was	I-Claim
not	I-Claim
seen	I-Claim
in	I-Claim
the	I-Claim
EuroQol	I-Claim
assessment	I-Claim
or	I-Claim
in	I-Claim
the	I-Claim
functionality	I-Claim
and	I-Claim
symptoms	I-Claim
summary	I-Claim
domains	I-Claim
of	I-Claim
the	I-Claim
European	I-Claim
Organisation	I-Claim
for	I-Claim
Research	I-Claim
in	I-Claim
the	I-Claim
Treatment	I-Claim
of	I-Claim
Cancer	I-Claim
(EORTC)	I-Claim
scales.	I-Claim

Some	O
differences	O
were	O
apparent	O
within	O
subscales	O
of	O
the	O
EORTC	O
questionnaires,	O
and	O
insights	O
into	O
the	O
impact	O
of	O
treatment	O
were	O
also	O
provided	O
by	O
the	O
qualitative	O
data	O
obtained	O
by	O
open-ended	O
questions.	O

Differences	B-Premise
were	I-Premise
most	I-Premise
apparent	I-Premise
shortly	I-Premise
after	I-Premise
the	I-Premise
time	I-Premise
of	I-Premise
completion	I-Premise
of	I-Premise
radiotherapy.	I-Premise

Radiotherapy	B-Claim
was	I-Claim
then	I-Claim
associated	I-Claim
with	I-Claim
increased	I-Claim
breast	I-Claim
symptoms	I-Claim
and	I-Claim
with	I-Claim
greater	I-Claim
fatigue	I-Claim
but	I-Claim
with	I-Claim
less	I-Claim
insomnia	I-Claim
and	I-Claim
endocrine	I-Claim
side-effects.	I-Claim

Patients	B-Premise
had	I-Premise
significant	I-Premise
concerns	I-Premise
about	I-Premise
the	I-Premise
delivery	I-Premise
of	I-Premise
radiotherapy	I-Premise
services,	I-Premise
such	I-Premise
as	I-Premise
transport,	I-Premise
accommodation	I-Premise
and	I-Premise
travel	I-Premise
costs	I-Premise
associated	I-Premise
with	I-Premise
receiving	I-Premise
radiotherapy.	I-Premise

By	B-Premise
the	I-Premise
end	I-Premise
of	I-Premise
follow-up,	I-Premise
patients	I-Premise
receiving	I-Premise
radiotherapy	I-Premise
were	I-Premise
expressing	I-Premise
less	I-Premise
anxiety	I-Premise
about	I-Premise
recurrence	I-Premise
than	I-Premise
those	I-Premise
who	I-Premise
had	I-Premise
not	I-Premise
received	I-Premise
radiotherapy.	I-Premise

Functionality	B-Premise
was	I-Premise
not	I-Premise
greatly	I-Premise
affected	I-Premise
by	I-Premise
treatment.	I-Premise

Within	B-Premise
the	I-Premise
randomised	I-Premise
controlled	I-Premise
trial,	I-Premise
the	I-Premise
Barthel	I-Premise
Index	I-Premise
demonstrated	I-Premise
a	I-Premise
small	I-Premise
but	I-Premise
significant	I-Premise
fall	I-Premise
in	I-Premise
functionality	I-Premise
with	I-Premise
radiotherapy	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
no	I-Premise
radiotherapy	I-Premise
arm	I-Premise
of	I-Premise
the	I-Premise
trial.	I-Premise

Results	B-Premise
from	I-Premise
the	I-Premise
non-randomised	I-Premise
patients	I-Premise
did	I-Premise
not	I-Premise
confirm	I-Premise
this	I-Premise
effect,	I-Premise
however.	I-Premise

Cosmetic	B-Premise
results	I-Premise
were	I-Premise
better	I-Premise
in	I-Premise
those	I-Premise
not	I-Premise
receiving	I-Premise
radiotherapy	I-Premise
but	B-Premise
this	I-Premise
did	I-Premise
not	I-Premise
appear	I-Premise
to	I-Premise
be	I-Premise
an	I-Premise
important	I-Premise
issue	I-Premise
to	I-Premise
the	I-Premise
patients.	I-Premise

The	B-Claim
use	I-Claim
of	I-Claim
home-based	I-Claim
assessments	I-Claim
by	I-Claim
a	I-Claim
research	I-Claim
nurse	I-Claim
proved	I-Claim
to	I-Claim
be	I-Claim
an	I-Claim
effective	I-Claim
way	I-Claim
of	I-Claim
obtaining	I-Claim
high-quality	I-Claim
data.	I-Claim

Costs	O
to	O
the	O
NHS	O
associated	O
with	O
postoperative	O
radiotherapy	O
were	O
calculated	O
to	O
be	O
of	O
the	O
order	O
of	O
2000	O
pounds	O
per	O
patient.	O

In	B-Premise
the	I-Premise
follow-up	I-Premise
in	I-Premise
this	I-Premise
study,	I-Premise
there	I-Premise
were	I-Premise
no	I-Premise
recurrences,	I-Premise
and	I-Premise
the	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
utilities	I-Premise
from	I-Premise
EuroQol	I-Premise
were	I-Premise
almost	I-Premise
identical.	I-Premise

Although	B-Premise
there	I-Premise
are	I-Premise
no	I-Premise
differences	I-Premise
in	I-Premise
overall	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
scores	I-Premise
between	I-Premise
the	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
and	I-Premise
without	I-Premise
radiotherapy,	I-Premise
there	I-Premise
are	I-Premise
several	I-Premise
dimensions	I-Premise
that	I-Premise
exhibit	I-Premise
significant	I-Premise
advantage	I-Premise
to	I-Premise
the	I-Premise
omission	I-Premise
of	I-Premise
irradiation.	I-Premise

Over	B-Premise
the	I-Premise
first	I-Premise
15	I-Premise
months,	I-Premise
radiotherapy	I-Premise
for	I-Premise
this	I-Premise
population	I-Premise
is	I-Premise
not	I-Premise
a	I-Premise
cost-effective	I-Premise
treatment.	I-Premise

However,	O
the	O
early	B-Claim
postoperative	I-Claim
outcome	I-Claim
does	I-Claim
not	I-Claim
give	I-Claim
a	I-Claim
complete	I-Claim
answer	I-Claim
and	O
the	B-Claim
eventual	I-Claim
cost-effectiveness	I-Claim
will	I-Claim
only	I-Claim
become	I-Claim
clear	I-Claim
after	I-Claim
long-term	I-Claim
follow-up.	I-Claim

Extrapolations	B-Claim
from	I-Claim
these	I-Claim
data	I-Claim
suggest	I-Claim
that	I-Claim
radiotherapy	I-Claim
may	I-Claim
not	I-Claim
be	I-Claim
a	I-Claim
cost-effective	I-Claim
treatment	I-Claim
unless	I-Claim
it	I-Claim
results	I-Claim
in	I-Claim
a	I-Claim
recurrence	I-Claim
rate	I-Claim
that	I-Claim
is	I-Claim
at	I-Claim
least	I-Claim
5%	I-Claim
lower	I-Claim
in	I-Claim
absolute	I-Claim
terms	I-Claim
than	I-Claim
those	I-Claim
treated	I-Claim
without	I-Claim
radiotherapy.	I-Claim

Further	B-Claim
research	I-Claim
is	I-Claim
needed	I-Claim
into	I-Claim
a	I-Claim
number	I-Claim
of	I-Claim
areas	I-Claim
including	I-Claim
the	I-Claim
long-term	I-Claim
aspects	I-Claim
of	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
clinical	I-Claim
outcomes,	I-Claim
costs	I-Claim
and	I-Claim
consequences	I-Claim
of	I-Claim
omitting	I-Claim
radiotherapy.	I-Claim

This	O
double-blind	O
randomized	O
phase	O
II	O
trial	O
examined	O
whether	O
vandetanib,	O
an	O
inhibitor	O
of	O
vascular	O
endothelial	O
and	O
epidermal	O
growth	O
factor	O
receptors,	O
could	O
prolong	O
progression-free	O
survival	O
in	O
responding	O
patients	O
with	O
small-cell	O
lung	O
cancer.	O

Eligible	O
patients	O
with	O
complete	O
response	O
(CR)	O
or	O
partial	O
response	O
(PR)	O
to	O
combination	O
chemotherapy	O
(+/-	O
thoracic	O
or	O
prophylactic	O
cranial	O
radiation)	O
received	O
oral	O
vandetanib	O
300	O
mg/d	O
or	O
matched	O
placebo.	O

With	O
100	O
patients	O
and	O
77	O
events,	O
the	O
study	O
had	O
80%	O
power	O
to	O
detect	O
an	O
improvement	O
in	O
median	O
progression-free	O
survival	O
from	O
4	O
to	O
6.5	O
months	O
(one-sided,	O
10%-level	O
test).	O

Between	O
May	O
2003	O
and	O
March	O
2006,	O
107	O
patients	O
were	O
accrued;	O
46	O
had	O
limited	O
disease	O
and	O
61	O
extensive	O
disease.	O

There	O
were	O
fewer	O
patients	O
with	O
a	O
performance	O
status	O
of	O
0	O
(n	O
=	O
11	O
v	O
20),	O
and	O
fewer	O
had	O
CR	O
to	O
initial	O
therapy	O
(n	O
=	O
4	O
v	O
8)	O
in	O
the	O
vandetanib	O
arm.	O

Vandetanib	B-Premise
patients	I-Premise
had	I-Premise
more	I-Premise
toxicity	I-Premise
and	I-Premise
required	I-Premise
more	I-Premise
dose	I-Premise
modifications	I-Premise
for	I-Premise
gastrointestinal	I-Premise
toxicity	I-Premise
and	I-Premise
rash.	I-Premise

Asymptomatic	B-Premise
Corrected	I-Premise
QT	I-Premise
interval	I-Premise
(QTC)	I-Premise
prolongation	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
eight	I-Premise
vandetanib	I-Premise
patients.	I-Premise

Median	B-Premise
progression-free	I-Premise
survival	I-Premise
for	I-Premise
vandetanib	I-Premise
and	I-Premise
placebo	I-Premise
was	I-Premise
2.7	I-Premise
and	I-Premise
2.8	I-Premise
months,	I-Premise
respectively	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR],	I-Premise
1.01;	I-Premise
80%	I-Premise
CI,	I-Premise
0.75	I-Premise
to	I-Premise
1.36;	I-Premise
one-sided	I-Premise
P	I-Premise
=	I-Premise
.51).	I-Premise

Overall	B-Premise
survival	I-Premise
for	I-Premise
vandetanib	I-Premise
was	I-Premise
10.6	I-Premise
versus	I-Premise
11.9	I-Premise
months	I-Premise
for	I-Premise
placebo	I-Premise
(HR,	I-Premise
1.43;	I-Premise
80%	I-Premise
CI,	I-Premise
1.00	I-Premise
to	I-Premise
2.05;	I-Premise
one-sided	I-Premise
P	I-Premise
=	I-Premise
0.9).	I-Premise

In	B-Premise
planned	I-Premise
subgroup	I-Premise
analyses,	I-Premise
a	I-Premise
significant	I-Premise
interaction	I-Premise
was	I-Premise
noted	I-Premise
(P	I-Premise
=	I-Premise
.01):	I-Premise
limited-stage	I-Premise
vandetanib	I-Premise
patients	I-Premise
had	I-Premise
longer	I-Premise
overall	I-Premise
survival	I-Premise
(HR,	I-Premise
0.45;	I-Premise
one-sided	I-Premise
P	I-Premise
=	I-Premise
.07)	I-Premise
and	I-Premise
extensive-stage	I-Premise
vandetanib	I-Premise
patients	I-Premise
shorter	I-Premise
survival	I-Premise
compared	I-Premise
with	I-Premise
placebo	I-Premise
(HR,	I-Premise
2.27;	I-Premise
one-sided	I-Premise
P	I-Premise
=	I-Premise
.996).	I-Premise

Vandetanib	B-Claim
failed	I-Claim
to	I-Claim
demonstrate	I-Claim
efficacy	I-Claim
as	I-Claim
maintenance	I-Claim
therapy	I-Claim
for	I-Claim
small-cell	I-Claim
lung	I-Claim
cancer.	I-Claim

To	O
analyze	O
the	O
prospectively	O
collected	O
health-related	O
quality-of-life	O
(HRQOL)	O
data	O
from	O
patients	O
enrolled	O
in	O
two	O
Radiation	O
Therapy	O
Oncology	O
Group	O
randomized	O
Phase	O
III	O
head	O
and	O
neck	O
cancer	O
trials	O
(90-03	O
and	O
91-11)	O
to	O
assess	O
their	O
value	O
as	O
an	O
independent	O
prognostic	O
factor	O
for	O
locoregional	O
control	O
(LRC)	O
and/or	O
overall	O
survival	O
(OS).	O

HRQOL	O
questionnaires,	O
using	O
a	O
validated	O
instrument,	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Head	O
and	O
Neck	O
(FACT-H&amp;N),	O
version	O
2,	O
were	O
completed	O
by	O
patients	O
before	O
the	O
start	O
of	O
treatment.	O

OS	O
and	O
LRC	O
were	O
the	O
outcome	O
measures	O
analyzed	O
using	O
a	O
multivariate	O
Cox	O
proportional	O
hazard	O
model.	O

Baseline	O
FACT-H&amp;N	O
data	O
were	O
available	O
for	O
1,093	O
patients	O
and	O
missing	O
for	O
417	O
patients.	O

No	O
significant	O
difference	O
in	O
outcome	O
was	O
found	O
between	O
the	O
patients	O
with	O
and	O
without	O
baseline	O
FACT-H&amp;N	O
data	O
(p	O
=	O
0.58).	O

The	O
median	O
follow-up	O
time	O
was	O
27.2	O
months	O
for	O
all	O
patients	O
and	O
49	O
months	O
for	O
surviving	O
patients.	O

Multivariate	O
analyses	O
were	O
performed	O
for	O
both	O
OS	O
and	O
LRC.	O

Beyond	B-Premise
tumor	I-Premise
and	I-Premise
nodal	I-Premise
stage,	I-Premise
Karnofsky	I-Premise
performance	I-Premise
status,	I-Premise
primary	I-Premise
site,	I-Premise
cigarette	I-Premise
use,	I-Premise
use	I-Premise
of	I-Premise
concurrent	I-Premise
chemotherapy,	I-Premise
and	I-Premise
altered	I-Premise
fractionation	I-Premise
schedules,	I-Premise
the	I-Premise
FACT-H&amp;N	I-Premise
score	I-Premise
was	I-Premise
independently	I-Premise
predictive	I-Premise
of	I-Premise
LRC	I-Premise
(but	I-Premise
not	I-Premise
OS),	I-Premise
with	I-Premise
p	I-Premise
=	I-Premise
0.0038.	I-Premise

The	B-Premise
functional	I-Premise
well-being	I-Premise
component	I-Premise
of	I-Premise
the	I-Premise
FACT-H&amp;N	I-Premise
predicted	I-Premise
most	I-Premise
significantly	I-Premise
for	I-Premise
LRC	I-Premise
(p	I-Premise
=	I-Premise
0.0004).	I-Premise

This	B-Claim
study	I-Claim
represents,	I-Claim
to	I-Claim
our	I-Claim
knowledge,	I-Claim
the	I-Claim
largest	I-Claim
analysis	I-Claim
of	I-Claim
HRQOL	I-Claim
as	I-Claim
a	I-Claim
prognostic	I-Claim
factor	I-Claim
in	I-Claim
locally	I-Claim
advanced	I-Claim
head	I-Claim
and	I-Claim
neck	I-Claim
cancer	I-Claim
patients.	I-Claim

The	B-Claim
results	I-Claim
of	I-Claim
this	I-Claim
study	I-Claim
have	I-Claim
demonstrated	I-Claim
the	I-Claim
importance	I-Claim
of	I-Claim
baseline	I-Claim
HRQOL	I-Claim
as	I-Claim
a	I-Claim
significant	I-Claim
and	I-Claim
independent	I-Claim
predictor	I-Claim
of	I-Claim
LRC	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
locally	I-Claim
advanced	I-Claim
head	I-Claim
and	I-Claim
neck	I-Claim
cancer.	I-Claim

Relapse	B-Claim
after	I-Claim
completing	I-Claim
adjuvant	I-Claim
tamoxifen	I-Claim
therapy	I-Claim
is	I-Claim
a	I-Claim
persistent	I-Claim
threat	I-Claim
for	I-Claim
women	I-Claim
with	I-Claim
hormone-responsive	I-Claim
breast	I-Claim
cancer.	I-Claim

Third-generation	O
aromatase	O
inhibitors,	O
such	O
as	O
letrozole,	O
provide	O
a	O
new	O
option	O
for	O
extended	O
adjuvant	O
hormonal	O
therapy	O
after	O
5	O
years	O
of	O
tamoxifen.	O

MA.17	O
was	O
conducted	O
to	O
determine	O
whether	O
letrozole	O
improves	O
outcome	O
after	O
discontinuation	O
of	O
tamoxifen.	O

Postmenopausal	O
women	O
with	O
hormone	O
receptor-positive	O
breast	O
cancer	O
(N=5,187)	O
were	O
randomized	O
to	O
letrozole	O
2.5	O
mg	O
or	O
placebo	O
once	O
daily	O
for	O
5	O
years.	O

At	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
30	I-Premise
months,	I-Premise
letrozole	I-Premise
significantly	I-Premise
improved	I-Premise
disease-free	I-Premise
survival	I-Premise
(DFS;	I-Premise
P<0.001),	I-Premise
the	I-Premise
primary	I-Premise
end	I-Premise
point,	I-Premise
compared	I-Premise
with	I-Premise
placebo	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR]	I-Premise
for	I-Premise
recurrence	I-Premise
or	I-Premise
contralateral	I-Premise
breast	I-Premise
cancer	I-Premise
0.58;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
0.45,	I-Premise
0.76]	I-Premise
P<0.001).	I-Premise

Furthermore,	B-Premise
letrozole	I-Premise
significantly	I-Premise
improved	I-Premise
distant	I-Premise
DFS	I-Premise
(HR=0.60;	I-Premise
95%	I-Premise
CI	I-Premise
0.43,	I-Premise
0.84;	I-Premise
P=0.002)	I-Premise
and,	I-Premise
in	I-Premise
women	I-Premise
with	I-Premise
node-positive	I-Premise
tumors,	I-Premise
overall	I-Premise
survival	I-Premise
(HR=0.61;	I-Premise
95%	I-Premise
CI	I-Premise
0.38,	I-Premise
0.98;	I-Premise
P=0.04).	I-Premise

Clinical	B-Premise
benefits,	I-Premise
including	I-Premise
an	I-Premise
overall	I-Premise
survival	I-Premise
advantage,	I-Premise
were	I-Premise
also	I-Premise
seen	I-Premise
in	I-Premise
women	I-Premise
who	I-Premise
crossed	I-Premise
over	I-Premise
from	I-Premise
placebo	I-Premise
to	I-Premise
letrozole	I-Premise
after	I-Premise
unblinding,	I-Premise
indicating	I-Premise
that	I-Premise
tumors	I-Premise
remain	I-Premise
sensitive	I-Premise
to	I-Premise
hormone	I-Premise
therapy	I-Premise
despite	I-Premise
a	I-Premise
prolonged	I-Premise
period	I-Premise
since	I-Premise
discontinuation	I-Premise
of	I-Premise
tamoxifen.	I-Premise

The	O
efficacy	O
and	O
safety	O
of	O
letrozole	O
therapy	O
beyond	O
5	O
years	O
is	O
being	O
assessed	O
in	O
a	O
re-randomization	O
study,	O
following	O
the	O
emergence	O
of	O
new	O
data	O
suggesting	O
that	O
clinical	O
benefit	O
correlates	O
with	O
the	O
duration	O
of	O
letrozole.	O

MA.17	B-Claim
showed	I-Claim
that	I-Claim
letrozole	I-Claim
is	I-Claim
extremely	I-Claim
well-tolerated	I-Claim
relative	I-Claim
to	I-Claim
placebo.	I-Claim

Letrozole	B-Claim
should	I-Claim
be	I-Claim
considered	I-Claim
for	I-Claim
all	I-Claim
women	I-Claim
completing	I-Claim
tamoxifen;	I-Claim
new	B-Claim
results	I-Claim
from	I-Claim
the	I-Claim
post-unblinding	I-Claim
analysis	I-Claim
suggest	I-Claim
that	I-Claim
letrozole	I-Claim
treatment	I-Claim
should	I-Claim
also	I-Claim
be	I-Claim
considered	I-Claim
for	I-Claim
all	I-Claim
disease-free	I-Claim
women	I-Claim
for	I-Claim
periods	I-Claim
up	I-Claim
to	I-Claim
5	I-Claim
years	I-Claim
following	I-Claim
completion	I-Claim
of	I-Claim
adjuvant	I-Claim
tamoxifen.	I-Claim

To	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
abatacept	O
during	O
2	O
years	O
of	O
the	O
ATTAIN	O
(Abatacept	O
Trial	O
in	O
Treatment	O
of	O
Anti-TNF	O
INadequate	O
responders)	O
trial	O
in	O
patients	O
with	O
rheumatoid	O
arthritis.	O

Patients	O
completing	O
the	O
6-month,	O
double-blind	O
period	O
were	O
eligible	O
to	O
enter	O
the	O
long-term	O
extension;	O
patients	O
received	O
abatacept	O
approximately	O
10	O
mg/kg,	O
plus	O
disease-modifying	O
antirheumatic	O
drugs.	O

Safety	O
and	O
efficacy	O
(American	O
College	O
of	O
Rheumatology	O
(ACR)	O
criteria	O
responses,	O
DAS28	O
(C-reactive	O
protein),	O
HAQ-DI,	O
SF-36,	O
Medical	O
Outcomes	O
Study	O
Sleep	O
Problems	O
Index,	O
fatigue	O
VAS)	O
were	O
assessed	O
through	O
2	O
years.	O

317	O
patients	O
(218	O
from	O
the	O
abatacept	O
and	O
99	O
from	O
the	O
placebo	O
group)	O
entered	O
and	O
222	O
(70%)	O
completed	O
18	O
months	O
of	O
long-term	O
extension	O
treatment.	O

The	B-Premise
incidence	I-Premise
and	I-Premise
type	I-Premise
of	I-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
consistent	I-Premise
between	I-Premise
the	I-Premise
double-blind	I-Premise
and	I-Premise
cumulative	I-Premise
(double-blind	I-Premise
plus	I-Premise
long-term	I-Premise
extension)	I-Premise
periods.	I-Premise

Rates	B-Premise
of	I-Premise
serious	I-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
25.6	I-Premise
and	I-Premise
23.4	I-Premise
per	I-Premise
100	I-Premise
patient-years	I-Premise
in	I-Premise
the	I-Premise
double-blind	I-Premise
versus	I-Premise
cumulative	I-Premise
period.	I-Premise

At	B-Premise
6	I-Premise
months	I-Premise
and	I-Premise
2	I-Premise
years,	I-Premise
using	I-Premise
non-responder	I-Premise
analyses,	I-Premise
ACR	I-Premise
responses	I-Premise
in	I-Premise
abatacept-treated	I-Premise
patients	I-Premise
were:	I-Premise
ACR	I-Premise
20,	I-Premise
59.4%	I-Premise
and	I-Premise
56.2%;	I-Premise
ACR	I-Premise
50,	I-Premise
23.5%	I-Premise
and	I-Premise
33.2%;	I-Premise
ACR	I-Premise
70,	I-Premise
11.5%	I-Premise
and	I-Premise
16.1%;	I-Premise
HAQ-DI	I-Premise
responses	I-Premise
were	I-Premise
54.4%	I-Premise
and	I-Premise
47.9%.	I-Premise

At	B-Premise
6	I-Premise
months	I-Premise
and	I-Premise
2	I-Premise
years,	I-Premise
using	I-Premise
post-hoc	I-Premise
as-observed	I-Premise
analyses,	I-Premise
the	I-Premise
percentage	I-Premise
of	I-Premise
patients	I-Premise
(95%	I-Premise
confidence	I-Premise
interval)	I-Premise
achieving	I-Premise
DAS28	I-Premise
(C-reactive	I-Premise
protein)	I-Premise
low	I-Premise
disease	I-Premise
activity	I-Premise
score	I-Premise
(<	I-Premise
or	I-Premise
=	I-Premise
3.2)	I-Premise
and	I-Premise
DAS28	I-Premise
(C-reactive	I-Premise
protein)-defined	I-Premise
remission	I-Premise
(<	I-Premise
2.6)	I-Premise
increased	I-Premise
from	I-Premise
18.3%	I-Premise
(13.0,	I-Premise
23.5)	I-Premise
to	I-Premise
32.0%	I-Premise
(24.6,	I-Premise
39.4)	I-Premise
and	I-Premise
11.1%	I-Premise
(6.8,	I-Premise
15.3)	I-Premise
to	I-Premise
20.3%	I-Premise
(13.9,	I-Premise
26.6).	I-Premise

Clinically	B-Premise
meaningful	I-Premise
improvements	I-Premise
in	I-Premise
SF-36,	I-Premise
pain,	I-Premise
fatigue	I-Premise
and	I-Premise
sleep	I-Premise
problems	I-Premise
were	I-Premise
also	I-Premise
maintained	I-Premise
throughout	I-Premise
the	I-Premise
2	I-Premise
years	I-Premise
of	I-Premise
abatacept	I-Premise
treatment.	I-Premise

No	B-Premise
unique	I-Premise
safety	I-Premise
observations	I-Premise
were	I-Premise
reported	I-Premise
during	I-Premise
open-label	I-Premise
exposure.	I-Premise

Improvements	B-Premise
in	I-Premise
the	I-Premise
signs	I-Premise
and	I-Premise
symptoms	I-Premise
of	I-Premise
rheumatoid	I-Premise
arthritis,	I-Premise
physical	I-Premise
function	I-Premise
and	I-Premise
health-related	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
observed	I-Premise
after	I-Premise
6	I-Premise
months,	I-Premise
were	I-Premise
maintained	I-Premise
throughout	I-Premise
the	I-Premise
2	I-Premise
years	I-Premise
in	I-Premise
this	I-Premise
population	I-Premise
with	I-Premise
difficult-to-treat	I-Premise
disease.	I-Premise

Few	O
randomized	O
trials	O
have	O
compared	O
the	O
survival	O
benefit	O
of	O
interferon-alfa	O
over	O
controls	O
in	O
metastatic	O
renal	O
cell	O
carcinoma,	O
and	O
none	O
has	O
been	O
performed	O
using	O
interleukin-2.	O

The	O
Programme	O
Etude	O
Rein	O
Cytokines	O
(PERCY)	O
Quattro	O
trial	O
was	O
designed	O
to	O
evaluate	O
both	O
cytokines	O
for	O
their	O
survival	O
benefit	O
to	O
intermediate	O
prognosis	O
patients,	O
who	O
represent	O
the	O
majority	O
of	O
candidates	O
for	O
these	O
treatments.	O

Patients	O
were	O
randomized	O
in	O
a	O
2-by-2	O
factorial	O
design	O
to	O
medroxyprogesterone	O
acetate	O
200	O
mg	O
daily,	O
interferon-alfa	O
9	O
million	O
IU	O
3	O
times	O
a	O
week,	O
subcutaneous	O
interleukin-2	O
9	O
million	O
IU	O
daily,	O
or	O
a	O
combination	O
of	O
both	O
cytokines.	O

Tumor	O
response	O
was	O
evaluated	O
at	O
Week	O
12	O
and	O
Month	O
6;	O
progression-free	O
patients	O
received	O
further	O
identical	O
treatment	O
for	O
a	O
maximum	O
of	O
3	O
additional	O
months.	O

Primary	O
endpoint	O
was	O
overall	O
survival;	O
secondary	O
endpoints	O
were	O
disease-free	O
survival,	O
response	O
rate,	O
toxicity,	O
and	O
quality	O
of	O
life.	O

Survival	O
was	O
analyzed	O
on	O
an	O
intent-to-treat	O
basis.	O

From	O
January	O
2000	O
to	O
July	O
2004,	O
492	O
patients	O
were	O
enrolled.	O

Analysis	O
was	O
performed	O
after	O
a	O
29.2-month	O
median	O
follow-up	O
(range,	O
0	O
months	O
to	O
54.6	O
months).	O

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
survival	I-Premise
differences	I-Premise
between	I-Premise
the	I-Premise
244	I-Premise
interferon-alfa-treated	I-Premise
patients	I-Premise
and	I-Premise
248	I-Premise
noninterferon-alfa	I-Premise
patients	I-Premise
(hazard	I-Premise
ratio,	I-Premise
1.00;	I-Premise
95%	I-Premise
CI,	I-Premise
0.81-1.24)	I-Premise
or	I-Premise
between	I-Premise
the	I-Premise
247	I-Premise
interleukin-2	I-Premise
and	I-Premise
245	I-Premise
noninterleukin-2-treated	I-Premise
patients	I-Premise
(hazard	I-Premise
ratio,	I-Premise
1.07;	I-Premise
95%	I-Premise
CI,	I-Premise
0.87-1.33;	I-Premise
log	I-Premise
rank,	I-Premise
0.99	I-Premise
and	I-Premise
0.52,	I-Premise
respectively).	I-Premise

Grade	B-Premise
3-4	I-Premise
toxicities	I-Premise
were	I-Premise
significantly	I-Premise
more	I-Premise
frequent	I-Premise
in	I-Premise
cytokine-treated	I-Premise
patients	I-Premise
than	I-Premise
in	I-Premise
medroxyprogesterone-treated	I-Premise
patients.	I-Premise

Subcutaneous	B-Claim
interleukin-2	I-Claim
and/or	I-Claim
interferon-alfa	I-Claim
provide	I-Claim
no	I-Claim
survival	I-Claim
benefit	I-Claim
in	I-Claim
metastatic	I-Claim
renal	I-Claim
cancers	I-Claim
of	I-Claim
intermediate	I-Claim
prognosis,	I-Claim
and	I-Claim
they	I-Claim
induce	I-Claim
a	I-Claim
significant	I-Claim
risk	I-Claim
of	I-Claim
toxicity.	I-Claim

Newly	B-Claim
available	I-Claim
angiogenesis	I-Claim
inhibitors	I-Claim
should	I-Claim
be	I-Claim
preferred	I-Claim
for	I-Claim
these	I-Claim
patients.	I-Claim

Hormonal	B-Claim
breast	I-Claim
cancer	I-Claim
treatment	I-Claim
increases	I-Claim
menopausal	I-Claim
symptoms	I-Claim
in	I-Claim
women.	I-Claim

This	O
study	O
investigated	O
differences	O
between	O
the	O
symptoms	O
associated	O
with	O
either	O
adjuvant	O
tamoxifen	O
or	O
exemestane.	O

Ten	O
common	O
symptoms	O
were	O
assessed	O
by	O
self-report	O
questionnaire	O
administered	O
to	O
1,614	O
consecutive	O
patients	O
at	O
baseline	O
and	O
every	O
3	O
months	O
during	O
the	O
first	O
year	O
of	O
a	O
double-blind,	O
randomized	O
trial	O
of	O
postmenopausal	O
women	O
with	O
early	O
hormone	O
receptor-positive	O
breast	O
cancer.	O

Symptoms	O
were	O
categorized	O
as	O
none,	O
mild,	O
moderate,	O
or	O
severe.	O

A	O
hot	O
flash	O
score	O
was	O
calculated	O
at	O
each	O
time	O
point.	O

Symptoms	O
were	O
analyzed	O
by	O
repeated-measures	O
analysis	O
of	O
variance.	O

Each	O
time	O
period	O
was	O
tested	O
repeatedly	O
against	O
the	O
baseline;	O
an	O
overall	O
P	O
value	O
was	O
assigned	O
for	O
each	O
reported	O
symptom.	O

Compliance	O
was	O
excellent,	O
with	O
7,286	O
questionnaires	O
analyzed.	O

Baseline	O
symptom	O
prevalence	O
ranged	O
from	O
2%	O
(vaginal	O
bleeding)	O
to	O
60%	O
to	O
70%	O
(bone/muscle	O
aches	O
and	O
low	O
energy).	O

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
vaginal	I-Premise
bleeding,	I-Premise
mood	I-Premise
alteration,	I-Premise
or	I-Premise
low	I-Premise
energy.	I-Premise

Patients	B-Premise
receiving	I-Premise
tamoxifen	I-Premise
had	I-Premise
significantly	I-Premise
more	I-Premise
vaginal	I-Premise
discharge	I-Premise
(P	I-Premise
<	I-Premise
.0001).	I-Premise

Exemestane	B-Premise
patients	I-Premise
reported	I-Premise
more	I-Premise
bone/muscle	I-Premise
aches	I-Premise
(P	I-Premise
<	I-Premise
.0001),	I-Premise
vaginal	I-Premise
dryness	I-Premise
(P	I-Premise
=	I-Premise
.0004),	I-Premise
and	I-Premise
difficulty	I-Premise
sleeping	I-Premise
(P	I-Premise
=	I-Premise
.03).	I-Premise

In	B-Premise
both	I-Premise
groups,	I-Premise
the	I-Premise
hot	I-Premise
flash	I-Premise
score	I-Premise
peaked	I-Premise
at	I-Premise
3	I-Premise
months	I-Premise
and	I-Premise
decreased	I-Premise
thereafter.	I-Premise

At	B-Premise
12	I-Premise
months,	I-Premise
patients	I-Premise
receiving	I-Premise
tamoxifen	I-Premise
had	I-Premise
a	I-Premise
significantly	I-Premise
higher	I-Premise
mean	I-Premise
hot	I-Premise
flash	I-Premise
score	I-Premise
(P	I-Premise
=	I-Premise
.03),	I-Premise
with	I-Premise
daily	I-Premise
hot	I-Premise
flashes	I-Premise
increasing	I-Premise
from	I-Premise
baseline	I-Premise
by	I-Premise
33%	I-Premise
compared	I-Premise
with	I-Premise
a	I-Premise
7%	I-Premise
increase	I-Premise
from	I-Premise
baseline	I-Premise
with	I-Premise
exemestane.	I-Premise

At	B-Premise
12	I-Premise
months,	I-Premise
exemestane	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
fewer	I-Premise
hot	I-Premise
flashes	I-Premise
and	I-Premise
less	I-Premise
vaginal	I-Premise
discharge	I-Premise
than	I-Premise
tamoxifen,	I-Premise
but	I-Premise
with	I-Premise
more	I-Premise
vaginal	I-Premise
dryness,	I-Premise
bone/muscle	I-Premise
aches,	I-Premise
and	I-Premise
difficulty	I-Premise
sleeping.	I-Premise

Symptoms	B-Claim
were	I-Claim
common	I-Claim
in	I-Claim
both	I-Claim
groups.	I-Claim

Few	O
intervention	O
studies	O
have	O
been	O
conducted	O
to	O
help	O
couples	O
manage	O
the	O
effects	O
of	O
prostate	O
cancer	O
and	O
maintain	O
their	O
quality	O
of	O
life.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
a	O
family-based	O
intervention	O
could	O
improve	O
appraisal	O
variables	O
(appraisal	O
of	O
illness	O
or	O
caregiving,	O
uncertainty,	O
hopelessness),	O
coping	O
resources	O
(coping	O
strategies,	O
self-efficacy,	O
communication),	O
symptom	O
distress,	O
and	O
quality	O
of	O
life	O
in	O
men	O
with	O
prostate	O
cancer	O
and	O
their	O
spouses.	O

For	O
this	O
clinical	O
trial,	O
263	O
patient-spouse	O
dyads	O
were	O
stratified	O
by	O
research	O
site,	O
phase	O
of	O
illness,	O
and	O
treatment;	O
then,	O
they	O
were	O
randomized	O
to	O
the	O
control	O
group	O
(standard	O
care)	O
or	O
the	O
experimental	O
group	O
(standard	O
care	O
plus	O
a	O
5-session	O
family	O
intervention).	O

The	O
intervention	O
targeted	O
couples'	O
communication,	O
hope,	O
coping,	O
uncertainty,	O
and	O
symptom	O
management.	O

The	O
final	O
sample	O
consisted	O
of	O
235	O
couples:	O
123	O
couples	O
in	O
the	O
control	O
group	O
and	O
112	O
couples	O
in	O
the	O
experimental	O
group.	O

Data	O
collection	O
occurred	O
at	O
baseline	O
before	O
randomization	O
and	O
at	O
4	O
months,	O
8	O
months,	O
and	O
12	O
months.	O

At	B-Premise
4-month	I-Premise
follow-up,	I-Premise
intervention	I-Premise
patients	I-Premise
reported	I-Premise
less	I-Premise
uncertainty	I-Premise
and	I-Premise
better	I-Premise
communication	I-Premise
with	I-Premise
spouses	I-Premise
than	I-Premise
control	I-Premise
patients,	I-Premise
but	B-Premise
they	I-Premise
reported	I-Premise
no	I-Premise
other	I-Premise
effects.	I-Premise

Intervention	B-Premise
spouses	I-Premise
reported	I-Premise
higher	I-Premise
quality	I-Premise
of	I-Premise
life,	I-Premise
more	I-Premise
self-efficacy,	I-Premise
better	I-Premise
communication,	I-Premise
and	I-Premise
less	I-Premise
negative	I-Premise
appraisal	I-Premise
of	I-Premise
caregiving,	I-Premise
uncertainty,	I-Premise
hopelessness,	I-Premise
and	I-Premise
symptom	I-Premise
distress	I-Premise
at	I-Premise
4	I-Premise
months	I-Premise
compared	I-Premise
with	I-Premise
controls,	I-Premise
and	I-Premise
some	I-Premise
effects	I-Premise
were	I-Premise
sustained	I-Premise
to	I-Premise
8	I-Premise
months	I-Premise
and	I-Premise
12	I-Premise
months.	I-Premise

Men	B-Premise
with	I-Premise
prostate	I-Premise
cancer	I-Premise
and	I-Premise
their	I-Premise
spouses	I-Premise
reported	I-Premise
positive	I-Premise
outcomes	I-Premise
from	I-Premise
a	I-Premise
family	I-Premise
intervention	I-Premise
that	I-Premise
offered	I-Premise
them	I-Premise
information	I-Premise
and	I-Premise
support.	I-Premise

Programs	B-Claim
of	I-Claim
care	I-Claim
need	I-Claim
to	I-Claim
be	I-Claim
extended	I-Claim
to	I-Claim
spouses	I-Claim
who	I-Claim
likely	I-Claim
will	I-Claim
experience	I-Claim
multiple	I-Claim
benefits	I-Claim
from	I-Claim
intervention.	I-Claim

We	O
conducted	O
a	O
multicenter,	O
randomized	O
trial	O
to	O
compare	O
progression-free	O
survival	O
(PFS),	O
overall	O
survival	O
(OS),	O
and	O
quality	O
of	O
life	O
in	O
women	O
with	O
metastatic	O
breast	O
cancer	O
(MBC)	O
receiving	O
high-dose	O
chemotherapy	O
plus	O
autologous	O
stem-cell	O
transplantation	O
(ASCT;	O
HDCT)	O
compared	O
with	O
standard-dose	O
therapy.	O

Between	O
April	O
1997	O
and	O
December	O
2000,	O
386	O
women	O
with	O
MBC	O
and	O
no	O
prior	O
chemotherapy	O
for	O
metastatic	O
disease	O
were	O
registered.	O

After	O
initial	O
response	O
to	O
anthracycline-	O
or	O
taxane-based	O
induction	O
chemotherapy,	O
224	O
patients	O
were	O
randomly	O
assigned:	O
112	O
to	O
high-dose	O
cyclophosphamide,	O
mitoxantrone,	O
and	O
carboplatin	O
chemotherapy	O
and	O
ASCT	O
(HDCT),	O
and	O
112	O
to	O
standard	O
therapy	O
(ST).	O

Median	O
age	O
was	O
47	O
years	O
(range,	O
25	O
to	O
67	O
years).	O

Thirty	O
two	O
percent	O
of	O
women	O
randomly	O
assigned	O
had	O
estrogen	O
and	O
progesterone	O
receptor-negative	O
breast	O
cancer,	O
42%	O
had	O
visceral	O
metastases,	O
and	O
58%	O
had	O
bone	O
metastases.	O

Complete	O
remission	O
rates	O
before	O
random	O
assignment	O
were	O
11%	O
for	O
those	O
receiving	O
HDCT	O
and	O
12%	O
for	O
those	O
receiving	O
ST.	O

After	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
48	I-Premise
months,	I-Premise
79	I-Premise
deaths	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
HDCT	I-Premise
arm	I-Premise
and	I-Premise
77	I-Premise
deaths	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
ST	I-Premise
arm;	I-Premise
seven	B-Premise
patients	I-Premise
(6%)	I-Premise
in	I-Premise
the	I-Premise
HDCT	I-Premise
arm	I-Premise
died	I-Premise
as	I-Premise
a	I-Premise
result	I-Premise
of	I-Premise
toxicity.	I-Premise

The	B-Premise
median	I-Premise
OS	I-Premise
was	I-Premise
24	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
HDCT	I-Premise
arm	I-Premise
(95%	I-Premise
CI,	I-Premise
21	I-Premise
to	I-Premise
35	I-Premise
months)	I-Premise
and	I-Premise
28	I-Premise
months	I-Premise
for	I-Premise
ST	I-Premise
(95%	I-Premise
CI,	I-Premise
22	I-Premise
to	I-Premise
33	I-Premise
months;	I-Premise
hazard	I-Premise
ratio	I-Premise
[HR],	I-Premise
0.9;	I-Premise
95%	I-Premise
CI,	I-Premise
0.6	I-Premise
to	I-Premise
1.2;	I-Premise
P	I-Premise
=	I-Premise
.43).	I-Premise

PFS	B-Premise
was	I-Premise
11	I-Premise
months	I-Premise
for	I-Premise
HDCT	I-Premise
and	I-Premise
9	I-Premise
months	I-Premise
for	I-Premise
ST	I-Premise
(HR,	I-Premise
0.6	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
HDCT;	I-Premise
95%	I-Premise
CI,	I-Premise
0.5	I-Premise
to	I-Premise
0.9;	I-Premise
P	I-Premise
=	I-Premise
.006).	I-Premise

HDCT	B-Claim
did	I-Claim
not	I-Claim
improve	I-Claim
OS	I-Claim
in	I-Claim
women	I-Claim
with	I-Claim
MBC	I-Claim
when	I-Claim
used	I-Claim
as	I-Claim
consolidation	I-Claim
after	I-Claim
response	I-Claim
to	I-Claim
induction	I-Claim
chemotherapy.	I-Claim

Studies	O
have	O
shown	O
that	O
there	O
is	O
a	O
high	O
prevalence	O
of	O
depression	O
in	O
cancer	O
patients.	O

Women	B-Claim
with	I-Claim
breast	I-Claim
cancer	I-Claim
may	I-Claim
have	I-Claim
an	I-Claim
even	I-Claim
higher	I-Claim
risk	I-Claim
of	I-Claim
depression	I-Claim
particularly	I-Claim
in	I-Claim
a	I-Claim
postmenopausal	I-Claim
or	I-Claim
estrogen	I-Claim
deficiency	I-Claim
state.	I-Claim

A	O
small	O
number	O
of	O
randomized	O
controlled	O
trials	O
have	O
examined	O
the	O
efficacy	O
of	O
antidepressants	O
compared	O
to	O
that	O
of	O
a	O
placebo	O
in	O
cancer	O
patients,	O
but	O
some	O
results	O
have	O
been	O
difficult	O
to	O
interpret	O
due	O
to	O
a	O
heterogeneous	O
patient	O
group.	O

In	O
the	O
current	O
investigation,	O
we	O
screened	O
newly	O
diagnosed	O
early	O
stage	O
breast	O
cancer	O
patients	O
for	O
depressive	O
symptoms	O
prior	O
to	O
the	O
initiation	O
of	O
adjuvant	O
therapy	O
and	O
investigated	O
whether	O
the	O
oral	O
antidepressant	O
fluoxetine	O
affected	O
depressive	O
symptoms,	O
completion	O
of	O
adjuvant	O
treatment,	O
and	O
quality	O
of	O
life.	O

Patients	O
with	O
newly	O
diagnosed	O
early	O
stage	O
breast	O
cancer	O
were	O
screened	O
for	O
depressive	O
symptoms	O
prior	O
to	O
the	O
initiation	O
of	O
adjuvant	O
therapy.	O

Patients	O
with	O
depressive	O
symptoms	O
were	O
randomized	O
to	O
a	O
daily	O
oral	O
fluoxetine	O
or	O
a	O
placebo.	O

Patients	O
were	O
then	O
followed	O
for	O
6	O
months	O
and	O
evaluated	O
for	O
quality	O
of	O
life,	O
completion	O
of	O
adjuvant	O
treatment,	O
and	O
depressive	O
symptoms.	O

A	O
high	O
percentage	O
of	O
patients	O
with	O
newly	O
diagnosed	O
early	O
stage	O
breast	O
cancer	O
were	O
found	O
to	O
have	O
depressive	O
symptoms	O
prior	O
to	O
the	O
initiation	O
of	O
adjuvant	O
therapy.	O

The	B-Premise
use	I-Premise
of	I-Premise
fluoxetine	I-Premise
for	I-Premise
6	I-Premise
months	I-Premise
resulted	I-Premise
in	I-Premise
an	I-Premise
improvement	I-Premise
in	I-Premise
quality	I-Premise
of	I-Premise
life,	I-Premise
a	I-Premise
higher	I-Premise
completion	I-Premise
of	I-Premise
adjuvant	I-Premise
treatment	I-Premise
(chemotherapy,	I-Premise
hormonal	I-Premise
therapy,	I-Premise
chemotherapy	I-Premise
plus	I-Premise
hormonal	I-Premise
therapy),	I-Premise
and	I-Premise
a	I-Premise
reduction	I-Premise
in	I-Premise
depressive	I-Premise
symptoms	I-Premise
compared	I-Premise
to	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
placebo.	I-Premise

An	B-Claim
antidepressant	I-Claim
should	I-Claim
be	I-Claim
considered	I-Claim
for	I-Claim
early	I-Claim
stage	I-Claim
breast	I-Claim
cancer	I-Claim
patients	I-Claim
with	I-Claim
depressive	I-Claim
symptoms	I-Claim
who	I-Claim
are	I-Claim
receiving	I-Claim
adjuvant	I-Claim
treatment.	I-Claim

To	O
determine	O
the	O
immediate	O
and	O
long-term	O
effects	O
of	O
true	O
acupuncture	O
versus	O
sham	O
acupuncture	O
on	O
hot	O
flash	O
frequency	O
in	O
women	O
with	O
breast	O
cancer.	O

Seventy-two	O
women	O
with	O
breast	O
cancer	O
experiencing	O
three	O
or	O
more	O
hot	O
flashes	O
per	O
day	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
true	O
or	O
sham	O
acupuncture.	O

Interventions	O
were	O
given	O
twice	O
weekly	O
for	O
4	O
consecutive	O
weeks.	O

Hot	O
flash	O
frequency	O
was	O
evaluated	O
at	O
baseline,	O
at	O
6	O
weeks,	O
and	O
at	O
6	O
months	O
after	O
initiation	O
of	O
treatment.	O

Patients	O
initially	O
randomly	O
assigned	O
to	O
the	O
sham	O
group	O
were	O
crossed	O
over	O
to	O
true	O
acupuncture	O
starting	O
at	O
week	O
7.	O

The	O
mean	O
number	O
of	O
hot	O
flashes	O
per	O
day	O
was	O
reduced	O
from	O
8.7	O
(standard	O
deviation	O
[SD],	O
3.9)	O
to	O
6.2	O
(SD,	O
4.2)	O
in	O
the	O
true	O
acupuncture	O
group	O
and	O
from	O
10.0	O
(SD,	O
6.1)	O
to	O
7.6	O
(SD,	O
5.7)	O
in	O
the	O
sham	O
group.	O

True	B-Premise
acupuncture	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
0.8	I-Premise
fewer	I-Premise
hot	I-Premise
flashes	I-Premise
per	I-Premise
day	I-Premise
than	I-Premise
sham	I-Premise
at	I-Premise
6	I-Premise
weeks,	I-Premise
but	B-Premise
the	I-Premise
difference	I-Premise
did	I-Premise
not	I-Premise
reach	I-Premise
statistical	I-Premise
significance	I-Premise
(95%	I-Premise
CI,	I-Premise
-0.7	I-Premise
to	I-Premise
2.4;	I-Premise
P	I-Premise
=	I-Premise
.3).	I-Premise

When	B-Premise
participants	I-Premise
in	I-Premise
the	I-Premise
sham	I-Premise
acupuncture	I-Premise
group	I-Premise
were	I-Premise
crossed	I-Premise
over	I-Premise
to	I-Premise
true	I-Premise
acupuncture,	I-Premise
a	I-Premise
further	I-Premise
reduction	I-Premise
in	I-Premise
the	I-Premise
frequency	I-Premise
of	I-Premise
hot	I-Premise
flashes	I-Premise
was	I-Premise
seen.	I-Premise

This	O
reduction	O
in	O
hot	O
flash	O
frequency	O
persisted	O
for	O
up	O
to	O
6	O
months	O
after	O
the	O
completion	O
of	O
treatment.	O

Hot	B-Claim
flash	I-Claim
frequency	I-Claim
in	I-Claim
breast	I-Claim
cancer	I-Claim
patients	I-Claim
was	I-Claim
reduced	I-Claim
following	I-Claim
acupuncture.	I-Claim

However,	O
when	B-Premise
compared	I-Premise
with	I-Premise
sham	I-Premise
acupuncture,	I-Premise
the	I-Premise
reduction	I-Premise
by	I-Premise
the	I-Premise
acupuncture	I-Premise
regimen	I-Premise
as	I-Premise
provided	I-Premise
in	I-Premise
the	I-Premise
current	I-Premise
study	I-Premise
did	I-Premise
not	I-Premise
reach	I-Premise
statistical	I-Premise
significance.	I-Premise

We	B-Claim
cannot	I-Claim
exclude	I-Claim
the	I-Claim
possibility	I-Claim
that	I-Claim
a	I-Claim
longer	I-Claim
and	I-Claim
more	I-Claim
intense	I-Claim
acupuncture	I-Claim
intervention	I-Claim
could	I-Claim
produce	I-Claim
a	I-Claim
larger	I-Claim
reduction	I-Claim
of	I-Claim
these	I-Claim
symptoms.	I-Claim

Few	O
exercise	O
trials	O
in	O
cancer	O
patients	O
have	O
reported	O
longer-term	O
follow-up.	O

Here,	O
we	O
report	O
a	O
6-month	O
follow-up	O
of	O
exercise	O
behavior	O
and	O
patient-rated	O
outcomes	O
from	O
an	O
exercise	O
trial	O
in	O
breast	O
cancer	O
patients.	O

Breast	O
cancer	O
patients	O
initiating	O
adjuvant	O
chemotherapy	O
(n	O
=	O
242)	O
were	O
randomly	O
assigned	O
to	O
usual	O
care	O
(n	O
=	O
82),	O
resistance	O
exercise	O
training	O
(RET;	O
n	O
=	O
82),	O
or	O
aerobic	O
exercise	O
training	O
(AET;	O
n	O
=	O
78)	O
for	O
the	O
duration	O
of	O
their	O
chemotherapy.	O

At	O
6-month	O
follow-up,	O
participants	O
were	O
mailed	O
a	O
questionnaire	O
that	O
assessed	O
quality	O
of	O
life,	O
self-esteem,	O
fatigue,	O
anxiety,	O
depression,	O
and	O
exercise	O
behavior.	O

Two	O
hundred	O
one	O
(83.1%)	O
participants	O
provided	O
6-month	O
follow-up	O
data.	O

Adjusted	B-Premise
linear	I-Premise
mixed-model	I-Premise
analyses	I-Premise
showed	I-Premise
that,	I-Premise
at	I-Premise
6-month	I-Premise
follow-up,	I-Premise
the	I-Premise
RET	I-Premise
group	I-Premise
reported	I-Premise
higher	I-Premise
self-esteem	I-Premise
[adjusted	I-Premise
mean	I-Premise
difference,	I-Premise
1.6;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
(95%	I-Premise
CI),	I-Premise
0.1-3.2;	I-Premise
P	I-Premise
=	I-Premise
0.032]	I-Premise
and	I-Premise
the	I-Premise
AET	I-Premise
group	I-Premise
reported	I-Premise
lower	I-Premise
anxiety	I-Premise
(adjusted	I-Premise
mean	I-Premise
difference,	I-Premise
-4.7;	I-Premise
95%	I-Premise
CI,	I-Premise
-0.0	I-Premise
to	I-Premise
-9.3;	I-Premise
P	I-Premise
=	I-Premise
0.049)	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
usual	I-Premise
care	I-Premise
group.	I-Premise

Moreover,	O
compared	B-Premise
with	I-Premise
participants	I-Premise
reporting	I-Premise
no	I-Premise
regular	I-Premise
exercise	I-Premise
during	I-Premise
the	I-Premise
follow-up	I-Premise
period,	I-Premise
those	I-Premise
reporting	I-Premise
regular	I-Premise
aerobic	I-Premise
and	I-Premise
resistance	I-Premise
exercise	I-Premise
also	I-Premise
reported	I-Premise
better	I-Premise
patient-rated	I-Premise
outcomes,	I-Premise
including	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(adjusted	I-Premise
mean	I-Premise
difference,	I-Premise
9.5;	I-Premise
95%	I-Premise
CI,	I-Premise
1.2-17.8;	I-Premise
P	I-Premise
=	I-Premise
0.025).	I-Premise

Improvements	B-Premise
in	I-Premise
self-esteem	I-Premise
observed	I-Premise
with	I-Premise
RET	I-Premise
during	I-Premise
breast	I-Premise
cancer	I-Premise
chemotherapy	I-Premise
were	I-Premise
maintained	I-Premise
at	I-Premise
6-month	I-Premise
follow-up	I-Premise
whereas	O
reductions	B-Premise
in	I-Premise
anxiety	I-Premise
not	I-Premise
observed	I-Premise
with	I-Premise
AET	I-Premise
during	I-Premise
breast	I-Premise
cancer	I-Premise
chemotherapy	I-Premise
emerged	I-Premise
at	I-Premise
6-month	I-Premise
follow-up.	I-Premise

Moreover,	O
adopting	B-Premise
a	I-Premise
combined	I-Premise
aerobic	I-Premise
and	I-Premise
resistance	I-Premise
exercise	I-Premise
program	I-Premise
after	I-Premise
breast	I-Premise
cancer	I-Premise
chemotherapy	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
further	I-Premise
improvements	I-Premise
in	I-Premise
patient-rated	I-Premise
outcomes.	I-Premise

Exercise	B-Claim
training	I-Claim
during	I-Claim
breast	I-Claim
cancer	I-Claim
chemotherapy	I-Claim
may	I-Claim
result	I-Claim
in	I-Claim
some	I-Claim
longer-term	I-Claim
and	I-Claim
late	I-Claim
effects	I-Claim
for	I-Claim
selected	I-Claim
patient-rated	I-Claim
outcomes.	I-Claim

Standard	O
guidelines	O
for	O
cancer	O
pain	O
treatment	O
routinely	O
recommend	O
training	O
patients	O
to	O
reduce	O
barriers	O
to	O
pain	O
relief,	O
use	O
medications	O
appropriately,	O
and	O
communicate	O
their	O
pain-related	O
needs.	O

Methods	B-Claim
are	I-Claim
needed	I-Claim
to	I-Claim
reduce	I-Claim
professional	I-Claim
time	I-Claim
required	I-Claim
while	I-Claim
achieving	I-Claim
sustained	I-Claim
intervention	I-Claim
effectiveness.	I-Claim

In	O
a	O
multisite,	O
randomized	O
controlled	O
trial,	O
this	O
study	O
tested	O
a	O
pain	O
training	O
method	O
versus	O
a	O
nutrition	O
control.	O

At	O
six	O
oncology	O
clinics,	O
physicians	O
(N=22)	O
and	O
nurses	O
(N=23)	O
enrolled	O
patients	O
(N=93)	O
who	O
were	O
over	O
18	O
years	O
of	O
age,	O
with	O
cancer	O
diagnoses,	O
pain,	O
and	O
a	O
life	O
expectancy	O
of	O
at	O
least	O
6	O
months.	O

Pain	O
training	O
and	O
control	O
interventions	O
were	O
matched	O
for	O
materials	O
and	O
method.	O

Patients	O
watched	O
a	O
video	O
followed	O
by	O
about	O
20	O
min	O
of	O
manual-standardized	O
training	O
with	O
an	O
oncology	O
nurse	O
focused	O
on	O
reviewing	O
the	O
printed	O
material	O
and	O
adapted	O
to	O
individual	O
concerns	O
of	O
patients.	O

A	O
follow-up	O
phone	O
call	O
after	O
72	O
h	O
addressed	O
individualized	O
treatment	O
content	O
and	O
pain	O
communication.	O

Assessments	O
at	O
baseline,	O
one,	O
three,	O
and	O
6	O
months	O
included	O
barriers,	O
the	O
Brief	O
Pain	O
Inventory,	O
opioid	O
use,	O
and	O
physician	O
and	O
nurse	O
ratings	O
of	O
their	O
patients'	O
pain.	O

Trained	B-Premise
versus	I-Premise
control	I-Premise
patients	I-Premise
reported	I-Premise
reduced	I-Premise
barriers	I-Premise
to	I-Premise
pain	I-Premise
relief	I-Premise
(P<.001),	I-Premise
lower	I-Premise
usual	I-Premise
pain	I-Premise
(P=.03),	I-Premise
and	I-Premise
greater	I-Premise
opioid	I-Premise
use	I-Premise
(P<.001).	I-Premise

No	B-Premise
pain	I-Premise
training	I-Premise
patients	I-Premise
reported	I-Premise
severe	I-Premise
pain	I-Premise
(>6	I-Premise
on	I-Premise
a	I-Premise
0-10	I-Premise
scale)	I-Premise
at	I-Premise
1-month	I-Premise
outcomes	I-Premise
(P=.03).	I-Premise

Physician	O
and	O
nurse	O
ratings	O
were	O
closer	O
to	O
patients'	O
ratings	O
of	O
pain	O
for	O
trained	O
versus	O
nutrition	O
groups	O
(P=.04	O
and	O
<.001,	O
respectively).	O

Training	O
efficacy	O
was	O
not	O
modified	O
by	O
patient	O
characteristics.	O

Using	B-Claim
video	I-Claim
and	I-Claim
print	I-Claim
materials,	I-Claim
with	I-Claim
brief	I-Claim
individualized	I-Claim
training,	I-Claim
effectively	I-Claim
improved	I-Claim
pain	I-Claim
management	I-Claim
over	I-Claim
time	I-Claim
for	I-Claim
cancer	I-Claim
patients	I-Claim
of	I-Claim
varying	I-Claim
diagnostic	I-Claim
and	I-Claim
demographic	I-Claim
groups.	I-Claim

To	O
compare	O
short-	O
and	O
long-term	O
effects	O
of	O
adjuvant	O
treatment	O
versus	O
observation	O
after	O
surgery	O
on	O
health-related	O
quality	O
of	O
life	O
(HRQL)	O
of	O
prostate	O
cancer	O
patients.	O

The	O
Southwest	O
Oncology	O
Group	O
(SWOG)	O
intergroup	O
trial	O
compared	O
radical	O
prostatectomy	O
(RP)	O
plus	O
observation	O
versus	O
RP	O
plus	O
adjuvant	O
radiation	O
therapy	O
(RT).	O

Two-hundred	O
seventeen	O
of	O
425	O
therapeutic	O
trial	O
patients	O
were	O
eligible	O
and	O
registered	O
to	O
the	O
HRQL	O
study.	O

Patients	O
completed	O
the	O
SWOG	O
Quality	O
of	O
Life	O
Questionnaire	O
(emotional,	O
physical,	O
social,	O
and	O
role	O
function;	O
general	O
symptom	O
status;	O
treatment/disease-specific	O
symptoms;	O
and	O
global	O
HRQL	O
[GHRQL])	O
at	O
baseline,	O
6	O
weeks,	O
6	O
months,	O
and	O
annually	O
for	O
5	O
years.	O

Prespecified	O
outcomes	O
were	O
three	O
genitourinary	O
symptoms	O
(bowel	O
function	O
tenderness,	O
frequent	O
urination,	O
and	O
erectile	O
dysfunction	O
[ED])	O
and	O
measures	O
of	O
physical	O
and	O
emotional	O
function.	O

Adjustments	O
were	O
made	O
for	O
the	O
baseline	O
score.	O

Patients	O
receiving	O
adjuvant	O
RT	O
reported	O
worse	O
bowel	O
function	O
(through	O
approximately	O
2	O
years)	O
and	O
worse	O
urinary	O
function.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
for	O
ED.	O

GHRQL	B-Premise
was	I-Premise
initially	I-Premise
worse	I-Premise
for	I-Premise
the	I-Premise
RP+RT	I-Premise
arm	I-Premise
but	I-Premise
improved	I-Premise
over	I-Premise
time	I-Premise
and	I-Premise
was	I-Premise
better	I-Premise
at	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
the	I-Premise
period	I-Premise
than	I-Premise
the	I-Premise
GHRQL	I-Premise
reported	I-Premise
for	I-Premise
RP	I-Premise
alone	I-Premise
(treatment	I-Premise
arm	I-Premise
x	I-Premise
time	I-Premise
interaction,	I-Premise
P	I-Premise
=	I-Premise
.0004).	I-Premise

Symptom	B-Premise
distress	I-Premise
was	I-Premise
significantly	I-Premise
worse	I-Premise
for	I-Premise
the	I-Premise
RP+RT	I-Premise
arm	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
RP	I-Premise
alone	I-Premise
arm,	I-Premise
but	B-Premise
the	I-Premise
treatment	I-Premise
arms	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
with	I-Premise
respect	I-Premise
to	I-Premise
other	I-Premise
general	I-Premise
measures	I-Premise
of	I-Premise
HRQL.	I-Premise

The	B-Premise
addition	I-Premise
of	I-Premise
RT	I-Premise
to	I-Premise
surgery	I-Premise
resulted	I-Premise
in	I-Premise
more	I-Premise
frequent	I-Premise
urination,	I-Premise
as	I-Premise
well	I-Premise
as	I-Premise
early	I-Premise
report	I-Premise
of	I-Premise
more	I-Premise
bowel	I-Premise
dysfunction,	I-Premise
although	B-Premise
bowel	I-Premise
function	I-Premise
differences	I-Premise
disappeared	I-Premise
over	I-Premise
the	I-Premise
5-year	I-Premise
period.	I-Premise

The	B-Claim
addition	I-Claim
of	I-Claim
RT	I-Claim
did	I-Claim
not	I-Claim
negatively	I-Claim
impact	I-Claim
ED.	I-Claim

The	O
TAX	O
327	O
study	O
compared	O
docetaxel	O
administered	O
every	O
3	O
weeks	O
(D3),	O
weekly	O
docetaxel	O
(D1),	O
and	O
mitoxantrone	O
(M),	O
each	O
with	O
prednisone	O
(P),	O
in	O
1,006	O
men	O
with	O
metastatic	O
hormone-resistant	O
prostate	O
cancer	O
(HRPC).	O

The	O
original	O
analysis,	O
undertaken	O
in	O
August	O
2003	O
when	O
557	O
deaths	O
had	O
occurred,	O
showed	O
significantly	O
better	O
survival	O
and	O
response	O
rates	O
for	O
pain,	O
prostate-specific	O
antigen	O
(PSA),	O
and	O
quality	O
of	O
life	O
for	O
D3P	O
when	O
compared	O
with	O
MP.	O

Here,	O
we	O
report	O
an	O
updated	O
analysis	O
of	O
survival.	O

Investigators	O
were	O
asked	O
to	O
provide	O
the	O
date	O
of	O
death	O
or	O
last	O
follow-up	O
for	O
all	O
participants	O
who	O
were	O
alive	O
in	O
August	O
2003.	O

By	O
March	O
2007,	O
data	O
on	O
310	O
additional	O
deaths	O
were	O
obtained	O
(total	O
=	O
867	O
deaths).	O

The	B-Premise
survival	I-Premise
benefit	I-Premise
of	I-Premise
D3P	I-Premise
compared	I-Premise
with	I-Premise
MP	I-Premise
has	I-Premise
persisted	I-Premise
with	I-Premise
extended	I-Premise
follow-up	I-Premise
(P	I-Premise
=	I-Premise
.004).	I-Premise

Median	O
survival	O
time	O
was	O
19.2	O
months	O
(95%	O
CI,	O
17.5	O
to	O
21.3	O
months)	O
in	O
the	O
D3P	O
arm,	O
17.8	O
months	O
(95%	O
CI,	O
16.2	O
to	O
19.2	O
months)	O
in	O
the	O
D1P	O
arm,	O
and	O
16.3	O
months	O
(95%	O
CI,	O
14.3	O
to	O
17.9	O
months)	O
in	O
the	O
MP	O
arm.	O

More	B-Premise
patients	I-Premise
survived	I-Premise
>/=	I-Premise
3	I-Premise
years	I-Premise
in	I-Premise
the	I-Premise
D3P	I-Premise
and	I-Premise
D1P	I-Premise
arms	I-Premise
(18.6%	I-Premise
and	I-Premise
16.6%,	I-Premise
respectively)	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
MP	I-Premise
arm	I-Premise
(13.5%).	I-Premise

Similar	B-Premise
trends	I-Premise
in	I-Premise
survival	I-Premise
between	I-Premise
treatment	I-Premise
arms	I-Premise
were	I-Premise
seen	I-Premise
for	I-Premise
men	I-Premise
greater	I-Premise
than	I-Premise
and	I-Premise
less	I-Premise
than	I-Premise
65	I-Premise
years	I-Premise
of	I-Premise
age,	I-Premise
for	I-Premise
those	I-Premise
with	I-Premise
and	I-Premise
without	I-Premise
pain	I-Premise
at	I-Premise
baseline,	I-Premise
and	I-Premise
for	I-Premise
those	I-Premise
with	I-Premise
baseline	I-Premise
PSA	I-Premise
greater	I-Premise
than	I-Premise
and	I-Premise
less	I-Premise
than	I-Premise
the	I-Premise
median	I-Premise
value	I-Premise
of	I-Premise
115	I-Premise
ng/mL.	I-Premise

The	B-Claim
present	I-Claim
analysis	I-Claim
confirms	I-Claim
that	I-Claim
survival	I-Claim
of	I-Claim
men	I-Claim
with	I-Claim
metastatic	I-Claim
HRPC	I-Claim
is	I-Claim
significantly	I-Claim
longer	I-Claim
after	I-Claim
treatment	I-Claim
with	I-Claim
D3P	I-Claim
than	I-Claim
with	I-Claim
MP.	I-Claim

Consistent	O
results	O
are	O
observed	O
across	O
subgroups	O
of	O
patients.	O

To	O
prospectively	O
evaluate	O
health-related	O
quality	O
of	O
life	O
(HRQOL)	O
outcomes	O
for	O
uterine	O
artery	O
embolization	O
(UAE)	O
and	O
hysterectomy	O
up	O
to	O
24	O
months	O
after	O
the	O
intervention	O
in	O
terms	O
of	O
mental	O
and	O
physical	O
health,	O
urinary	O
and	O
defecatory	O
function,	O
and	O
overall	O
patient	O
satisfaction.	O

Ethics	O
committee	O
approval	O
and	O
informed	O
consent	O
were	O
obtained	O
for	O
the	O
Embolisation	O
versus	O
Hysterectomy	O
Trial.	O

Women	O
(n	O
=	O
177)	O
with	O
uterine	O
fibroids	O
and	O
heavy	O
menstrual	O
bleeding	O
who	O
were	O
scheduled	O
to	O
undergo	O
hysterectomy	O
were	O
randomly	O
assigned	O
to	O
undergo	O
UAE	O
(n	O
=	O
88)	O
or	O
hysterectomy	O
(n	O
=	O
89).	O

HRQOL	O
was	O
measured	O
six	O
times	O
during	O
a	O
24-month	O
follow-up	O
period	O
with	O
the	O
following	O
validated	O
questionnaires:	O
Medical	O
Outcome	O
Study	O
Short	O
Form	O
36	O
(SF-36)	O
mental	O
component	O
summary	O
(MCS)	O
and	O
physical	O
component	O
summary	O
(PCS),	O
Health	O
Utilities	O
Index	O
Mark	O
3,	O
EuroQol	O
5D,	O
urogenital	O
distress	O
inventory	O
(UDI),	O
incontinence	O
impact	O
questionnaire,	O
and	O
defecation	O
distress	O
inventory	O
(DDI).	O

Satisfaction	O
was	O
assessed	O
with	O
a	O
seven-point	O
Likert	O
scale.	O

Repeated	O
measurement	O
analysis	O
was	O
performed	O
for	O
between-group	O
analysis.	O

Paired	O
t	O
tests	O
were	O
performed	O
for	O
within-group	O
analysis.	O

Satisfaction	O
was	O
analyzed	O
with	O
the	O
Fisher	O
exact	O
test.	O

The	B-Premise
SF-36	I-Premise
MCS	I-Premise
and	I-Premise
PCS,	I-Premise
Health	I-Premise
Utilities	I-Premise
Index	I-Premise
Mark	I-Premise
3,	I-Premise
EuroQol	I-Premise
5D,	I-Premise
and	I-Premise
UDI	I-Premise
scores	I-Premise
were	I-Premise
improved	I-Premise
significantly	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
and	I-Premise
afterward	I-Premise
(P	I-Premise
<	I-Premise
.05).	I-Premise

The	O
DDI	O
score	O
was	O
improved	O
significantly	O
in	O
only	O
the	O
UAE	O
group	O
at	O
6	O
months	O
and	O
afterward	O
(P	O
<	O
.05).	O

No	O
differences	O
between	O
groups	O
were	O
observed,	O
with	O
the	O
exception	O
of	O
PCS	O
scores	O
at	O
6-week	O
follow-up:	O
Patients	O
in	O
the	O
UAE	O
group	O
had	O
significantly	O
better	O
scores	O
than	O
did	O
patients	O
in	O
the	O
hysterectomy	O
group	O
(P	O
<	O
.001).	O

Improvement	O
in	O
PCS	O
score	O
at	O
24-month	O
follow-up	O
was	O
significantly	O
higher	O
for	O
patients	O
who	O
were	O
employed	O
at	O
baseline	O
(P	O
=	O
.035).	O

At	B-Premise
24-month	I-Premise
follow-up,	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
hysterectomy	I-Premise
group	I-Premise
were	I-Premise
significantly	I-Premise
more	I-Premise
satisfied	I-Premise
than	I-Premise
those	I-Premise
in	I-Premise
the	I-Premise
UAE	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
.02).	I-Premise

Both	B-Claim
UAE	I-Claim
and	I-Claim
hysterectomy	I-Claim
improved	I-Claim
HRQOL.	I-Claim

No	B-Claim
differences	I-Claim
were	I-Claim
observed	I-Claim
between	I-Claim
groups	I-Claim
regarding	I-Claim
HRQOL	I-Claim
at	I-Claim
24-month	I-Claim
follow-up.	I-Claim

On	B-Claim
the	I-Claim
basis	I-Claim
of	I-Claim
HRQOL	I-Claim
results,	I-Claim
the	I-Claim
authors	I-Claim
determined	I-Claim
that	I-Claim
UAE	I-Claim
is	I-Claim
a	I-Claim
good	I-Claim
alternative	I-Claim
to	I-Claim
hysterectomy.	I-Claim

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
quality	O
of	O
life	O
(QOL)	O
of	O
high-risk	O
breast	O
cancer	O
patients	O
included	O
in	O
a	O
randomized	O
clinical	O
trial	O
(PEGASE	O
01)	O
comparing	O
conventional	O
chemotherapy	O
versus	O
adding	O
an	O
additional	O
high-dose	O
chemotherapy	O
(HDC)	O
cycle	O
with	O
blood	O
stem	O
cell	O
support.	O

A	O
total	O
of	O
314	O
patients	O
were	O
included	O
in	O
the	O
clinical	O
trial.	O

QOL	O
evaluations	O
were	O
available	O
for	O
199	O
patients.	O

QOL	O
was	O
assessed	O
over	O
a	O
1-year	O
follow-up	O
period,	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
C-30.	O

The	O
results	O
were	O
analyzed	O
using	O
a	O
linear	O
mixed-effects	O
model.	O

Toxicity	B-Premise
of	I-Premise
HDC	I-Premise
has	I-Premise
a	I-Premise
strong	I-Premise
negative	I-Premise
impact	I-Premise
on	I-Premise
patients'	I-Premise
QOL	I-Premise
during	I-Premise
the	I-Premise
treatment	I-Premise
phase.	I-Premise

This	B-Premise
negative	I-Premise
impact	I-Premise
tended	I-Premise
to	I-Premise
last	I-Premise
longer	I-Premise
in	I-Premise
the	I-Premise
HDC	I-Premise
group,	I-Premise
as	I-Premise
for	I-Premise
most	I-Premise
of	I-Premise
the	I-Premise
QLQ-C30	I-Premise
scales,	I-Premise
the	I-Premise
QOL	I-Premise
scores	I-Premise
of	I-Premise
HDC	I-Premise
patients	I-Premise
tend	I-Premise
to	I-Premise
improve	I-Premise
at	I-Premise
a	I-Premise
slower	I-Premise
rate	I-Premise
than	I-Premise
that	I-Premise
of	I-Premise
patients	I-Premise
receiving	I-Premise
standard	I-Premise
chemotherapy.	I-Premise

In	O
particular,	O
physical	B-Premise
functioning	I-Premise
remains	I-Premise
deteriorated	I-Premise
1	I-Premise
year	I-Premise
after	I-Premise
inclusion	I-Premise
for	I-Premise
HDC	I-Premise
patients	I-Premise
comparatively	I-Premise
to	I-Premise
conventional	I-Premise
chemotherapy	I-Premise
patients	I-Premise
(85.99	I-Premise
vs.	I-Premise
76.65,	I-Premise
P	I-Premise
=	I-Premise
0.021),	I-Premise
and	B-Premise
the	I-Premise
pain	I-Premise
score	I-Premise
was	I-Premise
still	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
HDC	I-Premise
group	I-Premise
at	I-Premise
that	I-Premise
time	I-Premise
(28.32	I-Premise
vs.	I-Premise
15.97,	I-Premise
P	I-Premise
=	I-Premise
0.004).	I-Premise

HDC	B-Claim
has	I-Claim
a	I-Claim
negative	I-Claim
impact	I-Claim
on	I-Claim
QOL	I-Claim
even	I-Claim
after	I-Claim
treatment	I-Claim
phase.	I-Claim

In	O
the	O
absence	O
of	O
an	O
overall	O
survival	O
benefit	O
of	O
using	O
HDC	O
for	O
high-risk	O
breast	O
cancer	O
patients,	O
QOL	O
studies	O
with	O
a	O
longer	O
follow-up	O
play	O
an	O
important	O
role	O
in	O
informing	O
the	O
complex	O
trade-off	O
implied	O
by	O
HDC	O
between	O
higher	O
toxicity,	O
reduced	O
risk	O
of	O
relapse,	O
and	O
QOL	O
decrease	O
after	O
the	O
active	O
phase	O
of	O
treatment.	O

The	O
aim	O
of	O
this	O
multicenter	O
randomized	O
trial	O
was	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
sentinel	O
lymph	O
node	O
(SLN)	O
biopsy	O
compared	O
with	O
axillary	O
lymph	O
node	O
dissection	O
(ALND).	O

All	O
studies	O
on	O
SLN	O
biopsy	O
in	O
breast	O
cancer	O
report	O
a	O
variable	O
false	O
negative	O
rate,	O
whose	O
prognostic	O
consequences	O
are	O
still	O
unclear.	O

From	O
May	O
1999	O
to	O
December	O
2004,	O
patients	O
with	O
breast	O
cancer	O
<	O
or	O
=3	O
cm	O
were	O
randomly	O
assigned	O
to	O
receive	O
SLN	O
biopsy	O
associated	O
with	O
ALND	O
(ALND	O
arm)	O
or	O
SLN	O
biopsy	O
followed	O
by	O
ALND	O
only	O
if	O
the	O
SLN	O
was	O
metastatic	O
(SLN	O
arm).	O

The	O
main	O
aim	O
was	O
the	O
comparison	O
of	O
disease-free	O
survival	O
in	O
the	O
2	O
arms.	O

A	O
total	O
of	O
749	O
patients	O
were	O
randomized	O
and	O
697	O
were	O
available	O
for	O
analysis.	O

SLNs	O
were	O
identified	O
in	O
662	O
of	O
697	O
patients	O
(95%)	O
and	O
positive	O
SLNs	O
were	O
found	O
in	O
189	O
of	O
662	O
patients	O
(28.5%).	O

In	O
the	O
ALND	O
group,	O
positive	O
non-SLNs	O
were	O
found	O
in	O
18	O
patients	O
with	O
negative	O
SLN,	O
giving	O
a	O
false	O
negative	O
rate	O
of	O
16.7%	O
(18	O
of	O
108).	O

Postoperative	B-Premise
side	I-Premise
effects	I-Premise
were	I-Premise
significantly	I-Premise
less	I-Premise
in	I-Premise
the	I-Premise
SLN	I-Premise
group	I-Premise
and	I-Premise
there	I-Premise
was	I-Premise
no	I-Premise
negative	I-Premise
impact	I-Premise
of	I-Premise
the	I-Premise
SLN	I-Premise
procedure	I-Premise
on	I-Premise
psychologic	I-Premise
well	I-Premise
being.	I-Premise

At	O
a	O
median	O
follow-up	O
of	O
56	O
months,	O
there	O
were	O
more	O
locoregional	O
recurrences	O
in	O
the	O
SLN	O
arm,	O
and	O
the	O
5-year	O
disease-free	O
survival	O
was	O
89.9%	O
in	O
the	O
ALND	O
arm	O
and	O
87.6%	O
in	O
the	O
SLN	O
arm,	O
with	O
a	O
difference	O
of	O
2.3%	O
(95%	O
confidence	O
interval:	O
-3.1%	O
to	O
7.6%).	O

However,	B-Premise
the	I-Premise
number	I-Premise
of	I-Premise
enrolled	I-Premise
patients	I-Premise
was	I-Premise
not	I-Premise
sufficient	I-Premise
to	I-Premise
draw	I-Premise
definitive	I-Premise
conclusions.	I-Premise

SLN	B-Claim
biopsy	I-Claim
is	I-Claim
an	I-Claim
effective	I-Claim
and	I-Claim
well-tolerated	I-Claim
procedure.	I-Claim

However,	B-Claim
its	I-Claim
safety	I-Claim
should	I-Claim
be	I-Claim
confirmed	I-Claim
by	I-Claim
the	I-Claim
results	I-Claim
of	I-Claim
larger	I-Claim
randomized	I-Claim
trials	I-Claim
and	I-Claim
meta-analyses.	I-Claim

The	O
purpose	O
of	O
this	O
analysis	O
was	O
to	O
assess	O
the	O
impact	O
of	O
pretreatment	O
factors	O
on	O
quality	O
of	O
life	O
(QOL)	O
in	O
patients	O
with	O
locally	O
advanced	O
nonsmall	O
cell	O
lung	O
cancer	O
(NSCLC).	O

In	O
particular,	O
this	O
study	O
focused	O
on	O
the	O
possible	O
interaction	O
between	O
gender-specific	O
baseline	O
health-related	O
QOL	O
and	O
Karnofsky	O
performance	O
score	O
(KPS)	O
in	O
a	O
prospective	O
randomized	O
lung	O
cancer	O
trial.	O

QOL	O
information,	O
using	O
validated	O
instruments	O
(Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Lung	O
[FACT-L],	O
version	O
2,	O
and	O
Functional	O
Living	O
Index-Cancer	O
[FLIC]),	O
was	O
prospectively	O
collected	O
in	O
patients	O
with	O
locally	O
advanced	O
NSCLC	O
treated	O
on	O
Radiation	O
Therapy	O
Oncology	O
Group	O
(RTOG)	O
trial	O
89-01.	O

Between	O
April	O
1990	O
and	O
April	O
1994,	O
70	O
eligible	O
patients	O
participated	O
in	O
a	O
phase	O
III	O
trial	O
comparing	O
a	O
regimen	O
containing	O
sequential	O
chemotherapy	O
and	O
radiation	O
therapy	O
versus	O
sequential	O
chemotherapy	O
plus	O
surgery.	O

Of	O
these	O
70	O
patients,	O
46	O
underwent	O
pretreatment	O
FLIC	O
and	O
49	O
underwent	O
pretreatment	O
FACT-L.	O

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
interaction	I-Premise
between	I-Premise
gender	I-Premise
and	I-Premise
KPS	I-Premise
using	I-Premise
FLIC	I-Premise
(P	I-Premise
=	I-Premise
0.009),	I-Premise
which	I-Premise
also	I-Premise
showed	I-Premise
a	I-Premise
trend	I-Premise
toward	I-Premise
significance	I-Premise
with	I-Premise
FACT	I-Premise
(P	I-Premise
=	I-Premise
0.09).	I-Premise

Significant	B-Premise
KPS-by-gender	I-Premise
interactions	I-Premise
were	I-Premise
noted	I-Premise
for	I-Premise
FACT-L	I-Premise
in	I-Premise
the	I-Premise
physical	I-Premise
well-being	I-Premise
and	I-Premise
additional	I-Premise
concerns-lung	I-Premise
subscales	I-Premise
(P	I-Premise
=	I-Premise
0.012	I-Premise
and	I-Premise
P	I-Premise
=	I-Premise
0.0003,	I-Premise
respectively).	I-Premise

The	B-Premise
results	I-Premise
of	I-Premise
both	I-Premise
the	I-Premise
FLIC	I-Premise
and	I-Premise
FACT-L	I-Premise
demonstrated	I-Premise
significantly	I-Premise
lower	I-Premise
scores	I-Premise
corresponding	I-Premise
to	I-Premise
lower	I-Premise
KPS	I-Premise
values	I-Premise
(P	I-Premise
=	I-Premise
0.009	I-Premise
and	I-Premise
P	I-Premise
=	I-Premise
0.016,	I-Premise
respectively).	I-Premise

Results	B-Claim
of	I-Claim
this	I-Claim
randomized	I-Claim
study	I-Claim
incorporating	I-Claim
prospective	I-Claim
QOL	I-Claim
measurements	I-Claim
suggested	I-Claim
that	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
locally	I-Claim
advanced	I-Claim
NSCLC,	I-Claim
analyzing	I-Claim
QOL	I-Claim
data	I-Claim
by	I-Claim
either	I-Claim
gender	I-Claim
or	I-Claim
performance	I-Claim
status	I-Claim
alone	I-Claim
may	I-Claim
not	I-Claim
accurately	I-Claim
reflect	I-Claim
how	I-Claim
these	I-Claim
factors	I-Claim
depend	I-Claim
upon	I-Claim
each	I-Claim
another.	I-Claim

Understanding	O
the	O
interaction	O
between	O
gender	O
and	O
performance	O
status	O
could	O
lead	O
to	O
better	O
prognosticators	O
and	O
potentially	O
could	O
tailor	O
interventions	O
for	O
specific	O
groups	O
of	O
patients	O
with	O
lung	O
cancer.	O

We	O
aimed	O
at	O
investigating	O
the	O
efficacy,	O
tolerability,	O
and	O
quality	O
of	O
life	O
(QOL)	O
of	O
gemcitabine	O
(GEM)	O
compared	O
with	O
pegylated	O
liposomal	O
doxorubicin	O
(PLD)	O
in	O
the	O
salvage	O
treatment	O
of	O
recurrent	O
ovarian	O
cancer.	O

A	O
phase	O
III	O
randomized	O
multicenter	O
trial	O
was	O
planned	O
to	O
compare	O
GEM	O
(1,000	O
mg/m(2)	O
on	O
days	O
1,	O
8,	O
and	O
15	O
every	O
28	O
days)	O
with	O
PLD	O
(40	O
mg/m(2)	O
every	O
28	O
days)	O
in	O
ovarian	O
cancer	O
patients	O
who	O
experienced	O
treatment	O
failure	O
with	O
only	O
one	O
platinum/paclitaxel	O
regimen	O
and	O
who	O
experienced	O
recurrence	O
or	O
progression	O
within	O
12	O
months	O
after	O
completion	O
of	O
primary	O
treatment.	O

One	O
hundred	O
fifty-three	O
patients	O
were	O
randomly	O
assigned	O
to	O
PLD	O
(n	O
=	O
76)	O
or	O
GEM	O
(n	O
=	O
77).	O

Treatment	O
arms	O
were	O
well	O
balanced	O
for	O
clinicopathologic	O
characteristics.	O

Grade	O
3	O
or	O
4	O
neutropenia	O
was	O
more	O
frequent	O
in	O
GEM-treated	O
patients	O
versus	O
PLD-treated	O
patients	O
(P	O
=	O
.007).	O

Grade	O
3	O
or	O
4	O
palmar-plantar	O
erythrodysesthesia	O
was	O
documented	O
in	O
a	O
higher	O
proportion	O
of	O
PLD	O
patients	O
(6%)	O
versus	O
GEM	O
patients	O
(0%;	O
P	O
=	O
.061).	O

The	B-Premise
overall	I-Premise
response	I-Premise
rate	I-Premise
was	I-Premise
16%	I-Premise
in	I-Premise
the	I-Premise
PLD	I-Premise
arm	I-Premise
compared	I-Premise
with	I-Premise
29%	I-Premise
in	I-Premise
the	I-Premise
GEM	I-Premise
arm	I-Premise
(P	I-Premise
=	I-Premise
.056).	I-Premise

No	B-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
time	I-Premise
to	I-Premise
progression	I-Premise
(TTP)	I-Premise
curves	I-Premise
according	I-Premise
to	I-Premise
treatment	I-Premise
allocation	I-Premise
was	I-Premise
documented	I-Premise
(P	I-Premise
=	I-Premise
.411).	I-Premise

However,	B-Premise
a	I-Premise
trend	I-Premise
for	I-Premise
more	I-Premise
favorable	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
documented	I-Premise
in	I-Premise
the	I-Premise
PLD	I-Premise
arm	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
GEM	I-Premise
arm,	I-Premise
although	B-Premise
the	I-Premise
P	I-Premise
value	I-Premise
was	I-Premise
of	I-Premise
borderline	I-Premise
statistical	I-Premise
significance	I-Premise
(P	I-Premise
=	I-Premise
.048).	I-Premise

Statistically	B-Premise
significantly	I-Premise
higher	I-Premise
global	I-Premise
QOL	I-Premise
scores	I-Premise
were	I-Premise
found	I-Premise
in	I-Premise
PLD-treated	I-Premise
patients	I-Premise
at	I-Premise
the	I-Premise
first	I-Premise
and	I-Premise
second	I-Premise
postbaseline	I-Premise
QOL	I-Premise
assessments.	I-Premise

GEM	B-Claim
does	I-Claim
not	I-Claim
provide	I-Claim
an	I-Claim
advantage	I-Claim
compared	I-Claim
with	I-Claim
PLD	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
TTP	I-Claim
in	I-Claim
ovarian	I-Claim
cancer	I-Claim
patients	I-Claim
who	I-Claim
experience	I-Claim
recurrence	I-Claim
within	I-Claim
12	I-Claim
months	I-Claim
after	I-Claim
primary	I-Claim
treatment	I-Claim
but	I-Claim
should	I-Claim
be	I-Claim
considered	I-Claim
in	I-Claim
the	I-Claim
spectrum	I-Claim
of	I-Claim
drugs	I-Claim
to	I-Claim
be	I-Claim
possibly	I-Claim
used	I-Claim
in	I-Claim
the	I-Claim
salvage	I-Claim
setting.	I-Claim

Dermatitis	B-Claim
is	I-Claim
a	I-Claim
frequent	I-Claim
adverse	I-Claim
effect	I-Claim
of	I-Claim
adjuvant	I-Claim
breast	I-Claim
radiotherapy.	I-Claim

It	B-Claim
is	I-Claim
more	I-Claim
likely	I-Claim
in	I-Claim
full-breasted	I-Claim
women	I-Claim
and	I-Claim
when	I-Claim
the	I-Claim
radiation	I-Claim
is	I-Claim
distributed	I-Claim
nonhomogeneously	I-Claim
in	I-Claim
the	I-Claim
breast.	I-Claim

Breast	O
intensity-modulated	O
radiation	O
therapy	O
(IMRT)	O
is	O
a	O
technique	O
that	O
ensures	O
a	O
more	O
homogeneous	O
dose	O
distribution.	O

A	O
multicenter,	O
double-blind,	O
randomized	O
clinical	O
trial	O
was	O
performed	O
to	O
test	O
if	O
breast	O
IMRT	O
would	O
reduce	O
the	O
rate	O
of	O
acute	O
skin	O
reaction	O
(notably	O
moist	O
desquamation),	O
decrease	O
pain,	O
and	O
improve	O
quality	O
of	O
life	O
compared	O
with	O
standard	O
radiotherapy	O
using	O
wedges.	O

Patients	O
were	O
assessed	O
each	O
week	O
during	O
and	O
up	O
to	O
6	O
weeks	O
after	O
radiotherapy.	O

A	O
total	O
of	O
358	O
patients	O
were	O
randomly	O
assigned	O
between	O
July	O
2003	O
and	O
March	O
2005	O
in	O
two	O
Canadian	O
centers,	O
and	O
331	O
were	O
included	O
in	O
the	O
analysis.	O

Breast	B-Premise
IMRT	I-Premise
significantly	I-Premise
improved	I-Premise
the	I-Premise
dose	I-Premise
distribution	I-Premise
compared	I-Premise
with	I-Premise
standard	I-Premise
radiation.	I-Premise

This	B-Premise
translated	I-Premise
into	I-Premise
a	I-Premise
lower	I-Premise
proportion	I-Premise
of	I-Premise
patients	I-Premise
experiencing	I-Premise
moist	I-Premise
desquamation	I-Premise
during	I-Premise
or	I-Premise
up	I-Premise
to	I-Premise
6	I-Premise
weeks	I-Premise
after	I-Premise
their	I-Premise
radiation	I-Premise
treatment;	I-Premise
31.2%	I-Premise
with	I-Premise
IMRT	I-Premise
compared	I-Premise
with	I-Premise
47.8%	I-Premise
with	I-Premise
standard	I-Premise
treatment	I-Premise
(P	I-Premise
=	I-Premise
.002).	I-Premise

A	B-Premise
multivariate	I-Premise
analysis	I-Premise
found	I-Premise
the	I-Premise
use	I-Premise
of	I-Premise
breast	I-Premise
IMRT	I-Premise
(P	I-Premise
=	I-Premise
.003)	I-Premise
and	I-Premise
smaller	I-Premise
breast	I-Premise
size	I-Premise
(P	I-Premise
<	I-Premise
.001)	I-Premise
were	I-Premise
significantly	I-Premise
associated	I-Premise
with	I-Premise
a	I-Premise
decreased	I-Premise
risk	I-Premise
of	I-Premise
moist	I-Premise
desquamation.	I-Premise

The	B-Premise
use	I-Premise
of	I-Premise
IMRT	I-Premise
did	I-Premise
not	I-Premise
correlate	I-Premise
with	I-Premise
pain	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life,	I-Premise
but	O
the	B-Premise
presence	I-Premise
of	I-Premise
moist	I-Premise
desquamation	I-Premise
did	I-Premise
significantly	I-Premise
correlate	I-Premise
with	I-Premise
pain	I-Premise
(P	I-Premise
=	I-Premise
.002)	I-Premise
and	I-Premise
a	I-Premise
reduced	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(P	I-Premise
=	I-Premise
.003).	I-Premise

Breast	B-Claim
IMRT	I-Claim
significantly	I-Claim
reduced	I-Claim
the	I-Claim
occurrence	I-Claim
of	I-Claim
moist	I-Claim
desquamation	I-Claim
compared	I-Claim
with	I-Claim
a	I-Claim
standard	I-Claim
wedged	I-Claim
technique.	I-Claim

Moist	B-Claim
desquamation	I-Claim
was	I-Claim
correlated	I-Claim
with	I-Claim
increased	I-Claim
pain	I-Claim
and	I-Claim
reduction	I-Claim
in	I-Claim
the	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

Cancer	O
cachexia	O
is	O
a	O
common	O
problem	O
among	O
advanced	O
cancer	O
patients.	O

A	O
mixture	O
of	O
beta-hydroxyl	O
beta-methyl	O
butyrate,	O
glutamine,	O
and	O
arginine	O
(HMB/Arg/Gln)	O
previously	O
showed	O
activity	O
for	O
increasing	O
lean	O
body	O
mass	O
(LBM)	O
among	O
patients	O
with	O
cancer	O
cachexia.	O

Therefore	O
a	O
phase	O
III	O
trial	O
was	O
implemented	O
to	O
confirm	O
this	O
activity.	O

Four	O
hundred	O
seventy-two	O
advanced	O
cancer	O
patients	O
with	O
between	O
2%	O
and	O
10%	O
weight	O
loss	O
were	O
randomized	O
to	O
a	O
mixture	O
of	O
beta-hydroxyl	O
beta-methyl	O
butyrate,	O
glutamine,	O
and	O
arginine	O
or	O
an	O
isonitrogenous,	O
isocaloric	O
control	O
mixture	O
taken	O
twice	O
a	O
day	O
for	O
8	O
weeks.	O

Lean	O
body	O
mass	O
was	O
estimated	O
by	O
bioimpedance	O
and	O
skin-fold	O
measurements.	O

Body	O
plethysmography	O
was	O
used	O
when	O
available.	O

Weight,	O
the	O
Schwartz	O
Fatigue	O
Scale,	O
and	O
the	O
Spitzer	O
Quality	O
of	O
Life	O
Scale	O
were	O
also	O
measured.	O

Only	O
37%	O
of	O
the	O
patients	O
completed	O
protocol	O
treatment.	O

The	O
majority	O
of	O
the	O
patient	O
loss	O
was	O
because	O
of	O
patient	O
preference	O
(45%	O
of	O
enrolled	O
patients).	O

However,	O
loss	O
of	O
power	O
was	O
not	O
an	O
issue	O
because	O
of	O
the	O
planned	O
large	O
target	O
sample	O
size.	O

Based	O
on	O
an	O
intention	O
to	O
treat	O
analysis,	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
8-week	O
lean	O
body	O
mass	O
between	O
the	O
two	O
arms.	O

The	O
secondary	O
endpoints	O
were	O
also	O
not	O
significantly	O
different	O
between	O
the	O
arms.	O

Based	B-Premise
on	I-Premise
the	I-Premise
results	I-Premise
of	I-Premise
the	I-Premise
area	I-Premise
under	I-Premise
the	I-Premise
curve	I-Premise
(AUC)	I-Premise
analysis,	I-Premise
patients	I-Premise
receiving	I-Premise
HMB/Arg/Gln	I-Premise
had	I-Premise
a	I-Premise
strong	I-Premise
trend	I-Premise
higher	I-Premise
LBM	I-Premise
throughout	I-Premise
the	I-Premise
study	I-Premise
as	I-Premise
measured	I-Premise
by	I-Premise
both	I-Premise
bioimpedance	I-Premise
(p	I-Premise
=	I-Premise
0.08)	I-Premise
and	I-Premise
skin-fold	I-Premise
measurements	I-Premise
(p	I-Premise
=	I-Premise
0.08).	I-Premise

Among	B-Premise
the	I-Premise
subset	I-Premise
of	I-Premise
patients	I-Premise
receiving	I-Premise
concurrent	I-Premise
chemotherapy,	I-Premise
there	I-Premise
were	I-Premise
again	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
the	I-Premise
endpoints.	I-Premise

The	B-Premise
secondary	I-Premise
endpoints	I-Premise
were	I-Premise
also	I-Premise
not	I-Premise
significantly	I-Premise
different	I-Premise
between	I-Premise
the	I-Premise
arms.	I-Premise

This	B-Claim
trial	I-Claim
was	I-Claim
unable	I-Claim
to	I-Claim
adequately	I-Claim
test	I-Claim
the	I-Claim
ability	I-Claim
of	I-Claim
beta-hydroxy	I-Claim
beta-methylbutyrate,	I-Claim
glutamine,	I-Claim
and	I-Claim
arginine	I-Claim
to	I-Claim
reverse	I-Claim
or	I-Claim
prevent	I-Claim
lean	I-Claim
body	I-Claim
mass	I-Claim
wasting	I-Claim
among	I-Claim
cancer	I-Claim
patients.	I-Claim

Possible	O
contributing	O
factors	O
beyond	O
the	O
efficacy	O
of	O
the	O
intervention	O
were	O
the	O
inability	O
of	O
patients	O
to	O
complete	O
an	O
8-week	O
course	O
of	O
treatment	O
and	O
return	O
in	O
a	O
timely	O
fashion	O
for	O
follow-up	O
assessment,	O
and	O
because	O
the	O
patients	O
may	O
have	O
only	O
had	O
weight	O
loss	O
possible	O
not	O
related	O
to	O
cachexia,	O
but	O
other	O
causes	O
of	O
weight	O
loss,	O
such	O
as	O
decreased	O
appetite.	O

However,	O
there	O
was	O
a	O
strong	O
trend	O
towards	O
an	O
increased	O
body	O
mass	O
among	O
patients	O
taking	O
the	O
Juven	O
compound	O
using	O
the	O
secondary	O
endpoint	O
of	O
AUC.	O

Exercise	O
training	O
improves	O
supportive	O
care	O
outcomes	O
in	O
patients	O
with	O
breast	O
cancer	O
who	O
are	O
receiving	O
adjuvant	O
therapy,	O
but	O
the	O
responses	O
are	O
heterogeneous.	O

In	O
this	O
study,	O
the	O
authors	O
examined	O
personal	O
and	O
clinical	O
factors	O
that	O
may	O
predict	O
exercise	O
training	O
responses.	O

Breast	O
cancer	O
patients	O
who	O
were	O
initiating	O
adjuvant	O
chemotherapy	O
(N=242)	O
were	O
assigned	O
randomly	O
to	O
receive	O
usual	O
care	O
(UC)	O
(n=82),	O
resistance	O
exercise	O
training	O
(RET)	O
(n=82),	O
or	O
aerobic	O
exercise	O
training	O
(AET)	O
(n=78)	O
for	O
the	O
duration	O
of	O
chemotherapy.	O

Endpoints	O
were	O
quality	O
of	O
life	O
(QoL),	O
aerobic	O
fitness,	O
muscular	O
strength,	O
lean	O
body	O
mass,	O
and	O
body	O
fat.	O

Moderators	O
were	O
patient	O
preference	O
for	O
group	O
assignment,	O
marital	O
status,	O
age,	O
disease	O
stage,	O
and	O
chemotherapy	O
regimen.	O

Adjusted	O
linear	O
mixed-model	O
analyses	O
demonstrated	O
that	O
patient	O
preference	O
moderated	O
QoL	O
response	O
(P=	O
.005).	O

Patients	B-Premise
who	I-Premise
preferred	I-Premise
RET	I-Premise
improved	I-Premise
QoL	I-Premise
when	I-Premise
they	I-Premise
were	I-Premise
assigned	I-Premise
to	I-Premise
receive	I-Premise
RET	I-Premise
compared	I-Premise
with	I-Premise
UC	I-Premise
(mean	I-Premise
difference,	I-Premise
16.5;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
[95%	I-Premise
CI],	I-Premise
4.3-28.7;	I-Premise
P=	I-Premise
.008)	I-Premise
or	I-Premise
AET	I-Premise
(mean	I-Premise
difference,	I-Premise
11;	I-Premise
95%	I-Premise
CI,	I-Premise
-1.1-23.4;	I-Premise
P=	I-Premise
.076).	I-Premise

Patients	B-Premise
who	I-Premise
had	I-Premise
no	I-Premise
preference	I-Premise
had	I-Premise
improved	I-Premise
QoL	I-Premise
when	I-Premise
they	I-Premise
were	I-Premise
assigned	I-Premise
to	I-Premise
receive	I-Premise
AET	I-Premise
compared	I-Premise
with	I-Premise
RET	I-Premise
(mean	I-Premise
difference,	I-Premise
23;	I-Premise
95%	I-Premise
CI,	I-Premise
4.9-41;	I-Premise
P=	I-Premise
.014).	I-Premise

Marital	B-Premise
status	I-Premise
also	I-Premise
moderated	I-Premise
QoL	I-Premise
response	I-Premise
(P=	I-Premise
.026),	I-Premise
age	I-Premise
moderated	I-Premise
aerobic	I-Premise
fitness	I-Premise
response	I-Premise
(P=	I-Premise
.029),	I-Premise
chemotherapy	I-Premise
regimen	I-Premise
moderated	I-Premise
strength	I-Premise
gain	I-Premise
(P=	I-Premise
.009),	I-Premise
and	I-Premise
disease	I-Premise
stage	I-Premise
moderated	I-Premise
both	I-Premise
lean	I-Premise
body	I-Premise
mass	I-Premise
gain	I-Premise
(P<	I-Premise
.001)	I-Premise
and	I-Premise
fat	I-Premise
loss	I-Premise
(P=	I-Premise
.059).	I-Premise

Unmarried,	B-Premise
younger	I-Premise
patients	I-Premise
who	I-Premise
were	I-Premise
receiving	I-Premise
nontaxane-based	I-Premise
therapies	I-Premise
and	I-Premise
had	I-Premise
more	I-Premise
advanced	I-Premise
disease	I-Premise
stage	I-Premise
experienced	I-Premise
better	I-Premise
outcomes.	I-Premise

The	O
findings	O
were	O
not	O
explained	O
by	O
differences	O
in	O
adherence.	O

Patient	B-Claim
preference,	I-Claim
demographic	I-Claim
variables,	I-Claim
and	I-Claim
medical	I-Claim
variables	I-Claim
moderated	I-Claim
the	I-Claim
effects	I-Claim
of	I-Claim
exercise	I-Claim
training	I-Claim
in	I-Claim
breast	I-Claim
cancer	I-Claim
patients	I-Claim
who	I-Claim
were	I-Claim
receiving	I-Claim
chemotherapy.	I-Claim

If	O
replicated,	O
these	O
results	O
may	O
inform	O
clinical	O
practice.	O

A	O
phase	O
III	O
randomized	O
trial	O
was	O
carried	O
out	O
to	O
compare	O
two	O
schedules	O
of	O
the	O
vinorelbine	O
(VNR)-cisplatin	O
(CDDP)	O
regimen	O
in	O
patients	O
with	O
locally	O
advanced	O
unresectable	O
poor	O
prognosis	O
stage	O
IIIB	O
or	O
metastatic	O
stage	O
IV	O
non-small	O
cell	O
lung	O
cancer.	O

The	O
primary	O
endpoints	O
were	O
overall	O
survival	O
(OS)	O
and	O
analysis	O
of	O
toxicity,	O
while	O
secondary	O
endpoints	O
included	O
response	O
rates,	O
time-to-progression	O
(TTP)	O
and	O
quality	O
of	O
life	O
(QoL).	O

Eligible	O
patients	O
were	O
randomized	O
to	O
receive:	O
(a)	O
VNR	O
25mg/m(2)	O
on	O
day	O
1,	O
8	O
and	O
15	O
plus	O
CDDP	O
100mg/m(2)	O
on	O
day	O
1	O
every	O
4	O
weeks	O
or	O
(b)	O
VNR	O
30	O
mg/m(2)	O
on	O
day	O
1	O
and	O
8	O
plus	O
CDDP	O
80	O
mg/m(2)	O
on	O
day	O
1	O
every	O
3	O
weeks.	O

All	O
patients	O
were	O
chemotherapy-nave	O
and	O
had	O
an	O
ECOG	O
performance	O
status	O
(PS)	O
of	O
0-1.	O

Overall	O
278	O
patients	O
were	O
enrolled	O
into	O
the	O
trial.	O

Overall	O
response	O
rate	O
was	O
34%	O
(95%	O
CL	O
26-42%)	O
in	O
the	O
weekly	O
VNR/CDDP	O
arm,	O
and	O
32%	O
(95%	O
CL	O
24-40%)	O
in	O
patients	O
treated	O
with	O
day	O
1-8	O
VNR/CDDP	O
without	O
any	O
statistically	O
significant	O
difference.	O

Median	B-Premise
TTP	I-Premise
was	I-Premise
4.5	I-Premise
and	I-Premise
4.6	I-Premise
months	I-Premise
respectively	I-Premise
for	I-Premise
weekly	I-Premise
VNR/CDDP	I-Premise
arm	I-Premise
and	I-Premise
the	I-Premise
day	I-Premise
1-8	I-Premise
VNR/CDDP	I-Premise
one.	I-Premise

This	B-Premise
difference	I-Premise
was	I-Premise
not	I-Premise
statistically	I-Premise
significant	I-Premise
(log-rank	I-Premise
test,	I-Premise
p=0.818).	I-Premise

Median	B-Premise
OS	I-Premise
was	I-Premise
9.45	I-Premise
and	I-Premise
10	I-Premise
months	I-Premise
respectively	I-Premise
for	I-Premise
weekly	I-Premise
VNR/CDDP	I-Premise
arm	I-Premise
and	I-Premise
the	I-Premise
day	I-Premise
1-8	I-Premise
VNR/CDDP	I-Premise
one	I-Premise
without	I-Premise
statistically	I-Premise
a	I-Premise
significant	I-Premise
difference	I-Premise
(log-rank	I-Premise
test,	I-Premise
p=0.259).	I-Premise

The	B-Premise
1-	I-Premise
and	I-Premise
2-year	I-Premise
survival	I-Premise
rates	I-Premise
were	I-Premise
31	I-Premise
and	I-Premise
36%,	I-Premise
and	I-Premise
10	I-Premise
and	I-Premise
11%	I-Premise
respectively.	I-Premise

The	B-Premise
incidence	I-Premise
of	I-Premise
severe	I-Premise
neutropenia	I-Premise
(34%	I-Premise
versus	I-Premise
68%;	I-Premise
p=0.0001)	I-Premise
and	I-Premise
of	I-Premise
febrile	I-Premise
neutropenia	I-Premise
(5%	I-Premise
versus	I-Premise
12%;	I-Premise
p=0.026),	I-Premise
as	I-Premise
well	I-Premise
as	I-Premise
the	I-Premise
rate	I-Premise
of	I-Premise
therapy	I-Premise
omissions	I-Premise
(10%	I-Premise
versus	I-Premise
24%;	I-Premise
p=0.0037)	I-Premise
were	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
weekly	I-Premise
VNR/CDDP	I-Premise
arm	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
day	I-Premise
1-8	I-Premise
VNR/CDDP	I-Premise
one.	I-Premise

The	B-Premise
weekly	I-Premise
VNR/CDDP	I-Premise
regimen	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
a	I-Premise
lower	I-Premise
received	I-Premise
dose	I-Premise
intensity	I-Premise
in	I-Premise
a	I-Premise
statistically	I-Premise
significant	I-Premise
fashion	I-Premise
(9%	I-Premise
versus	I-Premise
22%;	I-Premise
p=0.0001)	I-Premise
and	I-Premise
with	I-Premise
a	I-Premise
lower	I-Premise
non-statistically	I-Premise
significant	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
score	I-Premise
as	I-Premise
compared	I-Premise
to	I-Premise
the	I-Premise
day	I-Premise
1-8	I-Premise
VNR/CDDP	I-Premise
schedule.	I-Premise

The	B-Claim
combination	I-Claim
of	I-Claim
day	I-Claim
1-8	I-Claim
VNR	I-Claim
plus	I-Claim
CDDP	I-Claim
every	I-Claim
3	I-Claim
weeks	I-Claim
is	I-Claim
less	I-Claim
toxic	I-Claim
and	I-Claim
better	I-Claim
tolerated	I-Claim
than	I-Claim
the	I-Claim
regimen	I-Claim
of	I-Claim
weekly	I-Claim
VNR	I-Claim
plus	I-Claim
CDDP	I-Claim
every	I-Claim
4	I-Claim
weeks.	I-Claim

The	B-Claim
two	I-Claim
schedules	I-Claim
are	I-Claim
equivalent	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
overall	I-Claim
response	I-Claim
rate,	I-Claim
median	I-Claim
time-to-progression	I-Claim
and	I-Claim
overall	I-Claim
survival.	I-Claim

The	B-Claim
combination	I-Claim
of	I-Claim
VNR	I-Claim
on	I-Claim
day	I-Claim
1-8	I-Claim
plus	I-Claim
CDDP	I-Claim
every	I-Claim
3	I-Claim
weeks	I-Claim
may	I-Claim
be	I-Claim
considered	I-Claim
as	I-Claim
a	I-Claim
reference	I-Claim
regimen	I-Claim
for	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
disease	I-Claim
and	I-Claim
those	I-Claim
who	I-Claim
deserve	I-Claim
a	I-Claim
postoperative	I-Claim
therapy,	I-Claim
and	I-Claim
for	I-Claim
future	I-Claim
studies.	I-Claim

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
analgesic	O
and	O
adverse	O
effects,	O
doses,	O
as	O
well	O
as	O
cost	O
of	O
opioid	O
drugs,	O
supportive	O
drug	O
therapy	O
and	O
other	O
analgesic	O
drugs	O
in	O
patients	O
treated	O
with	O
oral	O
sustained-release	O
morphine,	O
transdermal	O
fentanyl,	O
and	O
oral	O
methadone.	O

One	O
hundred	O
and	O
eight	O
cancer	O
patients,	O
no	O
longer	O
responsive	O
to	O
opioids	O
for	O
moderate	O
pain,	O
were	O
selected	O
to	O
randomly	O
receive	O
initial	O
daily	O
doses	O
of	O
60	O
mg	O
of	O
oral	O
sustained-release	O
morphine,	O
15	O
mg	O
of	O
oral	O
methadone,	O
or	O
0.6	O
mg	O
(25	O
microg/h)	O
of	O
transdermal	O
fentanyl.	O

Oral	O
morphine	O
was	O
used	O
as	O
breakthrough	O
pain	O
medication	O
during	O
opioid	O
titration.	O

Opioid	O
doses,	O
pain	O
intensity,	O
adverse	O
effects,	O
symptomatic	O
drugs,	O
were	O
recorded	O
at	O
week	O
intervals	O
for	O
4	O
weeks.	O

Costs	O
of	O
opioid	O
therapy,	O
supportive	O
drugs,	O
and	O
other	O
analgesic	O
drugs	O
were	O
also	O
evaluated.	O

Seventy	O
patients	O
completed	O
the	O
4	O
weeks	O
period	O
of	O
study.	O

Five,	O
five,	O
and	O
four	O
patients,	O
treated	O
with	O
oral	O
morphine,	O
transdermal	O
fentanyl,	O
and	O
oral	O
methadone,	O
respectively,	O
required	O
opioid	O
switching.	O

No	B-Premise
differences	I-Premise
in	I-Premise
pain	I-Premise
and	I-Premise
symptom	I-Premise
intensity	I-Premise
were	I-Premise
observed.	I-Premise

Opioid	B-Premise
escalation	I-Premise
index	I-Premise
was	I-Premise
significantly	I-Premise
lower	I-Premise
in	I-Premise
patients	I-Premise
receiving	I-Premise
methadone	I-Premise
(p<0.0001),	I-Premise
although	I-Premise
requiring	I-Premise
up	I-Premise
and	I-Premise
down	I-Premise
changes	I-Premise
in	I-Premise
doses.	I-Premise

At	B-Premise
the	I-Premise
doses	I-Premise
used,	I-Premise
methadone	I-Premise
was	I-Premise
significantly	I-Premise
less	I-Premise
expensive	I-Premise
(p<0.0001),	I-Premise
while	I-Premise
the	I-Premise
use	I-Premise
and	I-Premise
costs	I-Premise
of	I-Premise
supportive	I-Premise
drugs	I-Premise
and	I-Premise
other	I-Premise
analgesics	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
the	I-Premise
three	I-Premise
groups.	I-Premise

No	B-Premise
relevant	I-Premise
differences	I-Premise
in	I-Premise
adverse	I-Premise
effects	I-Premise
were	I-Premise
observed	I-Premise
among	I-Premise
the	I-Premise
groups	I-Premise
during	I-Premise
either	I-Premise
the	I-Premise
titration	I-Premise
phase	I-Premise
and	I-Premise
chronic	I-Premise
treatment.	I-Premise

All	B-Claim
the	I-Claim
three	I-Claim
opioids	I-Claim
used	I-Claim
as	I-Claim
first-line	I-Claim
therapy	I-Claim
were	I-Claim
effective,	I-Claim
well	I-Claim
tolerated,	I-Claim
and	I-Claim
required	I-Claim
similar	I-Claim
amounts	I-Claim
of	I-Claim
symptomatic	I-Claim
drugs	I-Claim
or	I-Claim
co-analgesics.	I-Claim

Methadone	B-Claim
was	I-Claim
significantly	I-Claim
less	I-Claim
expensive,	I-Claim
but	I-Claim
required	I-Claim
more	I-Claim
changes,	I-Claim
up	I-Claim
and	I-Claim
down,	I-Claim
of	I-Claim
the	I-Claim
doses,	I-Claim
suggesting	I-Claim
that	I-Claim
dose	I-Claim
titration	I-Claim
of	I-Claim
this	I-Claim
drug	I-Claim
requires	I-Claim
major	I-Claim
clinical	I-Claim
expertise.	I-Claim

To	O
observe	O
the	O
clinical	O
efficacy	O
of	O
Shenqi	O
Fuzheng	O
Injection	O
(SFI)	O
combined	O
with	O
chemotherapy	O
in	O
treating	O
patients	O
with	O
advanced	O
breast	O
cancer.	O

Sixty	O
patients	O
were	O
randomly	O
assigned	O
to	O
two	O
groups	O
by	O
digital	O
table,	O
the	O
control	O
group	O
and	O
the	O
treatment	O
group,	O
30	O
in	O
each	O
group.	O

All	O
patients	O
were	O
treated	O
with	O
the	O
same	O
CTF	O
regimen	O
of	O
chemotherapy	O
for	O
21	O
days	O
as	O
one	O
therapeutic	O
cycle,	O
while	O
those	O
in	O
the	O
treatment	O
group	O
were	O
given	O
SFI	O
additionally	O
in	O
the	O
meanwhite.	O

The	O
therapeutic	O
efficacy	O
was	O
evaluated	O
after	O
2	O
cycles	O
of	O
treatment	O
by	O
observing	O
the	O
changes	O
of	O
short-term	O
efficacy,	O
TCM	O
syndrome,	O
quality	O
of	O
life	O
and	O
immune	O
function,	O
as	O
well	O
as	O
the	O
adverse	O
reaction.	O

The	B-Premise
total	I-Premise
short-term	I-Premise
remission	I-Premise
rate,	I-Premise
the	I-Premise
improvement	I-Premise
rate	I-Premise
of	I-Premise
clinical	I-Premise
syndrome	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
was	I-Premise
50.0%,	I-Premise
70.0%	I-Premise
and	I-Premise
76.7%	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group,	I-Premise
and	I-Premise
43.3%,	I-Premise
46.7%	I-Premise
and	I-Premise
50.0%	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group,	I-Premise
respectively,	I-Premise
showing	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups	I-Premise
(all	I-Premise
P	I-Premise
<	I-Premise
0.05).	I-Premise

The	B-Premise
occurrence	I-Premise
of	I-Premise
adverse	I-Premise
reaction	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group	I-Premise
was	I-Premise
lower	I-Premise
than	I-Premise
that	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(P	I-Premise
<	I-Premise
0.05).	I-Premise

The	B-Premise
level	I-Premise
of	I-Premise
CD3+	I-Premise
CD4+	I-Premise
and	I-Premise
CD4+/CD8+	I-Premise
ratio	I-Premise
increased	I-Premise
(P	I-Premise
<	I-Premise
0.05)	I-Premise
and	I-Premise
CD8+	I-Premise
decreased	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group	I-Premise
(P	I-Premise
<	I-Premise
0.01),	I-Premise
while	I-Premise
they	I-Premise
showed	I-Premise
insignificant	I-Premise
change	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

For	B-Claim
treatment	I-Claim
of	I-Claim
advanced	I-Claim
breast	I-Claim
cancer,	I-Claim
SFI	I-Claim
can	I-Claim
alleviate	I-Claim
the	I-Claim
bone	I-Claim
marrow	I-Claim
inhibition	I-Claim
caused	I-Claim
by	I-Claim
chemotherapy,	I-Claim
improve	I-Claim
clinical	I-Claim
symptoms	I-Claim
and	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
and	I-Claim
prolong	I-Claim
the	I-Claim
survival	I-Claim
period	I-Claim
by	I-Claim
regulating	I-Claim
cellular	I-Claim
immune	I-Claim
function	I-Claim
of	I-Claim
patients,	I-Claim
so	I-Claim
as	I-Claim
to	I-Claim
enhance	I-Claim
the	I-Claim
therapeutic	I-Claim
effect	I-Claim
of	I-Claim
chemotherapy.	I-Claim

To	O
observe	O
the	O
effect	O
of	O
TCM	O
therapy	O
for	O
removing	O
toxic	O
substance	O
and	O
unblocking	O
meridians	O
on	O
post-radiation	O
quality	O
of	O
life	O
(QOF)	O
in	O
55	O
patients	O
with	O
lung	O
cancer.	O

All	O
patients	O
were	O
randomly	O
assigned	O
to	O
two	O
groups,	O
the	O
55	O
patients	O
in	O
the	O
treated	O
group	O
were	O
treated	O
with	O
radiotherapy	O
combined	O
with	O
the	O
TCM	O
therapy,	O
and	O
the	O
53	O
in	O
the	O
control	O
group	O
were	O
given	O
radiotherapy	O
alone.	O

The	O
clinical	O
efficacy	O
was	O
evaluated	O
by	O
indexes	O
including	O
KPS	O
scores,	O
QLQ-C30	O
questionnaire,	O
LC13	O
specific	O
scale	O
for	O
lung	O
cancer,	O
evaluation	O
criteria	O
for	O
TCM	O
efficacy,	O
the	O
6-min	O
walking	O
distance,	O
and	O
body	O
weight,	O
etc.	O

The	B-Premise
KPS	I-Premise
score	I-Premise
in	I-Premise
the	I-Premise
treated	I-Premise
group	I-Premise
after	I-Premise
treatment	I-Premise
was	I-Premise
improved	I-Premise
in	I-Premise
13	I-Premise
patients	I-Premise
(23.6%),	I-Premise
stabilized	I-Premise
in	I-Premise
27	I-Premise
(49.6%)	I-Premise
and	I-Premise
declined	I-Premise
in	I-Premise
15	I-Premise
(27.3%),	I-Premise
while	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group,	I-Premise
it	I-Premise
was	I-Premise
improved	I-Premise
in	I-Premise
7	I-Premise
(13.2%),	I-Premise
stabilized	I-Premise
in	I-Premise
21	I-Premise
(39.6%)	I-Premise
and	I-Premise
declined	I-Premise
in	I-Premise
25	I-Premise
(47.2%),	I-Premise
the	I-Premise
difference	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups	I-Premise
was	I-Premise
significant	I-Premise
(P	I-Premise
<	I-Premise
0.05).	I-Premise

The	B-Premise
results	I-Premise
from	I-Premise
evaluation	I-Premise
with	I-Premise
QLQ-C30	I-Premise
questionnaire	I-Premise
and	I-Premise
LC30	I-Premise
scale	I-Premise
in	I-Premise
the	I-Premise
treated	I-Premise
group	I-Premise
was	I-Premise
also	I-Premise
superior	I-Premise
to	I-Premise
those	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(P	I-Premise
<	I-Premise
0.05),	I-Premise
respectively.	I-Premise

The	B-Premise
scores	I-Premise
of	I-Premise
TCM	I-Premise
efficacy	I-Premise
(24.52	I-Premise
+/-	I-Premise
8.98	I-Premise
vs	I-Premise
29.76	I-Premise
+/-	I-Premise
7.09,	I-Premise
P	I-Premise
<	I-Premise
0.05)	I-Premise
and	I-Premise
the	I-Premise
6-min	I-Premise
walking	I-Premise
distance	I-Premise
(233.4	I-Premise
+/-	I-Premise
29.2	I-Premise
m	I-Premise
vs	I-Premise
205.8	I-Premise
+/-	I-Premise
31.9	I-Premise
m,	I-Premise
P	I-Premise
<	I-Premise
0.05)	I-Premise
were	I-Premise
better	I-Premise
in	I-Premise
the	I-Premise
treated	I-Premise
group.	I-Premise

After	B-Premise
treatment	I-Premise
in	I-Premise
the	I-Premise
treated	I-Premise
group,	I-Premise
the	I-Premise
body	I-Premise
weight	I-Premise
was	I-Premise
increased	I-Premise
in	I-Premise
11	I-Premise
patients	I-Premise
(20.0%),	I-Premise
stabilized	I-Premise
in	I-Premise
28	I-Premise
(50.9%)	I-Premise
and	I-Premise
decreased	I-Premise
in	I-Premise
16	I-Premise
(29.1%),	I-Premise
while	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
it	I-Premise
was	I-Premise
increased	I-Premise
in	I-Premise
5	I-Premise
(9.4%),	I-Premise
stabilized	I-Premise
in	I-Premise
26	I-Premise
(49.1%)	I-Premise
and	I-Premise
decreased	I-Premise
in	I-Premise
22	I-Premise
(41.5%),	I-Premise
difference	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups	I-Premise
was	I-Premise
significant,	I-Premise
too	I-Premise
(P	I-Premise
<	I-Premise
0.05).	I-Premise

TCM	B-Claim
therapy	I-Claim
for	I-Claim
removing	I-Claim
toxic	I-Claim
substance	I-Claim
and	I-Claim
unblocking	I-Claim
meridians	I-Claim
can	I-Claim
improve	I-Claim
the	I-Claim
post-radiation	I-Claim
QOL	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
lung	I-Claim
cancer	I-Claim
to	I-Claim
some	I-Claim
extent.	I-Claim

Anaemia	O
is	O
common	O
in	O
patients	O
receiving	O
chemotherapy,	O
causing	O
symptoms	O
that	O
have	O
a	O
major	O
impact	O
on	O
quality	O
of	O
life	O
(QoL).	O

Epoetin	O
beta	O
rapidly	O
increases	O
haemoglobin	O
(Hb)	O
levels	O
and	O
improves	O
QoL	O
in	O
anaemic	O
patients	O
with	O
a	O
variety	O
of	O
tumours.	O

This	O
was	O
a	O
randomized,	O
double-blind,	O
parallel-group,	O
dose-finding	O
study	O
assessing	O
the	O
efficacy	O
and	O
safety	O
of	O
once-weekly	O
epoetin	O
beta	O
in	O
patients	O
with	O
solid	O
tumours	O
receiving	O
chemotherapy.	O

Adult	O
patients	O
with	O
anaemia	O
(Hb	O
<	O
11	O
g/dL)	O
were	O
randomized	O
to	O
receive	O
epoetin	O
beta	O
30,000	O
IU	O
or	O
20,000	O
IU	O
once	O
weekly	O
for	O
12	O
weeks.	O

All	O
patients	O
received	O
oral	O
iron	O
supplementation.	O

Haemoglobin	O
levels,	O
transfusion	O
need	O
and	O
QoL	O
[Functional	O
Assessment	O
of	O
Cancer	O
Therapy-fatigue	O
(FACT-F)	O
subscale	O
score]	O
were	O
assessed	O
at	O
regular	O
intervals.	O

Fifty	O
patients	O
were	O
randomized;	O
30	O
patients	O
received	O
epoetin	O
beta	O
30,000	O
IU	O
once	O
weekly	O
and	O
20	O
received	O
20,000	O
IU	O
once	O
weekly.	O

Mean	B-Premise
(+/-	I-Premise
SD)	I-Premise
increase	I-Premise
in	I-Premise
Hb	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
week	I-Premise
12	I-Premise
was	I-Premise
1.75	I-Premise
+/-	I-Premise
2.15	I-Premise
g/dL	I-Premise
in	I-Premise
the	I-Premise
30,000	I-Premise
IU	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.008	I-Premise
vs.	I-Premise
baseline)	I-Premise
and	I-Premise
1.04	I-Premise
+/-	I-Premise
1.75	I-Premise
g/dL	I-Premise
in	I-Premise
the	I-Premise
20,000	I-Premise
IU	I-Premise
group	I-Premise
(non-significant).	I-Premise

Haemoglobin	B-Premise
response	I-Premise
(increase	I-Premise
in	I-Premise
Hb	I-Premise
>or=2	I-Premise
g/dL	I-Premise
from	I-Premise
baseline)	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
78.3%	I-Premise
of	I-Premise
patients	I-Premise
receiving	I-Premise
epoetin	I-Premise
beta	I-Premise
30,000	I-Premise
IU	I-Premise
and	I-Premise
66.7%	I-Premise
receiving	I-Premise
epoetin	I-Premise
beta	I-Premise
20,000	I-Premise
IU.	I-Premise

Improvements	O
in	O
FACT-F	O
subscale	O
score	O
were	O
significantly	O
(P	O
<	O
0.001)	O
correlated	O
with	O
increases	O
in	O
Hb	O
level.	O

Transfusion	O
use	O
was	O
low	O
during	O
the	O
study	O
in	O
both	O
groups.	O

Both	B-Premise
epoetin	I-Premise
beta	I-Premise
regiments	I-Premise
were	I-Premise
well	I-Premise
tolerated	I-Premise
and	I-Premise
there	I-Premise
were	I-Premise
no	I-Premise
dose-dependent	I-Premise
adverse	I-Premise
events.	I-Premise

Epoetin	B-Claim
beta	I-Claim
30,000	I-Claim
IU	I-Claim
once	I-Claim
weekly	I-Claim
is	I-Claim
an	I-Claim
effective	I-Claim
and	I-Claim
well-tolerated	I-Claim
treatment	I-Claim
of	I-Claim
anaemia	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
solid	I-Claim
tumours.	I-Claim

The	O
combination	O
of	O
cisplatin	O
and	O
etoposide	O
(PE)	O
has	O
been	O
a	O
standard	O
treatment	O
for	O
patients	O
with	O
poor-prognosis	O
small	O
cell	O
lung	O
cancer	O
(SCLC).	O

This	O
non-inferiority	O
design	O
trial	O
aimed	O
to	O
determine	O
whether	O
the	O
combination	O
of	O
gemcitabine	O
and	O
carboplatin	O
(GC)	O
results	O
in	O
similar	O
survival	O
but	O
is	O
less	O
toxic	O
with	O
better	O
quality	O
of	O
life.	O

Previously	O
untreated	O
patients	O
with	O
SCLC	O
with	O
extensive	O
disease	O
or	O
limited	O
stage	O
with	O
poor	O
prognostic	O
factors	O
were	O
randomly	O
assigned	O
to	O
six	O
3-weekly	O
cycles	O
of	O
GC	O
or	O
PE.	O

241	O
patients	O
(121	O
GC,	O
120	O
PE)	O
were	O
recruited,	O
of	O
which	O
216	O
(90%)	O
had	O
died.	O

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
overall	I-Premise
survival	I-Premise
(HR	I-Premise
1.01,	I-Premise
95%	I-Premise
CI	I-Premise
0.77	I-Premise
to	I-Premise
1.32).	I-Premise

Median	B-Premise
survival	I-Premise
with	I-Premise
GC	I-Premise
and	I-Premise
PE	I-Premise
was	I-Premise
8.0	I-Premise
and	I-Premise
8.1	I-Premise
months,	I-Premise
respectively.	I-Premise

Median	B-Premise
progression-free	I-Premise
survival	I-Premise
was	I-Premise
5.9	I-Premise
months	I-Premise
with	I-Premise
GC	I-Premise
and	I-Premise
6.3	I-Premise
months	I-Premise
with	I-Premise
PE.	I-Premise

Grade	B-Premise
3	I-Premise
or	I-Premise
4	I-Premise
myelosuppressions	I-Premise
were	I-Premise
more	I-Premise
frequent	I-Premise
with	I-Premise
GC	I-Premise
(anaemia:	I-Premise
14%	I-Premise
GC	I-Premise
vs	I-Premise
2%	I-Premise
PE;	I-Premise
leucopenia:	I-Premise
32%	I-Premise
GC	I-Premise
vs	I-Premise
13%	I-Premise
PE;	I-Premise
thrombocytopenia:	I-Premise
22%	I-Premise
GC	I-Premise
vs	I-Premise
4%	I-Premise
PE),	I-Premise
but	B-Premise
these	I-Premise
were	I-Premise
not	I-Premise
associated	I-Premise
with	I-Premise
increased	I-Premise
hospital	I-Premise
admissions,	I-Premise
infections	I-Premise
or	I-Premise
fatalities.	I-Premise

Grade	B-Premise
2-3	I-Premise
alopecia	I-Premise
(68%	I-Premise
PE	I-Premise
vs	I-Premise
17%	I-Premise
GC)	I-Premise
and	I-Premise
nausea	I-Premise
(43%	I-Premise
PE	I-Premise
vs	I-Premise
26%	I-Premise
GC)	I-Premise
were	I-Premise
more	I-Premise
frequent	I-Premise
with	I-Premise
PE.	I-Premise

Patients	O
given	O
GC	O
received	O
more	O
chemotherapy	O
as	O
outpatients	O
(89%	O
GC	O
vs	O
66%	O
PE	O
of	O
treatment	O
cycles).	O

In	B-Premise
QoL	I-Premise
questionnaires,	I-Premise
more	I-Premise
patients	I-Premise
receiving	I-Premise
PE	I-Premise
reported	I-Premise
being	I-Premise
upset	I-Premise
by	I-Premise
hair	I-Premise
loss	I-Premise
(p	I-Premise
=	I-Premise
0.004)	I-Premise
and	I-Premise
impaired	I-Premise
cognitive	I-Premise
functioning	I-Premise
(p	I-Premise
=	I-Premise
0.04).	I-Premise

GC	B-Claim
is	I-Claim
as	I-Claim
effective	I-Claim
as	I-Claim
PE	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
overall	I-Claim
survival	I-Claim
and	I-Claim
progression-free	I-Claim
survival	I-Claim
and	I-Claim
has	I-Claim
a	I-Claim
toxicity	I-Claim
profile	I-Claim
more	I-Claim
acceptable	I-Claim
to	I-Claim
patients.	I-Claim

To	O
determine	O
the	O
effectiveness	O
of	O
the	O
Alleviating	O
Depression	O
Among	O
Patients	O
With	O
Cancer	O
(ADAPt-C)	O
collaborative	O
care	O
management	O
for	O
major	O
depression	O
or	O
dysthymia.	O

Study	O
patients	O
included	O
472	O
low-income,	O
predominantly	O
female	O
Hispanic	O
patients	O
with	O
cancer	O
age	O
>or=	O
18	O
years	O
with	O
major	O
depression	O
(49%),	O
dysthymia	O
(5%),	O
or	O
both	O
(46%).	O

Patients	O
were	O
randomly	O
assigned	O
to	O
intervention	O
(n	O
=	O
242)	O
or	O
enhanced	O
usual	O
care	O
(EUC;	O
n	O
=	O
230).	O

Intervention	O
patients	O
had	O
access	O
for	O
up	O
to	O
12	O
months	O
to	O
a	O
depression	O
clinical	O
specialist	O
(supervised	O
by	O
a	O
psychiatrist)	O
who	O
offered	O
education,	O
structured	O
psychotherapy,	O
and	O
maintenance/relapse	O
prevention	O
support.	O

The	O
psychiatrist	O
prescribed	O
antidepressant	O
medications	O
for	O
patients	O
preferring	O
or	O
assessed	O
to	O
require	O
medication.	O

At	B-Premise
12	I-Premise
months,	I-Premise
63%	I-Premise
of	I-Premise
intervention	I-Premise
patients	I-Premise
had	I-Premise
a	I-Premise
50%	I-Premise
or	I-Premise
greater	I-Premise
reduction	I-Premise
in	I-Premise
depressive	I-Premise
symptoms	I-Premise
from	I-Premise
baseline	I-Premise
as	I-Premise
assessed	I-Premise
by	I-Premise
the	I-Premise
Patient	I-Premise
Health	I-Premise
Questionnaire-9	I-Premise
(PHQ-9)	I-Premise
depression	I-Premise
scale	I-Premise
compared	I-Premise
with	I-Premise
50%	I-Premise
of	I-Premise
EUC	I-Premise
patients	I-Premise
(odds	I-Premise
ratio	I-Premise
[OR]	I-Premise
=	I-Premise
1.98;	I-Premise
95%	I-Premise
CI,	I-Premise
1.16	I-Premise
to	I-Premise
3.38;	I-Premise
P	I-Premise
=	I-Premise
.01).	I-Premise

Improvement	B-Premise
was	I-Premise
also	I-Premise
found	I-Premise
for	I-Premise
5-point	I-Premise
decrease	I-Premise
in	I-Premise
PHQ-9	I-Premise
score	I-Premise
among	I-Premise
72.2%	I-Premise
of	I-Premise
intervention	I-Premise
patients	I-Premise
compared	I-Premise
with	I-Premise
59.7%	I-Premise
of	I-Premise
EUC	I-Premise
patients	I-Premise
(OR	I-Premise
=	I-Premise
1.99;	I-Premise
95%	I-Premise
CI,	I-Premise
1.14	I-Premise
to	I-Premise
3.50;	I-Premise
P	I-Premise
=	I-Premise
.02).	I-Premise

Intervention	B-Premise
patients	I-Premise
also	I-Premise
experienced	I-Premise
greater	I-Premise
rates	I-Premise
of	I-Premise
depression	I-Premise
treatment	I-Premise
(72.3%	I-Premise
v	I-Premise
10.4%	I-Premise
of	I-Premise
EUC	I-Premise
patients;	I-Premise
P	I-Premise
<	I-Premise
.0001)	I-Premise
and	I-Premise
significantly	I-Premise
better	I-Premise
quality-of-life	I-Premise
outcomes,	I-Premise
including	I-Premise
social/family	I-Premise
(adjusted	I-Premise
mean	I-Premise
difference	I-Premise
between	I-Premise
groups,	I-Premise
2.7;	I-Premise
95%	I-Premise
CI,	I-Premise
1.22	I-Premise
to	I-Premise
4.17;	I-Premise
P	I-Premise
<	I-Premise
.001),	I-Premise
emotional	I-Premise
(adjusted	I-Premise
mean	I-Premise
difference,	I-Premise
1.29;	I-Premise
95%	I-Premise
CI,	I-Premise
0.26	I-Premise
to	I-Premise
2.22;	I-Premise
P	I-Premise
=	I-Premise
.01),	I-Premise
functional	I-Premise
(adjusted	I-Premise
mean	I-Premise
difference,	I-Premise
1.34;	I-Premise
95%	I-Premise
CI,	I-Premise
0.08	I-Premise
to	I-Premise
2.59;	I-Premise
P	I-Premise
=	I-Premise
.04),	I-Premise
and	I-Premise
physical	I-Premise
well-being	I-Premise
(adjusted	I-Premise
mean	I-Premise
difference,	I-Premise
2.79;	I-Premise
95%	I-Premise
CI,	I-Premise
0.49	I-Premise
to	I-Premise
5.1;	I-Premise
P	I-Premise
=	I-Premise
.02).	I-Premise

ADAPt-C	B-Claim
collaborative	I-Claim
care	I-Claim
is	I-Claim
feasible	I-Claim
and	I-Claim
results	I-Claim
in	I-Claim
significant	I-Claim
reduction	I-Claim
in	I-Claim
depressive	I-Claim
symptoms,	I-Claim
improvement	I-Claim
in	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
and	I-Claim
lower	I-Claim
pain	I-Claim
levels	I-Claim
compared	I-Claim
with	I-Claim
EUC	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
depressive	I-Claim
disorders	I-Claim
in	I-Claim
a	I-Claim
low-income,	I-Claim
predominantly	I-Claim
Hispanic	I-Claim
population	I-Claim
in	I-Claim
public	I-Claim
sector	I-Claim
oncology	I-Claim
clinics.	I-Claim

Recombinant	O
human	O
TSH	O
(rhTSH)	O
has	O
become	O
the	O
modality	O
of	O
choice	O
for	O
radioiodine	O
remnant	O
ablation	O
(RRA)	O
in	O
low-risk	O
thyroid	O
cancer	O
patients.	O

The	O
aims	O
of	O
the	O
present	O
prospective	O
randomized	O
study	O
were	O
to	O
evaluate	O
the	O
impact	O
of	O
TSH	O
stimulation	O
procedure	O
(hypothyroidism	O
vs.	O
rhTSH)	O
on	O
quality	O
of	O
life	O
(QoL)	O
of	O
thyroid	O
cancer	O
patients	O
undergoing	O
RRA	O
and	O
to	O
evaluate	O
efficacy	O
of	O
both	O
procedures.	O

L-T4	O
was	O
initiated	O
in	O
both	O
groups	O
after	O
thyroidectomy.	O

After	O
randomization,	O
L-T4	O
was	O
discontinued	O
in	O
hypothyroid	O
(hypo)	O
group	O
and	O
continued	O
in	O
rhTSH	O
group.	O

A	O
measure	O
of	O
3.7	O
GBq	O
of	O
radioiodine	O
was	O
given	O
to	O
both	O
groups.	O

The	O
functional	O
assessment	O
of	O
chronic	O
illness	O
therapy-fatigue	O
(FACIT-F)	O
was	O
administered	O
from	O
the	O
early	O
postoperative	O
period	O
to	O
9	O
months.	O

Socio-demographic	O
parameters,	O
anxiety	O
and	O
depression	O
scales	O
were	O
also	O
evaluated	O
(CES-D,	O
BDI	O
and	O
Spielberger	O
state-trait	O
questionnaires).	O

At	O
9	O
months,	O
patients	O
underwent	O
an	O
rhTSH	O
stimulation	O
test,	O
diagnostic	O
(131)I	O
whole	O
body	O
scan	O
(dxWBS)	O
and	O
neck	O
ultrasonography.	O

A	O
total	O
of	O
74	O
patients	O
were	O
enrolled	O
for	O
the	O
study.	O

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
decrease	I-Premise
in	I-Premise
QoL	I-Premise
from	I-Premise
baseline	I-Premise
(t0)	I-Premise
to	I-Premise
t1	I-Premise
(RRA	I-Premise
period)	I-Premise
in	I-Premise
the	I-Premise
hypothyroid	I-Premise
group	I-Premise
with	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
FACIT-F	I-Premise
TOI	I-Premise
(P	I-Premise
<	I-Premise
10(-3)),	I-Premise
FACT-G	I-Premise
total	I-Premise
score	I-Premise
(P	I-Premise
=	I-Premise
0.005)	I-Premise
and	I-Premise
FACIT-F	I-Premise
total	I-Premise
score	I-Premise
(P	I-Premise
=	I-Premise
0.003).	I-Premise

By	B-Premise
contrast,	I-Premise
QoL	I-Premise
was	I-Premise
preserved	I-Premise
in	I-Premise
the	I-Premise
rhTSH	I-Premise
group.	I-Premise

In	O
the	O
multivariate	O
analysis,	O
FACIT-TOI	O
changes	O
were	O
only	O
affected	O
by	O
the	O
modality	O
of	O
TSH	O
stimulation	O
performed	O
for	O
RRA.	O

From	B-Premise
3	I-Premise
to	I-Premise
9	I-Premise
months,	I-Premise
changes	I-Premise
of	I-Premise
QoL	I-Premise
scales	I-Premise
and	I-Premise
subscales	I-Premise
were	I-Premise
no	I-Premise
longer	I-Premise
statistically	I-Premise
different	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
of	I-Premise
patients.	I-Premise

Based	B-Premise
on	I-Premise
serum	I-Premise
rhTSH-stimulated	I-Premise
Tg	I-Premise
alone	I-Premise
(Tg	I-Premise
<	I-Premise
0.8	I-Premise
microg/l,	I-Premise
BRAHMS	I-Premise
Tg	I-Premise
Kryptor),	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
ablation	I-Premise
success	I-Premise
was	I-Premise
observed	I-Premise
between	I-Premise
rhTSH	I-Premise
and	I-Premise
hypothyroidism	I-Premise
groups,	I-Premise
91.7%	I-Premise
and	I-Premise
97.1%,	I-Premise
respectively.	I-Premise

A	B-Premise
higher	I-Premise
rate	I-Premise
of	I-Premise
persistent	I-Premise
thyroid	I-Premise
remnants	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
rhTSH	I-Premise
arm,	I-Premise
although	B-Premise
in	I-Premise
most	I-Premise
cases	I-Premise
uptake	I-Premise
was	I-Premise
<	I-Premise
0.1%	I-Premise
and	I-Premise
of	I-Premise
no	I-Premise
clinical	I-Premise
significance.	I-Premise

rhTSH	B-Claim
preserves	I-Claim
QoL	I-Claim
of	I-Claim
patients	I-Claim
undergoing	I-Claim
RRA	I-Claim
with	I-Claim
similar	I-Claim
rates	I-Claim
of	I-Claim
ablation	I-Claim
success	I-Claim
compared	I-Claim
to	I-Claim
hypothyrodism.	I-Claim

However,	O
there	O
is	O
a	O
wide	O
heterogeneity	O
in	O
the	O
clinical	O
impact	O
of	O
hypothyroidism.	O

Hot	B-Claim
flashes	I-Claim
are	I-Claim
a	I-Claim
significant	I-Claim
problem	I-Claim
for	I-Claim
many	I-Claim
breast	I-Claim
cancer	I-Claim
survivors.	I-Claim

Hot	B-Claim
flashes	I-Claim
can	I-Claim
cause	I-Claim
discomfort,	I-Claim
disrupted	I-Claim
sleep,	I-Claim
anxiety,	I-Claim
and	I-Claim
decreased	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

A	O
well-tolerated	O
and	O
effective	O
mind-body	O
treatment	O
for	O
hot	O
flashes	O
would	O
be	O
of	O
great	O
value.	O

On	O
the	O
basis	O
of	O
previous	O
case	O
studies,	O
this	O
study	O
was	O
developed	O
to	O
evaluate	O
the	O
effect	O
of	O
a	O
hypnosis	O
intervention	O
for	O
hot	O
flashes.	O

Sixty	O
female	O
breast	O
cancer	O
survivors	O
with	O
hot	O
flashes	O
were	O
randomly	O
assigned	O
to	O
receive	O
hypnosis	O
intervention	O
(five	O
weekly	O
sessions)	O
or	O
no	O
treatment.	O

Eligible	O
patients	O
had	O
to	O
have	O
a	O
history	O
of	O
primary	O
breast	O
cancer	O
without	O
evidence	O
of	O
detectable	O
disease	O
and	O
14	O
or	O
more	O
weekly	O
hot	O
flashes	O
for	O
at	O
least	O
1	O
month.	O

The	O
major	O
outcome	O
measure	O
was	O
a	O
bivariate	O
construct	O
that	O
represented	O
hot	O
flash	O
frequency	O
and	O
hot	O
flash	O
score,	O
which	O
was	O
analyzed	O
by	O
a	O
classic	O
sums	O
and	O
differences	O
comparison.	O

Secondary	O
outcome	O
measures	O
were	O
self-reports	O
of	O
interference	O
of	O
hot	O
flashes	O
on	O
daily	O
activities.	O

Fifty-one	O
randomly	O
assigned	O
women	O
completed	O
the	O
study.	O

By	B-Premise
the	I-Premise
end	I-Premise
of	I-Premise
the	I-Premise
treatment	I-Premise
period,	I-Premise
hot	I-Premise
flash	I-Premise
scores	I-Premise
(frequency	I-Premise
x	I-Premise
average	I-Premise
severity)	I-Premise
decreased	I-Premise
68%	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
end	I-Premise
point	I-Premise
in	I-Premise
the	I-Premise
hypnosis	I-Premise
arm	I-Premise
(P	I-Premise
<	I-Premise
.001).	I-Premise

Significant	B-Premise
improvements	I-Premise
in	I-Premise
self-reported	I-Premise
anxiety,	I-Premise
depression,	I-Premise
interference	I-Premise
of	I-Premise
hot	I-Premise
flashes	I-Premise
on	I-Premise
daily	I-Premise
activities,	I-Premise
and	I-Premise
sleep	I-Premise
were	I-Premise
observed	I-Premise
for	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
the	I-Premise
hypnosis	I-Premise
intervention	I-Premise
(P	I-Premise
<	I-Premise
.005)	I-Premise
in	I-Premise
comparison	I-Premise
to	I-Premise
the	I-Premise
no	I-Premise
treatment	I-Premise
control	I-Premise
group.	I-Premise

Hypnosis	B-Claim
appears	I-Claim
to	I-Claim
reduce	I-Claim
perceived	I-Claim
hot	I-Claim
flashes	I-Claim
in	I-Claim
breast	I-Claim
cancer	I-Claim
survivors	I-Claim
and	I-Claim
may	I-Claim
have	I-Claim
additional	I-Claim
benefits	I-Claim
such	I-Claim
as	I-Claim
reduced	I-Claim
anxiety	I-Claim
and	I-Claim
depression,	I-Claim
and	I-Claim
improved	I-Claim
sleep.	I-Claim

Adjuvant	O
chemotherapy	O
for	O
early	O
stage	O
non-small-cell	O
lung	O
cancer	O
(NSCLC)	O
is	O
now	O
the	O
standard	O
of	O
care,	O
but	O
there	O
is	O
little	O
information	O
regarding	O
its	O
impact	O
on	O
quality	O
of	O
life	O
(QOL).	O

We	O
report	O
the	O
QOL	O
results	O
of	O
JBR.10,	O
a	O
North	O
American,	O
intergroup,	O
randomized	O
trial	O
of	O
adjuvant	O
cisplatin	O
and	O
vinorelbine	O
compared	O
with	O
observation	O
in	O
patients	O
who	O
have	O
completely	O
resected,	O
stages	O
IB	O
to	O
II	O
NSCLC.	O

QOL	O
was	O
assessed	O
with	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
C30	O
and	O
a	O
trial-specific	O
checklist	O
at	O
baseline	O
and	O
at	O
weeks	O
5	O
and	O
9	O
for	O
those	O
who	O
received	O
chemotherapy	O
and	O
at	O
follow-up	O
months	O
3,	O
6,	O
9,	O
12,	O
18,	O
24,	O
30	O
and	O
36.	O

A	O
10-point	O
change	O
in	O
QOL	O
scores	O
from	O
baseline	O
was	O
considered	O
clinically	O
significant.	O

Four	O
hundred	O
eighty-two	O
patients	O
were	O
randomly	O
assigned	O
on	O
JBR.10.	O

A	O
total	O
of	O
173	O
patients	O
(82%	O
of	O
the	O
expected)	O
in	O
the	O
observation	O
arm	O
and	O
186	O
(85%	O
of	O
expected)	O
in	O
the	O
chemotherapy	O
arm	O
completed	O
baseline	O
QOL	O
assessments.	O

The	B-Premise
two	I-Premise
groups	I-Premise
were	I-Premise
comparable,	I-Premise
with	I-Premise
low	I-Premise
global	I-Premise
QOL	I-Premise
scores	I-Premise
and	I-Premise
significant	I-Premise
symptom	I-Premise
burden,	I-Premise
especially	I-Premise
pain	I-Premise
and	I-Premise
fatigue,	I-Premise
after	I-Premise
thoracotomy.	I-Premise

Changes	O
in	O
QOL	O
during	O
chemotherapy	O
were	O
relatively	O
modest;	O
fatigue,	B-Premise
nausea,	I-Premise
and	I-Premise
vomiting	I-Premise
worsened,	I-Premise
but	B-Premise
there	I-Premise
was	I-Premise
a	I-Premise
reduction	I-Premise
in	I-Premise
pain	I-Premise
and	I-Premise
no	I-Premise
change	I-Premise
in	I-Premise
global	I-Premise
QOL.	I-Premise

Patients	B-Premise
in	I-Premise
the	I-Premise
observation	I-Premise
arm	I-Premise
showed	I-Premise
considerable	I-Premise
improvements	I-Premise
in	I-Premise
QOL	I-Premise
by	I-Premise
3	I-Premise
months.	I-Premise

QOL,	B-Premise
except	I-Premise
for	I-Premise
symptoms	I-Premise
of	I-Premise
sensory	I-Premise
neuropathy	I-Premise
and	I-Premise
hearing	I-Premise
loss,	I-Premise
in	I-Premise
those	I-Premise
treated	I-Premise
with	I-Premise
chemotherapy	I-Premise
returned	I-Premise
to	I-Premise
baseline	I-Premise
by	I-Premise
9	I-Premise
months.	I-Premise

The	B-Claim
findings	I-Claim
of	I-Claim
this	I-Claim
trial	I-Claim
indicate	I-Claim
that	I-Claim
the	I-Claim
negative	I-Claim
effects	I-Claim
of	I-Claim
adjuvant	I-Claim
chemotherapy	I-Claim
on	I-Claim
QOL	I-Claim
appear	I-Claim
to	I-Claim
be	I-Claim
temporary,	I-Claim
and	I-Claim
that	I-Claim
improvements	I-Claim
(with	I-Claim
a	I-Claim
return	I-Claim
to	I-Claim
baseline	I-Claim
function)	I-Claim
are	I-Claim
likely	I-Claim
in	I-Claim
most	I-Claim
patients.	I-Claim

The	O
physiological	O
and	O
psychological	O
stress	O
that	O
brain	O
tumor	O
patients	O
undergo	O
during	O
the	O
entire	O
surgical	O
experience	O
can	O
considerably	O
affect	O
several	O
aspects	O
of	O
their	O
hospitalization.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
live	O
music	O
therapy	O
on	O
quality	O
of	O
life	O
indicators,	O
amount	O
of	O
medications	O
administered	O
and	O
length	O
of	O
stay	O
for	O
persons	O
receiving	O
elective	O
surgical	O
procedures	O
of	O
the	O
brain.	O

Subjects	O
(N	O
=	O
27)	O
were	O
patients	O
admitted	O
for	O
some	O
type	O
of	O
surgical	O
procedure	O
of	O
the	O
brain.	O

Subjects	O
were	O
randomly	O
assigned	O
to	O
either	O
the	O
control	O
group	O
receiving	O
no	O
music	O
intervention	O
(n	O
=	O
13)	O
or	O
the	O
experimental	O
group	O
receiving	O
pre	O
and	O
postoperative	O
live	O
music	O
therapy	O
sessions	O
(n	O
=	O
14).	O

Anxiety,	O
mood,	O
pain,	O
perception	O
of	O
hospitalization	O
or	O
procedure,	O
relaxation,	O
and	O
stress	O
were	O
measured	O
using	O
a	O
self-report	O
Visual	O
Analog	O
Scale	O
(VAS)	O
for	O
each	O
of	O
the	O
variables.	O

The	O
documented	O
administration	O
of	O
postoperative	O
pain	O
medications;	O
the	O
frequency,	O
dosage,	O
type,	O
and	O
how	O
it	O
was	O
given	O
was	O
also	O
compared	O
between	O
groups.	O

Experimental	O
subjects	O
live	O
and	O
interactive	O
music	O
therapy	O
sessions,	O
including	O
a	O
pre-operative	O
session	O
and	O
continuing	O
with	O
daily	O
sessions	O
until	O
the	O
patient	O
was	O
discharged	O
home.	O

Control	O
subjects	O
received	O
routine	O
hospital	O
care	O
without	O
any	O
music	O
therapy	O
intervention.	O

Differences	O
in	O
experimental	O
pretest	O
and	O
posttest	O
scores	O
were	O
analyzed	O
using	O
a	O
Wilcoxon	O
Matched-Pairs	O
Signed-Rank	O
test.	O

Results	B-Premise
indicated	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
for	I-Premise
4	I-Premise
of	I-Premise
the	I-Premise
6	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
measures:	I-Premise
anxiety	I-Premise
(p	I-Premise
=	I-Premise
.03),	I-Premise
perception	I-Premise
of	I-Premise
hospitalization	I-Premise
(p	I-Premise
=	I-Premise
.03),	I-Premise
relaxation	I-Premise
(p	I-Premise
=	I-Premise
.001),	I-Premise
and	I-Premise
stress	I-Premise
(p	I-Premise
=	I-Premise
.001).	I-Premise

No	B-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
were	I-Premise
found	I-Premise
for	I-Premise
mood	I-Premise
(p	I-Premise
>	I-Premise
.05)	I-Premise
or	I-Premise
pain	I-Premise
(p	I-Premise
>	I-Premise
.05)	I-Premise
levels.	I-Premise

Administration	O
amounts	O
of	O
nausea	O
and	O
pain	O
medications	O
were	O
compared	O
with	O
a	O
Two-Way	O
ANOVA	O
with	O
One	O
Repeated	O
Measure	O
resulting	O
in	O
no	O
significant	O
differences	O
between	O
groups	O
and	O
medications,	O
F(1,	O
51)	O
=	O
0.03;	O
p	O
>	O
.05.	O

Results	O
indicate	O
no	O
significant	O
differences	O
between	O
groups	O
for	O
length	O
of	O
stay	O
(t	O
=	O
.97,	O
df	O
=	O
25,	O
p	O
>	O
.05).	O

This	B-Claim
research	I-Claim
study	I-Claim
indicates	I-Claim
that	I-Claim
live	I-Claim
music	I-Claim
therapy	I-Claim
using	I-Claim
patient-preferred	I-Claim
music	I-Claim
can	I-Claim
be	I-Claim
beneficial	I-Claim
in	I-Claim
improving	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
indicators	I-Claim
such	I-Claim
as	I-Claim
anxiety,	I-Claim
perception	I-Claim
of	I-Claim
the	I-Claim
hospitalization	I-Claim
or	I-Claim
procedure,	I-Claim
relaxation,	I-Claim
and	I-Claim
stress	I-Claim
in	I-Claim
patients	I-Claim
undergoing	I-Claim
surgical	I-Claim
procedures	I-Claim
of	I-Claim
the	I-Claim
brain.	I-Claim

Many	O
women	O
with	O
breast	O
cancer	O
need	O
psychological	O
help	O
to	O
cope	O
more	O
effectively	O
after	O
treatment.	O

Cognitive	O
and	O
behavioural	O
techniques	O
are	O
not	O
yet	O
well	O
established	O
in	O
France.	O

A	O
multi-site	O
randomized	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
effects	O
of	O
a	O
psycho-educational	O
group	O
intervention	O
in	O
this	O
population.	O

Two	O
hundred	O
and	O
three	O
patients,	O
recruited	O
after	O
primary	O
treatment,	O
were	O
randomly	O
assigned	O
either	O
to	O
a	O
treatment	O
group	O
(psycho-educational	O
intervention)	O
or	O
to	O
a	O
waiting-list	O
control	O
group.	O

The	O
8-week	O
programme	O
of	O
2	O
h	O
sessions	O
comprised	O
of	O
thematic	O
discussions,	O
information	O
and	O
training	O
in	O
stress	O
management	O
techniques.	O

Evaluation	O
at	O
baseline,	O
after	O
8	O
sessions,	O
and	O
1	O
month	O
after	O
programme	O
completion,	O
included	O
evaluations	O
using	O
the	O
STAI,	O
POMS,	O
MAC,	O
EORTC	O
QLQ-C30	O
and	O
EORTC	O
QLQ-BR23	O
breast	O
module	O
scales.	O

We	B-Premise
observed	I-Premise
a	I-Premise
significant	I-Premise
reduction	I-Premise
in	I-Premise
anxiety	I-Premise
(STAI,	I-Premise
POMS)	I-Premise
among	I-Premise
group	I-Premise
participants,	I-Premise
a	I-Premise
reduction	I-Premise
in	I-Premise
anger,	I-Premise
depression	I-Premise
and	I-Premise
fatigue	I-Premise
(POMS),	I-Premise
a	I-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
vigor	I-Premise
and	I-Premise
interpersonal	I-Premise
relationships	I-Premise
(POMS),	I-Premise
in	I-Premise
emotional	I-Premise
and	I-Premise
role	I-Premise
functioning,	I-Premise
in	I-Premise
health	I-Premise
status	I-Premise
and	I-Premise
fatigue	I-Premise
level	I-Premise
(EORTC	I-Premise
QLQ-C30).	I-Premise

In	O
contrast,	O
coping	B-Premise
strategies	I-Premise
(MAC)	I-Premise
were	I-Premise
not	I-Premise
significantly	I-Premise
different	I-Premise
between	I-Premise
groups.	I-Premise

No	B-Premise
group-related	I-Premise
negative	I-Premise
effects	I-Premise
were	I-Premise
observed	I-Premise
and	I-Premise
the	I-Premise
global	I-Premise
satisfaction	I-Premise
levels	I-Premise
were	I-Premise
very	I-Premise
high.	I-Premise

This	B-Claim
study	I-Claim
demonstrates	I-Claim
the	I-Claim
feasibility	I-Claim
and	I-Claim
effectiveness	I-Claim
of	I-Claim
a	I-Claim
psycho-educational	I-Claim
intervention,	I-Claim
which	I-Claim
can	I-Claim
accelerate	I-Claim
the	I-Claim
reduction	I-Claim
of	I-Claim
those	I-Claim
negative	I-Claim
affects	I-Claim
which	I-Claim
are	I-Claim
present	I-Claim
at	I-Claim
the	I-Claim
end	I-Claim
of	I-Claim
treatment.	I-Claim

It	B-Claim
represents	I-Claim
an	I-Claim
excellent	I-Claim
complement	I-Claim
or	I-Claim
an	I-Claim
alternative	I-Claim
to	I-Claim
individual	I-Claim
psycho-oncologic	I-Claim
therapeutic	I-Claim
support,	I-Claim
widely	O
proposed	O
in	O
France,	O
and	O
should	O
now	O
be	O
tested	O
in	O
groups	O
with	O
other	O
types	O
of	O
cancer	O
and	O
at	O
other	O
disease	O
phases.	O

We	O
sought	O
the	O
extent	O
to	O
which	O
arm	O
morbidity	O
could	O
be	O
reduced	O
by	O
using	O
sentinel-lymph-node-based	O
management	O
in	O
women	O
with	O
clinically	O
node-negative	O
early	O
breast	O
cancer.	O

One	O
thousand	O
eighty-eight	O
women	O
were	O
randomly	O
allocated	O
to	O
sentinel-lymph-node	O
biopsy	O
followed	O
by	O
axillary	O
clearance	O
if	O
the	O
sentinel	O
node	O
was	O
positive	O
or	O
not	O
detected	O
(SNBM)	O
or	O
routine	O
axillary	O
clearance	O
(RAC,	O
sentinel-lymph-node	O
biopsy	O
followed	O
immediately	O
by	O
axillary	O
clearance).	O

Sentinel	O
nodes	O
were	O
located	O
using	O
blue	O
dye,	O
alone	O
or	O
with	O
technetium-labeled	O
antimony	O
sulfide	O
colloid.	O

The	O
primary	O
endpoint	O
was	O
increase	O
in	O
arm	O
volume	O
from	O
baseline	O
to	O
the	O
average	O
of	O
measurements	O
at	O
6	O
and	O
12	O
months.	O

Secondary	O
endpoints	O
were	O
the	O
proportions	O
of	O
women	O
with	O
at	O
least	O
15%	O
increase	O
in	O
arm	O
volume	O
or	O
early	O
axillary	O
morbidity,	O
and	O
average	O
scores	O
for	O
arm	O
symptoms,	O
dysfunctions,	O
and	O
disabilities	O
assessed	O
at	O
6	O
and	O
12	O
months	O
by	O
patients	O
with	O
the	O
SNAC	O
Study-Specific	O
Scales	O
and	O
other	O
quality-of-life	O
instruments.	O

Sensitivity,	O
false-negative	O
rates,	O
and	O
negative	O
predictive	O
values	O
for	O
sentinel-lymph-node	O
biopsy	O
were	O
estimated	O
in	O
the	O
RAC	O
group.	O

The	B-Premise
average	I-Premise
increase	I-Premise
in	I-Premise
arm	I-Premise
volume	I-Premise
was	I-Premise
2.8%	I-Premise
in	I-Premise
the	I-Premise
SNBM	I-Premise
group	I-Premise
and	I-Premise
4.2%	I-Premise
in	I-Premise
the	I-Premise
RAC	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.002).	I-Premise

Patients	B-Premise
in	I-Premise
the	I-Premise
SNBM	I-Premise
group	I-Premise
gave	I-Premise
lower	I-Premise
ratings	I-Premise
for	I-Premise
arm	I-Premise
swelling	I-Premise
(P	I-Premise
<	I-Premise
0.001),	I-Premise
symptoms	I-Premise
(P	I-Premise
<	I-Premise
0.001),	I-Premise
and	I-Premise
dysfunctions	I-Premise
(P	I-Premise
=	I-Premise
0.02),	I-Premise
but	I-Premise
not	I-Premise
disabilities	I-Premise
(P	I-Premise
=	I-Premise
0.5).	I-Premise

Sentinel	B-Premise
nodes	I-Premise
were	I-Premise
found	I-Premise
in	I-Premise
95%	I-Premise
of	I-Premise
the	I-Premise
SNBM	I-Premise
group	I-Premise
(29%	I-Premise
positive)	I-Premise
and	I-Premise
93%	I-Premise
of	I-Premise
the	I-Premise
RAC	I-Premise
group	I-Premise
(25%	I-Premise
positive).	I-Premise

SNB	O
had	O
sensitivity	O
94.5%,	O
false-negative	O
rate	O
5.5%,	O
and	O
negative	O
predictive	O
value	O
98%.	O

SNBM	B-Claim
was	I-Claim
successfully	I-Claim
undertaken	I-Claim
in	I-Claim
a	I-Claim
wide	I-Claim
range	I-Claim
of	I-Claim
surgical	I-Claim
centers	I-Claim
and	I-Claim
caused	I-Claim
significantly	I-Claim
less	I-Claim
morbidity	I-Claim
than	I-Claim
RAC.	I-Claim

To	O
compare	O
the	O
toxicities,	O
tumor	O
control,	O
survival,	O
and	O
quality	O
of	O
life	O
of	O
nasopharyngeal	O
cancer	O
(NPC)	O
patients	O
treated	O
with	O
sequential	O
neoadjuvant	O
chemotherapy	O
followed	O
by	O
concurrent	O
cisplatin-radiotherapy	O
(CRT)	O
or	O
CRT	O
alone.	O

Previously	O
untreated	O
stage	O
III	O
to	O
IVB	O
NPC	O
were	O
randomly	O
assigned	O
to	O
(1)	O
neoadjuvant	O
docetaxel	O
75	O
mg/m(2)	O
and	O
cisplatin	O
75	O
mg/m(2)	O
every	O
3	O
weeks	O
for	O
two	O
cycles,	O
followed	O
by	O
cisplatin	O
40	O
mg/m(2)/wk	O
concurrent	O
with	O
radiotherapy,	O
or	O
(2)	O
CRT	O
alone.	O

Planned	O
accrual	O
was	O
30	O
patients	O
per	O
arm	O
to	O
detect	O
20%	O
difference	O
of	O
toxicities	O
based	O
on	O
95%	O
CIs.	O

From	O
November	O
2002	O
to	O
November	O
2004,	O
65	O
eligible	O
patients	O
were	O
randomly	O
assigned	O
to	O
neoadjuvant	O
chemotherapy	O
followed	O
by	O
CRT	O
(n	O
=	O
34)	O
or	O
CRT	O
alone	O
(n	O
=	O
31).	O

There	B-Premise
was	I-Premise
a	I-Premise
high	I-Premise
rate	I-Premise
of	I-Premise
grade	I-Premise
3/4	I-Premise
neutropenia	I-Premise
(97%)	I-Premise
but	I-Premise
not	I-Premise
neutropenic	I-Premise
fever	I-Premise
(12%)	I-Premise
during	I-Premise
neoadjuvant	I-Premise
chemotherapy.	I-Premise

No	B-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
rates	I-Premise
of	I-Premise
acute	I-Premise
toxicities	I-Premise
were	I-Premise
observed	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
arms	I-Premise
during	I-Premise
CRT.	I-Premise

Dose	B-Premise
intensities	I-Premise
of	I-Premise
concurrent	I-Premise
cisplatin,	I-Premise
late	I-Premise
RT	I-Premise
toxicities	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
scores	I-Premise
were	I-Premise
comparable	I-Premise
in	I-Premise
both	I-Premise
arms.	I-Premise

The	B-Premise
3-year	I-Premise
progression-free	I-Premise
survival	I-Premise
for	I-Premise
neoadjuvant	I-Premise
versus	I-Premise
control	I-Premise
arm	I-Premise
was	I-Premise
88.2%	I-Premise
and	I-Premise
59.5%	I-Premise
(hazard	I-Premise
ratio	I-Premise
=	I-Premise
0.49;	I-Premise
95%	I-Premise
CI,	I-Premise
0.20	I-Premise
to	I-Premise
1.19;	I-Premise
P	I-Premise
=	I-Premise
.12).	I-Premise

The	B-Premise
3-year	I-Premise
overall	I-Premise
survival	I-Premise
for	I-Premise
neoadjuvant	I-Premise
versus	I-Premise
control	I-Premise
arm	I-Premise
was	I-Premise
94.1%	I-Premise
and	I-Premise
67.7%	I-Premise
(hazard	I-Premise
ratio	I-Premise
=	I-Premise
0.24;	I-Premise
95%	I-Premise
CI,	I-Premise
0.078	I-Premise
to	I-Premise
0.73;	I-Premise
P	I-Premise
=	I-Premise
.012).	I-Premise

Neoadjuvant	B-Claim
docetaxel-cisplatin	I-Claim
followed	I-Claim
by	I-Claim
CRT	I-Claim
was	I-Claim
well	I-Claim
tolerated	I-Claim
with	I-Claim
a	I-Claim
manageable	I-Claim
toxicity	I-Claim
profile	I-Claim
that	I-Claim
allowed	I-Claim
subsequent	I-Claim
delivery	I-Claim
of	I-Claim
full-dose	I-Claim
CRT.	I-Claim

Preliminary	B-Claim
results	I-Claim
suggested	I-Claim
a	I-Claim
positive	I-Claim
impact	I-Claim
on	I-Claim
survival.	I-Claim

A	O
phase	O
III	O
study	O
to	O
definitively	O
test	O
this	O
neoadjuvant-concurrent	O
strategy	O
is	O
warranted.	O

To	O
assess	O
the	O
safety,	O
tolerability	O
and	O
efficacy	O
of	O
abatacept	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(RA)	O
who	O
had	O
failed	O
anti-tumour	O
necrosis	O
factor	O
(TNF)	O
therapy	O
and	O
were	O
switched	O
to	O
abatacept	O
directly	O
or	O
after	O
completing	O
washout.	O

In	O
this	O
international,	O
6-month,	O
open-label	O
trial,	O
patients	O
had	O
active	O
RA,	O
an	O
inadequate	O
response	O
to	O
anti-TNF	O
therapy	O
for	O
3	O
months	O
or	O
longer	O
and	O
a	O
disease	O
activity	O
score	O
in	O
28	O
joints	O
(DAS28	O
(C-reactive	O
protein;	O
CRP)	O
of	O
5.1	O
or	O
greater.	O

"Washout"	O
patients	O
discontinued	O
anti-TNF	O
therapy	O
2	O
months	O
or	O
longer	O
pre-screening;	O
"direct-switch"	O
patients	O
began	O
abatacept	O
(	O
approximately	O
10	O
mg/kg)	O
at	O
their	O
next	O
scheduled	O
anti-TNF	O
therapy	O
dose.	O

1046	O
patients	O
were	O
treated	O
(449	O
washout,	O
597	O
direct-switch;	O
baseline	O
characteristics	O
were	O
similar	O
between	O
groups).	O

At	B-Premise
6	I-Premise
months,	I-Premise
adverse	I-Premise
events	I-Premise
(AE;	I-Premise
78.0%	I-Premise
vs	I-Premise
79.2%),	I-Premise
serious	I-Premise
AE	I-Premise
(11.1%	I-Premise
vs	I-Premise
9.9%)	I-Premise
and	I-Premise
discontinuations	I-Premise
due	I-Premise
to	I-Premise
AE	I-Premise
(3.8%	I-Premise
vs	I-Premise
4.0%)	I-Premise
and	I-Premise
serious	I-Premise
AE	I-Premise
(2.0%	I-Premise
vs	I-Premise
1.3%)	I-Premise
were	I-Premise
comparable	I-Premise
in	I-Premise
washout	I-Premise
versus	I-Premise
direct-switch	I-Premise
patients.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
opportunistic	I-Premise
infections.	I-Premise

At	B-Premise
6	I-Premise
months,	I-Premise
in	I-Premise
washout	I-Premise
versus	I-Premise
direct-switch	I-Premise
patients,	I-Premise
similar	I-Premise
clinically	I-Premise
meaningful	I-Premise
improvements	I-Premise
were	I-Premise
seen	I-Premise
in	I-Premise
DAS28	I-Premise
(CRP)	I-Premise
(>	I-Premise
or	I-Premise
=1.2	I-Premise
unit	I-Premise
improvement,	I-Premise
59.5%	I-Premise
vs	I-Premise
53.6%,	I-Premise
respectively;	I-Premise
low	I-Premise
disease	I-Premise
activity	I-Premise
state,	I-Premise
22.5%	I-Premise
vs	I-Premise
22.3%;	I-Premise
DAS28-defined	I-Premise
remission,	I-Premise
12.0%	I-Premise
vs	I-Premise
13.7%),	I-Premise
physical	I-Premise
function	I-Premise
(health	I-Premise
assessment	I-Premise
questionnaire	I-Premise
disability	I-Premise
index	I-Premise
>	I-Premise
or	I-Premise
=0.22	I-Premise
improvement;	I-Premise
46.3%	I-Premise
vs	I-Premise
47.1%)	I-Premise
and	I-Premise
health-related	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(mean	I-Premise
change	I-Premise
in	I-Premise
short-form	I-Premise
36	I-Premise
scores:	I-Premise
physical	I-Premise
component	I-Premise
summary,	I-Premise
5.5	I-Premise
vs	I-Premise
6.1;	I-Premise
mental	I-Premise
component	I-Premise
summary,	I-Premise
4.8	I-Premise
vs	I-Premise
5.4).	I-Premise

Abatacept	B-Claim
demonstrated	I-Claim
acceptable	I-Claim
safety	I-Claim
and	I-Claim
tolerability	I-Claim
and	I-Claim
clinically	I-Claim
meaningful	I-Claim
efficacy	I-Claim
over	I-Claim
6	I-Claim
months	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
inadequate	I-Claim
response	I-Claim
to	I-Claim
anti-TNF	I-Claim
therapy.	I-Claim

Results	B-Claim
were	I-Claim
comparable	I-Claim
with	I-Claim
or	I-Claim
without	I-Claim
a	I-Claim
washout,	I-Claim
supporting	I-Claim
direct	I-Claim
switching	I-Claim
from	I-Claim
anti-TNF	I-Claim
therapy	I-Claim
to	I-Claim
abatacept	I-Claim
as	I-Claim
an	I-Claim
option	I-Claim
in	I-Claim
clinical	I-Claim
practice.	I-Claim

To	O
assess	O
the	O
effects	O
of	O
an	O
expressive	O
writing	O
(EW)	O
intervention	O
on	O
perceptions	O
of	O
emotional	O
support	O
in	O
women	O
completing	O
treatment	O
for	O
early	O
stage	O
breast	O
cancer.	O

Women	O
were	O
recruited	O
to	O
the	O
study	O
during	O
their	O
final	O
week	O
of	O
treatment.	O

Of	O
260	O
eligible	O
patients,	O
104	O
(40%)	O
agreed	O
to	O
participate,	O
and	O
93	O
were	O
randomised.	O

Women	O
in	O
the	O
writing	O
group	O
wrote	O
for	O
20	O
min	O
on	O
four	O
consecutive	O
days.	O

The	O
control	O
group	O
received	O
normal	O
care.	O

Women's	O
perceptions	O
of	O
emotional	O
support,	O
quality	O
of	O
life	O
(QOL),	O
mood,	O
and	O
healthcare	O
utilisation	O
were	O
assessed	O
at	O
baseline,	O
1	O
month,	O
3	O
months	O
and	O
6	O
months.	O

Interviews	O
were	O
conducted	O
to	O
explore	O
women's	O
experience	O
of	O
writing.	O

Eighty	O
participants	O
completed	O
all	O
follow-ups.	O

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
effect	I-Premise
of	I-Premise
group	I-Premise
on	I-Premise
women's	I-Premise
perceptions	I-Premise
of	I-Premise
social	I-Premise
support	I-Premise
with	I-Premise
those	I-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
group	I-Premise
being	I-Premise
more	I-Premise
satisfied	I-Premise
with	I-Premise
the	I-Premise
emotional	I-Premise
support	I-Premise
they	I-Premise
received	I-Premise
(p<0.05).	I-Premise

Satisfaction	B-Premise
with	I-Premise
emotional	I-Premise
support	I-Premise
was	I-Premise
negatively	I-Premise
correlated	I-Premise
with	I-Premise
depression/dejection	I-Premise
(p<0.05)	I-Premise
and	I-Premise
anger/hostility	I-Premise
(p<0.05)	I-Premise
and	I-Premise
positively	I-Premise
correlated	I-Premise
with	I-Premise
social	I-Premise
and	I-Premise
family	I-Premise
well-being	I-Premise
(p<0.001)	I-Premise
6	I-Premise
months	I-Premise
post	I-Premise
intervention.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
effects	I-Premise
of	I-Premise
the	I-Premise
intervention	I-Premise
on	I-Premise
mood,	I-Premise
QOL	I-Premise
or	I-Premise
healthcare	I-Premise
utilisation.	I-Premise

Most	B-Premise
participants	I-Premise
found	I-Premise
writing	I-Premise
valuable	I-Premise
and	I-Premise
did	I-Premise
not	I-Premise
report	I-Premise
any	I-Premise
long-term	I-Premise
negative	I-Premise
effects.	I-Premise

EW	B-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
a	I-Claim
higher	I-Claim
level	I-Claim
of	I-Claim
satisfaction	I-Claim
with	I-Claim
emotional	I-Claim
support	I-Claim
compared	I-Claim
with	I-Claim
controls.	I-Claim

Given	O
the	O
existing	O
evidence	O
supporting	O
the	O
importance	O
of	O
social	O
support	O
in	O
adjustment	O
to	O
breast	O
cancer,	O
it	B-Claim
seems	I-Claim
feasible	I-Claim
to	I-Claim
suggest	I-Claim
that	I-Claim
EW	I-Claim
may	I-Claim
be	I-Claim
a	I-Claim
cost	I-Claim
effective	I-Claim
accessible	I-Claim
treatment	I-Claim
that	I-Claim
could	I-Claim
be	I-Claim
incorporated	I-Claim
into	I-Claim
the	I-Claim
ongoing	I-Claim
care	I-Claim
of	I-Claim
women.	I-Claim

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
compare	O
the	O
treatment	O
and	O
retention	O
effects	O
between	O
standard	O
decongestive	O
lymphatic	O
therapy	O
(DLT)	O
combined	O
with	O
pneumatic	O
compression	O
(PC)	O
and	O
modified	O
DLT,	O
in	O
which	O
the	O
use	O
of	O
a	O
short-stretch	O
bandage	O
is	O
replaced	O
with	O
the	O
use	O
of	O
Kinesio	O
tape	O
(K-tape)	O
combined	O
with	O
PC.	O

Forty-one	O
patients	O
with	O
unilateral	O
breast-cancer-related	O
lymphedema	O
for	O
at	O
least	O
3	O
months	O
were	O
randomly	O
grouped	O
into	O
the	O
DLT	O
group	O
(bandage	O
group,	O
N	O
=	O
21)	O
or	O
the	O
modified	O
DLT	O
group	O
(K-tape	O
group,	O
N	O
=	O
20).	O

Skin	O
care,	O
30-min	O
manual	O
lymphatic	O
drainage,	O
1-h	O
pneumatic	O
compression	O
therapy,	O
application	O
of	O
a	O
short-stretch	O
bandage	O
or	O
K-tape	O
for	O
each	O
group,	O
and	O
a	O
20-min	O
physical	O
therapy	O
exercise	O
were	O
given	O
during	O
every	O
treatment	O
session.	O

Patient	O
evaluation	O
items	O
included	O
physical	O
therapy	O
assessment,	O
limb	O
size,	O
water	O
composition	O
of	O
the	O
upper	O
extremity,	O
lymphedema-related	O
symptoms,	O
quality	O
of	O
life,	O
and	O
patients'	O
acceptance	O
to	O
the	O
bandage	O
or	O
tape.	O

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
groups	I-Premise
in	I-Premise
all	I-Premise
outcome	I-Premise
variables	I-Premise
(P	I-Premise
>	I-Premise
0.05)	I-Premise
through	I-Premise
the	I-Premise
whole	I-Premise
study	I-Premise
period.	I-Premise

Excess	B-Premise
limb	I-Premise
size	I-Premise
(circumference	I-Premise
and	I-Premise
water	I-Premise
displacement)	I-Premise
and	I-Premise
excess	I-Premise
water	I-Premise
composition	I-Premise
were	I-Premise
reduced	I-Premise
significantly	I-Premise
in	I-Premise
the	I-Premise
bandage	I-Premise
group;	I-Premise
excess	B-Premise
circumference	I-Premise
and	I-Premise
excess	I-Premise
water	I-Premise
composition	I-Premise
were	I-Premise
reduced	I-Premise
significantly	I-Premise
in	I-Premise
the	I-Premise
tape	I-Premise
group.	I-Premise

The	B-Premise
acceptance	I-Premise
of	I-Premise
K-tape	I-Premise
was	I-Premise
better	I-Premise
than	I-Premise
the	I-Premise
bandage,	I-Premise
and	I-Premise
benefits	I-Premise
included	I-Premise
longer	I-Premise
wearing	I-Premise
time,	I-Premise
less	I-Premise
difficulty	I-Premise
in	I-Premise
usage,	I-Premise
and	I-Premise
increased	I-Premise
comfort	I-Premise
and	I-Premise
convenience	I-Premise
(P	I-Premise
<	I-Premise
0.05).	I-Premise

The	B-Claim
study	I-Claim
results	I-Claim
suggest	I-Claim
that	I-Claim
K-tape	I-Claim
could	I-Claim
replace	I-Claim
the	I-Claim
bandage	I-Claim
in	I-Claim
DLT,	I-Claim
and	I-Claim
it	I-Claim
could	I-Claim
be	I-Claim
an	I-Claim
alternative	I-Claim
choice	I-Claim
for	I-Claim
the	I-Claim
breast-cancer-related	I-Claim
lymphedema	I-Claim
patient	I-Claim
with	I-Claim
poor	I-Claim
short-stretch	I-Claim
bandage	I-Claim
compliance	I-Claim
after	I-Claim
1-month	I-Claim
intervention.	I-Claim

If	O
the	O
intervention	O
period	O
was	O
prolonged,	O
we	O
might	O
get	O
different	O
conclusion.	O

Moreover,	O
these	B-Claim
two	I-Claim
treatment	I-Claim
protocols	I-Claim
are	I-Claim
inefficient	I-Claim
and	I-Claim
cost	I-Claim
time	I-Claim
in	I-Claim
application.	I-Claim

More	B-Claim
efficient	I-Claim
treatment	I-Claim
protocol	I-Claim
is	I-Claim
needed	I-Claim
for	I-Claim
clinical	I-Claim
practice.	I-Claim

National	O
Cancer	O
Institute	O
of	O
Canada	O
Clinical	O
Trials	O
Group	O
CO.17	O
demonstrated	O
the	O
antiepidermal	O
growth	O
factor	O
receptor	O
(anti-EGFR)	O
monoclonal	O
antibody	O
cetuximab	O
improves	O
overall	O
and	O
progression-free	O
survival	O
in	O
patients	O
with	O
advanced,	O
chemotherapy-refractory	O
colorectal	O
cancer	O
(CRC),	O
particularly	O
in	O
patients	O
with	O
wild-type	O
KRAS	O
tumors.	O

This	O
article	O
reports	O
the	O
health-related	O
quality-of-life	O
(HRQL)	O
outcomes	O
from	O
CO.17.	O

Patients	O
(N	O
=	O
572)	O
with	O
pretreated	O
EGFR-detectable	O
advanced	O
CRC	O
were	O
randomly	O
assigned	O
to	O
cetuximab	O
and	O
best	O
supportive	O
care	O
(BSC)	O
or	O
to	O
BSC	O
alone.	O

HRQL	O
primary	O
end	O
points	O
assessed	O
by	O
the	O
EORTC	O
QLQ-C30	O
were	O
physical	O
function	O
(PF)	O
and	O
global	O
health	O
status	O
(GHS);	O
mean	O
changes	O
from	O
baseline	O
to	O
8	O
and	O
16	O
weeks	O
were	O
assessed.	O

Post	O
hoc	O
analysis	O
by	O
KRAS	O
mutation	O
status	O
was	O
performed.	O

Questionnaire	O
compliance	O
was	O
94%	O
at	O
baseline,	O
but	O
it	O
declined	O
differentially	O
(67%	O
v	O
47%	O
for	O
cetuximab	O
v	O
BSC	O
at	O
16	O
weeks).	O

PF	B-Premise
change	I-Premise
scores	I-Premise
were	I-Premise
-3.9	I-Premise
for	I-Premise
cetuximab	I-Premise
and	I-Premise
-8.6	I-Premise
for	I-Premise
BSC	I-Premise
(P	I-Premise
=	I-Premise
.046)	I-Premise
at	I-Premise
8	I-Premise
weeks	I-Premise
and	I-Premise
were	I-Premise
-5.9	I-Premise
and	I-Premise
-12.5	I-Premise
for	I-Premise
cetuximab	I-Premise
and	I-Premise
BSC,	I-Premise
respectively,	I-Premise
(P	I-Premise
=	I-Premise
.027)	I-Premise
at	I-Premise
16	I-Premise
weeks.	I-Premise

GHS	B-Premise
change	I-Premise
scores	I-Premise
were	I-Premise
-0.5	I-Premise
and	I-Premise
-7.1	I-Premise
(P	I-Premise
=	I-Premise
.008)	I-Premise
at	I-Premise
8	I-Premise
weeks	I-Premise
and	I-Premise
were	I-Premise
-3.6	I-Premise
and	I-Premise
-15.2	I-Premise
(P	I-Premise
=	I-Premise
.008)	I-Premise
at	I-Premise
16	I-Premise
weeks	I-Premise
for	I-Premise
cetuximab	I-Premise
and	I-Premise
BSC,	I-Premise
respectively.	I-Premise

In	B-Premise
patients	I-Premise
who	I-Premise
had	I-Premise
tumors	I-Premise
with	I-Premise
wild-type	I-Premise
KRAS	I-Premise
status,	I-Premise
cetuximab	I-Premise
resulted	I-Premise
in	I-Premise
less	I-Premise
PF	I-Premise
deterioration	I-Premise
at	I-Premise
8	I-Premise
weeks	I-Premise
(-0.7	I-Premise
v	I-Premise
-7.2;	I-Premise
P	I-Premise
=	I-Premise
.11)	I-Premise
and	I-Premise
16	I-Premise
weeks	I-Premise
(-3.4	I-Premise
v	I-Premise
-13.8;	I-Premise
P	I-Premise
=	I-Premise
.008)	I-Premise
compared	I-Premise
with	I-Premise
BSC.	I-Premise

Patients	B-Premise
with	I-Premise
wild-type	I-Premise
status	I-Premise
who	I-Premise
received	I-Premise
cetuximab	I-Premise
experienced	I-Premise
improved	I-Premise
GHS	I-Premise
at	I-Premise
8	I-Premise
weeks,	I-Premise
whereas	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
BSC	I-Premise
alone	I-Premise
deteriorated	I-Premise
(3.2	I-Premise
v	I-Premise
-7.7;	I-Premise
P	I-Premise
=	I-Premise
.002).	I-Premise

Cetuximab	B-Premise
preserved	I-Premise
GHS	I-Premise
at	I-Premise
16	I-Premise
weeks	I-Premise
(-0.2	I-Premise
v	I-Premise
-18.1;	I-Premise
P	I-Premise
<	I-Premise
.001).	I-Premise

No	B-Premise
significant	I-Premise
differences	I-Premise
were	I-Premise
noted	I-Premise
between	I-Premise
study	I-Premise
arms	I-Premise
for	I-Premise
patients	I-Premise
with	I-Premise
mutated	I-Premise
KRAS	I-Premise
tumors.	I-Premise

Cetuximab	B-Claim
offers	I-Claim
important	I-Claim
HRQL	I-Claim
and	I-Claim
survival	I-Claim
benefits	I-Claim
for	I-Claim
pretreated	I-Claim
patients	I-Claim
with	I-Claim
advanced,	I-Claim
wild-type	I-Claim
KRAS	I-Claim
CRC.	I-Claim

Androgen	O
treatment	O
for	O
prostate	O
cancer	O
can	O
adversely	O
affect	O
functional	O
domains	O
of	O
quality	O
of	O
life.	O

We	O
aimed	O
to	O
assess	O
quality	O
of	O
life	O
in	O
men	O
with	O
locally	O
advanced	O
prostate	O
cancer	O
in	O
an	O
open-label	O
phase	O
III	O
randomised	O
comparison	O
between	O
lifelong	O
endocrine	O
treatment	O
with	O
and	O
without	O
radiotherapy.	O

We	O
obtained	O
quality-of-life	O
information	O
from	O
872	O
(99%)	O
of	O
875	O
eligible	O
men	O
with	O
locally	O
advanced	O
prostate	O
cancer	O
(T3;	O
78%)	O
who	O
were	O
randomly	O
assigned,	O
between	O
1996	O
and	O
2002,	O
to	O
3	O
months	O
of	O
total	O
androgen	O
blockade	O
followed	O
by	O
continuous	O
endocrine	O
treatment	O
(439	O
patients)	O
or	O
the	O
same	O
hormonal	O
treatment	O
with	O
radiotherapy	O
3	O
months	O
after	O
randomisation	O
(436	O
patients).	O

Prospective	O
outcomes	O
included	O
patient-reported	O
symptoms	O
and	O
quality	O
of	O
life	O
assessed	O
with	O
questionnaires	O
from	O
baseline	O
to	O
4	O
years	O
after	O
randomisation.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat.	O

This	O
study	O
is	O
registered	O
as	O
an	O
international	O
standard	O
randomised	O
controlled	O
trial,	O
number	O
ISRCTN01534787.	O

438	O
of	O
439	O
men	O
assigned	O
endocrine	O
treatment	O
and	O
434	O
of	O
436	O
assigned	O
endocrine	O
plus	O
radiotherapy	O
completed	O
at	O
least	O
one	O
questionnaire.	O

Missing	O
data	O
at	O
baseline	O
and	O
during	O
follow-up	O
was	O
equally	O
distributed	O
between	O
groups.	O

At	B-Premise
4	I-Premise
years,	I-Premise
64	I-Premise
(18%)	I-Premise
of	I-Premise
353	I-Premise
patients	I-Premise
on	I-Premise
combined	I-Premise
therapy	I-Premise
and	I-Premise
39	I-Premise
(12%)	I-Premise
of	I-Premise
337	I-Premise
on	I-Premise
endocrine-alone	I-Premise
therapy	I-Premise
had	I-Premise
moderate	I-Premise
to	I-Premise
severe	I-Premise
urinary	I-Premise
bother	I-Premise
(p=0.005),	I-Premise
and	I-Premise
16	I-Premise
(4%)	I-Premise
of	I-Premise
355	I-Premise
on	I-Premise
combined	I-Premise
therapy	I-Premise
and	I-Premise
five	I-Premise
(2%)	I-Premise
of	I-Premise
338	I-Premise
on	I-Premise
endocrine	I-Premise
treatment	I-Premise
alone	I-Premise
had	I-Premise
pain	I-Premise
while	I-Premise
urinating	I-Premise
(p=0.024).	I-Premise

37	B-Premise
(11%)	I-Premise
of	I-Premise
350	I-Premise
in	I-Premise
the	I-Premise
combined	I-Premise
group	I-Premise
and	I-Premise
23	I-Premise
(7%)	I-Premise
of	I-Premise
35	I-Premise
in	I-Premise
the	I-Premise
endocrine-only	I-Premise
group	I-Premise
had	I-Premise
overall	I-Premise
bother	I-Premise
from	I-Premise
all	I-Premise
bowel	I-Premise
symptoms	I-Premise
(p=0.022).	I-Premise

281	B-Premise
(85%)	I-Premise
of	I-Premise
332	I-Premise
in	I-Premise
the	I-Premise
combined-treatment	I-Premise
group	I-Premise
and	I-Premise
227	I-Premise
(72%)	I-Premise
of	I-Premise
313	I-Premise
in	I-Premise
the	I-Premise
endocrine-only	I-Premise
group	I-Premise
had	I-Premise
erectile	I-Premise
dysfunction	I-Premise
(p=0.0002).	I-Premise

Quality	B-Premise
of	I-Premise
life	I-Premise
at	I-Premise
4	I-Premise
years	I-Premise
was	I-Premise
similar,	I-Premise
with	I-Premise
the	I-Premise
exception	I-Premise
of	I-Premise
decreased	I-Premise
social	I-Premise
function	I-Premise
in	I-Premise
patients	I-Premise
receiving	I-Premise
endocrine	I-Premise
treatment	I-Premise
plus	I-Premise
radiotherapy.	I-Premise

Although	B-Claim
addition	I-Claim
of	I-Claim
radiotherapy	I-Claim
to	I-Claim
endocrine	I-Claim
treatment	I-Claim
significantly	I-Claim
increased	I-Claim
some	I-Claim
treatment-related	I-Claim
symptoms,	I-Claim
none	I-Claim
were	I-Claim
serious.	I-Claim

Given	O
the	O
substantial	O
survival	O
benefit	O
of	O
combined	O
treatment,	O
the	B-Claim
increase	I-Claim
of	I-Claim
symptoms	I-Claim
seems	I-Claim
acceptable	I-Claim
and	I-Claim
has	I-Claim
little	I-Claim
extra	I-Claim
effect	I-Claim
on	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
after	I-Claim
4	I-Claim
years	I-Claim
compared	I-Claim
with	I-Claim
endocrine	I-Claim
treatment	I-Claim
alone.	I-Claim

To	O
compare	O
survival	O
in	O
patients	O
with	O
recurrent	O
or	O
metastatic	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
(SCCHN)	O
treated	O
with	O
gefitinib	O
250	O
or	O
500	O
mg/day	O
or	O
standard	O
methotrexate.	O

Four	O
hundred	O
eighty-six	O
patients	O
with	O
recurrent	O
SCCHN	O
were	O
randomly	O
assigned	O
to	O
oral	O
gefitinib	O
250	O
mg/day,	O
gefitinib	O
500	O
mg/day,	O
or	O
methotrexate	O
40	O
mg/m(2)	O
intravenously	O
weekly.	O

Primary	O
end	O
point	O
was	O
overall	O
survival,	O
secondary	O
end	O
points	O
were	O
objective	O
response	O
rate	O
(ORR),	O
safety,	O
symptom	O
improvement,	O
and	O
quality	O
of	O
life	O
(QOL).	O

Exploratory	O
end	O
points	O
included	O
association	O
of	O
efficacy	O
with	O
epidermal	O
growth	O
factor	O
receptor	O
gene	O
copy	O
number	O
and	O
other	O
biomarkers.	O

Neither	B-Premise
gefitinib	I-Premise
250	I-Premise
nor	I-Premise
500	I-Premise
mg/day	I-Premise
improved	I-Premise
overall	I-Premise
survival	I-Premise
compared	I-Premise
with	I-Premise
methotrexate	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR],	I-Premise
1.22;	I-Premise
95%	I-Premise
CI,	I-Premise
0.95	I-Premise
to	I-Premise
1.57;	I-Premise
P	I-Premise
=	I-Premise
.12;	I-Premise
and	I-Premise
HR,	I-Premise
1.12;	I-Premise
95%	I-Premise
CI,	I-Premise
0.87	I-Premise
to	I-Premise
1.43;	I-Premise
P	I-Premise
=	I-Premise
.39,	I-Premise
respectively).	I-Premise

In	B-Premise
the	I-Premise
gefitinib	I-Premise
250	I-Premise
mg/day,	I-Premise
500	I-Premise
mg/day,	I-Premise
and	I-Premise
methotrexate	I-Premise
groups,	I-Premise
respectively,	I-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
5.6,	I-Premise
6.0,	I-Premise
and	I-Premise
6.7	I-Premise
months;	I-Premise
ORRs	I-Premise
(Response	I-Premise
Evaluation	I-Premise
Criteria	I-Premise
in	I-Premise
Solid	I-Premise
Tumors)	I-Premise
were	I-Premise
2.7%,	I-Premise
7.6%	I-Premise
and	I-Premise
3.9%,	I-Premise
with	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
either	I-Premise
gefitinib	I-Premise
arm	I-Premise
and	I-Premise
methotrexate.	I-Premise

No	B-Premise
unexpected	I-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
observed,	I-Premise
except	B-Premise
for	I-Premise
tumor	I-Premise
hemorrhage-type	I-Premise
events	I-Premise
with	I-Premise
gefitinib	I-Premise
(8.9%,	I-Premise
gefitinib	I-Premise
250	I-Premise
mg/day;	I-Premise
11.4%,	I-Premise
gefitinib	I-Premise
500	I-Premise
mg/day;	I-Premise
1.9%,	I-Premise
methotrexate).	I-Premise

QOL	B-Premise
improvement	I-Premise
rates	I-Premise
(Functional	I-Premise
Assessment	I-Premise
of	I-Premise
Cancer	I-Premise
Therapy-Head	I-Premise
&amp;	I-Premise
Neck	I-Premise
total	I-Premise
score)	I-Premise
were	I-Premise
13.4%,	I-Premise
18.0%,	I-Premise
and	I-Premise
6.0%	I-Premise
for	I-Premise
gefitinib	I-Premise
250	I-Premise
mg/day,	I-Premise
500	I-Premise
mg/day,	I-Premise
and	I-Premise
methotrexate,	I-Premise
respectively.	I-Premise

In	B-Claim
patients	I-Claim
with	I-Claim
recurrent	I-Claim
or	I-Claim
metastatic	I-Claim
SCCHN,	I-Claim
while	I-Claim
responses	I-Claim
with	I-Claim
gefitinib	I-Claim
were	I-Claim
seen,	I-Claim
neither	I-Claim
gefitinib	I-Claim
250	I-Claim
nor	I-Claim
500	I-Claim
mg/day	I-Claim
improved	I-Claim
overall	I-Claim
survival	I-Claim
compared	I-Claim
with	I-Claim
methotrexate.	I-Claim

With	B-Claim
the	I-Claim
exception	I-Claim
of	I-Claim
tumor	I-Claim
hemorrhage-type	I-Claim
events	I-Claim
with	I-Claim
gefitinib,	I-Claim
the	I-Claim
adverse	I-Claim
event	I-Claim
profiles	I-Claim
were	I-Claim
generally	I-Claim
consistent	I-Claim
with	I-Claim
those	I-Claim
previously	I-Claim
observed.	I-Claim

The	O
European	O
Study	O
Group	O
for	O
Pancreatic	O
Cancer	O
(ESPAC-1)	O
study	O
is	O
the	O
largest	O
study	O
of	O
adjuvant	O
treatment	O
for	O
pancreatic	O
ductal	O
adenocarcinoma	O
to	O
date	O
and	O
confirmed	O
a	O
survival	O
advantage	O
for	O
adjuvant	O
chemotherapy	O
but	O
not	O
for	O
chemoradiation.	O

The	O
importance	O
of	O
parallel	O
evaluation	O
of	O
survival	O
and	O
quality	O
of	O
life	O
(QoL)	O
has	O
been	O
recognized	O
as	O
fundamental	O
and	O
the	O
aim	O
was	O
to	O
assess	O
QoL	O
and	O
quality	O
adjusted	O
survival.	O

A	O
longitudinal	O
QoL	O
study	O
on	O
a	O
subset	O
of	O
ESPAC-1	O
patients	O
who	O
prospectively	O
completed	O
the	O
EORTC	O
QLQ	O
C-30	O
questionnaire	O
during	O
treatment	O
and	O
follow-up.	O

An	O
integrated	O
quality-survival	O
product	O
method	O
was	O
used	O
to	O
adjust	O
any	O
treatment	O
effect	O
on	O
survival	O
by	O
a	O
function	O
of	O
measured	O
QoL,	O
calculated	O
over	O
a	O
restricted	O
24-month-period	O
(QALM-24).	O

Three	O
hundred	O
and	O
sixteen	O
patients	O
completed	O
1,201	O
questionnaires.	O

There	O
were	O
no	O
differences	O
between	O
treatment	O
groups	O
in	O
dimension	O
scores	O
at	O
baseline	O
(randomization).	O

For	B-Premise
the	I-Premise
chemotherapy	I-Premise
group,	I-Premise
the	I-Premise
mean	I-Premise
Quality	I-Premise
Adjusted	I-Premise
Life	I-Premise
Months	I-Premise
over	I-Premise
24	I-Premise
months	I-Premise
(QALM-24)	I-Premise
was	I-Premise
9.6	I-Premise
(95%	I-Premise
CI:	I-Premise
8.7,	I-Premise
11.2)	I-Premise
months	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
mean	I-Premise
QALM-24	I-Premise
of	I-Premise
8.6	I-Premise
(95%	I-Premise
CI:	I-Premise
7.6,	I-Premise
10.5)	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
no	I-Premise
chemotherapy	I-Premise
group.	I-Premise

For	B-Premise
the	I-Premise
chemoradiation	I-Premise
group,	I-Premise
the	I-Premise
mean	I-Premise
QALM-24	I-Premise
was	I-Premise
7.1	I-Premise
(95%	I-Premise
CI:	I-Premise
6.0,	I-Premise
9.0)	I-Premise
months	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
mean	I-Premise
QALM-24	I-Premise
of	I-Premise
8.1	I-Premise
(95%	I-Premise
CI:	I-Premise
7.0,	I-Premise
10.0)	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
no	I-Premise
chemoradiation	I-Premise
group.	I-Premise

The	B-Claim
previously	I-Claim
reported	I-Claim
survival	I-Claim
advantage	I-Claim
supporting	I-Claim
the	I-Claim
use	I-Claim
of	I-Claim
adjuvant	I-Claim
chemotherapy	I-Claim
is	I-Claim
maintained	I-Claim
when	I-Claim
adjusted	I-Claim
using	I-Claim
quality	I-Claim
adjusted	I-Claim
survival	I-Claim
methodology.	I-Claim

Chemotherapy	B-Claim
provided	I-Claim
on	I-Claim
average	I-Claim
an	I-Claim
additional	I-Claim
1.0	I-Claim
quality-adjusted	I-Claim
life	I-Claim
months	I-Claim
within	I-Claim
a	I-Claim
restricted	I-Claim
2-year	I-Claim
time	I-Claim
period	I-Claim
from	I-Claim
the	I-Claim
time	I-Claim
of	I-Claim
resection.	I-Claim

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
compare	O
clinical	O
outcomes	O
and	O
quality	O
of	O
life	O
in	O
patients	O
undergoing	O
surgery	O
for	O
pilonidal	O
disease	O
with	O
unroofing	O
and	O
marsupialization	O
(UM)	O
or	O
rhomboid	O
excision	O
and	O
Limberg	O
flap	O
(RELP)	O
procedures.	O

One	O
hundred	O
forty	O
consecutive	O
patients	O
with	O
pilonidal	O
sinus	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
UM	O
or	O
RELP	O
procedures.	O

A	O
specifically	O
designed	O
questionnaire	O
was	O
administered	O
at	O
three	O
months	O
to	O
assess	O
time	O
from	O
the	O
operation	O
until	O
the	O
patient	O
was	O
able	O
to	O
walk,	O
return	O
to	O
daily	O
activities,	O
or	O
sit	O
without	O
pain,	O
time	O
to	O
return	O
to	O
work	O
or	O
school,	O
and	O
time	O
to	O
healing.	O

Postoperative	O
pain	O
was	O
assessed	O
with	O
a	O
visual	O
analog	O
scale	O
and	O
the	O
McGill	O
Pain	O
Questionnaire.	O

Patients'	O
quality	O
of	O
life	O
was	O
evaluated	O
with	O
the	O
Cardiff	O
Wound	O
Impact	O
Schedule	O
(CWIS).	O

Questionnaires	O
were	O
administered	O
by	O
a	O
clinician	O
blinded	O
to	O
treatment.	O

Compared	B-Premise
with	I-Premise
RELP,	I-Premise
patients	I-Premise
receiving	I-Premise
UM	I-Premise
had	I-Premise
significantly	I-Premise
shorter	I-Premise
duration	I-Premise
of	I-Premise
operation	I-Premise
and	I-Premise
hospital	I-Premise
stay,	I-Premise
shorter	I-Premise
time	I-Premise
periods	I-Premise
to	I-Premise
walk,	I-Premise
return	I-Premise
to	I-Premise
daily	I-Premise
activities,	I-Premise
or	I-Premise
sit	I-Premise
without	I-Premise
pain	I-Premise
and	I-Premise
to	I-Premise
return	I-Premise
to	I-Premise
work	I-Premise
or	I-Premise
school,	I-Premise
and	I-Premise
fewer	I-Premise
complications.	I-Premise

Time	B-Premise
to	I-Premise
final	I-Premise
healing	I-Premise
was	I-Premise
significantly	I-Premise
shorter	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
scores	I-Premise
on	I-Premise
the	I-Premise
CWIS	I-Premise
were	I-Premise
higher	I-Premise
in	I-Premise
patients	I-Premise
receiving	I-Premise
RELP	I-Premise
than	I-Premise
in	I-Premise
those	I-Premise
receiving	I-Premise
UM.	I-Premise

Patients	B-Premise
with	I-Premise
UM	I-Premise
had	I-Premise
lower	I-Premise
levels	I-Premise
of	I-Premise
pain	I-Premise
one	I-Premise
week	I-Premise
after	I-Premise
surgery.	I-Premise

The	B-Claim
unroofing	I-Claim
and	I-Claim
marsupialization	I-Claim
procedure	I-Claim
provides	I-Claim
more	I-Claim
clinical	I-Claim
benefits	I-Claim
in	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
pilonidal	I-Claim
disease	I-Claim
than	I-Claim
rhomboid	I-Claim
excision	I-Claim
and	I-Claim
Limberg	I-Claim
flap	I-Claim
and	I-Claim
should	I-Claim
be	I-Claim
considered	I-Claim
the	I-Claim
procedure	I-Claim
of	I-Claim
choice.	I-Claim

However,	B-Claim
it	I-Claim
may	I-Claim
be	I-Claim
associated	I-Claim
with	I-Claim
more	I-Claim
inconvenience	I-Claim
in	I-Claim
wound	I-Claim
care	I-Claim
and	I-Claim
longer	I-Claim
healing	I-Claim
time	I-Claim
than	I-Claim
rhomboid	I-Claim
excision	I-Claim
and	I-Claim
Lindberg	I-Claim
flap.	I-Claim

We	O
evaluated	O
the	O
role	O
of	O
glutathione-related	O
genotypes	O
on	O
overall	O
survival,	O
time	O
to	O
progression,	O
adverse	O
events,	O
and	O
quality	O
of	O
life	O
(QOL)	O
in	O
stage	O
IIIB/IV	O
non-small	O
cell	O
lung	O
cancer	O
patients	O
who	O
were	O
stable	O
or	O
responding	O
from	O
initial	O
treatment	O
with	O
platinum-based	O
chemotherapy	O
and	O
subsequently	O
randomized	O
to	O
receive	O
daily	O
oral	O
carboxyaminoimidazole	O
or	O
a	O
placebo.	O

Of	O
the	O
186	O
total	O
patients,	O
113	O
had	O
initial	O
treatment	O
with	O
platinum	O
therapy	O
and	O
DNA	O
samples	O
of	O
whom	O
46	O
also	O
had	O
QOL	O
data.	O

These	O
samples	O
were	O
analyzed	O
using	O
six	O
polymorphic	O
DNA	O
markers	O
that	O
encode	O
five	O
important	O
enzymes	O
in	O
the	O
glutathione	O
metabolic	O
pathway.	O

Patient	O
QOL	O
was	O
assessed	O
using	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Lung	O
and	O
the	O
UNISCALE	O
QOL	O
questionnaires.	O

A	O
clinically	O
significant	O
decline	O
in	O
QOL	O
was	O
defined	O
as	O
a	O
10%	O
decrease	O
from	O
baseline	O
to	O
week-8.	O

Multivariate	O
analyses	O
were	O
used	O
to	O
evaluate	O
the	O
association	O
of	O
the	O
genotypes	O
on	O
the	O
four	O
endpoints.	O

Patients	B-Premise
carrying	I-Premise
a	I-Premise
GCLC	I-Premise
77	I-Premise
genotype	I-Premise
had	I-Premise
a	I-Premise
worse	I-Premise
overall	I-Premise
survival	I-Premise
(hazard	I-Premise
ratio	I-Premise
(HR)	I-Premise
=	I-Premise
1.5,	I-Premise
p	I-Premise
=	I-Premise
0.05).	I-Premise

Patients	B-Premise
carrying	I-Premise
the	I-Premise
GPX1-CC	I-Premise
genotype	I-Premise
had	I-Premise
a	I-Premise
clinically	I-Premise
significant	I-Premise
decline	I-Premise
in	I-Premise
the	I-Premise
UNISCALE	I-Premise
(odds	I-Premise
ratio	I-Premise
(OR):	I-Premise
7.5;	I-Premise
p	I-Premise
=	I-Premise
0.04),	I-Premise
total	I-Premise
Functional	I-Premise
Assessment	I-Premise
of	I-Premise
Cancer	I-Premise
Therapy-Lung	I-Premise
score	I-Premise
(OR:	I-Premise
11.0;	I-Premise
p	I-Premise
=	I-Premise
0.04),	I-Premise
physical	I-Premise
(OR:	I-Premise
7.1;	I-Premise
p	I-Premise
=	I-Premise
0.03),	I-Premise
functional	I-Premise
(OR:	I-Premise
5.2;	I-Premise
p	I-Premise
=	I-Premise
0.04),	I-Premise
and	I-Premise
emotional	I-Premise
well-being	I-Premise
constructs	I-Premise
(OR:	I-Premise
23.8;	I-Premise
p	I-Premise
=	I-Premise
0.01).	I-Premise

Genotypes	B-Claim
of	I-Claim
glutathione-related	I-Claim
enzymes,	I-Claim
especially	I-Claim
GCLC,	I-Claim
may	I-Claim
be	I-Claim
used	I-Claim
as	I-Claim
host	I-Claim
factors	I-Claim
in	I-Claim
predicting	I-Claim
patients'	I-Claim
survival	I-Claim
after	I-Claim
platinum-based	I-Claim
chemotherapy.	I-Claim

GPX1	B-Claim
may	I-Claim
be	I-Claim
an	I-Claim
inherited	I-Claim
factor	I-Claim
in	I-Claim
predicting	I-Claim
patients'	I-Claim
QOL.	I-Claim

Further	B-Claim
investigation	I-Claim
to	I-Claim
define	I-Claim
and	I-Claim
measure	I-Claim
the	I-Claim
effects	I-Claim
of	I-Claim
these	I-Claim
genes	I-Claim
in	I-Claim
chemotherapeutic	I-Claim
regimens,	I-Claim
drug	I-Claim
toxicities,	I-Claim
disease	I-Claim
progression,	I-Claim
and	I-Claim
QOL	I-Claim
are	I-Claim
critical.	I-Claim

To	O
analyze	O
and	O
compare	O
radiologic	O
lung	O
expansion	O
after	O
talc	O
pleurodesis	O
performed	O
either	O
by	O
videothoracoscopy	O
or	O
chest	O
tube	O
and	O
correlate	O
it	O
with	O
clinical	O
outcome.	O

Secondary	O
end	O
points	O
evaluated	O
were	O
as	O
follows:	O
clinical	O
efficacy;	O
quality	O
of	O
life;	O
safety;	O
and	O
survival.	O

Prospective	O
randomized	O
study	O
that	O
included	O
60	O
patients	O
(45	O
women,	O
15	O
men;	O
mean	O
age,	O
55.2	O
years)	O
with	O
recurrent	O
malignant	O
pleural	O
effusion	O
between	O
January	O
2005	O
and	O
January	O
2008.	O

They	O
were	O
randomized	O
into	O
the	O
following	O
two	O
groups:	O
video-assisted	O
thoracic	O
surgery	O
(VATS)	O
talc	O
poudrage;	O
and	O
talc	O
slurry	O
(TS)	O
administered	O
through	O
a	O
chest	O
tube.	O

Lung	O
expansion	O
was	O
evaluated	O
through	O
chest	O
CT	O
scans	O
obtained	O
0,	O
1,	O
3	O
and	O
6	O
months	O
after	O
pleurodesis.	O

Complications,	O
drainage	O
time,	O
hospital	O
stay,	O
and	O
quality	O
of	O
life	O
(Medical	O
Outcomes	O
Study	O
36-item	O
short	O
form	O
and	O
World	O
Health	O
Organization	O
quality-of-life	O
questionnaires)	O
were	O
also	O
analyzed.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
preprocedure	O
clinical	O
and	O
pathologic	O
variables	O
between	O
groups.	O

The	O
immediate	O
total	O
(ie,	O
>	O
90%)	O
lung	O
expansion	O
was	O
observed	O
in	O
27	O
patients	O
(45%)	O
and	O
was	O
more	O
frequent	O
in	O
the	O
VATS	O
group	O
(60%	O
vs	O
30%,	O
respectively;	O
p	O
=	O
0.027).	O

During	B-Premise
follow-up,	I-Premise
71%	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
showed	I-Premise
unaltered	I-Premise
or	I-Premise
improved	I-Premise
lung	I-Premise
expansion	I-Premise
and	I-Premise
9	I-Premise
patients	I-Premise
(15%)	I-Premise
needed	I-Premise
new	I-Premise
pleural	I-Premise
procedures	I-Premise
(VATS	I-Premise
group,	I-Premise
5	I-Premise
recurrences;	I-Premise
TS	I-Premise
group,	I-Premise
4	I-Premise
recurrences;	I-Premise
p	I-Premise
=	I-Premise
0.999).	I-Premise

No	B-Premise
differences	I-Premise
were	I-Premise
found	I-Premise
between	I-Premise
groups	I-Premise
regarding	I-Premise
quality	I-Premise
of	I-Premise
life,	I-Premise
complications,	I-Premise
drainage	I-Premise
time,	I-Premise
hospital	I-Premise
stay,	I-Premise
and	I-Premise
survival.	I-Premise

Immediate	B-Premise
lung	I-Premise
expansion	I-Premise
did	I-Premise
not	I-Premise
correlate	I-Premise
with	I-Premise
radiologic	I-Premise
recurrence,	I-Premise
clinical	I-Premise
recurrence,	I-Premise
or	I-Premise
complications	I-Premise
(p	I-Premise
=	I-Premise
0.60,	I-Premise
0.15,	I-Premise
and	I-Premise
0.20,	I-Premise
respectively).	I-Premise

Immediate	B-Premise
partial	I-Premise
lung	I-Premise
expansion	I-Premise
was	I-Premise
a	I-Premise
frequent	I-Premise
finding	I-Premise
and	I-Premise
was	I-Premise
more	I-Premise
frequent	I-Premise
after	I-Premise
TS.	I-Premise

Nonetheless,	O
no	B-Claim
correlation	I-Claim
between	I-Claim
immediate	I-Claim
lung	I-Claim
expansion	I-Claim
and	I-Claim
clinical	I-Claim
outcome	I-Claim
was	I-Claim
found	I-Claim
in	I-Claim
this	I-Claim
study.	I-Claim

A	O
dramatic	O
rise	O
in	O
incidence,	O
an	O
aging	O
population,	O
and	O
expensive	O
palliative	O
treatments	O
have	O
led	O
to	O
an	O
escalating	O
burden	O
on	O
clinicians	O
managing	O
inoperable	O
esophageal	O
cancer	O
with	O
only	O
limited	O
evidence	O
of	O
effectiveness.	O

This	O
study	O
compares	O
the	O
clinical	O
effectiveness	O
and	O
cost-effectiveness	O
of	O
self-expanding	O
metal	O
stents	O
(SEMSs)	O
with	O
other	O
palliative	O
therapies	O
to	O
aid	O
clinicians	O
in	O
making	O
an	O
evidence-based	O
treatment	O
choice.	O

We	O
conducted	O
a	O
prospective,	O
multicenter,	O
randomized,	O
controlled,	O
clinical	O
trial	O
with	O
215	O
patients	O
followed	O
until	O
death	O
or	O
study	O
closure.	O

The	O
primary	O
outcome	O
measures	O
were	O
dysphagia,	O
quality	O
of	O
life	O
(QL)	O
6	O
weeks	O
following	O
treatment,	O
and	O
total	O
cost	O
of	O
treatment.	O

Secondary	O
outcome	O
measures	O
included	O
treatment-associated	O
morbidity,	O
mortality,	O
survival,	O
and	O
cost-effectiveness.	O

An	O
intention-to-treat	O
analysis	O
was	O
carried	O
out.	O

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
mean	I-Premise
dysphagia	I-Premise
grade	I-Premise
between	I-Premise
treatment	I-Premise
arms	I-Premise
6	I-Premise
weeks	I-Premise
following	I-Premise
treatment	I-Premise
(P=0.046),	I-Premise
with	I-Premise
worse	I-Premise
swallowing	I-Premise
reported	I-Premise
by	I-Premise
rigid	I-Premise
stent-treated	I-Premise
patients	I-Premise
(mean	I-Premise
dysphagia	I-Premise
score	I-Premise
difference=-0.49;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
(CI)	I-Premise
-0.10	I-Premise
to	I-Premise
-0.89,	I-Premise
P=0.014).	I-Premise

Global	B-Premise
QL	I-Premise
scores	I-Premise
were	I-Premise
lower	I-Premise
at	I-Premise
both	I-Premise
1	I-Premise
and	I-Premise
6	I-Premise
weeks	I-Premise
following	I-Premise
treatment	I-Premise
for	I-Premise
patients	I-Premise
treated	I-Premise
by	I-Premise
SEMSs	I-Premise
(mean	I-Premise
difference	I-Premise
QL	I-Premise
index	I-Premise
week	I-Premise
1=-0.66;	I-Premise
95%	I-Premise
CI:	I-Premise
-0.02	I-Premise
to	I-Premise
-1.30,	I-Premise
P=0.04;	I-Premise
mean	I-Premise
difference	I-Premise
QL	I-Premise
index	I-Premise
week	I-Premise
6=-1.01;	I-Premise
95%	I-Premise
CI	I-Premise
-0.30	I-Premise
to	I-Premise
-1.72,	I-Premise
P=0.006).	I-Premise

These	B-Premise
findings	I-Premise
were	I-Premise
associated	I-Premise
with	I-Premise
higher	I-Premise
post-procedure	I-Premise
pain	I-Premise
scores	I-Premise
in	I-Premise
the	I-Premise
SEMS	I-Premise
patient	I-Premise
group	I-Premise
(mean	I-Premise
difference	I-Premise
of	I-Premise
the	I-Premise
European	I-Premise
Organisation	I-Premise
for	I-Premise
Research	I-Premise
and	I-Premise
Treatment	I-Premise
of	I-Premise
Cancer	I-Premise
QLQ	I-Premise
C-30	I-Premise
pain	I-Premise
symptom	I-Premise
score	I-Premise
at	I-Premise
week	I-Premise
1=11.13;	I-Premise
95%	I-Premise
CI:	I-Premise
2.89-19.4;	I-Premise
P=0.01).	I-Premise

Although	B-Premise
mean	I-Premise
EQ-5D	I-Premise
QL	I-Premise
values	I-Premise
differed	I-Premise
between	I-Premise
the	I-Premise
treatments	I-Premise
(P<0.001),	I-Premise
this	I-Premise
difference	I-Premise
dissipated	I-Premise
following	I-Premise
generation	I-Premise
of	I-Premise
quality-adjusted	I-Premise
life	I-Premise
year	I-Premise
values.	I-Premise

Total	O
costs	O
varied	O
between	O
treatment	O
arms	O
but	O
these	O
findings	O
canceled	O
out	O
when	O
SEMSs	O
were	O
compared	O
with	O
non-SEMS	O
therapies	O
(95%	O
CI	O
-845.15-1,332.62).	O

These	O
results	O
were	O
robust	O
to	O
sensitivity	O
analysis.	O

There	B-Premise
were	I-Premise
no	I-Premise
differences	I-Premise
in	I-Premise
the	I-Premise
in-hospital	I-Premise
mortality	I-Premise
or	I-Premise
early	I-Premise
complication	I-Premise
rates,	I-Premise
but	B-Premise
late	I-Premise
complications	I-Premise
were	I-Premise
more	I-Premise
frequent	I-Premise
after	I-Premise
rigid	I-Premise
stenting	I-Premise
(risk	I-Premise
ratio=2.47;	I-Premise
95%	I-Premise
CI	I-Premise
1.88-3.04).	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
survival	I-Premise
advantage	I-Premise
for	I-Premise
non-stent-treated	I-Premise
patients	I-Premise
(log-rank	I-Premise
statistic=4.21,	I-Premise
P=0.04).	I-Premise

The	B-Claim
treatment	I-Claim
choice	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
inoperable	I-Claim
esophageal	I-Claim
cancer	I-Claim
should	I-Claim
be	I-Claim
between	I-Claim
a	I-Claim
SEMS	I-Claim
or	I-Claim
a	I-Claim
non-stent	I-Claim
treatment	I-Claim
after	I-Claim
consideration	I-Claim
has	I-Claim
been	I-Claim
given	I-Claim
to	I-Claim
both	I-Claim
patient	I-Claim
and	I-Claim
tumor	I-Claim
characteristics	I-Claim
and	I-Claim
clinician	I-Claim
and	I-Claim
patient	I-Claim
preferences.	I-Claim

Lymphedema	O
is	O
an	O
adverse	O
effect	O
of	O
breast	O
cancer	O
surgery.	O

Aqua	O
lymphatic	O
therapy	O
(ALT)	O
is	O
a	O
novel	O
treatment	O
for	O
limb	O
volume	O
reduction.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
ALT	O
is	O
a	O
safe	O
method	O
and	O
whether	O
there	O
are	O
differences	O
in	O
adherence,	O
limb	O
volume,	O
and	O
quality	O
of	O
life	O
between	O
women	O
who	O
perform	O
only	O
self-management	O
treatment	O
and	O
women	O
who	O
participate	O
as	O
well	O
in	O
ALT.	O

Design	O
of	O
the	O
study	O
was	O
single-blind	O
randomized	O
clinical	O
trial.	O

The	O
setting	O
was	O
in	O
a	O
hydrotherapy	O
pool,	O
1.2	O
m	O
depth,	O
and	O
a	O
temperature	O
of	O
32-33	O
degrees	O
capital	O
ES,	O
Cyrillic.	O

Forty-eight	O
women	O
(56	O
+/-	O
10	O
years),	O
with	O
a	O
12.8%	O
lymphedema	O
relative	O
volume,	O
participated	O
in	O
the	O
study.	O

The	O
control	O
group	O
was	O
instructed	O
to	O
perform	O
the	O
self-management	O
treatment.	O

The	O
study	O
group	O
joined	O
a	O
weekly	O
session	O
of	O
ALT	O
for	O
3	O
months	O
in	O
addition	O
to	O
the	O
self-management	O
therapy.	O

Adherence	O
was	O
assessed	O
by	O
a	O
self-reported	O
diary,	O
limb	O
volume	O
by	O
a	O
water	O
displacement	O
device,	O
quality	O
of	O
life	O
by	O
the	O
Upper	O
Limb	O
Lymphedema	O
Questionnaire	O
(ULL27),	O
prior	O
to,	O
and	O
after	O
the	O
intervention	O
period.	O

There	B-Premise
was	I-Premise
no	I-Premise
episode	I-Premise
of	I-Premise
arm	I-Premise
infection	I-Premise
or	I-Premise
aggravation	I-Premise
in	I-Premise
limb	I-Premise
volume	I-Premise
during	I-Premise
the	I-Premise
study	I-Premise
period.	I-Premise

ALT	B-Premise
had	I-Premise
a	I-Premise
positive,	I-Premise
statistically	I-Premise
and	I-Premise
clinically	I-Premise
significant	I-Premise
immediate	I-Premise
effect	I-Premise
on	I-Premise
limb	I-Premise
volume	I-Premise
but	B-Premise
no	I-Premise
long-term	I-Premise
effect	I-Premise
was	I-Premise
noted.	I-Premise

The	B-Premise
adherence	I-Premise
rate	I-Premise
to	I-Premise
ALT	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
than	I-Premise
the	I-Premise
adherence	I-Premise
to	I-Premise
self-management	I-Premise
therapy.	I-Premise

QOL	B-Premise
improved	I-Premise
in	I-Premise
the	I-Premise
study	I-Premise
group.	I-Premise

ALT	B-Claim
was	I-Claim
found	I-Claim
to	I-Claim
be	I-Claim
a	I-Claim
safe	I-Claim
method,	I-Claim
with	I-Claim
high	I-Claim
adherence,	I-Claim
in	I-Claim
treating	I-Claim
women	I-Claim
who	I-Claim
suffer	I-Claim
from	I-Claim
mild	I-Claim
to	I-Claim
moderate	I-Claim
lymphedema.	I-Claim

A	B-Claim
significant	I-Claim
immediate	I-Claim
and	I-Claim
insignificant	I-Claim
long-term	I-Claim
effect	I-Claim
on	I-Claim
limb	I-Claim
volume	I-Claim
was	I-Claim
noted.	I-Claim

The	O
combination	O
of	O
radiotherapy	O
plus	O
long-term	O
medical	O
suppression	O
of	O
androgens	O
(>	O
or	O
=	O
2	O
years)	O
improves	O
overall	O
survival	O
in	O
patients	O
with	O
locally	O
advanced	O
prostate	O
cancer.	O

We	O
compared	O
the	O
use	O
of	O
radiotherapy	O
plus	O
short-term	O
androgen	O
suppression	O
with	O
the	O
use	O
of	O
radiotherapy	O
plus	O
long-term	O
androgen	O
suppression	O
in	O
the	O
treatment	O
of	O
locally	O
advanced	O
prostate	O
cancer.	O

We	O
randomly	O
assigned	O
patients	O
with	O
locally	O
advanced	O
prostate	O
cancer	O
who	O
had	O
received	O
external-beam	O
radiotherapy	O
plus	O
6	O
months	O
of	O
androgen	O
suppression	O
to	O
two	O
groups,	O
one	O
to	O
receive	O
no	O
further	O
treatment	O
(short-term	O
suppression)	O
and	O
the	O
other	O
to	O
receive	O
2.5	O
years	O
of	O
further	O
treatment	O
with	O
a	O
luteinizing	O
hormone-releasing	O
hormone	O
agonist	O
(long-term	O
suppression).	O

An	O
outcome	O
of	O
noninferiority	O
of	O
short-term	O
androgen	O
suppression	O
as	O
compared	O
with	O
long-term	O
suppression	O
required	O
a	O
hazard	O
ratio	O
of	O
more	O
than	O
1.35	O
for	O
overall	O
survival,	O
with	O
a	O
one-sided	O
alpha	O
level	O
of	O
0.05.	O

An	O
interim	O
analysis	O
showed	O
futility,	O
and	O
the	O
results	O
are	O
presented	O
with	O
an	O
adjusted	O
one-sided	O
alpha	O
level	O
of	O
0.0429.	O

A	O
total	O
of	O
1113	O
men	O
were	O
registered,	O
of	O
whom	O
970	O
were	O
randomly	O
assigned,	O
483	O
to	O
short-term	O
suppression	O
and	O
487	O
to	O
long-term	O
suppression.	O

After	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
6.4	I-Premise
years,	I-Premise
132	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
short-term	I-Premise
group	I-Premise
and	I-Premise
98	I-Premise
in	I-Premise
the	I-Premise
long-term	I-Premise
group	I-Premise
had	I-Premise
died;	I-Premise
the	B-Premise
number	I-Premise
of	I-Premise
deaths	I-Premise
due	I-Premise
to	I-Premise
prostate	I-Premise
cancer	I-Premise
was	I-Premise
47	I-Premise
in	I-Premise
the	I-Premise
short-term	I-Premise
group	I-Premise
and	I-Premise
29	I-Premise
in	I-Premise
the	I-Premise
long-term	I-Premise
group.	I-Premise

The	B-Premise
5-year	I-Premise
overall	I-Premise
mortality	I-Premise
for	I-Premise
short-term	I-Premise
and	I-Premise
long-term	I-Premise
suppression	I-Premise
was	I-Premise
19.0%	I-Premise
and	I-Premise
15.2%,	I-Premise
respectively;	I-Premise
the	O
observed	O
hazard	O
ratio	O
was	O
1.42	O
(upper	O
95.71%	O
confidence	O
limit,	O
1.79;	O
P=0.65	O
for	O
noninferiority).	O

Adverse	B-Premise
events	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
included	I-Premise
fatigue,	I-Premise
diminished	I-Premise
sexual	I-Premise
function,	I-Premise
and	I-Premise
hot	I-Premise
flushes.	I-Premise

The	B-Claim
combination	I-Claim
of	I-Claim
radiotherapy	I-Claim
plus	I-Claim
6	I-Claim
months	I-Claim
of	I-Claim
androgen	I-Claim
suppression	I-Claim
provides	I-Claim
inferior	I-Claim
survival	I-Claim
as	I-Claim
compared	I-Claim
with	I-Claim
radiotherapy	I-Claim
plus	I-Claim
3	I-Claim
years	I-Claim
of	I-Claim
androgen	I-Claim
suppression	I-Claim
in	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
locally	I-Claim
advanced	I-Claim
prostate	I-Claim
cancer.	I-Claim

Studies	O
on	O
quality	O
of	O
life	O
(QOL)	O
among	O
women	O
with	O
endometrial	O
cancer	O
have	O
shown	O
that	O
patients	O
who	O
undergo	O
pelvic	O
radiotherapy	O
report	O
lower	O
role	O
functioning	O
and	O
more	O
diarrhea	O
and	O
fatigue.	O

In	O
the	O
Post	O
Operative	O
Radiation	O
Therapy	O
in	O
Endometrial	O
Cancer	O
(PORTEC)	O
trial,	O
patients	O
with	O
endometrial	O
carcinoma	O
were	O
randomly	O
assigned	O
to	O
receive	O
external-beam	O
radiotherapy	O
(EBRT)	O
or	O
vaginal	O
brachytherapy	O
(VBT).	O

QOL	O
was	O
evaluated	O
by	O
using	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
C30	O
and	O
subscales	O
from	O
the	O
prostate	O
cancer	O
module,	O
PR-25,	O
and	O
the	O
ovarian	O
cancer	O
module,	O
OV-28.	O

PORTEC-2	O
accrued	O
427	O
patients	O
between	O
2002	O
and	O
2006,	O
of	O
whom	O
214	O
were	O
randomly	O
assigned	O
to	O
EBRT,	O
and	O
213	O
were	O
randomly	O
assigned	O
to	O
VBT.	O

Three-hundred	O
forty-eight	O
patients	O
(81%)	O
were	O
evaluable	O
for	O
QOL.	O

QOL	O
outcomes	O
were	O
analyzed	O
at	O
a	O
median	O
follow-up	O
of	O
2	O
years.	O

At	O
baseline	O
after	O
surgery,	O
patient	O
functioning	O
was	O
at	O
the	O
lowest	O
level,	O
and	O
it	O
increased	O
during	O
and	O
after	O
radiotherapy	O
to	O
reach	O
a	O
plateau	O
after	O
12	O
months.	O

Patients	B-Premise
in	I-Premise
the	I-Premise
VBT	I-Premise
group	I-Premise
reported	I-Premise
better	I-Premise
social	I-Premise
functioning	I-Premise
(P	I-Premise
<	I-Premise
.002)	I-Premise
and	I-Premise
lower	I-Premise
symptom	I-Premise
scores	I-Premise
for	I-Premise
diarrhea,	I-Premise
fecal	I-Premise
leakage,	I-Premise
the	I-Premise
need	I-Premise
to	I-Premise
stay	I-Premise
close	I-Premise
to	I-Premise
the	I-Premise
toilet,	I-Premise
and	I-Premise
limitation	I-Premise
in	I-Premise
daily	I-Premise
activities	I-Premise
because	I-Premise
of	I-Premise
bowel	I-Premise
symptoms	I-Premise
(P	I-Premise
<	I-Premise
.001).	I-Premise

At	O
baseline,	O
15%	O
of	O
patients	O
were	O
sexually	O
active;	O
this	O
increased	O
significantly	O
to	O
39%	O
during	O
the	O
first	O
year	O
(P	O
<	O
.001).	O

Sexual	B-Premise
functioning	I-Premise
and	I-Premise
symptoms	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
between	I-Premise
the	I-Premise
treatment	I-Premise
groups.	I-Premise

Patients	B-Premise
who	I-Premise
received	I-Premise
EBRT	I-Premise
reported	I-Premise
significantly	I-Premise
higher	I-Premise
levels	I-Premise
of	I-Premise
diarrhea	I-Premise
and	I-Premise
bowel	I-Premise
symptoms.	I-Premise

This	O
resulted	O
in	O
a	O
higher	O
need	O
to	O
remain	O
close	O
to	O
a	O
toilet	O
and,	O
as	O
a	O
consequence,	O
more	O
limitation	O
of	O
daily	O
activities	O
because	O
of	O
bowel	O
symptoms	O
and	O
decreased	O
social	O
functioning.	O

Vaginal	B-Claim
brachytherapy	I-Claim
provides	I-Claim
a	I-Claim
better	I-Claim
QOL,	I-Claim
and	I-Claim
should	I-Claim
be	I-Claim
the	I-Claim
preferred	I-Claim
treatment	I-Claim
from	I-Claim
a	I-Claim
QOL	I-Claim
perspective.	I-Claim

Cancer	O
cells	O
rely	O
on	O
angiogenesis	O
for	O
growth	O
and	O
dissemination,	O
and	O
small	O
cell	O
lung	O
cancer	O
(SCLC)	O
is	O
a	O
highly	O
angiogenic	O
tumor.	O

We	O
evaluated	O
thalidomide,	O
an	O
anti-angiogenic	O
agent,	O
when	O
combined	O
with	O
chemotherapy	O
and	O
as	O
maintenance	O
treatment.	O

A	O
total	O
of	O
724	O
patients	O
(51%	O
with	O
limited	O
and	O
49%	O
with	O
extensive	O
disease)	O
were	O
randomly	O
assigned	O
to	O
receive	O
placebo	O
or	O
thalidomide	O
capsules,	O
100-200	O
mg	O
daily	O
for	O
up	O
to	O
2	O
years.	O

All	O
patients	O
received	O
etoposide	O
and	O
carboplatin	O
every	O
3	O
weeks	O
for	O
up	O
to	O
six	O
cycles.	O

Endpoints	O
were	O
overall	O
survival,	O
progression-free	O
survival,	O
tumor	O
response	O
rate,	O
toxicity,	O
and	O
quality	O
of	O
life	O
(QoL).	O

Hazard	O
ratios	O
(HRs)	O
for	O
comparing	O
thalidomide	O
against	O
placebo	O
were	O
estimated	O
using	O
Cox	O
regression	O
modeling.	O

Statistical	O
tests	O
were	O
two-sided.	O

The	B-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
10.5	I-Premise
months	I-Premise
(placebo)	I-Premise
and	I-Premise
10.1	I-Premise
months	I-Premise
(thalidomide)	I-Premise
(HR	I-Premise
for	I-Premise
death	I-Premise
=	I-Premise
1.09,	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
=	I-Premise
0.93	I-Premise
to	I-Premise
1.27;	I-Premise
P	I-Premise
=	I-Premise
.28).	I-Premise

Among	B-Premise
patients	I-Premise
with	I-Premise
limited-stage	I-Premise
disease,	I-Premise
there	I-Premise
was	I-Premise
no	I-Premise
evidence	I-Premise
of	I-Premise
a	I-Premise
survival	I-Premise
difference	I-Premise
(HR	I-Premise
for	I-Premise
death	I-Premise
=	I-Premise
0.91,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
0.73	I-Premise
to	I-Premise
1.15),	I-Premise
but	B-Premise
among	I-Premise
patients	I-Premise
with	I-Premise
extensive	I-Premise
disease,	I-Premise
survival	I-Premise
was	I-Premise
worse	I-Premise
in	I-Premise
the	I-Premise
thalidomide	I-Premise
group	I-Premise
(HR	I-Premise
for	I-Premise
death	I-Premise
=	I-Premise
1.36,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
1.10	I-Premise
to	I-Premise
1.68).	I-Premise

Progression-free	B-Premise
survival	I-Premise
rates	I-Premise
were	I-Premise
also	I-Premise
similar	I-Premise
in	I-Premise
the	I-Premise
two	I-Premise
groups	I-Premise
(HR	I-Premise
=	I-Premise
1.07,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
0.92	I-Premise
to	I-Premise
1.24).	I-Premise

Thalidomide	B-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
an	I-Premise
increased	I-Premise
risk	I-Premise
of	I-Premise
having	I-Premise
a	I-Premise
thrombotic	I-Premise
event,	I-Premise
mainly	I-Premise
pulmonary	I-Premise
embolus	I-Premise
and	I-Premise
deep	I-Premise
vein	I-Premise
thrombosis	I-Premise
(19%	I-Premise
thalidomide	I-Premise
vs	I-Premise
10%	I-Premise
placebo;	I-Premise
HR	I-Premise
=	I-Premise
2.13,	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
1.41	I-Premise
to	I-Premise
3.20;	I-Premise
P	I-Premise
<	I-Premise
.001).	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
treatments	I-Premise
in	I-Premise
hematological	I-Premise
and	I-Premise
nonhematological	I-Premise
toxic	I-Premise
effects,	I-Premise
except	B-Premise
more	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
thalidomide	I-Premise
group	I-Premise
had	I-Premise
rash,	I-Premise
constipation,	I-Premise
or	I-Premise
neuropathy.	I-Premise

Overall,	O
QoL	B-Claim
scores	I-Claim
were	I-Claim
similar	I-Claim
in	I-Claim
the	I-Claim
two	I-Claim
treatment	I-Claim
groups,	I-Claim
but	B-Claim
thalidomide	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
less	I-Claim
insomnia	I-Claim
and	I-Claim
diarrhea	I-Claim
and	I-Claim
more	I-Claim
constipation	I-Claim
and	I-Claim
peripheral	I-Claim
neuropathy.	I-Claim

In	O
this	O
large	O
randomized	O
trial,	O
thalidomide	B-Claim
in	I-Claim
combination	I-Claim
with	I-Claim
chemotherapy	I-Claim
did	I-Claim
not	I-Claim
improve	I-Claim
survival	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
SCLC	I-Claim
but	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
an	I-Claim
increased	I-Claim
risk	I-Claim
of	I-Claim
thrombotic	I-Claim
events.	I-Claim

Transthoracic	O
and	O
transhiatal	O
esophagectomy	O
are	O
two	O
common	O
procedures	O
for	O
esophageal	O
cancer	O
resection.	O

Prospective	O
studies	O
comparing	O
the	O
two	O
methods	O
in	O
Asian	O
people	O
are	O
few.	O

In	O
addition,	O
the	O
data	O
comparing	O
their	O
effects	O
on	O
the	O
quality	O
of	O
life	O
are	O
lacking.	O

A	O
prospective	O
randomized	O
study	O
was	O
conducted	O
from	O
January	O
2003.	O

Patients	O
of	O
resectable	O
esophageal	O
cancer	O
of	O
comparable	O
stage	O
were	O
allocated	O
to	O
undergo	O
the	O
transthoracic	O
or	O
transhiatal	O
procedure	O
in	O
turn.	O

They	O
were	O
all	O
reconstructed	O
with	O
stomach	O
interposition	O
through	O
the	O
retrosternal	O
route.	O

Discharged	O
patients	O
were	O
followed-up	O
in	O
the	O
outpatient	O
clinic.	O

They	O
were	O
questioned	O
on	O
the	O
topics	O
of	O
(i)	O
severity	O
of	O
pain,	O
(ii)	O
ease	O
of	O
swallowing,	O
(iii)	O
satisfaction	O
of	O
daily	O
activities,	O
(iv)	O
dependence	O
on	O
medications,	O
(v)	O
working	O
ability,	O
(vi)	O
fatigue,	O
(vii)	O
appetite,	O
(viii)	O
sociality,	O
(ix)	O
happiness	O
and	O
(x)	O
self	O
respect,	O
in	O
the	O
third,	O
sixth	O
and	O
twelfth	O
month.	O

Also	O
the	O
demographic	O
data,	O
operative	O
results	O
and	O
survival	O
were	O
recorded.	O

Up	O
to	O
December	O
2006,	O
eighty-seven	O
patients	O
of	O
stage	O
II	O
and	O
III,	O
including	O
71	O
patients	O
of	O
middle	O
third	O
lesions	O
and	O
16	O
lower	O
third	O
lesions	O
were	O
enrolled.	O

The	B-Premise
operation	I-Premise
time	I-Premise
was	I-Premise
significantly	I-Premise
longer,	I-Premise
and	I-Premise
the	I-Premise
leakage	I-Premise
rate	I-Premise
was	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
transthoracic	I-Premise
group	I-Premise
(Student's	I-Premise
t-test	I-Premise
and	I-Premise
Fischer's	I-Premise
exact	I-Premise
test,	I-Premise
respectively).	I-Premise

However,	O
intraoperative	B-Premise
blood	I-Premise
loss	I-Premise
and	I-Premise
postoperative	I-Premise
hospital	I-Premise
stay	I-Premise
were	I-Premise
not	I-Premise
significantly	I-Premise
different	I-Premise
(Student	I-Premise
t-test).	I-Premise

Also,	O
the	B-Premise
Kaplan-Meier	I-Premise
survival	I-Premise
curves	I-Premise
of	I-Premise
these	I-Premise
two	I-Premise
groups	I-Premise
were	I-Premise
not	I-Premise
significantly	I-Premise
different	I-Premise
by	I-Premise
log-rank	I-Premise
test	I-Premise
(p=0.286).	I-Premise

The	B-Premise
score	I-Premise
on	I-Premise
the	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
of	I-Premise
transhiatal	I-Premise
patients	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
than	I-Premise
that	I-Premise
of	I-Premise
transthoracic	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
third,	I-Premise
sixth	I-Premise
and	I-Premise
twelfth	I-Premise
month.	I-Premise

Transhiatal	B-Claim
esophagectomy	I-Claim
is	I-Claim
a	I-Claim
safe	I-Claim
and	I-Claim
fast	I-Claim
procedure.	I-Claim

The	B-Claim
survival	I-Claim
was	I-Claim
similar	I-Claim
to	I-Claim
that	I-Claim
of	I-Claim
transthoracic	I-Claim
approach.	I-Claim

Its	B-Claim
leakage	I-Claim
rate	I-Claim
was	I-Claim
lower	I-Claim
and	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
was	I-Claim
better.	I-Claim

Therapy	O
for	O
polycystic	O
liver	O
is	O
invasive,	O
expensive,	O
and	O
has	O
disappointing	O
long-term	O
results.	O

Treatment	O
with	O
somatostatin	O
analogues	O
slowed	O
kidney	O
growth	O
in	O
patients	O
with	O
polycystic	O
kidney	O
disease	O
(PKD)	O
and	O
reduced	O
liver	O
and	O
kidney	O
volume	O
in	O
a	O
PKD	O
rodent	O
model.	O

We	O
evaluated	O
the	O
effects	O
of	O
lanreotide,	O
a	O
somatostatin	O
analogue,	O
in	O
patients	O
with	O
polycystic	O
liver	O
because	O
of	O
autosomal-dominant	O
(AD)	O
PKD	O
or	O
autosomal-dominant	O
polycystic	O
liver	O
disease	O
(PCLD).	O

We	O
performed	O
a	O
randomized,	O
double-blind,	O
placebo-controlled	O
trial	O
in	O
2	O
tertiary	O
referral	O
centers.	O

Patients	O
with	O
polycystic	O
liver	O
(n	O
=	O
54)	O
were	O
randomly	O
assigned	O
to	O
groups	O
given	O
lanreotide	O
(120	O
mg)	O
or	O
placebo,	O
administered	O
every	O
28	O
days	O
for	O
24	O
weeks.	O

The	O
primary	O
end	O
point	O
was	O
the	O
difference	O
in	O
total	O
liver	O
volume,	O
measured	O
by	O
computerized	O
tomography	O
at	O
weeks	O
0	O
and	O
24.	O

Analyses	O
were	O
performed	O
on	O
an	O
intention-to-treat	O
basis.	O

Baseline	B-Premise
characteristics	I-Premise
were	I-Premise
comparable	I-Premise
for	I-Premise
both	I-Premise
groups,	I-Premise
except	B-Premise
that	I-Premise
more	I-Premise
patients	I-Premise
with	I-Premise
ADPKD	I-Premise
were	I-Premise
assigned	I-Premise
to	I-Premise
the	I-Premise
placebo	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
.03).	I-Premise

The	B-Premise
mean	I-Premise
liver	I-Premise
volume	I-Premise
decreased	I-Premise
2.9%,	I-Premise
from	I-Premise
4606	I-Premise
mL	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
(CI):	I-Premise
547-8665)	I-Premise
to	I-Premise
4471	I-Premise
mL	I-Premise
(95%	I-Premise
CI:	I-Premise
542-8401	I-Premise
mL),	I-Premise
in	I-Premise
patients	I-Premise
given	I-Premise
lanreotide.	I-Premise

In	B-Premise
the	I-Premise
placebo	I-Premise
group,	I-Premise
the	I-Premise
mean	I-Premise
liver	I-Premise
volume	I-Premise
increased	I-Premise
1.6%,	I-Premise
from	I-Premise
4689	I-Premise
mL	I-Premise
(95%	I-Premise
CI:	I-Premise
613-8765	I-Premise
mL)	I-Premise
to	I-Premise
4895	I-Premise
mL	I-Premise
(95%	I-Premise
CI:	I-Premise
739-9053	I-Premise
mL)	I-Premise
(P	I-Premise
<	I-Premise
.01).	I-Premise

Post	B-Premise
hoc	I-Premise
stratification	I-Premise
for	I-Premise
patients	I-Premise
with	I-Premise
ADPKD	I-Premise
or	I-Premise
PCLD	I-Premise
revealed	I-Premise
similar	I-Premise
changes	I-Premise
in	I-Premise
liver	I-Premise
volume,	I-Premise
with	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
patients	I-Premise
given	I-Premise
lanreotide	I-Premise
(P	I-Premise
<	I-Premise
.01	I-Premise
for	I-Premise
both	I-Premise
diseases).	I-Premise

In	B-Claim
patients	I-Claim
with	I-Claim
polycystic	I-Claim
liver,	I-Claim
6	I-Claim
months	I-Claim
of	I-Claim
treatment	I-Claim
with	I-Claim
lanreotide	I-Claim
reduces	I-Claim
liver	I-Claim
volume.	I-Claim

Sunitinib	O
has	O
demonstrated	O
antitumor	O
activity	O
in	O
metastatic	O
renal	O
cell	O
carcinoma	O
(mRCC)	O
when	O
given	O
at	O
50	O
mg/d	O
on	O
a	O
4-weeks-on	O
2-weeks-off	O
regimen.	O

Herein,	O
we	O
report	O
results	O
of	O
an	O
open-label,	O
multicenter	O
phase	O
II	O
mRCC	O
study	O
of	O
sunitinib	O
administered	O
on	O
a	O
continuous	O
once-daily	O
dosing	O
regimen.	O

Eligibility	O
criteria	O
included	O
histologically	O
proven	O
mRCC	O
with	O
measurable	O
disease,	O
failure	O
of	O
one	O
prior	O
cytokine	O
regimen,	O
and	O
good	O
performance	O
status.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
a	O
sunitinib	O
starting	O
dose	O
of	O
37.5	O
mg/d	O
in	O
the	O
morning	O
(AM)	O
or	O
evening	O
(PM).	O

RECIST-defined	O
objective	O
response	O
rate	O
(ORR)	O
was	O
the	O
primary	O
end	O
point.	O

Secondary	O
end	O
points	O
included	O
progression-free	O
survival	O
(PFS),	O
overall	O
survival	O
(OS),	O
adverse	O
events	O
(AEs),	O
and	O
quality-of-life	O
measures.	O

One	O
hundred	O
seven	O
patients	O
were	O
randomly	O
assigned	O
to	O
AM	O
(n	O
=	O
54)	O
or	O
PM	O
(n	O
=	O
53)	O
dosing	O
and	O
on	O
study	O
for	O
a	O
median	O
8.3	O
months.	O

Eighty-three	O
patients	O
discontinued,	O
65	O
due	O
to	O
disease	O
progression	O
and	O
16	O
because	O
of	O
AEs;	O
two	O
patients	O
withdrew	O
consent.	O

Dosing	O
was	O
reduced	O
to	O
25	O
mg/d	O
in	O
46	O
patients	O
(43%)	O
due	O
to	O
grade	O
3/4	O
AEs.	O

The	B-Premise
most	I-Premise
common	I-Premise
grade	I-Premise
3	I-Premise
treatment-related	I-Premise
AEs	I-Premise
were	I-Premise
asthenia/fatigue	I-Premise
(16%),	I-Premise
diarrhea	I-Premise
(11%),	I-Premise
hypertension	I-Premise
(11%),	I-Premise
hand-foot	I-Premise
syndrome	I-Premise
(9%),	I-Premise
and	I-Premise
anorexia	I-Premise
(8%).	I-Premise

ORR	O
was	O
20%	O
with	O
a	O
7.2-month	O
median	O
response	O
duration.	O

Median	B-Premise
PFS	I-Premise
and	I-Premise
OS	I-Premise
were	I-Premise
8.2	I-Premise
and	I-Premise
19.8	I-Premise
months,	I-Premise
respectively,	I-Premise
at	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
26.4	I-Premise
months.	I-Premise

Efficacy,	B-Premise
tolerability,	I-Premise
and	I-Premise
quality-of-life	I-Premise
results	I-Premise
were	I-Premise
similar	I-Premise
between	I-Premise
patients	I-Premise
dosed	I-Premise
in	I-Premise
the	I-Premise
AM	I-Premise
or	I-Premise
PM.	I-Premise

Sunitinib	B-Claim
37.5	I-Claim
mg,	I-Claim
administered	I-Claim
on	I-Claim
a	I-Claim
continuous	I-Claim
once-daily	I-Claim
dosing	I-Claim
regimen,	I-Claim
has	I-Claim
a	I-Claim
manageable	I-Claim
safety	I-Claim
profile	I-Claim
as	I-Claim
second-line	I-Claim
mRCC	I-Claim
therapy,	I-Claim
providing	I-Claim
flexible	I-Claim
dosing,	I-Claim
which	I-Claim
can	I-Claim
be	I-Claim
explored	I-Claim
in	I-Claim
combination	I-Claim
studies.	I-Claim

Lymphoma	O
patients	O
commonly	O
experience	O
declines	O
in	O
physical	O
functioning	O
and	O
quality	O
of	O
life	O
(QoL)	O
that	O
may	O
be	O
reversed	O
with	O
exercise	O
training.	O

We	O
conducted	O
a	O
randomized	O
controlled	O
trial	O
in	O
Edmonton,	O
Alberta,	O
Canada,	O
between	O
2005	O
and	O
2008	O
that	O
stratified	O
122	O
lymphoma	O
patients	O
by	O
major	O
disease	O
type	O
and	O
current	O
treatment	O
status	O
and	O
randomly	O
assigned	O
them	O
to	O
usual	O
care	O
(UC;	O
n	O
=	O
62)	O
or	O
12	O
weeks	O
of	O
supervised	O
aerobic	O
exercise	O
training	O
(AET;	O
n	O
=	O
60).	O

Our	O
primary	O
end	O
point	O
was	O
patient-rated	O
physical	O
functioning	O
assessed	O
by	O
the	O
Trial	O
Outcome	O
Index-Anemia.	O

Secondary	O
end	O
points	O
were	O
overall	O
QoL,	O
psychosocial	O
functioning,	O
cardiovascular	O
fitness,	O
and	O
body	O
composition.	O

Follow-up	O
assessment	O
for	O
our	O
primary	O
end	O
point	O
was	O
96%	O
(117	O
of	O
122)	O
at	O
postintervention	O
and	O
90%	O
(110	O
of	O
122)	O
at	O
6-month	O
follow-up.	O

Median	O
adherence	O
to	O
the	O
supervised	O
exercise	O
program	O
was	O
92%.	O

At	B-Premise
postintervention,	I-Premise
AET	I-Premise
was	I-Premise
superior	I-Premise
to	I-Premise
UC	I-Premise
for	I-Premise
patient-rated	I-Premise
physical	I-Premise
functioning	I-Premise
(mean	I-Premise
group	I-Premise
difference,	I-Premise
+9.0;	I-Premise
95%	I-Premise
CI,	I-Premise
2.0	I-Premise
to	I-Premise
16.0;	I-Premise
P	I-Premise
=	I-Premise
.012),	I-Premise
overall	I-Premise
QoL	I-Premise
(P	I-Premise
=	I-Premise
.021),	I-Premise
fatigue	I-Premise
(P	I-Premise
=	I-Premise
.013),	I-Premise
happiness	I-Premise
(P	I-Premise
=	I-Premise
.004),	I-Premise
depression	I-Premise
(P	I-Premise
=	I-Premise
.005),	I-Premise
general	I-Premise
health	I-Premise
(P	I-Premise
<	I-Premise
.001),	I-Premise
cardiovascular	I-Premise
fitness	I-Premise
(P	I-Premise
<	I-Premise
.001),	I-Premise
and	I-Premise
lean	I-Premise
body	I-Premise
mass	I-Premise
(P	I-Premise
=	I-Premise
.008).	I-Premise

Change	O
in	O
peak	O
cardiovascular	O
fitness	O
mediated	O
the	O
change	O
in	O
patient-rated	O
physical	O
functioning.	O

AET	B-Premise
did	I-Premise
not	I-Premise
interfere	I-Premise
with	I-Premise
chemotherapy	I-Premise
completion	I-Premise
rate	I-Premise
or	I-Premise
treatment	I-Premise
response.	I-Premise

At	B-Premise
6-month	I-Premise
follow-up,	I-Premise
AET	I-Premise
was	I-Premise
still	I-Premise
borderline	I-Premise
or	I-Premise
significantly	I-Premise
superior	I-Premise
to	I-Premise
UC	I-Premise
for	I-Premise
overall	I-Premise
QoL	I-Premise
(P	I-Premise
=	I-Premise
.054),	I-Premise
happiness	I-Premise
(P	I-Premise
=	I-Premise
.034),	I-Premise
and	I-Premise
depression	I-Premise
(P	I-Premise
=	I-Premise
.009)	I-Premise
without	I-Premise
an	I-Premise
increased	I-Premise
risk	I-Premise
of	I-Premise
disease	I-Premise
recurrence/progression.	I-Premise

AET	B-Claim
significantly	I-Claim
improved	I-Claim
important	I-Claim
patient-rated	I-Claim
outcomes	I-Claim
and	I-Claim
objective	I-Claim
physical	I-Claim
functioning	I-Claim
in	I-Claim
lymphoma	I-Claim
patients	I-Claim
without	I-Claim
interfering	I-Claim
with	I-Claim
medical	I-Claim
treatments	I-Claim
or	I-Claim
response.	I-Claim

Exercise	B-Claim
training	I-Claim
to	I-Claim
improve	I-Claim
cardiovascular	I-Claim
fitness	I-Claim
should	I-Claim
be	I-Claim
considered	I-Claim
in	I-Claim
the	I-Claim
management	I-Claim
of	I-Claim
lymphoma	I-Claim
patients.	I-Claim

There	O
are	O
few	O
randomized	O
controlled	O
trials	O
on	O
the	O
effectiveness	O
of	O
palliative	O
care	O
interventions	O
to	O
improve	O
the	O
care	O
of	O
patients	O
with	O
advanced	O
cancer.	O

To	O
determine	O
the	O
effect	O
of	O
a	O
nursing-led	O
intervention	O
on	O
quality	O
of	O
life,	O
symptom	O
intensity,	O
mood,	O
and	O
resource	O
use	O
in	O
patients	O
with	O
advanced	O
cancer.	O

Randomized	O
controlled	O
trial	O
conducted	O
from	O
November	O
2003	O
through	O
May	O
2008	O
of	O
322	O
patients	O
with	O
advanced	O
cancer	O
in	O
a	O
rural,	O
National	O
Cancer	O
Institute-designated	O
comprehensive	O
cancer	O
center	O
in	O
New	O
Hampshire	O
and	O
affiliated	O
outreach	O
clinics	O
and	O
a	O
VA	O
medical	O
center	O
in	O
Vermont.	O

A	O
multicomponent,	O
psychoeducational	O
intervention	O
(Project	O
ENABLE	O
[Educate,	O
Nurture,	O
Advise,	O
Before	O
Life	O
Ends])	O
conducted	O
by	O
advanced	O
practice	O
nurses	O
consisting	O
of	O
4	O
weekly	O
educational	O
sessions	O
and	O
monthly	O
follow-up	O
sessions	O
until	O
death	O
or	O
study	O
completion	O
(n	O
=	O
161)	O
vs	O
usual	O
care	O
(n	O
=	O
161).	O

Quality	O
of	O
life	O
was	O
measured	O
by	O
the	O
Functional	O
Assessment	O
of	O
Chronic	O
Illness	O
Therapy	O
for	O
Palliative	O
Care	O
(score	O
range,	O
0-184).	O

Symptom	O
intensity	O
was	O
measured	O
by	O
the	O
Edmonton	O
Symptom	O
Assessment	O
Scale	O
(score	O
range,	O
0-900).	O

Mood	O
was	O
measured	O
by	O
the	O
Center	O
for	O
Epidemiological	O
Studies	O
Depression	O
Scale	O
(range,	O
0-60).	O

These	O
measures	O
were	O
assessed	O
at	O
baseline,	O
1	O
month,	O
and	O
every	O
3	O
months	O
until	O
death	O
or	O
study	O
completion.	O

Intensity	O
of	O
service	O
was	O
measured	O
as	O
the	O
number	O
of	O
days	O
in	O
the	O
hospital	O
and	O
in	O
the	O
intensive	O
care	O
unit	O
(ICU)	O
and	O
the	O
number	O
of	O
emergency	O
department	O
visits	O
recorded	O
in	O
the	O
electronic	O
medical	O
record.	O

A	O
total	O
of	O
322	O
participants	O
with	O
cancer	O
of	O
the	O
gastrointestinal	O
tract	O
(41%;	O
67	O
in	O
the	O
usual	O
care	O
group	O
vs	O
66	O
in	O
the	O
intervention	O
group),	O
lung	O
(36%;	O
58	O
vs	O
59),	O
genitourinary	O
tract	O
(12%;	O
20	O
vs	O
19),	O
and	O
breast	O
(10%;	O
16	O
vs	O
17)	O
were	O
randomized.	O

The	B-Premise
estimated	I-Premise
treatment	I-Premise
effects	I-Premise
(intervention	I-Premise
minus	I-Premise
usual	I-Premise
care)	I-Premise
for	I-Premise
all	I-Premise
participants	I-Premise
were	I-Premise
a	I-Premise
mean	I-Premise
(SE)	I-Premise
of	I-Premise
4.6	I-Premise
(2)	I-Premise
for	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(P	I-Premise
=	I-Premise
.02),	I-Premise
-27.8	I-Premise
(15)	I-Premise
for	I-Premise
symptom	I-Premise
intensity	I-Premise
(P	I-Premise
=	I-Premise
.06),	I-Premise
and	I-Premise
-1.8	I-Premise
(0.81)	I-Premise
for	I-Premise
depressed	I-Premise
mood	I-Premise
(P	I-Premise
=	I-Premise
.02).	I-Premise

The	B-Premise
estimated	I-Premise
treatment	I-Premise
effects	I-Premise
in	I-Premise
participants	I-Premise
who	I-Premise
died	I-Premise
during	I-Premise
the	I-Premise
study	I-Premise
were	I-Premise
a	I-Premise
mean	I-Premise
(SE)	I-Premise
of	I-Premise
8.6	I-Premise
(3.6)	I-Premise
for	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(P	I-Premise
=	I-Premise
.02),	I-Premise
-24.2	I-Premise
(20.5)	I-Premise
for	I-Premise
symptom	I-Premise
intensity	I-Premise
(P	I-Premise
=	I-Premise
.24),	I-Premise
and	I-Premise
-2.7	I-Premise
(1.2)	I-Premise
for	I-Premise
depressed	I-Premise
mood	I-Premise
(P	I-Premise
=	I-Premise
.03).	I-Premise

Intensity	O
of	O
service	O
did	O
not	O
differ	O
between	O
the	O
2	O
groups.	O

Compared	B-Claim
with	I-Claim
participants	I-Claim
receiving	I-Claim
usual	I-Claim
oncology	I-Claim
care,	I-Claim
those	I-Claim
receiving	I-Claim
a	I-Claim
nurse-led,	I-Claim
palliative	I-Claim
care-focused	I-Claim
intervention	I-Claim
addressing	I-Claim
physical,	I-Claim
psychosocial,	I-Claim
and	I-Claim
care	I-Claim
coordination	I-Claim
provided	I-Claim
concurrently	I-Claim
with	I-Claim
oncology	I-Claim
care	I-Claim
had	I-Claim
higher	I-Claim
scores	I-Claim
for	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
and	I-Claim
mood,	I-Claim
but	B-Claim
did	I-Claim
not	I-Claim
have	I-Claim
improvements	I-Claim
in	I-Claim
symptom	I-Claim
intensity	I-Claim
scores	I-Claim
or	I-Claim
reduced	I-Claim
days	I-Claim
in	I-Claim
the	I-Claim
hospital	I-Claim
or	I-Claim
ICU	I-Claim
or	I-Claim
emergency	I-Claim
department	I-Claim
visits.	I-Claim

A	O
recent	O
randomized	O
trial	O
to	O
compare	O
external	O
beam	O
radiation	O
therapy	O
(EBRT)	O
to	O
cryoablation	O
for	O
localized	O
disease	O
showed	O
cryoablation	O
to	O
be	O
noninferior	O
to	O
external	O
beam	O
EBRT	O
in	O
disease	O
progression	O
and	O
overall	O
and	O
disease-specific	O
survival.	O

We	O
report	O
on	O
the	O
quality	O
of	O
life	O
(QOL)	O
outcomes	O
for	O
this	O
trial.	O

From	O
December	O
1997	O
through	O
February	O
2003,	O
244	O
men	O
with	O
newly	O
diagnosed	O
localized	O
prostate	O
cancer	O
were	O
randomly	O
assigned	O
to	O
cryoablation	O
or	O
EBRT	O
(median	O
dose	O
68	O
Gy).	O

All	O
patients	O
received	O
neoadjuvant	O
antiandrogen	O
therapy.	O

Patients	O
completed	O
the	O
EORTC	O
QLQ	O
C30	O
and	O
the	O
Prostate	O
Cancer	O
Index	O
(PCI)	O
before	O
treatment	O
and	O
at	O
1.5,	O
3,	O
6,	O
12,	O
18,	O
24,	O
and	O
36	O
months	O
post-treatment.	O

Regardless	B-Premise
of	I-Premise
treatment	I-Premise
arm,	I-Premise
participants	I-Premise
reported	I-Premise
high	I-Premise
levels	I-Premise
of	I-Premise
QOL	I-Premise
with	I-Premise
few	I-Premise
exceptions.	I-Premise
cryoablation	B-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
more	I-Premise
acute	I-Premise
urinary	I-Premise
dysfunction	I-Premise
(mean	I-Premise
PCI	I-Premise
urinary	I-Premise
function	I-Premise
cryoablation=69.4;	I-Premise
mean	I-Premise
EBRT=90.7;	I-Premise
P<.001),	I-Premise
which	I-Premise
resolved	I-Premise
over	I-Premise
time.	I-Premise

No	B-Premise
late	I-Premise
arising	I-Premise
QOL	I-Premise
issues	I-Premise
were	I-Premise
observed.	I-Premise

Both	B-Premise
EBRT	I-Premise
and	I-Premise
cryoablation	I-Premise
participants	I-Premise
reported	I-Premise
decreases	I-Premise
in	I-Premise
sexual	I-Premise
function	I-Premise
at	I-Premise
3	I-Premise
months	I-Premise
with	I-Premise
the	I-Premise
cryoablation	I-Premise
patients	I-Premise
reporting	I-Premise
poorer	I-Premise
functioning	I-Premise
(mean	I-Premise
cryoablation=7.2:	I-Premise
mean	I-Premise
EBRT=32.9;	I-Premise
P<.001).	I-Premise

Mean	B-Premise
sexual	I-Premise
function	I-Premise
score	I-Premise
was	I-Premise
15	I-Premise
points	I-Premise
lower	I-Premise
at	I-Premise
3	I-Premise
years	I-Premise
for	I-Premise
the	I-Premise
cryoablation	I-Premise
group	I-Premise
and	I-Premise
13%	I-Premise
more	I-Premise
of	I-Premise
the	I-Premise
cryoablation	I-Premise
men	I-Premise
said	I-Premise
that	I-Premise
sexuality	I-Premise
was	I-Premise
a	I-Premise
moderate	I-Premise
or	I-Premise
big	I-Premise
problem.	I-Premise

In	B-Claim
this	I-Claim
randomized	I-Claim
trial,	I-Claim
no	I-Claim
long-term	I-Claim
QOL	I-Claim
advantage	I-Claim
for	I-Claim
either	I-Claim
treatment	I-Claim
was	I-Claim
apparent	I-Claim
with	B-Claim
the	I-Claim
exception	I-Claim
of	I-Claim
poorer	I-Claim
sexual	I-Claim
function	I-Claim
reported	I-Claim
by	I-Claim
those	I-Claim
treated	I-Claim
with	I-Claim
cryoablation.	I-Claim

Men	O
who	O
wish	O
to	O
increase	O
their	O
odds	O
of	O
retaining	O
sexual	O
function	O
might	O
be	O
counseled	O
to	O
choose	O
EBRT	O
over	O
cryoablation.	O

Gemcitabine	O
(G)	O
is	O
standard	O
therapy	O
for	O
pancreatic	O
cancer.	O

Enzastaurin	O
(E)	O
inhibits	O
PKC	O
and	O
PI3K/AKT	O
signaling	O
pathways	O
with	O
a	O
dose-dependent	O
effect	O
on	O
growth	O
of	O
pancreatic	O
carcinoma	O
xenografts.	O

Data	B-Claim
suggest	I-Claim
that	I-Claim
the	I-Claim
GE	I-Claim
combination	I-Claim
may	I-Claim
improve	I-Claim
clinical	I-Claim
outcomes.	I-Claim

Primary	O
objective	O
was	O
overall	O
survival	O
(OS);	O
secondary	O
objectives	O
assessed	O
progression-free	O
survival	O
(PFS),	O
response	O
rate	O
(RR),	O
quality	O
of	O
life	O
(QOL),	O
toxicity,	O
and	O
relationships	O
between	O
biomarker	O
expression	O
and	O
clinical	O
outcomes.	O

Patients	O
were	O
randomly	O
assigned	O
(2:1)	O
to	O
GE	O
or	O
G	O
treatment;	O
GE	O
arm:	O
E	O
500	O
mg	O
p.o.	O
daily;	O
loading-dose	O
(1200	O
mg;	O
Day	O
1	O
Cycle	O
1	O
only)	O
and	O
G	O
1000	O
mg/m(2)	O
i.v.	O
Days	O
1,	O
8,	O
and	O
15	O
in	O
28-day	O
cycles;	O
G	O
arm:	O
G	O
as	O
in	O
GE.	O

Biomarker	O
expression	O
was	O
assessed	O
by	O
immunohistochemistry.	O

Randomization	O
totaled	O
130	O
patients	O
(GE	O
=	O
86,	O
G	O
=	O
44);	O
121	O
patients	O
were	O
treated	O
(GE	O
=	O
82,	O
G	O
=	O
39).	O

GE/G	O
median	O
OS	O
was	O
5.6/5.1	O
months;	O
median	O
PFS	O
was	O
3.4/3.0	O
months.	O

GE	O
responses:	O
1	O
complete	O
response	O
(CR,	O
1.2%),	O
6	O
partial	O
response	O
(PR,	O
7.4%),	O
and	O
33	O
stable	O
disease	O
(SD,	O
40.7%);	O
disease	O
control	O
rate	O
(DCR=CR+PR+SD,	O
49.4%).	O

G	O
responses:	O
2	O
PR	O
(5.3%)	O
and	O
16	O
SD	O
(42.1%);	O
DCR	O
(47.4%).	O

No	B-Premise
QOL	I-Premise
differences	I-Premise
were	I-Premise
noted	I-Premise
between	I-Premise
arms.	I-Premise

GE/G	B-Premise
Grade	I-Premise
3-4	I-Premise
toxicities	I-Premise
included:	I-Premise
neutropenia	I-Premise
(18.3%/28.2%);	I-Premise
thrombocytopenia	I-Premise
(14.6%/25.6%);	I-Premise
and	I-Premise
fatigue	I-Premise
(11.0%/7.7%).	I-Premise

No	B-Premise
statistically	I-Premise
significant	I-Premise
relationships	I-Premise
between	I-Premise
biomarker	I-Premise
expression	I-Premise
and	I-Premise
outcomes	I-Premise
were	I-Premise
observed.	I-Premise

However,	O
patients	B-Premise
with	I-Premise
low	I-Premise
expression	I-Premise
of	I-Premise
cytoplasmic	I-Premise
pGSK-3	I-Premise
trended	I-Premise
toward	I-Premise
greater	I-Premise
OS	I-Premise
with	I-Premise
GE	I-Premise
treatment.	I-Premise

OS,	B-Premise
PFS,	I-Premise
QOL,	I-Premise
and	I-Premise
RR	I-Premise
were	I-Premise
comparable	I-Premise
between	I-Premise
arms.	I-Premise

Adding	B-Claim
E	I-Claim
to	I-Claim
G	I-Claim
did	I-Claim
not	I-Claim
increase	I-Claim
hematologic	I-Claim
toxicities.	I-Claim

GE	O
does	O
not	O
warrant	O
further	O
investigation	O
in	O
unselected	O
pancreatic	O
cancer	O
patients.	O

Assess	O
toxicity	O
and	O
efficacy	O
of	O
cisplatin	O
(Cis)	O
doublet	O
combinations	O
in	O
advanced	O
and	O
recurrent	O
cervical	O
carcinoma.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
paclitaxel	O
135	O
mg/m(2)	O
over	O
24	O
hours	O
plus	O
Cis	O
50	O
mg/m(2)	O
day	O
2	O
every	O
3	O
weeks	O
(PC,	O
reference	O
arm);	O
vinorelbine	O
30	O
mg/m(2)	O
days	O
1	O
and	O
8	O
plus	O
Cis	O
50	O
mg/m(2)	O
day	O
1	O
every	O
3	O
weeks	O
(VC);	O
gemcitabine	O
1,000	O
mg/m(2)	O
day	O
1	O
and	O
8	O
plus	O
Cis	O
50	O
mg/m(2)	O
day	O
1	O
every	O
3	O
weeks	O
(GC);	O
or	O
topotecan	O
0.75	O
mg/m(2)	O
days	O
1,	O
2,	O
and	O
3	O
plus	O
Cis	O
50	O
mg/m(2)	O
day	O
1	O
every	O
3	O
weeks	O
(TC).	O

Survival	O
was	O
the	O
primary	O
end	O
point	O
with	O
a	O
33%	O
improvement	O
relative	O
to	O
PC	O
considered	O
important	O
(85%	O
power,	O
alpha	O
=	O
5%).	O

Quality-of-life	O
data	O
were	O
prospectively	O
collected.	O

A	O
total	O
of	O
513	O
patients	O
were	O
enrolled	O
when	O
a	O
planned	O
interim	O
analysis	O
recommended	O
early	O
closure	O
for	O
futility.	O

The	B-Premise
experimental-to-PC	I-Premise
hazard	I-Premise
ratios	I-Premise
of	I-Premise
death	I-Premise
were	I-Premise
1.15	I-Premise
(95%	I-Premise
CI,	I-Premise
0.79	I-Premise
to	I-Premise
1.67)	I-Premise
for	I-Premise
VC,	I-Premise
1.32	I-Premise
(95%	I-Premise
CI,	I-Premise
0.91	I-Premise
to	I-Premise
1.92)	I-Premise
for	I-Premise
GC,	I-Premise
and	I-Premise
1.26	I-Premise
(95%	I-Premise
CI,	I-Premise
0.86	I-Premise
to	I-Premise
1.82)	I-Premise
for	I-Premise
TC.	I-Premise

The	B-Premise
hazard	I-Premise
ratios	I-Premise
for	I-Premise
progression-free	I-Premise
survival	I-Premise
(PFS)	I-Premise
were	I-Premise
1.36	I-Premise
(95%	I-Premise
CI,	I-Premise
0.97	I-Premise
to	I-Premise
1.90)	I-Premise
for	I-Premise
VC,	I-Premise
1.39	I-Premise
(95%	I-Premise
CI,	I-Premise
0.99	I-Premise
to	I-Premise
1.96)	I-Premise
for	I-Premise
GC,	I-Premise
and	I-Premise
1.27	I-Premise
(95%	I-Premise
CI,	I-Premise
0.90	I-Premise
to	I-Premise
1.78)	I-Premise
for	I-Premise
TC.	I-Premise

Response	B-Premise
rates	I-Premise
(RRs)	I-Premise
for	I-Premise
PC,	I-Premise
VC,	I-Premise
GC,	I-Premise
and	I-Premise
TC	I-Premise
were	I-Premise
29.1%,	I-Premise
25.9%,	I-Premise
22.3%,	I-Premise
and	I-Premise
23.4%,	I-Premise
respectively.	I-Premise

The	B-Premise
arms	I-Premise
were	I-Premise
comparable	I-Premise
with	I-Premise
respect	I-Premise
to	I-Premise
toxicity	I-Premise
except	I-Premise
for	I-Premise
leucopenia,	I-Premise
neutropenia,	I-Premise
infection,	I-Premise
and	I-Premise
alopecia.	I-Premise

VC,	B-Claim
GC,	I-Claim
and	I-Claim
TC	I-Claim
are	I-Claim
not	I-Claim
superior	I-Claim
to	I-Claim
PC	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
overall	I-Claim
survival	I-Claim
(OS).	I-Claim

However,	B-Claim
the	I-Claim
trend	I-Claim
in	I-Claim
RR,	I-Claim
PFS,	I-Claim
and	I-Claim
OS	I-Claim
favors	I-Claim
PC.	I-Claim

Differences	B-Claim
in	I-Claim
chemotherapy	I-Claim
scheduling,	I-Claim
pre-existing	I-Claim
morbidity,	I-Claim
and	I-Claim
toxicity	I-Claim
are	I-Claim
important	I-Claim
in	I-Claim
individualizing	I-Claim
therapy.	I-Claim

A	O
randomized	O
controlled	O
trial	O
was	O
performed	O
to	O
assess	O
the	O
outcome	O
of	O
early	O
oral	O
postoperative	O
feeding	O
(EOF)	O
compared	O
with	O
traditional	O
oral	O
feeding	O
(TOF)	O
in	O
gynecologic	O
oncology	O
patients	O
undergoing	O
a	O
complex	O
laparotomy,	O
including	O
upper	O
abdominal	O
surgery.	O

Patients	O
aged	O
18-75	O
years,	O
undergoing	O
an	O
elective	O
laparotomy	O
and	O
with	O
a	O
preoperative	O
suspicion	O
of	O
gynecologic	O
malignancy,	O
were	O
eligible.	O

Exclusion	O
criteria	O
included	O
infectious	O
conditions,	O
intestinal	O
obstruction,	O
severe	O
malnutrition,	O
American	O
Society	O
of	O
Anesthesiologists	O
score	O
C4,	O
intestinal	O
resection,	O
and	O
postoperative	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
lasting	O
24	O
h.	O

Patients	O
allocated	O
to	O
EOF	O
received	O
liquid	O
diet	O
in	O
the	O
first	O
postoperative	O
day	O
and	O
then	O
regular	O
diet.	O

Patients	O
received	O
traditional	O
feeding	O
scheme	O
until	O
resolution	O
of	O
postoperative	O
ileus	O
to	O
start	O
liquid	O
diet.	O

The	O
primary	O
end-point	O
of	O
the	O
trial	O
was	O
length	O
of	O
hospital	O
stay.	O

Between	O
January	O
1,	O
2007,	O
and	O
November	O
17,	O
2007,	O
a	O
total	O
of	O
143	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
EOF	O
or	O
TOF.	O

Hospital	B-Premise
stay	I-Premise
for	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
EOF	I-Premise
(n=71)	I-Premise
was	I-Premise
4.7	I-Premise
vs.	I-Premise
5.8	I-Premise
days	I-Premise
for	I-Premise
the	I-Premise
TOF	I-Premise
group	I-Premise
(n=72)	I-Premise
(P=0.006).	I-Premise

The	B-Premise
mean	I-Premise
level	I-Premise
of	I-Premise
postoperative	I-Premise
satisfaction	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
EOF	I-Premise
group	I-Premise
(82.8	I-Premise
vs.	I-Premise
71.7	I-Premise
mm,	I-Premise
P	I-Premise
B	I-Premise
0.001).	I-Premise

Patients	B-Premise
who	I-Premise
received	I-Premise
the	I-Premise
TOF	I-Premise
scheme	I-Premise
had	I-Premise
significantly	I-Premise
higher	I-Premise
overall	I-Premise
postoperative	I-Premise
complications	I-Premise
(39	I-Premise
vs.	I-Premise
17%	I-Premise
in	I-Premise
EOF	I-Premise
group,	I-Premise
P=0.003)	I-Premise
and	I-Premise
infective	I-Premise
complications	I-Premise
(14%	I-Premise
in	I-Premise
TOF	I-Premise
group	I-Premise
vs.	I-Premise
3%	I-Premise
in	I-Premise
EOF	I-Premise
group,	I-Premise
P=0.017).	I-Premise

Variables	B-Premise
such	I-Premise
as	I-Premise
nausea	I-Premise
and	I-Premise
vomiting,	I-Premise
analgesic	I-Premise
and	I-Premise
antiemetic	I-Premise
requirement	I-Premise
as	I-Premise
well	I-Premise
as	I-Premise
level	I-Premise
of	I-Premise
pain	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
were	I-Premise
not	I-Premise
different	I-Premise
between	I-Premise
groups.	I-Premise

On	B-Claim
the	I-Claim
basis	I-Claim
of	I-Claim
these	I-Claim
findings,	I-Claim
the	I-Claim
policy	I-Claim
of	I-Claim
EOF	I-Claim
should	I-Claim
be	I-Claim
used	I-Claim
after	I-Claim
a	I-Claim
complex	I-Claim
gynecologic	I-Claim
oncologic	I-Claim
laparotomy.	I-Claim

To	O
assess	O
the	O
effect	O
of	O
a	O
multimodal	O
group	O
exercise	O
intervention,	O
as	O
an	O
adjunct	O
to	O
conventional	O
care,	O
on	O
fatigue,	O
physical	O
capacity,	O
general	O
wellbeing,	O
physical	O
activity,	O
and	O
quality	O
of	O
life	O
in	O
patients	O
with	O
cancer	O
who	O
were	O
undergoing	O
adjuvant	O
chemotherapy	O
or	O
treatment	O
for	O
advanced	O
disease.	O

Randomised	O
controlled	O
trial.	O

Two	O
university	O
hospitals	O
in	O
Copenhagen,	O
Denmark.	O

269	O
patients	O
with	O
cancer;	O
73	O
men,	O
196	O
women,	O
mean	O
age	O
47	O
years	O
(range	O
20-65)	O
representing	O
21	O
diagnoses.	O

Main	O
exclusion	O
criteria	O
were	O
brain	O
or	O
bone	O
metastases.	O

235	O
patients	O
completed	O
follow-up.	O

Supervised	O
exercise	O
comprising	O
high	O
intensity	O
cardiovascular	O
and	O
resistance	O
training,	O
relaxation	O
and	O
body	O
awareness	O
training,	O
massage,	O
nine	O
hours	O
weekly	O
for	O
six	O
weeks	O
in	O
addition	O
to	O
conventional	O
care,	O
compared	O
with	O
conventional	O
care.	O

The	O
general	O
linear	O
model	O
was	O
used	O
for	O
continuous	O
outcome	O
while	O
analysis	O
of	O
associates	O
between	O
categorical	O
outcomes	O
was	O
performed	O
as	O
analysis	O
of	O
marginal	O
homogeneity	O
in	O
contingency	O
tables.	O

Adjusted	B-Premise
for	I-Premise
baseline	I-Premise
score,	I-Premise
disease,	I-Premise
and	I-Premise
demographic	I-Premise
covariates,	I-Premise
the	I-Premise
intervention	I-Premise
group	I-Premise
showed	I-Premise
an	I-Premise
estimated	I-Premise
improvement	I-Premise
at	I-Premise
six	I-Premise
weeks	I-Premise
for	I-Premise
the	I-Premise
primary	I-Premise
outcome,	I-Premise
fatigue,	I-Premise
of	I-Premise
-6.6	I-Premise
points	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
-12.3	I-Premise
to	I-Premise
-0.9,	I-Premise
P=0.02;	I-Premise
effect	I-Premise
size=0.33,	I-Premise
0.04	I-Premise
to	I-Premise
0.61).	I-Premise

Significant	B-Premise
effects	I-Premise
were	I-Premise
seen	I-Premise
on	I-Premise
vitality	I-Premise
(effect	I-Premise
size	I-Premise
0.55,	I-Premise
95%	I-Premise
CI	I-Premise
0.27	I-Premise
to	I-Premise
0.82),	I-Premise
physical	I-Premise
functioning	I-Premise
(0.37,	I-Premise
0.09	I-Premise
to	I-Premise
0.65),	I-Premise
role	I-Premise
physical	I-Premise
(0.37,	I-Premise
0.10	I-Premise
to	I-Premise
0.64),	I-Premise
role	I-Premise
emotional	I-Premise
(0.32,	I-Premise
0.05	I-Premise
to	I-Premise
0.59),	I-Premise
and	I-Premise
mental	I-Premise
health	I-Premise
(0.28,	I-Premise
0.02	I-Premise
to	I-Premise
0.56)	I-Premise
scores.	I-Premise

Improvement	B-Premise
was	I-Premise
noted	I-Premise
in	I-Premise
physical	I-Premise
capacity:	I-Premise
estimated	I-Premise
mean	I-Premise
difference	I-Premise
between	I-Premise
groups	I-Premise
for	I-Premise
maximum	I-Premise
oxygen	I-Premise
consumption	I-Premise
was	I-Premise
0.16	I-Premise
l/min	I-Premise
(95%	I-Premise
CI	I-Premise
0.1	I-Premise
to	I-Premise
0.2,	I-Premise
P<0.0001)	I-Premise
and	I-Premise
for	I-Premise
muscular	I-Premise
strength	I-Premise
(leg	I-Premise
press)	I-Premise
was	I-Premise
29.7	I-Premise
kg	I-Premise
(23.4	I-Premise
to	I-Premise
34.9,	I-Premise
P<0.0001).	I-Premise

No	B-Premise
significant	I-Premise
effect	I-Premise
was	I-Premise
seen	I-Premise
on	I-Premise
global	I-Premise
health	I-Premise
status/quality	I-Premise
of	I-Premise
life.	I-Premise

A	B-Claim
supervised	I-Claim
multimodal	I-Claim
exercise	I-Claim
intervention	I-Claim
including	I-Claim
high	I-Claim
and	I-Claim
low	I-Claim
intensity	I-Claim
components	I-Claim
was	I-Claim
feasible	I-Claim
and	I-Claim
could	I-Claim
safely	I-Claim
be	I-Claim
used	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
various	I-Claim
cancers	I-Claim
who	I-Claim
were	I-Claim
receiving	I-Claim
adjuvant	I-Claim
chemotherapy	I-Claim
or	I-Claim
treatment	I-Claim
for	I-Claim
advanced	I-Claim
disease.	I-Claim

The	B-Claim
intervention	I-Claim
reduced	I-Claim
fatigue	I-Claim
and	I-Claim
improved	I-Claim
vitality,	I-Claim
aerobic	I-Claim
capacity,	I-Claim
muscular	I-Claim
strength,	I-Claim
and	I-Claim
physical	I-Claim
and	I-Claim
functional	I-Claim
activity,	I-Claim
and	I-Claim
emotional	I-Claim
wellbeing,	I-Claim
but	B-Claim
not	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

Depression	O
is	O
common	O
among	O
older	O
cancer	O
patients,	O
but	O
little	O
is	O
known	O
about	O
the	O
optimal	O
approach	O
to	O
caring	O
for	O
this	O
population.	O

This	O
analysis	O
evaluates	O
the	O
effectiveness	O
of	O
the	O
Improving	O
Mood-Promoting	O
Access	O
to	O
Collaborative	O
Treatment	O
(IMPACT)	O
program,	O
a	O
stepped	O
care	O
management	O
program	O
for	O
depression	O
in	O
primary	O
care	O
patients	O
who	O
had	O
an	O
ICD-9	O
cancer	O
diagnosis.	O

Two	O
hundred	O
fifteen	O
cancer	O
patients	O
were	O
identified	O
from	O
the	O
1,801	O
participants	O
in	O
the	O
parent	O
study.	O

Subjects	O
were	O
60	O
years	O
or	O
older	O
with	O
major	O
depression	O
(18%),	O
dysthymic	O
disorder	O
(33%),	O
or	O
both	O
(49%),	O
recruited	O
from	O
18	O
primary	O
care	O
clinics	O
belonging	O
to	O
8	O
health-care	O
organizations	O
in	O
5	O
states.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
the	O
IMPACT	O
intervention	O
(n	O
=	O
112)	O
or	O
usual	O
care	O
(n	O
=	O
103).	O

Intervention	O
patients	O
had	O
access	O
for	O
up	O
to	O
12	O
months	O
to	O
a	O
depression	O
care	O
manager	O
who	O
was	O
supervised	O
by	O
a	O
psychiatrist	O
and	O
a	O
primary	O
care	O
provider	O
and	O
who	O
offered	O
education,	O
care	O
management,	O
support	O
of	O
antidepressant	O
management,	O
and	O
brief,	O
structured	O
psychosocial	O
interventions	O
including	O
behavioral	O
activation	O
and	O
problem-solving	O
treatment.	O

At	B-Premise
6	I-Premise
and	I-Premise
12	I-Premise
months,	I-Premise
55%	I-Premise
and	I-Premise
39%	I-Premise
of	I-Premise
intervention	I-Premise
patients	I-Premise
had	I-Premise
a	I-Premise
50%	I-Premise
or	I-Premise
greater	I-Premise
reduction	I-Premise
in	I-Premise
depressive	I-Premise
symptoms	I-Premise
(SCL-20)	I-Premise
from	I-Premise
baseline	I-Premise
compared	I-Premise
to	I-Premise
34%	I-Premise
and	I-Premise
20%	I-Premise
of	I-Premise
usual	I-Premise
care	I-Premise
participants	I-Premise
(P	I-Premise
=	I-Premise
0.003	I-Premise
and	I-Premise
P	I-Premise
=	I-Premise
0.029).	I-Premise

Intervention	B-Premise
patients	I-Premise
also	I-Premise
experienced	I-Premise
greater	I-Premise
remission	I-Premise
rates	I-Premise
(P	I-Premise
=	I-Premise
0.031),	I-Premise
more	I-Premise
depression-free	I-Premise
days	I-Premise
(P	I-Premise
<	I-Premise
0.001),	I-Premise
less	I-Premise
functional	I-Premise
impairment	I-Premise
(P	I-Premise
=	I-Premise
0.011),	I-Premise
and	I-Premise
greater	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(P	I-Premise
=	I-Premise
0.039)	I-Premise
at	I-Premise
12	I-Premise
months	I-Premise
than	I-Premise
usual	I-Premise
care	I-Premise
participants.	I-Premise

The	B-Claim
IMPACT	I-Claim
collaborative	I-Claim
care	I-Claim
program	I-Claim
appears	I-Claim
to	I-Claim
be	I-Claim
feasible	I-Claim
and	I-Claim
effective	I-Claim
for	I-Claim
depression	I-Claim
among	I-Claim
older	I-Claim
cancer	I-Claim
patients	I-Claim
in	I-Claim
diverse	I-Claim
primary	I-Claim
care	I-Claim
settings.	I-Claim

Both	O
gemcitabine	O
(GEM)	O
and	O
fluoropyrimidines	O
are	O
valuable	O
treatment	O
for	O
advanced	O
pancreatic	O
cancer.	O

This	O
open-label	O
study	O
was	O
designed	O
to	O
compare	O
the	O
overall	O
survival	O
(OS)	O
of	O
patients	O
randomly	O
assigned	O
to	O
GEM	O
alone	O
or	O
GEM	O
plus	O
capecitabine	O
(GEM-CAP).	O

Patients	O
with	O
previously	O
untreated	O
histologically	O
or	O
cytologically	O
proven	O
locally	O
advanced	O
or	O
metastatic	O
carcinoma	O
of	O
the	O
pancreas	O
with	O
a	O
performance	O
status	O
<or=	O
2	O
were	O
recruited.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
GEM	O
or	O
GEM-CAP.	O

The	O
primary	O
outcome	O
measure	O
was	O
survival.	O

Meta-analysis	O
of	O
published	O
studies	O
was	O
also	O
conducted.	O

Between	O
May	O
2002	O
and	O
January	O
2005,	O
533	O
patients	O
were	O
randomly	O
assigned	O
to	O
GEM	O
(n	O
=	O
266)	O
and	O
GEM-CAP	O
(n	O
=	O
267)	O
arms.	O

GEM-CAP	B-Premise
significantly	I-Premise
improved	I-Premise
objective	I-Premise
response	I-Premise
rate	I-Premise
(19.1%	I-Premise
v	I-Premise
12.4%;	I-Premise
P	I-Premise
=	I-Premise
.034)	I-Premise
and	I-Premise
progression-free	I-Premise
survival	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR],	I-Premise
0.78;	I-Premise
95%	I-Premise
CI,	I-Premise
0.66	I-Premise
to	I-Premise
0.93;	I-Premise
P	I-Premise
=	I-Premise
.004)	I-Premise
and	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
a	I-Premise
trend	I-Premise
toward	I-Premise
improved	I-Premise
OS	I-Premise
(HR,	I-Premise
0.86;	I-Premise
95%	I-Premise
CI,	I-Premise
0.72	I-Premise
to	I-Premise
1.02;	I-Premise
P	I-Premise
=	I-Premise
.08)	I-Premise
compared	I-Premise
with	I-Premise
GEM	I-Premise
alone.	I-Premise

This	B-Premise
trend	I-Premise
for	I-Premise
OS	I-Premise
benefit	I-Premise
for	I-Premise
GEM-CAP	I-Premise
was	I-Premise
consistent	I-Premise
across	I-Premise
different	I-Premise
prognostic	I-Premise
subgroups	I-Premise
according	I-Premise
to	I-Premise
baseline	I-Premise
stratification	I-Premise
factors	I-Premise
(stage	I-Premise
and	I-Premise
performance	I-Premise
status)	I-Premise
and	I-Premise
remained	I-Premise
after	I-Premise
adjusting	I-Premise
for	I-Premise
these	I-Premise
stratification	I-Premise
factors	I-Premise
(P	I-Premise
=	I-Premise
.077).	I-Premise

Moreover,	O
the	B-Premise
meta-analysis	I-Premise
of	I-Premise
two	I-Premise
additional	I-Premise
studies	I-Premise
involving	I-Premise
935	I-Premise
patients	I-Premise
showed	I-Premise
a	I-Premise
significant	I-Premise
survival	I-Premise
benefit	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
GEM-CAP	I-Premise
(HR,	I-Premise
0.86;	I-Premise
95%	I-Premise
CI,	I-Premise
0.75	I-Premise
to	I-Premise
0.98;	I-Premise
P	I-Premise
=	I-Premise
.02)	I-Premise
with	I-Premise
no	I-Premise
intertrial	I-Premise
heterogeneity.	I-Premise

On	B-Claim
the	I-Claim
basis	I-Claim
of	I-Claim
our	I-Claim
trial	I-Claim
and	I-Claim
the	I-Claim
meta-analysis,	I-Claim
GEM-CAP	I-Claim
should	I-Claim
be	I-Claim
considered	I-Claim
as	I-Claim
one	I-Claim
of	I-Claim
the	I-Claim
standard	I-Claim
first-line	I-Claim
options	I-Claim
in	I-Claim
locally	I-Claim
advanced	I-Claim
and	I-Claim
metastatic	I-Claim
pancreatic	I-Claim
cancer.	I-Claim

To	O
determine	O
1-year	O
outcomes	O
of	O
a	O
four-component	O
behavioral	O
therapy	O
(BT)	O
sleep	O
intervention	O
(Individualized	O
Sleep	O
Promotion	O
Plan	O
[ISPP])	O
versus	O
a	O
healthy	O
eating	O
control	O
(HEC)	O
on	O
cancer-related	O
fatigue	O
in	O
women	O
receiving	O
breast	O
cancer	O
adjuvant	O
chemotherapy	O
treatment	O
(CTX).	O

A	O
total	O
of	O
219	O
participants	O
from	O
12	O
oncology	O
clinics	O
were	O
randomly	O
assigned	O
in	O
a	O
clinical	O
trial.	O

Before	O
CTX,	O
research	O
nurses	O
coached	O
intervention	O
participants	O
to	O
develop	O
a	O
BT	O
plan	O
including	O
stimulus	O
control,	O
modified	O
sleep	O
restriction,	O
relaxation	O
therapy,	O
and	O
sleep	O
hygiene.	O

BT	O
plans	O
were	O
revised	O
before	O
each	O
CTX	O
and	O
30,	O
60,	O
and	O
90	O
days	O
after	O
the	O
last	O
CTX	O
and	O
reinforced	O
7	O
to	O
9	O
days	O
later.	O

HEC	O
participants	O
received	O
nutritional	O
information	O
and	O
equal	O
attention.	O

Pittsburgh	O
Sleep	O
Quality	O
Index	O
(PSQI),	O
Daily	O
Diary,	O
Wrist	O
Actigraph,	O
and	O
Piper	O
Fatigue	O
Scale	O
measures	O
and	O
Repeated	O
Linear	O
Mixed	O
Model	O
analysis	O
following	O
the	O
Intent	O
to	O
Treat	O
paradigm	O
were	O
used.	O

Sleep	B-Premise
quality	I-Premise
differed	I-Premise
over	I-Premise
1	I-Premise
years	I-Premise
time	I-Premise
(F	I-Premise
[4,162]	I-Premise
=	I-Premise
7.7,	I-Premise
P	I-Premise
<	I-Premise
.001;	I-Premise
by	I-Premise
group,	I-Premise
F	I-Premise
[1,173]	I-Premise
=	I-Premise
4.8,	I-Premise
P	I-Premise
=	I-Premise
.029;	I-Premise
and	I-Premise
over	I-Premise
time	I-Premise
by	I-Premise
group,	I-Premise
F	I-Premise
[4,162]	I-Premise
=	I-Premise
3.3,	I-Premise
P	I-Premise
=	I-Premise
.013).	I-Premise

Pairwise	B-Premise
comparisons	I-Premise
revealed	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
groups	I-Premise
at	I-Premise
90	I-Premise
days	I-Premise
(P	I-Premise
=	I-Premise
.002)	I-Premise
but	B-Premise
not	I-Premise
at	I-Premise
1	I-Premise
year	I-Premise
(P	I-Premise
=	I-Premise
.052).	I-Premise

Seven	O
days	O
of	O
diary	O
and	O
actigraphy	O
data	O
did	O
not	O
corroborate	O
with	O
monthly	O
reflections	O
(PSQI).	O

The	B-Premise
night	I-Premise
awakenings	I-Premise
(Actigraph)	I-Premise
pattern	I-Premise
was	I-Premise
significantly	I-Premise
different	I-Premise
by	I-Premise
group	I-Premise
over	I-Premise
time	I-Premise
(P	I-Premise
=	I-Premise
.046),	I-Premise
with	I-Premise
no	I-Premise
differences	I-Premise
between	I-Premise
groups	I-Premise
at	I-Premise
90	I-Premise
days	I-Premise
or	I-Premise
at	I-Premise
1	I-Premise
year.	I-Premise

Fatigue	B-Premise
was	I-Premise
lower	I-Premise
at	I-Premise
1	I-Premise
year	I-Premise
than	I-Premise
before	I-Premise
CTX;	I-Premise
no	B-Premise
group	I-Premise
effects	I-Premise
were	I-Premise
found.	I-Premise

The	B-Claim
BT	I-Claim
group,	I-Claim
on	I-Claim
average,	I-Claim
experienced	I-Claim
significant	I-Claim
improvement	I-Claim
on	I-Claim
global	I-Claim
sleep	I-Claim
quality	I-Claim
compared	I-Claim
with	I-Claim
the	I-Claim
HEC	I-Claim
group,	I-Claim
but	B-Claim
not	I-Claim
on	I-Claim
objective	I-Claim
sleep	I-Claim
or	I-Claim
fatigue	I-Claim
outcomes.	I-Claim

Both	O
gastrojejunostomy	O
(GJJ)	O
and	O
stent	O
placement	O
are	O
commonly	O
used	O
palliative	O
treatments	O
of	O
obstructive	O
symptoms	O
caused	O
by	O
malignant	O
gastric	O
outlet	O
obstruction	O
(GOO).	O

Compare	O
GJJ	O
and	O
stent	O
placement.	O

Multicenter,	O
randomized	O
trial.	O

Twenty-one	O
centers	O
in	O
The	O
Netherlands.	O

Patients	O
with	O
GOO.	O

GJJ	O
and	O
stent	O
placement.	O

Outcomes	O
were	O
medical	O
effects,	O
quality	O
of	O
life,	O
and	O
costs.	O

Analysis	O
was	O
by	O
intent	O
to	O
treat.	O

Eighteen	O
patients	O
were	O
randomized	O
to	O
GJJ	O
and	O
21	O
to	O
stent	O
placement.	O

Food	B-Premise
intake	I-Premise
improved	I-Premise
more	I-Premise
rapidly	I-Premise
after	I-Premise
stent	I-Premise
placement	I-Premise
than	I-Premise
after	I-Premise
GJJ	I-Premise
(GOO	I-Premise
Scoring	I-Premise
System	I-Premise
score	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
2:	I-Premise
median	I-Premise
5	I-Premise
vs	I-Premise
8	I-Premise
days,	I-Premise
respectively;	I-Premise
P	I-Premise
<	I-Premise
.01)	I-Premise
but	B-Premise
long-term	I-Premise
relief	I-Premise
was	I-Premise
better	I-Premise
after	I-Premise
GJJ,	I-Premise
with	I-Premise
more	I-Premise
patients	I-Premise
living	I-Premise
more	I-Premise
days	I-Premise
with	I-Premise
a	I-Premise
GOO	I-Premise
Scoring	I-Premise
System	I-Premise
score	I-Premise
of	I-Premise
2	I-Premise
or	I-Premise
more	I-Premise
than	I-Premise
after	I-Premise
stent	I-Premise
placement	I-Premise
(72	I-Premise
vs	I-Premise
50	I-Premise
days,	I-Premise
respectively;	I-Premise
P	I-Premise
=	I-Premise
.05).	I-Premise

More	B-Premise
major	I-Premise
complications	I-Premise
(stent:	I-Premise
6	I-Premise
in	I-Premise
4	I-Premise
patients	I-Premise
vs	I-Premise
GJJ:	I-Premise
0;	I-Premise
P	I-Premise
=	I-Premise
.02),	I-Premise
recurrent	I-Premise
obstructive	I-Premise
symptoms	I-Premise
(stent:	I-Premise
8	I-Premise
in	I-Premise
5	I-Premise
patients	I-Premise
vs	I-Premise
GJJ:	I-Premise
1	I-Premise
in	I-Premise
1	I-Premise
patient;	I-Premise
P	I-Premise
=	I-Premise
.02),	I-Premise
and	I-Premise
reinterventions	I-Premise
(stent:	I-Premise
10	I-Premise
in	I-Premise
7	I-Premise
patients	I-Premise
vs	I-Premise
GJJ:	I-Premise
2	I-Premise
in	I-Premise
2	I-Premise
patients;	I-Premise
P	I-Premise
<	I-Premise
.01)	I-Premise
were	I-Premise
observed	I-Premise
after	I-Premise
stent	I-Premise
placement	I-Premise
compared	I-Premise
with	I-Premise
GJJ.	I-Premise

When	B-Premise
stent	I-Premise
obstruction	I-Premise
was	I-Premise
not	I-Premise
regarded	I-Premise
as	I-Premise
a	I-Premise
major	I-Premise
complication,	I-Premise
no	I-Premise
differences	I-Premise
in	I-Premise
complications	I-Premise
were	I-Premise
found	I-Premise
(P	I-Premise
=	I-Premise
.4).	I-Premise

There	B-Premise
were	I-Premise
also	I-Premise
no	I-Premise
differences	I-Premise
in	I-Premise
median	I-Premise
survival	I-Premise
(stent:	I-Premise
56	I-Premise
days	I-Premise
vs	I-Premise
GJJ:	I-Premise
78	I-Premise
days)	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life.	I-Premise

Mean	B-Premise
total	I-Premise
costs	I-Premise
of	I-Premise
GJJ	I-Premise
were	I-Premise
higher	I-Premise
compared	I-Premise
with	I-Premise
stent	I-Premise
placement	I-Premise
($16,535	I-Premise
vs	I-Premise
$11,720,	I-Premise
respectively;	I-Premise
P	I-Premise
=	I-Premise
.049	I-Premise
[comparing	I-Premise
medians]).	I-Premise

Because	O
of	O
the	O
small	O
study	O
population,	O
only	O
initial	O
hospital	O
costs	O
would	O
have	O
been	O
statistically	O
significant	O
if	O
the	O
Bonferroni	O
correction	O
for	O
multiple	O
testing	O
had	O
been	O
applied.	O

Relatively	O
small	O
patient	O
population.	O

Despite	B-Premise
slow	I-Premise
initial	I-Premise
symptom	I-Premise
improvement,	I-Premise
GJJ	B-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
better	I-Claim
long-term	I-Claim
results	I-Claim
and	I-Claim
is	I-Claim
therefore	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
choice	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
a	I-Claim
life	I-Claim
expectancy	I-Claim
of	I-Claim
2	I-Claim
months	I-Claim
or	I-Claim
longer.	I-Claim

Because	B-Claim
stent	I-Claim
placement	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
better	I-Claim
short-term	I-Claim
outcomes,	I-Claim
this	B-Claim
treatment	I-Claim
is	I-Claim
preferable	I-Claim
for	I-Claim
patients	I-Claim
expected	I-Claim
to	I-Claim
live	I-Claim
less	I-Claim
than	I-Claim
2	I-Claim
months.	I-Claim

Gastrojejunostomy	O
(GJJ)	O
and	O
stent	O
placement	O
are	O
the	O
most	O
commonly	O
used	O
palliative	O
treatments	O
for	O
malignant	O
gastric	O
outlet	O
obstruction	O
(GOO).	O

In	O
a	O
recent	O
randomized	O
trial,	O
stent	O
placement	O
was	O
preferred	O
in	O
patients	O
with	O
a	O
relatively	O
short	O
survival	O
and	O
GJJ	O
in	O
patients	O
with	O
a	O
longer	O
survival.	O

As	O
health	O
economic	O
aspects	O
have	O
only	O
been	O
studied	O
in	O
general	O
terms,	O
we	O
estimated	O
the	O
cost	O
of	O
GJJ	O
and	O
that	O
of	O
stent	O
placement	O
in	O
such	O
patients.	O

In	O
the	O
SUSTENT	O
study,	O
patients	O
were	O
randomized	O
to	O
GJJ	O
(n	O
=	O
18)	O
or	O
stent	O
placement	O
(n	O
=	O
21).	O

Pancreatic	O
cancer	O
was	O
the	O
most	O
common	O
cause	O
of	O
GOO.	O

We	O
compared	O
initial	O
costs	O
and	O
costs	O
during	O
follow-up.	O

For	O
cost-effectiveness,	O
the	O
incremental	O
cost-effectiveness	O
ratio	O
was	O
calculated.	O

Food	B-Premise
intake	I-Premise
improved	I-Premise
more	I-Premise
rapidly	I-Premise
after	I-Premise
stent	I-Premise
placement	I-Premise
than	I-Premise
after	I-Premise
GJJ,	I-Premise
but	B-Premise
long-term	I-Premise
relief	I-Premise
of	I-Premise
obstructive	I-Premise
symptoms	I-Premise
was	I-Premise
better	I-Premise
after	I-Premise
GJJ.	I-Premise

More	B-Premise
major	I-Premise
complications	I-Premise
(P	I-Premise
=	I-Premise
0.02)	I-Premise
occurred	I-Premise
and	I-Premise
more	I-Premise
reinterventions	I-Premise
were	I-Premise
performed	I-Premise
(P	I-Premise
<	I-Premise
0.01)	I-Premise
after	I-Premise
stent	I-Premise
placement	I-Premise
than	I-Premise
after	I-Premise
GJJ.	I-Premise

Initial	B-Premise
costs	I-Premise
were	I-Premise
higher	I-Premise
for	I-Premise
GJJ	I-Premise
compared	I-Premise
to	I-Premise
stent	I-Premise
placement	I-Premise
(euro8315	I-Premise
vs.	I-Premise
euro4820,	I-Premise
P	I-Premise
<	I-Premise
0.001).	I-Premise

We	B-Premise
found	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
follow-up	I-Premise
costs.	I-Premise

Total	B-Premise
costs	I-Premise
per	I-Premise
patient	I-Premise
were	I-Premise
higher	I-Premise
for	I-Premise
GJJ	I-Premise
compared	I-Premise
to	I-Premise
stent	I-Premise
placement	I-Premise
(euro12433	I-Premise
vs.	I-Premise
euro8819,	I-Premise
P	I-Premise
=	I-Premise
0.049).	I-Premise

The	B-Premise
incremental	I-Premise
cost-effectiveness	I-Premise
ratio	I-Premise
of	I-Premise
GJJ	I-Premise
compared	I-Premise
to	I-Premise
stent	I-Premise
placement	I-Premise
was	I-Premise
euro164	I-Premise
per	I-Premise
extra	I-Premise
day	I-Premise
with	I-Premise
a	I-Premise
gastric	I-Premise
outlet	I-Premise
obstruction	I-Premise
scoring	I-Premise
system	I-Premise
(GOOSS)	I-Premise
>or=2	I-Premise
adjusted	I-Premise
for	I-Premise
survival.	I-Premise

Medical	B-Claim
effects	I-Claim
were	I-Claim
better	I-Claim
after	I-Claim
GJJ,	I-Claim
although	B-Claim
GJJ	I-Claim
had	I-Claim
higher	I-Claim
total	I-Claim
costs.	I-Claim

Since	B-Claim
the	I-Claim
cost	I-Claim
difference	I-Claim
between	I-Claim
the	I-Claim
two	I-Claim
treatments	I-Claim
was	I-Claim
only	I-Claim
small,	I-Claim
cost	B-Claim
should	I-Claim
not	I-Claim
play	I-Claim
a	I-Claim
predominant	I-Claim
role	I-Claim
when	I-Claim
deciding	I-Claim
on	I-Claim
the	I-Claim
type	I-Claim
of	I-Claim
treatment	I-Claim
assigned	I-Claim
to	I-Claim
patients	I-Claim
with	I-Claim
malignant	I-Claim
GOO.	I-Claim

Vasomotor	O
symptoms	O
are	O
common	O
adverse	O
effects	O
of	O
antiestrogen	O
hormone	O
treatment	O
in	O
conventional	O
breast	O
cancer	O
care.	O

Hormone	O
replacement	O
therapy	O
is	O
contraindicated	O
in	O
patients	O
with	O
breast	O
cancer.	O

Venlafaxine	O
(Effexor),	O
the	O
therapy	O
of	O
choice	O
for	O
these	O
symptoms,	O
has	O
numerous	O
adverse	O
effects.	O

Recent	O
studies	O
suggest	O
acupuncture	O
may	O
be	O
effective	O
in	O
reducing	O
vasomotor	O
symptoms	O
in	O
menopausal	O
women.	O

This	O
randomized	O
controlled	O
trial	O
tested	O
whether	O
acupuncture	O
reduces	O
vasomotor	O
symptoms	O
and	O
produces	O
fewer	O
adverse	O
effects	O
than	O
venlafaxine.	O

Fifty	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
12	O
weeks	O
of	O
acupuncture	O
(n	O
=	O
25)	O
or	O
venlafaxine	O
(n	O
=	O
25)	O
treatment.	O

Health	O
outcomes	O
were	O
measured	O
for	O
up	O
to	O
1	O
year	O
post-treatment.	O

Both	B-Premise
groups	I-Premise
exhibited	I-Premise
significant	I-Premise
decreases	I-Premise
in	I-Premise
hot	I-Premise
flashes,	I-Premise
depressive	I-Premise
symptoms,	I-Premise
and	I-Premise
other	I-Premise
quality-of-life	I-Premise
symptoms,	I-Premise
including	I-Premise
significant	I-Premise
improvements	I-Premise
in	I-Premise
mental	I-Premise
health	I-Premise
from	I-Premise
pre-	I-Premise
to	I-Premise
post-treatment.	I-Premise

These	B-Premise
changes	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
both	I-Premise
groups,	I-Premise
indicating	I-Premise
that	I-Premise
acupuncture	I-Premise
was	I-Premise
as	I-Premise
effective	I-Premise
as	I-Premise
venlafaxine.	I-Premise

By	B-Premise
2	I-Premise
weeks	I-Premise
post-treatment,	I-Premise
the	I-Premise
venlafaxine	I-Premise
group	I-Premise
experienced	I-Premise
significant	I-Premise
increases	I-Premise
in	I-Premise
hot	I-Premise
flashes,	I-Premise
whereas	I-Premise
hot	I-Premise
flashes	I-Premise
in	I-Premise
the	I-Premise
acupuncture	I-Premise
group	I-Premise
remained	I-Premise
at	I-Premise
low	I-Premise
levels.	I-Premise

The	B-Premise
venlafaxine	I-Premise
group	I-Premise
experienced	I-Premise
18	I-Premise
incidences	I-Premise
of	I-Premise
adverse	I-Premise
effects	I-Premise
(eg,	I-Premise
nausea,	I-Premise
dry	I-Premise
mouth,	I-Premise
dizziness,	I-Premise
anxiety),	I-Premise
whereas	I-Premise
the	I-Premise
acupuncture	I-Premise
group	I-Premise
experienced	I-Premise
no	I-Premise
negative	I-Premise
adverse	I-Premise
effects.	I-Premise

Acupuncture	B-Premise
had	I-Premise
the	I-Premise
additional	I-Premise
benefit	I-Premise
of	I-Premise
increased	I-Premise
sex	I-Premise
drive	I-Premise
in	I-Premise
some	I-Premise
women,	I-Premise
and	I-Premise
most	I-Premise
reported	I-Premise
an	I-Premise
improvement	I-Premise
in	I-Premise
their	I-Premise
energy,	I-Premise
clarity	I-Premise
of	I-Premise
thought,	I-Premise
and	I-Premise
sense	I-Premise
of	I-Premise
well-being.	I-Premise

Acupuncture	B-Claim
appears	I-Claim
to	I-Claim
be	I-Claim
equivalent	I-Claim
to	I-Claim
drug	I-Claim
therapy	I-Claim
in	I-Claim
these	I-Claim
patients.	I-Claim

It	B-Claim
is	I-Claim
a	I-Claim
safe,	I-Claim
effective	I-Claim
and	I-Claim
durable	I-Claim
treatment	I-Claim
for	I-Claim
vasomotor	I-Claim
symptoms	I-Claim
secondary	I-Claim
to	I-Claim
long-term	I-Claim
antiestrogen	I-Claim
hormone	I-Claim
use	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
breast	I-Claim
cancer.	I-Claim

Few	O
reports	O
have	O
examined	O
the	O
use	O
of	O
recombinant	O
human	O
thyroid-stimulating	O
hormone	O
(rhTSH)	O
for	O
ablation	O
of	O
postsurgical	O
thyroid	O
remnants	O
after	O
low-dose	O
radioactive	O
iodine	O
(RI)	O
therapy,	O
compared	O
with	O
conventional	O
thyroid	O
hormone	O
withdrawal.	O

We	O
investigated	O
whether	O
patient	O
preparation	O
using	O
rhTSH	O
was	O
comparable	O
to	O
conventional	O
thyroid	O
hormone	O
withdrawal	O
with	O
respect	O
to	O
efficacy	O
of	O
postsurgical	O
remnant	O
ablation	O
in	O
low-risk	O
patients	O
receiving	O
a	O
30	O
mCi	O
RI.	O

In	O
addition,	O
we	O
also	O
evaluated	O
the	O
impact	O
of	O
rhTSH	O
(rhTSH	O
vs.	O
conventional	O
thyroid	O
hormone	O
withdrawal)	O
on	O
quality	O
of	O
life	O
(QoL)	O
of	O
thyroid	O
cancer	O
patients	O
undergoing	O
RI	O
ablation.	O

This	O
study	O
included	O
three	O
groups	O
of	O
patients,	O
enrolled	O
consecutively.	O

From	O
February	O
2006	O
to	O
March	O
2007,	O
291	O
patients	O
were	O
enrolled	O
and	O
randomized,	O
after	O
total	O
thyroidectomy:	O
(1)	O
withdrawal	O
of	O
levothyroxine	O
(LT4)	O
for	O
4	O
weeks	O
(T4-WD	O
Group,	O
n	O
=	O
89),	O
(2)	O
withdrawal	O
of	O
LT4	O
for	O
4	O
weeks	O
plus	O
2	O
weeks	O
on	O
and	O
then	O
2	O
weeks	O
off	O
liothyronine	O
(LT3)	O
(T3-WD	O
Group,	O
n	O
=	O
133),	O
and	O
(3)	O
rhTSH	O
administration	O
(rhTSH	O
Group,	O
n	O
=	O
69).	O

QoL	O
was	O
determined	O
at	O
the	O
time	O
of	O
ablation.	O

Patients	O
in	O
the	O
three	O
groups	O
did	O
not	O
differ	O
significantly	O
in	O
baseline	O
characteristics	O
or	O
tumor,	O
node	O
and	O
metastasis	O
(TNM)	O
staging.	O

In	B-Premise
all	I-Premise
study	I-Premise
groups,	I-Premise
serum	I-Premise
TSH	I-Premise
levels	I-Premise
showed	I-Premise
very	I-Premise
good	I-Premise
stimulation	I-Premise
(mean,	I-Premise
82.24	I-Premise
+/-	I-Premise
18.21	I-Premise
mU/L),	I-Premise
without	I-Premise
significant	I-Premise
between-group	I-Premise
differences	I-Premise
(p	I-Premise
=	I-Premise
0.5213).	I-Premise

Follow-up	O
examinations	O
were	O
performed	O
12	O
months	O
after	O
ablation	O
to	O
assess	O
ablation	O
outcome	O
in	O
each	O
group	O
by	O
131	O
whole	O
body	O
scans	O
(WBSs),	O
serum	O
thyroglobulin	O
measurement	O
after	O
TSH	O
stimulation,	O
and	O
neck	O
ultrasonography.	O

The	B-Premise
successful	I-Premise
ablation	I-Premise
rate	I-Premise
was	I-Premise
91.0%	I-Premise
in	I-Premise
T4-WD	I-Premise
Group,	I-Premise
91.7%	I-Premise
in	I-Premise
T3-WD	I-Premise
Group,	I-Premise
and	I-Premise
91.3%	I-Premise
in	I-Premise
rhTSH	I-Premise
Group,	I-Premise
without	I-Premise
significant	I-Premise
between-preparation	I-Premise
differences	I-Premise
(p	I-Premise
=	I-Premise
0.2061).	I-Premise

QoL	B-Premise
was	I-Premise
better	I-Premise
preserved	I-Premise
in	I-Premise
rhTSH	I-Premise
Group	I-Premise
than	I-Premise
in	I-Premise
T4-WD	I-Premise
and	I-Premise
T3-WD	I-Premise
Groups	I-Premise
(p	I-Premise
<	I-Premise
0.0001).	I-Premise

However,	B-Premise
there	I-Premise
was	I-Premise
no	I-Premise
QoL	I-Premise
difference	I-Premise
at	I-Premise
the	I-Premise
time	I-Premise
of	I-Premise
ablation	I-Premise
between	I-Premise
T4-WD	I-Premise
and	I-Premise
T3-WD	I-Premise
Groups.	I-Premise

Our	B-Claim
study	I-Claim
indicates	I-Claim
that	I-Claim
use	I-Claim
of	I-Claim
rhTSH	I-Claim
preserves	I-Claim
QoL	I-Claim
in	I-Claim
patients	I-Claim
undergoing	I-Claim
RI	I-Claim
ablation	I-Claim
and	I-Claim
affords	I-Claim
an	I-Claim
ablation	I-Claim
success	I-Claim
rate	I-Claim
comparable	I-Claim
to	I-Claim
that	I-Claim
seen	I-Claim
after	I-Claim
thyroid	I-Claim
hormone	I-Claim
withdrawal.	I-Claim

Notably,	O
ablation	O
preparation	O
using	O
withdrawal	O
of	O
LT3	O
for	O
2	O
weeks	O
did	O
not	O
prevent	O
development	O
of	O
profound	O
hypothyroidism,	O
as	O
also	O
occurred	O
when	O
LT4	O
alone	O
was	O
withdrawn	O
for	O
4	O
weeks.	O

To	O
test	O
the	O
hypothesis	O
that	O
modulation	O
of	O
Bcl-2	O
with	O
13-cis	O
retinoic	O
acid	O
(CRA)/interferon-alpha2b	O
(IFN)	O
with	O
paclitaxel	O
(TAX),	O
or	O
mitoxantrone,	O
estramustine	O
and	O
vinorelbine	O
(MEV)	O
will	O
have	O
clinical	O
activity	O
in	O
men	O
with	O
metastatic	O
castrate-resistant	O
prostate	O
cancer	O
(CRPC).	O

70	O
patients	O
were	O
treated	O
with	O
either	O
MEV	O
(Arm	O
A)	O
in	O
a	O
3-week	O
cycle	O
or	O
CRA/IFN/TAX	O
with	O
an	O
8-week	O
cycle	O
(Arm	O
B).	O

Patients	O
were	O
assessed	O
for	O
response,	O
toxicity,	O
quality	O
of	O
life	O
(QOL),	O
and	O
the	O
effect	O
of	O
treatment	O
on	O
Bcl-2	O
levels	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(PBMC).	O

The	B-Premise
PSA	I-Premise
response	I-Premise
rates	I-Premise
were	I-Premise
50%	I-Premise
and	I-Premise
23%,	I-Premise
measurable	I-Premise
disease	I-Premise
response	I-Premise
rates	I-Premise
(CR+PR)	I-Premise
14%	I-Premise
and	I-Premise
15%,	I-Premise
and	I-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
19.4	I-Premise
months	I-Premise
and	I-Premise
13.9	I-Premise
months	I-Premise
on	I-Premise
Arm	I-Premise
A	I-Premise
and	I-Premise
Arm	I-Premise
B	I-Premise
respectively.	I-Premise

Transient	B-Premise
grade	I-Premise
4	I-Premise
neutropenia	I-Premise
occurred	I-Premise
in	I-Premise
18	I-Premise
and	I-Premise
2	I-Premise
patients,	I-Premise
and	I-Premise
grade	I-Premise
3	I-Premise
to	I-Premise
4	I-Premise
thrombosis	I-Premise
in	I-Premise
7	I-Premise
patients	I-Premise
and	I-Premise
1	I-Premise
patient	I-Premise
in	I-Premise
Arm	I-Premise
A	I-Premise
and	I-Premise
Arm	I-Premise
B	I-Premise
respectively.	I-Premise

Patients	B-Premise
on	I-Premise
Arm	I-Premise
B	I-Premise
reported	I-Premise
a	I-Premise
clinically	I-Premise
significant	I-Premise
decline	I-Premise
in	I-Premise
QOL	I-Premise
between	I-Premise
baseline	I-Premise
and	I-Premise
week	I-Premise
9/10	I-Premise
(.71	I-Premise
s.d.),	I-Premise
and	I-Premise
a	I-Premise
significantly	I-Premise
lower	I-Premise
level	I-Premise
of	I-Premise
QOL	I-Premise
than	I-Premise
Arm	I-Premise
A	I-Premise
(p	I-Premise
=	I-Premise
0.01).	I-Premise

As	B-Premise
hypothesized,	I-Premise
Bcl-2	I-Premise
levels	I-Premise
decreased	I-Premise
with	I-Premise
CRA/IFN	I-Premise
therapy	I-Premise
only	I-Premise
in	I-Premise
Arm	I-Premise
B	I-Premise
(p	I-Premise
=	I-Premise
0.03).	I-Premise

Treatment	B-Claim
with	I-Claim
MEV	I-Claim
was	I-Claim
well	I-Claim
tolerated	I-Claim
and	I-Claim
demonstrated	I-Claim
clinical	I-Claim
activity	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
CRPC.	I-Claim

Given	B-Claim
the	I-Claim
adverse	I-Claim
effect	I-Claim
of	I-Claim
CRA/IFN/TAX	I-Claim
on	I-Claim
QOL,	I-Claim
the	I-Claim
study	I-Claim
of	I-Claim
other	I-Claim
novel	I-Claim
agents	I-Claim
that	I-Claim
target	I-Claim
Bcl-2	I-Claim
family	I-Claim
proteins	I-Claim
is	I-Claim
warranted.	I-Claim

The	O
feasibility	O
of	O
measuring	O
Bcl-2	O
protein	O
in	O
a	O
cooperative	O
group	O
setting	O
is	O
hypothesis	O
generating	O
and	O
supports	O
further	O
study	O
as	O
a	O
marker	O
for	O
Bcl-2	O
targeted	O
therapy.	O

To	O
determine	O
the	O
feasibility	O
of	O
administering	O
a	O
flavonoid-rich	O
adjunctive	O
treatment	O
(Concord	O
grape	O
juice)	O
for	O
the	O
management	O
of	O
chemotherapy-induced	O
nausea	O
and	O
vomiting	O
(CINV);	O
to	O
evaluate	O
the	O
usefulness	O
of	O
existing	O
measures	O
for	O
assessing	O
CINV	O
frequency	O
and	O
severity,	O
quality	O
of	O
life,	O
control	O
over	O
life	O
events,	O
and	O
psychological	O
state;	O
to	O
identify	O
any	O
actual	O
or	O
potential	O
adverse	O
events	O
associated	O
with	O
frequent	O
grape	O
juice	O
intake;	O
and	O
to	O
provide	O
preliminary	O
data	O
concerning	O
the	O
effect	O
of	O
Concord	O
grape	O
juice	O
on	O
CINV,	O
quality	O
of	O
life,	O
perceived	O
control	O
over	O
life	O
events,	O
and	O
psychological	O
state.	O

Double-blind,	O
randomized	O
clinical	O
trial.	O

A	O
cancer	O
center	O
in	O
an	O
academic	O
health	O
science	O
center	O
in	O
the	O
northeastern	O
United	O
States.	O

77	O
adult	O
patients	O
with	O
cancer	O
receiving	O
moderately	O
or	O
highly	O
emetogenic	O
chemotherapy	O
agents.	O

Participants	O
drank	O
4	O
oz.	O
of	O
grape	O
juice	O
or	O
placebo	O
prior	O
to	O
meals	O
for	O
one	O
week	O
following	O
each	O
of	O
four	O
chemotherapy	O
treatment	O
cycles.	O

They	O
recorded	O
frequency,	O
duration,	O
and	O
distress	O
of	O
nausea,	O
vomiting,	O
and	O
retching	O
daily,	O
beginning	O
the	O
evening	O
of	O
chemotherapy	O
administration	O
and	O
continuing	O
for	O
seven	O
days.	O

Data	O
were	O
analyzed	O
with	O
generalized	O
estimating	O
equations	O
methodology	O
to	O
model	O
differences	O
between	O
groups	O
over	O
time.	O

Nausea	B-Premise
and	I-Premise
vomiting	I-Premise
frequency,	I-Premise
duration,	I-Premise
and	I-Premise
distress	I-Premise
were	I-Premise
lower	I-Premise
for	I-Premise
experimental	I-Premise
group	I-Premise
members,	I-Premise
although	B-Premise
a	I-Premise
high	I-Premise
attrition	I-Premise
rate	I-Premise
(50%)	I-Premise
resulted	I-Premise
in	I-Premise
insufficient	I-Premise
power	I-Premise
to	I-Premise
detect	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
over	I-Premise
time.	I-Premise

Greater	O
levels	O
of	O
anxiety,	O
depression,	O
and	O
hostility	O
at	O
baseline	O
were	O
related	O
to	O
nausea	O
and	O
vomiting,	O
quality	O
of	O
life,	O
and	O
perceived	O
control	O
over	O
decision	O
making.	O

The	B-Claim
effect	I-Claim
of	I-Claim
grape	I-Claim
juice	I-Claim
flavonoids	I-Claim
on	I-Claim
CINV	I-Claim
should	I-Claim
be	I-Claim
investigated	I-Claim
further	I-Claim
with	I-Claim
a	I-Claim
larger	I-Claim
sample	I-Claim
to	I-Claim
determine	I-Claim
whether	I-Claim
preliminary	I-Claim
findings	I-Claim
are	I-Claim
supported.	I-Claim

Alterations	O
to	O
the	O
study	O
protocol	O
will	O
be	O
necessary	O
to	O
decrease	O
attrition.	O

Flavonoid-rich	B-Claim
fruits	I-Claim
and	I-Claim
vegetables	I-Claim
may	I-Claim
provide	I-Claim
additional	I-Claim
protection	I-Claim
against	I-Claim
CINV.	I-Claim

If	O
the	O
compounds	O
work,	O
they	O
would	O
offer	O
a	O
low-cost,	O
readily	O
available	O
adjunctive	O
treatment	O
for	O
the	O
management	O
of	O
CINV.	O

Promising	O
results	O
in	O
a	O
randomized	O
phase	O
II	O
trial	O
with	O
the	O
hypoxic	O
cytotoxin	O
tirapazamine	O
(TPZ)	O
combined	O
with	O
cisplatin	O
(CIS)	O
and	O
radiation	O
led	O
to	O
this	O
phase	O
III	O
trial.	O

Patients	O
with	O
previously	O
untreated	O
stage	O
III	O
or	O
IV	O
(excluding	O
T1-2N1	O
and	O
M1)	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
oral	O
cavity,	O
oropharynx,	O
hypopharynx,	O
or	O
larynx	O
were	O
randomly	O
assigned	O
to	O
receive	O
definitive	O
radiotherapy	O
(70	O
Gy	O
in	O
7	O
weeks)	O
concurrently	O
with	O
either	O
CIS	O
(100	O
mg/m(2))	O
on	O
day	O
1	O
of	O
weeks	O
1,	O
4,	O
and	O
7	O
or	O
CIS	O
(75	O
mg/m(2))	O
plus	O
TPZ	O
(290	O
mg/m(2)/d)	O
on	O
day	O
1	O
of	O
weeks	O
1,	O
4,	O
and	O
7	O
and	O
TPZ	O
alone	O
(160	O
mg/m(2)/d)	O
on	O
days	O
1,	O
3,	O
and	O
5	O
of	O
weeks	O
2	O
and	O
3	O
(TPZ/CIS).	O

The	O
primary	O
end	O
point	O
was	O
overall	O
survival	O
(OS).	O

The	O
planned	O
sample	O
size	O
was	O
850,	O
estimated	O
to	O
result	O
in	O
334	O
deaths,	O
which	O
would	O
provide	O
90%	O
power	O
to	O
detect	O
a	O
difference	O
in	O
2-year	O
survival	O
rates	O
of	O
60%	O
v	O
70%	O
for	O
CIS	O
versus	O
TPZ/CIS,	O
respectively	O
(hazard	O
ratio	O
=	O
0.69).	O

Eight	O
hundred	O
sixty-one	O
patients	O
were	O
accrued	O
from	O
89	O
sites	O
in	O
16	O
countries.	O

In	B-Premise
an	I-Premise
intent-to-treat	I-Premise
analysis,	I-Premise
the	I-Premise
2-year	I-Premise
OS	I-Premise
rates	I-Premise
were	I-Premise
65.7%	I-Premise
for	I-Premise
CIS	I-Premise
and	I-Premise
66.2%	I-Premise
for	I-Premise
TPZ/CIS	I-Premise
(TPZ/CIS--CIS:	I-Premise
95%	I-Premise
CI,	I-Premise
-5.9%	I-Premise
to	I-Premise
6.9%).	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
failure-free	I-Premise
survival,	I-Premise
time	I-Premise
to	I-Premise
locoregional	I-Premise
failure,	I-Premise
or	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
as	I-Premise
measured	I-Premise
by	I-Premise
Functional	I-Premise
Assessment	I-Premise
of	I-Premise
Cancer	I-Premise
Therapy-Head	I-Premise
and	I-Premise
Neck.	I-Premise

We	B-Claim
found	I-Claim
no	I-Claim
evidence	I-Claim
that	I-Claim
the	I-Claim
addition	I-Claim
of	I-Claim
TPZ	I-Claim
to	I-Claim
chemoradiotherapy,	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
head	I-Claim
and	I-Claim
neck	I-Claim
cancer	I-Claim
not	I-Claim
selected	I-Claim
for	I-Claim
the	I-Claim
presence	I-Claim
of	I-Claim
hypoxia,	I-Claim
improves	I-Claim
OS.	I-Claim

To	O
examine	O
the	O
effects	O
of	O
a	O
scapula-oriented	O
exercise	O
on	O
upper	O
limb	O
dysfunction	O
in	O
breast	O
cancer	O
survivors.	O

A	O
prospective	O
randomized,	O
controlled	O
pilot	O
trial	O
with	O
historical	O
control.	O

Rehabilitation	O
department	O
at	O
a	O
university	O
hospital.	O

Thirty-two	O
women	O
with	O
breast	O
cancer	O
were	O
randomly	O
assigned	O
to	O
scapula-oriented	O
exercise	O
group	O
(n	O
=	O
16)	O
and	O
general	O
exercise	O
group	O
(n	O
=	O
16).	O

An	O
historical	O
control	O
group	O
(n	O
=	O
18)	O
without	O
exercise	O
was	O
enrolled	O
from	O
breast	O
cancer	O
survivors.	O

The	O
scapula-oriented	O
exercises	O
were	O
designed	O
focusing	O
on	O
scapulothoracic	O
movement.	O

The	O
general	O
exercise	O
group	O
performed	O
body	O
conditioning	O
exercise.	O

Exercise	O
therapies	O
were	O
performed	O
for	O
one	O
session	O
per	O
week	O
for	O
eight	O
weeks.	O

Pain	O
and	O
physical	O
disabilities	O
related	O
to	O
upper	O
limb	O
dysfunction,	O
quality	O
of	O
life	O
and	O
depression	O
were	O
used	O
as	O
subjective	O
outcomes.	O

Objective	O
outcome	O
measures	O
included	O
shoulder	O
range	O
of	O
motion	O
and	O
strength.	O

Outcomes	O
were	O
assessed	O
at	O
baseline	O
and	O
post	O
exercise.	O

At	O
baseline,	O
no	O
significant	O
difference	O
was	O
observed	O
among	O
the	O
three	O
groups.	O

The	B-Premise
scapula-oriented	I-Premise
exercise	I-Premise
group	I-Premise
showed	I-Premise
improvements	I-Premise
in	I-Premise
pain,	I-Premise
physical	I-Premise
function,	I-Premise
social	I-Premise
function,	I-Premise
and	I-Premise
global	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
compared	I-Premise
with	I-Premise
baseline,	I-Premise
whereas	I-Premise
the	I-Premise
general	I-Premise
exercise	I-Premise
group	I-Premise
showed	I-Premise
improved	I-Premise
fatigue	I-Premise
and	I-Premise
range	I-Premise
of	I-Premise
motion.	I-Premise

The	B-Premise
change	I-Premise
in	I-Premise
global	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(P	I-Premise
=	I-Premise
0.067;	I-Premise
effect	I-Premise
size,	I-Premise
0.33)	I-Premise
and	I-Premise
strength	I-Premise
of	I-Premise
external	I-Premise
rotation	I-Premise
(P	I-Premise
=	I-Premise
0.001;	I-Premise
effect	I-Premise
size,	I-Premise
0.55)	I-Premise
were	I-Premise
significantly	I-Premise
greater	I-Premise
in	I-Premise
the	I-Premise
scapula-oriented	I-Premise
exercise	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
general	I-Premise
exercise	I-Premise
and	I-Premise
control	I-Premise
group.	I-Premise

Scapula-oriented	B-Claim
exercise	I-Claim
had	I-Claim
beneficial	I-Claim
effects	I-Claim
on	I-Claim
pain,	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
and	I-Claim
aspects	I-Claim
of	I-Claim
strength.	I-Claim

The	O
sample	O
size	O
required	O
in	O
a	O
larger	O
definitive	O
study	O
is	O
32	O
subjects	O
per	O
group.	O

For	O
patients	O
undergoing	O
oncologic	O
surgery,	O
the	O
quality	O
of	O
life	O
(QoL)	O
is	O
generally	O
accepted	O
as	O
an	O
important	O
outcome	O
parameter	O
in	O
addition	O
to	O
long-term	O
survival,	O
mortality	O
and	O
complication	O
rates.	O

This	O
study	O
focussed	O
on	O
the	O
QoL	O
in	O
patients	O
after	O
oesophagectomy	O
for	O
cancer,	O
comparing	O
the	O
method	O
of	O
reconstruction	O
(narrow	O
gastric	O
tube	O
vs	O
whole	O
stomach).	O

In	O
a	O
prospective	O
randomised	O
single-centre	O
study	O
from	O
2007	O
to	O
2008,	O
104	O
patients	O
underwent	O
oesophagectomy	O
for	O
cancer.	O

To	O
assess	O
the	O
QoL,	O
a	O
questionnaire	O
in	O
reference	O
to	O
the	O
EORTC-QLQ-C30	O
and	O
the	O
QLQ-OES24	O
was	O
administered	O
at	O
3	O
weeks,	O
6	O
months	O
and	O
1	O
year	O
after	O
surgery.	O

Clinical	O
data	O
were	O
collected	O
prospectively,	O
and	O
follow-up	O
was	O
performed	O
regularly.	O

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
the	I-Premise
narrow	I-Premise
gastric	I-Premise
tube	I-Premise
group	I-Premise
(NGT	I-Premise
group,	I-Premise
n=52)	I-Premise
and	I-Premise
the	I-Premise
whole-stomach	I-Premise
group	I-Premise
(WS	I-Premise
group,	I-Premise
n=52)	I-Premise
with	I-Premise
regard	I-Premise
to	I-Premise
patient	I-Premise
and	I-Premise
cancer	I-Premise
characteristics,	I-Premise
operative	I-Premise
procedure,	I-Premise
postoperative	I-Premise
intensive	I-Premise
care	I-Premise
unit	I-Premise
(ICU)	I-Premise
hospitalisation,	I-Premise
and	I-Premise
overall	I-Premise
survival	I-Premise
at	I-Premise
1	I-Premise
year.	I-Premise

Regarding	B-Premise
the	I-Premise
postoperative	I-Premise
complication,	I-Premise
there	I-Premise
were	I-Premise
more	I-Premise
cases	I-Premise
of	I-Premise
postoperative	I-Premise
reflux	I-Premise
oesophagitis	I-Premise
and	I-Premise
impairment	I-Premise
of	I-Premise
pulmonary	I-Premise
function	I-Premise
in	I-Premise
the	I-Premise
WS	I-Premise
group	I-Premise
(P<0.05).	I-Premise

Regarding	B-Premise
the	I-Premise
QoL	I-Premise
investigation,	I-Premise
the	I-Premise
scores	I-Premise
of	I-Premise
QoL	I-Premise
dropped	I-Premise
for	I-Premise
all	I-Premise
patients	I-Premise
at	I-Premise
3	I-Premise
weeks	I-Premise
after	I-Premise
surgery.	I-Premise

Slowly,	O
recovery	B-Premise
was	I-Premise
found	I-Premise
at	I-Premise
both	I-Premise
6	I-Premise
months	I-Premise
and	I-Premise
1	I-Premise
year	I-Premise
in	I-Premise
both	I-Premise
groups.	I-Premise

Patients	B-Premise
in	I-Premise
the	I-Premise
NGT	I-Premise
group	I-Premise
reported	I-Premise
significantly	I-Premise
(P<0.05)	I-Premise
better	I-Premise
scores	I-Premise
of	I-Premise
QoL	I-Premise
at	I-Premise
both	I-Premise
6	I-Premise
months	I-Premise
and	I-Premise
1	I-Premise
year.	I-Premise

Patients	B-Claim
who	I-Claim
underwent	I-Claim
gastric	I-Claim
tube	I-Claim
reconstruction	I-Claim
develop	I-Claim
less	I-Claim
postoperative	I-Claim
digestive	I-Claim
tract	I-Claim
complications,	I-Claim
and	I-Claim
have	I-Claim
a	I-Claim
quicker	I-Claim
recovery	I-Claim
and	I-Claim
a	I-Claim
better	I-Claim
QoL	I-Claim
during	I-Claim
the	I-Claim
follow-up	I-Claim
period.	I-Claim

Further	O
investigation	O
and	O
data	O
collection	O
will	O
allow	O
the	O
assessment	O
of	O
this	O
procedure	O
beyond	O
1	O
year	O
after	O
operation.	O

Paclitaxel	O
and	O
pegylated	O
liposomal	O
doxorubicin	O
(PLD)	O
are	O
active	O
cytotoxic	O
agents	O
for	O
the	O
treatment	O
of	O
human	O
immunodeficiency	O
virus	O
(HIV)-associated	O
Kaposi	O
sarcoma	O
(KS).	O

A	O
randomized	O
trial	O
comparing	O
the	O
efficacy	O
and	O
toxicity	O
of	O
paclitaxel	O
and	O
PLD	O
was	O
performed,	O
and	O
the	O
effects	O
of	O
therapy	O
on	O
symptom	O
palliation	O
and	O
quality	O
of	O
life	O
were	O
determined.	O

Patients	O
with	O
advanced	O
HIV-associated	O
KS	O
were	O
randomly	O
assigned	O
to	O
receive	O
paclitaxel	O
at	O
a	O
dose	O
of	O
100	O
mg/m2	O
intravenously	O
(iv)	O
every	O
2	O
weeks	O
or	O
PLD	O
at	O
a	O
dose	O
of	O
20	O
mg/m2	O
iv	O
every	O
3	O
weeks.	O

The	O
KS	O
Functional	O
Assessment	O
of	O
HIV	O
(FAHI)	O
quality	O
of	O
life	O
instrument	O
was	O
used	O
before	O
and	O
after	O
every	O
other	O
treatment	O
cycle.	O

The	O
study	O
included	O
73	O
analyzable	O
patients	O
enrolled	O
between	O
1998	O
and	O
2002,	O
including	O
36	O
in	O
the	O
paclitaxel	O
arm	O
and	O
37	O
in	O
the	O
PLD	O
arm;	O
73%	O
of	O
patients	O
received	O
highly	O
active	O
antiretroviral	O
therapy	O
(HAART)	O
and	O
32%	O
had	O
an	O
undetectable	O
viral	O
load	O
(<400	O
copies/mL).	O

Treatment	B-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
significant	I-Premise
improvements	I-Premise
in	I-Premise
pain	I-Premise
(P=.024)	I-Premise
and	I-Premise
swelling	I-Premise
(P<.001).	I-Premise

Of	B-Premise
the	I-Premise
36	I-Premise
patients	I-Premise
who	I-Premise
reported	I-Premise
that	I-Premise
pain	I-Premise
interfered	I-Premise
with	I-Premise
their	I-Premise
normal	I-Premise
work	I-Premise
or	I-Premise
activities	I-Premise
at	I-Premise
baseline,	I-Premise
25	I-Premise
(69%)	I-Premise
improved.	I-Premise

Of	B-Premise
the	I-Premise
41	I-Premise
patients	I-Premise
who	I-Premise
reported	I-Premise
swelling	I-Premise
at	I-Premise
baseline,	I-Premise
38	I-Premise
(93%)	I-Premise
improved.	I-Premise

Comparing	B-Premise
the	I-Premise
paclitaxel	I-Premise
and	I-Premise
PLD	I-Premise
arms	I-Premise
revealed	I-Premise
comparable	I-Premise
response	I-Premise
rates	I-Premise
(56%	I-Premise
vs	I-Premise
46%;	I-Premise
P=.49),	I-Premise
median	I-Premise
progression-free	I-Premise
survival	I-Premise
(17.5	I-Premise
months	I-Premise
vs	I-Premise
12.2	I-Premise
months;	I-Premise
P=.66),	I-Premise
and	I-Premise
2-year	I-Premise
survival	I-Premise
rates	I-Premise
(79%	I-Premise
vs	I-Premise
78%;	I-Premise
P=.75),	I-Premise
but	B-Premise
somewhat	I-Premise
more	I-Premise
grade	I-Premise
3	I-Premise
to	I-Premise
5	I-Premise
toxicity	I-Premise
for	I-Premise
paclitaxel	I-Premise
(84%	I-Premise
vs	I-Premise
66%;	I-Premise
P=.077).	I-Premise

Treatment	B-Claim
with	I-Claim
either	I-Claim
paclitaxel	I-Claim
or	I-Claim
PLD	I-Claim
appears	I-Claim
to	I-Claim
produce	I-Claim
significant	I-Claim
improvements	I-Claim
in	I-Claim
pain	I-Claim
and	I-Claim
swelling	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced,	I-Claim
symptomatic,	I-Claim
HIV-associated	I-Claim
KS	I-Claim
treated	I-Claim
in	I-Claim
the	I-Claim
HAART	I-Claim
era.	I-Claim

Lung	O
cancer	O
is	O
one	O
of	O
the	O
most	O
common	O
cancers	O
in	O
the	O
United	O
States	O
and	O
is	O
associated	O
with	O
high	O
levels	O
of	O
symptoms,	O
including	O
pain,	O
fatigue,	O
shortness	O
of	O
breath,	O
and	O
psychological	O
distress.	O

Caregivers	O
and	O
patients	O
are	O
adversely	O
affected.	O

However,	O
previous	O
studies	O
of	O
coping	O
skills	O
training	O
(CST)	O
interventions	O
have	O
not	O
been	O
tested	O
in	O
patients	O
with	O
lung	O
cancer	O
nor	O
have	O
systematically	O
included	O
caregivers.	O

This	O
study	O
tested	O
the	O
efficacy	O
of	O
a	O
caregiver-assisted	O
CST	O
protocol	O
in	O
a	O
sample	O
of	O
patients	O
with	O
lung	O
cancer.	O

Two	O
hundred	O
thirty-three	O
lung	O
cancer	O
patients	O
and	O
their	O
caregivers	O
were	O
randomly	O
assigned	O
to	O
receive	O
14	O
telephone-based	O
sessions	O
of	O
either	O
caregiver-assisted	O
CST	O
or	O
education/support	O
involving	O
the	O
caregiver.	O

Patients	O
completed	O
measures	O
assessing	O
pain,	O
psychological	O
distress,	O
quality	O
of	O
life	O
(QOL),	O
and	O
self-efficacy	O
for	O
symptom	O
management;	O
caregivers	O
completed	O
measures	O
assessing	O
psychological	O
distress,	O
caregiver	O
strain,	O
and	O
self-efficacy	O
for	O
helping	O
the	O
patient	O
manage	O
symptoms.	O

Patients	B-Premise
in	I-Premise
both	I-Premise
treatment	I-Premise
conditions	I-Premise
showed	I-Premise
improvements	I-Premise
in	I-Premise
pain,	I-Premise
depression,	I-Premise
QOL,	I-Premise
and	I-Premise
self-efficacy,	I-Premise
and	I-Premise
caregivers	I-Premise
in	I-Premise
both	I-Premise
conditions	I-Premise
showed	I-Premise
improvements	I-Premise
in	I-Premise
anxiety	I-Premise
and	I-Premise
self-efficacy	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
four-month	I-Premise
follow-up.	I-Premise

Results	B-Premise
of	I-Premise
exploratory	I-Premise
analyses	I-Premise
suggested	I-Premise
that	I-Premise
the	I-Premise
CST	I-Premise
intervention	I-Premise
was	I-Premise
more	I-Premise
beneficial	I-Premise
to	I-Premise
patients/caregivers	I-Premise
with	I-Premise
Stage	I-Premise
II	I-Premise
and	I-Premise
III	I-Premise
cancers,	I-Premise
whereas	O
the	B-Premise
education/support	I-Premise
intervention	I-Premise
was	I-Premise
more	I-Premise
beneficial	I-Premise
to	I-Premise
patients/caregivers	I-Premise
with	I-Premise
Stage	I-Premise
I	I-Premise
cancer.	I-Premise

Taken	B-Premise
together	I-Premise
with	I-Premise
the	I-Premise
broader	I-Premise
literature	I-Premise
in	I-Premise
this	I-Premise
area,	I-Premise
results	B-Claim
from	I-Claim
this	I-Claim
study	I-Claim
suggest	I-Claim
that	I-Claim
psychosocial	I-Claim
interventions	I-Claim
can	I-Claim
lead	I-Claim
to	I-Claim
improvements	I-Claim
in	I-Claim
a	I-Claim
range	I-Claim
of	I-Claim
outcomes	I-Claim
for	I-Claim
cancer	I-Claim
patients.	I-Claim

Suggestions	O
for	O
future	O
studies	O
include	O
the	O
use	O
of	O
three-group	O
designs	O
(e.g.,	O
comparing	O
two	O
active	O
interventions	O
with	O
a	O
standard-care	O
control)	O
and	O
examining	O
mechanisms	O
of	O
change.	O

The	O
EORTC	O
24971/TAX	O
323,	O
a	O
phase	O
III	O
study	O
of	O
358	O
patients	O
with	O
unresectable	O
locoregionally	O
advanced	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck,	O
showed	O
an	O
improved	O
progression-free	O
and	O
overall	O
survival	O
(OS)	O
with	O
less	O
toxicity	O
when	O
docetaxel	O
(T)	O
was	O
added	O
to	O
cisplatin	O
and	O
5-fluorouracil	O
(PF)	O
for	O
induction	O
and	O
given	O
before	O
radiotherapy	O
(RT).	O

The	O
impact	O
of	O
the	O
addition	O
of	O
docetaxel	O
on	O
patients'	O
health-related	O
quality	O
of	O
life	O
(HRQOL)	O
and	O
symptoms	O
was	O
investigated.	O

HRQOL	O
was	O
assessed	O
at	O
baseline,	O
at	O
end	O
of	O
cycle	O
2,	O
and	O
4,	O
6,	O
and	O
9	O
months	O
after	O
completion	O
of	O
RT	O
using	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
Quality	O
of	O
Life	O
Questionnaire	O
C30	O
(QLQ-C30)	O
and	O
the	O
EORTC	O
QLQ	O
Head	O
and	O
Neck	O
Cancer-Specific	O
Module	O
(EORTC	O
QLQ-H&amp;N35).	O

The	O
primary	O
HRQOL	O
scale	O
was	O
global	O
HRQOL	O
per	O
protocol.	O

Compliance	O
to	O
HRQOL	O
assessments	O
was	O
97%	O
at	O
baseline,	O
but	O
dropped	O
to	O
54%	O
by	O
6	O
months.	O

Data	O
were	O
analysed	O
up	O
to	O
6	O
months.	O

There	B-Premise
was	I-Premise
a	I-Premise
trend	I-Premise
towards	I-Premise
improved	I-Premise
global	I-Premise
HRQOL	I-Premise
during	I-Premise
the	I-Premise
treatment	I-Premise
period.	I-Premise

At	B-Premise
6	I-Premise
months	I-Premise
after	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
RT,	I-Premise
global	I-Premise
HRQOL	I-Premise
was	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
TPF	I-Premise
arm	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
PF	I-Premise
arm,	I-Premise
but	B-Premise
the	I-Premise
low	I-Premise
compliance	I-Premise
does	I-Premise
not	I-Premise
allow	I-Premise
to	I-Premise
draw	I-Premise
definitive	I-Premise
conclusions.	I-Premise

Swallowing	B-Premise
and	I-Premise
coughing	I-Premise
problems	I-Premise
decreased	I-Premise
more	I-Premise
in	I-Premise
the	I-Premise
TPF	I-Premise
arm	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
PF	I-Premise
arm	I-Premise
at	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
cycle	I-Premise
2,	I-Premise
but	B-Premise
to	I-Premise
a	I-Premise
limited	I-Premise
extent.	I-Premise

Induction	B-Claim
chemotherapy	I-Claim
with	I-Claim
TPF	I-Claim
before	I-Claim
RT	I-Claim
not	I-Claim
only	I-Claim
improves	I-Claim
survival	I-Claim
and	I-Claim
reduces	I-Claim
toxicity	I-Claim
compared	I-Claim
with	I-Claim
PF	I-Claim
but	I-Claim
also	I-Claim
seems	I-Claim
to	I-Claim
improve	I-Claim
global	I-Claim
HRQOL	I-Claim
in	I-Claim
a	I-Claim
more	I-Claim
sustainable	I-Claim
manner.	I-Claim

We	O
compared	O
fulvestrant	O
500	O
mg	O
regimen	O
with	O
the	O
approved	O
dose	O
of	O
fulvestrant	O
250	O
mg	O
per	O
month	O
for	O
treatment	O
of	O
postmenopausal	O
women	O
with	O
estrogen	O
receptor-positive	O
advanced	O
breast	O
cancer	O
who	O
experienced	O
progression	O
after	O
prior	O
endocrine	O
therapy.	O

Comparison	O
of	O
Faslodex	O
in	O
Recurrent	O
or	O
Metastatic	O
Breast	O
Cancer	O
(CONFIRM)	O
is	O
a	O
double-blind,	O
parallel-group,	O
multicenter,	O
phase	O
III	O
study.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
fulvestrant	O
500	O
mg	O
(500	O
mg	O
intramuscularly	O
[IM]	O
on	O
day	O
0,	O
then	O
500	O
mg	O
IM	O
on	O
days	O
14	O
and	O
28	O
and	O
every	O
28	O
days	O
thereafter)	O
or	O
250	O
mg	O
every	O
28	O
days.	O

Primary	O
end	O
point	O
was	O
progression-free	O
survival	O
(PFS).	O

Secondary	O
end	O
points	O
included	O
objective	O
response	O
rate,	O
clinical	O
benefit	O
rate	O
(CBR),	O
duration	O
of	O
clinical	O
benefit	O
(DoCB),	O
overall	O
survival	O
(OS),	O
and	O
quality	O
of	O
life	O
(QOL).	O

PFS	B-Premise
was	I-Premise
significantly	I-Premise
longer	I-Premise
for	I-Premise
fulvestrant	I-Premise
500	I-Premise
mg	I-Premise
(n	I-Premise
=	I-Premise
362)	I-Premise
than	I-Premise
250	I-Premise
mg	I-Premise
(n	I-Premise
=	I-Premise
374)	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR]	I-Premise
=	I-Premise
0.80;	I-Premise
95%	I-Premise
CI,	I-Premise
0.68	I-Premise
to	I-Premise
0.94;	I-Premise
P	I-Premise
=	I-Premise
.006),	I-Premise
corresponding	I-Premise
to	I-Premise
a	I-Premise
20%	I-Premise
reduction	I-Premise
in	I-Premise
risk	I-Premise
of	I-Premise
progression.	I-Premise

Objective	B-Premise
response	I-Premise
rate	I-Premise
was	I-Premise
similar	I-Premise
for	I-Premise
fulvestrant	I-Premise
500	I-Premise
mg	I-Premise
and	I-Premise
250	I-Premise
mg	I-Premise
(9.1%	I-Premise
v	I-Premise
10.2%,	I-Premise
respectively).	I-Premise

CBR	B-Premise
was	I-Premise
45.6%	I-Premise
for	I-Premise
fulvestrant	I-Premise
500	I-Premise
mg	I-Premise
and	I-Premise
39.6%	I-Premise
for	I-Premise
fulvestrant	I-Premise
250	I-Premise
mg.	I-Premise

DoCB	B-Premise
and	I-Premise
OS	I-Premise
were	I-Premise
16.6	I-Premise
and	I-Premise
25.1	I-Premise
months,	I-Premise
respectively,	I-Premise
for	I-Premise
the	I-Premise
500-mg	I-Premise
group,	I-Premise
whereas	I-Premise
DoCB	I-Premise
and	I-Premise
OS	I-Premise
were	I-Premise
13.9	I-Premise
and	I-Premise
22.8	I-Premise
months,	I-Premise
respectively,	I-Premise
in	I-Premise
the	I-Premise
250-mg	I-Premise
group.	I-Premise

Fulvestrant	B-Claim
500	I-Claim
mg	I-Claim
was	I-Claim
well	I-Claim
tolerated	I-Claim
with	I-Claim
no	I-Claim
dose-dependent	I-Claim
adverse	I-Claim
events.	I-Claim

QOL	B-Claim
was	I-Claim
similar	I-Claim
for	I-Claim
both	I-Claim
arms.	I-Claim

Fulvestrant	B-Claim
500	I-Claim
mg	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
a	I-Claim
statistically	I-Claim
significant	I-Claim
increase	I-Claim
in	I-Claim
PFS	I-Claim
and	I-Claim
not	I-Claim
associated	I-Claim
with	I-Claim
increased	I-Claim
toxicity,	I-Claim
corresponding	O
to	O
a	O
clinically	O
meaningful	O
improvement	O
in	O
benefit	O
versus	O
risk	O
compared	O
with	O
fulvestrant	O
250	O
mg.	O

Temozolomide	O
(TMZ)	O
is	O
an	O
alkylating	O
agent	O
licensed	O
for	O
treatment	O
of	O
high-grade	O
glioma	O
(HGG).	O

No	O
prospective	O
comparison	O
with	O
nitrosourea-based	O
chemotherapy	O
exists.	O

We	O
report,	O
to	O
our	O
knowledge,	O
the	O
first	O
randomized	O
trial	O
of	O
procarbazine,	O
lomustine,	O
and	O
vincristine	O
(PCV)	O
versus	O
TMZ	O
in	O
chemotherapy-naive	O
patients	O
with	O
recurrent	O
HGG.	O

Four	O
hundred	O
forty-seven	O
patients	O
were	O
randomly	O
assigned	O
to	O
PCV	O
(224	O
patients)	O
or	O
TMZ	O
(sub-random	O
assignment:	O
TMZ-5	O
[200	O
mg/m(2)	O
for	O
5	O
days,	O
112	O
patients]	O
or	O
TMZ-21	O
[100	O
mg/m(2)	O
for	O
21	O
days,	O
111	O
patients])	O
for	O
up	O
to	O
9	O
months	O
or	O
until	O
progression.	O

The	O
primary	O
outcomes	O
were	O
survival	O
(PCV	O
v	O
TMZ)	O
and	O
12-week	O
progression-free	O
survival	O
(PFS;	O
TMZ-5	O
v	O
TMZ-21).	O

This	O
study	O
is	O
registered	O
as	O
ISRCTN83176944.	O

Percentages	O
of	O
patients	O
completing	O
9	O
months	O
of	O
treatment	O
in	O
the	O
PCV,	O
TMZ-5,	O
and	O
TMZ-21	O
arms	O
were	O
17%,	O
26%,	O
and	O
13%,	O
respectively.	O

Major	B-Premise
toxicity	I-Premise
was	I-Premise
similar	I-Premise
across	I-Premise
all	I-Premise
three	I-Premise
groups.	I-Premise

With	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
time	I-Premise
of	I-Premise
12	I-Premise
months	I-Premise
and	I-Premise
382	I-Premise
deaths,	I-Premise
there	I-Premise
was	I-Premise
no	I-Premise
clear	I-Premise
survival	I-Premise
benefit	I-Premise
when	I-Premise
comparing	I-Premise
PCV	I-Premise
with	I-Premise
TMZ	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR],	I-Premise
0.91;	I-Premise
95%	I-Premise
CI,	I-Premise
0.74	I-Premise
to	I-Premise
1.11;	I-Premise
P	I-Premise
=	I-Premise
.350).	I-Premise

For	B-Premise
TMZ-5	I-Premise
versus	I-Premise
TMZ-21,	I-Premise
12-week	I-Premise
PFS	I-Premise
rates	I-Premise
were	I-Premise
similar	I-Premise
(63.6%	I-Premise
and	I-Premise
65.7%,	I-Premise
respectively;	I-Premise
P	I-Premise
=	I-Premise
.745),	I-Premise
but	B-Premise
TMZ-5	I-Premise
improved	I-Premise
overall	I-Premise
PFS	I-Premise
(HR,	I-Premise
1.38;	I-Premise
95%	I-Premise
CI,	I-Premise
1.05	I-Premise
to	I-Premise
1.82;	I-Premise
P	I-Premise
=	I-Premise
.023),	I-Premise
survival	I-Premise
(HR,	I-Premise
1.32;	I-Premise
95%	I-Premise
CI,	I-Premise
0.99	I-Premise
to	I-Premise
1.75;	I-Premise
P	I-Premise
=	I-Premise
.056),	I-Premise
and	I-Premise
global	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(49%	I-Premise
v	I-Premise
19%	I-Premise
improved	I-Premise
>	I-Premise
10	I-Premise
points	I-Premise
at	I-Premise
6	I-Premise
months,	I-Premise
respectively;	I-Premise
P	I-Premise
=	I-Premise
.005).	I-Premise

Although	B-Claim
TMZ	I-Claim
(both	I-Claim
arms	I-Claim
combined)	I-Claim
did	I-Claim
not	I-Claim
show	I-Claim
a	I-Claim
clear	I-Claim
benefit	I-Claim
compared	I-Claim
with	I-Claim
PCV,	I-Claim
comparison	I-Claim
of	I-Claim
the	I-Claim
TMZ	I-Claim
schedules	I-Claim
demonstrated	I-Claim
that	I-Claim
the	I-Claim
21-day	I-Claim
schedule	I-Claim
was	I-Claim
inferior	I-Claim
to	I-Claim
the	I-Claim
5-day	I-Claim
schedule	I-Claim
in	I-Claim
this	I-Claim
setting.	I-Claim

This	B-Claim
challenges	I-Claim
the	I-Claim
current	I-Claim
understanding	I-Claim
of	I-Claim
increasing	I-Claim
TMZ	I-Claim
dose-intensity	I-Claim
by	I-Claim
prolonged	I-Claim
scheduling.	I-Claim

Compared	O
with	O
placebo,	O
prophylactic	O
treatment	O
with	O
bisphosphonates	O
reduces	O
risk	O
of	O
skeletal	O
events	O
in	O
patients	O
with	O
multiple	O
myeloma.	O

However,	O
because	O
of	O
toxicity	O
associated	O
with	O
long-term	O
bisphosphonate	O
treatment,	O
establishing	O
the	O
lowest	O
effective	O
dose	O
is	O
important.	O

This	O
study	O
compared	O
the	O
effect	O
of	O
two	O
doses	O
of	O
pamidronate	O
on	O
health-related	O
quality	O
of	O
life	O
and	O
skeletal	O
morbidity	O
in	O
patients	O
with	O
newly	O
diagnosed	O
multiple	O
myeloma.	O

This	O
double-blind,	O
randomised,	O
phase	O
3	O
trial	O
was	O
undertaken	O
at	O
37	O
clinics	O
in	O
Denmark,	O
Norway,	O
and	O
Sweden.	O

Patients	O
with	O
multiple	O
myeloma	O
who	O
were	O
starting	O
antimyeloma	O
treatment	O
were	O
randomly	O
assigned	O
in	O
a	O
1:1	O
ratio	O
to	O
receive	O
one	O
of	O
two	O
doses	O
of	O
pamidronate	O
(30	O
mg	O
or	O
90	O
mg)	O
given	O
by	O
intravenous	O
infusion	O
once	O
a	O
month	O
for	O
at	O
least	O
3	O
years.	O

Randomisation	O
was	O
done	O
by	O
use	O
of	O
a	O
central,	O
computerised	O
minimisation	O
system.	O

Primary	O
outcome	O
was	O
physical	O
function	O
after	O
12	O
months	O
estimated	O
by	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
QLQ-C30	O
questionnaire	O
(scale	O
0-100).	O

All	O
patients	O
who	O
returned	O
questionnaires	O
at	O
12	O
months	O
and	O
were	O
still	O
on	O
study	O
treatment	O
were	O
included	O
in	O
the	O
analysis	O
of	O
the	O
primary	O
endpoint.	O

From	O
January,	O
2001,	O
until	O
August,	O
2005,	O
504	O
patients	O
were	O
randomly	O
assigned	O
to	O
pamidronate	O
30	O
mg	O
or	O
90	O
mg	O
(252	O
in	O
each	O
group).	O

157	O
patients	O
in	O
the	O
90	O
mg	O
group	O
and	O
156	O
in	O
the	O
30	O
mg	O
group	O
were	O
included	O
in	O
the	O
primary	O
analysis.	O

Mean	B-Premise
physical	I-Premise
function	I-Premise
at	I-Premise
12	I-Premise
months	I-Premise
was	I-Premise
66	I-Premise
points	I-Premise
(95%	I-Premise
CI	I-Premise
629-700)	I-Premise
in	I-Premise
the	I-Premise
90	I-Premise
mg	I-Premise
group	I-Premise
and	I-Premise
68	I-Premise
points	I-Premise
(646-714)	I-Premise
in	I-Premise
the	I-Premise
30	I-Premise
mg	I-Premise
group	I-Premise
(95%	I-Premise
CI	I-Premise
of	I-Premise
difference	I-Premise
-66	I-Premise
to	I-Premise
33;	I-Premise
p=052).	I-Premise

Median	B-Premise
time	I-Premise
to	I-Premise
first	I-Premise
skeletal-related	I-Premise
event	I-Premise
in	I-Premise
patients	I-Premise
who	I-Premise
had	I-Premise
such	I-Premise
an	I-Premise
event	I-Premise
was	I-Premise
92	I-Premise
months	I-Premise
(81-107)	I-Premise
in	I-Premise
the	I-Premise
90	I-Premise
mg	I-Premise
group	I-Premise
and	I-Premise
102	I-Premise
months	I-Premise
(73-140)	I-Premise
in	I-Premise
the	I-Premise
30	I-Premise
mg	I-Premise
group	I-Premise
(p=063).	I-Premise

In	O
a	O
retrospective	O
analysis,	O
eight	B-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
pamidronate	I-Premise
90	I-Premise
mg	I-Premise
group	I-Premise
developed	I-Premise
osteonecrosis	I-Premise
of	I-Premise
the	I-Premise
jaw	I-Premise
compared	I-Premise
with	I-Premise
two	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
30	I-Premise
mg	I-Premise
group.	I-Premise

Monthly	B-Claim
infusion	I-Claim
of	I-Claim
pamidronate	I-Claim
30	I-Claim
mg	I-Claim
should	I-Claim
be	I-Claim
the	I-Claim
recommended	I-Claim
dose	I-Claim
for	I-Claim
prevention	I-Claim
of	I-Claim
bone	I-Claim
disease	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
multiple	I-Claim
myeloma.	I-Claim

Before	O
the	O
knowledge	O
that	O
5	O
years	O
of	O
adjuvant	O
tamoxifen	O
is	O
less	O
efficacious	O
than	O
2	O
to	O
3	O
years	O
of	O
tamoxifen	O
followed	O
by	O
2	O
to	O
3	O
years	O
of	O
anastrozole/exemestane,	O
we	O
designed	O
a	O
multicenter	O
double-blind	O
randomized	O
controlled	O
trial	O
in	O
women	O
taking	O
tamoxifen	O
with	O
a	O
thickened	O
endometrium	O
to	O
compare	O
uterine	O
and	O
quality-of-life	O
parameters	O
between	O
those	O
switching	O
to	O
anastrozole	O
and	O
those	O
continuing	O
tamoxifen.	O

Asymptomatic	O
postmenopausal	O
women	O
who	O
took	O
adjuvant	O
tamoxifen	O
for	O
2	O
to	O
3	O
years	O
for	O
operable	O
breast	O
cancer	O
with	O
a	O
double	O
endometrial	O
thickness	O
greater	O
than	O
7	O
mm	O
were	O
randomized	O
to	O
20	O
mg	O
tamoxifen	O
or	O
1	O
mg	O
anastrozole	O
for	O
the	O
remaining	O
duration,	O
totaling	O
5	O
years.	O

Tablets	O
were	O
unrecognizable	O
for	O
drug	O
assignment.	O

The	O
primary	O
endpoints	O
were	O
the	O
differences	O
in	O
double	O
endometrial	O
thickness	O
and	O
uterine	O
volume	O
after	O
1	O
year.	O

Uterine	O
and	O
quality-of-life	O
data	O
were	O
analyzed	O
using	O
regression	O
methods,	O
and	O
missing	O
values	O
were	O
handled	O
using	O
multiple	O
imputation.	O

Seventy-two	O
women	O
(median	O
age,	O
60	O
y)	O
were	O
randomized	O
in	O
five	O
hospitals.	O

Relative	B-Premise
to	I-Premise
women	I-Premise
continuing	I-Premise
tamoxifen,	I-Premise
women	I-Premise
switching	I-Premise
to	I-Premise
anastrozole	I-Premise
experienced	I-Premise
a	I-Premise
decrease	I-Premise
of	I-Premise
53%	I-Premise
(95%	I-Premise
CI,	I-Premise
41%-63%)	I-Premise
in	I-Premise
double	I-Premise
endometrial	I-Premise
thickness	I-Premise
and	I-Premise
a	I-Premise
decrease	I-Premise
of	I-Premise
51%	I-Premise
(95%	I-Premise
CI,	I-Premise
39%-60%)	I-Premise
in	I-Premise
uterine	I-Premise
volume.	I-Premise

Vaginal	B-Premise
dryness	I-Premise
(b	I-Premise
=	I-Premise
0.064;	I-Premise
95%	I-Premise
CI,	I-Premise
0.016-0.112)	I-Premise
and	I-Premise
sexual	I-Premise
problems	I-Premise
(b	I-Premise
=	I-Premise
0.054;	I-Premise
95%	I-Premise
CI,	I-Premise
0.007-0.102)	I-Premise
increased	I-Premise
in	I-Premise
women	I-Premise
taking	I-Premise
anastrozole	I-Premise
compared	I-Premise
with	I-Premise
women	I-Premise
taking	I-Premise
tamoxifen.	I-Premise

Treatment	B-Premise
arms	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
regarding	I-Premise
withdrawal	I-Premise
rate	I-Premise
and	I-Premise
the	I-Premise
experience	I-Premise
of	I-Premise
(serious)	I-Premise
adverse	I-Premise
events.	I-Premise

Despite	O
premature	O
trial	O
closure,	O
our	O
data	O
provided	O
valuable	O
insights.	O

Switching	B-Claim
to	I-Claim
anastrozole	I-Claim
strongly	I-Claim
decreased	I-Claim
the	I-Claim
endometrial	I-Claim
thickness	I-Claim
and	I-Claim
uterine	I-Claim
volume	I-Claim
but	I-Claim
increased	I-Claim
sexual	I-Claim
disturbances.	I-Claim

Safe	B-Claim
and	I-Claim
effective	I-Claim
interventions	I-Claim
are	I-Claim
needed	I-Claim
to	I-Claim
alleviate	I-Claim
sexual	I-Claim
dysfunction.	I-Claim

Systematic	B-Claim
assessment	I-Claim
is	I-Claim
vital	I-Claim
to	I-Claim
palliative	I-Claim
care,	I-Claim
but	O
documentation	O
confirming	O
completion	O
of	O
systematic	O
assessment	O
in	O
hospice	O
settings	O
is	O
often	O
inadequate	O
or	O
absent.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
efficacy	O
of	O
systematic	O
feedback	O
from	O
standardized	O
assessment	O
tools	O
for	O
hospice	O
patient-caregiver	O
dyads	O
in	O
improving	O
hospice	O
outcomes	O
compared	O
with	O
the	O
usual	O
clinical	O
practice.	O

The	O
sample	O
of	O
patients	O
(n	O
=	O
709)	O
newly	O
admitted	O
to	O
hospice	O
home	O
care	O
in	O
2	O
hospices	O
had	O
designated	O
family	O
caregivers.	O

The	O
interdisciplinary	O
teams	O
(IDTs)	O
caring	O
for	O
these	O
dyads	O
were	O
randomly	O
assigned	O
to	O
either	O
experimental	O
(n	O
=	O
338)	O
or	O
control	O
(n	O
=	O
371)	O
conditions.	O

Data	O
were	O
collected	O
from	O
both	O
groups	O
of	O
dyads	O
using	O
standardized	O
assessments	O
on	O
admission	O
and	O
1	O
week	O
after	O
each	O
of	O
the	O
first	O
2	O
IDT	O
meetings	O
in	O
which	O
these	O
dyads	O
were	O
discussed.	O

The	O
experimental	O
intervention	O
consisted	O
of	O
reporting	O
data	O
from	O
the	O
standardized	O
assessments	O
to	O
the	O
IDTs.	O

Results	B-Premise
showed	I-Premise
improved	I-Premise
patient	I-Premise
depression	I-Premise
(P	I-Premise
<	I-Premise
.001)	I-Premise
as	I-Premise
a	I-Premise
result	I-Premise
of	I-Premise
the	I-Premise
intervention	I-Premise
and	I-Premise
improvement	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
in	I-Premise
patients'	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(P	I-Premise
<	I-Premise
.001).	I-Premise

No	B-Premise
other	I-Premise
patient	I-Premise
outcomes	I-Premise
(symptom	I-Premise
distress,	I-Premise
spiritual	I-Premise
needs)	I-Premise
or	I-Premise
caregiver	I-Premise
outcomes	I-Premise
(depression,	I-Premise
support,	I-Premise
spiritual	I-Premise
needs)	I-Premise
were	I-Premise
significantly	I-Premise
different.	I-Premise

Assessment	O
of	O
depression	O
added	O
to	O
usual	O
care	O
probably	O
had	O
an	O
effect	O
because	O
it	O
is	O
not	O
normally	O
a	O
focus	O
of	O
hospice	O
staff.	O

Hospice	B-Premise
care	I-Premise
was	I-Premise
so	I-Premise
good	I-Premise
during	I-Premise
the	I-Premise
study	I-Premise
that	I-Premise
overall	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
improved	I-Premise
as	I-Premise
a	I-Premise
result	I-Premise
of	I-Premise
standard	I-Premise
care	I-Premise
and	I-Premise
left	I-Premise
little	I-Premise
room	I-Premise
for	I-Premise
improvement	I-Premise
in	I-Premise
other	I-Premise
variables.	I-Premise

Systematic	B-Claim
assessment	I-Claim
of	I-Claim
depression	I-Claim
is	I-Claim
needed	I-Claim
in	I-Claim
hospice	I-Claim
patients.	I-Claim

No	O
caregiver	O
variables	O
changed,	O
which	O
may	O
indicate	O
a	O
need	O
for	O
a	O
focus	O
on	O
caregivers.	O

Serum	O
CA125	O
concentration	O
often	O
rises	O
several	O
months	O
before	O
clinical	O
or	O
symptomatic	O
relapse	O
in	O
women	O
with	O
ovarian	O
cancer.	O

In	O
the	O
MRC	O
OV05/EORTC	O
55955	O
collaborative	O
trial,	O
we	O
aimed	O
to	O
establish	O
the	O
benefits	O
of	O
early	O
treatment	O
on	O
the	O
basis	O
of	O
increased	O
CA125	O
concentrations	O
compared	O
with	O
delayed	O
treatment	O
on	O
the	O
basis	O
of	O
clinical	O
recurrence.	O

Women	O
with	O
ovarian	O
cancer	O
in	O
complete	O
remission	O
after	O
first-line	O
platinum-based	O
chemotherapy	O
and	O
a	O
normal	O
CA125	O
concentration	O
were	O
registered	O
for	O
this	O
randomised	O
controlled	O
trial.	O

Clinical	O
examination	O
and	O
CA125	O
measurement	O
were	O
done	O
every	O
3	O
months.	O

Patients	O
and	O
investigators	O
were	O
masked	O
to	O
CA125	O
results,	O
which	O
were	O
monitored	O
by	O
coordinating	O
centres.	O

If	O
CA125	O
concentration	O
exceeded	O
twice	O
the	O
upper	O
limit	O
of	O
normal,	O
patients	O
were	O
randomly	O
assigned	O
(1:1)	O
by	O
minimisation	O
to	O
early	O
or	O
delayed	O
chemotherapy.	O

Patients	O
and	O
clinical	O
sites	O
were	O
informed	O
of	O
allocation	O
to	O
early	O
treatment,	O
and	O
treatment	O
was	O
started	O
as	O
soon	O
as	O
possible	O
within	O
28	O
days	O
of	O
the	O
increased	O
CA125	O
measurement.	O

Patients	O
assigned	O
to	O
delayed	O
treatment	O
continued	O
masked	O
CA125	O
measurements,	O
with	O
treatment	O
commencing	O
at	O
clinical	O
or	O
symptomatic	O
relapse.	O

All	O
patients	O
were	O
treated	O
according	O
to	O
standard	O
local	O
practice.	O

The	O
primary	O
outcome	O
was	O
overall	O
survival.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat.	O

This	O
study	O
is	O
registered,	O
ISRCTN87786644.	O

1442	O
patients	O
were	O
registered	O
for	O
the	O
trial,	O
of	O
whom	O
529	O
were	O
randomly	O
assigned	O
to	O
treatment	O
groups	O
and	O
were	O
included	O
in	O
our	O
analysis	O
(265	O
early,	O
264	O
delayed).	O

With	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
569	I-Premise
months	I-Premise
(IQR	I-Premise
374-818)	I-Premise
from	I-Premise
randomisation	I-Premise
and	I-Premise
370	I-Premise
deaths	I-Premise
(186	I-Premise
early,	I-Premise
184	I-Premise
delayed),	I-Premise
there	I-Premise
was	I-Premise
no	I-Premise
evidence	I-Premise
of	I-Premise
a	I-Premise
difference	I-Premise
in	I-Premise
overall	I-Premise
survival	I-Premise
between	I-Premise
early	I-Premise
and	I-Premise
delayed	I-Premise
treatment	I-Premise
(HR	I-Premise
098,	I-Premise
95%	I-Premise
CI	I-Premise
080-120,	I-Premise
p=085).	I-Premise

Median	B-Premise
survival	I-Premise
from	I-Premise
randomisation	I-Premise
was	I-Premise
257	I-Premise
months	I-Premise
(95%	I-Premise
CI	I-Premise
230-279)	I-Premise
for	I-Premise
patients	I-Premise
on	I-Premise
early	I-Premise
treatment	I-Premise
and	I-Premise
271	I-Premise
months	I-Premise
(228-309)	I-Premise
for	I-Premise
those	I-Premise
on	I-Premise
delayed	I-Premise
treatment.	I-Premise

Our	B-Claim
findings	I-Claim
showed	I-Claim
no	I-Claim
evidence	I-Claim
of	I-Claim
a	I-Claim
survival	I-Claim
benefit	I-Claim
with	I-Claim
early	I-Claim
treatment	I-Claim
of	I-Claim
relapse	I-Claim
on	I-Claim
the	I-Claim
basis	I-Claim
of	I-Claim
a	I-Claim
raised	I-Claim
CA125	I-Claim
concentration	I-Claim
alone,	I-Claim
and	B-Claim
therefore	I-Claim
the	I-Claim
value	I-Claim
of	I-Claim
routine	I-Claim
measurement	I-Claim
of	I-Claim
CA125	I-Claim
in	I-Claim
the	I-Claim
follow-up	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
ovarian	I-Claim
cancer	I-Claim
who	I-Claim
attain	I-Claim
a	I-Claim
complete	I-Claim
response	I-Claim
after	I-Claim
first-line	I-Claim
treatment	I-Claim
is	I-Claim
not	I-Claim
proven.	I-Claim

Chemotherapy-induced	O
anemia	O
(CIA)	O
is	O
responsive	O
to	O
treatment	O
with	O
erythropoiesis-stimulating	O
agents	O
(ESAs)	O
such	O
as	O
darbepoetin	O
alfa.	O

Administration	O
of	O
ESAs	O
on	O
a	O
synchronous	O
schedule	O
with	O
chemotherapy	O
administration	O
could	O
benefit	O
patients	O
by	O
reducing	O
clinic	O
visits	O
and	O
potentially	O
enhancing	O
on-time	O
chemotherapy	O
delivery.	O

This	O
phase	O
2,	O
25-week,	O
open-label	O
study	O
evaluated	O
the	O
noninferiority	O
of	O
darbepoetin	O
alfa	O
administered	O
weekly	O
vs.	O
as	O
an	O
extended	O
dosing	O
schedule	O
(every	O
2	O
or	O
3	O
weeks)	O
in	O
patients	O
with	O
CIA.	O

Patients	O
were	O
randomized	O
1:1	O
to	O
an	O
extended	O
dosing	O
schedule	O
(EDS:	O
darbepoetin	O
alfa	O
300	O
g	O
Q2W	O
if	O
chemotherapy	O
was	O
QW,	O
Q2W,	O
or	O
Q4W	O
or	O
darbepoetin	O
alfa	O
500	O
g	O
Q3W	O
if	O
chemotherapy	O
was	O
Q3W)	O
or	O
weekly	O
(150	O
g	O
QW	O
regardless	O
of	O
chemotherapy	O
schedule).	O

Stratification	O
factors	O
included	O
chemotherapy	O
cycle	O
length,	O
screening	O
hemoglobin	O
(<10	O
g/dL	O
vs.	O
10	O
g/dL),	O
and	O
tumor	O
type	O
(lung/gynecological	O
vs.	O
other	O
nonmyeloid	O
malignancies).	O

The	O
primary	O
endpoint	O
was	O
change	O
in	O
hemoglobin	O
from	O
baseline	O
to	O
Week	O
13.	O

Seven	O
hundred	O
fifty-two	O
patients	O
(374	O
QW	O
patients;	O
378	O
EDS	O
patients)	O
received	O
1	O
dose	O
of	O
darbepoetin	O
alfa	O
and	O
were	O
included	O
in	O
the	O
analysis.	O

Demographics	O
and	O
disease	O
state	O
were	O
similar	O
between	O
groups.	O

Seventy-one	B-Premise
percent	I-Premise
of	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
EDS	I-Premise
group	I-Premise
and	I-Premise
76%	I-Premise
in	I-Premise
the	I-Premise
QW	I-Premise
group	I-Premise
achieved	I-Premise
the	I-Premise
target	I-Premise
hemoglobin	I-Premise
of	I-Premise
11.0	I-Premise
g/dL.	I-Premise

There	O
was	O
a	O
minimal	O
difference	O
in	O
the	O
primary	O
endpoint	O
of	O
mean	O
change	O
in	O
hemoglobin	O
(baseline	O
to	O
Week	O
13)	O
between	O
the	O
QW	O
and	O
the	O
EDS	O
groups	O
(-0.04	O
g/dL;	O
95%	O
confidence	O
interval:	O
-0.26,	O
0.17	O
g/dL).	O

The	O
upper	O
limit	O
of	O
the	O
95%	O
confidence	O
interval	O
was	O
less	O
than	O
the	O
prespecified	O
limit	O
of	O
<0.75	O
g/dL,	O
supporting	O
noninferiority	O
of	O
the	O
EDS	O
dosing	O
schedule.	O

Reported	B-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
similar	I-Premise
between	I-Premise
groups.	I-Premise

A	B-Premise
slight	I-Premise
increase	I-Premise
in	I-Premise
transfusions	I-Premise
was	I-Premise
reported	I-Premise
in	I-Premise
the	I-Premise
QW	I-Premise
group.	I-Premise

Darbepoetin	B-Claim
alfa,	I-Claim
when	I-Claim
administered	I-Claim
synchronously	I-Claim
with	I-Claim
chemotherapy,	I-Claim
on	I-Claim
an	I-Claim
EDS	I-Claim
appears	I-Claim
to	I-Claim
be	I-Claim
similarly	I-Claim
efficacious	I-Claim
to	I-Claim
darbepoetin	I-Claim
alfa	I-Claim
weekly	I-Claim
dosing	I-Claim
with	I-Claim
no	I-Claim
unexpected	I-Claim
adverse	I-Claim
events.	I-Claim

This	O
study	O
provides	O
prospective	O
data	O
on	O
how	O
multiple	O
dosing	O
regimens	O
available	O
with	O
darbepoetin	O
alfa	O
can	O
be	O
synchronized	O
with	O
chemotherapy	O
administered	O
across	O
a	O
range	O
of	O
dosing	O
schedules.	O

To	O
perform	O
a	O
randomized	O
trial	O
comparing	O
70	O
and	O
80	O
Gy	O
radiotherapy	O
for	O
prostate	O
cancer.	O

A	O
total	O
of	O
306	O
patients	O
with	O
localized	O
prostate	O
cancer	O
were	O
randomized.	O

No	O
androgen	O
deprivation	O
was	O
allowed.	O

The	O
primary	O
endpoint	O
was	O
biochemical	O
relapse	O
according	O
to	O
the	O
modified	O
1997-American	O
Society	O
for	O
Therapeutic	O
Radiology	O
and	O
Oncology	O
and	O
Phoenix	O
definitions.	O

Toxicity	O
was	O
graded	O
using	O
the	O
Radiation	O
Therapy	O
Oncology	O
Group	O
1991	O
criteria	O
and	O
the	O
late	O
effects	O
on	O
normal	O
tissues-subjective,	O
objective,	O
management,	O
analytic	O
scales	O
(LENT-SOMA)	O
scales.	O

The	O
patients'	O
quality	O
of	O
life	O
was	O
scored	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
30-item	O
cancer-specific	O
and	O
25-item	O
prostate-specific	O
modules.	O

The	O
median	O
follow-up	O
was	O
61	O
months.	O

According	O
to	O
the	O
1997-American	O
Society	O
for	O
Therapeutic	O
Radiology	O
and	O
Oncology	O
definition,	O
the	O
5-year	O
biochemical	O
relapse	O
rate	O
was	O
39%	O
and	O
28%	O
in	O
the	O
70-	O
and	O
80-Gy	O
arms,	O
respectively	O
(p	O
=	O
.036).	O

Using	O
the	O
Phoenix	O
definition,	O
the	O
5-year	O
biochemical	O
relapse	O
rate	O
was	O
32%	O
and	O
23.5%,	O
respectively	O
(p	O
=	O
.09).	O

The	O
subgroup	O
analysis	O
showed	O
a	O
better	O
biochemical	O
outcome	O
for	O
the	O
higher	O
dose	O
group	O
with	O
an	O
initial	O
prostate-specific	O
antigen	O
level	O
>15	O
ng/mL.	O

At	O
the	O
last	O
follow-up	O
date,	O
26	O
patients	O
had	O
died,	O
10	O
of	O
their	O
disease	O
and	O
none	O
of	O
toxicity,	O
with	O
no	O
differences	O
between	O
the	O
two	O
arms.	O

According	B-Premise
to	I-Premise
the	I-Premise
Radiation	I-Premise
Therapy	I-Premise
Oncology	I-Premise
Group	I-Premise
scale,	I-Premise
the	I-Premise
Grade	I-Premise
2	I-Premise
or	I-Premise
greater	I-Premise
rectal	I-Premise
toxicity	I-Premise
rate	I-Premise
was	I-Premise
14%	I-Premise
and	I-Premise
19.5%	I-Premise
for	I-Premise
the	I-Premise
70-	I-Premise
and	I-Premise
80-Gy	I-Premise
arms	I-Premise
(p	I-Premise
=	I-Premise
.22),	I-Premise
respectively.	I-Premise

The	B-Premise
Grade	I-Premise
2	I-Premise
or	I-Premise
greater	I-Premise
urinary	I-Premise
toxicity	I-Premise
was	I-Premise
10%	I-Premise
at	I-Premise
70	I-Premise
Gy	I-Premise
and	I-Premise
17.5%	I-Premise
at	I-Premise
80	I-Premise
Gy	I-Premise
(p	I-Premise
=	I-Premise
.046).	I-Premise

Similar	B-Premise
results	I-Premise
were	I-Premise
observed	I-Premise
using	I-Premise
the	I-Premise
LENT-SOMA	I-Premise
scale.	I-Premise

Bladder	B-Premise
toxicity	I-Premise
was	I-Premise
more	I-Premise
frequent	I-Premise
at	I-Premise
80	I-Premise
Gy	I-Premise
than	I-Premise
at	I-Premise
70	I-Premise
Gy	I-Premise
(p	I-Premise
=	I-Premise
.039).	I-Premise

The	B-Premise
quality-of-life	I-Premise
questionnaire	I-Premise
results	I-Premise
before	I-Premise
and	I-Premise
5	I-Premise
years	I-Premise
after	I-Premise
treatment	I-Premise
were	I-Premise
available	I-Premise
for	I-Premise
103	I-Premise
patients	I-Premise
with	I-Premise
no	I-Premise
differences	I-Premise
found	I-Premise
between	I-Premise
the	I-Premise
70-	I-Premise
and	I-Premise
80-Gy	I-Premise
arms.	I-Premise

High-dose	B-Claim
radiotherapy	I-Claim
provided	I-Claim
a	I-Claim
better	I-Claim
5-year	I-Claim
biochemical	I-Claim
outcome	I-Claim
with	I-Claim
slightly	I-Claim
greater	I-Claim
toxicity.	I-Claim

Numerous	O
studies	O
have	O
examined	O
the	O
comorbidity	O
of	O
depression	O
with	O
cancer,	O
and	O
some	O
have	O
indicated	O
that	O
depression	O
may	O
be	O
associated	O
with	O
cancer	O
progression	O
or	O
survival.	O

However,	O
few	O
studies	O
have	O
assessed	O
whether	O
changes	O
in	O
depression	O
symptoms	O
are	O
associated	O
with	O
survival.	O

In	O
a	O
secondary	O
analysis	O
of	O
a	O
randomized	O
trial	O
of	O
supportive-expressive	O
group	O
therapy,	O
125	O
women	O
with	O
metastatic	O
breast	O
cancer	O
(MBC)	O
completed	O
a	O
depression	O
symptom	O
measure	O
(Center	O
for	O
Epidemiologic	O
Studies-Depression	O
Scale	O
[CES-D])	O
at	O
baseline	O
and	O
were	O
randomly	O
assigned	O
to	O
a	O
treatment	O
group	O
or	O
to	O
a	O
control	O
group	O
that	O
received	O
educational	O
materials.	O

At	O
baseline	O
and	O
three	O
follow-up	O
points,	O
101	O
of	O
125	O
women	O
completed	O
a	O
depression	O
symptom	O
measure.	O

We	O
used	O
these	O
data	O
in	O
a	O
Cox	O
proportional	O
hazards	O
analysis	O
to	O
examine	O
whether	O
decreasing	O
depression	O
symptoms	O
over	O
the	O
first	O
year	O
of	O
the	O
study	O
(the	O
length	O
of	O
the	O
intervention)	O
would	O
be	O
associated	O
with	O
longer	O
survival.	O

Median	B-Premise
survival	I-Premise
time	I-Premise
was	I-Premise
53.6	I-Premise
months	I-Premise
for	I-Premise
women	I-Premise
with	I-Premise
decreasing	I-Premise
CES-D	I-Premise
scores	I-Premise
over	I-Premise
1	I-Premise
year	I-Premise
and	I-Premise
25.1	I-Premise
months	I-Premise
for	I-Premise
women	I-Premise
with	I-Premise
increasing	I-Premise
CES-D	I-Premise
scores.	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
effect	I-Premise
of	I-Premise
change	I-Premise
in	I-Premise
CES-D	I-Premise
over	I-Premise
the	I-Premise
first	I-Premise
year	I-Premise
on	I-Premise
survival	I-Premise
out	I-Premise
to	I-Premise
14	I-Premise
years	I-Premise
(P	I-Premise
=	I-Premise
.007)	I-Premise
but	B-Premise
no	I-Premise
significant	I-Premise
interaction	I-Premise
between	I-Premise
treatment	I-Premise
condition	I-Premise
and	I-Premise
CES-D	I-Premise
change	I-Premise
on	I-Premise
survival.	I-Premise

Neither	O
demographic	O
nor	O
medical	O
variables	O
explained	O
this	O
association.	O

Decreasing	B-Claim
depression	I-Claim
symptoms	I-Claim
over	I-Claim
the	I-Claim
first	I-Claim
year	I-Claim
were	I-Claim
associated	I-Claim
with	I-Claim
longer	I-Claim
subsequent	I-Claim
survival	I-Claim
for	I-Claim
women	I-Claim
with	I-Claim
MBC	I-Claim
in	I-Claim
this	I-Claim
sample.	I-Claim

Further	B-Claim
research	I-Claim
is	I-Claim
necessary	I-Claim
to	I-Claim
confirm	I-Claim
this	I-Claim
hypothesis	I-Claim
in	I-Claim
other	I-Claim
samples,	I-Claim
and	I-Claim
causation	I-Claim
cannot	I-Claim
be	I-Claim
assumed	I-Claim
based	I-Claim
on	I-Claim
this	I-Claim
analysis.	I-Claim

The	O
American	O
College	O
of	O
Surgeons	O
Oncology	O
Group	O
phase	O
III	O
Surgical	O
Prostatectomy	O
Versus	O
Interstitial	O
Radiation	O
Intervention	O
Trial	O
comparing	O
radical	O
prostatectomy	O
(RP)	O
and	O
brachytherapy	O
(BT)	O
closed	O
after	O
2	O
years	O
due	O
to	O
poor	O
accrual.	O

We	O
report	O
health-related	O
quality	O
of	O
life	O
(HRQOL)	O
at	O
a	O
mean	O
of	O
5.3	O
years	O
for	O
168	O
trial-eligible	O
men	O
who	O
either	O
chose	O
or	O
were	O
randomly	O
assigned	O
to	O
RP	O
or	O
BT	O
following	O
a	O
multidisciplinary	O
educational	O
session.	O

After	O
initial	O
lack	O
of	O
accrual,	O
a	O
multidisciplinary	O
educational	O
session	O
was	O
introduced	O
for	O
eligible	O
patients.	O

In	O
all,	O
263	O
men	O
attended	O
47	O
sessions.	O

Of	O
those,	O
34	O
consented	O
to	O
random	O
assignment,	O
62	O
chose	O
RP,	O
and	O
94	O
chose	O
BT.	O

Five	O
years	O
later,	O
these	O
190	O
men	O
underwent	O
HRQOL	O
evaluation	O
by	O
using	O
the	O
cancer-specific	O
50-item	O
Expanded	O
Prostate	O
Cancer	O
Index	O
Composite,	O
the	O
Short	O
Form	O
12	O
Physical	O
Component	O
Score,	O
and	O
Short	O
Form	O
12	O
Mental	O
Component	O
Score.	O

Response	O
rate	O
was	O
88.4%.	O

The	O
Wilcoxon	O
rank	O
sum	O
test	O
was	O
used	O
to	O
compare	O
summary	O
scores	O
between	O
the	O
two	O
interventions.	O

Of	O
168	O
survey	O
responders,	O
60.7%	O
had	O
BT	O
(9.5%	O
randomly	O
assigned)	O
and	O
39.3%	O
had	O
RP	O
(9.5%	O
randomly	O
assigned).	O

Median	O
age	O
was	O
61.4	O
years	O
for	O
BT	O
and	O
59.4	O
for	O
RP	O
(P	O
=	O
.05).	O

Median	O
follow-up	O
was	O
5.2	O
years	O
(range,	O
3.2	O
to	O
6.5	O
years).	O

For	B-Premise
BT	I-Premise
versus	I-Premise
RP,	I-Premise
there	I-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
bowel	I-Premise
or	I-Premise
hormonal	I-Premise
domains,	I-Premise
but	O
men	B-Premise
treated	I-Premise
with	I-Premise
BT	I-Premise
scored	I-Premise
better	I-Premise
in	I-Premise
urinary	I-Premise
(91.8	I-Premise
v	I-Premise
88.1;	I-Premise
P	I-Premise
=	I-Premise
.02)	I-Premise
and	I-Premise
sexual	I-Premise
(52.5	I-Premise
v	I-Premise
39.2;	I-Premise
P	I-Premise
=	I-Premise
.001)	I-Premise
domains,	I-Premise
and	I-Premise
in	I-Premise
patient	I-Premise
satisfaction	I-Premise
(93.6	I-Premise
v	I-Premise
76.9;	I-Premise
P	I-Premise
<	I-Premise
.001).	I-Premise

Although	O
treatment	O
allocation	O
was	O
random	O
in	O
only	O
19%,	O
all	O
patients	O
received	O
identical	O
information	O
in	O
a	O
multidisciplinary	O
setting	O
before	O
selecting	O
RP,	O
BT,	O
or	O
random	O
assignment.	O

HRQOL	B-Claim
evaluated	I-Claim
3.2	I-Claim
to	I-Claim
6.5	I-Claim
years	I-Claim
after	I-Claim
treatment	I-Claim
showed	I-Claim
an	I-Claim
advantage	I-Claim
for	I-Claim
BT	I-Claim
in	I-Claim
urinary	I-Claim
and	I-Claim
sexual	I-Claim
domains	I-Claim
and	I-Claim
in	I-Claim
patient	I-Claim
satisfaction.	I-Claim

Bone-cancer	O
pain	O
is	O
a	O
common	O
and	O
refractory	O
cancer	O
pain.	O

Opioids,	O
on	O
their	O
own,	O
do	O
not	O
control	O
this	O
type	O
of	O
pain	O
well	O
enough,	O
and	O
co-analgesics	O
are	O
necessary.	O

Patients	O
with	O
bone	O
metastasis-related	O
pain	O
at	O
Numeric	O
Rating	O
Scale	O
4	O
were	O
enrolled	O
to	O
this	O
randomized	O
placebo-controlled	O
trial.	O

They	O
had	O
also	O
received	O
morphine	O
or	O
transdermal	O
fentanyl	O
patches	O
for	O
at	O
least	O
1	O
week.	O

During	O
the	O
3-day	O
efficacy	O
phase,	O
patients	O
received	O
placebo	O
or	O
1-3	O
tablets	O
of	O
oxycodone/paracetamol	O
(5/325	O
mg),	O
four	O
times	O
daily	O
for	O
3	O
days.	O

All	O
patients	O
kept	O
a	O
daily	O
pain	O
diary.	O

The	O
primary	O
endpoint	O
was	O
the	O
Pain	O
Intensity	O
Difference	O
(PID).	O

Secondary	O
endpoints	O
were	O
cases	O
of	O
breakthrough	O
pain	O
and	O
rescue	O
morphine	O
consumption.	O

Additional	O
analyses	O
included	O
the	O
Short	O
Form-6	O
Dimensions	O
(SF-6D)	O
quality-of-life	O
scale	O
and	O
a	O
general	O
impression	O
(GI)	O
of	O
patient	O
satisfaction	O
with	O
treatment	O
at	O
the	O
end	O
of	O
the	O
phase.	O

Of	O
the	O
246	O
patients	O
in	O
the	O
intent-to-treat	O
set,	O
894%	O
completed	O
the	O
3-day	O
efficacy	O
phase.	O

PIDs	B-Premise
were	I-Premise
09	I-Premise
and	I-Premise
03	I-Premise
in	I-Premise
the	I-Premise
oxycodone/paracetamol	I-Premise
and	I-Premise
placebo	I-Premise
groups	I-Premise
respectively,	I-Premise
on	I-Premise
day	I-Premise
1	I-Premise
(P	I-Premise
<	I-Premise
0001),	I-Premise
and	I-Premise
15	I-Premise
and	I-Premise
03	I-Premise
respectively	I-Premise
on	I-Premise
day	I-Premise
3	I-Premise
(P	I-Premise
<	I-Premise
0001).	I-Premise

Thirty-eight	B-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group,	I-Premise
and	I-Premise
58	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group,	I-Premise
suffered	I-Premise
breakthrough	I-Premise
pain	I-Premise
on	I-Premise
day	I-Premise
3	I-Premise
(P	I-Premise
<	I-Premise
0001).	I-Premise

The	B-Premise
SF-6D	I-Premise
score	I-Premise
decreased	I-Premise
to	I-Premise
212	I-Premise
	I-Premise
25	I-Premise
in	I-Premise
the	I-Premise
oxycodone/paracetamol	I-Premise
group	I-Premise
at	I-Premise
the	I-Premise
end	I-Premise
of	I-Premise
the	I-Premise
phase	I-Premise
(P	I-Premise
=	I-Premise
0001).	I-Premise

In	B-Premise
the	I-Premise
oxycodone/paracetamol	I-Premise
group,	I-Premise
67%	I-Premise
rated	I-Premise
GI	I-Premise
as	I-Premise
good,	I-Premise
very	I-Premise
good,	I-Premise
or	I-Premise
excellent.	I-Premise

Patients	B-Claim
with	I-Claim
bone-cancer	I-Claim
pain,	I-Claim
already	I-Claim
on	I-Claim
opioids,	I-Claim
obtain	I-Claim
clinically	I-Claim
important,	I-Claim
additional	I-Claim
pain-control,	I-Claim
with	I-Claim
regular	I-Claim
oxycodone/paracetamol	I-Claim
dosing.	I-Claim

There	O
are	O
very	O
few	O
randomized	O
controlled	O
studies	O
on	O
exercise	O
in	O
cancer	O
patients.	O

Consequently,	O
there	O
are	O
no	O
guidelines	O
available	O
with	O
regard	O
to	O
the	O
exercises	O
that	O
can	O
be	O
recommended	O
and	O
difficulties	O
are	O
encountered	O
in	O
the	O
clinical	O
practice	O
as	O
to	O
which	O
exercise	O
is	O
more	O
suitable	O
to	O
the	O
patients.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
impact	O
of	O
pilates	O
exercises	O
on	O
physical	O
performance,	O
flexibility,	O
fatigue,	O
depression	O
and	O
quality	O
of	O
life	O
in	O
women	O
who	O
had	O
been	O
treated	O
for	O
breast	O
cancer.	O

Randomized	O
controlled	O
trial.	O

Out	O
patient	O
group,	O
Department	O
of	O
Physical	O
Medicine	O
and	O
Rehabilitation	O
and	O
Medical	O
Oncology	O
Department,	O
University	O
Hospital.	O

Fifty-two	O
patients	O
with	O
breast	O
cancer	O
were	O
divided	O
into	O
either	O
pilates	O
exercise	O
(group	O
1)	O
and	O
control	O
group	O
(group	O
2).	O

Patients	O
in	O
Group	O
1	O
performed	O
pilates	O
and	O
home	O
exercises	O
and	O
patients	O
in	O
group	O
2	O
performed	O
only	O
home	O
exercises.	O

Pilates	O
exercise	O
sessions	O
were	O
performed	O
three	O
times	O
a	O
week	O
for	O
a	O
period	O
of	O
eight	O
weeks	O
in	O
the	O
rehabilitation	O
unit.	O

Subjects	O
were	O
assessed	O
before	O
and	O
after	O
rehabilitation	O
program,	O
with	O
respect	O
to,	O
6-min	O
walk	O
test	O
(6MWT),	O
modified	O
sit	O
and	O
reach	O
test,	O
Brief	O
Fatigue	O
Inventory	O
(BFI),	O
Beck	O
Depression	O
Index	O
(BDI)	O
and	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
C30	O
(EORTC	O
QLQ-C30)	O
and	O
EORTC	O
QLQ	O
BR23.	O

After	B-Premise
the	I-Premise
exercise	I-Premise
program,	I-Premise
improvements	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
Group	I-Premise
1	I-Premise
in	I-Premise
6-minute	I-Premise
walk	I-Premise
test,	I-Premise
BDI,	I-Premise
EORTC	I-Premise
QLQ-C30	I-Premise
functional,	I-Premise
and	I-Premise
EORTC	I-Premise
QLQ-C30	I-Premise
BR23	I-Premise
functional	I-Premise
scores	I-Premise
(P<0.05).	I-Premise

In	O
contrast,	O
no	B-Premise
significant	I-Premise
improvement	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
Group	I-Premise
2	I-Premise
after	I-Premise
the	I-Premise
exercise	I-Premise
program	I-Premise
in	I-Premise
any	I-Premise
of	I-Premise
parameters	I-Premise
in	I-Premise
comparison	I-Premise
to	I-Premise
the	I-Premise
pre-exercise	I-Premise
period	I-Premise
(P>0.05).	I-Premise

When	B-Premise
the	I-Premise
two	I-Premise
exercise	I-Premise
groups	I-Premise
were	I-Premise
compared,	I-Premise
there	I-Premise
were	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
6MWT	I-Premise
in	I-Premise
pilates-exercise	I-Premise
group	I-Premise
(P<0.05).	I-Premise

Pilates	B-Claim
exercises	I-Claim
are	I-Claim
effective	I-Claim
and	I-Claim
safe	I-Claim
in	I-Claim
female	I-Claim
breast	I-Claim
cancer	I-Claim
patients.	I-Claim

There	B-Claim
is	I-Claim
a	I-Claim
need	I-Claim
for	I-Claim
further	I-Claim
studies	I-Claim
so	I-Claim
that	I-Claim
its	I-Claim
effect	I-Claim
can	I-Claim
be	I-Claim
confirmed.	I-Claim

This	O
study	O
addressed	O
the	O
effects	O
of	O
pilates	O
exercise,	O
as	O
a	O
new	O
approach,	O
on	O
functional	O
capacity,	O
fatigue,	O
depression	O
and	O
quality	O
of	O
life	O
in	O
breast	O
cancer	O
patients	O
in	O
whom	O
there	O
are	O
doubts	O
regarding	O
the	O
efficacy	O
and	O
usefulness	O
of	O
the	O
exercise.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
2-year	O
functional	O
performance	O
and	O
quality	O
of	O
life	O
in	O
patients	O
with	O
operable	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
esophagus,	O
who	O
have	O
received	O
either	O
surgery	O
or	O
definitive	O
chemoradiation	O
(CRT).	O

The	O
functional	O
outcomes	O
and	O
quality	O
of	O
life	O
in	O
patients	O
receiving	O
esophagectomy	O
or	O
definitive	O
CRT	O
is	O
uncertain.	O

Data	O
were	O
extracted	O
from	O
the	O
database	O
of	O
a	O
prospective	O
randomized	O
controlled	O
trial	O
that	O
included	O
patients	O
with	O
resectable	O
mid	O
or	O
lower	O
thoracic	O
esophageal	O
cancers.	O

The	O
patients	O
were	O
randomized	O
to	O
either	O
standard	O
esophagectomy	O
or	O
definitive	O
CRT.	O

Quality	O
of	O
life	O
assessments	O
were	O
performed	O
using	O
the	O
EORTC	O
QLQ-C30	O
and	O
QLQ-OES24	O
modules.	O

Other	O
functional	O
assessments	O
included	O
pulmonary	O
and	O
eating	O
functions.	O

From	O
July	O
2000	O
to	O
December	O
2004,	O
a	O
total	O
of	O
81	O
patients	O
were	O
enrolled	O
into	O
the	O
study.	O

No	B-Premise
significant	I-Premise
longitudinal	I-Premise
changes	I-Premise
were	I-Premise
detected	I-Premise
in	I-Premise
the	I-Premise
global	I-Premise
health	I-Premise
status	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
upon	I-Premise
available	I-Premise
follow-up.	I-Premise

Surgery	B-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
worsened	I-Premise
physical	I-Premise
functioning	I-Premise
and	I-Premise
fatigue	I-Premise
symptoms	I-Premise
up	I-Premise
to	I-Premise
6	I-Premise
months	I-Premise
after	I-Premise
treatment	I-Premise
(P	I-Premise
<	I-Premise
0.001	I-Premise
and	I-Premise
P	I-Premise
=	I-Premise
0.021,	I-Premise
respectively)	I-Premise
and	I-Premise
these	I-Premise
scales	I-Premise
improved	I-Premise
at	I-Premise
2	I-Premise
years.	I-Premise

In	B-Premise
terms	I-Premise
of	I-Premise
pulmonary	I-Premise
function,	I-Premise
dyspnoic	I-Premise
and	I-Premise
coughing	I-Premise
symptoms	I-Premise
were	I-Premise
significantly	I-Premise
worsened	I-Premise
3	I-Premise
months	I-Premise
after	I-Premise
surgery	I-Premise
(P	I-Premise
=	I-Premise
0.024	I-Premise
and	I-Premise
P	I-Premise
=	I-Premise
0.036,	I-Premise
respectively)	I-Premise
whereas	I-Premise
symptoms	I-Premise
in	I-Premise
the	I-Premise
CRT	I-Premise
group	I-Premise
progressively	I-Premise
deteriorated	I-Premise
over	I-Premise
time.	I-Premise

Concerning	B-Premise
the	I-Premise
eating	I-Premise
function,	I-Premise
both	I-Premise
groups	I-Premise
had	I-Premise
improvements	I-Premise
in	I-Premise
dysphagia	I-Premise
but	I-Premise
there	I-Premise
were	I-Premise
frequent	I-Premise
need	I-Premise
for	I-Premise
endoscopic	I-Premise
intervention.	I-Premise

Neither	B-Premise
surgery	I-Premise
nor	I-Premise
definitive	I-Premise
CRT	I-Premise
significantly	I-Premise
impaired	I-Premise
the	I-Premise
global	I-Premise
health	I-Premise
status	I-Premise
of	I-Premise
patients.	I-Premise

Surgery	B-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
a	I-Claim
short-term	I-Claim
negative	I-Claim
impact	I-Claim
in	I-Claim
some	I-Claim
aspects	I-Claim
of	I-Claim
health	I-Claim
related	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
assessments	I-Claim
but	B-Claim
these	I-Claim
changes	I-Claim
became	I-Claim
insignificant	I-Claim
2	I-Claim
years	I-Claim
after	I-Claim
treatment.	I-Claim

However,	O
CRT	B-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
progressive	I-Claim
deteriorations	I-Claim
in	I-Claim
pulmonary	I-Claim
function	I-Claim
in	I-Claim
the	I-Claim
longer	I-Claim
term.	I-Claim

Anti-aromatase	B-Claim
therapy	I-Claim
is	I-Claim
important	I-Claim
in	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
breast	I-Claim
cancer	I-Claim
in	I-Claim
postmenopausal	I-Claim
women	I-Claim
but	O
they	O
have	O
effects	O
on	O
the	O
bone	O
mineral	O
density	O
(BMD)	O
and	O
osteoporosis.	O

Cyclooxygenase-2	B-Claim
(COX-2)	I-Claim
inhibitors	I-Claim
have	I-Claim
been	I-Claim
shown	I-Claim
to	I-Claim
be	I-Claim
effective	I-Claim
in	I-Claim
chemoprevention	I-Claim
in	I-Claim
animal	I-Claim
and	I-Claim
clinical	I-Claim
studies.	I-Claim

A	O
proof	O
of	O
principle	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
efficacy	O
of	O
combing	O
anti-aromatase	O
therapy	O
(exemestane)	O
and	O
COX-2	O
inhibitors	O
neoadjuvantly.	O

The	O
changes	O
in	O
the	O
BMD,	O
bone	O
turnover	O
proteins	O
and	O
quality-of-life	O
(QoL)	O
were	O
analyzed	O
and	O
presented	O
here.	O

82	O
postmenopausal	O
patients	O
with	O
histologically	O
confirmed	O
invasive	O
hormone-sensitive	O
breast	O
cancers	O
were	O
included	O
for	O
the	O
neoadjuvant	O
therapy	O
(NHT).	O

30	O
patients	O
received	O
exemestane	O
(EXE)	O
25	O
mg	O
daily	O
and	O
celecoxib	O
(CXB)	O
400	O
mg	O
twice	O
daily	O
(group	O
A),	O
24	O
patients	O
received	O
EXE	O
25	O
mg	O
daily	O
(group	O
B)	O
and	O
28	O
patients	O
received	O
letrozole	O
(LET)	O
2.5	O
mg	O
daily	O
(group	O
C).	O

The	O
same	O
assigned	O
treatment	O
was	O
intended	O
to	O
continue	O
for	O
2	O
years	O
to	O
study	O
the	O
changes	O
in	O
the	O
bone	O
metabolism.	O

BMD	O
of	O
48	O
patients	O
were	O
analyzed;	O
23	O
belongs	O
to	O
group	O
A,	O
10	O
to	O
group	O
B	O
and	O
15	O
to	O
group	O
C.	O

The	O
serum	O
bone	O
turnover	O
proteins	O
bone-specific	O
alkaline	O
phosphatase	O
(BAP)	O
and	O
carboxyterminal	O
crosslinked	O
telopeptide	O
of	O
type	O
I	O
collagen	O
(ICTP),	O
were	O
measured	O
with	O
commercially	O
available	O
test	O
kits	O
before	O
treatment,	O
3	O
months	O
and	O
15	O
months	O
after	O
treatment.	O

Functional	O
Assessment	O
of	O
Cancer	O
Therapy	O
core	O
questionnaire	O
(FACT-G)	O
with	O
its	O
additional	O
breast	O
cancer	O
subscale	O
were	O
performed	O
at	O
baseline,	O
4,	O
8,	O
and	O
12	O
weeks	O
after	O
NHT.	O

Difference	B-Premise
between	I-Premise
groups	I-Premise
(p=0.007)	I-Premise
for	I-Premise
BMD	I-Premise
at	I-Premise
femur	I-Premise
was	I-Premise
significant.	I-Premise

The	B-Premise
changes	I-Premise
of	I-Premise
BMD	I-Premise
in	I-Premise
group	I-Premise
B	I-Premise
patients	I-Premise
were	I-Premise
significantly	I-Premise
greater	I-Premise
than	I-Premise
patients	I-Premise
in	I-Premise
group	I-Premise
A	I-Premise
(p=0.011,	I-Premise
CI=0.063-0.437),	I-Premise
and	I-Premise
group	I-Premise
C	I-Premise
(p=0.003,	I-Premise
CI=0.146-0.620).	I-Premise

The	B-Premise
mean	I-Premise
BAP	I-Premise
increased	I-Premise
from	I-Premise
baseline	I-Premise
in	I-Premise
group	I-Premise
B	I-Premise
patients	I-Premise
but	I-Premise
decreased	I-Premise
from	I-Premise
baseline	I-Premise
in	I-Premise
group	I-Premise
C	I-Premise
patients	I-Premise
at	I-Premise
3	I-Premise
months	I-Premise
and	I-Premise
15	I-Premise
months.	I-Premise

No	B-Premise
statistical	I-Premise
significance	I-Premise
was	I-Premise
found	I-Premise
in	I-Premise
the	I-Premise
FACT-G	I-Premise
scores	I-Premise
and	I-Premise
FACT-B	I-Premise
scores	I-Premise
among	I-Premise
different	I-Premise
groups	I-Premise
at	I-Premise
baseline,	I-Premise
week	I-Premise
4,	I-Premise
week	I-Premise
8	I-Premise
and	I-Premise
week	I-Premise
12	I-Premise
after	I-Premise
NHT.	I-Premise

The	B-Premise
Breast	I-Premise
Cancer	I-Premise
Subscale	I-Premise
scores	I-Premise
in	I-Premise
group	I-Premise
A	I-Premise
patients	I-Premise
were	I-Premise
significantly	I-Premise
higher	I-Premise
than	I-Premise
that	I-Premise
of	I-Premise
group	I-Premise
C	I-Premise
patients	I-Premise
(p=0.021).	I-Premise

After	B-Premise
4	I-Premise
weeks	I-Premise
of	I-Premise
NHT,	I-Premise
negative	I-Premise
changes	I-Premise
of	I-Premise
FACT-B	I-Premise
and	I-Premise
FACT-G	I-Premise
scores	I-Premise
were	I-Premise
found	I-Premise
in	I-Premise
group	I-Premise
B	I-Premise
and	I-Premise
C	I-Premise
patients,	I-Premise
but	B-Premise
there	I-Premise
were	I-Premise
positive	I-Premise
changes	I-Premise
in	I-Premise
group	I-Premise
A	I-Premise
patients.	I-Premise

Significant	B-Premise
differences	I-Premise
of	I-Premise
FACT-B	I-Premise
score	I-Premise
(p=0.008)	I-Premise
and	I-Premise
FACT-G	I-Premise
score	I-Premise
(p=0.019)	I-Premise
were	I-Premise
observed	I-Premise
at	I-Premise
that	I-Premise
time	I-Premise
point.	I-Premise

Article	O
from	O
the	O
Special	O
issue	O
on	O
Targeted	O
Inhibitors.	O

To	O
investigate	O
whether	O
frequent	O
hospital	O
follow-up	O
in	O
the	O
first	O
year	O
after	O
breast	O
cancer	O
treatment	O
might	O
partly	O
be	O
replaced	O
by	O
nurse-led	O
telephone	O
follow-up	O
without	O
deteriorating	O
health-related	O
quality	O
of	O
life	O
(HRQoL),	O
and	O
whether	O
a	O
short	O
educational	O
group	O
programme	O
(EGP)	O
would	O
enhance	O
HRQoL.	O

A	O
multicentre	O
pragmatic	O
randomised	O
controlled	O
trial	O
(RCT)	O
with	O
a	O
22	O
factorial	O
design	O
was	O
performed	O
among	O
320	O
breast	O
cancer	O
patients	O
who	O
were	O
treated	O
with	O
curative	O
intent.	O

Participants	O
were	O
randomised	O
to	O
follow-up	O
care	O
as	O
usual	O
(3-monthly	O
outpatient	O
clinic	O
visits),	O
nurse-led	O
telephone	O
follow-up,	O
or	O
the	O
former	O
strategies	O
combined	O
with	O
an	O
educational	O
group	O
programme.	O

The	O
primary	O
outcome	O
for	O
both	O
interventions	O
was	O
HRQoL,	O
measured	O
by	O
EORTC	O
QLQ-C30.	O

Secondary	O
outcomes	O
were	O
role	O
and	O
emotional	O
functioning	O
and	O
feelings	O
of	O
control	O
and	O
anxiety.	O

Data	O
of	O
299	O
patients	O
were	O
available	O
for	O
evaluation.	O

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
HRQoL	I-Premise
between	I-Premise
nurse-led	I-Premise
telephone	I-Premise
and	I-Premise
hospital	I-Premise
follow-up	I-Premise
at	I-Premise
12	I-Premise
months	I-Premise
after	I-Premise
treatment	I-Premise
(p	I-Premise
=	I-Premise
0.42;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
(CI)	I-Premise
for	I-Premise
difference:	I-Premise
-1.93-4.64)	I-Premise
and	I-Premise
neither	I-Premise
between	I-Premise
follow-up	I-Premise
with	I-Premise
or	I-Premise
without	I-Premise
EGP	I-Premise
(p	I-Premise
=	I-Premise
0.86;	I-Premise
95%	I-Premise
CI	I-Premise
for	I-Premise
difference:	I-Premise
-3.59-3.00).	I-Premise

Furthermore,	O
no	B-Premise
differences	I-Premise
between	I-Premise
the	I-Premise
intervention	I-Premise
groups	I-Premise
and	I-Premise
their	I-Premise
corresponding	I-Premise
control	I-Premise
groups	I-Premise
were	I-Premise
found	I-Premise
in	I-Premise
role	I-Premise
and	I-Premise
emotional	I-Premise
functioning,	I-Premise
and	I-Premise
feelings	I-Premise
of	I-Premise
control	I-Premise
and	I-Premise
anxiety	I-Premise
(all	I-Premise
p-values	I-Premise
>	I-Premise
0.05).	I-Premise

Replacement	B-Claim
of	I-Claim
most	I-Claim
hospital	I-Claim
follow-up	I-Claim
visits	I-Claim
in	I-Claim
the	I-Claim
first	I-Claim
year	I-Claim
after	I-Claim
breast	I-Claim
cancer	I-Claim
treatment	I-Claim
by	I-Claim
nurse-led	I-Claim
telephone	I-Claim
follow-up	I-Claim
does	I-Claim
not	I-Claim
impede	I-Claim
patient	I-Claim
outcomes.	I-Claim

Hence,	O
nurse-led	B-Claim
telephone	I-Claim
follow-up	I-Claim
seems	I-Claim
an	I-Claim
appropriate	I-Claim
way	I-Claim
to	I-Claim
reduce	I-Claim
clinic	I-Claim
visits	I-Claim
and	I-Claim
represents	I-Claim
an	I-Claim
accepted	I-Claim
alternative	I-Claim
strategy.	I-Claim

An	O
EGP	O
does	O
not	O
unequivocally	O
affect	O
positive	O
HRQoL	O
outcomes.	O

A	O
phase	O
III	O
trial	O
(Cancer	O
and	O
Leukemia	O
Group	O
B	O
CALGB-49907)	O
was	O
conducted	O
to	O
test	O
whether	O
older	O
patients	O
with	O
early-stage	O
breast	O
cancer	O
would	O
have	O
equivalent	O
relapse-free	O
and	O
overall	O
survival	O
with	O
capecitabine	O
compared	O
with	O
standard	O
chemotherapy.	O

The	O
quality	O
of	O
life	O
(QoL)	O
substudy	O
tested	O
whether	O
capecitabine	O
treatment	O
would	O
be	O
associated	O
with	O
a	O
better	O
QoL	O
than	O
standard	O
chemotherapy.	O

QoL	O
was	O
assessed	O
in	O
350	O
patients	O
randomly	O
assigned	O
to	O
either	O
standard	O
chemotherapy	O
(cyclophosphamide,	O
methotrexate,	O
and	O
fluorouracil	O
[CMF]	O
or	O
doxorubicin	O
and	O
cyclophosphamide	O
[AC];	O
n	O
=	O
182)	O
or	O
capecitabine	O
(n	O
=	O
168).	O

Patients	O
were	O
interviewed	O
by	O
telephone	O
before	O
treatment	O
(baseline),	O
midtreatment,	O
within	O
1	O
month	O
post-treatment,	O
and	O
at	O
12,	O
18,	O
and	O
24	O
months	O
postbaseline	O
by	O
using	O
questionnaires	O
from	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
C30	O
(EORTC	O
QLQ-C30),	O
a	O
breast	O
systemic	O
adverse	O
effects	O
scale	O
(EORTC	O
BR23),	O
and	O
the	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
(HADS).	O

Compared	B-Premise
with	I-Premise
patients	I-Premise
who	I-Premise
were	I-Premise
treated	I-Premise
with	I-Premise
standard	I-Premise
chemotherapy,	I-Premise
patients	I-Premise
who	I-Premise
were	I-Premise
treated	I-Premise
with	I-Premise
capecitabine	I-Premise
had	I-Premise
significantly	I-Premise
better	I-Premise
QoL,	I-Premise
role	I-Premise
function,	I-Premise
and	I-Premise
social	I-Premise
function,	I-Premise
fewer	I-Premise
systemic	I-Premise
adverse	I-Premise
effects,	I-Premise
less	I-Premise
psychological	I-Premise
distress,	I-Premise
and	I-Premise
less	I-Premise
fatigue	I-Premise
during	I-Premise
and	I-Premise
at	I-Premise
the	I-Premise
completion	I-Premise
of	I-Premise
treatment	I-Premise
(P	I-Premise
	I-Premise
.005).	I-Premise

Capecitabine	B-Premise
treatment	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
less	I-Premise
nausea,	I-Premise
vomiting,	I-Premise
and	I-Premise
constipation	I-Premise
and	I-Premise
with	I-Premise
better	I-Premise
appetite	I-Premise
than	I-Premise
standard	I-Premise
treatment	I-Premise
(P	I-Premise
	I-Premise
.004),	I-Premise
but	I-Premise
worse	I-Premise
hand-foot	I-Premise
syndrome	I-Premise
and	I-Premise
diarrhea	I-Premise
(P	I-Premise
<	I-Premise
.005).	I-Premise

These	O
differences	O
all	O
resolved	O
by	O
12	O
months.	O

Standard	B-Claim
chemotherapy	I-Claim
was	I-Claim
superior	I-Claim
to	I-Claim
capecitabine	I-Claim
in	I-Claim
improving	I-Claim
relapse-free	I-Claim
and	I-Claim
overall	I-Claim
survival	I-Claim
for	I-Claim
older	I-Claim
women	I-Claim
with	I-Claim
early-stage	I-Claim
breast	I-Claim
cancer.	I-Claim

Although	O
capecitabine	B-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
better	I-Claim
QoL	I-Claim
during	I-Claim
treatment,	I-Claim
QoL	B-Premise
was	I-Premise
similar	I-Premise
for	I-Premise
both	I-Premise
groups	I-Premise
at	I-Premise
1	I-Premise
year.	I-Premise

The	O
brief	O
period	O
of	O
poorer	O
QoL	O
with	O
standard	O
treatment	O
is	O
a	O
modest	O
price	O
to	O
pay	O
for	O
a	O
chance	O
at	O
improved	O
survival.	O

Premenopausal	O
women	O
with	O
breast	O
cancer	O
receiving	O
adjuvant	O
chemotherapy	O
are	O
at	O
risk	O
for	O
amenorrhea.	O

The	O
National	O
Surgical	O
Adjuvant	O
Breast	O
and	O
Bowel	O
Project	O
B-30	O
trial	O
included	O
menstrual	O
history	O
(MH)	O
and	O
quality-of-life	O
(QOL)	O
studies	O
to	O
compare	O
treatments	O
on	O
these	O
outcomes.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
sequential	O
doxorubicin	O
(A)	O
and	O
cyclophosphamide	O
(C)	O
followed	O
by	O
docetaxel	O
(T;	O
ACT),	O
concurrent	O
TAC,	O
or	O
AT,	O
which	O
varied	O
in	O
duration	O
(24,	O
12,	O
12	O
weeks,	O
respectively),	O
and	O
use	O
of	O
C.	O

Endocrine	O
therapy	O
was	O
prescribed	O
for	O
women	O
with	O
hormone	O
receptor-positive	O
tumors.	O

MH	O
and	O
QOL	O
were	O
assessed	O
with	O
standardized	O
questionnaires	O
at	O
baseline;	O
cycle	O
4,	O
day	O
1;	O
and	O
every	O
6	O
months	O
through	O
24	O
months.	O

Prespecified	O
analyses	O
examined	O
rates	O
of	O
amenorrhea	O
by	O
treatment	O
arm,	O
the	O
relationship	O
between	O
amenorrhea	O
and	O
QOL,	O
and	O
QOL	O
by	O
treatment	O
arm.	O

Amenorrhea	B-Premise
12	I-Premise
months	I-Premise
after	I-Premise
random	I-Premise
assignment	I-Premise
was	I-Premise
significantly	I-Premise
different	I-Premise
between	I-Premise
treatment	I-Premise
groups:	I-Premise
69.8%	I-Premise
for	I-Premise
ACT,	I-Premise
57.7%	I-Premise
for	I-Premise
TAC,	I-Premise
and	I-Premise
37.9%	I-Premise
for	I-Premise
AT	I-Premise
(P	I-Premise
<	I-Premise
.001).	I-Premise

The	B-Premise
AT	I-Premise
group	I-Premise
without	I-Premise
tamoxifen	I-Premise
had	I-Premise
the	I-Premise
lowest	I-Premise
rate	I-Premise
of	I-Premise
amenorrhea.	I-Premise

QOL	B-Premise
was	I-Premise
poorer	I-Premise
for	I-Premise
patients	I-Premise
receiving	I-Premise
ACT	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
but	I-Premise
similar	I-Premise
to	I-Premise
others	I-Premise
by	I-Premise
12	I-Premise
months.	I-Premise

Post-treatment	B-Premise
symptoms	I-Premise
were	I-Premise
increased	I-Premise
above	I-Premise
baseline	I-Premise
for	I-Premise
all	I-Premise
treatments.	I-Premise

Multivariable	B-Premise
repeated	I-Premise
measures	I-Premise
modeling	I-Premise
demonstrated	I-Premise
that	I-Premise
treatment	I-Premise
arm,	I-Premise
time	I-Premise
point,	I-Premise
age,	I-Premise
and	I-Premise
tamoxifen	I-Premise
use	I-Premise
were	I-Premise
significantly	I-Premise
associated	I-Premise
with	I-Premise
symptom	I-Premise
severity	I-Premise
(all	I-Premise
P	I-Premise
values	I-Premise
<	I-Premise
.002).	I-Premise

Amenorrhea	B-Claim
rates	I-Claim
differed	I-Claim
significantly	I-Claim
by	I-Claim
treatment	I-Claim
arm,	I-Claim
with	I-Claim
the	I-Claim
AT	I-Claim
arm	I-Claim
having	I-Claim
the	I-Claim
lowest	I-Claim
rate.	I-Claim

Patients	B-Claim
treated	I-Claim
with	I-Claim
longer	I-Claim
duration	I-Claim
therapy	I-Claim
(ACT)	I-Claim
had	I-Claim
greater	I-Claim
symptom	I-Claim
severity	I-Claim
and	I-Claim
poorer	I-Claim
QOL	I-Claim
at	I-Claim
6	I-Claim
months,	I-Claim
but	I-Claim
did	I-Claim
not	I-Claim
differ	I-Claim
from	I-Claim
shorter	I-Claim
duration	I-Claim
treatments	I-Claim
at	I-Claim
12	I-Claim
months.	I-Claim

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
explore	O
the	O
inflammatory	O
modulation	O
effect	O
of	O
glutamine-enriched	O
total	O
parenteral	O
nutrition	O
(TPN)	O
by	O
investigating	O
the	O
alterations	O
of	O
inflammation-related	O
cytokines	O
in	O
gastrointestinal	O
(GI)	O
cancer	O
patients	O
postoperatively.	O

Fifty	O
GI	O
cancer	O
patients	O
received	O
postoperative	O
7	O
days	O
of	O
isocaloric	O
and	O
isonitrogenous	O
TPN	O
after	O
operation.	O

They	O
were	O
randomly	O
divided	O
to	O
receive	O
either	O
glutamine-enriched	O
TPN	O
or	O
standard	O
TPN.	O

The	O
inflammation-related	O
cytokines	O
including	O
interleukin-6,	O
interleukin-10,	O
and	O
tumor	O
necrosis	O
factor-	O
were	O
also	O
determined.	O

Records	O
of	O
nutritional	O
assessments,	O
inflammatory	O
status,	O
and	O
postoperative	O
complications	O
were	O
compared	O
between	O
the	O
two	O
groups.	O

Of	O
50	O
enrolled	O
patients,	O
25	O
patients	O
were	O
classified	O
as	O
the	O
intervention	O
group,	O
and	O
the	O
control	O
group	O
also	O
comprised	O
25	O
patients.	O

The	O
differences	O
of	O
gender,	O
age,	O
primary	O
GI	O
malignancies,	O
and	O
hematological	O
and	O
biochemical	O
data	O
between	O
the	O
two	O
compared	O
groups	O
were	O
not	O
statistically	O
significant	O
(all	O
P	O
>	O
0.05).	O

Compared	B-Premise
with	I-Premise
standard	I-Premise
TPN,	I-Premise
a	I-Premise
higher	I-Premise
serum	I-Premise
prealbumin	I-Premise
level	I-Premise
and	I-Premise
better	I-Premise
nitrogen	I-Premise
balance	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
glutamine-enriched	I-Premise
TPN	I-Premise
(P	I-Premise
=	I-Premise
0.039	I-Premise
and	I-Premise
0.048	I-Premise
respectively).	I-Premise

A	B-Premise
significantly	I-Premise
lower	I-Premise
serum	I-Premise
interleukin-6	I-Premise
level	I-Premise
was	I-Premise
found	I-Premise
in	I-Premise
comparing	I-Premise
glutamine-enriched	I-Premise
with	I-Premise
standard	I-Premise
TPN	I-Premise
(P	I-Premise
=	I-Premise
0.01),	I-Premise
but	B-Premise
not	I-Premise
in	I-Premise
interleukin-10	I-Premise
(P	I-Premise
=	I-Premise
0.374)	I-Premise
and	I-Premise
tumor	I-Premise
necrosis	I-Premise
factor-	I-Premise
levels	I-Premise
(P	I-Premise
=	I-Premise
0.653).	I-Premise

Moreover,	O
a	B-Premise
significant	I-Premise
lower	I-Premise
serum	I-Premise
C-reactive	I-Premise
protein	I-Premise
level	I-Premise
was	I-Premise
detected	I-Premise
in	I-Premise
glutamine-enriched	I-Premise
TPN	I-Premise
compared	I-Premise
with	I-Premise
standard	I-Premise
TPN	I-Premise
(P	I-Premise
=	I-Premise
0.013).	I-Premise

Indeed,	O
four	B-Premise
cases	I-Premise
of	I-Premise
postoperative	I-Premise
infectious	I-Premise
complications	I-Premise
were	I-Premise
noted	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group,	I-Premise
but	I-Premise
no	I-Premise
postoperative	I-Premise
infectious	I-Premise
complications	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
interventional	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.037).	I-Premise

Our	B-Claim
present	I-Claim
study	I-Claim
shows	I-Claim
that	I-Claim
glutamine-enriched	I-Claim
TPN	I-Claim
may	I-Claim
be	I-Claim
beneficial	I-Claim
in	I-Claim
improving	I-Claim
the	I-Claim
inflammatory	I-Claim
status	I-Claim
and	I-Claim
decreasing	I-Claim
the	I-Claim
infectious	I-Claim
morbidity	I-Claim
in	I-Claim
postoperative	I-Claim
GI	I-Claim
cancer	I-Claim
patients.	I-Claim

We	O
aimed	O
to	O
determine	O
the	O
effectiveness	O
of	O
a	O
lay-administered	O
tailored	O
education	O
and	O
coaching	O
(TEC)	O
intervention	O
(aimed	O
at	O
reducing	O
pain	O
misconceptions	O
and	O
enhancing	O
self-efficacy	O
for	O
communicating	O
with	O
physicians)	O
on	O
cancer	O
pain	O
severity,	O
pain-related	O
impairment,	O
and	O
quality	O
of	O
life.	O

Cancer	O
patients	O
with	O
baseline	O
"worst	O
pain"	O
of	O
4	O
on	O
a	O
0-10	O
scale	O
or	O
at	O
least	O
moderate	O
functional	O
impairment	O
due	O
to	O
pain	O
were	O
randomly	O
assigned	O
to	O
TEC	O
or	O
enhanced	O
usual	O
care	O
(EUC)	O
during	O
a	O
telephone	O
interview	O
conducted	O
in	O
advance	O
of	O
a	O
planned	O
oncology	O
office	O
visit	O
(265	O
patients	O
randomized	O
to	O
TEC	O
or	O
EUC;	O
258	O
completed	O
at	O
least	O
one	O
follow-up).	O

Patients	O
completed	O
questionnaires	O
before	O
and	O
after	O
the	O
visit	O
and	O
were	O
interviewed	O
by	O
telephone	O
at	O
2,	O
6,	O
and	O
12	O
weeks.	O

Mixed	O
effects	O
regressions	O
were	O
used	O
to	O
evaluate	O
the	O
intervention	O
adjusting	O
for	O
patient,	O
practice,	O
and	O
site	O
characteristics.	O

Compared	B-Premise
to	I-Premise
EUC,	I-Premise
TEC	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
increased	I-Premise
pain	I-Premise
communication	I-Premise
self-efficacy	I-Premise
after	I-Premise
the	I-Premise
intervention	I-Premise
(P<.001);	I-Premise
both	B-Premise
groups	I-Premise
showed	I-Premise
significant	I-Premise
(P<.0001),	I-Premise
similar,	I-Premise
reductions	I-Premise
in	I-Premise
pain	I-Premise
misconceptions.	I-Premise

At	B-Premise
2	I-Premise
weeks,	I-Premise
assignment	I-Premise
to	I-Premise
TEC	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
improvement	I-Premise
in	I-Premise
pain-related	I-Premise
impairment	I-Premise
(-0.25	I-Premise
points	I-Premise
on	I-Premise
a	I-Premise
5-point	I-Premise
scale,	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
-0.43	I-Premise
to	I-Premise
-0.06,	I-Premise
P=.01)	I-Premise
but	B-Premise
not	I-Premise
in	I-Premise
pain	I-Premise
severity	I-Premise
(-0.21	I-Premise
points	I-Premise
on	I-Premise
an	I-Premise
11-point	I-Premise
scale,	I-Premise
-0.60	I-Premise
to	I-Premise
0.17,	I-Premise
P=.27).	I-Premise

The	B-Premise
improvement	I-Premise
in	I-Premise
pain-related	I-Premise
impairment	I-Premise
was	I-Premise
not	I-Premise
sustained	I-Premise
at	I-Premise
6	I-Premise
and	I-Premise
12	I-Premise
weeks.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
intervention	I-Premise
by	I-Premise
subgroup	I-Premise
interactions	I-Premise
(P>.10).	I-Premise

We	B-Claim
conclude	I-Claim
that	I-Claim
TEC,	I-Claim
compared	I-Claim
with	I-Claim
EUC,	I-Claim
resulted	I-Claim
in	I-Claim
improved	I-Claim
pain	I-Claim
communication	I-Claim
self-efficacy	I-Claim
and	I-Claim
temporary	I-Claim
improvement	I-Claim
in	I-Claim
pain-related	I-Claim
impairment,	I-Claim
but	I-Claim
no	I-Claim
improvement	I-Claim
in	I-Claim
pain	I-Claim
severity.	I-Claim

To	O
determine	O
the	O
long-term	O
outcome	O
and	O
health-related	O
quality	O
of	O
life	O
(HRQL)	O
of	O
patients	O
with	O
endometrial	O
carcinoma	O
(EC)	O
treated	O
with	O
or	O
without	O
pelvic	O
radiotherapy	O
in	O
the	O
Post	O
Operative	O
Radiation	O
Therapy	O
in	O
Endometrial	O
Carcinoma	O
1	O
(PORTEC-1)	O
trial.	O

Between	O
1990	O
and	O
1997,	O
714	O
patients	O
with	O
stage	O
IC	O
grade	O
1	O
to	O
2	O
or	O
IB	O
grade	O
2	O
to	O
3	O
EC	O
were	O
randomly	O
allocated	O
to	O
pelvic	O
external-beam	O
radiotherapy	O
(EBRT)	O
or	O
no	O
additional	O
treatment	O
(NAT).	O

HRQL	O
was	O
evaluated	O
with	O
the	O
Short	O
Form	O
36-Item	O
(SF-36)	O
questionnaire;	O
subscales	O
from	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
PR25	O
module	O
for	O
bowel	O
and	O
bladder	O
symptoms	O
and	O
the	O
OV28	O
and	O
CX24	O
modules	O
for	O
sexual	O
symptoms;	O
and	O
demographic	O
questions.	O

Analysis	O
was	O
by	O
intention-to-treat.	O

Median	O
follow-up	O
was	O
13.3	O
years.	O

The	B-Premise
15-year	I-Premise
actuarial	I-Premise
locoregional	I-Premise
recurrence	I-Premise
rates	I-Premise
were	I-Premise
5.8%	I-Premise
for	I-Premise
EBRT	I-Premise
versus	I-Premise
15.5%	I-Premise
for	I-Premise
NAT	I-Premise
(P	I-Premise
<	I-Premise
.001),	I-Premise
and	I-Premise
15-year	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
52%	I-Premise
versus	I-Premise
60%	I-Premise
(P	I-Premise
=	I-Premise
.14).	I-Premise

Of	O
the	O
351	O
patients	O
confirmed	O
to	O
be	O
alive	O
with	O
correct	O
address,	O
246	O
(70%)	O
returned	O
the	O
questionnaire.	O

Patients	B-Premise
treated	I-Premise
with	I-Premise
EBRT	I-Premise
reported	I-Premise
significant	I-Premise
(P	I-Premise
<	I-Premise
.01)	I-Premise
and	I-Premise
clinically	I-Premise
relevant	I-Premise
higher	I-Premise
rates	I-Premise
of	I-Premise
urinary	I-Premise
incontinence,	I-Premise
diarrhea,	I-Premise
and	I-Premise
fecal	I-Premise
leakage	I-Premise
leading	I-Premise
to	I-Premise
more	I-Premise
limitations	I-Premise
in	I-Premise
daily	I-Premise
activities.	I-Premise

Increased	B-Premise
symptoms	I-Premise
were	I-Premise
reflected	I-Premise
by	I-Premise
the	I-Premise
frequent	I-Premise
use	I-Premise
of	I-Premise
incontinence	I-Premise
materials	I-Premise
after	I-Premise
EBRT	I-Premise
(day	I-Premise
and	I-Premise
night	I-Premise
use,	I-Premise
42.9%	I-Premise
v	I-Premise
15.2%	I-Premise
for	I-Premise
NAT;	I-Premise
P	I-Premise
<	I-Premise
.001).	I-Premise

Patients	B-Premise
treated	I-Premise
with	I-Premise
EBRT	I-Premise
reported	I-Premise
lower	I-Premise
scores	I-Premise
on	I-Premise
the	I-Premise
SF-36	I-Premise
scales	I-Premise
"physical	I-Premise
functioning"	I-Premise
(P	I-Premise
=	I-Premise
.004)	I-Premise
and	I-Premise
"role-physical"	I-Premise
(P	I-Premise
=	I-Premise
.003).	I-Premise

EBRT	B-Claim
for	I-Claim
endometrial	I-Claim
cancer	I-Claim
is	I-Claim
associated	I-Claim
with	I-Claim
long-term	I-Claim
urinary	I-Claim
and	I-Claim
bowel	I-Claim
symptoms	I-Claim
and	I-Claim
lower	I-Claim
physical	I-Claim
and	I-Claim
role-physical	I-Claim
functioning,	I-Claim
even	I-Claim
15	I-Claim
years	I-Claim
after	I-Claim
treatment.	I-Claim

Despite	B-Claim
its	I-Claim
efficacy	I-Claim
in	I-Claim
reducing	I-Claim
locoregional	I-Claim
recurrence,	I-Claim
EBRT	I-Claim
should	I-Claim
be	I-Claim
avoided	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
low-	I-Claim
and	I-Claim
intermediate-risk	I-Claim
EC.	I-Claim

Postoperative	B-Claim
outcomes	I-Claim
of	I-Claim
patients	I-Claim
undergoing	I-Claim
laparoscopic-assisted	I-Claim
colectomy	I-Claim
(LAC)	I-Claim
have	I-Claim
shown	I-Claim
modest	I-Claim
improvements	I-Claim
in	I-Claim
recovery	I-Claim
but	I-Claim
only	I-Claim
minimal	I-Claim
differences	I-Claim
in	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
(QOL)	I-Claim
compared	I-Claim
with	I-Claim
open	I-Claim
colectomy.	I-Claim

We	O
therefore	O
sought	O
to	O
assess	O
the	O
effect	O
of	O
LAC	O
on	O
QOL	O
in	O
the	O
short	O
and	O
long	O
term,	O
using	O
individual	O
item	O
analysis	O
of	O
multi-item	O
QOL	O
assessments.	O

QOL	O
variables	O
were	O
analyzed	O
in	O
449	O
randomized	O
patients	O
from	O
the	O
COST	O
trial	O
93-46-53	O
(INT	O
0146).	O

Both	O
cross-sectional	O
single-time	O
and	O
change	O
from	O
baseline	O
assessments	O
were	O
run	O
at	O
day	O
2,	O
week	O
2,	O
month	O
2,	O
and	O
month	O
18	O
postoperatively	O
in	O
an	O
intention-to-treat	O
analysis	O
using	O
Wilcoxon	O
rank-sum	O
tests.	O

Stepwise	O
regression	O
models	O
were	O
used	O
to	O
determine	O
predictors	O
of	O
QOL.	O

Of	O
449	O
colon	O
cancer	O
patients,	O
230	O
underwent	O
LAC	O
and	O
219	O
underwent	O
open	O
colectomy.	O

Subdomain	B-Premise
analysis	I-Premise
revealed	I-Premise
a	I-Premise
clinically	I-Premise
moderate	I-Premise
improvement	I-Premise
from	I-Premise
baseline	I-Premise
for	I-Premise
LAC	I-Premise
in	I-Premise
total	I-Premise
QOL	I-Premise
index	I-Premise
at	I-Premise
18	I-Premise
months	I-Premise
(P	I-Premise
=	I-Premise
0.02)	I-Premise
as	I-Premise
well	I-Premise
as	I-Premise
other	I-Premise
small	I-Premise
symptomatic	I-Premise
improvements.	I-Premise

Poor	O
preoperative	O
QOL	O
as	O
indicated	O
by	O
a	O
rating	O
scale	O
of	O
	O
50	O
was	O
an	O
independent	O
predictor	O
of	O
poor	O
QOL	O
at	O
2	O
months	O
postoperatively.	O

QOL	O
variables	O
related	O
to	O
survival	O
were	O
baseline	O
support	O
(P	O
=	O
0.001)	O
and	O
baseline	O
outlook	O
(P	O
=	O
0.01).	O

Eighteen	B-Premise
months	I-Premise
after	I-Premise
surgery,	I-Premise
any	I-Premise
differences	I-Premise
in	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
between	I-Premise
patients	I-Premise
randomized	I-Premise
to	I-Premise
LAC	I-Premise
or	I-Premise
open	I-Premise
colectomy	I-Premise
favored	I-Premise
LAC.	I-Premise

However,	B-Premise
the	I-Premise
magnitude	I-Premise
of	I-Premise
the	I-Premise
benefits	I-Premise
was	I-Premise
small.	I-Premise

Patients	B-Claim
with	I-Claim
poor	I-Claim
preoperative	I-Claim
QOL	I-Claim
appear	I-Claim
to	I-Claim
be	I-Claim
at	I-Claim
higher	I-Claim
risk	I-Claim
for	I-Claim
difficult	I-Claim
postoperative	I-Claim
courses,	I-Claim
and	I-Claim
may	I-Claim
be	I-Claim
candidates	I-Claim
for	I-Claim
enhanced	I-Claim
ancillary	I-Claim
services	I-Claim
to	I-Claim
address	I-Claim
their	I-Claim
particular	I-Claim
needs.	I-Claim

Improvements	O
can	O
be	O
made	O
in	O
the	O
quality	O
of	O
cancer	O
care	O
if	O
supportive	O
care	O
needs	O
are	O
addressed;	O
however,	O
there	O
are	O
few	O
trials	O
of	O
supportive	O
care	O
interventions	O
to	O
guide	O
policy	O
and	O
practice.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
effectiveness	O
of	O
a	O
nurse-delivered	O
telephone	O
supportive	O
intervention	O
(the	O
"CONNECT"	O
intervention).	O

This	O
study	O
was	O
a	O
pilot	O
randomized	O
controlled	O
trial.	O

Intervention	O
group	O
patients	O
received	O
5	O
calls	O
from	O
a	O
specialist	O
colorectal	O
nurse	O
in	O
the	O
6	O
months	O
after	O
hospital	O
discharge.	O

Each	O
call	O
was	O
standardized,	O
comprising	O
the	O
assessment	O
of	O
unmet	O
need	O
and	O
the	O
provision	O
of	O
information	O
and	O
emotional	O
support.	O

CONNECT	O
was	O
in	O
addition	O
to	O
standard	O
clinical	O
follow-up.	O

Patients	O
allocated	O
to	O
the	O
control	O
group	O
received	O
standard	O
follow-up	O
only.	O

This	O
study	O
took	O
place	O
at	O
the	O
Royal	O
Prince	O
Alfred	O
Hospital,	O
Sydney,	O
Australia.	O

Patients	O
(n	O
=	O
75)	O
were	O
included	O
who	O
had	O
been	O
surgically	O
treated	O
for	O
colorectal	O
cancer	O
(any	O
stage).	O

The	O
main	O
outcome	O
measures	O
were	O
the	O
unmet	O
supportive	O
care	O
needs,	O
health	O
service	O
utilization,	O
and	O
quality	O
of	O
life	O
at	O
1,	O
3,	O
and	O
6	O
months	O
postdischarge.	O

Of	O
87	O
eligible	O
patients,	O
75	O
consented	O
(86%	O
consent	O
rate).	O

Thirty-nine	O
patients	O
were	O
randomly	O
assigned	O
to	O
CONNECT	O
and	O
36	O
to	O
usual	O
care.	O

At	B-Premise
6	I-Premise
months,	I-Premise
there	I-Premise
was	I-Premise
a	I-Premise
clinically	I-Premise
relevant,	I-Premise
but	I-Premise
nonsignificant	I-Premise
reduction	I-Premise
in	I-Premise
presentations	I-Premise
to	I-Premise
emergency	I-Premise
departments	I-Premise
(21%	I-Premise
vs	I-Premise
33%;	I-Premise
1	I-Premise
=	I-Premise
1.41,	I-Premise
P	I-Premise
=	I-Premise
.23)	I-Premise
and	I-Premise
readmission	I-Premise
to	I-Premise
the	I-Premise
hospital	I-Premise
(37%	I-Premise
vs	I-Premise
47%;	I-Premise
1	I-Premise
=	I-Premise
0.82,	I-Premise
P	I-Premise
=	I-Premise
.37)	I-Premise
among	I-Premise
intervention	I-Premise
compared	I-Premise
with	I-Premise
control	I-Premise
group	I-Premise
participants.	I-Premise

Nonsignificant	B-Premise
differences	I-Premise
between	I-Premise
groups	I-Premise
were	I-Premise
found	I-Premise
for	I-Premise
all	I-Premise
unmet	I-Premise
supportive	I-Premise
care	I-Premise
need	I-Premise
and	I-Premise
quality-of-life	I-Premise
scores,	I-Premise
change	I-Premise
scores,	I-Premise
and	I-Premise
trends.	I-Premise

However,	B-Premise
at	I-Premise
6	I-Premise
months,	I-Premise
total	I-Premise
quality-of-life	I-Premise
scores	I-Premise
were	I-Premise
higher	I-Premise
for	I-Premise
intervention	I-Premise
group	I-Premise
patients	I-Premise
than	I-Premise
controls	I-Premise
(106.0	I-Premise
vs	I-Premise
98.6).	I-Premise

This	O
difference	O
(7.4)	O
was	O
clinically	O
relevant.	O

Improvements	B-Claim
in	I-Claim
total	I-Claim
quality-of-life	I-Claim
change	I-Claim
scores	I-Claim
demonstrated	I-Claim
that	I-Claim
at	I-Claim
6	I-Claim
months,	I-Claim
improvements	I-Claim
were	I-Claim
more	I-Claim
than	I-Claim
twice	I-Claim
as	I-Claim
large	I-Claim
and	I-Claim
clinically	I-Claim
significant	I-Claim
in	I-Claim
the	I-Claim
intervention	I-Claim
compared	I-Claim
with	I-Claim
the	I-Claim
control	I-Claim
group.	I-Claim

CONNECT	B-Claim
has	I-Claim
shown	I-Claim
promising	I-Claim
indications	I-Claim
on	I-Claim
health	I-Claim
system	I-Claim
and	I-Claim
patient	I-Claim
outcomes	I-Claim
that	I-Claim
warrant	I-Claim
a	I-Claim
larger	I-Claim
study	I-Claim
to	I-Claim
further	I-Claim
investigate	I-Claim
the	I-Claim
potential	I-Claim
of	I-Claim
this	I-Claim
intervention.	I-Claim

Thalidomide	O
with	O
melphalan/prednisone	O
(MPT)	O
was	O
defined	O
as	O
standard	O
treatment	O
in	O
elderly	O
patients	O
with	O
multiple	O
myeloma	O
(MM)	O
based	O
on	O
five	O
randomized	O
trials.	O

In	O
one	O
of	O
these	O
trials,	O
HOVON49,	O
a	O
prospective	O
health-related	O
quality-of-life	O
(HRQoL)	O
study	O
was	O
initiated	O
in	O
order	O
to	O
assess	O
the	O
impact	O
of	O
thalidomide	O
on	O
QoL.	O

Patients	O
aged	O
>65	O
years	O
with	O
newly	O
diagnosed	O
MM	O
were	O
randomized	O
to	O
receive	O
melphalan	O
plus	O
prednisone	O
(MP)	O
or	O
MPT,	O
followed	O
by	O
thalidomide	O
maintenance	O
in	O
the	O
MPT	O
arm.	O

Two	O
hundred	O
eighty-four	O
patients	O
were	O
included	O
in	O
this	O
side	O
study	O
(MP,	O
n=149;	O
MPT	O
n=135).	O

HRQoL	O
was	O
assessed	O
with	O
the	O
EORTC	O
Core	O
QoL	O
Questionnaire	O
(QLQ-C30)	O
and	O
the	O
myeloma-specific	O
module	O
(QLQ-MY24)	O
at	O
baseline	O
and	O
at	O
predetermined	O
intervals	O
during	O
treatment.	O

The	B-Premise
QLQ-C30	I-Premise
subscales	I-Premise
physical	I-Premise
function	I-Premise
(P=0.044)	I-Premise
and	I-Premise
constipation	I-Premise
(P<0.001)	I-Premise
showed	I-Premise
an	I-Premise
improvement	I-Premise
during	I-Premise
induction	I-Premise
in	I-Premise
favour	I-Premise
of	I-Premise
the	I-Premise
MP	I-Premise
arm.	I-Premise

During	B-Premise
thalidomide	I-Premise
maintenance,	I-Premise
the	I-Premise
scores	I-Premise
for	I-Premise
the	I-Premise
QLQ-MY24	I-Premise
paraesthesia	I-Premise
became	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
MPT	I-Premise
arm	I-Premise
(P<0.001).	I-Premise

The	B-Premise
QLQ-C30	I-Premise
subscales	I-Premise
pain	I-Premise
(P=0.12),	I-Premise
insomnia	I-Premise
(P=0.068),	I-Premise
appetite	I-Premise
loss	I-Premise
(P=0.074)	I-Premise
and	I-Premise
the	I-Premise
QLQ-MY24	I-Premise
item	I-Premise
sick	I-Premise
(P=0.086)	I-Premise
scored	I-Premise
marginally	I-Premise
better	I-Premise
during	I-Premise
thalidomide	I-Premise
maintenance.	I-Premise

The	B-Premise
overall	I-Premise
QoL-scale	I-Premise
QLQ-C30-HRQoL	I-Premise
showed	I-Premise
a	I-Premise
significant	I-Premise
time	I-Premise
trend	I-Premise
towards	I-Premise
more	I-Premise
favourable	I-Premise
mean	I-Premise
values	I-Premise
during	I-Premise
protocol	I-Premise
treatment	I-Premise
without	I-Premise
differences	I-Premise
between	I-Premise
MP	I-Premise
and	I-Premise
MPT.	I-Premise

For	B-Premise
the	I-Premise
QLQ-C30	I-Premise
subscales	I-Premise
emotional	I-Premise
function	I-Premise
and	I-Premise
future	I-Premise
perspectives,	I-Premise
difference	I-Premise
in	I-Premise
favour	I-Premise
of	I-Premise
the	I-Premise
MPT	I-Premise
arm	I-Premise
from	I-Premise
the	I-Premise
start	I-Premise
of	I-Premise
treatment	I-Premise
was	I-Premise
observed	I-Premise
(P=0.018	I-Premise
and	I-Premise
P=0.045,	I-Premise
respectively)	I-Premise
with	I-Premise
no	I-Premise
significant	I-Premise
'time	I-Premise
	I-Premise
arm'	I-Premise
interaction,	I-Premise
indicating	I-Premise
a	I-Premise
persistent	I-Premise
better	I-Premise
patient	I-Premise
perspective	I-Premise
with	I-Premise
MPT	I-Premise
treatment.	I-Premise

This	B-Claim
study	I-Claim
shows	I-Claim
that	I-Claim
the	I-Claim
higher	I-Claim
frequency	I-Claim
of	I-Claim
toxicity	I-Claim
associated	I-Claim
with	I-Claim
MPT	I-Claim
does	I-Claim
not	I-Claim
translate	I-Claim
into	I-Claim
a	I-Claim
negative	I-Claim
effect	I-Claim
on	I-Claim
HRQoL	I-Claim
and	I-Claim
that	I-Claim
MPT	I-Claim
holds	I-Claim
a	I-Claim
better	I-Claim
patient	I-Claim
perspective.	I-Claim

Insomnia	B-Claim
is	I-Claim
a	I-Claim
common	I-Claim
complaint	I-Claim
among	I-Claim
cancer	I-Claim
survivors.	I-Claim

Fortunately,	O
cognitive-behavioral	O
therapy	O
for	O
insomnia	O
(CBT-I)	O
has	O
been	O
shown	O
to	O
be	O
an	O
effective	O
treatment	O
in	O
this	O
population.	O

However,	O
it	O
is	O
rarely	O
implemented	O
given	O
its	O
limited	O
availability.	O

To	O
address	O
this	O
barrier,	O
we	O
examined	O
the	O
ability	O
of	O
an	O
easily	O
accessible	O
online	O
CBT-I	O
program	O
to	O
improve	O
insomnia	O
symptoms	O
in	O
cancer	O
survivors.	O

Twenty-eight	O
cancer	O
survivors	O
with	O
insomnia	O
were	O
randomly	O
assigned	O
to	O
either	O
an	O
Internet	O
insomnia	O
intervention	O
(n	O
=	O
14)	O
or	O
to	O
a	O
waitlist	O
control	O
group	O
(n	O
=	O
14).	O

The	O
online	O
program,	O
Sleep	O
Healthy	O
Using	O
The	O
Internet,	O
delivers	O
the	O
primary	O
components	O
of	O
CBT-I	O
(sleep	O
restriction,	O
stimulus	O
control,	O
cognitive	O
restructuring,	O
sleep	O
hygiene,	O
and	O
relapse	O
prevention).	O

Pre-	O
and	O
post-assessment	O
data	O
were	O
collected	O
via	O
online	O
questionnaires	O
and	O
daily	O
sleep	O
diaries.	O

Participants	B-Premise
in	I-Premise
the	I-Premise
Internet	I-Premise
group	I-Premise
showed	I-Premise
significant	I-Premise
improvements	I-Premise
at	I-Premise
post-assessment	I-Premise
compared	I-Premise
with	I-Premise
those	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
in	I-Premise
overall	I-Premise
insomnia	I-Premise
severity	I-Premise
(F(1,26)	I-Premise
=	I-Premise
22.8;	I-Premise
p<0.001),	I-Premise
sleep	I-Premise
efficiency	I-Premise
(F(1,24)	I-Premise
=	I-Premise
11.45;	I-Premise
P	I-Premise
=	I-Premise
0.002),	I-Premise
sleep	I-Premise
onset	I-Premise
latency	I-Premise
(F(1,24)	I-Premise
=	I-Premise
5.18;	I-Premise
P	I-Premise
=	I-Premise
0.03),	I-Premise
soundness	I-Premise
of	I-Premise
sleep	I-Premise
(F(1,24)	I-Premise
=	I-Premise
9.34;	I-Premise
P	I-Premise
=	I-Premise
0.005),	I-Premise
restored	I-Premise
feeling	I-Premise
upon	I-Premise
awakening	I-Premise
(F(1,24)	I-Premise
=	I-Premise
11.95;	I-Premise
P	I-Premise
=	I-Premise
0.002),	I-Premise
and	I-Premise
general	I-Premise
fatigue	I-Premise
(F(1,26)	I-Premise
=	I-Premise
13.88;	I-Premise
P	I-Premise
=	I-Premise
0.001).	I-Premise

Although	B-Premise
other	I-Premise
group	I-Premise
	I-Premise
time	I-Premise
interactions	I-Premise
were	I-Premise
not	I-Premise
significant,	I-Premise
overall	I-Premise
adjusted	I-Premise
effect	I-Premise
sizes	I-Premise
for	I-Premise
all	I-Premise
sleep	I-Premise
variables	I-Premise
as	I-Premise
well	I-Premise
as	I-Premise
for	I-Premise
fatigue,	I-Premise
depression,	I-Premise
anxiety,	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
ranged	I-Premise
from	I-Premise
small	I-Premise
to	I-Premise
large.	I-Premise

CBT-I	B-Claim
delivered	I-Claim
through	I-Claim
an	I-Claim
interactive,	I-Claim
individually	I-Claim
tailored	I-Claim
Internet	I-Claim
intervention	I-Claim
may	I-Claim
be	I-Claim
a	I-Claim
viable	I-Claim
treatment	I-Claim
option	I-Claim
for	I-Claim
cancer	I-Claim
survivors	I-Claim
experiencing	I-Claim
insomnia.	I-Claim

A	O
randomised	O
controlled	O
trial	O
(RCT)	O
demonstrated	O
that	O
cognitive	O
behaviour	O
therapy	O
(CBT)	O
for	O
fatigue	O
during	O
curative	O
cancer	O
treatment	O
was	O
effective	O
shortly	O
after	O
cancer	O
treatment.	O

This	O
study	O
aimed	O
to	O
identify	O
which	O
patient	O
characteristics	O
predict	O
fatigue	O
improvement	O
after	O
CBT.	O

In	O
addition,	O
the	O
long-term	O
effectiveness	O
was	O
investigated.	O

Patients	O
with	O
various	O
malignancies	O
participated	O
in	O
the	O
RCT	O
(n	O
=	O
210).	O

Participants	O
were	O
assessed	O
before	O
cancer	O
treatment	O
(T1),	O
postintervention	O
(T2),	O
which	O
was	O
at	O
least	O
2	O
months	O
after	O
cancer	O
treatment,	O
and	O
after	O
1-year	O
follow-up	O
(T3).	O

Monthly	O
fatigue	O
assessments	O
were	O
completed	O
between	O
T2	O
and	O
T3.	O

A	O
regression	O
analysis	O
with	O
interactions	O
was	O
performed	O
to	O
determine	O
if	O
domains	O
of	O
quality	O
of	O
life	O
(EORTC-QLQ-C30)	O
functioning	O
(Health	O
Survey	O
Short	O
Form-36)	O
or	O
psychological	O
distress	O
(Symptom	O
Checklist-90)	O
moderated	O
the	O
effect	O
of	O
CBT	O
on	O
fatigue.	O

Analyses	O
of	O
covariance	O
were	O
used	O
to	O
study	O
the	O
long-term	O
effectiveness	O
of	O
CBT.	O

Fatigue	B-Premise
at	I-Premise
T2	I-Premise
was	I-Premise
predicted	I-Premise
by	I-Premise
a	I-Premise
significant	I-Premise
interaction	I-Premise
between	I-Premise
self-reported	I-Premise
cognitive	I-Premise
functioning	I-Premise
and	I-Premise
CBT.	I-Premise

No	B-Premise
interactions	I-Premise
were	I-Premise
found	I-Premise
between	I-Premise
other	I-Premise
domains	I-Premise
of	I-Premise
quality	I-Premise
of	I-Premise
life,	I-Premise
functioning,	I-Premise
psychological	I-Premise
distress	I-Premise
and	I-Premise
CBT.	I-Premise

At	B-Premise
T3,	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
on	I-Premise
fatigue	I-Premise
was	I-Premise
found	I-Premise
between	I-Premise
CBT	I-Premise
and	I-Premise
usual	I-Premise
care.	I-Premise

Exploratory	B-Premise
analyses	I-Premise
showed	I-Premise
that	I-Premise
the	I-Premise
difference	I-Premise
nearly	I-Premise
reached	I-Premise
significance	I-Premise
until	I-Premise
7	I-Premise
months	I-Premise
postintervention.	I-Premise

Patients	B-Premise
who	I-Premise
experienced	I-Premise
more	I-Premise
concentration	I-Premise
and	I-Premise
memory	I-Premise
problems	I-Premise
at	I-Premise
T1	I-Premise
benefited	I-Premise
more	I-Premise
from	I-Premise
CBT	I-Premise
for	I-Premise
fatigue	I-Premise
and	I-Premise
are	I-Premise
indicators.	I-Premise

After	B-Premise
a	I-Premise
year	I-Premise
of	I-Premise
follow-up,	I-Premise
the	I-Premise
effect	I-Premise
of	I-Premise
CBT	I-Premise
for	I-Premise
fatigue	I-Premise
was	I-Premise
no	I-Premise
longer	I-Premise
observed,	I-Premise
and	I-Premise
the	I-Premise
effect	I-Premise
on	I-Premise
fatigue	I-Premise
seemed	I-Premise
to	I-Premise
be	I-Premise
diminished	I-Premise
7	I-Premise
months	I-Premise
postintervention.	I-Premise

The	B-Claim
implication	I-Claim
is	I-Claim
that	I-Claim
CBT	I-Claim
for	I-Claim
fatigue	I-Claim
should	I-Claim
be	I-Claim
offered	I-Claim
to	I-Claim
patients	I-Claim
with	I-Claim
cancer	I-Claim
with	I-Claim
the	I-Claim
highest	I-Claim
chance	I-Claim
to	I-Claim
benefit.	I-Claim

To	O
analyze	O
the	O
predictive	O
value	O
of	O
PSA	O
for	O
progression	O
and	O
the	O
role	O
of	O
testosterone	O
for	O
quality	O
of	O
life	O
(QOL)	O
in	O
patients	O
with	O
androgen	O
deprivation	O
therapy	O
(ADT)	O
for	O
metastatic	O
prostate	O
cancer.	O

PSA	O
and	O
testosterone	O
data	O
were	O
used	O
from	O
a	O
phase	O
III	O
trial	O
randomizing	O
patients	O
without	O
progression	O
and	O
PSA	O
<	O
4	O
ng/ml	O
(n	O
=	O
193),	O
after	O
6	O
months	O
induction	O
course,	O
between	O
continuous	O
(CAD)	O
(n	O
=	O
96)	O
and	O
intermittent	O
(IAD)	O
(n	O
=	O
97)	O
ADT.	O

The	O
2-year	O
risk	O
of	O
progression	O
was	O
calculated	O
for	O
baseline	O
PSA,	O
'fast'	O
and	O
'slow'	O
PSA	O
decline	O
to	O
<	O
4	O
ng/ml	O
(60	O
days	O
cut-off),	O
PSA	O
nadir,	O
performance	O
status	O
and	O
pain.	O

Testosterone	O
kinetics	O
and	O
QOL	O
were	O
also	O
evaluated.	O

Univariate	O
Kaplan	O
Meier	O
survival	O
analysis	O
and	O
log	O
rank	O
tests	O
were	O
used	O
to	O
compare	O
the	O
risk	O
of	O
progression.	O

For	O
progression	O
analysis,	O
173	O
patients'	O
data	O
were	O
available.	O

The	O
2-year	O
risk	O
of	O
progression	O
for	O
baseline	O
PSA	O
<	O
50	O
ng/ml,	O
50	O
to	O
<500	O
ng/ml,	O
and	O
	O
500	O
ng/ml	O
was	O
25%,	O
55%,	O
and	O
76%	O
(P	O
=	O
0.03)	O
in	O
CAD,	O
and	O
38%,	O
64%,	O
and	O
85%	O
(P	O
=	O
0.006)	O
in	O
IAD,	O
respectively.	O

The	B-Premise
2-year	I-Premise
risk	I-Premise
of	I-Premise
progression	I-Premise
for	I-Premise
PSA	I-Premise
nadir	I-Premise
	I-Premise
0.2	I-Premise
ng/ml,	I-Premise
and	I-Premise
>	I-Premise
0.2	I-Premise
to	I-Premise
4	I-Premise
ng/ml	I-Premise
in	I-Premise
CAD	I-Premise
was	I-Premise
31%	I-Premise
and	I-Premise
70%	I-Premise
(P	I-Premise
<	I-Premise
0.001),	I-Premise
respectively.	I-Premise

In	B-Premise
the	I-Premise
IAD	I-Premise
group,	I-Premise
a	I-Premise
similar	I-Premise
trend	I-Premise
was	I-Premise
seen.	I-Premise

Patients	B-Premise
with	I-Premise
PSA	I-Premise
nadir	I-Premise
	I-Premise
0.2	I-Premise
ng/ml,	I-Premise
though	I-Premise
had	I-Premise
significantly	I-Premise
higher	I-Premise
2-year	I-Premise
risk	I-Premise
of	I-Premise
progression	I-Premise
compared	I-Premise
to	I-Premise
CAD	I-Premise
(53%	I-Premise
vs.	I-Premise
31%	I-Premise
(P	I-Premise
=	I-Premise
0.03),	I-Premise
respectively.	I-Premise

PSA	O
decline	O
showed	O
no	O
predictive	O
value.	O

Patients	B-Premise
without	I-Premise
pain	I-Premise
had	I-Premise
a	I-Premise
significantly	I-Premise
lower	I-Premise
2-year	I-Premise
risk	I-Premise
of	I-Premise
progression	I-Premise
in	I-Premise
both	I-Premise
groups.	I-Premise

Without	B-Premise
ADT	I-Premise
testosterone	I-Premise
remained	I-Premise
at	I-Premise
castrate	I-Premise
level	I-Premise
for	I-Premise
4	I-Premise
months.	I-Premise

After	O
the	O
first	O
and	O
second	O
IAD	O
cycle	O
92%	O
and	O
46%,	O
respectively,	O
had	O
a	O
normalized	O
testosterone.	O

No	B-Premise
QOL	I-Premise
difference	I-Premise
was	I-Premise
found,	I-Premise
although	I-Premise
more	I-Premise
side	I-Premise
effects	I-Premise
occurred	I-Premise
in	I-Premise
CAD.	I-Premise

Metastatic	B-Claim
prostate	I-Claim
cancer	I-Claim
patients	I-Claim
with	I-Claim
high	I-Claim
baseline	I-Claim
PSA,	I-Claim
pain,	I-Claim
and	I-Claim
high	I-Claim
PSA	I-Claim
nadir	I-Claim
have	I-Claim
a	I-Claim
poor	I-Claim
prognosis	I-Claim
with	I-Claim
ADT.	I-Claim

Patients	B-Claim
with	I-Claim
low	I-Claim
PSA	I-Claim
nadir	I-Claim
do	I-Claim
significantly	I-Claim
worse	I-Claim
with	I-Claim
IAD	I-Claim
compared	I-Claim
with	I-Claim
CAD.	I-Claim

Low	O
testosterone	O
after	O
ADT	O
and	O
incomplete	O
testosterone	O
recovery	O
may	O
explain	O
similar	O
QOL.	O

Therefore,	O
IAD	B-Claim
is	I-Claim
not	I-Claim
a	I-Claim
good	I-Claim
treatment	I-Claim
option	I-Claim
for	I-Claim
many	I-Claim
metastatic	I-Claim
prostate	I-Claim
cancer	I-Claim
patients.	I-Claim

This	O
randomised	O
non-inferiority	O
trial	O
was	O
designed	O
to	O
assess	O
whether	O
radiosurgery	O
plus	O
adjuvant	O
whole	O
brain	O
radiotherapy	O
(RS	O
+	O
WBRT)	O
is	O
as	O
effective	O
as	O
surgery	O
plus	O
whole	O
brain	O
radiotherapy	O
(S	O
+	O
WBRT)	O
for	O
cancer	O
patients	O
with	O
a	O
solitary	O
brain	O
metastasis,	O
with	O
respect	O
to	O
overall	O
survival	O
and	O
quality	O
of	O
life.	O

Major	O
inclusion	O
criteria	O
were	O
a	O
history	O
of	O
systemic	O
cancer	O
within	O
5	O
years	O
and	O
enhanced	O
magnetic	O
resonance	O
imaging-confirmed	O
solitary	O
brain	O
metastasis	O
suitable	O
for	O
both	O
radiosurgery	O
and	O
surgery.	O

All	O
patients	O
were	O
to	O
receive	O
WBRT	O
(30	O
Gy	O
in	O
10	O
fractions).	O

Between	O
February	O
2003	O
and	O
April	O
2009,	O
40	O
patients	O
were	O
considered	O
eligible,	O
22	O
consented	O
to	O
randomisation	O
and	O
21	O
were	O
analysed	O
(11	O
RS	O
+	O
WBRT,	O
10	O
S	O
+	O
WBRT).	O

The	O
trial	O
was	O
closed	O
early	O
due	O
to	O
slow	O
accrual.	O

The	B-Premise
estimated	I-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
times	I-Premise
for	I-Premise
RS	I-Premise
+	I-Premise
WBRT	I-Premise
and	I-Premise
S	I-Premise
+	I-Premise
WBRT	I-Premise
patients	I-Premise
were	I-Premise
6.2	I-Premise
and	I-Premise
2.8	I-Premise
months,	I-Premise
respectively	I-Premise
(hazard	I-Premise
ratio	I-Premise
0.53,	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
0.20-1.43,	I-Premise
P	I-Premise
=	I-Premise
0.20).	I-Premise

Corresponding	B-Premise
median	I-Premise
failure-free	I-Premise
survival	I-Premise
times	I-Premise
were	I-Premise
3.1	I-Premise
and	I-Premise
1.7	I-Premise
months	I-Premise
(P	I-Premise
=	I-Premise
0.20).	I-Premise

For	B-Premise
19	I-Premise
'per	I-Premise
protocol'	I-Premise
patients,	I-Premise
2/10	I-Premise
in	I-Premise
the	I-Premise
RS	I-Premise
+	I-Premise
WBRT	I-Premise
arm	I-Premise
had	I-Premise
distant	I-Premise
intracranial	I-Premise
failure	I-Premise
(one	I-Premise
also	I-Premise
had	I-Premise
local	I-Premise
failure)	I-Premise
and	I-Premise
3/9	I-Premise
S	I-Premise
+	I-Premise
WBRT	I-Premise
patients	I-Premise
had	I-Premise
distant	I-Premise
intracranial	I-Premise
failure	I-Premise
(no	I-Premise
local	I-Premise
failures).	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
grade	I-Premise
3-4	I-Premise
late	I-Premise
radiation	I-Premise
toxicities.	I-Premise

Two	B-Claim
months	I-Claim
after	I-Claim
starting	I-Claim
treatment	I-Claim
there	I-Claim
were	I-Claim
no	I-Claim
significant	I-Claim
differences	I-Claim
in	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
between	I-Claim
the	I-Claim
arms.	I-Claim

This	B-Claim
randomised	I-Claim
trial	I-Claim
encountered	I-Claim
the	I-Claim
accrual	I-Claim
difficulties	I-Claim
and	I-Claim
consequent	I-Claim
low	I-Claim
statistical	I-Claim
power	I-Claim
commonly	I-Claim
associated	I-Claim
with	I-Claim
interdisciplinary	I-Claim
studies	I-Claim
drawing	I-Claim
from	I-Claim
a	I-Claim
small	I-Claim
eligible	I-Claim
population,	I-Claim
but	O
can	O
contribute	O
to	O
future	O
overviews	O
on	O
the	O
management	O
of	O
solitary	O
brain	O
metastases.	O

Regularly	O
collecting	O
patient-reported	O
outcomes	O
(PROs)	O
of	O
health-related	O
quality	O
of	O
life	O
with	O
feedback	O
to	O
oncologists	O
may	O
assist	O
in	O
eliciting	O
and	O
monitoring	O
patients'	O
problems	O
during	O
cancer	O
treatment.	O

This	O
study	O
examined	O
how	O
PRO	O
feedback	O
had	O
an	O
impact	O
on	O
patient-physician	O
communication	O
over	O
time	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
how	O
it	O
may	O
influence	O
patient	O
care.	O

Exploratory	O
analyses	O
were	O
performed	O
on	O
a	O
data	O
set	O
from	O
a	O
previous	O
study.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
intervention	O
(regular	O
completion	O
of	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire-Core	O
30	O
and	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
with	O
feedback	O
to	O
oncologists),	O
attention-control	O
(completion	O
of	O
same	O
questionnaires	O
without	O
feedback),	O
and	O
control	O
(standard	O
care)	O
arms.	O

The	O
content	O
of	O
consultation	O
audio	O
recordings	O
between	O
28	O
oncologists	O
and	O
198	O
patients	O
over	O
four	O
consecutive	O
visits	O
(792	O
consultations)	O
was	O
analyzed.	O

Mixed-effects	O
models	O
and	O
multivariate	O
regressions	O
were	O
used	O
to	O
examine	O
the	O
longitudinal	O
impact	O
of	O
the	O
intervention	O
on	O
patient-physician	O
communication,	O
dynamics	O
of	O
patient-physician	O
interaction,	O
and	O
the	O
association	O
between	O
PROs	O
and	O
the	O
content	O
of	O
clinic	O
discussion.	O

Patients	B-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
arm	I-Premise
discussed	I-Premise
more	I-Premise
symptoms	I-Premise
over	I-Premise
time	I-Premise
compared	I-Premise
with	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
attention-control	I-Premise
(P	I-Premise
=	I-Premise
.008)	I-Premise
and	I-Premise
control	I-Premise
(P	I-Premise
=	I-Premise
.04)	I-Premise
arms.	I-Premise

No	B-Premise
study	I-Premise
arm	I-Premise
effect	I-Premise
was	I-Premise
observed	I-Premise
for	I-Premise
function	I-Premise
discussions.	I-Premise

Discussion	O
topics	O
were	O
predominantly	O
raised	O
by	O
patients/relatives,	O
regardless	O
of	O
arm	O
allocation.	O

Clinic	B-Premise
discussions	I-Premise
were	I-Premise
associated	I-Premise
with	I-Premise
severity	I-Premise
of	I-Premise
patient-reported	I-Premise
symptoms	I-Premise
but	I-Premise
not	I-Premise
with	I-Premise
patient-reported	I-Premise
functional	I-Premise
concerns.	I-Premise

A	B-Premise
positive	I-Premise
longitudinal	I-Premise
impact	I-Premise
of	I-Premise
the	I-Premise
intervention	I-Premise
on	I-Premise
symptom	I-Premise
discussion	I-Premise
was	I-Premise
observed,	I-Premise
but	B-Premise
not	I-Premise
for	I-Premise
function	I-Premise
discussion,	I-Premise
suggesting	I-Premise
that	I-Premise
potentially	I-Premise
serious	I-Premise
problems	I-Premise
may	I-Premise
remain	I-Premise
unaddressed.	I-Premise

Training	B-Claim
oncologists	I-Claim
in	I-Claim
responding	I-Claim
to	I-Claim
patient-reported	I-Claim
functional	I-Claim
concerns	I-Claim
may	I-Claim
increase	I-Claim
the	I-Claim
impact	I-Claim
of	I-Claim
this	I-Claim
intervention.	I-Claim

This	O
phase	O
III	O
trial	O
was	O
conducted	O
to	O
test	O
whether	O
the	O
novel	O
vascular	O
disrupting	O
agent	O
ASA404	O
(vadimezan),	O
when	O
combined	O
with	O
first-line	O
platinum-based	O
chemotherapy,	O
improves	O
survival	O
in	O
patients	O
with	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(NSCLC)	O
versus	O
chemotherapy	O
alone.	O

Patients	O
with	O
advanced	O
stage	O
IIIB	O
or	O
IV	O
NSCLC,	O
stratified	O
by	O
sex	O
and	O
tumor	O
histology,	O
were	O
randomly	O
assigned	O
1:1	O
to	O
paclitaxel	O
(200	O
mg/m(2))	O
and	O
carboplatin	O
(area	O
under	O
the	O
curve,	O
6.0)	O
with	O
or	O
without	O
ASA404	O
(1,800	O
mg	O
m(2)),	O
given	O
intravenously	O
once	O
every	O
3	O
weeks	O
for	O
six	O
cycles	O
followed	O
by	O
maintenance	O
ASA404	O
or	O
placebo.	O

Primary	O
end	O
point	O
was	O
overall	O
survival	O
(OS);	O
secondary	O
end	O
points	O
included	O
overall	O
response	O
rate	O
(ORR)	O
and	O
progression-free	O
survival	O
(PFS).	O

One	O
thousand	O
two	O
hundred	O
ninety-nine	O
patients	O
were	O
randomly	O
assigned.	O

The	O
trial	O
was	O
stopped	O
for	O
futility	O
at	O
interim	O
analysis.	O

At	O
final	O
analysis,	O
there	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
OS	I-Premise
seen	I-Premise
between	I-Premise
ASA404	I-Premise
(n	I-Premise
=	I-Premise
649)	I-Premise
and	I-Premise
placebo	I-Premise
(n	I-Premise
=	I-Premise
650)	I-Premise
arms:	I-Premise
median	I-Premise
OS	I-Premise
was	I-Premise
13.4	I-Premise
and	I-Premise
12.7	I-Premise
months	I-Premise
respectively	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR],	I-Premise
1.01;	I-Premise
95%	I-Premise
CI,	I-Premise
0.85	I-Premise
to	I-Premise
1.19;	I-Premise
P	I-Premise
=	I-Premise
.535).	I-Premise

Similarly,	O
no	B-Premise
OS	I-Premise
difference	I-Premise
was	I-Premise
seen	I-Premise
in	I-Premise
the	I-Premise
histologic	I-Premise
(squamous	I-Premise
or	I-Premise
nonsquamous)	I-Premise
and	I-Premise
sex	I-Premise
(male	I-Premise
or	I-Premise
female)	I-Premise
strata.	I-Premise

Median	B-Premise
PFS	I-Premise
was	I-Premise
5.5	I-Premise
months	I-Premise
in	I-Premise
both	I-Premise
arms	I-Premise
(HR,	I-Premise
1.04;	I-Premise
P	I-Premise
=	I-Premise
.727),	I-Premise
while	I-Premise
ORR	I-Premise
was	I-Premise
25%	I-Premise
in	I-Premise
both	I-Premise
arms	I-Premise
(P	I-Premise
=	I-Premise
1.0).	I-Premise

Overall	B-Premise
rate	I-Premise
of	I-Premise
adverse	I-Premise
events	I-Premise
(AEs)	I-Premise
was	I-Premise
comparable	I-Premise
between	I-Premise
the	I-Premise
ASA404	I-Premise
and	I-Premise
placebo	I-Premise
arms.	I-Premise

Grade	B-Premise
4	I-Premise
neutropenia	I-Premise
(27%	I-Premise
v	I-Premise
19%)	I-Premise
and	I-Premise
infusion	I-Premise
site	I-Premise
pain	I-Premise
(10%	I-Premise
v	I-Premise
0.5%)	I-Premise
were	I-Premise
reported	I-Premise
more	I-Premise
frequently	I-Premise
in	I-Premise
the	I-Premise
ASA404	I-Premise
arm.	I-Premise

The	B-Claim
addition	I-Claim
of	I-Claim
ASA404	I-Claim
to	I-Claim
carboplatin	I-Claim
and	I-Claim
paclitaxel,	I-Claim
although	I-Claim
generally	I-Claim
well	I-Claim
tolerated,	I-Claim
failed	I-Claim
to	I-Claim
improve	I-Claim
frontline	I-Claim
efficacy	I-Claim
in	I-Claim
advanced	I-Claim
NSCLC.	I-Claim

The	B-Claim
addition	I-Claim
of	I-Claim
bevacizumab	I-Claim
to	I-Claim
paclitaxel	I-Claim
improved	I-Claim
progression-free	I-Claim
survival	I-Claim
(PFS)	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
metastatic	I-Claim
breast	I-Claim
cancer	I-Claim
(MBC).	I-Claim

We	O
examined	O
the	O
efficacy	O
and	O
safety	O
of	O
adding	O
gemcitabine	O
to	O
paclitaxel/bevacizumab	O
(PB).	O

In	O
this	O
multicenter,	O
open-label,	O
randomized	O
phase	O
II	O
trial,	O
women	O
with	O
locally	O
advanced	O
or	O
MBC	O
were	O
randomly	O
assigned	O
to	O
receive	O
paclitaxel	O
90	O
mg/m(2)	O
(days	O
1,	O
8,	O
15)	O
and	O
bevacizumab	O
10	O
mg/kg	O
(days	O
1,	O
15)	O
with	O
or	O
without	O
gemcitabine	O
1500	O
mg/m(2)	O
(days	O
1,	O
15)	O
in	O
28-day	O
cycles.	O

Patients	O
with	O
prior	O
cytotoxic	O
therapy	O
for	O
MBC	O
were	O
ineligible.	O

The	O
primary	O
endpoint	O
was	O
investigator-assessed	O
overall	O
response	O
rate	O
(ORR);	O
secondary	O
endpoints	O
were	O
PFS,	O
overall	O
survival	O
(OS),	O
safety,	O
and	O
quality	O
of	O
life.	O

Ninety-four	O
patients	O
received	O
PB,	O
and	O
93	O
received	O
paclitaxel/bevacizumab/gemcitabine	O
(PB+G).	O

The	B-Premise
ORRs	I-Premise
were	I-Premise
48.9%	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI],	I-Premise
38.5%-59.5%)	I-Premise
and	I-Premise
58.7%	I-Premise
(95%	I-Premise
CI,	I-Premise
47.9%-68.9%;	I-Premise
P	I-Premise
=	I-Premise
.117)	I-Premise
with	I-Premise
PB	I-Premise
and	I-Premise
PB+G,	I-Premise
respectively.	I-Premise

The	B-Premise
median	I-Premise
PFS	I-Premise
was	I-Premise
8.8	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
8.1-10.4	I-Premise
months)	I-Premise
and	I-Premise
11.3	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
9.7-12.7	I-Premise
months;	I-Premise
P	I-Premise
=	I-Premise
.247;	I-Premise
hazard	I-Premise
ratio,	I-Premise
0.82);	I-Premise
the	I-Premise
median	I-Premise
OS	I-Premise
was	I-Premise
25.0	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
18.8-not	I-Premise
assessable	I-Premise
[N/A]	I-Premise
months)	I-Premise
and	I-Premise
24.3	I-Premise
months	I-Premise
(95%	I-Premise
CI,	I-Premise
20.3-N/A	I-Premise
months;	I-Premise
P	I-Premise
=	I-Premise
.475;	I-Premise
hazard	I-Premise
ratio,	I-Premise
0.84),	I-Premise
with	I-Premise
PB	I-Premise
and	I-Premise
PB+G,	I-Premise
respectively.	I-Premise

There	B-Premise
was	I-Premise
significantly	I-Premise
more	I-Premise
grade	I-Premise
3-4	I-Premise
neutropenia	I-Premise
(P	I-Premise
=	I-Premise
.001)	I-Premise
and	I-Premise
dyspnea	I-Premise
(P	I-Premise
=	I-Premise
.014)	I-Premise
with	I-Premise
PB+G.	I-Premise

Patients	B-Premise
treated	I-Premise
with	I-Premise
PB	I-Premise
experienced	I-Premise
more	I-Premise
improvement	I-Premise
in	I-Premise
total	I-Premise
FACT-B	I-Premise
(Functional	I-Premise
Assessment	I-Premise
of	I-Premise
Cancer	I-Premise
Therapy-Breast)	I-Premise
(P	I-Premise
=	I-Premise
.021),	I-Premise
FACT-B	I-Premise
Social/Family	I-Premise
Well-being	I-Premise
(P	I-Premise
=	I-Premise
.041),	I-Premise
and	I-Premise
Breast	I-Premise
Cancer-Additional	I-Premise
Concerns	I-Premise
(P	I-Premise
=	I-Premise
.008)	I-Premise
scores	I-Premise
than	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
PB+G.	I-Premise

The	B-Claim
addition	I-Claim
of	I-Claim
gemcitabine	I-Claim
to	I-Claim
PB	I-Claim
was	I-Claim
not	I-Claim
associated	I-Claim
with	I-Claim
a	I-Claim
statistically	I-Claim
significant	I-Claim
improvement	I-Claim
in	I-Claim
ORR.	I-Claim

Treatment	B-Claim
with	I-Claim
PB+G	I-Claim
increased	I-Claim
the	I-Claim
incidence	I-Claim
of	I-Claim
severe	I-Claim
neutropenia	I-Claim
and	I-Claim
dyspnea,	I-Claim
although	B-Claim
the	I-Claim
regimen	I-Claim
generally	I-Claim
was	I-Claim
well	I-Claim
tolerated.	I-Claim

Dignity	O
therapy	O
is	O
a	O
unique,	O
individualised,	O
short-term	O
psychotherapy	O
that	O
was	O
developed	O
for	O
patients	O
(and	O
their	O
families)	O
living	O
with	O
life-threatening	O
or	O
life-limiting	O
illness.	O

We	O
investigated	O
whether	O
dignity	O
therapy	O
could	O
mitigate	O
distress	O
or	O
bolster	O
the	O
experience	O
in	O
patients	O
nearing	O
the	O
end	O
of	O
their	O
lives.	O

Patients	O
(aged	O
18	O
years)	O
with	O
a	O
terminal	O
prognosis	O
(life	O
expectancy	O
6	O
months)	O
who	O
were	O
receiving	O
palliative	O
care	O
in	O
a	O
hospital	O
or	O
community	O
setting	O
(hospice	O
or	O
home)	O
in	O
Canada,	O
USA,	O
and	O
Australia	O
were	O
randomly	O
assigned	O
to	O
dignity	O
therapy,	O
client-centred	O
care,	O
or	O
standard	O
palliative	O
care	O
in	O
a	O
1:1:1	O
ratio.	O

Randomisation	O
was	O
by	O
use	O
of	O
a	O
computer-generated	O
table	O
of	O
random	O
numbers	O
in	O
blocks	O
of	O
30.	O

Allocation	O
concealment	O
was	O
by	O
use	O
of	O
opaque	O
sealed	O
envelopes.	O

The	O
primary	O
outcomes--reductions	O
in	O
various	O
dimensions	O
of	O
distress	O
before	O
and	O
after	O
completion	O
of	O
the	O
study--were	O
measured	O
with	O
the	O
Functional	O
Assessment	O
of	O
Chronic	O
Illness	O
Therapy	O
Spiritual	O
Well-Being	O
Scale,	O
Patient	O
Dignity	O
Inventory,	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale,	O
items	O
from	O
the	O
Structured	O
Interview	O
for	O
Symptoms	O
and	O
Concerns,	O
Quality	O
of	O
Life	O
Scale,	O
and	O
modified	O
Edmonton	O
Symptom	O
Assessment	O
Scale.	O

Secondary	O
outcomes	O
of	O
self-reported	O
end-of-life	O
experiences	O
were	O
assessed	O
in	O
a	O
survey	O
that	O
was	O
undertaken	O
after	O
the	O
completion	O
of	O
the	O
study.	O

Outcomes	O
were	O
assessed	O
by	O
research	O
staff	O
with	O
whom	O
the	O
participant	O
had	O
no	O
previous	O
contact	O
to	O
avoid	O
any	O
possible	O
response	O
bias	O
or	O
contamination.	O

Analyses	O
were	O
done	O
on	O
all	O
patients	O
with	O
available	O
data	O
at	O
baseline	O
and	O
at	O
the	O
end	O
of	O
the	O
study	O
intervention.	O

165	O
of	O
441	O
patients	O
were	O
assigned	O
to	O
dignity	O
therapy,	O
140	O
standard	O
palliative	O
care,	O
and	O
136	O
client-centred	O
care.	O

108,	O
111,	O
and	O
107	O
patients,	O
respectively,	O
were	O
analysed.	O

No	B-Premise
significant	I-Premise
differences	I-Premise
were	I-Premise
noted	I-Premise
in	I-Premise
the	I-Premise
distress	I-Premise
levels	I-Premise
before	I-Premise
and	I-Premise
after	I-Premise
completion	I-Premise
of	I-Premise
the	I-Premise
study	I-Premise
in	I-Premise
the	I-Premise
three	I-Premise
groups.	I-Premise

For	B-Premise
the	I-Premise
secondary	I-Premise
outcomes,	I-Premise
patients	I-Premise
reported	I-Premise
that	I-Premise
dignity	I-Premise
therapy	I-Premise
was	I-Premise
significantly	I-Premise
more	I-Premise
likely	I-Premise
than	I-Premise
the	I-Premise
other	I-Premise
two	I-Premise
interventions	I-Premise
to	I-Premise
have	I-Premise
been	I-Premise
helpful	I-Premise
((2)=3550,	I-Premise
df=2;	I-Premise
p<00001),	I-Premise
improve	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
((2)=1452;	I-Premise
p=0001),	I-Premise
increase	I-Premise
sense	I-Premise
of	I-Premise
dignity	I-Premise
((2)=1266;	I-Premise
p=0002),	I-Premise
change	I-Premise
how	I-Premise
their	I-Premise
family	I-Premise
saw	I-Premise
and	I-Premise
appreciated	I-Premise
them	I-Premise
((2)=3381;	I-Premise
p<00001),	I-Premise
and	I-Premise
be	I-Premise
helpful	I-Premise
to	I-Premise
their	I-Premise
family	I-Premise
((2)=3386;	I-Premise
p<00001).	I-Premise

Dignity	B-Premise
therapy	I-Premise
was	I-Premise
significantly	I-Premise
better	I-Premise
than	I-Premise
client-centred	I-Premise
care	I-Premise
in	I-Premise
improving	I-Premise
spiritual	I-Premise
wellbeing	I-Premise
((2)=1035;	I-Premise
p=0006),	I-Premise
and	I-Premise
was	I-Premise
significantly	I-Premise
better	I-Premise
than	I-Premise
standard	I-Premise
palliative	I-Premise
care	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
lessening	I-Premise
sadness	I-Premise
or	I-Premise
depression	I-Premise
((2)=938;	I-Premise
p=0009);	I-Premise
significantly	B-Premise
more	I-Premise
patients	I-Premise
who	I-Premise
had	I-Premise
received	I-Premise
dignity	I-Premise
therapy	I-Premise
reported	I-Premise
that	I-Premise
the	I-Premise
study	I-Premise
group	I-Premise
had	I-Premise
been	I-Premise
satisfactory,	I-Premise
compared	I-Premise
with	I-Premise
those	I-Premise
who	I-Premise
received	I-Premise
standard	I-Premise
palliative	I-Premise
care	I-Premise
((2)=2958;	I-Premise
p<00001).	I-Premise

Although	B-Claim
the	I-Claim
ability	I-Claim
of	I-Claim
dignity	I-Claim
therapy	I-Claim
to	I-Claim
mitigate	I-Claim
outright	I-Claim
distress,	I-Claim
such	I-Claim
as	I-Claim
depression,	I-Claim
desire	I-Claim
for	I-Claim
death	I-Claim
or	I-Claim
suicidality,	I-Claim
has	I-Claim
yet	I-Claim
to	I-Claim
be	I-Claim
proven,	I-Claim
its	B-Claim
benefits	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
self-reported	I-Claim
end-of-life	I-Claim
experiences	I-Claim
support	I-Claim
its	I-Claim
clinical	I-Claim
application	I-Claim
for	I-Claim
patients	I-Claim
nearing	I-Claim
death.	I-Claim

Anemia	B-Claim
is	I-Claim
an	I-Claim
expected	I-Claim
consequence	I-Claim
of	I-Claim
intensive	I-Claim
chemotherapy	I-Claim
regimens	I-Claim
administered	I-Claim
to	I-Claim
patients	I-Claim
with	I-Claim
acute	I-Claim
leukemia.	I-Claim

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
epoetin	O
alpha	O
would	O
decrease	O
the	O
number	O
of	O
transfusion	O
events	O
and	O
units	O
of	O
packed	O
erythrocytes	O
(PRBCs)	O
transfused,	O
and	O
the	O
secondary	O
objective	O
was	O
to	O
study	O
the	O
effects	O
of	O
epoetin	O
alpha	O
on	O
quality	O
of	O
life	O
(QOL)	O
and	O
complete	O
remission	O
(CR)	O
rates.	O

Patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(ALL),	O
lymphoblastic	O
lymphoma	O
(LL),	O
or	O
Burkitt	O
lymphoma	O
(BL)	O
who	O
were	O
receiving	O
frontline	O
myelosuppressive	O
chemotherapy	O
were	O
randomized	O
to	O
receive	O
epoetin	O
alpha	O
or	O
no	O
epoetin	O
during	O
the	O
first	O
6	O
cycles	O
of	O
their	O
planned	O
chemotherapy.	O

QOL	O
was	O
assessed	O
by	O
using	O
the	O
Edmonton	O
Symptom	O
Assessment	O
Scale	O
(ESAS)	O
and	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy	O
(FACT)-Anemia	O
questionnaires.	O

Fifty-five	O
patients	O
were	O
randomized	O
to	O
receive	O
epoetin	O
alpha,	O
and	O
54	O
patients	O
received	O
no	O
epoetin.	O

Transfusion	O
data	O
were	O
available	O
for	O
79	O
of	O
81	O
evaluable	O
patients	O
(98%)	O
who	O
completed	O
the	O
treatment/observation	O
period.	O

The	B-Premise
trial	I-Premise
was	I-Premise
stopped	I-Premise
early	I-Premise
because	I-Premise
of	I-Premise
poor	I-Premise
accrual	I-Premise
before	I-Premise
the	I-Premise
target	I-Premise
of	I-Premise
123	I-Premise
evaluable	I-Premise
patients	I-Premise
was	I-Premise
met.	I-Premise

A	B-Premise
mean	I-Premise
of	I-Premise
10.6	I-Premise
units	I-Premise
of	I-Premise
PRBCs	I-Premise
over	I-Premise
5	I-Premise
months	I-Premise
were	I-Premise
administered	I-Premise
to	I-Premise
those	I-Premise
who	I-Premise
received	I-Premise
epoetin	I-Premise
alpha	I-Premise
compared	I-Premise
with	I-Premise
13	I-Premise
units	I-Premise
for	I-Premise
those	I-Premise
who	I-Premise
did	I-Premise
not	I-Premise
receive	I-Premise
epoetin	I-Premise
(P	I-Premise
=	I-Premise
.04).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
QOL	I-Premise
as	I-Premise
assessed	I-Premise
by	I-Premise
the	I-Premise
FACT-Anemia	I-Premise
or	I-Premise
ESAS	I-Premise
instruments.	I-Premise

The	B-Premise
CR	I-Premise
rate	I-Premise
and	I-Premise
the	I-Premise
3-year	I-Premise
CR	I-Premise
duration	I-Premise
were	I-Premise
not	I-Premise
affected	I-Premise
adversely	I-Premise
by	I-Premise
use	I-Premise
of	I-Premise
epoetin	I-Premise
alpha.	I-Premise

Epoetin	B-Claim
alpha	I-Claim
decreased	I-Claim
the	I-Claim
number	I-Claim
of	I-Claim
PRBC	I-Claim
transfusions	I-Claim
and	I-Claim
did	I-Claim
not	I-Claim
appear	I-Claim
to	I-Claim
have	I-Claim
a	I-Claim
negative	I-Claim
impact	I-Claim
on	I-Claim
remission	I-Claim
duration.	I-Claim

No	B-Claim
difference	I-Claim
in	I-Claim
QOL	I-Claim
was	I-Claim
observed.	I-Claim

The	B-Claim
generalizability	I-Claim
of	I-Claim
palliative	I-Claim
care	I-Claim
intervention	I-Claim
research	I-Claim
is	I-Claim
often	I-Claim
limited	I-Claim
by	I-Claim
high	I-Claim
rates	I-Claim
of	I-Claim
study	I-Claim
attrition.	I-Claim

This	O
study	O
examined	O
factors	O
associated	O
with	O
attrition	O
from	O
a	O
randomized	O
controlled	O
trial	O
comparing	O
meaning-centered	O
group	O
psychotherapy	O
(MCGP),	O
an	O
intervention	O
designed	O
to	O
help	O
advanced	O
cancer	O
patients	O
sustain	O
or	O
enhance	O
their	O
sense	O
of	O
meaning	O
to	O
the	O
supportive	O
group	O
psychotherapy	O
(SGP),	O
a	O
standardized	O
support	O
group.	O

Patients	O
with	O
advanced	O
solid	O
tumor	O
cancers	O
(n	O
=	O
153)	O
were	O
randomized	O
to	O
eight	O
sessions	O
of	O
either	O
the	O
MCGP	O
or	O
SGP.	O

They	O
completed	O
assessments	O
of	O
psychosocial,	O
spiritual,	O
and	O
physical	O
well-being	O
pretreatment,	O
midtreatment,	O
and	O
2	O
months	O
post-treatment.	O

Attrition	O
was	O
assessed	O
in	O
terms	O
of	O
the	O
percent	O
of	O
participants	O
who	O
failed	O
to	O
complete	O
these	O
assessments,	O
and	O
demographic,	O
psychiatric,	O
medical,	O
and	O
study-related	O
correlates	O
of	O
attrition	O
were	O
examined	O
for	O
the	O
participants	O
in	O
each	O
of	O
these	O
categories.	O

The	B-Premise
rates	I-Premise
of	I-Premise
attrition	I-Premise
at	I-Premise
these	I-Premise
time	I-Premise
points	I-Premise
were	I-Premise
28.1%,	I-Premise
17.7%,	I-Premise
and	I-Premise
11.1%,	I-Premise
respectively;	I-Premise
43.1%	I-Premise
of	I-Premise
the	I-Premise
participants	I-Premise
(66	I-Premise
of	I-Premise
153)	I-Premise
completed	I-Premise
the	I-Premise
entire	I-Premise
study.	I-Premise

The	B-Premise
most	I-Premise
common	I-Premise
reason	I-Premise
for	I-Premise
dropout	I-Premise
was	I-Premise
patients	I-Premise
feeling	I-Premise
too	I-Premise
ill.	I-Premise

Attrition	B-Premise
rates	I-Premise
did	I-Premise
not	I-Premise
vary	I-Premise
significantly	I-Premise
between	I-Premise
study	I-Premise
arms.	I-Premise

The	O
participants	O
who	O
dropped	O
out	O
pretreatment	O
reported	O
less	O
financial	O
concerns	O
than	O
post-treatment	O
dropouts,	O
and	O
the	O
participants	O
who	O
dropped	O
out	O
of	O
the	O
study	O
midtreatment	O
had	O
poorer	O
physical	O
health	O
than	O
treatment	O
completers.	O

There	B-Premise
were	I-Premise
no	I-Premise
other	I-Premise
significant	I-Premise
associations	I-Premise
between	I-Premise
attrition	I-Premise
and	I-Premise
any	I-Premise
demographic,	I-Premise
medical,	I-Premise
psychiatric,	I-Premise
or	I-Premise
study-related	I-Premise
variables.	I-Premise

These	B-Claim
findings	I-Claim
highlight	I-Claim
the	I-Claim
challenge	I-Claim
of	I-Claim
maintaining	I-Claim
advanced	I-Claim
cancer	I-Claim
patients	I-Claim
in	I-Claim
longitudinal	I-Claim
research	I-Claim
and	I-Claim
suggest	I-Claim
the	I-Claim
need	I-Claim
to	I-Claim
consider	I-Claim
alternative	I-Claim
approaches	I-Claim
(e.g.,	I-Claim
telemedicine)	I-Claim
for	I-Claim
patients	I-Claim
who	I-Claim
might	I-Claim
benefit	I-Claim
from	I-Claim
group	I-Claim
interventions	I-Claim
but	I-Claim
are	I-Claim
too	I-Claim
ill	I-Claim
to	I-Claim
travel.	I-Claim

For	B-Claim
men	I-Claim
with	I-Claim
localised	I-Claim
prostate	I-Claim
cancer,	I-Claim
surgery	I-Claim
provides	I-Claim
a	I-Claim
survival	I-Claim
benefit	I-Claim
compared	I-Claim
with	I-Claim
watchful	I-Claim
waiting.	I-Claim

Treatments	O
are	O
associated	O
with	O
morbidity.	O

Results	O
for	O
functional	O
outcome	O
and	O
quality	O
of	O
life	O
are	O
rarely	O
reported	O
beyond	O
10	O
years	O
and	O
are	O
lacking	O
from	O
randomised	O
settings.	O

We	O
report	O
results	O
for	O
quality	O
of	O
life	O
for	O
men	O
in	O
the	O
Scandinavian	O
Prostate	O
Cancer	O
Group	O
Study	O
Number	O
4	O
(SPCG-4)	O
after	O
a	O
median	O
follow-up	O
of	O
more	O
than	O
12	O
years.	O

All	O
living	O
Swedish	O
and	O
Finnish	O
men	O
(400	O
of	O
695)	O
randomly	O
assigned	O
to	O
radical	O
prostatectomy	O
or	O
watchful	O
waiting	O
in	O
SPCG-4	O
from	O
1989	O
to	O
1999	O
were	O
included	O
in	O
our	O
analysis.	O

An	O
additional	O
281	O
men	O
were	O
included	O
in	O
a	O
population-based	O
control	O
group	O
matched	O
for	O
region	O
and	O
age.	O

Physical	O
symptoms,	O
symptom-induced	O
stress,	O
and	O
self-assessed	O
quality	O
of	O
life	O
were	O
evaluated	O
with	O
a	O
study-specific	O
questionnaire.	O

Longitudinal	O
data	O
were	O
available	O
for	O
166	O
Swedish	O
men	O
who	O
had	O
answered	O
quality-of-life	O
questionnaires	O
at	O
an	O
earlier	O
timepoint.	O

182	O
(88%)	O
of	O
208	O
men	O
in	O
the	O
radical	O
prostatectomy	O
group,	O
167	O
(87%)	O
of	O
192	O
men	O
in	O
the	O
watchful-waiting	O
group,	O
and	O
214	O
(76%)	O
of	O
281	O
men	O
in	O
the	O
population-based	O
control	O
group	O
answered	O
the	O
questionnaire.	O

Men	O
in	O
SPCG-4	O
had	O
a	O
median	O
follow-up	O
of	O
122	O
years	O
(range	O
7-17)	O
and	O
a	O
median	O
age	O
of	O
770	O
years	O
(range	O
61-88).	O

High	B-Premise
self-assessed	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
was	I-Premise
reported	I-Premise
by	I-Premise
62	I-Premise
(35%)	I-Premise
of	I-Premise
179	I-Premise
men	I-Premise
allocated	I-Premise
radical	I-Premise
prostatectomy,	I-Premise
55	I-Premise
(34%)	I-Premise
of	I-Premise
160	I-Premise
men	I-Premise
assigned	I-Premise
to	I-Premise
watchful	I-Premise
waiting,	I-Premise
and	I-Premise
93	I-Premise
(45%)	I-Premise
of	I-Premise
208	I-Premise
men	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

Anxiety	B-Premise
was	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
SPCG-4	I-Premise
groups	I-Premise
(77	I-Premise
[43%]	I-Premise
of	I-Premise
178	I-Premise
and	I-Premise
69	I-Premise
[43%]	I-Premise
of	I-Premise
161	I-Premise
men)	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(68	I-Premise
[33%]	I-Premise
of	I-Premise
208	I-Premise
men;	I-Premise
relative	I-Premise
risk	I-Premise
142,	I-Premise
95%	I-Premise
CI	I-Premise
107-188).	I-Premise

Prevalence	B-Premise
of	I-Premise
erectile	I-Premise
dysfunction	I-Premise
was	I-Premise
84%	I-Premise
(146	I-Premise
of	I-Premise
173	I-Premise
men)	I-Premise
in	I-Premise
the	I-Premise
radical	I-Premise
prostatectomy	I-Premise
group,	I-Premise
80%	I-Premise
(122	I-Premise
of	I-Premise
153)	I-Premise
in	I-Premise
the	I-Premise
watchful-waiting	I-Premise
group,	I-Premise
and	I-Premise
46%	I-Premise
(95	I-Premise
of	I-Premise
208)	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
and	I-Premise
prevalence	I-Premise
of	I-Premise
urinary	I-Premise
leakage	I-Premise
was	I-Premise
41%	I-Premise
(71	I-Premise
of	I-Premise
173),	I-Premise
11%	I-Premise
(18	I-Premise
of	I-Premise
164),	I-Premise
and	I-Premise
3%	I-Premise
(six	I-Premise
of	I-Premise
209),	I-Premise
respectively.	I-Premise

Distress	B-Premise
caused	I-Premise
by	I-Premise
these	I-Premise
symptoms	I-Premise
was	I-Premise
reported	I-Premise
significantly	I-Premise
more	I-Premise
often	I-Premise
by	I-Premise
men	I-Premise
allocated	I-Premise
radical	I-Premise
prostatectomy	I-Premise
than	I-Premise
by	I-Premise
men	I-Premise
assigned	I-Premise
to	I-Premise
watchful	I-Premise
waiting.	I-Premise

In	B-Premise
a	I-Premise
longitudinal	I-Premise
analysis	I-Premise
of	I-Premise
men	I-Premise
in	I-Premise
SPCG-4	I-Premise
who	I-Premise
provided	I-Premise
information	I-Premise
at	I-Premise
two	I-Premise
follow-up	I-Premise
points	I-Premise
9	I-Premise
years	I-Premise
apart,	I-Premise
38	I-Premise
(45%)	I-Premise
of	I-Premise
85	I-Premise
men	I-Premise
allocated	I-Premise
radical	I-Premise
prostatectomy	I-Premise
and	I-Premise
48	I-Premise
(60%)	I-Premise
of	I-Premise
80	I-Premise
men	I-Premise
allocated	I-Premise
watchful	I-Premise
waiting	I-Premise
reported	I-Premise
an	I-Premise
increase	I-Premise
in	I-Premise
number	I-Premise
of	I-Premise
physical	I-Premise
symptoms;	I-Premise
50	I-Premise
(61%)	I-Premise
of	I-Premise
82	I-Premise
and	I-Premise
47	I-Premise
(64%)	I-Premise
of	I-Premise
74	I-Premise
men,	I-Premise
respectively,	I-Premise
reported	I-Premise
a	I-Premise
reduction	I-Premise
in	I-Premise
quality	I-Premise
of	I-Premise
life.	I-Premise

For	B-Premise
men	I-Premise
in	I-Premise
SPCG-4,	I-Premise
negative	I-Premise
side-effects	I-Premise
were	I-Premise
common	I-Premise
and	I-Premise
added	I-Premise
more	I-Premise
stress	I-Premise
than	I-Premise
was	I-Premise
reported	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
population.	I-Premise

In	B-Claim
the	I-Claim
radical	I-Claim
prostatectomy	I-Claim
group,	I-Claim
erectile	I-Claim
dysfunction	I-Claim
and	I-Claim
urinary	I-Claim
leakage	I-Claim
were	I-Claim
often	I-Claim
consequences	I-Claim
of	I-Claim
surgery.	I-Claim

In	B-Claim
the	I-Claim
watchful-waiting	I-Claim
group,	I-Claim
side-effects	I-Claim
can	I-Claim
be	I-Claim
caused	I-Claim
by	I-Claim
tumour	I-Claim
progression.	I-Claim

The	B-Claim
number	I-Claim
and	I-Claim
severity	I-Claim
of	I-Claim
side-effects	I-Claim
changes	I-Claim
over	I-Claim
time	I-Claim
at	I-Claim
a	I-Claim
higher	I-Claim
rate	I-Claim
than	I-Claim
is	I-Claim
caused	I-Claim
by	I-Claim
normal	I-Claim
ageing	I-Claim
and	I-Claim
a	I-Claim
loss	I-Claim
of	I-Claim
sexual	I-Claim
ability	I-Claim
is	I-Claim
a	I-Claim
persistent	I-Claim
psychological	I-Claim
problem	I-Claim
for	I-Claim
both	I-Claim
interventions.	I-Claim

An	O
understanding	O
of	O
the	O
patterns	O
of	O
side-effects	O
and	O
time	O
dimension	O
of	O
their	O
occurrence	O
for	O
each	O
treatment	O
is	O
important	O
for	O
full	O
patient	O
information.	O

This	O
randomized	O
controlled	O
trial	O
assessed	O
the	O
effect	O
of	O
a	O
SMART	O
(Stress	O
Management	O
and	O
Resiliency	O
Training)	O
program	O
among	O
25	O
women	O
diagnosed	O
with	O
breast	O
cancer.	O

Resilience,	O
perceived	O
stress,	O
anxiety,	O
and	O
quality	O
of	O
life	O
improved	O
at	O
12	O
weeks	O
in	O
the	O
active	O
but	O
not	O
the	O
control	O
arm.	O

A	O
brief	O
training	O
in	O
the	O
SMART	O
program	O
can	O
enhance	O
resilience	O
and	O
quality	O
of	O
life	O
and	O
decrease	O
stress	O
and	O
anxiety.	O

Patients	O
with	O
breast	O
cancer	O
experience	O
stress	O
and	O
anxiety	O
related	O
to	O
their	O
diagnosis,	O
with	O
resulting	O
lower	O
quality	O
of	O
life.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effect	O
of	O
a	O
SMART	O
(Stress	O
Management	O
and	O
Resiliency	O
Training)	O
program	O
for	O
increasing	O
resiliency	O
and	O
for	O
decreasing	O
stress	O
and	O
anxiety	O
among	O
mentors	O
who	O
themselves	O
were	O
previously	O
diagnosed	O
with	O
breast	O
cancer.	O

The	O
program	O
consisted	O
of	O
two	O
90-minute	O
group	O
training	O
sessions,	O
a	O
brief	O
individual	O
session,	O
and	O
3	O
follow-up	O
telephone	O
calls.	O

Twenty-four	O
mentors	O
at	O
Mayo	O
Clinic	O
in	O
Rochester,	O
Minnesota,	O
were	O
randomized	O
in	O
a	O
single-blind,	O
wait-list	O
controlled	O
clinical	O
trial	O
to	O
either	O
the	O
SMART	O
intervention	O
or	O
a	O
control	O
group	O
for	O
12	O
weeks.	O

Primary	O
outcome	O
measures	O
assessed	O
at	O
baseline	O
and	O
at	O
week	O
12	O
included	O
the	O
Connor	O
Davidson	O
Resilience	O
Scale,	O
Perceived	O
Stress	O
Scale,	O
Smith	O
Anxiety	O
Scale,	O
and	O
Linear	O
Analog	O
Self	O
Assessment	O
Scale.	O

Twenty	O
patients	O
completed	O
the	O
study.	O

A	B-Premise
statistically	I-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
resilience,	I-Premise
perceived	I-Premise
stress,	I-Premise
anxiety,	I-Premise
and	I-Premise
overall	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
at	I-Premise
12	I-Premise
weeks,	I-Premise
compared	I-Premise
with	I-Premise
baseline	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
study	I-Premise
arm.	I-Premise

No	B-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
any	I-Premise
of	I-Premise
these	I-Premise
measures	I-Premise
was	I-Premise
noted	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

This	B-Claim
study	I-Claim
demonstrates	I-Claim
that	I-Claim
a	I-Claim
brief,	I-Claim
predominantly	I-Claim
group-based	I-Claim
resilience	I-Claim
training	I-Claim
intervention	I-Claim
is	I-Claim
feasible	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
previous	I-Claim
breast	I-Claim
cancer;	I-Claim
also,	I-Claim
it	I-Claim
may	I-Claim
be	I-Claim
efficacious.	I-Claim

To	O
examine	O
health-related	O
quality	O
of	O
life,	O
we	O
investigated	O
the	O
effect	O
of	O
adjuvant	O
chemotherapy	O
regimens	O
on	O
utility	O
scores	O
assessed	O
by	O
the	O
EuroQoL-5D	O
(EQ-5D)	O
instrument	O
in	O
a	O
randomized,	O
controlled	O
trial	O
for	O
breast	O
cancer	O
patients	O
after	O
surgery.	O

We	O
also	O
investigated	O
the	O
relationship	O
between	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy	O
(FACT)	O
scale	O
scores	O
and	O
EQ-5D	O
utilities.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
the	O
following	O
four	O
chemotherapy	O
regimens:	O
four	O
cycles	O
of	O
anthracycline	O
followed	O
by	O
paclitaxel	O
(ACP),	O
four	O
cycles	O
of	O
anthracycline-containing	O
regimens	O
followed	O
by	O
docetaxel	O
(ACD),	O
eight	O
cycles	O
of	O
paclitaxel	O
(PTX),	O
and	O
eight	O
cycles	O
of	O
docetaxel	O
(DTX).	O

Of	O
1060	O
registered,	O
the	O
first	O
300	O
consecutive	O
patients	O
were	O
included	O
in	O
the	O
current	O
utility	O
study.	O

Utility	O
scores	O
were	O
assessed	O
using	O
the	O
EQ-5D	O
instrument	O
at	O
baseline;	O
cycles	O
3,	O
5,	O
and	O
7;	O
7	O
months;	O
and	O
1	O
year.	O

We	O
also	O
evaluated	O
the	O
correlation	O
between	O
these	O
scores	O
and	O
FACT-G,	O
-B,	O
and	O
-Taxane	O
scores	O
at	O
each	O
time	O
point.	O

Utility	B-Premise
scores	I-Premise
were	I-Premise
significantly	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
DTX	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
ACP	I-Premise
and	I-Premise
ACD	I-Premise
groups.	I-Premise

Mean	B-Premise
utility	I-Premise
scores	I-Premise
in	I-Premise
the	I-Premise
DTX	I-Premise
group	I-Premise
were	I-Premise
lowest	I-Premise
at	I-Premise
7	I-Premise
months	I-Premise
and	I-Premise
tended	I-Premise
to	I-Premise
remain	I-Premise
low	I-Premise
for	I-Premise
a	I-Premise
long	I-Premise
time.	I-Premise

The	B-Premise
combined	I-Premise
anthracycline	I-Premise
followed	I-Premise
by	I-Premise
taxane	I-Premise
group	I-Premise
had	I-Premise
significantly	I-Premise
higher	I-Premise
utility	I-Premise
scores	I-Premise
that	I-Premise
the	I-Premise
taxane-alone	I-Premise
group,	I-Premise
with	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
depending	I-Premise
on	I-Premise
the	I-Premise
type	I-Premise
of	I-Premise
taxane.	I-Premise

Only	B-Premise
the	I-Premise
FACT-G	I-Premise
social/family	I-Premise
well-being	I-Premise
subscale	I-Premise
had	I-Premise
no	I-Premise
relationship	I-Premise
with	I-Premise
EQ-5D	I-Premise
responses	I-Premise
and	I-Premise
utility	I-Premise
scores.	I-Premise

Although	B-Claim
the	I-Claim
regimens	I-Claim
in	I-Claim
this	I-Claim
study	I-Claim
were	I-Claim
similar	I-Claim
in	I-Claim
that	I-Claim
they	I-Claim
included	I-Claim
taxane,	I-Claim
the	I-Claim
mean	I-Claim
utility	I-Claim
scores	I-Claim
and	I-Claim
longitudinal	I-Claim
patterns	I-Claim
of	I-Claim
utility	I-Claim
scores	I-Claim
were	I-Claim
different	I-Claim
among	I-Claim
regimens.	I-Claim

The	B-Claim
postoperative	I-Claim
clinical	I-Claim
superiority	I-Claim
of	I-Claim
the	I-Claim
interposition	I-Claim
of	I-Claim
jejunum	I-Claim
reconstruction	I-Claim
(INT)	I-Claim
to	I-Claim
Roux-en-Y	I-Claim
reconstruction	I-Claim
(RY)	I-Claim
after	I-Claim
total	I-Claim
gastrectomy	I-Claim
has	I-Claim
not	I-Claim
been	I-Claim
clarified.	I-Claim

Postoperative	O
quality	O
of	O
life	O
(QOL)	O
was	O
evaluated	O
between	O
the	O
2	O
methods	O
by	O
a	O
multi-institutional	O
prospective	O
randomized	O
trial.	O

A	O
total	O
of	O
103	O
patients	O
with	O
gastric	O
cancer	O
were	O
prospectively	O
randomly	O
divided	O
into	O
groups	O
for	O
RY	O
(n	O
=	O
51)	O
or	O
INT	O
reconstruction	O
(n	O
=	O
52)	O
after	O
total	O
gastrectomy.	O

They	O
were	O
stratified	O
by	O
sex,	O
age,	O
institute,	O
histology,	O
and	O
degree	O
of	O
lymph	O
node	O
dissection.	O

Postoperatively,	O
body	O
mass	O
index	O
(BMI)	O
and	O
nutritional	O
conditions	O
were	O
measured	O
serially,	O
and	O
QOL	O
and	O
postoperative	O
squalor	O
scores	O
were	O
evaluated	O
at	O
3,	O
12,	O
and	O
60	O
months	O
and	O
compared	O
between	O
the	O
2	O
groups.	O

After	O
removing	O
patients	O
who	O
did	O
not	O
complete	O
the	O
follow-up	O
survey	O
or	O
censured	O
cases,	O
24	O
patients	O
in	O
the	O
RY	O
group	O
and	O
18	O
patients	O
in	O
the	O
INT	O
group	O
were	O
clinically	O
available	O
and	O
their	O
postoperative	O
status	O
was	O
assessed.	O

QOL	B-Premise
scores	I-Premise
were	I-Premise
increased	I-Premise
and	I-Premise
complication	I-Premise
scores	I-Premise
were	I-Premise
improved	I-Premise
in	I-Premise
the	I-Premise
postoperative	I-Premise
periods	I-Premise
(P	I-Premise
<	I-Premise
.01).	I-Premise

Postoperative	B-Premise
BMI	I-Premise
significantly	I-Premise
deteriorated	I-Premise
compared	I-Premise
with	I-Premise
preoperative	I-Premise
BMI	I-Premise
in	I-Premise
each	I-Premise
group.	I-Premise

The	B-Premise
postoperative	I-Premise
QOL	I-Premise
and	I-Premise
complication	I-Premise
scores	I-Premise
at	I-Premise
60	I-Premise
months	I-Premise
after	I-Premise
surgery	I-Premise
were	I-Premise
significantly	I-Premise
better	I-Premise
than	I-Premise
those	I-Premise
at	I-Premise
3	I-Premise
months	I-Premise
after	I-Premise
surgery	I-Premise
in	I-Premise
each	I-Premise
group	I-Premise
(P	I-Premise
<	I-Premise
.01).	I-Premise

However,	O
there	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
of	I-Premise
QOL	I-Premise
scores	I-Premise
and	I-Premise
postoperative	I-Premise
complication	I-Premise
scores	I-Premise
between	I-Premise
the	I-Premise
2	I-Premise
reconstruction	I-Premise
groups.	I-Premise

The	B-Premise
nutritional	I-Premise
condition	I-Premise
in	I-Premise
the	I-Premise
INT	I-Premise
group	I-Premise
was	I-Premise
nearly	I-Premise
the	I-Premise
same	I-Premise
as	I-Premise
that	I-Premise
in	I-Premise
the	I-Premise
RY	I-Premise
group.	I-Premise

Although	B-Premise
our	I-Premise
patient	I-Premise
sample	I-Premise
was	I-Premise
small	I-Premise
and	I-Premise
patients	I-Premise
who	I-Premise
did	I-Premise
not	I-Premise
complete	I-Premise
the	I-Premise
follow-up	I-Premise
survey	I-Premise
were	I-Premise
present,	I-Premise
we	B-Claim
could	I-Claim
not	I-Claim
identify	I-Claim
any	I-Claim
clinical	I-Claim
difference	I-Claim
between	I-Claim
INT	I-Claim
and	I-Claim
RY	I-Claim
after	I-Claim
total	I-Claim
gastrectomy	I-Claim
60	I-Claim
months	I-Claim
after	I-Claim
surgery.	I-Claim

The	B-Claim
safer	I-Claim
and	I-Claim
simpler	I-Claim
RY	I-Claim
method	I-Claim
may	I-Claim
be	I-Claim
a	I-Claim
more	I-Claim
suitable	I-Claim
reconstruction	I-Claim
method	I-Claim
than	I-Claim
INT	I-Claim
after	I-Claim
total	I-Claim
gastrectomy.	I-Claim

Gemcitabine	O
for	O
advanced	O
pancreatic	O
cancer	O
(APC)	O
is	O
palliative	O
and	O
the	O
prognosis	O
is	O
poor,	O
making	O
health-related	O
quality	O
of	O
life	O
(HRQOL)	O
particularly	O
important.	O

We	O
evaluated	O
HRQOL	O
with	O
the	O
EuroQol	O
(EQ-5D)	O
in	O
patients	O
with	O
APC	O
participating	O
in	O
Cancer	O
and	O
Leukemia	O
Group	O
B	O
80303,	O
a	O
multicenter,	O
double-blind,	O
randomized	O
trial	O
comparing	O
overall	O
survival	O
(OS)	O
between	O
two	O
treatment	O
arms:	O
gemcitabine	O
with	O
bevacizumab	O
or	O
gemcitabine	O
with	O
placebo.	O

A	O
consecutive	O
subsample	O
of	O
patients	O
was	O
invited	O
to	O
complete	O
the	O
EQ-5D	O
surveys.	O

Because	O
neither	O
clinical	O
nor	O
HRQOL	O
outcomes	O
differed	O
based	O
on	O
the	O
study	O
arm,	O
analyses	O
were	O
pooled.	O

Changes	O
in	O
mean	O
scores	O
from	O
baseline	O
to	O
eight	O
weeks	O
and	O
the	O
prognostic	O
value	O
of	O
the	O
EQ-5D	O
were	O
evaluated.	O

Mean	B-Premise
index	I-Premise
scores	I-Premise
remained	I-Premise
stable	I-Premise
(0.78	I-Premise
at	I-Premise
baseline	I-Premise
[n=267],	I-Premise
0.79	I-Premise
at	I-Premise
eight	I-Premise
weeks	I-Premise
[n=186],	I-Premise
P=0.34,	I-Premise
Wilcoxon	I-Premise
signed	I-Premise
rank	I-Premise
test),	I-Premise
attributable	I-Premise
to	I-Premise
a	I-Premise
modest	I-Premise
deterioration	I-Premise
of	I-Premise
physical	I-Premise
function	I-Premise
domain	I-Premise
scores	I-Premise
coincident	I-Premise
with	I-Premise
small	I-Premise
improvements	I-Premise
in	I-Premise
pain	I-Premise
and	I-Premise
anxiety/depression	I-Premise
scores.	I-Premise

A	B-Premise
small	I-Premise
decline	I-Premise
in	I-Premise
visual	I-Premise
analogue	I-Premise
scale	I-Premise
scores	I-Premise
was	I-Premise
observed	I-Premise
(70.7	I-Premise
vs.	I-Premise
68.2,	I-Premise
P=0.026).	I-Premise

HRQOL	B-Premise
changes	I-Premise
within	I-Premise
chemotherapy	I-Premise
response	I-Premise
strata	I-Premise
revealed	I-Premise
stable	I-Premise
index	I-Premise
scores	I-Premise
but	B-Premise
a	I-Premise
trend	I-Premise
of	I-Premise
worsened	I-Premise
physical	I-Premise
function	I-Premise
among	I-Premise
patients	I-Premise
with	I-Premise
disease	I-Premise
progression	I-Premise
compared	I-Premise
with	I-Premise
those	I-Premise
with	I-Premise
stable	I-Premise
or	I-Premise
improved	I-Premise
disease.	I-Premise

Visual	B-Premise
analogue	I-Premise
scale	I-Premise
scores	I-Premise
trended	I-Premise
downward	I-Premise
over	I-Premise
time	I-Premise
irrespective	I-Premise
of	I-Premise
chemotherapy	I-Premise
response	I-Premise
status,	I-Premise
with	I-Premise
a	I-Premise
statistically	I-Premise
meaningful	I-Premise
deterioration	I-Premise
in	I-Premise
patients	I-Premise
who	I-Premise
progressed	I-Premise
(68.9	I-Premise
vs.	I-Premise
64.4,	I-Premise
P=0.029).	I-Premise

Baseline	O
scores	O
from	O
both	O
EQ-5D	O
scales	O
were	O
significant	O
predictors	O
of	O
OS	O
in	O
Cox	O
proportional	O
hazard	O
models.	O

Response	B-Claim
to	I-Claim
gemcitabine	I-Claim
treatment	I-Claim
in	I-Claim
APC	I-Claim
is	I-Claim
not	I-Claim
associated	I-Claim
with	I-Claim
appreciable	I-Claim
improvement	I-Claim
of	I-Claim
global	I-Claim
HRQOL.	I-Claim

Small	O
improvements	O
in	O
pain	O
and	O
mood	O
are	O
observed	O
despite	O
progressive	O
functional	O
decline.	O

Those	B-Claim
who	I-Claim
respond	I-Claim
to	I-Claim
gemcitabine	I-Claim
may	I-Claim
experience	I-Claim
a	I-Claim
slight	I-Claim
slowing	I-Claim
of	I-Claim
functional	I-Claim
deterioration.	I-Claim

Observational	O
studies	O
demonstrate	O
an	O
association	O
between	O
physical	O
activity	O
and	O
improved	O
outcomes	O
in	O
breast	O
and	O
colon	O
cancer	O
survivors.	O

To	O
test	O
these	O
observations	O
with	O
a	O
large,	O
randomized	O
clinical	O
trial,	O
an	O
intervention	O
that	O
significantly	O
impacts	O
physical	O
activity	O
in	O
these	O
patients	O
is	O
needed.	O

The	O
Active	O
After	O
Cancer	O
Trial	O
(AACT)	O
was	O
a	O
multicenter	O
pilot	O
study	O
evaluating	O
the	O
feasibility	O
of	O
a	O
telephone-based	O
exercise	O
intervention	O
in	O
a	O
cooperative	O
group	O
setting.	O

Sedentary	O
(engaging	O
in	O
<60	O
min	O
of	O
recreational	O
activity/week)	O
breast	O
and	O
colorectal	O
cancer	O
survivors	O
were	O
randomized	O
to	O
a	O
telephone-based	O
exercise	O
intervention	O
or	O
usual	O
care	O
control	O
group.	O

The	O
intervention	O
was	O
delivered	O
through	O
the	O
University	O
of	O
California	O
at	O
San	O
Diego;	O
participants	O
received	O
ten	O
phone	O
calls	O
over	O
the	O
course	O
of	O
the	O
16-week	O
intervention.	O

All	O
participants	O
underwent	O
assessment	O
of	O
physical	O
activity,	O
fitness,	O
physical	O
functioning,	O
fatigue	O
and	O
exercise	O
self-efficacy	O
at	O
baseline	O
and	O
after	O
the	O
16-week	O
intervention.	O

One	O
hundred	O
and	O
twenty-one	O
patients	O
were	O
enrolled	O
through	O
ten	O
Cancer	O
and	O
Leukemia	O
Group	O
B	O
(CALGB)	O
institutions;	O
100	O
patients	O
had	O
breast	O
cancer	O
and	O
21	O
had	O
colorectal	O
cancer.	O

Participants	B-Premise
randomized	I-Premise
to	I-Premise
the	I-Premise
exercise	I-Premise
group	I-Premise
increased	I-Premise
physical	I-Premise
activity	I-Premise
by	I-Premise
more	I-Premise
than	I-Premise
100	I-Premise
versus	I-Premise
22%	I-Premise
in	I-Premise
controls	I-Premise
(54.5	I-Premise
vs.	I-Premise
14.6	I-Premise
min,	I-Premise
P	I-Premise
=	I-Premise
0.13),	I-Premise
and	I-Premise
experienced	I-Premise
significant	I-Premise
increases	I-Premise
in	I-Premise
fitness	I-Premise
(increased	I-Premise
6-min	I-Premise
walk	I-Premise
test	I-Premise
distance	I-Premise
by	I-Premise
186.9	I-Premise
vs.	I-Premise
81.9	I-Premise
feet,	I-Premise
P	I-Premise
=	I-Premise
0.006)	I-Premise
and	I-Premise
physical	I-Premise
functioning	I-Premise
(7.1	I-Premise
vs.	I-Premise
2.6,	I-Premise
P	I-Premise
=	I-Premise
0.04)	I-Premise
as	I-Premise
compared	I-Premise
to	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

Breast	B-Claim
and	I-Claim
colorectal	I-Claim
cancer	I-Claim
survivors	I-Claim
enrolled	I-Claim
in	I-Claim
a	I-Claim
multicenter,	I-Claim
telephone-based	I-Claim
physical	I-Claim
activity	I-Claim
intervention	I-Claim
increased	I-Claim
physical	I-Claim
activity	I-Claim
and	I-Claim
experienced	I-Claim
significant	I-Claim
improvements	I-Claim
in	I-Claim
fitness	I-Claim
and	I-Claim
physical	I-Claim
functioning.	I-Claim

Lifestyle	B-Claim
intervention	I-Claim
research	I-Claim
is	I-Claim
feasible	I-Claim
in	I-Claim
a	I-Claim
cooperative	I-Claim
group	I-Claim
setting.	I-Claim

This	O
study	O
sought	O
to	O
evaluate	O
effectiveness	O
of	O
autologous	O
dendritic	O
cell	O
vaccine	O
(immunotherapy)	O
for	O
glioblastoma	O
multiforme	O
(GBM).	O

Patients	O
14	O
to	O
70	O
years	O
of	O
age	O
with	O
newly	O
diagnosed	O
GBM	O
and	O
Karnofsky	O
Performance	O
Scale	O
(KPS)	O
score	O
>70	O
who	O
were	O
receiving	O
initial	O
treatment	O
were	O
enrolled	O
and	O
were	O
randomized	O
into	O
2	O
groups	O
during	O
the	O
5-year	O
study	O
period.	O

Eighteen	O
patients	O
underwent	O
conventional	O
treatment	O
(surgery,	O
radiotherapy,	O
and	O
chemotherapy)	O
and	O
received	O
adjuvant	O
autologous	O
dendritic	O
cell	O
vaccine,	O
and	O
16	O
patients	O
(control	O
group)	O
underwent	O
conventional	O
treatment	O
only.	O

Administration	O
of	O
the	O
vaccine	O
was	O
begun	O
within	O
1	O
to	O
2	O
months	O
postoperatively,	O
with	O
10	O
inoculations	O
given	O
over	O
6	O
months.	O

Outcome	O
measures	O
were	O
overall	O
survival	O
(OS);	O
progression-free	O
survival	O
(PFS);	O
1-,	O
2-,	O
and	O
3-year	O
survival	O
rates,	O
and	O
quality	O
of	O
life	O
(QoL).	O

Follow-up	O
time	O
ranged	O
from	O
14	O
to	O
56	O
months	O
(median,	O
33	O
months).	O

The	B-Premise
1-,	I-Premise
2-,	I-Premise
and	I-Premise
3-year	I-Premise
survival	I-Premise
rates	I-Premise
were	I-Premise
88.9%,	I-Premise
44.4%,	I-Premise
and	I-Premise
16.7%	I-Premise
for	I-Premise
the	I-Premise
vaccine	I-Premise
group,	I-Premise
respectively,	I-Premise
and	I-Premise
75.0%,	I-Premise
18.8%,	I-Premise
and	I-Premise
0%,	I-Premise
respectively,	I-Premise
for	I-Premise
the	I-Premise
control	I-Premise
group,	I-Premise
(P	I-Premise
=	I-Premise
0.299,	I-Premise
0.0035,	I-Premise
0.0014,	I-Premise
respectively).	I-Premise

The	B-Premise
median	I-Premise
OS	I-Premise
for	I-Premise
the	I-Premise
vaccine	I-Premise
group	I-Premise
was	I-Premise
31.9	I-Premise
months	I-Premise
and	I-Premise
for	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
was	I-Premise
15.0	I-Premise
months	I-Premise
(P	I-Premise
<	I-Premise
0.002).	I-Premise

The	B-Premise
median	I-Premise
progression-free	I-Premise
survival	I-Premise
(PFS)	I-Premise
for	I-Premise
the	I-Premise
vaccine	I-Premise
group	I-Premise
was	I-Premise
8.5	I-Premise
months,	I-Premise
and	I-Premise
8.0	I-Premise
months	I-Premise
for	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
0.075).	I-Premise

The	B-Premise
surviving	I-Premise
fraction	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
vaccine	I-Premise
group	I-Premise
based	I-Premise
on	I-Premise
Kaplan-Meier	I-Premise
analysis.	I-Premise

Adjuvant	B-Claim
immunotherapy	I-Claim
with	I-Claim
whole-cell	I-Claim
lysate	I-Claim
dendritic	I-Claim
cell	I-Claim
vaccine	I-Claim
may	I-Claim
improve	I-Claim
short-term	I-Claim
survival.	I-Claim

It	B-Claim
seems	I-Claim
to	I-Claim
be	I-Claim
safe,	I-Claim
and	I-Claim
its	I-Claim
long-term	I-Claim
effectiveness	I-Claim
is	I-Claim
worthy	I-Claim
of	I-Claim
further	I-Claim
investigation.	I-Claim

Molecular	O
markers	O
to	O
predict	O
response	O
to	O
5-fluorouracil	O
(FU)-based	O
treatment	O
of	O
recurrent	O
or	O
metastasised	O
colorectal	O
cancer	O
(mCRC)	O
are	O
not	O
established.	O

The	O
aim	O
of	O
this	O
trial	O
was	O
to	O
determine	O
the	O
value	O
of	O
thymidylate	O
synthase	O
(TS),	O
a	O
key	O
enzyme	O
of	O
DNA	O
synthesis	O
and	O
target	O
of	O
5-FU,	O
to	O
predict	O
response	O
to	O
chemotherapy	O
of	O
mCRC.	O

Tumour	O
tissue	O
was	O
obtained	O
from	O
168	O
patients	O
with	O
mCRC	O
for	O
relative	O
thymidylate	O
synthase	O
(TS)	O
mRNA	O
quantitation.	O

Patients	O
were	O
randomised	O
to	O
receive	O
either	O
5-FU/folinic	O
acid	O
(FA,	O
FUFA)	O
alone	O
or	O
in	O
combination	O
with	O
irinotecan	O
5-fluorouracil/folinic	O
acid	O
and	O
irinotecan	O
(FOLFIRI)	O
stratified	O
by	O
TS	O
(low	O
versus	O
high).	O

Primary	O
end-point	O
was	O
overall	O
response	O
to	O
first-line	O
treatment	O
among	O
TS	O
high	O
patients.	O

All	O
parties,	O
except	O
for	O
the	O
randomisation	O
centre,	O
were	O
blinded	O
for	O
TS	O
status.	O

Biopsies	O
(n=168)	O
were	O
taken	O
without	O
complications.	O

TS	O
levels	O
were	O
available	O
for	O
147	O
patients	O
(87.5%).	O

Analysing	B-Premise
response	I-Premise
to	I-Premise
FUFA	I-Premise
and	I-Premise
FOLFIRI	I-Premise
in	I-Premise
the	I-Premise
per	I-Premise
protocol	I-Premise
set	I-Premise
(n=119)	I-Premise
after	I-Premise
un-blinding	I-Premise
TS	I-Premise
in	I-Premise
the	I-Premise
data	I-Premise
base	I-Premise
revealed	I-Premise
a	I-Premise
trend	I-Premise
to	I-Premise
better	I-Premise
overall	I-Premise
response	I-Premise
to	I-Premise
FOLFIRI	I-Premise
(9/19,	I-Premise
47%)	I-Premise
in	I-Premise
TS	I-Premise
high	I-Premise
compared	I-Premise
to	I-Premise
FUFA	I-Premise
(5/23,	I-Premise
22%,	I-Premise
p=0.077).	I-Premise

In	B-Premise
patients	I-Premise
with	I-Premise
biopsies	I-Premise
taken	I-Premise
from	I-Premise
liver	I-Premise
lesions	I-Premise
(n=91)	I-Premise
overall	I-Premise
response	I-Premise
to	I-Premise
FOLFIRI	I-Premise
and	I-Premise
FUFA	I-Premise
in	I-Premise
TS	I-Premise
high	I-Premise
was	I-Premise
53%	I-Premise
(9/17)	I-Premise
and	I-Premise
18%	I-Premise
(3/17),	I-Premise
respectively	I-Premise
(p=0.035).	I-Premise

In	B-Premise
patients	I-Premise
with	I-Premise
low	I-Premise
TS,	I-Premise
no	I-Premise
remarkable	I-Premise
difference	I-Premise
in	I-Premise
overall	I-Premise
response	I-Premise
to	I-Premise
FOLFIRI	I-Premise
and	I-Premise
FUFA	I-Premise
was	I-Premise
observed.	I-Premise

Taking	B-Claim
a	I-Claim
pre-treatment	I-Claim
biopsy	I-Claim
is	I-Claim
a	I-Claim
safe	I-Claim
and	I-Claim
feasible	I-Claim
procedure	I-Claim
in	I-Claim
mCRC.	I-Claim

After	B-Claim
validation	I-Claim
of	I-Claim
our	I-Claim
data	I-Claim
in	I-Claim
a	I-Claim
larger	I-Claim
group	I-Claim
TS	I-Claim
determination	I-Claim
may	I-Claim
have	I-Claim
the	I-Claim
potential	I-Claim
to	I-Claim
better	I-Claim
help	I-Claim
direct	I-Claim
systemic	I-Claim
treatment	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
primarily	I-Claim
non-resectable	I-Claim
mCRC.	I-Claim

The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
response	O
rates	O
of	O
elderly,	O
chemonaive	O
patients	O
with	O
advanced	O
non-small	O
cell	O
lung	O
cancer	O
(NSCLC)	O
treated	O
with	O
daily	O
oral	O
erlotinib	O
versus	O
oral	O
vinorelbine.	O

Chemonaive	O
Taiwanese	O
patients	O
aged	O
70	O
years	O
or	O
older	O
who	O
had	O
advanced	O
NSCLC	O
were	O
randomized	O
to	O
receive	O
either	O
oral	O
erlotinib	O
150	O
mg	O
(E)	O
daily	O
or	O
oral	O
vinorelbine	O
60	O
mg/m	O
(V)	O
on	O
days	O
1	O
and	O
8	O
every	O
3	O
weeks.	O

From	O
February	O
2007	O
to	O
July	O
2008,	O
116	O
patients	O
were	O
enrolled	O
and	O
113	O
were	O
included	O
in	O
the	O
intent-to-treat	O
population:	O
57	O
patients	O
in	O
the	O
E	O
group	O
and	O
56	O
patients	O
in	O
the	O
V	O
group.	O

Objective	B-Premise
response	I-Premise
rates	I-Premise
were	I-Premise
22.8%	I-Premise
(13	I-Premise
of	I-Premise
57)	I-Premise
in	I-Premise
E	I-Premise
and	I-Premise
8.9%	I-Premise
(5	I-Premise
of	I-Premise
56)	I-Premise
in	I-Premise
V	I-Premise
(p	I-Premise
=	I-Premise
0.0388).	I-Premise

Median	B-Premise
progression-free	I-Premise
survival	I-Premise
(PFS)	I-Premise
was	I-Premise
4.57	I-Premise
months	I-Premise
in	I-Premise
E	I-Premise
and	I-Premise
2.53	I-Premise
months	I-Premise
in	I-Premise
V	I-Premise
(p	I-Premise
=	I-Premise
0.0287),	I-Premise
with	I-Premise
an	I-Premise
80.6%	I-Premise
increase	I-Premise
in	I-Premise
median	I-Premise
PFS	I-Premise
for	I-Premise
E	I-Premise
compared	I-Premise
with	I-Premise
V.	I-Premise

Median	B-Premise
survival	I-Premise
time	I-Premise
was	I-Premise
11.67	I-Premise
months	I-Premise
in	I-Premise
E	I-Premise
and	I-Premise
9.3	I-Premise
months	I-Premise
in	I-Premise
V	I-Premise
(p	I-Premise
=	I-Premise
0.6975).	I-Premise

Toxicities	B-Premise
were	I-Premise
generally	I-Premise
mild	I-Premise
in	I-Premise
both	I-Premise
groups.	I-Premise

Median	B-Premise
PFS	I-Premise
was	I-Premise
longest	I-Premise
for	I-Premise
epidermal	I-Premise
growth	I-Premise
factor	I-Premise
receptor	I-Premise
gene	I-Premise
(EGFR)-mutated	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
E	I-Premise
group,	I-Premise
followed	I-Premise
by	I-Premise
EGFR-mutated	I-Premise
patients	I-Premise
in	I-Premise
V,	I-Premise
EGFR	I-Premise
wild	I-Premise
type	I-Premise
in	I-Premise
E,	I-Premise
and	I-Premise
EGFR	I-Premise
wild	I-Premise
type	I-Premise
in	I-Premise
V	I-Premise
(p	I-Premise
=	I-Premise
0.0034).	I-Premise

Overall	B-Premise
survival	I-Premise
was	I-Premise
longer	I-Premise
for	I-Premise
EGFR-mutated	I-Premise
patients	I-Premise
than	I-Premise
for	I-Premise
EGFR	I-Premise
wild-type	I-Premise
patients	I-Premise
(p	I-Premise
<	I-Premise
0.0001).	I-Premise

Erlotinib	B-Claim
is	I-Claim
highly	I-Claim
effective	I-Claim
compared	I-Claim
with	I-Claim
oral	I-Claim
vinorelbine	I-Claim
in	I-Claim
elderly,	I-Claim
chemonaive,	I-Claim
Taiwanese	I-Claim
patients	I-Claim
with	I-Claim
NSCLC.	I-Claim

EGFR-mutated	B-Claim
patients	I-Claim
had	I-Claim
better	I-Claim
survival	I-Claim
than	I-Claim
those	I-Claim
with	I-Claim
EGFR	I-Claim
wild-type	I-Claim
disease,	I-Claim
regardless	I-Claim
of	I-Claim
the	I-Claim
treatment	I-Claim
received.	I-Claim

To	O
compare	O
the	O
efficacy	O
of	O
low-frequency	O
low-intensity	O
electrotherapy	O
and	O
manual	O
lymphatic	O
drainage	O
in	O
the	O
treatment	O
of	O
chronic	O
upper	O
limb	O
breast	O
cancer-related	O
lymphoedema.	O

Cross-over	O
single-blind	O
random	O
clinical	O
trial.	O

Rehabilitation	O
service.	O

Thirty-six	O
women	O
with	O
chronic	O
upper	O
limb	O
breast	O
cancer-related	O
lymphoedema.	O

Patients	O
were	O
randomized	O
to	O
undergo	O
10	O
sessions	O
of	O
manual	O
lymphatic	O
drainage	O
followed	O
by	O
10	O
sessions	O
of	O
low-frequency	O
low-intensity	O
electrotherapy	O
or	O
to	O
undergo	O
first	O
low-frequency	O
low-intensity	O
electrotherapy	O
followed	O
by	O
manual	O
lymphatic	O
drainage.	O

There	O
was	O
a	O
month	O
of	O
washout	O
time	O
between	O
treatments.	O

Each	O
patient	O
was	O
examined	O
just	O
before	O
and	O
after	O
each	O
treatment.	O

Researchers	O
and	O
outcome	O
assessors	O
were	O
blinded	O
for	O
assigned	O
treatment.	O

Outcomes	O
were	O
lymphoedema	O
volume,	O
pain,	O
heaviness	O
and	O
tightness,	O
and	O
health-related	O
quality	O
of	O
life	O
measured	O
with	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy	O
Questionnaire	O
for	O
Breast	O
Cancer	O
version	O
4	O
(FACT-B+4).	O

Carry-over,	O
period	O
and	O
treatment	O
effects	O
were	O
analysed.	O

Treatment	O
effect	O
was	O
assessed	O
using	O
paired	O
t-test.	O

Thirty	O
patients	O
finalized	O
treatment.	O

Comparing	B-Premise
the	I-Premise
changes	I-Premise
in	I-Premise
low-frequency	I-Premise
low-intensity	I-Premise
electrotherapy	I-Premise
with	I-Premise
manual	I-Premise
lymphatic	I-Premise
drainage	I-Premise
changes,	I-Premise
there	I-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences.	I-Premise

Low-frequency	B-Premise
low-intensity	I-Premise
electrotherapy	I-Premise
did	I-Premise
not	I-Premise
reduce	I-Premise
lymphoedema	I-Premise
volume	I-Premise
(mean	I-Premise
of	I-Premise
change	I-Premise
=	I-Premise
19.77	I-Premise
mL,	I-Premise
P	I-Premise
=	I-Premise
0.36),	I-Premise
but	O
significant	B-Premise
reductions	I-Premise
were	I-Premise
observed	I-Premise
in	I-Premise
pain,	I-Premise
heaviness	I-Premise
and	I-Premise
tightness	I-Premise
(mean	I-Premise
of	I-Premise
change	I-Premise
=	I-Premise
13.1,	I-Premise
16.2	I-Premise
and	I-Premise
6.4	I-Premise
mm,	I-Premise
respectively),	I-Premise
and	I-Premise
FACT-B+4	I-Premise
summaries	I-Premise
improved	I-Premise
significantly	I-Premise
(Trial	I-Premise
Outcome	I-Premise
Index	I-Premise
mean	I-Premise
of	I-Premise
change	I-Premise
=	I-Premise
5.4,	I-Premise
P	I-Premise
=	I-Premise
0.015).	I-Premise

Manual	B-Premise
lymphatic	I-Premise
drainage	I-Premise
showed	I-Premise
no	I-Premise
significant	I-Premise
changes	I-Premise
in	I-Premise
any	I-Premise
of	I-Premise
the	I-Premise
outcomes.	I-Premise

Although	B-Claim
there	I-Claim
are	I-Claim
no	I-Claim
significant	I-Claim
differences	I-Claim
between	I-Claim
treatment	I-Claim
changes,	I-Claim
the	B-Claim
observed	I-Claim
trend	I-Claim
towards	I-Claim
a	I-Claim
better	I-Claim
health-related	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
is	I-Claim
remarkable	I-Claim
in	I-Claim
low-frequency	I-Claim
low-intensity	I-Claim
electrotherapy.	I-Claim

Gynecological	O
neoplastic	O
disease	O
progression	O
is	O
characterized	O
by	O
specific	O
energy	O
metabolism	O
alterations	O
and	O
by	O
symptoms	O
including	O
fatigue,	O
anorexia,	O
nausea,	O
anemia,	O
and	O
immunodepression,	O
which	O
result	O
in	O
a	O
cachexia	O
syndrome	O
and	O
a	O
marked	O
decrease	O
in	O
patient	O
quality	O
of	O
life	O
(QoL).	O

Therapeutic	O
protocols	O
associated	O
with	O
appropriate	O
and	O
effective	O
psychological	O
and	O
social	O
support	O
systems	O
are	O
essential	O
to	O
counteract	O
the	O
symptoms	O
of	O
neoplastic	O
disease	O
in	O
incurable	O
patients.	O

A	O
phase	O
III	O
randomized	O
study	O
was	O
performed	O
to	O
establish	O
the	O
most	O
effective	O
and	O
safest	O
treatment	O
to	O
improve	O
the	O
key	O
symptoms	O
in	O
advanced	O
gynecological	O
cancer	O
patients,	O
i.e.,	O
lean	O
body	O
mass	O
(LBM),	O
resting	O
energy	O
expenditure	O
(REE),	O
fatigue,	O
and	O
QoL.	O

In	O
addition,	O
the	O
impact	O
of	O
the	O
treatment	O
arms	O
on	O
the	O
main	O
metabolic	O
and	O
inflammatory	O
parameters,	O
including	O
C-reactive	O
protein	O
(CRP),	O
interleukin	O
(IL)-6,	O
tumor	O
necrosis	O
factor	O
(TNF)-,	O
leptin,	O
reactive	O
oxygen	O
species	O
(ROS),	O
and	O
glutathione	O
peroxidase,	O
was	O
evaluated.	O

The	O
change	O
in	O
the	O
Glasgow	O
Prognostic	O
Score	O
(GPS)	O
during	O
treatment	O
was	O
also	O
assessed.	O

A	O
total	O
of	O
104	O
advanced-stage	O
gynecological	O
cancer	O
patients	O
were	O
enrolled	O
and	O
randomly	O
assigned	O
to	O
receive	O
either	O
megestrol	O
acetate	O
(MA)	O
plus	O
l-carnitine,	O
celecoxib,	O
and	O
antioxidants	O
(arm	O
1)	O
or	O
MA	O
alone	O
(arm	O
2).	O

The	O
treatment	O
duration	O
was	O
4	O
months.	O

The	B-Premise
combination	I-Premise
arm	I-Premise
was	I-Premise
more	I-Premise
effective	I-Premise
than	I-Premise
arm	I-Premise
2	I-Premise
with	I-Premise
respect	I-Premise
to	I-Premise
LBM,	I-Premise
REE,	I-Premise
fatigue,	I-Premise
and	I-Premise
global	I-Premise
QoL.	I-Premise

As	B-Premise
for	I-Premise
the	I-Premise
secondary	I-Premise
efficacy	I-Premise
endpoints,	I-Premise
patient	I-Premise
appetite	I-Premise
increased,	I-Premise
and	I-Premise
ECOG	I-Premise
PS	I-Premise
decreased	I-Premise
significantly	I-Premise
in	I-Premise
both	I-Premise
arms.	I-Premise

The	B-Premise
inflammation	I-Premise
and	I-Premise
oxidative	I-Premise
stress	I-Premise
parameters	I-Premise
IL-6,	I-Premise
TNF-,	I-Premise
CRP,	I-Premise
and	I-Premise
ROS	I-Premise
decreased	I-Premise
significantly	I-Premise
in	I-Premise
arm	I-Premise
1,	I-Premise
while	I-Premise
no	I-Premise
significant	I-Premise
change	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
arm	I-Premise
2.	I-Premise

The	B-Claim
combined	I-Claim
treatment	I-Claim
improved	I-Claim
both	I-Claim
immunometabolic	I-Claim
alterations	I-Claim
and	I-Claim
patient	I-Claim
QoL.	I-Claim

Multimodality	B-Claim
therapies	I-Claim
for	I-Claim
cachexia	I-Claim
ideally	I-Claim
should	I-Claim
be	I-Claim
introduced	I-Claim
within	I-Claim
a	I-Claim
context	I-Claim
of	I-Claim
"best	I-Claim
supportive	I-Claim
care"	I-Claim
that	I-Claim
includes	I-Claim
optimal	I-Claim
symptom	I-Claim
management	I-Claim
and	I-Claim
careful	I-Claim
psychosocial	I-Claim
counseling.	I-Claim

Pain	O
is	O
1	O
of	O
the	O
most	O
common	O
symptoms	O
that	O
a	O
cancer	O
patient	O
would	O
experience.	O

A	O
significant	O
barrier	O
to	O
positive	O
pain	O
management	O
is	O
patients'	O
misconceptions	O
regarding	O
analgesics	O
and	O
inadequate	O
use	O
of	O
nonpharmacological	O
strategies	O
as	O
pain	O
relief.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effectiveness	O
of	O
a	O
pain	O
management	O
program	O
(PMP)	O
on	O
pain	O
intensity,	O
use	O
of	O
PRN	O
drugs	O
and	O
nonpharmacological	O
strategies	O
as	O
pain	O
relief,	O
and	O
barriers	O
to	O
managing	O
pain	O
in	O
cancer	O
patients.	O

The	O
study	O
was	O
conducted	O
in	O
the	O
palliative	O
care	O
and	O
hospice	O
ward	O
of	O
a	O
public	O
hospital	O
in	O
Hong	O
Kong.	O

Patients	O
were	O
randomized	O
to	O
either	O
an	O
experimental	O
group	O
(receiving	O
the	O
PMP)	O
or	O
a	O
control	O
group	O
(routine	O
care).	O

There	O
were	O
38	O
hospitalized	O
patients,	O
with	O
20	O
(13	O
males	O
and	O
7	O
females)	O
in	O
the	O
experimental	O
group	O
and	O
18	O
(11	O
males	O
and	O
7	O
females)	O
in	O
the	O
control	O
group;	O
mean	O
age	O
was	O
61.95	O
years	O
(experimental	O
group)	O
to	O
63.94	O
years	O
(control	O
group).	O

Upon	B-Premise
the	I-Premise
completion	I-Premise
of	I-Premise
PMP,	I-Premise
pain	I-Premise
scores	I-Premise
were	I-Premise
significantly	I-Premise
reduced	I-Premise
in	I-Premise
both	I-Premise
groups,	I-Premise
yet	B-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
experimental	I-Premise
group	I-Premise
showed	I-Premise
a	I-Premise
significant	I-Premise
increase	I-Premise
in	I-Premise
the	I-Premise
use	I-Premise
of	I-Premise
PRN	I-Premise
analgesics	I-Premise
and	I-Premise
nonpharmacological	I-Premise
strategies	I-Premise
to	I-Premise
relieve	I-Premise
pain	I-Premise
(P	I-Premise
<	I-Premise
.05)	I-Premise
and	I-Premise
significantly	I-Premise
reduce	I-Premise
barriers	I-Premise
to	I-Premise
managing	I-Premise
their	I-Premise
cancer	I-Premise
pain	I-Premise
(P	I-Premise
<	I-Premise
.05)	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

Cancer	B-Claim
patients	I-Claim
should	I-Claim
be	I-Claim
empowered	I-Claim
with	I-Claim
pain	I-Claim
management	I-Claim
education	I-Claim
to	I-Claim
gain	I-Claim
knowledge	I-Claim
and	I-Claim
correct	I-Claim
misconceptions	I-Claim
in	I-Claim
managing	I-Claim
their	I-Claim
cancer	I-Claim
pain.	I-Claim

Integration	B-Claim
of	I-Claim
the	I-Claim
PMP	I-Claim
into	I-Claim
routine	I-Claim
clinical	I-Claim
work	I-Claim
may	I-Claim
help	I-Claim
to	I-Claim
improve	I-Claim
the	I-Claim
standard	I-Claim
of	I-Claim
care	I-Claim
for	I-Claim
cancer	I-Claim
patients.	I-Claim

It	O
is	O
recommended	O
to	O
provide	O
pain	O
management	O
education	O
to	O
all	O
cancer	O
patients.	O

Health-related	O
quality	O
of	O
life	O
(HRQOL),	O
symptoms	O
of	O
depression,	O
and	O
adverse	O
events	O
(AEs)	O
were	O
compared	O
between	O
Japanese	O
postmenopausal	O
patients	O
with	O
hormone-sensitive	O
breast	O
cancer	O
(BC)	O
who	O
received	O
adjuvant	O
tamoxifen,	O
exemestane,	O
or	O
anastrozole	O
in	O
an	O
open-labeled,	O
randomized,	O
multicenter	O
trial	O
designated	O
as	O
the	O
National	O
Surgical	O
Adjuvant	O
Study	O
of	O
Breast	O
Cancer	O
(N-SAS	O
BC)	O
04	O
substudy	O
of	O
the	O
Tamoxifen	O
Exemestane	O
Adjuvant	O
Multinational	O
(TEAM)	O
trial.	O

During	O
the	O
first	O
year	O
of	O
treatment,	O
HRQOL	O
and	O
symptoms	O
of	O
depression	O
were	O
analyzed	O
using	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Breast	O
(FACT-B)	O
and	O
its	O
Endocrine	O
Symptom	O
Subscale	O
(ES),	O
and	O
the	O
Center	O
for	O
Epidemiologic	O
Studies	O
Depression	O
Scale	O
(CES-D),	O
respectively.	O

In	O
addition,	O
predefined	O
AEs	O
were	O
analyzed.	O

A	O
total	O
of	O
166	O
eligible	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
adjuvant	O
tamoxifen,	O
exemestane,	O
or	O
anastrozole.	O

FACT-B	B-Premise
scores	I-Premise
increased	I-Premise
after	I-Premise
treatment	I-Premise
began	I-Premise
and	I-Premise
remained	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
tamoxifen	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
exemestane	I-Premise
group	I-Premise
or	I-Premise
anastrozole	I-Premise
group	I-Premise
during	I-Premise
the	I-Premise
first	I-Premise
year	I-Premise
(P	I-Premise
=	I-Premise
0.045).	I-Premise

FACT-B	B-Premise
scores	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
the	I-Premise
exemestane	I-Premise
group	I-Premise
and	I-Premise
anastrozole	I-Premise
group.	I-Premise

ES	B-Premise
scores	I-Premise
and	I-Premise
CES-D	I-Premise
scores	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
all	I-Premise
treatment	I-Premise
groups.	I-Premise

Arthralgia	B-Premise
and	I-Premise
fatigue	I-Premise
were	I-Premise
less	I-Premise
frequent,	I-Premise
but	I-Premise
vaginal	I-Premise
discharge	I-Premise
was	I-Premise
more	I-Premise
frequent	I-Premise
in	I-Premise
the	I-Premise
tamoxifen	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
exemestane	I-Premise
group	I-Premise
or	I-Premise
anastrozole	I-Premise
group.	I-Premise

HRQOL	B-Claim
was	I-Claim
better	I-Claim
in	I-Claim
Japanese	I-Claim
postmenopausal	I-Claim
women	I-Claim
treated	I-Claim
with	I-Claim
tamoxifen	I-Claim
than	I-Claim
those	I-Claim
treated	I-Claim
with	I-Claim
exemestane	I-Claim
or	I-Claim
anastrozole.	I-Claim

HRQOL	B-Claim
and	I-Claim
AEs	I-Claim
were	I-Claim
similar	I-Claim
with	I-Claim
exemestane	I-Claim
and	I-Claim
anastrozole.	I-Claim

Given	B-Claim
the	I-Claim
results	I-Claim
of	I-Claim
the	I-Claim
TEAM	I-Claim
trial,	I-Claim
upfront	I-Claim
use	I-Claim
of	I-Claim
tamoxifen	I-Claim
followed	I-Claim
by	I-Claim
an	I-Claim
aromatase	I-Claim
inhibitor	I-Claim
(AI)	I-Claim
may	I-Claim
be	I-Claim
an	I-Claim
important	I-Claim
option	I-Claim
for	I-Claim
adjuvant	I-Claim
endocrine	I-Claim
therapy	I-Claim
in	I-Claim
Japanese	I-Claim
postmenopausal	I-Claim
women.	I-Claim

Cisplatin	B-Claim
reduces	I-Claim
plasma	I-Claim
ghrelin	I-Claim
levels	I-Claim
through	I-Claim
the	I-Claim
5-hydroxytryptamine	I-Claim
(5-HT)	I-Claim
receptor.	I-Claim

This	O
may	O
cause	O
cisplatin-induced	O
gastrointestinal	O
disorders	O
and	O
hinders	O
the	O
continuation	O
of	O
chemotherapy.	O

The	O
authors	O
of	O
this	O
report	O
conducted	O
a	O
prospective,	O
randomized	O
phase	O
2	O
trial	O
to	O
evaluate	O
the	O
effects	O
of	O
exogenous	O
ghrelin	O
during	O
cisplatin-based	O
chemotherapy.	O

Forty-two	O
patients	O
with	O
esophageal	O
cancer	O
who	O
were	O
receiving	O
cisplatin-based	O
neoadjuvant	O
chemotherapy	O
were	O
assigned	O
to	O
either	O
a	O
ghrelin	O
group	O
(n	O
=	O
21)	O
or	O
a	O
placebo	O
group	O
(n	O
=	O
21).	O

They	O
received	O
either	O
intravenous	O
infusions	O
of	O
synthetic	O
human	O
ghrelin	O
(3	O
g/kg)	O
or	O
saline	O
twice	O
daily	O
for	O
1	O
week	O
with	O
cisplatin	O
administration.	O

The	O
primary	O
endpoint	O
was	O
changes	O
in	O
oral	O
calorie	O
intake,	O
and	O
the	O
secondary	O
endpoints	O
were	O
chemotherapy-related	O
adverse	O
events;	O
appetite	O
visual	O
analog	O
scale	O
(VAS)	O
scores;	O
changes	O
in	O
gastrointestinal	O
hormones	O
and	O
nutritional	O
status,	O
including	O
rapid	O
turnover	O
proteins,	O
and	O
quality	O
of	O
life	O
(QoL)	O
estimated	O
with	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
QoL	O
core	O
questionnaire	O
(QLQ-C30).	O

Two	O
patients	O
were	O
excluded	O
from	O
the	O
final	O
analysis:	O
One	O
patient	O
suspended	O
ghrelin	O
administration	O
because	O
of	O
excessive	O
diaphoresis,	O
and	O
another	O
patient	O
in	O
the	O
placebo	O
group	O
failed	O
to	O
monitor	O
the	O
self-questionnaire.	O

Food	B-Premise
intake	I-Premise
and	I-Premise
appetite	I-Premise
VAS	I-Premise
scores	I-Premise
were	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
ghrelin	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group	I-Premise
(18.2	I-Premise
	I-Premise
5.2	I-Premise
kcal/kg/day	I-Premise
vs	I-Premise
12.7	I-Premise
	I-Premise
3.4	I-Premise
kcal/kg/day	I-Premise
[P	I-Premise
=	I-Premise
.001]	I-Premise
and	I-Premise
6.2	I-Premise
	I-Premise
0.9	I-Premise
vs	I-Premise
4.1	I-Premise
	I-Premise
0.9	I-Premise
[P	I-Premise
<	I-Premise
.0001],	I-Premise
respectively).	I-Premise

Patients	B-Premise
in	I-Premise
the	I-Premise
ghrelin	I-Premise
group	I-Premise
had	I-Premise
fewer	I-Premise
adverse	I-Premise
events	I-Premise
during	I-Premise
chemotherapy	I-Premise
related	I-Premise
to	I-Premise
anorexia	I-Premise
and	I-Premise
nausea	I-Premise
than	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

Significant	B-Premise
deterioration	I-Premise
was	I-Premise
noted	I-Premise
after	I-Premise
chemotherapy	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group	I-Premise
in	I-Premise
QoL	I-Premise
scores,	I-Premise
appetite,	I-Premise
nausea	I-Premise
and	I-Premise
vomiting,	I-Premise
and	I-Premise
global	I-Premise
health	I-Premise
status.	I-Premise

Short-term	B-Claim
administration	I-Claim
of	I-Claim
exogenous	I-Claim
ghrelin	I-Claim
at	I-Claim
the	I-Claim
start	I-Claim
of	I-Claim
cisplatin-based	I-Claim
chemotherapy	I-Claim
stimulated	I-Claim
food	I-Claim
intake	I-Claim
and	I-Claim
minimized	I-Claim
adverse	I-Claim
events.	I-Claim

This	O
study	O
aims	O
to	O
examine	O
the	O
effectiveness	O
of	O
a	O
self-management	O
multimodal	O
comprehensive	O
coping	O
strategy	O
program	O
(CCSP)	O
on	O
quality	O
of	O
life	O
(QOL)	O
among	O
breast	O
cancer	O
patients	O
1	O
year	O
after	O
treatment.	O

Patients	O
(n	O
=	O
110)	O
with	O
stage	O
II,	O
III,	O
or	O
IV	O
breast	O
cancer	O
scheduled	O
to	O
receive	O
high	O
dose	O
chemotherapy	O
and	O
autologous	O
hematopoietic	O
stem	O
cell	O
transplantation	O
were	O
randomized	O
to	O
either	O
CCSP	O
treatment	O
or	O
control	O
group.	O

The	O
CCSP	O
intervention	O
was	O
taught	O
2	O
week	O
before	O
hospital	O
admission	O
with	O
reinforcement	O
at	O
specified	O
times	O
during	O
treatment	O
and	O
3	O
months	O
after	O
discharge.	O

The	O
CCSP	O
components	O
included	O
educational	O
information,	O
cognitive	O
restructuring,	O
coping	O
skills	O
enhancement,	O
and	O
relaxation	O
with	O
guided	O
imagery.	O

Instruments	O
administered	O
at	O
baseline	O
included	O
the	O
following:	O
Quality	O
of	O
Life	O
Index-Cancer	O
Version	O
(QOLI-CV),	O
State-Trait	O
Anxiety	O
Inventory,	O
Beck	O
Depression	O
Inventory,	O
and	O
Coping	O
Strategies	O
Questionnaire.	O

At	O
1-year	O
follow-up,	O
patients	O
(n	O
=	O
73)	O
completed	O
and	O
returned	O
the	O
follow-up	O
QOLI-CV.	O

Patients	O
were	O
mainly	O
	O
40	O
years	O
of	O
age,	O
married,	O
Caucasian,	O
and	O
diagnosed	O
with	O
advanced	O
breast	O
cancer.	O

A	B-Premise
model	I-Premise
measuring	I-Premise
effectiveness	I-Premise
of	I-Premise
CCSP	I-Premise
on	I-Premise
QOL	I-Premise
(total	I-Premise
and	I-Premise
subscale)	I-Premise
at	I-Premise
1-year	I-Premise
follow-up	I-Premise
showed	I-Premise
that	I-Premise
the	I-Premise
CCSP	I-Premise
group	I-Premise
(n	I-Premise
=	I-Premise
38)	I-Premise
had	I-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
overall	I-Premise
QOL	I-Premise
(p	I-Premise
<	I-Premise
0.01),	I-Premise
health	I-Premise
and	I-Premise
functioning	I-Premise
(p	I-Premise
<	I-Premise
0.05),	I-Premise
and	I-Premise
socioeconomic	I-Premise
(p	I-Premise
<	I-Premise
0.05)	I-Premise
and	I-Premise
psychological/spiritual	I-Premise
well-being	I-Premise
(p	I-Premise
<	I-Premise
0.01)	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
(n	I-Premise
=	I-Premise
35).	I-Premise

The	B-Premise
CCSP	I-Premise
patients	I-Premise
frequently	I-Premise
used	I-Premise
the	I-Premise
CCSP	I-Premise
to	I-Premise
manage	I-Premise
psychological	I-Premise
(51%)	I-Premise
and	I-Premise
sleep	I-Premise
problems	I-Premise
(60%).	I-Premise

The	B-Premise
CCSP	I-Premise
improved	I-Premise
QOL	I-Premise
for	I-Premise
patients	I-Premise
at	I-Premise
1-year	I-Premise
follow-up.	I-Premise

Patients	B-Premise
overwhelmingly	I-Premise
reported	I-Premise
that	I-Premise
CCSP	I-Premise
was	I-Premise
beneficial.	I-Premise

The	B-Claim
CCSP	I-Claim
as	I-Claim
an	I-Claim
effective	I-Claim
coping	I-Claim
intervention	I-Claim
has	I-Claim
potential	I-Claim
as	I-Claim
a	I-Claim
self-management	I-Claim
program	I-Claim
for	I-Claim
breast	I-Claim
cancer	I-Claim
survivors.	I-Claim

Few	O
intervention	O
programs	O
assist	O
patients	O
and	O
their	O
family	O
caregivers	O
to	O
manage	O
advanced	O
cancer	O
and	O
maintain	O
their	O
quality	O
of	O
life	O
(QOL).	O

This	O
study	O
examined	O
(i)	O
whether	O
patient-caregiver	O
dyads	O
(i.e.,	O
pairs)	O
randomly	O
assigned	O
to	O
a	O
brief	O
or	O
extensive	O
dyadic	O
intervention	O
(the	O
FOCUS	O
Program)	O
had	O
better	O
outcomes	O
than	O
dyads	O
randomly	O
assigned	O
to	O
usual	O
care	O
and	O
(ii)	O
whether	O
patients'	O
risk	O
for	O
distress	O
and	O
other	O
factors	O
moderated	O
the	O
effect	O
of	O
the	O
brief	O
or	O
extensive	O
program	O
on	O
outcomes.	O

Advanced	O
cancer	O
patients	O
and	O
their	O
caregivers	O
(N	O
=	O
484	O
dyads)	O
were	O
stratified	O
by	O
patients'	O
baseline	O
risk	O
for	O
distress	O
(high	O
versus	O
low),	O
cancer	O
type	O
(lung,	O
colorectal,	O
breast,	O
or	O
prostate),	O
and	O
research	O
site	O
and	O
then	O
randomly	O
assigned	O
to	O
a	O
brief	O
(three-session)	O
or	O
extensive	O
(six-session)	O
intervention	O
or	O
control.	O

The	O
interventions	O
offered	O
dyads	O
information	O
and	O
support.	O

Intermediary	O
outcomes	O
were	O
appraisals	O
(i.e.,	O
appraisal	O
of	O
illness/caregiving,	O
uncertainty,	O
and	O
hopelessness)	O
and	O
resources	O
(i.e.,	O
coping,	O
interpersonal	O
relationships,	O
and	O
self-efficacy).	O

The	O
primary	O
outcome	O
was	O
QOL.	O

Data	O
were	O
collected	O
prior	O
to	O
intervention	O
and	O
post-intervention	O
(3	O
and	O
6	O
months	O
from	O
baseline).	O

The	O
final	O
sample	O
was	O
302	O
dyads.	O

Repeated	O
measures	O
MANCOVA	O
was	O
used	O
to	O
evaluate	O
outcomes.	O

Significant	B-Premise
group	I-Premise
by	I-Premise
time	I-Premise
interactions	I-Premise
showed	I-Premise
that	I-Premise
there	I-Premise
was	I-Premise
an	I-Premise
improvement	I-Premise
in	I-Premise
dyads'	I-Premise
coping	I-Premise
(p	I-Premise
<	I-Premise
0.05),	I-Premise
self-efficacy	I-Premise
(p	I-Premise
<	I-Premise
0.05),	I-Premise
and	I-Premise
social	I-Premise
QOL	I-Premise
(p	I-Premise
<	I-Premise
0.01)	I-Premise
and	I-Premise
in	I-Premise
caregivers'	I-Premise
emotional	I-Premise
QOL	I-Premise
(p	I-Premise
<	I-Premise
0.05).	I-Premise

Effects	O
varied	O
by	O
intervention	O
dose.	O

Most	O
effects	O
were	O
found	O
at	O
3	O
months	O
only.	O

Risk	B-Premise
for	I-Premise
distress	I-Premise
accounted	I-Premise
for	I-Premise
very	I-Premise
few	I-Premise
moderation	I-Premise
effects.	I-Premise

Both	B-Premise
brief	I-Premise
and	I-Premise
extensive	I-Premise
programs	I-Premise
had	I-Premise
positive	I-Premise
outcomes	I-Premise
for	I-Premise
patient-caregiver	I-Premise
dyads,	I-Premise
but	B-Premise
few	I-Premise
sustained	I-Premise
effects.	I-Premise

Patient-caregiver	B-Claim
dyads	I-Claim
benefit	I-Claim
when	I-Claim
viewed	I-Claim
as	I-Claim
the	I-Claim
'unit	I-Claim
of	I-Claim
care'.	I-Claim

As	O
patients	O
with	O
pancreas	O
and	O
periampullary	O
cancer	O
(PPC)	O
experience	O
improved	O
survival	O
rates	O
and	O
longevity,	O
the	O
focus	O
shifts	O
toward	O
living	O
life	O
while	O
surviving	O
cancer.	O

Fatigue	O
is	O
the	O
most	O
commonly	O
reported	O
symptom	O
in	O
all	O
cancer	O
patients.	O

Exercise	O
has	O
been	O
found	O
to	O
effectively	O
decrease	O
fatigue	O
levels	O
and	O
improve	O
physical	O
functioning	O
in	O
cancer	O
patients.	O

One	O
hundred	O
two	O
patients	O
with	O
resected	O
PPC	O
consented	O
to	O
participate	O
in	O
this	O
study	O
and	O
were	O
randomized	O
to	O
either	O
an	O
intervention	O
group	O
(IG)	O
or	O
a	O
usual	O
care	O
group	O
(UCG).	O

Subjects	O
completed	O
visual	O
analog	O
scales,	O
the	O
FACIT-Fatigue	O
Scale	O
and	O
the	O
Short	O
Form-36v2	O
after	O
surgery	O
and	O
again	O
3	O
to	O
6	O
months	O
after	O
hospital	O
discharge.	O

Patients	O
in	O
the	O
IG	O
and	O
UCG	O
were	O
comparable	O
with	O
regard	O
to	O
demographics,	O
comorbidities,	O
cancer	O
type	O
and	O
staging,	O
type	O
of	O
resection,	O
preoperative	O
fatigue	O
and	O
pain	O
levels,	O
adjuvant	O
therapy,	O
and	O
baseline	O
walking	O
distance.	O

Patients	B-Premise
in	I-Premise
the	I-Premise
IG	I-Premise
had	I-Premise
significantly	I-Premise
improved	I-Premise
scores	I-Premise
on	I-Premise
the	I-Premise
FACIT-Fatigue	I-Premise
Scale	I-Premise
at	I-Premise
study	I-Premise
completion,	I-Premise
improved	I-Premise
fatigue	I-Premise
and	I-Premise
pain	I-Premise
scores,	I-Premise
as	I-Premise
well	I-Premise
as	I-Premise
overall	I-Premise
physical	I-Premise
functioning	I-Premise
and	I-Premise
mental	I-Premise
health	I-Premise
composite	I-Premise
scores.	I-Premise

At	B-Premise
study	I-Premise
completion,	I-Premise
participants	I-Premise
in	I-Premise
the	I-Premise
IG	I-Premise
were	I-Premise
walking	I-Premise
twice	I-Premise
as	I-Premise
far	I-Premise
and	I-Premise
were	I-Premise
significantly	I-Premise
more	I-Premise
likely	I-Premise
to	I-Premise
have	I-Premise
continued	I-Premise
walking	I-Premise
or	I-Premise
another	I-Premise
form	I-Premise
of	I-Premise
exercise	I-Premise
as	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
UCG.	I-Premise

Using	O
hierarchical	O
cluster	O
analysis,	O
3	O
mutually	O
exclusive	O
symptom	O
groupings	O
were	O
identified	O
in	O
the	O
cohort.	O

Kaplan-Meier	B-Premise
survival	I-Premise
analysis	I-Premise
did	I-Premise
not	I-Premise
indicate	I-Premise
an	I-Premise
overall	I-Premise
survival	I-Premise
benefit	I-Premise
for	I-Premise
the	I-Premise
IG.	I-Premise

This	B-Claim
is	I-Claim
the	I-Claim
first	I-Claim
prospective,	I-Claim
randomized	I-Claim
controlled	I-Claim
trial	I-Claim
to	I-Claim
report	I-Claim
that	I-Claim
participation	I-Claim
in	I-Claim
a	I-Claim
home	I-Claim
walking	I-Claim
program	I-Claim
confers	I-Claim
a	I-Claim
significant	I-Claim
benefit	I-Claim
in	I-Claim
resected	I-Claim
PPC	I-Claim
patients	I-Claim
with	I-Claim
regard	I-Claim
to	I-Claim
fatigue	I-Claim
levels,	I-Claim
physical	I-Claim
functioning,	I-Claim
and	I-Claim
health-related	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

Pemetrexed	O
maintenance	O
therapy	O
significantly	O
improved	O
overall	O
survival	O
and	O
progression-free	O
survival	O
compared	O
with	O
placebo,	O
and	O
had	O
a	O
good	O
safety	O
profile	O
in	O
a	O
phase	O
3	O
placebo-controlled	O
study	O
in	O
patients	O
with	O
advanced	O
non-small-cell	O
lung	O
cancer	O
(NSCLC).	O

Results	O
for	O
quality	O
of	O
life,	O
symptom	O
palliation,	O
and	O
tolerability	O
are	O
presented	O
here.	O

After	O
four	O
cycles	O
of	O
platinum-based	O
induction	O
therapy,	O
663	O
patients	O
with	O
stage	O
IIIB	O
or	O
stage	O
IV	O
NSCLC	O
and	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
of	O
0	O
or	O
1	O
were	O
randomly	O
assigned	O
(in	O
a	O
2:1	O
ratio)	O
from	O
March	O
15,	O
2005,	O
to	O
July	O
20,	O
2007,	O
using	O
the	O
Pocock	O
and	O
Simon	O
minimisation	O
method	O
to	O
receive	O
pemetrexed	O
(500	O
mg/m(2)	O
every	O
21	O
days;	O
n=441)	O
or	O
placebo	O
(n=222)	O
plus	O
best	O
supportive	O
care	O
until	O
disease	O
progression.	O

The	O
primary	O
efficacy	O
data	O
have	O
been	O
reported	O
previously.	O

Patients	O
completed	O
the	O
Lung	O
Cancer	O
Symptom	O
Scale	O
(LCSS)	O
at	O
baseline,	O
after	O
each	O
cycle,	O
and	O
post-discontinuation.	O

Worsening	O
of	O
symptoms	O
was	O
defined	O
as	O
an	O
increase	O
of	O
15	O
mm	O
or	O
more	O
from	O
baseline	O
on	O
a	O
100	O
mm	O
scale	O
for	O
each	O
LCSS	O
item.	O

The	O
primary	O
outcome	O
for	O
these	O
quality-of-life	O
analyses	O
was	O
time	O
to	O
worsening	O
of	O
symptoms,	O
analysed	O
for	O
all	O
randomised	O
patients.	O

Baseline	O
characteristics,	O
including	O
LCSS	O
scores,	O
were	O
well	O
balanced	O
between	O
groups.	O

Baseline	O
LCSS	O
scores	O
were	O
low,	O
indicating	O
low	O
symptom	O
burden	O
for	O
patients	O
without	O
disease	O
progression	O
after	O
completion	O
of	O
first-line	O
treatment.	O

Longer	B-Premise
time	I-Premise
to	I-Premise
worsening	I-Premise
was	I-Premise
recorded	I-Premise
for	I-Premise
pain	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR]	I-Premise
076,	I-Premise
95%	I-Premise
CI	I-Premise
059-099;	I-Premise
p=0041)	I-Premise
and	I-Premise
haemoptysis	I-Premise
(HR	I-Premise
058,	I-Premise
95%	I-Premise
CI	I-Premise
034-097;	I-Premise
p=0038)	I-Premise
with	I-Premise
pemetrexed	I-Premise
than	I-Premise
with	I-Premise
placebo;	I-Premise
no	B-Premise
other	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
analyses	I-Premise
of	I-Premise
time	I-Premise
to	I-Premise
worsening	I-Premise
were	I-Premise
noted.	I-Premise

Additional	B-Premise
longitudinal	I-Premise
analyses	I-Premise
showed	I-Premise
a	I-Premise
greater	I-Premise
increase	I-Premise
in	I-Premise
loss	I-Premise
of	I-Premise
appetite	I-Premise
in	I-Premise
the	I-Premise
pemetrexed	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group	I-Premise
(43	I-Premise
mm	I-Premise
vs	I-Premise
02	I-Premise
mm;	I-Premise
p=0028).	I-Premise

Rates	B-Premise
of	I-Premise
resource	I-Premise
use	I-Premise
were	I-Premise
statistically	I-Premise
higher	I-Premise
for	I-Premise
pemetrexed	I-Premise
than	I-Premise
for	I-Premise
placebo:	I-Premise
admissions	I-Premise
to	I-Premise
hospital	I-Premise
for	I-Premise
drug-related	I-Premise
adverse	I-Premise
events	I-Premise
(19	I-Premise
[4%]	I-Premise
vs	I-Premise
none;	I-Premise
p=0001),	I-Premise
transfusions	I-Premise
(42	I-Premise
[10%]	I-Premise
vs	I-Premise
seven	I-Premise
[3%];	I-Premise
p=0003),	I-Premise
and	I-Premise
erythropoiesis-stimulating	I-Premise
agents	I-Premise
(26	I-Premise
[6%]	I-Premise
vs	I-Premise
four	I-Premise
[2%];	I-Premise
p=0017).	I-Premise

Quality	B-Claim
of	I-Claim
life	I-Claim
during	I-Claim
maintenance	I-Claim
therapy	I-Claim
with	I-Claim
pemetrexed	I-Claim
is	I-Claim
similar	I-Claim
to	I-Claim
placebo,	I-Claim
except	B-Claim
for	I-Claim
a	I-Claim
small	I-Claim
increase	I-Claim
in	I-Claim
loss	I-Claim
of	I-Claim
appetite,	I-Claim
and	I-Claim
significantly	I-Claim
delayed	I-Claim
worsening	I-Claim
of	I-Claim
pain	I-Claim
and	I-Claim
haemoptysis.	I-Claim

In	O
view	O
of	O
the	O
improvements	O
in	O
overall	O
and	O
progression-free	O
survival	O
noted	O
with	O
pemetrexed	O
maintenance	O
therapy,	O
such	B-Claim
treatment	I-Claim
is	I-Claim
an	I-Claim
option	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
non-squamous	I-Claim
NSCLC	I-Claim
who	I-Claim
have	I-Claim
not	I-Claim
progressed	I-Claim
after	I-Claim
platinum-based	I-Claim
induction	I-Claim
therapy.	I-Claim

Topical	O
photodynamic	O
therapy	O
(PDT)	O
with	O
aminolevulinic	O
acid	O
(ALA)	O
and	O
5%	O
imiquimod	O
cream	O
are	O
effective	O
therapies	O
for	O
the	O
treatment	O
of	O
actinic	O
keratoses	O
(AKs),	O
but	O
no	O
split-face	O
studies	O
directly	O
comparing	O
these	O
treatment	O
options	O
are	O
available	O
in	O
the	O
literature.	O

To	O
compare	O
the	O
efficacy	O
and	O
tolerability	O
of	O
ALA-PDT	O
and	O
imiquimod	O
5%	O
cream	O
for	O
the	O
treatment	O
of	O
AKs.	O

Sixty-one	O
patients	O
were	O
enrolled	O
from	O
the	O
Salt	O
Lake	O
City	O
Veterans	O
Affairs	O
Hospital;	O
51	O
completed	O
the	O
study	O
and	O
were	O
included	O
in	O
the	O
analysis.	O

All	O
patients	O
were	O
randomized	O
to	O
receive	O
half	O
of	O
a	O
sachet	O
of	O
imiquimod	O
5%	O
cream	O
twice	O
weekly	O
on	O
half	O
of	O
their	O
face	O
and	O
two	O
sessions	O
of	O
PDT	O
with	O
20%	O
solution	O
of	O
ALA	O
applied	O
for	O
1	O
hour	O
to	O
the	O
other	O
side	O
of	O
the	O
face.	O

The	B-Premise
75%	I-Premise
AK	I-Premise
clearance	I-Premise
rate	I-Premise
was	I-Premise
34.6%	I-Premise
for	I-Premise
ALA-PDT	I-Premise
and	I-Premise
25%	I-Premise
for	I-Premise
imiquimod	I-Premise
5%	I-Premise
cream	I-Premise
(p	I-Premise
=	I-Premise
.30).	I-Premise

The	B-Premise
mean	I-Premise
reduction	I-Premise
in	I-Premise
AK	I-Premise
count	I-Premise
was	I-Premise
59.2%	I-Premise
for	I-Premise
ALA-PDT	I-Premise
and	I-Premise
41.4%	I-Premise
for	I-Premise
imiquimod	I-Premise
5%	I-Premise
cream	I-Premise
(p	I-Premise
=	I-Premise
.002).	I-Premise

Dermatology	B-Premise
Life	I-Premise
Quality	I-Premise
Index	I-Premise
(DLQI)	I-Premise
scores	I-Premise
were	I-Premise
assessed	I-Premise
for	I-Premise
each	I-Premise
treatment	I-Premise
modality	I-Premise
at	I-Premise
week	I-Premise
4	I-Premise
and	I-Premise
were	I-Premise
1.95	I-Premise
and	I-Premise
1.38,	I-Premise
respectively	I-Premise
(p	I-Premise
=	I-Premise
.20).	I-Premise

The	B-Premise
sample	I-Premise
size	I-Premise
was	I-Premise
small,	I-Premise
and	I-Premise
patients	I-Premise
applied	I-Premise
a	I-Premise
small	I-Premise
amount	I-Premise
of	I-Premise
imiquimod	I-Premise
5%	I-Premise
cream	I-Premise
(half	I-Premise
a	I-Premise
sachet)	I-Premise
to	I-Premise
a	I-Premise
large	I-Premise
surface	I-Premise
area.	I-Premise

There	B-Claim
was	I-Claim
no	I-Claim
statistically	I-Claim
significant	I-Claim
difference	I-Claim
in	I-Claim
treatment	I-Claim
response	I-Claim
when	I-Claim
the	I-Claim
100%	I-Claim
or	I-Claim
75%	I-Claim
clearance	I-Claim
rate	I-Claim
cutoff	I-Claim
was	I-Claim
used,	I-Claim
but	B-Claim
our	I-Claim
secondary	I-Claim
outcome	I-Claim
suggests	I-Claim
that	I-Claim
two	I-Claim
sessions	I-Claim
of	I-Claim
ALA-PDT	I-Claim
is	I-Claim
superior	I-Claim
to	I-Claim
imiquimod	I-Claim
5%	I-Claim
cream	I-Claim
for	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
AKs.	I-Claim

There	B-Claim
was	I-Claim
no	I-Claim
statistically	I-Claim
significant	I-Claim
difference	I-Claim
in	I-Claim
effect	I-Claim
on	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
as	I-Claim
assessed	I-Claim
using	I-Claim
the	I-Claim
DLQI.	I-Claim

Hot	O
flushes	O
and	O
night	O
sweats	O
(HFNS)	O
affect	O
65-85%	O
of	O
women	O
after	O
breast	O
cancer	O
treatment;	O
they	O
are	O
distressing,	O
causing	O
sleep	O
problems	O
and	O
decreased	O
quality	O
of	O
life.	O

Hormone	B-Claim
replacement	I-Claim
therapy	I-Claim
is	I-Claim
often	I-Claim
either	I-Claim
undesirable	I-Claim
or	I-Claim
contraindicated.	I-Claim

Safe,	B-Claim
effective	I-Claim
non-hormonal	I-Claim
treatments	I-Claim
are	I-Claim
needed.	I-Claim

We	O
investigated	O
whether	O
cognitive	O
behavioural	O
therapy	O
(CBT)	O
can	O
help	O
breast	O
cancer	O
survivors	O
to	O
effectively	O
manage	O
HFNS.	O

In	O
this	O
randomised	O
controlled	O
trial,	O
we	O
recruited	O
women	O
from	O
breast	O
clinics	O
in	O
London,	O
UK,	O
who	O
had	O
problematic	O
HFNS	O
(minimum	O
ten	O
problematic	O
episodes	O
a	O
week)	O
after	O
breast-cancer	O
treatment.	O

Participants	O
were	O
randomly	O
allocated	O
to	O
receive	O
either	O
usual	O
care	O
or	O
usual	O
care	O
plus	O
group	O
CBT	O
(1:1).	O

Randomisation	O
was	O
done	O
in	O
blocks	O
of	O
12-20	O
participants,	O
stratifying	O
by	O
age	O
(younger	O
than	O
50	O
years,	O
50	O
years	O
or	O
older),	O
and	O
was	O
done	O
with	O
a	O
computer-generated	O
sequence.	O

The	O
trial	O
statistician	O
and	O
researchers	O
collecting	O
outcome	O
measures	O
were	O
masked	O
to	O
group	O
allocation.	O

Group	O
CBT	O
comprised	O
one	O
90	O
min	O
session	O
a	O
week	O
for	O
6	O
weeks,	O
and	O
included	O
psycho-education,	O
paced	O
breathing,	O
and	O
cognitive	O
and	O
behavioural	O
strategies	O
to	O
manage	O
HFNS.	O

Assessments	O
were	O
done	O
at	O
baseline,	O
9	O
weeks,	O
and	O
26	O
weeks	O
after	O
randomisation.	O

The	O
primary	O
outcome	O
was	O
the	O
adjusted	O
mean	O
difference	O
in	O
HFNS	O
problem	O
rating	O
(1-10)	O
between	O
CBT	O
and	O
usual	O
care	O
groups	O
at	O
9	O
weeks	O
after	O
randomisation.	O

Analysis	O
of	O
the	O
primary	O
endpoint	O
was	O
done	O
by	O
modified	O
intention	O
to	O
treat.	O

The	O
trial	O
is	O
registered,	O
ISRCTN13771934,	O
and	O
was	O
closed	O
March	O
15,	O
2011.	O

Between	O
May	O
5,	O
2009,	O
and	O
Aug	O
27,	O
2010,	O
96	O
women	O
were	O
randomly	O
allocated	O
to	O
group	O
CBT	O
(n=47)	O
or	O
usual	O
care	O
(n=49).	O

Group	B-Premise
CBT	I-Premise
significantly	I-Premise
reduced	I-Premise
HFNS	I-Premise
problem	I-Premise
rating	I-Premise
at	I-Premise
9	I-Premise
weeks	I-Premise
after	I-Premise
randomisation	I-Premise
compared	I-Premise
with	I-Premise
usual	I-Premise
care	I-Premise
(mean	I-Premise
difference	I-Premise
-167,	I-Premise
95%	I-Premise
CI	I-Premise
-243	I-Premise
to	I-Premise
-091;	I-Premise
p<00001)	I-Premise
and	I-Premise
improvements	I-Premise
were	I-Premise
maintained	I-Premise
at	I-Premise
26	I-Premise
weeks	I-Premise
(mean	I-Premise
difference	I-Premise
-176,	I-Premise
-254	I-Premise
to	I-Premise
-099;	I-Premise
p<00001).	I-Premise

We	B-Premise
recorded	I-Premise
no	I-Premise
CBT-related	I-Premise
adverse	I-Premise
events.	I-Premise

Group	B-Claim
CBT	I-Claim
seems	I-Claim
to	I-Claim
be	I-Claim
a	I-Claim
safe	I-Claim
and	I-Claim
effective	I-Claim
treatment	I-Claim
for	I-Claim
women	I-Claim
who	I-Claim
have	I-Claim
problematic	I-Claim
HFNS	I-Claim
after	I-Claim
breast	I-Claim
cancer	I-Claim
treatment	I-Claim
with	I-Claim
additional	I-Claim
benefits	I-Claim
to	I-Claim
mood,	I-Claim
sleep,	I-Claim
and	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

The	O
treatment	O
could	O
be	O
incorporated	O
into	O
breast	O
cancer	O
survivorship	O
programmes	O
and	O
delivered	O
by	O
trained	O
breast	O
cancer	O
nurses.	O

To	O
evaluate	O
the	O
analgesic	O
effect,	O
safety,	O
and	O
cost-effectiveness	O
of	O
controlled-release	O
oxycodone	O
(CRO)	O
to	O
control	O
postoperative	O
pain	O
in	O
patients	O
with	O
liver	O
cancer	O
who	O
are	O
undergoing	O
transarterial	O
chemoembolization.	O

This	O
randomized,	O
double-blind,	O
placebo-controlled,	O
prospective	O
clinical	O
study	O
received	O
institutional	O
review	O
board	O
approval.	O

After	O
written	O
informed	O
consent	O
was	O
obtained,	O
210	O
patients	O
with	O
liver	O
cancer	O
were	O
randomized	O
into	O
three	O
groups	O
of	O
70	O
patients.	O

Group	O
1	O
received	O
20	O
mg	O
of	O
CRO,	O
group	O
2	O
received	O
10	O
mg	O
of	O
CRO,	O
and	O
group	O
3	O
received	O
a	O
placebo	O
at	O
1	O
hour	O
before	O
transarterial	O
chemoembolization	O
(T(0))	O
and	O
12	O
(T(12))	O
and	O
24	O
(T(24))	O
hours	O
after	O
T(0).	O

Pain	O
intensity	O
on	O
a	O
numeric	O
rating	O
scale,	O
percentage	O
of	O
patients	O
with	O
each	O
degree	O
of	O
pain,	O
quality	O
of	O
life,	O
adverse	O
reactions,	O
analgesic	O
costs,	O
and	O
hospital	O
stays	O
were	O
evaluated	O
and	O
compared	O
among	O
the	O
three	O
groups.	O

Numeric	B-Premise
rating	I-Premise
scale	I-Premise
scores	I-Premise
for	I-Premise
pain	I-Premise
intensity	I-Premise
in	I-Premise
group	I-Premise
1	I-Premise
and	I-Premise
group	I-Premise
2	I-Premise
were	I-Premise
significantly	I-Premise
lower	I-Premise
than	I-Premise
those	I-Premise
in	I-Premise
group	I-Premise
3	I-Premise
at	I-Premise
T(0-12)	I-Premise
(P	I-Premise
<	I-Premise
.001);	I-Premise
T(12-24)	I-Premise
(P	I-Premise
<	I-Premise
.001);	I-Premise
and	I-Premise
T(24-48)	I-Premise
(P	I-Premise
<	I-Premise
.001).	I-Premise

When	B-Premise
group	I-Premise
1	I-Premise
with	I-Premise
group	I-Premise
2	I-Premise
were	I-Premise
compared,	I-Premise
numeric	I-Premise
rating	I-Premise
scale	I-Premise
scores	I-Premise
were	I-Premise
significantly	I-Premise
lower	I-Premise
in	I-Premise
group	I-Premise
1	I-Premise
than	I-Premise
in	I-Premise
group	I-Premise
2	I-Premise
during	I-Premise
the	I-Premise
period	I-Premise
of	I-Premise
T(0-12)	I-Premise
(P	I-Premise
<	I-Premise
.001)	I-Premise
but	B-Premise
were	I-Premise
not	I-Premise
significantly	I-Premise
different	I-Premise
at	I-Premise
T(12-24)	I-Premise
(P	I-Premise
=	I-Premise
.68)	I-Premise
and	I-Premise
T(24-48)	I-Premise
(P	I-Premise
=	I-Premise
.10).	I-Premise

Analgesic	B-Premise
cost	I-Premise
and	I-Premise
hospital	I-Premise
stay	I-Premise
were	I-Premise
significantly	I-Premise
lower	I-Premise
in	I-Premise
treated	I-Premise
groups	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group.	I-Premise

No	B-Premise
significant	I-Premise
difference	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
and	I-Premise
adverse	I-Premise
events	I-Premise
between	I-Premise
the	I-Premise
treated	I-Premise
groups	I-Premise
and	I-Premise
the	I-Premise
placebo	I-Premise
group.	I-Premise

CRO	B-Claim
is	I-Claim
effective,	I-Claim
safe,	I-Claim
and	I-Claim
cost-effective	I-Claim
in	I-Claim
the	I-Claim
control	I-Claim
of	I-Claim
postoperative	I-Claim
pain	I-Claim
after	I-Claim
transarterial	I-Claim
chemoembolization	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
inoperable	I-Claim
liver	I-Claim
cancer.	I-Claim

Gefitinib	O
has	O
shown	O
high	O
response	O
rate	O
and	O
improved	O
progression-free	O
survival	O
(PFS)	O
in	O
never-smokers	O
with	O
lung	O
adenocarcinoma	O
(NSLAs).	O

We	O
compared	O
efficacy	O
of	O
gefitinib	O
with	O
gemcitabine	O
and	O
cisplatin	O
(GP)	O
chemotherapy	O
in	O
this	O
group	O
of	O
patients	O
as	O
first-line	O
therapy.	O

In	O
this	O
randomized	O
phase	O
III	O
trial,	O
a	O
total	O
of	O
313	O
Korean	O
never-smokers	O
with	O
stage	O
IIIB	O
or	O
IV	O
lung	O
adenocarcinoma,	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
0	O
to	O
2,	O
and	O
adequate	O
organ	O
function	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
gefitinib	O
(250	O
mg	O
daily)	O
or	O
GP	O
chemotherapy	O
(gemcitabine	O
1,250	O
mg/m(2)	O
on	O
days	O
1	O
and	O
8;	O
cisplatin	O
80	O
mg/m(2)	O
on	O
day	O
1	O
every	O
3	O
weeks,	O
for	O
up	O
to	O
nine	O
courses).	O

The	O
primary	O
objective	O
was	O
to	O
demonstrate	O
better	O
overall	O
survival	O
(OS)	O
for	O
gefitinib	O
compared	O
with	O
GP	O
in	O
chemotherapy-naive	O
NSLAs.	O

Three	O
hundred	O
nine	O
patients	O
were	O
analyzed	O
per	O
protocol	O
(gefitinib	O
arm,	O
n	O
=	O
159;	O
GP	O
arm,	O
n	O
=	O
150).	O

Gefitinib	B-Premise
did	I-Premise
not	I-Premise
show	I-Premise
better	I-Premise
OS	I-Premise
compared	I-Premise
with	I-Premise
GP	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR],	I-Premise
0.932;	I-Premise
95%	I-Premise
CI,	I-Premise
0.716	I-Premise
to	I-Premise
1.213;	I-Premise
P	I-Premise
=	I-Premise
.604;	I-Premise
median	I-Premise
OS,	I-Premise
22.3	I-Premise
v	I-Premise
22.9	I-Premise
months,	I-Premise
respectively).	I-Premise

The	B-Premise
1-year	I-Premise
PFS	I-Premise
rates	I-Premise
were	I-Premise
16.7%	I-Premise
with	I-Premise
gefitinib	I-Premise
and	I-Premise
2.8%	I-Premise
with	I-Premise
GP	I-Premise
(HR,	I-Premise
1.198;	I-Premise
95%	I-Premise
CI,	I-Premise
0.944	I-Premise
to	I-Premise
1.520).	I-Premise

Response	B-Premise
rates	I-Premise
were	I-Premise
55%	I-Premise
with	I-Premise
gefitinib	I-Premise
and	I-Premise
46%	I-Premise
with	I-Premise
GP	I-Premise
(P	I-Premise
=	I-Premise
.101).	I-Premise

Myelosuppression,	B-Premise
renal	I-Premise
insufficiency,	I-Premise
and	I-Premise
fatigue	I-Premise
were	I-Premise
more	I-Premise
common	I-Premise
in	I-Premise
the	I-Premise
GP	I-Premise
arm,	I-Premise
but	O
skin	B-Premise
toxicities	I-Premise
and	I-Premise
liver	I-Premise
dysfunction	I-Premise
were	I-Premise
more	I-Premise
common	I-Premise
in	I-Premise
the	I-Premise
gefitinib	I-Premise
arm.	I-Premise

Two	B-Premise
patients	I-Premise
(1.3%)	I-Premise
in	I-Premise
the	I-Premise
gefitinib	I-Premise
arm	I-Premise
developed	I-Premise
interstitial	I-Premise
lung	I-Premise
disease	I-Premise
and	I-Premise
died.	I-Premise

Gefitinib	B-Claim
failed	I-Claim
to	I-Claim
demonstrate	I-Claim
superior	I-Claim
OS	I-Claim
compared	I-Claim
with	I-Claim
GP	I-Claim
as	I-Claim
first-line	I-Claim
therapy	I-Claim
for	I-Claim
NSLAs.	I-Claim

Spiritual	O
well-being	O
and	O
sense	O
of	O
meaning	O
are	O
important	O
concerns	O
for	O
clinicians	O
who	O
care	O
for	O
patients	O
with	O
cancer.	O

We	O
developed	O
Individual	O
Meaning-Centered	O
Psychotherapy	O
(IMCP)	O
to	O
address	O
the	O
need	O
for	O
brief	O
interventions	O
targeting	O
spiritual	O
well-being	O
and	O
meaning	O
for	O
patients	O
with	O
advanced	O
cancer.	O

Patients	O
with	O
stage	O
III	O
or	O
IV	O
cancer	O
(N	O
=	O
120)	O
were	O
randomly	O
assigned	O
to	O
seven	O
sessions	O
of	O
either	O
IMCP	O
or	O
therapeutic	O
massage	O
(TM).	O

Patients	O
were	O
assessed	O
before	O
and	O
after	O
completing	O
the	O
intervention	O
and	O
2	O
months	O
postintervention.	O

Primary	O
outcome	O
measures	O
assessed	O
spiritual	O
well-being	O
and	O
quality	O
of	O
life;	O
secondary	O
outcomes	O
included	O
anxiety,	O
depression,	O
hopelessness,	O
symptom	O
burden,	O
and	O
symptom-related	O
distress.	O

Of	O
the	O
120	O
participants	O
randomly	O
assigned,	O
78	O
(65%)	O
completed	O
the	O
post-treatment	O
assessment	O
and	O
67	O
(56%)	O
completed	O
the	O
2-month	O
follow-up.	O

At	B-Premise
the	I-Premise
post-treatment	I-Premise
assessment,	I-Premise
IMCP	I-Premise
participants	I-Premise
demonstrated	I-Premise
significantly	I-Premise
greater	I-Premise
improvement	I-Premise
than	I-Premise
the	I-Premise
control	I-Premise
condition	I-Premise
for	I-Premise
the	I-Premise
primary	I-Premise
outcomes	I-Premise
of	I-Premise
spiritual	I-Premise
well-being	I-Premise
(b	I-Premise
=	I-Premise
0.39;	I-Premise
P	I-Premise
<.001,	I-Premise
including	I-Premise
both	I-Premise
components	I-Premise
of	I-Premise
spiritual	I-Premise
well-being	I-Premise
(sense	I-Premise
of	I-Premise
meaning:	I-Premise
b	I-Premise
=	I-Premise
0.34;	I-Premise
P	I-Premise
=	I-Premise
.003	I-Premise
and	I-Premise
faith:	I-Premise
b	I-Premise
=	I-Premise
0.42;	I-Premise
P	I-Premise
=	I-Premise
.03),	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(b	I-Premise
=	I-Premise
0.76;	I-Premise
P	I-Premise
=	I-Premise
.013).	I-Premise

Significantly	B-Premise
greater	I-Premise
improvements	I-Premise
for	I-Premise
IMCP	I-Premise
patients	I-Premise
were	I-Premise
also	I-Premise
observed	I-Premise
for	I-Premise
the	I-Premise
secondary	I-Premise
outcomes	I-Premise
of	I-Premise
symptom	I-Premise
burden	I-Premise
(b	I-Premise
=	I-Premise
-6.56;	I-Premise
P	I-Premise
<	I-Premise
.001)	I-Premise
and	I-Premise
symptom-related	I-Premise
distress	I-Premise
(b	I-Premise
=	I-Premise
-0.47;	I-Premise
P	I-Premise
<	I-Premise
.001)	I-Premise
but	I-Premise
not	I-Premise
for	I-Premise
anxiety,	I-Premise
depression,	I-Premise
or	I-Premise
hopelessness.	I-Premise

At	B-Premise
the	I-Premise
2-month	I-Premise
follow-up	I-Premise
assessment,	I-Premise
the	I-Premise
improvements	I-Premise
observed	I-Premise
for	I-Premise
the	I-Premise
IMCP	I-Premise
group	I-Premise
were	I-Premise
no	I-Premise
longer	I-Premise
significantly	I-Premise
greater	I-Premise
than	I-Premise
those	I-Premise
observed	I-Premise
for	I-Premise
the	I-Premise
TM	I-Premise
group.	I-Premise

IMCP	B-Claim
has	I-Claim
clear	I-Claim
short-term	I-Claim
benefits	I-Claim
for	I-Claim
spiritual	I-Claim
suffering	I-Claim
and	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
cancer.	I-Claim

Clinicians	O
working	O
with	O
patients	O
who	O
have	O
advanced	O
cancer	O
should	O
consider	O
IMCP	O
as	O
an	O
approach	O
to	O
enhance	O
quality	O
of	O
life	O
and	O
spiritual	O
well-being.	O

To	O
determine	O
whether	O
an	O
Internet-based	B-Claim
tailored	I-Claim
education	I-Claim
program	I-Claim
is	I-Claim
effective	I-Claim
for	I-Claim
disease-free	I-Claim
cancer	I-Claim
survivors	I-Claim
with	I-Claim
cancer-related	I-Claim
fatigue	I-Claim
(CRF).	I-Claim

We	O
randomly	O
assigned	O
patients	O
who	O
had	O
completed	O
primary	O
cancer	O
treatment	O
within	O
the	O
past	O
24	O
months	O
in	O
any	O
of	O
four	O
Korean	O
hospitals	O
and	O
had	O
reported	O
moderate	O
to	O
severe	O
fatigue	O
for	O
at	O
least	O
1	O
week	O
to	O
participate	O
in	O
a	O
12-week,	O
Internet-based,	O
individually	O
tailored	O
CRF	O
education	O
program	O
or	O
to	O
receive	O
routine	O
care.	O

We	O
based	O
the	O
program	O
on	O
the	O
CRF	O
guidelines	O
of	O
the	O
National	O
Comprehensive	O
Cancer	O
Network	O
(NCCN)	O
and	O
incorporated	O
the	O
transtheoretic	O
model	O
(TTM).	O

At	O
baseline	O
and	O
12	O
weeks,	O
we	O
used	O
the	O
Brief	O
Fatigue	O
Inventory	O
(BFI)	O
and	O
Fatigue	O
Severity	O
Scale	O
(FSS)	O
as	O
primary	O
outcomes	O
and	O
the	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
(HADS)	O
and	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
C30	O
(EORTC	O
QLQ-C30)	O
for	O
secondary	O
outcomes.	O

We	O
recruited	O
273	O
participants	O
and	O
randomly	O
assigned	O
136	O
to	O
the	O
intervention	O
group.	O

Compared	B-Premise
with	I-Premise
the	I-Premise
control	I-Premise
group,	I-Premise
the	I-Premise
intervention	I-Premise
group	I-Premise
had	I-Premise
an	I-Premise
improvement	I-Premise
in	I-Premise
fatigue	I-Premise
as	I-Premise
shown	I-Premise
by	I-Premise
a	I-Premise
significantly	I-Premise
greater	I-Premise
decrease	I-Premise
in	I-Premise
BFI	I-Premise
global	I-Premise
score	I-Premise
(-0.66	I-Premise
points;	I-Premise
95%	I-Premise
CI	I-Premise
-1.04	I-Premise
to	I-Premise
-0.27)	I-Premise
and	I-Premise
FSS	I-Premise
total	I-Premise
score	I-Premise
(-0.49;	I-Premise
95%	I-Premise
CI,	I-Premise
-0.78	I-Premise
to	I-Premise
-0.21).	I-Premise

In	B-Premise
secondary	I-Premise
outcomes,	I-Premise
the	I-Premise
intervention	I-Premise
group	I-Premise
experienced	I-Premise
a	I-Premise
significantly	I-Premise
greater	I-Premise
decrease	I-Premise
in	I-Premise
HADS	I-Premise
anxiety	I-Premise
score	I-Premise
(-0.90;	I-Premise
95%	I-Premise
CI,	I-Premise
-1.51	I-Premise
to	I-Premise
-0.29)	I-Premise
as	I-Premise
well	I-Premise
as	I-Premise
global	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(5.22;	I-Premise
95%	I-Premise
CI,	I-Premise
0.93	I-Premise
to	I-Premise
9.50)	I-Premise
and	I-Premise
several	I-Premise
functioning	I-Premise
scores	I-Premise
of	I-Premise
the	I-Premise
EORTC	I-Premise
QLQ-C30.	I-Premise

An	B-Claim
Internet-based	I-Claim
education	I-Claim
program	I-Claim
based	I-Claim
on	I-Claim
NCCN	I-Claim
guidelines	I-Claim
and	I-Claim
TTM	I-Claim
may	I-Claim
help	I-Claim
patients	I-Claim
manage	I-Claim
CRF.	I-Claim

To	O
assess	O
the	O
effectiveness	O
of	O
mindfulness-based	O
stress	O
reduction	O
(MBSR)	O
for	O
mood,	O
breast-	O
and	O
endocrine-specific	O
quality	O
of	O
life,	O
and	O
well-being	O
after	O
hospital	O
treatment	O
in	O
women	O
with	O
stage	O
0	O
to	O
III	O
breast	O
cancer.	O

A	O
randomized,	O
wait-listed,	O
controlled	O
trial	O
was	O
carried	O
out	O
in	O
229	O
women	O
after	O
surgery,	O
chemotherapy,	O
and	O
radiotherapy	O
for	O
breast	O
cancer.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
the	O
8-week	O
MBSR	O
program	O
or	O
standard	O
care.	O

Profile	O
of	O
Mood	O
States	O
(POMS;	O
primary	O
outcome),	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Breast	O
(FACT-B),	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Endocrine	O
Symptoms	O
(FACT-ES)	O
scales	O
and	O
the	O
WHO	O
five-item	O
well-being	O
questionnaire	O
(WHO-5)	O
evaluated	O
mood,	O
quality	O
of	O
life,	O
and	O
well-being	O
at	O
weeks	O
0,	O
8,	O
and	O
12.	O

For	O
each	O
outcome	O
measure,	O
a	O
repeated-measures	O
analysis	O
of	O
variance	O
model,	O
which	O
incorporated	O
week	O
0	O
measurements	O
as	O
a	O
covariate,	O
was	O
used	O
to	O
compare	O
treatment	O
groups	O
at	O
8	O
and	O
12	O
weeks.	O

There	B-Premise
were	I-Premise
statistically	I-Premise
significant	I-Premise
improvements	I-Premise
in	I-Premise
outcome	I-Premise
in	I-Premise
the	I-Premise
experimental	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
control	I-Premise
group	I-Premise
at	I-Premise
both	I-Premise
8	I-Premise
and	I-Premise
12	I-Premise
weeks	I-Premise
(except	I-Premise
as	I-Premise
indicated)	I-Premise
for	I-Premise
POMS	I-Premise
total	I-Premise
mood	I-Premise
disturbance	I-Premise
(and	I-Premise
its	I-Premise
subscales	I-Premise
of	I-Premise
anxiety,	I-Premise
depression	I-Premise
[8	I-Premise
weeks	I-Premise
only],	I-Premise
anger	I-Premise
[12	I-Premise
weeks	I-Premise
only],	I-Premise
vigor,	I-Premise
fatigue,	I-Premise
and	I-Premise
confusion	I-Premise
[8	I-Premise
weeks	I-Premise
only]),	I-Premise
FACT-B,	I-Premise
FACT-ES,	I-Premise
(and	I-Premise
Functional	I-Premise
Assessment	I-Premise
of	I-Premise
Cancer	I-Premise
Therapy	I-Premise
subscales	I-Premise
of	I-Premise
physical,	I-Premise
social	I-Premise
[8	I-Premise
weeks	I-Premise
only],	I-Premise
emotional,	I-Premise
and	I-Premise
functional	I-Premise
well-being),	I-Premise
and	I-Premise
WHO-5.	I-Premise

MSBR	B-Premise
improved	I-Premise
mood,	I-Premise
breast-	I-Premise
and	I-Premise
endocrine-related	I-Premise
quality	I-Premise
of	I-Premise
life,	I-Premise
and	I-Premise
well-being	I-Premise
more	I-Premise
effectively	I-Premise
than	I-Premise
standard	I-Premise
care	I-Premise
in	I-Premise
women	I-Premise
with	I-Premise
stage	I-Premise
0	I-Premise
to	I-Premise
III	I-Premise
breast	I-Premise
cancer,	I-Premise
and	I-Premise
these	I-Premise
results	I-Premise
persisted	I-Premise
at	I-Premise
three	I-Premise
months.	I-Premise

To	B-Claim
our	I-Claim
knowledge,	I-Claim
this	I-Claim
study	I-Claim
provided	I-Claim
novel	I-Claim
evidence	I-Claim
that	I-Claim
MBSR	I-Claim
can	I-Claim
help	I-Claim
alleviate	I-Claim
long-term	I-Claim
emotional	I-Claim
and	I-Claim
physical	I-Claim
adverse	I-Claim
effects	I-Claim
of	I-Claim
medical	I-Claim
treatments,	I-Claim
including	I-Claim
endocrine	I-Claim
treatments.	I-Claim

MBSR	B-Claim
is	I-Claim
recommended	I-Claim
to	I-Claim
support	I-Claim
survivors	I-Claim
of	I-Claim
breast	I-Claim
cancer.	I-Claim

This	O
study	O
examined	O
the	O
feasibility	O
and	O
acceptability	O
of	O
an	O
Individual	O
Internet	O
Intervention	O
(III)	O
embedded	O
and	O
integrated	O
into	O
an	O
Internet	O
Support	O
Group	O
(ISG)	O
with	O
the	O
ultimate	O
goal	O
of	O
enhancing	O
adherence	O
and	O
learning,	O
compared	O
with	O
an	O
individual	O
internet	O
invention	O
alone.	O

Thirty-one	O
posttreatment	O
cancer	O
survivors	O
were	O
randomized	O
in	O
groups	O
of	O
seven	O
to	O
nine	O
to	O
either	O
the	O
8-week	O
III	O
+	O
ISG	O
intervention	O
or	O
the	O
8-week	O
III	O
condition.	O

Seventeen	O
participants	O
met	O
the	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale	O
(HADS)	O
criteria	O
for	O
depressive	O
symptoms	O
(HADS	O
	O
8).	O

Among	O
all	O
participants,	O
the	O
mean	O
number	O
of	O
logins	O
over	O
8	O
weeks	O
was	O
20.8	O
	O
17.7	O
logins	O
for	O
the	O
III	O
+	O
ISG	O
compared	O
with	O
12.5	O
	O
12.5	O
in	O
III-only	O
(p	O
=	O
0.15).	O

Two	O
participants	O
in	O
the	O
III	O
+	O
ISG	O
dropped	O
out,	O
compared	O
with	O
five	O
in	O
III	O
(p	O
=	O
0.39).	O

Among	B-Premise
the	I-Premise
17	I-Premise
participants	I-Premise
with	I-Premise
depressive	I-Premise
symptoms	I-Premise
at	I-Premise
baseline,	I-Premise
both	I-Premise
the	I-Premise
Onward	I-Premise
and	I-Premise
the	I-Premise
III-only	I-Premise
condition	I-Premise
showed	I-Premise
large	I-Premise
reductions	I-Premise
in	I-Premise
the	I-Premise
depression	I-Premise
scale	I-Premise
of	I-Premise
HADS	I-Premise
(d	I-Premise
=	I-Premise
1.27	I-Premise
and	I-Premise
0.89,	I-Premise
respectively).	I-Premise

Improvement	B-Premise
over	I-Premise
time	I-Premise
and	I-Premise
time	I-Premise
x	I-Premise
treatment	I-Premise
effects	I-Premise
only	I-Premise
reached	I-Premise
trend	I-Premise
significance	I-Premise
levels	I-Premise
(ps	I-Premise
=	I-Premise
0.07	I-Premise
&amp;	I-Premise
0.12)	I-Premise
as	I-Premise
this	I-Premise
pilot	I-Premise
was	I-Premise
not	I-Premise
powered	I-Premise
to	I-Premise
detect	I-Premise
these	I-Premise
differences.	I-Premise

Both	B-Claim
the	I-Claim
III	I-Claim
+	I-Claim
ISG	I-Claim
and	I-Claim
III-only	I-Claim
demonstrated	I-Claim
pre-post	I-Claim
reductions	I-Claim
in	I-Claim
depressive	I-Claim
symptoms	I-Claim
and	I-Claim
high	I-Claim
rates	I-Claim
of	I-Claim
utilization	I-Claim
compared	I-Claim
with	I-Claim
other	I-Claim
web-based	I-Claim
treatments	I-Claim
for	I-Claim
depression.	I-Claim

Although	B-Claim
it	I-Claim
is	I-Claim
premature	I-Claim
to	I-Claim
make	I-Claim
any	I-Claim
determination	I-Claim
as	I-Claim
to	I-Claim
the	I-Claim
efficacy	I-Claim
of	I-Claim
the	I-Claim
interventions	I-Claim
tested	I-Claim
in	I-Claim
this	I-Claim
feasibility	I-Claim
study,	I-Claim
these	B-Claim
results	I-Claim
indicate	I-Claim
that	I-Claim
pursuing	I-Claim
the	I-Claim
III	I-Claim
+	I-Claim
ISG	I-Claim
model,	I-Claim
as	I-Claim
well	I-Claim
as	I-Claim
standard	I-Claim
IIIs,	I-Claim
may	I-Claim
be	I-Claim
fruitful	I-Claim
areas	I-Claim
of	I-Claim
future	I-Claim
research.	I-Claim

The	O
phase	O
3	O
VISTA	O
study	O
in	O
transplant-ineligible	O
myeloma	O
patients	O
demonstrated	O
superior	O
efficacy	O
with	O
bortezomib-melphalan-prednisone	O
(VMP;	O
nine	O
6-wk	O
cycles)	O
vs.	O
melphalan-prednisone	O
(MP)	O
but	O
also	O
increased	O
toxicity.	O

Health-related	O
quality	O
of	O
life	O
(HRQoL;	O
exploratory	O
endpoint)	O
was	O
evaluated	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
Quality	O
of	O
Life	O
Questionnaire	O
(QLQ-C30).	O

The	O
phase	O
3	O
VISTA	O
study	O
in	O
transplant-ineligible	O
myeloma	O
patients	O
demonstrated	O
superior	O
efficacy	O
with	O
bortezomib-melphalan-prednisone	O
(VMP;	O
nine	O
6-wk	O
cycles)	O
vs.	O
melphalan-prednisone	O
(MP)	O
but	O
also	O
increased	O
toxicity.	O

Health-related	O
quality	O
of	O
life	O
(HRQoL;	O
exploratory	O
endpoint)	O
was	O
evaluated	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
Quality	O
of	O
Life	O
Questionnaire	O
(QLQ-C30).	O

EORTC	O
QLQ-C30	O
was	O
administered	O
at	O
screening,	O
on	O
day	O
1	O
of	O
each	O
cycle,	O
at	O
the	O
end-of-treatment	O
visit,	O
and	O
every	O
8	O
wk	O
until	O
progression.	O

EORTC	O
QLQ-C30	O
scores	O
were	O
evaluated	O
among	O
patients	O
with	O
a	O
valid	O
baseline	O
and	O
at	O
least	O
one	O
post-baseline	O
HRQoL	O
assessment.	O

At	O
baseline,	O
domain	O
scores	O
were	O
similar	O
between	O
arms.	O

By	B-Premise
cycle	I-Premise
4,	I-Premise
mean	I-Premise
differences	I-Premise
were	I-Premise
clinically	I-Premise
meaningful	I-Premise
for	I-Premise
most	I-Premise
domains,	I-Premise
indicating	I-Premise
poorer	I-Premise
health	I-Premise
status	I-Premise
with	I-Premise
VMP.	I-Premise

From	B-Premise
cycle	I-Premise
5	I-Premise
onwards,	I-Premise
improvements	I-Premise
relative	I-Premise
to	I-Premise
baseline/MP	I-Premise
were	I-Premise
observed	I-Premise
for	I-Premise
all	I-Premise
domains	I-Premise
with	I-Premise
VMP.	I-Premise

Mean	B-Premise
scores	I-Premise
were	I-Premise
generally	I-Premise
improved	I-Premise
by	I-Premise
the	I-Premise
end-of-treatment	I-Premise
assessment	I-Premise
vs.	I-Premise
baseline	I-Premise
in	I-Premise
both	I-Premise
arms.	I-Premise

Among	B-Premise
responding	I-Premise
patients,	I-Premise
mean	I-Premise
scores	I-Premise
generally	I-Premise
improved	I-Premise
from	I-Premise
time	I-Premise
of	I-Premise
response	I-Premise
to	I-Premise
end-of-treatment	I-Premise
assessment,	I-Premise
substantially	I-Premise
driven	I-Premise
by	I-Premise
patients	I-Premise
achieving	I-Premise
complete	I-Premise
response	I-Premise
(CR).	I-Premise

Multivariate	B-Premise
analysis	I-Premise
showed	I-Premise
a	I-Premise
significant	I-Premise
impact	I-Premise
of	I-Premise
duration	I-Premise
of	I-Premise
response/CR	I-Premise
on	I-Premise
improving	I-Premise
global	I-Premise
health	I-Premise
status,	I-Premise
pain,	I-Premise
and	I-Premise
appetite	I-Premise
loss	I-Premise
scores.	I-Premise

Analyses	B-Claim
by	I-Claim
bortezomib	I-Claim
dose	I-Claim
intensity	I-Claim
indicated	I-Claim
better	I-Claim
HRQoL	I-Claim
in	I-Claim
patients	I-Claim
receiving	I-Claim
lower	I-Claim
dose	I-Claim
intensity.	I-Claim

These	B-Claim
findings	I-Claim
demonstrate	I-Claim
clinically	I-Claim
meaningful,	I-Claim
transitory	I-Claim
HRQoL	I-Claim
decrements	I-Claim
with	I-Claim
VMP	I-Claim
and	I-Claim
relatively	I-Claim
lower	I-Claim
HRQoL	I-Claim
vs.	I-Claim
MP	I-Claim
during	I-Claim
early	I-Claim
treatment	I-Claim
cycles,	I-Claim
associated	I-Claim
with	I-Claim
the	I-Claim
expected	I-Claim
additional	I-Claim
toxicities.	I-Claim

However,	B-Claim
HRQoL	I-Claim
is	I-Claim
not	I-Claim
compromised	I-Claim
in	I-Claim
the	I-Claim
long	I-Claim
term,	I-Claim
recovering	I-Claim
by	I-Claim
the	I-Claim
end-of-treatment	I-Claim
visit	I-Claim
to	I-Claim
be	I-Claim
comparable	I-Claim
vs.	I-Claim
MP.	I-Claim

Maintenance	O
therapy,	O
commenced	O
immediately	O
after	O
the	O
completion	O
of	O
first-line	O
chemotherapy,	O
is	O
a	O
promising	O
strategy	O
for	O
improving	O
treatment	O
outcomes	O
in	O
patients	O
with	O
non-small-cell	O
lung	O
cancer	O
(NSCLC).	O

The	O
global	O
phase	O
III	O
SequentiAl	O
Tarceva	O
in	O
UnResectable	O
NSCLC	O
(SATURN)	O
study	O
evaluated	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(EGFR)	O
tyrosine-kinase	O
inhibitor	O
erlotinib	O
as	O
maintenance	O
treatment	O
in	O
NSCLC	O
patients	O
without	O
progression	O
after	O
first-line	O
chemotherapy.	O

We	O
report	O
a	O
retrospective	O
subanalysis	O
of	O
Asian	O
patients	O
enrolled	O
in	O
SATURN.	O

Patients	O
with	O
advanced	O
NSCLC	O
with	O
no	O
evidence	O
of	O
progression	O
after	O
four	O
cycles	O
of	O
chemotherapy	O
were	O
randomized	O
to	O
receive	O
erlotinib	O
150	O
mg/day	O
or	O
placebo,	O
until	O
progressive	O
disease	O
or	O
limiting	O
toxicity.	O

The	O
co-primary	O
endpoints	O
of	O
SATURN	O
were	O
progression-free	O
survival	O
(PFS)	O
in	O
all	O
patients	O
and	O
in	O
those	O
with	O
positive	O
EGFR	O
immunohistochemistry	O
(IHC)	O
status.	O

Secondary	O
endpoints	O
included	O
overall	O
survival	O
(OS),	O
disease	O
control	O
rate,	O
safety,	O
quality	O
of	O
life	O
(QoL)	O
and	O
biomarker	O
analyses.	O

In	O
total,	O
126	O
patients	O
from	O
East	O
and	O
South-East	O
Asian	O
centers	O
were	O
randomized	O
(14%	O
of	O
the	O
intent-to-treat	O
population):	O
88	O
from	O
Korea,	O
28	O
from	O
China	O
and	O
10	O
from	O
Malaysia;	O
one	O
patient	O
was	O
excluded	O
from	O
this	O
analysis	O
due	O
to	O
Indian	O
ethnicity.	O

PFS	B-Premise
was	I-Premise
significantly	I-Premise
prolonged	I-Premise
in	I-Premise
the	I-Premise
erlotinib	I-Premise
treatment	I-Premise
arm,	I-Premise
both	I-Premise
overall	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR]:	I-Premise
0.57;	I-Premise
p=0.0067)	I-Premise
and	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
EGFR	I-Premise
IHC-positive	I-Premise
disease	I-Premise
(HR=0.50;	I-Premise
p=0.0057).	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
trend	I-Premise
towards	I-Premise
an	I-Premise
increase	I-Premise
in	I-Premise
OS,	I-Premise
which	I-Premise
reached	I-Premise
statistical	I-Premise
significance	I-Premise
in	I-Premise
the	I-Premise
EGFR	I-Premise
IHC-positive	I-Premise
subgroup	I-Premise
(p=0.0233).	I-Premise

The	B-Premise
overall	I-Premise
response	I-Premise
rate	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
with	I-Premise
erlotinib	I-Premise
compared	I-Premise
with	I-Premise
placebo	I-Premise
(24%	I-Premise
versus	I-Premise
5%;	I-Premise
p=0.0025).	I-Premise

Erlotinib	B-Claim
was	I-Claim
generally	I-Claim
well	I-Claim
tolerated	I-Claim
and	I-Claim
had	I-Claim
no	I-Claim
negative	I-Claim
impact	I-Claim
on	I-Claim
QoL	I-Claim
in	I-Claim
this	I-Claim
subpopulation.	I-Claim

The	B-Premise
most	I-Premise
common	I-Premise
treatment-related	I-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
rash,	I-Premise
diarrhea	I-Premise
and	I-Premise
pruritus.	I-Premise

Erlotinib	B-Claim
was	I-Claim
effective	I-Claim
and	I-Claim
well	I-Claim
tolerated	I-Claim
in	I-Claim
Asian	I-Claim
patients,	I-Claim
producing	I-Claim
benefits	I-Claim
consistent	I-Claim
with	I-Claim
those	I-Claim
observed	I-Claim
in	I-Claim
the	I-Claim
overall	I-Claim
SATURN	I-Claim
population.	I-Claim

Maintenance	B-Claim
treatment	I-Claim
with	I-Claim
erlotinib	I-Claim
appears	I-Claim
to	I-Claim
be	I-Claim
a	I-Claim
useful	I-Claim
option	I-Claim
for	I-Claim
the	I-Claim
management	I-Claim
of	I-Claim
Asian	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
NSCLC	I-Claim
without	I-Claim
progression	I-Claim
after	I-Claim
first-line	I-Claim
chemotherapy.	I-Claim

Study	O
Type--Therapy	O
(RCT)	O
Level	O
of	O
Evidence	O
1b.	O

What's	O
known	O
on	O
the	O
subject?	O
and	O
What	O
does	O
the	O
study	O
add?	O

Androgen	O
deprivation	O
therapy	O
(ADT)	O
is	O
commonly	O
used	O
as	O
a	O
primary	O
treatment	O
for	O
patients	O
with	O
prostate	O
cancer	O
(PCa)	O
who	O
are	O
not	O
eligible	O
for	O
radical	O
treatment	O
options.	O

ADT	O
is	O
also	O
used	O
in	O
patients	O
with	O
PCa	O
as	O
neo-adjuvant	O
hormone	O
therapy	O
to	O
reduce	O
prostate	O
volume	O
and	O
down-stage	O
the	O
disease	O
before	O
radiotherapy	O
with	O
curative	O
intent.	O

The	O
present	O
study	O
showed	O
that	O
ADT	O
with	O
the	O
gonadotropin	O
hormone-releasing	O
hormone	O
(GhRH)	O
antagonist	O
degarelix	O
is	O
non-inferior	O
to	O
combined	O
treatment	O
with	O
the	O
LHRH	O
agonist	O
goserelin	O
and	O
bicalutamide	O
in	O
terms	O
of	O
reducing	O
prostate	O
volume	O
during	O
the	O
treatment	O
period	O
of	O
3	O
months.	O

Degarelix	O
treatment	O
evokes,	O
however,	O
significantly	O
better	O
relief	O
of	O
lower	O
urinary	O
tract	O
symptoms	O
in	O
patients	O
having	O
moderate	O
and	O
severe	O
voiding	O
problems.	O

To	O
assess	O
the	O
efficacy	O
of	O
monthly	O
degarelix	O
treatment	O
for	O
reduction	O
of	O
total	O
prostate	O
volume	O
(TPV),	O
relief	O
of	O
lower	O
urinary	O
tract	O
symptoms	O
(LUTS)	O
and	O
improvement	O
of	O
quality	O
of	O
life	O
(QoL)	O
in	O
patients	O
with	O
prostate	O
cancer	O
(PCa)	O
using	O
monthly	O
goserelin	O
as	O
active	O
control.	O

This	O
was	O
a	O
randomized,	O
parallel-arm,	O
active-controlled,	O
open-label,	O
multicentre	O
trial	O
on	O
182	O
patients	O
treated	O
with	O
either	O
monthly	O
degarelix	O
(240/80	O
mg)	O
or	O
goserelin	O
(3.6	O
mg)	O
for	O
12	O
weeks.	O

For	O
flare	O
protection,	O
goserelin-treated	O
patients	O
also	O
received	O
daily	O
bicalutamide	O
(50	O
mg)	O
during	O
the	O
initial	O
28	O
days.	O

Key	O
trial	O
variables	O
monitored	O
monthly	O
were	O
TPV	O
(primary	O
endpoint),	O
serum	O
testosterone,	O
prostate-specific	O
antigen	O
(PSA),	O
the	O
International	O
Prostate	O
Symptom	O
Score	O
(IPSS)	O
and	O
the	O
Benign	O
Prostate	O
Hyperplasia	O
Impact	O
Index.	O

In	O
all,	O
175	O
patients	O
completed	O
the	O
trial	O
(96.1%).	O

At	B-Premise
week	I-Premise
12,	I-Premise
changes	I-Premise
in	I-Premise
TPV	I-Premise
for	I-Premise
degarelix	I-Premise
and	I-Premise
goserelin	I-Premise
were	I-Premise
similar	I-Premise
(-37.2%	I-Premise
vs	I-Premise
-39.0%)	I-Premise
and	I-Premise
met	I-Premise
the	I-Premise
predefined	I-Premise
non-inferiority	I-Premise
criterion.	I-Premise

Decreases	B-Premise
in	I-Premise
IPSS	I-Premise
were	I-Premise
greater	I-Premise
in	I-Premise
degarelix	I-Premise
than	I-Premise
in	I-Premise
goserelin-treated	I-Premise
patients,	I-Premise
differences	I-Premise
being	I-Premise
statistically	I-Premise
significant	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
baseline	I-Premise
IPSS	I-Premise
>	I-Premise
13	I-Premise
(-6.7	I-Premise
	I-Premise
1.8	I-Premise
vs	I-Premise
-4.0	I-Premise
	I-Premise
1.0;	I-Premise
P	I-Premise
=	I-Premise
0.02).	I-Premise

The	B-Premise
number	I-Premise
of	I-Premise
patients	I-Premise
with	I-Premise
an	I-Premise
IPSS	I-Premise
change	I-Premise
of	I-Premise
	I-Premise
3	I-Premise
over	I-Premise
baseline	I-Premise
was	I-Premise
also	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
degarelix	I-Premise
(61.0	I-Premise
vs	I-Premise
44.3%,	I-Premise
P	I-Premise
=	I-Premise
0.02).	I-Premise

Both	B-Claim
treatments	I-Claim
were	I-Claim
safe	I-Claim
and	I-Claim
well	I-Claim
tolerated.	I-Claim

Medical	B-Claim
castration	I-Claim
reduces	I-Claim
TPV	I-Claim
and	I-Claim
could	I-Claim
also	I-Claim
improve	I-Claim
LUTS	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
PCa.	I-Claim

While	O
the	B-Claim
short-term	I-Claim
efficacy	I-Claim
of	I-Claim
degarelix	I-Claim
and	I-Claim
goserelin	I-Claim
+	I-Claim
bicalutamide	I-Claim
was	I-Claim
the	I-Claim
same	I-Claim
in	I-Claim
terms	I-Claim
of	I-Claim
TPV	I-Claim
reduction,	I-Claim
degarelix	B-Claim
showed	I-Claim
superiority	I-Claim
in	I-Claim
LUTS	I-Claim
relief	I-Claim
in	I-Claim
symptomatic	I-Claim
patients,	I-Claim
which	I-Claim
could	I-Claim
highlight	I-Claim
the	I-Claim
different	I-Claim
actions	I-Claim
of	I-Claim
these	I-Claim
drugs	I-Claim
on	I-Claim
extrapituitary	I-Claim
gonadotrophin-releasing	I-Claim
hormone	I-Claim
(GnRH)	I-Claim
receptors	I-Claim
in	I-Claim
the	I-Claim
bladder	I-Claim
and/or	I-Claim
the	I-Claim
prostate.	I-Claim

To	O
assess	O
the	O
efficacy	O
of	O
prophylactic	O
swallowing	O
exercises	O
on	O
swallowing	O
function	O
in	O
patients	O
undergoing	O
chemoradiation	O
therapy	O
(CRT)	O
for	O
head	O
and	O
neck	O
cancer.	O

Randomized	O
controlled	O
trial.	O

Tertiary	O
care,	O
academic	O
medical	O
center.	O

Twenty-six	O
patients	O
with	O
head	O
and	O
neck	O
cancer	O
receiving	O
CRT.	O

Patients	O
performed	O
5	O
targeted	O
swallowing	O
exercises	O
throughout	O
their	O
CRT	O
and	O
participated	O
in	O
weekly	O
swallowing	O
therapy	O
sessions	O
to	O
promote	O
adherence	O
and	O
accurate	O
technique.	O

Controls	O
had	O
no	O
prophylactic	O
exercises	O
and	O
were	O
referred	O
for	O
swallowing	O
treatment	O
after	O
completion	O
of	O
CRT	O
if	O
indicated.	O

Swallowing	O
function	O
was	O
assessed	O
with	O
the	O
Functional	O
Oral	O
Intake	O
Scale	O
(FOIS)	O
and	O
the	O
Performance	O
Status	O
Scale	O
for	O
Head	O
and	O
Neck	O
Cancer	O
Patients	O
(PSS-H&N)	O
at	O
baseline,	O
immediately	O
after	O
CRT,	O
and	O
at	O
3,	O
6,	O
9,	O
and	O
12	O
months	O
after	O
CRT.	O

There	B-Premise
were	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
FOIS	I-Premise
scores	I-Premise
between	I-Premise
intervention	I-Premise
and	I-Premise
control	I-Premise
patients	I-Premise
immediately	I-Premise
after	I-Premise
CRT	I-Premise
(immediately	I-Premise
after	I-Premise
CRT:	I-Premise
intervention	I-Premise
group	I-Premise
median	I-Premise
score,	I-Premise
3	I-Premise
[range,	I-Premise
1-7],	I-Premise
vs	I-Premise
median	I-Premise
control	I-Premise
score,	I-Premise
4	I-Premise
[range,	I-Premise
1-6]	I-Premise
(P	I-Premise
=	I-Premise
.88).	I-Premise

However,	O
intervention	B-Premise
patients	I-Premise
had	I-Premise
significantly	I-Premise
better	I-Premise
scores	I-Premise
at	I-Premise
months	I-Premise
3	I-Premise
and	I-Premise
6	I-Premise
(median	I-Premise
3-month	I-Premise
intervention	I-Premise
score,	I-Premise
7	I-Premise
[range,	I-Premise
5-7],	I-Premise
vs	I-Premise
median	I-Premise
control	I-Premise
score,	I-Premise
5	I-Premise
[range,	I-Premise
3-7]	I-Premise
[P	I-Premise
=	I-Premise
.03];	I-Premise
median	I-Premise
6-month	I-Premise
intervention	I-Premise
score,	I-Premise
7	I-Premise
[range,	I-Premise
6-7],	I-Premise
vs	I-Premise
median	I-Premise
control	I-Premise
score,	I-Premise
6	I-Premise
[range,	I-Premise
3-7]	I-Premise
[P	I-Premise
=	I-Premise
.009]).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
scores	I-Premise
at	I-Premise
months	I-Premise
9	I-Premise
and	I-Premise
12	I-Premise
(P	I-Premise
=	I-Premise
.24	I-Premise
and	I-Premise
P	I-Premise
=	I-Premise
.93,	I-Premise
respectively).	I-Premise

The	B-Premise
same	I-Premise
pattern	I-Premise
between	I-Premise
intervention	I-Premise
and	I-Premise
control	I-Premise
patients	I-Premise
was	I-Premise
observed	I-Premise
for	I-Premise
scores	I-Premise
on	I-Premise
the	I-Premise
PSS-H&N.	I-Premise

Patients	B-Claim
who	I-Claim
performed	I-Claim
prophylactic	I-Claim
swallowing	I-Claim
exercises	I-Claim
had	I-Claim
improved	I-Claim
swallowing	I-Claim
function	I-Claim
at	I-Claim
3	I-Claim
and	I-Claim
6	I-Claim
months	I-Claim
after	I-Claim
CRT	I-Claim
but	I-Claim
not	I-Claim
immediately	I-Claim
after	I-Claim
CRT	I-Claim
or	I-Claim
at	I-Claim
9	I-Claim
and	I-Claim
12	I-Claim
months	I-Claim
after	I-Claim
CRT.	I-Claim

The	B-Claim
small	I-Claim
sample	I-Claim
size	I-Claim
may	I-Claim
have	I-Claim
limited	I-Claim
our	I-Claim
ability	I-Claim
to	I-Claim
detect	I-Claim
significant	I-Claim
differences	I-Claim
beyond	I-Claim
6	I-Claim
months	I-Claim
of	I-Claim
observation	I-Claim
as	I-Claim
well	I-Claim
as	I-Claim
additional	I-Claim
significant	I-Claim
differences	I-Claim
in	I-Claim
our	I-Claim
study.	I-Claim

Patients	O
with	O
lymphoma	O
experience	O
sleep	O
problems	O
that	O
may	O
be	O
managed	O
with	O
aerobic	O
exercise	O
but	O
no	O
previous	O
study	O
has	O
examined	O
this	O
issue.	O

We	O
randomized	O
122	O
patients	O
with	O
lymphoma	O
to	O
usual	O
care	O
(n	O
=	O
62)	O
or	O
12	O
weeks	O
of	O
supervised	O
aerobic	O
exercise	O
training	O
(AET;	O
n	O
=	O
60).	O

Our	O
primary	O
sleep	O
endpoint	O
was	O
global	O
sleep	O
quality	O
assessed	O
by	O
the	O
Pittsburgh	O
Sleep	O
Quality	O
Index	O
(PSQI).	O

Secondary	O
endpoints	O
were	O
the	O
PSQI	O
component	O
scores.	O

Planned	O
subgroup	O
analyses	O
were	O
also	O
conducted.	O

Intention-to-treat	B-Premise
analyses	I-Premise
indicated	I-Premise
that	I-Premise
AET	I-Premise
resulted	I-Premise
in	I-Premise
a	I-Premise
nonsignificant	I-Premise
(P	I-Premise
=	I-Premise
0.16)	I-Premise
improvement	I-Premise
in	I-Premise
global	I-Premise
sleep	I-Premise
quality	I-Premise
compared	I-Premise
with	I-Premise
usual	I-Premise
care	I-Premise
[mean	I-Premise
group	I-Premise
difference	I-Premise
=	I-Premise
-0.64;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
(CI),	I-Premise
-1.56	I-Premise
to	I-Premise
+0.27].	I-Premise

In	B-Premise
planned	I-Premise
subgroup	I-Premise
analyses,	I-Premise
statistically	I-Premise
significant	I-Premise
or	I-Premise
borderline	I-Premise
significant	I-Premise
interactions	I-Premise
were	I-Premise
identified	I-Premise
for	I-Premise
type	I-Premise
of	I-Premise
lymphoma	I-Premise
(P(interaction)	I-Premise
=	I-Premise
0.006),	I-Premise
current	I-Premise
treatment	I-Premise
status	I-Premise
(P(interaction)	I-Premise
=	I-Premise
0.036),	I-Premise
time	I-Premise
since	I-Premise
diagnosis	I-Premise
(P(interaction)	I-Premise
=	I-Premise
0.010),	I-Premise
body	I-Premise
mass	I-Premise
index	I-Premise
(P(interaction)	I-Premise
=	I-Premise
0.075),	I-Premise
and	I-Premise
baseline	I-Premise
sleep	I-Premise
quality	I-Premise
(P(interaction)	I-Premise
=	I-Premise
0.041).	I-Premise

Specifically,	O
AET	B-Premise
improved	I-Premise
global	I-Premise
sleep	I-Premise
quality	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
lymphoma	I-Premise
who	I-Premise
had	I-Premise
indolent	I-Premise
non-Hodgkin	I-Premise
lymphoma	I-Premise
(P	I-Premise
=	I-Premise
0.001),	I-Premise
were	I-Premise
receiving	I-Premise
chemotherapy	I-Premise
(P	I-Premise
=	I-Premise
0.013),	I-Premise
were	I-Premise
<2	I-Premise
years	I-Premise
post-diagnosis	I-Premise
(P	I-Premise
=	I-Premise
0.005),	I-Premise
were	I-Premise
obese	I-Premise
(P	I-Premise
=	I-Premise
0.025),	I-Premise
and	I-Premise
were	I-Premise
poor	I-Premise
sleepers	I-Premise
at	I-Premise
baseline	I-Premise
(P	I-Premise
=	I-Premise
0.007).	I-Premise

AET	B-Claim
did	I-Claim
not	I-Claim
significantly	I-Claim
improve	I-Claim
sleep	I-Claim
quality	I-Claim
in	I-Claim
this	I-Claim
heterogeneous	I-Claim
sample	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
lymphoma;	I-Claim
however,	B-Claim
clinically	I-Claim
identifiable	I-Claim
subgroups	I-Claim
appeared	I-Claim
to	I-Claim
benefit.	I-Claim

Future	O
exercise	O
trials	O
targeting	O
these	O
responsive	O
subgroups	O
are	O
needed	O
to	O
confirm	O
these	O
findings.	O

If	O
replicated	O
in	O
larger	O
and	O
more	O
focused	O
trials,	O
aerobic	O
exercise	O
may	O
be	O
an	O
attractive	O
option	O
to	O
manage	O
sleep	O
dysfunction	O
in	O
patients	O
with	O
cancer	O
because	O
of	O
its	O
favorable	O
safety	O
profile	O
and	O
other	O
documented	O
health	O
benefits.	O

Treosulfan,	O
an	O
alkylating	O
agent,	O
has	O
demonstrated	O
activity	O
in	O
recurrent	O
ovarian	O
carcinoma.	O

It	O
is	O
equieffective	O
as	O
oral	O
(p.o.)	O
and	O
intravenous	O
(i.v.)	O
formulation.	O

To	O
explore	O
the	O
preference	O
and	O
compliance	O
of	O
elderly	O
patients	O
regarding	O
p.o.	O
or	O
i.v.	O
treosulfan	O
for	O
the	O
treatment	O
of	O
relapsed	O
ovarian	O
carcinoma,	O
women	O
aged	O
65	O
years	O
or	O
older	O
were	O
included	O
in	O
this	O
prospective	O
multicenter	O
study.	O

Since	O
elderly	O
patients	O
usually	O
have	O
several	O
concomitant	O
diseases	O
and	O
experience	O
more	O
treatment	O
toxicity,	O
an	O
interim	O
safety	O
analysis	O
was	O
planned	O
and	O
performed	O
after	O
25	O
patients	O
finished	O
therapy	O
to	O
assess	O
the	O
tolerability	O
of	O
the	O
treatment	O
regimens.	O

Patients	O
had	O
a	O
free	O
choice	O
of	O
treosulfan	O
i.v.	O
(7,000	O
mg/m(2)	O
day	O
1	O
of	O
a	O
28-day	O
cycle)	O
or	O
p.o.	O

(600	O
mg/m(2)	O
day	O
1-28	O
of	O
a	O
56-day	O
cycle)	O
for	O
a	O
maximum	O
of	O
12	O
cycles	O
(i.v.)	O
or	O
12	O
months	O
(p.o.).	O

Indecisive	O
patients	O
were	O
randomized.	O

Toxicity	O
was	O
evaluated	O
according	O
to	O
the	O
NCI-CTC	O
version	O
2.0.	O

Twenty-five	O
of	O
51	O
recruited	O
patients	O
completed	O
therapy	O
at	O
the	O
time	O
of	O
the	O
planned	O
interim	O
analysis	O
(median	O
age,	O
75	O
years;	O
range,	O
70-82).	O

Median	O
ECOG	O
was	O
1,	O
and	O
median	O
number	O
of	O
prior	O
chemotherapy	O
regimens	O
was	O
2.	O

A	O
median	O
number	O
of	O
4	O
cycles	O
(range,	O
1-12)	O
were	O
administered	O
per	O
patient.	O

Anemia	B-Premise
was	I-Premise
the	I-Premise
most	I-Premise
common	I-Premise
hematological	I-Premise
toxicity	I-Premise
(88	I-Premise
%	I-Premise
of	I-Premise
patients).	I-Premise

Most	B-Premise
frequent	I-Premise
non-hematological	I-Premise
toxicities	I-Premise
were	I-Premise
nausea	I-Premise
(76	I-Premise
%),	I-Premise
constipation	I-Premise
(68	I-Premise
%),	I-Premise
and	I-Premise
fatigue	I-Premise
(64	I-Premise
%).	I-Premise

Treatment	B-Claim
was	I-Claim
generally	I-Claim
well	I-Claim
tolerated	I-Claim
despite	I-Claim
the	I-Claim
fact	I-Claim
that	I-Claim
most	I-Claim
patients	I-Claim
suffered	I-Claim
from	I-Claim
multiple	I-Claim
comorbidities	I-Claim
and	I-Claim
were	I-Claim
heavily	I-Claim
pretreated.	I-Claim

There	B-Claim
were	I-Claim
no	I-Claim
unexpected	I-Claim
hematological	I-Claim
or	I-Claim
non-hematological	I-Claim
toxicities.	I-Claim

Based	O
on	O
this	O
safety	O
analysis,	O
the	O
next	O
step	O
of	O
study	O
recruitment	O
was	O
continued.	O

This	O
study	O
examined	O
whether	O
changes	O
in	O
self-efficacy	O
explain	O
the	O
effects	O
of	O
a	O
mailed	O
print	O
intervention	O
on	O
long-term	O
dietary	O
practices	O
of	O
breast	O
and	O
prostate	O
cancer	O
survivors.	O

The	O
relationship	O
between	O
change	O
in	O
self-efficacy	O
and	O
long-term	O
physical	O
activity	O
(PA)	O
also	O
was	O
examined.	O

Breast	O
and	O
prostate	O
cancer	O
survivors	O
(N	O
=	O
543)	O
from	O
39	O
US	O
states	O
and	O
two	O
Canadian	O
provinces	O
participated	O
in	O
the	O
FRESH	O
START	O
intervention	O
trial.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	O
10-month	O
program	O
of	O
mailed	O
print	O
materials	O
on	O
diet	O
and	O
PA	O
available	O
in	O
the	O
public	O
domain	O
or	O
a	O
10-month	O
program	O
of	O
tailored	O
materials	O
designed	O
to	O
increase	O
fruit	O
and	O
vegetable	O
(F&V)	O
intake,	O
decrease	O
fat	O
intake,	O
and/or	O
increase	O
PA.	O

Changes	O
in	O
self-efficacy	O
for	O
F&V	O
intake	O
and	O
fat	O
restriction	O
were	O
analyzed	O
as	O
potential	O
mediators	O
of	O
the	O
intervention's	O
effects	O
on	O
diet	O
at	O
2-year	O
follow-up.	O

Because	O
we	O
previously	O
found	O
that	O
change	O
in	O
self-efficacy	O
for	O
PA	O
did	O
not	O
vary	O
by	O
group	O
assignment,	O
the	O
relationship	O
between	O
change	O
in	O
self-efficacy	O
and	O
PA	O
at	O
2-year	O
follow-up	O
was	O
examined	O
across	O
study	O
conditions.	O

Results	B-Claim
suggest	I-Claim
that	I-Claim
change	I-Claim
in	I-Claim
self-efficacy	I-Claim
for	I-Claim
fat	I-Claim
restriction	I-Claim
partially	I-Claim
explained	I-Claim
the	I-Claim
intervention's	I-Claim
effect	I-Claim
on	I-Claim
fat	I-Claim
intake	I-Claim
(mean	I-Claim
indirect	I-Claim
effect	I-Claim
=	I-Claim
-0.28),	I-Claim
and	I-Claim
change	I-Claim
in	I-Claim
self-efficacy	I-Claim
for	I-Claim
F&V	I-Claim
consumption	I-Claim
partially	I-Claim
explained	I-Claim
the	I-Claim
intervention's	I-Claim
effect	I-Claim
on	I-Claim
daily	I-Claim
F&V	I-Claim
intake	I-Claim
(mean	I-Claim
indirect	I-Claim
effect	I-Claim
=	I-Claim
.11).	I-Claim

Change	B-Premise
in	I-Premise
self-efficacy	I-Premise
for	I-Premise
fat	I-Premise
restriction	I-Premise
partially	I-Premise
accounted	I-Premise
for	I-Premise
the	I-Premise
intervention's	I-Premise
impact	I-Premise
on	I-Premise
overall	I-Premise
diet	I-Premise
quality	I-Premise
among	I-Premise
men	I-Premise
only	I-Premise
(mean	I-Premise
indirect	I-Premise
effect	I-Premise
=	I-Premise
0.60).	I-Premise

Finally,	O
change	O
in	O
self-efficacy	O
for	O
PA	O
predicted	O
PA	O
at	O
2-year	O
follow-up.	O

Findings	B-Claim
suggest	I-Claim
that	I-Claim
self-efficacy	I-Claim
may	I-Claim
influence	I-Claim
long-term	I-Claim
maintenance	I-Claim
of	I-Claim
healthy	I-Claim
lifestyle	I-Claim
practices	I-Claim
among	I-Claim
cancer	I-Claim
survivors.	I-Claim

It	O
is	O
not	O
clear	O
whether	O
the	O
administration	O
of	O
radioiodine	O
provides	O
any	O
benefit	O
to	O
patients	O
with	O
low-risk	O
thyroid	O
cancer	O
after	O
a	O
complete	O
surgical	O
resection.	O

The	O
administration	O
of	O
the	O
smallest	O
possible	O
amount	O
of	O
radioiodine	O
would	O
improve	O
care.	O

In	O
our	O
randomized,	O
phase	O
3	O
trial,	O
we	O
compared	O
two	O
thyrotropin-stimulation	O
methods	O
(thyroid	O
hormone	O
withdrawal	O
and	O
use	O
of	O
recombinant	O
human	O
thyrotropin)	O
and	O
two	O
radioiodine	O
((131)I)	O
doses	O
(i.e.,	O
administered	O
activities)	O
(1.1	O
GBq	O
and	O
3.7	O
GBq)	O
in	O
a	O
2-by-2	O
design.	O

Inclusion	O
criteria	O
were	O
an	O
age	O
of	O
18	O
years	O
or	O
older;	O
total	O
thyroidectomy	O
for	O
differentiated	O
thyroid	O
carcinoma;	O
tumor-node-metastasis	O
(TNM)	O
stage,	O
ascertained	O
on	O
pathological	O
examination	O
(p)	O
of	O
a	O
surgical	O
specimen,	O
of	O
pT1	O
(with	O
tumor	O
diameter	O
1	O
cm)	O
and	O
N1	O
or	O
Nx,	O
pT1	O
(with	O
tumor	O
diameter	O
>1	O
to	O
2	O
cm)	O
and	O
any	O
N	O
stage,	O
or	O
pT2N0;	O
absence	O
of	O
distant	O
metastasis;	O
and	O
no	O
iodine	O
contamination.	O

Thyroid	O
ablation	O
was	O
assessed	O
8	O
months	O
after	O
radioiodine	O
administration	O
by	O
neck	O
ultrasonography	O
and	O
measurement	O
of	O
recombinant	O
human	O
thyrotropin-stimulated	O
thyroglobulin.	O

Comparisons	O
were	O
based	O
on	O
an	O
equivalence	O
framework.	O

There	O
were	O
752	O
patients	O
enrolled	O
between	O
2007	O
and	O
2010;	O
92%	O
had	O
papillary	O
cancer.	O

There	B-Premise
were	I-Premise
no	I-Premise
unexpected	I-Premise
serious	I-Premise
adverse	I-Premise
events.	I-Premise

In	B-Premise
the	I-Premise
684	I-Premise
patients	I-Premise
with	I-Premise
data	I-Premise
that	I-Premise
could	I-Premise
be	I-Premise
evaluated,	I-Premise
ultrasonography	I-Premise
of	I-Premise
the	I-Premise
neck	I-Premise
was	I-Premise
normal	I-Premise
in	I-Premise
652	I-Premise
(95%),	I-Premise
and	I-Premise
the	I-Premise
stimulated	I-Premise
thyroglobulin	I-Premise
level	I-Premise
was	I-Premise
1.0	I-Premise
ng	I-Premise
per	I-Premise
milliliter	I-Premise
or	I-Premise
less	I-Premise
in	I-Premise
621	I-Premise
of	I-Premise
the	I-Premise
652	I-Premise
patients	I-Premise
(95%)	I-Premise
without	I-Premise
detectable	I-Premise
thyroglobulin	I-Premise
antibodies.	I-Premise

Thyroid	B-Premise
ablation	I-Premise
was	I-Premise
complete	I-Premise
in	I-Premise
631	I-Premise
of	I-Premise
the	I-Premise
684	I-Premise
patients	I-Premise
(92%).	I-Premise

The	B-Premise
ablation	I-Premise
rate	I-Premise
was	I-Premise
equivalent	I-Premise
between	I-Premise
the	I-Premise
(131)I	I-Premise
doses	I-Premise
and	I-Premise
between	I-Premise
the	I-Premise
thyrotropin-stimulation	I-Premise
methods.	I-Premise

The	B-Claim
use	I-Claim
of	I-Claim
recombinant	I-Claim
human	I-Claim
thyrotropin	I-Claim
and	I-Claim
low-dose	I-Claim
(1.1	I-Claim
GBq)	I-Claim
postoperative	I-Claim
radioiodine	I-Claim
ablation	I-Claim
may	I-Claim
be	I-Claim
sufficient	I-Claim
for	I-Claim
the	I-Claim
management	I-Claim
of	I-Claim
low-risk	I-Claim
thyroid	I-Claim
cancer.	I-Claim

It	O
is	O
not	O
known	O
whether	O
low-dose	O
radioiodine	O
(1.1	O
GBq	O
[30	O
mCi])	O
is	O
as	O
effective	O
as	O
high-dose	O
radioiodine	O
(3.7	O
GBq	O
[100	O
mCi])	O
for	O
treating	O
patients	O
with	O
differentiated	O
thyroid	O
cancer	O
or	O
whether	O
the	O
effects	O
of	O
radioiodine	O
(especially	O
at	O
a	O
low	O
dose)	O
are	O
influenced	O
by	O
using	O
either	O
recombinant	O
human	O
thyrotropin	O
(thyrotropin	O
alfa)	O
or	O
thyroid	O
hormone	O
withdrawal.	O

At	O
29	O
centers	O
in	O
the	O
United	O
Kingdom,	O
we	O
conducted	O
a	O
randomized	O
noninferiority	O
trial	O
comparing	O
low-dose	O
and	O
high-dose	O
radioiodine,	O
each	O
in	O
combination	O
with	O
either	O
thyrotropin	O
alfa	O
or	O
thyroid	O
hormone	O
withdrawal	O
before	O
ablation.	O

Patients	O
(age	O
range,	O
16	O
to	O
80	O
years)	O
had	O
tumor	O
stage	O
T1	O
to	O
T3,	O
with	O
possible	O
spread	O
to	O
nearby	O
lymph	O
nodes	O
but	O
without	O
metastasis.	O

End	O
points	O
were	O
the	O
rate	O
of	O
success	O
of	O
ablation	O
at	O
6	O
to	O
9	O
months,	O
adverse	O
events,	O
quality	O
of	O
life,	O
and	O
length	O
of	O
hospital	O
stay.	O

A	O
total	O
of	O
438	O
patients	O
underwent	O
randomization;	O
data	O
could	O
be	O
analyzed	O
for	O
421.	O

Ablation	B-Premise
success	I-Premise
rates	I-Premise
were	I-Premise
85.0%	I-Premise
in	I-Premise
the	I-Premise
group	I-Premise
receiving	I-Premise
low-dose	I-Premise
radioiodine	I-Premise
versus	I-Premise
88.9%	I-Premise
in	I-Premise
the	I-Premise
group	I-Premise
receiving	I-Premise
the	I-Premise
high	I-Premise
dose	I-Premise
and	I-Premise
87.1%	I-Premise
in	I-Premise
the	I-Premise
thyrotropin	I-Premise
alfa	I-Premise
group	I-Premise
versus	I-Premise
86.7%	I-Premise
in	I-Premise
the	I-Premise
group	I-Premise
undergoing	I-Premise
thyroid	I-Premise
hormone	I-Premise
withdrawal.	I-Premise

All	B-Premise
95%	I-Premise
confidence	I-Premise
intervals	I-Premise
for	I-Premise
the	I-Premise
differences	I-Premise
were	I-Premise
within	I-Premise
10	I-Premise
percentage	I-Premise
points,	I-Premise
indicating	I-Premise
noninferiority.	I-Premise

Similar	B-Premise
results	I-Premise
were	I-Premise
found	I-Premise
for	I-Premise
low-dose	I-Premise
radioiodine	I-Premise
plus	I-Premise
thyrotropin	I-Premise
alfa	I-Premise
(84.3%)	I-Premise
versus	I-Premise
high-dose	I-Premise
radioiodine	I-Premise
plus	I-Premise
thyroid	I-Premise
hormone	I-Premise
withdrawal	I-Premise
(87.6%)	I-Premise
or	I-Premise
high-dose	I-Premise
radioiodine	I-Premise
plus	I-Premise
thyrotropin	I-Premise
alfa	I-Premise
(90.2%).	I-Premise

More	B-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
high-dose	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
low-dose	I-Premise
group	I-Premise
were	I-Premise
hospitalized	I-Premise
for	I-Premise
at	I-Premise
least	I-Premise
3	I-Premise
days	I-Premise
(36.3%	I-Premise
vs.	I-Premise
13.0%,	I-Premise
P<0.001).	I-Premise

The	B-Premise
proportions	I-Premise
of	I-Premise
patients	I-Premise
with	I-Premise
adverse	I-Premise
events	I-Premise
were	I-Premise
21%	I-Premise
in	I-Premise
the	I-Premise
low-dose	I-Premise
group	I-Premise
versus	I-Premise
33%	I-Premise
in	I-Premise
the	I-Premise
high-dose	I-Premise
group	I-Premise
(P=0.007)	I-Premise
and	I-Premise
23%	I-Premise
in	I-Premise
the	I-Premise
thyrotropin	I-Premise
alfa	I-Premise
group	I-Premise
versus	I-Premise
30%	I-Premise
in	I-Premise
the	I-Premise
group	I-Premise
undergoing	I-Premise
thyroid	I-Premise
hormone	I-Premise
withdrawal	I-Premise
(P=0.11).	I-Premise

Low-dose	B-Claim
radioiodine	I-Claim
plus	I-Claim
thyrotropin	I-Claim
alfa	I-Claim
was	I-Claim
as	I-Claim
effective	I-Claim
as	I-Claim
high-dose	I-Claim
radioiodine,	I-Claim
with	I-Claim
a	I-Claim
lower	I-Claim
rate	I-Claim
of	I-Claim
adverse	I-Claim
events.	I-Claim

Surgical	O
resection	O
is	O
regarded	O
as	O
the	O
only	O
curative	O
option	O
for	O
resectable	O
oesophageal	O
cancer,	O
but	O
pulmonary	O
complications	O
occurring	O
in	O
more	O
than	O
half	O
of	O
patients	O
after	O
open	O
oesophagectomy	O
are	O
a	O
great	O
concern.	O

We	O
assessed	O
whether	O
minimally	O
invasive	O
oesophagectomy	O
reduces	O
morbidity	O
compared	O
with	O
open	O
oesophagectomy.	O

We	O
did	O
a	O
multicentre,	O
open-label,	O
randomised	O
controlled	O
trial	O
at	O
five	O
study	O
centres	O
in	O
three	O
countries	O
between	O
June	O
1,	O
2009,	O
and	O
March	O
31,	O
2011.	O

Patients	O
aged	O
18-75	O
years	O
with	O
resectable	O
cancer	O
of	O
the	O
oesophagus	O
or	O
gastro-oesophageal	O
junction	O
were	O
randomly	O
assigned	O
via	O
a	O
computer-generated	O
randomisation	O
sequence	O
to	O
receive	O
either	O
open	O
transthoracic	O
or	O
minimally	O
invasive	O
transthoracic	O
oesophagectomy.	O

Randomisation	O
was	O
stratified	O
by	O
centre.	O

Patients,	O
and	O
investigators	O
undertaking	O
interventions,	O
assessing	O
outcomes,	O
and	O
analysing	O
data,	O
were	O
not	O
masked	O
to	O
group	O
assignment.	O

The	O
primary	O
outcome	O
was	O
pulmonary	O
infection	O
within	O
the	O
first	O
2	O
weeks	O
after	O
surgery	O
and	O
during	O
the	O
whole	O
stay	O
in	O
hospital.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat.	O

This	O
trial	O
is	O
registered	O
with	O
the	O
Netherlands	O
Trial	O
Register,	O
NTR	O
TC	O
2452.	O

We	O
randomly	O
assigned	O
56	O
patients	O
to	O
the	O
open	O
oesophagectomy	O
group	O
and	O
59	O
to	O
the	O
minimally	O
invasive	O
oesophagectomy	O
group.	O

16	B-Premise
(29%)	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
open	I-Premise
oesophagectomy	I-Premise
group	I-Premise
had	I-Premise
pulmonary	I-Premise
infection	I-Premise
in	I-Premise
the	I-Premise
first	I-Premise
2	I-Premise
weeks	I-Premise
compared	I-Premise
with	I-Premise
five	I-Premise
(9%)	I-Premise
in	I-Premise
the	I-Premise
minimally	I-Premise
invasive	I-Premise
group	I-Premise
(relative	I-Premise
risk	I-Premise
[RR]	I-Premise
030,	I-Premise
95%	I-Premise
CI	I-Premise
012-076;	I-Premise
p=0005).	I-Premise

19	B-Premise
(34%)	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
open	I-Premise
oesophagectomy	I-Premise
group	I-Premise
had	I-Premise
pulmonary	I-Premise
infection	I-Premise
in-hospital	I-Premise
compared	I-Premise
with	I-Premise
seven	I-Premise
(12%)	I-Premise
in	I-Premise
the	I-Premise
minimally	I-Premise
invasive	I-Premise
group	I-Premise
(035,	I-Premise
016-078;	I-Premise
p=0005).	I-Premise

For	B-Premise
in-hospital	I-Premise
mortality,	I-Premise
one	I-Premise
patient	I-Premise
in	I-Premise
the	I-Premise
open	I-Premise
oesophagectomy	I-Premise
group	I-Premise
died	I-Premise
from	I-Premise
anastomotic	I-Premise
leakage	I-Premise
and	I-Premise
two	I-Premise
in	I-Premise
the	I-Premise
minimally	I-Premise
invasive	I-Premise
group	I-Premise
from	I-Premise
aspiration	I-Premise
and	I-Premise
mediastinitis	I-Premise
after	I-Premise
anastomotic	I-Premise
leakage.	I-Premise

These	B-Claim
findings	I-Claim
provide	I-Claim
evidence	I-Claim
for	I-Claim
the	I-Claim
short-term	I-Claim
benefits	I-Claim
of	I-Claim
minimally	I-Claim
invasive	I-Claim
oesophagectomy	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
resectable	I-Claim
oesophageal	I-Claim
cancer.	I-Claim

Phase	O
III	O
EGF104900	O
data	O
demonstrated	O
that	O
lapatinib	O
plus	O
trastuzumab	O
significantly	O
improved	O
progression-free	O
survival	O
(PFS)	O
and	O
clinical	O
benefit	O
rate	O
versus	O
lapatinib	O
monotherapy,	O
offering	O
a	O
chemotherapy-free	O
option	O
for	O
patients	O
with	O
heavily	O
pretreated	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(HER2)	O
-positive	O
metastatic	O
breast	O
cancer	O
(MBC).	O

Final	O
planned	O
overall	O
survival	O
(OS)	O
analysis	O
from	O
EGF104900	O
is	O
reported	O
here.	O

Patients	O
with	O
HER2-positive	O
MBC	O
whose	O
disease	O
progressed	O
during	O
prior	O
trastuzumab-based	O
therapies	O
were	O
randomly	O
assigned	O
to	O
receive	O
lapatinib	O
monotherapy	O
or	O
lapatinib	O
in	O
combination	O
with	O
trastuzumab.	O

OS	O
and	O
updated	O
PFS	O
data	O
are	O
presented	O
using	O
Kaplan-Meier	O
curves	O
and	O
log-rank	O
tests	O
stratified	O
for	O
hormone	O
receptor	O
and	O
visceral	O
disease	O
status.	O

Subgroup	O
analyses	O
were	O
conducted	O
to	O
identify	O
characteristics	O
of	O
patients	O
deriving	O
the	O
greatest	O
clinical	O
benefit.	O

In	B-Premise
this	I-Premise
updated	I-Premise
final	I-Premise
analysis	I-Premise
of	I-Premise
all	I-Premise
patients	I-Premise
randomly	I-Premise
assigned	I-Premise
with	I-Premise
strata	I-Premise
(n	I-Premise
=	I-Premise
291),	I-Premise
lapatinib	I-Premise
plus	I-Premise
trastuzumab	I-Premise
continued	I-Premise
to	I-Premise
show	I-Premise
superiority	I-Premise
to	I-Premise
lapatinib	I-Premise
monotherapy	I-Premise
in	I-Premise
PFS	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR],	I-Premise
0.74;	I-Premise
95%	I-Premise
CI,	I-Premise
0.58	I-Premise
to	I-Premise
0.94;	I-Premise
P	I-Premise
=	I-Premise
.011)	I-Premise
and	I-Premise
offered	I-Premise
significant	I-Premise
OS	I-Premise
benefit	I-Premise
(HR,	I-Premise
0.74;	I-Premise
95%	I-Premise
CI,	I-Premise
0.57	I-Premise
to	I-Premise
0.97;	I-Premise
P	I-Premise
=	I-Premise
.026).	I-Premise

Improvements	B-Premise
in	I-Premise
absolute	I-Premise
OS	I-Premise
rates	I-Premise
were	I-Premise
10%	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
and	I-Premise
15%	I-Premise
at	I-Premise
12	I-Premise
months	I-Premise
in	I-Premise
the	I-Premise
combination	I-Premise
arm	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
monotherapy	I-Premise
arm.	I-Premise

Multiple	B-Premise
baseline	I-Premise
factors,	I-Premise
including	I-Premise
Eastern	I-Premise
Cooperative	I-Premise
Oncology	I-Premise
Group	I-Premise
performance	I-Premise
status	I-Premise
of	I-Premise
0,	I-Premise
nonvisceral	I-Premise
disease,	I-Premise
<	I-Premise
three	I-Premise
metastatic	I-Premise
sites,	I-Premise
and	I-Premise
less	I-Premise
time	I-Premise
from	I-Premise
initial	I-Premise
diagnosis	I-Premise
until	I-Premise
random	I-Premise
assignment,	I-Premise
were	I-Premise
associated	I-Premise
with	I-Premise
improved	I-Premise
OS.	I-Premise

Incidence	B-Premise
of	I-Premise
adverse	I-Premise
events	I-Premise
was	I-Premise
consistent	I-Premise
with	I-Premise
previously	I-Premise
reported	I-Premise
rates.	I-Premise

These	B-Claim
data	I-Claim
demonstrated	I-Claim
a	I-Claim
significant	I-Claim
4.5-month	I-Claim
median	I-Claim
OS	I-Claim
advantage	I-Claim
with	I-Claim
the	I-Claim
lapatinib	I-Claim
and	I-Claim
trastuzumab	I-Claim
combination	I-Claim
and	I-Claim
support	I-Claim
dual	I-Claim
HER2	I-Claim
blockade	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
heavily	I-Claim
pretreated	I-Claim
HER2-positive	I-Claim
MBC.	I-Claim

This	O
study	O
tested	O
hyperbaric	O
oxygen	O
(HBO)	O
as	O
an	O
adjunct	O
to	O
surgery	O
and	O
antibiotics	O
in	O
the	O
treatment	O
of	O
bisphosphonate-related	O
osteonecrosis	O
of	O
the	O
jaw	O
(ONJ)	O
and	O
evaluated	O
its	O
effects	O
on	O
gingival	O
healing,	O
pain,	O
and	O
quality	O
of	O
life.	O

The	O
investigators	O
implemented	O
a	O
randomized	O
controlled	O
trial	O
and	O
enrolled	O
a	O
sample	O
composed	O
of	O
patients	O
with	O
ONJ,	O
where	O
the	O
predictor	O
variable	O
was	O
HBO	O
administered	O
at	O
2	O
atm	O
twice	O
a	O
day	O
for	O
40	O
treatments	O
as	O
an	O
adjunct	O
to	O
conventional	O
therapy	O
of	O
surgery	O
and	O
antibiotics	O
versus	O
conventional	O
therapy	O
alone.	O

Over	O
the	O
next	O
24	O
months,	O
oral	O
lesion	O
size	O
and	O
number,	O
pain,	O
and	O
quality	O
of	O
life	O
were	O
assessed.	O

Forty-six	O
patients	O
(mean	O
age,	O
66	O
yrs;	O
57%	O
women)	O
contributed	O
data	O
to	O
the	O
trial.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
the	O
distribution	O
of	O
variables	O
used	O
to	O
assess	O
randomization	O
success	O
between	O
the	O
HBO	O
and	O
standard	O
treatment	O
groups.	O

Seventeen	B-Premise
of	I-Premise
25	I-Premise
HBO-treated	I-Premise
patients	I-Premise
(68%)	I-Premise
improved	I-Premise
versus	I-Premise
8	I-Premise
of	I-Premise
21	I-Premise
controls	I-Premise
(38.1%;	I-Premise
P	I-Premise
=	I-Premise
.043,	I-Premise
(2)	I-Premise
test).	I-Premise

Mean	B-Premise
time	I-Premise
to	I-Premise
improvement	I-Premise
was	I-Premise
39.7	I-Premise
weeks	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI],	I-Premise
22.4	I-Premise
to	I-Premise
57.0	I-Premise
weeks)	I-Premise
for	I-Premise
HBO-treated	I-Premise
patients	I-Premise
versus	I-Premise
67.9	I-Premise
weeks	I-Premise
(95	I-Premise
CI,	I-Premise
48.4	I-Premise
to	I-Premise
87.5	I-Premise
weeks)	I-Premise
for	I-Premise
controls	I-Premise
(P	I-Premise
=	I-Premise
.03,	I-Premise
log-rank	I-Premise
test).	I-Premise

However,	B-Premise
complete	I-Premise
gingival	I-Premise
healing	I-Premise
occurred	I-Premise
in	I-Premise
only	I-Premise
14	I-Premise
of	I-Premise
25	I-Premise
HBO-treated	I-Premise
patients	I-Premise
(52%)	I-Premise
versus	I-Premise
7	I-Premise
of	I-Premise
21	I-Premise
controls	I-Premise
(33.3%;	I-Premise
P	I-Premise
=	I-Premise
.203,	I-Premise
(2)	I-Premise
test),	I-Premise
and	I-Premise
time	I-Premise
to	I-Premise
healing	I-Premise
was	I-Premise
59	I-Premise
weeks	I-Premise
(95%	I-Premise
CI,	I-Premise
42.8%	I-Premise
to	I-Premise
75.8%)	I-Premise
for	I-Premise
HBO-treated	I-Premise
patients	I-Premise
versus	I-Premise
70	I-Premise
weeks	I-Premise
(95	I-Premise
CI,	I-Premise
52.2%	I-Premise
to	I-Premise
88.36%)	I-Premise
for	I-Premise
controls	I-Premise
(P	I-Premise
=	I-Premise
.32,	I-Premise
log-rank	I-Premise
test).	I-Premise

Pain	B-Premise
decreased	I-Premise
faster	I-Premise
for	I-Premise
HBO-treated	I-Premise
subjects	I-Premise
(P	I-Premise
<	I-Premise
.01,	I-Premise
linear	I-Premise
regression).	I-Premise

Quality-of-life	B-Premise
scores	I-Premise
for	I-Premise
physical	I-Premise
health	I-Premise
(P	I-Premise
=	I-Premise
.002)	I-Premise
and	I-Premise
perceived	I-Premise
health	I-Premise
(P	I-Premise
=	I-Premise
.043)	I-Premise
decreased	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
for	I-Premise
control	I-Premise
group	I-Premise
but	I-Premise
for	I-Premise
not	I-Premise
the	I-Premise
HBO	I-Premise
group.	I-Premise

ONJ	B-Claim
is	I-Claim
multifactorial	I-Claim
and	I-Claim
no	I-Claim
single	I-Claim
treatment	I-Claim
modality	I-Claim
is	I-Claim
likely	I-Claim
to	I-Claim
reverse	I-Claim
it;	I-Claim
however,	B-Claim
it	I-Claim
is	I-Claim
treatable	I-Claim
and	I-Claim
even	I-Claim
advanced	I-Claim
presentations	I-Claim
can	I-Claim
improve	I-Claim
with	I-Claim
intensive	I-Claim
multimodal	I-Claim
therapy.	I-Claim

Clinically,	B-Claim
HBO	I-Claim
appears	I-Claim
to	I-Claim
be	I-Claim
a	I-Claim
useful	I-Claim
adjunct	I-Claim
to	I-Claim
ONJ	I-Claim
treatment,	I-Claim
particularly	I-Claim
for	I-Claim
more	I-Claim
severe	I-Claim
cases,	I-Claim
although	I-Claim
this	I-Claim
study	I-Claim
was	I-Claim
underpowered	I-Claim
to	I-Claim
fully	I-Claim
support	I-Claim
this	I-Claim
claim.	I-Claim

Older	O
breast	O
cancer	O
survivors	O
(BCSs)	O
are	O
at	O
risk	O
for	O
late	O
and	O
long-term	O
treatment	O
effects	O
on	O
quality	O
of	O
life	O
(QOL),	O
including	O
lower	O
physical	O
functioning	O
and	O
fear	O
of	O
recurrence.	O

Two	O
promising	O
approaches	O
to	O
address	O
this	O
include	O
dance/movement	O
therapy	O
and	O
mindfulness.	O

The	O
purpose	O
of	O
this	O
2-group	O
randomized	O
controlled	O
pilot	O
feasibility	O
study	O
was	O
to	O
test	O
short-term	O
effects	O
of	O
a	O
12-week	O
Mindful	O
Movement	O
Program	O
(MMP)	O
intervention	O
combining	O
mindfulness	O
with	O
self-directed	O
movement	O
on	O
QOL	O
and	O
mindfulness	O
in	O
female	O
BCSs	O
50	O
years	O
or	O
older	O
and	O
at	O
12	O
months	O
or	O
more	O
following	O
treatment.	O

Consented	O
participants	O
were	O
randomized	O
to	O
an	O
experimental	O
group	O
(EG)	O
(12	O
weekly	O
MMP	O
sessions)	O
or	O
a	O
control	O
group	O
(no	O
sessions).	O

All	O
completed	O
questionnaires	O
3	O
times.	O

The	O
EG	O
participants	O
kept	O
home	O
practice	O
diaries.	O

Analysis	O
was	O
conducted	O
after	O
intervention	O
for	O
immediate	O
effects	O
on	O
outcome	O
variables	O
and	O
6	O
weeks	O
later	O
for	O
maintenance	O
of	O
effects.	O

Participants	O
(n	O
=	O
49)	O
ranged	O
in	O
age	O
from	O
50	O
to	O
90	O
years	O
(average,	O
65.6	O
years)	O
and	O
were	O
at	O
9.8	O
years	O
since	O
diagnosis	O
(range,	O
1-32	O
years),	O
and	O
the	O
majority	O
were	O
white,	O
unpartnered,	O
and	O
retired.	O

After	B-Premise
intervention,	I-Premise
EG	I-Premise
participants	I-Premise
showed	I-Premise
improved	I-Premise
QOL	I-Premise
via	I-Premise
decreased	I-Premise
fear	I-Premise
of	I-Premise
recurrence	I-Premise
and	I-Premise
increased	I-Premise
mindfulness	I-Premise
attitude.	I-Premise

At	B-Premise
6	I-Premise
weeks,	I-Premise
initial	I-Premise
effects	I-Premise
were	I-Premise
retained.	I-Premise

The	B-Premise
MMP	I-Premise
appears	I-Premise
to	I-Premise
benefit	I-Premise
older	I-Premise
BCSs	I-Premise
by	I-Premise
reducing	I-Premise
fear	I-Premise
of	I-Premise
recurrence	I-Premise
and	I-Premise
improving	I-Premise
mindfulness	I-Premise
attitude.	I-Premise

Although	B-Claim
these	I-Claim
findings	I-Claim
are	I-Claim
promising,	I-Claim
a	I-Claim
larger	I-Claim
study	I-Claim
is	I-Claim
needed	I-Claim
to	I-Claim
determine	I-Claim
more	I-Claim
specifically	I-Claim
what	I-Claim
short-	I-Claim
and	I-Claim
long-term	I-Claim
effects	I-Claim
are	I-Claim
possible.	I-Claim

The	B-Claim
combination	I-Claim
of	I-Claim
self-directed	I-Claim
movement	I-Claim
and	I-Claim
mindfulness,	I-Claim
as	I-Claim
tested	I-Claim
here,	I-Claim
may	I-Claim
be	I-Claim
a	I-Claim
valuable	I-Claim
tool	I-Claim
for	I-Claim
promoting	I-Claim
health	I-Claim
and	I-Claim
well-being	I-Claim
in	I-Claim
older	I-Claim
long-term	I-Claim
survivors	I-Claim
of	I-Claim
breast	I-Claim
cancer.	I-Claim

Research	O
has	O
shown	O
that	O
self-directed	O
stress	O
management	O
training	O
improves	O
mental	O
well-being	O
in	O
patients	O
undergoing	O
chemotherapy.	O

The	O
present	O
study	O
extends	O
this	O
work	O
by	O
evaluating	O
separate	O
and	O
combined	O
effects	O
of	O
stress	O
management	O
training	O
and	O
home-based	O
exercise.	O

Following	O
assessment	O
of	O
mental	O
and	O
physical	O
well-being,	O
depression,	O
anxiety,	O
exercise,	O
and	O
stress	O
reduction	O
activity	O
before	O
chemotherapy	O
started,	O
patients	O
were	O
randomized	O
to	O
stress	O
management	O
training	O
(SM),	O
exercise	O
(EX),	O
combined	O
stress	O
management	O
and	O
exercise	O
(SMEX),	O
or	O
usual	O
care	O
only	O
(UCO).	O

Outcomes	O
were	O
reassessed	O
6	O
and	O
12	O
weeks	O
after	O
chemotherapy	O
started.	O

Significance	O
testing	O
of	O
group-by-time	O
interactions	O
in	O
286	O
patients	O
who	O
completed	O
all	O
assessments	O
was	O
used	O
to	O
evaluate	O
intervention	O
efficacy.	O

Interaction	B-Premise
effects	I-Premise
for	I-Premise
mental	I-Premise
and	I-Premise
physical	I-Premise
well-being	I-Premise
scores	I-Premise
were	I-Premise
not	I-Premise
significant.	I-Premise

Depression	B-Premise
scores	I-Premise
yielded	I-Premise
a	I-Premise
linear	I-Premise
interaction	I-Premise
comparing	I-Premise
UCO	I-Premise
and	I-Premise
SMEX	I-Premise
(p	I-Premise
=	I-Premise
0.019),	I-Premise
with	I-Premise
decreases	I-Premise
in	I-Premise
SMEX	I-Premise
but	I-Premise
not	I-Premise
UCO.	I-Premise

Anxiety	B-Premise
scores	I-Premise
yielded	I-Premise
a	I-Premise
quadratic	I-Premise
interaction	I-Premise
comparing	I-Premise
UCO	I-Premise
and	I-Premise
SMEX	I-Premise
(p	I-Premise
=	I-Premise
0.049),	I-Premise
with	I-Premise
trends	I-Premise
for	I-Premise
changes	I-Premise
in	I-Premise
SMEX	I-Premise
but	I-Premise
not	I-Premise
UCO.	I-Premise

Additional	B-Premise
analyses	I-Premise
yielded	I-Premise
quadratic	I-Premise
interactions	I-Premise
for	I-Premise
exercise	I-Premise
activity	I-Premise
comparing	I-Premise
UCO	I-Premise
and	I-Premise
SMEX	I-Premise
(p	I-Premise
=	I-Premise
0.022),	I-Premise
with	I-Premise
positive	I-Premise
changes	I-Premise
in	I-Premise
SMEX	I-Premise
but	I-Premise
not	I-Premise
UCO,	I-Premise
and	I-Premise
for	I-Premise
stress	I-Premise
management	I-Premise
activity	I-Premise
comparing	I-Premise
UCO	I-Premise
and	I-Premise
SM	I-Premise
(p	I-Premise
<	I-Premise
0.001)	I-Premise
and	I-Premise
UCO	I-Premise
and	I-Premise
SMEX	I-Premise
(p	I-Premise
=	I-Premise
0.013),	I-Premise
with	I-Premise
positive	I-Premise
changes	I-Premise
in	I-Premise
SM	I-Premise
and	I-Premise
SMEX	I-Premise
but	I-Premise
not	I-Premise
UCO.	I-Premise

Only	B-Claim
the	I-Claim
combined	I-Claim
intervention	I-Claim
yielded	I-Claim
effects	I-Claim
on	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
outcomes,	I-Claim
and	I-Claim
these	I-Claim
were	I-Claim
limited	I-Claim
to	I-Claim
anxiety	I-Claim
and	I-Claim
depression.	I-Claim

These	B-Premise
findings	I-Premise
are	I-Premise
consistent	I-Premise
with	I-Premise
evidence	I-Premise
that	I-Premise
only	I-Premise
the	I-Premise
combined	I-Premise
intervention	I-Premise
yielded	I-Premise
increases	I-Premise
in	I-Premise
both	I-Premise
exercise	I-Premise
and	I-Premise
stress	I-Premise
management	I-Premise
activity.	I-Premise

Future	O
research	O
should	O
investigate	O
ways	O
to	O
augment	O
this	O
intervention	O
to	O
enhance	O
its	O
benefits.	O

The	B-Claim
incidence	I-Claim
and	I-Claim
development	I-Claim
of	I-Claim
cancer	I-Claim
are	I-Claim
closely	I-Claim
related	I-Claim
to	I-Claim
dysfunction	I-Claim
of	I-Claim
immune	I-Claim
function.	I-Claim

The	O
immune	O
system	O
cannot	O
identify	O
and	O
remove	O
malignant	O
and	O
mutant	O
cells,	O
which	O
cause	O
tumor	O
cells	O
to	O
escape	O
from	O
surveillance	O
and	O
clearance	O
of	O
the	O
immune	O
system.	O

Immunobiological	O
cancer	O
therapy	O
plays	O
an	O
important	O
role	O
in	O
strengthening	O
body	O
immunological	O
surveillance	O
function	O
and	O
killing	O
remaining	O
tumor	O
cells	O
in	O
the	O
body.	O

We	O
investigated	O
the	O
role	O
of	O
DC/CIK	O
(dendritic	O
cell/cytokine-induced	O
killer	O
cells)	O
immunobiological	O
cancer	O
therapy	O
in	O
maintenance	O
therapy	O
of	O
advanced	O
non-small	O
cell	O
lung	O
cancer.	O

When	O
60	O
cases	O
of	O
non-small	O
cell	O
lung	O
cancer	O
patients	O
in	O
stage	O
IIIb	O
and	O
IV	O
reached	O
stable	O
disease	O
after	O
treatment	O
with	O
4	O
cycles	O
of	O
a	O
two-drug	O
regimen	O
with	O
platinum,	O
they	O
were	O
randomly	O
divided	O
into	O
two	O
groups.	O

One	O
group	O
was	O
treated	O
with	O
DC/CIK	O
immunobiological	O
cancer	O
therapy,	O
and	O
the	O
other	O
was	O
taken	O
as	O
a	O
control	O
group.	O

Finally,	O
cancer	O
progression	O
time	O
and	O
toxicity	O
reaction	O
of	O
the	O
two	O
groups	O
were	O
evaluated.	O

DC/CIK	B-Premise
treatment	I-Premise
prolongs	I-Premise
progression-free	I-Premise
survival	I-Premise
(3.20	I-Premise
months	I-Premise
[95%	I-Premise
CI,	I-Premise
2.94-3.50]	I-Premise
vs	I-Premise
2.56	I-Premise
months	I-Premise
[95%	I-Premise
CI,	I-Premise
2.39-2.73];	I-Premise
P	I-Premise
<0.05).	I-Premise

In	B-Premise
the	I-Premise
treatment	I-Premise
group,	I-Premise
the	I-Premise
proportion	I-Premise
of	I-Premise
NK	I-Premise
cells,	I-Premise
T-cell	I-Premise
subgroups	I-Premise
CD3+,	I-Premise
CD4+	I-Premise
and	I-Premise
CD8+	I-Premise
had	I-Premise
a	I-Premise
significant	I-Premise
change	I-Premise
before	I-Premise
and	I-Premise
after	I-Premise
treatment.	I-Premise

Liver	B-Premise
and	I-Premise
kidney	I-Premise
function	I-Premise
and	I-Premise
blood	I-Premise
tests	I-Premise
of	I-Premise
the	I-Premise
treatment	I-Premise
group	I-Premise
were	I-Premise
within	I-Premise
the	I-Premise
normal	I-Premise
range	I-Premise
before	I-Premise
and	I-Premise
after	I-Premise
treatment.	I-Premise

In	B-Premise
the	I-Premise
treatment	I-Premise
group,	I-Premise
1	I-Premise
case	I-Premise
suffered	I-Premise
from	I-Premise
chest	I-Premise
distress,	I-Premise
3	I-Premise
cases	I-Premise
suffered	I-Premise
from	I-Premise
acratia,	I-Premise
and	I-Premise
4	I-Premise
cases	I-Premise
suffered	I-Premise
from	I-Premise
pyrexia.	I-Premise

DC/CIK	B-Claim
treatment	I-Claim
had	I-Claim
potential	I-Claim
benefit	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
non-small	I-Claim
cell	I-Claim
lung	I-Claim
cancer	I-Claim
compared	I-Claim
with	I-Claim
the	I-Claim
control	I-Claim
group	I-Claim
and	I-Claim
had	I-Claim
no	I-Claim
obvious	I-Claim
side	I-Claim
effects.	I-Claim

DC/CIK	B-Claim
treatment	I-Claim
is	I-Claim
a	I-Claim
safe	I-Claim
and	I-Claim
effective	I-Claim
method	I-Claim
for	I-Claim
maintenance	I-Claim
therapy	I-Claim
of	I-Claim
advanced	I-Claim
non-small	I-Claim
cell	I-Claim
lung	I-Claim
cancer.	I-Claim

Nocturnal	O
administration	O
of	O
branched-chain	O
amino	O
acid	O
(BCAA)	O
granules	O
improves	O
serum	O
albumin	O
levels	O
in	O
patients	O
with	O
cirrhosis.	O

However,	O
it	O
is	O
unclear	O
whether	O
or	O
not	O
this	O
administration	O
method	O
can	O
improve	O
the	O
patients'	O
quality	O
of	O
life	O
(QOL).	O

In	O
this	O
study,	O
we	O
aimed	O
to	O
investigate	O
the	O
efficacy	O
of	O
BCAA	O
granules,	O
given	O
nocturnally,	O
in	O
improving	O
QOL	O
in	O
these	O
patients.	O

We	O
performed	O
a	O
multicenter,	O
randomized	O
controlled	O
trial	O
examining	O
the	O
comparative	O
effects	O
of	O
BCAA	O
granules	O
given	O
orally	O
for	O
3	O
months	O
with	O
daytime	O
or	O
nocturnal	O
administration	O
in	O
patients	O
with	O
compensated	O
cirrhosis.	O

Health-related	O
QOL	O
was	O
measured	O
by	O
a	O
Japanese	O
version	O
of	O
the	O
questionnaire	O
on	O
subjective	O
and	O
objective	O
symptoms,	O
and	O
the	O
Short	O
Form-8	O
(SF-8)	O
questionnaire.	O

Twenty-one	O
patients	O
received	O
BCAA	O
granules	O
three	O
times	O
a	O
day	O
(one	O
sachet	O
after	O
each	O
meal:	O
the	O
daytime	O
group),	O
and	O
16	O
patients	O
received	O
the	O
granules	O
twice	O
a	O
day	O
(one	O
sachet	O
after	O
breakfast,	O
and	O
two	O
sachets	O
before	O
bedtime:	O
the	O
nocturnal	O
group).	O

Baseline	O
characteristics	O
did	O
not	O
differ	O
between	O
the	O
groups	O
(whole	O
cohort:	O
Child-Pugh	O
grade	O
A/B,	O
21/16;	O
mean	O
age,	O
68.2	O
years).	O

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
any	I-Premise
of	I-Premise
the	I-Premise
subjects	I-Premise
revealed	I-Premise
by	I-Premise
the	I-Premise
questionnaire	I-Premise
regarding	I-Premise
subjective	I-Premise
or	I-Premise
objective	I-Premise
symptoms,	I-Premise
or	I-Premise
by	I-Premise
the	I-Premise
SF-8	I-Premise
between	I-Premise
the	I-Premise
daytime	I-Premise
group	I-Premise
and	I-Premise
the	I-Premise
nocturnal	I-Premise
group	I-Premise
after	I-Premise
3	I-Premise
months	I-Premise
of	I-Premise
treatment.	I-Premise

The	B-Premise
daytime	I-Premise
group	I-Premise
showed	I-Premise
a	I-Premise
significant	I-Premise
effect	I-Premise
on	I-Premise
general	I-Premise
health,	I-Premise
vitality,	I-Premise
social	I-Premise
functioning,	I-Premise
mental	I-Premise
health,	I-Premise
and	I-Premise
role	I-Premise
emotional	I-Premise
as	I-Premise
revealed	I-Premise
on	I-Premise
the	I-Premise
SF-8.	I-Premise

Conversely,	B-Premise
the	I-Premise
nocturnal	I-Premise
group	I-Premise
exhibited	I-Premise
a	I-Premise
significant	I-Premise
decrease	I-Premise
in	I-Premise
the	I-Premise
occurrence	I-Premise
of	I-Premise
muscle	I-Premise
cramps	I-Premise
in	I-Premise
the	I-Premise
legs	I-Premise
(P	I-Premise
=	I-Premise
0.014)	I-Premise
and	I-Premise
significantly	I-Premise
improved	I-Premise
Fisher's	I-Premise
ratio	I-Premise
after	I-Premise
3	I-Premise
months	I-Premise
(P	I-Premise
=	I-Premise
0.04).	I-Premise

Nocturnal	B-Claim
administration	I-Claim
of	I-Claim
BCAA	I-Claim
granules	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
cirrhosis	I-Claim
reduced	I-Claim
the	I-Claim
occurrence	I-Claim
of	I-Claim
muscle	I-Claim
cramps	I-Claim
in	I-Claim
the	I-Claim
leg	I-Claim
but	I-Claim
did	I-Claim
not	I-Claim
improve	I-Claim
the	I-Claim
patients'	I-Claim
QOL.	I-Claim

The	O
aim	O
of	O
this	O
prospective	O
controlled	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
of	O
two	O
different	O
combination	O
treatment	O
modalities	O
of	O
lymphedema	O
(LE).	O

Manual	O
lymphatic	O
drainage	O
(MLD)	O
and	O
compression	O
bandage	O
combination	O
(complex	O
decongestive	O
therapy)	O
have	O
been	O
compared	O
with	O
intermittent	O
pneumatic	O
compression	O
(IPC)	O
plus	O
self-lymphatic	O
drainage	O
(SLD).	O

Both	O
MLD	O
with	O
compression	O
bandage	O
(complex	O
decongestive	O
therapy)	O
group	O
(Group	O
I,	O
n=15)	O
and	O
IPC	O
with	O
SLD	O
group	O
(Group	O
II,	O
n=15)	O
received	O
treatment	O
for	O
LE	O
3	O
days	O
in	O
a	O
week	O
and	O
every	O
other	O
day	O
for	O
6	O
weeks.	O

Arm	O
circumferences	O
were	O
measured	O
before	O
and	O
the	O
1st,	O
3rd,	O
and	O
6th	O
weeks	O
of	O
the	O
treatment.	O

EORTC-QLQ	O
and	O
ASES-tests	O
were	O
performed	O
to	O
assess	O
the	O
quality	O
of	O
life	O
before	O
and	O
after	O
6	O
week-treatment.	O

Patients	O
in	O
both	O
groups	O
had	O
similar	O
demographic	O
and	O
clinical	O
characteristics.	O

Even	O
though	O
both	B-Premise
treatment	I-Premise
modalities	I-Premise
resulted	I-Premise
in	I-Premise
significant	I-Premise
decrease	I-Premise
in	I-Premise
the	I-Premise
total	I-Premise
arm	I-Premise
volume	I-Premise
(12.2%	I-Premise
decrease	I-Premise
in	I-Premise
Group	I-Premise
II	I-Premise
and	I-Premise
14.9%	I-Premise
decrease	I-Premise
in	I-Premise
Group	I-Premise
I)	I-Premise
(p<0.001),	I-Premise
no	B-Premise
significant	I-Premise
difference	I-Premise
(p=0.582)	I-Premise
was	I-Premise
found	I-Premise
between	I-Premise
those	I-Premise
two	I-Premise
groups.	I-Premise

Similarly,	B-Premise
ASES	I-Premise
scores	I-Premise
were	I-Premise
significantly	I-Premise
(p=0.001)	I-Premise
improved	I-Premise
in	I-Premise
both	I-Premise
Group	I-Premise
I	I-Premise
and	I-Premise
II	I-Premise
without	I-Premise
any	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
the	I-Premise
groups.	I-Premise

While	B-Premise
emotional	I-Premise
functioning,	I-Premise
fatigue,	I-Premise
and	I-Premise
pain	I-Premise
scores	I-Premise
were	I-Premise
significantly	I-Premise
improved	I-Premise
in	I-Premise
both	I-Premise
groups,	I-Premise
global	I-Premise
health	I-Premise
status,	I-Premise
functional	I-Premise
and	I-Premise
cognitive	I-Premise
functioning	I-Premise
scores	I-Premise
appeared	I-Premise
to	I-Premise
be	I-Premise
improved	I-Premise
only	I-Premise
in	I-Premise
patients	I-Premise
of	I-Premise
group	I-Premise
I.	I-Premise

Different	B-Claim
treatment	I-Claim
modalities	I-Claim
consisting	I-Claim
of	I-Claim
MLD	I-Claim
and	I-Claim
compression	I-Claim
bandage(complex	I-Claim
decongestive	I-Claim
therapy)	I-Claim
or	I-Claim
IPC	I-Claim
and	I-Claim
SLD	I-Claim
appear	I-Claim
to	I-Claim
be	I-Claim
effective	I-Claim
in	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
LE	I-Claim
with	I-Claim
similar	I-Claim
therapeutic	I-Claim
efficacy	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
breast	I-Claim
cancer.	I-Claim

However,	B-Claim
combination	I-Claim
modalities	I-Claim
including	I-Claim
IPC	I-Claim
and	I-Claim
SLD	I-Claim
may	I-Claim
be	I-Claim
the	I-Claim
preferred	I-Claim
choices	I-Claim
for	I-Claim
their	I-Claim
applicability	I-Claim
at	I-Claim
home.	I-Claim

The	O
aim	O
of	O
the	O
study	O
is	O
to	O
demonstrate	O
that	O
intrapatient	O
dose	O
escalation	O
of	O
carboplatin	O
would	O
improve	O
the	O
outcome	O
in	O
ovarian	O
cancer	O
compared	O
with	O
flat	O
dosing.	O

Patients	O
with	O
untreated	O
stage	O
IC-IV	O
ovarian	O
cancer	O
received	O
six	O
cycles	O
of	O
carboplatin	O
area	O
under	O
the	O
curve	O
6	O
(AUC	O
6)	O
3	O
weekly	O
either	O
with	O
no	O
dose	O
modification	O
except	O
for	O
toxicity	O
(Arm	O
A)	O
or	O
with	O
dose	O
escalations	O
in	O
cycles	O
2-6	O
based	O
on	O
nadir	O
neutrophil	O
and	O
platelet	O
counts	O
(Arm	O
B).	O

The	O
primary	O
end-point	O
was	O
progression-free	O
survival	O
(PFS).	O

Nine	O
hundred	O
and	O
sixty-four	O
patients	O
were	O
recruited	O
from	O
71	O
centers.	O

Dose	O
escalation	O
was	O
achieved	O
in	O
77%	O
of	O
patients	O
who	O
had	O
1	O
cycle.	O

The	B-Premise
median	I-Premise
AUCs	I-Premise
(cycle	I-Premise
2-6)	I-Premise
received	I-Premise
were	I-Premise
6.0	I-Premise
(Arm	I-Premise
A)	I-Premise
and	I-Premise
7.2	I-Premise
(Arm	I-Premise
B)	I-Premise
(P	I-Premise
<	I-Premise
0.001).	I-Premise

Grade	B-Premise
3/4	I-Premise
non-hematological	I-Premise
toxicity	I-Premise
was	I-Premise
higher	I-Premise
in	I-Premise
Arm	I-Premise
B	I-Premise
(31%	I-Premise
versus	I-Premise
22%	I-Premise
P	I-Premise
=	I-Premise
0.001).	I-Premise

The	B-Premise
median	I-Premise
PFS	I-Premise
was	I-Premise
12.1	I-Premise
months	I-Premise
in	I-Premise
Arm	I-Premise
A	I-Premise
and	I-Premise
B	I-Premise
[hazard	I-Premise
ratio	I-Premise
(HR)	I-Premise
0.99;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
(CI)	I-Premise
0.85-1.15;	I-Premise
P	I-Premise
=	I-Premise
0.93].	I-Premise

The	B-Premise
median	I-Premise
overall	I-Premise
survival	I-Premise
(OS)	I-Premise
was	I-Premise
34.1	I-Premise
and	I-Premise
30.7	I-Premise
months	I-Premise
in	I-Premise
Arms	I-Premise
A	I-Premise
and	I-Premise
B,	I-Premise
respectively	I-Premise
(HR	I-Premise
0.98;	I-Premise
95%	I-Premise
CI	I-Premise
0.81-1.18,	I-Premise
P	I-Premise
=	I-Premise
0.82).	I-Premise

In	B-Premise
multivariate	I-Premise
analysis,	I-Premise
baseline	I-Premise
neutrophil	I-Premise
(P	I-Premise
<	I-Premise
0.001),	I-Premise
baseline	I-Premise
platelet	I-Premise
counts	I-Premise
(P	I-Premise
<	I-Premise
0.001)	I-Premise
and	I-Premise
the	I-Premise
difference	I-Premise
between	I-Premise
white	I-Premise
blood	I-Premise
cell	I-Premise
(WBC)	I-Premise
and	I-Premise
neutrophil	I-Premise
count	I-Premise
(P	I-Premise
=	I-Premise
0.009)	I-Premise
had	I-Premise
a	I-Premise
significant	I-Premise
adverse	I-Premise
prognostic	I-Premise
value.	I-Premise

Intrapatient	B-Claim
dose	I-Claim
escalation	I-Claim
of	I-Claim
carboplatin	I-Claim
based	I-Claim
on	I-Claim
nadir	I-Claim
blood	I-Claim
counts	I-Claim
is	I-Claim
feasible	I-Claim
and	I-Claim
safe.	I-Claim

However,	B-Claim
it	I-Claim
provided	I-Claim
no	I-Claim
improvement	I-Claim
in	I-Claim
PFS	I-Claim
or	I-Claim
OS	I-Claim
compared	I-Claim
with	I-Claim
flat	I-Claim
dosing.	I-Claim

Baseline	O
neutrophils	O
over-ride	O
nadir	O
counts	O
in	O
prognostic	O
significance.	O

These	O
data	O
may	O
have	O
wider	O
implications	O
particularly	O
in	O
respect	O
of	O
the	O
management	O
of	O
chemotherapy-induced	O
neutropenia.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
cognitive	O
behavioral	O
therapy	O
(CBT),	O
physical	O
exercise	O
(PE),	O
and	O
of	O
these	O
two	O
interventions	O
combined	O
(CBT/PE)	O
on	O
menopausal	O
symptoms	O
(primary	O
outcome),	O
body	O
image,	O
sexual	O
functioning,	O
psychological	O
well-being,	O
and	O
health-related	O
quality	O
of	O
life	O
(secondary	O
outcomes)	O
in	O
patients	O
with	O
breast	O
cancer	O
experiencing	O
treatment-induced	O
menopause.	O

Patients	O
with	O
breast	O
cancer	O
reporting	O
treatment-induced	O
menopausal	O
symptoms	O
(N=422)	O
were	O
randomly	O
assigned	O
to	O
CBT	O
(n=109),	O
PE	O
(n=104),	O
CBT/PE	O
(n=106),	O
or	O
to	O
a	O
waiting	O
list	O
control	O
group	O
(n=103).	O

Self-report	O
questionnaires	O
were	O
completed	O
at	O
baseline,	O
12	O
weeks,	O
and	O
6	O
months.	O

Multilevel	O
procedures	O
were	O
used	O
to	O
compare	O
the	O
intervention	O
groups	O
with	O
the	O
control	O
group	O
over	O
time.	O

Compared	B-Premise
with	I-Premise
the	I-Premise
control	I-Premise
group,	I-Premise
the	I-Premise
intervention	I-Premise
groups	I-Premise
had	I-Premise
a	I-Premise
significant	I-Premise
decrease	I-Premise
in	I-Premise
levels	I-Premise
of	I-Premise
endocrine	I-Premise
symptoms	I-Premise
(Functional	I-Premise
Assessment	I-Premise
of	I-Premise
Cancer	I-Premise
Therapy-Endocrine	I-Premise
Symptoms;	I-Premise
P<.001;	I-Premise
effect	I-Premise
size,	I-Premise
0.31-0.52)	I-Premise
and	I-Premise
urinary	I-Premise
symptoms	I-Premise
(Bristol	I-Premise
Female	I-Premise
Lower	I-Premise
Urinary	I-Premise
Tract	I-Premise
Symptoms	I-Premise
Questionnaire;	I-Premise
P=.002;	I-Premise
effect	I-Premise
size,	I-Premise
0.29-0.33),	I-Premise
and	I-Premise
they	I-Premise
showed	I-Premise
an	I-Premise
improvement	I-Premise
in	I-Premise
physical	I-Premise
functioning	I-Premise
(36-Item	I-Premise
Short	I-Premise
Form	I-Premise
Health	I-Premise
Survey	I-Premise
physical	I-Premise
functioning	I-Premise
subscale;	I-Premise
P=.002;	I-Premise
effect	I-Premise
size,	I-Premise
0.37-0.46).	I-Premise

The	B-Premise
groups	I-Premise
that	I-Premise
included	I-Premise
CBT	I-Premise
also	I-Premise
showed	I-Premise
a	I-Premise
significant	I-Premise
decrease	I-Premise
in	I-Premise
the	I-Premise
perceived	I-Premise
burden	I-Premise
of	I-Premise
hot	I-Premise
flashes	I-Premise
and	I-Premise
night	I-Premise
sweats	I-Premise
(problem	I-Premise
rating	I-Premise
scale	I-Premise
of	I-Premise
the	I-Premise
Hot	I-Premise
Flush	I-Premise
Rating	I-Premise
Scale;	I-Premise
P<.001;	I-Premise
effect	I-Premise
size,	I-Premise
0.39-0.56)	I-Premise
and	I-Premise
an	I-Premise
increase	I-Premise
in	I-Premise
sexual	I-Premise
activity	I-Premise
(Sexual	I-Premise
Activity	I-Premise
Questionnaire	I-Premise
habit	I-Premise
subscale;	I-Premise
P=.027;	I-Premise
effect	I-Premise
size,	I-Premise
0.65).	I-Premise

Most	O
of	O
these	O
effects	O
were	O
observed	O
at	O
both	O
the	O
12-week	O
and	O
6-month	O
follow-ups.	O

CBT	B-Claim
and	I-Claim
PE	I-Claim
can	I-Claim
have	I-Claim
salutary	I-Claim
effects	I-Claim
on	I-Claim
endocrine	I-Claim
symptoms	I-Claim
and,	I-Claim
to	I-Claim
a	I-Claim
lesser	I-Claim
degree,	I-Claim
on	I-Claim
sexuality	I-Claim
and	I-Claim
physical	I-Claim
functioning	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
breast	I-Claim
cancer	I-Claim
experiencing	I-Claim
treatment-induced	I-Claim
menopause.	I-Claim

Future	B-Claim
work	I-Claim
is	I-Claim
needed	I-Claim
to	I-Claim
improve	I-Claim
the	I-Claim
design	I-Claim
and	I-Claim
the	I-Claim
planning	I-Claim
of	I-Claim
these	I-Claim
interventions	I-Claim
to	I-Claim
improve	I-Claim
program	I-Claim
adherence.	I-Claim

To	O
report	O
5-year	O
contrast-enhanced	O
magnetic	O
resonance	O
imaging	O
findings	O
of	O
the	O
REST	O
trial	O
recruits	O
who	O
underwent	O
either	O
uterine	O
artery	O
embolization	O
(UAE)	O
or	O
myomectomy.	O

A	O
total	O
of	O
157	O
patients	O
were	O
randomized	O
to	O
UAE	O
or	O
surgery	O
(hysterectomy	O
or	O
myomectomy).	O

Ninety-nine	O
patients	O
who	O
had	O
UAE	O
and	O
eight	O
patients	O
who	O
had	O
myomectomy	O
were	O
analyzed.	O

MRI	O
scans	O
at	O
baseline,	O
6	O
months,	O
and	O
5	O
years	O
were	O
independently	O
interpreted	O
by	O
two	O
radiologists.	O

Dominant	O
fibroid	O
diameter,	O
uterine	O
volume,	O
total	O
fibroid	O
infarction	O
(complete	O
100	O
%,	O
almost	O
complete	O
90-99	O
%,	O
partial	O
<90	O
%),	O
and	O
new	O
fibroid	O
formation	O
were	O
the	O
main	O
parameters	O
assessed	O
and	O
related	O
to	O
the	O
need	O
for	O
reintervention.	O

In	B-Premise
the	I-Premise
UAE	I-Premise
group,	I-Premise
mean	I-Premise
	I-Premise
standard	I-Premise
deviation	I-Premise
uterine	I-Premise
volume	I-Premise
was	I-Premise
670	I-Premise
	I-Premise
503,	I-Premise
422	I-Premise
	I-Premise
353,	I-Premise
and	I-Premise
292	I-Premise
	I-Premise
287	I-Premise
mL	I-Premise
at	I-Premise
baseline,	I-Premise
6	I-Premise
months,	I-Premise
and	I-Premise
5	I-Premise
years,	I-Premise
respectively.	I-Premise

Mean	B-Premise
dominant	I-Premise
fibroid	I-Premise
diameter	I-Premise
was	I-Premise
7.6	I-Premise
	I-Premise
3.0,	I-Premise
5.8	I-Premise
	I-Premise
2.9,	I-Premise
and	I-Premise
5	I-Premise
	I-Premise
2.9	I-Premise
cm	I-Premise
at	I-Premise
baseline,	I-Premise
6	I-Premise
months,	I-Premise
and	I-Premise
5	I-Premise
years.	I-Premise

Fibroid	B-Premise
infarction	I-Premise
at	I-Premise
6	I-Premise
months	I-Premise
was	I-Premise
complete	I-Premise
in	I-Premise
35	I-Premise
%	I-Premise
of	I-Premise
women,	I-Premise
almost	I-Premise
complete	I-Premise
in	I-Premise
29	I-Premise
%,	I-Premise
and	I-Premise
partial	I-Premise
in	I-Premise
36	I-Premise
%.	I-Premise

Need	B-Premise
for	I-Premise
reintervention	I-Premise
was	I-Premise
19,	I-Premise
10,	I-Premise
and	I-Premise
33	I-Premise
%	I-Premise
in	I-Premise
these	I-Premise
groups,	I-Premise
respectively	I-Premise
(p	I-Premise
=	I-Premise
0.123).	I-Premise

No	B-Premise
myomectomy	I-Premise
cases	I-Premise
had	I-Premise
further	I-Premise
intervention.	I-Premise

At	B-Premise
5	I-Premise
years,	I-Premise
the	I-Premise
prevalence	I-Premise
of	I-Premise
new	I-Premise
fibroid	I-Premise
was	I-Premise
60	I-Premise
%	I-Premise
in	I-Premise
the	I-Premise
myomectomy	I-Premise
group	I-Premise
and	I-Premise
7	I-Premise
%	I-Premise
in	I-Premise
the	I-Premise
UAE	I-Premise
group	I-Premise
(p	I-Premise
=	I-Premise
0.008).	I-Premise

There	B-Premise
is	I-Premise
a	I-Premise
further	I-Premise
significant	I-Premise
reduction	I-Premise
in	I-Premise
both	I-Premise
uterine	I-Premise
volume	I-Premise
and	I-Premise
dominant	I-Premise
fibroid	I-Premise
diameter	I-Premise
between	I-Premise
6	I-Premise
months	I-Premise
and	I-Premise
5	I-Premise
years	I-Premise
after	I-Premise
UAE.	I-Premise

Complete	B-Claim
fibroid	I-Claim
infarction	I-Claim
does	I-Claim
not	I-Claim
translate	I-Claim
into	I-Claim
total	I-Claim
freedom	I-Claim
from	I-Claim
a	I-Claim
subsequent	I-Claim
reintervention.	I-Claim

New	B-Claim
fibroid	I-Claim
formation	I-Claim
is	I-Claim
significantly	I-Claim
higher	I-Claim
after	I-Claim
myomectomy.	I-Claim

Due	O
to	O
the	O
various	O
inter-individual	O
differences	O
in	O
the	O
biological	O
characteristics	O
of	O
tumor	O
cells,	O
as	O
well	O
as	O
issues	O
on	O
the	O
efficacy,	O
adverse	O
reactions,	O
and	O
defects	O
of	O
existing	O
drugs,	O
we	O
compared	O
the	O
clinical	O
efficacy	O
and	O
toxicity	O
of	O
pemetrexed	O
and	O
gemcitabine	O
combined	O
with	O
cisplatin	O
for	O
the	O
treatment	O
of	O
previously	O
untreated	O
advanced	O
non-small	O
cell	O
lung	O
cancer	O
(NSCLC).	O

251	O
patients	O
were	O
randomly	O
divided	O
into	O
pemetrexed	O
combined	O
with	O
cisplatin	O
group	O
(PP	O
group)	O
with	O
127	O
cases	O
and	O
gemcitabine	O
combined	O
with	O
cisplatin	O
group	O
(GP	O
group)	O
with	O
124	O
cases.	O

PP	O
group	O
received	O
pemetrexed	O
500	O
mg/m	O
iv	O
infusion	O
d1	O
and	O
cisplatin	O
75	O
mg/m	O
iv	O
infusion	O
d1,	O
whereas	O
GP	O
group	O
received	O
gemcitabine	O
1,000	O
mg/m	O
iv	O
infusion	O
d1,8	O
and	O
cisplatin	O
75	O
mg/m	O
iv	O
infusion	O
d1.	O

The	O
treatment	O
cycle	O
was	O
once	O
every	O
three	O
weeks.	O

In	O
addition,	O
folic	O
acid,	O
vitamin	O
B12,	O
and	O
dexamethasone	O
were	O
administered	O
in	O
both	O
groups.	O

The	B-Premise
total	I-Premise
clinical	I-Premise
effective	I-Premise
rates	I-Premise
in	I-Premise
PP	I-Premise
group	I-Premise
and	I-Premise
GP	I-Premise
group	I-Premise
were	I-Premise
25.20%	I-Premise
and	I-Premise
17.74%,	I-Premise
respectively.	I-Premise

The	B-Premise
total	I-Premise
efficiencies	I-Premise
of	I-Premise
non-squamous	I-Premise
cell	I-Premise
carcinoma	I-Premise
were	I-Premise
27.62%	I-Premise
and	I-Premise
16.00%.	I-Premise

The	B-Premise
tumor	I-Premise
progression	I-Premise
duration	I-Premise
in	I-Premise
these	I-Premise
two	I-Premise
groups	I-Premise
was	I-Premise
6.5	I-Premise
and	I-Premise
5.6	I-Premise
months,	I-Premise
respectively.	I-Premise

The	B-Premise
median	I-Premise
survival	I-Premise
time	I-Premise
in	I-Premise
the	I-Premise
two	I-Premise
groups	I-Premise
was	I-Premise
16.9	I-Premise
and	I-Premise
17.0	I-Premise
months,	I-Premise
respectively,	I-Premise
with	I-Premise
59.62%	I-Premise
and	I-Premise
65.87%	I-Premise
survival	I-Premise
rates	I-Premise
of	I-Premise
1	I-Premise
year	I-Premise
and	I-Premise
27.28%	I-Premise
and	I-Premise
27.93%	I-Premise
survival	I-Premise
rates	I-Premise
of	I-Premise
2	I-Premise
years,	I-Premise
respectively.	I-Premise

The	B-Premise
total	I-Premise
efficacy	I-Premise
of	I-Premise
non-squamous	I-Premise
cell	I-Premise
carcinoma	I-Premise
in	I-Premise
the	I-Premise
PP	I-Premise
group	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
than	I-Premise
that	I-Premise
in	I-Premise
GP	I-Premise
group.	I-Premise

The	B-Premise
results	I-Premise
were	I-Premise
statistically	I-Premise
significant.	I-Premise

However,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
total	O
response	O
rates,	O
tumor	O
progression	O
duration,	O
and	O
median	O
survival	O
rates	O
of	O
1	O
and	O
2	O
years.	O

The	B-Premise
rate	I-Premise
of	I-Premise
adverse	I-Premise
reactions,	I-Premise
including	I-Premise
white	I-Premise
blood	I-Premise
cell	I-Premise
reduction,	I-Premise
lower	I-Premise
platelet	I-Premise
count,	I-Premise
lower	I-Premise
hemoglobin,	I-Premise
and	I-Premise
hair	I-Premise
loss	I-Premise
in	I-Premise
the	I-Premise
PP	I-Premise
group	I-Premise
was	I-Premise
significantly	I-Premise
lower	I-Premise
than	I-Premise
that	I-Premise
in	I-Premise
the	I-Premise
GP	I-Premise
group.	I-Premise

The	B-Premise
results	I-Premise
were	I-Premise
statistically	I-Premise
significant.	I-Premise

The	B-Claim
clinical	I-Claim
efficacy	I-Claim
of	I-Claim
pemetrexed	I-Claim
and	I-Claim
gemcitabine	I-Claim
combined	I-Claim
with	I-Claim
cisplatin	I-Claim
for	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
previously	I-Claim
untreated	I-Claim
advanced	I-Claim
NSCLC	I-Claim
was	I-Claim
roughly	I-Claim
the	I-Claim
same,	I-Claim
but	B-Claim
the	I-Claim
adverse	I-Claim
reactions	I-Claim
decreased	I-Claim
significantly	I-Claim
in	I-Claim
the	I-Claim
PP	I-Claim
group	I-Claim
compared	I-Claim
with	I-Claim
those	I-Claim
in	I-Claim
the	I-Claim
GP	I-Claim
group.	I-Claim

Therefore,	B-Claim
pemetrexed	I-Claim
combined	I-Claim
with	I-Claim
cisplatin	I-Claim
can	I-Claim
be	I-Claim
used	I-Claim
as	I-Claim
a	I-Claim
safe	I-Claim
and	I-Claim
effective	I-Claim
drug	I-Claim
for	I-Claim
clinical	I-Claim
first-line	I-Claim
treatment	I-Claim
for	I-Claim
previously	I-Claim
untreated	I-Claim
NSCLC.	I-Claim

Cancer	O
related	O
fatigue	O
(CRF)	O
is	O
a	O
common	O
problem	O
for	O
cancer	O
patients	O
across	O
diagnoses	O
during	O
chemotherapy	O
and	O
is	O
associated	O
with	O
physical	O
inactivity,	O
lower	O
functional	O
level	O
and	O
lack	O
of	O
energy.	O

Few	O
RCT	O
exercise	O
intervention	O
studies	O
have	O
included	O
cancer	O
patients	O
undergoing	O
chemotherapy.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
whether	O
a	O
six-week	O
supervised	O
multimodal	O
exercise	O
intervention,	O
adjunct	O
to	O
chemotherapy	O
and	O
standard	O
care,	O
can	O
reduce	O
the	O
patient's	O
CRF	O
level.	O

Data	O
is	O
based	O
on	O
analyses	O
of	O
a	O
prospective	O
randomised	O
controlled	O
trial	O
'The	O
Body	O
Cancer	O
Trial'.	O

213	O
cancer	O
patients	O
with	O
different	O
diagnoses	O
were	O
randomised	O
into	O
an	O
intervention	O
group	O
or	O
wait-list	O
control	O
group.	O

The	O
primary	O
outcome,	O
Fatigue	O
score	O
(CRF),	O
was	O
evaluated	O
by	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Anaemia	O
Questionnaire	O
(FACT-An-)	O
(FACT-G	O
score	O
&	O
FACT-An	O
Anemia	O
subscale).	O

Supervised	O
exercise,	O
comprising	O
high-intensity	O
cardiovascular	O
and	O
heavy	O
resistance	O
training,	O
relaxation-	O
and	O
body	O
awareness	O
training	O
and	O
massage,	O
9	O
h	O
weekly	O
for	O
6	O
weeks.	O

CRF	B-Premise
was	I-Premise
significantly	I-Premise
reduced	I-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
group,	I-Premise
corresponding	I-Premise
to	I-Premise
a	I-Premise
Fatigue	I-Premise
score	I-Premise
reduction	I-Premise
of	I-Premise
3.04	I-Premise
(effect	I-Premise
size	I-Premise
of	I-Premise
0.44,	I-Premise
95%	I-Premise
CI	I-Premise
0.17-0.72)	I-Premise
(P	I-Premise
=	I-Premise
.002),	I-Premise
the	I-Premise
FACT-An	I-Premise
score	I-Premise
by	I-Premise
5.40	I-Premise
(P	I-Premise
=	I-Premise
.015),	I-Premise
the	I-Premise
FACT-An	I-Premise
Toi	I-Premise
score	I-Premise
by	I-Premise
5.22	I-Premise
(P	I-Premise
=	I-Premise
.009)	I-Premise
and	I-Premise
the	I-Premise
Anaemia-ANS	I-Premise
by	I-Premise
3.76	I-Premise
(P	I-Premise
=	I-Premise
.002).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
effect	I-Premise
on	I-Premise
the	I-Premise
General	I-Premise
Quality	I-Premise
of	I-Premise
Life	I-Premise
score	I-Premise
(FACT-G)	I-Premise
or	I-Premise
on	I-Premise
any	I-Premise
of	I-Premise
the	I-Premise
individual	I-Premise
wellbeing	I-Premise
scores;	I-Premise
Physical	I-Premise
(P	I-Premise
=	I-Premise
.13),	I-Premise
Emotional	I-Premise
(P	I-Premise
=	I-Premise
.87),	I-Premise
Social	I-Premise
(P	I-Premise
=	I-Premise
.83)	I-Premise
and	I-Premise
Functional	I-Premise
(P	I-Premise
=	I-Premise
.26).	I-Premise

In	B-Claim
summary,	I-Claim
this	I-Claim
six-week	I-Claim
supervised	I-Claim
multimodal	I-Claim
exercise	I-Claim
intervention	I-Claim
can	I-Claim
lead	I-Claim
to	I-Claim
significant	I-Claim
reduction	I-Claim
in	I-Claim
self-reported	I-Claim
CRF	I-Claim
in	I-Claim
cancer	I-Claim
patients	I-Claim
undergoing	I-Claim
chemotherapy.	I-Claim

We	O
aimed	O
to	O
assess	O
the	O
effectiveness	O
of	O
acupuncture	O
for	O
cancer-related	O
fatigue	O
(CRF)	O
in	O
patients	O
with	O
breast	O
cancer.	O

We	O
conducted	O
a	O
pragmatic,	O
randomized	O
controlled	O
trial	O
comparing	O
acupuncture	O
with	O
enhanced	O
usual	O
care.	O

Three	O
hundred	O
two	O
outpatients	O
with	O
breast	O
cancer	O
participated.	O

We	O
randomly	O
assigned	O
75	O
patients	O
to	O
usual	O
care	O
and	O
227	O
patients	O
to	O
acupuncture	O
plus	O
usual	O
care	O
(random	O
assignment	O
of	O
1:3	O
respectively)	O
with	O
minimization	O
controlling	O
for	O
baseline	O
general	O
fatigue	O
and	O
maintenance	O
treatment.	O

Treatment	O
was	O
delivered	O
by	O
acupuncturists	O
once	O
a	O
week	O
for	O
6	O
weeks	O
through	O
needling	O
three	O
pairs	O
of	O
acupoints.	O

The	O
usual	O
care	O
group	O
received	O
a	O
booklet	O
with	O
information	O
about	O
fatigue	O
and	O
its	O
management.	O

Primary	O
outcome	O
was	O
general	O
fatigue	O
at	O
6	O
weeks,	O
measured	O
with	O
the	O
Multidimensional	O
Fatigue	O
Inventory	O
(MFI).	O

Other	O
measurements	O
included	O
the	O
Hospital	O
Anxiety	O
and	O
Depression	O
Scale,	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-General	O
quality-of-life	O
scale,	O
and	O
expectation	O
of	O
acupuncture	O
effect.	O

Analyses	O
were	O
by	O
intention	O
to	O
treat.	O

Two	O
hundred	O
forty-six	O
of	O
302	O
patients	O
randomly	O
assigned	O
provided	O
complete	O
data	O
at	O
6	O
weeks.	O

The	B-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
mean	I-Premise
General	I-Premise
Fatigue	I-Premise
score,	I-Premise
between	I-Premise
those	I-Premise
who	I-Premise
received	I-Premise
the	I-Premise
intervention	I-Premise
and	I-Premise
those	I-Premise
who	I-Premise
did	I-Premise
not,	I-Premise
was	I-Premise
-3.11	I-Premise
(95%	I-Premise
CI,	I-Premise
-3.97	I-Premise
to	I-Premise
-2.25;	I-Premise
P	I-Premise
<	I-Premise
.001).	I-Premise

The	B-Premise
intervention	I-Premise
also	I-Premise
improved	I-Premise
all	I-Premise
other	I-Premise
fatigue	I-Premise
aspects	I-Premise
measured	I-Premise
by	I-Premise
MFI,	I-Premise
including	I-Premise
Physical	I-Premise
Fatigue	I-Premise
and	I-Premise
Mental	I-Premise
Fatigue	I-Premise
(acupuncture	I-Premise
effect,	I-Premise
-2.36	I-Premise
and	I-Premise
-1.94,	I-Premise
respectively;	I-Premise
both	I-Premise
at	I-Premise
P	I-Premise
<	I-Premise
.001),	I-Premise
anxiety	I-Premise
and	I-Premise
depression	I-Premise
(acupuncture	I-Premise
effect,	I-Premise
-1.83	I-Premise
and	I-Premise
-2.13,	I-Premise
respectively;	I-Premise
both	I-Premise
at	I-Premise
P	I-Premise
<	I-Premise
.001),	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(Physical	I-Premise
Well-Being	I-Premise
effect,	I-Premise
3.30;	I-Premise
Functional	I-Premise
Well-Being	I-Premise
effect,	I-Premise
3.57;	I-Premise
both	I-Premise
at	I-Premise
P	I-Premise
<	I-Premise
.001;	I-Premise
Emotional	I-Premise
Well-Being	I-Premise
effect,	I-Premise
1.93;	I-Premise
P	I-Premise
=	I-Premise
.001;	I-Premise
and	I-Premise
Social	I-Premise
Functioning	I-Premise
Well-Being	I-Premise
effect,	I-Premise
1.05;	I-Premise
P	I-Premise
<	I-Premise
.05).	I-Premise

Acupuncture	B-Claim
is	I-Claim
an	I-Claim
effective	I-Claim
intervention	I-Claim
for	I-Claim
managing	I-Claim
the	I-Claim
symptom	I-Claim
of	I-Claim
CRF	I-Claim
and	I-Claim
improving	I-Claim
patients'	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

Exercise	O
for	O
Health	O
was	O
a	O
randomized,	O
controlled	O
trial	O
designed	O
to	O
evaluate	O
two	O
modes	O
of	O
delivering	O
(face-to-face	O
[FtF]	O
and	O
over-the-telephone	O
[Tel])	O
an	O
8-month	O
translational	O
exercise	O
intervention,	O
commencing	O
6-weeks	O
post-breast	O
cancer	O
surgery	O
(PS).	O

Outcomes	O
included	O
quality	O
of	O
life	O
(QoL),	O
function	O
(fitness	O
and	O
upper	O
body)	O
and	O
treatment-related	O
side	O
effects	O
(fatigue,	O
lymphoedema,	O
body	O
mass	O
index,	O
menopausal	O
symptoms,	O
anxiety,	O
depression	O
and	O
pain).	O

Generalised	O
estimating	O
equation	O
modelling	O
determined	O
time	O
(baseline	O
[5	O
weeks	O
PS],	O
mid-intervention	O
[6	O
months	O
PS],	O
post-intervention	O
[12	O
months	O
PS]),	O
group	O
(FtF,	O
Tel,	O
Usual	O
Care	O
[UC])	O
and	O
time-by-group	O
effects.	O

194	O
women	O
representative	O
of	O
the	O
breast	O
cancer	O
population	O
were	O
randomised	O
to	O
the	O
FtF	O
(n	O
=	O
67),	O
Tel	O
(n	O
=	O
67)	O
and	O
UC	O
(n	O
=	O
60)	O
groups.	O

There	B-Premise
were	I-Premise
significant	I-Premise
(p	I-Premise
<	I-Premise
0.05)	I-Premise
interaction	I-Premise
effects	I-Premise
on	I-Premise
QoL,	I-Premise
fitness	I-Premise
and	I-Premise
fatigue	I-Premise
with	I-Premise
differences	I-Premise
being	I-Premise
observed	I-Premise
between	I-Premise
the	I-Premise
treatment	I-Premise
groups	I-Premise
and	I-Premise
the	I-Premise
UC	I-Premise
group.	I-Premise

Trends	B-Premise
observed	I-Premise
for	I-Premise
the	I-Premise
treatment	I-Premise
groups	I-Premise
were	I-Premise
similar.	I-Premise

The	B-Premise
treatment	I-Premise
groups	I-Premise
reported	I-Premise
improved	I-Premise
QoL,	I-Premise
fitness	I-Premise
and	I-Premise
fatigue	I-Premise
over	I-Premise
time	I-Premise
and	I-Premise
changes	I-Premise
observed	I-Premise
between	I-Premise
baseline	I-Premise
and	I-Premise
post-intervention	I-Premise
were	I-Premise
clinically	I-Premise
relevant.	I-Premise

In	B-Premise
contrast,	I-Premise
the	I-Premise
UC	I-Premise
group	I-Premise
experienced	I-Premise
no	I-Premise
change,	I-Premise
or	I-Premise
worsening	I-Premise
QoL,	I-Premise
fitness	I-Premise
and	I-Premise
fatigue,	I-Premise
mid-intervention.	I-Premise

Although	B-Premise
improvements	I-Premise
in	I-Premise
the	I-Premise
UC	I-Premise
group	I-Premise
occurred	I-Premise
by	I-Premise
12-months	I-Premise
post-surgery,	I-Premise
the	B-Premise
change	I-Premise
did	I-Premise
not	I-Premise
meet	I-Premise
the	I-Premise
clinically	I-Premise
relevant	I-Premise
threshold.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
differences	I-Premise
in	I-Premise
other	I-Premise
treatment-related	I-Premise
side	I-Premise
effects	I-Premise
between	I-Premise
groups.	I-Premise

This	B-Claim
translational	I-Claim
intervention	I-Claim
trial,	I-Claim
delivered	I-Claim
either	I-Claim
FtF	I-Claim
or	I-Claim
Tel,	I-Claim
supports	I-Claim
exercise	I-Claim
as	I-Claim
a	I-Claim
form	I-Claim
of	I-Claim
adjuvant	I-Claim
breast	I-Claim
cancer	I-Claim
therapy	I-Claim
that	I-Claim
can	I-Claim
prevent	I-Claim
declines	I-Claim
in	I-Claim
fitness	I-Claim
and	I-Claim
function	I-Claim
during	I-Claim
treatment	I-Claim
and	I-Claim
optimise	I-Claim
recovery	I-Claim
post-treatment.	I-Claim

Two	O
million	O
people	O
across	O
the	O
U.K.	O
are	O
living	O
with	O
cancer,	O
often	O
experienced	O
as	O
a	O
long-term	O
condition.	O

They	O
may	O
have	O
unmet	O
needs	O
after	O
active	O
treatment.	O

Rehabilitation	O
aims	O
to	O
address	O
these	O
needs,	O
maximize	O
psychological	O
and	O
physical	O
function,	O
and	O
enable	O
minimum	O
dependency	O
regardless	O
of	O
life	O
expectancy.	O

We	O
aimed	O
to	O
test,	O
in	O
a	O
randomized	O
controlled	O
trial,	O
the	O
clinical	O
and	O
cost	O
effectiveness	O
of	O
a	O
rehabilitation	O
intervention	O
for	O
patients	O
with	O
advanced,	O
recurrent	O
cancer.	O

We	O
conducted	O
a	O
two-arm,	O
wait-list	O
control,	O
randomized	O
trial	O
of	O
a	O
complex	O
rehabilitation	O
intervention	O
delivered	O
by	O
a	O
hospice-based	O
multidisciplinary	O
team	O
vs.	O
usual	O
care	O
for	O
active,	O
progressive,	O
recurrent	O
hematological	O
and	O
breast	O
malignancies,	O
with	O
a	O
follow-up	O
at	O
three	O
months.	O

The	O
primary	O
outcome	O
was	O
the	O
psychological	O
subscale	O
of	O
the	O
Supportive	O
Care	O
Needs	O
Survey	O
(SCNS).	O

Secondary	O
outcomes	O
were	O
other	O
domains	O
of	O
the	O
SCNS,	O
psychological	O
status,	O
continuity	O
of	O
care,	O
quality	O
of	O
life,	O
and	O
resource	O
use.	O

Forty-one	O
participants	O
were	O
enrolled	O
and	O
36	O
completed	O
the	O
trial.	O

The	B-Premise
primary	I-Premise
outcome	I-Premise
was	I-Premise
significantly	I-Premise
lower	I-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
arm	I-Premise
(adjusted	I-Premise
difference	I-Premise
-16.8,	I-Premise
95%	I-Premise
CI	I-Premise
-28.34	I-Premise
to	I-Premise
-5.3;	I-Premise
P	I-Premise
=	I-Premise
0.006).	I-Premise

The	B-Premise
SCNS	I-Premise
physical	I-Premise
and	I-Premise
patient	I-Premise
care	I-Premise
subscales	I-Premise
(-14.2,	I-Premise
95%	I-Premise
CI	I-Premise
-26.2	I-Premise
to	I-Premise
-2.2;	I-Premise
P	I-Premise
=	I-Premise
0.02	I-Premise
and	I-Premise
-7.4,	I-Premise
95%	I-Premise
CI	I-Premise
-13.7	I-Premise
to	I-Premise
-1.1;	I-Premise
P	I-Premise
=	I-Premise
0.02,	I-Premise
respectively)	I-Premise
and	I-Premise
self-reported	I-Premise
health	I-Premise
state	I-Premise
(12.8,	I-Premise
95%	I-Premise
CI	I-Premise
3.2	I-Premise
to	I-Premise
22.4;	I-Premise
P	I-Premise
=	I-Premise
0.01)	I-Premise
also	I-Premise
differed	I-Premise
significantly.	I-Premise

The	B-Premise
incremental	I-Premise
cost-effectiveness	I-Premise
ratio	I-Premise
was	I-Premise
19,390	I-Premise
per	I-Premise
quality-adjusted	I-Premise
life	I-Premise
year.	I-Premise

This	B-Claim
intervention	I-Claim
significantly	I-Claim
reduced	I-Claim
the	I-Claim
unmet	I-Claim
needs	I-Claim
of	I-Claim
cancer	I-Claim
survivors	I-Claim
and	I-Claim
it	I-Claim
is	I-Claim
likely	I-Claim
that	I-Claim
it	I-Claim
is	I-Claim
cost-effective.	I-Claim

Despite	B-Claim
small	I-Claim
numbers,	I-Claim
the	I-Claim
main	I-Claim
effect	I-Claim
size	I-Claim
was	I-Claim
robust.	I-Claim

We	B-Claim
recommend	I-Claim
implementation	I-Claim
alongside	I-Claim
evaluation	I-Claim
in	I-Claim
wider	I-Claim
clinical	I-Claim
settings	I-Claim
and	I-Claim
patient	I-Claim
populations.	I-Claim

To	O
study	O
the	O
effects	O
of	O
Fuzheng	O
Jianpi	O
Decoction	O
(FJD)	O
combined	O
chemotherapy	O
on	O
the	O
quality	O
of	O
life	O
(QOL)	O
and	O
the	O
survival	O
time	O
of	O
children	O
with	O
solid	O
tumor.	O

Recruited	O
were	O
167	O
solid	O
tumor	O
children	O
patients	O
at	O
Department	O
of	O
Tumor,	O
Beijing	O
Children's	O
Hospital.	O

They	O
were	O
randomly	O
assigned	O
to	O
the	O
treatment	O
group	O
(83	O
cases)	O
and	O
the	O
control	O
group	O
(84	O
cases)	O
according	O
to	O
the	O
random	O
digit	O
table.	O

All	O
had	O
chemotherapy.	O

Those	O
in	O
the	O
treatment	O
group	O
additionally	O
took	O
FJD,	O
50	O
-100	O
mL	O
each	O
time,	O
twice	O
daily.	O

After	O
chemotherapy	O
those	O
in	O
the	O
treatment	O
group	O
took	O
modified	O
FJD.	O

The	O
WBC,	O
Hb,	O
and	O
PLT	O
were	O
detected	O
in	O
all	O
patients	O
before	O
treatment,	O
6	O
months	O
after	O
treatment,	O
and	O
1	O
year	O
after	O
treatment.	O

The	O
1-,	O
2-,	O
and	O
3-year	O
QOL,	O
3-year	O
survival	O
rate,	O
and	O
the	O
survival	O
life	O
of	O
dead	O
children	O
patients	O
were	O
observed.	O

Compared	B-Premise
with	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
of	I-Premise
the	I-Premise
same	I-Premise
period,	I-Premise
the	I-Premise
6-month	I-Premise
and	I-Premise
1-year	I-Premise
WBC	I-Premise
and	I-Premise
Hb	I-Premise
increased,	I-Premise
the	I-Premise
1-year	I-Premise
PLT	I-Premise
increased	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group,	I-Premise
showing	I-Premise
statistical	I-Premise
difference	I-Premise
(P<0.05,	I-Premise
P<0.01).	I-Premise

Compared	B-Premise
with	I-Premise
1-year	I-Premise
treatment	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group,	I-Premise
the	I-Premise
2-and	I-Premise
3-year	I-Premise
psychological	I-Premise
functions	I-Premise
and	I-Premise
the	I-Premise
general	I-Premise
symptoms	I-Premise
scores	I-Premise
decreased	I-Premise
(P<0.05,	I-Premise
P<0.01).	I-Premise

Compared	B-Premise
with	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
of	I-Premise
the	I-Premise
same	I-Premise
period,	I-Premise
the	I-Premise
2-and	I-Premise
3-year	I-Premise
somatic	I-Premise
functions,	I-Premise
psychological	I-Premise
functions,	I-Premise
and	I-Premise
the	I-Premise
general	I-Premise
symptoms	I-Premise
scores	I-Premise
decreased	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group;	I-Premise
the	B-Premise
2-year	I-Premise
somatic	I-Premise
functions	I-Premise
and	I-Premise
psychological	I-Premise
functions	I-Premise
decreased	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group;	I-Premise
the	B-Premise
3-year	I-Premise
psychological	I-Premise
functions	I-Premise
and	I-Premise
the	I-Premise
general	I-Premise
symptoms	I-Premise
scores	I-Premise
decreased	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group,	I-Premise
all	I-Premise
with	I-Premise
statistical	I-Premise
difference	I-Premise
(all	I-Premise
P<0.05).	I-Premise

Compared	B-Premise
with	I-Premise
the	I-Premise
control	I-Premise
group,	I-Premise
the	I-Premise
death	I-Premise
number	I-Premise
decreased,	I-Premise
the	I-Premise
survival	I-Premise
rate	I-Premise
increased,	I-Premise
the	I-Premise
life	I-Premise
span	I-Premise
of	I-Premise
dead	I-Premise
children	I-Premise
was	I-Premise
prolonged	I-Premise
in	I-Premise
the	I-Premise
treatment	I-Premise
group,	I-Premise
showing	I-Premise
statistical	I-Premise
difference	I-Premise
(P<0.05).	I-Premise

FJD	B-Claim
combined	I-Claim
chemotherapy	I-Claim
could	I-Claim
effectively	I-Claim
improve	I-Claim
the	I-Claim
QOL	I-Claim
of	I-Claim
solid	I-Claim
tumor	I-Claim
children	I-Claim
patients,	I-Claim
elevate	I-Claim
their	I-Claim
survival	I-Claim
rate,	I-Claim
and	I-Claim
prolong	I-Claim
their	I-Claim
life	I-Claim
spans.	I-Claim

Over	O
30%	O
of	O
patients	O
with	O
non-small	O
cell	O
lung	O
cancer	O
(NSCLC)	O
develop	O
brain	O
metastases.	O

If	O
inoperable,	O
optimal	O
supportive	O
care	O
(OSC),	O
including	O
steroids,	O
and	O
whole	O
brain	O
radiotherapy	O
(WBRT)	O
are	O
generally	O
considered	O
to	O
be	O
standard	O
care,	O
although	O
there	O
is	O
no	O
randomised	O
evidence	O
demonstrating	O
that	O
the	O
addition	O
of	O
WBRT	O
to	O
OSC	O
improves	O
survival	O
or	O
quality	O
of	O
life.	O

QUARTZ	O
is	O
a	O
randomised,	O
non-inferiority,	O
phase	O
III	O
trial	O
comparing	O
OSC	O
+	O
WBRT	O
versus	O
OSC	O
in	O
patients	O
with	O
inoperable	O
brain	O
metastases	O
from	O
NSCLC.	O

The	O
primary	O
outcome	O
measure	O
is	O
quality-adjusted	O
life	O
years	O
(QALYs).	O

QUARTZ	O
was	O
threatened	O
with	O
both	O
loss	O
of	O
funding	O
and	O
early	O
closure	O
due	O
to	O
poor	O
accrual.	O

A	O
lack	O
of	O
preliminary	O
randomised	O
data	O
supporting	O
the	O
trial's	O
hypotheses	O
was	O
thought	O
to	O
underlie	O
the	O
poor	O
accrual,	O
so,	O
with	O
no	O
knowledge	O
of	O
the	O
data,	O
the	O
independent	O
trial	O
steering	O
committee	O
agreed	O
to	O
the	O
unusual	O
step	O
of	O
releasing	O
interim	O
data.	O

Between	O
March	O
2007	O
and	O
April	O
2010,	O
151	O
(of	O
the	O
planned	O
534)	O
patients	O
were	O
randomised	O
(75	O
OSC	O
+	O
WBRT,	O
76	O
OSC).	O

Participants'	O
baseline	O
demographics	O
included	O
median	O
age	O
67	O
years	O
(interquartile	O
range	O
62-73),	O
60%	O
male,	O
50%	O
with	O
a	O
Karnofsky	O
performance	O
status	O
<70;	O
steroid	O
usage	O
was	O
similar	O
in	O
the	O
two	O
groups;	O
64/75	O
(85%)	O
received	O
WBRT	O
(20	O
Gy	O
in	O
five	O
fractions).	O

Median	B-Premise
survival	I-Premise
was:	I-Premise
OSC	I-Premise
+	I-Premise
WBRT	I-Premise
49	I-Premise
days	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
39-61),	I-Premise
OSC	I-Premise
51	I-Premise
days	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
27-57)	I-Premise
-	I-Premise
hazard	I-Premise
ratio	I-Premise
1.11	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
0.80-1.53)	I-Premise
in	I-Premise
favour	I-Premise
of	I-Premise
WBRT.	I-Premise

Quality	B-Premise
of	I-Premise
life	I-Premise
assessed	I-Premise
using	I-Premise
EQ-5D	I-Premise
showed	I-Premise
no	I-Premise
evidence	I-Premise
of	I-Premise
a	I-Premise
difference.	I-Premise

The	B-Premise
estimated	I-Premise
mean	I-Premise
QALYs	I-Premise
was:	I-Premise
OSC	I-Premise
+	I-Premise
WBRT	I-Premise
31	I-Premise
days	I-Premise
and	I-Premise
OSC	I-Premise
30	I-Premise
days,	I-Premise
difference	I-Premise
-1	I-Premise
day	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
-12.0	I-Premise
to	I-Premise
+13.2	I-Premise
days).	I-Premise

These	B-Claim
interim	I-Claim
data	I-Claim
indicate	I-Claim
no	I-Claim
early	I-Claim
evidence	I-Claim
of	I-Claim
detriment	I-Claim
to	I-Claim
quality	I-Claim
of	I-Claim
life,	I-Claim
overall	I-Claim
survival	I-Claim
or	I-Claim
QALYs	I-Claim
for	I-Claim
patients	I-Claim
allocated	I-Claim
to	I-Claim
OSC	I-Claim
alone.	I-Claim

They	O
provide	O
key	O
information	O
for	O
discussing	O
the	O
trial	O
with	O
patients	O
and	O
strengthen	O
the	O
argument	O
for	O
continuing	O
QUARTZ	O
to	O
definitively	O
answer	O
this	O
important	O
clinical	O
question.	O

Chemoradiotherapy	O
(CRT)-induced	O
oral	O
mucositis	O
(OM)	O
adversely	O
affects	O
a	O
patient's	O
oral	O
functions	O
and	O
quality	O
of	O
life	O
(QOL).	O

Low-level	O
laser	O
therapy	O
(LLLT)	O
showed	O
some	O
preventive	O
and	O
curative	O
effects	O
against	O
clinically	O
reported	O
objective	O
measures	O
of	O
OM	O
in	O
few	O
trials	O
including	O
our	O
recently	O
published	O
study.	O

There	O
is	O
dearth	O
of	O
evidence	O
regarding	O
the	O
effects	O
of	O
LLLT	O
on	O
patient's	O
subjective	O
experience	O
of	O
OM	O
and	O
QOL.	O

Hence,	O
we	O
did	O
this	O
study	O
to	O
evaluate	O
the	O
effects	O
of	O
LLLT	O
on	O
a	O
patient's	O
reported	O
measures	O
of	O
OM	O
and	O
QOL	O
in	O
head	O
and	O
neck	O
cancer	O
(HNC)	O
patients	O
receiving	O
CRT.	O

This	O
triple	O
blinded	O
study	O
randomized	O
220	O
HNC	O
patients	O
scheduled	O
for	O
CRT	O
(three	O
weekly	O
Cisplatin	O
+	O
RT	O
=	O
66	O
Gray	O
(2	O
Gy/session),	O
five	O
fractions/week	O
for	O
6.5	O
weeks,	O
total	O
33	O
fractions)	O
into	O
laser	O
(110)	O
and	O
placebo	O
(110)	O
groups.	O

The	O
laser	O
group	O
received	O
LLLT	O
(Technomed	O
Electronics	O
Advanced	O
Laser	O
Therapy	O
1000,	O
He-Ne,	O
	O
=	O
632.8	O
nm,	O
power	O
density	O
=	O
24	O
mW/cm(2),	O
dosage	O
=	O
3.0	O
J	O
at	O
each	O
point,	O
total	O
dose/session	O
=	O
36-40	O
J,	O
spot	O
size	O
1	O
cm(2),	O
irradiation	O
time/point	O
125	O
s)	O
before	O
each	O
radiation	O
session,	O
while	O
the	O
placebo	O
group	O
did	O
not	O
receive	O
laser	O
therapy.	O

Methodology	O
was	O
similar	O
to	O
our	O
recently	O
published	O
study	O
(Gautam	O
et	O
al.	O
Radiother	O
Oncol	O
104:349-354,	O
2012).	O

In	O
this	O
part	O
of	O
our	O
study,	O
a	O
blinded	O
assessor	O
collected	O
subjective	O
outcomes	O
of	O
the	O
patient's	O
reported	O
measures	O
of	O
OM	O
using	O
Oral	O
Mucositis	O
Weekly	O
Questionnaire-Head	O
and	O
Neck	O
(OMWQ-HN)	O
and	O
QOL	O
using	O
Functional	O
Assessment	O
of	O
Cancer	O
Treatment-Head	O
and	O
Neck	O
(FACT-HN)	O
Questionnaire.	O

Data	O
were	O
analyzed	O
using	O
repeated	O
measure	O
ANOVA	O
through	O
general	O
linear	O
model.	O

Statistical	O
significance	O
was	O
kept	O
at	O
p	O
<	O
0.05.	O

Results	B-Premise
analysis	I-Premise
revealed	I-Premise
that	I-Premise
OMWQ-HN	I-Premise
(F	I-Premise
=	I-Premise
12.199,	I-Premise
df	I-Premise
=	I-Premise
6,1314,	I-Premise
p	I-Premise
<	I-Premise
0.001)	I-Premise
and	I-Premise
FACT-HN	I-Premise
(p	I-Premise
<	I-Premise
0.05)	I-Premise
scores	I-Premise
were	I-Premise
significantly	I-Premise
lower	I-Premise
in	I-Premise
LLLT	I-Premise
than	I-Premise
placebo	I-Premise
group	I-Premise
patients.	I-Premise

Also,	O
a	B-Premise
significant	I-Premise
reduction	I-Premise
(p	I-Premise
<	I-Premise
0.001)	I-Premise
in	I-Premise
incidence	I-Premise
of	I-Premise
severe	I-Premise
OM,	I-Premise
need	I-Premise
for	I-Premise
opioid	I-Premise
analgesics,	I-Premise
and	I-Premise
total	I-Premise
parenteral	I-Premise
nutrition	I-Premise
was	I-Premise
observed.	I-Premise

LLLT	B-Claim
was	I-Claim
effective	I-Claim
in	I-Claim
improving	I-Claim
the	I-Claim
patient's	I-Claim
subjective	I-Claim
experience	I-Claim
of	I-Claim
OM	I-Claim
and	I-Claim
QOL	I-Claim
in	I-Claim
HNC	I-Claim
patients	I-Claim
receiving	I-Claim
CRT.	I-Claim

The	O
purpose	O
of	O
this	O
blinded,	O
randomized	O
clinical	O
trial	O
was	O
to	O
compare	O
two	O
topical	O
agents	O
(Calendula	O
Weleda	O
cream	O
vs.	O
Essex	O
cream)	O
in	O
reducing	O
the	O
risk	O
of	O
severe	O
acute	O
radiation	O
skin	O
reactions	O
(ARSR)	O
in	O
relation	O
to	O
adjuvant	O
radiotherapy	O
(RT)	O
for	O
breast	O
cancer.	O

The	O
primary	O
endpoint	O
was	O
the	O
difference	O
in	O
proportion	O
of	O
patients	O
with	O
ARSR,	O
assessed	O
with	O
the	O
Radiation	O
Therapy	O
Oncology	O
Group/The	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Acute	O
Radiation	O
Morbidity	O
Scoring	O
Criteria	O
(RTOG/EORTC	O
scale)	O
at	O
follow-up.	O

The	O
secondary	O
endpoints	O
included	O
patient	O
reported	O
outcome	O
measures;	O
Quality	O
of	O
Life	O
Questionnaire	O
(QLQ-C30),	O
Sleep	O
disturbances	O
(MOS-sleep	O
questionnaire)	O
and	O
symptoms	O
from	O
the	O
irradiated	O
area	O
(visual	O
analogue	O
scale).	O

Patients'	O
experiences	O
and	O
adherence	O
to	O
the	O
topical	O
agents	O
were	O
also	O
evaluated.	O

A	O
total	O
of	O
420	O
patients	O
were	O
randomised	O
and	O
411	O
were	O
analysed.	O

With	O
the	O
exception	O
of	O
previous	O
chemotherapy,	O
the	O
treatment	O
groups	O
were	O
well	O
balanced,	O
both	O
regarding	O
treatment-	O
and	O
patient-related	O
factors.	O

The	B-Premise
incidence	I-Premise
of	I-Premise
severe	I-Premise
ARSR	I-Premise
(RTOG/EORTC	I-Premise
grade	I-Premise
2)	I-Premise
at	I-Premise
the	I-Premise
follow-up	I-Premise
visit	I-Premise
was	I-Premise
23%	I-Premise
(n	I-Premise
=	I-Premise
45)	I-Premise
in	I-Premise
the	I-Premise
Calendula	I-Premise
group	I-Premise
and	I-Premise
19%	I-Premise
(n	I-Premise
=	I-Premise
38)	I-Premise
in	I-Premise
the	I-Premise
Essex	I-Premise
group.	I-Premise

We	B-Premise
found	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
severe	I-Premise
ARSR	I-Premise
between	I-Premise
the	I-Premise
groups	I-Premise
at	I-Premise
any	I-Premise
point	I-Premise
of	I-Premise
assessment.	I-Premise

The	B-Premise
patients	I-Premise
reported	I-Premise
low	I-Premise
levels	I-Premise
of	I-Premise
skin	I-Premise
related	I-Premise
symptoms	I-Premise
and	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
the	I-Premise
groups	I-Premise
were	I-Premise
found.	I-Premise

No	B-Claim
differences	I-Claim
in	I-Claim
ARSR	I-Claim
between	I-Claim
patients	I-Claim
randomised	I-Claim
to	I-Claim
Calendula	I-Claim
or	I-Claim
Essex	I-Claim
cream	I-Claim
was	I-Claim
found.	I-Claim

ARSR	B-Claim
seem	I-Claim
to	I-Claim
be	I-Claim
a	I-Claim
relatively	I-Claim
limited	I-Claim
problem,	I-Claim
probably	I-Claim
more	I-Claim
influenced	I-Claim
by	I-Claim
treatment	I-Claim
related	I-Claim
factors	I-Claim
than	I-Claim
by	I-Claim
choice	I-Claim
of	I-Claim
skin	I-Claim
care	I-Claim
products	I-Claim
in	I-Claim
this	I-Claim
patient	I-Claim
group.	I-Claim

With	O
the	O
adoption	O
of	O
enhanced	O
recovery	O
and	O
emerging	O
new	O
modalities	O
of	O
analgesia	O
after	O
laparoscopic	O
colorectal	O
resection	O
(LCR),	O
the	O
role	O
of	O
epidural	O
analgesia	O
has	O
been	O
questioned.	O

This	O
pilot	O
trial	O
assessed	O
the	O
feasibility	O
of	O
a	O
randomized	O
controlled	O
trial	O
(RCT)	O
comparing	O
epidural	O
analgesia	O
and	O
use	O
of	O
a	O
local	O
anaesthetic	O
wound	O
infusion	O
catheter	O
(WIC)	O
following	O
LCR.	O

Between	O
April	O
2010	O
and	O
May	O
2011,	O
patients	O
undergoing	O
elective	O
LCR	O
in	O
two	O
centres	O
were	O
randomized	O
to	O
analgesia	O
via	O
epidural	O
or	O
WIC.	O

Sham	O
procedures	O
were	O
used	O
to	O
blind	O
surgeons,	O
patients	O
and	O
outcome	O
assessors.	O

The	O
primary	O
outcome	O
was	O
the	O
feasibility	O
of	O
a	O
large	O
RCT,	O
and	O
all	O
outcomes	O
for	O
a	O
definitive	O
trial	O
were	O
tested.	O

The	O
success	O
of	O
blinding	O
was	O
assessed	O
using	O
a	O
mixed-methods	O
approach.	O

Forty-five	O
patients	O
were	O
eligible,	O
of	O
whom	O
34	O
were	O
randomized	O
(mean(s.d.)	O
age	O
70(118)	O
years).	O

Patients	O
were	O
followed	O
up	O
per-protocol;	O
there	O
were	O
no	O
deaths,	O
and	O
five	O
patients	O
had	O
a	O
total	O
of	O
six	O
complications.	O

Challenges	O
with	O
capturing	O
pain	O
data	O
were	O
identified	O
and	O
resolved.	O

Mean(s.d.)	B-Premise
pain	I-Premise
scores	I-Premise
on	I-Premise
the	I-Premise
day	I-Premise
of	I-Premise
discharge	I-Premise
were	I-Premise
19(31)	I-Premise
in	I-Premise
the	I-Premise
epidural	I-Premise
group	I-Premise
and	I-Premise
07(07)	I-Premise
in	I-Premise
the	I-Premise
WIC	I-Premise
group.	I-Premise

Median	B-Premise
length	I-Premise
of	I-Premise
stay	I-Premise
was	I-Premise
4	I-Premise
(range	I-Premise
2-35,	I-Premise
interquartile	I-Premise
range	I-Premise
3-5)	I-Premise
days.	I-Premise

Mean	B-Premise
use	I-Premise
of	I-Premise
additional	I-Premise
analgesia	I-Premise
(intravenous	I-Premise
morphine	I-Premise
equivalents)	I-Premise
was	I-Premise
12	I-Premise
mg	I-Premise
in	I-Premise
the	I-Premise
WIC	I-Premise
arm	I-Premise
and	I-Premise
9	I-Premise
mg	I-Premise
in	I-Premise
the	I-Premise
epidural	I-Premise
arm.	I-Premise

Patient	O
blinding	O
was	O
successful	O
in	O
both	O
arms.	O

Qualitative	B-Claim
interviews	I-Claim
suggested	I-Claim
that	I-Claim
patients	I-Claim
found	I-Claim
participation	I-Claim
in	I-Claim
the	I-Claim
trial	I-Claim
acceptable	I-Claim
and	I-Claim
that	I-Claim
they	I-Claim
would	I-Claim
consider	I-Claim
participating	I-Claim
in	I-Claim
a	I-Claim
future	I-Claim
trial.	I-Claim

A	B-Claim
blinded	I-Claim
RCT	I-Claim
investigating	I-Claim
the	I-Claim
role	I-Claim
of	I-Claim
epidural	I-Claim
and	I-Claim
WIC	I-Claim
administration	I-Claim
for	I-Claim
postoperative	I-Claim
analgesia	I-Claim
following	I-Claim
LCR	I-Claim
is	I-Claim
feasible.	I-Claim

Rigorous	B-Claim
standard	I-Claim
operating	I-Claim
procedures	I-Claim
for	I-Claim
data	I-Claim
collection	I-Claim
are	I-Claim
required.	I-Claim

Several	O
guidelines	O
on	O
the	O
treatment	O
of	O
cancer-related	O
fatigue	O
recommend	O
optimizing	O
treatment	O
of	O
accompanying	O
symptoms.	O

However,	O
evidence	O
for	O
this	O
recommendation	O
from	O
randomized	O
clinical	O
trials	O
is	O
lacking.	O

We	O
investigated	O
whether	O
monitoring	O
and	O
protocolized	O
treatment	O
of	O
physical	O
symptoms	O
alleviates	O
fatigue.	O

In	O
all,	O
152	O
fatigued	O
patients	O
with	O
advanced	O
cancer	O
were	O
randomly	O
assigned	O
to	O
protocolized	O
patient-tailored	O
treatment	O
(PPT)	O
of	O
symptoms	O
or	O
care	O
as	O
usual.	O

The	O
PPT	O
group	O
had	O
four	O
appointments	O
with	O
a	O
nurse	O
who	O
assessed	O
nine	O
symptoms	O
on	O
a	O
0	O
to	O
10	O
numeric	O
rating	O
scale	O
(NRS).	O

Patients	O
received	O
a	O
nonpharmacologic	O
intervention	O
for	O
symptoms	O
with	O
a	O
score	O
	O
1	O
and	O
a	O
medical	O
intervention	O
for	O
symptoms	O
with	O
a	O
score	O
	O
4.	O

Fatigue	O
dimensions,	O
fatigue	O
NRS	O
score,	O
interference	O
of	O
fatigue	O
with	O
daily	O
life,	O
symptom	O
burden,	O
quality	O
of	O
life,	O
anxiety,	O
and	O
depression	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
1,	O
2,	O
and	O
3	O
months.	O

Differences	O
between	O
the	O
groups	O
over	O
time	O
were	O
assessed	O
by	O
using	O
mixed	O
modeling.	O

Seventy-six	O
patients	O
were	O
randomly	O
assigned	O
to	O
each	O
study	O
arm.	O

Mean	O
age	O
was	O
58	O
	O
10	O
years,	O
57%	O
were	O
female,	O
and	O
65%	O
were	O
given	O
palliative	O
chemotherapy.	O

We	B-Premise
found	I-Premise
significant	I-Premise
improvements	I-Premise
over	I-Premise
time	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
PPT	I-Premise
for	I-Premise
the	I-Premise
primary	I-Premise
outcome	I-Premise
general	I-Premise
fatigue	I-Premise
(P	I-Premise
=	I-Premise
.01),	I-Premise
with	I-Premise
significant	I-Premise
group	I-Premise
differences	I-Premise
at	I-Premise
month	I-Premise
1	I-Premise
(effect	I-Premise
size,	I-Premise
0.26;	I-Premise
P	I-Premise
=	I-Premise
.007)	I-Premise
and	I-Premise
month	I-Premise
2	I-Premise
(effect	I-Premise
size,	I-Premise
0.35;	I-Premise
P	I-Premise
=	I-Premise
.005).	I-Premise

Improvements	B-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
PPT	I-Premise
were	I-Premise
also	I-Premise
found	I-Premise
for	I-Premise
the	I-Premise
following	I-Premise
secondary	I-Premise
outcomes:	I-Premise
fatigue	I-Premise
dimensions	I-Premise
"reduced	I-Premise
activity"	I-Premise
and	I-Premise
"reduced	I-Premise
motivation,"	I-Premise
fatigue	I-Premise
NRS,	I-Premise
symptom	I-Premise
burden,	I-Premise
interference	I-Premise
of	I-Premise
fatigue	I-Premise
with	I-Premise
daily	I-Premise
life,	I-Premise
and	I-Premise
anxiety	I-Premise
(all	I-Premise
P	I-Premise
	I-Premise
.03).	I-Premise

In	B-Claim
fatigued	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
cancer,	I-Claim
nurse-led	I-Claim
monitoring	I-Claim
and	I-Claim
protocolized	I-Claim
treatment	I-Claim
of	I-Claim
physical	I-Claim
symptoms	I-Claim
is	I-Claim
effective	I-Claim
in	I-Claim
alleviating	I-Claim
fatigue.	I-Claim

Behavioral	O
symptoms	O
are	O
common	O
in	O
breast	O
cancer	O
survivors,	O
including	O
disturbances	O
in	O
energy,	O
sleep,	O
and	O
mood,	O
though	O
few	O
risk	O
factors	O
for	O
these	O
negative	O
outcomes	O
have	O
been	O
identified.	O

Our	O
study	O
examined	O
intrusive	O
thoughts	O
as	O
a	O
predictor	O
of	O
lingering	O
symptoms	O
in	O
breast	O
cancer	O
survivors	O
in	O
the	O
year	O
following	O
treatment.	O

Data	O
come	O
from	O
the	O
Moving	O
Beyond	O
Cancer	O
psychoeducational	O
intervention	O
trial,	O
aimed	O
at	O
easing	O
the	O
transition	O
from	O
patient	O
to	O
survivor.	O

Women	O
(n	O
=	O
558)	O
completed	O
psychosocial	O
questionnaires	O
within	O
4	O
weeks	O
posttreatment	O
and	O
again	O
2,	O
6,	O
and	O
12	O
months	O
later.	O

We	O
examined	O
intrusive	O
thoughts	O
about	O
cancer	O
at	O
the	O
baseline	O
assessment	O
as	O
a	O
predictor	O
of	O
fatigue,	O
sleep	O
problems,	O
pain,	O
breast	O
cancer-specific	O
symptoms,	O
depressive	O
symptoms,	O
negative	O
affect,	O
and	O
quality	O
of	O
life	O
using	O
growth	O
curve	O
modeling,	O
controlling	O
for	O
study	O
condition	O
and	O
other	O
covariates.	O

Intrusive	B-Premise
thoughts	I-Premise
were	I-Premise
associated	I-Premise
with	I-Premise
higher	I-Premise
levels	I-Premise
of	I-Premise
all	I-Premise
symptoms	I-Premise
at	I-Premise
baseline	I-Premise
and	I-Premise
at	I-Premise
the	I-Premise
12-month	I-Premise
assessment.	I-Premise

Intrusive	B-Premise
thoughts	I-Premise
also	I-Premise
influenced	I-Premise
the	I-Premise
trajectory	I-Premise
of	I-Premise
pain,	I-Premise
depressive	I-Premise
symptoms,	I-Premise
negative	I-Premise
affect,	I-Premise
and	I-Premise
physical	I-Premise
functioning	I-Premise
over	I-Premise
time;	I-Premise
women	B-Premise
with	I-Premise
higher	I-Premise
intrusions	I-Premise
at	I-Premise
baseline	I-Premise
started	I-Premise
worse	I-Premise
and	I-Premise
improved	I-Premise
over	I-Premise
time,	I-Premise
whereas	I-Premise
those	I-Premise
with	I-Premise
lower	I-Premise
intrusions	I-Premise
remained	I-Premise
at	I-Premise
a	I-Premise
constant,	I-Premise
lower	I-Premise
level	I-Premise
over	I-Premise
time.	I-Premise

Intrusions	B-Premise
were	I-Premise
not	I-Premise
associated	I-Premise
with	I-Premise
the	I-Premise
trajectory	I-Premise
of	I-Premise
fatigue,	I-Premise
sleep,	I-Premise
breast	I-Premise
cancer-specific	I-Premise
symptoms,	I-Premise
or	I-Premise
mental	I-Premise
functioning;	I-Premise
women	B-Premise
with	I-Premise
higher	I-Premise
intrusions	I-Premise
at	I-Premise
baseline	I-Premise
started	I-Premise
worse	I-Premise
and	I-Premise
remained	I-Premise
worse	I-Premise
over	I-Premise
time.	I-Premise

Intrusive	B-Claim
thoughts	I-Claim
are	I-Claim
associated	I-Claim
with	I-Claim
enduring	I-Claim
elevations	I-Claim
in	I-Claim
behavioral	I-Claim
symptoms	I-Claim
and	I-Claim
impaired	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
in	I-Claim
the	I-Claim
year	I-Claim
after	I-Claim
breast	I-Claim
cancer	I-Claim
treatment	I-Claim
and	I-Claim
may	I-Claim
be	I-Claim
a	I-Claim
risk	I-Claim
factor	I-Claim
for	I-Claim
poor	I-Claim
outcomes.	I-Claim

The	O
management	O
of	O
cancer-related	O
anorexia/cachexia	O
syndrome	O
(CACS)	O
is	O
a	O
great	O
challenge	O
in	O
clinical	O
practice.	O

To	O
date,	O
practice	O
guidelines	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
CACS	O
are	O
lacking.	O

The	O
authors	O
conducted	O
a	O
randomized	O
study	O
to	O
confirm	O
the	O
effectiveness	O
and	O
safety	O
of	O
treatment	O
of	O
CACS	O
utilizing	O
megestrol	O
acetate	O
(MA)	O
plus	O
thalidomide.	O

One	O
hundred	O
and	O
two	O
candidates	O
with	O
CACS	O
were	O
randomly	O
assigned	O
to	O
two	O
treatment	O
groups	O
(trial	O
group	O
and	O
control	O
group):	O
the	O
trial	O
group	O
received	O
MA	O
(160	O
mg	O
po,	O
bid)	O
plus	O
thalidomide	O
(50	O
mg	O
po,	O
bid),	O
while	O
the	O
control	O
group	O
received	O
MA	O
(160	O
mg	O
po,	O
bid)	O
alone.	O

Treatment	O
duration	O
was	O
8	O
weeks.	O

Analysis	B-Premise
of	I-Premise
the	I-Premise
trial	I-Premise
group	I-Premise
demonstrated	I-Premise
a	I-Premise
significant	I-Premise
increase	I-Premise
from	I-Premise
baseline	I-Premise
in	I-Premise
body	I-Premise
weight	I-Premise
(<0.01),	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(p	I-Premise
=	I-Premise
0.02),	I-Premise
appetite	I-Premise
(p	I-Premise
=	I-Premise
0.01),	I-Premise
and	I-Premise
grip	I-Premise
strength	I-Premise
(p	I-Premise
=	I-Premise
0.01),	I-Premise
and	I-Premise
a	I-Premise
significant	I-Premise
decrease	I-Premise
in	I-Premise
fatigue,	I-Premise
Glasgow	I-Premise
Prognostic	I-Premise
Score	I-Premise
(p	I-Premise
=	I-Premise
0.05),	I-Premise
Eastern	I-Premise
Cooperative	I-Premise
Oncology	I-Premise
Group	I-Premise
performance	I-Premise
status	I-Premise
(p	I-Premise
=	I-Premise
0.03),	I-Premise
IL-6	I-Premise
(p	I-Premise
<	I-Premise
0.01),	I-Premise
and	I-Premise
tumor	I-Premise
necrosis	I-Premise
factor-	I-Premise
(p	I-Premise
=	I-Premise
0.02).	I-Premise

In	B-Premise
contrast,	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group,	I-Premise
endpoints	I-Premise
with	I-Premise
a	I-Premise
significant	I-Premise
improvement	I-Premise
from	I-Premise
baseline	I-Premise
included	I-Premise
body	I-Premise
weight	I-Premise
(p	I-Premise
<	I-Premise
0.02)	I-Premise
and	I-Premise
appetite	I-Premise
(p	I-Premise
=	I-Premise
0.02).	I-Premise

The	B-Premise
mean	I-Premise
changes	I-Premise
in	I-Premise
the	I-Premise
endpoints	I-Premise
from	I-Premise
baseline	I-Premise
in	I-Premise
the	I-Premise
trial	I-Premise
group	I-Premise
were	I-Premise
significantly	I-Premise
greater	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
control	I-Premise
group:	I-Premise
in	I-Premise
the	I-Premise
primary	I-Premise
endpoints,	I-Premise
body	I-Premise
weight	I-Premise
(p	I-Premise
=	I-Premise
0.05),	I-Premise
fatigue	I-Premise
(p	I-Premise
<	I-Premise
0.01)	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(p	I-Premise
=	I-Premise
0.01),	I-Premise
and	I-Premise
in	I-Premise
the	I-Premise
secondary	I-Premise
endpoints,	I-Premise
grip	I-Premise
strength	I-Premise
(p	I-Premise
=	I-Premise
0.05),	I-Premise
Glasgow	I-Premise
Prognostic	I-Premise
Score	I-Premise
(p	I-Premise
=	I-Premise
0.02),	I-Premise
Eastern	I-Premise
Cooperative	I-Premise
Oncology	I-Premise
Group	I-Premise
performance	I-Premise
status	I-Premise
(p	I-Premise
=	I-Premise
0.02),	I-Premise
IL-6	I-Premise
(p	I-Premise
<	I-Premise
0.01)	I-Premise
and	I-Premise
tumor	I-Premise
necrosis	I-Premise
factor-	I-Premise
(p	I-Premise
=	I-Premise
0.01).	I-Premise

Toxicity	B-Premise
was	I-Premise
found	I-Premise
to	I-Premise
be	I-Premise
relatively	I-Premise
negligible	I-Premise
in	I-Premise
both	I-Premise
groups.	I-Premise

A	B-Claim
combination	I-Claim
regimen	I-Claim
of	I-Claim
MA	I-Claim
and	I-Claim
thalidomide	I-Claim
is	I-Claim
more	I-Claim
effective	I-Claim
than	I-Claim
MA	I-Claim
alone	I-Claim
in	I-Claim
the	I-Claim
treatment	I-Claim
of	I-Claim
CACS.	I-Claim

Prior	O
studies	O
have	O
suggested	O
that	O
melatonin,	O
a	O
frequently	O
used	O
integrative	O
medicine,	O
can	O
attenuate	O
weight	O
loss,	O
anorexia,	O
and	O
fatigue	O
in	O
patients	O
with	O
cancer.	O

These	O
studies	O
were	O
limited	O
by	O
a	O
lack	O
of	O
blinding	O
and	O
absence	O
of	O
placebo	O
controls.	O

The	O
primary	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
melatonin	O
with	O
placebo	O
for	O
appetite	O
improvement	O
in	O
patients	O
with	O
cancer	O
cachexia.	O

We	O
performed	O
a	O
randomized,	O
double-blind,	O
28-day	O
trial	O
of	O
melatonin	O
20	O
mg	O
versus	O
placebo	O
in	O
patients	O
with	O
advanced	O
lung	O
or	O
GI	O
cancer,	O
appetite	O
scores	O
	O
4	O
on	O
a	O
0	O
to	O
10	O
scale	O
(10	O
=	O
worst	O
appetite),	O
and	O
history	O
of	O
weight	O
loss	O
	O
5%.	O

Assessments	O
included	O
weight,	O
symptoms	O
by	O
the	O
Edmonton	O
Symptom	O
Assessment	O
Scale,	O
and	O
quality	O
of	O
life	O
by	O
the	O
Functional	O
Assessment	O
of	O
Anorexia/Cachexia	O
Therapy	O
(FAACT)	O
questionnaire.	O

Differences	O
between	O
groups	O
from	O
baseline	O
to	O
day	O
28	O
were	O
analyzed	O
using	O
one-sided,	O
two-sample	O
t	O
tests	O
or	O
Wilcoxon	O
two-sample	O
tests.	O

Interim	O
analysis	O
halfway	O
through	O
the	O
trial	O
had	O
a	O
Lan-DeMets	O
monitoring	O
boundary	O
with	O
an	O
O'Brien-Fleming	O
stopping	O
rule.	O

Decision	O
boundaries	O
were	O
to	O
accept	O
the	O
null	O
hypothesis	O
of	O
futility	O
if	O
the	O
test	O
statistic	O
z	O
<	O
0.39	O
(P	O
	O
.348)	O
and	O
reject	O
the	O
null	O
hypothesis	O
if	O
z	O
>	O
2.54	O
(P	O
	O
.0056).	O

After	O
interim	O
analysis	O
of	O
48	O
patients,	O
the	O
study	O
was	O
closed	O
for	O
futility.	O

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
groups	I-Premise
for	I-Premise
appetite	I-Premise
(P	I-Premise
=	I-Premise
.78)	I-Premise
or	I-Premise
other	I-Premise
symptoms,	I-Premise
weight	I-Premise
(P	I-Premise
=	I-Premise
.17),	I-Premise
FAACT	I-Premise
score	I-Premise
(P	I-Premise
=	I-Premise
.95),	I-Premise
toxicity,	I-Premise
or	I-Premise
survival	I-Premise
from	I-Premise
baseline	I-Premise
to	I-Premise
day	I-Premise
28.	I-Premise

In	B-Claim
cachectic	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
cancer,	I-Claim
oral	I-Claim
melatonin	I-Claim
20	I-Claim
mg	I-Claim
at	I-Claim
night	I-Claim
did	I-Claim
not	I-Claim
improve	I-Claim
appetite,	I-Claim
weight,	I-Claim
or	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
compared	I-Claim
with	I-Claim
placebo.	I-Claim

Treatment	O
of	O
patients	O
with	O
advanced	O
or	O
metastatic	O
esophagogastric	O
adenocarcinoma	O
should	O
not	O
only	O
prolong	O
life	O
but	O
also	O
provide	O
relief	O
of	O
symptoms	O
and	O
improve	O
quality	O
of	O
life	O
(QOL).	O

Esophagogastric	O
adenocarcinoma	O
mainly	O
occurs	O
in	O
elderly	O
patients,	O
but	O
they	O
are	O
underrepresented	O
in	O
most	O
clinical	O
trials	O
and	O
often	O
do	O
not	O
receive	O
effective	O
combination	O
chemotherapy,	O
most	O
probably	O
for	O
fear	O
of	O
intolerance.	O

Using	O
validated	O
instruments,	O
we	O
prospectively	O
assessed	O
QOL	O
within	O
the	O
randomized	O
FLOT65+	O
phase	O
II	O
trial.	O

Within	O
the	O
FLOT65+	O
trial,	O
a	O
total	O
of	O
143	O
patients	O
aged	O
65	O
years	O
were	O
randomly	O
allocated	O
to	O
receive	O
biweekly	O
oxaliplatin	O
plus	O
5-fluorouracil	O
(5-FU)	O
continuous	O
infusion	O
and	O
folinic	O
acid	O
(FLO)	O
or	O
the	O
same	O
regimen	O
in	O
combination	O
with	O
docetaxel	O
50	O
mg/m(2)	O
(FLOT).	O

The	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire	O
C30	O
(EORTC	O
QLQ-C30)	O
and	O
the	O
gastric	O
module	O
STO22	O
were	O
administered	O
every	O
8	O
weeks	O
until	O
progression.	O

Time	O
to	O
definitive	O
deterioration	O
of	O
QOL	O
parameters	O
was	O
analyzed	O
and	O
compared	O
within	O
the	O
treatment	O
arms.	O

The	O
median	O
age	O
of	O
patients	O
was	O
70	O
years.	O

Patients	B-Premise
receiving	I-Premise
FLOT	I-Premise
exhibited	I-Premise
higher	I-Premise
response	I-Premise
rates	I-Premise
and	I-Premise
had	I-Premise
improved	I-Premise
disease-free	I-Premise
and	I-Premise
progression-free	I-Premise
survival	I-Premise
(PFS).	I-Premise

The	O
proportions	O
of	O
patients	O
with	O
evaluable	O
baseline	O
EORTC	O
QLQ-C30	O
and	O
STO22	O
questionnaires	O
were	O
balanced	O
(83	O
%	O
in	O
FLOT	O
and	O
89	O
%	O
in	O
FLO).	O

Considering	O
evaluable	O
patients	O
with	O
assessable	O
questionnaires	O
(n	O
=	O
123),	O
neither	O
functioning	O
nor	O
symptom	O
parameters	O
differed	O
significantly	O
in	O
favor	O
of	O
one	O
of	O
the	O
two	O
treatment	O
groups.	O

Particularly,	O
there	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
regarding	I-Premise
time	I-Premise
to	I-Premise
definitive	I-Premise
deterioration	I-Premise
of	I-Premise
global	I-Premise
health	I-Premise
status/quality	I-Premise
of	I-Premise
life	I-Premise
from	I-Premise
baseline	I-Premise
(primary	I-Premise
endpoint).	I-Premise

Notably,	O
patients	B-Premise
receiving	I-Premise
FLO	I-Premise
or	I-Premise
FLOT	I-Premise
as	I-Premise
palliative	I-Premise
treatment	I-Premise
(n	I-Premise
=	I-Premise
98)	I-Premise
achieved	I-Premise
comparable	I-Premise
QOL	I-Premise
results.	I-Premise

Although	B-Premise
toxicity	I-Premise
was	I-Premise
higher	I-Premise
in	I-Premise
patients	I-Premise
receiving	I-Premise
FLOT,	I-Premise
no	B-Premise
negative	I-Premise
impact	I-Premise
of	I-Premise
the	I-Premise
addition	I-Premise
of	I-Premise
docetaxel	I-Premise
on	I-Premise
QOL	I-Premise
parameters	I-Premise
could	I-Premise
be	I-Premise
demonstrated.	I-Premise

Thus,	O
elderly	B-Claim
patients	I-Claim
in	I-Claim
need	I-Claim
of	I-Claim
intensified	I-Claim
chemotherapy	I-Claim
may	I-Claim
receive	I-Claim
FLOT	I-Claim
without	I-Claim
compromising	I-Claim
patient-reported	I-Claim
outcome	I-Claim
parameters.	I-Claim

To	O
compare	O
dose-volume	O
histogram	O
variables	O
for	O
the	O
internal	O
and	O
external	O
urinary	O
sphincters	O
(IUS/EUS)	O
with	O
urinary	O
quality	O
of	O
life	O
after	O
prostate	O
brachytherapy.	O

Subjects	O
were	O
42	O
consecutive	O
men	O
from	O
a	O
prospective	O
study	O
of	O
brachytherapy	O
as	O
monotherapy	O
with	O
(125)I	O
for	O
intermediate-risk	O
localized	O
prostate	O
cancer.	O

No	O
patient	O
received	O
hormonal	O
therapy.	O

Preplanning	O
constraints	O
included	O
prostate	O
V100	O
higher	O
than	O
95%,	O
V150	O
lower	O
than	O
60%,	O
and	O
V200	O
lower	O
than	O
20%	O
and	O
rectal	O
R100	O
less	O
than	O
1cm(3).	O

Patients	O
completed	O
the	O
Expanded	O
Prostate	O
Cancer	O
Index	O
Composite	O
quality-of-life	O
questionnaire	O
before	O
and	O
at	O
1,	O
4,	O
8,	O
and	O
12	O
months	O
after	O
implantation,	O
and	O
urinary	O
domain	O
scores	O
were	O
analyzed.	O

All	O
structures	O
including	O
the	O
IUS	O
and	O
EUS	O
were	O
contoured	O
on	O
T2-weighted	O
MRI	O
at	O
day	O
30,	O
and	O
doses	O
received	O
were	O
calculated	O
from	O
identification	O
of	O
seeds	O
on	O
CT.	O

Spearman's	O
(nonparametric)	O
rank	O
correlation	O
coefficient	O
()	O
was	O
used	O
for	O
statistical	O
analyses.	O

Overall	O
urinary	O
morbidity	O
was	O
worst	O
at	O
1	O
month	O
after	O
the	O
implant.	O

Urinary	B-Premise
function	I-Premise
declined	I-Premise
when	I-Premise
the	I-Premise
IUS	I-Premise
V285	I-Premise
was	I-Premise
0.4%	I-Premise
(=-0.32,	I-Premise
p=0.04);	I-Premise
bother	B-Premise
worsened	I-Premise
when	I-Premise
the	I-Premise
IUS	I-Premise
V35	I-Premise
was	I-Premise
99%	I-Premise
(=-0.31,	I-Premise
p=0.05)	I-Premise
or	I-Premise
the	I-Premise
EUS	I-Premise
V240	I-Premise
was	I-Premise
63%	I-Premise
(=-0.31,	I-Premise
p=0.05);	I-Premise
irritation	B-Premise
increased	I-Premise
when	I-Premise
the	I-Premise
IUS	I-Premise
V35	I-Premise
was	I-Premise
95%	I-Premise
(=-0.37,	I-Premise
p=0.02)	I-Premise
and	I-Premise
the	I-Premise
EUS	I-Premise
V265	I-Premise
was	I-Premise
24%	I-Premise
(=-0.32,	I-Premise
p=0.04);	I-Premise
and	O
urgency	B-Premise
worsened	I-Premise
when	I-Premise
the	I-Premise
IUS	I-Premise
V35	I-Premise
was	I-Premise
99.5%	I-Premise
(=-0.38,	I-Premise
p=0.02).	I-Premise

Incontinence	B-Premise
did	I-Premise
not	I-Premise
correlate	I-Premise
with	I-Premise
EUS	I-Premise
or	I-Premise
IUS	I-Premise
dose.	I-Premise

Doses	B-Claim
to	I-Claim
the	I-Claim
IUS	I-Claim
and	I-Claim
EUS	I-Claim
on	I-Claim
MRI/CT	I-Claim
predicted	I-Claim
worse	I-Claim
urinary	I-Claim
function,	I-Claim
with	I-Claim
greater	I-Claim
bother,	I-Claim
irritative	I-Claim
symptoms,	I-Claim
and	I-Claim
urgency.	I-Claim

Incorporating	B-Claim
MRI-based	I-Claim
dose-volume	I-Claim
histogram	I-Claim
analysis	I-Claim
into	I-Claim
the	I-Claim
treatment	I-Claim
planning	I-Claim
process	I-Claim
may	I-Claim
reduce	I-Claim
acute	I-Claim
urinary	I-Claim
morbidity	I-Claim
after	I-Claim
brachytherapy.	I-Claim

Maintenance	O
therapy	O
can	O
delay	O
progression	O
and	O
prolong	O
survival	O
in	O
metastatic	O
non-small-cell	O
lung	O
cancer	O
(mNSCLC).	O

As	O
treatment	O
for	O
mNSCLC	O
is	O
non-curative,	O
its	O
impact	O
on	O
patient	O
health-related	O
quality	O
of	O
life	O
(HRQoL)	O
is	O
an	O
important	O
consideration.	O

SATURN	O
(Sequential	O
Tarceva	O
in	O
Unresectable	O
NSCLC)	O
was	O
a	O
randomised,	O
double-blind,	O
placebo-controlled,	O
multicentre	O
study	O
investigating	O
the	O
impact	O
of	O
erlotinib	O
maintenance	O
therapy	O
on	O
HRQoL	O
in	O
patients	O
with	O
locally	O
advanced	O
or	O
recurrent	O
NSCLC.	O

Eligible	O
patients	O
who	O
had	O
previously	O
completed	O
four	O
cycles	O
of	O
platinum-based	O
chemotherapy	O
were	O
randomised	O
1:1	O
to	O
receive	O
erlotinib	O
150	O
mg/day	O
or	O
placebo	O
until	O
disease	O
progression,	O
unacceptable	O
toxicity	O
or	O
death.	O

Patient	O
HRQoL	O
was	O
assessed	O
using	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Lung	O
questionnaire,	O
in	O
terms	O
of	O
time	O
to	O
symptom	O
progression	O
(TSP),	O
time	O
to	O
deterioration	O
(TTD)	O
in	O
Trial	O
Outcome	O
Index	O
(TOI)	O
and	O
TTD.	O

Exploratory	O
analysis	O
was	O
based	O
on	O
time	O
to	O
analgesia	O
and	O
appearance	O
of	O
key	O
symptoms	O
(pain,	O
cough	O
and	O
dyspnoea).	O

Compared	B-Premise
with	I-Premise
placebo,	I-Premise
erlotinib	I-Premise
maintenance	I-Premise
therapy	I-Premise
prolonged	I-Premise
progression-free	I-Premise
and	I-Premise
overall	I-Premise
survival	I-Premise
by	I-Premise
41%	I-Premise
and	I-Premise
23%,	I-Premise
respectively.	I-Premise

At	O
baseline,	O
HRQoL	O
measures	O
were	O
comparable	O
between	O
the	O
two	O
treatment	O
groups.	O

Maintenance	B-Premise
therapy	I-Premise
with	I-Premise
erlotinib	I-Premise
did	I-Premise
not	I-Premise
impact	I-Premise
on	I-Premise
deterioration	I-Premise
in	I-Premise
HRQoL:	I-Premise
TSP	I-Premise
(hazard	I-Premise
ratio	I-Premise
[HR]=0.91	I-Premise
[95%	I-Premise
confidence	I-Premise
interval	I-Premise
(CI)	I-Premise
0.74-1.12];	I-Premise
n=785),	I-Premise
TTD	I-Premise
in	I-Premise
TOI	I-Premise
(HR=1.06	I-Premise
[95%	I-Premise
CI	I-Premise
0.87-1.31];	I-Premise
n=781)	I-Premise
and	I-Premise
TTD	I-Premise
in	I-Premise
HRQoL	I-Premise
(HR=0.96	I-Premise
[95%	I-Premise
CI	I-Premise
0.79-1.16];	I-Premise
n=776).	I-Premise

Time	B-Premise
to	I-Premise
pain	I-Premise
and	I-Premise
time	I-Premise
to	I-Premise
analgesic	I-Premise
use	I-Premise
were	I-Premise
significantly	I-Premise
delayed	I-Premise
in	I-Premise
patients	I-Premise
receiving	I-Premise
erlotinib	I-Premise
compared	I-Premise
with	I-Premise
placebo	I-Premise
(HR=0.61	I-Premise
[95%	I-Premise
CI	I-Premise
0.42-0.88];	I-Premise
p=0.0080	I-Premise
and	I-Premise
HR=0.66	I-Premise
[95%	I-Premise
CI	I-Premise
0.46-0.94];	I-Premise
p=0.0199,	I-Premise
respectively).	I-Premise

A	B-Premise
non-significant	I-Premise
trend	I-Premise
towards	I-Premise
delayed	I-Premise
time	I-Premise
to	I-Premise
cough	I-Premise
and	I-Premise
time	I-Premise
to	I-Premise
dyspnoea	I-Premise
(HR=0.77	I-Premise
[95%	I-Premise
CI	I-Premise
0.49-1.21]	I-Premise
and	I-Premise
HR=0.75	I-Premise
[95%	I-Premise
CI	I-Premise
0.48-1.17],	I-Premise
respectively)	I-Premise
was	I-Premise
also	I-Premise
observed.	I-Premise

Erlotinib	B-Claim
maintenance	I-Claim
therapy	I-Claim
significantly	I-Claim
extends	I-Claim
progression-free	I-Claim
survival	I-Claim
without	I-Claim
compromising	I-Claim
patient	I-Claim
HRQoL	I-Claim
in	I-Claim
comparison	I-Claim
with	I-Claim
placebo,	I-Claim
with	I-Claim
some	I-Claim
improvement	I-Claim
in	I-Claim
symptoms.	I-Claim

The	O
randomized,	O
controlled	O
BOLERO-2	O
(Breast	O
Cancer	O
Trials	O
of	O
Oral	O
Everolimus)	O
trial	O
demonstrated	O
significantly	O
improved	O
progression-free	O
survival	O
with	O
the	O
use	O
of	O
everolimus	O
plus	O
exemestane	O
(EVE	O
+	O
EXE)	O
versus	O
placebo	O
plus	O
exemestane	O
(PBO	O
+	O
EXE)	O
in	O
patients	O
with	O
advanced	O
breast	O
cancer	O
who	O
developed	O
disease	O
progression	O
after	O
treatment	O
with	O
nonsteroidal	O
aromatase	O
inhibitors.	O

This	O
analysis	O
investigated	O
the	O
treatment	O
effects	O
on	O
health-related	O
quality	O
of	O
life	O
(HRQOL).	O

Using	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire-Core	O
30	O
(EORTC	O
QLQ-C30)	O
questionnaire,	O
HRQOL	O
was	O
assessed	O
at	O
baseline	O
and	O
every	O
6	O
weeks	O
thereafter	O
until	O
disease	O
progression	O
and/or	O
treatment	O
discontinuation.	O

The	O
30	O
items	O
in	O
15	O
subscales	O
of	O
the	O
QLQ-C30	O
include	O
global	O
health	O
status	O
wherein	O
higher	O
scores	O
(range,	O
0-100)	O
indicate	O
better	O
HRQOL.	O

This	O
analysis	O
included	O
a	O
protocol-specified	O
time	O
to	O
definitive	O
deterioration	O
(TDD)	O
analysis	O
at	O
a	O
5%	O
decrease	O
in	O
HRQOL	O
versus	O
baseline,	O
with	O
no	O
subsequent	O
increase	O
above	O
this	O
threshold.	O

The	O
authors	O
report	O
additional	O
sensitivity	O
analyses	O
using	O
10-point	O
minimal	O
important	O
difference	O
decreases	O
in	O
the	O
global	O
health	O
status	O
score	O
versus	O
baseline.	O

Treatment	O
arms	O
were	O
compared	O
using	O
the	O
stratified	O
log-rank	O
test	O
and	O
Cox	O
proportional	O
hazards	O
model	O
adjusted	O
for	O
trial	O
stratum	O
(visceral	O
metastases,	O
previous	O
hormone	O
sensitivity),	O
age,	O
sex,	O
race,	O
baseline	O
global	O
health	O
status	O
score	O
and	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status,	O
prognostic	O
risk	O
factors,	O
and	O
treatment	O
history.	O

Baseline	O
global	O
health	O
status	O
scores	O
were	O
found	O
to	O
be	O
similar	O
between	O
treatment	O
groups	O
(64.7	O
vs	O
65.3).	O

The	B-Premise
median	I-Premise
TDD	I-Premise
in	I-Premise
HRQOL	I-Premise
was	I-Premise
8.3	I-Premise
months	I-Premise
with	I-Premise
EVE	I-Premise
+	I-Premise
EXE	I-Premise
versus	I-Premise
5.8	I-Premise
months	I-Premise
with	I-Premise
PBO	I-Premise
+	I-Premise
EXE	I-Premise
(hazard	I-Premise
ratio,	I-Premise
0.74;	I-Premise
P	I-Premise
=	I-Premise
.0084).	I-Premise

At	B-Premise
the	I-Premise
10-point	I-Premise
minimal	I-Premise
important	I-Premise
difference,	I-Premise
the	I-Premise
median	I-Premise
TDD	I-Premise
with	I-Premise
EVE	I-Premise
+	I-Premise
EXE	I-Premise
was	I-Premise
11.7	I-Premise
months	I-Premise
versus	I-Premise
8.4	I-Premise
months	I-Premise
with	I-Premise
PBO	I-Premise
+	I-Premise
EXE	I-Premise
(hazard	I-Premise
ratio,	I-Premise
0.80;	I-Premise
P	I-Premise
=	I-Premise
.1017).	I-Premise

In	B-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
breast	I-Claim
cancer	I-Claim
who	I-Claim
develop	I-Claim
disease	I-Claim
progression	I-Claim
after	I-Claim
treatment	I-Claim
with	I-Claim
nonsteroidal	I-Claim
aromatase	I-Claim
inhibitors,	I-Claim
EVE	I-Claim
+	I-Claim
EXE	I-Claim
was	I-Claim
associated	I-Claim
with	I-Claim
a	I-Claim
longer	I-Claim
TDD	I-Claim
in	I-Claim
global	I-Claim
HRQOL	I-Claim
versus	I-Claim
PBO	I-Claim
+	I-Claim
EXE.	I-Claim

Malignant	B-Claim
pleural	I-Claim
effusion	I-Claim
(MPE)	I-Claim
is	I-Claim
a	I-Claim
common	I-Claim
complication	I-Claim
of	I-Claim
advanced	I-Claim
non-small	I-Claim
cell	I-Claim
lung	I-Claim
cancer	I-Claim
(NSCLC).	I-Claim

Bevacizumab,	B-Claim
a	I-Claim
humanized	I-Claim
monoclonal	I-Claim
antibody	I-Claim
against	I-Claim
vascular	I-Claim
endothelial	I-Claim
growth	I-Claim
factor	I-Claim
(VEGF),	I-Claim
has	I-Claim
been	I-Claim
shown	I-Claim
to	I-Claim
be	I-Claim
efficient	I-Claim
in	I-Claim
suppressing	I-Claim
the	I-Claim
accumulation	I-Claim
of	I-Claim
pleural	I-Claim
fluid.	I-Claim

However,	O
whether	O
intrapleural	O
delivery	O
of	O
bevacizumab	O
can	O
be	O
used	O
to	O
treat	O
MPE	O
remains	O
unknown.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
combined	O
intrapleural	O
therapy	O
with	O
bevacizumab	O
and	O
cisplatin,	O
an	O
antineoplastic	O
agent,	O
in	O
controlling	O
MPE.	O

A	O
total	O
of	O
72	O
NSCLC	O
study	O
subjects	O
with	O
MPE	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
groups.	O

The	O
first	O
group	O
received	O
intrapleural	O
bevacizumab	O
(300	O
mg)	O
with	O
cisplatin	O
(30	O
mg)	O
therapy	O
and	O
the	O
second	O
group	O
received	O
intrapleural	O
cisplatin	O
(30	O
mg)	O
therapy	O
alone.	O

Pleural	O
fluid	O
was	O
collected	O
from	O
both	O
groups	O
prior	O
to	O
and	O
following	O
treatment.	O

The	O
levels	O
of	O
VEGF	O
and	O
carcinoembryonic	O
antigen	O
(CEA)	O
in	O
the	O
pleural	O
fluid	O
were	O
determined	O
by	O
ELISA.	O

In	B-Premise
70	I-Premise
evaluable	I-Premise
study	I-Premise
subjects,	I-Premise
the	I-Premise
curative	I-Premise
efficacy	I-Premise
in	I-Premise
the	I-Premise
bevacizumab	I-Premise
group	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
than	I-Premise
that	I-Premise
found	I-Premise
in	I-Premise
the	I-Premise
cisplatin	I-Premise
group	I-Premise
(83.33	I-Premise
vs.	I-Premise
50.00%,	I-Premise
respectively;	I-Premise
p<0.05).	I-Premise

Therapy	B-Premise
with	I-Premise
combined	I-Premise
bevacizumab	I-Premise
plus	I-Premise
cisplatin	I-Premise
significantly	I-Premise
reduced	I-Premise
VEGF	I-Premise
levels	I-Premise
in	I-Premise
the	I-Premise
pleural	I-Premise
fluid	I-Premise
(p<0.01).	I-Premise

In	B-Premise
the	I-Premise
bevacizumab	I-Premise
group,	I-Premise
the	I-Premise
levels	I-Premise
of	I-Premise
VEGF	I-Premise
in	I-Premise
the	I-Premise
pleural	I-Premise
fluid	I-Premise
were	I-Premise
significantly	I-Premise
lower	I-Premise
compared	I-Premise
to	I-Premise
those	I-Premise
of	I-Premise
the	I-Premise
cisplatin	I-Premise
group	I-Premise
after	I-Premise
treatment,	I-Premise
which	I-Premise
showed	I-Premise
greater	I-Premise
efficacy	I-Premise
(p<0.01).	I-Premise

In	B-Premise
addition,	I-Premise
combination	I-Premise
therapy	I-Premise
showed	I-Premise
greater	I-Premise
efficacy	I-Premise
in	I-Premise
the	I-Premise
patients	I-Premise
with	I-Premise
high	I-Premise
levels	I-Premise
of	I-Premise
VEGF	I-Premise
expression	I-Premise
(p<0.01).	I-Premise

There	B-Premise
was	I-Premise
no	I-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
grade	I-Premise
III/IV	I-Premise
adverse	I-Premise
events	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups.	I-Premise

All	B-Premise
procedures	I-Premise
were	I-Premise
well	I-Premise
tolerated	I-Premise
by	I-Premise
the	I-Premise
patients.	I-Premise

Combined	B-Claim
intrapleural	I-Claim
therapy	I-Claim
with	I-Claim
bevacizumab	I-Claim
and	I-Claim
cisplatin	I-Claim
was	I-Claim
effective	I-Claim
and	I-Claim
safe	I-Claim
in	I-Claim
managing	I-Claim
NSCLC-mediated	I-Claim
MPE.	I-Claim

We	B-Claim
propose	I-Claim
that	I-Claim
VEGF	I-Claim
expression	I-Claim
levels	I-Claim
in	I-Claim
MPE	I-Claim
could	I-Claim
serve	I-Claim
as	I-Claim
a	I-Claim
prognostic	I-Claim
marker	I-Claim
for	I-Claim
bevacizumab	I-Claim
therapy.	I-Claim

There	O
are	O
no	O
known	O
effective	O
treatments	O
for	O
painful	O
chemotherapy-induced	O
peripheral	O
neuropathy.	O

To	O
determine	O
the	O
effect	O
of	O
duloxetine,	O
60	O
mg	O
daily,	O
on	O
average	O
pain	O
severity.	O

Randomized,	O
double-blind,	O
placebo-controlled	O
crossover	O
trial	O
at	O
8	O
National	O
Cancer	O
Institute	O
(NCI)-funded	O
cooperative	O
research	O
networks	O
that	O
enrolled	O
231	O
patients	O
who	O
were	O
25	O
years	O
or	O
older	O
being	O
treated	O
at	O
community	O
and	O
academic	O
settings	O
between	O
April	O
2008	O
and	O
March	O
2011.	O

Study	O
follow-up	O
was	O
completed	O
July	O
2012.	O

Stratified	O
by	O
chemotherapeutic	O
drug	O
and	O
comorbid	O
pain	O
risk,	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
duloxetine	O
followed	O
by	O
placebo	O
or	O
placebo	O
followed	O
by	O
duloxetine.	O

Eligibility	O
required	O
that	O
patients	O
have	O
grade	O
1	O
or	O
higher	O
sensory	O
neuropathy	O
according	O
to	O
the	O
NCI	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
and	O
at	O
least	O
4	O
on	O
a	O
scale	O
of	O
0	O
to	O
10,	O
representing	O
average	O
chemotherapy-induced	O
pain,	O
after	O
paclitaxel,	O
other	O
taxane,	O
or	O
oxaliplatin	O
treatment.	O

The	O
initial	O
treatment	O
consisted	O
of	O
taking	O
1	O
capsule	O
daily	O
of	O
either	O
30	O
mg	O
of	O
duloxetine	O
or	O
placebo	O
for	O
the	O
first	O
week	O
and	O
2	O
capsules	O
of	O
either	O
30	O
mg	O
of	O
duloxetine	O
or	O
placebo	O
daily	O
for	O
4	O
additional	O
weeks.	O

The	O
primary	O
hypothesis	O
was	O
that	O
duloxetine	O
would	O
be	O
more	O
effective	O
than	O
placebo	O
in	O
decreasing	O
chemotherapy-induced	O
peripheral	O
neuropathic	O
pain.	O

Pain	O
severity	O
was	O
assessed	O
using	O
the	O
Brief	O
Pain	O
Inventory-Short	O
Form	O
"average	O
pain"	O
item	O
with	O
0	O
representing	O
no	O
pain	O
and	O
10	O
representing	O
as	O
bad	O
as	O
can	O
be	O
imagined.	O

Individuals	B-Premise
receiving	I-Premise
duloxetine	I-Premise
as	I-Premise
their	I-Premise
initial	I-Premise
5-week	I-Premise
treatment	I-Premise
reported	I-Premise
a	I-Premise
mean	I-Premise
decrease	I-Premise
in	I-Premise
average	I-Premise
pain	I-Premise
of	I-Premise
1.06	I-Premise
(95%	I-Premise
CI,	I-Premise
0.72-1.40)	I-Premise
vs	I-Premise
0.34	I-Premise
(95%	I-Premise
CI,	I-Premise
0.01-0.66)	I-Premise
among	I-Premise
those	I-Premise
who	I-Premise
received	I-Premise
placebo	I-Premise
(P	I-Premise
=	I-Premise
.003;	I-Premise
effect	I-Premise
size,	I-Premise
0.513).	I-Premise

The	B-Premise
observed	I-Premise
mean	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
average	I-Premise
pain	I-Premise
score	I-Premise
between	I-Premise
duloxetine	I-Premise
and	I-Premise
placebo	I-Premise
was	I-Premise
0.73	I-Premise
(95%	I-Premise
CI,	I-Premise
0.26-1.20).	I-Premise

Fifty-nine	B-Premise
percent	I-Premise
of	I-Premise
those	I-Premise
initially	I-Premise
receiving	I-Premise
duloxetine	I-Premise
vs	I-Premise
38%	I-Premise
of	I-Premise
those	I-Premise
initially	I-Premise
receiving	I-Premise
placebo	I-Premise
reported	I-Premise
decreased	I-Premise
pain	I-Premise
of	I-Premise
any	I-Premise
amount.	I-Premise

Among	B-Claim
patients	I-Claim
with	I-Claim
painful	I-Claim
chemotherapy-induced	I-Claim
peripheral	I-Claim
neuropathy,	I-Claim
the	I-Claim
use	I-Claim
of	I-Claim
duloxetine	I-Claim
compared	I-Claim
with	I-Claim
placebo	I-Claim
for	I-Claim
5	I-Claim
weeks	I-Claim
resulted	I-Claim
in	I-Claim
a	I-Claim
greater	I-Claim
reduction	I-Claim
in	I-Claim
pain.	I-Claim

Sexual	O
dysfunction	O
represents	O
a	O
complex	O
and	O
multifactorial	O
construct	O
that	O
can	O
affect	O
both	O
men	O
and	O
women	O
and	O
has	O
been	O
noted	O
to	O
often	O
deteriorate	O
significantly	O
after	O
treatment	O
for	O
rectal	O
and	O
anal	O
cancer.	O

Despite	O
this,	O
it	O
remains	O
an	O
understudied,	O
underreported,	O
and	O
undertreated	O
issue	O
in	O
the	O
field	O
of	O
cancer	O
survivorship.	O

This	O
study	O
examined	O
the	O
characteristics	O
of	O
women	O
enrolled	O
in	O
an	O
intervention	O
trial	O
to	O
treat	O
sexual	O
dysfunction,	O
and	O
explored	O
the	O
relationship	O
between	O
sexual	O
functioning	O
and	O
psychological	O
well-being.	O

There	O
were	O
70	O
female	O
posttreatment	O
anal	O
or	O
rectal	O
cancer	O
survivors	O
assessed	O
as	O
part	O
of	O
the	O
current	O
study.	O

Participants	O
were	O
enrolled	O
in	O
a	O
randomized	O
intervention	O
trial	O
to	O
treat	O
sexual	O
dysfunction	O
and	O
completed	O
outcome	O
measures	O
prior	O
to	O
randomization.	O

The	O
main	O
outcome	O
measures	O
are	O
quality	O
of	O
life	O
(QOL)	O
(European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Core	O
Quality	O
of	O
Life	O
Questionnaire	O
[EORTC-QLQ-C30]	O
and	O
Colorectal	O
Cancer-Specific	O
Module	O
[QLQ-CR38]),	O
sexual	O
functioning	O
(Female	O
Sexual	O
Functioning	O
Index),	O
and	O
psychological	O
well-being	O
(Brief	O
Symptom	O
Inventory	O
Depression/Anxiety,	O
Impact	O
of	O
Events	O
Scale-Revised,	O
CR-38	O
Body	O
Image).	O

Women	O
enrolled	O
in	O
the	O
study	O
intervention	O
were	O
on	O
average	O
55	O
years	O
old,	O
predominantly	O
Caucasian	O
(79%),	O
married	O
(57%),	O
and	O
a	O
median	O
of	O
4	O
years	O
postprimary	O
treatment.	O

For	O
those	O
reporting	O
sexual	O
activity	O
at	O
baseline	O
(N=41),	O
sexual	O
dysfunction	O
was	O
associated	O
with	O
a	O
range	O
of	O
specific	O
measures	O
of	O
psychological	O
well-being,	O
all	O
in	O
the	O
hypothesized	O
direction.	O

The	B-Premise
Sexual/Relationship	I-Premise
Satisfaction	I-Premise
subscale	I-Premise
was	I-Premise
associated	I-Premise
with	I-Premise
all	I-Premise
measures	I-Premise
of	I-Premise
psychological	I-Premise
well-being	I-Premise
(r=-0.45	I-Premise
to	I-Premise
-0.70,	I-Premise
all	I-Premise
P<0.01).	I-Premise

Body	B-Premise
image,	I-Premise
anxiety,	I-Premise
and	I-Premise
cancer-specific	I-Premise
posttraumatic	I-Premise
distress	I-Premise
were	I-Premise
notable	I-Premise
in	I-Premise
their	I-Premise
association	I-Premise
with	I-Premise
subscales	I-Premise
of	I-Premise
sexual	I-Premise
functioning,	I-Premise
while	I-Premise
a	I-Premise
global	I-Premise
QOL	I-Premise
measure	I-Premise
was	I-Premise
largely	I-Premise
unrelated.	I-Premise

For	B-Premise
sexually	I-Premise
active	I-Premise
female	I-Premise
rectal	I-Premise
and	I-Premise
anal	I-Premise
cancer	I-Premise
survivors	I-Premise
enrolled	I-Premise
in	I-Premise
a	I-Premise
sexual	I-Premise
health	I-Premise
intervention,	I-Premise
sexual	I-Premise
dysfunction	I-Premise
was	I-Premise
significantly	I-Premise
and	I-Premise
consistently	I-Premise
associated	I-Premise
with	I-Premise
specific	I-Premise
measures	I-Premise
of	I-Premise
psychological	I-Premise
well-being,	I-Premise
most	I-Premise
notably	I-Premise
Sexual/Relationship	I-Premise
Satisfaction.	I-Premise

These	B-Claim
results	I-Claim
suggest	I-Claim
that	I-Claim
sexual	I-Claim
functioning	I-Claim
may	I-Claim
require	I-Claim
focused	I-Claim
assessment	I-Claim
by	I-Claim
providers,	I-Claim
beyond	I-Claim
broad	I-Claim
QOL	I-Claim
assessments,	I-Claim
and	O
that	O
attention	B-Claim
to	I-Claim
Sexual/Relationship	I-Claim
Satisfaction	I-Claim
may	I-Claim
be	I-Claim
critical	I-Claim
in	I-Claim
the	I-Claim
development	I-Claim
and	I-Claim
implementation	I-Claim
of	I-Claim
interventions	I-Claim
for	I-Claim
this	I-Claim
cohort	I-Claim
of	I-Claim
patients.	I-Claim

To	O
prospectively	O
evaluate	O
and	O
compare	O
health-related	O
quality-of-life	O
(QOL)	O
outcomes	O
in	O
patients	O
with	O
head-neck	O
squamous	O
cell	O
carcinoma	O
randomized	O
to	O
either	O
intensity-modulated	O
radiation	O
therapy	O
(IMRT)	O
or	O
three-dimensional	O
conformal	O
radiotherapy	O
(3D-CRT)	O
and	O
assess	O
serial	O
longitudinal	O
change	O
in	O
QOL	O
over	O
time.	O

QOL	O
outcomes	O
were	O
assessed	O
using	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(EORTC)	O
QOL	O
questionnaire	O
(QLQ-C30)	O
and	O
Head-Neck	O
module	O
(HN-35)	O
at	O
baseline	O
(pre-treatment)	O
and	O
subsequently	O
periodically	O
on	O
follow-up.	O

Mean	O
scores	O
of	O
individual	O
domains/scales	O
of	O
3D-CRT	O
and	O
IMRT	O
were	O
compared	O
using	O
't'	O
test	O
at	O
each	O
time	O
point;	O
while	O
longitudinal	O
change	O
in	O
mean	O
scores	O
of	O
both	O
groups	O
over	O
time	O
was	O
evaluated	O
by	O
repeated	O
measurement	O
analysis	O
of	O
variance.	O

Fifty	O
eight	O
of	O
the	O
60	O
randomized	O
patients	O
who	O
filled	O
the	O
QOL	O
questionnaire	O
at	O
least	O
at	O
one	O
time	O
point	O
were	O
included	O
in	O
the	O
analysis.	O

Several	O
general	O
(emotional	O
functioning,	O
role	O
functioning,	O
social	O
contact)	O
as	O
well	O
as	O
head	O
and	O
neck	O
cancer-specific	O
(dry	O
mouth,	O
opening	O
mouth,	O
sticky	O
saliva,	O
pain,	O
senses)	O
QOL	O
domains	O
were	O
better	O
preserved	O
with	O
IMRT	O
compared	O
to	O
3D-CRT	O
at	O
different	O
time	O
points.	O

Importantly,	O
none	O
of	O
the	O
QOL	O
domains	O
were	O
worse	O
with	O
IMRT	O
at	O
any	O
time	O
point.	O

There	B-Premise
was	I-Premise
substantial	I-Premise
deterioration	I-Premise
in	I-Premise
QOL	I-Premise
scores	I-Premise
immediate	I-Premise
post-treatment	I-Premise
(3-months)	I-Premise
in	I-Premise
both	I-Premise
arms.	I-Premise

However,	B-Premise
QOL	I-Premise
scores	I-Premise
gradually	I-Premise
but	I-Premise
definitely	I-Premise
improved	I-Premise
over	I-Premise
time	I-Premise
for	I-Premise
most	I-Premise
domains.	I-Premise

Global	B-Premise
QOL,	I-Premise
emotional/role	I-Premise
functioning,	I-Premise
nausea/vomiting,	I-Premise
pain,	I-Premise
swallowing,	I-Premise
speech,	I-Premise
social	I-Premise
contact/eating,	I-Premise
insomnia	I-Premise
showed	I-Premise
rapid	I-Premise
recovery	I-Premise
(<6months)	I-Premise
while	I-Premise
physical/cognitive	I-Premise
functioning,	I-Premise
dry	I-Premise
mouth,	I-Premise
sticky	I-Premise
saliva,	I-Premise
fatigue,	I-Premise
senses	I-Premise
showed	I-Premise
delayed	I-Premise
recovery	I-Premise
(>6months).	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
loco-regional	I-Premise
or	I-Premise
survival	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
arms.	I-Premise

There	B-Claim
is	I-Claim
substantial	I-Claim
deterioration	I-Claim
in	I-Claim
QOL	I-Claim
after	I-Claim
curative-intent	I-Claim
head-neck	I-Claim
irradiation	I-Claim
that	I-Claim
gradually	I-Claim
improves	I-Claim
over	I-Claim
time.	I-Claim

IMRT	B-Claim
results	I-Claim
in	I-Claim
clinically	I-Claim
meaningful	I-Claim
and	I-Claim
statistically	I-Claim
better	I-Claim
QOL	I-Claim
scores	I-Claim
for	I-Claim
some	I-Claim
domains	I-Claim
compared	I-Claim
to	I-Claim
3D-CRT	I-Claim
at	I-Claim
several	I-Claim
time	I-Claim
points	I-Claim
with	I-Claim
comparable	I-Claim
disease	I-Claim
outcomes	I-Claim
that	I-Claim
could	I-Claim
support	I-Claim
its	I-Claim
widespread	I-Claim
adoption	I-Claim
in	I-Claim
routine	I-Claim
clinical	I-Claim
practice.	I-Claim

The	O
AVEREL	O
trial	O
[A	O
Study	O
of	O
Avastin	O
(Bevacizumab)	O
in	O
Combination	O
With	O
Herceptin	O
(Trastuzumab)/Docetaxel	O
in	O
Patients	O
With	O
HER2-Positive	O
Metastatic	O
Breast	O
Cancer]	O
evaluated	O
first-line	O
bevacizumab-containing	O
therapy	O
for	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(HER2)	O
-positive	O
locally	O
recurrent/metastatic	O
breast	O
cancer	O
(LR/MBC).	O

Patients	O
with	O
measurable/evaluable	O
HER2-positive	O
LR/MBC	O
who	O
had	O
not	O
received	O
trastuzumab	O
or	O
chemotherapy	O
for	O
LR/MBC	O
were	O
stratified	O
by	O
prior	O
adjuvant	O
trastuzumab,	O
prior	O
(neo)adjuvant	O
taxane,	O
hormone	O
receptor	O
status,	O
and	O
measurable	O
disease	O
and	O
were	O
randomly	O
assigned	O
to	O
receive	O
docetaxel	O
100	O
mg/m(2)	O
plus	O
trastuzumab	O
8	O
mg/kg	O
loading	O
dose	O
followed	O
by	O
6	O
mg/kg	O
either	O
with	O
bevacizumab	O
15	O
mg/kg	O
or	O
without	O
bevacizumab,	O
all	O
administered	O
every	O
3	O
weeks.	O

The	O
primary	O
end	O
point	O
was	O
progression-free	O
survival	O
(PFS).	O

Additional	O
end	O
points	O
included	O
overall	O
survival,	O
response	O
rate	O
(RR),	O
safety,	O
quality	O
of	O
life,	O
and	O
translational	O
research.	O

Results	O
Baseline	O
characteristics	O
of	O
the	O
424	O
patients	O
were	O
balanced	O
between	O
treatment	O
arms.	O

Most	O
patients	O
had	O
visceral	O
metastases,	O
43%	O
had	O
a	O
disease-free	O
interval	O
less	O
than	O
12	O
months,	O
and	O
85%	O
had	O
measurable	O
disease.	O

Median	O
follow-up	O
was	O
26	O
months.	O

The	B-Premise
hazard	I-Premise
ratio	I-Premise
for	I-Premise
investigator-assessed	I-Premise
PFS	I-Premise
was	I-Premise
0.82	I-Premise
(95%	I-Premise
CI,	I-Premise
0.65	I-Premise
to	I-Premise
1.02;	I-Premise
P	I-Premise
=	I-Premise
.0775;	I-Premise
median	I-Premise
PFS,	I-Premise
13.7	I-Premise
v	I-Premise
16.5	I-Premise
months	I-Premise
in	I-Premise
the	I-Premise
non-bevacizumab	I-Premise
and	I-Premise
bevacizumab	I-Premise
arms,	I-Premise
respectively;	I-Premise
PFS	I-Premise
events	I-Premise
in	I-Premise
72%).	I-Premise

The	B-Premise
Independent	I-Premise
Review	I-Premise
Committee-assessed	I-Premise
PFS	I-Premise
hazard	I-Premise
ratio	I-Premise
was	I-Premise
0.72	I-Premise
(95%	I-Premise
CI,	I-Premise
0.54	I-Premise
to	I-Premise
0.94;	I-Premise
P	I-Premise
=	I-Premise
.0162;	I-Premise
median	I-Premise
PFS,	I-Premise
13.9	I-Premise
v	I-Premise
16.8	I-Premise
months,	I-Premise
respectively;	I-Premise
PFS	I-Premise
events	I-Premise
in	I-Premise
53%).	I-Premise

The	B-Premise
RR	I-Premise
was	I-Premise
70%	I-Premise
versus	I-Premise
74%,	I-Premise
respectively	I-Premise
(P	I-Premise
=	I-Premise
.3492).	I-Premise

Grade	B-Claim
	I-Claim
3	I-Claim
febrile	I-Claim
neutropenia	I-Claim
and	I-Claim
hypertension	I-Claim
were	I-Claim
more	I-Claim
common	I-Claim
with	I-Claim
bevacizumab-containing	I-Claim
therapy.	I-Claim

High	B-Premise
baseline	I-Premise
plasma	I-Premise
vascular	I-Premise
endothelial	I-Premise
growth	I-Premise
factor	I-Premise
A	I-Premise
(VEGF-A)	I-Premise
concentrations	I-Premise
were	I-Premise
associated	I-Premise
with	I-Premise
greater	I-Premise
bevacizumab	I-Premise
benefit	I-Premise
(not	I-Premise
statistically	I-Premise
significant).	I-Premise

Combining	B-Claim
bevacizumab	I-Claim
with	I-Claim
docetaxel	I-Claim
and	I-Claim
trastuzumab	I-Claim
did	I-Claim
not	I-Claim
significantly	I-Claim
improve	I-Claim
investigator-assessed	I-Claim
PFS.	I-Claim

The	O
potential	O
predictive	O
value	O
of	O
plasma	O
VEGF-A	O
is	O
consistent	O
with	O
findings	O
in	O
HER2-negative	O
LR/MBC,	O
warranting	O
prospective	O
evaluation.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
efficacy,	O
toxicity,	O
and	O
adverse	O
effects	O
of	O
combination	O
of	O
chemotherapy	O
drugs	O
and	O
intraperitoneal	O
perfusion	O
of	O
verapamil	O
in	O
the	O
treatment	O
of	O
malignant	O
ascites.	O

Seventy-two	O
patients	O
with	O
malignant	O
ascites	O
were	O
divided	O
into	O
two	O
study	O
groups.	O

Patients	O
in	O
control	O
group	O
(31	O
cases)	O
received	O
conventional	O
chemotherapy,	O
whereas	O
patients	O
in	O
the	O
combined	O
treatment	O
group	O
(41	O
cases)	O
were	O
given	O
verapamil	O
intraperitoneally	O
in	O
addition	O
to	O
chemotherapy	O
drugs.	O

Thirty	O
days	O
after	O
the	O
treatment,	O
efficacy,	O
toxicity,	O
and	O
adverse	O
effects	O
were	O
assessed	O
in	O
both	O
study	O
groups.	O

The	B-Premise
treatment	I-Premise
of	I-Premise
control	I-Premise
group	I-Premise
led	I-Premise
to	I-Premise
1	I-Premise
case	I-Premise
of	I-Premise
complete	I-Premise
remission	I-Premise
and	I-Premise
2	I-Premise
cases	I-Premise
of	I-Premise
partial	I-Premise
remission,	I-Premise
making	I-Premise
the	I-Premise
rate	I-Premise
of	I-Premise
efficacy	I-Premise
(complete	I-Premise
+	I-Premise
partial	I-Premise
remission)	I-Premise
of	I-Premise
9.7	I-Premise
%.	I-Premise

The	B-Premise
combined	I-Premise
treatment	I-Premise
group	I-Premise
demonstrated	I-Premise
13	I-Premise
cases	I-Premise
of	I-Premise
complete	I-Premise
remission	I-Premise
and	I-Premise
22	I-Premise
cases	I-Premise
of	I-Premise
partial	I-Premise
remission.	I-Premise

Thus,	O
the	B-Premise
rate	I-Premise
of	I-Premise
efficacy	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
combined	I-Premise
treatment	I-Premise
group	I-Premise
(85.36	I-Premise
%;	I-Premise
p	I-Premise
<	I-Premise
0.05	I-Premise
vs.	I-Premise
control	I-Premise
group).	I-Premise

Using	O
KPS	O
scores,	O
changes	O
in	O
quality	O
of	O
life	O
were	O
compared	O
before	O
and	O
after	O
the	O
treatment.	O

The	B-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
improved	I-Premise
in	I-Premise
control	I-Premise
group	I-Premise
by	I-Premise
13.7	I-Premise
%,	I-Premise
while	I-Premise
combined	I-Premise
treatment	I-Premise
group	I-Premise
showed	I-Premise
improvement	I-Premise
of	I-Premise
83.5	I-Premise
%	I-Premise
(p	I-Premise
<	I-Premise
0.05	I-Premise
vs.	I-Premise
control	I-Premise
group).	I-Premise

Further,	O
cumulative	B-Premise
survival	I-Premise
rate	I-Premise
was	I-Premise
also	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
combined	I-Premise
treatment	I-Premise
group.	I-Premise

Treatment	B-Premise
toxicity	I-Premise
and	I-Premise
the	I-Premise
rate	I-Premise
of	I-Premise
adverse	I-Premise
effects	I-Premise
and	I-Premise
intestinal	I-Premise
adhesion	I-Premise
were	I-Premise
not	I-Premise
significantly	I-Premise
different	I-Premise
between	I-Premise
study	I-Premise
groups.	I-Premise

Intraperitoneal	B-Claim
perfusion	I-Claim
of	I-Claim
verapamil	I-Claim
enhances	I-Claim
the	I-Claim
efficacy	I-Claim
of	I-Claim
chemotherapy	I-Claim
drugs,	I-Claim
prolongs	I-Claim
survival,	I-Claim
and	I-Claim
improves	I-Claim
the	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

Intraperitoneal	B-Claim
administration	I-Claim
limits	I-Claim
cardiotoxicity	I-Claim
of	I-Claim
verapamil.	I-Claim

Many	O
patients	O
with	O
cancer	O
experience	O
depression	O
and	O
anxiety,	O
and	O
an	O
associated	O
decrease	O
in	O
quality	O
of	O
life	O
(QOL)	O
during	O
radiation	O
therapy	O
(RT).	O

The	O
main	O
objective	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
benefits	O
of	O
psychosocial	O
interventions	O
for	O
cancer	O
patients	O
who	O
received	O
RT.	O

Patients	O
with	O
cancer	O
(n	O
=	O
178)	O
who	O
agreed	O
to	O
participate	O
in	O
the	O
study	O
were	O
randomized	O
to	O
the	O
intervention	O
arm	O
(n	O
=	O
89)	O
or	O
the	O
control	O
arm	O
(n	O
=	O
89).	O

Patients	O
in	O
the	O
intervention	O
group	O
received	O
psychosocial	O
care	O
during	O
RT,	O
whereas	O
the	O
control	O
group	O
received	O
RT	O
only.	O

The	O
benefits	O
of	O
the	O
intervention	O
were	O
evaluated	O
using	O
the	O
Zung	O
Self-rating	O
Depression	O
Scale	O
(SDS)	O
to	O
measure	O
depression,	O
the	O
Self-rating	O
Anxiety	O
Scale	O
(SAS)	O
to	O
assess	O
anxiety,	O
and	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Quality	O
of	O
Life	O
Questionnaire-Core	O
30	O
(EORTC	O
QLQ-C30)	O
to	O
survey	O
health-related	O
QOL.	O

The	O
association	O
between	O
intervention	O
and	O
survival	O
was	O
also	O
assessed.	O

Patients	B-Premise
randomly	I-Premise
assigned	I-Premise
to	I-Premise
the	I-Premise
intervention	I-Premise
arm	I-Premise
showed	I-Premise
significant	I-Premise
improvements	I-Premise
on	I-Premise
symptoms	I-Premise
of	I-Premise
depression	I-Premise
(p	I-Premise
<	I-Premise
0.05)	I-Premise
and	I-Premise
anxiety	I-Premise
(p	I-Premise
<	I-Premise
0.05),	I-Premise
health-related	I-Premise
QOL	I-Premise
(p	I-Premise
<	I-Premise
0.05)	I-Premise
(i.e.	I-Premise
better	I-Premise
global	I-Premise
health	I-Premise
status,	I-Premise
and	I-Premise
physical	I-Premise
and	I-Premise
emotional	I-Premise
functioning,	I-Premise
and	I-Premise
less	I-Premise
insomnia)	I-Premise
when	I-Premise
compared	I-Premise
with	I-Premise
controls.	I-Premise

In	B-Claim
the	I-Claim
subset	I-Claim
analysis,	I-Claim
female	I-Claim
patients,	I-Claim
those	I-Claim
that	I-Claim
received	I-Claim
high	I-Claim
dose	I-Claim
irradiation,	I-Claim
and	I-Claim
those	I-Claim
that	I-Claim
underwent	I-Claim
adjuvant	I-Claim
chemotherapy	I-Claim
could	I-Claim
benefit	I-Claim
more	I-Claim
from	I-Claim
psychosocial	I-Claim
intervention.	I-Claim

There	B-Premise
was	I-Premise
no	I-Premise
difference	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups	I-Premise
in	I-Premise
disease-free	I-Premise
survival	I-Premise
(DFS)	I-Premise
(2-year	I-Premise
DFS	I-Premise
79.8%	I-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
arm	I-Premise
and	I-Premise
76.4%	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
arm;	I-Premise
p	I-Premise
=	I-Premise
0.527)	I-Premise
and	I-Premise
overall	I-Premise
survival	I-Premise
(OS)	I-Premise
(2-year	I-Premise
OS	I-Premise
83.1%	I-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
arm	I-Premise
and	I-Premise
84.3%	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
arm;	I-Premise
p	I-Premise
=	I-Premise
0.925).	I-Premise

Psychosocial	B-Claim
intervention	I-Claim
is	I-Claim
a	I-Claim
cost-effective	I-Claim
approach	I-Claim
that	I-Claim
can	I-Claim
improve	I-Claim
a	I-Claim
patient's	I-Claim
mood	I-Claim
and	I-Claim
QOL	I-Claim
both	I-Claim
during	I-Claim
and	I-Claim
after	I-Claim
RT.	I-Claim

However,	B-Claim
the	I-Claim
intervention	I-Claim
was	I-Claim
not	I-Claim
found	I-Claim
to	I-Claim
reduce	I-Claim
the	I-Claim
risk	I-Claim
of	I-Claim
cancer	I-Claim
recurrence	I-Claim
and	I-Claim
death.	I-Claim

It	O
is	O
well	O
documented	O
that	O
stress	O
is	O
associated	O
with	O
negative	O
health	O
outcomes	O
in	O
cancer	O
patients.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effects	O
of	O
a	O
novel	O
mindfulness	O
intervention	O
called	O
mindfulness-based	O
art	O
therapy	O
(MBAT)	O
versus	O
standard	O
educational	O
support,	O
on	O
indices	O
of	O
stress	O
and	O
quality	O
of	O
life	O
in	O
breast	O
cancer	O
patients	O
with	O
high	O
stress	O
levels.	O

A	O
total	O
of	O
191	O
women	O
were	O
enrolled,	O
stratified	O
by	O
age	O
and	O
stress	O
level,	O
and	O
randomized	O
to	O
receive	O
either	O
an	O
8-week	O
MBAT	O
intervention	O
or	O
a	O
breast	O
cancer	O
educational	O
support	O
program	O
of	O
equal	O
time	O
and	O
duration.	O

Psychosocial	O
stress	O
was	O
measured	O
using	O
the	O
Symptoms	O
Checklist-90-Revised,	O
and	O
quality	O
of	O
life	O
was	O
measured	O
using	O
the	O
Medical	O
Outcomes	O
Study	O
Short-Form	O
Health	O
Survey	O
at	O
baseline,	O
immediately	O
post-intervention,	O
and	O
at	O
6	O
months.	O

Results	B-Premise
showed	I-Premise
overall	I-Premise
significant	I-Premise
improvements	I-Premise
in	I-Premise
psychosocial	I-Premise
stress	I-Premise
and	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
in	I-Premise
both	I-Premise
the	I-Premise
MBAT	I-Premise
and	I-Premise
educational	I-Premise
support	I-Premise
groups	I-Premise
immediately	I-Premise
post-intervention;	I-Premise
however,	B-Premise
participants	I-Premise
with	I-Premise
high	I-Premise
stress	I-Premise
levels	I-Premise
at	I-Premise
baseline	I-Premise
had	I-Premise
significantly	I-Premise
improved	I-Premise
overall	I-Premise
outcomes	I-Premise
only	I-Premise
in	I-Premise
the	I-Premise
MBAT	I-Premise
group,	I-Premise
both	I-Premise
immediately	I-Premise
post-intervention	I-Premise
and	I-Premise
at	I-Premise
6	I-Premise
months.	I-Premise

In	O
addition,	O
at	B-Premise
6	I-Premise
months	I-Premise
follow-up,	I-Premise
participants	I-Premise
attending	I-Premise
five	I-Premise
or	I-Premise
more	I-Premise
sessions	I-Premise
trended	I-Premise
toward	I-Premise
retaining	I-Premise
treatment	I-Premise
effects	I-Premise
better	I-Premise
in	I-Premise
the	I-Premise
MBAT	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group.	I-Premise

Finally,	O
black	B-Premise
women	I-Premise
and	I-Premise
white	I-Premise
women	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
how	I-Premise
they	I-Premise
benefited	I-Premise
from	I-Premise
the	I-Premise
MBAT	I-Premise
intervention,	I-Premise
even	I-Premise
though	I-Premise
white	I-Premise
participants	I-Premise
tended	I-Premise
to	I-Premise
have	I-Premise
higher	I-Premise
educational	I-Premise
level	I-Premise
and	I-Premise
marital	I-Premise
status.	I-Premise

In	B-Claim
conclusion,	I-Claim
MBAT	I-Claim
is	I-Claim
associated	I-Claim
with	I-Claim
significant,	I-Claim
sustained	I-Claim
benefits	I-Claim
across	I-Claim
a	I-Claim
diverse	I-Claim
range	I-Claim
of	I-Claim
breast	I-Claim
cancer	I-Claim
patients,	I-Claim
particularly	I-Claim
those	I-Claim
with	I-Claim
high	I-Claim
stress	I-Claim
levels.	I-Claim

The	O
current	O
study	O
examined	O
the	O
effect	O
of	O
recombinant	O
human	O
deoxyribonuclease	O
(rhDNase)	O
on	O
quality	O
of	O
life	O
(QOL)	O
measures,	O
clinical	O
improvement,	O
and	O
DNA	O
content	O
of	O
thick	O
oropharyngeal	O
secretions	O
(OPS)	O
in	O
patients	O
with	O
head-and-neck	O
(H&N)	O
cancers.	O

Thirty-six	O
patients	O
with	O
local-regional	O
advanced	O
H&amp;N	O
cancer	O
receiving	O
chemoradiationtherapy	O
(CRT)	O
were	O
randomized	O
to	O
receive	O
either	O
placebo	O
or	O
rhDNase.	O

Endpoints	O
included	O
MD	O
Anderson	O
Symptom	O
Inventory-Head	O
and	O
Neck	O
(MDASI-HN)	O
and	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Head	O
and	O
Neck	O
(FACT-NH)	O
scores,	O
along	O
with	O
clinical	O
assessment	O
and	O
DNA	O
concentration	O
of	O
OPS.	O

There	B-Premise
were	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
in	I-Premise
patients'	I-Premise
QOL	I-Premise
outcomes	I-Premise
over	I-Premise
the	I-Premise
study	I-Premise
period.	I-Premise

Both	B-Premise
groups	I-Premise
showed	I-Premise
an	I-Premise
increase	I-Premise
in	I-Premise
symptom	I-Premise
and	I-Premise
interference	I-Premise
scores,	I-Premise
although	O
patients	B-Premise
in	I-Premise
the	I-Premise
rhDNase	I-Premise
group	I-Premise
showed	I-Premise
a	I-Premise
greater	I-Premise
decline	I-Premise
in	I-Premise
both	I-Premise
scores	I-Premise
during	I-Premise
the	I-Premise
3	I-Premise
months	I-Premise
posttreatment.	I-Premise

Similarly,	B-Premise
both	I-Premise
groups	I-Premise
showed	I-Premise
a	I-Premise
decline	I-Premise
in	I-Premise
physical	I-Premise
and	I-Premise
functional	I-Premise
well	I-Premise
being	I-Premise
but	I-Premise
recovered	I-Premise
in	I-Premise
the	I-Premise
3	I-Premise
months	I-Premise
posttreatment	I-Premise
follow-up,	I-Premise
with	I-Premise
the	I-Premise
rhDNase	I-Premise
group	I-Premise
exhibiting	I-Premise
speedier	I-Premise
recovery.	I-Premise

Patients	B-Premise
in	I-Premise
the	I-Premise
rhDNase	I-Premise
group	I-Premise
exhibited	I-Premise
significant	I-Premise
clinical	I-Premise
improvement	I-Premise
in	I-Premise
OPS,	I-Premise
blindly	I-Premise
assessed	I-Premise
by	I-Premise
a	I-Premise
physician,	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
placebo	I-Premise
group	I-Premise
(67%	I-Premise
vs	I-Premise
27%,	I-Premise
respectively;	I-Premise
P=.046).	I-Premise

The	B-Premise
rhDNase	I-Premise
group	I-Premise
showed	I-Premise
no	I-Premise
change	I-Premise
in	I-Premise
OPS-DNA	I-Premise
concentration,	I-Premise
although	O
the	B-Premise
placebo	I-Premise
group	I-Premise
showed	I-Premise
a	I-Premise
significant	I-Premise
increase	I-Premise
in	I-Premise
DNA	I-Premise
concentration	I-Premise
during	I-Premise
the	I-Premise
drug	I-Premise
trial	I-Premise
(P=.045).	I-Premise

There	B-Claim
was	I-Claim
no	I-Claim
differences	I-Claim
in	I-Claim
acute	I-Claim
toxicities	I-Claim
between	I-Claim
the	I-Claim
2	I-Claim
groups.	I-Claim

Our	B-Claim
preliminary	I-Claim
data	I-Claim
suggest	I-Claim
that	I-Claim
rhDNase	I-Claim
did	I-Claim
not	I-Claim
significantly	I-Claim
improve	I-Claim
study	I-Claim
primary	I-Claim
endpoints	I-Claim
of	I-Claim
QOL	I-Claim
measures	I-Claim
compared	I-Claim
with	I-Claim
the	I-Claim
placebo	I-Claim
group.	I-Claim

However,	O
there	B-Claim
was	I-Claim
a	I-Claim
significant	I-Claim
improvement	I-Claim
in	I-Claim
secondary	I-Claim
endpoints	I-Claim
of	I-Claim
clinically	I-Claim
assessed	I-Claim
OPS	I-Claim
and	I-Claim
DNA	I-Claim
concentration	I-Claim
compared	I-Claim
with	I-Claim
placebo	I-Claim
in	I-Claim
H&N	I-Claim
cancer	I-Claim
patients	I-Claim
treated	I-Claim
with	I-Claim
CRT.	I-Claim

Further	O
investigation	O
in	O
larger	O
numbers	O
of	O
patients	O
is	O
warranted.	O

Due	O
to	O
concerns	O
of	O
fragility	O
fracture,	O
exercise	O
is	O
a	O
perceived	O
contraindication	O
for	O
prostate	O
cancer	O
patients	O
with	O
bone	O
metastases.	O

These	O
patients	O
experience	O
significant	O
functional	O
impairment	O
and	O
muscle	O
atrophy,	O
which	O
may	O
lead	O
to	O
an	O
increased	O
likelihood	O
of	O
skeletal	O
complicaTIOns	O
(i.e.,	O
pathological	O
fracture,	O
bone	O
pain)	O
and/or	O
falls.	O

Safe	O
resistance	O
exercise	O
prescription	O
may	O
counteract	O
this	O
effect.	O

The	O
aim	O
of	O
this	O
feasibility	O
trial	O
was	O
to	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
resistance	O
exercise	O
by	O
prostate	O
cancer	O
survivors	O
with	O
bone	O
metastatic	O
disease.	O

Twenty	O
men	O
with	O
established	O
bone	O
metastases	O
secondary	O
to	O
prostate	O
cancer	O
were	O
randomly	O
assigned	O
to	O
a	O
12-week	O
resistance	O
exercise	O
program	O
in	O
which	O
exercise	O
prescription	O
was	O
based	O
on	O
the	O
location	O
of	O
bone	O
lesions	O
(n=10)	O
or	O
usual	O
care	O
(n=10).	O

Outcomes	O
included	O
safety	O
and	O
tolerance	O
of	O
the	O
exercise	O
program,	O
physical	O
function,	O
physical	O
activity	O
level,	O
body	O
composition,	O
fatigue,	O
quality	O
of	O
life	O
and	O
psychological	O
distress.	O

Outcomes	O
were	O
compared	O
between	O
groups	O
using	O
analysis	O
of	O
covariance	O
adjusted	O
for	O
baseline	O
values.	O

Participants	O
had	O
significant	O
disease	O
load	O
with	O
65%	O
of	O
participants	O
presenting	O
with	O
two	O
or	O
more	O
regions	O
affected	O
by	O
bone	O
metastases	O
and	O
an	O
average	O
Gleason	O
score	O
of	O
8.20.9.	O

Five	O
participants	O
(exercise=2;	O
usual	O
care=3)	O
did	O
not	O
complete	O
the	O
intervention,	O
three	O
of	O
which	O
were	O
due	O
to	O
advancing	O
disease	O
(exercise=2;	O
usual	O
care=1).	O

No	B-Premise
adverse	I-Premise
events	I-Premise
or	I-Premise
skeletal	I-Premise
complications	I-Premise
occurred	I-Premise
during	I-Premise
the	I-Premise
supervised	I-Premise
exercise	I-Premise
sessions.	I-Premise

The	B-Premise
exercise	I-Premise
program	I-Premise
was	I-Premise
well	I-Premise
tolerated	I-Premise
as	I-Premise
evidenced	I-Premise
by	I-Premise
high	I-Premise
attendance	I-Premise
(83%)	I-Premise
and	I-Premise
compliance	I-Premise
rates	I-Premise
(93%),	I-Premise
and	I-Premise
the	I-Premise
ability	I-Premise
of	I-Premise
the	I-Premise
participants	I-Premise
to	I-Premise
exercise	I-Premise
at	I-Premise
an	I-Premise
intensity	I-Premise
within	I-Premise
the	I-Premise
target	I-Premise
range	I-Premise
for	I-Premise
cancer	I-Premise
survivors	I-Premise
(rating	I-Premise
of	I-Premise
perceived	I-Premise
exertion	I-Premise
=13.81.5).	I-Premise

The	B-Premise
change	I-Premise
in	I-Premise
physical	I-Premise
function	I-Premise
(muscle	I-Premise
strength	I-Premise
11%;	I-Premise
submaximal	I-Premise
aerobic	I-Premise
exercise	I-Premise
capacity	I-Premise
5%	I-Premise
and	I-Premise
ambulation	I-Premise
12%),	I-Premise
physical	I-Premise
activity	I-Premise
level	I-Premise
(24%)	I-Premise
and	I-Premise
lean	I-Premise
mass	I-Premise
(3%)	I-Premise
differed	I-Premise
significantly	I-Premise
between	I-Premise
groups	I-Premise
following	I-Premise
the	I-Premise
intervention,	I-Premise
with	I-Premise
favorable	I-Premise
changes	I-Premise
in	I-Premise
the	I-Premise
exercise	I-Premise
group	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
usual	I-Premise
care	I-Premise
group.	I-Premise

No	B-Premise
significant	I-Premise
between-group	I-Premise
differences	I-Premise
were	I-Premise
observed	I-Premise
for	I-Premise
fatigue,	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
or	I-Premise
psychological	I-Premise
distress.	I-Premise

This	B-Claim
initial	I-Claim
evidence	I-Claim
involving	I-Claim
a	I-Claim
small	I-Claim
sample	I-Claim
size	I-Claim
suggests	I-Claim
that	I-Claim
appropriately	I-Claim
designed	I-Claim
and	I-Claim
supervised	I-Claim
resistance	I-Claim
exercise	I-Claim
may	I-Claim
be	I-Claim
safe	I-Claim
and	I-Claim
well	I-Claim
tolerated	I-Claim
by	I-Claim
prostate	I-Claim
cancer	I-Claim
patients	I-Claim
with	I-Claim
bone	I-Claim
metastatic	I-Claim
disease	I-Claim
and	I-Claim
can	I-Claim
lead	I-Claim
to	I-Claim
improvements	I-Claim
in	I-Claim
physical	I-Claim
function,	I-Claim
physical	I-Claim
activity	I-Claim
levels	I-Claim
and	I-Claim
lean	I-Claim
mass.	I-Claim

Future	B-Claim
trials	I-Claim
involving	I-Claim
larger	I-Claim
sample	I-Claim
sizes	I-Claim
are	I-Claim
required	I-Claim
to	I-Claim
expand	I-Claim
these	I-Claim
preliminary	I-Claim
findings.	I-Claim

Gefitinib	O
and	O
Pemetrexed	O
are	O
drugs	O
used	O
as	O
second-line	O
therapy	O
for	O
advanced	O
non-small	O
cell	O
lung	O
cancer	O
(NSCLC),	O
although	O
studies	O
comparing	O
the	O
two	O
drugs	O
are	O
limited.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
explore	O
the	O
effects,	O
safety,	O
and	O
quality	O
of	O
life	O
(QoL)	O
of	O
Gefitinib	O
and	O
Pemetrexed	O
on	O
patients	O
with	O
advanced	O
non-squamous	O
NSCLC.	O

Forty-six	O
advanced	O
non-squamous	O
NSCLC	O
patients	O
who	O
failed	O
to	O
first-line	O
therapy	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
with	O
23	O
patients	O
each,	O
one	O
using	O
oral	O
Gefitinib	O
(Gefitinib	O
group)	O
and	O
the	O
other	O
using	O
intravenous	O
injection	O
Pemetrexed	O
(Pemetrexed	O
group).	O

The	O
effects,	O
safety,	O
and	O
QoL	O
were	O
determined	O
and	O
analyzed.	O

For	B-Premise
the	I-Premise
Pemetrexed	I-Premise
group,	I-Premise
objective	I-Premise
response	I-Premise
rate	I-Premise
(ORR)	I-Premise
was	I-Premise
13.0%	I-Premise
(3/23),	I-Premise
disease	I-Premise
control	I-Premise
rate	I-Premise
(DCR)	I-Premise
was	I-Premise
30.4%	I-Premise
(7/23),	I-Premise
and	I-Premise
median	I-Premise
progression-free	I-Premise
survival	I-Premise
(mPFS)	I-Premise
was	I-Premise
3.1	I-Premise
months.	I-Premise

In	B-Premise
the	I-Premise
Gefitinib	I-Premise
group,	I-Premise
ORR	I-Premise
was	I-Premise
17.3%	I-Premise
(4/23),	I-Premise
DCR	I-Premise
was	I-Premise
39.1%	I-Premise
(9/23),	I-Premise
and	I-Premise
mPFS	I-Premise
was	I-Premise
4.4	I-Premise
months.	I-Premise

Compared	B-Premise
with	I-Premise
the	I-Premise
Pemetrexed	I-Premise
group,	I-Premise
the	I-Premise
ORR,	I-Premise
DCR,	I-Premise
and	I-Premise
mPFS	I-Premise
in	I-Premise
the	I-Premise
Gefitinib	I-Premise
group	I-Premise
exhibited	I-Premise
no	I-Premise
statistical	I-Premise
significance	I-Premise
(P>0.05).	I-Premise

Furthermore,	O
the	B-Premise
most	I-Premise
common	I-Premise
toxicities	I-Premise
in	I-Premise
the	I-Premise
Pemetrexed	I-Premise
group	I-Premise
were	I-Premise
neutropenia	I-Premise
(n=9,	I-Premise
39.13%)	I-Premise
and	I-Premise
fatigue	I-Premise
(n=8,	I-Premise
34.78%),	I-Premise
whereas	I-Premise
those	I-Premise
in	I-Premise
the	I-Premise
in	I-Premise
Gefitinib	I-Premise
group	I-Premise
were	I-Premise
skin	I-Premise
rash	I-Premise
(n=8,	I-Premise
34.78%)	I-Premise
and	I-Premise
diarrhea	I-Premise
(n=4,	I-Premise
17.39%).	I-Premise

Compared	B-Premise
with	I-Premise
baseline,	I-Premise
the	I-Premise
QoL	I-Premise
improved	I-Premise
in	I-Premise
both	I-Premise
groups	I-Premise
but	I-Premise
to	I-Premise
different	I-Premise
degrees.	I-Premise

Likewise,	O
emotional,	B-Premise
functional	I-Premise
well-being,	I-Premise
and	I-Premise
QoL	I-Premise
aspects	I-Premise
specifically	I-Premise
related	I-Premise
to	I-Premise
lung	I-Premise
cancer	I-Premise
were	I-Premise
better	I-Premise
improved	I-Premise
in	I-Premise
the	I-Premise
Gefitinib	I-Premise
group	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
Pemetrexed	I-Premise
group	I-Premise
(P<0.05).	I-Premise

The	B-Claim
effects	I-Claim
of	I-Claim
Pemetrexed	I-Claim
and	I-Claim
Gefitinib	I-Claim
as	I-Claim
second	I-Claim
line	I-Claim
therapy	I-Claim
were	I-Claim
similar,	I-Claim
although	B-Premise
with	I-Premise
different	I-Premise
AEs.	I-Premise

Both	B-Claim
drugs	I-Claim
could	I-Claim
improve	I-Claim
the	I-Claim
QoL,	I-Claim
but	O
Gefitinib	B-Claim
showed	I-Claim
better	I-Claim
overall	I-Claim
results	I-Claim
than	I-Claim
Pemetrexed.	I-Claim

Everolimus	O
(EVE)+exemestane	O
(EXE;	O
n	O
=	O
485)	O
more	O
than	O
doubled	O
median	O
progression-free	O
survival	O
versus	O
placebo	O
(PBO)	O
+	O
EXE	O
(n	O
=	O
239),	O
with	O
a	O
manageable	O
safety	O
profile	O
and	O
no	O
deterioration	O
in	O
health-related	O
quality-of-life	O
(HRQOL)	O
in	O
patients	O
with	O
hormone-receptor-positive	O
(HR(+))	O
advanced	O
breast	O
cancer	O
(ABC)	O
who	O
recurred	O
or	O
progressed	O
on/after	O
nonsteroidal	O
aromatase	O
inhibitor	O
(NSAI)	O
therapy.	O

To	O
further	O
evaluate	O
EVE	O
+	O
EXE	O
impact	O
on	O
disease	O
burden,	O
we	O
conducted	O
additional	O
post-hoc	O
analyses	O
of	O
patient-reported	O
HRQOL.	O

HRQOL	O
was	O
assessed	O
using	O
EORTC	O
QLQ-C30	O
and	O
QLQ-BR23	O
questionnaires	O
at	O
baseline	O
and	O
every	O
6	O
weeks	O
thereafter	O
until	O
treatment	O
discontinuation	O
because	O
of	O
disease	O
progression,	O
toxicity,	O
or	O
consent	O
withdrawal.	O

Endpoints	O
included	O
the	O
QLQ-C30	O
Global	O
Health	O
Status	O
(QL2)	O
scale,	O
the	O
QLQ-BR23	O
breast	O
symptom	O
(BRBS),	O
and	O
arm	O
symptom	O
(BRAS)	O
scales.	O

Between-group	O
differences	O
in	O
change	O
from	O
baseline	O
were	O
assessed	O
using	O
linear	O
mixed	O
models	O
with	O
selected	O
covariates.	O

Sensitivity	O
analysis	O
using	O
pattern-mixture	O
models	O
determined	O
the	O
effect	O
of	O
study	O
discontinuation	O
on/before	O
week	O
24.	O

Treatment	O
arms	O
were	O
compared	O
using	O
differences	O
of	O
least	O
squares	O
mean	O
(LSM)	O
changes	O
from	O
baseline	O
and	O
95%	O
confidence	O
intervals	O
(CIs)	O
at	O
each	O
timepoint	O
and	O
overall.	O

Progression-free	O
survival,	O
survival,	O
response	O
rate,	O
safety,	O
and	O
HRQOL.	O

Linear	B-Premise
mixed	I-Premise
models	I-Premise
(primary	I-Premise
model)	I-Premise
demonstrated	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
overall	I-Premise
difference	I-Premise
between	I-Premise
EVE	I-Premise
+	I-Premise
EXE	I-Premise
and	I-Premise
PBO	I-Premise
+	I-Premise
EXE	I-Premise
for	I-Premise
QL2	I-Premise
(LSM	I-Premise
difference	I-Premise
=	I-Premise
-1.91;	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
-4.61,	I-Premise
0.78),	I-Premise
BRBS	I-Premise
(LSM	I-Premise
difference	I-Premise
=	I-Premise
-0.18;	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
-1.98,	I-Premise
1.62),	I-Premise
or	I-Premise
BRAS	I-Premise
(LSM	I-Premise
difference	I-Premise
=	I-Premise
-0.42;	I-Premise
95%	I-Premise
CI	I-Premise
=	I-Premise
-2.94,	I-Premise
2.10).	I-Premise

Based	O
on	O
pattern-mixture	O
models,	O
patients	O
who	O
dropped	O
out	O
early	O
had	O
worse	O
QL2	O
decline	O
on	O
both	O
treatments.	O

In	B-Premise
the	I-Premise
expanded	I-Premise
pattern-mixture	I-Premise
model,	I-Premise
EVE	I-Premise
+	I-Premise
EXE-treated	I-Premise
patients	I-Premise
who	I-Premise
did	I-Premise
not	I-Premise
drop	I-Premise
out	I-Premise
early	I-Premise
had	I-Premise
stable	I-Premise
BRBS	I-Premise
and	I-Premise
BRAS	I-Premise
relative	I-Premise
to	I-Premise
PBO	I-Premise
+	I-Premise
EXE.	I-Premise

HRQOL	O
data	O
were	O
not	O
collected	O
after	O
disease	O
progression.	O

These	B-Claim
analyses	I-Claim
confirm	I-Claim
that	I-Claim
EVE	I-Claim
+	I-Claim
EXE	I-Claim
provides	I-Claim
clinical	I-Claim
benefit	I-Claim
without	I-Claim
adversely	I-Claim
impacting	I-Claim
HRQOL	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
HR(+)	I-Claim
ABC	I-Claim
who	I-Claim
recurred/progressed	I-Claim
on	I-Claim
prior	I-Claim
NSAIs	I-Claim
versus	I-Claim
endocrine	I-Claim
therapy	I-Claim
alone.	I-Claim

Care	O
closer	O
to	O
home	O
is	O
being	O
explored	O
as	O
a	O
means	O
of	O
improving	O
patient	O
experience	O
as	O
well	O
as	O
efficiency	O
in	O
terms	O
of	O
cost	O
savings.	O

Evidence	O
that	O
community	O
cancer	O
services	O
improve	O
care	O
quality	O
and/or	O
generate	O
cost	O
savings	O
is	O
currently	O
limited.	O

A	O
randomised	O
study	O
was	O
undertaken	O
to	O
compare	O
delivery	O
of	O
cancer	O
treatment	O
in	O
the	O
hospital	O
with	O
two	O
different	O
community	O
settings.	O

Ninety-seven	O
patients	O
being	O
offered	O
outpatient-based	O
cancer	O
treatment	O
were	O
randomised	O
to	O
treatment	O
delivered	O
in	O
a	O
hospital	O
day	O
unit,	O
at	O
the	O
patient's	O
home	O
or	O
in	O
local	O
general	O
practice	O
(GP)	O
surgeries.	O

The	O
primary	O
outcome	O
was	O
patient-perceived	O
benefits,	O
using	O
the	O
emotional	O
function	O
domain	O
of	O
the	O
EORTC	O
quality	O
of	O
life	O
(QOL)	O
QLQC30	O
questionnaire	O
evaluated	O
after	O
12	O
weeks.	O

Secondary	O
outcomes	O
included	O
additional	O
QOL	O
measures,	O
patient	O
satisfaction,	O
safety	O
and	O
health	O
economics.	O

There	B-Premise
was	I-Premise
no	I-Premise
statistically	I-Premise
significant	I-Premise
QOL	I-Premise
difference	I-Premise
between	I-Premise
treatment	I-Premise
in	I-Premise
the	I-Premise
combined	I-Premise
community	I-Premise
locations	I-Premise
relative	I-Premise
to	I-Premise
hospital	I-Premise
(difference	I-Premise
of	I-Premise
-7.2,	I-Premise
95%	I-Premise
confidence	I-Premise
interval:	I-Premise
-195	I-Premise
to	I-Premise
+52,	I-Premise
P=0.25).	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
community	I-Premise
locations	I-Premise
in	I-Premise
favour	I-Premise
of	I-Premise
home	I-Premise
(+152,	I-Premise
13	I-Premise
to	I-Premise
291,	I-Premise
P=0.033).	I-Premise

Hospital	O
anxiety	O
and	O
depression	O
scale	O
scores	O
were	O
consistent	O
with	O
the	O
primary	O
outcome	O
measure.	O

There	B-Premise
was	I-Premise
no	I-Premise
evidence	I-Premise
that	I-Premise
community	I-Premise
treatment	I-Premise
compromised	I-Premise
patient	I-Premise
safety	I-Premise
and	O
no	B-Premise
significant	I-Premise
difference	I-Premise
between	I-Premise
treatment	I-Premise
arms	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
overall	I-Premise
costs	I-Premise
or	I-Premise
Quality	I-Premise
Adjusted	I-Premise
Life	I-Premise
Year.	I-Premise

Seventy-eight	B-Premise
percent	I-Premise
of	I-Premise
patients	I-Premise
expressed	I-Premise
satisfaction	I-Premise
with	I-Premise
their	I-Premise
treatment	I-Premise
whatever	I-Premise
their	I-Premise
location,	I-Premise
whereas	I-Premise
57%	I-Premise
of	I-Premise
patients	I-Premise
preferred	I-Premise
future	I-Premise
treatment	I-Premise
to	I-Premise
continue	I-Premise
at	I-Premise
the	I-Premise
hospital,	I-Premise
81%	I-Premise
at	I-Premise
GP	I-Premise
surgeries	I-Premise
and	I-Premise
90%	I-Premise
at	I-Premise
home.	I-Premise

Although	O
initial	O
pre-trial	O
interviews	O
revealed	O
concerns	O
among	O
health-care	O
professionals	O
and	O
some	O
patients	O
regarding	O
community	O
treatment,	O
opinions	O
were	O
largely	O
more	O
favourable	O
in	O
post-trial	O
interviews.	O

Patient	B-Claim
QOL	I-Claim
favours	I-Claim
delivering	I-Claim
cancer	I-Claim
treatment	I-Claim
in	I-Claim
the	I-Claim
home	I-Claim
rather	I-Claim
than	I-Claim
GP	I-Claim
surgeries.	I-Claim

Nevertheless,	B-Claim
both	I-Claim
community	I-Claim
settings	I-Claim
were	I-Claim
acceptable	I-Claim
to	I-Claim
and	I-Claim
preferred	I-Claim
by	I-Claim
patients	I-Claim
compared	I-Claim
with	I-Claim
hospital,	I-Claim
were	I-Claim
safe,	I-Claim
with	I-Claim
no	I-Claim
detrimental	I-Claim
impact	I-Claim
on	I-Claim
overall	I-Claim
health-care	I-Claim
costs.	I-Claim

The	O
optimal	O
duration	O
over	O
which	O
lung	O
SBRT	O
should	O
be	O
delivered	O
is	O
unknown.	O

We	O
conducted	O
a	O
randomized	O
pilot	O
study	O
in	O
patients	O
treated	O
with	O
four	O
fractions	O
of	O
lung	O
SBRT	O
delivered	O
over	O
4	O
or	O
over	O
11	O
days.	O

Patients	O
with	O
a	O
peripheral	O
solitary	O
lung	O
tumor	O
(NSCLC	O
or	O
pulmonary	O
metastasis)	O
	O
5	O
cm	O
were	O
eligible.	O

For	O
NSCLC	O
lung	O
tumors	O
	O
3	O
cm,	O
a	O
dose	O
of	O
48	O
Gy	O
in	O
4	O
fractions	O
was	O
used,	O
otherwise	O
52	O
Gy	O
in	O
4	O
fractions	O
was	O
delivered.	O

Patients	O
were	O
randomized	O
to	O
receive	O
treatment	O
over	O
4	O
consecutive	O
days	O
or	O
over	O
11	O
days.	O

The	O
primary	O
end-point	O
was	O
acute	O
grade	O
	O
2	O
toxicity.	O

Secondary	O
end-points	O
included	O
quality	O
of	O
life	O
(QOL)	O
assessed	O
using	O
the	O
EORTC	O
QLQ-C30	O
and	O
QLQ-LC13	O
questionnaires.	O

Fifty	O
four	O
patients	O
were	O
enrolled.	O

More	O
patients	O
in	O
the	O
11	O
day	O
group	O
had	O
respiratory	O
symptoms	O
at	O
baseline.	O

55.6%	B-Premise
patients	I-Premise
treated	I-Premise
over	I-Premise
4	I-Premise
days	I-Premise
and	I-Premise
33.3%	I-Premise
of	I-Premise
patients	I-Premise
treated	I-Premise
over	I-Premise
11	I-Premise
days	I-Premise
experienced	I-Premise
acute	I-Premise
grade	I-Premise
	I-Premise
2	I-Premise
toxicity	I-Premise
(p=0.085).	I-Premise

Dyspnea,	B-Premise
fatigue	I-Premise
and	I-Premise
coughing	I-Premise
domains	I-Premise
were	I-Premise
worse	I-Premise
in	I-Premise
the	I-Premise
11	I-Premise
day	I-Premise
group	I-Premise
at	I-Premise
baseline.	I-Premise

At	B-Premise
1	I-Premise
and	I-Premise
4	I-Premise
months,	I-Premise
more	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
4	I-Premise
day	I-Premise
group	I-Premise
experienced	I-Premise
a	I-Premise
clinically	I-Premise
meaningful	I-Premise
worsening	I-Premise
in	I-Premise
the	I-Premise
dyspnea	I-Premise
QOL	I-Premise
domain	I-Premise
compared	I-Premise
to	I-Premise
the	I-Premise
11	I-Premise
day	I-Premise
group	I-Premise
(44.5%	I-Premise
vs	I-Premise
15.4%,	I-Premise
p=0.02;	I-Premise
38.5%	I-Premise
vs	I-Premise
12.0%,	I-Premise
p=0.03,	I-Premise
respectively).	I-Premise

However,	B-Premise
raw	I-Premise
QOL	I-Premise
scores	I-Premise
were	I-Premise
not	I-Premise
different	I-Premise
at	I-Premise
these	I-Premise
time-points	I-Premise
between	I-Premise
treatment	I-Premise
groups.	I-Premise

Grade	B-Claim
2	I-Claim
or	I-Claim
higher	I-Claim
acute	I-Claim
toxicity	I-Claim
was	I-Claim
more	I-Claim
common	I-Claim
in	I-Claim
the	I-Claim
4	I-Claim
day	I-Claim
group,	I-Claim
approaching	I-Claim
statistical	I-Claim
significance.	I-Claim

More	B-Claim
patients	I-Claim
treated	I-Claim
on	I-Claim
4	I-Claim
consecutive	I-Claim
days	I-Claim
reported	I-Claim
a	I-Claim
clinically	I-Claim
meaningful	I-Claim
increase	I-Claim
in	I-Claim
dyspnea,	I-Claim
although	B-Claim
interpretation	I-Claim
of	I-Claim
these	I-Claim
results	I-Claim
is	I-Claim
challenging	I-Claim
due	I-Claim
to	I-Claim
baseline	I-Claim
imbalance	I-Claim
between	I-Claim
treatment	I-Claim
groups.	I-Claim

Larger	B-Claim
studies	I-Claim
are	I-Claim
required	I-Claim
to	I-Claim
validate	I-Claim
these	I-Claim
results.	I-Claim

Patients	O
experience	O
reductions	O
in	O
quality	O
of	O
life	O
(QOL)	O
while	O
receiving	O
cancer	O
treatment	O
and	O
several	O
approaches	O
have	O
been	O
proposed	O
to	O
address	O
QOL	O
issues.	O

In	O
this	O
project,	O
the	O
QOL	O
differences	O
between	O
older	O
adult	O
(age	O
65+)	O
and	O
younger	O
adult	O
(age	O
18-64)	O
advanced	O
cancer	O
patients	O
in	O
response	O
to	O
a	O
multidisciplinary	O
intervention	O
designed	O
to	O
improve	O
QOL	O
were	O
examined.	O

This	O
study	O
was	O
registered	O
on	O
ClinicalTrials.gov.	O

Newly	O
diagnosed	O
advanced	O
cancer	O
patients	O
undergoing	O
radiation	O
therapy	O
were	O
randomized	O
to	O
active	O
QOL	O
intervention	O
or	O
control	O
groups.	O

Those	O
in	O
the	O
intervention	O
group	O
received	O
six	O
multidisciplinary	O
90-minute	O
sessions	O
designed	O
to	O
address	O
the	O
five	O
major	O
domains	O
of	O
QOL.	O

Outcomes	O
measured	O
at	O
baseline	O
and	O
weeks	O
4,	O
27,	O
and	O
52	O
included	O
QOL	O
(Linear	O
Analogue	O
Self-Assessment	O
(LASA),	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-General	O
(FACT-G))	O
and	O
mood	O
(Profile	O
of	O
Mood	O
States	O
(POMS)).	O

Kruskall-Wallis	O
methodology	O
was	O
used	O
to	O
compare	O
scores	O
between	O
older	O
and	O
younger	O
adult	O
patients	O
randomized	O
to	O
the	O
intervention.	O

Of	O
131	O
patients	O
in	O
the	O
larger	O
randomized	O
controlled	O
study,	O
we	O
report	O
data	O
on	O
54	O
evaluable	O
patients	O
(16	O
older	O
adults	O
and	O
38	O
younger	O
adults)	O
randomized	O
to	O
the	O
intervention.	O

Older	B-Premise
adult	I-Premise
patients	I-Premise
reported	I-Premise
better	I-Premise
overall	I-Premise
QOL	I-Premise
(LASA	I-Premise
74.4	I-Premise
vs.	I-Premise
62.9,	I-Premise
p	I-Premise
=	I-Premise
0.040),	I-Premise
higher	I-Premise
social	I-Premise
well-being	I-Premise
(FACT-G	I-Premise
91.1	I-Premise
vs.	I-Premise
83.3,	I-Premise
p	I-Premise
=	I-Premise
0.045),	I-Premise
and	I-Premise
fewer	I-Premise
problems	I-Premise
with	I-Premise
anger	I-Premise
(POMS	I-Premise
anger-hostility	I-Premise
95.0	I-Premise
vs.	I-Premise
86.4,	I-Premise
p	I-Premise
=	I-Premise
0.028).	I-Premise

Long-term	B-Premise
benefits	I-Premise
for	I-Premise
older	I-Premise
patients	I-Premise
were	I-Premise
seen	I-Premise
in	I-Premise
the	I-Premise
anger-hostility	I-Premise
scale	I-Premise
at	I-Premise
week	I-Premise
27	I-Premise
(92.2	I-Premise
vs.	I-Premise
84.2,	I-Premise
p	I-Premise
=	I-Premise
0.027)	I-Premise
and	I-Premise
week	I-Premise
52	I-Premise
(96.3	I-Premise
vs.	I-Premise
85.9,	I-Premise
p	I-Premise
=	I-Premise
0.005).	I-Premise

Older	B-Claim
adult	I-Claim
patients	I-Claim
who	I-Claim
received	I-Claim
a	I-Claim
multidisciplinary	I-Claim
intervention	I-Claim
to	I-Claim
improve	I-Claim
QOL	I-Claim
while	I-Claim
undergoing	I-Claim
advanced	I-Claim
cancer	I-Claim
treatments	I-Claim
benefited	I-Claim
differently	I-Claim
in	I-Claim
some	I-Claim
QOL	I-Claim
domains,	I-Claim
compared	I-Claim
to	I-Claim
younger	I-Claim
adult	I-Claim
patients.	I-Claim

Future	O
studies	O
can	O
provide	O
further	O
insight	O
on	O
how	O
to	O
tailor	O
QOL	O
interventions	O
for	O
these	O
age	O
groups.	O

Chronic	O
gastrointestinal	O
symptoms	O
after	O
pelvic	O
radiotherapy	O
are	O
common,	O
multifactorial	O
in	O
cause,	O
and	O
affect	O
patients'	O
quality	O
of	O
life.	O

We	O
assessed	O
whether	O
such	O
patients	O
could	O
be	O
helped	O
if	O
a	O
practitioner	O
followed	O
an	O
investigative	O
and	O
management	O
algorithm,	O
and	O
whether	O
outcomes	O
differed	O
by	O
whether	O
a	O
nurse	O
or	O
a	O
gastroenterologist	O
led	O
this	O
algorithm-based	O
care.	O

For	O
this	O
three-arm	O
randomised	O
controlled	O
trial	O
we	O
recruited	O
patients	O
(aged	O
18	O
years)	O
from	O
clinics	O
in	O
London,	O
UK,	O
with	O
new-onset	O
gastrointestinal	O
symptoms	O
persisting	O
6	O
months	O
after	O
pelvic	O
radiotherapy.	O

Using	O
a	O
computer-generated	O
randomisation	O
sequence,	O
we	O
randomly	O
allocated	O
patients	O
to	O
one	O
of	O
three	O
groups	O
(1:1:1;	O
stratified	O
by	O
tumour	O
site	O
[urological,	O
gynaecological,	O
or	O
gastrointestinal],	O
and	O
degree	O
of	O
bowel	O
dysfunction	O
[IBDQ-B	O
score	O
<60	O
vs	O
60-70]):	O
usual	O
care	O
(a	O
detailed	O
self-help	O
booklet),	O
gastroenterologist-led	O
algorithm-based	O
treatment,	O
or	O
nurse-led	O
algorithm-based	O
treatment.	O

The	O
primary	O
endpoint	O
was	O
change	O
in	O
Inflammatory	O
Bowel	O
Disease	O
Questionnaire-Bowel	O
subset	O
score	O
(IBDQ-B)	O
at	O
6	O
months,	O
analysed	O
by	O
intention	O
to	O
treat.	O

Between	O
Nov	O
26,	O
2007,	O
and	O
Dec	O
12,	O
2011,	O
we	O
enrolled	O
and	O
randomly	O
allocated	O
218	O
patients	O
to	O
treatment:	O
80	O
to	O
the	O
nurse	O
group,	O
70	O
to	O
the	O
gastroenterologist	O
group,	O
and	O
68	O
to	O
the	O
booklet	O
group	O
(figure).	O

Most	O
had	O
a	O
baseline	O
IBDQ-B	O
score	O
indicating	O
moderate-to-severe	O
symptoms.	O

We	B-Premise
recorded	I-Premise
the	I-Premise
following	I-Premise
pair-wise	I-Premise
mean	I-Premise
difference	I-Premise
in	I-Premise
change	I-Premise
in	I-Premise
IBDQ-B	I-Premise
score	I-Premise
between	I-Premise
groups:	I-Premise
nurse	I-Premise
versus	I-Premise
booklet	I-Premise
412	I-Premise
(95%	I-Premise
CI	I-Premise
004-819;	I-Premise
p=004),	I-Premise
gastroenterologist	I-Premise
versus	I-Premise
booklet	I-Premise
547	I-Premise
(114-981;	I-Premise
p=001).	I-Premise

Outcomes	B-Premise
in	I-Premise
the	I-Premise
nurse	I-Premise
group	I-Premise
were	I-Premise
not	I-Premise
inferior	I-Premise
to	I-Premise
outcomes	I-Premise
in	I-Premise
the	I-Premise
gastroenterologist	I-Premise
group	I-Premise
(mean	I-Premise
difference	I-Premise
136,	I-Premise
one	I-Premise
sided	I-Premise
95%	I-Premise
CI	I-Premise
-148).	I-Premise

Patients	B-Claim
given	I-Claim
targeted	I-Claim
intervention	I-Claim
following	I-Claim
a	I-Claim
detailed	I-Claim
clinical	I-Claim
algorithm	I-Claim
had	I-Claim
better	I-Claim
improvements	I-Claim
in	I-Claim
radiotherapy-induced	I-Claim
gastrointestinal	I-Claim
symptoms	I-Claim
than	I-Claim
did	I-Claim
patients	I-Claim
given	I-Claim
usual	I-Claim
care.	I-Claim

Our	B-Claim
findings	I-Claim
suggest	I-Claim
that,	I-Claim
for	I-Claim
most	I-Claim
patients,	I-Claim
this	I-Claim
algorithm-based	I-Claim
care	I-Claim
can	I-Claim
be	I-Claim
given	I-Claim
by	I-Claim
a	I-Claim
trained	I-Claim
nurse.	I-Claim

Abiraterone	B-Claim
acetate	I-Claim
plus	I-Claim
prednisone	I-Claim
significantly	I-Claim
improves	I-Claim
radiographic	I-Claim
progression-free	I-Claim
survival	I-Claim
in	I-Claim
asymptomatic	I-Claim
or	I-Claim
mildly	I-Claim
symptomatic,	I-Claim
chemotherapy-naive	I-Claim
patients	I-Claim
with	I-Claim
metastatic	I-Claim
castration-resistant	I-Claim
prostate	I-Claim
cancer	I-Claim
compared	I-Claim
with	I-Claim
prednisone	I-Claim
alone.	I-Claim

We	O
describe	O
analyses	O
of	O
data	O
for	O
patient-reported	O
pain	O
and	O
functional	O
status	O
in	O
a	O
preplanned	O
interim	O
analysis	O
of	O
a	O
phase	O
3	O
trial.	O

Between	O
April	O
28,	O
2009,	O
and	O
June	O
23,	O
2010,	O
patients	O
with	O
progressive,	O
metastatic	O
castration-resistant	O
prostate	O
cancer	O
were	O
enrolled	O
into	O
a	O
multinational,	O
double-blind,	O
placebo-controlled	O
trial.	O

Patients	O
were	O
eligible	O
if	O
they	O
were	O
asymptomatic	O
(score	O
of	O
0	O
or	O
1	O
on	O
item	O
three	O
of	O
the	O
Brief	O
Pain	O
Inventory	O
Short	O
Form	O
[BPI-SF]	O
questionnaire)	O
or	O
mildly	O
symptomatic	O
(score	O
of	O
2	O
or	O
3)	O
and	O
had	O
not	O
previously	O
received	O
chemotherapy.	O

Patients	O
were	O
randomly	O
assigned	O
(1:1)	O
to	O
receive	O
oral	O
abiraterone	O
(1	O
g	O
daily)	O
plus	O
prednisone	O
(5	O
mg	O
twice	O
daily)	O
or	O
placebo	O
plus	O
prednisone	O
in	O
continuous	O
4-week	O
cycles.	O

Pain	O
was	O
assessed	O
with	O
the	O
BPI-SF	O
questionnaire,	O
and	O
health-related	O
quality	O
of	O
life	O
(HRQoL)	O
with	O
the	O
Functional	O
Assessment	O
of	O
Cancer	O
Therapy-Prostate	O
(FACT-P)	O
questionnaire.	O

We	O
analysed	O
data	O
with	O
prespecified	O
criteria	O
for	O
clinically	O
meaningful	O
pain	O
progression	O
and	O
deterioration	O
in	O
HRQoL.	O

All	O
patients	O
who	O
underwent	O
randomisation	O
were	O
included	O
in	O
analyses.	O

1088	O
patients	O
underwent	O
randomisation:	O
546	O
were	O
assigned	O
to	O
abiraterone	O
plus	O
prednisone	O
and	O
542	O
to	O
placebo	O
plus	O
prednisone.	O

At	O
the	O
time	O
of	O
the	O
second	O
prespecified	O
interim	O
analysis,	O
median	O
follow-up	O
was	O
222	O
months	O
(IQR	O
202-248).	O

Median	B-Premise
time	I-Premise
to	I-Premise
progression	I-Premise
of	I-Premise
mean	I-Premise
pain	I-Premise
intensity	I-Premise
was	I-Premise
longer	I-Premise
in	I-Premise
patients	I-Premise
assigned	I-Premise
to	I-Premise
abiraterone	I-Premise
plus	I-Premise
prednisone	I-Premise
(267	I-Premise
months	I-Premise
[95%	I-Premise
CI	I-Premise
193-not	I-Premise
estimable])	I-Premise
than	I-Premise
in	I-Premise
those	I-Premise
assigned	I-Premise
to	I-Premise
placebo	I-Premise
plus	I-Premise
prednisone	I-Premise
(184	I-Premise
months	I-Premise
[149-not	I-Premise
estimable];	I-Premise
hazard	I-Premise
ratio	I-Premise
[HR]	I-Premise
082,	I-Premise
95%	I-Premise
CI	I-Premise
067-100;	I-Premise
p=00490),	I-Premise
as	I-Premise
was	I-Premise
median	I-Premise
time	I-Premise
to	I-Premise
progression	I-Premise
of	I-Premise
pain	I-Premise
interference	I-Premise
with	I-Premise
daily	I-Premise
activities	I-Premise
(103	I-Premise
months	I-Premise
[95%	I-Premise
CI	I-Premise
93-130]	I-Premise
vs	I-Premise
74	I-Premise
months	I-Premise
[64-86];	I-Premise
HR	I-Premise
079,	I-Premise
95%	I-Premise
CI	I-Premise
067-093;	I-Premise
p=0005).	I-Premise

Median	B-Premise
time	I-Premise
to	I-Premise
progression	I-Premise
of	I-Premise
worst	I-Premise
pain	I-Premise
was	I-Premise
also	I-Premise
longer	I-Premise
with	I-Premise
abiraterone	I-Premise
plus	I-Premise
prednisone	I-Premise
(267	I-Premise
months	I-Premise
[95%	I-Premise
CI	I-Premise
194-not	I-Premise
estimable])	I-Premise
than	I-Premise
with	I-Premise
placebo	I-Premise
plus	I-Premise
prednisone	I-Premise
(194	I-Premise
months	I-Premise
[166-not	I-Premise
estimable]),	I-Premise
but	I-Premise
the	I-Premise
difference	I-Premise
was	I-Premise
not	I-Premise
significant	I-Premise
(HR	I-Premise
085,	I-Premise
95%	I-Premise
CI	I-Premise
069-104;	I-Premise
p=0109).	I-Premise

Median	B-Premise
time	I-Premise
to	I-Premise
HRQoL	I-Premise
deterioration	I-Premise
was	I-Premise
longer	I-Premise
in	I-Premise
patients	I-Premise
assigned	I-Premise
to	I-Premise
abiraterone	I-Premise
plus	I-Premise
prednisone	I-Premise
than	I-Premise
in	I-Premise
those	I-Premise
assigned	I-Premise
to	I-Premise
placebo	I-Premise
plus	I-Premise
prednisone	I-Premise
as	I-Premise
assessed	I-Premise
by	I-Premise
the	I-Premise
FACT-P	I-Premise
total	I-Premise
score	I-Premise
(127	I-Premise
months	I-Premise
[95%	I-Premise
CI	I-Premise
111-140]	I-Premise
vs	I-Premise
83	I-Premise
months	I-Premise
[74-106];	I-Premise
HR	I-Premise
078,	I-Premise
95%	I-Premise
CI	I-Premise
066-092;	I-Premise
p=0003)	I-Premise
and	I-Premise
by	I-Premise
the	I-Premise
score	I-Premise
on	I-Premise
its	I-Premise
prostate-cancer-specific	I-Premise
subscale	I-Premise
(111	I-Premise
months	I-Premise
[86-138]	I-Premise
vs	I-Premise
58	I-Premise
months	I-Premise
[55-83];	I-Premise
HR	I-Premise
070,	I-Premise
95%	I-Premise
CI	I-Premise
060-083;	I-Premise
p<00001).	I-Premise

Abiraterone	B-Claim
plus	I-Claim
prednisone	I-Claim
delays	I-Claim
patient-reported	I-Claim
pain	I-Claim
progression	I-Claim
and	I-Claim
HRQoL	I-Claim
deterioration	I-Claim
in	I-Claim
chemotherapy-naive	I-Claim
patients	I-Claim
with	I-Claim
metastatic	I-Claim
castration-resistant	I-Claim
prostate	I-Claim
cancer.	I-Claim

These	B-Claim
results	I-Claim
provide	I-Claim
further	I-Claim
support	I-Claim
for	I-Claim
the	I-Claim
efficacy	I-Claim
of	I-Claim
abiraterone	I-Claim
in	I-Claim
this	I-Claim
population.	I-Claim

Single-agent	O
therapy	O
with	O
bicalutamide,	O
a	O
nonsteroidal	O
antiandrogen,	O
was	O
compared	O
with	O
castration,	O
either	O
surgical	O
or	O
medical,	O
in	O
patients	O
with	O
untreated	O
Stage	O
D2	O
prostate	O
cancer.	O

In	O
an	O
open,	O
randomized,	O
multicenter	O
trial,	O
patients	O
were	O
randomized	O
to	O
treatment	O
with	O
50	O
mg	O
bicalutamide	O
(n	O
=	O
243)	O
once	O
daily	O
or	O
to	O
castration	O
(n	O
=	O
243),	O
either	O
orchiectomy	O
or	O
depot	O
injection	O
of	O
goserelin	O
acetate	O
every	O
28	O
days.	O

Primary	O
efficacy	O
endpoints	O
were	O
times	O
to	O
treatment	O
failure	O
and	O
objective	O
disease	O
progression	O
and	O
survival.	O

Assessments	O
included	O
review	O
of	O
measurable	O
metastases,	O
prostate	O
dimensions,	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status,	O
pain,	O
analgesic	O
requirements,	O
and	O
quality	O
of	O
life	O
responses.	O

The	O
median	O
duration	O
of	O
therapy	O
was	O
39	O
weeks	O
for	O
bicalutamide-treated	O
patients	O
and	O
42	O
weeks	O
for	O
castrated	O
patients;	O
treatment	O
failure	O
occurred	O
in	O
53%	O
and	O
42%	O
and	O
disease	O
progression	O
in	O
43%	O
and	O
33%,	O
respectively.	O

Treatment	B-Premise
effects	I-Premise
favored	I-Premise
castration	I-Premise
for	I-Premise
both	I-Premise
endpoints	I-Premise
(P	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
0.002),	I-Premise
with	I-Premise
hazard	I-Premise
ratios	I-Premise
(bicalutamide:castration)	I-Premise
of	I-Premise
1.54	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI],	I-Premise
1.18	I-Premise
to	I-Premise
2.00)	I-Premise
for	I-Premise
time	I-Premise
to	I-Premise
treatment	I-Premise
failure	I-Premise
and	I-Premise
1.6	I-Premise
(95%	I-Premise
CI,	I-Premise
1.19	I-Premise
to	I-Premise
2.15)	I-Premise
for	I-Premise
time	I-Premise
to	I-Premise
disease	I-Premise
progression.	I-Premise

From	B-Premise
the	I-Premise
1-year	I-Premise
survival	I-Premise
analysis,	I-Premise
the	I-Premise
hazard	I-Premise
ratio	I-Premise
for	I-Premise
probability	I-Premise
of	I-Premise
death	I-Premise
was	I-Premise
1.29	I-Premise
(95%	I-Premise
CI,	I-Premise
0.96	I-Premise
to	I-Premise
1.72).	I-Premise

Thus	B-Premise
far,	I-Premise
with	I-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
86	I-Premise
weeks,	I-Premise
median	I-Premise
survival	I-Premise
has	I-Premise
not	I-Premise
been	I-Premise
reached	I-Premise
in	I-Premise
either	I-Premise
group.	I-Premise

Changes	B-Premise
from	I-Premise
baseline	I-Premise
in	I-Premise
several	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
variables	I-Premise
were	I-Premise
significantly	I-Premise
different	I-Premise
(P	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
0.01)	I-Premise
between	I-Premise
treatment	I-Premise
groups	I-Premise
periodically	I-Premise
from	I-Premise
months	I-Premise
1	I-Premise
to	I-Premise
6,	I-Premise
and	I-Premise
all	I-Premise
favored	I-Premise
bicalutamide.	I-Premise

Overall,	B-Premise
the	I-Premise
antiandrogen	I-Premise
was	I-Premise
well	I-Premise
tolerated	I-Premise
compared	I-Premise
with	I-Premise
castration;	I-Premise
with	B-Premise
bicalutamide,	I-Premise
hot	I-Premise
flushes	I-Premise
occurred	I-Premise
less	I-Premise
often	I-Premise
and	I-Premise
breast	I-Premise
tenderness	I-Premise
and	I-Premise
gynecomastia	I-Premise
more	I-Premise
often.	I-Premise

Although	B-Premise
a	I-Premise
dosage	I-Premise
of	I-Premise
50	I-Premise
mg	I-Premise
of	I-Premise
bicalutamide	I-Premise
once	I-Premise
daily	I-Premise
was	I-Premise
not	I-Premise
as	I-Premise
effective	I-Premise
as	I-Premise
castration,	I-Premise
the	B-Claim
favorable	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
outcomes	I-Claim
and	I-Claim
the	I-Claim
low	I-Claim
incidence	I-Claim
of	I-Claim
nonhormonal	I-Claim
adverse	I-Claim
events	I-Claim
provide	I-Claim
reasons	I-Claim
to	I-Claim
evaluate	I-Claim
bicalutamide,	I-Claim
as	I-Claim
a	I-Claim
single	I-Claim
therapeutic	I-Claim
agent,	I-Claim
at	I-Claim
higher	I-Claim
doses.	I-Claim

An	O
open,	O
randomized	O
study	O
was	O
performed	O
to	O
assess	O
the	O
effects	O
of	O
supportive	O
pamidronate	O
treatment	O
on	O
morbidity	O
from	O
bone	O
metastases	O
in	O
breast	O
cancer	O
patients.	O

Eighty-one	O
pamidronate	O
patients	O
and	O
80	O
control	O
patients	O
were	O
monitored	O
for	O
a	O
median	O
of	O
18	O
and	O
21	O
months,	O
respectively,	O
for	O
events	O
of	O
skeletal	O
morbidity	O
and	O
the	O
radiologic	O
course	O
of	O
metastatic	O
bone	O
disease.	O

The	O
oral	O
pamidronate	O
dose	O
was	O
600	O
mg/d	O
(high	O
dose	O
[HD])	O
during	O
the	O
earliest	O
study	O
years,	O
then	O
changed	O
to	O
300	O
mg/d	O
(low	O
dose	O
[LD])	O
because	O
of	O
gastrointestinal	O
toxicity.	O

Twenty-nine	O
of	O
81	O
pamidronate	O
(HD/LD)	O
patients	O
first	O
received	O
600	O
mg/d	O
and	O
were	O
then	O
changed	O
to	O
300	O
mg/d;	O
52	O
of	O
81	O
pamidronate	O
LD	O
patients	O
received	O
300	O
mg/d	O
throughout	O
the	O
study.	O

Tumor	O
treatment	O
was	O
unrestricted.	O

An	O
overall	O
intent-to-treat	O
analysis	O
was	O
performed.	O

In	B-Premise
the	I-Premise
pamidronate	I-Premise
group,	I-Premise
the	I-Premise
occurrence	I-Premise
of	I-Premise
hypercalcemia,	I-Premise
severe	I-Premise
bone	I-Premise
pain,	I-Premise
and	I-Premise
symptomatic	I-Premise
impending	I-Premise
fractures	I-Premise
decreased	I-Premise
by	I-Premise
65%,	I-Premise
30%,	I-Premise
and	I-Premise
50%,	I-Premise
respectively;	I-Premise
event-rates	I-Premise
of	I-Premise
systemic	I-Premise
treatment	I-Premise
and	I-Premise
radiotherapy	I-Premise
decreased	I-Premise
by	I-Premise
35%	I-Premise
(P	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
.02).	I-Premise

The	B-Premise
event-free	I-Premise
period	I-Premise
(EFP),	I-Premise
radiologic	I-Premise
course	I-Premise
of	I-Premise
disease,	I-Premise
and	I-Premise
survival	I-Premise
did	I-Premise
not	I-Premise
improve.	I-Premise

Subgroup	B-Claim
analyses	I-Claim
suggested	I-Claim
a	I-Claim
dose-dependent	I-Claim
treatment	I-Claim
effect.	I-Claim

Compared	B-Premise
with	I-Premise
their	I-Premise
controls,	I-Premise
in	I-Premise
pamidronate	I-Premise
HD/LD	I-Premise
patients,	I-Premise
events	I-Premise
occurred	I-Premise
60%	I-Premise
to	I-Premise
90%	I-Premise
less	I-Premise
frequently	I-Premise
(P	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
.03)	I-Premise
and	I-Premise
the	I-Premise
EFP	I-Premise
was	I-Premise
prolonged	I-Premise
(P	I-Premise
=	I-Premise
.002).	I-Premise

In	B-Premise
pamidronate	I-Premise
LD	I-Premise
patients,	I-Premise
event-rates	I-Premise
decreased	I-Premise
by	I-Premise
15%	I-Premise
to	I-Premise
45%	I-Premise
(P	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
.04).	I-Premise

Gastrointestinal	B-Premise
toxicity	I-Premise
of	I-Premise
pamidronate	I-Premise
caused	I-Premise
a	I-Premise
23%	I-Premise
drop-out	I-Premise
rate,	I-Premise
but	B-Claim
other	I-Claim
cancer-associated	I-Claim
factors	I-Claim
seemed	I-Claim
to	I-Claim
contribute	I-Claim
to	I-Claim
this	I-Claim
toxicity.	I-Claim

Pamidronate	B-Claim
treatment	I-Claim
of	I-Claim
breast	I-Claim
cancer	I-Claim
patients	I-Claim
efficaciously	I-Claim
reduced	I-Claim
skeletal	I-Claim
morbidity.	I-Claim

The	B-Claim
effect	I-Claim
appeared	I-Claim
to	I-Claim
be	I-Claim
dose-dependent.	I-Claim

Further	B-Claim
research	I-Claim
on	I-Claim
dose	I-Claim
and	I-Claim
mode	I-Claim
of	I-Claim
treatment	I-Claim
is	I-Claim
mandatory.	I-Claim

From	O
1984	O
to	O
1989,	O
the	O
Swiss	O
Group	O
for	O
Clinical	O
Cancer	O
Research	O
(SAKK)	O
performed	O
a	O
randomized	O
phase	O
III	O
trial	O
comparing	O
early	O
versus	O
late	O
alternating	O
chemotherapy	O
in	O
patients	O
with	O
small-cell	O
lung	O
cancer.	O

406	O
eligible	O
patients	O
were	O
entered	O
into	O
the	O
trial.	O

Regimen	O
A	O
consisted	O
of	O
PAV	O
(cisPlatin,	O
Adriamycin,	O
VP	O
16-213,	O
and	O
Regimen	O
B	O
of	O
CyMOC	O
(Cyclophosphamide,	O
Methotrexate,	O
Oncovin,	O
CCNU).	O

Cycles	O
were	O
repeated	O
as	O
rapidly	O
as	O
possible.	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
ABABAB	O
(early	O
alternating	O
chemotherapy)	O
or	O
AAABBB	O
(late	O
alternating	O
chemotherapy).	O

After	O
six	O
cycles	O
patients	O
with	O
limited	O
disease	O
in	O
complete	O
or	O
partial	O
remission	O
and	O
those	O
with	O
extensive	O
disease	O
in	O
complete	O
remission	O
received	O
irradiation	O
to	O
the	O
primary	O
(45	O
Gy)	O
and	O
the	O
CNS	O
(36	O
Gy).	O

The	B-Premise
overall	I-Premise
remission	I-Premise
rate	I-Premise
was	I-Premise
87%	I-Premise
with	I-Premise
31%	I-Premise
complete	I-Premise
remissions.	I-Premise

The	B-Premise
median	I-Premise
survival	I-Premise
of	I-Premise
all	I-Premise
406	I-Premise
eligible	I-Premise
patients	I-Premise
was	I-Premise
346	I-Premise
days	I-Premise
with	I-Premise
15%	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
alive	I-Premise
at	I-Premise
two	I-Premise
years.	I-Premise

The	B-Premise
overall	I-Premise
remission	I-Premise
rate,	I-Premise
the	I-Premise
rate	I-Premise
of	I-Premise
complete	I-Premise
remission,	I-Premise
the	I-Premise
median	I-Premise
survival	I-Premise
and	I-Premise
the	I-Premise
rate	I-Premise
of	I-Premise
long-term	I-Premise
survival	I-Premise
were	I-Premise
not	I-Premise
significantly	I-Premise
different	I-Premise
in	I-Premise
the	I-Premise
two	I-Premise
treatment	I-Premise
arms.	I-Premise

In	B-Premise
limited	I-Premise
disease	I-Premise
the	I-Premise
estimated	I-Premise
percentages	I-Premise
of	I-Premise
survival	I-Premise
at	I-Premise
2	I-Premise
years	I-Premise
were	I-Premise
33%	I-Premise
in	I-Premise
the	I-Premise
early	I-Premise
and	I-Premise
24%	I-Premise
in	I-Premise
the	I-Premise
late	I-Premise
alternating	I-Premise
chemotherapy	I-Premise
arms.	I-Premise

Patients	B-Premise
with	I-Premise
extensive	I-Premise
disease	I-Premise
survived	I-Premise
significantly	I-Premise
longer	I-Premise
with	I-Premise
late	I-Premise
alternating	I-Premise
chemotherapy	I-Premise
than	I-Premise
on	I-Premise
the	I-Premise
early	I-Premise
alternation	I-Premise
regimen	I-Premise
(median	I-Premise
survival	I-Premise
336	I-Premise
days	I-Premise
versus	I-Premise
301	I-Premise
days,	I-Premise
p	I-Premise
=	I-Premise
0.01).	I-Premise

In	B-Premise
the	I-Premise
latter	I-Premise
patients	I-Premise
the	I-Premise
received	I-Premise
dose	I-Premise
intensities	I-Premise
(RDI)	I-Premise
of	I-Premise
cisplatin,	I-Premise
adriamycin	I-Premise
and	I-Premise
etoposide	I-Premise
were	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
the	I-Premise
late-alternation	I-Premise
arm.	I-Premise

Patients	B-Premise
treated	I-Premise
with	I-Premise
early	I-Premise
alternating	I-Premise
chemotherapy	I-Premise
rated	I-Premise
their	I-Premise
tumor	I-Premise
symptoms,	I-Premise
functional	I-Premise
states,	I-Premise
fatigue/malaise	I-Premise
and	I-Premise
restriction	I-Premise
of	I-Premise
social	I-Premise
activity	I-Premise
significantly	I-Premise
better,	I-Premise
reflecting	I-Premise
an	I-Premise
improved	I-Premise
subjective	I-Premise
adjustment.	I-Premise

Alternating	B-Claim
chemotherapy	I-Claim
with	I-Claim
PAV-CyMOC	I-Claim
plus	I-Claim
consolidating	I-Claim
radiotherapy	I-Claim
is	I-Claim
a	I-Claim
feasible	I-Claim
and	I-Claim
effective	I-Claim
treatment	I-Claim
for	I-Claim
small-cell	I-Claim
lung	I-Claim
cancer,	I-Claim
with	I-Claim
acceptable	I-Claim
toxicity.	I-Claim

Whereas	O
patients	B-Claim
with	I-Claim
early	I-Claim
alternating	I-Claim
chemotherapy	I-Claim
achieve	I-Claim
a	I-Claim
better	I-Claim
subjective	I-Claim
adjustment,	I-Claim
late	B-Claim
alternating	I-Claim
chemotherapy	I-Claim
allows	I-Claim
for	I-Claim
a	I-Claim
higher	I-Claim
RDI	I-Claim
of	I-Claim
cisplatin,	I-Claim
adriamycin	I-Claim
and	I-Claim
etoposide,	I-Claim
which	I-Claim
results	I-Claim
in	I-Claim
a	I-Claim
significantly	I-Claim
longer	I-Claim
median	I-Claim
survival	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
extensive	I-Claim
disease.	I-Claim

Taxol	B-Premise
(paclitaxel;	I-Premise
Bristol-Myers	I-Premise
Squibb,	I-Premise
Wallingford,	I-Premise
CT)	I-Premise
is	I-Premise
a	I-Premise
new	I-Premise
anticancer	I-Premise
agent	I-Premise
with	I-Premise
activity	I-Premise
in	I-Premise
a	I-Premise
number	I-Premise
of	I-Premise
human	I-Premise
tumors,	I-Premise
including	I-Premise
epithelial	I-Premise
ovarian	I-Premise
cancer.	I-Premise

In	O
nonrandomized	O
trials,	O
doses	O
studied	O
have	O
ranged	O
from	O
135	O
mg/m2	O
to	O
250	O
mg/m2	O
administered	O
over	O
24	O
hours	O
with	O
premedication	O
to	O
avoid	O
hypersensitivity	O
reactions	O
(HSRs).	O

This	O
study	O
addressed	O
two	O
questions:	O
the	O
dose-response	O
relationship	O
of	O
Taxol	O
in	O
relapsed	O
ovarian	O
cancer	O
and	O
the	O
safety	O
of	O
a	O
short	O
infusion	O
given	O
with	O
premedication.	O

Women	O
with	O
platinum-pretreated	O
epithelial	O
ovarian	O
cancer	O
and	O
measurable	O
recurrent	O
disease	O
were	O
randomized	O
in	O
a	O
bifactorial	O
design	O
to	O
receive	O
either	O
175	O
or	O
135	O
mg/m2	O
of	O
Taxol	O
over	O
either	O
24	O
or	O
3	O
hours.	O

Major	O
end	O
points	O
were	O
the	O
frequency	O
of	O
significant	O
HSRs	O
and	O
objective	O
response	O
rate.	O

Secondary	O
end	O
points	O
were	O
progression-free	O
and	O
overall	O
survival.	O

Of	O
407	O
patients	O
randomized,	O
391	O
were	O
eligible	O
and	O
382	O
assessable	O
for	O
response.	O

Analysis	O
was	O
performed	O
according	O
to	O
the	O
bifactorial	O
design.	O

Severe	B-Premise
HSRs	I-Premise
were	I-Premise
rare	I-Premise
(1.5%	I-Premise
patients)	I-Premise
and	I-Premise
were	I-Premise
not	I-Premise
affected	I-Premise
by	I-Premise
either	I-Premise
dose	I-Premise
or	I-Premise
schedule.	I-Premise

Response	B-Premise
was	I-Premise
slightly	I-Premise
higher	I-Premise
at	I-Premise
the	I-Premise
175-mg/m2	I-Premise
dose	I-Premise
(20%)	I-Premise
than	I-Premise
at	I-Premise
135	I-Premise
mg/m2	I-Premise
(15%),	I-Premise
but	B-Premise
this	I-Premise
was	I-Premise
not	I-Premise
statistically	I-Premise
significant	I-Premise
(P	I-Premise
=	I-Premise
.2).	I-Premise

However,	B-Premise
progression-free	I-Premise
survival	I-Premise
was	I-Premise
significantly	I-Premise
longer	I-Premise
in	I-Premise
the	I-Premise
high-dose	I-Premise
group	I-Premise
(19	I-Premise
v	I-Premise
14	I-Premise
weeks;	I-Premise
P	I-Premise
=	I-Premise
.02).	I-Premise

Significantly	B-Premise
more	I-Premise
neutropenia	I-Premise
was	I-Premise
seen	I-Premise
when	I-Premise
Taxol	I-Premise
was	I-Premise
administered	I-Premise
as	I-Premise
a	I-Premise
24-hour	I-Premise
infusion.	I-Premise

Response	B-Premise
rates	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
the	I-Premise
24-	I-Premise
and	I-Premise
3-hour	I-Premise
groups	I-Premise
(19%	I-Premise
and	I-Premise
16%,	I-Premise
respectively;	I-Premise
P	I-Premise
=	I-Premise
.6).	I-Premise

No	B-Premise
survival	I-Premise
differences	I-Premise
were	I-Premise
noted.	I-Premise

The	B-Claim
3-hour	I-Claim
infusion	I-Claim
of	I-Claim
Taxol	I-Claim
is	I-Claim
safe	I-Claim
when	I-Claim
given	I-Claim
with	I-Claim
premedication	I-Claim
and	I-Claim
is	I-Claim
associated	I-Claim
with	I-Claim
less	I-Claim
neutropenia.	I-Claim

There	O
is	O
a	O
modest	O
dose	O
effect	O
with	O
longer	O
time	O
to	O
progression	O
at	O
175	O
mg/m2.	O

The	B-Claim
observation	I-Claim
that	I-Claim
longer	I-Claim
infusion	I-Claim
produces	I-Claim
more	I-Claim
myelosuppression	I-Claim
but	I-Claim
does	I-Claim
not	I-Claim
yield	I-Claim
higher	I-Claim
response	I-Claim
rates	I-Claim
should	I-Claim
lead	I-Claim
to	I-Claim
further	I-Claim
studies	I-Claim
to	I-Claim
determine	I-Claim
the	I-Claim
optimal	I-Claim
dose	I-Claim
and	I-Claim
schedule	I-Claim
of	I-Claim
this	I-Claim
interesting	I-Claim
new	I-Claim
agent.	I-Claim

The	O
impact	O
of	O
the	O
side	O
effects	O
of	O
megestrol	O
acetate	O
on	O
the	O
quality	O
of	O
life	O
of	O
noncachectic	O
women	O
with	O
advanced	O
breast	O
cancer	O
was	O
studied	O
in	O
a	O
dose-response	O
clinical	O
trial	O
of	O
the	O
Cancer	O
and	O
Leukemia	O
Group	O
B	O
(CALGB	O
8741).	O

Side	O
effects	O
of	O
appetite	O
increase	O
and	O
weight	O
gain	O
at	O
higher	O
doses	O
were	O
predicted	O
to	O
have	O
a	O
negative	O
effect	O
on	O
quality	O
of	O
life.	O

Stage	O
IV	O
breast	O
cancer	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
160,	O
800,	O
or	O
1,600	O
mg/d	O
of	O
megestrol	O
acetate.	O

Quality	O
of	O
life	O
was	O
assessed	O
in	O
131	O
patients	O
at	O
trial	O
entry	O
and	O
at	O
1	O
and	O
3	O
months	O
while	O
on	O
treatment,	O
by	O
telephone	O
interview,	O
using	O
the	O
following	O
measures:	O
the	O
Functional	O
Living	O
Index-Cancer	O
(FLIC),	O
Rand	O
Functional	O
Limitations	O
Scale,	O
Rand	O
Mental	O
Health	O
Inventory	O
(MHI),	O
the	O
Body	O
Image	O
Subscale,	O
and	O
linear	O
analog	O
scales	O
of	O
drug	O
side	O
effects.	O

At	B-Premise
3	I-Premise
months,	I-Premise
women	I-Premise
treated	I-Premise
with	I-Premise
160	I-Premise
mg/d	I-Premise
reported	I-Premise
less	I-Premise
severe	I-Premise
side	I-Premise
effects	I-Premise
(P	I-Premise
<	I-Premise
.0005),	I-Premise
better	I-Premise
physical	I-Premise
functioning	I-Premise
(FLS,	I-Premise
P	I-Premise
<	I-Premise
.0005),	I-Premise
less	I-Premise
psychologic	I-Premise
distress	I-Premise
(MHI,	I-Premise
P	I-Premise
=	I-Premise
.008),	I-Premise
and	I-Premise
an	I-Premise
improvement	I-Premise
in	I-Premise
overall	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
(FLIC,	I-Premise
P	I-Premise
=	I-Premise
.003)	I-Premise
from	I-Premise
the	I-Premise
time	I-Premise
of	I-Premise
study	I-Premise
entry	I-Premise
as	I-Premise
compared	I-Premise
with	I-Premise
those	I-Premise
treated	I-Premise
with	I-Premise
1,600	I-Premise
mg/d.	I-Premise

Patients	B-Premise
who	I-Premise
received	I-Premise
the	I-Premise
800-mg/d	I-Premise
dose	I-Premise
fell	I-Premise
between	I-Premise
the	I-Premise
low-	I-Premise
and	I-Premise
high-dose	I-Premise
arms	I-Premise
in	I-Premise
reported	I-Premise
intensity	I-Premise
of	I-Premise
drug	I-Premise
side	I-Premise
effects,	I-Premise
but	B-Premise
responded	I-Premise
similarly	I-Premise
to	I-Premise
those	I-Premise
in	I-Premise
the	I-Premise
160-mg/d	I-Premise
group	I-Premise
in	I-Premise
terms	I-Premise
of	I-Premise
physical	I-Premise
functioning,	I-Premise
psychologic	I-Premise
distress,	I-Premise
and	I-Premise
overall	I-Premise
quality	I-Premise
of	I-Premise
life.	I-Premise

Unless	B-Claim
additional	I-Claim
follow-up	I-Claim
data	I-Claim
demonstrate	I-Claim
a	I-Claim
survival	I-Claim
advantage	I-Claim
at	I-Claim
higher	I-Claim
doses,	I-Claim
the	I-Claim
160-mg/d	I-Claim
dose	I-Claim
is	I-Claim
optimal,	I-Claim
achieving	I-Claim
maximal	I-Claim
treatment	I-Claim
effect	I-Claim
with	I-Claim
the	I-Claim
fewest	I-Claim
side	I-Claim
effects	I-Claim
and	I-Claim
better	I-Claim
quality	I-Claim
of	I-Claim
life.	I-Claim

A	O
single-item	O
linear	O
analogue	O
self-assessment	O
scale	O
for	O
mood	O
was	O
compared	O
with	O
a	O
28-item	O
adjective	O
checklist	O
for	O
emotional	O
well-being.	O

To	O
confirm	O
its	O
concurrent	O
validity	O
and	O
responsiveness	O
to	O
treatment	O
and	O
recurrence	O
in	O
patients	O
with	O
breast	O
cancer,	O
emotional	O
well-being	O
was	O
assessed	O
every	O
3	O
months	O
for	O
2	O
years	O
and	O
at	O
1	O
and	O
6	O
months	O
after	O
recurrence	O
in	O
1,169	O
patients	O
who	O
were	O
premenopausal	O
and	O
960	O
patients	O
who	O
were	O
postmenopausal.	O

These	O
patients	O
were	O
enrolled	O
in	O
two	O
International	O
Breast	O
Cancer	O
Study	O
Group	O
randomized	O
clinical	O
trials	O
in	O
operable	O
breast	O
cancer	O
conducted	O
from	O
1986	O
to	O
1993.	O

To	O
assess	O
concurrent	O
validity,	O
Pearson's	O
correlation	O
between	O
the	O
linear	O
analogue	O
self-assessment	O
scale	O
and	O
the	O
adjective	O
checklist	O
were	O
calculated	O
for	O
each	O
time-point	O
within	O
each	O
treatment	O
group	O
and	O
for	O
the	O
two	O
assessments	O
after	O
recurrence.	O

Responsiveness	O
to	O
treatment	O
and	O
recurrence	O
were	O
analyzed	O
using	O
paired	O
t	O
tests	O
and	O
the	O
squared	O
ratio	O
of	O
these	O
t	O
tests,	O
an	O
estimate	O
of	O
relative	O
efficiency.	O

Concurrent	O
validity	O
of	O
the	O
mood	O
linear	O
analogue	O
self-assessment	O
was	O
consistently	O
confirmed	O
across	O
four	O
language	O
groups.	O

Both	B-Claim
measures	I-Claim
were	I-Claim
responsive;	I-Claim
out	B-Premise
of	I-Premise
24	I-Premise
changes	I-Premise
over	I-Premise
time,	I-Premise
19	I-Premise
were	I-Premise
in	I-Premise
the	I-Premise
expected	I-Premise
direction	I-Premise
for	I-Premise
the	I-Premise
linear	I-Premise
analogue	I-Premise
self-assessment	I-Premise
scale	I-Premise
(p	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
0.05	I-Premise
for	I-Premise
9	I-Premise
of	I-Premise
19)	I-Premise
and	I-Premise
17	I-Premise
for	I-Premise
the	I-Premise
adjective	I-Premise
checklist	I-Premise
(p	I-Premise
<	I-Premise
or	I-Premise
=	I-Premise
0.05	I-Premise
for	I-Premise
10	I-Premise
of	I-Premise
17).	I-Premise

The	B-Premise
linear	I-Premise
analogue	I-Premise
self-assessment	I-Premise
scale	I-Premise
was	I-Premise
less	I-Premise
but	I-Premise
significantly	I-Premise
efficient	I-Premise
for	I-Premise
detection	I-Premise
of	I-Premise
treatment	I-Premise
effects,	I-Premise
with	I-Premise
relative	I-Premise
efficiency	I-Premise
estimates	I-Premise
ranging	I-Premise
from	I-Premise
0.16	I-Premise
to	I-Premise
2.45	I-Premise
and	I-Premise
a	I-Premise
median	I-Premise
of	I-Premise
0.66	I-Premise
among	I-Premise
the	I-Premise
comparisons	I-Premise
with	I-Premise
relatively	I-Premise
stable	I-Premise
estimates	I-Premise
(/t/	I-Premise
>	I-Premise
or	I-Premise
=	I-Premise
1.0)	I-Premise
and	I-Premise
more	I-Premise
efficient	I-Premise
for	I-Premise
recurrence	I-Premise
than	I-Premise
the	I-Premise
adjective	I-Premise
checklist.	I-Premise

The	B-Claim
mood	I-Claim
linear	I-Claim
analogue	I-Claim
self-assessment	I-Claim
scale	I-Claim
is	I-Claim
a	I-Claim
valid	I-Claim
indicator	I-Claim
of	I-Claim
emotional	I-Claim
well-being	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
breast	I-Claim
cancer	I-Claim
in	I-Claim
large	I-Claim
multicenter,	I-Claim
multicultural	I-Claim
trials	I-Claim
in	I-Claim
which	I-Claim
comprehensive	I-Claim
scales	I-Claim
are	I-Claim
less	I-Claim
feasible.	I-Claim

This	B-Claim
investigation	I-Claim
supports	I-Claim
the	I-Claim
clinical	I-Claim
relevance	I-Claim
of	I-Claim
linear	I-Claim
analogue	I-Claim
self-assessment	I-Claim
scales	I-Claim
as	I-Claim
indicators	I-Claim
of	I-Claim
components	I-Claim
of	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
in	I-Claim
cancer	I-Claim
clinical	I-Claim
trials.	I-Claim

To	O
assess	O
whether	O
the	O
administration	O
of	O
recombinant	O
human	O
erythropoietin	O
(r-HuEPO)	O
would	O
increase	O
the	O
hematocrit,	O
reduce	O
the	O
requirement	O
for	O
transfusion,	O
and	O
improve	O
the	O
quality	O
of	O
life	O
in	O
anemic	O
cancer	O
patients	O
receiving	O
myelosuppressive,	O
cisplatin-based	O
chemotherapy.	O

One	O
hundred	O
thirty-two	O
anemic	O
cancer	O
patients	O
receiving	O
cyclic,	O
cisplatin-containing,	O
myelosuppressive	O
chemotherapy	O
were	O
evaluated.	O

Patients	O
received	O
either	O
r-HuEPO	O
(150	O
U/kg)	O
or	O
placebo,	O
subcutaneously,	O
three	O
times	O
a	O
week	O
for	O
3	O
months.	O

Responses	O
were	O
assessed	O
by	O
measuring	O
changes	O
in	O
hemoglobin/hematocrit,	O
transfusion	O
requirement,	O
and	O
quality	O
of	O
life.	O

The	B-Premise
mean	I-Premise
hematocrit	I-Premise
increased	I-Premise
by	I-Premise
6.0	I-Premise
percentage	I-Premise
points	I-Premise
in	I-Premise
the	I-Premise
r-HuEPO	I-Premise
group	I-Premise
versus	I-Premise
1.3	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
group.	I-Premise

A	B-Premise
decrease	I-Premise
in	I-Premise
transfusion	I-Premise
requirement	I-Premise
did	I-Premise
not	I-Premise
reach	I-Premise
significance	I-Premise
over	I-Premise
all	I-Premise
3	I-Premise
months,	I-Premise
but	I-Premise
there	I-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
reduction	I-Premise
in	I-Premise
the	I-Premise
percentage	I-Premise
of	I-Premise
patients	I-Premise
transfused	I-Premise
in	I-Premise
the	I-Premise
second	I-Premise
and	I-Premise
third	I-Premise
months	I-Premise
(27%	I-Premise
r-HuEPO	I-Premise
vs.	I-Premise
56%	I-Premise
placebo)	I-Premise
and	I-Premise
a	I-Premise
trend	I-Premise
toward	I-Premise
reduction	I-Premise
in	I-Premise
the	I-Premise
mean	I-Premise
total	I-Premise
number	I-Premise
of	I-Premise
units	I-Premise
transfused	I-Premise
(1.20	I-Premise
units	I-Premise
r-HuEPO	I-Premise
vs.	I-Premise
2.02	I-Premise
units	I-Premise
placebo),	I-Premise
suggesting	I-Premise
a	I-Premise
lag	I-Premise
of	I-Premise
1	I-Premise
month	I-Premise
before	I-Premise
r-HuEPO	I-Premise
can	I-Premise
affect	I-Premise
the	I-Premise
transfusion	I-Premise
requirement.	I-Premise

Pretreatment	B-Premise
serum	I-Premise
erythropoietin	I-Premise
levels	I-Premise
were	I-Premise
lower	I-Premise
in	I-Premise
responders	I-Premise
than	I-Premise
in	I-Premise
nonresponders	I-Premise
(73.5	I-Premise
IU/L	I-Premise
and	I-Premise
86.3	I-Premise
IU/L	I-Premise
means,	I-Premise
respectively).	I-Premise

However,	B-Premise
the	I-Premise
magnitude	I-Premise
of	I-Premise
this	I-Premise
difference	I-Premise
was	I-Premise
not	I-Premise
helpful	I-Premise
in	I-Premise
defining	I-Premise
which	I-Premise
patients	I-Premise
were	I-Premise
likely	I-Premise
to	I-Premise
respond.	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
significant	I-Premise
improvement	I-Premise
in	I-Premise
overall	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
treatment	I-Premise
arms	I-Premise
in	I-Premise
favor	I-Premise
of	I-Premise
the	I-Premise
r-HuEPO-treated	I-Premise
group.	I-Premise

There	B-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
adverse	I-Premise
effects	I-Premise
associated	I-Premise
with	I-Premise
r-HuEPO.	I-Premise

r-HuEPO	B-Claim
is	I-Claim
safe	I-Claim
and	I-Claim
can	I-Claim
cause	I-Claim
a	I-Claim
significant	I-Claim
improvement	I-Claim
in	I-Claim
the	I-Claim
hematocrit	I-Claim
and	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
of	I-Claim
anemic	I-Claim
cancer	I-Claim
patients	I-Claim
receiving	I-Claim
myelosuppressive,	I-Claim
cisplatin-based	I-Claim
chemotherapy.	I-Claim

After	B-Claim
1	I-Claim
month	I-Claim
of	I-Claim
r-HuEPO,	I-Claim
there	I-Claim
is	I-Claim
also	I-Claim
a	I-Claim
reduction	I-Claim
in	I-Claim
transfusion	I-Claim
requirement.	I-Claim

To	O
compare	O
protracted	O
venous	O
infusion	O
(PVI)	O
5-fluorouracil	O
(5-FU)	O
with	O
and	O
without	O
mitomycin	O
C	O
(MMC)	O
in	O
a	O
prospectively	O
randomised	O
study	O
and	O
analyse	O
for	O
tumour	O
response,	O
survival,	O
toxicity	O
and	O
quality	O
of	O
life	O
(QL).	O

Two	O
hundred	O
patients	O
with	O
advanced	O
colorectal	O
cancer	O
received	O
PVI	O
5-FU	O
300	O
mg/m2/day	O
for	O
a	O
maximum	O
of	O
24	O
weeks	O
and	O
were	O
randomised	O
to	O
PVI	O
5-FU	O
alone	O
or	O
PVI	O
5-FU	O
+	O
MMC	O
10	O
mg/m2	O
(7	O
mg/m2	O
from	O
June	O
1995)	O
6	O
weekly	O
for	O
4	O
courses.	O

Overall	B-Premise
response	I-Premise
was	I-Premise
54%	I-Premise
(95%	I-Premise
confidence	I-Premise
interval	I-Premise
[CI]	I-Premise
44.1%-63.9%)	I-Premise
with	I-Premise
PVI	I-Premise
5-FU	I-Premise
+	I-Premise
MMC	I-Premise
compared	I-Premise
to	I-Premise
38%	I-Premise
(95%	I-Premise
CI:	I-Premise
28.3%-47.7%)	I-Premise
for	I-Premise
PVI	I-Premise
5-FU	I-Premise
alone	I-Premise
(P	I-Premise
=	I-Premise
0.024).	I-Premise

The	B-Premise
median	I-Premise
failure	I-Premise
free	I-Premise
survival	I-Premise
was	I-Premise
7.9	I-Premise
months	I-Premise
in	I-Premise
PVI	I-Premise
5-FU	I-Premise
plus	I-Premise
MMC	I-Premise
and	I-Premise
5.4	I-Premise
months	I-Premise
with	I-Premise
PVI	I-Premise
5-FU	I-Premise
alone	I-Premise
(P	I-Premise
=	I-Premise
0.033)	I-Premise
and	I-Premise
at	I-Premise
one	I-Premise
year	I-Premise
31.9%	I-Premise
for	I-Premise
the	I-Premise
combination	I-Premise
compared	I-Premise
to	I-Premise
17.7%	I-Premise
for	I-Premise
PVI	I-Premise
5-FU	I-Premise
alone.	I-Premise

Median	B-Premise
survival	I-Premise
was	I-Premise
14	I-Premise
months	I-Premise
with	I-Premise
MMC	I-Premise
and	I-Premise
15	I-Premise
months	I-Premise
in	I-Premise
5-FU	I-Premise
alone;	I-Premise
one-year	I-Premise
survival	I-Premise
51.7%	I-Premise
vs.	I-Premise
57.2%.	I-Premise

PVI	B-Premise
5-FU	I-Premise
+	I-Premise
MMC	I-Premise
caused	I-Premise
more	I-Premise
overall	I-Premise
haematological	I-Premise
toxicity	I-Premise
but	I-Premise
CTC	I-Premise
grades	I-Premise
3/4	I-Premise
was	I-Premise
increased	I-Premise
only	I-Premise
for	I-Premise
thrombocytopaenia.	I-Premise

Two	B-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
a	I-Premise
cumulative	I-Premise
dose	I-Premise
of	I-Premise
MMC	I-Premise
of	I-Premise
40	I-Premise
mg/m2	I-Premise
developed	I-Premise
haemolytic	I-Premise
uraemic	I-Premise
syndrome	I-Premise
warranting	I-Premise
the	I-Premise
reduction	I-Premise
in	I-Premise
cumulative	I-Premise
MMC	I-Premise
dose	I-Premise
to	I-Premise
28	I-Premise
mg/m2.	I-Premise

The	B-Premise
global	I-Premise
QL	I-Premise
scores	I-Premise
were	I-Premise
better	I-Premise
for	I-Premise
PVI	I-Premise
5-FU	I-Premise
+	I-Premise
MMC	I-Premise
arm	I-Premise
at	I-Premise
24	I-Premise
weeks,	I-Premise
but	B-Premise
the	I-Premise
remaining	I-Premise
QL	I-Premise
data	I-Premise
showed	I-Premise
no	I-Premise
differences.	I-Premise

PVI	B-Claim
5-FU	I-Claim
+	I-Claim
MMC	I-Claim
results	I-Claim
in	I-Claim
failure-free	I-Claim
survival	I-Claim
and	I-Claim
response	I-Claim
advantage,	I-Claim
tolerable	I-Claim
toxicity	I-Claim
and	I-Claim
better	I-Claim
QL	I-Claim
when	I-Claim
compared	I-Claim
to	I-Claim
PVI	I-Claim
5-FU	I-Claim
alone	I-Claim
but	I-Claim
no	I-Claim
overall	I-Claim
survival	I-Claim
advantage.	I-Claim

There	B-Premise
is	I-Premise
no	I-Premise
irreversible	I-Premise
toxicity	I-Premise
with	I-Premise
MMC	I-Premise
at	I-Premise
a	I-Premise
cumulative	I-Premise
dose	I-Premise
of	I-Premise
28	I-Premise
mg/m2.	I-Premise

The	O
effectiveness	O
of	O
a	O
Pain	O
Education	O
Program	O
in	O
cancer	O
patients	O
with	O
chronic	O
pain	O
offered	O
by	O
nurses	O
was	O
investigated	O
in	O
a	O
randomized	O
controlled	O
clinical	O
trial.	O

A	O
multi-method	O
approach	O
was	O
used	O
in	O
which	O
verbal	O
instruction,	O
written	O
material,	O
an	O
audio	O
cassette	O
tape,	O
and	O
the	O
use	O
of	O
a	O
pain	O
diary	O
were	O
combined	O
to	O
inform	O
and	O
instruct	O
patients	O
about	O
pain	O
and	O
pain	O
management.	O

The	O
Pain	O
Education	O
Program	O
was	O
tailored	O
to	O
the	O
needs	O
of	O
the	O
individual	O
patient	O
and	O
consisted	O
of	O
three	O
elements:	O
(1)	O
educating	O
patients	O
about	O
the	O
basic	O
principles	O
regarding	O
pain	O
and	O
pain	O
management;	O
(2)	O
instructing	O
patients	O
how	O
to	O
report	O
their	O
pain	O
in	O
a	O
pain	O
diary;	O
and	O
(3)	O
instructing	O
patients	O
how	O
to	O
communicate	O
about	O
pain	O
and	O
how	O
to	O
contact	O
health	O
care	O
providers.	O

Following	O
pretesting	O
in	O
313	O
patients,	O
patients	O
who	O
needed	O
district	O
nursing	O
and	O
who	O
did	O
not	O
need	O
district	O
nursing	O
at	O
home	O
were	O
randomly	O
assigned	O
to	O
a	O
control	O
or	O
intervention	O
group.	O

Intervention	O
group	O
patients	O
received	O
the	O
Pain	O
Education	O
Program	O
in	O
the	O
hospital,	O
and	O
3	O
and	O
7	O
days	O
postdischarge	O
by	O
telephone;	O
this	O
was	O
done	O
by	O
nurses	O
who	O
were	O
specially	O
trained	O
as	O
pain	O
counselors.	O

Follow-up	O
assessments	O
were	O
at	O
2,	O
4	O
and	O
8	O
weeks	O
postdischarge.	O

Results	O
of	O
the	O
pretest	O
showed	O
that	O
many	O
patients	O
lacked	O
knowledge	O
about	O
pain	O
and	O
pain	O
management.	O

The	O
majority	O
of	O
pain	O
topics	O
had	O
to	O
be	O
discussed.	O

The	B-Claim
Pain	I-Claim
Education	I-Claim
Program	I-Claim
proved	I-Claim
to	I-Claim
be	I-Claim
feasible:	I-Claim
75.0%	B-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
had	I-Premise
read	I-Premise
the	I-Premise
entire	I-Premise
pain	I-Premise
brochure,	I-Premise
55.7%	I-Premise
had	I-Premise
listened	I-Premise
to	I-Premise
the	I-Premise
audio	I-Premise
cassette,	I-Premise
and	I-Premise
85.6%	I-Premise
of	I-Premise
pain	I-Premise
scores	I-Premise
were	I-Premise
completed	I-Premise
in	I-Premise
the	I-Premise
pain	I-Premise
diary.	I-Premise

Results	B-Claim
showed	I-Claim
a	I-Claim
significant	I-Claim
increase	I-Claim
in	I-Claim
pain	I-Claim
knowledge	I-Claim
in	I-Claim
patients	I-Claim
who	I-Claim
received	I-Claim
the	I-Claim
Pain	I-Claim
Education	I-Claim
Program	I-Claim
and	I-Claim
a	I-Claim
significant	I-Claim
decrease	I-Claim
in	I-Claim
pain	I-Claim
intensity.	I-Claim

However,	B-Premise
pain	I-Premise
relief	I-Premise
was	I-Premise
mainly	I-Premise
found	I-Premise
in	I-Premise
the	I-Premise
intervention	I-Premise
group	I-Premise
patients	I-Premise
without	I-Premise
district	I-Premise
nursing.	I-Premise

It	B-Claim
can	I-Claim
be	I-Claim
concluded	I-Claim
that	I-Claim
the	I-Claim
tailored	I-Claim
Pain	I-Claim
Education	I-Claim
Program	I-Claim
is	I-Claim
effective	I-Claim
for	I-Claim
cancer	I-Claim
patients	I-Claim
in	I-Claim
chronic	I-Claim
pain.	I-Claim

The	B-Claim
use	I-Claim
of	I-Claim
the	I-Claim
Pain	I-Claim
Education	I-Claim
Program	I-Claim
by	I-Claim
nurses	I-Claim
should	I-Claim
be	I-Claim
seriously	I-Claim
considered	I-Claim
on	I-Claim
oncology	I-Claim
units.	I-Claim

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
pamidronate	O
for	O
bone	O
pain	O
in	O
a	O
randomised	O
double-blind	O
trial	O
and	O
to	O
evaluate	O
the	O
contribution	O
of	O
new	O
markers	O
of	O
bone	O
resorption	O
in	O
patients	O
with	O
bone	O
metastases.	O

Fifty-two	O
patients	O
with	O
painful	O
bone	O
metastases	O
were	O
randomised	O
to	O
receive	O
a	O
two-hour	O
infusion	O
of	O
pamidronate	O
120	O
mg	O
or	O
an	O
identical	O
infusion	O
of	O
saline.	O

Four	O
weeks	O
later,	O
all	O
patients	O
received	O
pamidronate	O
120	O
mg.	O

Bone	O
resorption	O
markers	O
measured	O
included	O
urinary	O
calcium	O
(uCa),	O
hydroxyproline	O
(Hyp),	O
and	O
the	O
collagen	O
breakdown	O
products:	O
NTx,	O
Crosslaps	O
and	O
Free	O
Dpd.	O

Symptomatic	B-Premise
response	I-Premise
during	I-Premise
the	I-Premise
first	I-Premise
four	I-Premise
weeks	I-Premise
was	I-Premise
seen	I-Premise
after	I-Premise
pamidronate,	I-Premise
but	I-Premise
not	I-Premise
with	I-Premise
placebo	I-Premise
(P	I-Premise
<	I-Premise
0.05).	I-Premise

Quality	B-Premise
of	I-Premise
life	I-Premise
was	I-Premise
maintained	I-Premise
with	I-Premise
pamidronate	I-Premise
and	I-Premise
deteriorated	I-Premise
after	I-Premise
placebo	I-Premise
(P	I-Premise
<	I-Premise
0.05).	I-Premise

Resorption	B-Premise
markers	I-Premise
did	I-Premise
not	I-Premise
decrease	I-Premise
after	I-Premise
placebo,	I-Premise
but	B-Premise
NTx	I-Premise
and	I-Premise
Crosslaps	I-Premise
both	I-Premise
decreased	I-Premise
by	I-Premise
70%	I-Premise
after	I-Premise
pamidronate	I-Premise
(P	I-Premise
=	I-Premise
0.001).	I-Premise

A	B-Premise
second	I-Premise
infusion	I-Premise
of	I-Premise
pamidronate	I-Premise
did	I-Premise
not	I-Premise
decrease	I-Premise
resorption	I-Premise
further,	I-Premise
but	B-Premise
maintained	I-Premise
the	I-Premise
suppression	I-Premise
of	I-Premise
resorption	I-Premise
at	I-Premise
similar	I-Premise
levels	I-Premise
for	I-Premise
a	I-Premise
further	I-Premise
four	I-Premise
weeks.	I-Premise

Symptomatic	B-Premise
response	I-Premise
to	I-Premise
pamidronate	I-Premise
correlated	I-Premise
closely	I-Premise
with	I-Premise
the	I-Premise
rate	I-Premise
of	I-Premise
bone	I-Premise
resorption;	I-Premise
it	B-Premise
was	I-Premise
more	I-Premise
frequent	I-Premise
in	I-Premise
those	I-Premise
patients	I-Premise
with	I-Premise
an	I-Premise
initial	I-Premise
NTx	I-Premise
value	I-Premise
of	I-Premise
<	I-Premise
2	I-Premise
times	I-Premise
the	I-Premise
upper	I-Premise
limit	I-Premise
of	I-Premise
normal	I-Premise
(17	I-Premise
of	I-Premise
27,	I-Premise
62%)	I-Premise
and	I-Premise
in	I-Premise
those	I-Premise
where	I-Premise
the	I-Premise
level	I-Premise
of	I-Premise
Ntx	I-Premise
returned	I-Premise
to	I-Premise
normal	I-Premise
(19	I-Premise
of	I-Premise
32,	I-Premise
59%),	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
patients	I-Premise
with	I-Premise
either	I-Premise
high	I-Premise
baseline	I-Premise
values	I-Premise
of	I-Premise
NTx	I-Premise
(>	I-Premise
2	I-Premise
times	I-Premise
the	I-Premise
upper	I-Premise
limit	I-Premise
of	I-Premise
normal)	I-Premise
or	I-Premise
Ntx	I-Premise
levels	I-Premise
which	I-Premise
failed	I-Premise
to	I-Premise
normalise	I-Premise
for	I-Premise
whom	I-Premise
the	I-Premise
response	I-Premise
frequencies	I-Premise
were	I-Premise
2	I-Premise
of	I-Premise
16	I-Premise
(13%)	I-Premise
and	I-Premise
0	I-Premise
of	I-Premise
11	I-Premise
(0%),	I-Premise
respectively.	I-Premise

Subjective	B-Claim
benefit	I-Claim
after	I-Claim
intravenous	I-Claim
pamidronate	I-Claim
is	I-Claim
confirmed	I-Claim
in	I-Claim
this	I-Claim
placebo-controlled	I-Claim
study.	I-Claim

The	B-Claim
new	I-Claim
bone	I-Claim
resorption	I-Claim
markers	I-Claim
of	I-Claim
collagen	I-Claim
breakdown	I-Claim
were	I-Claim
able	I-Claim
to	I-Claim
predict	I-Claim
clinical	I-Claim
response	I-Claim
to	I-Claim
pamidronate.	I-Claim

We	O
conducted	O
a	O
prospective,	O
randomized,	O
multicentre	O
clinical	O
trial	O
comparing	O
the	O
effects	O
and	O
costs	O
of	O
GM-CSF	O
as	O
an	O
adjunct	O
to	O
intensive	O
chemotherapy	O
in	O
elderly	O
patients	O
with	O
acute	O
myeloid	O
leukaemia	O
(AML).	O

The	O
patients	O
were	O
randomized	O
to	O
either	O
daunomycin-cytosine	O
arabinoside	O
(control	O
arm:	O
n	O
=	O
161)	O
or	O
daunomycin-cytosine	O
arabinoside	O
with	O
GM-CSF	O
(GM-CSF	O
arm:	O
n	O
=	O
157).	O

The	O
primary	O
end-point	O
was	O
the	O
effect	O
of	O
GM-CSF	O
on	O
the	O
percentage	O
of	O
complete	O
remissions	O
(CR).	O

Survival	O
duration,	O
disease-free	O
survival,	O
quality	O
of	O
life	O
and	O
costs	O
were	O
evaluated	O
separately.	O

CR	B-Premise
after	I-Premise
remission	I-Premise
induction	I-Premise
treatment	I-Premise
was	I-Premise
achieved	I-Premise
in	I-Premise
55%	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
and	I-Premise
in	I-Premise
56%	I-Premise
of	I-Premise
the	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
GM-CSF	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
NS).	I-Premise

The	B-Premise
duration	I-Premise
of	I-Premise
survival	I-Premise
and	I-Premise
disease-free	I-Premise
survival	I-Premise
at	I-Premise
2	I-Premise
years	I-Premise
after	I-Premise
randomization	I-Premise
were	I-Premise
estimated	I-Premise
at	I-Premise
22%	I-Premise
and	I-Premise
19%	I-Premise
for	I-Premise
the	I-Premise
control	I-Premise
group	I-Premise
and	I-Premise
22%	I-Premise
and	I-Premise
14%	I-Premise
for	I-Premise
the	I-Premise
GM-CSF	I-Premise
group	I-Premise
(P	I-Premise
=	I-Premise
NS).	I-Premise

Considering	B-Premise
the	I-Premise
short-term	I-Premise
quality	I-Premise
of	I-Premise
life,	I-Premise
the	I-Premise
administration	I-Premise
of	I-Premise
GM-CSF	I-Premise
resulted	I-Premise
in	I-Premise
more	I-Premise
problems	I-Premise
with	I-Premise
regard	I-Premise
to	I-Premise
depressed	I-Premise
mood,	I-Premise
diarrhoea	I-Premise
and	I-Premise
rash/eczema.	I-Premise

With	B-Premise
regard	I-Premise
to	I-Premise
the	I-Premise
long-term	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
there	I-Premise
were	I-Premise
no	I-Premise
significant	I-Premise
differences	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups.	I-Premise

The	B-Premise
average	I-Premise
costs	I-Premise
of	I-Premise
the	I-Premise
primary	I-Premise
treatment	I-Premise
were	I-Premise
higher	I-Premise
in	I-Premise
GM-CSF-treated	I-Premise
patients	I-Premise
than	I-Premise
in	I-Premise
the	I-Premise
control	I-Premise
group,	I-Premise
i.e.	I-Premise
US$40782	I-Premise
and	I-Premise
US$34465,	I-Premise
respectively	I-Premise
(P	I-Premise
<	I-Premise
0.01).	I-Premise

The	B-Premise
costs	I-Premise
during	I-Premise
the	I-Premise
follow-up	I-Premise
period	I-Premise
did	I-Premise
not	I-Premise
differ	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
groups.	I-Premise

The	B-Claim
results	I-Claim
of	I-Claim
this	I-Claim
randomized	I-Claim
clinical	I-Claim
trial	I-Claim
indicate	I-Claim
that	I-Claim
daunomycin-cytosine	I-Claim
arabinoside	I-Claim
plus	I-Claim
GM-CSF	I-Claim
is	I-Claim
not	I-Claim
a	I-Claim
cost-effective	I-Claim
treatment	I-Claim
strategy	I-Claim
when	I-Claim
compared	I-Claim
with	I-Claim
daunomycin-cytosine	I-Claim
arabinoside	I-Claim
alone.	I-Claim

Although	O
many	O
drug	O
combination	O
therapies	O
have	O
been	O
proposed,	O
there	B-Claim
is	I-Claim
no	I-Claim
standard	I-Claim
therapy	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
gastric	I-Claim
carcinoma.	I-Claim

The	B-Claim
superiority	I-Claim
of	I-Claim
combination	I-Claim
therapy	I-Claim
over	I-Claim
monochemotherapy	I-Claim
has	I-Claim
not	I-Claim
been	I-Claim
demonstrated	I-Claim
convincingly.	I-Claim

To	O
explore	O
the	O
role	O
of	O
monochemotherapy,	O
the	O
authors	O
evaluated	O
5-fluorouracil	O
(5-FU),	O
modulated	O
by	O
6S-leucovorin	O
(6S-LV)	O
and	O
a	O
cisplatin-containing	O
regimen,	O
which	O
was	O
comprised	O
of	O
epirubicin,	O
etoposide,	O
and	O
cisplatin	O
with	O
the	O
addition	O
of	O
the	O
reversal	O
agent	O
lonidamine	O
(EEP-L).	O

After	O
stratification	O
according	O
to	O
performance	O
status	O
(PS)	O
and	O
resection	O
of	O
the	O
primary	O
tumor,	O
72	O
patients	O
with	O
advanced	O
gastric	O
carcinoma	O
were	O
randomized	O
to	O
2	O
parallel	O
Phase	O
II	O
trials	O
with	O
5-FU/6S-LV	O
and	O
EEP-L,	O
respectively.	O

Thirty-six	O
patients	O
in	O
Study	O
A	O
received	O
bolus	O
6S-LV,	O
100	O
mg/m2,	O
followed	O
by	O
bolus	O
5-FU,	O
370	O
mg/m2,	O
on	O
Days	O
1-5	O
and	O
36	O
others	O
in	O
Study	O
B	O
received	O
epirubicin,	O
30	O
mg/m2,	O
on	O
Days	O
1	O
and	O
5;	O
etoposide,	O
100	O
mg/m2,	O
on	O
Days	O
1,	O
3,	O
and	O
5;	O
cisplatin,	O
30	O
mg/m2,	O
on	O
Days	O
2	O
and	O
4;	O
and	O
lonidamine,	O
150	O
mg/day.	O

There	O
were	O
6	O
partial	O
responses	O
(18.2%)	O
(95%	O
confidence	O
interval	O
[CI]	O
+/-	O
13.2)	O
in	O
Study	O
A	O
and	O
7	O
partial	O
responses	O
(21.9%)	O
(95%	O
CI	O
+/-	O
14.3)	O
in	O
Study	O
B.	O
Partial	O
responses	O
were	O
more	O
frequent	O
in	O
patients	O
with	O
resected	O
tumors	O
or	O
with	O
an	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
PS	O
of	O
0-1.	O

The	B-Premise
median	I-Premise
duration	I-Premise
of	I-Premise
response	I-Premise
was	I-Premise
8.8	I-Premise
and	I-Premise
8.3	I-Premise
months,	I-Premise
respectively,	I-Premise
in	I-Premise
Study	I-Premise
A	I-Premise
and	I-Premise
Study	I-Premise
B.	I-Premise

The	B-Premise
median	I-Premise
survival	I-Premise
reached	I-Premise
8	I-Premise
months	I-Premise
in	I-Premise
Study	I-Premise
A	I-Premise
and	I-Premise
9	I-Premise
months	I-Premise
in	I-Premise
Study	I-Premise
B.	I-Premise

In	B-Premise
the	I-Premise
whole	I-Premise
population	I-Premise
of	I-Premise
patients	I-Premise
survival	I-Premise
was	I-Premise
significantly	I-Premise
higher	I-Premise
in	I-Premise
patients	I-Premise
with	I-Premise
a	I-Premise
PS	I-Premise
of	I-Premise
0-1	I-Premise
(P	I-Premise
<	I-Premise
0.05).	I-Premise

Patients	B-Premise
with	I-Premise
a	I-Premise
PS	I-Premise
of	I-Premise
0-1	I-Premise
and	I-Premise
a	I-Premise
resected	I-Premise
tumor	I-Premise
had	I-Premise
the	I-Premise
significantly	I-Premise
longest	I-Premise
survival	I-Premise
both	I-Premise
in	I-Premise
EEP-L	I-Premise
treated	I-Premise
patients	I-Premise
and	I-Premise
in	I-Premise
all	I-Premise
evaluable	I-Premise
patients	I-Premise
in	I-Premise
the	I-Premise
two	I-Premise
studies.	I-Premise

The	B-Premise
most	I-Premise
frequent	I-Premise
World	I-Premise
Health	I-Premise
Organization	I-Premise
Grade	I-Premise
3-4	I-Premise
toxic	I-Premise
effects	I-Premise
were	I-Premise
gastrointestinal	I-Premise
in	I-Premise
Study	I-Premise
A	I-Premise
and	I-Premise
hematologic	I-Premise
in	I-Premise
Study	I-Premise
B.	I-Premise

No	B-Premise
treatment-related	I-Premise
death	I-Premise
was	I-Premise
observed.	I-Premise

The	B-Claim
efficacy	I-Claim
of	I-Claim
5-FU,	I-Claim
modulated	I-Claim
with	I-Claim
6S-LV,	I-Claim
is	I-Claim
moderate	I-Claim
in	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
gastric	I-Claim
carcinoma,	I-Claim
similar	I-Claim
to	I-Claim
cisplatin-containing	I-Claim
regimens.	I-Claim

PS	B-Claim
and	I-Claim
other	I-Claim
prognostic	I-Claim
factors	I-Claim
could	I-Claim
influence	I-Claim
the	I-Claim
response	I-Claim
rate,	I-Claim
which	I-Claim
does	I-Claim
not	I-Claim
appear	I-Claim
to	I-Claim
be	I-Claim
a	I-Claim
reliable	I-Claim
parameter	I-Claim
for	I-Claim
evaluating	I-Claim
the	I-Claim
outcome	I-Claim
of	I-Claim
chemotherapy	I-Claim
trials.	I-Claim

The	O
Intergroup	O
conducted	O
this	O
breast	O
cancer	O
adjuvant	O
trial	O
to	O
compare	O
an	O
investigational	O
16-week	O
regimen	O
with	O
cyclophosphamide,	O
doxorubicin,	O
and	O
fluorouracil	O
(5-FU;	O
CAF).	O

The	O
16-week	O
regimen	O
features	O
greater	O
doxorubicin	O
and	O
5-FU	O
dose-intensity	O
than	O
CAF	O
and	O
improved	O
scheduling	O
of	O
antimetabolites	O
with	O
sequential	O
methotrexate	O
and	O
5-FU,	O
as	O
well	O
as	O
infusion	O
5-FU.	O

A	O
total	O
of	O
646	O
node-positive,	O
receptor-negative	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
the	O
1	O
6-week	O
regimen	O
or	O
six	O
cycles	O
of	O
CAF.	O

Breast	O
cancer	O
outcomes	O
included	O
recurrence	O
as	O
well	O
as	O
disease-free	O
and	O
overall	O
survival.	O

Toxicity	O
was	O
evaluated	O
by	O
the	O
Common	O
Toxicity	O
Criteria	O
(CTC).	O

Treatment-related	O
quality	O
of	O
life	O
was	O
assessed	O
by	O
the	O
Breast	O
Chemotherapy	O
Questionnaire	O
(BCQ)	O
before,	O
during,	O
and	O
4	O
months	O
after	O
treatment	O
in	O
163	O
patients.	O

The	O
trial	O
was	O
designed	O
to	O
use	O
one-sided	O
tests	O
of	O
significance	O
for	O
power	O
calculations,	O
but	O
is	O
now	O
reported	O
with	O
both	O
one-sided	O
and	O
the	O
traditional	O
two-sided	O
tests	O
of	O
significance.	O

At	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
3.9	I-Premise
years,	I-Premise
the	I-Premise
estimated	I-Premise
4-year	I-Premise
recurrence-free	I-Premise
survival	I-Premise
rate	I-Premise
was	I-Premise
67.5%	I-Premise
with	I-Premise
the	I-Premise
16-week	I-Premise
regimen	I-Premise
versus	I-Premise
62.7%	I-Premise
with	I-Premise
CAF	I-Premise
(P	I-Premise
=	I-Premise
.19,	I-Premise
two-sided;	I-Premise
P	I-Premise
=	I-Premise
.095,	I-Premise
one-sided).	I-Premise

The	B-Premise
estimated	I-Premise
4-year	I-Premise
survival	I-Premise
rate	I-Premise
was	I-Premise
78.1%	I-Premise
with	I-Premise
the	I-Premise
16-week	I-Premise
regimen	I-Premise
versus	I-Premise
71.4%	I-Premise
with	I-Premise
CAF	I-Premise
(P	I-Premise
=	I-Premise
.10,	I-Premise
two-sided;	I-Premise
P	I-Premise
=	I-Premise
.05,	I-Premise
one-sided).	I-Premise

CAF	B-Premise
produced	I-Premise
significantly	I-Premise
higher	I-Premise
grades	I-Premise
of	I-Premise
leukopenia,	I-Premise
granulocytopenia,	I-Premise
and	I-Premise
thrombocytopenia,	I-Premise
as	I-Premise
well	I-Premise
as	I-Premise
liver	I-Premise
and	I-Premise
cardiac	I-Premise
toxicity,	I-Premise
whereas	O
the	B-Premise
16-week	I-Premise
regimen	I-Premise
produced	I-Premise
significantly	I-Premise
higher	I-Premise
grades	I-Premise
of	I-Premise
anemia,	I-Premise
nausea,	I-Premise
stomatitis,	I-Premise
and	I-Premise
weight	I-Premise
loss,	I-Premise
as	I-Premise
well	I-Premise
as	I-Premise
skin	I-Premise
and	I-Premise
neurotoxicity.	I-Premise

There	B-Premise
were	I-Premise
three	I-Premise
treatment-related	I-Premise
deaths	I-Premise
with	I-Premise
CAF	I-Premise
but	B-Premise
none	I-Premise
with	I-Premise
the	I-Premise
16-week	I-Premise
regimen.	I-Premise

During	B-Premise
treatment,	I-Premise
quality	I-Premise
of	I-Premise
life	I-Premise
declined	I-Premise
significantly	I-Premise
more	I-Premise
with	I-Premise
the	I-Premise
16-week	I-Premise
regimen	I-Premise
than	I-Premise
CAF,	I-Premise
but	B-Premise
by	I-Premise
4	I-Premise
months	I-Premise
posttreatment,	I-Premise
there	I-Premise
was	I-Premise
no	I-Premise
difference.	I-Premise

The	B-Premise
16-week	I-Premise
regimen	I-Premise
produced	I-Premise
marginally	I-Premise
better	I-Premise
breast	I-Premise
cancer	I-Premise
outcomes	I-Premise
than	I-Premise
CAF	I-Premise
with	I-Premise
similar	I-Premise
toxicity	I-Premise
but	I-Premise
a	I-Premise
greater	I-Premise
reduction	I-Premise
in	I-Premise
during-treatment	I-Premise
quality	I-Premise
of	I-Premise
life.	I-Premise

The	B-Claim
16-week	I-Claim
regimen	I-Claim
should	I-Claim
not	I-Claim
be	I-Claim
used	I-Claim
instead	I-Claim
of	I-Claim
a	I-Claim
standard-dose	I-Claim
regimen	I-Claim
without	I-Claim
careful	I-Claim
consideration	I-Claim
of	I-Claim
the	I-Claim
16-week	I-Claim
regimen's	I-Claim
pros	I-Claim
and	I-Claim
cons,	I-Claim
which	I-Claim
include	I-Claim
its	I-Claim
complicated	I-Claim
schedule.	I-Claim

It	B-Claim
should	I-Claim
probably	I-Claim
not	I-Claim
be	I-Claim
tested	I-Claim
further,	I-Claim
but	B-Claim
its	I-Claim
antimetabolite	I-Claim
schedules	I-Claim
and	I-Claim
frequent	I-Claim
drug	I-Claim
administration	I-Claim
(ie,	I-Claim
dose	I-Claim
density)	I-Claim
should	I-Claim
be	I-Claim
considered	I-Claim
in	I-Claim
the	I-Claim
development	I-Claim
of	I-Claim
new	I-Claim
regimens.	I-Claim

The	O
finding	O
of	O
a	O
decrease	O
in	O
contralateral	O
breast	O
cancer	O
incidence	O
following	O
tamoxifen	O
administration	O
for	O
adjuvant	O
therapy	O
led	O
to	O
the	O
concept	O
that	O
the	O
drug	O
might	O
play	O
a	O
role	O
in	O
breast	O
cancer	O
prevention.	O

To	O
test	O
this	O
hypothesis,	O
the	O
National	O
Surgical	O
Adjuvant	O
Breast	O
and	O
Bowel	O
Project	O
initiated	O
the	O
Breast	O
Cancer	O
Prevention	O
Trial	O
(P-1)	O
in	O
1992.	O

Women	O
(N=13388)	O
at	O
increased	O
risk	O
for	O
breast	O
cancer	O
because	O
they	O
1)	O
were	O
60	O
years	O
of	O
age	O
or	O
older,	O
2)	O
were	O
35-59	O
years	O
of	O
age	O
with	O
a	O
5-year	O
predicted	O
risk	O
for	O
breast	O
cancer	O
of	O
at	O
least	O
1.66%,	O
or	O
3)	O
had	O
a	O
history	O
of	O
lobular	O
carcinoma	O
in	O
situ	O
were	O
randomly	O
assigned	O
to	O
receive	O
placebo	O
(n=6707)	O
or	O
20	O
mg/day	O
tamoxifen	O
(n=6681)	O
for	O
5	O
years.	O

Gail's	O
algorithm,	O
based	O
on	O
a	O
multivariate	O
logistic	O
regression	O
model	O
using	O
combinations	O
of	O
risk	O
factors,	O
was	O
used	O
to	O
estimate	O
the	O
probability	O
(risk)	O
of	O
occurrence	O
of	O
breast	O
cancer	O
over	O
time.	O

Tamoxifen	B-Premise
reduced	I-Premise
the	I-Premise
risk	I-Premise
of	I-Premise
invasive	I-Premise
breast	I-Premise
cancer	I-Premise
by	I-Premise
49%	I-Premise
(two-sided	I-Premise
P<.00001),	I-Premise
with	I-Premise
cumulative	I-Premise
incidence	I-Premise
through	I-Premise
69	I-Premise
months	I-Premise
of	I-Premise
follow-up	I-Premise
of	I-Premise
43.4	I-Premise
versus	I-Premise
22.0	I-Premise
per	I-Premise
1000	I-Premise
women	I-Premise
in	I-Premise
the	I-Premise
placebo	I-Premise
and	I-Premise
tamoxifen	I-Premise
groups,	I-Premise
respectively.	I-Premise

The	O
decreased	O
risk	O
occurred	O
in	O
women	O
aged	O
49	O
years	O
or	O
younger	O
(44%),	O
50-59	O
years	O
(51%),	O
and	O
60	O
years	O
or	O
older	O
(55%);	O
risk	B-Premise
was	I-Premise
also	I-Premise
reduced	I-Premise
in	I-Premise
women	I-Premise
with	I-Premise
a	I-Premise
history	I-Premise
of	I-Premise
lobular	I-Premise
carcinoma	I-Premise
in	I-Premise
situ	I-Premise
(56%)	I-Premise
or	I-Premise
atypical	I-Premise
hyperplasia	I-Premise
(86%)	I-Premise
and	I-Premise
in	I-Premise
those	I-Premise
with	I-Premise
any	I-Premise
category	I-Premise
of	I-Premise
predicted	I-Premise
5-year	I-Premise
risk.	I-Premise

Tamoxifen	B-Premise
reduced	I-Premise
the	I-Premise
risk	I-Premise
of	I-Premise
noninvasive	I-Premise
breast	I-Premise
cancer	I-Premise
by	I-Premise
50%	I-Premise
(two-sided	I-Premise
P<.002).	I-Premise

Tamoxifen	B-Premise
reduced	I-Premise
the	I-Premise
occurrence	I-Premise
of	I-Premise
estrogen	I-Premise
receptor-positive	I-Premise
tumors	I-Premise
by	I-Premise
69%,	I-Premise
but	I-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
the	I-Premise
occurrence	I-Premise
of	I-Premise
estrogen	I-Premise
receptor-negative	I-Premise
tumors	I-Premise
was	I-Premise
seen.	I-Premise

Tamoxifen	B-Premise
administration	I-Premise
did	I-Premise
not	I-Premise
alter	I-Premise
the	I-Premise
average	I-Premise
annual	I-Premise
rate	I-Premise
of	I-Premise
ischemic	I-Premise
heart	I-Premise
disease;	I-Premise
however,	I-Premise
a	I-Premise
reduction	I-Premise
in	I-Premise
hip,	I-Premise
radius	I-Premise
(Colles'),	I-Premise
and	I-Premise
spine	I-Premise
fractures	I-Premise
was	I-Premise
observed.	I-Premise

The	B-Premise
rate	I-Premise
of	I-Premise
endometrial	I-Premise
cancer	I-Premise
was	I-Premise
increased	I-Premise
in	I-Premise
the	I-Premise
tamoxifen	I-Premise
group	I-Premise
(risk	I-Premise
ratio	I-Premise
=	I-Premise
2.53;	I-Premise
95%	I-Premise
confidence	I-Premise
interval	I-Premise
=	I-Premise
1.35-4.97);	I-Premise
this	I-Premise
increased	I-Premise
risk	I-Premise
occurred	I-Premise
predominantly	I-Premise
in	I-Premise
women	I-Premise
aged	I-Premise
50	I-Premise
years	I-Premise
or	I-Premise
older.	I-Premise

All	O
endometrial	O
cancers	O
in	O
the	O
tamoxifen	O
group	O
were	O
stage	O
I	O
(localized	O
disease);	O
no	B-Premise
endometrial	I-Premise
cancer	I-Premise
deaths	I-Premise
have	I-Premise
occurred	I-Premise
in	I-Premise
this	I-Premise
group.	I-Premise

No	B-Premise
liver	I-Premise
cancers	I-Premise
or	I-Premise
increase	I-Premise
in	I-Premise
colon,	I-Premise
rectal,	I-Premise
ovarian,	I-Premise
or	I-Premise
other	I-Premise
tumors	I-Premise
was	I-Premise
observed	I-Premise
in	I-Premise
the	I-Premise
tamoxifen	I-Premise
group.	I-Premise

The	B-Premise
rates	I-Premise
of	I-Premise
stroke,	I-Premise
pulmonary	I-Premise
embolism,	I-Premise
and	I-Premise
deep-vein	I-Premise
thrombosis	I-Premise
were	I-Premise
elevated	I-Premise
in	I-Premise
the	I-Premise
tamoxifen	I-Premise
group;	I-Premise
these	I-Premise
events	I-Premise
occurred	I-Premise
more	I-Premise
frequently	I-Premise
in	I-Premise
women	I-Premise
aged	I-Premise
50	I-Premise
years	I-Premise
or	I-Premise
older.	I-Premise

Tamoxifen	B-Claim
decreases	I-Claim
the	I-Claim
incidence	I-Claim
of	I-Claim
invasive	I-Claim
and	I-Claim
noninvasive	I-Claim
breast	I-Claim
cancer.	I-Claim

Despite	B-Claim
side	I-Claim
effects	I-Claim
resulting	I-Claim
from	I-Claim
administration	I-Claim
of	I-Claim
tamoxifen,	I-Claim
its	I-Claim
use	I-Claim
as	I-Claim
a	I-Claim
breast	I-Claim
cancer	I-Claim
preventive	I-Claim
agent	I-Claim
is	I-Claim
appropriate	I-Claim
in	I-Claim
many	I-Claim
women	I-Claim
at	I-Claim
increased	I-Claim
risk	I-Claim
for	I-Claim
the	I-Claim
disease.	I-Claim

For	B-Claim
patients	I-Claim
with	I-Claim
metastatic	I-Claim
prostate	I-Claim
cancer,	I-Claim
treatment	I-Claim
is	I-Claim
primarily	I-Claim
palliative,	I-Claim
relying	I-Claim
mainly	I-Claim
on	I-Claim
the	I-Claim
suppression	I-Claim
of	I-Claim
systemic	I-Claim
androgen	I-Claim
hormone	I-Claim
levels.	I-Claim

To	O
help	O
document	O
the	O
achievement	O
of	O
palliation	O
and	O
to	O
characterize	O
positive	O
and	O
negative	O
effects	O
of	O
treatment,	O
we	O
evaluated	O
quality-of-life	O
(QOL)	O
parameters	O
in	O
patients	O
with	O
metastatic	O
prostate	O
cancer	O
who	O
were	O
randomly	O
assigned	O
to	O
two	O
methods	O
of	O
androgen	O
deprivation.	O

Patients	O
(n	O
=	O
739)	O
with	O
stage	O
M1	O
(bone	O
or	O
soft	O
tissue	O
metastasis)	O
prostate	O
cancer	O
were	O
enrolled	O
in	O
a	O
QOL	O
protocol	O
that	O
was	O
a	O
companion	O
to	O
Southwest	O
Oncology	O
Group	O
INT-0105,	O
a	O
randomized	O
double-blind	O
trial	O
comparing	O
treatment	O
with	O
bilateral	O
orchiectomy	O
(surgical	O
castration)	O
plus	O
either	O
flutamide	O
or	O
placebo.	O

Patients	O
completed	O
a	O
comprehensive	O
battery	O
of	O
QOL	O
questionnaires	O
at	O
random	O
assignment	O
to	O
treatment	O
and	O
at	O
1,	O
3,	O
and	O
6	O
months	O
later.	O

Data	O
were	O
collected	O
on	O
three	O
treatment-specific	O
symptoms	O
(diarrhea,	O
gas	O
pain,	O
and	O
body	O
image),	O
on	O
physical	O
functioning,	O
and	O
on	O
emotional	O
functioning.	O

All	O
P	O
values	O
are	O
two-sided.	O

Questionnaire	O
return	O
rates	O
for	O
this	O
study	O
never	O
dropped	O
below	O
80%;	O
only	O
2%	O
of	O
the	O
patients	O
did	O
not	O
submit	O
baseline	O
QOL	O
assessments.	O

Cross-sectional	B-Premise
analyses	I-Premise
(corrected	I-Premise
for	I-Premise
multiple	I-Premise
testing)	I-Premise
identified	I-Premise
statistically	I-Premise
significant	I-Premise
differences	I-Premise
that	I-Premise
favored	I-Premise
orchiectomy	I-Premise
plus	I-Premise
placebo	I-Premise
for	I-Premise
two	I-Premise
of	I-Premise
the	I-Premise
five	I-Premise
primary	I-Premise
QOL	I-Premise
parameters	I-Premise
as	I-Premise
follows:	I-Premise
patients	I-Premise
receiving	I-Premise
flutamide	I-Premise
reported	I-Premise
more	I-Premise
diarrhea	I-Premise
at	I-Premise
3	I-Premise
months	I-Premise
(P	I-Premise
=	I-Premise
.001)	I-Premise
and	I-Premise
worse	I-Premise
emotional	I-Premise
functioning	I-Premise
at	I-Premise
3	I-Premise
and	I-Premise
6	I-Premise
months	I-Premise
(both	I-Premise
P<.003).	I-Premise

Longitudinal	B-Premise
analyses	I-Premise
replicated	I-Premise
these	I-Premise
findings.	I-Premise

Other	B-Premise
analyzed	I-Premise
QOL	I-Premise
parameters	I-Premise
favored	I-Premise
the	I-Premise
group	I-Premise
receiving	I-Premise
placebo	I-Premise
but	B-Premise
were	I-Premise
not	I-Premise
statistically	I-Premise
significant	I-Premise
after	I-Premise
adjustment	I-Premise
for	I-Premise
multiple	I-Premise
testing.	I-Premise

We	B-Claim
found	I-Claim
a	I-Claim
consistent	I-Claim
pattern	I-Claim
of	I-Claim
better	I-Claim
QOL	I-Claim
outcomes	I-Claim
at	I-Claim
each	I-Claim
follow-up	I-Claim
assessment	I-Claim
during	I-Claim
the	I-Claim
first	I-Claim
6	I-Claim
months	I-Claim
of	I-Claim
treatment	I-Claim
for	I-Claim
orchiectomized	I-Claim
patients	I-Claim
with	I-Claim
metastatic	I-Claim
prostate	I-Claim
cancer	I-Claim
who	I-Claim
received	I-Claim
placebo	I-Claim
versus	I-Claim
flutamide.	I-Claim

Improvement	B-Claim
over	I-Claim
time	I-Claim
was	I-Claim
evident	I-Claim
in	I-Claim
both	I-Claim
treatment	I-Claim
groups	I-Claim
but	I-Claim
more	I-Claim
so	I-Claim
for	I-Claim
patients	I-Claim
receiving	I-Claim
placebo.	I-Claim

In	O
phase	O
II	O
studies,	O
irinotecan	O
is	O
active	O
in	O
metastatic	O
colorectal	O
cancer,	O
but	O
the	O
overall	O
benefit	O
has	O
not	O
been	O
assessed	O
in	O
a	O
randomised	O
clinical	O
trial.	O

Patients	O
with	O
proven	O
metastatic	O
colorectal	O
cancer,	O
which	O
had	O
progressed	O
within	O
6	O
months	O
of	O
treatment	O
with	O
fluorouracil,	O
were	O
randomly	O
assigned	O
either	O
300-350	O
mg/m2	O
irinotecan	O
every	O
3	O
weeks	O
with	O
supportive	O
care	O
or	O
supportive	O
care	O
alone,	O
in	O
a	O
2:1	O
ratio.	O

189	O
patients	O
were	O
allocated	O
irinotecan	O
and	O
supportive	O
care	O
and	O
90	O
supportive	O
care	O
alone.	O

The	O
mean	O
age	O
of	O
the	O
participants	O
was	O
58.8	O
years;	O
181	O
(65%)	O
were	O
men	O
and	O
98	O
(35%)	O
were	O
women.	O

WHO	O
performance	O
status	O
was	O
0	O
in	O
79	O
(42%)	O
patients,	O
1	O
in	O
77	O
(41%)	O
patients,	O
and	O
2	O
in	O
32	O
(17%)	O
patients.	O

Tumour-related	O
symptoms	O
were	O
present	O
in	O
134	O
(71%)	O
patients	O
and	O
weight	O
loss	O
of	O
more	O
than	O
5%	O
was	O
seen	O
in	O
15	O
(8%)	O
patients.	O

With	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
13	I-Premise
months,	I-Premise
the	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
significantly	I-Premise
better	I-Premise
in	I-Premise
the	I-Premise
irinotecan	I-Premise
group	I-Premise
(p=0.0001),	I-Premise
with	I-Premise
36.2%	I-Premise
1-year	I-Premise
survival	I-Premise
in	I-Premise
the	I-Premise
irinotecan	I-Premise
group	I-Premise
versus	I-Premise
13.8%	I-Premise
in	I-Premise
the	I-Premise
supportive-care	I-Premise
group.	I-Premise

The	B-Premise
survival	I-Premise
benefit,	I-Premise
adjusted	I-Premise
for	I-Premise
prognostic	I-Premise
factors	I-Premise
in	I-Premise
a	I-Premise
multivariate	I-Premise
analysis,	I-Premise
remained	I-Premise
significant	I-Premise
(p=0.001).	I-Premise

Survival	B-Premise
without	I-Premise
performance-status	I-Premise
deterioration	I-Premise
(p=0.0001),	I-Premise
without	I-Premise
weight	I-Premise
loss	I-Premise
of	I-Premise
more	I-Premise
than	I-Premise
5%	I-Premise
(p=0.018),	I-Premise
and	I-Premise
pain-free	I-Premise
survival	I-Premise
(p=0.003)	I-Premise
were	I-Premise
significantly	I-Premise
better	I-Premise
in	I-Premise
the	I-Premise
patients	I-Premise
given	I-Premise
irinotecan.	I-Premise

In	B-Premise
a	I-Premise
quality-of-life	I-Premise
analysis,	I-Premise
all	I-Premise
significant	I-Premise
differences,	I-Premise
except	I-Premise
on	I-Premise
diarrhoea	I-Premise
score,	I-Premise
were	I-Premise
in	I-Premise
favour	I-Premise
of	I-Premise
the	I-Premise
irinotecan	I-Premise
group.	I-Premise

Our	B-Claim
study	I-Claim
shows	I-Claim
that	I-Claim
despite	I-Claim
the	I-Claim
side-effects	I-Claim
of	I-Claim
treatment,	I-Claim
patients	I-Claim
who	I-Claim
have	I-Claim
metastatic	I-Claim
colorectal	I-Claim
cancer,	I-Claim
and	I-Claim
for	I-Claim
whom	I-Claim
fluorouracil	I-Claim
has	I-Claim
failed,	I-Claim
have	I-Claim
a	I-Claim
longer	I-Claim
survival,	I-Claim
fewer	I-Claim
tumour-related	I-Claim
symptoms,	I-Claim
and	I-Claim
a	I-Claim
better	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
when	I-Claim
treated	I-Claim
with	I-Claim
irinotecan	I-Claim
than	I-Claim
with	I-Claim
supportive	I-Claim
care	I-Claim
alone.	I-Claim

The	O
aim	O
of	O
the	O
present	O
trial	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
chemotherapy	O
on	O
the	O
quality	O
of	O
life	O
and	O
survival	O
of	O
patients	O
with	O
advanced	O
non-small	O
cell	O
lung	O
cancer	O
(NSCLC)	O
(stage	O
IIIB	O
or	O
IV).	O

In	O
a	O
controlled	O
multicentre	O
trial,	O
patients	O
were	O
randomised	O
to	O
receive	O
supportive	O
care	O
only	O
or	O
supportive	O
care	O
plus	O
chemotherapy.	O

Chemotherapy	O
consisted	O
of	O
intravenous	O
(i.v.)	O
carboplatin	O
300	O
mg/m2	O
on	O
day	O
1	O
and	O
etoposide	O
120	O
mg/m2	O
orally	O
on	O
days	O
1-5	O
every	O
4	O
weeks	O
for	O
a	O
maximum	O
of	O
eight	O
courses.	O

Quality	O
of	O
life	O
was	O
measured	O
at	O
randomisation	O
and	O
prior	O
to	O
each	O
treatment	O
course	O
and	O
at	O
corresponding	O
4-week	O
intervals	O
in	O
the	O
control	O
arm,	O
using	O
the	O
EORTC	O
QLQ-C30	O
+	O
LC13	O
questionnaire.	O

48	O
patients	O
were	O
randomised	O
(supportive	O
care	O
26,	O
chemotherapy	O
22),	O
being	O
eligible	O
for	O
comparative	O
analyses.	O

Another	O
102	O
patients,	O
97	O
of	O
which	O
received	O
chemotherapy,	O
were	O
subsequently	O
included	O
in	O
the	O
study	O
on	O
an	O
individual	O
treatment	O
preference	O
basis.	O

Data	O
from	O
these	O
patients	O
were	O
used	O
for	O
confirmative	O
purposes.	O

Patients	B-Premise
in	I-Premise
the	I-Premise
chemotherapy	I-Premise
group	I-Premise
reported	I-Premise
better	I-Premise
overall	I-Premise
physical	I-Premise
functioning	I-Premise
and	I-Premise
symptom	I-Premise
control	I-Premise
compared	I-Premise
with	I-Premise
the	I-Premise
supportive	I-Premise
care	I-Premise
group.	I-Premise

Group	B-Premise
differences	I-Premise
were	I-Premise
smaller	I-Premise
within	I-Premise
the	I-Premise
psychosocial	I-Premise
domain,	I-Premise
although	B-Premise
trends	I-Premise
were	I-Premise
seen	I-Premise
in	I-Premise
favour	I-Premise
of	I-Premise
the	I-Premise
chemotherapy	I-Premise
group.	I-Premise

No	B-Premise
significant	I-Premise
differences	I-Premise
were	I-Premise
seen	I-Premise
in	I-Premise
favour	I-Premise
of	I-Premise
the	I-Premise
supportive	I-Premise
care	I-Premise
group,	I-Premise
except	B-Premise
for	I-Premise
hair	I-Premise
loss.	I-Premise

Median	B-Premise
survival	I-Premise
times	I-Premise
were	I-Premise
29	I-Premise
weeks	I-Premise
in	I-Premise
the	I-Premise
chemotherapy	I-Premise
group	I-Premise
versus	I-Premise
11	I-Premise
weeks	I-Premise
in	I-Premise
the	I-Premise
supportive	I-Premise
care	I-Premise
group,	I-Premise
and	I-Premise
1-year	I-Premise
survival	I-Premise
rates	I-Premise
were	I-Premise
28%	I-Premise
versus	I-Premise
8%.	I-Premise

Quality	B-Premise
of	I-Premise
life	I-Premise
and	I-Premise
survival	I-Premise
outcomes	I-Premise
were	I-Premise
similar	I-Premise
in	I-Premise
the	I-Premise
randomised	I-Premise
and	I-Premise
non-randomised	I-Premise
patients	I-Premise
receiving	I-Premise
chemotherapy.	I-Premise

No	B-Premise
treatment-related	I-Premise
deaths	I-Premise
occurred.	I-Premise

In	B-Claim
conclusion,	I-Claim
treatment	I-Claim
with	I-Claim
carboplatin	I-Claim
and	I-Claim
etoposide	I-Claim
can	I-Claim
improve	I-Claim
both	I-Claim
the	I-Claim
quality	I-Claim
of	I-Claim
life	I-Claim
and	I-Claim
the	I-Claim
survival	I-Claim
of	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
NSCLC.	I-Claim

The	O
second	O
International	O
Society	O
of	O
Paediatric	O
Oncology	O
(SIOP)	O
study	O
for	O
rhabdomyosarcoma	O
(MMT84)	O
had	O
several	O
goals.	O

The	O
two	O
principal	O
aims	O
were:	O
(1)	O
to	O
improve	O
the	O
survival	O
of	O
children	O
with	O
rhabdomyosarcoma;	O
and	O
(2)	O
to	O
reduce	O
the	O
late	O
effects	O
from	O
therapy	O
by	O
restricting	O
the	O
indications	O
for	O
surgery	O
and/or	O
radiotherapy	O
after	O
good	O
response	O
to	O
initial	O
chemotherapy.	O

A	O
further	O
aim	O
was	O
to	O
investigate	O
the	O
role	O
of	O
high-dose	O
chemotherapy	O
in	O
young	O
patients	O
with	O
parameningeal	O
primary	O
tumours.	O

186	O
previously	O
untreated	O
eligible	O
patients	O
entered	O
the	O
study.	O

Patients	O
with	O
completely	O
resected	O
primary	O
tumour	O
received	O
three	O
courses	O
of	O
IVA	O
(ifosfamide,	O
vincristine	O
and	O
actinomycin	O
D).	O

Patients	O
with	O
incompletely	O
resected	O
tumour	O
received	O
six	O
to	O
10	O
courses	O
of	O
IVA	O
according	O
to	O
stage.	O

Patients	O
achieving	O
complete	O
remission	O
with	O
chemotherapy	O
alone	O
did	O
not	O
usually	O
receive	O
radiotherapy	O
or	O
undergo	O
extensive	O
surgery,	O
but	O
patients	O
remaining	O
in	O
partial	O
remission	O
received	O
local	O
therapy	O
with	O
surgery	O
and/or	O
radiotherapy.	O

Only	O
patients	O
over	O
5	O
years	O
of	O
age	O
with	O
parameningeal	O
disease	O
and	O
patients	O
over	O
12	O
years	O
with	O
tumours	O
at	O
any	O
site	O
were	O
given	O
systematic	O
irradiation.	O

Complete	B-Premise
remission	I-Premise
was	I-Premise
achieved	I-Premise
in	I-Premise
91%	I-Premise
(170/186)	I-Premise
of	I-Premise
all	I-Premise
patients.	I-Premise

With	B-Premise
a	I-Premise
median	I-Premise
follow-up	I-Premise
of	I-Premise
8	I-Premise
years,	I-Premise
the	I-Premise
5-year	I-Premise
overall	I-Premise
survival	I-Premise
was	I-Premise
68%	I-Premise
(+/-	I-Premise
3%	I-Premise
standard	I-Premise
error	I-Premise
of	I-Premise
the	I-Premise
mean	I-Premise
(SEM)	I-Premise
and	I-Premise
the	I-Premise
5-year	I-Premise
event-free	I-Premise
survival	I-Premise
53%	I-Premise
(+/-	I-Premise
4%	I-Premise
SEM).	I-Premise

These	B-Premise
results	I-Premise
show	I-Premise
an	I-Premise
improvement	I-Premise
over	I-Premise
previous	I-Premise
SIOP	I-Premise
study	I-Premise
(RMS75)	I-Premise
in	I-Premise
which	I-Premise
survival	I-Premise
was	I-Premise
52%	I-Premise
and	I-Premise
event-free	I-Premise
survival	I-Premise
was	I-Premise
47%.	I-Premise

Among	B-Premise
the	I-Premise
54	I-Premise
patients	I-Premise
who	I-Premise
exhibited	I-Premise
isolated	I-Premise
local	I-Premise
relapse,	I-Premise
35%	I-Premise
(19/54)	I-Premise
survived	I-Premise
in	I-Premise
further	I-Premise
remission	I-Premise
longer	I-Premise
than	I-Premise
2	I-Premise
years	I-Premise
after	I-Premise
retreatment,	I-Premise
including	I-Premise
local	I-Premise
therapy	I-Premise
(surgery	I-Premise
+/-	I-Premise
radiotherapy).	I-Premise

Analysis	O
of	O
the	O
overall	O
burden	O
of	O
therapy	O
received	O
by	O
all	O
surviving	O
children	O
(including	O
primary	O
treatment	O
and	O
treatment	O
for	O
relapse	O
if	O
required)	O
showed	O
that	O
24%	O
(28/116)	O
were	O
treated	O
by	O
limited	O
surgery	O
followed	O
by	O
three	O
courses	O
of	O
IVA,	O
29%	O
(34/116)	O
were	O
treated	O
by	O
chemotherapy	O
alone	O
(after	O
initial	O
biopsy)	O
and	O
13%	O
(15/116)	O
received	O
chemotherapy	O
plus	O
conservative	O
local	O
treatment	O
(limited	O
surgery	O
or	O
radiotherapy	O
for	O
residual	O
disease).	O

Only	O
34%	O
(39/116)	O
received	O
intensive	O
local	O
therapy	O
defined	O
as	O
radical	O
wide	O
field	O
radiotherapy	O
or	O
radical	O
surgery	O
or	O
both.	O

Compared	B-Claim
with	I-Claim
the	I-Claim
results	I-Claim
obtained	I-Claim
in	I-Claim
the	I-Claim
previous	I-Claim
SIOP	I-Claim
study,	I-Claim
treatment	I-Claim
in	I-Claim
MMT84	I-Claim
was	I-Claim
based	I-Claim
on	I-Claim
response	I-Claim
to	I-Claim
initial	I-Claim
chemotherapy	I-Claim
and,	I-Claim
despite	I-Claim
an	I-Claim
overall	I-Claim
reduction	I-Claim
of	I-Claim
the	I-Claim
use	I-Claim
of	I-Claim
local	I-Claim
therapy,	I-Claim
significantly	I-Claim
improved	I-Claim
survival	I-Claim
for	I-Claim
patients	I-Claim
with	I-Claim
non-metastatic	I-Claim
disease.	I-Claim

This	B-Claim
trial,	I-Claim
also	I-Claim
for	I-Claim
the	I-Claim
first	I-Claim
time,	I-Claim
provides	I-Claim
evidence	I-Claim
that	I-Claim
retreatment	I-Claim
after	I-Claim
local	I-Claim
relapse	I-Claim
can	I-Claim
achieve	I-Claim
long-term	I-Claim
second	I-Claim
remissions.	I-Claim

We	O
report	O
results	O
of	O
a	O
randomized	O
prospective	O
study	O
that	O
compared	O
single	O
agents	O
of	O
low	O
toxicity	O
given	O
both	O
as	O
the	O
first-line	O
and	O
second-line	O
chemotherapy	O
with	O
combination	O
chemotherapy	O
in	O
advanced	O
breast	O
cancer	O
with	O
distant	O
metastases.	O

Patients	O
in	O
the	O
single-agent	O
arm	O
(n	O
=	O
153)	O
received	O
weekly	O
epirubicin	O
(E)	O
20	O
mg/m2	O
until	O
progression	O
or	O
until	O
the	O
cumulative	O
dose	O
of	O
1,000	O
mg/m2,	O
followed	O
by	O
mitomycin	O
(M)	O
8	O
mg/m2	O
every	O
4	O
weeks,	O
and	O
those	O
in	O
the	O
combination	O
chemotherapy	O
arm	O
(n	O
=	O
150)	O
were	O
first	O
given	O
cyclophosphamide	O
500	O
mg/m2,	O
E	O
60	O
mg/m2,	O
and	O
fluorouracil	O
500	O
mg/m2	O
three	O
times	O
per	O
week	O
(CEF)	O
followed	O
by	O
M	O
8	O
mg/m2	O
plus	O
vinblastine	O
(V)	O
6	O
mg/m2	O
every	O
4	O
weeks.	O

Exclusion	O
criteria	O
included	O
age	O
greater	O
than	O
70	O
years,	O
World	O
Health	O
Organization	O
(WHO)	O
performance	O
status	O
greater	O
than	O
2,	O
prior	O
chemotherapy	O
for	O
metastatic	O
disease,	O
and	O
presence	O
of	O
liver	O
metastases	O
in	O
patients	O
younger	O
than	O
50.	O

An	B-Premise
objective	I-Premise
response	I-Premise
(complete	I-Premise
[CR]	I-Premise
or	I-Premise
partial	I-Premise
[PR])	I-Premise
was	I-Premise
obtained	I-Premise
in	I-Premise
55%,	I-Premise
48%,	I-Premise
16%,	I-Premise
and	I-Premise
7%	I-Premise
of	I-Premise
patients	I-Premise
treated	I-Premise
with	I-Premise
CEF,	I-Premise
E,	I-Premise
M,	I-Premise
and	I-Premise
MV,	I-Premise
respectively.	I-Premise

A	B-Premise
response	I-Premise
to	I-Premise
CEF	I-Premise
tended	I-Premise
to	I-Premise
last	I-Premise
longer	I-Premise
than	I-Premise
a	I-Premise
response	I-Premise
to	I-Premise
E	I-Premise
(median,	I-Premise
12	I-Premise
v	I-Premise
10.5	I-Premise
months;	I-Premise
P	I-Premise
=	I-Premise
.07).	I-Premise

Treatment-related	B-Premise
toxicity	I-Premise
was	I-Premise
less	I-Premise
in	I-Premise
the	I-Premise
single-agent	I-Premise
arm	I-Premise
and	I-Premise
quality-of-life	I-Premise
(QOL)	I-Premise
analysis	I-Premise
favored	I-Premise
the	I-Premise
single-agent	I-Premise
arm.	I-Premise

No	B-Premise
significant	I-Premise
difference	I-Premise
in	I-Premise
time	I-Premise
to	I-Premise
progression	I-Premise
or	I-Premise
survival	I-Premise
was	I-Premise
found	I-Premise
between	I-Premise
the	I-Premise
two	I-Premise
arms.	I-Premise

Similarly,	B-Premise
no	I-Premise
difference	I-Premise
in	I-Premise
survival	I-Premise
was	I-Premise
found	I-Premise
when	I-Premise
the	I-Premise
patients	I-Premise
who	I-Premise
received	I-Premise
both	I-Premise
the	I-Premise
planned	I-Premise
first-and	I-Premise
second-line	I-Premise
treatments	I-Premise
were	I-Premise
compared	I-Premise
or	I-Premise
when	I-Premise
survival	I-Premise
was	I-Premise
calculated	I-Premise
from	I-Premise
the	I-Premise
beginning	I-Premise
of	I-Premise
the	I-Premise
second-line	I-Premise
therapy.	I-Premise

Patients	B-Claim
treated	I-Claim
with	I-Claim
single-agent	I-Claim
E	I-Claim
followed	I-Claim
by	I-Claim
single-agent	I-Claim
M	I-Claim
had	I-Claim
similar	I-Claim
survival,	I-Claim
but	I-Claim
less	I-Claim
treatment-related	I-Claim
toxicity	I-Claim
and	I-Claim
better	I-Claim
QOL	I-Claim
as	I-Claim
compared	I-Claim
with	I-Claim
those	I-Claim
treated	I-Claim
with	I-Claim
CEF	I-Claim
followed	I-Claim
by	I-Claim
MV.	I-Claim

Vinorelbine,	B-Claim
a	I-Claim
semisynthetic	I-Claim
vinca	I-Claim
alkaloid,	I-Claim
represents	I-Claim
a	I-Claim
well-tolerated	I-Claim
treatment	I-Claim
for	I-Claim
elderly	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
non-small-cell	I-Claim
lung	I-Claim
cancer	I-Claim
(NSCLC).	I-Claim

We	O
explored	O
the	O
quality	O
of	O
life	O
(QoL)	O
of	O
such	O
patients	O
in	O
a	O
multicenter	O
randomized	O
trial	O
that	O
compared	O
vinorelbine	O
treatment	O
with	O
supportive	O
care	O
alone.	O

Eligible	O
patients	O
were	O
70	O
years	O
of	O
age	O
or	O
older,	O
had	O
stage	O
IV	O
or	O
IIIB	O
NSCLC	O
that	O
was	O
ineligible	O
for	O
radiotherapy,	O
and	O
had	O
a	O
performance	O
status	O
of	O
0-2	O
(a	O
status	O
of	O
fully	O
active	O
to	O
a	O
status	O
of	O
capable	O
of	O
all	O
self-care	O
but	O
unable	O
to	O
work).	O

Vinorelbine	O
was	O
given	O
intravenously	O
on	O
days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
treatment	O
cycle,	O
for	O
a	O
total	O
of	O
six	O
cycles.	O

QoL	O
was	O
evaluated	O
with	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
questionnaires	O
QLQ-C30	O
and	O
QLQ-LC13,	O
and	O
the	O
QoL	O
data	O
were	O
analyzed	O
by	O
fitting	O
a	O
linear	O
mixed	O
model	O
for	O
each	O
QoL	O
scale.	O

Survival	O
curves	O
were	O
plotted	O
and	O
were	O
compared	O
with	O
the	O
Mantel-Haenszel	O
test.	O

Relative	O
hazards	O
of	O
death	O
and	O
95%	O
confidence	O
intervals	O
(CIs)	O
were	O
estimated	O
by	O
the	O
Cox	O
model.	O

Investigators,	O
blinded	O
to	O
the	O
results,	O
stopped	O
the	O
trial	O
early	O
because	O
of	O
a	O
low	O
enrollment	O
rate.	O

(From	O
April	O
1996	O
to	O
November	O
1997,	O
191	O
of	O
the	O
350	O
targeted	O
patients	O
were	O
randomly	O
assigned.)	O
Data	O
from	O
161	O
patients	O
have	O
been	O
analyzed.	O

Vinorelbine-treated	B-Premise
patients	I-Premise
scored	I-Premise
better	I-Premise
than	I-Premise
control	I-Premise
patients	I-Premise
on	I-Premise
QoL	I-Premise
functioning	I-Premise
scales,	I-Premise
and	I-Premise
they	I-Premise
reported	I-Premise
fewer	I-Premise
lung	I-Premise
cancer-related	I-Premise
symptoms	I-Premise
but	I-Premise
reported	I-Premise
worse	I-Premise
toxicity-related	I-Premise
symptoms.	I-Premise

There	B-Premise
was	I-Premise
a	I-Premise
statistically	I-Premise
significant	I-Premise
(two-sided	I-Premise
P	I-Premise
=	I-Premise
.03)	I-Premise
survival	I-Premise
advantage	I-Premise
for	I-Premise
patients	I-Premise
receiving	I-Premise
vinorelbine;	I-Premise
median	B-Premise
survival	I-Premise
increased	I-Premise
from	I-Premise
21	I-Premise
to	I-Premise
28	I-Premise
weeks	I-Premise
in	I-Premise
the	I-Premise
vinorelbine-treated	I-Premise
group.	I-Premise

The	B-Premise
relative	I-Premise
hazard	I-Premise
of	I-Premise
death	I-Premise
for	I-Premise
vinorelbine-treated	I-Premise
patients	I-Premise
was	I-Premise
0.65	I-Premise
(95%	I-Premise
CI	I-Premise
=	I-Premise
0.45-0.93).	I-Premise

Vinorelbine	B-Claim
improves	I-Claim
survival	I-Claim
of	I-Claim
elderly	I-Claim
patients	I-Claim
with	I-Claim
advanced	I-Claim
NSCLC	I-Claim
and	I-Claim
possibly	I-Claim
improves	I-Claim
overall	I-Claim
QoL.	I-Claim

